,date,title,article,url,thumbnail,author
0,2022-05-10,Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines,"Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases Bagsværd, Denmark and Cambridge, MA, 10 May 2022 – Flagship Pioneering and Novo Nordisk A/S today announced a collaboration to create a portfolio of novel research programmes to develop transformational medicines. The companies will explore opportunities to apply Flagship’s innovative bioplatforms - an ecosystem that currently comprises 41 companies - to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these. This is a novel approach to collaboration, between companies providing extensive access to innovation, leveraging the technology platforms of multiple biotech companies to create a portfolio of medicines across several disease areas. “We are excited about this new agreement which will give Novo Nordisk access to Flagships’ large and diverse portfolio of companies, representing a wide variety of novel cutting-edge technologies and therapeutic modalities,” said Marcus Schindler, PhD, professor, executive vice president and chief scientific officer of Novo Nordisk. “This is a new and innovative way of collaborating, which combines the strength of Flagship Pioneering’s bioplatforms with Novo Nordisk’s cardiometabolic and rare disease expertise.” Novo Nordisk will provide funding for initiated research programmes and have an exclusive option to license each program. The ambition is to initiate three to five research programs within the first three years of the collaboration. “We enter into this collaboration with Novo Nordisk with a shared vision of creating transformational medicines in disease areas where there continue to be significant needs,” said Paul Biondi, president, Pioneering Medicines and executive partner, Flagship Pioneering. “This strategic partnership demonstrates the unique advantages of our Pioneering Medicines model in which we bring together complementary capabilities and expertise from multiple companies to deliver life-changing medicines to patients.” Through the collaboration, Flagship’s Pioneering Medicines and the Novo Nordisk Bio Innovation Hub will jointly select the most promising product concepts and conduct research programmes. Pioneering Medicines is a strategic initiative within Flagship Pioneering that is dedicated to conceiving and developing a broad portfolio of life-changing treatments by leveraging and expanding the use of Flagship’s innovations. The Novo Nordisk Bio Innovation Hub is a cross-functional R&D team within Novo Nordisk based in Cambridge, Massachusetts, with an ambition to establish and drive an externally anchored portfolio of co-created breakthrough therapeutic concepts and technologies and delivery projects. The Bio Innovation Hub, together with the recently acquired Dicerna Pharmaceuticals Inc. in Lexington, Massachusetts, are two of four transformational research units (TRUs) in the Novo Nordisk R&D organisation. About Flagship Pioneering Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in more than $100 billion in aggregate value. To date, Flagship has deployed over $2.9 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including Axcella Therapeutics (Nasdaq: AXLA), Codiak Biosciences (Nasdaq: CDAK) Denali Therapeutics (Nasdaq: DNLI), Evelo Biosciences (Nasdaq: EVLO), Foghorn Therapeutics (Nasdaq: FHTX), Indigo Ag, Moderna (Nasdaq: MRNA), Omega Therapeutics (Nasdaq: OMGA), Rubius Therapeutics (Nasdaq: RUBY), Sana Biotechnology (Nasdaq: SANA), Seres Therapeutics (Nasdaq: MCRB), and Sigilon Therapeutics (Nasdaq: SGTX). About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 49,300 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube. Further information   Attachment ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=114563,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
1,2022-05-06,Novo Nordisk A/S:,"Novo Nordisk – major shareholder announcement Bagsværd, Denmark, 6 May 2022 – Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 29 April 2022 holds B shares equal to 5.06% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act. The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Danish Capital Markets Act and financial instruments with similar effects according to section 39(2)(2) of the Danish Capital Markets Act held by Blackrock correspond to 5.07% of the entire share capital and below 5% of the voting rights. For a full chain of controlled undertakings through which the voting rights and/or the financial instruments are held, please see the annex. About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 49,300 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). or more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube. Further information Company announcement No 44 /2022 Annex:   Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity as of 3 May 2022  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=114095,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
2,2022-05-02,Novo Nordisk – major shareholder announcement,"Bagsværd, Denmark, 2 May 2022 – Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) as follows: Blackrock holds as of 25 April 2022 B shares equal to 4.99% of the entire share capital of Novo Nordisk. The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Danish Capital Markets Act and financial instruments with similar effects according to section 39(2)(2) of the Danish Capital Markets Act held by Blackrock correspond to 5.00% of the entire share capital and below 5% of the voting rights. Blackrock holds as of 26 April 2022 B shares equal to below 5% of the entire share capital of Novo Nordisk. The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Danish Capital Markets Act and financial instruments with similar effects according to section 39(2)(2) of the Danish Capital Markets Act held by Blackrock correspond to below 5% of the entire share capital and below 5% of the voting rights. Blackrock holds as of 27 April 2022 B shares equal to 4.99% of the entire share capital of Novo Nordisk. The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Danish Capital Markets Act and financial instruments with similar effects according to section 39(2)(2) of the Danish Capital Markets Act held by Blackrock correspond to 5.00% of the entire share capital and below 5% of the voting rights. The announcement is in accordance with section 30 of the Danish Capital Markets Act. For a full chain of controlled undertakings through which the voting rights and/or the financial instruments are held, please see the annexes. About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 49,300 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). or more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube. Further information Company announcement No 37 / 2022 Annex 1: Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity as of 25 April 2022 Annex 2: Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity as of 26 April 2022 Annex 3: Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity as of 27 April 2022  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=113465,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
3,2022-04-29,Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 29 April 2022,"Bagsværd, Denmark, 29 April 2022 – In accordance with Section 32 of the Danish Capital Markets Act, Novo Nordisk A/S is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred. Referring to Company Announcement no 31/2022 dated 27 April 2022, please find below a statement regarding the total number of voting rights and share capital in Novo Nordisk A/S as per 29 April 2022. 1 Each A share of DKK 0.01 carries 10 votes, whereas each B share of DKK 0.01 carries one vote. Thus, each A share of DKK 0.20 carries 200 votes and each B share of DKK 0.20 (the present denomination of the company's shares) carries 20 votes. Treasury shares are included in the table above but voting rights of treasury shares are suspended at the general meetings of Novo Nordisk A/S. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, and YouTube. Further information Company announcement No 35 / 2022 Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=112996,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
4,2022-04-29,Novo Nordisk's sales increased by 24% in Danish kroner and by 18% at constant exchange rates to DKK 42.0 billion in the first three months of 2022,"Financial report for the period 1 January 2022 to 31 March 2022 * CER: Constant exchange rates (average 2021). Lars Fruergaard Jørgensen, president and CEO: ""We are very pleased with the sales growth in the first three months of 2022 which is driven by increasing demand for our GLP-1-based treatments. The sales momentum has enabled us to raise our outlook for the full year. Within R&D, we are encouraged by the first phase 3 trial with once-weekly insulin icodec showing the potential to reduce the number of injections and improve quality of life for people needing insulin treatment as well as the progress with our late-stage pipeline in Rare disease."" On 29 April 2022 at 13.00 CEST, corresponding to 07.00 am EDT, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’. About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 49,300 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.  Further information about Novo Nordisk is available on novonordisk.com.  Company announcement No 33 / 2022 Attachment ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=112995,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
5,2022-04-29,Novo Nordisk's sales increased by 24% in Danish kroner and by 18% at constant exchange rates to DKK 42.0 billion in the first three months of 2022,"Financial report for the period 1 January 2022 to 31 March 2022 * CER: Constant exchange rates (average 2021). Lars Fruergaard Jørgensen, president and CEO: ""We are very pleased with the sales growth in the first three months of 2022 which is driven by increasing demand for our GLP-1-based treatments. The sales momentum has enabled us to raise our outlook for the full year. Within R&D, we are encouraged by the first phase 3 trial with once-weekly insulin icodec showing the potential to reduce the number of injections and improve quality of life for people needing insulin treatment as well as the progress with our late-stage pipeline in Rare disease."" On 29 April 2022 at 13.00 CEST, corresponding to 07.00 am EDT, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’. About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 49,300 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.  Further information about Novo Nordisk is available on novonordisk.com.  Company announcement No 34 / 2022 Attachment ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=112994,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
6,2022-04-28,Once-weekly insulin icodec demonstrates superior reduction in HbA1c vs insulin degludec in people with type 2 diabetes in ONWARDS 2 phase 3a trial,"Bagsværd, Denmark, 28 April 2022 – Novo Nordisk today announced headline results from the ONWARDS 2 trial, a phase 3a, 26-week efficacy and safety treat-to-target trial investigating once-weekly insulin icodec vs insulin degludec in 526 people with type 2 diabetes switching from daily insulin. The trial achieved its primary endpoint of demonstrating non-inferiority in reducing HbA1c at week 26 with insulin icodec compared to insulin degludec. From an overall baseline HbA1c of 8.13%, once-weekly insulin icodec achieved a superior reduction in estimated HbA1c of 0.93% compared to 0.71% for insulin degludec (estimated treatment difference: -0.22%). In the trial, there was no statistical difference in estimated hypoglycaemia rates, and no severe hypoglycaemia events were observed for people treated with insulin icodec. The rates of severe or clinically significant hypoglycaemia (blood glucose below 3 mmol/L) were 0.73 events per patient year exposed to once-weekly insulin icodec and 0.27 events per patient-year exposed to insulin degludec. In the trial, once-weekly insulin icodec appeared to have a safe and well-tolerated profile. “We are very pleased with the results seen in ONWARDS 2, and once-weekly insulin icodec is the first insulin to demonstrate the ability to reduce the number of yearly basal insulin injections from 365 to 52 in a phase 3 trial”, says Martin Holst Lange, executive vice president for Development at Novo Nordisk. “Novo Nordisk has for 100 years been committed to develop insulin treatment to improve glycaemic outcome and reduce the disease burden for people living with diabetes and we are excited to share additional results of the ONWARDS programme later this year.” About the ONWARDS clinical programmeThe ONWARDS clinical development programme for once-weekly insulin icodec currently comprises six phase 3a global clinical trials, including a trial with real-world elements, involving more than 4,000 adults with type 1 or type 2 diabetes. ONWARDS 1 is a 78-week trial comparing the efficacy and safety of once-weekly insulin icodec with once-daily insulin glargine U100 both in combination with non-insulin anti-diabetic treatment in 984 insulin-naïve people with type 2 diabetes. ONWARDS 3 is a 26-week trial comparing once-weekly insulin icodec with once-daily insulin degludec. The objective of the trial is to assess the efficacy and safety of insulin icodec in 588 insulin-naïve people with type 2 diabetes. ONWARDS 4 is a 26-week trial comparing once-weekly insulin icodec with once-daily insulin degludec, both in combination with mealtime insulin. The objective of the trial is to assess the efficacy and safety of insulin icodec in 582 people with type 2 diabetes treated with basal and bolus insulin. ONWARDS 5 is a 52-week trial comparing once-weekly insulin icodec with once-daily basal insulin. The objective of the trial is to assess the effectiveness and safety of insulin icodec, with an app providing dosing recommendation, in 1085 insulin-naïve people with type 2 diabetes in a clinical practice setting. ONWARDS 6 is a 52-week trial comparing once-weekly insulin icodec with once-daily insulin degludec, both in combination with mealtime insulin. The objective of the trial is to assess the efficacy and safety of insulin icodec in 583 people with type 1 diabetes. About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube Further information Company announcement No 32 / 2022  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=112839,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
7,2022-04-27,Novo Nordisk A/S – Reduction of the share capital,"Bagsværd, Denmark, 27 April 2022 – At Novo Nordisk’s Annual General Meeting on 24 March 2022, it was decided to reduce the company’s B share capital from DKK 354,512,800 to DKK 348,512,800 by cancellation of part of the company’s portfolio of own B shares equal to a nominal value of DKK 6,000,000 divided into 30,000,000 B shares of DKK 0.20 each. Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled B shares at a nominal value of DKK 6,000,000. After the reduction of the share capital, the company’s share capital is nominally DKK 456,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 348,512,800. The reduction of the share capital will not affect Novo Nordisk’s share repurchase programme which will continue as previously announced. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, and YouTube. Further information Company announcement No 31 /2022  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=112683,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
8,2022-03-28,Ozempic® 2.0 mg approved in the US for the treatment of type 2 diabetes,"Bagsværd, Denmark, 28 March 2022 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a 2.0 mg dose of Ozempic® (once-weekly semaglutide subcutaneous injection), a glucagon-like peptide-1 (GLP-1) analogue for the treatment of adults with type 2 diabetes. Ozempic® is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the treatment of type 2 diabetes in adults. Further, Ozempic® is indicated to reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes and known heart disease. The FDA approval is based on the results from the SUSTAIN FORTE trial. In the trial, people treated with semaglutide 2.0 mg achieved a statistically significant and superior reduction in HbA1c at week 40 compared to semaglutide 1.0 mg. In the trial, both doses of semaglutide appeared to have a safe and well-tolerated profile. The most common adverse events were gastrointestinal. Compared to semaglutide 1.0 mg, the gastrointestinal adverse events were similar for semaglutide 2.0 mg. “We are pleased with the FDA approval for a higher 2.0 mg dose of Ozempic®, which further supports our purpose of driving change in diabetes care” said Martin Lange, executive vice president, Development at Novo Nordisk. “The approval of the 2.0 mg dose allows more people with type 2 diabetes to achieve and maintain individualised glycaemic targets and remain on the same medication for longer as their needs evolve.” Novo Nordisk expects to launch Ozempic® 2.0 mg in the United States in the second quarter of 2022. Ozempic® 2.0 mg is now approved in the US, the EU, Canada and Switzerland. About the SUSTAIN clinical programme The SUSTAIN clinical development programme for once-weekly subcutaneous semaglutide injection currently comprises 11 phase 3 global clinical trials, including a cardiovascular outcomes trial, involving more than 11,000 adults with type 2 diabetes. For more information about the SUSTAIN FORTE trial, please read the headline results here. About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube. Further information Company announcement No 27 / 2022  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=108096,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
9,2022-03-24,Resolutions from the Annual General Meeting of Novo Nordisk A/S,"Bagsværd, Denmark, 24 March 2022 - Today, Novo Nordisk A/S held its Annual General Meeting. At the Annual General Meeting, Helge Lund, chair of the Board of Directors communicated: “Novo Nordisk made good progress in the past year and exceeded expectations with strong financial performance. We broadened our technology platforms and product pipeline to strengthen the basis for long-term growth, whilst investing significantly in expanding our future production capacity. Our long-standing aspiration of creating value for society is more relevant than ever, and we continue to serve more patients in need around the world in line with our purpose of driving change in diabetes and other serious chronic disease.” Resolutions adopted at the Annual General MeetingFinancial year 2021 and board remuneration Elections Shares and capital Other The meeting was held as a partially electronic meeting enabling shareholders to participate either in person or virtually. The shareholders had been encouraged to exercise their rights by submitting proxies or votes by correspondence in advance of the Annual General Meeting. Composition of the Board of Directors and its committeesIn February 2022, Novo Nordisk employees in Denmark elected four board members, Elisabeth Dahl Christensen, Liselotte Hyveled, Mette Bøjer Jensen and Thomas Rantzau for a period of four years following the Annual General Meeting 2022. After the Annual General Meeting, the Board of Directors held a board meeting to appoint members of its committees. The Board of Directors, including its committees, is now composed as follows: Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Company announcement No 25 / 2022  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=107473,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
10,2022-03-14,Novo Nordisk – major shareholder announcement,"Bagsværd, Denmark, 14 March 2022 – Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 8 March 2022 holds B shares equal to below 5% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act. The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Danish Capital Markets Act and financial instruments with similar effects according to section 39(2)(2) of the Danish Capital Markets Act held by Blackrock correspond to below 5% of the entire share capital and below 5% of the voting rights. For a full chain of controlled undertakings through which the voting rights and/or the financial instruments are held, please see the annex. About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). Further information Company announcement No 23 / 2022 Annex  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=105891,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
11,2022-03-09,Novo Nordisk expands research collaboration in novel delivery technologies for biologic medicines,"Bagsværd, Denmark, 9 March 2022 – Novo Nordisk today announced the expansion of its existing research collaboration in oral drug delivery technologies with the Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital (BWH). Since 2015, scientists from Novo Nordisk and the laboratories of Prof. Giovanni Traverso and Prof. Robert Langer have explored novel technologies as alternatives to syringes and pen injectors, by co-creating new devices that safely and effectively deliver biologic medicines through oral administration. This collaboration has resulted in several high-impact scientific publications describing breakthrough inventions, including the SOMA robotic pill, which has subsequently been licensed exclusively to Novo Nordisk for clinical development. “Working with the Langer and Traverso teams continues to be a unique opportunity for Novo Nordisk to live out our aspiration of bringing transformational new solutions to patients by thinking big, working with the best, and using our distinct capabilities to aim to achieve what might otherwise seem impossible,” said Marcus Schindler, PhD, professor, executive vice president and chief scientific officer of Novo Nordisk. The new agreement extends the collaboration through 2026, expanding the scope to encompass the creation and integration of bioelectronics, biosensors and stimuli-responsive delivery devices. “We continue to explore the immense potential for enhanced delivery of biologic drugs and stem cell-derived therapeutics through the platforms we are developing,” said Giovanni Traverso, the Karl van Tassel, Career Development Assistant Professor of Mechanical Engineering at MIT and a gastroenterologist at Brigham and Women’s Hospital, Harvard Medical School. “Our group at MIT strives to combine engineering and medicine to solve important problems and find the best ways to get those solutions to the people who need them,” added Robert Langer, David H. Koch Institute Professor at MIT. “Our work together with Novo Nordisk has shown that they share this vision, and we are thrilled to expand into this ambitious new program together”. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube. Further information   Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=105110,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
12,2022-03-04,Novo Nordisk – major shareholder announcement,"Bagsværd, Denmark, 4 March 2022 – Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 28 February 2022 holds B shares equal to 5.03% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act. The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Danish Capital Markets Act and financial instruments with similar effects according to section 39(2)(2) of the Danish Capital Markets Act held by Blackrock correspond to 5.04% of the entire share capital and below 5% of the voting rights. For a full chain of controlled undertakings through which the voting rights and/or the financial instruments are held, please see the annex. About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). Further information Company announcement No 20 / 2022 Annex  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=104312,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
13,2022-03-03,Highlights to be presented at Novo Nordisk’s Capital Markets Day 2022,"Bagsværd, Denmark, 3 March 2022 – Novo Nordisk is today hosting a Capital Markets Day (CMD) where the company is providing a progress update on its Strategic Aspirations 2025. The Strategic Aspirations 2025 were introduced in 2019 to reflect the broad aspects of Novo Nordisk’s business including purpose and sustainability (ESG), the sustained growth opportunities until 2025 across therapy areas and geographies as well as future growth drivers of Novo Nordisk in the research and development pipeline. The day will be centred around the Strategic Aspirations and during the day, senior management presentations will cover corporate strategy and research and early development strategy, Environmental, Social and Governance (ESG) strategies and performance as well as commercial strategies, research and development pipeline and performance within Diabetes care, Obesity care and Biopharm, which is renamed to Rare Disease. In addition, Novo Nordisk’s approach to cardiovascular disease, product supply and financials are presented. The CMD will also include break-out sessions covering technology platforms, Non-alcoholic steatohepatitis (NASH) and Alzheimer’s Disease (AD) and Region EMEA. Key highlights of the day are: All sessions of the CMD are webcasted live, and a replay will be made available on the investor section of novonordisk.com. Presentation material from the CMD will also be available throughout the day on the investor section of novonordisk.com. About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). Further information Company announcement No 19 / 2022  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=104130,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
14,2022-02-28,Election of employee representatives to the Board of Directors of Novo Nordisk A/S,"Bagsværd, Denmark, 28 February 2022 – The employees in Novo Nordisk A/S have completed the election of employee representatives to the Board of Directors of Novo Nordisk A/S. The following were elected for the next four years: As substitutes for the employee-elected board members, the following were elected: The new employee-elected board members will join the Board of Directors following the annual general meeting of Novo Nordisk A/S on 24 March 2022. At the same time the current board members Anne Marie Kverneland, who did not run for election, and Stig Strøbæk, who was not re-elected, will resign. About employee-elected board membersAccording to the Danish Companies Act, the employees of Novo Nordisk A/S are entitled to be represented by half of the total shareholder-elected Board members. Employee-elected board members serve for a statutory four-year term and have the same rights, duties and responsibilities as shareholder-elected board members. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube. Further information Company announcement No 18 / 2022  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=103635,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
15,2022-02-21,Novo Nordisk – major shareholder announcement,"Bagsværd, Denmark, 21 February 2022 – Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) as follows: Blackrock holds as of 15 February 2022 B shares equal to 4.98% of the entire share capital of Novo Nordisk. The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Danish Capital Markets Act and financial instruments with similar effects according to section 39(2)(2) of the Danish Capital Markets Act held by Blackrock correspond to 5.00% of the entire share capital and below 5% of the voting rights. Blackrock holds as of 16 February 2022 B shares below 5% of the entire share capital of Novo Nordisk. The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Danish Capital Markets Act and financial instruments with similar effects according to section 39(2)(2) of the Danish Capital Markets Act held by Blackrock correspond to below 5% of the entire share capital and below 5% of the voting rights. This announcement is in accordance with section 30 of the Danish Capital Markets Act. For a full chain of controlled undertakings through which the voting rights and/or the financial instruments are held, please see the annexes. About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). Further information Company announcement No 16 / 2022 Annex 1: Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity as of 15 February 2022 Annex 2: Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity as of 16 February 2022  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=102484,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
16,2022-02-21,Notice for the Annual General Meeting of Novo Nordisk A/S,"Bagsværd, Denmark, 21 February 2022 – The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 24 March 2022 at 14.00 (CET) The Annual General Meeting is held as a partially electronic general meeting. Accordingly, shareholders can choose between participating in person at Bella Center, Center Boulevard 5, DK-2300 Copenhagen S, Denmark or participating virtually via an IT application. We encourage shareholders to exercise their rights by submitting proxies or votes by correspondence in advance of the Annual General Meeting. Also, Novo Nordisk offers the possibility of viewing the Annual General Meeting via live webcast on Novo Nordisk’s website. Please refer to the notice for further information. The notice for the Annual General Meeting, including Appendix: Candidates for the Board of Directors, is enclosed. BOARD OF DIRECTORS All Board members elected by the Annual General Meeting are up for election. The Board of Directors proposes re-election of Helge Lund as chair of the Board. Jeppe Christiansen has decided to seek election as Board member and consequently not to seek re-election as vice chair. The Board proposes current member of the Board Henrik Poulsen as vice chair, primarily because of his extensive executive and board experience in large international companies, significant financial knowledge and in-depth knowledge of business development, strategy, transformation, innovation, mergers and acquisitions as well as ESG. The nomination of Henrik Poulsen is a part of a planned succession process in relation to the vice chair position. The Board proposes re-election of the following Board members: Jeppe Christiansen, Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Kasim Kutay and Martin Mackay as members of the Board. The Board proposes election of Christina Law as a new member of the Board. Christina Law serves as Group CEO and member of the boards of Raintree Group Limited, Hong Kong, China, Raintree Investment Pte Ltd., Singapore, and La Fondation des Champions, France, as well as member of the board of INSEAD Business School, Singapore/France. The Board of Directors proposes election of Christina Law primarily as she will add important perspectives to the Novo Nordisk Board through her deep leadership experience in Asia and other emerging markets, broad consumer sector innovation experience, as well as extensive executive experience from several large global companies. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information  Company announcement No 15/ 2022 Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=102482,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
17,2022-02-14,Novo Nordisk – major shareholder announcement,"Bagsværd, Denmark, 14 February 2022 – Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 8 February 2022 holds B shares equal to 5.05% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act. The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Danish Capital Markets Act and financial instruments with similar effects according to section 39(2)(2) of the Danish Capital Markets Act held by Blackrock correspond to 5.07% of the entire share capital and below 5% of the voting rights. For a full chain of controlled undertakings through which the voting rights and/or the financial instruments are held, please see the annex. About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). Further information Company announcement No 12 / 2022 Annex  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=101349,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
18,2022-02-02,Novo Nordisk files annual report with the SEC,"Bagsværd, Denmark, 2 February 2022 – Novo Nordisk A/S has filed its Annual Report 2021 on Form 20-F for the financial year 2021 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2021. The reports are available at the SEC's website, www.sec.gov, as well as on novonordisk.com. Shareholders may receive a hardcopy of Novo Nordisk’s completed audited financial statements free of charge upon request to kasq@novonordisk.com. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). Further information   Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=99428,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
19,2022-02-02,Novo Nordisk's sales increased by 11% in Danish kroner and by 14% at constant exchange rates to DKK 140.8 billion in 2021,"Financial report for the period 1 January 2021 to 31 December 2021 * CER: Constant exchange rates (average 2020). Lars Fruergaard Jørgensen, president and CEO: ""We are very pleased with the double-digit sales growth in 2021 and the progress we have made on our Strategic Aspirations. The results reflect that almost 35 million people with diabetes are now benefiting from our treatments worldwide. In obesity, we are making progress in resolving the Wegovy® supply issue and we expect to be able to meet demand from people living with obesity in the US in the second half of 2022"". On 2 February 2022 at 13.00 CET, corresponding to 07.00 am EST, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’. About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.  Company announcement No 7 /2022   Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=99413,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
20,2022-01-14,Novo Nordisk announces settlement of securities lawsuit in Denmark,"Bagsværd, Denmark, 14 January 2022 – Novo Nordisk today announced that the company has settled a securities lawsuit in Denmark filed in August 2019. The settlement contains no admission of liability, wrongdoing or responsibility by Novo Nordisk and no payment will be made by Novo Nordisk to the plaintiffs. The lawsuit was filed by a number of shareholders and alleged that Novo Nordisk had made misleading statements and did not make appropriate disclosures regarding its sales of insulin products in the US. The original claim was for a total amount of DKK 11,785,192,218. About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). Further information Company announcement No 2 /2022  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=96392,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
21,2021-12-28,Novo Nordisk announces completion of Dicerna Pharmaceuticals acquisition,"Bagsværd, Denmark, 28 December 2021 – Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals (Dicerna), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstanding shares of common stock of Dicerna at a price of USD 38.25 per share in cash, without interest and less any applicable tax withholding. Novo Nordisk has been advised by the depositary for the tender offer that a total of approximately 64,946,526 shares of Dicerna’s common stock were validly tendered and not validly withdrawn in the tender offer as of the tender offer expiration at 5.00 pm EST on 27 December 2021, which represent approximately 82.6% of the total number of shares of Dicerna’s common stock outstanding. Following the finalisation of the tender offer, Novo Nordisk completed the acquisition of Dicerna today through a merger of Novo Nordisk’s wholly owned subsidiary with and into Dicerna in which all shares not tendered into the offer were cancelled and converted into the right to receive cash equal to the USD 38.25 offer price per share, without interest, less any applicable tax withholding. At the completion of the merger, Dicerna became a wholly owned subsidiary of Novo Nordisk. The common stock of Dicerna will no longer be listed or traded on the Nasdaq Global Select Market. About the acquisition For more information, please see: Novo Nordisk to acquire Dicerna Pharmaceuticals including the RNAi research technology platform About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube. Further information  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=93736,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
22,2021-12-17,Novo Nordisk announces supply challenges for Wegovy® in the US,"Bagsværd, Denmark, 17 December 2021 – Novo Nordisk today announced that a contract manufacturer filling syringes for Wegovy® pens for the US market has temporarily stopped deliveries and manufacturing following issues with Good Manufacturing Practices. As a consequence, Novo Nordisk does not expect to be able to meet demand in the US in the first half of 2022 and few new patients are expected to be able to initiate treatment. The priority for Novo Nordisk is patients who have already initiated treatment with Wegovy®. Novo Nordisk currently expects to be able to meet demand in the US in the second half of 2022. The supply challenges will not impact the previously communicated financial outlook for 2021. Novo Nordisk will provide the financial outlook for 2022 in connection with the announcement of the full-year 2021 results on 2 February 2022. Conference callOn 20 December at 8.30 am CET, corresponding to 2.30 am EST, a conference call for investors will be held where members of management will elaborate on the issue. Investors will be able to listen in via a link on the investor section of novonordisk.com About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). Further information Company announcement No 80 /2021  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=92023,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
23,2021-12-13,"Novo Nordisk invests more than DKK 17 bn in expansion of the manufacturing facilities in Kalundborg, Denmark","December 13, 2021 - Novo Nordisk today announced plans to invest more than 17 bn Danish kroner in construction of three new manufacturing facilities as well as expansion of one existing facility at its production site in Kalundborg, Denmark.​ The investment will establish additional capacity across the entire global value chain from manufacturing of active pharmaceutical ingredients (API) to assembly and packaging, with the vast majority being invested in API capacity. These expansions will provide capacity for the production of Novo Nordisk’s current and future oral and injectable products.​ The new facilities will be automated and include state-of-the-art production technologies. “This major investment in our manufacturing facilities in Kalundborg is an important step in building and ensuring future capacity for production of our current and future oral and injectable product portfolio. Kalundborg is currently the cornerstone in our production of API and the expansion of the manufacturing capacity is important to meeting the future demands of patients. The investment announced today emphasises our continued commitment to Denmark and Kalundborg being at the heart of our global manufacturing setup”, said Henrik Wulff, EVP, Product Supply, Quality & IT, Novo Nordisk. ​ The investment projects are expected to be finalised in 2027 and will create around 400 new jobs. More than 2,500 external staff will be engaged in the building phase. ​ Facts about Novo Nordisk manufacturing in Kalundborg​Novo Nordisk's production facilities in Kalundborg were established in 1969. Today, the facilities cover an area of 1,200,000 m2 and employ about 3,200 people. In Kalundborg, Novo Nordisk manufactures products for the treatment of obesity and diabetes as well as several biopharmaceutical products. Since the turn of the millennium and until today, Novo Nordisk has invested more than 18 bn Danish kroner in the production facilities in Kalundborg. The investment announced today almost doubles 20 years of investments. Visit novonordisk.com for photos and b-roll supporting this press release. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube. Further information   Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=91381,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
24,2021-12-13,Novo Nordisk investerer mere end 17 mia. kr. i udbygning af produktionsfaciliteterne i Kalundborg,"13. december 2021 - Novo Nordisk annoncerer i dag planer om at investere mere end 17 mia. kr. i opførelsen af tre nye produktionsanlæg samt udvidelse af et eksisterende anlæg på produktionsanlægget i Kalundborg. Investeringen vil etablere yderligere kapacitet på tværs af hele den globale værdikæde fra fremstilling af aktive farmaceutiske ingredienser (API) til samling og emballering, hvor langt de fleste investeres i API-kapacitet. Disse udvidelser vil give kapacitet til produktion af Novo Nordisks nuværende og fremtidige orale og injicerbare produkter. De nye faciliteter vil blive automatiserede og omfatte de nyeste produktionsteknologier. ""Denne betydelige investering i vores produktionsfaciliteter i Kalundborg er et vigtigt skridt i opbygningen og sikringen af fremtidig kapacitet til produktion af vores nuværende og fremtidige orale og injicerbare produktportefølje. Kalundborg er i øjeblikket hjørnestenen i vores produktion af API, og udvidelsen af produktionskapaciteten er vigtig for at imødekomme patienternes fremtidige krav. Den investering, vi annoncerer i dag, understreger vores fortsatte engagement i, at Danmark og Kalundborg er kernen i vores globale produktionsopsætning"", siger Henrik Wulff, EVP, Product Supply, Quality & IT, Novo Nordisk. Investeringsprojekterne forventes afsluttet i 2027 og vil skabe omkring 400 nye arbejdspladser. Flere end 2.500 eksterne personer vil blive beskæftiget i byggefasen. Fakta om Novo Nordisks produktion i KalundborgNovo Nordisks produktionsfaciliteter i Kalundborg blev grundlagt i 1969. I dag dækker faciliteterne et areal på 1.200.000 m2 og beskæftiger omkring 3.200 mennesker. I Kalundborg producerer Novo Nordisk produkter til behandling af svær overvægt og diabetes samt flere biofarmaceutiske produkter. Siden årtusindskiftet og frem til i dag har Novo Nordisk investeret mere end 18 milliarder kroner i produktionsfaciliteterne i Kalundborg. Den investering, der annonceres i dag, fordobler næsten 20 års investeringer. Billeder og dækbilleder kan downloades fra novonordisk.com. Yderligere information  Vedhæftet fil",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=91382,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
25,2021-11-26,Novo Nordisk announces impact from Volume Based Procurement for insulin in China,"Bagsværd, Denmark, 26 November 2021 – Novo Nordisk today announced that the company has received the results from the Volume Based Procurement (VBP) tender for insulin in China. The Chinese National Healthcare Security Administration has tendered insulin sold at hospitals, and Novo Nordisk has participated in the tender. All Novo Nordisk’s insulin were included in the tender except for Ryzodeg® and Xultophy®. Novo Nordisk currently expects an estimated negative impact on global sales growth of around 3% in 2022 as a result of reduced prices and reduced volumes of insulin sold in China. The VBP for insulin is expected to be implemented during the first half of 2022. Novo Nordisk will provide the financial outlook for 2022 in connection with the announcement of the full-year 2021 results on 2 February 2022. About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). Further information Company announcement No 76 / 2021  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=88703,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
26,2021-11-18,Novo Nordisk to acquire Dicerna Pharmaceuticals including the RNAi research technology platform,"Bagsværd, Denmark, 18 November 2021 – Novo Nordisk today announced that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals (Dicerna). The acquisition of Dicerna’s ribonucleic acid interference (RNAi) platform is a strategic addition to Novo Nordisk’s existing research technology platforms and supports the strategy of using a broad range of technology platforms applicable across all Novo Nordisk’s therapeutic focus areas. Dicerna is a publicly held company focusing on RNAi-based therapeutics. Using its proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease. Dicerna’s RNAi technology platform enables access to intracellular disease targets across hepatic and extrahepatic cell and tissue types. In 2019, Novo Nordisk entered a research collaboration with Dicerna to discover and develop RNAi therapies using Dicerna’s proprietary GalXC™ RNAi platform technology. The collaboration between Novo Nordisk and Dicerna encompassed the exploration of more than 30 liver cell targets with the potential to deliver multiple clinical candidates for disorders including non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases. Novo Nordisk expects to initiate clinical development with the first target in 2022. Under the terms of the agreement, Novo Nordisk will commence a cash tender offer to acquire all outstanding shares of Dicerna common stock for USD 38.25 per share in cash for a total equity value of approximately USD 3.3 billion. The transaction will not impact Novo Nordisk’s previously communicated operating profit outlook for 2021 or the ongoing share buyback programme. The transaction will mainly be debt financed.The acquisition will lead to an increase in research and development costs, with an estimated negative impact on operating profit growth in 2022 of around 3% due to higher operating costs and amortisations of intangible assets. “The acquisition of Dicerna accelerates Novo Nordisk’s research within RNAi and expands the usage of the RNAi technology,” said Marcus Schindler, PhD, professor, executive vice president and chief scientific officer of Novo Nordisk. “We build on our successful collaboration and by combining Dicerna’s state-of-the-art RNAi drug engine and intracellular delivery with our deep capabilities in disease biology understanding and tissue targeting through peptides and proteins we have the potential to expand our pipeline and deliver life-changing precision medicines for people living with chronic diseases such as diabetes, obesity, cardiovascular disease and NASH as well as rare diseases like endocrine disorders and bleeding disorders”. “Since the start of our collaboration two years ago, the Dicerna and Novo Nordisk teams have established a strong rapport built on a foundation of mutual respect for one another’s capabilities, culture and expertise,” said Douglas Fambrough, PhD, founder, president and chief executive officer of Dicerna. “The combination of Dicerna’s expertise in RNAi and oligonucleotide therapeutics and highly skilled employees with Novo Nordisk’s industry leadership in developing and commercialising medicines to treat serious chronic diseases, has the potential to significantly accelerate and expand our mission to deliver GalXC RNAi therapies for the benefit of patients and all our stakeholders”. Under the terms of the acquisition agreement, Novo Nordisk will initiate a tender offer to acquire all outstanding shares of Dicerna. The closing of the tender offer will be subject to certain conditions, including the tender of shares representing a majority of Dicerna’s outstanding shares, receipt of applicable regulatory approvals and other customary conditions. Upon the successful completion of the tender offer, Novo Nordisk’s acquisition subsidiary will merge into Dicerna, and any shares of common stock of Dicerna not tendered into the offer will receive the same USD per share price payable in the tender offer. The transaction is expected to close in the fourth quarter of 2021. Novo Nordisk is represented by Evercore as financial advisor and Davis Polk & Wardwell LLP as legal advisor. About DicernaDicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) is a biopharmaceutical company focused on discovering, developing and commercialising medicines that are designed to leverage RNAi to silence selectively genes that cause or contribute to disease. Using the proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. In addition to the internal pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world’s leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and the collaborative partners, the company currently has more than 20 active discovery, preclinical or clinical programmes focused on cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain. Dicerna is headquartered in Lexington, Massachusetts, and employs around 320 people. For more information, please visit www.dicerna.com About RNAi and the GalXC platform        By silencing disease-causing genes, the GalXC platform has the potential to address conditions that are difficult to treat with other modalities like peptides, proteins or monoclonal antibodies. Instead of targeting proteins after they have been produced and released, RNAi silences the genes themselves via the specific degradation of the messenger RNA (mRNA) made from the gene. Rather than seeking to inhibit a protein, the RNAi approach can prevent a disease causingprotein’s creation, directly impacting disease manifestation. Initially focused on disease-causing genes in the liver, Dicerna has continued to innovate and is exploring new applications of its RNAi technology with GalXC-Plus. GalXC-Plus expands the functionality of the platform to extrahepatic cell and tissue types, significantly expanding the platform’s potential to treat diseases across multiple therapeutic areas with an origin outside of the liver. About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube. Further information Forward looking statementsThis communication related to Novo Nordisk, Dicerna and the acquisition of Dicerna by Novo Nordisk, as well as Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the company’s statutory Annual Report 2020 and Form 20-F both filed with the SEC in February 2021 in continuation of the publication of the Annual Report 2020, and written information released, or oral statements made, to the public in the future by or on behalf of Novo Nordisk, may contain forward-looking statements. Words such as ‘believe’, ‘expect’, ‘may’, ‘will’, ‘plan’, ‘strategy’, ‘prospect’, ‘foresee’, ‘estimate’, ‘project’, ‘anticipate’, ‘can’, ‘intend’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance identify forward-looking statements. Examples of such forward-looking statements include, but are not limited to: These statements are based on current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. Novo Nordisk cautions that a number of important factors, including those described in this document, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results include, but are not limited to, uncertainties as to the timing of the tender offer and merger, uncertainties as to how many of Dicerna’s stockholders will tender their stock in the offer; the possibility that competing offers will be made; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the effects of the transaction on relationships with employees, other business partners or governmental entities; the difficulty of predicting the timing or outcome of regulatory approvals or actions, if any, global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations, delay or failure of projects related to research and/or development, unplanned loss of patents, interruptions of supplies and production, product recalls, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Novo Nordisk’s products, introduction of competing products, reliance on information technology, Novo Nordisk’s ability to successfully market current and new products, exposure to product liability and legal proceedings and investigations, changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing and marketing, perceived or actual failure to adhere to ethical marketing practices, investments in and divestitures of domestic and foreign companies, unexpected growth in costs and expenses, failure to recruit and retain the right employees, failure to maintain a culture of compliance and epidemics, pandemics or other public health crises. For an overview of some, but not all, of the risks that could adversely affect future results or the accuracy of forward-looking statements in this document, reference is made to the overview of risk factors in ‘Risk Management’ of the Annual Report 2020. Unless required by law, Novo Nordisk is under no duty and undertakes no obligation to update or revise any forward-looking statement after the distribution of this document, whether as a result of new information, future events or otherwise. Additional information and where to find it The tender offer described in this document has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of Dicerna, nor is it a substitute for any tender offer materials that Novo Nordisk or Dicerna will file with the SEC. A solicitation and an offer to buy shares of Dicerna will be made only pursuant to an offer to purchase and related materials that Novo Nordisk intends to file with the SEC. At the time the tender offer is commenced, Novo Nordisk will file a Tender Offer Statement on Schedule TO with the SEC, and Dicerna will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. DICERNA’S STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO READ THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION WHICH SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be sent to all stockholders of Dicerna at no expense to them. The Tender Offer Statement and the Solicitation/Recommendation Statement will be made available for free at the SEC’s web site at www.sec.gov. Additional copies may be obtained for free by contacting Novo Nordisk or Dicerna. Free copies of these materials and certain other offering documents will be made available by Novo Nordisk on Novo Nordisk’s internet website at www.novonordisk.com/investors or by contacting Novo Nordisk’s Investor Relations Department at listed above, or by directing requests for such materials to the information agent for the offer, which will be named in the Tender Offer Statement. Copies of the documents filed with the SEC by Dicerna will be available free of charge under the “Investors” section of Dicerna’s internet website at www.dicerna.com. In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Novo Nordisk and Dicerna file annual, quarterly and current reports and other information with the SEC. Novo Nordisk’s and Dicerna’s filings with the SEC are also available for free to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.   Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=87435,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
27,2021-11-12,Ozempic® 2.0 mg recommended for approval for the treatment of type 2 diabetes by the European Medicines Agency,"Bagsværd, Denmark, 12 November 2021 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a label extension for the existing marketing authorisation for Ozempic®, a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2.0 mg. Ozempic® is currently approved in the EU in 0.5 mg and 1.0 mg doses for the treatment of type 2 diabetes in adults. The positive opinion is based on the results from the SUSTAIN FORTE trial. In the trial, people treated with semaglutide 2.0 mg achieved a statistically significant and superior reduction in HbA1c at week 40 compared to semaglutide 1.0 mg. In the trial, both doses of semaglutide appeared to have a safe and well-tolerated profile. The most common adverse events were gastrointestinal. “The recommendation for the EU label extension of Ozempic® with the 2.0 mg dose is an important step towards offering additional options to people with type 2 diabetes who need treatment intensification to achieve their individualised glycaemic targets,” said Martin Lange, executive vice president, Development at Novo Nordisk. Novo Nordisk expects a final approval by the European Commission within approximately two months, and Ozempic® 2.0 mg will be launched in the EU in the first half of 2022. The label expansion for semaglutide 2.0 mg is under regulatory review in the US. About the SUSTAIN clinical programme The SUSTAIN clinical development programme for once-weekly subcutaneous semaglutide injection currently comprises 11 phase 3 global clinical trials, including a cardiovascular outcomes trial, involving more than 11,000 adults with type 2 diabetes. For more information about the SUSTAIN Forte trial, please read the headline results here. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube. Further information Company announcement No 73 / 2021  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=86489,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
28,2021-11-11,Wegovy™ recommended for approval for the treatment of obesity by the European regulatory authorities,"Bagsværd, Denmark, 11 November 2021 – Novo Nordisk today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorisation for Wegovy™ for chronic weight management in adults with obesity. Wegovy™ is a once-weekly semaglutide 2.4 mg injection for chronic weight management in adults living with obesity (initial BMI≥30 kg/m2) or overweight (initial BMI≥27 kg/m2) with at least one weight-related comorbidity such as high blood pressure, heart disease or type 2 diabetes. The positive CHMP opinion is based on results from the STEP phase 3a clinical trial programme. Across the trials in people with obesity or overweight without type 2 diabetes, an average weight loss of 17-18%1 sustained over 68 weeks was reported for those treated with Wegovy™. Wegovy™ demonstrated a safe and well-tolerated profile across the programme, with the most common adverse events being gastrointestinal. “With the unprecedented and sustained weight loss for an anti-obesity medication, Wegovy™ has the potential to transform obesity management and help millions of people living with obesity,” said Martin Holst Lange, executive vice president, Development at Novo Nordisk. “We are looking forward to driving change for people with obesity by introducing Wegovy™ in Europe next year.” Novo Nordisk expects to receive final marketing authorisation from the European Commission in approximately two months. Wegovy™ was launched in the US in June 2021 following approval by the U.S. Food and Drug Administration (FDA). In September 2021, Wegovy™ was approved by the UK Medicines and Health products Regulations Agency (MHRA). Novo Nordisk expects to launch Wegovy™ in Europe in the second half of 2022. About obesity Obesity is a chronic disease that requires long-term management. It is associated with many serious health complications and decreased life expectancy. Obesity-related complications are numerous and include type 2 diabetes, heart disease, obstructive sleep apnoea, non-alcoholic fatty liver disease and certain types of cancer. The current COVID-19 pandemic has highlighted that obesity also increases the risk of severe illness and hospitalisation due to COVID-19. The global increase in the prevalence of obesity is a public health issue that has severe cost implications to healthcare systems. Approximately 650 million adults are estimated to live with obesity worldwide and specifically 53% of the adults living in the EU are considered to be living with overweight. About Wegovy™ (semaglutide 2.4 mg) and STEPSemaglutide 2.4 mg is an analogue of the human glucagon-like peptide-1 (GLP-1) hormone. It induces weight loss by reducing hunger, increasing feeling of fullness and thereby helping people eat less and reduce their calorie intake. Once-weekly semaglutide 2.4 mg injection is approved for the treatment of adults with obesity or overweight in the US and UK, as an adjunct to diet and exercise. The approval is based on the results from the STEP (Semaglutide Treatment Effect in People with obesity) phase 3 clinical development programme. The global clinical phase 3a programme consists of four trials and enrolled approximately 4,500 adults with overweight or obesity. About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube Further information Company Announcement No 72 / 2021 1 Based on the trial product estimand (secondary statistical approach): treatment effect if all people adhered to treatment and did not initiate other anti-obesity therapies. When using a treatment policy estimand, 15-17% weight loss was reported.  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=86334,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
29,2021-11-03,Novo Nordisk's net profit increased by 12% in the first nine months of 2021,"Financial report for the period 1 January 2021 to 30 September 2021 3 November 2021 Novo Nordisk's net profit increased by 12% in the first nine months of 2021 * CER: Constant exchange rates (average 2020). Lars Fruergaard Jørgensen, president and CEO: ""We are very pleased with the sales growth in the first nine months of 2021 which has enabled us to raise our outlook for the full year. The growth is driven by all geographical areas and by all therapy areas, in particular by accelerated growth of our portfolio of GLP-1 treatments for diabetes and obesity. In the US, the initial demand for Wegovy™ has significantly exceeded our expectations, underscoring the high unmet need for people living with obesity. With the initiation of two phase 3 programmes in the third quarter, we continue to expand our late-stage clinical pipeline."" On 3 November 2021 at 13.00 CET, corresponding to 08.00 AM EDT, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’. About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.  Further information about Novo Nordisk is available on novonordisk.com. Company announcement No 66 / 2021  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=85057,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
30,2021-10-29,Novo Nordisk raises sales and operating profit outlook for 2021,"Bagsværd, Denmark, 29 October 2021 – Novo Nordisk today announced that the full-year sales and operating profit outlook at constant exchange rates (CER) has been raised. In the third quarter of 2021, Novo Nordisk’s sales increased by 15% and operating profit increased by 19%, both at CER. The operating profit increase was positively impacted by the amortisation of the priority review voucher for Wegovy™ in the third quarter of 2020. Following the financial results for the first nine months of 2021, the outlook for 2021 is updated. The updated outlook is reflecting higher than expected Ozempic® market share gains, GLP-1 market growth and obesity care sales, mainly in the US. Novo Nordisk’s full disclosure of the financial results for the first nine months of 2021 will be published on 3 November 2021. The above expectations are based on assumptions including those described on pages 16 and 17 of the Financial report for the period 1 January 2021 to 30 June 2021 (Company Announcement No 48 / 2021). The forward-looking statements on page 21 of the Financial report for the period 1 January 2021 to 30 June 2021 (Company Announcement No 48 / 2021) also apply to this company announcement. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Company announcement No 64 / 2021  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=84277,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
31,2021-09-24,Novo Nordisk announces settlement of US securities class action litigation,"Bagsværd, Denmark, 24 September 2021 – Today, Novo Nordisk announced that it has reached an agreement in principle to settle the previously disclosed securities class action litigation pending in the Federal District Court of New Jersey, US. The lawsuit was filed in January 2017 on behalf of purchasers of American Depository Receipts during the class period 3 February 2015 to 2 February 2017 against Novo Nordisk A/S, Lars Rebien Sørensen, Jesper Brandgaard and Jakob Riis. The settlement was reached after a voluntary mediation process and resolves claims brought by plaintiffs for alleged violations of US securities laws. The settlement contains no admission of liability, wrongdoing or responsibility by any of the defendants and will include a full release of all defendants in connection with the allegations made in the lawsuit. Novo Nordisk believes that the plaintiffs’ claims are without any merit, but is settling the lawsuit to avoid the burden, inherent risk and expense of further litigation. Under the terms of the settlement agreement, Novo Nordisk has agreed to pay 100 million US dollars (inclusive of all plaintiffs’ attorneys fees and expenses and settlement costs). The payment, which is covered by insurance, will be made into a settlement fund and distributed among plaintiffs. “At Novo Nordisk, we take our responsibility to our shareholders seriously and remain committed to timely and accurate communication” said Tomas Haagen, General Counsel, Novo Nordisk. “While we are confident in the facts and merits of our position, we believe that resolving this matter is the right business decision for Novo Nordisk and our shareholders.” The settlement is subject to a court approval process, which could take several months. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube. Further information   Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=78734,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
32,2021-08-04,Novo Nordisk's net profit increased by 10% in the first six months of 2021,"4 August 2021 - Financial report for the period 1 January 2021 to 30 June 2021 * CER: Constant exchange rates (average 2020). Lars Fruergaard Jørgensen, president and CEO: ""We are pleased with the sales growth in the first half of 2021. The growth is driven by all geographical areas within International Operations as well as North America Operations, and by all therapy areas, in particular by our portfolio of GLP-1 treatments. Within R&D, we reached a very important milestone with the approval of Wegovy™ in the US, offering people living with obesity a new, efficacious treatment option. The strong financial performance in the first half of 2021 and the initial substantial demand for Wegovy™ in the US have enabled us to raise our outlook for the full year."" On 4 August 2021 at 19.00 CEST, corresponding to 13.00 PM EDT, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’. About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.  Company announcement No 49 / 2021 Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=71008,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
33,2021-08-04,Novo Nordisk's net profit increased by 10% in the first six months of 2021,"4 August 2021 - Financial report for the period 1 January 2021 to 30 June 2021 * CER: Constant exchange rates (average 2020). Lars Fruergaard Jørgensen, president and CEO: ""We are pleased with the sales growth in the first half of 2021. The growth is driven by all geographical areas within International Operations as well as North America Operations, and by all therapy areas, in particular by our portfolio of GLP-1 treatments. Within R&D, we reached a very important milestone with the approval of Wegovy™ in the US, offering people living with obesity a new, efficacious treatment option. The strong financial performance in the first half of 2021 and the initial substantial demand for Wegovy™ in the US have enabled us to raise our outlook for the full year."" On 4 August 2021 at 19.00 CEST, corresponding to 13.00 PM EDT, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’. About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.  Company announcement No 48 / 2021  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=71007,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
34,2021-07-12,Prothena and Novo Nordisk announce acquisition agreement for Prothena’s ATTR amyloidosis programme,"Dublin, Ireland and Bagsværd, Denmark 12 July 2021 – Prothena Corporation plc and Novo Nordisk A/S today announced that the companies have entered into a definitive purchase agreement under which Novo Nordisk has acquired Prothena’s clinical stage antibody PRX004 and broader ATTR amyloidosis programme. PRX004 is a phase 2ready anti-amyloid immunotherapy designed to deplete the amyloid deposits that are associated with the disease pathology of ATTR amyloidosis. ATTR amyloidosis is a rare, progressive and fatal disease characterised by the abnormal build-up of amyloid deposits composed of misfolded transthyretin protein in organs and tissues, most commonly the heart and/or nervous system. Prothena has completed a phase 1 study with PRX004 in patients with hereditary forms of ATTR, in which PRX004 was found to be safe and well tolerated. Novo Nordisk will initially focus on the clinical development of PRX004 in ATTR cardiomyopathy - an underdiagnosed and potentially fatal form of ATTR amyloidosis characterised by build-up of amyloid deposits in cardiac tissue. Under the terms of the definitive purchase agreement, Novo Nordisk acquires Prothena’s wholly-owned subsidiary and gains full worldwide rights to the intellectual property and related rights of Prothena’s ATTR amyloidosis business and pipeline. Prothena is eligible to receive development and sales milestone payments totalling up to 1.2 billion US dollars including 100 million dollars in upfront and near-term clinical milestone payments. “Today’s announcement is consistent with our commitment to create a better future for patients in critical need of new treatment options. We are confident that Novo Nordisk will leverage its extensive expertise in developing treatments for those affected by cardiovascular diseases to advance this promising potential treatment to patients on an expedited timeline,” said Hideki Garren, MD, PhD, chief medical officer of Prothena. “With Novo Nordisk’s commitment to further develop PRX004 in ATTR cardiomyopathy, Prothena will continue to focus on our mission to advance our robust portfolio designed to address rare peripheral amyloid and neurodegenerative diseases. We also wish to extend our sincere thanks and appreciation to all the patients and investigators who participated in the PRX004 phase 1 study.” “With its innovative amyloid-depleting mechanism, PRX004 has the potential to offer a novel treatment option for ATTR cardiomyopathy – an often fatal disease with significant unmet medical need,” said Marcus Schindler, chief scientific officer, EVP Research and Early Development at Novo Nordisk. “This acquisition is a testament to Prothena’s pioneering work in ATTR amyloidosis and Novo Nordisk’s dedication to advancing new disease-modifying therapies for the benefit of people with cardiovascular diseases which are the world’s leading cause of death.” About PRX004PRX004 is an investigational humanised monoclonal antibody designed to deplete amyloid associated with disease pathology that underlies hereditary and wild type ATTR amyloidosis (hATTR and wtATTR, respectively), without affecting the native, normal tetrameric form of the protein. It is generally accepted that at the time of diagnosis, affected organs in ATTR patients contain extracellular amyloid deposits that cause organ dysfunction. PRX004 has been shown in preclinical studies to promote clearance of insoluble amyloid fibrils through antibody-mediated phagocytosis and inhibit amyloid formation. This depleter mechanism of action has the potential to provide benefit for ATTR patients at high risk for early mortality due to amyloid deposition in vital organs. Prothena has completed a Phase 1, open-label, multicenter dose-escalation study (NCT03336580). 21 patients with hereditary ATTR Amyloidosis (hATTR) were enrolled to receive PRX004 intravenously once every 28 days for up to 3 infusions in the dose escalation phase of the study. Patients were enrolled into 1 of the following 6 PRX004 dose cohorts: 0.1, 0.3, 1, 3, 10, and 30 mg/kg. Eligible patients who completed dose-escalation were provided the opportunity to enrol in the long-term extension (LTE) portion of the study. All 21 patients enrolled in the Phase 1 study successfully completed dose-escalation and 17 patients were subsequently enrolled in the LTE. PRX004 was found to be safe and well tolerated across all dose levels. About Prothena Prothena Corporation plc is a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise with the potential to change the course of devastating rare peripheral amyloid and neurodegenerative diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp. About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information   Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=67562,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
35,2021-06-04,"Wegovy™ (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the US","Bagsværd, Denmark, 4 June 2021 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Wegovy™ (the brand name for once-weekly semaglutide 2.4 mg injection in the US) for chronic weight management. Wegovy™ is indicated as an adjunct to diet and exercise for chronic weight management in adults with obesity (initial BMI≥30 kg/m2) or overweight (initial BMI≥27 kg/m2) with at least one weight-related comorbidity. Wegovy™ is the first and only once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist   therapy approved for weight management for people living with obesity. The approval is based on the results from the STEP phase 3a clinical trial programme. Across the trials in people without type 2 diabetes, an average weight loss of 17-18%1 sustained over 68 weeks was reported for people with obesity treated with Wegovy™. Wegovy™ demonstrated a safe and well-tolerated profile across the programme, with the most common adverse events being gastrointestinal. “The approval of Wegovy™ in the US brings great promise to people with obesity. Despite the best efforts to lose weight, many people with obesity struggle to achieve and maintain weight loss due to physiological responses that favour weight regain,” said Martin Holst Lange, executive vice president, Development at Novo Nordisk. “The unprecedented weight loss for an anti-obesity medication marks a new era in the treatment of obesity, and we now look forward to making Wegovy™ available to people living with obesity in the US”. Novo Nordisk expects to launch WegovyTM in the United States later in June 2021. Conference callOn 7 June at 8.30 CEST, corresponding to 2.30 am EDT, a conference call for investors will be held. Investors will be able to listen in via a link on the investor section of novonordisk.com. About obesityObesity is a chronic disease that requires long-term management. It is associated with many serious health complications and decreased life expectancy. Obesity-related complications are numerous and include type 2 diabetes, heart disease, obstructive sleep apnoea, non-alcoholic fatty liver disease and certain types of cancer. The current COVID-19 pandemic has highlighted that obesity also increases the risk for severe illness and hospitalisation due to COVID-19. The global increase in the prevalence of obesity is a public health issue that has severe cost implications to healthcare systems. Approximately 650 million adults are estimated to live with obesity worldwide. About Wegovy™ (semaglutide 2.4 mg) and STEPSemaglutide 2.4 mg is a GLP-1 receptor agonist, with 94% similarity to naturally occurring human GLP-1 hormone. It induces weight loss by reducing hunger, increasing feeling of fullness and thereby helping people eat less and reduce their calorie intake. Once-weekly semaglutide 2.4 mg injection is approved for the treatment of adults with obesity or overweight in the US, in addition to diet and exercise. Semaglutide 2.4 mg for weight management is currently under regulatory review in the EU and other countries. The submissions are based on the results from the STEP (Semaglutide Treatment Effect in People with obesity) phase 3 clinical development programme. The global clinical phase 3a programme consists of four trials and enrolled approximately 4,500 adults with overweight or obesity. About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Company announcement No 38 / 2021 1 Based on the trial product estimand (secondary statistical approach): treatment effect if all people adhered to treatment and did not initiate other anti-obesity therapies. When using a treatment policy estimand, 15-17% weight loss was reported.   Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=62112,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
36,2021-06-01,Heartseed and Novo Nordisk enter into global collaboration and licence agreement for stem cell-based therapy for heart failure,"Bagsværd, Denmark and Tokyo, Japan, 1 June 2021 – Heartseed Inc. and Novo Nordisk A/S today announced that they have entered into an exclusive worldwide collaboration and licence agreement for development, manufacturing and commercialisation of Heartseed’s lead asset HS-001. HS-001 is an investigational cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells (iPSC), which is currently under development by Heartseed for the treatment of heart failure. Heartseed is planning to initiate a phase 1/2 clinical trial in Japan (LAPiS Study) in the second half of 2021 evaluating the safety and efficacy of HS-001 for the treatment of heart failure caused by ischemic heart disease. Japan’s Pharmaceutical and Medical Devices Agency has approved Heartseed’s Clinical Trial Application to carry out the clinical trial. Under the terms of the agreement, Novo Nordisk gains exclusive rights to develop, manufacture and commercialise HS-001 worldwide except in Japan. Heartseed will maintain the rights to solely develop HS-001 in Japan and Novo Nordisk has the rights to co-commercialise the product in Japan with Heartseed with 50/50 profit and cost sharing. Heartseed is eligible to receive payments totalling up to 598 million US dollars including 55 million dollars in upfront and near-term milestone payments. Heartseed is also eligible to receive tiered high single-digit to low double-digit royalties of annual net sales outside of Japan. ""We are delighted to have a company with the expertise and resources of Novo Nordisk as our partner for development and commercialisation of HS-001, and are also honoured that Novo Nordisk has recognised the innovativeness and high potential of our technology,"" said Keiichi Fukuda, CEO of Heartseed. ""We believe that the partnership with Novo Nordisk is very valuable as we seek to disseminate our Japan-origin innovation globally as early as possible."" “Through this important collaboration with Heartseed, we aim to pioneer novel treatment solutions for people with cardiovascular disease. We gain access to an innovative clinical asset, underlying technology and deep expertise within the field of iPSC biology and cardiac cell transplantation, which can be combined with our knowledge and capabilities in stem cell biology and manufacturing,” said Marcus Schindler, chief scientific officer, EVP Research and Early Development at Novo Nordisk. “Novo Nordisk Stem Cell R&D is uniquely placed to accelerate the development of this potential therapy, and this exciting deal fits with our increased focus on cardiovascular disease which is the world’s leading cause of death.” About HS-001Heartseed's lead pipeline, HS-001, is allogeneic iPSC-derived, highly purified ventricular cardiomyocyte spheroids. By forming micro-tissue-like spheroids, retention rate and viability of cell transplant are improved. The spheroids are transplanted using a special administration needle (SEEDPLANTER®) and guide adapter developed for the administration of the spheroids into the myocardial layer of the heart. The expected mechanism of action is that the transplanted cardiomyocytes electrically couple with the patient's myocardium to improve cardiac output by remuscularisation, and secretion of angiogenic factors to form new blood vessels around the transplant site (neovascularisation). The review of the Clinical Trial Application of a phase I/II clinical trial (LAPiS Study) evaluating the safety and efficacy of HS-001 for the treatment of heart failure caused by ischemic heart disease in Japan was successfully completed in March 2021 by Japan's Pharmaceutical and Medical Devices Agency. About HeartseedHeartseed Inc. was founded in 2015 to develop and commercialize cardiac remuscularization therapy developed by Professor Keiichi Fukuda and his group at the Department of Cardiology, Keio University, Tokyo, Japan. Heartseed has proprietary technologies throughout the entire manufacturing process of the cardiomyocyte-cell product, including purification, cell delivery and iPSC production. Heartseed was named “Healthcare Company of the Year 2020” by Healthcare Magazine and “Top 10 Startup in Japan” by Startup City and ""Minister of Science and Technology Policy Award” at Japan Venture Awards 2021. For more information, visit LinkedIn. About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information   Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=61691,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
37,2021-05-28,Novo Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US regulatory approval,"Bagsværd, Denmark, 28 May 2021 – Novo Nordisk today announced the resubmission of a label expansion application to the US Food and Drug Administration (FDA) for the existing marketing authorisation for Ozempic®, a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2.0 mg. The resubmission follows the Refusal to File letter received by the FDA on 22 March 2021. The standard review time by the FDA is 10 months. About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Company announcement No 36 / 2021  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=61134,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
38,2021-05-27,Novo Nordisk successfully prices EUR 1.3 billion notes under its newly established Euro Medium Term Note programme,"NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES. NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO ANY PERSON IN ANY JURISDICTION WHERE RELEASE, PUBLICATION OR DISTRIBUTION TO SUCH PERSON IS RESTRICTED BY ANY LAW OR REGULATION APPLICABLE IN SUCH JURISDICTION. Bagsværd, Denmark, 27 May 2021 - Novo Nordisk today announced the successful launch and pricing of the first Eurobond issuance under its newly established EUR 5 billion Euro Medium Term Note (EMTN) programme in two tranches with an aggregate principal amount of EUR 1.3 billion. The first tranche maturing on 4 June 2024 will be issued in an aggregate principal amount of EUR 650 million with a coupon of 0%. The second tranche maturing on 4 June 2028 will be issued in an aggregate principal amount of EUR 650 million with a coupon of 0.125%. Net proceeds of the issuances will be used by Novo Nordisk for general corporate purposes, including refinancing of the bridge loan facility established in connection with Novo Nordisk’s acquisition of Emisphere Technologies Inc. in 2020. Both bonds will be issued on 4 June 2021 and will be listed on Euronext Dublin. Standard & Poor’s and Moody’s rated the notes at AA- and A1 in line with Novo Nordisk’s company ratings of AA- and A1 with stable outlook. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.   Further information This announcement does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any sale of the Notes in or into any jurisdiction where such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any investment decision made in connection with the Notes MUST be based solely on the information contained in the base prospectus in relation to the Programme published on 20 May 2021 (the ""Prospectus"") and the Final Terms to be published in in connection with the Notes (the “Final Terms”). Please note that the information contained in the Prospectus and the Final Terms is addressed to and/or targeted at persons who are residents of particular countries (as specified in the Prospectus and the Final Terms) only and is not intended for use and should not be relied upon by any person outside those countries and/or to whom the offer contained in the Prospectus and the Final Terms is not addressed. Prior to relying on the information contained in the Prospectus and the Final Terms you must ascertain from the Prospectus and the Final Terms whether or not you are part of the intended addressees of the information contained therein. No action has been taken that would, or is intended to, permit a public offer of the Notes in any country or jurisdiction where any such action for that purpose is required. THIS ANNOUNCEMENT IS NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OR TO U.S. PERSONS (AS DEFINED IN REGULATION S) UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE ""SECURITIES ACT""). ANY PERSON WHO RECEIVES THIS ANNOUNCEMENT CONTRARY TO THE FOREGOING SHOULD NOT ACT OR RELY ON THIS ANNOUNCEMENT OR ANY OF ITS CONTENTS IN RELATION TO THE SECURITIES. THE SECURITIES DESCRIBED HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS EXCEPT PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=60995,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
39,2021-05-21,Novo Nordisk establishes Euro Medium Term Note programme,"NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES. NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO ANY PERSON IN ANY JURISDICTION WHERE RELEASE, PUBLICATION OR DISTRIBUTION TO SUCH PERSON IS RESTRICTED BY ANY LAW OR REGULATION APPLICABLE IN SUCH JURISDICTION. Bagsværd, Denmark, 21 May 2021 - Novo Nordisk today announced that it has established a Euro Medium Term Note (EMTN) programme. The EMTN programme provides a framework for issuances of senior unsecured notes up to an aggregated principal amount of EUR 5 billion. Novo Nordisk intends to initially issue two series of notes aggregating to a principal amount EUR 1.3 billion. The expected net proceeds from the issuances will be used by Novo Nordisk for general corporate purposes, including refinancing of the bridge loan facility established in connection with Novo Nordisk’s acquisition of Emisphere Technologies Inc. in 2020. The notes will be listed on the Euronext Dublin. The prospectus, which has been prepared by Novo Nordisk in connection with the establishment of the EMTN programme, has been approved by Euronext Dublin and the Central Bank of Ireland and is available here Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information This announcement does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any sale of the Notes in or into any jurisdiction where such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any investment decision made in connection with the Notes MUST be based solely on the information contained in the base prospectus in relation to the Programme published on 20 May 2021 (the ""Prospectus"") and the Final Terms to be published in in connection with the Notes (the “Final Terms”). Please note that the information contained in the Prospectus and the Final Terms is addressed to and/or targeted at persons who are residents of particular countries (as specified in the Prospectus and the Final Terms) only and is not intended for use and should not be relied upon by any person outside those countries and/or to whom the offer contained in the Prospectus and the Final Terms is not addressed. Prior to relying on the information contained in the Prospectus and the Final Terms you must ascertain from the Prospectus and the Final Terms whether or not you are part of the intended addressees of the information contained therein. No action has been taken that would, or is intended to, permit a public offer of the Notes in any country or jurisdiction where any such action for that purpose is required. THIS ANNOUNCEMENT IS NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OR TO U.S. PERSONS (AS DEFINED IN REGULATION S) UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE ""SECURITIES ACT""). ANY PERSON WHO RECEIVES THIS ANNOUNCEMENT CONTRARY TO THE FOREGOING SHOULD NOT ACT OR RELY ON THIS ANNOUNCEMENT OR ANY OF ITS CONTENTS IN RELATION TO THE SECURITIES. THE SECURITIES DESCRIBED HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS XCEPT PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT.   Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=60142,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
40,2021-05-07,Novo Nordisk A/S – Share repurchase programme,"Bagsværd, Denmark, 7 May 2021 — As part of the up to DKK 18 billion 2021 share repurchase programme, Novo Nordisk A/S has now initiated a new share repurchase programme for an amount of up to DKK 3.3 billion in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the ""Safe Harbour Rules”). For that purpose, Novo Nordisk A/S has appointed Skandinaviska Enskilda Banken, Danmark, filial af Skandinaviska Enskilda Banken AB, as lead manager to execute the programme independently and without influence from Novo Nordisk A/S. The purpose of the programme is to reduce the company’s share capital and to meet obligations arising from share-based incentive programmes. Under the agreement, Skandinaviska Enskilda Banken, Danmark, filial af Skandinaviska Enskilda Banken AB, will repurchase B shares on behalf of Novo Nordisk A/S during the trading period starting 10 May 2021 and ending on 3 August 2021. A maximum of 190,000,000 B shares in total can be bought during the trading period. The maximum number of B shares that can be repurchased on a single trading day may not exceed 20% of the average daily trading volume of Novo Nordisk B shares on the trading venue, on which the purchase takes place, in the preceding 20 trading days of the purchase (excluding the day of the purchase). At least once every seven trading days, Novo Nordisk A/S will issue an announcement in respect of the transactions made under the repurchase programme. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Company announcement No 32 / 2021  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=58162,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
41,2021-05-07,"Novo Nordisk A/S purchases B shares worth DKK 2,586 million from Novo Holdings A/S under the 2021 share repurchase programme","Bagsværd, Denmark, 7 May 2021 — Novo Nordisk A/S has today entered into an agreement to purchase 5,610,000 B shares of DKK 0.20 to a value of DKK 2,586 million from Novo Holdings A/S. This transaction is part of Novo Nordisk A/S’ 2021 share repurchase programme of up to a total of DKK 18 billion to be executed during a 12-month period beginning 3 February 2021. The transaction price is DKK 461.04 per share and has been calculated as the three-day volume weighted average market price from 5 May 2021 to 7 May 2021 in the open window following the announcement of Novo Nordisk A/S’ quarterly financial results. Prior to the sale of B shares, Novo Holdings A/S’ ownership of Novo Nordisk A/S was 28.5% of the share capital and 76.9% of the votes. Following the transaction, Novo Holdings A/S owns 537,436,000 A shares of DKK 0.20 and 116,129,000 B shares of DKK 0.20, corresponding to 28.3% of the capital and 76.8% of the votes in Novo Nordisk A/S. The transaction is in line with the announcement on 5 May 2021 that Novo Holdings A/S intends to maintain its ownership of Novo Nordisk A/S’ share capital around 28%. In addition, transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 9,954 B shares in the period from 5 May 2021 to 7 May 2021. With the transactions stated above, Novo Nordisk A/S owns a total of 11,257,435 B shares of DKK 0.20, corresponding to 0.5% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,310,000,000 of DKK 0.20 including treasury shares. About Novo Holdings A/S         Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation’s assets. Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets. Further information: www.novoholdings.dk. About Novo Nordisk A/SNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Company announcement No 31 / 2021  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=58161,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
42,2021-05-05,Novo Nordisk's net profit increased by 6% in the first three months of 2021,"Financial report for the period 1 January 2021 to 31 March 2021 * CER: Constant exchange rates (average 2020). Lars Fruergaard Jørgensen, president and CEO: ""We are very encouraged with the sales growth in the first three months of 2021. Sales growth was driven by all therapy areas and across geographical areas within International Operations as well as North America Operations where growth has accelerated in the US. We were also pleased to announce plans to develop oral semaglutide as a convenient and effective treatment option for people with obesity, complementing our injectable obesity medications. The solid financial performance in the first three months of 2021 has enabled us to raise our outlook range for the full year."" On 5 May 2021 at 13.00 CEST, corresponding to 7.00 am EDT, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’. About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.  Company announcement No 30 / 2021 Attachment ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=57871,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
43,2021-04-29,Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 29 April 2021,"Bagsværd, Denmark, 29 April 2021 – In accordance with Section 32 of the Danish Capital Markets Act, Novo Nordisk A/S is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred. Referring to Company Announcement no 27/2021 dated 27 April 2021, please find below a statement regarding the total number of voting rights and share capital in Novo Nordisk A/S as per 29 April 2021. 1 Each A share of DKK 0.01 carries 10 votes, whereas each B share of DKK 0.01 carries one vote. Thus, each A share of DKK 0.20 carries 200 votes and each B share of DKK 0.20 (the present denomination of the company's shares) carries 20 votes. Treasury shares are included in the table above but voting rights of treasury shares are suspended at the general meetings of Novo Nordisk A/S. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Company announcement No 28 / 2021  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=57023,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
44,2021-04-27,Novo Nordisk A/S – Reduction of the share capital,"Bagsværd, Denmark, 27 April 2021 – At Novo Nordisk’s Annual General Meeting on 25 March 2021, it was decided to reduce the company’s B share capital from DKK 362,512,800 to DKK 354,512,800 by cancellation of part of the company’s portfolio of own B shares equal to a nominal value of DKK 8,000,000 divided into 40,000,000 B shares of DKK 0.20 each. Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled B shares at a nominal value of DKK 8,000,000. After the reduction of the share capital, the company’s share capital is nominally DKK 462,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 354,512,800. The reduction of the share capital will not affect Novo Nordisk’s share repurchase programme which will continue as previously announced. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Company announcement No. 27 / 2021  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=56743,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
45,2021-04-21,Novo Nordisk to initiate phase 3a development in obesity with oral semaglutide,"Bagsværd, Denmark, 21 April 2021 – Novo Nordisk today announced the decision to enter phase 3a development in obesity with oral semaglutide 50 mg. The decision follows the completion of the STEP phase 3a clinical programme with once-weekly subcutaneous (sc) semaglutide 2.4 mg. Novo Nordisk intends to initiate a pivotal phase 3a programme with approximately 1,000 people with obesity or overweight with comorbidities. The global 68-week trial is planned for initiation in the second half of 2021 and will investigate the efficacy and safety of oral semaglutide compared to placebo. “There is a significant unmet medical need within obesity treatment today. With oral semaglutide we aim to introduce a convenient and effective treatment option for people with obesity and healthcare providers enabling broader use of anti-obesity medication,” said Martin Holst Lange, executive vice president, Development at Novo Nordisk. “As a complement to our injectable anti-obesity medications, oral semaglutide has the potential to help more people living with obesity achieve weight loss goals and improve their health.” About obesityObesity is a chronic disease that requires long-term management. It is associated with many serious health complications and decreased life expectancy. Obesity-related complications are numerous and include type 2 diabetes, cardiovascular disease, obstructive sleep apnoea, non-alcoholic fatty liver disease and certain types of cancer. The current COVID-19 pandemic has shown that obesity also increases the risk of severe illness and hospitalisation due to COVID-19. The global increase in the prevalence of obesity is a public health issue that has severe cost implications to healthcare systems. Approximately 650 million adults are estimated to live with obesity worldwide. About semaglutide 2.4 mg for weight management and STEPOnce-weekly sc semaglutide 2.4 mg is currently under regulatory review in the US and the EU as a treatment for adults with obesity. Semaglutide is an analogue of the human glucagon-like peptide-1 (GLP-1) hormone. It induces weight loss by reducing hunger, increasing feeling of fullness and thereby helping people eat less and reduce their calorie intake. The submissions for regulatory review are based on the results from the STEP (Semaglutide Treatment Effect in People with obesity) phase 3 clinical development programme. The global clinical phase 3a programme consisted of four trials and enrolled approximately 4,500 adults with overweight or obesity. About oral semaglutideOral semaglutide (7 mg and 14 mg) is approved as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes in the US, EU and Japan under the trade name, Rybelsus®. The approval of Rybelsus® is based on the results from 10 clinical trials which included 9,543 adults with type 2 diabetes. Rybelsus® demonstrated a safe and well-tolerated profile across the clinical trials, with the most common adverse event being mild to moderate nausea which diminished over time. About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Company announcement No 25 / 2021  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=55895,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
46,2021-03-25,Correction: Resolutions from the Annual General Meeting of Novo Nordisk A/S,"Correction due to missing pdf-file. Bagsværd, Denmark, 25 March 2021 - Today, Novo Nordisk A/S held its Annual General Meeting. At the Annual General Meeting, Helge Lund, chair of the of Board of Directors stated: “In 2020, Novo Nordisk showed agility and resilience in very challenging times, and the COVID-19 pandemic has underscored the importance of continued innovation and relevance of businesses in times of crisis. We have delivered on our financial guidance and invested significantly in commercial launches and research and development. All in all, we are very satisfied with the progress made on our strategic aspirations, which has resulted in an attractive capital allocation to shareholders.” He continued: “Despite the pandemic and turbulent business environment, Novo Nordisk made important steps towards delivering on our purpose of driving change to defeat diabetes and other serious chronic diseases”. Resolutions adopted at the Annual General Meeting Financial year 2020 and board remuneration Elections Shares and capital Other COVID-19 situation Due to the current COVID-19 pandemic and in order to minimise the spread of the virus, the meeting was held as a fully virtual meeting. Accordingly, shareholders attended by electronic means and had been encouraged to exercise their rights by submitting proxies or votes by correspondence in advance of the Annual General Meeting. Composition of the Board of Directors and its committees After the Annual General Meeting, the Board of Directors held a board meeting to appoint members of its committees. The Board of Directors, including its committees, is now composed as follows: Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Company announcement No 21 / 2021  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=52224,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
47,2021-03-25,Resolutions from the Annual General Meeting of Novo Nordisk A/S,"Bagsværd, Denmark, 25 March 2021 - Today, Novo Nordisk A/S held its Annual General Meeting. At the Annual General Meeting, Helge Lund, chair of the of Board of Directors stated: “In 2020, Novo Nordisk showed agility and resilience in very challenging times, and the COVID-19 pandemic has underscored the importance of continued innovation and relevance of businesses in times of crisis. We have delivered on our financial guidance and invested significantly in commercial launches and research and development. All in all, we are very satisfied with the progress made on our strategic aspirations, which has resulted in an attractive capital allocation to shareholders.” He continued: “Despite the pandemic and turbulent business environment, Novo Nordisk made important steps towards delivering on our purpose of driving change to defeat diabetes and other serious chronic diseases”. Resolutions adopted at the Annual General Meeting Financial year 2020 and board remuneration Elections Shares and capital Other COVID-19 situation Due to the current COVID-19 pandemic and in order to minimise the spread of the virus, the meeting was held as a fully virtual meeting. Accordingly, shareholders attended by electronic means and had been encouraged to exercise their rights by submitting proxies or votes by correspondence in advance of the Annual General Meeting. Composition of the Board of Directors and its committees After the Annual General Meeting, the Board of Directors held a board meeting to appoint members of its committees. The Board of Directors, including its committees, is now composed as follows: Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Company announcement No 21 / 2021 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=52221,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
48,2021-03-22,Novo Nordisk receives Refusal to File letter for once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes,"Bagsværd, Denmark, 22 March 2021 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has issued a Refusal to File letter covering the label expansion application for once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes which was filed on 20 January 2021. A refusal to file letter is received when the FDA determines additional information is required to review a complete application. In the letter, FDA has requested additional information including data relating to a proposed new manufacturing site. While additional information needs to be included in the resubmission, Novo Nordisk believes the already completed clinical trial programme will be sufficient for approval of the label expansion application. Novo Nordisk expects to resubmit the application to FDA during the second quarter of 2021. About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Company announcement No 20 / 2021  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=51806,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
49,2021-03-18,Gilead Sciences and Novo Nordisk expand NASH clinical collaboration,"Triple combination regimen to be investigated in new phase 2b study in NASH patients with cirrhosis Foster City, California, US and Bagsværd, Denmark, 18 March 2021 – Gilead Sciences, Inc. and Novo Nordisk A/S today announced that the companies have expanded their clinical collaboration in non-alcoholic steatohepatitis (NASH). The companies will conduct a phase 2b double-blind, placebo-controlled study to investigate the safety and efficacy of Novo Nordisk’s semaglutide, a GLP-1 receptor agonist, and a fixed-dose combination of Gilead’s investigational FXR agonist cilofexor and investigational ACC inhibitor firsocostat, alone and in combination in people with compensated cirrhosis (F4) due to NASH. The four-arm study in approximately 440 patients will evaluate the treatments’ impact on liver fibrosis improvement and NASH resolution and will begin recruitment in the second half of 2021. This new phase 2b study builds on positive results from a phase 2a proof-of-concept study presented at the Liver Meeting Digital Experience™ in November 2020 investigating semaglutide alone and in combination with cilofexor and/or firsocostat in 108 people with NASH, and mild to moderate fibrosis. The study met its primary endpoint, demonstrating that all regimens were well tolerated over 24 weeks. The most common adverse events were gastrointestinal. Across all groups, 5–14% of people discontinued any trial treatment due to adverse events. In addition, post-hoc analyses of exploratory efficacy endpoints assessing biomarkers of liver health at 24 weeks showed statistically significant improvements in hepatic steatosis (measured by magnetic resonance imaging proton density fat fraction; MRI-PDFF) and liver injury (measured by serum alanine aminotransferase; ALT) in the combination treatment arms versus semaglutide alone. Liver stiffness and the Enhanced Liver Fibrosis (ELF) score declined in all groups; however, statistically significant differences between groups were not observed. “NASH is a disease with a high unmet medical need, as no drugs are currently approved to treat this potentially life-threatening condition. Building on the positive results from our proof-of-concept trial, we hope together with Gilead to demonstrate the potential for semaglutide with cilofexor and firsocostat to help people living with NASH,” said Martin Holst Lange, executive vice president and head of Development at Novo Nordisk. “Gilead is pleased to expand our collaboration with Novo Nordisk and advance understanding of the potential for combination approaches in treating people living with cirrhosis due to NASH,” said Mark Genovese, MD, senior vice president, Inflammation Clinical Development at Gilead Sciences. “This study is the latest example of our persistent focus on driving innovation to improve the lives of people living with liver diseases and fibrosis.” Cilofexor and firsocostat are investigational compounds and are not approved by the U.S. Food & Drug Administration (FDA) or any other regulatory authority. Their safety and efficacy have not been established. Semaglutide has not been approved by the FDA or any other regulatory authority for the treatment of patients living with NASH but has been approved for the treatment of type 2 diabetes. About NASH NASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver, which can lead to scarring, or fibrosis, that impairs liver function. The risk of progression to advanced liver disease, including liver decompensation (loss of liver function) and liver cancer, is higher in people with NASH than in the general population, and NASH could become the leading reason for liver transplants in most countries. Currently, no pharmacotherapy is globally approved for the treatment of NASH, and people with NASH are left with very few management options. About Gilead SciencesGilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information   Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=51246,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
50,2021-02-24,Novo Nordisk and the University of Toronto announce joint 200 DKK million investment to address diabetes and chronic disease prevention,"Transformative partnership reunites University of Toronto and Novo Nordisk to commemorate the 100th anniversary of the discovery of insulin and jumpstart a new era in precision public health Toronto, Canada and Bagsværd, Denmark 24 February 2021 – Novo Nordisk A/S and the University of Toronto (U of T) today announced a DKK 200 million (CAD 40 million) investment to establish the Novo Nordisk Network for Healthy Populations. The network will focus on new ways to support healthier urban populations and will draw on U of T’s leading expertise in public health research and education programmes to impact the global fight against diabetes and other serious chronic diseases. Based at U of T Mississauga, the new network will be a partnership between the Dalla Lana School of Public Health, the Temerty Faculty of Medicine and University of Toronto Mississauga. “As we commemorate the 100th anniversary of the discovery of insulin at U of T, we are thrilled to once again partner with Novo Nordisk, a company that understands the vital importance of helping those living with diabetes and other chronic diseases,” said U of T President Meric Gertler. “Their historic investment will build capacity for research and education at the University. It will bring together existing expertise from across U of T, our health sector partners in the Mississauga community and the broader region. It will make a real difference to people coping with chronic diseases not just here in Canada, but around the world.” In 1921, a U of T research team of Frederick Banting, Charles Best, J.J.R. MacLeod and James Bertram Collip discovered insulin. Novo Nordisk predecessors, Nordisk Insulin Laboratorium and Novo Terapeutisk Laboratorium, were among the first to produce insulin at a large scale, bringing this life-saving treatment from University of Toronto labs to people with diabetes around the world.  Now, 100 years later, U of T and Novo Nordisk will once again work together to improve the lives of people living with diabetes – with an ambition to prevent type 2 disease. “Fulfilling our company’s purpose to defeat diabetes, obesity and other serious chronic diseases requires much more than innovative medicine,” said Lars Fruergaard Jørgensen, CEO and President of Novo Nordisk. “One hundred years after the discovery of insulin, we’re proud to once again partner with the University of Toronto with the ambition of helping society to address the root causes of type 2 diabetes and obesity. As we recognise insulin’s success in saving millions of lives around the world, we are excited to expand our commitment towards the prevention of these serious chronic diseases.” Novo Nordisk’s is donating DKK 100 million (CAD 20 million) to the network which is being matched by U of T with further DKK 100 million in financial and in-kind contributions. In addition, Novo Nordisk has made an additional DKK 10 million (CAD 2 million) donation to U of T’s Banting and Best Diabetes Centre in support of discovery research and to honour Banting and Best’s enduring legacy. About University of TorontoFounded in 1827, the university has evolved into Canada’s leading institution of learning, discovery and knowledge creation. We are proud to be one of the world’s top research-intensive universities, driven to invent and innovate. Our students have the opportunity to learn from and work with preeminent thought leaders through our multidisciplinary network of teaching and research faculty, alumni and partners. The ideas, innovations and actions of more than 560,000 graduates continue to have a positive impact on the world. About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=48196,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
51,2021-02-23,Notice for the Annual General Meeting of Novo Nordisk A/S,"Bagsværd, Denmark, 23 February 2021 – The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 25 March 2021 at 14:00 (CET) Due to COVID-19, the Annual General Meeting is held as a fully virtual meeting and shareholders will not be able to be physically present at the meeting. Instead, shareholders will be able to participate via an IT application and we encourage shareholders to exercise their rights by submitting proxies or votes by correspondence in advance of the Annual General Meeting. Also, Novo Nordisk offers the possibility of viewing the Annual General Meeting via live webcast on Novo Nordisk’s website. Please refer to the notice for further information. The notice for the Annual General Meeting, including Appendix: Candidates for the Board of Directors, is enclosed. BOARD OF DIRECTORS All board members elected by the Annual General Meeting are up for election. Brian Daniels and Liz Hewitt have decided not to seek re-election. The Board of Directors proposes re-election of the following board members elected by the Annual General Meeting: Helge Lund (chair), Jeppe Christiansen (vice-chair), Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Kasim Kutay and Martin Mackay. The Board of Directors proposes the election of Henrik Poulsen as a new member of the Board. Mr Poulsen served as CEO and president of the renewable energy company Ørsted A/S, Denmark, in the period 2012-2020. Prior to that Mr Poulsen was CEO and president of the telecommunication company TDC A/S, Denmark. From 2007-2008 Mr Poulsen served as operating executive of Kohlberg Kravis Roberts & Co. in the UK preceded by executive roles with the LEGO group, Denmark, in the period 1999-2006. The Board of Directors proposes the election of Henrik Poulsen to the Board of Directors primarily because of his extensive executive and board experience in large international companies, significant financial knowledge and in-depth knowledge of strategy, transformation, innovation, and mergers and acquisitions. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Company announcement No 15 / 2021  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=48065,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
52,2021-02-11,Novo Nordisk files annual report with the SEC,"Bagsværd, Denmark, 11 February 2021 ­– Novo Nordisk A/S has filed its Annual Report 2020 on Form 20-F for the financial year 2020 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2020. The reports are available at the SEC's website, www.sec.gov, as well as on novonordisk.com. Shareholders may receive a hardcopy of Novo Nordisk’s completed audited financial statements free of charge upon request to cbzs@novonordisk.com. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=46396,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
53,2021-02-04,Novo Nordisk files annual report with the SEC,"Bagsværd, Denmark, 4 February 2021 ­– Novo Nordisk A/S has filed its Annual Report 2020 on Form 20-F for the financial year 2020 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2020. The reports are available at the SEC's website, www.sec.gov, as well as on novonordisk.com. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information   Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=45502,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
54,2021-02-03,Novo Nordisk's net profit increased by 8% in 2020,"Financial report for the period 1 January 2020 to 31 December 2020  * CER: Constant exchange rates (average 2019). Lars Fruergaard Jørgensen, president and CEO: ""We are very satisfied with the progress on our Strategic Aspirations in 2020 despite the challenges of COVID-19. This was only possible due to the commitment from all our employees. The financial results reflect sales growth in both International Operations and North America Operations driven by more patients using our GLP-1 treatments. Within R&D, key milestones in the fourth quarter were the regulatory submissions of semaglutide 2.4 mg which has the potential to redefine the treatment of obesity. In 2021, we will continue our focus on commercial execution while conducting more late-stage clinical trial programmes than ever to meet the unmet needs of people living with diabetes and other serious chronic diseases."" On 3 February 2021 at 13.00 CET, corresponding to 7.00 am EST, a conference call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’. About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.  Further information about Novo Nordisk is available on novonordisk.com. Company announcement No 6 / 2020  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=45373,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
55,2021-01-20,Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes,"Bagsværd, Denmark, 20 January 2021 – Novo Nordisk today announced the submission of a label expansion application to the US Food and Drug Administration (FDA) for the existing marketing authorisation for Ozempic®, a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2.0 mg. Ozempic® is currently approved in the US in 0.5 mg and 1.0 mg doses for the treatment of type 2 diabetes in adults and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. The submission follows the application on 29 December 2020 for label extension to the European Medicines Agency (EMA). The submission is based on the results from the SUSTAIN FORTE trial, which included 961 people with type 2 diabetes in need of treatment intensification. In the trial, people treated with semaglutide 2.0 mg achieved a statistically significant and superior reduction in HbA1c compared to semaglutide 1.0 mg. In the trial, both doses of semaglutide appeared to have safe and well-tolerated profiles. The most common adverse events were gastrointestinal, the vast majority were mild to moderate and diminished over time and were consistent with the GLP-1 receptor agonist class. Compared to semaglutide 1.0 mg, the gastrointestinal adverse events were similar for semaglutide 2.0 mg. “We are excited about the regulatory submission of semaglutide 2.0 mg to the FDA,” said Mads Krogsgaard Thomsen, executive vice president and chief scientific officer of Novo Nordisk. “In the SUSTAIN programme most people achieved the treatment target of HbA1c levels below 7%. However, some patients need treatment intensification and with the 2.0 mg dose, more people with type 2 diabetes will be able to achieve treatment target”. About the SUSTAIN clinical programme The SUSTAIN clinical development programme for once-weekly subcutaneous semaglutide injection currently comprises 11 phase 3 global clinical trials, including a cardiovascular outcomes trial, involving more than 11,000 adults with type 2 diabetes. For more information about the SUSTAIN FORTE trial, please read the headline results here About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 44,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Company announcement No 3 / 2021  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=43581,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
56,2020-12-29,Novo Nordisk files for EU regulatory approval of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes,"Bagsværd, Denmark, 29 December 2020 – Novo Nordisk today announced the submission of a label extension application to the European Medicines Agency (EMA) for the existing marketing authorisation for Ozempic®, a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2.0 mg. Ozempic® is currently approved in the EU in 0.5 mg and 1.0 mg doses for the treatment of type 2 diabetes in adults. The submission is based on the results from the SUSTAIN FORTE trial, which included 961 people with type 2 diabetes in need of treatment intensification. In the trial, people treated with semaglutide 2.0 mg achieved a statistically significant and superior reduction in HbA1c at week 40 compared to semaglutide 1.0 mg. In the trial, both doses of semaglutide appeared safe and well-tolerated. The most common adverse events were gastrointestinal, the vast majority were mild to moderate and diminished over time and were consistent with the GLP-1 receptor agonist class. Compared to semaglutide 1.0 mg, the gastrointestinal adverse events were similar for semaglutide 2.0 mg. “Following the announcement of the headline results in November, we have expeditiously prepared the submission file. The submission in the EU represents an important milestone for people living with type 2 diabetes who have poor glycaemic control and need treatment intensification” said Mads Krogsgaard Thomsen, executive vice president and chief scientific officer of Novo Nordisk. ""With the 2.0 mg dose, more people with type 2 diabetes will be able to achieve treatment target”. About the SUSTAIN clinical programme The SUSTAIN clinical development programme for once-weekly subcutaneous semaglutide injection currently comprises 11 phase 3 global clinical trials, including a cardiovascular outcomes trial, involving more than 11,000 adults with type 2 diabetes. For more information about the SUSTAIN Forte trial, please read the headline results here About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 44,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=40773,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
57,2020-12-18,Novo Nordisk files for EU regulatory approval of once-weekly semaglutide 2.4 mg for weight management,"Bagsværd, Denmark 18 December 2020 ­– Novo Nordisk today announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for subcutaneous semaglutide 2.4 mg, a once-weekly glucagon-like peptide-1 (GLP-1) analogue for weight management. The potential indication is for the treatment of adults with obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) with at least one weight-related comorbidity, as an adjunct to reduced-calorie diet and increased physical activity. The submission is based on the results from the STEP phase 3a clinical trial programme, which included more than 4,500 adults with obesity or overweight. Across the STEP programme, people with obesity treated with once-weekly semaglutide 2.4 mg achieved a statistically significant and superior reduction in body weight compared to placebo. Across the trials in people without diabetes STEP 1, 3 and 4, a weight loss of 15-18% was reported for people treated with semaglutide 2.4 mg. Furthermore, once-weekly semaglutide 2.4 mg appeared to have a safe and well-tolerated profile. The most common side effects were gastrointestinal and were transient, and mild or moderate in severity. “We are excited about this regulatory filing following the recent regulatory filing with the FDA in the US,” said Mads Krogsgaard Thomsen, executive vice president and chief scientific officer of Novo Nordisk. “It is a milestone for Novo Nordisk but more importantly it represents a new treatment option with the potential to transform the medical management for people living with obesity in Europe”. About obesity and subcutaneous semaglutide 2.4 mg for weight management Obesity is a chronic disease that requires long-term management. It is associated with many serious health consequences and decreased life expectancy. Obesity-related complications are numerous and include type 2 diabetes, heart disease, obstructive sleep apnoea, non-alcoholic fatty liver disease and cancer. Once-weekly subcutaneous semaglutide 2.4 mg is being investigated by Novo Nordisk as a potential treatment for obesity. Semaglutide is an analogue of the human glucagon‑like peptide-1 (GLP-1) hormone. It induces weight loss by reducing hunger, increasing feelings of fullness and thereby helping people eat less and reduce their calorie intake. For more information on the FDA filing for semaglutide 2.4 mg, please read the company announcement here About the STEP clinical programme STEP (Semaglutide Treatment Effect in People with obesity) is a phase 3 clinical development programme with once-weekly subcutaneous semaglutide 2.4 mg in obesity. The global phase 3a programme consists of four trials and has enrolled approximately 4,500 adults with overweight or obesity. STEP 1 – a 68-week safety and efficacy trial of subcutaneous semaglutide 2.4 mg versus placebo in 1,961 adults with obesity or overweight. For more information, please read the company announcement here STEP 2 – a 68-week safety and efficacy trial of subcutaneous semaglutide 2.4 mg versus placebo and once-weekly subcutaneous semaglutide 1.0 mg in 1,210 adults with type 2 diabetes and either obesity or overweight. For more information, please read the company announcement here STEP 3 – a 68-week safety and efficacy trial of subcutaneous semaglutide 2.4 mg versus placebo in combination with intensive behavioural treatment in 611 adults with obesity or overweight. For more information, please read the company announcement here STEP 4 – a 68-week safety and efficacy trial of subcutaneous semaglutide 2.4 mg versus placebo in 803 adults with obesity or overweight who have reached the target dose of 2.4 mg after a 20-week run-in. For more information, please read the company announcement here About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 44,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Company announcement No 78 / 2020  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=39374,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
58,2020-12-16,Novo Nordisk to enter phase 3 development in Alzheimer’s disease with oral semaglutide,"Bagsværd, Denmark, 16 December 2020 – Novo Nordisk today announced the decision to enter phase 3 development in Alzheimer’s disease with 14 mg oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analogue semaglutide. The decision follows evaluation of GLP-1 data from preclinical models, real-world evidence studies, post-hoc analysis of data from large cardiovascular outcomes trials, as well as discussions with regulatory authorities. Novo Nordisk intends to initiate a pivotal phase 3a programme with approximately 3,700 people with early Alzheimer’s disease. The programme is planned for initiation in the first half of 2021 and will investigate the efficacy and safety of once-daily oral semaglutide, compared to placebo. The expected main treatment period in the trials is around two years. “As a company we aspire to address high unmet medical needs within serious chronic diseases, and we are therefore pleased to initiate phase 3 development of semaglutide within Alzheimer’s disease,” said Mads Krogsgaard Thomsen, executive vice president and chief scientific officer at Novo Nordisk. “Alzheimer’s disease has been an area of extensive research in the past decades, unfortunately without any major medical breakthroughs. Due to the growing unmet medical need and the increasing evidence of a potential therapeutic role for GLP-1, we will investigate the benefits of oral semaglutide in early Alzheimer’s disease.” Conference callOn 16 December at 4 pm CET, corresponding to 10 am EST, a conference call for investors will be held where members of management will elaborate on the decision and provide a brief update on the GLP-1 R&D strategy. Investors will be able to listen in via a link on the investor section of novonordisk.com. About Alzheimer’s diseaseAlzheimer’s disease represents a rapidly growing public health concern causing significant detrimental consequences to the affected people and their families and has led to substantial and increasing global socioeconomic impact. Worldwide, 70-100 million people are estimated to have early Alzheimer’s disease (mild cognitive impairment and mild dementia stages). About data from preclinical models, real-world evidence studies and the post-hoc analysisAnimal studies highlight the key effects of GLP-1 relevant for Alzheimer’s disease including improved memory function and reduced phospho-tau accumulation. Semaglutide has specifically been shown to reduce measures of neuro-inflammation which may affect cognition and function. Further, real-world evidence from two Danish nationwide registries, the US Truven claims database and the US FDA FAERS database support a potential association between lower risk of dementia following treatment with GLP-1. Finally, in a post-hoc analysis of data from three large cardiovascular outcomes trials conducted by Novo Nordisk (LEADER, SUSTAIN 6 and PIONEER 6), which included 15,820 patients with type 2 diabetes with median follow-up of 3.6 years, a total number of 47 people were identified with development of dementia, of which 32 were on placebo and 15 on GLP-1 (liraglutide or semaglutide). The rate of developing dementia was statistically significantly reduced by 53% in favour of GLP-1. About oral semaglutideOral semaglutide (7 mg and 14 mg) is approved as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes in the US, EU and Japan. The approval of Rybelsus® is based on the results from 10 clinical trials which included 9,543 adults with type 2 diabetes. Rybelsus® demonstrated a safe and well-tolerated profile across the clinical trials, with the most common adverse event being mild to moderate nausea which diminished over time. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 44,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Company announcement No. 77 / 2020 Attachment ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=39097,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
59,2020-12-08,Novo Nordisk announces completion of the Emisphere Technologies acquisition,"Bagsværd, Denmark, 8 December 2020 – Novo Nordisk today announced that the acquisition of Emisphere Technologies Inc. (Emisphere), announced on 6 November 2020, has now been completed. The adoption of the merger agreement was approved by Emisphere shareholders today, and early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 was granted on 23 November 2020. About the acquisitionFor more information, please see: Novo Nordisk to acquire Emisphere Technologies and obtain ownership of the Eligen® SNAC oral delivery technology About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 44,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information   Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=38064,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
60,2020-12-04,Novo Nordisk files for US FDA regulatory approval of once-weekly semaglutide 2.4 mg for weight management,"Bagsværd, Denmark, 4 December 2020 – Novo Nordisk today announced the submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for subcutaneous semaglutide 2.4 mg, a once-weekly glucagon-like peptide-1 (GLP-1) analogue for chronic weight management. A priority review voucher has been applied to the NDA, leading to an anticipated review time of six months from the submission date, according to standard FDA review timelines. The potential indication is for the treatment of adults with obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) with at least one weight-related comorbidity, as an adjunct to reduced-calorie diet and increased physical activity. The submission is based on the results from the STEP phase 3a clinical trial programme, which included more than 4,500 adults with obesity or overweight. Across the STEP programme, people with obesity treated with once-weekly semaglutide 2.4 mg achieved a statistically significant and superior reduction in body weight compared to placebo. Across STEP 1, 3 and 4 a weight loss of 15-18% was reported for people treated with semaglutide 2.4 mg. Furthermore, once-weekly semaglutide 2.4 mg appeared to have a safe and well-tolerated profile. The most common side effects were gastrointestinal and were transient, and mild or moderate in severity. “Obesity is associated with a wide range of serious complications, yet many healthcare providers still do not have sufficient medical options available to help people with this chronic disease ,” said Mads Krogsgaard Thomsen, executive vice president and chief scientific officer of Novo Nordisk. ""We are excited about the regulatory filing of semaglutide 2.4 mg in the US and we believe once-weekly semaglutide 2.4 mg has the potential to transform the medical management of obesity."" About obesity and subcutaneous semaglutide 2.4 mg for weight management Obesity is a chronic disease that requires long-term management. It is associated with many serious health consequences and decreased life expectancy. Obesity-related complications are numerous and include type 2 diabetes, heart disease, obstructive sleep apnoea, non-alcoholic fatty liver disease and cancer. Once-weekly subcutaneous semaglutide 2.4 mg is being investigated by Novo Nordisk as a potential treatment for obesity. Semaglutide is an analogue of the human glucagon‑like peptide-1 (GLP-1) hormone. It induces weight loss by reducing hunger, increasing feelings of fullness and thereby helping people eat less and reduce their calorie intake. About the STEP clinical programme STEP (Semaglutide Treatment Effect in People with obesity) is a phase 3 clinical development programme with once-weekly subcutaneous semaglutide 2.4 mg in obesity. The global phase 3a programme consists of four trials and has enrolled approximately 4,500 adults with overweight or obesity. STEP 1 – a 68-week safety and efficacy trial of subcutaneous semaglutide 2.4 mg versus placebo in 1,961 adults with obesity or overweight. For more information, please read the company announcement here STEP 2 – a 68-week safety and efficacy trial of subcutaneous  semaglutide 2.4 mg versus placebo and once-weekly subcutaneous semaglutide 1.0 mg in 1,210 adults with type 2 diabetes and either obesity or overweight. For more information, please read the company announcement here STEP 3 – a 68-week safety and efficacy trial of subcutaneous  semaglutide 2.4 mg versus placebo in combination with intensive behavioural treatment in 611 adults with obesity or overweight. For more information, please read the company announcement here STEP 4 – a 68-week safety and efficacy trial of subcutaneous  semaglutide 2.4 mg versus placebo in 803 adults with obesity or overweight who have reached the target dose of 2.4 mg after a 20-week run-in. For more information, please read the company announcement here About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 44,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Company announcement No 74 / 2020  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=37551,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
61,2020-11-17,Once-weekly semaglutide 2.0 mg demonstrates superior reduction in HbA1c vs once-weekly semaglutide 1.0 mg in people with type 2 diabetes in the SUSTAIN FORTE trial,"Bagsværd, Denmark, 17 November 2020 - Novo Nordisk today announced headline results from the SUSTAIN FORTE trial, a phase 3b 40-week, efficacy and safety trial with once-weekly semaglutide 2.0 mg vs once-weekly semaglutide 1.0 mg as add-on to metformin and/or sulfonylureas in 961 people with type 2 diabetes in need for treatment intensification. The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in HbA1c at week 40 with semaglutide 2.0 mg compared to semaglutide 1.0 mg. When evaluating the effects of treatment taken as intended1 and from a high mean baseline HbA1c of 8.9%, people treated with semaglutide 2.0 mg achieved a statistically significant and superior reduction in HbA1c of 2.2% compared with a reduction of 1.9% with semaglutide 1.0 mg at week 40. The American Diabetes Association (ADA) treatment target of HbA1c below 7.0% was achieved by 68% of people treated with semaglutide 2.0 mg vs 58% on semaglutide 1.0 mg. From a mean baseline body weight of 99.3 kg, people treated with semaglutide 2.0 mg experienced a statistically significant1 and superior weight loss of 6.9 kg compared with 6.0 kg with semaglutide 1.0 mg. When applying the treatment policy estimand2, people treated with semaglutide 2.0 mg experienced a reduction in HbA1c of 2.1% compared to 1.9% for people treated with 1.0 mg dose at week 40. People treated with semaglutide 2.0 mg experienced a statistically non-significant weight loss of 6.4 kg compared with 5.6 kg with semaglutide 1.0 mg. *Statistically significant vs once-weekly semaglutide 1.0 mg In the trial, both doses of semaglutide appeared safe and well-tolerated. The most common adverse events were gastrointestinal, the vast majority were mild to moderate and diminished over time and were consistent with the GLP-1 receptor agonist class. Compared to semaglutide 1.0 mg, the gastrointestinal adverse events were similar for semaglutide 2.0 mg with nausea rates around 15% for both doses. The treatment discontinuation rates due to adverse events were similar and below 5% for both doses of semaglutide. “We are very pleased with the results from the SUSTAIN FORTE trial with the large HbA1c reduction from a high baseline as well as the safety and tolerability profile, which establish a attractive benefit-risk ratio for treatment of type 2 diabetes with semaglutide” said Mads Krogsgaard Thomsen, executive vice president and chief scientific officer of Novo Nordisk. “Semaglutide 1.0 mg has across the SUSTAIN programme demonstrated that up to 80% of patients achieved HbA1c levels below 7%. This study demonstrates that patients in poor glycaemic control increase the likelihood of achieving their HbA1c target when treated with semaglutide 2.0 mg.” About the SUSTAIN clinical programme The SUSTAIN clinical development programme for once-weekly subcutaneous semaglutide injection currently comprises 11 phase 3 global clinical trials, including a cardiovascular outcomes trial, involving more than 11,000 adults with type 2 diabetes in total. Semaglutide 1.0 mg is approved under the brand name Ozempic® indicated for type 2 diabetes. About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 44,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Company announcement No 71 / 2020  1 Based on the trial product estimand: treatment effect if all people adhered to treatment and did not initiate other type 2 diabetes therapies 2 Based on the treatment policy estimand: treatment effect regardless of treatment adherence or initiation of other type 2 diabetes therapies   Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=34777,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
62,2020-11-15,Gilead and Novo Nordisk present new data from proof-of-concept trial in NASH,"Results from first phase 2 trial describing a triple combination regimen targeting NASH presented at The Liver Meeting Digital Experience Foster City, California, US and Bagsværd, Denmark 15 November 2020 – Gilead Sciences, Inc. and Novo Nordisk A/S today announced results from a phase 2 proof-of-concept trial. The five-arm trial evaluated combinations of Novo Nordisk’s semaglutide, a GLP-1 receptor agonist, with Gilead’s investigational FXR agonist cilofexor and/or Gilead’s investigational ACC inhibitor firsocostat over 24 weeks in 108 people with non-alcoholic steatohepatitis (NASH). The results were presented at The Liver Meeting Digital Experience (TLMdX), 13–16 November 2020 (Late Breaker #L02). The trial met its primary endpoint by demonstrating that in people with NASH and mild to moderate fibrosis all regimens were well tolerated. The most common adverse events (AEs) were gastrointestinal. Minimal pruritus (itching) was observed in people treated with cilofexor. Across all groups, 5–14% of people discontinued any trial treatment due to AEs. Exploratory efficacy endpoints assessing biomarkers of liver health at 24 weeks in post-hoc analyses showed statistically significant improvements in hepatic steatosis (measured by magnetic resonance imaging proton density fat fraction; MRI-PDFF) and liver injury (measured by serum alanine aminotransferase; ALT) in the combination arms versus semaglutide alone. Although liver stiffness measured by vibration-controlled transient elastography (VCTE) and enhanced liver fibrosis (ELF) score declined in all groups, statistically significant differences between groups were not observed. “These results offer novel insights around the multiple mechanisms that drive NASH and demonstrate the potential of combination approaches for patients in significant need of a treatment option for this condition,” said Naim Alkhouri, MD, director of the Fatty Liver Program, Chief of Transplant Hepatology, Arizona Liver Health, Chandler. “We are encouraged that these data showcase the potential for combination approaches to elicit improvements in liver fat content, liver biochemistry, and certain non-invasive tests of fibrosis, all of which have been associated with meaningful histologic improvement in NASH.” “Gilead is focused on delivering scientific advances that can improve the lives of people with liver disease, both through our own innovation and in partnership with companies with complementary expertise, such as Novo Nordisk,” said Mark Genovese, MD, Senior Vice President, Inflammation Clinical Development at Gilead Sciences. “These data offer new insights into potential therapeutic approaches to treating NASH, a disease which currently has limited treatment options.” “This trial brings together Gilead and Novo Nordisk’s respective expertise and science to provide important insights into potential new combination therapies involving semaglutide to help people living with NASH,” said Martin Holst Lange, senior vice president, Global Development at Novo Nordisk. “We are now carefully evaluating next steps together based on a thorough assessment of data.” The companies are also presenting preclinical data supporting the development of combination approaches in NASH. In the preclinical trial, semaglutide alone and in combination with cilofexor and/or GS-834356 (an analogue of firsocostat) were administered daily for 12 weeks in a murine model of diet-induced NASH (n=15-16/group). The results demonstrated that while semaglutide significantly improved NASH and fibrosis-related endpoints, the addition of either cilofexor or the firsocostat analogue further improved liver fat reduction. The combination of all three agents had the greatest impact on changes in the NAFLD Activity Score (NAS). The safety and efficacy of firsocostat, GS-834356 and cilofexor have not been established. Firsocostat, GS-834356 and cilofexor are investigational compounds and are not approved by the FDA or any other regulatory authority. Semaglutide has not been approved by the FDA or any other regulatory authority for the treatment of people living with NASH but has been approved for the treatment of type 2 diabetes. About NASHNASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver, which can lead to scarring, or fibrosis, that impairs liver function. The risk of progression to advanced liver disease, including liver decompensation (loss of liver function) and liver cancer, is higher in people with NASH than in the general population and NASH could become the leading reason for liver transplants in most countries. Currently, no pharmacotherapy is globally approved for the treatment of NASH, and people with NASH are left with very few management options. About Gilead SciencesGilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@Gilead Sciences). About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 44,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information   Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=34520,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
63,2020-11-06,Novo Nordisk to acquire Emisphere Technologies and obtain ownership of the Eligen® SNAC oral delivery technology,"Bagsværd, Denmark, 6 November 2020 – Novo Nordisk A/S today announced that the company has entered into a definitive agreement to acquire Emisphere Technologies Inc. (Emisphere), a drug delivery company with proprietary technologies, such as the Eligen® SNAC technology, that enable oral formulations of therapeutics. Novo Nordisk and Emisphere have collaborated since 2007 and Emisphere’s proprietary drug delivery technology Eligen® SNAC is used by Novo Nordisk under an existing licence agreement in the oral formulation of Novo Nordisk’s GLP-1 receptor agonist semaglutide, which is marketed and sold under the brand name Rybelsus®. Under the terms of the agreement, Novo Nordisk will acquire all outstanding shares of Emisphere for USD 1.350 billion. As part of the transaction, Novo Nordisk will also acquire related Eligen® SNAC royalty stream obligations owed to MHR Fund Management LLC (MHR), the largest shareholder of Emisphere, for USD 450 million. Consequently, the total acquisition price is USD 1.8 billion. With these acquisitions, Novo Nordisk eliminates its future royalty obligations to Emisphere and MHR and obtains full access to the Eligen® SNAC technology platform thereby enabling Novo Nordisk to expand the portfolio of oral biologic pipeline assets across therapy areas. The transaction will be debt financed and will not impact Novo Nordisk’s previously communicated operating profit outlook for 2020 or the ongoing share buyback programme. The acquisition is expected to have a net negative impact on operating profit of less than one percent in 2021 and broadly neutral to positive impact in the following years. The acquisition of Emisphere provides Novo Nordisk full ownership of the Eligen® SNAC technology, which has been successfully used under a licence agreement to develop the first oral biologic, Rybelsus®” said Mads Krogsgaard Thomsen, executive vice president and chief scientific officer of Novo Nordisk.  “We intend to apply and further develop the technology and use it on current and future pipeline assets with the aim of making more biologic medicines orally available for patients”. The transaction is subject to customary closing conditions, including approval by Emisphere shareholders and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. MHR and certain other shareholders of Emisphere, collectively owning a majority of the Emisphere shares, have agreed to vote their shares in favour of the transaction. Novo Nordisk is represented by Davis Polk & Wardwell LLP as legal advisor and Evercore as financial advisor. About Eligen® SNAC Carrier Technology Eligen® SNAC technology enables drug therapies to be provided in a tablet formulation with an absorption-enhancing excipient. Emisphere created Eligen® SNAC technology, its proprietary oral drug delivery platform, to facilitate the absorption of small and large molecules without altering their chemical form, biological integrity or pharmacological properties. Notably, the technology enables the transport of therapeutic molecules including large peptides and proteins across biological membranes such as those of the gastrointestinal tract.  About Emisphere Emisphere is a drug delivery company that utilises its proprietary technologies to develop new oral formulations of therapeutic agents. For more information, please visit Emisphere's website at www.emisphere.com. About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 44,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=33374,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
64,2020-10-30,Novo Nordisk's operating profit increased by 6% in Danish kroner and by 7% at constant exchange rates (CER) in the first nine months of 2020,"30 October 2020 - Financial report for the period 1 January 2020 to 30 September 2020 * CER: Constant exchange rates (average 2019). The growth at CER was announced on 8 October Lars Fruergaard Jørgensen, president and CEO: ""We are very satisfied with the performance in the first nine months of 2020 despite the negative impacts from COVID-19. More patients use our GLP-1 treatments, and our diabetes market leadership continues to expand. Within R&D, an important milestone was reached with the encouraging results from the phase 2b trial in cardiovascular disease with ziltivekimab, the lead candidate from Corvidia Therapeutics that was acquired this year"". On 30 October 2020 at 13.00 CET, corresponding to 8.00 am EDT, a conference call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’. About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 44,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Company announcement No 63 / 2020  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=32471,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
65,2020-10-08,Novo Nordisk raises sales and operating profit outlook for 2020,"Bagsværd, Denmark, 8 October 2020 – Novo Nordisk today announced that the full-year sales and operating profit outlook at constant exchange rates (CER) has been raised. In the third quarter of 2020, Novo Nordisk’s sales increased by 7% and operating profit increased by 7%, both at CER. This reflects lower than anticipated negative impacts from COVID-19 as well as underlying market demand. Sales growth was positively impacted by inventory changes at wholesaler level in the US. Following lower than anticipated negative COVID-19 impacts and underlying market demand, full-year outlook is increased for sales and operating profit, both at CER. Novo Nordisk’s full disclosure of the financial results for the first nine months of 2020 will be published on 30 October 2020. The outlook is based on a number of assumptions related to the severity and duration of impacts from COVID-19. In addition, the above expectations are based on assumptions which are further described on pages 15 and 16 of the Financial Report for the period 1 January 2020 to 30 June 2020 (Company Announcement No 49 / 2020) including that the global or regional macroeconomic and political environment will not significantly change business conditions for Novo Nordisk during the remainder of 2020. The forward-looking statements on page 21 of the Financial Report for the period 1 January 2020 to 30 June 2020 (Company Announcement No 49 / 2020) also apply to this company announcement. Conference call to be held on 9 October 2020 at 08.30 CEST On 9 October 2020 at 08.30 CEST, corresponding to 2.30 am EDT, a conference call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’. During a 30 minutes call, representatives from Novo Nordisk will elaborate on the changed 2020 outlook and host a Q&A session. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 43,500 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Company announcement No 58 / 2020  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=29768,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
66,2020-09-21,Novo Nordisk lancerer nyt mål om 100% grøn strøm for leverandører,"Bagsværd, den 21. september 2020 – Novo Nordisk har sat et ambitiøst mål om at sikre, at alle leverancer fra virksomhedens direkte leverandører er baseret på 100% grøn strøm senest i 2030. Novo Nordisk vil samarbejde med alle nuværende og nye leverandører om at nå dette mål. Planen bliver præsenteret i forbindelse med Climate Week NYC, som afholdes i denne uge sammen med FN og City of New York. Det nye mål er næste skridt i Novo Nordisks miljøstrategi, ‘Circular for Zero’, som blev lanceret i april 2019 og satte en ultimativ ambition om nul miljøpåvirkning. Størstedelen af Novo Nordisks samlede CO2-udledning stammer fra leverandørkæden, og den nye målsætning om, at leverandørerne også skal bruge grøn strøm, er derfor næste skridt for at opfylde virksomhedens miljøstrategi. Novo Nordisk vil på den måde kunne eliminere mindst 300.000 tons drivhusgasser fra leverandørkæden. Novo Nordisk har i forvejen forpligtet sig til et mål om nul CO2-udledning fra al drift og transport senest i 2030 og nåede i 2020 målet om 100% grøn strøm i virksomhedens globale produktion. “Vores ambition om nul miljøpåvirkning er en af grundpillerne i målet om at være en bæredygtig forretning,” siger Lars Fruergaard Jørgensen, administrerende direktør for Novo Nordisk. “Hvis det skal lykkes, er vi nødt til at kigge ud over vores egen organisation og samarbejde med leverandører indenfor mange forskellige områder om at få sat skub i omstillingen til grøn strøm. Vi håber, at dette initiativ også vil blive til gavn for andre erhvervsvirksomheder, og jeg vil gerne rose vores leverandører for deres engagement – vores nye ambition afhænger af dem.” For at nå målet vil Novo Nordisk samarbejde med leverandørerne og dele virksomhedens erfaringer med at indføre grøn strøm overalt i driften. Leverandørernes evne til at opfylde målet om 100% grøn strøm vil løbende blive evalueret. En af de leverandører, der har forpligtet sig til at blive CO2-neutral senest i 2030, er SCHOTT, som producerer specialglas og leverer emballage til Novo Nordisk. Indkøb af strøm fra vedvarende energikilder bliver en af grundpillerne i virksomhedens strategi. Dr. Frank Heinricht, administrerende direktør for SCHOTT, siger: “Vores omstilling til CO2-neutralitet bliver godt hjulpet på vej af tæt samarbejde med gode kunder, som kan videregive deres erfaringer. For eksempel har Novo Nordisk delt værdifuld viden om deres erfaringer med indkøb af grøn strøm. Som led i vores strategi om at blive CO2-neutral gør vi en målrettet indsats for at reducere miljøpåvirkningen fra vores aktiviteter.” Novo Nordisk håber, at støtten til den grønne omstilling hos leverandørerne også kan bidrage til yderligere reduktion i CO2-udledningen, fordi andre virksomheder også kan få gavn af deres leverandørers omstilling til større bæredygtighed. Om Novo Nordisks miljøstrategi, ‘Circular for Zero’ Miljøstrategien indebærer, at Novo Nordisk skal finde nye veje til at designe produkter, så de kan genbruges; minimere forbruget og sikre, at affald bliver til nye ressourcer; og samtidig samarbejde med leverandører, der deler virksomhedens mål. Novo Nordisk har allerede taget de første skridt i retning af nul miljøpåvirkning, men der er stadig behov for innovation og nytænkning. Novo Nordisk tror på, at nye løsninger vil opstå i takt med, at organisationen får indarbejdet den cirkulære tankegang, som sikrer, at produkter og materialer kan genanvendes som nye ressourcer. Læs mere her. Dette er en oversættelse af den engelske pressemeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske pressemeddelelse gældende. Yderligere information  Vedhæftet fil",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=27498,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
67,2020-09-21,Novo Nordisk launches new 100% renewable power target for suppliers,"Bagsværd, Denmark, 21 September 2020 - Novo Nordisk today announced an ambitious target to ensure all its direct suppliers supply the company based on 100% renewable power by 2030. Novo Nordisk will work with all existing and new suppliers to meet the target. The plan will be presented in connection with Climate Week NYC hosted this week in association with the United Nations and the City of New York. This commitment is the next step in Novo Nordisk’s ‘Circular for Zero’ environmental strategy, which launched in April 2019 and set an ultimate ambition for the company to have zero environmental impact. The majority of Novo Nordisk’s total carbon emissions originate in its supply chain, making this commitment with suppliers on renewable power integral to achieving Novo Nordisk’s environmental strategy. In achieving this target, Novo Nordisk would therefore be eliminating at least 300,000 tons of greenhouse gases from its supply chain. Novo Nordisk has already committed to achieve zero CO2 emissions from the company’s own global operations and transport by 2030 and, in 2020, achieved the target of using 100% renewable power across its global production. “Our ambition of achieving zero environmental impact is a cornerstone of our aspiration to be a truly sustainable business,” said CEO Lars Fruergaard Jørgensen. “Achieving it requires that we look beyond our own organisation and collaborate across multiple sectors with suppliers to accelerate the transition to renewable power. We hope that others across the corporate sector will also benefit from these actions. I would like to pay tribute to the commitment of our suppliers, on whom this new ambition depends.” To reach the target, Novo Nordisk will work alongside suppliers, sharing with them what it has learned on embedding renewable power through its operations. Suppliers’ ability to meet the 100% renewable power target will be continually evaluated. SCHOTT, a producer of specialty glass and supplier of pharma packaging to Novo Nordisk, has committed to becoming carbon neutral by 2030. Sourcing renewable power will be one pillar of their company strategy. SCHOTT CEO Dr Frank Heinricht said: “Our transition to carbon neutrality is fuelled by close exchange and collaboration with valued customers. As one example, Novo Nordisk has shared valuable insights from their own experiences of sourcing renewable power. As part of our Zero Carbon strategy, we are taking action to reduce the environmental impact of our operations.” Novo Nordisk hopes that by supporting its suppliers to use renewable power, it will also be contributing to a reduction in emissions more broadly, as other companies may benefit from their suppliers’ shift to greater sustainability. About Novo Nordisk’s ‘Circular for Zero’ environmental strategy The environmental strategy challenges Novo Nordisk to find new ways to design products that can be recycled or re-used, reshape the business to minimise consumption and waste, and work with suppliers who share the company’s goal. Novo Nordisk is already taking the first steps towards zero environmental impact. But the company is always searching for new ways to do more and believes the answers will come as the business adopts a circular mindset that keeps the products and materials in use. Read more here. About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 43,500 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.  Further information  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=27497,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
68,2020-08-14,Novo Nordisk investerer 850 millioner kroner i produktionsfaciliteterne i Kalundborg,"Bagsværd, Danmark, den 14. August 2020 – Novo Nordisk annoncerer i dag en investering på DKK 850 mio. i udvidelse af sine produktionsfaciliteter i Kalundborg. Med den nye investering runder Novo Nordisk i Kalundborg en samlet investering på DKK 2 mia. i 2020. I Kalundborg producerer Novo Nordisk i dag en række produkter til diabetesbehandling, og med den seneste investering vil et eksisterende produktionsanlæg blive ombygget og udvidet for at skabe yderligere kapacitet til produktion af fremtidens lægemidler. ”Vi har 50 års ekspertise i Kalundborg, og alene fra årtusindeskiftet og frem til 2019 har Novo Nordisk investeret mere end DKK 16 mia. i produktionsfaciliteterne i Kalundborg. I år har vi annonceret en række yderligere investeringer, hvilket understreger Novo Nordisks ambition om en fortsat styrket tilstedeværelse i Danmark og Kalundborg,” siger Michael Hallgren, produktionsdirektør, Novo Nordisk Kalundborg. I februar annoncerede Novo Nordisk investeringer for DKK 800 mio. i opgraderinger og udvidelser af produktionsanlægget i Kalundborg, så de i fremtiden vil kunne producere både eksisterende samt næste generations diabetesprodukter. I maj annoncerede virksomheden endnu en investering på DKK 150 mio. i en ny produktionslinje til pak af tabletter. I juni fulgte en investering på DKK 225 mio. Den nye investering på DKK 850 mio. skaber yderligere kapacitet til produktion af fremtidens produkter. Om Novo Nordisk Kalundborg Novo Nordisks produktionsfaciliteter i Kalundborg blev etableret i 1969 og dækker i dag et areal på 1.200.000 m2. Novo Nordisk Kalundborg beskæftiger omkring 3.000 medarbejdere, og produktionsfaciliteterne i Kalundborg udgør en hjørnesten i Novo Nordisks globale produktion. Her produceres 50% af verdens insulin samt en række biofarmaceutiske produkter. Derudover pakkes og monteres eksisterende diabetes- samt biofarmaceutiske produkter og i fremtiden også tabletter i Kalundborg. Yderligere information  Vedhæftet fil",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=24368,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
69,2020-08-14,Novo Nordisk invests DKK 850 million in production facilities in Kalundborg,"Bagsværd, Denmark, 14 August 2020 – Novo Nordisk today announced plans to invest DKK 850 million in expanding its production facilities in Kalundborg, Denmark. This new investment brings Novo Nordisk’s total investments in site Kalundborg to more than DKK 2 billion in 2020. Novo Nordisk currently manufactures a range of diabetes care products in Kalundborg, and the new investment will be used to rebuild and expand an existing production facility to create additional capacity for manufacturing the pharmaceuticals of the future. “We have 50 years’ expertise in Kalundborg, and from the turn of the millennium until 2019 alone, Novo Nordisk invested more than DKK 16 billion in the Kalundborg facility. This year we have announced several additional investments, underscoring Novo Nordisk’s ambition to continue strengthening its presence in Denmark and Kalundborg,” said Michael Hallgren, senior vice president and head of production, Novo Nordisk Kalundborg. In February, Novo Nordisk announced an investment of DKK 800 million in upgrading and expanding facilities at its production site in Kalundborg to ensure capacity for future production of existing and new-generation diabetes care products. In May, the company announced a further investment of DKK 150 million in a new tablet packaging production line, followed up in June by an investment of DKK 225 million. The new investment of DKK 850 million will expand the company’s capacity for manufacturing the products of the future. About Novo Nordisk Kalundborg Established in 1969, Novo Nordisk’s production site in Kalundborg today covers a total area of 1,200,000 square metres. Novo Nordisk Kalundborg employs around 3,000 people, and the production facilities at Kalundborg are a cornerstone of Novo Nordisk’s global production network. Novo Nordisk manufactures half of the world’s insulin and a range of biopharm products in Kalundborg. In addition, the plant carries out assembly and packaging of diabetes care and biopharm products, in the future also of oral products. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 43,500 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=24367,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
70,2020-08-06,Novo Nordisk's operating profit increased by 9% in Danish kroner and by 8% at constant exchange rates (CER) in the first six months of 2020,"Financial report for the period 1 January 2020 to 30 June 2020 6 August 2020 Novo Nordisk's operating profit increased by 9% in Danish kroner and by 8% at constant exchange rates (CER) in the first six months of 2020 * CER: Constant exchange rates (average 2019) Lars Fruergaard Jørgensen, president and CEO: ""Despite COVID-19, we are satisfied by the performance in the first half of 2020 and by the progress made on our strategic aspirations. We saw a strong uptake of our GLP-1 portfolio and we continue to increase our diabetes value market share. Within R&D, the obesity clinical trial results are very encouraging. As COVID-19 continues to severely impact societies around the world, our priorities continue to be to safeguard our employees, continue supply of our life-saving medicines and help societies around the world to fight the pandemic."" On 6 August 2020 at 13.00 CEST, corresponding to 7.00 am EDT, a conference call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’.  Company announcement No 49 / 2020 Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=9467,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
71,2020-06-29,Rybelsus® approved in Japan for the treatment of type 2 diabetes,"Bagsværd, Denmark, 29 June 2020 - Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Rybelsus® (oral semaglutide), the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) in a tablet, for the treatment of adults with type 2 diabetes. The approval of Rybelsus® in Japan is based on results from the PIONEER clinical trial programme, which involved more than 9,500 adults with type 2 diabetes, including approximately 1,300 adults from Japan. The approved label reflects the Japanese studies, which showed that Rybelsus® 7 mg once daily was comparable to liraglutide 0.9 mg once daily and, in combination with one other oral antidiabetic treatment, Rybelsus® 7 mg once daily was comparable to dulaglutide 0.75 mg once weekly, while Rybelsus® 14 mg once daily resulted in significantly greater reductions in HbA1c than both liraglutide and dulaglutide - the two most widely used injectable GLP-1 receptor agonists in Japan. “We are very excited about the approval of Rybelsus® in Japan, offering people living with type 2 diabetes the first and only oral GLP-1 in a tablet,” said Mads Krogsgaard Thomsen, executive vice president and chief scientific officer. “Providing people living with type 2 diabetes with efficacious and convenient treatment options is essential, as millions of people are currently not achieving target blood sugar levels on available oral antidiabetic medications.” Novo Nordisk will now initiate reimbursement negotiations and expects to launch Rybelsus® in Japan thereafter. Novo Nordisk and MSD will be co-promoting Rybelsus® in Japan. About Rybelsus® Rybelsus® (oral semaglutide), which has the brand name リベルサス® in Japan, is the first and only oral GLP-1 RA approved for the treatment of type 2 diabetes. It is an analogue of the naturally occurring hormone GLP-1. The approval of Rybelsus® is based on the PIONEER programme, a global clinical development programme that comprises eight global and two Japanese phase 3a trials, encompassing more than 9,500 adults with type 2 diabetes. Rybelsus® is administered orally once daily and is approved for use in three therapeutic dosages, 3 mg, 7 mg and 14 mg in Japan. Rybelsus® has also been approved in the US, the EU, Switzerland and Canada. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 43,100 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Company announcement No 42 / 2020   Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=272,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
72,2020-06-18,Novo Nordisk successfully completes AM833 phase 2 trial and phase 1 combination trial with AM833 and semaglutide in obesity,"Bagsværd, Denmark, 18 June 2020 – Novo Nordisk today announced the headline results from two clinical trials with a novel once-weekly subcutaneous amylin analogue (AM833), a phase 2 monotherapy trial and a phase 1 combination trial of AM833 and once-weekly subcutaneous semaglutide 2.4 mg. AM833 phase 2 monotherapy trial The 26-week blinded phase 2 monotherapy trial with AM833 investigated safety, tolerability and efficacy for weight management in 706 people with obesity or overweight  with at least one weight-related comorbidity. The patients were randomised to treatment with five different weekly doses of AM833 (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg, 4.5 mg), liraglutide 3.0 mg or placebo. Approximately 100 people were included in each treatment arm. All treatments were administered in combination with lifestyle intervention therapy. The mean baseline body weight in the trial was 107.4 kg. The trial reached its primary endpoint by demonstrating a weight loss of 10.8% at week 26 with AM833 at the 4.5 mg dose, compared to a weight loss of 3.0 % with placebo1. The treatment difference was statistically significant. AM833 appeared to have a safe and well-tolerated profile. AM833 and semaglutide phase 1 combination trial The 20-week multiple ascending dose phase 1 trial investigated safety, tolerability, pharmacokinetics and weight loss potential of AM833 administrated in combination with semaglutide 2.4 mg in 80 people with obesity or overweight. After 20 weeks of treatment, participants receiving the highest dose lost an average of 17.1% body weight from a mean baseline body weight of 95.1 kg (secondary end-point)1. The trial investigated the number of treatment-emergent adverse events (primary end-point) and AM833 was well-tolerated, with the most common adverse events being gastrointestinal disorders including nausea and vomiting, the majority being non-serious and mild or moderate in severity. The level of gastrointestinal disorders observed for the combination of AM833 and semaglutide in the trial was comparable to what is generally seen for glucagon-like peptides-1 (GLP-1) in monotherapy. ""We are encouraged by these impressive results and we look forward to further assessing the efficacy and safety of AM833,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “The phase 1 and 2 data with AM833 for weight management, especially the combination with semaglutide, further strengthen Novo Nordisk’s obesity pipeline and hold potential to close the gap between pharmacotherapy and bariatric surgery” said Mads Krogsgaard Thomsen. About obesity and AM833 for weight management Obesity is a chronic disease that requires long-term management. It is associated with many serious health consequences and decreased life expectancy. Obesity-related complications are numerous and include type 2 diabetes, heart disease, obstructive sleep apnoea, chronic kidney disease, non-alcoholic fatty liver disease and cancer. AM833 is being investigated by Novo Nordisk for weight management in people with obesity and overweight with at least one weight-related comorbidity. AM833 is an acylated long-acting analogue of the human amylin hormone that induces weight loss by reducing energy intake. About sc semaglutide 2.4 mg for weight management Once-weekly sc semaglutide 2.4 mg is being investigated by Novo Nordisk as a treatment for adults with obesity. Semaglutide is an analogue of the human GLP-1 hormone. It induces weight loss by reducing hunger, increasing feelings of fullness and thereby helping people eat less and reduce their calorie intake. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 43,100 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Company announcement No 40 / 2020  1 Based on trial product estimand: treatment effect if all people adhered to treatment and did not initiate other anti-obesity therapies   Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=274,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
73,2020-06-12,"Semaglutide 2.4 mg shows superior weight loss versus placebo in the phase 3 trials STEP 2 and STEP 3, thereby successfully completing the programme","Semaglutide 2.4 mg shows superior weight loss versus placebo in the phase 3 trials STEP 2 and STEP 3, thereby successfully completing the programme Bagsværd, Denmark, 12 June 2020 – Novo Nordisk today announced headline results from the final two phase 3a clinical trials investigating once-weekly subcutaneous (sc) semaglutide 2.4 mg for weight management. STEP 2 in adults with obesity and type 2 diabetes (T2D) and STEP 3 as an adjunct to intensive behavioural therapy (IBT) in adults with obesity. STEP 2 (obesity and type 2 diabetes)STEP 2 is a 68-week randomised, double-blind, multicentre, placebo-controlled trial. The trial compared the efficacy and safety of once-weekly sc semaglutide 2.4 mg after 68 weeks to placebo and once-weekly sc semaglutide 1.0 mg. Treatment was provided in conjunction with lifestyle intervention, in 1,210 adults with T2D and either obesity or overweight with comorbidities. The trial met both primary endpoints. In all people randomised1, a statistically significant greater weight loss of 9.6% was achieved at 68 weeks with sc semaglutide 2.4 mg, from a mean baseline bodyweight of 99.8 kg, compared to placebo (3.4% weight loss) and sc semaglutide 1.0 mg (7.0% weight loss). 68.8% of those who received sc semaglutide 2.4 mg achieved a weight loss of 5% or more after 68 weeks, compared to 28.5% with placebo. When evaluating the effects of treatment if taken as intended2, people treated with sc semaglutide 2.4 mg achieved a weight loss of 10.6%, compared to a 3.1% weight loss with placebo and 7.5% weight loss with semaglutide 1.0 mg at 68 weeks. 73.2% of those who stayed on sc semaglutide 2.4 mg for 68 weeks achieved a weight loss of 5% or more, compared to 27.6% with placebo. STEP 3 (adjunct to intensive behavioural therapy)STEP 3 is a 68-week randomised, double-blind, multicentre, placebo-controlled trial. The trial investigated the effect of once-weekly sc semaglutide 2.4 mg after 68 weeks compared to placebo in 611 adults with obesity or overweight with comorbidities. Both treatments were in conjunction with IBT, defined as weekly behavioural support, dietician counselling and reduced calorie diet. The trial met both of its primary endpoints. In all people randomised1, a statistically significantly greater weight loss of 16.0% was achieved with sc semaglutide 2.4 mg as an adjunct to IBT, from a mean baseline bodyweight of 105.8 kg, compared to a 5.7% weight loss with placebo plus IBT after the 68‑week treatment period. 86.6% of those treated with sc semaglutide 2.4 mg achieved a weight loss of 5% or more after 68 weeks as an adjunct to IBT, compared to 47.6% with placebo plus IBT. When evaluating the effects of treatment if taken as intended2, people treated with sc semaglutide 2.4 mg plus IBT achieved a weight loss of 17.6%, compared to a 5.0% weight loss with placebo plus IBT. 89.8% of those who received sc semaglutide 2.4 mg plus IBT achieved a weight loss of 5% or more after 68 weeks, compared to 50.0% with placebo plus IBT. In both STEP 2 and STEP 3, sc semaglutide 2.4 mg appeared to have a safe and well‑tolerated profile, consistent with previous findings. The most common adverse events among people treated with sc semaglutide 2.4 mg were gastrointestinal events. Most events were transient, and mild or moderate in severity. “These results continue to build on the highly impressive weight loss reported previously in STEP 1 and 4. Altogether, the results indicate that semaglutide 2.4 mg will play a key role in improving the treatment of people with obesity,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “We have now reported on all the four trials in the STEP programme and we look forward to sharing the results with regulatory authorities.” About obesity and sc semaglutide 2.4 mg for weight management Obesity is a chronic disease that requires long-term management. It is associated with many serious health consequences and decreased life expectancy. Obesity-related complications are numerous and include T2D, heart disease, obstructive sleep apnoea, chronic kidney disease, non-alcoholic fatty liver disease and cancer. Once-weekly sc semaglutide 2.4 mg is being investigated by Novo Nordisk as a treatment for adults with obesity. Semaglutide is an analogue of the human glucagon‑like peptide-1 (GLP-1) hormone. It induces weight loss by reducing hunger, increasing feelings of fullness and thereby helping people eat less and reduce their calorie intake. About the STEP clinical programme STEP (Semaglutide Treatment Effect in People with obesity) is a phase 3 clinical development programme with once-weekly sc semaglutide 2.4 mg in obesity. The global clinical phase 3a programme consists of four trials and has enrolled approximately 4,500 adults with overweight or obesity. STEP 1 – a 68-week safety and efficacy trial of sc semaglutide 2.4 mg versus placebo in 1,961 adults with obesity or overweight. The results were reported on 4 June. STEP 2 – a 68-week safety and efficacy trial of sc semaglutide 2.4 mg versus placebo and once-weekly sc semaglutide 1.0 mg once-weekly in 1,210 adults with type 2 diabetes and either obesity or overweight. STEP 3 – a 68-week safety and efficacy trial of sc semaglutide 2.4 mg versus placebo in combination with intensive behavioural treatment in 611 adults with obesity or overweight. STEP 4 – a 68-week safety and efficacy trial of sc semaglutide 2.4 mg versus placebo in 803 adults with obesity or overweight who have reached the target dose of 2.4 mg after a 20-week run-in. The results were reported on 13 May. About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 43,100 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information   1 Based on the treatment policy estimand (primary statistical approach): treatment effect regardless of treatment adherence or initiation of other anti-obesity therapies 2 Based on the trial product estimand (secondary statistical approach): treatment effect if all people adhered to treatment and did not initiate other anti-obesity therapies  ﻿  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=278,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
74,2020-06-11,Novo Nordisk to acquire Corvidia Therapeutics and expand presence in cardiovascular disease,"Bagsværd, Denmark, 11 June 2020 – Novo Nordisk A/S today announced that it has entered into a definitive agreement to acquire Corvidia Therapeutics Inc., a privately held, clinical stage company focused on the research and development of transformative therapies for cardio-renal diseases. Corvidia Therapeutics’ lead candidate, ziltivekimab, a fully human monoclonal antibody directed against Interleukin-6 (IL-6), is being developed to reduce the risk of major adverse cardiovascular events in chronic kidney disease (CKD) patients with atherosclerotic cardiovascular disease (ASCVD) and inflammation. Under the terms of the agreement, Novo Nordisk will acquire all outstanding shares of Corvidia Therapeutics for an upfront payment of 725 million US dollars in cash. Total payments to Corvidia Therapeutics shareholders could ultimately amount to 2.1 billion US dollars in cash upon the achievement of certain regulatory and sales milestones by Novo Nordisk. The transaction will not impact Novo Nordisk’s previously communicated operating profit outlook for 2020. Novo Nordisk will fund the upfront payment from financial reserves and the ongoing share buyback programme will not be impacted. The acquisition of Corvidia Therapeutics and its lead candidate, ziltivekimab, is aligned with Novo Nordisk’s strategy to expand its presence across a range of cardiometabolic diseases that are closely linked to Novo Nordisk’s core business within diabetes and obesity. Ziltivekimab is being evaluated in a phase 2b dose-finding clinical trial in patients who have an increased risk of ASCVD with CKD and inflammation. “We believe that ziltivekimab has the potential to become a first- and best-in-class treatment to lower the burden of cardiovascular disease in a patient population that is at high risk of major adverse cardiovascular events,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ”This acquisition recognises the important scientific work Corvidia has been doing over the last five years in cardio-renal diseases with a focus on inflammation,” said Marc de Garidel, chief executive officer of Corvidia Therapeutics. “In Novo Nordisk, we have found a partner that has deep expertise in cardiometabolic disease, a proven track record of success in conducting cardiovascular outcomes trials (CVOT), and the infrastructure to accelerate the development of ziltivekimab in order to help patients who need it most.” The transaction is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions. Novo Nordisk was represented by Davis Polk & Wardwell LLP as legal advisor. Corvidia Therapeutics was represented by J.P. Morgan Securities LLC as exclusive financial advisor and Goodwin Procter LLP as legal advisor. About ziltivekimab Ziltivekimab is a fully human monoclonal antibody directed against IL-6, with extended half-life technology. Ziltivekimab has completed two early-stage trials in chronic kidney disease patients where ziltivekimab administered at low doses reduced the levels of C-reactive protein (CRP), a marker of inflammation. Ziltivekimab is currently in an ongoing phase 2b trial (RESCUE) to evaluate ziltivekimab as a once-a-month subcutaneous injection in patients with CKD stage 3-5 and high levels of CRP. RESCUE is designed as a dose-finding trial to enable a global phase 3 cardiovascular outcomes trial to assess the impact of ziltivekimab on major adverse cardiovascular events (MACE) in a patient population with elevated cardiovascular risk. About Corvidia Therapeutics Corvidia Therapeutics is a clinical stage company focused on the research, development, and commercialization of transformative therapies for cardio-renal diseases. The Company is currently developing potential treatments for chronic kidney disease with atherosclerotic cardiovascular disease and inflammation, and high triglyceride-induced acute pancreatitis. Founded in 2015, Corvidia Therapeutics is headquartered in Waltham, Massachusetts. Learn more at: www.corvidiatx.com About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 43,100 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.  Further information   Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=279,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
75,2020-06-04,Novo Nordisk reports weight loss of 14.9% (16.9% if taken as intended) in STEP 1 trial,"Bagsværd, Denmark, 4 June 2020 – Novo Nordisk today announced headline results from STEP 1, a phase 3a trial in the STEP programme. STEP 1 is a 68-week randomised, double-blind, multicentre, placebo-controlled weight management trial. The trial investigated the efficacy and safety of once-weekly subcutaneous (sc) semaglutide 2.4 mg on body weight over 68 weeks compared to placebo in 1,961 adults with obesity or overweight with comorbidities, both in conjunction with lifestyle intervention. The STEP 1 trial met both primary endpoints. In all people randomised1, a statistically significant and superior reduction in body weight was achieved with sc semaglutide 2.4 mg compared to placebo after 68 weeks. People treated with sc semaglutide 2.4 mg achieved a weight loss of 14.9%, from a mean baseline body weight of 105.3 kg, compared to a 2.4% weight loss with placebo. In addition, 86.4% of those who received sc semaglutide 2.4 mg reached a weight loss of 5% or more after 68 weeks, compared to 31.5% with placebo. When evaluating the effects of treatment taken as intended2, people treated with sc semaglutide 2.4 mg achieved a weight loss of 16.9%, compared to a 2.4% weight loss with placebo after 68 weeks and 92.4% achieved a weight loss of 5% or more, compared to 33.1% with placebo. The treatment differences were statistically significant. In the trial, sc semaglutide 2.4 mg appeared to have a safe and well-tolerated profile, as seen with previous trials. The most common adverse events among people treated with sc semaglutide 2.4 mg were gastrointestinal events. Most events were transient, and mild or moderate in severity. “The results from the pivotal STEP 1 trial show that semaglutide 2.4 mg provides unprecedented weight loss after 68 weeks. Further, almost all patients achieved a weight loss of at least 5%, which is widely recognised as clinically relevant. The results from this trial are very encouraging, boding well for the treatment outlook for people with obesity“ says Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “We now look forward to soon sharing additional data from the remaining two STEP clinical trials.” About obesity and sc semaglutide 2.4 mg for weight management Obesity is a chronic disease that requires long-term management. It is associated with many serious health consequences and decreased life expectancy. Obesity-related complications are numerous and include type 2 diabetes, heart disease, obstructive sleep apnoea, chronic kidney disease, non-alcoholic fatty liver disease and cancer. Once-weekly sc semaglutide 2.4 mg is being investigated by Novo Nordisk as a treatment for adults with obesity. Semaglutide is an analogue of the human glucagon‑like peptide-1 (GLP-1) hormone. It induces weight loss by reducing hunger, increasing feelings of fullness and thereby helping people eat less and reduce their calorie intake. About the STEP clinical programme STEP (Semaglutide Treatment Effect in People with obesity) is a phase 3 clinical development programme with once-weekly sc semaglutide 2.4 mg in obesity. The global clinical phase 3a programme consists of four trials, having enrolled approximately 4,500 adults with overweight or obesity. STEP 1 – a 68-week safety and efficacy trial of sc semaglutide 2.4 mg versus placebo in 1,961 adults with obesity or overweight. STEP 2 – a 68-week safety and efficacy trial of sc semaglutide 2.4 mg versus placebo and once-weekly sc semaglutide 1.0 mg once-weekly in 1,210 adults with type 2 diabetes and either obesity or overweight. STEP 3 – a 68-week safety and efficacy trial of sc semaglutide 2.4 mg versus placebo in combination with intensive behavioural treatment in 611 adults with obesity or overweight. STEP 4 – a 68-week safety and efficacy trial of sc semaglutide 2.4 mg versus placebo in 803 adults with obesity or overweight who reached the target dose of 2.4 mg after a 20-week run-in. The results were reported on 13 May 2020. About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 43,100 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Company announcement No 37 / 2020  1 Based on the treatment policy estimand (primary statistical approach): treatment effect regardless of treatment adherence or initiation of other anti-obesity therapies 2 Based on the trial product estimand (secondary statistical approach): treatment effect if all people adhered to treatment and did not initiate other anti-obesity therapies   Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=280,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
76,2020-06-02,EU-supported international research project aims to improve obesity treatment and change the narrative around obesity,"Novo Nordisk leads the international, public-private research consortium ‘SOPHIA’ (Stratification of Obese Phenotypes to Optimize Future Obesity Therapy), which was launched today with the aim of improving risk assessment of comorbidities and treatment for people with obesity. Bagsværd, Denmark, 2 June 2020 ­– Twenty-nine leading international partners from civil society, academia and industry have joined forces to better understand obesity and optimise future treatment. Obesity is a global pandemic currently affecting around 150 million people in Europe and 650 million people worldwide. Obesity complications are common, but we cannot yet predict who will develop any of the 200 known complications of obesity. Moreover, there are insufficient predictors for who will respond to obesity treatments. SOPHIA will identify, characterise and stratify clinically meaningful subpopulations of patients living with obesity to match the right treatment for the right person at the right time. SOPHIA will provide evidence-based classification of predictors for obesity complications and response to obesity treatment while also identifying and charting models for sustainably developing treatment pathways that will be valuable for patients, healthcare systems, researchers and clinicians. “Our mission within SOPHIA is to enable healthcare professionals to reliably predict the complications of obesity and who will respond to treatment,” said Prof Carel le Roux, coordinator of SOPHIA and obesity physician at the Diabetes Complications Research Centre at University College Dublin. SOPHIA Project Leader Dr Marianne Ølholm Larsen Grønning of Novo Nordisk, says: “Obesity is a complex, chronic disease and there is still a lot we do not know, both about the biology of the disease itself and how treatment can improve the lives of patients with obesity. SOPHIA is an important step towards understanding obesity better. The collaboration between excellent contributors from academia, industry and associations holds a big promise that we can deliver strong and unique results.”The voices of people living with obesity will be at the heart of SOPHIA through the establishment of a Patient Advisory Board. It will ensure that patients’ insights, opinions and wishes are placed at the core of SOPHIA and interwoven into the multiple layers of the study. The research group will use its findings to contribute to a more patient-centric and equitable narrative around obesity and its multiple impacts on individuals from both a social and medical perspective. It all starts with obesity being a chronic disease, not something people choose to live with. SOPHIA has been granted €16 million in funding from the Innovative Medicines Initiative (IMI) - a joint undertaking of the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA); JDRF; the Obesity Action Coalition; and T1D Exchange. Some of the methods used in SOPHIA will be: SOPHIA will also investigate health outcomes in people with obesity who have type 1 diabetes. According to Dr Sanjoy Dutta, JDRF Vice President of Research, “With the statistical power afforded by such a large European collaboration, we will be able to investigate the two-way relationship between obesity and type 1 diabetes and ultimately be able to make valid predictions about health outcomes in this traditionally underappreciated population. Since recent epidemiological data indicate that nearly half of adults with T1D in some European countries have overweight or obesity, it is critical for the T1D community to address this challenge.” The project will officially kick off its activities across Europe on 1 June 2020.  It will last until 31 May 2025 and the first milestone is already planned for September 2020.  Project facts Project acronym: SOPHIAStart date: 01 June 2020Duration: 60 monthsBudget: € 16 Mio Coordination: University College Dublin, Prof Carel le RouxProject Lead: Novo Nordisk A/S, Dr Marianne Ølholm Larsen Grønning  SOPHIA partners at a glance  About IMI The Innovative Medicines Initiative (IMI) is Europe’s largest public-private initiative aiming to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. IMI facilitates collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). For further information: www.imi.europa.eu  About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 43,100 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875534. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and T1D Exchange, JDRF, and Obesity Action Coalition.  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=282,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
77,2020-05-27,Novo Nordisk launches new social responsibility strategy to defeat diabetes,"With the strategy, Novo Nordisk’s long-term ambition is to provide access to affordable care to vulnerable patients in every country and accelerate prevention to halt the rise of diabetes. Copenhagen, Denmark, 27 May 2020 ­– At a time of acute global health need, Novo Nordisk today announced the launch of a new social responsibility strategy: ‘Defeat Diabetes’. The strategy strengthens Novo Nordisk’s commitment and introduces new long-term ambitions to provide access to affordable diabetes care to vulnerable patients in every country and to ensure that no child should die from type 1 diabetes. Today, one in every 11 people in the world has diabetes, a figure that is projected to rise to one in nine by 2045 if action is not taken. Diabetes places a great burden on health systems, and Novo Nordisk is committed to work with health authorities and other partners in the countries where it operates, to prevent and treat the disease. “Our purpose to defeat diabetes is necessary now more than ever as diabetes continues to rise, and at a time when the world is suffering from the most devastating pandemic in recent times,” said Lars Fruergaard Jørgensen, CEO of Novo Nordisk. “In addition to innovative medicine, we are committed to help societies defeat diabetes by accelerating prevention to halt the rise of the disease and providing access to affordable care to vulnerable patients in every country. Vulnerability has many faces, and diabetes hits the hardest in vulnerable communities. I am proud that we are stepping up our efforts and working in partnerships to tackle the diabetes crisis at a time of profound need.” As a first step in our ambition to provide access to affordable insulin to vulnerable patients in every country, Novo Nordisk is reducing the ceiling price of human insulin from USD 4 to USD 3 per vial in 76 low- and middle-income countries, which are part of the company’s existing Access to Insulin Commitment. This applies to Least Developed Countries as defined by the UN, other low-income countries as defined by the World Bank and middle-income countries where large low-income populations lack sufficient health coverage. To support the company’s aspiration that no child should die from type 1 diabetes, Novo Nordisk is expanding its Changing Diabetes in Children programme to reach 100,000 children by 2030, up from 25,000. The programme provides care and life-saving medicine for children with type 1 diabetes in low-resource settings. Vice-President of the International Diabetes Federation and partner of the Changing Diabetes in Children initiative Dr Naby Balde states the urgency of action: “Diabetes is rising in every part of the world and good health is not an equal opportunity. The lives of thousands of children living with type 1 diabetes in vulnerable communities have been saved by the Changing Diabetes in Children initiative. I welcome Novo Nordisk’s efforts to vastly expand its reach and their broader efforts to defeat diabetes.” As part of Defeat Diabetes, the company’s Partnering for Change programme with the International Committee of the Red Cross and the Danish Red Cross, supporting care for people with serious chronic diseases in humanitarian crises, is also being extended. The partnership is supporting the integration of diabetes and hypertension care into the Red Cross’s global health operations. Initiatives under Novo Nordisk’s Defeat Diabetes strategy are: Read more about the Defeat Diabetes initiatives here: https://www.novonordisk.com/about-novo-nordisk/defeat-diabetes.html  Further information _______________________  References      1.    Atkinson S, Sigfrid L, Eeles M, Atkinson Z, McKee M. From surviving to thriving: evaluation of the international diabetes federation—life for a child programme. London School of Tropical Medicine and Hygiene; 2015. Accessed 12 Dec 2017.  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=283,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
78,2020-05-27,Novo Nordisk lancerer ny strategi for social ansvarlighed,"København, den 27. maj 2020 ­– Novo Nordisk lancerer i dag en ny strategi for social ansvarlighed under navnet ’Defeat Diabetes’. Med strategien styrker Novo Nordisk en række initiativer for at forebygge og bekæmpe diabetes, og introducerer en ny, langsigtet ambition om at sikre adgang til diabetesbehandling, der er til at betale, for udsatte patienter i alle lande og en ambition om, at ingen børn skal dø af type 1-diabetes. I dag har én ud af 11 mennesker i verden diabetes, og det tal ventes at stige til én ud af ni i 2045, hvis der ikke gøres noget. Diabetes er en betydelig økonomisk byrde for verdens sundhedssystemer, og Novo Nordisk forpligter sig til at arbejde sammen med sundhedsmyndigheder og andre partnere i de lande, hvor virksomheden driver forretning, for at forebygge og behandle sygdommen. ”Vores mål om at bekæmpe diabetes er vigtigere nu end nogensinde, fordi antallet af mennesker med diabetes bliver ved med at stige, samtidig med at verden er ramt af den mest ødelæggende pandemi i nyere tid,” siger Lars Fruergaard Jørgensen, administrerende direktør for Novo Nordisk. ”Diabetes rammer hårdt blandt udsatte befolkningsgrupper, og derfor vil vi sørge for, at der altid er adgang til insulin, der er til at betale, for udsatte patienter, uanset hvor i verden de bor. Mens vi fortsat vil fokusere på at udvikle innovative lægemidler, forpligter vi os med Defeat Diabetes også til at øge den forebyggende indsats for at knække den stigende diabeteskurve.” Som et første skridt i Novo Nordisks ambition om at skabe adgang til insulin, der er til at betale, for udsatte patienter i alle lande, sænker vi prisloftet for human insulin fra 4 til 3 dollars per hætteglas i 76 lav- og mellemindkomstlande, som indgår i virksomhedens eksisterende Access to Insulin Commitment-program. Det omfatter udviklingslande som defineret af FN, andre lavindkomstlande som defineret af Verdensbanken og mellemindkomstlande, hvor store befolkningsgrupper med lav indkomst ikke har adgang til tilstrækkelig sundhedsdækning. For at understøtte virksomhedens ambition om, at ingen børn skal dø af type 1-diabetes, udvider Novo Nordisk programmet Changing Diabetes in Children med målet om at nå ud til 100.000 børn i 2030 fra 25.000 børn i dag. Programmet stiller behandling og livsvigtig medicin til rådighed for børn med type 1-diabetes i lavressourceområder. Dr. Naby Balde, vicepræsident i International Diabetes Federation og partner i Changing Diabetes in Children-programmet, understreger vigtigheden af at handle nu: ”Antallet af mennesker med diabetes stiger overalt i verden, og der er ikke lige muligheder, når det gælder sundhed. Tusinder af børn, der lever med type 1-diabetes i udsatte lokalsamfund, er blevet reddet af Changing Diabetes in Children-programmet. Jeg hilser det velkommen, at Novo Nordisk nu udvider sin indsats betydeligt for at nå ud til flere og sætter bredere fokus på at bekæmpe diabetes.” Som led i Defeat Diabetes udvides også samarbejdsprogrammet Partnering for Change med Den Internationale Røde Kors Komité og Røde Kors i Danmark, som støtter behandling til mennesker med alvorlige kroniske sygdomme under humanitære kriser. Partnerskabet støtter integrationen af diabetes- og blodtryksbehandling i Røde Kors’ globale sundhedsaktiviteter. Initiativerne under Novo Nordisks Defeat Diabetes-strategi: Læs mere om Defeat Diabetes her: https://www.novonordisk.com/about-novo-nordisk/defeat-diabetes.html  Dette er en oversættelse af den originale engelske pressemeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information   Referencer [1]     Atkinson S, Sigfrid L, Eeles M, Atkinson Z, McKee M. From surviving to thriving: evaluation of the international diabetes federation—life for a child programme. London School of Tropical Medicine and Hygiene; 2015. Accessed 12 Dec 2017.   Vedhæftet fil",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=284,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
79,2020-05-13,Semaglutide 2.4 mg demonstrates superior and sustained weight loss versus placebo and in addition a 17.4% weight loss after 68 weeks in STEP 4 trial,"Bagsværd, Denmark, 13 May 2020 – Novo Nordisk today announced headline results from STEP 4, the first completed phase 3a trial in the STEP programme. STEP 4 is a randomised, double-blind, multicentre, placebo-controlled, withdrawal trial exploring sustained weight management with semaglutide vs placebo. The 68-week trial investigated the effect of once-weekly subcutaneous (sc) semaglutide 2.4 mg on body weight in 902 people with obesity or overweight with comorbidities. After the 20-week run-in period, the 803 people reaching the target dose of semaglutide 2.4 mg had reduced their mean body weight from 107.2 kg to 96.1 kg and were randomised to continued treatment with either once-weekly sc semaglutide 2.4 mg or placebo for 48 weeks. The trial achieved its primary objective by demonstrating that in all people randomised1, continued treatment with sc semaglutide 2.4 mg for 48 weeks (after the run-in period) resulted in an additional mean weight loss of 7.9%, from a mean baseline body weight at randomisation of 96.1 kg, whereas people on placebo regained 6.9% of the body weight. The treatment difference was statistically significant. People who received sc semaglutide 2.4 mg for 68 weeks (run-in period plus 48 weeks) achieved a total weight loss of 17.4%. When evaluating the effects of treatment if taken as intended2, people who continued treatment with sc semaglutide 2.4 mg achieved an additional mean weight loss of 8.8% whereas people on placebo regained 6.5%. The treatment difference was statistically significant. People who stayed on sc semaglutide 2.4 mg for 68 weeks achieved a weight loss of 18.2%. In the trial, sc semaglutide 2.4 mg appeared to have a safe and well-tolerated profile. The most common adverse events among people treated with sc semaglutide 2.4 mg were gastrointestinal events. As seen previously with GLP-1 receptor agonists, most events were transient and mild or moderate in severity. “Achieving sustained weight loss without medical therapy is known to be very challenging. STEP 4 shows that people continuing treatment with semaglutide achieved a further substantial weight loss while people switching to placebo, on the other hand, regained a significant amount of weight,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk and continues, “this highlights that obesity is a chronic disease requiring sustained treatment, and we look forward to sharing additional results from the ongoing STEP programme”. About obesity and sc semaglutide 2.4 mg for weight management Obesity is a chronic disease that requires long-term management. It is associated with many serious health consequences and decreased life expectancy. Obesity-related complications are numerous and include type 2 diabetes, heart disease, obstructive sleep apnoea, chronic kidney disease, non-alcoholic fatty liver disease and cancer. Once-weekly sc semaglutide 2.4 mg is being investigated by Novo Nordisk as a treatment for adults with obesity. Semaglutide is an analogue of the human glucagon-like peptide-1 (GLP-1) hormone. It induces weight loss by reducing hunger, increasing feelings of fullness and thereby helping people eat less and reduce their calorie intake. About the STEP clinical programmeSTEP (Semaglutide Treatment Effect in People with obesity) is a phase 3 clinical development programme with once-weekly sc semaglutide 2.4 mg in obesity. The global clinical phase 3a programme consists of 4 trials, having enrolled approximately 4,500 adults with overweight or obesity. STEP 1 – a 68-week safety and efficacy trial of sc semaglutide 2.4 mg versus placebo in 1,961 adults with obesity or overweight. STEP 2 – a 68-week safety and efficacy trial of sc semaglutide 2.4 mg versus placebo and once-weekly sc semaglutide 1.0 mg in 1,210 adults with type 2 diabetes and either obesity or overweight. STEP 3 - a 68-week safety and efficacy trial of sc semaglutide 2.4 mg versus placebo in combination with intensive behavioural treatment in 611 adults with obesity or overweight. STEP 4 – a 68-week safety and efficacy trial of sc semaglutide 2.4 mg versus placebo in 803 adults with obesity or overweight who have reached the target dose of 2.4 mg after a 20-week run-in.  Further information   1 Based on the treatment policy estimand (primary statistical approach): treatment effect regardless of treatment adherence or initiation of other anti-obesity therapies2 Based on the trial product estimand (secondary statistical approach): treatment effect if all people adhered to treatment and did not initiate other anti-obesity therapies Company announcement No 34 / 2020    Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=286,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
80,2020-05-06,Novo Nordisk's sales increased by 16% in Danish kroner and by 14% at constant exchange rates (CER) to DKK 33.9 billion in the first three months of 2020,"Estimated sales growth adjusted for COVID-19-related stocking around 7% at CER * CER: Constant exchange rates (average 2019) Lars Fruergaard Jørgensen, president and CEO: ""Societies are severely impacted by the COVID-19 outbreak, and during the pandemic our key priorities are to safeguard our employees, continue the supply of our life-saving medicines and use our expertise, resources and global reach to help societies around the world during the pandemic. COVID-19-related stocking impacted our results; however, we are satisfied with the underlying commercial performance as well as the progression of our pipeline with the approval of Rybelsus® in the EU and the encouraging phase 2 data for semaglutide in NASH."" On 6 May 2020 at 13.00 CEST, corresponding to 7.00 am EDT, a conference call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’.   Further information about Novo Nordisk is available on novonordisk.com Company announcement No 28 / 2020  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=292,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
81,2020-04-30,Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 30 April 2020,"Bagsværd, Denmark, 30 April 2020 – In accordance with Section 32 of the Danish Capital Markets Act, Novo Nordisk A/S is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred. Referring to Company Announcement no 25/2020 dated 28 April 2020, please find below a statement regarding the total number of voting rights and share capital in Novo Nordisk A/S as per 30 April 2020. 1 Each A share of DKK 0.01 carries 10 votes, whereas each B share of DKK 0.01 carries one vote. Thus, each A share of DKK 0.20 carries 200 votes and each B share of DKK 0.20 (the present denomination of the company's shares) carries 20 votes. Treasury shares are included in the table above but voting rights of treasury shares are suspended at the general meetings of Novo Nordisk A/S. Further information Company announcement No 26 / 2020  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=294,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
82,2020-04-28,Novo Nordisk A/S – Reduction of the share capital,"Novo Nordisk A/S – Reduction of the share capital Bagsværd, Denmark, 28 April 2020 – At Novo Nordisk’s Annual General Meeting on 26 March 2020, it was decided to reduce the company’s B share capital from DKK 372,512,800 to DKK 362,512,800 by cancellation of part of the company’s portfolio of own B shares equal to a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each. Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled B shares at a nominal value of DKK 10,000,000. After the reduction of the share capital, the company’s share capital is nominally DKK 470,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 362,512,800. The reduction of the share capital will not affect Novo Nordisk’s share repurchase programme which will continue as previously announced. Further information  Company announcement No. 25 / 2020 Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=297,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
83,2020-04-04,Rybelsus® (oral semaglutide) approved for the treatment of adults with type 2 diabetes in the EU,"Bagsværd, Denmark, 4 April 2020 - Novo Nordisk today announced that the European Commission (EC) has granted marketing authorisation for Rybelsus® (oral semaglutide), for the treatment of adults with insufficiently controlled type 2 diabetes to improve glycaemic control as an adjunct to diet and exercise. The marketing authorisation applies to all 27 European Union member states and the United Kingdom. Rybelsus® is the first and only oral glucagon-like-peptide-1 (GLP-1) receptor agonist. The approval is based on the results from 10 PIONEER clinical trials, in which Rybelsus® after 52 weeks demonstrated statistically significant reductions in HbA1c vs sitagliptin, empagliflozin and liraglutide and with up to 4.3 kg weight reduction. Across the PIONEER programme, Rybelsus® demonstrated a safe and well-tolerated profile, with the most common adverse event being mild to moderate nausea which diminished over time. “We are very excited about the approval of Rybelsus® as we can now offer people in Europe living with type 2 diabetes the first and only GLP-1 in a tablet,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer. “Based on its strong clinical profile, we believe Rybelsus® has the potential to set a new standard for the treatment of type 2 diabetes, as millions of people are currently not achieving target blood sugar levels on available oral antidiabetic medications.” The launch of Rybelsus® is expected to take place in the first EU countries in the second half of 2020. About Rybelsus® Rybelsus® (oral semaglutide) is an analogue of the naturally occurring hormone GLP-1. Rybelsus® is approved in the US, Switzerland and EU as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is administered once daily and is approved for use in two therapeutic dosages, 7 mg and 14 mg. Rybelsus® is currently under review by several regulatory agencies, including the Japanese Pharmaceuticals and Medical Devices Agency. Further information Company announcement No 21 / 2020  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=301,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
84,2020-03-26,Resolutions from the Annual General Meeting of Novo Nordisk A/S,"Bagsværd, Denmark, 26 March 2020 - Today, Novo Nordisk A/S held its Annual General Meeting (AGM). To comply with all instructions and precautions taken by the Danish authorities in response to the coronavirus pandemic, shareholders were requested not to attend the meeting in person and instead follow the meeting via the live webcast. “The global outbreak of coronavirus is a worldwide humanitarian crisis with serious and tragic consequences for thousands of people, and it is putting our societies under immense pressure” said Helge Lund, chairman of the of Board of Directors. “Our key priorities are to safeguard the wellbeing of our employees and secure the continued supply of lifesaving medicines to the millions of people around the world who rely on these every day. Furthermore, we support impacted societies through different measures” said Lars Fruergaard Jørgensen, president and chief executive officer. “We follow the situation closely and adhere to the local authorities’ recommendations as circumstances change, and many employees across the company are currently working from home using digital tools”.  At the AGM Novo Nordisk further reviewed the coronavirus situation Novo Nordisk continues conduct of all already-initiated clinical trials and no significant delays are expected in trials already close to finalisation. To reflect the current strain on the healthcare system, no new clinical trials are initiated. All Novo Nordisk manufacturing sites are currently in operation ensuring continued supply of medicine to patients worldwide. Most Novo Nordisk products are used for chronic treatment. However, during the period of social distancing implemented in many markets, fewer new patients are temporarily expected to initiate treatment. Novo Nordisk maintains the financial outlook for 2020 as communicated on 5 February 2020. This is based on a number of assumptions in relation to impacts of the coronavirus including normalisation of patient flows in the beginning of second half of 2020. Further update on the coronavirus impact will be provided in connection with the release of the financial results for the first three months of 2020 on 6 May 2020.  Resolutions adopted at the AGM Financial year 2019 Elections Shares and capital Other Composition of the Board of Directors and its committees After the Annual General Meeting, the Board of Directors held a board meeting to appoint members of its committees. The Board of Directors, including its committees, is now composed as follows: Further information Company announcement No 19 / 2020  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=306,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
85,2020-03-16,Novo Nordisk pauses the clinical trials investigating concizumab (anti-TFPI mAB) in haemophilia A and B with or without inhibitors,"Bagsværd, Denmark, 16 March 2020 - Novo Nordisk today announced that two clinical trials in the concizumab phase 3 programme (explorer7 and 8) and one clinical trial in the phase 2 programme (explorer5) have been paused. The three clinical trials were investigating concizumab prophylaxis treatment in haemophilia A and B patients regardless of inhibitor status. Consequently, no additional patients will be recruited, and further treatment of patients currently enrolled in the trials with concizumab will cease. The decision is a result of the occurrence of non-fatal thrombotic events in three patients enrolled in the ongoing phase 3 programme. Novo Nordisk and an independent Data Monitoring Committee are currently assessing the relevance of the events to the continuation of the programme and no conclusions have yet been made.     “While it is disappointing to pause the trials, patient safety is of utmost importance to Novo Nordisk – both for those taking part in our clinical trials and those who use our products on a daily basis” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “Together with relevant authorities, we will now carefully evaluate all available data and decide how to best move forward”. About the concizumab phase 2 and 3 programmes In October 2019, Novo Nordisk initiated the explorer7 phase 3 clinical trial with concizumab in patients with haemophilia A or B with inhibitors towards FVIII or FIX. The objective of the trial was to establish the safety and efficacy of once-daily prophylactic subcutaneous concizumab delivered in a pen device to reduce the number of bleeds. A parallel phase 3 trial in haemophilia A or B patients without inhibitors, explorer8, was initiated in November 2019. The trials were to enrol approximately 293 patients from 32 countries. The explorer5 phase 2 trial was initiated in October 2017 to evaluate the efficacy and safety of once-daily prophylactic subcutaneous concizumab delivered in a pen device to reduce the number of bleeds of haemophilia A patients. The trial currently includes 15 patients. Approximately 109 patients are currently being treated with concizumab. Further information Company announcement No 17 / 2020  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=308,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
86,2020-02-21,Notice for the Annual General Meeting of Novo Nordisk A/S,"Bagsværd, Denmark, 21 February 2020 – The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 26 March 2020 at 2.00 pm (CET) at Bella Center, Center Boulevard 5, DK-2300 Copenhagen S, Denmark. The notice for the Annual General Meeting, including Appendix 1: Proposed Remuneration Policy and Appendix 2: Candidates for the Board of Directors is enclosed. BOARD OF DIRECTORS All board members elected by the Annual General Meeting are up for election. The Board of Directors proposes re-election of all board members elected by the Annual General Meeting: Helge Lund (chairman) Jeppe Christiansen (vice chairman), Brian Daniels, Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Liz Hewitt, Kasim Kutay and Martin Mackay. Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Company announcement No 12 /2020  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=313,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
87,2020-02-07,Novo Nordisk invests DKK 800 million in upgrading and expanding production facilities in Kalundborg,"Bagsværd, Denmark, 7 February 2020 – Novo Nordisk today announced plans to invest DKK 800 million in upgrading and expanding facilities at its production site in Kalundborg, Denmark. The facilities currently manufacture a range of products for diabetes treatment and will be rebuilt and expanded to allow for future production of these products as well as the next generation of diabetes products. The projects are expected to be completed in 2022. “This investment in our production facilities highlights our ambition to continue strengthening our presence in Denmark and Kalundborg. Today, we manufacture around half of the world’s insulin in Kalundborg where we have been present for 50 years. Since the turn of the millennium alone, we have invested more than DKK 16 billion in these facilities, which are a cornerstone of our global production network”, said Michael Hallgren, senior vice president for Novo Nordisk production in Kalundborg. About Novo Nordisk Kalundborg Established in 1969, the site covers a total area of 1,200,000 square metres and employs more than 3,000 people. Besides diabetes products a range of biopharmaceutical products are also produced at the production site in Kalundborg. Further information  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=318,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
88,2020-02-05,Novo Nordisk files annual report with the SEC,"Bagsværd, Denmark, 5 February 2020 ­– Novo Nordisk A/S has filed its Annual Report 2019 on Form 20-F for the financial year 2019 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2019. The reports are available at the SEC's website, www.sec.gov, as well as on novonordisk.com. Further information  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=319,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
89,2020-02-05,Novo Nordisk's operating profit increased by 11% in Danish kroner and by 6% at constant exchange rates (CER) in 2019,"Financial report for the period 1 January 2019 to 31 December 2019 5 February 2020 Novo Nordisk's operating profit increased by 11% in Danish kroner and by 6% at constant exchange rates (CER) in 2019 * CER: Constant exchange rates (average 2018) Lars Fruergaard Jørgensen, president and CEO: ""We are very satisfied with the financial performance in 2019. The results reflect an accelerated sales growth in International Operations and a strong launch of Ozempic® in particular in North America Operations and Region Europe. The Rybelsus® launch in the USA is off to a good start, and we are pleased with the CV label indication for Ozempic® in the USA, and the EU recommendation to approve Rybelsus®, all for the benefit of patients."" On 5 February 2020 at 13.00 CET, corresponding to 7.00 am EST, a conference call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’.  Company announcement No 7 / 2020  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=320,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
90,2020-01-31,Rybelsus® (oral semaglutide) recommended for approval for the treatment of adults with type 2 diabetes by the European regulatory authorities,"Bagsværd, Denmark, 31 January 2020 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorisation for Rybelsus® (oral semaglutide) for the treatment of adults with insufficiently controlled type 2 diabetes to improve glycaemic control as an adjunct to diet and exercise. The CHMP recommends Rybelsus® to be indicated as monotherapy when metformin is considered inappropriate, as well as in combination with other medicinal products for the treatment of type 2 diabetes. The label also refers to clinical trial results with respect to combination with other diabetes medications, effects on glycaemic control, cardiovascular events and the populations studied. “We are very excited about the positive opinion for Rybelsus®, as it is the first and only GLP-1 in a tablet, and we believe it has the potential to set a new standard for the treatment of type 2 diabetes in the EU,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer. “A high proportion of people with type 2 diabetes does not achieve target blood sugar levels, which underpins the need for new and more efficacious solutions to better manage their disease.” Novo Nordisk expects to receive final marketing authorisation from the European Commission in the beginning of second quarter of 2020. About Rybelsus® Rybelsus® (oral semaglutide) is an analogue of the naturally occurring hormone GLP-1, and it is the world’s first and only GLP-1 in a tablet. Rybelsus® is approved in the US and it is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes. It is administered once daily and is approved for use in two therapeutic dosages, 7 mg and 14 mg in the US.  Further information Company announcement No 5 / 2020  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=322,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
91,2020-01-16,Ozempic® approved in the US for CV risk reduction in people with type 2 diabetes and established CVD,"Rybelsus® label updated with additional information from the PIONEER 6 CV outcomes trial Bagsværd, Denmark, 16 January 2020 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a label expansion based on a supplemental New Drug Application (sNDA) for Ozempic® (once-weekly semaglutide) for the indication of reducing the risk of major adverse cardiovascular events (MACE) including cardiovascular death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes and established cardiovascular disease (CVD). The approval is based on the SUSTAIN 6 cardiovascular outcomes trial (CVOT), which demonstrated that Ozempic® statistically significantly reduced the risk of CV death, non-fatal heart attack or non-fatal stroke by 26% versus placebo, when added to standard of care in people with type 2 diabetes with increased CV risk. The FDA also updated the Rybelsus® label to include additional information from the PIONEER 6 CVOT demonstrating CV safety. Rybelsus® demonstrated CV safety by meeting the primary endpoint of non-inferiority for the composite MACE endpoint. The proportion of patients who experienced at least one MACE was 3.8% with Rybelsus® and 4.8% with placebo. “We strongly believe in the benefits of semaglutide and this approval marks an important milestone. Ozempic® now offers people in the US with type 2 diabetes and established cardiovascular disease an effective treatment option to both lower their blood glucose and reduce their cardiovascular risk,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “We also appreciate that the results from the PIONEER 6 study are reflected in the label for Rybelsus® and to further evaluate the cardiovascular risk reduction profile we are currently conducting the cardiovascular outcomes trial, SOUL.” About Ozempic®Ozempic® (once-weekly semaglutide) is an analogue of the naturally occurring hormone glucagon-like peptide-1 (GLP-1). It is administered in a once-weekly injection of 0.5 mg or 1 mg and indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes as well as to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Ozempic® was first approved by the US FDA in 2017 and is now launched in 25 countries. About Rybelsus®Rybelsus® (oral semaglutide) is an analogue of the naturally occurring hormone GLP-1, and it is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes. Rybelsus® is the world’s first and only GLP-1 in a tablet. It is administered once daily and is approved for use in two therapeutic dosages, 7 mg and 14 mg. Rybelsus® was approved by the US FDA in September 2019 and is currently under review by several regulatory agencies, including the European Medicines Agency and the Japanese Pharmaceuticals and Medical Devices Agency. About SUSTAIN 6 and PIONEER 6SUSTAIN 6 was an event and time-driven CVOT for Ozempic®. It was a randomised, double-blinded, placebo-controlled trial evaluating the CV safety of Ozempic® versus placebo when added to standard of care in 3,297 adults with type 2 diabetes with established CVD or high risk of CV events. PIONEER 6 was a purely event-driven, pre-approval CVOT for oral semaglutide. It was a randomised, double-blinded, placebo-controlled trial evaluating the CV safety of Rybelsus® versus placebo when added to standard of care in 3,183 adults with type 2 diabetes with established CVD or high risk of CV events. About the SOUL trialNovo Nordisk is conducting SOUL, a CVOT for Rybelsus® in 9,642 people with type 2 diabetes and established cardiovascular disease, investigating the effects of oral semaglutide on the incidence of MACE, compared to placebo, both on top of standard of care.  Further information Company announcement No 2 /2020  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=325,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
92,2019-12-30,Financial calendar 2020,"Bagsværd, Denmark, 30 December 2019 - Novo Nordisk today publishes its financial calendar for 2020. Further information Company announcement No 76 / 2019  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=327,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
93,2019-12-19,University of Virginia Center for Diabetes Technology and Novo Nordisk enter into research collaboration to develop virtual patient modelling for type 2 diabetes,"Charlottesville, Virginia, US and Bagsværd, Denmark 19 December 2019 – University of Virginia (UVA) Center for Diabetes Technology and Novo Nordisk today announced that they have entered into a five-year research collaboration where UVA and Novo Nordisk will work together on the development of virtual environments focused on modelling of patients with type 2 diabetes. The goal of the collaboration is to enable simulation of the human metabolic system of different types of individual people with type 2 diabetes and simulating virtual patient populations. The research collaboration will utilise UVA’s work within diabetes and extensive knowledge on patient simulation and data-driven models within diabetes.  Aligned with Novo Nordisk’s digital therapeutics strategy, the research collaboration will initially focus on establishing a ‘virtual innovation lab’ between Novo Nordisk and University of Virginia Center for Diabetes Technology to gain a deep understanding of type 2 diabetes for the purpose of enabling virtual simulation. “We are pleased to announce our collaboration with UVA’s Center for Diabetes Technology whose demonstrated capabilities in virtual patient modelling will help enable us to create a highly differentiated approach to the treatment of type 2 diabetes,” said Kenneth Strømdahl, senior vice president for Device R&D in Novo Nordisk. “This important research collaboration reflects Novo Nordisk’s enduring commitment to innovation within the area of digital therapeutics and changing the lives for people living with type 2 diabetes.” “UVA has made solid progress in understanding and quantifying the physiological pathways and treatment behaviour related to diabetes,” said Boris Kovatchev, PhD, director of University of Virginia Center for Diabetes Technology. “We believe this technology has the potential to assist the design of advisory and automated support systems, and we are looking forward to working with Novo Nordisk to extend our research into improving care for patients with type 2 diabetes through data-driven models, analytics, computer simulation and artificial intelligence.” UVA and Novo Nordisk will initially dedicate around 15 employees to the collaboration and expect the support to grow as the research develops. About UVA Center for Diabetes Technology The UVA Center for Diabetes Technology advances the use of technology, including analytics, to allow improved management, monitoring and therapies for patients with diabetes. The Center is a recognized world leader in the technological treatment of diabetes and a hub of an international research network of leading U.S. institutions and research groups in Italy, France, and Argentina. About Novo Nordisk Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,200 people in 80 countries and markets its products in more than 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=329,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
94,2019-11-20,Novo Nordisk and UNICEF announce new partnership  to help prevent childhood overweight and obesity,"New York, US, and Bagsværd, Denmark, 20 November 2019 – Novo Nordisk and UNICEF announced a new partnership today to help prevent childhood overweight and obesity worldwide with an initial focus on interventions in Latin America and the Caribbean. Under this partnership, the United Nations children’s agency and the global healthcare company will combine efforts to enhance knowledge and awareness on how to prevent overweight and obesity and address their root causes. The partnership will initially cover a period of three years. “Childhood overweight and obesity can contribute to ill health, stigmatisation and even reduced educational attainment,” said UNICEF Executive Director Henrietta Fore. “With partners like Novo Nordisk, we want to ensure that preventing childhood obesity and overweight becomes a broader societal responsibility, involving governments, civil society, the private sector, communities and families.” Recent figures from UNICEF’s State of the World’s Children Report 2019 show that childhood overweight and obesity are on the rise almost everywhere. Today, there are 40 million children under the age of five who are overweight. The number of children 5–19 years old who are overweight has nearly doubled in the past 15 years. “There is no doubt that childhood overweight and obesity is a public health crisis that requires immediate attention. Childhood overweight and obesity is more than an individual choice, this is everybody’s business. Together with UNICEF, we hope to help millions of children lead healthy lives and at the same time ease the burden of obesity to society,” says Novo Nordisk President and CEO Lars Fruergaard Jørgensen. The high burden of childhood overweight and obesity presents serious health, societal and economic consequences for the individual, families, their communities and healthcare systems, both immediately and in the longer term. The partnership – announced on World Children’s Day, the 30th anniversary of the Child Rights Convention – aims to: About UNICEF UNICEF works in some of the world’s toughest places, to reach the world’s most disadvantaged children. Across more than 190 countries and territories, we work for every child, everywhere, to build a better world for everyone. UNICEF does not endorse any company, product, brand or service. For more information about UNICEF and its work for children, visit www.unicef.org. Follow UNICEF on Twitter and Facebook. Further information Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=334,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
95,2019-11-20,Novo Nordisk expects to meet its current long-term financial targets and introduces strategic aspirations at the Capital Markets Day 2019,"Bagsværd, Denmark, 20 November 2019 - Novo Nordisk is today hosting a Capital Markets Day where the company is introducing its strategic aspirations. Based on the latest financial guidance provided in connection with the financial report for the first nine months of 2019, Novo Nordisk is on track to meet its current long-term financial targets comprising average operating profit growth of 5%, cash-to-earnings of 85% (3-year average) and operating profit after tax over net operating assets (OPAT/NOA) of 80%. To reflect the broad growth aspects of Novo Nordisk across therapy areas and geographies, the current approach to long-term financial targets focusing on specific financial aspects is no longer sufficiently describing Novo Nordisk’s future growth outlook. Consequently, Novo Nordisk is replacing the current long-term financial targets structure with a more comprehensive approach describing the future growth aspirations of the company under the headline: strategic aspirations for 2025. The strategic aspirations reflecting the sustained growth opportunities until 2025 are intended to cover future growth drivers of Novo Nordisk and thereby providing investors with an understanding of Novo Nordisk’s growth and investment opportunities across therapy areas and geographies. The strategic aspirations are based on four dimensions: Purpose and sustainability: Novo Nordisk is a company with a clear purpose and with the aspiration to be respected for adding value to society. Innovation: Novo Nordisk has a clear therapeutic focus and aspiration to bring innovative treatment to people with serious chronic diseases. Commercial execution: Novo Nordisk sees solid growth opportunities across therapeutic areas and geographies with its broad product portfolio and market-fit approach. Financial outlook: Novo Nordisk is driving operational efficiencies and expects solid sales and operating profit growth leading to attractive capital allocation to shareholders. Throughout today’s presentations, Novo Nordisk is presenting the strategic aspirations for the four dimensions, which reflect the aspirations across therapy areas and commercial units. During the day, based on the Novo Nordisk corporate strategy, senior management presentations are covering the therapeutic areas: Diabetes, Obesity, Biopharm and Other serious chronic diseases as well as all commercial regions including North America Operations and the five regions in International Operations. In addition, Novo Nordisk’s approaches to innovation, product supply and financials are presented. “Novo Nordisk is on track to meet its current long-term financial targets, and we have therefore decided to introduce our new strategic aspirations covering the future growth opportunities,” said Lars Fruergaard Jørgensen, CEO of Novo Nordisk. “We believe the future growth opportunities for Novo Nordisk are very promising and with the introduction of the strategic aspirations, we are now providing a more comprehensive approach to describe our growth drivers.” All main sessions of the Capital Markets Day 2019 are webcast live, and a replay will be made available on the investor section of novonordisk.com. Presentation material for the Capital Markets Day 2019 will be also available throughout the day on the investor section of novonordisk.com.  Further information Company announcement No 70 / 2019  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=335,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
96,2019-11-18,Dicerna and Novo Nordisk enter agreement to discover and develop RNAi therapies for liver-related cardio-metabolic diseases,"Lexington, Massachusetts, US, and Bagsværd, Denmark, 18 November 2019 – Dicerna™ Pharmaceuticals, Inc. and Novo Nordisk A/S today announced an agreement to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases using Dicerna’s proprietary GalXC™ RNAi platform technology. The collaboration plans to explore more than 30 liver cell targets and may deliver multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity, and rare diseases. Dicerna will conduct and fund discovery and preclinical development to clinical candidate selection for each liver cell target, and Novo Nordisk will be responsible for all further development. The agreement represents a significant investment by Novo Nordisk to secure access to Dicerna’s proprietary GalXC RNAi platform, which complements its existing technology base. The collaboration provides Novo Nordisk with the capability to inhibit hepatocyte targets involved in disease regulation and has the potential to generate a number of clinical development candidates. “We are excited to collaborate with Novo Nordisk on this broad research and development effort that extends the reach of our GalXC platform to a wide range of liver cell targets and maximises our opportunities in serious liver diseases,” said Douglas M Fambrough, PhD, president and chief executive officer of Dicerna. “Our efforts will benefit from Novo Nordisk’s expertise in cardio-metabolic diseases and years of experience developing and commercialising innovative therapies worldwide, which will help us advance novel RNAi treatments for underserved patient populations.” The agreement enables each company to co-develop and co-commercialise product candidates discovered under the collaboration. Novo Nordisk will lead programmes targeting cardio-metabolic disorders and other indications with Dicerna having the option to opt into two programmes during clinical development. Dicerna retains rights to initiate two new orphan liver disease programmes for which Novo Nordisk can opt in. For all co-development programmes, the companies will share in the profit/loss of net sales of products consistent with each company’s contribution to co-development costs. “Through this important collaboration with Dicerna, we gain access to an innovative technology and deep expertise in RNA interference,” said Marcus Schindler, senior vice president of Global Drug Discovery in Novo Nordisk. “Dicerna is the ideal partner to discover and develop molecules for targets that may yield multiple potential treatments across disease areas such as diabetes, obesity, cardiovascular and NASH. We will work closely together to unlock the true potential of treating a range of diseases using RNAi therapies, for the benefit of patients.” Under the terms of the agreement, Dicerna will receive: The transaction is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions. About Dicerna's GalXC™ RNAi technology platform Dicerna’s proprietary RNA interference (RNAi) technology platform, called GalXC™, aims to advance the development of next-generation RNAi-based therapies designed to silence disease-driving genes in the liver and other tissues. Liver-targeted GalXC-based compounds enable subcutaneous delivery of RNAi therapies that are designed to bind specifically to receptors on liver cells, leading to internalisation and access to the RNAi machinery within the cells. The GalXC approach seeks to optimise the activity of the RNAi pathway so that it operates in the most specific and potent fashion. Compounds produced via GalXC are intended to be broadly applicable across multiple therapeutic areas, including both liver and non-liver indications. About Dicerna™ Pharmaceuticals, Inc. Dicerna™ Pharmaceuticals, Inc., is a biopharmaceutical company using ribonucleic acid (RNA) interference (RNAi) to develop medicines that silence genes that cause disease. The company is applying its proprietary GalXC™ technology to develop potent, selective, and safe RNAi therapies for treatment of rare diseases, chronic liver diseases, cardiovascular diseases, neurodegenerative diseases, pain and viral infectious disease. Dicerna aims to treat disease by addressing the underlying causes of illness with capabilities that extend beyond the liver to address a broad range of diseases, focusing on target genes where connections between gene and disease are well understood and documented. Dicerna intends to discover, develop and commercialise novel therapies either on its own or in collaboration with pharmaceutical partners. Dicerna has strategic collaborations with Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc. and Boehringer Ingelheim International GmbH. For more information, please visit www.dicerna.com. * Novo Nordisk A/S and Roche transactions are subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary closing conditions. Dicerna™ and GalXC™ are trademarks of Dicerna Pharmaceuticals, Inc. Further information   Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=337,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
97,2019-11-07,Novo Nordisk obtains exclusive worldwide licence to potential NASH candidate UD-014 from UBE Industries,"Bagsværd, Denmark and Yamaguchi, Japan, 7 November ­– Novo Nordisk A/S and UBE Industries Ltd. today announced that Novo Nordisk has obtained an exclusive worldwide licence to UBE’s preclinical asset UD-014, a selective Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) inhibitor small molecule, which has shown promising efficacy in preclinical studies for its anti-inflammatory mechanism of action and antioxidative effect on endothelial cells, and can potentially be used for the treatment of non-alcoholic steatohepatitis (NASH). NASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver, which can lead to fibrosis and impaired liver function. If left untreated, individuals living with NASH may face serious consequences, including end-stage liver disease, liver cancer and the need for liver transplantation, and are at a significantly higher risk of liver-related mortality. Under the terms of the agreement, UBE will receive an upfront payment as well as development and sales milestones plus tiered royalties on the annual net sales. Novo Nordisk will be responsible for the further development, manufacturing and commercialisation of UD-014. “This is a great opportunity for Novo Nordisk, to extend our presence and investment in NASH. We are looking forward to working closely with UBE to transfer the project and to continue the development of UD-014 as there are currently no treatments available for non-alcoholic steatohepatitis,” says Marcus Schindler, senior vice president for Global Drug Discovery in Novo Nordisk. “NASH is a complex disease and we hope that patients living with NASH will get more treatment options for which we believe that UD-014 is a strong potential candidate. We are excited that Novo Nordisk with its broad expertise related to diabetes and metabolic diseases takes on the responsibility for the development. We look forward to working with Novo Nordisk’s team for the transfer of this important project that has a potential to make a difference for the many untreated NASH patients,” says Yoichi Funayama, executive officer of UBE Industries. About UBE Ube Industries, Ltd. is a chemistry-focused company engaged in the areas of pharmaceuticals, construction materials, machinery, energy and environment. In our pharmaceutical business, we particularly focus on producing a new drug from our region with abundant technological innovation and aim to contribute to better health for everyone. To allow us to contribute to progress of medication, we will continue our efforts to produce the seeds for new drugs based on both Drug Discovery”through our own and collaboration research projects and “Manufacture and Supply of API and Intermediates”. For more detailed information on Ube Industries, please visit the website. http://www.ube.co.jp  Further information  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=340,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
98,2019-11-01,Novo Nordisk's operating profit increased by 11% in Danish kroner and by 5% at constant exchange rates (CER) in the first nine months of 2019,"* CER: Constant exchange rates (average 2018) Lars Fruergaard Jørgensen, president and CEO: ""We are very satisfied with the sales growth for the first nine months of 2019, which was driven by all regions in International Operations and growth across our therapy areas Diabetes, Obesity and Biopharmaceuticals. During the third quarter of 2019, we have reached two very important milestones: the US FDA approval of Rybelsus® and the blockbuster status of Ozempic® following the successful launch in the USA; two major events that emphasise the strength of our current and future GLP-1 franchise.”  On 1 November 2019 at 13.00 CET, corresponding to 8.00 am EDT, a conference call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’.   Company announcement No 62 / 2019 Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=345,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
99,2019-10-09,bluebird bio and Novo Nordisk enter into research agreement to develop in vivo genome editing candidates for haemophilia and other severe genetic diseases,"Cambridge, Massachusetts, US and Bagsværd, Denmark 9 October 2019 – bluebird bio, Inc. and Novo Nordisk today announced that they have entered into a three-year research collaboration to jointly develop next-generation in vivo genome editing treatments for genetic diseases, including haemophilia. During the three-year research collaboration, bluebird and Novo Nordisk will focus on identifying a development gene therapy candidate with the ambition of offering people with haemophilia A a lifetime free of factor replacement therapy. The research collaboration will utilise bluebird bio’s proprietary mRNA-based megaTAL™ technology that has the potential to provide a highly specific and efficient way to silence, edit or insert genetic components. Aligned with Novo Nordisk’s haemophilia portfolio, the research collaboration will initially focus on correcting FVIII-clotting factor deficiency, with the potential to explore additional therapeutic targets. “We are pleased to announce our collaboration with bluebird whose demonstrated capabilities in gene therapy will enable the next-generation of innovative products to make a significant impact on patients’ lives,” said Marcus Schindler, senior vice president for Global Drug Discovery in Novo Nordisk. “This important research collaboration aimed at addressing genetic diseases at the DNA level reflects Novo Nordisk’s enduring commitment and dedication to inventing disease-modifying medicines that can truly change the lives of people living with haemophilia and other genetic diseases.” “bluebird has made tremendous progress on enabling an in vivo gene editing platform based on our megaTAL technology, including important advances in high-quality mRNA production and purification,” said Philip Gregory, D. Phil, chief scientific officer, bluebird bio. “We believe this technology has the potential to create a highly differentiated approach to the treatment of many severe genetic diseases. Moreover, we are thrilled to be able to combine this new platform technology with Novo Nordisk’s deep expertise in haemophilia research and therapeutics. We believe this collaboration will move us toward our shared goal of recoding the treatment paradigm and substantially reduce the burden of disease for patients with factor VIII deficiency.” About megaTALs MegaTALs are a single-chain fusion enzyme that combines the natural DNA cleaving processes of Homing Endonucleases (HEs) with the DNA binding region of transcription activator-like (TAL) effectors. TALs are easily engineered proteins that recognize specific DNA sequences. This protein fusion architecture allows the generation of extremely active and highly specific and compact nucleases that are compatible with all current viral and non-viral cell delivery methods. About haemophilia The incidence of haemophilia A is approximately one in 5,000 and of haemophilia B it is approximately one in 25,000 male births respectively1. Over 400,000 males have haemophilia A or B and the disease is severely underdiagnosed in developing countries2.An estimated 304,0003 people live with haemophilia A, which is a result of decreased or defective production of the blood clotting factor VIII. People with haemophilia B, of which there are some 136,0004, have deficiencies in producing clotting factor IX. For people with haemophilia, bleeds often occur in the joints, particularly knees and ankles. Bleeds can also occur in the muscles, soft tissues, gastrointestinal tract or even the brain. Trauma, major surgery, tooth extractions or other minor surgical interventions require medical supervision to manage the associated bleeding. Without treatment, bleeds are painful and can cause lasting damages and lead to impaired mobility. About bluebird bio, Inc. bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Massachusetts headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit. bluebird bio is a human company powered by human stories. We’re putting our care and expertise to work across a spectrum of disorders by researching cerebral adrenoleukodystrophy, sickle cell disease, transfusion-dependent β-thalassemia and multiple myeloma using three gene therapy technologies: gene addition, cell therapy and (megaTAL-enabled) gene editing. bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland. For more information, visit bluebirdbio.com. Follow bluebird bio on social media: @bluebirdbio, LinkedIn, Instagram and YouTube. bluebird bio is a trademark of bluebird bio, Inc. About Novo Nordisk Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 80 countries and markets its products in more than 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. bluebird bio Forward Looking Statements This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the research and development plans for bluebird bio’s gene therapy products and megaTAL platform. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that bluebird bio’s megaTAL platform will not be successful or will not be safe or effective in clinical trials, the risks that our collaboration with Novo Nordisk A/S will not continue or be successful, and the risk that we will not be successful in identifying a gene therapy candidate for development. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our most recent Form 10-K as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and bluebird bio undertakes no duty to update this information unless required by law. Further information _______________________References Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=350,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
100,2019-10-01,Novo Nordisk and Noom to partner around digital health solutions to help people with obesity lose weight and keep it off," Bagsværd, Denmark, 1 October 2019 – Novo Nordisk, a global healthcare company, and Noom, a leading behaviour change company, today announced a collaboration on digital health solutions focusing on weight management and education, with the aim of improving the lives of people living with obesity. The collaboration follows a successful 8-month pilot that combined Noom’s proven, science-backed behaviour change programmes with Novo Nordisk’s more than 95 years of experience in helping people living with chronic diseases. This collaboration, as one of many ways Novo Nordisk is partnering to improve care, will initially make solutions for behaviour change and education available to people with obesity in the US. “We are passionate about improving the lives of people with obesity and finding new solutions to support respectful and complete care, which includes lifestyle change and medical management,” said Camilla Sylvest, Novo Nordisk executive vice president, Commercial Strategy & Corporate Affairs. “We believe that the combination of Noom’s services, with Novo Nordisk’s offerings to support people with obesity, will help educate and empower people with obesity to lose weight, keep it off – and live healthy lives.” Noom's solutions seek to understand individual motivations and obstacles and use cutting-edge technology, including artificial intelligence, behavioural coaching by over 1,000 personal health coaches, data and wellness insights, to guide people towards sustainable change. “Sustainable change can’t happen in a vacuum, and those living with obesity who want to manage their weight are in need of personalised human coaching to help them change their habits, so they can lose weight for good,” said Saeju Jeong, CEO and co-founder of Noom. “We’ve worked with the Novo Nordisk team for over a year and have engaged with over 4,000 people with obesity. We’re enthused by the exciting feedback and know that by jointly testing and refining what works, we will continue to deliver much-needed, sustainable solutions and support, as part of a scientific, insight-driven treatment plan.” About obesity Obesity is a complex, chronic disease that is influenced by multiple aspects, including physiological, psychological, genetic, environmental and socioeconomic factors.1 It is associated with many serious health consequences2 and decreased life expectancy.3 Obesity is not a life choice or simply a question about willpower4 and necessary help and support can be hard to find. There are few healthcare professionals trained in obesity care and patients often see their excess weight as something they should be able to solve on their own.5,6 Like any other chronic disease, the long-term management of obesity requires a full spectrum of treatment approaches, including lifestyle change and intervention, as well as pharmacotherapy or surgery.7 The global increase in the prevalence of obesity is a public health issue that has severe cost implications to healthcare systems.9,10 In 2016, 13% of adults, or approximately 650 million adults, were living with obesity worldwide.9 About Noom, Inc. Noom is the world's leading behaviour change company, disrupting the weight loss and healthcare industries. By combining the power of artificial intelligence, mobile tech, and psychology with the empathy of over 1,000 personal coaches, Noom helps people live healthier lives by changing their long-term habits. More than 50 million people have benefited from Noom’s behaviour change courses, including its virtual diabetes prevention programme, which was the first of its kind to be recognised by the CDC. The Noom platform is already being used by leading healthcare and pharmaceutical companies to improve treatment outcomes for patients worldwide. The company is headquartered in New York City with offices in Seoul and Tokyo. About Novo Nordisk Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 80 countries and markets its products in more than 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Changing Obesity™ is our long-term commitment to improve the lives of people with obesity by changing how the world sees, prevents and treats obesity.  Further information ______________________  References 1.            National Institutes of Health. Clinical Guidelines On The Identification, Evaluation, And Treatment Of Overweight And Obesity In Adults. Available at:                http://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf. Last accessed: April 2018. 2.            Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health.                2009; 9:1–20.3.            Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet.                2009; 373:1083–1096.4.            Rosen H. Is Obesity A Disease or A Behavior Abnormality? Did the AMA Get It Right? . Mo Med. 2014; 111:104–108.5.            Kaplan L, Golden A, Jinnett K, et al. Perceptions of Barriers to Effective Obesity Care: Results from the National ACTION Study. Obesity. 2018; 26:61–69.6.            Caterson I, Alfadda A, Auerbach P, et al. Gaps to bridge: misalignment between perception, reality, and action in obesity. Diabetes Obes Metab. 2019:1–11.7.            Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of                Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014; 129:S102–138.8.            Ferguson C, David S, Divine L, et al. Obesity Drug Outcome Measures – A Consensus Report of Considerations Regarding Pharmacologic Intervention. Available at:                https://publichealth.gwu.edu/pdf/obesitydrugmeasures.pdf. Last accessed: September 2019. 9.            World Health Organization. Obesity and Overweight Factsheet no. 311. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/. Last accessed:                September 2019. 10.          Cawley J, Meyerhoefer C, Biener A, et al. Savings in Medical Expenditures Associated with Reductions in Body Mass Index Among US Adults with Obesity, by Diabetes                Status. Pharmacoeconomics. 2015; 33:707–722.  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=352,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
101,2019-09-20,"Rybelsus® (semaglutide tablets), the first GLP-1 in a tablet approved in the US","Bagsværd, Denmark, 20 September 2019 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Rybelsus® (semaglutide tablets), as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. Rybelsus®, the brand name for oral semaglutide in the US, is the first approved glucagon-like peptide-1 (GLP-1) receptor agonist in a tablet. The approval of Rybelsus® is based on the results from 10 PIONEER clinical trials which included 9,543 adults with type 2 diabetes. Rybelsus® more effectively lowered blood sugar than sitagliptin and empagliflozin. Furthermore, treatment with Rybelsus® resulted in up to 4.4 kg reduction in body weight. Rybelsus® demonstrated a safe and well-tolerated profile across the PIONEER programme, with the most common adverse event being mild to moderate nausea which diminished over time. “We are very excited that we can make the first oral GLP-1 available in the US and thereby expand the treatment options for adults living with type 2 diabetes,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “Novo Nordisk has a very long legacy of developing innovative injectable medicines for people living with diabetes and, with the approval of Rybelsus®, we are now able to bring our innovation into the market for oral antidiabetics.” Novo Nordisk plans to make Rybelsus® available to adults with type 2 diabetes in the US in the fourth quarter of 2019. Conference call On 23 September at 8 am CEST, corresponding to 2 am EDT, a conference call for investors will be held. Investors will be able to listen in via a link on the investor section of novonordisk.com. About Rybelsus® Rybelsus® (oral semaglutide) is an analogue of the naturally occurring hormone glucagon-like peptide-1 (GLP-1). Rybelsus® is the first and only GLP-1 receptor agonist (RA) in a tablet. It is administered once daily and is approved for use in two therapeutic dosages, 7 mg and 14 mg. Rybelsus® is currently under review by several regulatory agencies, including the European Medicines Agency and the Japanese Pharmaceuticals and Medical Devices Agency. Furthermore, Rybelsus® has been applied for a separate indication with the FDA for the reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, with expected review completion by Q1 2020. Further information Company announcement No 54 / 2019  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=356,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
102,2019-09-16,Medtronic and Novo Nordisk enter agreement to provide integrated digital solutions for people with diabetes," The new collaboration aims to develop solutions enabling dosing data from Novo Nordisk smart insulin pens to be shared with Medtronic Continuous Glucose Monitoring devices Dublin, Ireland and Bagsværd, Denmark, 16 September 2019 ­– Medtronic plc and Novo Nordisk A/S today announced a collaboration that will develop solutions to integrate insulin dosing data from future Novo Nordisk smart insulin pens into Continuous Glucose Monitoring (CGM) devices from Medtronic, such as the Guardian™ Connect system. People with diabetes spend an average of one hour a day on self-care, amounting to a full two years devoted exclusively to their disease over their lifetime.1,[2] This new, non-exclusive collaboration reflects both companies′ commitment to making diabetes management easier by integrating key health technologies. “Millions of people living with diabetes work to control their sugar levels and track their insulin injections every day. To help ease the hassle of diabetes management, we are excited to be partnering with Medtronic, the largest medical device company in the world,” said Camilla Sylvest, executive vice president, Commercial Strategy & Corporate Affairs, Novo Nordisk. “We now collaborate with all major CGM device producers, which means we can bring the benefits of smart insulin pens to even more people.” “We see incredible power in combining a variety of data points to drive insights that help people living with diabetes make more informed decisions around managing their glucose levels,” said Alejandro Galindo, president of the Advanced Insulin Management division within the Diabetes Group at Medtronic. “Our new agreement with Novo Nordisk, the world’s largest producer of insulin, will streamline the sharing of two of the most important pieces of information – glucose measurements and insulin dosed. With this, Medtronic can further enhance our market-leading analytics and insights to help ease the burden of diabetes.” By integrating glucose monitoring and insulin dosing data, people with diabetes and their healthcare professionals and caregivers (with permission from the person with diabetes) will be able to automatically track these two important items in a single place, giving people living with diabetes one less thing to think about in the daily management of their condition. Further, being able to view both glucose and insulin data together can facilitate more productive conversations between people and their doctors, enabling more informed decisions on how to better manage glucose levels and increase Time in Range (TIR) – the percentage of time people with diabetes spend in the optimal glycaemic range of 70–180 mg/dL.3 Novo Nordisk expects to launch its durable smart insulin pens, NovoPen® 6 and NovoPen Echo® Plus, as well as its disposable, pre-filled injection solution starting in 2020. Once available, smart insulin pens will be compatible with both Android and iOS devices. The Guardian Connect system will be updated as well to integrate data from these Novo Nordisk smart pens. Time in Range Time in Range refers to the percentage of time people with diabetes spend in the optimal glycaemic range of 70–180 mg/dL. The goal with diabetes management is to increase time spent in this target range and to minimise high and low sugar levels. Poor glycaemic control can lead to both immediate and long-term complications such as damage to blood vessels – increasing the risk of coronary artery disease and stroke. Damage to blood vessels can also lead to loss of vision, kidney disease and nerve damage. About the Guardian Connect system As the only CGM system with predictive alerts up to 60 minutes in advance, the Guardian™ Connect system is a smart CGM system that helps people with diabetes stay ahead of high and low glucose events by empowering people using multiple daily injections (MDI) to more proactively manage their diabetes with meaningful, personalised insights. Healthcare providers may access this CGM data with their patient’s permission to run robust reports that help them inform therapy decisions and improve engagement with patients. About Medtronic Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together. The Diabetes Group at Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health. About Novo Nordisk Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 80 countries and markets its products in more than 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information References  1 Safford MM, Russell L, Suh DC, Roman S, Pogach L. How much time do patients with diabetes spend on self-care? J Am Board Fam Pract. 2005;18:262-270. 2 Iyengar V, Wolf A, Brown A, Close K. Challenges in diabetes care: can digital health help address them? Clin Diabetes. 2016;34:133-141. 3 Battelino et al., Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019 Aug; 42(8): 1593-1603.  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=360,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
103,2019-08-16,Novo Nordisk A/S: Securities lawsuit filed in Denmark against Novo Nordisk,"Bagsværd, Denmark, 16 August 2019 - Novo Nordisk A/S has today been informed that a securities lawsuit has been filed against the company in Denmark. The lawsuit is filed by a number of shareholders. The claim is for a total amount of DKK 11,785,192,218 based on their trading and holding of shares in Novo Nordisk A/S during the period 3 February 2015 to 2 February 2017. The lawsuit alleges that Novo Nordisk made misleading statements and did not make appropriate disclosures regarding its sales of insulin products in the USA. The lawsuit appears to contain broadly similar allegations to those of the previously announced securities class-action lawsuit filed in the USA in 2017 on behalf of all purchasers of Novo Nordisk American Depository Receipts (ADRs). Novo Nordisk disagrees with the allegations and is prepared to defend the company in this matter. Further information Company announcement No 48 / 2019  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=366,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
104,2019-08-09,Novo Nordisk's operating profit increased by 12% in Danish kroner and by 6% at constant exchange rates (CER) in the first six months of 2019," * CER: Constant exchange rates (average 2018) Lars Fruergaard Jørgensen, president and CEO: ""We are pleased with the sales growth in the first half of 2019, which is driven by all regions in International Operations. The launch of Ozempic® is expanding the GLP-1 market, and we are encouraged by the positive market reception in both North America and Europe. With the initiation of four major late-stage clinical trials, we continue to investigate the clinical benefits of semaglutide across multiple indications. The solid financial performance in the first half of 2019 has enabled us to raise our outlook for the full-year”. On 9 August 2019 at 13.00 CEST, corresponding to 7.00 am EDT, a conference call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’.  Further information Company announcement No 46 /2019 Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=368,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
105,2019-06-20,"Esperoct® (turoctocog alfa pegol, N8-GP) approved in the EU","Bagsværd, Denmark, 20 June 2019 – Novo Nordisk today announced that the European Commission has granted marketing authorisation for Esperoct® for the treatment of adolescents (≥12 years of age) and adults with haemophilia A. The authorisation covers all 28 European Union member states. Esperoct® is the brand name for turoctocog alfa pegol, N8-GP. Esperoct® is indicated for prophylaxis and on-demand treatment of bleeding as well as for surgical procedures in adolescents and adults with haemophilia A (congenital factor VIII deficiency). The efficacy and safety evaluation was based on the results from the largest pre-registration clinical programme conducted in haemophilia A, with inclusion of 270 previously treated people (PTPs) with severe haemophilia A and more than 5 years of clinical exposure. The marketing authorisation follows the positive opinion from the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), provided 26 April 2019. “We are excited about the approval of Esperoct® in the EU, and we consider it an important expansion of the treatment options for patients with haemophilia A,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “We are confident that Esperoct® will provide people with haemophilia A a simple and less burdensome, predictable dosing regimen for prophylaxis as well as treatment of bleeding episodes, resulting in improved quality of life."" Novo Nordisk expects to launch Esperoct® in the first European countries during the second half of 2019. About Esperoct®Esperoct® (turoctocog alfa pegol, N8-GP) is an extended half-life factor VIII molecule for replacement therapy in people with haemophilia A, which provides a 1.6-fold half-life prolongation in adults/adolescents compared to standard half-life factor VIII products.Esperoct® was shown to provide effective routine prophylaxis in people with severe haemophilia A through a simple, predictable dosing regimen of one injection every 4 days in adults and adolescents. Esperoct ® provided effective prophylaxis with an annual bleeding rate of 1.18 when dosed at 50 IU/kg every 4 days in adults and adolescents. Furthermore, Esperoct® was found to be efficacious in treatment and control of bleeding episodes and perioperative management. Across the clinical trials and age groups, Esperoct® was well tolerated and no safety concerns were identified. The overall safety profile of Esperoct® is similar to what has been reported for other long-action FVIII products.  Further information  Attachment",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=379,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
106,2019-05-03,Novo Nordisk's operating profit increased by 14% in Danish kroner and by 8% at constant exchange rates (CER) in the first three months of 2019," * CER: Constant exchange rates (average 2018) On 3 May 2019 at 13.00 CEST, corresponding to 7.00 am EDT, a conference call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under 'Investors'. Presentation material for the conference call will be available approximately one hour before on the same page. Contacts for further information Company announcement No 30 / 2019",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=389,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
107,2019-04-30,Novo Nordisk A/S - Total number of voting rights and share capital in Novo Nordisk A/S as of 30 April 2019,"Bagsværd, Denmark, 30 April 2019 - In accordance with Section 32 of the Danish Capital Markets Act, Novo Nordisk A/S is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred. Referring to Company Announcement no 24/2019 dated 24 April 2019, please find below a statement regarding the total number of voting rights and share capital in Novo Nordisk A/S as per 30 April 2019. Further information Company announcement no. 28 / 2019  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=391,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
108,2019-04-30,Novo Nordisk to achieve target of 100% renewable power in production and launches new ambition aiming for zero environmental impact,"Bagsværd, Denmark, 30 April 2019 - Novo Nordisk today announced that it will achieve its target to use only renewable electricity in its global production facilities by 2020. The announcement follows a new investment in a 672-acre solar panel installation, roughly the size of 500 football fields, in North Carolina, US, which will provide power to Novo Nordisk's entire US operations from early 2020. Novo Nordisk is the first pharmaceutical company in RE100 to use only renewable electricity in production. RE100 is a collaborative, global initiative of businesses committed to using 100% renewable electricity. Novo Nordisk furthermore announced a new target of achieving zero CO2 emissions from all operations and transport by 2030. The goal is part of a new and ambitious 'Circular for Zero' environmental strategy with the ultimate aim of making Novo Nordisk a company that has zero environmental impact. The strategy will see Novo Nordisk take steps to minimise consumption and turn waste into resources, design and produce products so that they can be recovered and re-used and collaborate with suppliers to embed circularity in its supply chain. ""More than 29 million people use our medicines and from early next year, they can do so knowing that they're produced using only renewable electricity,"" said Lars Fruergaard Jørgensen, president and CEO. ""By committing to achieve zero emissions across our operations and transport by 2030 and by applying a circular mindset across our entire business, we are working towards a day when we will be able to say that Novo Nordisk is a company with zero environmental impact."" In addition to the zero emissions target, the Circular for Zero strategy commits the company to a significant shift towards circular thinking within three focus areas: 1. Circular company:Novo Nordisk will continue to reduce the environmental footprint of its production by working towards the elimination of waste sent to landfill and zero loss of water, energy and resources. 2. Circular supply: Novo Nordisk will reduce environmental impact across its supply chain by collaborating with suppliers to encourage circular business practices and by increasing procurement of recycled and carbon-neutral materials and resources. 3. Circular products: Novo Nordisk will upgrade existing products and design new products based on circular principles and work towards a sustainable solution for the reuse and recycling of products. To help achieve its new ambitious target and to accelerate the adoption of circular thinking across the business, Novo Nordisk will partner with the Ellen MacArthur Foundation, which has a mission to accelerate the transition to a circular economy. Joe Murphy, CE100 Lead at Ellen MacArthur Foundation, said, ""We are happy that Novo Nordisk has become the first pharmaceutical company to join CE100, which is the world's leading circular economy network. Novo Nordisk brings a track record of delivering on their commitments, having already shifted to 100% renewable power within its production. With its 10-year ambition to implement circularity across the company, Novo Nordisk now belongs to a select group of leading organisations who are breaking new ground on the transition to a circular economy."" Notes to editors Every year, Novo Nordisk uses large amounts of energy to manufacture and distribute vials and injection pens to people who need them. That puts the company on the frontline of some of today's biggest environmental challenges. In 2015, Novo Nordisk made a commitment with The Climate Group and CDP joining RE100, alongside 165 other global companies, to put reaching the ambitious goal of 100% renewable power in its production facilities by 2020 at the heart of its work. Today an agreement to run its new facility in North Carolina using 100% solar power means it is now on course to use only renewable electricity across its production plants. Novo Nordisk is the first pharmaceutical company in RE100 to have reached this goal. Novo Nordisk's production in Tianjin in China uses 100% windmill power. In Montes Claros in Brazil the company uses 100% water power, and in Europe all production sites use 100% windmill power. In Denmark all facilities - production and offices - run on 100% renewable power. Visit novonordisk.com for photos and information on Circular for Zero supporting this press release. Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=392,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
109,2019-04-30,"Novo Nordisk når mål om 100% grøn strøm i produktionen i 2020 og lancerer ny ambition, der sigter mod nul miljøpåvirkning","Bagsværd, den 30. april 2019 - Novo Nordisk meddeler i dag, at virksomheden når sit mål om udelukkende at bruge elektricitet fra vedvarende energikilder på alle sine fabrikker i hele verden i 2020. Det sker på baggrund af en ny investering i et solcelleanlæg på 272 hektarer - et areal på størrelse med 500 fodboldbaner - i North Carolina i USA, som skal levere elektricitet til alle Novo Nordisks amerikanske driftsenheder fra begyndelsen af 2020. Novo Nordisk er den første farmavirksomhed i RE100, der udelukkende bruger strøm fra vedvarende energikilder i produktionen. RE100 er en global sammenslutning af virksomheder, der har forpligtet sig til udelukkende at bruge elektricitet fra vedvarende energikilder. Novo Nordisk har samtidig sat et nyt mål om nul CO2-udledning fra global drift og transport senest i 2030. Målet er led i en ny og ambitiøs miljøstrategi, 'Circular for Zero', der skal gøre Novo Nordisk til en virksomhed med nul miljøpåvirkning. Strategien indebærer, at Novo Nordisk skal minimere forbruget; sikre, at affald bliver til nye ressourcer; designe og fremstille produkter, som kan genbruges; og samtidig samarbejde med leverandører om at indarbejde en cirkulær tilgang i hele forsyningskæden. ""Flere end 29 mio. mennesker overalt i verden bruger vores medicin, og fra starten af næste år kan de gøre det med bevidstheden om, at den er fremstillet udelukkende ved hjælp af grøn strøm,"" siger Lars Fruergaard Jørgensen, administrerende direktør for Novo Nordisk. ""Ved at forpligte os til målet om nul CO2-udledning fra al drift og transport senest i 2030, samtidig med at vi indarbejder den cirkulære tankegang i hele virksomheden, arbejder vi os frem mod en dag, hvor vi kan sige, at Novo Nordisk er en virksomhed, der ingen påvirkning har på miljøet."" Foruden målet om nul CO2-udledning forpligter Circular for Zero-strategien Novo Nordisk til at indføre en cirkulær tankegang indenfor tre fokusområder: 1. Cirkulær virksomhed:Novo Nordisk vil fortsætte med at reducere miljøaftrykket fra produktionen ved at arbejde hen imod eliminering af affald, der sendes til deponering, og nul spild af vand, energi og ressourcer. 2. Cirkulære indkøb: Novo Nordisk vil reducere miljøpåvirkningen i hele forsyningskæden ved at samarbejde med leverandører om at tilskynde til cirkulære forretningsprincipper og øge indkøb af genanvendte og CO2-neutrale materialer og ressourcer. 3. Cirkulære produkter: Novo Nordisk vil opgradere eksisterende produkter og designe nye produkter baseret på cirkulære principper og arbejde hen imod en bæredygtig løsning for genbrug og genanvendelse af produkter. For at hjælpe med til at nå det nye, ambitiøse mål og få indført den cirkulære tankegang hurtigere i hele virksomheden vil Novo Nordisk samarbejde med Ellen MacArthur Foundation, som arbejder for at fremme omstillingen til en cirkulær økonomi. ""Vi er glade for, at Novo Nordisk som den første farmavirksomhed har tilsluttet sig CE100, som er verdens førende netværk af virksomheder, der ønsker at fremme dagsordenen om cirkulær økonomi,"" siger Joe Murphy, CE100 Lead hos Ellen MacArthur Foundation. ""Novo Nordisk har en lang tradition for at opfylde deres målsætninger og har allerede nået målet om omstilling til 100% grøn strøm i produktionen. Med ambitionen om at indføre cirkulære principper overalt i virksomheden i løbet af de næste 10 år tilhører Novo Nordisk nu en eksklusiv gruppe af førende organisationer, der går forrest i omstillingen til en cirkulær økonomi."" Bemærkninger til redaktionen Novo Nordisk bruger årligt store mængder energi til fremstilling og distribution af hætteglas og injektionspenne og kæmper derfor med en række af tidens store miljøudfordringer. I 2015 tilsluttede Novo Nordisk sig sammen med 165 andre globale virksomheder RE100-initiativet, som ledes af The Climate Group og CDP, og forpligtede sig dermed til, at hele elforbruget i produktionen skal dækkes af vedvarende energikilder senest i 2020. På baggrund af en ny aftale om at drive den nye fabrik i North Carolina ved hjælp af 100% solenergi er Novo Nordisk i dag på vej til at nå målet om udelukkende at bruge grøn strøm i den globale produktion. Novo Nordisk er den første farmavirksomhed i RE100, der har nået dette mål. Novo Nordisks produktionsanlæg i Tianjin i Kina bruger 100% vindenergi. Fabrikken i Montes Claros i Brasilien bruger 100% vandenergi, og alle produktionsanlæg i Europa bruger100% vindenergi. I Danmark bruger alle driftsenheder - både produktion og kontorer - udelukkende strøm fra vedvarende energikilder. Fotos og information om Circular for Zero kan findes på novonordisk.com. Dette er en oversættelse af den originale engelske pressemeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=393,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
110,2019-04-26,"Novo Nordisk receives positive opinion from the European regulatory authorities for Esperoct® (turoctocog alfa pegol, N8-GP) for the treatment of haemophilia A","Bagsværd, Denmark, 26 April 2019 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), adopted a positive opinion for the use of Esperoct® (turoctocog alfa pegol, N8-GP) recommending marketing authorisation for the treatment of adolescents and adults with haemophilia A. The CHMP recommends Esperoct®, the brand name for turoctocog alfa pegol, N8-GP, to be indicated for prophylaxis and on-demand treatment of bleeding as well as for surgical procedures in adolescents (>=12 years of age) and adults with haemophilia A (congenital factor VIII deficiency). The recommendation is based on the results from the largest pre-registration clinical programme conducted in haemophilia A, with inclusion of 270 previously treated people (PTPs) with severe haemophilia A and more than 5 years of clinical exposure. ""We are happy to receive the positive opinion for Esperoct® in the EU, and we consider it an important expansion of the treatment options Novo Nordisk can offer people with haemophilia A,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""We are confident that Esperoct® can provide a less burdensome and simple dosing regimen for prophylaxis and treatment of bleeding episodes, resulting in improved quality of life for people with haemophilia A."" About Esperoct® Esperoct® (turoctocog alfa pegol, N8-GP) is an extended half-life factor VIII molecule for replacement therapy in people with haemophilia A, which provides a 1.6-fold half-life prolongation in adults/adolescents compared to standard half-life factor VIII products. Esperoct® was shown to provide effective routine prophylaxis in people with severe haemophilia A through a simple, fixed dosing regimen of one injection every 4 days in adults and adolescents. Esperoct® provided effective prophylaxis and maintained a low median ABR of 1.18 when dosed at 50 IU/kg every 4 days in adults and adolescents. Furthermore, Esperoct® was found to be efficacious in treatment and control of bleeding episodes and perioperative management. Across the clinical trials and age groups, Esperoct® was well tolerated and no safety concerns were identified. The overall safety profile of Esperoct® is similar to what has been reported for other long-action FVIII products. Further information Company announcement No 26/2019",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=395,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
111,2019-04-26,Novo Nordisk files for EU regulatory approval of oral semaglutide for the treatment of type 2 diabetes,"The submission is based on the results from 10 PIONEER clinical trials, which included 9,543 adults with type 2 diabetes. In the PIONEER programme, people treated with oral semaglutide demonstrated greater HbA1c reductions and weight loss in all completed head-to-head trials versus sitagliptin, empagliflozin, liraglutide and dulaglutide, at the end of the trials. Across the PIONEER trials, oral semaglutide had a safe and well-tolerated profile consistent with the GLP-1 receptor agonist (RA) class, with the most common adverse event being nausea. ""Achieving glycaemic control remains a challenge for people with type 2 diabetes, and despite availability of several oral treatment options, a high proportion do not achieve target blood sugar levels,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""We are excited about the regulatory filing of oral semaglutide in Europe, the first GLP-1 receptor agonist in a tablet, as we believe oral semaglutide has the potential to further improve the treatment of adults living with type 2 diabetes."" Oral semaglutide has now been submitted for regulatory approval in the US, the EU and Canada. Further information Company announcement No 25 / 2019",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=396,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
112,2019-04-24,Novo Nordisk A/S - Reduction of the share capital,"Bagsværd, Denmark, 24 April 2019 - At Novo Nordisk's Annual General Meeting on 21 March 2019, it was decided to reduce the company's B share capital from DKK 382,512,800 to DKK 372,512,800 by cancellation of part of the company's portfolio of own B shares equal to a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each. Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled B shares at a nominal value of DKK 10,000,000. After the reduction of the share capital, the company's share capital is nominally DKK 480,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 372,512,800. The reduction of the share capital will not affect Novo Nordisk's share repurchase programme which will continue as previously announced. Further information Company announcement no. 24 / 2019 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=399,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
113,2019-04-12,Gilead Sciences and Novo Nordisk announce intent to initiate a clinical collaboration in NASH,"Foster City, California, and Bagsværd, Denmark, 12 April 2019 - Gilead Sciences, Inc. and Novo Nordisk A/S today announced that the companies intend to collaborate on a clinical trial combining compounds from their respective pipelines in nonalcoholic steatohepatitis (NASH). The intended clinical trial will be a proof-of-concept study combining Novo Nordisk's semaglutide (GLP-1 analogue) and Gilead's cilofexor (FXR agonist) and firsocostat (ACC inhibitor) for the treatment of patients with NASH. The companies are also exploring the potential to collaborate on preclinical research to advance understanding of the disease. NASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver, which can lead to scarring, or fibrosis, that impairs liver function. If left untreated, individuals living with NASH may face serious consequences, including end-stage liver disease, liver cancer and the need for liver transplantation, and are at a significantly higher risk of liver-related mortality. ""NASH is a complex disease that often affects people with diabetes and metabolic syndrome. Currently, patients living with NASH have limited treatment options. We are excited to work with Novo Nordisk on this important collaboration, which would bring together Novo Nordisk's broad expertise related to diabetes and metabolism and Gilead's expertise in both liver disease and combination therapies,"" said John McHutchison, AO, MD, chief scientific officer and head of Research and Development at Gilead Sciences. ""We look forward to working with the Novo Nordisk team to explore opportunities to advance our complementary research capabilities and approaches in NASH to help address this significant unmet need for patients."" ""We are very pleased about the potential to enter into this clinical collaboration with Gilead, which would combine Novo Nordisk's semaglutide programme in NASH with Gilead's clinical programmes to provide novel approaches for the treatment of the disease. By combining the leading molecular science and clinical expertise of our two companies within the rapidly expanding liver and metabolic diseases, we aim to develop innovative, new and effective combination therapies to help people with NASH,"" said Mads Krogsgaard Thomsen, chief science officer and executive vice president of Novo Nordisk. Cilofexor and firsocostat, alone or in combination, are investigational compounds and are not approved by the US Food & Drug Administration (FDA) or any other regulatory authority. Safety and efficacy have not been established for these agents. Semaglutide has not been approved by the FDA or any other regulatory authority for the treatment of patients living with NASH. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercialises innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company's website at www.gilead.com. Further information ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=401,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
114,2019-03-29,Novo Nordisk investerer 650 mio. kr. i optimering og udvidelse af produktionsfaciliteterne i Kalundborg,"Bagsværd, den 29. marts 2019 - Novo Nordisk investerer 650 mio. kr. i optimering og udvidelse af fabrikker på produktionssitet i Kalundborg. Fabrikkerne, der i dag producerer produkter til diabetesbehandling, skal bygges om, så de fremadrettet også kan producere næste generation af produkter. Projekterne forventes afsluttet i 2020. ""Investeringerne i fabrikkerne er med til at understrege Novo Nordisks ambition om en fortsat styrket tilstedeværelse i Danmark og Kalundborg. Novo Nordisk producerer i dag ca. halvdelen af verdens insulin i Kalundborg, og vi har været til stede i Kalundborg i 50 år. Alene fra årtusindeskiftet har Novo Nordisk investeret mere end 15 mia. kr. i Kalundborg, der er en hjørnesten i det globale produktionsnetværk,"" siger Michael Hallgren, produktionsdirektør, Novo Nordisk Kalundborg. Novo Nordisk og Novozymes er aktive partnere i Kalundborg Symbiose, der er et ressourcesamarbejde mellem seks private virksomheder og tre offentlige aktører. I symbiosen bliver én virksomheds reststrøm eller biprodukt anvendt som en ressource i en anden virksomheds produktion. Samarbejdet udveksler i dag 22 forskellige ressourcestrømme til gavn for miljø og økonomi. Novo Nordisks produktionssite i Kalundborg, hvor Novozymes også har produktionsfaciliteter, blev etableret i 1969 og dækker i dag et areal på 1.200.000 m2. Novo Nordisk Kalundborg beskæftiger næsten 3.500 medarbejdere, og de 14 fabrikker udgør en hjørnesten i Novo Nordisks globale produktion. Her produceres 50% af verdens insulin samt en række biofarmaceutiske produkter. Yderligere information ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=406,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
115,2019-03-29,Novo Nordisk invests DKK 650 million in upgrading and expanding production facilities in Kalundborg,"Bagsværd, Denmark, 29 March, 2019 - Novo Nordisk today announced plans to invest DKK 650 million in upgrading and expanding facilities at its production site in Kalundborg, Denmark. The facilities in question are currently manufacturing a range of products for diabetes treatment and will be rebuilt to allow for future production of the next generation of products. The projects are expected to be completed in 2020. ""The investments in production facilities highlight Novo Nordisk's ambition to continue strengthening its presence in Denmark and Kalundborg. Today, Novo Nordisk manufactures around half of the world's insulin in Kalundborg and we have had a presence in Kalundborg for 50 years. Since the turn of the millennium alone, Novo Nordisk has invested more than DKK 15 billion in Kalundborg, which is a cornerstone of the company's global production network"", says Michael Hallgren, SVP for Novo Nordisk production in Kalundborg. Novo Nordisk and Novozymes are active partners of the Kalundborg Symbiosis, which is a resource partnership between six private companies and three public operators. The main principle of the industrial symbiosis is that a residue or byproduct from one company becomes a resource in another company's production process. Today, 22 different types of resources are exchanged in the network, resulting in economic and environmental benefits. Novo Nordisk's production site in Kalundborg also houses production facilities for Novozymes. Established in 1969, the site today covers a total area of 1,200,000 square metres. Novo Nordisk Kalundborg employs close to 3,500 people, and the 14 factories housed on the site are a cornerstone of Novo Nordisk's global production network. The site produces 50% of the world's insulin as well as a range of biopharmaceutical products. Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=405,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
116,2019-03-21,Resolutions from the Annual General Meeting of Novo Nordisk A/S,"Bagsværd, Denmark, 21 March 2019 - Today, Novo Nordisk A/S held its Annual General Meeting, at which the following resolutions were adopted: Financial year 2018 and 2019 Elections Shares and capital Other Composition of the Board of Directors and its committees After the Annual General Meeting, the Board of Directors held a board meeting to appoint members of its committees. The Board of Directors, including its committees, is now composed as follows: Further information  Company Announcement No 19/2019 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=411,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
117,2019-03-20,"Novo Nordisk files oral semaglutide for US regulatory approval of glycaemic control, as well as for CV risk reduction for oral semaglutide and Ozempic®","Bagsværd, Denmark, 20 March 2019 - Novo Nordisk today announced the submission of two New Drug Applications (NDAs) to the US Food and Drug Administration (FDA) for oral semaglutide, a once-daily glucagon-like peptide-1 (GLP-1) analogue in a tablet, as well as a supplemental NDA (sNDA) for once-weekly Ozempic® (semaglutide). An NDA was submitted for oral semaglutide seeking approval for an indication for the treatment of adults with type 2 diabetes. A priority review voucher (PRV) has been applied to the NDA, leading to an anticipated review time of six months from the submission date, according to standard FDA review timelines. The submission for oral semaglutide for the treatment of glycaemic control in adults with type 2 diabetes is based on the results from 10 PIONEER clinical trials, which included 9,543 adults with type 2 diabetes. In the PIONEER programme, people treated with oral semaglutide achieved greater blood glucose reductions compared to sitagliptin, empagliflozin, liraglutide and placebo. In addition, oral semaglutide demonstrated greater reductions in mean body weight vs most comparators. Across the PIONEER trials, oral semaglutide had a safe and well-tolerated profile, with the most common adverse event being nausea. A second NDA was submitted for oral semaglutide seeking approval for a cardiovascular (CV) risk reduction indication in adults with type 2 diabetes. The NDA for an oral semaglutide cardiovascular risk reduction indication has an anticipated 10-month review time from the submission date, according to standard FDA review timelines. Finally, an sNDA was submitted for Ozempic® for a cardiovascular risk reduction indication in adults with type 2 diabetes. The sNDA for an Ozempic® cardiovascular risk reduction indication has an anticipated 10-month review time from the submission date, according to standard FDA review timelines. The applications for the oral semaglutide and Ozempic® cardiovascular risk reduction indications are based on the results of two cardiovascular outcomes trials (CVOTs) evaluating the effects of adding semaglutide or placebo to standard of care on the risk of cardiovascular events; PIONEER 6 with oral semaglutide and SUSTAIN 6 with Ozempic®. ""Achieving glycaemic control and managing cardiovascular risk remains a challenge for many adults living with type 2 diabetes,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""We are excited about the regulatory filings of the first GLP-1 receptor agonist in a tablet, as we believe oral semaglutide has the potential to further improve the treatment of adults living with type 2 diabetes."" PIONEER is the global clinical trial programme for oral semaglutide that comprises 10 phase 3a clinical trials, including a cardiovascular outcomes trial, and involving 9,543 adults with type 2 diabetes across all 10 trials. PIONEER 6 was an event-driven, pre-approval CVOT for oral semaglutide. It was a randomised, double-blinded, placebo-controlled trial evaluating the cardiovascular safety of oral semaglutide vs placebo when added to standard of care in 3,183 adults with type 2 diabetes at high risk of cardiovascular events. The trial achieved its primary objective by ruling out an excess cardiovascular risk of 80% vs placebo, both in addition to standard of care. SUSTAIN 6 was an event and time-driven, pre-approval CVOT for Ozempic®. It was a randomised, double-blinded, placebo-controlled trial evaluating the cardiovascular safety of Ozempic® vs placebo when added to standard of care in 3,297 adults with type 2 diabetes at high risk of cardiovascular events. In SUSTAIN 6, Ozempic® significantly reduced the risk of the primary composite endpoint of major adverse cardiovascular events by 26% vs placebo, both in addition to standard of care. Further information Company announcement No 18/2019",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=412,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
118,2019-03-18,Novo Nordisk settles US patent litigation case on Victoza® (liraglutide) with Teva,"Bagsværd, Denmark, 18 March 2019 - Novo Nordisk today announced that a settlement between Novo Nordisk and Teva Pharmaceuticals USA, Inc. (Teva) has been reached on the US patent litigation case for Victoza® (liraglutide). Consequently, Teva is licensed to launch a generic version of Victoza® as of 22 December 2023. Under certain circumstances Teva could launch a generic version of Victoza® earlier, but not before 22 March 2023, unless the Victoza® patents are no longer in force or there is another generic version of Victoza® on the market. If Novo Nordisk is granted six months paediatric extension for Victoza®, all above-mentioned timelines will be extended by six months. All other terms of the agreement are confidential. The agreement is subject to review by the US Federal Trade Commission and the US Department of Justice. ""This settlement reflects the comprehensive US patent portfolio for liraglutide. Novo Nordisk will continue to defend our broad intellectual property portfolio for innovative drugs against challenges,"" said Jesper Brandgaard, executive vice president and head of Biopharm and Legal Affairs of Novo Nordisk. Further information Company announcement No 16/2019",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=414,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
119,2019-02-22,Novo Nordisk: Notice for the Annual General Meeting of Novo Nordisk A/S,"Bagsværd, Denmark, 22 February 2019 - The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 21 March 2019 at 2.00 pm (CET) at Bella Center, Center Boulevard 5, DK-2300 Copenhagen S, Denmark. The notice for the Annual General Meeting is attached. BOARD OF DIRECTORS - PROPOSED CHANGES IN COMPOSITION All current board members elected by the Annual General Meeting in 2018 are up for election. The Board of Directors proposes re-election of all current board members elected by the Annual General Meeting: Helge Lund (chairman) Jeppe Christiansen (vice chairman), Brian Daniels, Andreas Fibig, Sylvie Grégoire, Liz Hewitt, Kasim Kutay and Martin Mackay. The Board of Directors proposes election of Laurence Debroux at the Annual General Meeting. Laurence Debroux is Group Chief Financial Officer and member of the Executive Board of Heineken N.V., the Netherlands. The Board of Directors recommends election of Laurence Debroux primarily because of her significant experience with financial and accounting practices, extensive global experience within the pharmaceutical industry and experience from executive positions in major international companies. Further information Company announcement No 12 / 2019",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=420,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
120,2019-02-20,Abbott and Novo Nordisk enter partnership to provide integrated digital solution to people with diabetes using insulin,"Abbott Park, Ill, US and Bagsværd, Denmark 20 February 2019 ­- Abbott and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital health tools compatible with the FreeStyle Libre system (FreeStyle LibreLink[2] mobile app and LibreView[3] cloud-based system). The partnership reflects both companies' commitment to make diabetes management easier by connecting key technologies such as continuous glucose monitoring (CGM) and connected insulin pens. Integrating these two products will enable healthcare professionals, caregivers and people with diabetes to view glucose and insulin data together to help them make more informed treatment decisions and to have a more meaningful and productive conversation about health outcomes. ""Lack of reliable information is a cause of huge frustration for many people with diabetes and their doctors,"" said Anders Dyhr Toft, corporate vice president, Commercial Innovation, Novo Nordisk. ""Together with partners like Abbott, our connected pens will give healthcare professionals a better understanding of a patient's individual diabetes management and can help people with diabetes feel more confident in their treatment."" ""It is our aim at Abbott to continuously provide life-changing technology to people living with diabetes,"" said Jared Watkin, senior vice president, Diabetes Care, Abbott. ""Diabetes is a time-intensive condition to manage. People with diabetes must make a variety of decisions every single day about their glucose monitoring, nutrition, insulin and medication intake. By enabling insulin dosing data from Novo Nordisk's connected pens to be shared with our digital health tools, we'll be able to help further eliminate those daily hassles for people, so they have more time to live a fuller, healthier life."" Abbott and Novo Nordisk are working hard to bring these integrated solutions to patients as soon as possible. Abbott's FreeStyle Libre system reads glucose levels through a sensor that can be worn on the back of the upper arm eliminating the need for routine finger pricks[4]. Abbott's FreeStyle LibreLink app enables users to capture and view their real-time glucose levels, their eight-hour glucose history, and how their glucose is currently changing on their smartphone. LibreView is a secure cloud-based diabetes management system that gives people with diabetes and healthcare professionals clear, easy-to-understand reports from major glucose monitoring devices - including the FreeStyle Libre system. Important safety information: https://www.freestylelibre.us/safety-information.html Abbott is a global healthcare leader that helps people live more fully at all stages of life. The portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. The 103,000 colleagues serve people in more than 160 countries. For more information, visit www.abbott.com, LinkedIn, Facebook and Twitter @AbbottNews and @AbbottGlobal. Further information: References [1] FreeStyle LibreLink and LibreView are the only authorized digital health tools that are compatible with FreeStyle Libre [2] The FreeStyle LibreLink app is compatible with NFC enabled phones on Apple's iPhone 7 and later, running iOS 11 and later [3] LibreView data, a product of NewYu, can be viewed in the Safari Browser on Mac OS X Mountain Lion or higher computers and on iOS 6 or later mobile devices. Currently, uploading of glucose data is only supported on Windows-based computers. Minimum system requirements are Windows Vista with IE10 or the latest versions of Google Chrome and Mozilla Firefox, running on a 550MHz Pentium III, 512MB DRAM, 2G Hard Drive, USB 2.0, LCD Screen with resolution of 1024x768 [4] Fingersticks using blood glucose meter are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=421,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
121,2019-02-19,"Novo Nordisk receives US FDA approval of ESPEROCT® (turoctocog alfa pegol, N8-GP)","Bagsværd, Denmark, 19 February 2019 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application for ESPEROCT® for the treatment of adults and children with haemophilia A. ESPEROCT® is the brand name for turoctocog alfa pegol, N8-GP. ESPEROCT® is indicated for use in adults and children with haemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding episodes, on-demand treatment and control of bleeding episodes and perioperative management of bleeding. The approval of ESPEROCT® is based on the results from the largest pre-registration clinical programme conducted in haemophilia A, which included 270 previously treated people (PTPs) with severe haemophilia A and more than 5 years of clinical exposure. ESPEROCT® was shown to provide effective routine prophylaxis in people with severe haemophilia A through a simple, fixed dosing regimen of one injection every 4 days in adults and adolescents or every 3-4 days (twice-weekly) in children. ESPEROCT® provided effective prophylaxis and maintained a low median ABR of 1.18 when dosed at 50 IU/kg every 4 days in adults and adolescents. Furthermore, ESPEROCT® was found to be efficacious in treatment and control of bleeding episodes and perioperative management. Across the clinical trials and age groups, ESPEROCT® was well tolerated and no safety concerns were identified. The overall safety profile of ESPEROCT® is similar to what has been reported for other long-action FVIII products. ""We are excited about the approval of ESPEROCT® in the US, and we consider it an important expansion of the treatment options Novo Nordisk can offer people with haemophilia A"", said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""We are confident that ESPEROCT® will provide people with haemophilia A a less burdensome and simple, fixed dosing regimen for prophylaxis and treatment of bleeding episodes, resulting in improved quality of life."" Due to third-party IP agreements, Novo Nordisk will not be able to launch ESPEROCT® before 2020 in the USA. About ESPEROCT® ESPEROCT® (turoctocog alfa pegol, N8-GP) is an extended half-life factor VIII molecule for replacement therapy in people with haemophilia A, which provides a 1.6-fold half-life prolongation in adults/adolescents and a 1.9-fold half-life prolongation in children, compared to standard half-life factor VIII products. About the pathfinder clinical programmeESPEROCT® has been evaluated in 270 people (202 adults/adolescents and 68 children) in five prospective, multi-centre clinical trials in previously treated people (PTPs) with severe haemophilia A (<1% endogenous FVIII activity) and no history of inhibitors. Total exposure to ESPEROCT® was 80,425 exposure days corresponding to 889 patient years of treatment. ESPEROCT® was well tolerated across all age groups and indications, and no safety concerns were identified after more than 5 years of clinical exposure. Further information Company announcement No 11 / 2019",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=422,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
122,2019-02-05,Novo Nordisk files annual report with the SEC,"Bagsværd, Denmark, 5 February 2019 - Novo Nordisk A/S has filed its Annual Report 2018 on Form 20-F for the financial year 2018 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2018. The reports are available at the SEC's website, www.sec.gov, as well as on novonordisk.com. Shareholders and ADR holders may receive a hard copy of the annual reports free of charge upon request by filling out a request form on novonordisk.com or upon request to chqt@novonordisk.com - please state the exact mailing address and the document(s) you wish to receive. Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=427,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
123,2019-02-01,Novo Nordisks resultat af primær drift faldt med 4% opgjort i kroner og steg med 3% i lokale valutaer i 2018,"Resultat af primær drift steg med 6% opgjort i lokale valutaer justeret for omkostninger til fratrædelser og en priority review voucher til oral semaglutid Salget var stort set uændret opgjort i kroner og steg med 5% i lokale valutaer til 111,8 mia. kr. Salget indenfor diabetes og fedme steg med 1% til 93,9 mia. kr. (6% i lokale valutaer), og salget indenfor biopharmaceuticals faldt med 5% til 17,9 mia. kr. (1% i lokale valutaer). Resultat af primær drift faldt med 4% opgjort i kroner og steg med 3% i lokale valutaer til 47,2 mia. kr. påvirket af kursfaldet på den amerikanske dollar og relaterede valutaer i forhold til kronen. Justeret for fratrædelsesomkostninger relateret til afskedigelser i andet halvår af 2018 og udgiften til en priority review voucher til brug i forbindelse med registreringsansøgningen for oral semaglutid steg resultatet af primær drift med 6% opgjort i lokale valutaer. Nettoresultatet steg med 1% til 38,6 mia. kr., og udvandet resultat pr. aktie steg med 4% til 15,93 kr. I februar 2018 lancerede Novo Nordisk Ozempic®, en ny GLP-1 til dosering én gang om ugen, i USA. Den ugentlige new-to-brand-markedsandel for recepter på Ozempic® er nu på 26% og stabiliserer dermed Novo Nordisks samlede GLP-1-markedsandel. Ozempic® er nu lanceret i 11 lande i Europa og Nordamerika. I november 2018 afsluttede Novo Nordisk fase 3a-programmet PIONEER med oral semaglutid, en ny GLP-1-tablet til dosering én gang dagligt ved behandling af type 2-diabetes, efter at de sidste to studier, PIONEER 6 og 9, blev afsluttet med succes. Novo Nordisk har besluttet at indsende registreringsansøgning for oral semaglutid i USA omkring slutningen af første kvartal af 2019 og har meddelt de amerikanske sundhedsmyndigheder, FDA, at virksomheden vil benytte en priority review voucher. For 2019 forventes en salgsvækst på 2-5% opgjort i lokale valutaer. Heri er inkluderet den tidligere kommunikerede negative påvirkning på ca. 2 mia. kr. fra ændringerne i finansieringen af Medicare Part D-dækningen. Salgsvæksten rapporteret i kroner forventes at blive 2 procentpoint højere end i lokale valutaer. Væksten i resultat af primær drift forventes at blive 2-6% opgjort i lokale valutaer. Væksten i resultat af primær drift rapporteret i kroner forventes at blive 4 procentpoint højere end i lokale valutaer. Bestyrelsen har justeret det langsigtede finansielle mål for resultat af primær drift efter skat i procent af nettodriftsaktiver fra 125% til 80% for at afspejle de nye regnskabsprincipper for behandling af leasingaftaler (IFRS 16) samt investeringsniveauet i materielle og immaterielle aktiver. For at afspejle investeringsniveauet justeres målet for cash to earnings fra 90% til 85%. Det langsigtede finansielle mål for vækst i resultat af primær drift er uændret. Bestyrelsen vil på generalforsamlingen den 21. marts 2019 fremsætte forslag om en endelig udbyttebetaling på 5,15 kr. for 2018 pr. aktie a 0,20 kr. Det forventede samlede udbytte for 2018 bliver således på 8,15 kr. pr. aktie, hvoraf 3,00 kr. pr. aktie blev udbetalt som interimudbytte i august 2018, hvilket svarer til en stigning på 4% sammenlignet med 2017. Bestyrelsen forventer at iværksætte et nyt 12-måneders aktietilbagekøbsprogram på op til 15 mia. kr. Adm. direktør Lars Fruergaard Jørgensen: ""2018 var et år præget af ændringer og betydelig fremgang for Novo Nordisk. Vi leverede på vores mål for salg og resultat af primær drift og lancerede Ozempic®, vores nye GLP-1 til ugentlig behandling af type 2-diabetes, i flere lande. Resultaterne fra det omfattende fase 3a-program PIONEER med oral semaglutid er særdeles opmuntrende for mennesker med type 2-diabetes, og vi er nu tæt på at indsende registreringsansøgning til FDA for oral semaglutid."" Telekonference Der vil den 1. februar 2019 kl. 13.00 CET blive afholdt en telekonference. Investorer kan lytte med via et link på novonordisk.com under menupunktet 'Investors', hvor der også vil kunne hentes præsentationsmateriale ca. en time før telekonferencen. Webcast Den 4. februar 2019 kl. 13.30 CET vil ledelsen give en præsentation for institutionelle investorer og sell side-analytikere i London. Præsentationen kan følges på en direkte webcast via et link på novonordisk.com under menupunktet 'Investors'. Præsentationsmateriale til denne webcast vil være tilgængeligt samme sted. Finansiel kalender Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Novo Nordisks selskabsmeddelelser vil fremover kun foreligge på engelsk.  Kontaktoplysninger Selskabsmeddelelse nr. 6 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=431,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
124,2019-02-01,Novo Nordisk's operating profit decreased by 4% in Danish kroner and increased by 3% in local currencies in 2018,"Operating profit increased by 6% measured in local currencies when adjusted for the cost of severance and the priority review voucher for oral semaglutide Sales remained broadly unchanged in Danish kroner and increased by 5% in local currencies to DKK 111.8 billion. Operating profit decreased by 4% in Danish kroner and increased by 3% in local currencies to DKK 47.2 billion, impacted by the depreciation of the US dollar and related currencies versus the Danish krone. Adjusting for severance costs related to lay-offs in second half of 2018 and the expense related to the priority review voucher for the filing of oral semaglutide, operating profit increased by 6% in local currencies. Net profit increased by 1% to DKK 38.6 billion and diluted earnings per share increased by 4% to DKK 15.93. In February 2018, Novo Nordisk launched Ozempic®, a new once-weekly GLP-1, in the USA. The weekly new-to-brand prescription market share for Ozempic® has now reached 26% and thereby stabilising the total Novo Nordisk GLP-1 market share. Ozempic® has now been launched in 11 countries in Europe and North America. In November 2018, Novo Nordisk completed the phase 3a PIONEER programme for oral semaglutide, a new once-daily GLP-1 tablet for people with type 2 diabetes, following successful completion of the remaining two trials, PIONEER 6 and 9. Novo Nordisk has decided to submit the oral semaglutide file around the end of first quarter 2019 and has notified the US Food and Drug Administration (FDA) that Novo Nordisk will request priority review of the oral semaglutide filing based on a priority review voucher. For 2019, sales growth is expected to be 2-5% measured in local currencies. This includes the previously communicated negative impact from the changes in the funding of the Medicare Part D coverage by approximately DKK 2 billion. Sales growth reported in Danish kroner is expected to be 2 percentage points higher than in local currencies. Operating profit growth is expected to be 2-6% measured in local currencies. Operating profit growth reported in Danish kroner is expected to be 4 percentage points higher than in local currencies. The Board of Directors has adjusted the long-term financial target for OPAT/NOA from 125% to 80% to reflect the new accounting principles for handling of leases (IFRS 16) as well as the investment level in tangible and intangible assets. Further, to reflect the investment level, the cash to earnings target is adjusted from 90% to 85%. The long-term financial target for operating profit growth remains unchanged. At the Annual General Meeting on 21 March 2019, the Board of Directors will propose a final dividend of DKK 5.15 for 2018 per share of DKK 0.20. The expected total dividend for 2018 of DKK 8.15 per share, of which DKK 3.00 per share was paid as interim dividend in August 2018, corresponds to an increase of 4% compared to 2017. The Board of Directors intends to initiate a new 12-month share repurchase programme of up to DKK 15 billion. Lars Fruergaard Jørgensen, president and CEO: ""2018 was a year of change and significant progress for Novo Nordisk. We delivered on our targets for sales and operating profit and have successfully launched Ozempic®, our new once-weekly GLP-1 for people with type 2 diabetes, in several countries. The results from the broad PIONEER phase 3a programme for oral semaglutide are very encouraging for people with type 2 diabetes, and we are now close to submitting oral semaglutide for FDA approval."" Conference call details On 1 February 2019 at 13.00 CET, corresponding to 7.00 am EST, a conference call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under 'Investors'. Presentation material for the conference call will be available approximately one hour before on the same page. Webcast details On 4 February 2019 at 13.30 CET, corresponding to 7.30 am EST, management will give a presentation to institutional investors and sell-side analysts in London. A webcast of the presentation can be followed via a link on novonordisk.com, which can be found under 'Investors'. Presentation material for the webcast will be made available on the same page. Contacts for further information Company announcement No 6 / 2019 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=430,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
125,2018-12-17,Staten Biotechnology B.V. and Novo Nordisk A/S announce collaboration to develop novel treatment for dyslipidaemia,"Nijmegen and Copenhagen, 17 December 2018 ­- Staten Biotechnology B.V. and Novo Nordisk today announced that they have entered into a collaboration and exclusive option agreement to develop novel therapeutics for the treatment of hypertriglyceridaemia. Under the collaboration agreement, Novo Nordisk will provide research and development (R&D) funding and support for Staten to develop its lead asset STT-5058 for treatment of dyslipidaemia. ""Novo Nordisk is joining forces with Staten Biotechnology at an exciting time for us, with the company's lead compound moving towards its first clinical trial, aiming to address the residual cardiovascular risk in patients with hypertriglyceridaemia,"" said Dr Hilde Steineger, CEO of Staten Biotechnology. ""This partnership provides the company not only with a knowledgeable development partner but also with a funding structure that allows founders, management and the founding investors to accelerate the development of the company"". ""Our partnership with Staten Biotechnology is a key step in executing our strategic priority to expand into cardiovascular diseases. Hypertriglyceridemia is a serious risk factor for cardiovascular disease, in particular often present in people with diabetes and obesity. Staten Biotechnology has developed STT-5058, a new promising concept validated by human genetics, for the treatment of hypertriglyceridemia. Combining Staten's know-how on STT-5058, the scientific excellence of the company's executive team and founders, with Novo Nordisk experience in drug development and commercialization, the project holds potential to make a real difference for people suffering from cardiovascular disease,"" said Marcus Schindler, Senior Vice President, Global Drug Discovery in Novo Nordisk. Under the exclusive option agreement, Novo Nordisk has the right to acquire Staten Biotechnology and gain worldwide rights to STT-5058. Staten Biotechnology and its shareholders will potentially receive signing and exercise fees, R&D funding, and milestone payments of up to 430 million euros. Staten Biotechnology develops novel and innovative strategies for the treatment of dyslipidemia, with a focus on hypertriglyceridemia treatment. With a unique approach towards neutralizing ApoC3, a key molecule in dyslipidaemia management, Staten Biotechnology is developing STT-5058, a humanized, monoclonal antibody, licensed from its co-development partner argenx (Euronext & Nasdaq: ARGX). This ""recycling"" antibody with extended half-life has the potential to lower triglyceride levels, and increase clearance of ApoC3-containing atherogenic particles.  Multiple studies have identified ApoC3 levels to be inversely associated with a favourable lipid profile and insulin resistance, both key components in managing residual cardiovascular risk. BioGeneration Ventures (BGV) provided the company's seed financing in 2014 and Forbion led the Series A round in 2015, as the sole new investor. Staten is a prime example of Forbion's and BGV's company building activities, growing great scientific ideas into promising companies. https://www.statenbiotech.com/ Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,200 people in 79 countries and markets its products in more than 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=446,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
126,2018-11-23,Oral semaglutide demonstrates favourable cardiovascular safety profile and significant reduction in cardiovascular death and all-cause mortality in people with type 2 diabetes in the PIONEER 6 trial,"Bagsværd, Denmark, 23 November 2018 - Novo Nordisk today announced the headline results from the last global phase 3a trial, PIONEER 6, for oral semaglutide, an investigational GLP-1 analogue taken once daily as a tablet. This double-blinded trial investigated the cardiovascular safety of oral semaglutide 14 mg compared with placebo, both in addition to standard of care, in 3,183 adults with type 2 diabetes at high risk of cardiovascular events. The trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with oral semaglutide compared with placebo, both in addition to standard of care. The results are based on the accumulated occurrence of 137 major adverse cardiovascular events, with a median follow-up time of 16 months. The primary endpoint of the PIONEER 6 trial was defined as the MACE composite outcome of the first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke and showed a hazard ratio of 0.79 in favour of oral semaglutide compared with placebo. The 21% reduction in MACE in favour of oral semaglutide did not reach statistical significance. The MACE results demonstrated by oral semaglutide were driven by a statistically significant reduction in cardiovascular death of 51% (HR 0.49, p=0.03), while non-fatal myocardial infarction (HR 1.18, non-significant) or non-fatal stroke (HR 0.74, non-significant) were broadly similarly distributed between the two treatment arms. In addition, a statistically significant reduction in all-cause mortality of 49% (HR 0.51, p=0.008) in favour of oral semaglutide was observed. The improvements in secondary endpoints including HbA1c, body weight and blood pressure were similar to results reported throughout the PIONEER programme for oral semaglutide. Furthermore, the safety profile of oral semaglutide in PIONEER 6 was consistent with the established safety profile observed in previous PIONEER clinical trials. ""We are very encouraged that PIONEER 6 demonstrated cardiovascular safety as well as a significant reduction in both CV and all-cause mortality following oral semaglutide treatment in people with type 2 diabetes at high cardiovascular risk,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""Based on the strong clinical data reported throughout the PIONEER clinical trial programme, we have now established a solid efficacy and safety profile for oral semaglutide and we are looking forward to sharing the results with regulatory authorities during 2019."" Novo Nordisk expects to file oral semaglutide for regulatory review in the US and EU in the first half of 2019. As announced in August 2018, Novo Nordisk has since the approval of Ozempic® (once-weekly injectable semaglutide) engaged in a constructive dialogue with the US FDA (Food and Drug Administration) on minimising the need for additional separate large cardiovascular outcomes trials (CVOTs) to obtain a cardiovascular (CV) indication for semaglutide in different formulations Following the results of the PIONEER 6 trial, Novo Nordisk is now evaluating the potential to obtain a CV indication for Ozempic® based on the already obtained clinical data from the CVOT SUSTAIN 6 in combination with the CVOT PIONEER 6 with oral semaglutide. Novo Nordisk will continue these discussions with the FDA. PIONEER 6 was an event-driven, pre-approval cardiovascular outcomes trial for oral semaglutide. It was a randomised, double-blinded, placebo-controlled trial evaluating the cardiovascular safety of oral semaglutide vs placebo when added to standard of care in 3,183 people with type 2 diabetes at high risk of cardiovascular events. The PIONEER phase 3a clinical development programme for oral semaglutide is a global development programme with enrolment of 8,845 people with type 2 diabetes across 10 clinical trials, which have all been completed in 2018. Further information Company announcement No 90/2018",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=453,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
127,2018-11-23,Oral semaglutid viser en positiv kardiovaskulær sikkerhedsprofil og en signifikant reduktion i hjerte-kar-dødsfald og den samlede dødelighed hos mennesker med type 2-diabetes i PIONEER 6-studiet,"Bagsværd, den 23. november 2018 - Novo Nordisk offentliggør i dag de overordnede resultater fra PIONEER 6, det sidste globale fase 3a-studie med oral semaglutid, en ny GLP-1 analog under udvikling, der tages én gang dagligt som en tablet. Dette dobbeltblindede studie undersøgte den kardiovaskulære sikkerhed af oral semaglutid 14 mg sammenlignet med placebo, begge givet som supplement til standardbehandling, i 3.183 voksne med type 2-diabetes med høj risiko for kardiovaskulære hændelser. Studiet opfyldte sit primære mål, idet det viste ikke-inferiøritet med hensyn til alvorlige kardiovaskulære hændelser for oral semaglutid sammenlignet med placebo, begge givet som supplement til standardbehandling. Resultaterne er baseret på den akkumulerede forekomst af 137 alvorlige kardiovaskulære hændelser med en median opfølgningstid på 16 måneder. Det primære mål i PIONEER 6 var defineret som et sammensat endepunkt bestående af den første forekomst af kardiovaskulær død, ikke-dødeligt myokardieinfarkt (hjerteanfald) eller ikke-dødeligt slagtilfælde og viste en risikoratio på 0,79 i oral semaglutids favør sammenlignet med placebo. Reduktionen i forekomsten af alvorlige kardiovaskulære hændelser på 21% i oral semaglutids favør nåede ikke statistisk signifikans. Resultaterne for forekomsten af alvorlige kardiovaskulære hændelser for oral semaglutid var drevet af en statistisk signifikant reduktion i kardiovaskulær død på 51% (risikoratio 0,49, p=0,03), mens ikke-dødeligt myokardieinfarkt (risikoratio 1,18, ikke-signifikant) eller ikke-dødeligt slagtilfælde (risikoratio 0,74, ikke-signifikant) var stort set ligeligt fordelt mellem de to behandlingsgrupper. Der blev endvidere observeret en statistisk signifikant reduktion i den samlede dødelighed på 49% (risikoratio 0,51, p=0,008) i oral semaglutids favør. Forbedringerne for de sekundære endepunkter, herunder langtidsblodsukker (HbA1c), vægt og blodtryk, svarede til de resultater, der er rapporteret for oral semaglutid gennem hele PIONEER-programmet. Endvidere var sikkerhedsprofilen for oral semaglutid i PIONEER 6 konsistent med den sikkerhedsprofil, tidligere kliniske PIONEER-studier har fastslået. ""Vi er meget tilfredse med, at PIONEER 6 cementerer den kardiovaskulære sikkerhed og samtidig viser, at både hjerte-kar-dødeligheden og den samlede dødelighed falder signifikant efter behandling med oral semaglutid hos mennesker med type 2-diabetes, som har høj risiko for hjerte-kar-sygdom,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Baseret på de stærke kliniske data, der er rapporteret hele vejen igennem PIONEER-programmet, har vi nu dokumenteret en solid effekt- og sikkerhedsprofil for oral semaglutid, og vi ser frem til at dele resultaterne med registreringsmyndighederne i 2019."" Novo Nordisk forventer at indsende registreringsansøgning for oral semaglutid i USA og EU i første halvår af 2019. Som meddelt i august 2018 har Novo Nordisk siden godkendelsen af Ozempic® (semaglutid til injektion én gang ugentligt) haft en konstruktiv dialog med de amerikanske sundhedsmyndigheder, FDA, om at minimere behovet for yderligere separate store kardiovaskulære sikkerhedsstudier for at opnå godkendelse af en kardiovaskulær indikation for semaglutid i forskellige formuleringer. Efter resultaterne fra PIONEER 6 evaluerer Novo Nordisk nu muligheden for at opnå en kardiovaskulær indikation for Ozempic® baseret på de allerede foreliggende kliniske data fra det kardiovaskulære sikkerhedsstudie SUSTAIN 6 i kombination med PIONEER 6 med oral semaglutid. Novo Nordisk vil fortsætte disse drøftelser med FDA. PIONEER 6 er et hændelsesdrevet kardiovaskulært sikkerhedsstudie med oral semaglutid gennemført inden godkendelse. Det randomiserede, dobbeltblindede, placebokontrollerede studie undersøgte den kardiovaskulære sikkerhed for oral semaglutid sammenlignet med placebo, begge givet som supplement til standardbehandling. Studiet omfattede 3.183 deltagere med type 2-diabetes med høj risiko for kardiovaskulære hændelser. PIONEER, det kliniske fase 3a-program for oral semaglutid, er et globalt udviklingsprogram med en samlet deltagelse af 8.845 mennesker med type 2-diabetes i 10 kliniske studier, som alle forventes afsluttet i 2018. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 90/2018",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=454,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
128,2018-11-22,Oral semaglutide demonstrates greater reductions in both HbA1c and body weight compared to Victoza® in Japanese people with type 2 diabetes,"Bagsværd, Denmark, 22 November 2018 - Novo Nordisk today announced the headline results from PIONEER 9, a 52-week trial with oral semaglutide vs Victoza® (0.9 mg liraglutide) and vs placebo, all as monotherapy, in Japanese adults with type 2 diabetes. Oral semaglutide is an investigational GLP-1 taken once daily as a tablet. PIONEER 9 was a phase 3a safety and efficacy trial investigating 3, 7 and 14 mg oral semaglutide compared with Victoza® and with placebo in 243 Japanese adults with type 2 diabetes. The trial successfully achieved its primary objective[1] by demonstrating that, from a mean baseline HbA1c of 8.2%, people treated with 3, 7 and 14 mg oral semaglutide experienced statistically significant reductions in HbA1c of 1.1%, 1.5% and 1.7%, respectively, compared to a reduction of 0.1% with placebo after 26 weeks. Furthermore, 14 mg oral semaglutide achieved a statistically significantly greater reduction in HbA1c compared to a reduction of 1.4% with Victoza®. After 52 weeks, people treated with 3, 7 and 14 mg oral semaglutide experienced statistically significantly greater reductions in HbA1c of 0.9%, 1.3% and 1.5%, respectively, compared to an increase of 0.5% for people treated with placebo. Furthermore, people treated with Victoza® experienced a reduction in HbA1c of 1.1%, which was not statistically significant in favour of oral semaglutide. The Japan Diabetes Society (JDS) treatment target of HbA1c <7.0% was achieved by 50%, 67% and 80% of people treated with 3, 7 and 14 mg oral semaglutide, respectively, compared to 49% of people treated with Victoza® and 12% of people treated with placebo at week 52. From a mean baseline body weight of 71.1 kg, people treated with 14 mg oral semaglutide experienced a statistically significantly greater weight reduction of 2.8 kg after 52 weeks compared to 1.0 kg with placebo and a weight increase of 0.4 kg with Victoza®. People treated with 3 and 7 mg oral semaglutide experienced a body weight reduction of 0.0 kg and 0.6 kg, respectively. In this 52-week trial, oral semaglutide was well-tolerated and with a safety profile consistent with GLP-1-based therapy. The most common adverse events for oral semaglutide were constipation and mild to moderate nausea, which diminished over time. The proportion of people who discontinued treatment due to adverse events was 2-4% for people treated with oral semaglutide. ""Achieving target blood glucose levels remains a challenge for many people living with type 2 diabetes,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""In PIONEER 9, an impressive 80% of Japanese people with type 2 diabetes treated with the highest dose of oral semaglutide achieved the Japan Diabetes Society target for good glycaemic control, with a safety profile consistent with injectable GLP-1 therapies."" PIONEER 9 was a 52-week, randomised, double-blinded placebo-controlled and open-label active-controlled phase 3 safety and efficacy trial. It had 5 treatment arms comparing the dose-response, safety, and efficacy of 3, 7 and 14 mg oral semaglutide with placebo and with Victoza® 0.9 mg in Japanese people with type 2 diabetes, treated with diet and exercise alone or in addition to an oral anti-diabetic drug as monotherapy. PIONEER 9 randomised 243 people in a 1:1:1:1:1 manner to receive once-daily treatment with either a dose of oral semaglutide 3, 7 or 14 mg, Victoza® or placebo. The primary endpoint was the change in baseline HbA1c to week 26. Key secondary endpoints included change in HbA1c at week 52, change in plasma glucose, body weight and number of participants achieving a target of HbA1c <7% at weeks 26 and 52. The PIONEER phase 3a clinical development programme for oral semaglutide is a global development programme with enrolment of 8,845 people with type 2 diabetes across 10 clinical trials, which are all expected to complete in 2018. Further information Company announcement No 89 / 2018 [1] Analysed by Mixed Models for Repeated Measurements (MMRM), which was the similar statistical methodology as applied in the SUSTAIN programme for subcutaneous semaglutide.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=455,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
129,2018-11-22,Oral semaglutid giver større reduktioner i både langtidsblodsukker og vægt sammenlignet med Victoza® hos japanere med type 2-diabetes,"Bagsværd, den 22. november 2018 - Novo Nordisk offentliggør i dag de overordnede resultater fra PIONEER 9, et 52-ugers studie, som har sammenholdt oral semaglutid med Victoza® (0,9 mg liraglutid) og med placebo, alle givet som monoterapi, i voksne japanere med type 2-diabetes. Oral semaglutid er en ny GLP-1 under udvikling, der tages én gang dagligt som en tablet. PIONEER 9 var et fase 3a-sikkerheds- og effektstudie, der undersøgte 3, 7 og 14 mg oral semaglutid sammenlignet med Victoza® og med placebo i 243 voksne japanere med type 2-diabetes. Studiet opfyldte sit primære mål[1], idet det viste, at i forhold til et gennemsnitligt baselineniveau for langtidsblodsukkeret (HbA1c) ved studiets begyndelse på 8,2% opnåede deltagere i behandling med 3, 7 og 14 mg oral semaglutid statistisk signifikante reduktioner i HbA1c på henholdsvis 1,1%, 1,5% og 1,7%, mod en reduktion på 0,1% med placebo efter 26 uger. Endvidere medførte 14 mg oral semaglutid en statistisk signifikant større reduktion i HbA1c, mod en reduktion på 1,4% med Victoza®. Efter 52 uger oplevede deltagere i behandling med 3, 7 og 14 mg oral semaglutid statistisk signifikant større reduktioner i HbA1c på henholdsvis 0,9%, 1,3% og 1,5%, mod en stigning på 0,5% for deltagere i behandling med placebo. Endvidere oplevede deltagere i behandling med Victoza® en reduktion i HbA1c på 1,1%, hvilket ikke var statistisk signifikant i oral semaglutids favør. Behandlingsmålet om HbA1c <7,0% som fastsat af den japanske diabetesorganisation Japan Diabetes Society (JDS) blev ved uge 52 nået af 50%, 67% og 80% af deltagere i behandling med henholdsvis 3, 7 og 14 mg oral semaglutid, mod 49% af deltagere i behandling med Victoza® og 12% af deltagere, der fik placebo. I forhold til en gennemsnitsvægt på 71,1 kg ved studiets begyndelse opnåede deltagere i behandling med 14 mg oral semaglutid et statistisk signifikant større vægttab på 2,8 kg efter 52 uger, mod et vægttab på 1,0 kg med placebo og en vægtstigning på 0,4 kg med Victoza®. Deltagere i behandling med 3 og 7 mg oral semaglutid opnåede vægttab på henholdsvis 0,0 kg og 0,6 kg. Oral semaglutid var i dette 52-ugers studie veltolereret med en sikkerhedsprofil, der var konsistent med GLP-1-baseret behandling. De mest almindelige bivirkninger for oral semaglutid var forstoppelse og mild til moderat kvalme, som aftog med tiden. Andelen af deltagere, som afsluttede behandlingen før tid på grund af bivirkninger, var 2-4% for deltagere, som blev behandlet med oral semaglutid. ""Det er stadig en udfordring for mange med type 2-diabetes at nå de anbefalede behandlingsmål for blodsukkerniveauet,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""I PIONEER 9 var det hele 80% af de japanere med type 2-diabetes, som blev behandlet med den højeste dosis oral semaglutid, der nåede Japan Diabetes Societys behandlingsmål for god blodsukkerregulering - med en sikkerhedsprofil, der er konsistent med GLP-1-behandlinger i injektionsform."" Om PIONEER 9 og det kliniske udviklingsprogram PIONEER PIONEER 9 var et 52-ugers randomiseret, dobbeltblindet placebo-kontrolleret og ikke-blindet aktivt kontrolleret fase 3-sikkerheds- og effektstudie. Studiet havde fem behandlingsarme, som sammenlignede dosisrespons, sikkerhed og effekt for 3, 7 og 14 mg oral semaglutid med placebo og med Victoza® 0,9 mg i japanere med type 2-diabetes, som blev behandlet med diæt og motion alene eller som supplement til et diabeteslægemiddel i tabletform som monoterapi. PIONEER 9 omfattede 243 deltagere, som blev randomiseret 1:1:1:1:1 til at modtage behandling én gang dagligt med enten en dosis oral semaglutid 3, 7 eller 14 mg, Victoza® eller placebo. Det primære endepunkt var ændring i HbA1c ved uge 26 i forhold til baseline. Vigtige sekundære endepunkter var bl.a. ændring i HbA1c ved uge 52, ændring i plasmaglukose, vægt og antal deltagere, der nåede behandlingsmålet om HbA1c <7% ved uge 26 og 52. PIONEER, det kliniske fase 3a-program for oral semaglutid, er et globalt udviklingsprogram med en samlet deltagelse af 8.845 mennesker med type 2-diabetes i 10 kliniske studier, som alle forventes afsluttet i 2018. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information [1] Analyseret ved hjælp af Mixed Models for Repeated Measurements (MMRM) - den samme statistiske metodik som den, der blev anvendt i SUSTAIN-programmet for subkutan semaglutid.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=456,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
130,2018-11-02,Embark and Novo Nordisk enter collaboration to discover novel therapeutics for obesity and metabolic disease,"Copenhagen, Denmark, 2 November 2018 ­- Embark Biotech ApS and Novo Nordisk A/S today announced that they have entered into a research collaboration focusing on the discovery of novel treatments for obesity and its associated metabolic pathologies through mechanisms that increase energy expenditure. The research platform of Embark Biotech, a recent spin-out from Center for Basic Metabolic Research at University of Copenhagen, builds on novel and unique insights into receptors that stimulate energy expenditure without triggering the sympathetic nervous system (the 'fight-or-flight' response). The aim of the collaboration is to develop novel drug candidates that help people with obesity lose weight by burning off excess energy instead of storing it as fat. The potential addition of energy expenditure drugs would make a meaningful difference in the treatment of obesity. The work behind the research platform and the spin-out of Embark Biotech has been supported by Novo Seeds and the Novo Nordisk Foundation since 2016. ""The present project builds on the frontline insight into energy expenditure of the group of Zach Gerhart-Hines, who we recruited from the US to Center for Basic Metabolic Research just few years ago. Zach's group has fully exploited the special knowledge we have in cell surface receptor pharmacology to generate several innovative drug discovery projects, and we see the research collaboration with Novo Nordisk, a global leader within obesity care, as the optimal way of developing the technology to ultimately benefit the patients"", says Thue W. Schwartz, professor at Center for Basic Metabolic Research and co-founder of Embark. As part of the collaboration agreement, Embark will receive research support for activities conducted in the collaboration, and Novo Nordisk has an option to license exclusive worldwide rights to develop and commercialise products discovered in the collaboration. ""We are excited to get started on this project which aims at developing next- generation anti-obesity therapies"" says Marcus Schindler, senior vice president of Global Drug Discovery in Novo Nordisk. ""There is a huge unmet medical need for treatment of obesity. While more than 650 million people are currently living with obesity[1], it is rarely acknowledged, diagnosed or treated as a serious chronic and complex disease. We believe that Novo Nordisk and Embark together have both the capability and capacity to explore this new mechanism of action."" Embark Biotech ApS is a spin-out platform biotech company from University of Copenhagen, dedicated to deciphering the therapeutic potential of energy expenditure. The academic founders include Professor Thue W Schwartz, Associate Professor Zach Gerhart-Hines, Postdoc Jakob Bondo Hansen and CEO, Casper Tind Hansen. The research platform and spin-out of Embark Biotech has been supported by exploratory pre-seed and pre-seed grants from Novo Seeds administered on behalf of the Novo Nordisk Foundation and by starting grants from the European Research Council (ERC) and the Danish Council for Independent Research, as well as proof-of-concept grants from the European Research Council and the University of Copenhagen Tech Transfer Office. For more information, see www.embarkbiotech.com or contact Casper Tind Hansen at cth@embarkbiotech.com Further information Reference [1] NCD Risk Factor Collaboration (NCD-RisC). Lancet 2017:390;2627-42",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=479,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
131,2018-11-01,Novo Nordisk's operating profit decreased by 6% in Danish kroner and increased by 2% in local currencies in the first nine months of 2018,"Sales decreased by 2% in Danish kroner and increased by 4% in local currencies to DKK 82.1 billion. Operating profit decreased by 6% in Danish kroner and increased by 2% in local currencies to DKK 36.5 billion, impacted by the significant depreciation of the US dollar and related currencies versus the Danish krone in first half of 2018 compared with the same period in 2017. Adjusting for severance costs related to lay-offs in the third quarter of 2018, operating profit increased by 4% in local currencies. Net profit increased by 1% to DKK 30.1 billion. Diluted earnings per share increased by 3% to DKK 12.40. In February 2018, Novo Nordisk launched Ozempic® in the USA, a new once-weekly GLP-1, and the weekly new-to-brand prescription market share for Ozempic® has now reached 19% strengthening the total Novo Nordisk GLP-1 market share. Ozempic® has now been launched in seven countries in Europe and in North America. Since August 2018, Novo Nordisk has announced phase 3a results from additional three of the 10 clinical trials in the PIONEER programme for oral semaglutide, a new once-daily GLP-1 tablet for people with type 2 diabetes. The trials confirmed statistically significant reductions in both HbA1c and weight for oral semaglutide compared to placebo in people with renal impairment, add-on treatment to insulin and dulaglutide in Japanese people. Novo Nordisk has communicated plans to restructure the R&D organisation to accelerate the expansion and diversification of its pipeline and to enable increased investment in transformational biological and technological innovation. A number of additional restructuring initiatives across functions and geographies have been initiated to support the commercial activities for the portfolio of innovative products. As a consequence, the total workforce is expected to be reduced by approximately 1,300 employees before the end of 2018 and the majority of these reductions have been implemented as of 1 November 2018. For 2018, sales growth is now expected to be 4-5% and operating profit growth is still expected to be 2-5%, both measured in local currencies. Sales growth reported in Danish kroner is now expected to be 4 percentage points lower than in local currencies while operating profit growth is still expected to be 7 percentage points lower than in local currencies. Based on the increased expectations for cash flow generation in 2018, the Board of Directors has approved an expansion of the 2018 share repurchase programme with DKK 1.0 billion to DKK 15 billion. Lars Fruergaard Jørgensen, president and CEO: ""We are off to a very good start with Ozempic® which is strengthening our leadership position in the expanding GLP-1 market. Our other key innovative products Victoza®, Saxenda®, Tresiba® and Xultophy® continue the solid contribution to sales growth in the first nine months of 2018. With our ambition to bring innovative treatments to patients, we have made some important changes aimed at boosting our R&D innovation as well as redirecting resources in other parts of the organisation to focus on our future growth drivers."" Further information Company announcement No 83 / 2018 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=480,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
132,2018-11-01,Novo Nordisks resultat af primær drift faldt med 6% opgjort i kroner og steg med 2% i lokale valutaer i de første ni måneder af 2018,"Salget faldt med 2% i kroner og steg med 4% i lokale valutaer til 82,1 mia. kr. Resultat af primær drift faldt med 6% opgjort i kroner og steg med 2% i lokale valutaer til 36,5 mia. kr. påvirket af det betydelige kursfald for den amerikanske dollar og relaterede valutaer i forhold til kronen i første halvår af 2018 sammenlignet med samme periode i 2017. Justeret for fratrædelsesomkostninger relateret til afskedigelser i tredje kvartal af 2018 steg resultatet af primær drift med 4% opgjort i lokale valutaer. Nettoresultatet steg med 1% til 30,1 mia. kr. Udvandet resultat pr. aktie steg med 3% til 12,40 kr. I februar 2018 lancerede Novo Nordisk Ozempic® i USA, en ny GLP-1 til dosering én gang om ugen, og den ugentlige new-to-brand-markedsandel for recepter på Ozempic® er nu på 19% og styrker Novo Nordisks samlede GLP-1-markedsandel. Ozempic® er nu lanceret i syv lande i Europa og i Nordamerika. Siden august 2018 har Novo Nordisk offentliggjort fase 3a-resultaterne fra yderligere tre af de 10 kliniske studier i PIONEER-programmet for oral semaglutid, en ny GLP-1-tablet til dosering én gang dagligt ved behandling af type 2-diabetes. Studierne bekræftede statistisk signifikante reduktioner både i langtidsblodsukker (HbA1c) og vægt for oral semaglutid sammenlignet med placebo hos mennesker med nedsat nyrefunktion, supplement til insulinbehandling og dulaglutid hos japanere. Novo Nordisk har offentliggjort planer om en omstrukturering af forsknings- og udviklingsorganisationen, som skal fremskynde processen med at øge antallet og diversiteten af projekter i pipelinen og skabe muligheder for en øget satsning på transformationel biologisk og teknologisk innovation. Yderligere omstruktureringer på tværs af funktionsområder og landegrænser er iværksat for at støtte de kommercielle aktiviteter for porteføljen af innovative produkter. Derfor forventes den samlede medarbejderstab at blive reduceret med ca. 1.300 medarbejdere inden udgangen af 2018, og de fleste af disse reduktioner er gennemført pr. 1. november 2018. For 2018 forventes nu en salgsvækst på 4-5%, og væksten i resultat af primær drift forventes fortsat at blive på 2-5%, begge dele opgjort i lokale valutaer. Salgsvæksten rapporteret i kroner forventes nu at blive 4 procentpoint lavere end i lokale valutaer, mens væksten i resultat af primær drift fortsat forventes at blive 7 procentpoint lavere end i lokale valutaer. Bestyrelsen har på baggrund af de øgede forventninger til likviditetsskabelsen i 2018 godkendt, at aktietilbagekøbsprogrammet for 2018 forhøjes med 1,0 mia. kr. til 15 mia. kr. Adm. direktør Lars Fruergaard Jørgensen: ""Vi er kommet rigtig godt fra start med Ozempic®, som styrker vores førerposition i det voksende GLP-1-marked. Vores andre vigtige innovative produkter, Victoza®, Saxenda®, Tresiba® og  Xultophy®, bidrog fortsat solidt til salgsvæksten i de første ni måneder af 2018. For at understøtte vores ambition om at skabe innovative behandlinger for patienterne har vi gennemført en række vigtige ændringer, der skal styrke innovationen i vores forskning og udvikling og omallokere ressourcer i andre dele af organisationen for at fokusere på vores fremtidige vækstskabere."" Kontaktoplysninger  Selskabsmeddelelse nr. 83 / 2018",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=481,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
133,2018-10-31,Novo Nordisk expands its biopharm business with the acquisition of the US and Canadian rights to Macrilen(TM),"Bagsværd, Denmark, 31 October 2018 ­- Novo Nordisk today announced the expansion of its biopharm business with an agreement to acquire the US and Canadian rights to Macrilen(TM) (macimorelin), an enhancer of growth hormone secretion and the first and only FDA-approved oral product indicated for the diagnosis of Adult Growth Hormone Deficiency (AGHD), a rare endocrine disorder, from Strongbridge Biopharma Plc. Diagnosis of growth hormone deficiency is time consuming and a considerable burden for both patients and health care providers. By enabling a fast and deeper roll out of Macrilen(TM), Novo Nordisk can address a significant unmet medical need. Macrilen(TM) was approved by the US Food and Drug Administration (FDA) in December 2017 and FDA has granted Macrilen(TM) orphan drug exclusivity in the US. Macrilen(TM) was launched in the US in July 2018. With the acquisition of Macrilen(TM), Novo Nordisk can further leverage its long-standing scientific and commercial expertise and commitment to the growth disorders community. As a partner to the endocrinology community Novo Nordisk is committed to raising awareness of growth disorders and advancing patient care. Novo Nordisk will pay USD 145 million to Strongbridge as well as tiered royalties related to sales of Macrilen(TM). In addition, Strongbridge's current field organisation will continue to promote Macrilen(TM) in the US for up to three-year agreement. Novo Nordisk's existing biopharm field force will also support the commercialisation of Macrilen(TM). As part of the partnership with Strongbridge, Novo Nordisk will acquire newly issued Strongbridge shares representing approximately 10% of the outstanding shares of Strongbridge at a share price of USD 7 per share, corresponding to an investment of approximately USD 37 million. ""The acquisition of Macrilen(TM) is in line with the strategy for our biopharm business with growth being driven by both organic and bolt-on initiatives. Macrilen(TM) is highly complementary to Norditropin® and will allow Novo Nordisk to assist physicians and patients in the diagnosis as well as treatment of patients with growth hormone deficiency,"" said Jesper Brandgaard, executive vice president and head of Biopharm. The transaction is expected to close in December 2018 and is subject to US regulatory approval. About Macrilen(TM)Macrilen(TM) (macimorelin) is a prescription oral test that has been granted orphan drug designation in the US, as the first and only FDA-approved oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency (AGHD), a rare endocrine disorder. In an open-label, randomised, cross-over trial with 154 people, Macrilen(TM) was shown to diagnose AGHD accurately when comparing the diagnostic agreement between Macrilen(TM) and the benchmark, Insulin Tolerance Test (ITT)[1]. About Strongbridge BiopharmaStrongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Founded in 1996, Strongbridge is today based in Trevose, PA, USA and publicly listed on the US NASDAQ Global Market. Strongbridge's rare endocrine franchise includes Recorlev(TM) (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing's syndrome, and veldoreotide extended release, a pre-clinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation.  Strongbridge's rare neuromuscular franchise includes Keveyis® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Keveyis® has orphan drug exclusivity in the US. Forward-looking statementsThis press release contains forward-looking statements. Words such as 'believe', 'expect', 'may', 'would', 'will', 'plan', 'strategy', 'prospect', 'foresee', 'estimate', 'project', 'anticipate', 'can', 'intend', 'target' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or plans or proposals including regarding Macrilen(TM) identify forward-looking statements. Forward-looking statements are based on current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. Novo Nordisk cautions that a number of important factors could cause actual results or events to differ materially from those contemplated in any forward-looking statements. Unless required by law, Novo Nordisk is under no duty and undertakes no obligation to update or revise any forward-looking statement after the distribution of this press release, whether as a result of new information, future events or otherwise. Further information Novo Nordisk Strongbridge  [1] Macrilen US FDA prescribing information. Strongbridge Biopharma Inc, Trevose, PA; 2018.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=484,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
134,2018-10-31,Novo Nordisk udvider sin biopharm-forretning med køb af de amerikanske og canadiske rettigheder til Macrilen(TM),"Bagsværd, den 31. oktober 2018 ­- Novo Nordisk meddeler i dag, at virksomheden vil udvide sin biopharm-forretning med en aftale om at købe de amerikanske og canadiske rettigheder til Macrilen(TM) (macimorelin) fra Strongbridge Biopharma plc. Macrilen(TM) stimulerer sekretionen af væksthormon og er det første og eneste FDA-godkendte orale produkt til diagnosticering af væksthormonmangel hos voksne (AGHD), en sjælden endokrin sygdom. Diagnosticering af væksthormonmangel er tidskrævende og en betydelig byrde både for patienter og behandlere. Ved at skabe mulighed for en hurtig og mere omfattende lancering af Macrilen(TM) vil Novo Nordisk kunne adressere et stort udækket medicinsk behov. Macrilen(TM) blev godkendt af de amerikanske sundhedsmyndigheder (FDA) i december 2017 og har af FDA fået tildelt orphan drug-eksklusivitet i USA. Macrilen(TM) blev lanceret i USA i juli 2018. Med købet af Macrilen(TM) cementerer Novo Nordisk sin mangeårige forskningsmæssige og kommercielle ekspertise indenfor væksthormonområdet samt dedikerede indsats for mennesker med vækstforstyrrelser og deres behandlere. Sammen med det endokrinologiske samfund ønsker Novo Nordisk at skabe øget opmærksomhed om vækstforstyrrelser i håb om at skabe nye og bedre behandlingsmuligheder for patienterne. Novo Nordisk betaler 145 mio. amerikanske dollars til Strongbridge samt graduerede royalties på salget af Macrilen(TM). Endvidere vil Strongbridges nuværende salgsstyrke fortsætte med at promovere Macrilen(TM) i USA under en op til treårig aftale. Novo Nordisks nuværende biopharm-salgsstyrke vil også understøtte kommercialiseringen af Macrilen(TM). Som led i partnerskabet med Strongbridge vil Novo Nordisk købe nyudstedte Strongbridge-aktier, som repræsenterer ca. 10% af de udestående aktier i Strongbridge, til en kurs på 7 dollars pr. aktie, svarende til en investering på ca. 37 mio. dollars. ""Købet af Macrilen(TM) er i tråd med strategien for vores biopharm-forretning, som har fokus på vækst gennem både organiske tiltag og gennem opkøb. Macrilen(TM) supplerer Norditropin® rigtig godt og vil give Novo Nordisk mulighed for at hjælpe læger og patienter, både når det gælder diagnosticering og behandling af patienter med væksthormonmangel,"" siger Jesper Brandgaard, koncerndirektør med ansvar for Biopharm. Transaktionen forventes afsluttet i december 2018 og er betinget af godkendelse fra de amerikanske myndigheder. Macrilen(TM) (macimorelin) er en receptpligtig oral test, som har fået tildelt orphan drug-status i USA som den første og eneste FDA-godkendte orale væksthormon-secretagogue-receptoragonist til diagnosticering af væksthormonmangel hos voksne (AGHD), en sjælden endokrin sygdom. Det er i et ikke-blindet, randomiseret crossover-studie med 154 deltagere vist, at Macrilen(TM) diagnosticerer AGHD præcist, ved sammenholdelse af den diagnostiske overensstemmelse mellem Macrilen(TM) og benchmarktesten, Insulin Tolerance Test (ITT)[1]. Strongbridge Biopharma er en global biofarmaceutisk virksomhed, der fokuserer på udvikling og kommercialisering af behandlinger til sjældne sygdomme med et stort udækket behandlingsbehov. Strongbridge blev etableret i 1996 og har i dag til huse i Trevose, Pennsylvania, USA, og er noteret på US NASDAQ Global Market. Strongbridges aktiviteter indenfor sjældne endokrine sygdomme omfatter Recorlev(TM) (levoketoconazole), en kortisolsyntesehæmmer, som p.t. undersøges i kliniske fase 3-studier til behandling af endogent Cushings syndrom, og veldoreotide extended release, en præklinisk næstegenerations-somatostatin-analog, som undersøges til behandling af akromegali og andre potentielle anvendelser indenfor andre sygdomme, der er modtagelige for somatostatin-receptoraktivering. Strongbridges aktiviteter indenfor sjældne neuromuskulære sygdomme omfatter Keveyis® (dichlorphenamide), den første og eneste FDA-godkendte behandling for hyperkalæmisk, hypokalæmisk og relaterede varianter af primær periodisk paralyse. Keveyis® har orphan drug-eksklusivitet i USA. Udsagn om fremtidenDenne pressemeddelelse indeholder udsagn om fremtiden. I udsagn om fremtiden indgår ofte ord som 'mener', 'forventer', 'eventuelt', 'vil', 'planlægger', 'strategi', 'udsigt', 'forudser', 'skønner', 'fremskriver', 'regner med', 'kan', 'påtænker', 'mål' og andre ord og udtryk med tilsvarende betydning i forbindelse med omtale af fremtidige driftsmæssige eller finansielle resultater eller planer eller forslag, herunder vedrørende Macrilen(TM). Udsagn om fremtiden tager afsæt i nuværende planer, skøn og forventninger. Udsagn om fremtiden er i sagens natur forbundet med risikofaktorer og usikkerhedsmomenter af såvel generel som specifik karakter. Novo Nordisk understreger, at en række væsentlige forhold kan forårsage, at de faktiske resultater viser sig at afvige væsentligt fra dem, der tidligere er kommet til udtryk i udsagn om fremtiden. Medmindre der er tale om et lovkrav, er Novo Nordisk ikke forpligtet og frasiger sig enhver forpligtelse til at opdatere eller revidere udsagn om fremtiden efter offentliggørelsen af denne pressemeddelelse, hvad enten det skyldes nye oplysninger, fremtidige begivenheder eller andre forhold. Dette er en oversættelse af den originale engelske pressemeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Novo Nordisk Strongbridge [1] Macrilen US FDA prescribing information. Strongbridge Biopharma Inc, Trevose, PA; 2018.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=485,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
135,2018-10-26,"Oral semaglutid giver statistisk signifikante reduktioner i langtidsblodsukker og vægt hos mennesker, som længe har haft type 2-diabetes og får insulinbehandling","Bagsværd, den 26. oktober 2018 - Novo Nordisk offentliggør i dag de overordnede resultater fra PIONEER 8, et fase 3a-studie med oral semaglutid til behandling af voksne med type 2-diabetes. Oral semaglutid er en ny GLP-1-analog under udvikling, der tages én gang dagligt som en tablet. Studiet, som strakte sig over 52 uger, undersøgte effekten og sikkerheden af 3, 7 og 14 mg oral semaglutid sammenlignet med placebo hos 731 deltagere med type 2-diabetes, som blev behandlet med insulin og gennemsnitligt havde haft diabetes i 15 år. I de første 26 uger af behandlingsperioden måtte den samlede daglige insulindosis ikke overstige niveauet ved studiets start (baseline), mens insulinbehandlingen i den efterfølgende 26-ugers periode blev justeret uden restriktioner. Der blev i PIONEER 8 anvendt to forskellige statistiske metoder til at vurdere effekten af oral semaglutid: en primær statistisk metode[1], som kræves i henhold til nye regulatoriske retningslinjer, og som vurderer effekten uanset ophør af behandlingen og brug af anden behandling; og en sekundær statistisk metode[2], der beskriver effekten, mens behandlingen pågår og uden brug af anden behandling. Studiet opfyldte sit primære mål vurderet efter den primære statistiske metode, idet det viste statistisk signifikante og større reduktioner i langtidsblodsukker (HbA1c) og vægt ved alle tre doseringer af oral semaglutid sammenlignet med placebo, alle givet som supplement til insulin, ved uge 26. Vurderet efter den sekundære statistiske metode og ud fra et gennemsnitligt baselineniveau på 8,2% opnåede deltagere i behandling med 3, 7 og 14 mg oral semaglutid ved uge 26 reduktioner i HbA1c på henholdsvis 0,6%, 1,0% og 1,4% mod ingen reduktion (0,0%) hos deltagere, der fik placebo, alle givet som supplement til insulin, og henholdsvis 0,5%, 0,8% og 1,2% mod 0,0% ved uge 52. Behandlingsmålet om HbA1c på under 7,0% som fastsat af American Diabetes Association (ADA) blev ved uge 52 nået af 36%, 47% og 64% af deltagere i behandling med henholdsvis 3, 7 og 14 mg oral semaglutid, mod 10% af deltagere, der fik placebo. I forhold til en gennemsnitsvægt ved studiets begyndelse på 85,9 kg opnåede deltagere i behandling med 3, 7 og 14 mg oral semaglutid ved uge 52 endvidere et vægttab på henholdsvis 1,0 kg, 2,9 kg og 4,3 kg mod en vægtstigning på 0,6 kg hos deltagere, der fik placebo, alle givet som supplement til insulin. Den gennemsnitlige samlede insulindosis ved baseline var 60, 62 og 54 enheder pr. dag for deltagere i behandling med henholdsvis 3, 7 og 14 mg oral semaglutid, mod 56 enheder pr. dag for deltagere, der fik placebo, og den samlede insulindosis var ved uge 52 steget med 2 enheder pr. dag, reduceret med 6 enheder pr. dag og reduceret med 7 enheder pr. dag for deltagere i behandling med henholdsvis 3, 7 og 14 mg oral semaglutid, mod en stigning på 10 enheder pr. dag for deltagere, der fik placebo. I 52-ugers-studiet opnåede deltagere i behandling med 3, 7 og 14 mg oral semaglutid få tilfælde og sammenlignelige niveauer af hypoglykæmi (alvorlig eller bekræftet ved blodsukkermåling) sammenlignet med placebo. Oral semaglutid var veltolereret med en profil, der var konsistent med GLP-1-baseret behandling. Den mest almindelige bivirkning for oral semaglutid var mild til moderat kvalme, som aftog med tiden. I PIONEER 8 var der 11-23% af de deltagere, der blev behandlet med oral semaglutid, som oplevede kvalme, mod 7% af deltagere, der fik placebo. Andelen af deltagere, som afsluttede behandlingen før tid på grund af bivirkninger, var 7-14% for deltagere, som blev behandlet med oral semaglutid, mod 3% for deltagere, der fik placebo. ""Mennesker med type 2-diabetes, som har behov for insulinbehandling, kan have svært ved at opnå en optimal blodsukkerregulering på grund af vægtstigning og risiko for hypoglykæmi,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""I PIONEER 8 har vi set, at oral semaglutid er i stand til at forbedre blodsukkerreguleringen hos mennesker, som har haft diabetes i mange år og i forvejen er i behandling med insulin - samtidig med yderligere fordele i form af klinisk betydningsfuldt vægttab og uden øget risiko for hypoglykæmi."" PIONEER 8 var et 52-ugers randomiseret, dobbeltblindet, placebo-kontrolleret, multicenter-, multinationalt parallelgruppestudie med fire behandlingsgrupper. Studiet undersøgte effekt og sikkerhed af 3, 7 og 14 mg oral semaglutid sammenlignet med placebo hos mennesker med type 2-diabetes, som blev behandlet med basalinsulin alene eller alle kombinationer af basal/bolusinsulin eller miksinsulin, herunder kombinationer af opløselige insuliner. Insulinbehandlingen kunne kombineres med metformin. Den randomiserede 52-ugers behandlingsperiode blev delt i to: de første 26 uger, hvor insulindosis blev begrænset til niveauet før randomisering, efterfulgt af en 26-ugers-periode, hvor insulinbehandlingen blev justeret uden restriktioner. PIONEER 8 omfattede 731 deltagere, som gennemsnitligt havde haft diabetes i 15 år. De blev randomiseret 1:1:1:1 til at modtage enten en dosis på 3, 7 eller 14 mg oral semaglutid eller placebo som supplement til insulin. Det primære endepunkt og de bekræftende sekundære endepunkter var ændring i HbA1c og vægt ved uge 26 i forhold til baseline. Vigtige sekundære endepunkter var bl.a. ændring i HbA1c og vægt ved uge 52 i forhold til baseline. PIONEER, det kliniske fase 3a-program for oral semaglutid, er et globalt udviklingsprogram med en samlet deltagelse af 8.845 mennesker med type 2-diabetes i 10 kliniske studier, som alle forventes afsluttet i 2018. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information  Selskabsmeddelelse nr. 81 / 2018 [1] Behandlingspolitisk estimand: behandlingseffekt uanset ophør af behandlingen eller iværksættelse af anden behandling (analyseret ved hjælp af en pattern mixture-model baseret på multiple imputationer til håndtering af manglende data med en analyse af kovarians (ANCOVA)). [2] Hypotetisk estimand: behandlingseffekt mens behandlingen pågår uden brug af anden behandling (analyseret ved hjælp af Mixed Models for Repeated Measurements (MMRM)). Den anvendte statistiske metodik er den samme som den, der blev anvendt i SUSTAIN-programmet for subkutan semaglutid.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=487,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
136,2018-10-26,Oral semaglutide demonstrates statistically significant reductions in HbA1c and body weight in people with long duration of type 2 diabetes treated with insulin,"Bagsværd, Denmark, 26 October 2018 - Novo Nordisk today announced the headline results from PIONEER 8, a phase 3a trial with oral semaglutide for the treatment of adults with type 2 diabetes. Oral semaglutide is an investigational GLP-1 analogue taken once daily as a tablet. The 52-week trial investigated the efficacy and safety of 3, 7 and 14 mg oral semaglutide compared with placebo in 731 people with type 2 diabetes treated with insulin and an average duration of diabetes of 15 years. During the first 26-week treatment period, the total daily insulin dose was not allowed to be increased above baseline followed by a 26-week period where the insulin treatment was adjusted without restrictions. Two distinct statistical approaches to evaluating the effects of oral semaglutide were applied in the PIONEER 8 trial; a primary statistical approach[1] required by recent regulatory guidance evaluating the effect regardless of discontinuation of treatment and use of rescue medication, and a secondary statistical approach[2] describing the effect while on treatment and without use of rescue medication. When applying the primary statistical approach, the trial achieved its primary objective by demonstrating statistically significant and superior reductions in HbA1c and body weight with all three doses of oral semaglutide compared to placebo, all in addition to insulin, at week 26. When applying the secondary statistical approach, from a mean baseline of 8.2%, people treated with 3, 7 and 14 mg oral semaglutide achieved reductions in HbA1c of 0.6%, 1.0% and 1.4% respectively, compared to no reduction (0.0%) in people treated with placebo, all in addition to insulin, at week 26, and 0.5%, 0.8% and 1.2% respectively, compared with 0.0% at week 52. The American Diabetes Association (ADA) treatment target of HbA1c below 7.0% was achieved by 36%, 47% and 64% of people treated with 3, 7 and 14 mg oral semaglutide respectively, compared to 10% of people treated with placebo at week 52. In addition, from a mean baseline body weight of 85.9 kg, people treated with 3, 7 and 14 mg oral semaglutide experienced a weight loss of 1.0 kg, 2.9 kg and 4.3 kg, respectively, compared to a weight increase of 0.6 kg in people treated with placebo at week 52, all in addition to insulin. The mean total insulin dose at baseline was 60, 62 and 54 units/day for people treated with 3, 7 and 14 mg oral semaglutide respectively, compared to 56 IU/day for people treated with placebo, and the total insulin dose at week 52 was increased by 2 units/day, reduced by 6 units/day and reduced by 7 units/day for people treated with 3, 7 and 14 mg oral semaglutide respectively, compared to an increase of 10 units/day for people treated with placebo. In the 52-week trial, people treated with 3, 7 and 14 mg oral semaglutide experienced few and comparable levels of severe or blood glucose-confirmed hypoglycaemic episodes compared to placebo. Oral semaglutide was well-tolerated and with a profile consistent with GLP-1-based therapy. The most common adverse event for oral semaglutide was mild to moderate nausea, which diminished over time. In PIONEER 8, 11-23% of people treated with oral semaglutide experienced nausea, compared to 7% of people treated with placebo. The proportion of people who discontinued treatment due to adverse events was 7-14% for people treated with oral semaglutide compared to 3% with placebo. ""For people with type 2 diabetes and requiring insulin treatment, it can be challenging to reach optimal blood sugar control levels due to weight gain and risk of hypoglycaemia,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""In PIONEER 8, oral semaglutide was able to improve blood sugar control for people with a long duration of diabetes and already treated with insulin, with the benefit of clinically meaningful weight reduction, and without increasing the risk of hypoglycaemia."" About PIONEER 8 and the PIONEER clinical trial programmePIONEER 8 was a 52-week, randomised, double-blinded, placebo-controlled, parallel-group, multicentre, multinational trial with four arms comparing the efficacy and safety of 3, 7 and 14 mg oral semaglutide with placebo in people with type 2 diabetes treated with basal insulin alone or basal/bolus insulin in any combination or premix insulin including combinations of soluble insulins. The insulin treatment could be combined with metformin. The 52-week randomised treatment period was split into two; an initial 26-week period during which the insulin dose was capped at pre-randomisation levels, followed by a 26-week period where insulin treatment was adjusted without any restrictions. PIONEER 8 randomised 731 people with an average of duration of diabetes of 15 years in a 1:1:1:1 manner to receive either a dose of oral semaglutide 3, 7 and 14 mg or placebo in addition to insulin. The primary endpoint and confirmatory secondary endpoints were change from baseline to week 26 in HbA1c and body weight. Key secondary endpoints included change in HbA1c and bodyweight from baseline to week 52. The PIONEER phase 3a clinical development programme for oral semaglutide is a global development programme with enrolment of 8,845 people with type 2 diabetes across 10 clinical trials, which are all expected to complete in 2018. Further information  Company announcement No 81 / 2018 [1] Treatment policy estimand approach: treatment effect regardless of discontinuation of treatment or initiation of rescue medication (analysed by pattern mixture model using multiple imputations to handle missing data with an analysis of covariance (ANCOVA)). [2] Hypothetical estimand approach: treatment effect while on treatment without use of rescue medication (analysed by Mixed Models for Repeated Measurements (MMRM)). Similar statistical methodology as applied in the SUSTAIN programme for subcutaneous semaglutide.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=486,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
137,2018-10-15,Novo Nordisk udnævner Ludovic Helfgott til koncerndirektør for Biopharm,"Bagsværd, den 15. oktober 2018 - Novo Nordisk A/S meddeler i dag, at Ludovic Helfgott er udnævnt til koncerndirektør for Biopharm med virkning fra 3. april 2019. Ludovic Helfgott skal med base i Zürich i Schweiz stå i spidsen for udvikling af Novo Nordisks Biopharm-forretning, som omfatter virksomhedens aktiviteter indenfor hæmofili og humant væksthormon. Han bliver medlem af Novo Nordisks koncerndirektion og skal rapportere til administrerende direktør Lars Fruergaard Jørgensen. Ludovic Helfgott kommer fra AstraZeneca, hvor han senest har været direktør for virksomhedens globale aktiviteter indenfor hjerte-kar-, stofskifte- og nyresygdomme med ansvar for såvel aktiver under udvikling som markedsførte aktiver. Han blev ansat i AstraZeneca i 2005 med ansvar for international salgseffektivitet og har siden varetaget forskellige operationelle ledelsesroller med stigende ansvar i Italien, Spanien og koncernhovedkvarteret. Ludovic Helfgott er fransk statsborger og har en MBA fra Insead. I en kommentar til sin nye rolle siger han: ""Jeg glæder mig til at starte i Novo Nordisk og ser frem til sammen med Biopharm-teamet at arbejde for at skabe bedre livskvalitet for mennesker med hæmofili, vækstforstyrrelser og andre alvorlige kroniske sygdomme."" Jesper Brandgaard, koncerndirektør for Biopharm & Legal Affairs, har besluttet at trække sig tilbage efter en imponerende 20-årig karriere i Novo Nordisk. Han fortsætter som leder af Biopharm & Legal Affairs, indtil Ludovic Helfgott overtager ansvaret for Novo Nordisks Biopharm-forretning. Lars Fruergaard Jørgensen siger: ""Jeg er meget glad for at byde Ludovic Helfgott velkommen til Novo Nordisk og direktionen. Han kommer med stor erfaring med udvikling og lancering af behandlinger til mennesker med kroniske sygdomme og vil i sin nye rolle bidrage til at drive den fortsatte udvikling af vores Biopharm-forretning. Samtidig vil jeg gerne takke Jesper Brandgaard for hans enorme bidrag til Novo Nordisk, både som vores koncernøkonomidirektør gennem mange år og senest som leder af Biopharm, hvor han har taget vigtige skridt til at bringe forretningen tilbage på vækstsporet. Jeg er glad for, at Jesper fortsætter i sin nuværende rolle, indtil Ludovic tiltræder sin nye stilling i Novo Nordisk."" Jesper Brandgaard siger: ""Det har været et privilegium for mig at være en del af Novo Nordisks rejse gennem mine 20 år i virksomheden. Med stærke afløsere på plads indenfor Finance, Legal Affairs og Biopharm er april 2019 et godt tidspunkt for mig til at forlade virksomheden og i stedet forfølge en karriere i bestyrelsesregi."" Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 78 / 2018",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=493,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
138,2018-10-15,Novo Nordisk appoints Ludovic Helfgott executive vice president Biopharm,"Bagsværd, Denmark, 15 October 2018 - Novo Nordisk A/S today announced the appointment of Ludovic Helfgott as executive vice president of Biopharm, effective 3 April 2019. Based in Zürich, Switzerland, Helfgott will lead the development of Novo Nordisk's Biopharm business, which comprises the company's haemophilia and human growth hormone franchises. He will be a member of Novo Nordisk's Executive Management team and report to CEO Lars Fruergaard Jørgensen. Ludovic Helfgott joins Novo Nordisk from AstraZeneca where he most recently was global vice president in charge of the company's Cardiovascular, Metabolism and Renal global franchise, supervising both assets in development and on the market. He joined AstraZeneca in 2005 in an international sales effectiveness role and has since held operational leadership roles with increasing responsibilities in Italy, Spain and at corporate headquarters. A French national, Helfgott holds an MBA from Insead. Commenting on his new role, he says: ""I'm excited to join Novo Nordisk and look forward to working with the Biopharm team on improving lives for people with haemophilia, growth disorders and other serious chronic diseases"". Jesper Brandgaard, executive vice president, Biopharm & Legal Affairs, has decided to retire after a distinguished 20-year career at Novo Nordisk. He will remain in charge of Biopharm & Legal Affairs until Ludovic Helfgott assumes the responsibility of Novo Nordisk's Biopharm business. Lars Fruergaard Jørgensen says: ""I am delighted to welcome Ludovic Helfgott to Novo Nordisk and my executive team. He brings with him extensive experience in the development and launch of treatments for people with chronic diseases. In his new role, he will be instrumental in driving the continued development of our Biopharm business. I would also like to thank Jesper Brandgaard for his significant contributions to Novo Nordisk, both as our CFO for many years and most recently as head of Biopharm, where he has taken important steps towards bringing the business back on a growth track. I'm pleased that Jesper will continue in his current role until Ludovic joins Novo Nordisk."" Jesper Brandgaard says: ""It has been a privilege for me to be part of Novo Nordisk's journey during my 20 years with the company. With strong successors in place within Finance, Legal Affairs and Biopharm, April 2019 will be a good time for me to pursue a non-executive career."" Further information Company announcement No 78 / 2018",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=492,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
139,2018-10-12,"Fiasp® is effective at controlling blood sugar levels in children and adolescents living with type 1 diabetes, when compared to conventional insulin aspart","Hyderabad, India, 12 October 2018 ­- For children and adolescents (1 to <18 years old) living with type 1 diabetes, Fiasp® (an ultra-fast acting formulation of insulin aspart) could be an option to better manage their blood sugar levels, when used as part of a multiple daily injection routine (also known as a basal-bolus regimen)1. New data presented today at the 44th Annual Conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD) showed that the study population receiving Fiasp® achieved superior reductions in overall blood sugar levels (HbA1c), compared to the group on conventional insulin aspart, when both treatments were dosed at mealtime (estimated treatment difference (ETD) -0.17%). In addition, significantly lower overall post-meal blood sugar levels (1-hour after the meal) were achieved with Fiasp® compared to conventional insulin aspart1. ""Fiasp® has already helped to reduce challenges around mealtime blood sugar control for adults with diabetes, and it is exciting to see that similar benefits are achieved with children and adolescents in this trial,"" said Dr Bruce Bode, Diabetes Specialist with Atlanta Diabetes Associates in Atlanta, Georgia, and lead research of the study. ""These findings show that Fiasp® may offer a suitable option to improve blood sugar control and better meet the needs of this specific population."" Another group of study participants, that injected Fiasp® 20 minutes after the start of the meal, achieved similar overall blood sugar levels to those taking conventional insulin aspart dosed at mealtime (non-significant ETD of 0.13% in favour of conventional insulin aspart). These results confirm the non-inferior profile of action of Fiasp® when dosed 20 minutes after the start of the meal, compared with conventional insulin aspart dosed at mealtime1. ""It can be hard for the parents and caregivers of children with type 1 diabetes to know exactly how much or how fast their children will eat, making the dosing of mealtime insulin challenging in relation to both timing and quantity,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""These results show that Fiasp® may be able to ease some of the burden of diabetes management at mealtimes for children and adolescents, as well as those who care for them. We hope to make this ultra-fast treatment option available to benefit this population as soon possible."" There were no significant differences in the overall rate of severe or blood-sugar confirmed hypoglycaemic episodes, or overall rates of other adverse events such as nausea or injection site reactions, confirming the safety profile of Fiasp® in comparison to conventional insulin aspart1. The onset 7 trial (777 people randomised) was a 26-week, phase 3a, partially double-blinded, basal-bolus, treat-to-target trial, evaluating the efficacy and safety of Fiasp® compared with conventional insulin aspart in children and adolescents with type 1 diabetes. The study investigated Fiasp® dosed at mealtime (0-2 minutes before starting the meal) and 20 minutes after the start of the meal, in comparison to conventional insulin aspart dosed at mealtime (0-2 minutes before starting the meal). All treatment arms involved a multiple daily injection routine (basal-bolus) using Tresiba® (insulin degludec) as the basal insulin. Fiasp® (fast-acting insulin aspart) is the only approved, new-generation, ultra-fast acting2-4 mealtime insulin injection. Fiasp® is insulin aspart in an innovative formulation, in which two excipients have been added: Vitamin B3 (niacinamide) to increase the speed of absorption and a naturally occurring amino acid (L-Arginine) for stability5. The result is a mealtime insulin that more closely mimics the natural physiological insulin response of a person without diabetes after a meal, compared with conventional insulin aspart5. Fiasp® (fast-acting insulin aspart) is approved in the US, Canada, Switzerland, Australia and the EU (including Norway & Iceland), along with a number of other markets. It is also currently under regulatory review in several other countries around the world. Fiasp® is currently indicated for the treatment of adults with type 1 and type 2 diabetes only. Further information _______________________  References 1.    Bode B, et al. Efficacy and safety of fast-acting insulin aspart compared with insulin aspart, both in combination with insulin degludec, in children and adolescents with type 1 diabetes: the onset 7 trial. Poster presentation at the 44th Annual Conference of ISPAD. 11-14 October 2018; Hyderabad, India.2.    Cengiz E, et al. Moving toward the ideal insulin for insulin pumps. Expert Review of Medical Devices 2016; 13(1):57-69.3.    Heinemann L and Muchmore DB. Ultrafast-acting insulins: state of the art. Journal of Diabetes Science and Technology 2012; 6:728-42.4.    Russell-Jones D, et al. Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1). Diabetes Care 2017; 40(7):943-50.5.    Heise T, et al. A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes. Clinical Pharmacokinetics 2017; 56(5):551-9.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=494,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
140,2018-10-02,Addressing social and cultural drivers of type 2 diabetes is key to its treatment and prevention,"Berlin, Germany, 2 October 2018 - New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless they address social and cultural factors.1 Researchers linked factors such as food traditions and traditional gender roles to increasing vulnerability to diabetes in cities1, where three-quarters of people with the disease are set to live by 2045.3 The findings from the Cities Changing Diabetes research were presented at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD 2018) in Berlin, Germany. ""For many years, diabetes has continued to rise at an alarming rate despite the best efforts of policymaker and healthcare providers,"" says David Napier, professor of Medical Anthropology at University College London (UCL). ""In order to turn the table on this devastating and costly disease, we need to think differently and adopt new approaches. When public health strategies and individual care plans take into account the prevailing local cultures and associated conventions and behaviours, they are much more likely to be successful."" Fuelled by rapidly increasing rates of obesity, diabetes could affect one in nine adults by 2045 - more than 730 million people.2 Within the same time frame, annual diabetes-related healthcare costs are expected to increase by 39% from 775 billion US dollars to more than 1 trillion dollars, further highlighting the urgency for action.4 Within their findings, researchers pointed to a number of social and cultural factors contributing to the rise of diabetes in cities around the world, including:1 A second study presented by Cities Changing Diabetes researchers at EASD 2018 demonstrated that rates of diabetes and obesity are accelerating in every region of the world today. North America and Europe, where obesity has been rising for decades, are expected to have the highest future type 2 diabetes prevalence but also the slowest future increases.5 Africa, on the other hand, is projected to see a near-threefold increase in the number of people living with diabetes as the population ages and obesity prevalence increases.5 Achieving a 25% reduction of obesity prevalence on the continent would result in 15.3 million fewer people with type 2 diabetes in 2045.5 ""Whether it's by initiating door-to-door care provision, relocating clinics within urban communities or through enabling peer support among religious faith groups, the many partners in the Cities Changing Diabetes programme are already acting to great effect on these research findings,"" said Niels Lund, vice president for Health Advocacy, Novo Nordisk. ""However, halting the rise of diabetes requires others to learn from their approach and to develop strategies that reflect local needs. To this end, the Cities Changing Diabetes programme is an open and inclusive partnership in which anyone with a stake in the prevention and treatment of diabetes is welcome to participate."" The first study carried out Vulnerability Assessments in five highly diverse cities - Copenhagen, Houston, Mexico City, Shanghai and Tianjin - to assess the impact of cultural factors on vulnerability to type 2 diabetes. This included traditions and conventions, health beliefs and food practices, gender attitudes, and local practices to care seeking. Using semi-structured interviews, assessments were conducted with a total of 740 people.1 The second study investigated the regional prevalence of type 2 diabetes from 2017-2045, using past and target trend scenarios. The past trend scenario assumes that future increase in obesity prevalence is extrapolated linearly, and in a target scenario obesity prevalence is reduced by 25% in 2045. BMI data for all countries worldwide 2000-2014 were obtained from the Non-communicable Disease Risk Factor Collaboration, and the share of people in each age and BMI class were projected depending on scenario.5 Cities Changing Diabetes is a first-of-its-kind partnership programme with an ambitious global goal to reduce obesity by 25% so that only 1 in 10 people live with diabetes by 2045. More than 100 local partners - including city leaders and ministries, academia, diabetes associations, health insurers, community groups and business corporations - collaborate across disciplines and in new forms of public-private partnerships to map the diabetes problem, share solutions and drive actions to bend the curve on urban diabetes. The programme was initiated in 2014 by three global partners: University College London, Steno Diabetes Center Copenhagen and Novo Nordisk. Today, 17 cities representing more than 130 million citizens are active partners: Beijing, Beirut, Buenos Aires, Copenhagen, Hangzhou, Houston, Jakarta, Johannesburg, Koriyama, Leicester, Mérida, Mexico City, Rome, Shanghai, Tianjin, Vancouver and Xiamen. Further information _______________________  References 1.    Volkmann A-M, Hesseldal L, Bagger M, et al. Local traditions and conventions impact vulnerability to type 2 diabetes. Abstract presented at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD), Berlin, Germany; 1-5 October 2018.2.    Moses A, Lund N, Jensen BB, et al. Illustrating the pivotal role of obesity as a driver of diabetes. Abstract presented at the 25th European Congress on Obesity (ECO 2018), Vienna, Austria; 23-26 May 2018.3.    International Diabetes Federation. IDF Diabetes Atlas, 7 ed. Brussels, Belgium: International Diabetes Federation; 2015.4.    Cities Changing Diabetes. Diabetes Projection Model, Global. Data on file. Novo Nordisk. In: Incentive, ed. Holte, Denmark; 2017.5.    Nielsen S, Napier D, Jensen BB, et al. Regional burden of obesity and diabetes in adults - projections from 2017-2045. Abstract presented at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD), Berlin, Germany; 1-5 October 2018.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=497,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
141,2018-10-02,"People with diabetes may achieve improved glycaemic control with Tresiba® versus glargine U100, without an increase in hypoglycaemia","Berlin, Germany, 2 October 2018 ­- According to results of a post-hoc analysis people with both type 1 and type 2 diabetes in clinical practice may achieve improved glycaemic control (HbA1c) with Tresiba® (insulin degludec) versus insulin glargine U100, without an increase in hypoglycaemia (potentially dangerous low blood sugar).1 The results of this new analysis from the SWITCH 1 and 2 trials were presented today at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD 2018) in Berlin, Germany. Lowering blood sugar to target levels is important to help prevent the complications of diabetes, but reductions can increase the risk of hypoglycaemia. In this post-hoc analysis, based on the reduction in hypoglycaemia risk with Tresiba® found in the maintenance period of the SWITCH trials, it is estimated that people with diabetes may achieve a mean HbA1c reduction of 0.70% (type 1 diabetes) and 0.96% (type 2 diabetes) with Tresiba® compared to insulin glargine U100 at similar rates of hypoglycaemia.1 ""Episodes of hypoglycaemia can be dangerous for people with diabetes and can often be a significant barrier to achieving glycaemic control,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""These findings add to already published evidence showing a reduced risk of hypoglycaemia with Tresiba®, providing further confidence that this treatment may help people with diabetes achieve blood sugar control."" This post-hoc analysis is based on patient-level data from the SWITCH 1 and 2 trials. The SWITCH trials demonstrated statistically significantly lower rates of overall symptomatic hypoglycaemia versus insulin glargine U100 in people with type 1 and type 2 diabetes.2,3 About the new analysisThis post-hoc analysis investigated the individual patient-level risk of hypoglycaemia by HbA1c with Tresiba® and insulin glargine U100 to compare how glycaemic control differs at a similar rate of hypoglycaemia. For each trial participant at each visit their HbA1c level was linked with the number of hypoglycaemic events (blood glucose-confirmed [<3.1 mmol/L] with symptoms or severe [third-party assistance]) since last visit. Reduction of hypoglycaemia risk with Tresiba® was calculated using the reduction in hypoglycaemia seen with Tresiba® compared to insulin glargine U100 in the SWITCH trials.1 About SWITCH 1 and 2SWITCH 1 and SWITCH 2 were two phase 3b, 64-week, double-blinded, randomised, treat-to-target, 2-period cross-over trials that investigated the hypoglycaemia profile of Tresiba® compared with insulin glargine U100 in people with type 1 and type 2 diabetes and at least one risk factor for hypoglycaemia, respectively. The trial design included a titration period in which the doses of study treatments (Tresiba® or insulin glargine U100) were gradually increased over a 16-week period, followed by a 16-week maintenance period during which a stable dose of study treatment was maintained.2,3 The primary endpoint was the number of severe or blood glucose-confirmed symptomatic hypoglycaemic episodes observed in participants during the maintenance period.2,3 About hypoglycaemia Hypoglycaemia occurs when blood sugar levels are too low and cannot provide the body's organs with the energy they need. Hypoglycaemia can cause a range of symptoms including confusion, trembling, sweating, increased heart rate, difficulty with concentration and speech.4,5 In severe cases it can lead to a seizure, coma or even death.4,6 About Tresiba® Tresiba® (insulin degludec) is a once-daily basal insulin that provides a duration of action beyond 42 hours with a flat and stable glucose-lowering effect.7,8 Tresiba led to an effective reduction in HbA1c in clinical trials and showed a lower risk of hypoglycaemia in certain patient populations and studies compared to insulin glargine U100, in particular in type 2 diabetes.2,3,8,9 It also provides for a lower day-to-day variability in glucose lowering effect versus insulin glargine U100.8 Tresiba® received its first regulatory approval in September 2012 and has since been approved in more than 80 countries globally. It is commercially available in more than 61 countries. Further information _______________________  References 1.         Pedersen-Bjergard U, Philis-Tsimikas A, Lane W, et al. Relationship between HbA1c and hypoglycaemia risk in individual patients comparing insulin degludec with insulin glargine U100.  Poster presented at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD), Berlin, Germany; 1-5 October 2018. 2.         Lane W, Bailey TS, Gerety G, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes: The SWITCH 1 randomized clinical trial. JAMA. 2017;318:33-44. 3.         Wysham C, Bhargava A, Chaykin L, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: The SWITCH 2 randomized clinical trial. JAMA. 2017;318:45-56. 4.         Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36:1384-1395. 5.         International Hypoglycaemia Study Group. Diagnosis of hypoglycaemia. Available online at http://ihsgonline.com/understanding-hypoglycaemia/diagnosis. Last accessed: July 2018. 6.         Cryer PE. Hypoglycemia, functional brain failure, and brain death. J Clin Invest. 2007;117:868-870. 7.         Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014;53:787-800. 8.         EMA. Tresiba® Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002498/WC500138940.pdf. Last accessed: July 2018.9.         Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377:723-732.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=498,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
142,2018-10-02,Ryzodeg® offers a simpler solution with once-daily dosing and reduced risk of nocturnal hypoglycaemia vs insulin glargine U100 plus insulin aspart,"Berlin, Germany, 2 October 2018 ­- When treated with once-daily Ryzodeg®, people with type 2 diabetes achieved similar blood sugar control with half the number of daily injections, significantly lower total daily insulin dose and significantly reduced risk of nocturnal hypoglycaemia in the Step by Step trial compared with once-daily insulin glargine U100 plus once-daily insulin aspart after 26 weeks. Ryzodeg® is a combination of insulin degludec and insulin aspart (IDegAsp) in one pen for the treatment of people with type 2 diabetes. The results from the Step by Step trial were presented today at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD 2018) in Berlin, Germany.1 ""Complicated treatment regimens that require multiple injections at different times of day can be difficult for patients to adhere to, potentially leading to poor blood sugar control,"" said Dr Athena Philis-Tsimikas, Step by Step lead investigator and corporate vice president, Scripps Whittier Diabetes Institute. ""These trial results show that once-daily IDegAsp can offer people with type 2 diabetes a much simpler option with fewer injections compared with insulin glargine U100 plus insulin aspart, to achieve effective blood sugar control."" After 26 weeks, people in the once-daily Ryzodeg® treatment arm received 50% fewer injections and significantly fewer total daily insulin units (12%) compared with insulin glargine U100 plus insulin aspart.1 Once-daily Ryzodeg® demonstrated a statistically significant 45% lower rate of nocturnal severe or blood glucose (BG)-confirmed symptomatic hypoglycaemic episodes compared with insulin glargine U100 plus insulin aspart after 26 weeks. The rate of overall severe or BG-confirmed hypoglycaemic episodes was numerically lower for once-daily Ryzodeg® compared with insulin glargine U100 plus insulin aspart.1 ""Hypoglycaemic episodes, especially at night, are often frightening for people with diabetes. Not only does once-daily Ryzodeg® offer a much simpler solution but it also significantly reduces the risk of nocturnal hypoglycaemia compared with basal-bolus treatment,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""By reducing the number of daily injections, we hope that Ryzodeg® can help reduce the burden of diabetes, and make it easier for people with diabetes to comply with treatment and help them towards achieving better outcomes."" The Step by Step trial compared the efficacy and safety of Ryzodeg® with insulin glargine U100 plus insulin aspart in people with type 2 diabetes treated with basal insulin, with or without oral antidiabetic treatment in need of insulin intensification.1 The trial was a 38-week, international, open-label, randomised, treat-to-target trial involving 532 adults from seven countries.1,2 If participants were not on target at Week 26 or Week 32, they went on to receive an intensified insulin regimen, as would happen in real-life clinical practice.1 The primary endpoint was change from baseline in HbA1c after 26 weeks.1,2 Key secondary endpoints included change from baseline in HbA1c after 38 weeks, responder rate (%) for HbA1c <7% after 26 and 38 weeks, and number of treatment-emergent severe or BG-confirmed symptomatic hypoglycaemic episodes during 26 and 38 weeks.1,2 Ryzodeg® is a combination of two distinct insulin analogues (insulin degludec and insulin aspart in the ratio of 70% and 30%), making it the first combination of a long-acting basal insulin and a mealtime insulin in one pen for people with type 1 and 2 diabetes.3-6 Ryzodeg® incorporates the benefits of the insulin degludec molecule.7,8 Ryzodeg® is given as an injection once or twice daily with main meal(s).4 Ryzodeg® offers a simpler regimen with fewer injections than basal and bolus therapy, in one pen.3 Ryzodeg® received its first regulatory approval in December 2012 and European Medicines Agency approval in January 2013. Since then, Ryzodeg® has been approved in more than 90 countries, including the US in September 2015. It is now commercially available in 20 countries. Further information ______________________  References 1.         Gupta Y, Astamirova K, Fita E, et al. Similar glycaemic control and less nocturnal hypoglycaemia with intensification of IDegAsp QD or BID vs glargine U100 QD + IAsp 1-3 in adults with type 2 diabetes. Abstract and poster presented at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD), Berlin, Germany; 1-5 October 2018.2.         Clinicaltrials.gov. A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification. Available at: https://clinicaltrials.gov/ct2/show/NCT02906917?term=NN5401-4266&rank=1 Last accessed: September 2018. 3.         Heise T, Tack CJ, Cuddihy R, et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naïve people with type 2 diabetes: a randomized, controlled trial. Diabetes Care. 2011; 34:669-674.4.         EMA. Ryzodeg® Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002499/WC500139011.pdf Last accessed: September 2018.5.         Fulcher GR, Christiansen JS, Bantwal G, et al. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial. Diabetes Care. 2014; 37:2084-2090.6.         De Rycke A, Mathieu C. Degludec - first of a new generation of insulins. European Endocrinology. 2011; 7:84-87.7.         Marso SP, McGuire DK, Zinman B, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017; 377:723-732.8.         Haahr H, Fita EG, Heise T. A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic. Properties and Their Implications in Clinical Use. Clin Pharmacokinet. 2017; 56:339-354.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=499,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
143,2018-10-01,Novo Nordisk to establish California manufacturing site for stem cell-based therapies,"Bagsværd, Denmark, Monday 1 October ­- Novo Nordisk today announced the establishment of a manufacturing site in Fremont, California, US to develop and produce stem cell-based therapies. The announcement follows the signing of a long-term lease on a good manufacturing practice (GMP) facility, previously operated by Asterias Biotherapeutics. The site will support Novo Nordisk's increased commitment to develop stem-cell based therapies within type 1 diabetes and other serious chronic diseases. Once operational in 2019, the facility will fulfil the supply of stem cell-based therapies for Novo Nordisk's clinical trial programmes. ""Our ambition is to develop stem cell-based therapies for a range of serious chronic diseases where we see significant unmet medical need,"" said Jacob Sten Petersen, corporate vice president and head of Stem Cell Research & Development (R&D), Novo Nordisk. ""The reliable, large-scale supply of therapies is a vital component in our efforts, so I am delighted that we have established this facility that further demonstrates our strong commitment to this field."" In addition to the lease agreement, Novo Nordisk has secured a two-year non-exclusive licence on Asterias' intellectual property relating to stem cell manufacturing technology. To facilitate collaboration between the two parties and enable Asterias to progress its own clinical programmes, Novo Nordisk will sublease laboratory, manufacturing and office space within the facility back to Asterias until the end of 2021. The establishment of the production site follows Novo Nordisk's announcement in May of an agreement with the University of California San Francisco (UCSF) in which it licensed a technology to enable the generation of GMP compliant human embryonic stem cell (hESC) lines in addition to the rights to develop these into future regenerative medicine therapies. Working in a GMP laboratory at UCSF, the partners are deriving cell lines that are defining a new quality standard in the production of stem cell-based therapies. Novo Nordisk's R&D in this field is anchored in its recently established Stem Cell Transformational Research Unit, based in Måløv, Denmark. The unit oversees multiple partnership projects pursuing stem cell-based treatments for diabetes, Parkinson's disease, chronic heart failure and dry age-related macular degeneration (AMD). The new production facility will directly support these projects, enabling the future expansion of Novo Nordisk's stem cell research portfolio into the clinic. Stem cell-based therapy is emerging as a treatment option for a number of serious chronic diseases. It has the potential to provide novel treatments for diseases with high unmet medical needs where no or inadequate therapy exists. Pluripotent stem cells have an unlimited capacity for self-renewal and the potential to be differentiated into any specialised cell type in the body. The Novo Nordisk stem cell technology platform is based on human embryonic stem cells (hESC) that can be used for generation of cell products for a wide range of therapeutic indications. Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=502,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
144,2018-10-01,Novo Nordisk etablerer produktionsanlæg i Californien til fremstilling af stamcellebaseret behandling,"Bagsværd, den 1. oktober 2018 ­- Novo Nordisk offentliggør i dag planer om at etablere et produktionsanlæg i Fremont, Californien, USA, der skal udvikle og fremstille stamcellebaserede behandlinger. Det sker efter underskrivelsen af et langtidslejemål på en fabrik, som tidligere blev drevet af Asterias Biotherapeutics. Fabrikken er GMP-godkendt og lever op til de gældende standarder for god fremstillingspraksis. Det nye anlæg skal understøtte Novo Nordisks øgede engagement i udvikling af stamcellebaserede behandlinger til type 1-diabetes og andre alvorlige kroniske sygdomme. Fabrikken vil, når den står klar i 2019, levere stamcellebaserede behandlinger til Novo Nordisks kliniske forsøgsprogrammer. ""Det er vores ambition at udvikle stamcellebaserede behandlinger til en række alvorlige kroniske sygdomme, hvor vi ser et betydeligt udækket medicinsk behov,"" siger Jacob Sten Petersen, funktionschef og leder af Stem Cell Research & Development i Novo Nordisk. ""I den sammenhæng er det afgørende, at vi kan sikre en pålidelig produktion af behandlinger i stor skala, så jeg er meget glad for, at vi har etableret denne fabrik, som tydeligt understreger vores store engagement på dette område."" Foruden lejeaftalen har Novo Nordisk fået en toårig ikke-eksklusiv licens på Asterias' immaterielle rettigheder relateret til teknologien bag stamcelleproduktion. For at fremme samarbejdet mellem de to parter og gøre det muligt for Asterias at arbejde videre med egne kliniske programmer vil Novo Nordisk tilbageleje laboratorie-, produktions- og kontorlokaler på fabriksområdet til Asterias indtil slutningen af 2021. Etableringen af produktionsanlægget sker i forlængelse af en aftale, som Novo Nordisk indgik i maj med University of California San Francisco (UCSF). Denne aftale indebar, at Novo Nordisk fik licens på en teknologi, der skal gøre det muligt af fremstille humane embryonale stamcellelinjer (hESC) i overensstemmelse med god fremstillingspraksis, foruden rettighederne til at udvikle disse cellelinjer til fremtidige regenerative medicinske behandlinger. Cellelinjerne udvindes af partnerne i et GMP-laboratorium på UCSF og vil sætte en ny kvalitetsstandard indenfor fremstilling af stamcellebaserede behandlinger. Novo Nordisks forskning og udvikling indenfor dette område er forankret i det nyetablerede Stem Cell Transformational Research Unit, som er placeret i Måløv i Danmark. Enheden står for flere forskellige partnerskabsprojekter, der fokuserer på stamcellebaserede behandlinger for diabetes, Parkinsons sygdom, kronisk hjertesvigt og øjensygdommen tør aldersrelateret makuladegeneration (AMD). Den nye fabrik vil direkte støtte disse projekter og muliggøre en fremtidig udbredelse af Novo Nordisks portefølje indenfor stamcelleforskning til klinikken. Stamcellebaseret behandling er i stigende grad i fokus til behandling af en række alvorlige kroniske sygdomme. Det har potentiale til at blive banebrydende for behandlingen af sygdomme med et stort udækket medicinsk behov, hvor der ikke findes behandling, eller hvor behandlingen er mangelfuld. Pluripotente stamceller har ubegrænset evne til selvfornyelse og potentiale til at differentiere sig til en hvilken som helst specialiseret celletype i kroppen. Novo Nordisks stamcelleteknologiplatform er baseret på humane embryonale stamceller, der kan anvendes til at frembringe celleprodukter til en lang række terapeutiske indikationer. Dette er en oversættelse af den originale engelske pressemeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=503,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
145,2018-10-01,Novo Nordisk plans first global launch of connected insulin pens and announces key digital health partnerships,"Bagsværd, Denmark, 1 October 2018 ­- Novo Nordisk today announced plans to make the durable, connected insulin pens NovoPen® 6 and NovoPen Echo® Plus commercially available across key markets commencing in early 2019. In parallel, to support the future integration of its connected pens with broader digital health solutions, Novo Nordisk has signed new partnership agreements with leading diabetes technology companies that share Novo Nordisk's vision to improve the lives of people with diabetes: Dexcom, Glooko and Roche. The partnerships aim to advance the solutions available for people living with diabetes and their healthcare professionals. Building upon its existing work with IBM Watson Health® and Glooko, Novo Nordisk aims to seamlessly integrate insulin dosing data from connected pen devices with its partners' open ecosystems and diabetes management solutions, such as data from continuous glucose monitoring (CGM) systems and blood glucose meters (BGM). ""Our non-exclusive partnership strategy allows us to integrate with the various digital platforms that people are already using to help manage their diabetes,"" said Camilla Sylvest, executive vice president of Commercial Strategy & Corporate Affairs at Novo Nordisk. ""We firmly believe that this will help more people realise the full benefit of our innovative medicines and begin to ease the mental burden of diabetes treatment for those individuals."" The launch of Novo Nordisk's first connected insulin pens, NovoPen® 6 and NovoPen Echo® Plus, will commence in the first quarter of 2019 and roll out to over 50 countries in the coming years. NovoPen® 6 and NovoPen Echo® Plus will eventually be phased in to replace NovoPen® 5 and NovoPen Echo® in countries where those devices are currently available. ""After receiving caregiver feedback, we knew a global roll-out was the right thing to do,"" said Camilla Sylvest, referring to a 2017-18 Swedish pilot in collaboration with Glooko. ""During the pilot, healthcare providers noted that patient dialogues improved without having to invest additional time."" Global Head of Roche Diabetes Care Marcel Gmuender added that, ""synching Novo Nordisk insulin data with our digital diabetes management solutions like mySugr and Accu-Chek Smart Pix will allow us to enhance quality of care and help create more sustainable healthcare systems."" Novo Nordisk will also integrate insulin dosing data with Dexcom CGM data in the coming years. ""We believe that a fully connected ecosystem represents a significant opportunity to improve the lives of people on multiple daily injections,"" said Steve Pacelli, executive vice president of Strategy & Corporate Development at Dexcom. ""We are pleased to extend our collaboration with Novo Nordisk,"" said Russ Johannesson, CEO at Glooko. ""We are excited about evolving our integrated solutions and look forward to helping more people manage their diabetes via the Glooko platform."" Beyond launching connected durable devices, Novo Nordisk expects to deliver connectivity for its disposable, pre-filled injection pens later in 2019. In the longer term, Novo Nordisk aims to increase the availability of connected pens and offer solutions for personalised treatment guidance. Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=504,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
146,2018-10-01,Novo Nordisk planlægger første globale lancering af intelligente insulinpenne og annoncerer vigtige partnerskaber indenfor digital sundhed,"Bagsværd, den 1. oktober 2018 ­- Novo Nordisk offentliggør i dag planer om at gøre de intelligente flergangsinsulinpenne NovoPen® 6 og NovoPen Echo® Plus kommercielt tilgængelige på en række vigtige markeder med start i begyndelsen af 2019. For at understøtte fremtidig integration af de intelligente insulinpenne med bredere digitale sundhedsløsninger har Novo Nordisk samtidig underskrevet nye partnerskabsaftaler med førende diabetesteknologivirksomheder, som deler Novo Nordisks vision om at forbedre livskvaliteten for mennesker med diabetes: Dexcom, Glooko og Roche. Partnerskaberne har til formål at videreudvikle de sundhedsløsninger, der er tilgængelige for mennesker med diabetes og deres behandlere. Med afsæt i det eksisterende samarbejde med IBM Watson Health® og Glooko vil Novo Nordisk integrere insulindoseringsdata fra intelligente insulinpensystemer med samarbejdspartnernes åbne økosystemer og diabetesbehandlingsløsninger, herunder data fra kontinuerlig blodsukkermonitorering og blodsukkermålere. ""Vores ikke-eksklusive partnerskabsstrategi giver os mulighed for at integrere vores løsninger med de forskellige digitale platforme, som brugerne i forvejen benytter i forbindelse med deres diabetesbehandling,"" siger Camilla Sylvest, koncerndirektør for Commercial Strategy & Corporate Affairs i Novo Nordisk. ""Vi er overbeviste om, at dette vil hjælpe flere mennesker med at opnå de fulde fordele af vores innovative lægemidler og er et skridt på vejen til at mindske den mentale belastning, som diabetesbehandling kan medføre for disse mennesker."" Lanceringen af Novo Nordisks første intelligente insulinpenne, NovoPen® 6 og NovoPen Echo® Plus, begynder i første kvartal af 2019 og vil fortsætte i flere end 50 lande i de kommende år. NovoPen® 6 og NovoPen Echo® Plus skal på længere sigt gradvist erstatte NovoPen® 5 og NovoPen Echo® i de lande, hvor disse pensystemer markedsføres i dag. ""Efter tilbagemeldingerne fra behandlerne vidste vi, at en global lancering ville være det rigtige,"" siger Camilla Sylvest. Hun refererer til en svensk pilotlancering i 2017-18 i samarbejde med Glooko. ""Under afprøvningen noterede sundhedsudbyderne, at dialogen med patienterne blev bedre, uden at det var nødvendigt at investere mere tid."" Marcel Gmuender, som er globalt ansvarlig for Roche Diabetes Care, tilføjer: ""Synkronisering af Novo Nordisks insulindata med vores digitale diabetesbehandlingsløsninger som mySugr og Accu-Chek Smart Pix vil øge behandlingskvaliteten og hjælpe med til at skabe mere bæredygtige sundhedssystemer."" Novo Nordisk vil i de kommende år også integrere insulindoseringsdata med data fra Dexcoms systemer til kontinuerlig blodsukkermonitorering. ""Vi tror, at et fuldt integreret økosystem repræsenterer en væsentlig mulighed for at forbedre livskvaliteten for mennesker, der tager flere daglige injektioner,"" siger Steve Pacelli, direktør for Strategy & Corporate Development i Dexcom. ""Vi er glade for at udvide vores samarbejde med Novo Nordisk,"" siger Russ Johannesson, administrerende direktør for Glooko. ""Vi er spændte på at udvikle vores integrerede løsninger og ser frem til at hjælpe flere mennesker med at regulere deres diabetes via Glooko-platformen."" Novo Nordisk forventer efter lanceringen af de intelligente flergangsinsulinpenne at levere intelligente løsninger for præfyldte engangsinjektionspenne senere i 2019. På længere sigt ønsker Novo Nordisk at øge tilgængeligheden af intelligente insulinpenne og tilbyde løsninger til individualiseret behandlingsvejledning. Dette er en oversættelse af den originale engelske pressemeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=505,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
147,2018-09-28,International Diabetes Federation (IDF) global survey reveals 2 in 3 people with type 2 diabetes have cardiovascular disease risk factors and/or have experienced a cardiovascular event,"Bagsværd, Denmark, 28 September 2018 ­- To mark World Heart Day on 29 September, the International Diabetes Federation (IDF) in partnership with Novo Nordisk is announcing results from the Taking Diabetes to Heart survey. The global survey investigated cardiovascular disease (CVD) awareness among 12,695 people with type 2 diabetes and revealed that 2 in 3 had CVD risk factors such as high blood pressure, uncontrolled blood glucose levels and high cholesterol and/or had experienced a CVD event such as angina, heart attack, stroke or heart failure. However, 1 in 4 respondents had never discussed, or cannot remember discussing, CVD risk factors with a doctor and only 1 in 4 considered themselves to be at low risk of CVD.2 Commenting on the findings, IDF President Professor Nam H. Cho said: ""These survey findings confirm our concerns about the increasing global prevalence of diabetes and its associated complications. Awareness of the risks and consequences of the disease remains pitifully low and education to address diabetes complications is lacking. We urge governments to invest in measures to detect type 2 diabetes early and ensure that health professionals are trained to guide people to make positive changes to their lifestyle and better manage their diabetes. This will help people to avoid disabling and life-threating diabetes complications."" Diabetes currently affects 425 million adults worldwide,3 with most cases being type 2 diabetes. CVD, which includes stroke, coronary heart disease and peripheral artery disease,4 is the leading cause of disability and death in people with type 2 diabetes.1 In the Taking Diabetes to Heart survey, 3 in 4 people with type 2 diabetes said they relied on information about CVD from their doctor. More than half of respondents said they needed more information about the risk factors associated with the development of CVD to better understand the risks in order to help prevent them.2 ""Cardiovascular disease can have a devastating impact on the lives of people with type 2 diabetes and their families,"" said Professor Stephen Gough, global chief medical officer of Novo Nordisk. ""The IDF survey findings are striking and reinforce the importance of raising awareness of CVD risk and its impact on people living with type 2 diabetes. We are committed to continue working with IDF while utilising these global findings to inform future efforts that can help improve health outcomes."" Taking Diabetes to Heart will culminate in a comprehensive report with regional and country-specific results and resources to help support knowledge and awareness of CVD among people with type 2 diabetes and those at risk around the world. For more information about Taking Diabetes to Heart, visit www.idf.org/takingdiabetes2heart For more information about diabetes and cardiovascular disease, visit www.idf.org/cvd Taking Diabetes to Heart - www.idf.org/takingdiabetes2heart - is the first ever multi-country, online survey investigating the level of cardiovascular disease awareness and knowledge among people with type 2 diabetes. Respondents from over 130 countries participated around the world, with more than 12,000 responses received. The survey is now closed. Results from the survey will be used to inform policy and decision-making around this common and serious complication of diabetes.3 The International Diabetes Federation (IDF) is an umbrella organisation of over 240 national diabetes associations in 168 countries and territories. It represents the interests of the growing number of people with diabetes and those at risk. The Federation has been leading the global diabetes community since 1950. The Federation's activities aim to influence policy, increase public awareness and encourage health improvement, promote the exchange of high-quality information about diabetes, and provide education for people with diabetes and their healthcare providers. www.idf.org.  Further information References 1.       Low Wang CC, Hess CN, Hiatt WR, et al. Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. Circulation. 2016;133:2459-2502.2.       International Diabetes Federation. Taking Diabetes to Heart Survey Results. Available at https://www.idf.org/our-activities/care-prevention/cardiovascular-disease/taking-diabetes-to-heart.html.3.       International Diabetes Federation. IDF Diabetes Atlas. 8th edition. Brussels, Belgium. 2017. Available at: http://www.diabetesatlas.org/. Last accessed: September 2018.4.       International Diabetes Federation. Diabetes and Cardiovascular Disease. 2016. Available at: www.idf.org/cvd. Last accessed: September 2018.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=506,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
148,2018-09-28,"Global undersøgelse viser, at 2 ud af 3 med type 2-diabetes har risikofaktorer for hjerte-kar-sygdom og/eller har haft et hjerte-kar-tilfælde","Bagsværd, den 28. september 2018 ­- I anledning af den internationale hjertedag, World Heart Day, den 29. september, offentliggør International Diabetes Federation (IDF) i partnerskab med Novo Nordisk resultater fra den globale undersøgelse Taking Diabetes to Heart. Undersøgelsen afdækker kendskabet til hjerte-kar-sygdom blandt 12.695 mennesker med type 2-diabetes og viser, at 2 ud af 3 har risikofaktorer for hjerte-kar-sygdom såsom forhøjet blodtryk, ureguleret blodsukker og højt kolesterol og/eller har haft et hjerte-kar-tilfælde som f.eks. hjertekrampe, hjerteanfald, slagtilfælde eller hjertesvigt. 1 ud af 4 respondenter har aldrig talt med en læge om risikofaktorerne for hjerte-kar-sygdom eller husker ikke at have drøftet dem, og kun 1 ud af 4 mener, at de har lav risiko for hjerte-kar-sygdom.2 I en kommentar til resultaterne siger præsidenten for IDF, professor Nam H. Cho: ""Undersøgelsen bekræfter vores bekymringer omkring den stigende forekomst af diabetes og dens følgesygdomme overalt i verden. Der er stadig et utroligt ringe kendskab til de risici og konsekvenser, der er forbundet med diabetes, og der mangler uddannelse til at sætte ind overfor følgesygdommene. Vi opfordrer indtrængende regeringer til at investere i initiativer til tidlig diagnosticering af type 2-diabetes og sikre, at læger og andet sundhedsfagligt personale  får den fornødne træning, så de kan hjælpe folk til at gennemføre livsstilsændringer og derigennem opnå en bedre regulering af deres diabetes. Det vil hjælpe med til at undgå invaliderende og livstruende komplikationer."" Globalt set er der i dag 425 mio. voksne med diabetes,3 hvoraf størstedelen har type 2-diabetes. Hjerte-kar-sygdom, der bl.a. omfatter slagtilfælde, kranspulsåresygdom og perifer arteriesygdom,4 er den hyppigste årsag til invaliditet og død blandt mennesker med type 2-diabetes.1 I Taking Diabetes to Heart-undersøgelsen svarede 3 ud af 4 med type 2-diabetes, at de regnede med blive informeret om hjerte-kar-sygdom af deres læge. Over halvdelen af respondenterne svarede, at de havde brug for mere information om risikofaktorerne for udvikling af hjerte-kar-sygdom for bedre at forstå risikoen og forebygge den.2 ""Hjerte-kar-sygdom kan ødelægge tilværelsen for mennesker med type 2-diabetes og deres familier,"" siger professor Stephen Gough, global medicinsk direktør i Novo Nordisk. ""Resultaterne af IDF's undersøgelse er overbevisende og understreger, hvor vigtigt det er at øge kendskabet til risikoen for hjerte-kar-sygdom, og hvordan den påvirker mennesker med type 2-diabetes. Vi ser frem til at fortsætte samarbejdet med IDF og omsætte disse globale resultater til initiativer, der kan hjælpe med til at forbedre sundheden lokalt."" Taking Diabetes to Heart vil udmønte sig i en omfattende rapport med regionale og landespecifikke resultater og ressourcer, der skal hjælpe med at understøtte kendskabet i hele verden til hjerte-kar-sygdom blandt mennesker, der lever med type 2-diabetes eller har risiko for at udvikle sygdommen. Læs mere om Taking Diabetes to Heart på www.idf.org/takingdiabetes2heart Læs mere om diabetes og hjerte-kar-sygdom på www.idf.org/cvd Taking Diabetes to Heart - www.idf.org/takingdiabetes2heart - er den første globale onlineundersøgelse nogensinde af kendskabet til og viden om hjerte-kar-sygdom blandt mennesker med type 2-diabetes. I undersøgelsen deltog respondenter fra over 130 lande i hele verden, og der blev modtaget flere end 12.000 besvarelser. Undersøgelsen er nu lukket. Resultaterne fra undersøgelsen vil danne grundlag for den politiske indsats og den videre beslutningstagning vedrørende denne almindelige og alvorlige komplikation til diabetes.3 International Diabetes Federation (IDF) er en paraplyorganisation for over 240 nationale diabetesforeninger i 168 lande og regioner. Den varetager interesserne hos det voksende antal mennesker, der lever med diabetes eller har risiko for at udvikle sygdommen. IDF har stået i spidsen for det globale diabetessamfund siden 1950. Organisationens aktiviteter sigter mod at påvirke politiske beslutningstagere, skabe øget offentlig opmærksomhed og bane vejen for sundhedsforbedringer, fremme udvekslingen af kvalitetsinformation om diabetes og tilbyde undervisning for mennesker med diabetes og deres behandlere. www.idf.org. Dette er en oversættelse af den originale engelske pressemeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Referencer 1.       Low Wang CC, Hess CN, Hiatt WR, et al. Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. Circulation. 2016;133:2459-2502.2.       International Diabetes Federation. Taking Diabetes to Heart Survey Results. Available at https://www.idf.org/our-activities/care-prevention/cardiovascular-disease/taking-diabetes-to-heart.html.3.       International Diabetes Federation. IDF Diabetes Atlas. 8th edition. Brussels, Belgium. 2017. Available at: http://www.diabetesatlas.org/. Last accessed: September 2018.4.       International Diabetes Federation. Diabetes and Cardiovascular Disease. 2016. Available at: www.idf.org/cvd. Last accessed: September 2018.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=507,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
149,2018-09-28,New phase 2 data for somapacitan demonstrate its potential as an efficacious once-weekly treatment for childhood growth hormone deficiency,"Athens, Greece, 28 September 2018 ­- Somapacitan, a novel growth hormone derivative in development for once-weekly administration of growth hormone, matched the therapeutic benefits of once-daily Norditropin® (somatropin) in a phase 2 trial in children with growth hormone deficiency.1 There are currently no approved once-weekly treatments for growth hormone deficiency. The REAL 3 trial data were presented today at the 57th Annual Meeting of the European Society for Paediatric Endocrinology in Athens, Greece. The trial compared three somapacitan doses (0.04, 0.08 or 0.16 mg/kg/wk) to Norditropin® 0.034 mg/kg/day. Annualised height velocity did not differ significantly for the 0.08 and 0.16 mg/kg/wk doses compared to Norditropin®. The mean annualised height velocity for the three dose levels of somapacitan was 8.0 cm, 10.9 cm and 12.9 cm, respectively, as compared to 11.4 cm for daily Norditropin®. Somapacitan was well tolerated at all doses investigated, with no clinically relevant safety or local tolerability issues identified.1 ""Today children with growth hormone deficiency require daily injections, which can be a considerable treatment burden for patients and caregivers. A once-weekly treatment would represent a significant development for these children and their families, helping them to live less disrupted lives,"" said lead investigator Prof Lars Sävendahl of the Karolinska Institutet and Pediatric Endocrinology Unit, Karolinska University Hospital, Stockholm, Sweden. ""The injection fatigue following years of daily administration could negatively impact adherence, thereby leading to worse treatment outcomes,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""In line with our long-term commitment, we are investigating the potential of somapacitan as a once-weekly growth hormone treatment for children with growth hormone deficiency."" REAL 3 was a multinational, randomised, parallel-group, active-controlled trial with the primary endpoint to evaluate the efficacy of multiple dose regimens of once-weekly somapacitan after 26 weeks of treatment in 59 growth hormone treatment-naïve pre-pubertal children with growth hormone deficiency, compared to daily Norditropin® administration. Participants were randomised to either a dose of somapacitan (0.04, 0.08 or 0.16 mg/kg/wk) or Norditropin® 0.034 mg/kg/day. The trial demonstrated dose dependency with no statistically significant difference in height velocity between somapacitan and daily growth hormone at the two upper doses of somapacitan. The mean annualised height velocity for the three dose levels of somapacitan was 8.0 cm, 10.9 cm and 12.9 cm, respectively, as compared to 11.4 cm for daily Norditropin®. The observed safety profile in the trial was consistent with that known for Norditropin®.1,2 Somapacitan is a long-acting analogue of human growth hormone which is under investigation as a possible treatment for growth hormone deficiency. Somapacitan is built on the near twenty year-long protein technology applied for prolongations of insulins, GLP-1 and now growth hormone. Somapacitan has been modified from native human growth hormone to increase its binding to the plasma protein albumin, making it suitable for once-weekly dosing.3 Childhood growth hormone deficiency is a rare condition in which there is not enough growth hormone circulating in the blood to ensure normal growth. Affected children experience slowed or halted growth from the age of two to three years onwards. If treatment is started early, affected children may grow to a normal height. Currently available growth hormone treatments must be administered as a daily subcutaneous injection.4-6 Further information ______________________  References 1.       Sävendal L, Rasmussen MH, Horikawa R, et al. Efficacy and safety of once-weekly somapacitan in childhood growth hormone deficiency: results of a randomised open-label, controlled phase 2 trial. Presented at the 57th Annual Meeting of the European Society for Paediatric Endocrinology, Athens, Greece. 27-29 September 2018.2.       Clinicaltrials.gov. Investigating Efficacy and Safety of Once-weekly NNC0195-0092 (Somapacitan) Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency. Available online at https://clinicaltrials.gov/ct2/show/NCT02616562. Last accessed July 2018.3.       Battelino T, Rasmussen MH, De Schepper J, et al. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial. Clin Endocrinol (Oxf). 2017;87:350-358.4.       Murray PG, Dattani MT, Clayton PE. Controversies in the diagnosis and management of growth hormone deficiency in childhood and adolescence. Arch Dis Child. 2016;101:96-100.5.       Great Ormond Street Hospital For Children. Growth Hormone Deficiency. August 2014. Available online at https://www.gosh.nhs.uk/conditions-and-treatments/conditions-we-treat/growth-hormone-deficiency. Last accessed July 2018.6.       Polak M, Blair J, Kotnik P, et al. Early growth hormone treatment start in childhood growth hormone deficiency improves near adult height: analysis from NordiNet(R) International Outcome Study. Eur J Endocrinol. 2017;177:421-429.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=508,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
150,2018-09-24,Danish Government and Novo Nordisk first to partner with UN-anchored initiative on non-communicable diseases,"Non-communicable diseases (NCDs) such as diabetes and hypertension kill 15 million people prematurely each year.1 More than four in five of these deaths are in low- and middle-income countries where access to essential medicines is inadequate.1 New York, US, 24 September 2018 ­- Today, the Danish Government and Novo Nordisk are announcing grants of 3 and 5 million US dollars respectively to the newly established Defeat-NCD Partnership during a launch event at the UN General Assembly. These are the first grants made to the ambitious partnership that aims to initially raise 100 million dollars to fund the mobilisation of knowledge, tools, capacities and finances to scale-up action to defeat NCDs in low-resource countries. Through four tracks of action the Partnership will contribute to: For the Danish government, this grant is a way to show its commitment to developing and strengthening partnerships as an essential part of the achievement of the Sustainable Development Goals by 2030 set by the UN. ""We believe that this Partnership has high potential to address the increasing burden connected with diabetes and hypertension in low-resource countries in a new and innovative way. If we are to fulfil the promises of the Sustainable Development Goals we must engage with new partners and move out of the comfort zone of the usual development engagements,"" says Ulla Tørnæs, Minister for Development Cooperation, Denmark. For Novo Nordisk, this Partnership is a critical next step in improving access to diabetes care in low-resource countries where inefficient procurement and supply chains can result in high prices for patients due to mark-ups and shortage of essential NCD medicines. In supporting Defeat-NCD, Novo Nordisk will continue to optimise its supply chain procedures and share its knowledge on handling and distributing cold chain products. ""From experience, we know that the inefficient procurement and supply chains in many low-resource countries are critical barriers between life-saving medicines and the people who need them most. We hope that this Partnership can simplify processes around the tender bidding and ensure efficient supply of low-cost human insulin,"" says Lars Fruergaard Jørgensen, CEO of Novo Nordisk. The next step for the Partnership is to expand the number of partners to accelerate progress within the four tracks at national level in low-resource countries. About the Defeat-NCD PartnershipThe mission of the Defeat-NCD Partnership is to enable and assist all low-resource countries to scale-up action on NCDs. NCDs threaten progress towards the 2030 Agenda for Sustainable Development, which has a specific target (SDG 3.4) of reducing premature deaths from NCDs by one-third by 2030. The partnership will initially focus on diabetes and hypertension - conditions that are closely related and that contribute to the burden of premature death and disability caused by NCDs.2,3 Subsequently, the Partnership will address other NCDs of major prevalence and impact such as certain cancers and lung conditions. The Defeat-NCD Partnership was established in January 2018 to help tackle the most significant global health challenge of the century - NCDs. The public-private partnership is hosted by the United Nations Office for Project Services (UNOPS) and includes governments, multilateral agencies, civil society, academia, philanthropic foundations and the private sector. Further information and media contacts _______________________  References 1.       World Health Organization. Noncommunicable Diseases. Fact sheet. 2018; Accessed 2 September, 2018.2.       Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension. 1992;19(5):403-418.3.       Parving H-H, Hommel E, Mathiesen E, et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy, and neuropathy in patients with insulin dependent diabetes. British medical journal (Clinical research ed). 1988;296(6616):156.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=509,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
151,2018-09-24,Den danske regering og Novo Nordisk indgår partnerskab med FN-forankret initiativ til bekæmpelse af ikke-smitsomme sygdomme,"Hvert år dør 15 millioner mennesker for tidligt på grund af ikke-smitsomme sygdomme som diabetes og forhøjet blodtryk.1 Flere end fire ud af fem af disse for tidlige dødsfald sker i lav- og mellemindkomstlande, hvor adgangen til livsvigtig medicin er utilstrækkelig.1 New York, USA, den 24. september 2018 ­- Den danske regering og Novo Nordisk offentliggør i dag ved et arrangement under FN's generalforsamling bevillinger på henholdsvis 3 og 5 mio. amerikanske dollars til det nyligt etablerede Defeat-NCD Partnership. Bevillingerne er de første til det ambitiøse partnerskab, der i første omgang har sat sig som mål at rejse 100 mio. dollars. Formålet er at bidrage til mobilisering af viden, værktøjer, kompetencer og finansiering for at styrke indsatsen for at bekæmpe ikke-smitsomme sygdomme (non-communicable diseases, NCD) i lav- og middelindkomstlande. Partnerskabet vil bidrage indenfor fire fokusområder: For den danske regering er bevillingen en måde at vise sit engagement i at udvikle og styrke partnerskaber som et vigtigt skridt på vejen til opnåelse af FN's verdensmål for bæredygtig udvikling i 2030. ""Vi tror, at dette partnerskab har stort potentiale til at adressere den stigende byrde forårsaget af diabetes og forhøjet blodtryk i lav- og middelindkomstlande på en ny og innovativ måde. Hvis vi skal leve op til verdensmålene, er vi nødt til at bevæge os udenfor vores komfortzone med nye partnerskaber og nye udviklingssamarbejder,"" siger minister for udviklingssamarbejde Ulla Tørnæs. For Novo Nordisk er partnerskabet et vigtigt næste skridt i forhold til at forbedre adgangen til diabetesbehandling i lav- og middelindkomstlande, hvor ineffektive indkøbssystemer og prisforhøjelser i distributionsleddene kan medføre høje priser for patienterne og mangel på livsvigtige lægemidler til behandling af ikke-smitsomme sygdomme. Ved at støtte Defeat-NCD Partnership vil Novo Nordisk fortsætte med at optimere processerne omkring distributionsleddene og dele sin viden om håndtering og distribution af kølekrævende medicinske produkter. ""Vi ved af erfaring, at ineffektive indkøbssystemer og distributionsled i mange lande med lav- og middelindkomst skaber væsentlige forhindringer for at få livsvigtig medicin ud til de mennesker, der har mest brug for det. Vi håber, at dette partnerskab kan forenkle processerne omkring licitationer og sikre en effektiv forsyning af human insulin til overkommelige priser,"" siger Lars Fruergaard Jørgensen, administrerende direktør for Novo Nordisk. Næste skridt for partnerskabet er få flere partnere med i projektet for at fremskynde indsatsen indenfor de fire fokusområder på nationalt niveau i lav- og middelindkomstlande. Missionen for Defeat-NCD Partnership er at hjælpe alle lav- og middelindkomstlande med at styrke indsatsen mod ikke-smitsomme sygdomme. Ikke-smitsomme sygdomme truer fremgangen for den globale 2030-bæredygtighedsagenda, som har et specifikt mål (SDG 3.4) om at reducere for tidlige dødsfald som følge af ikke-smitsomme sygdomme med en tredjedel inden 2030. Partnerskabet vil i første omgang fokusere på diabetes og forhøjet blodtryk - sygdomme, der er tæt forbundne, og som bidrager til problemet med for tidlig død og invaliditet som følge af ikke-smitsomme sygdomme.2,3 Senere vil partnerskabet adressere andre alvorlige og almindeligt udbredte ikke-smitsomme sygdomme, herunder visse kræftsygdomme og lungelidelser. Defeat-NCD Partnership blev etableret i januar 2018 for at imødegå århundredets største globale sundhedsudfordring: ikke-smitsomme sygdomme. Det offentligt-private partnerskab er forankret i FN's kontor for projektledelse (UNOPS) og omfatter regeringer, multilaterale organisationer, civilsamfund, filantropiske fonde og den private sektor. Dette er en oversættelse af den originale engelske pressemeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=510,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
152,2018-09-20,Novo Nordisk - Oral semaglutide demonstrates greater reductions in HbA1c and body weight and comparable number of adverse events vs dulaglutide in Japanese people with type 2 diabetes,"Bagsværd, Denmark, 20 September 2018 - Novo Nordisk today announced the headline results from PIONEER 10, a phase 3a trial with oral semaglutide vs once-weekly subcutaneous dulaglutide, both in combination with one oral antidiabetic drug in Japanese adults with type 2 diabetes. Oral semaglutide is an investigational GLP-1 analogue taken once daily as a tablet. The trial investigated the safety, tolerability and efficacy of 3, 7 and 14 mg oral semaglutide compared with 0.75 mg once-weekly dulaglutide in 458 Japanese people with type 2 diabetes. Prior to enrolment, participants were inadequately controlled on one oral antidiabetic drug. The trial achieved its primary objective by demonstrating a comparable number of adverse events with oral semaglutide compared to 0.75 mg dulaglutide. The proportion of people treated with 3, 7 and 14 mg oral semaglutide who experienced gastro-intestinal adverse events were 31%, 39% and 54%, respectively, compared to 40% with dulaglutide; the most frequently reported events being constipation and nausea. The proportion of people who discontinued treatment due to adverse events was between 3% and 6% of people treated with oral semaglutide, compared to 3% of people treated with dulaglutide. Two distinct statistical approaches to evaluating the efficacy of oral semaglutide vs dulaglutide were applied in the PIONEER 10 trial; a primary statistical approach[1] evaluating the effect regardless of discontinuation of treatment and use of rescue medication, and a secondary statistical approach[2] describing the effect while on treatment and without use of rescue medication. When applying the primary statistical approach, statistically significantly greater reductions in HbA1c and body weight were seen with oral semaglutide 14 mg than 0.75 mg dulaglutide at week 52. When applying the secondary statistical approach, from a baseline of 8.3%, people treated with 14 mg oral semaglutide experienced a statistically significantly greater reduction in HbA1c of 1.8% compared to 1.3% with 0.75 mg dulaglutide after 52 weeks. The reductions in HbA1c were 0.7% and 1.4% for people treated with 3 and 7 mg oral semaglutide, respectively. Reductions in body weight from baseline were also statistically significantly greater with 14 mg oral semaglutide at week 52, with a reduction of 1.9 kg compared to a weight gain of 1.1 kg with dulaglutide. People treated with 3 and 7 mg oral semaglutide experienced a weight gain of 0.1 kg and weight reduction of 1.0 kg, respectively. In addition, applying the secondary statistical approach, The Japanese Diabetes Society (JDS)  treatment target of HbA1c below 6.5% was achieved by 21%, 43% and 58% of people on treatment with 3, 7 and 14 mg oral semaglutide, respectively, compared to 41% of the people treated with 0.75 mg dulaglutide. (TEXT UPDATED 28 SEPT 2018) ""Many people with type 2 diabetes in Japan remain uncontrolled on oral antidiabetic treatments,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""When adding oral semaglutide to the treatment of this group of people, this study has demonstrated that oral semaglutide is both well tolerated and more efficacious compared to subcutaneous dulaglutide."" About PIONEER 10 and the PIONEER clinical trial programmePIONEER 10 was a 57-week, randomised, open-label, active-controlled, parallel-group, multi-centre, single country trial with four treatment arms comparing the safety, tolerability and efficacy of 3, 7 and 14 mg oral semaglutide with 0.75 mg dulaglutide (the approved dose by the Pharmaceutical and Medical Devices Agency (PMDA) in Japan) in Japanese people with type 2 diabetes inadequately controlled with one oral antidiabetic drug (sulfonylurea, glinide, thiazolidinedione, alpha-glucosidase inhibitor or sodium glucose cotransporter-2 inhibitor). PIONEER 10 randomised 458 people in a 2:2:2:1 manner to receive either a dose of oral semaglutide 3, 7 or 14 mg once daily or 0.75 mg dulaglutide once weekly. The primary endpoint was the number of adverse events during exposure to the drug, assessed up to 57 weeks. Key secondary endpoints included the change from baseline to week 26 and 52 in HbA1c and change from baseline to week 26 and 52 in body weight. The PIONEER phase 3a clinical development programme for oral semaglutide is a global development programme with enrolment of 8,845 people with type 2 diabetes across 10 clinical trials, which are all expected to complete in 2018. Further information Company announcement No 74 / 2018 [1] Treatment policy estimand approach: treatment effect regardless of discontinuation of treatment or initiation of rescue medication (analysed by pattern mixture model using multiple imputations to handle missing data with an analysis of covariance (ANCOVA)). [2] Hypothetical estimand approach: treatment effect while on treatment without use of rescue medication (analysed by Mixed Models for Repeated Measurements (MMRM)). Similar statistical methodology as applied in the SUSTAIN programme for subcutaneous semaglutide.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=513,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
153,2018-09-20,Novo Nordisk - Oral semaglutid viser større reduktioner i langtidsblodsukker og vægt og et sammenligneligt antal bivirkninger sammenlignet med dulaglutid hos japanere med type 2-diabetes,"Bagsværd, den 20. september 2018 - Novo Nordisk offentliggør i dag de overordnede resultater fra PIONEER 10, et fase 3a-studie, der har sammenlignet oral semaglutid med subkutan dulaglutid én gang ugentligt, begge i kombination med ét diabeteslægemiddel i tabletform, hos voksne japanere med type 2-diabetes. Oral semaglutid er en ny GLP-1-analog under udvikling, der tages som en tablet én gang dagligt. Studiet undersøgte sikkerhed, tolerabilitet og effekt af 3, 7 og 14 mg oral semaglutid sammenlignet med 0,75 mg dulaglutid én gang ugentligt hos 458 japanere med type 2-diabetes. Deltagerne var inden indrullering i studiet utilstrækkeligt reguleret med ét diabeteslægemiddel i tabletform. Studiet opfyldte sit primære mål, idet det viste et sammenligneligt antal bivirkninger med oral semaglutid sammenlignet med 0,75 mg dulaglutid. Andelen af deltagere i behandling med 3, 7 og 14 mg oral semaglutid, som oplevede mave-tarm-bivirkninger, var henholdsvis 31%, 39% og 54%, mod 40% med dulaglutid; de hyppigst rapporterede bivirkninger var forstoppelse og kvalme. Andelen af deltagere, som afsluttede behandlingen før tid på grund af bivirkninger, var mellem 3% og 6% for deltagere, der blev behandlet med oral semaglutid, mod 3% for deltagere, der blev behandlet med dulaglutid. Der blev i PIONEER 10 anvendt to forskellige statistiske metoder til vurdering af effekten af oral semaglutid sammenlignet med dulaglutid: en primær statistisk metode[1], som vurderer effekten uanset ophør af behandlingen og brug af anden behandling; og en sekundær statistisk metode[2], der beskriver effekten, mens behandlingen pågår og uden brug af anden behandling. Vurderet efter den primære statistiske metode sås statistisk signifikant større reduktioner i langtidsblodsukker (HbA1c) og vægt ved behandling med 14 mg oral semaglutid end ved behandling med 0,75 mg dulaglutid ved uge 52. Vurderet efter den sekundære statistiske metode og ud fra et baselineniveau på 8,3% opnåede deltagere i behandling med 14 mg oral semaglutid en statistisk signifikant større reduktion i HbA1c på 1,8% mod 1,3% med 0,75 mg dulaglutid efter 52 uger. Reduktionerne i HbA1c var 0,7% og 1,4% for deltagere i behandling med henholdsvis 3 og 7 mg oral semaglutid. Reduktionerne i vægt i forhold til baseline var også statistisk signifikant større med 14 mg oral semaglutid ved uge 52 med en reduktion på 1,9 kg mod en vægtstigning på 1,1 kg med dulaglutid. Deltagere i behandling med 3 og 7 mg oral semaglutid oplevede henholdsvis en vægtstigning på 0,1 kg og en vægtreduktion på 1,0 kg. Ved anvendelse af den sekundære statistiske metode var der desuden 21%, 43% og 58% af deltagerne i behandling med henholdsvis 3, 7 og 14 mg oral semaglutid, der nåede behandlingsmålet om HbA1c på under 6,5% som fastsat af The Japanese Diabetes Society (JDS), mod 41% af deltagere, der blev behandlet med 0,75 mg dulaglutid. (TEKST OPDATERET 26. SEPT. 2018) ""Mange japanere med type 2-diabetes opnår ikke en tilfredsstillende blodsukkerregulering med diabeteslægemidler i tabletform,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Dette studie har vist, at oral semaglutid er både veltolereret og mere virkningsfuldt end subkutan dulaglutid, når man giver det som tillægsbehandling til denne gruppe mennesker."" PIONEER 10 var et 57-ugers randomiseret, ikke-blindet, aktivt kontrolleret, parallelgruppe- multicenterstudie, der blev gennemført i ét land med fire behandlingsgrupper. Studiet undersøgte sikkerhed, tolerabilitet og effekt af 3, 7 og 14 mg oral semaglutid sammenlignet med 0,75 mg dulaglutid (den af de japanske sundhedsmyndigheder (PMDA) godkendte dosis) i japanere med type 2-diabetes, som var utilstrækkeligt reguleret med ét diabeteslægemiddel i tabletform (sulfonylurinstof, glinid, thiazolidindion, en alpha-glucosidase-hæmmer eller en sodium-glucose co-transporter (SGLT)-2-hæmmer). PIONEER 10 omfattede 458 deltagere, som blev randomiseret 2:2:2:1 til at modtage enten en dosis oral semaglutid på 3, 7 eller 14 mg én gang dagligt eller 0,75 mg dulaglutid én gang ugentligt. Det primære endepunkt var antal bivirkninger opstået under eksponering for lægemidlet, vurderet i op til 57 uger. Vigtige sekundære endepunkter var bl.a. ændring i HbA1c ved uge 26 og 52 i forhold til baseline og ændring i vægt ved uge 26 og 52 i forhold til baseline. PIONEER, det kliniske fase 3a-program for oral semaglutid, er et globalt udviklingsprogram med en samlet deltagelse af 8.845 mennesker med type 2-diabetes i 10 kliniske studier, som alle forventes afsluttet i 2018. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 74 / 2018 [1] Behandlingspolitisk estimand: behandlingseffekt uanset ophør af behandlingen eller iværksættelse af anden behandling (analyseret ved hjælp af en pattern mixture-model baseret på multiple imputationer til håndtering af manglende data med en analyse af kovarians (ANCOVA)). [2] Hypotetisk estimand: behandlingseffekt mens behandlingen pågår uden brug af anden behandling (analyseret ved hjælp af Mixed Models for Repeated Measurements (MMRM)). Den anvendte statistiske metodik er den samme som den, der blev anvendt i SUSTAIN-programmet for subkutan semaglutid.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=514,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
154,2018-09-18,Novo Nordisk announces plans to transform its approach to Research & Development,"Bagsværd, Denmark, 18 September 2018 ­- Novo Nordisk today announced plans to restructure its Research & Development (R&D) organisation to accelerate the expansion and diversification of its pipeline across serious chronic diseases. To enable increased investment in transformational biological and technological innovation within both core and new therapy areas, approximately 400 employees will be laid off from R&D roles in Denmark and China. To support its strategic ambitions, Novo Nordisk will establish four Transformational Research Units in 2018 to pursue novel treatment modalities and platform technologies. The biotech-like units, based in Denmark, the US and the UK, will operate as satellites of Novo Nordisk's central R&D function and will drive innovation in priority fields such as translational cardio-metabolic research and stem cell research. Furthermore, to drive a faster and more efficient path towards lead molecule selection and development, Novo Nordisk will significantly increase its investment in automation and digital capabilities including machine learning and artificial intelligence (AI). The integration of laboratory infrastructure and IT systems will also be prioritised to increase the efficiency of the R&D organisation. ""Delivering on our ambition of achieving even higher levels of innovation across a broader and more diverse range of chronic diseases requires that we have the optimal future skill base and allocate resources to our priority areas,"" said Mads Krogsgaard Thomsen, chief science officer, Novo Nordisk. ""Unfortunately, this implies that a number of valued colleagues will lose their jobs in order to ensure that we have sufficient new research capabilities needed to support our long-term growth ambitions."" The restructuring and re-allocation of resources supports Novo Nordisk's ambition to transform the way it works within R&D in order to identify and develop truly innovative drug candidates. This will be facilitated by the identification and pursuit of new therapeutic approaches based on external collaborations - a priority that Novo Nordisk will accelerate via the establishment of a new Business Development unit in Cambridge, MA, US. To date in 2018, Novo Nordisk has announced a range of external agreements.  These include the acquisition of the UK-based biotech start-up Ziylo to enhance research within glucose-responsive insulins and a number of partnership agreements with universities and biotech in the fields of cardio-metabolic and stem cell research. ""Thanks to our exciting internal assets and external partnerships, we are well-positioned to continue our leadership position by providing innovation that improves the health of people living with serious chronic diseases,"" said Mads Krogsgaard Thomsen.  Further information ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=515,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
155,2018-09-18,Novo Nordisk annoncerer planer om markante ændringer i tilgangen til forskning og udvikling,"Bagsværd, den 18. september 2018 ­- Novo Nordisk har i dag offentliggjort planer om en række strukturelle ændringer i sin forsknings- og udviklingsorganisation (R&D), som skal fremskynde processen med at øge antallet og diversiteten af projekter i virksomhedens pipeline indenfor alvorlige kroniske sygdomme. Ændringerne indebærer, at ca. 400 medarbejdere i Novo Nordisks forsknings- og udviklingsenheder i Danmark og Kina vil blive afskediget for at allokere øgede ressourcer til transformationel biologisk og teknologisk innovation indenfor såvel eksisterende som nye terapiområder. For at understøtte Novo Nordisks strategiske ambitioner vil der blive etableret fire såkaldte Transformational Research Units i 2018, som skal forfølge nye behandlingsformer og teknologiplatforme. Disse bioteklignende enheder skal med base i Danmark, USA og Storbritannien fungere som satellitter af Novo Nordisks centrale R&D-funktion og drive innovation indenfor prioritetsområder som translationel kardiometabolisk forskning og stamcelleforskning. Med henblik på at etablere en hurtigere og mere effektiv proces til udvælgelse og udvikling af lovende molekyler vil Novo Nordisk desuden øge sin satsning markant indenfor automatisering og digitale kompetencer, herunder machine learning og kunstig intelligens (AI). Integrering af laboratorieinfrastruktur og IT-systemer vil også blive prioriteret for at øge effektiviteten i R&D-organisationen. ""Hvis vi skal levere på vores ambition om et endnu højere innovationsniveau indenfor en bredere og mere forskelligartet vifte af kroniske sygdomme, kræver det, at vi får den rigtige fremtidige kompetencebase og allokerer ressourcer til vores prioritetsområder,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Det betyder desværre samtidig, at vi må sige farvel til gode kolleger for at sikre, at vi har de fornødne nye forskningskompetencer til at understøtte vores langsigtede vækstambitioner."" Omstruktureringen og omflytningen af ressourcer understøtter Novo Nordisks ambition om at transformere den måde, virksomheden arbejder på indenfor forskning og udvikling med henblik på at identificere og udvikle innovative lægemiddelkandidater. Det vil blive muliggjort ved at identificere og forfølge nye terapeutiske tilgange baseret på eksterne samarbejder - et område, Novo Nordisk vil fremskynde gennem etablering af en ny forretningsudviklingsenhed i Cambridge, Massachusetts, USA. Indtil videre har Novo Nordisk i år annonceret en række eksterne aftaler. Disse omfatter bl.a. opkøbet af den britiske biotek-opstartsvirksomhed Ziylo for at accelerere forskningen i glukosefølsomme insuliner samt en række partnerskabsaftaler med universiteter og biotekvirksomheder indenfor områderne kardiometabolisk forskning og stamcelleforskning. ""Takket være vores spændende interne aktiver og eksterne partnerskaber er vi godt positioneret til at fortsætte vores lederskab ved at levere innovation, der forbedrer sundheden hos mennesker med alvorlige kroniske sygdomme,"" siger Mads Krogsgaard Thomsen. Dette er en oversættelse af den originale engelske pressemeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=516,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
156,2018-08-26,Ozempic® consistently reduced the risk of major cardiovascular events across type 2 diabetes populations at high CV risk regardless of prior CV events at baseline,"Munich, Germany, 26 August 2018 ­- Ozempic® (semaglutide) consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack, non-fatal stroke or cardiovascular death (collectively termed major adverse cardiovascular events, MACE) in people with type 2 diabetes at high cardiovascular risk regardless of previously having had a cardiovascular event at the start of the trial.1 Findings from two post-hoc subgroup analyses of the SUSTAIN 6 trial and one post-hoc meta-analysis of MACE in the SUSTAIN 1-5 trials were presented today at the ESC Congress 2018, organised by the European Society of Cardiology, in Munich, Germany.1 ""Cardiovascular disease remains the leading cause of disability and death in people with type 2 diabetes and there is an increasing focus on reducing cardiovascular risk in the clinic,"" said Professor Stephen Bain, School of Medicine, Swansea University, UK. ""We have seen from clinical trials that diabetes treatments confer variable effects on cardiovascular outcomes and the results of these post-hoc analyses provide further evidence of the consistent cardiovascular risk reduction of Ozempic® in people with type 2 diabetes, with varying profiles of cardiovascular risk at baseline."" The SUSTAIN 6 post-hoc analyses found that reduction in the risk of MACE was consistent in people at high cardiovascular risk treated with Ozempic® regardless of their cardiovascular risk profile at the start of the trial, including whether or not they had a prior heart attack or stroke, and whether they had cardiovascular risk factors or established cardiovascular disease.1 SUSTAIN 6 was a pre-approval cardiovascular outcomes trial in 3,297 people with type 2 diabetes and established cardiovascular disease or with at least one cardiovascular risk factor, compared to placebo, both in addition to standard of care.2 The post-hoc pooled meta-analysis of the SUSTAIN 1-5 efficacy trials, which included 4,807 people, trended towards a lower risk of MACE in people taking Ozempic®. The comparators included in SUSTAIN 1-5 were placebo, sitagliptin, exenatide extended release and insulin glargine U100. The overall incidence of MACE was low across the SUSTAIN 1-5 trials and, due to the low number of events, this reduction did not achieve statistical significance.1 About Ozempic®Ozempic® (semaglutide) is a once-weekly analogue of human glucagon-like peptide-1 (GLP-1) indicated for the treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes, as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, or in addition to other medicinal products for the treatment of diabetes.3 Ozempic® was approved by the U.S. Food and Drug Administration on 5 December, 2017, by Health Canada on 4 January, 2018, by the European Commission on 9 February, 2018 and on 23 March, 2018 by the Japanese Ministry of Health, Labour and Welfare.4-7 About the SUSTAIN clinical trial programmeThe SUSTAIN global clinical development programme for Ozempic® comprises eight phase 3a trials, encompassing more than 8,000 adults with type 2 diabetes. The phase 3a programme involves a broad range of people with type 2 diabetes, including some with high cardiovascular risk profiles. The primary analysis of the SUSTAIN 6 trial was published in The New England Journal of Medicine.2 The primary outcome measure was a composite outcome of major adverse cardiovascular events (MACE), defined as non-fatal myocardial infarction, non-fatal stroke or cardiovascular death. Ozempic® treated patients had a significant 26% lower risk of MACE vs those receiving placebo over 2 years (hazard ratio 0.74; 95% confidence interval 0.58-0.95).2 SUSTAIN 6 was designed to assess non-inferiority, i.e. demonstrate no increased risk of major cardiovascular events vs placebo, when added to standard of care. Testing for superiority was not part of the pre-specified analysis. About Novo Nordisk Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,100 people in 79 countries and markets its products in more than 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information References 1.         Bain S, Réa R, Warren ML, et al. Semaglutide consistently reduces cardiovascular risk in patients with type 2 diabetes regardless of baseline cardiovascular risk level: post hoc analyses of the SUSTAIN trial programme. Abstract number P-2859. Presented at the 2018 Congress of the European Society of Cardiology, Munich, Germany. 25-29 August.2.         Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-1844.3.         EMA. Ozempic® (semaglutide) SmPC. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004174/WC500244163.pdf. Last accessed: July 2018. 4.         Novo Nordisk. Ozempic® approved in the EU for the treatment of type 2 diabetes. Available at: https://www.novonordisk.com/bin/getPDF.2167679.pdf. Last accessed: August 2018. 5.         Novo Nordisk. Ozempic® (semaglutide) approved in the US. Available at: https://www.novonordisk.com/content/Denmark/HQ/www-novonordisk-com/en_gb/home/media/news-details.2154210.html. Last accessed: August 2018. 6.         Novo Nordisk. Ozempic® approved in Canada for the treatment of adults with type 2 diabetes. Available at: http://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-novonordisk-ca/News/Ozempic%20press%20release_Eng_01.08.2018_FINAL.pdf Last accessed: August 2018. 7.         Novo Nordisk. Ozempic® approved in Japan for the treatment of type 2 diabetes. Available at: https://www.novonordisk.com/content/Denmark/HQ/www-novonordisk-com/en_gb/home/media/news-details.2178681.html. Last accessed: August 2018. Company announcement no. 68 / 2018",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=527,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
157,2018-08-26,Ozempic® reducerer risikoen for alvorlig kardiovaskulær sygelighed hos type 2 diabetikere med høj risiko for hjerte-kar-sygdom uanset forekomsten af tidligere kardiovaskulær hændelse,"München, Tyskland, den 26. august 2018 ­- Ozempic® (semaglutid) reducerer risikoen for det sammensatte endepunkt: tiden til første forekomst af ikke-dødeligt hjerteanfald, ikke-dødeligt slagtilfælde eller hjerte-kar-relateret død (under ét benævnt alvorlige kardiovaskulære hændelser) hos mennesker med type 2-diabetes og høj risiko for hjerte-kar-sygdom, uanset om de allerede har haft en kardiovaskulær hændelse ved studiets begyndelse.1 Det viser resultaterne fra to post hoc-undergruppeanalyser af SUSTAIN 6-studiet og en post hoc-metaanalyse af alvorlig kardiovaskulær sygelighed i SUSTAIN 1-5. Disse resultater præsenteres i dag på ESC Congress 2018 arrangeret af European Society of Cardiology i München i Tyskland.1 ""Hjerte-kar-sygdom er den hyppigste årsag til invaliditet og død hos mennesker med type 2-diabetes, og lægerne har i stigende grad fokus på at reducere risikoen for hjerte-kar-sygdom,"" siger professor Stephen Bain, School of Medicine, Swansea University, Storbritannien. ""Vi har i kliniske studier set, at forskellige diabetesbehandlinger har forskellig effekt på forekomsten af hjerte-kar-sygdom. Disse post hoc-analyser dokumenterer yderligere, at Ozempic® gennemgående reducerer hjerte-kar-risikoen hos mennesker med type 2-diabetes, selvom deres kardiovaskulære risikoprofiler som udgangspunkt er forskellige."" Post hoc-analyserne af SUSTAIN 6 viste, at risikoen for alvorlig kardiovaskulær sygelighed gennemgående blev reduceret hos mennesker med høj risiko for hjerte-kar-sygdom, som blev behandlet med Ozempic®, uanset deres kardiovaskulære risikoprofil ved studiets begyndelse, herunder uanset om de tidligere havde haft et hjerteanfald eller et slagtilfælde, og uanset om de havde kardiovaskulære risikofaktorer eller konstateret hjerte-kar-sygdom.1 SUSTAIN 6-studiet, som blev gennemført før godkendelsen af Ozempic®, undersøgte forekomsten af hjerte-kar-sygdom hos 3.297 mennesker med type 2-diabetes og konstateret hjerte-kar-sygdom eller mindst én kardiovaskulær risikofaktor, sammenlignet med placebo, begge givet som supplement til standardbehandling.2 Den samlede post hoc-metaanalyse af effektstudierne SUSTAIN 1-5 med tilsammen 4.807 deltagere viste en tendens til lavere risiko for alvorlig kardiovaskulær sygelighed hos deltagere i behandling med Ozempic®. De behandlinger, der blev sammenlignet med i SUSTAIN 1-5, var placebo, sitagliptin, exenatid extended release og insulin glargin U100. Den samlede forekomst af alvorlig kardiovaskulær sygelighed var lav i alle SUSTAIN 1-5-studierne, og på grund af det lave antal hændelser var denne reduktion ikke statistisk signifikant.1 Ozempic (semaglutid) er en ugentlig analog af det naturlige hormon glukagonlignende peptid-1 (GLP-1), der er godkendt til behandling af voksne med utilstrækkeligt reguleret type 2-diabetes som supplement til diæt og motion med henblik på at forbedre blodsukkerreguleringen hos voksne med type 2-diabetes, som monoterapi, når metformin ikke er hensigtsmæssig på grund af intolerans eller kontraindikation, eller som supplement til andre lægemidler til behandling af diabetes.3 Ozempic® blev godkendt af de amerikanske sundhedsmyndigheder (FDA) den 5. december 2017, af de canadiske sundhedsmyndigheder (Health Canada) den 4. januar 2018, af Europa-Kommissionen den 9. februar 2018 og af det japanske sundhedsministerium (Ministry of Health, Labour and Welfare) den 23. marts 2018.4-7 Det globale kliniske udviklingsprogram SUSTAIN med Ozempic® omfatter otte fase 3a-studier med en samlet deltagelse af flere end 8.000 voksne med type 2-diabetes. Fase 3a-programmet omfatter en bred vifte af mennesker med type 2-diabetes, herunder deltagere med høj risiko for hjerte-kar-sygdom. Den primære analyse af SUSTAIN 6-studiet blev publiceret i The New England Journal of Medicine.2 Det primære endepunkt var forekomsten af alvorlige kardiovaskulære hændelser, defineret som ikke-dødeligt myokardieinfarkt (hjerteanfald), ikke-dødeligt slagtilfælde eller hjerte-kar-relateret død. Patienter i behandling med Ozempic® havde en signifikant 26% lavere risiko for alvorlig kardiovaskulær sygelighed sammenlignet med dem, der fik placebo, gennem to år (risikoratio 0,74; 95% konfidensinterval 0,58-0,95).2 SUSTAIN 6 havde til formål at vurdere ikke-inferiøritet, dvs. vise ingen øget risiko for alvorlig kardiovaskulær sygelighed sammenlignet med placebo, når det blev givet som supplement til standardbehandling. Afprøvning af superioritet var ikke en del af den præspecificerede analyse. Dette er en oversættelse af den originale engelske pressemeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Referencer 1.         Bain S, Réa R, Warren ML, et al. Semaglutide consistently reduces cardiovascular risk in patients with type 2 diabetes regardless of baseline cardiovascular risk level: post hoc analyses of the SUSTAIN trial programme. Abstract number P-2859. Presented at the 2018 Congress of the European Society of Cardiology, Munich, Germany. 25-29 August.2.         Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-1844.3.         EMA. Ozempic® (semaglutide) SmPC. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004174/WC500244163.pdf. Last accessed: July 2018. 4.         Novo Nordisk. Ozempic® approved in the EU for the treatment of type 2 diabetes. Available at: https://www.novonordisk.com/bin/getPDF.2167679.pdf. Last accessed: August 2018. 5.         Novo Nordisk. Ozempic® (semaglutide) approved in the US. Available at: https://www.novonordisk.com/content/Denmark/HQ/www-novonordisk-com/en_gb/home/media/news-details.2154210.html. Last accessed: August 2018. 6.         Novo Nordisk. Ozempic® approved in Canada for the treatment of adults with type 2 diabetes. Available at: http://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-novonordisk-ca/News/Ozempic%20press%20release_Eng_01.08.2018_FINAL.pdf Last accessed: August 2018. 7.         Novo Nordisk. Ozempic® approved in Japan for the treatment of type 2 diabetes. Available at: https://www.novonordisk.com/content/Denmark/HQ/www-novonordisk-com/en_gb/home/media/news-details.2178681.html. Last accessed: August 2018. Selskabsmeddelelse Nr 68 / 2018",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=528,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
158,2018-08-20,Oral semaglutide provides superior HbA1c and weight reductions versus placebo in people with type 2 diabetes and renal impairment in the PIONEER 5 trial,"Bagsværd, Denmark, 20 August 2018 - Novo Nordisk today announced the headline results from PIONEER 5, a phase 3a trial with oral semaglutide in adults with type 2 diabetes and moderate renal impairment. Oral semaglutide is an investigational GLP-1 analogue taken once daily as a tablet. The 26-week trial investigated the efficacy and safety of 14 mg oral semaglutide compared with placebo in 324 people with type 2 diabetes and moderate renal impairment inadequately controlled with metformin, sulfonylurea alone or in combination with metformin, or basal insulin alone or in combination with metformin. Two distinct statistical approaches to evaluating the effects of oral semaglutide were applied in the PIONEER 5 trial; a primary statistical approach[1] required by recent regulatory guidance evaluating the effect regardless of discontinuation of treatment and use of rescue medication, and a secondary statistical approach[2] describing the effect while on treatment and without use of rescue medication. The trial achieved its primary objective according to the primary statistical approach by demonstrating statistically significant and superior reductions in HbA1c with oral semaglutide compared to placebo at week 26. Furthermore, people treated with oral semaglutide achieved statistically significant and superior reductions in body weight compared to placebo at week 26. When applying the secondary statistical approach, people treated with oral semaglutide experienced a statistically significantly greater reduction in HbA1c of 1.1% compared to 0.1% with placebo. Reduction in body weight was statistically significantly greater with oral semaglutide at week 26, with a reduction of 3.7 kg compared to 1.1 kg with placebo. From a baseline HbA1c of 8.0%, the proportion of people achieving the American Diabetes Association (ADA) target of HbA1c below 7.0% was statistically significantly greater with 14 mg oral semaglutide, with 64% achieving the target at week 26, compared to 21% with placebo. In this 26-week trial, oral semaglutide was well-tolerated in people with moderate renal impairment, with a profile consistent with GLP-1-based therapies. The most common adverse event for oral semaglutide was mild to moderate nausea. In PIONEER 5, 19% of people treated with oral semaglutide experienced nausea, compared to 8% of people treated with placebo. The proportion of people who discontinued treatment due to adverse events was 15% for people treated with oral semaglutide compared to 6% with placebo. ""The results from PIONEER 5 showed that oral semaglutide is efficacious and has a solid safety profile in people with type 2 diabetes and moderate renal impairment, thereby further expanding the solid clinical profile of oral semaglutide,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""Renal impairment is a serious diabetes complication and people with this condition have limited oral anti-diabetic treatment options, and if approved oral semaglutide represents an efficacious new solution for these people."" About PIONEER 5 and the PIONEER clinical trial programme PIONEER 5 was a 26-week, randomised, double-blind, placebo-controlled, parallel-group, multicentre, multinational trial with two arms comparing the efficacy and safety of 14 mg oral semaglutide with placebo in people with type 2 diabetes and moderate renal impairment (estimated glomerular filtration rate [eGFR] 30-59 ml/min/1.73m2) inadequately controlled with metformin, sulfonylurea alone or in combination with metformin, or basal insulin alone or in combination with metformin. PIONEER 5 randomised 324 people in a 1:1 manner to receive either a dose of 14 mg oral semaglutide or placebo once daily. The primary endpoint was change from baseline to week 26 in HbA1c. Key secondary endpoints included change in body weight, change in fasting plasma glucose from baseline to week 26 and proportion of people achieving HbA1c below 7.0% at 26 weeks. The PIONEER phase 3a clinical development programme for oral semaglutide is a global development programme with enrolment of 8,845 people with type 2 diabetes across 10 clinical trials, which are all expected to complete in 2018. Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 79 countries and markets its products in more than 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information  Company announcement No 66 / 2018 [1] Treatment policy estimand approach: treatment effect regardless of discontinuation of treatment or initiation of rescue medication (analysed by pattern mixture model using multiple imputations to handle missing data with an analysis of covariance (ANCOVA)). [2] Hypothetical estimand approach: treatment effect while on treatment without use of rescue medication (analysed by Mixed Models for Repeated Measurements (MMRM)). Similar statistical methodology as applied in the SUSTAIN programme for subcutaneous semaglutide.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=531,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
159,2018-08-20,Oral semaglutid giver større reduktioner i langtidsblodsukker og vægt sammenlignet med placebo hos mennesker med type 2-diabetes og nedsat nyrefunktion i PIONEER 5-studiet,"Bagsværd, den 20. august 2018 - Novo Nordisk offentliggør i dag de overordnede resultater fra PIONEER 5, et fase 3a-studie med oral semaglutid til behandling af voksne med type 2-diabetes og moderat nedsat nyrefunktion. Oral semaglutid er en ny GLP-1-analog under udvikling, der tages som en tablet én gang dagligt. Studiet, som strakte sig over 26 uger, undersøgte effekten og sikkerheden af 14 mg oral semaglutid sammenlignet med placebo i 324 deltagere med type 2-diabetes og moderat nedsat nyrefunktion, som var utilstrækkeligt reguleret med metformin, sulfonylurinstof alene eller i kombination med metformin, eller med basalinsulin alene eller i kombination med metformin. Der blev i PIONEER 5 anvendt to forskellige statistiske metoder til vurdering af effekten af oral semaglutid: en primær statistisk metode[1], som kræves i henhold til nye regulatoriske retningslinjer, og som vurderer effekten uanset ophør af behandlingen og brug af anden behandling; og en sekundær statistisk metode[2], der beskriver effekten, mens behandlingen pågår og uden brug af anden behandling. Studiet opfyldte sit primære mål vurderet ud fra den primære statistiske metode, idet det viste statistisk signifikante og større reduktioner i langtidsblodsukkeret (HbA1c) ved behandling med oral semaglutid sammenlignet med placebo ved uge 26. Deltagere, der blev behandlet med oral semaglutid, opnåede endvidere statistisk signifikante og større reduktioner i vægt sammenlignet med placebo ved uge 26. Ved anvendelse af den sekundære statistiske metode opnåede deltagere i behandling med oral semaglutid en statistisk signifikant større reduktion i HbA1c på 1,1% mod 0,1% med placebo. Reduktionen i vægt var statistisk signifikant større med oral semaglutid ved uge 26 med en reduktion på 3,7 kg mod 1,1 kg med placebo. Fra et baselineniveau på 8,0% var andelen af deltagere, der nåede behandlingsmålet om HbA1c på under 7,0% som fastsat af American Diabetes Association (ADA), statistisk signifikant større med 14 mg oral semaglutid, idet 64% af deltagerne nåede målet ved uge 26 mod 21% af deltagere, der fik placebo. Oral semaglutid var i dette 26-ugers studie veltolereret hos deltagere med moderat nedsat nyrefunktion med en profil, der var konsistent med GLP-1-baserede behandlinger. Den mest almindelige bivirkning for oral semaglutid var mild til moderat kvalme. I PIONEER 5 oplevede 19% af deltagere i behandling med oral semaglutid kvalme mod 8% af deltagere, der fik placebo. Andelen af deltagere, som afsluttede behandlingen før tid på grund af bivirkninger, var 15% for deltagere, der blev behandlet med oral semaglutid, mod 6% for deltagere, der fik placebo. ""Resultaterne fra PIONEER 5 viser, at oral semaglutid er virkningsfuld og har en robust sikkerhedsprofil hos mennesker med type 2-diabetes og moderat nedsat nyrefunktion; det betyder således, at oral semaglutid får en endnu mere solid klinisk profil,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Nedsat nyrefunktion er en alvorlig komplikation forbundet med diabetes, og mennesker med denne sygdom har begrænsede behandlingsmuligheder med diabeteslægemidler i tabletform. Hvis godkendt bliver oral semaglutid en ny, virkningsfuld løsning for disse mennesker."" Om PIONEER 5 og det kliniske udviklingsprogram PIONEER PIONEER 5 var et 26-ugers randomiseret, dobbeltblindet, placebo-kontrolleret, multicenter-, multinationalt parallelgruppestudie med to behandlingsgrupper. Studiet undersøgte effekt og sikkerhed af 14 mg oral semaglutid sammenlignet med placebo hos mennesker med type 2-diabetes og moderat nedsat nyrefunktion (estimeret glomerulær filtreringshastighed [eGFR] 30-59 ml/min./1,73 m2), som var utilstrækkeligt reguleret med metformin, sulfonylurinstof alene eller i kombination med metformin, eller med basalinsulin alene eller i kombination med metformin. PIONEER 5 omfattede 324 deltagere, som blev randomiseret 1:1 til at modtage enten en dosis på 14 mg oral semaglutid eller placebo én gang dagligt. Det primære endepunkt var ændring i HbA1c ved uge 26 i forhold til baseline. Vigtige sekundære endepunkter var ændring i vægt, ændring i fastende plasmablodsukker fra baseline til uge 26 samt andelen af deltagere, der opnåede HbA1c på under 7,0% ved uge 26. PIONEER, det kliniske fase 3a-program for oral semaglutid, er et globalt udviklingsprogram med en samlet deltagelse af 8.845 mennesker med type 2-diabetes i 10 kliniske studier, som alle forventes afsluttet i 2018. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 66 / 2018 [1] Behandlingspolitisk estimand: behandlingseffekt uanset ophør af behandlingen eller iværksættelse af anden behandling (analyseret ved hjælp af en pattern mixture-model baseret på multiple imputationer til håndtering af manglende data med en analyse af kovarians (ANCOVA)). [2] Hypotetisk estimand: behandlingseffekt mens behandlingen pågår uden brug af anden behandling (analyseret ved hjælp af Mixed Models for Repeated Measurements (MMRM)). Den anvendte statistiske metodik er den samme som den, der blev anvendt i SUSTAIN-programmet for subkutan semaglutid.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=532,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
160,2018-08-17,Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins,"Novo Nordisk gains full rights to Ziylo's early-stage glucose binding molecules in a staged acquisition with a potential deal value that could exceed 800 million US dollars The acquisition supports Novo Nordisk's goal to develop glucose responsive insulins Parts of the research activities in Ziylo have been spun out in a new company, Carbometrics that has entered into a research collaboration with Novo Nordisk to optimise glucose binding molecules. Carbometrics has licenced rights for all non-therapeutic uses of glucose binding molecules including applications in diagnostics and glucose monitoring BRISTOL and COPENHAGEN, 17 August 2018 ­- Ziylo and Novo Nordisk A/S today announced that Novo Nordisk has acquired all of the shares of Ziylo, a University of Bristol spin-out company based at Unit DX science incubator in Bristol, UK. Ziylo has been pioneering the use of its platform technology - synthetic glucose binding molecules - for therapeutic and diagnostic applications. The acquisition gives Novo Nordisk full rights to Ziylo's glucose binding molecule platform to develop glucose responsive insulins. The development of glucose responsive insulins is a key strategic area for Novo Nordisk in its effort to develop this next generation of insulin which would lead to a safer and more effective insulin therapy. A glucose responsive insulin would help eliminate the risk of hypoglycaemia, which is the main risk associated with insulin therapy and one of the main barriers for achieving optimal glucose control. Thus, a glucose responsive insulin could also lead to better metabolic control and thus overall reduce the burden of diabetes for people living with the disease. Prior to closing of the acquisition, certain research activities have been spun out of Ziylo to a new company, Carbometrics. Carbometrics has entered into a research collaboration with Novo Nordisk to assist with ongoing optimisation of glucose binding molecules for use in glucose responsive insulins. Carbometrics has licenced rights to develop non-therapeutic applications of glucose binding molecules, with a focus on developing continuous glucose monitoring applications. Ziylo's glucose binding molecules are synthetic molecules that were designed by Professor Anthony Davis at the University of Bristol. These stable, synthetic molecules exhibit an unprecedented selectivity to glucose in complex environments such as blood. The combination of this technology with state-of-the-art insulin engineering pioneered by Novo Nordisk aspires to realise the world's first glucose responsive insulin and transform the treatment of diabetes. ""We believe the glucose binding molecules discovered by the Ziylo team together with Novo Nordisk world-class insulin capabilities have the potential to lead to the development of glucose responsive insulins which we hope can remove the risk of hypoglycaemia and ensure optimal glucose control for people with diabetes,"" said Marcus Schindler, senior vice president, Global Drug Discovery, Novo Nordisk. ""Novo Nordisk is the ideal company to maximise the potential of the Ziylo glucose binding molecules in glucose responsive insulins and diabetes applications, and it brings hope of a truly groundbreaking treatment to diabetes patients,"" said Harry Destecroix, PhD, chief executive officer and co-founder of Ziylo. ""Novo Nordisk is the leader in the diabetes field, with deep clinical development and regulatory expertise and an established commercial infrastructure to deliver important new therapies to patients."" Novo Nordisk acquires all shares in Ziylo for an upfront payment and earn-outs with contingent milestone payments. Total payments under the agreement could ultimately exceed 800 million dollars upon the achievement of certain development, regulatory and sales milestones by Novo Nordisk. Further information ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=533,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
161,2018-08-17,Novo Nordisk køber Ziylo Ltd med det formål at fremskynde udviklingen af glukoseresponsive insuliner,"Bristol og København, den 17. august 2018 ­- Ziylo og Novo Nordisk A/S meddeler i dag, at Novo Nordisk har overtaget den samlede aktiebeholdning i Ziylo, et selskab oprettet af forskere på University of Bristol og med base i væksthuset Unit DX i Bristol, Storbritannien. Ziylo har været pioner indenfor anvendelse af selskabets platformteknologi - syntetiske glukosebindende molekyler - til behandling og diagnostik. Købet giver Novo Nordisk de fulde rettigheder til Ziylos platformteknologi med henblik på udvikling af glukoseresponsive insuliner. Udvikling af glukoseresponsive insuliner er et vigtigt strategisk område for Novo Nordisk i relation til arbejdet med at udvikle den næste generation af insulin, der ventes at føre til sikrere og mere virkningsfuld behandling. En glukoseresponsiv insulin ville kunne hjælpe med til at eliminere risikoen for hypoglykæmi (lavt blodsukker), som er den væsentligste risiko i forbindelse med insulinbehandling og en af de største barrierer for at opnå optimal blodsukkerregulering. En glukoseresponsiv insulin vil således også kunne forbedre den metaboliske kontrol og dermed samlet set mindske generne ved diabetes for dem, der har sygdommen. Forud for indgåelse af aftalen er visse forskningsaktiviteter blevet skilt ud fra Ziylo og placeret i et nyt selskab ved navn Carbometrics. Carbometrics er indgået i et forskningssamarbejde med Novo Nordisk for at hjælpe med den løbende optimering af glukosebindende molekyler til brug i glukoseresponsive insuliner. Carbometrics har fået licensrettighederne til udvikling af ikke-terapeutiske anvendelser af glukosebindende molekyler med fokus på udvikling af anvendelser indenfor kontinuerlig blodsukkermåling. Ziylos glukosebindende molekyler er syntetiske molekyler udviklet af professor Anthony Davis fra University of Bristol. Disse stabile syntetiske molekyler udviser en hidtil uset selektivitet overfor glukose i komplekse omgivelser som f.eks. blod. Ambitionen er, at kombinationen af denne teknologi med Novo Nordisks avancerede insulinforskning vil føre til udviklingen af verdens første glukoseresponsive insulin og revolutionere behandlingen af diabetes. ""Vi er overbevist om, at Ziylos glukosebindende molekyler kombineret med Novo Nordisks verdensklasse-ekspertise på insulinområdet vil kunne skabe grobund for udvikling af glukoseresponsive insuliner, som, vi håber, vil kunne fjerne risikoen for hypoglykæmi og sikre optimal blodsukkerregulering for mennesker med diabetes,"" siger Marcus Schindler, direktør for Global Drug Discovery i Novo Nordisk. ""Novo Nordisk er den ideelle virksomhed til fuldt ud at udnytte potentialet i Ziylos glukosebindende molekyler i form af glukoseresponsive insuliner og andre diabetesrelaterede anvendelser, og det er vores håb, at det vil give helt nye og innovative behandlingsmuligheder for mennesker med diabetes,"" siger Harry Destecroix, ph.d., administrerende direktør for og medstifter af Ziylo. ""Novo Nordisk er førende indenfor diabetes og har en omfattende ekspertise indenfor klinisk udvikling og regulatoriske anliggender. Derudover har de en veletableret kommerciel infrastruktur, så vigtige nye behandlinger kan nå ud til patienterne."" Novo Nordisk overtager den samlede aktiebeholdning i Ziylo mod en forudbetaling samt resultatafhængige milepælsbetalinger. De samlede betalinger i henhold til aftalen kan potentielt overstige 800 mio. dollars, såfremt Novo Nordisk når visse milepæle relateret til udvikling, godkendelse og salg. Dette er en oversættelse af den originale engelske pressemeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=534,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
162,2018-08-08,Novo Nordisk's operating profit decreased by 8% in Danish kroner and increased by 4% in local currencies in the first six months of 2018,Contacts for further information,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=545,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
163,2018-08-08,Novo Nordisks resultat af primær drift faldt med 8% opgjort i kroner og steg med 4% i lokale valutaer i de første seks måneder af 2018,"Salget faldt med 5% i kroner og steg med 4% i lokale valutaer til 54,3 mia. kr. Salget af produkter til behandling af diabetes og fedme faldt med 4% til 45,6 mia. kr. (steg med 5% i lokale valutaer). Salget af biofarmaceutiske produkter faldt med 9% til 8,7 mia. kr. (faldt med 1% i lokale valutaer). Resultat af primær drift faldt med 8% i kroner og steg med 4% i lokale valutaer til 24,7 mia. kr. som følge af det betydelige kursfald for den amerikanske dollar og relaterede valutaer i forhold til kronen. Nettoresultatet steg med 5% til 21,1 mia. kr. Udvandet resultat pr. aktie steg med 7% til 8,66 kr. I februar 2018 lancerede Novo Nordisk Ozempic® i USA, en ny GLP-1 til dosering én gang om ugen. De foreløbige tilbagemeldinger fra receptudskrivere og betalere er positive, og det skrider fremad med tilskudsdækningen for Ozempic®. Den ugentlige såkaldte new-to-brand-markedsandel for recepter på Ozempic® er nu på 14%. I andet kvartal af 2018 offentliggjorde Novo Nordisk fase 3a-resultaterne fra fire af de 10 kliniske studier i PIONEER-programmet med oral semaglutid, en ny GLP-1-tablet, til behandling én gang dagligt af type 2-diabetes. Studierne bekræftede statistisk signifikante reduktioner både i langtidsblodsukker (HbA1c) og vægt for oral semaglutid sammenlignet med empagliflozin, sitagliptin og Victoza®. Bestyrelsen har godkendt et interimudbytte for 2018 på 3,00 kr. pr. aktie a 0,20 kr., som udbetales i august 2018. For 2018 forventes fortsat en salgsvækst på 3-5%, og væksten i resultat af primær drift forventes fortsat at blive på 2-5%, begge dele opgjort i lokale valutaer. Væksten i salg og resultat af primær drift rapporteret i kroner forventes nu at blive henholdsvis 5 og 7 procentpoint lavere end i lokale valutaer. Kontraktforhandlingerne i USA med pharmacy benefit managers (indkøbsorganisationer) og managed care-organisationer (private sundhedsforsikringsselskaber) om priser og medicintilskud for 2019 skrider fremad. Afhængigt af det endelige udfald af disse forhandlinger forventes det, at gennemsnitspriserne efter rabatter vil blive lavere end i 2018, hovedsageligt som følge af prissætningen for basalinsulin og ændringer i lovgivningen vedrørende det såkaldte Medicare Part D coverage gap (dækningsgab). Markedsadgangen for Novo Nordisks vigtigste produkter forventes at forblive stort set uændret sammenlignet med 2018. Adm. direktør Lars Fruergaard Jørgensen: ""Salgsvæksten i første halvår af 2018 var drevet af solide resultater for vores vigtigste innovative produkter, Victoza®, Tresiba®, Xultophy® og Saxenda®, og lanceringen af Ozempic® er kommet godt fra start i Nordamerika. Vi er opmuntrede over de resultater, vi har set i de kliniske studier med oral semaglutid, og vi glæder os til at gøre den første orale GLP-1-behandling tilgængelig for mennesker med type 2-diabetes."" Kontaktoplysninger Selskabsmeddelelse nr. 60 / 2018",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=546,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
164,2018-06-28,"Oral semaglutide shows superior reductions in HbA1c and weight compared to sitagliptin in the long-term safety and efficacy trial, PIONEER 3","Bagsværd, Denmark, 28 June 2018 - Novo Nordisk today announced the headline results from PIONEER 3, a phase 3a trial with oral semaglutide for the treatment of adults with type 2 diabetes. Oral semaglutide is an investigational GLP-1 analogue taken once daily as a tablet. The 78-week trial investigated the efficacy and long-term safety of 3, 7 and 14 mg oral semaglutide compared with 100 mg sitagliptin in 1,864 people with type 2 diabetes inadequately controlled with metformin, with or without sulfonylurea. The confirmatory endpoints were assessed after 26 weeks of treatment. Two distinct statistical approaches to evaluating the effects of oral semaglutide were applied in the PIONEER 3 trial; a primary statistical approach[1] required by recent regulatory guidance evaluating the effect regardless of discontinuation of treatment and use of rescue medication, and a secondary statistical approach[2] describing the effect while on treatment and without use of rescue medication. The trial achieved its primary objective according to the primary statistical approach by demonstrating statistically significant and superior reductions in HbA1c with oral semaglutide 7 and 14 mg compared to sitagliptin at week 26. Furthermore, people treated with oral semaglutide 7 and 14 mg achieved statistically significant and superior reductions in body weight compared to sitagliptin at week 26. When applying the secondary statistical approach for week 26 and week 78, respectively, people treated with 7 and 14 mg oral semaglutide experienced statistically significantly greater reductions in HbA1c of 1.1% and 0.7% with 7 mg oral semaglutide, 1.4% and 1.1% with 14 mg oral semaglutide compared to 0.8% and 0.4% with sitagliptin.  Reductions in HbA1c with 3 mg oral semaglutide at 26 and 78 weeks were 0.5% and 0.3%, respectively, and the reduction was statistically significantly less than sitagliptin at 26 week, but was not statistically different at week 78. Reductions in body weight from baseline were statistically significantly greater with 3, 7 and 14 mg oral semaglutide at week 26 and 78, respectively, with reductions of 1.2 and 1.9 kg for 3 mg oral semaglutide, 2.2 and 2.7 kg for 7 mg oral semaglutide and 3.3 and 3.5 kg for 14 mg oral semaglutide compared to 0.7 and 1.1 kg with sitagliptin. In this 78-week trial, oral semaglutide was well-tolerated and with a profile consistent with GLP-1-based therapy. The most common adverse event for oral semaglutide was mild to moderate nausea, which diminished over time. In PIONEER 3, 7-15% of people treated with oral semaglutide experienced nausea, compared to 7% of people treated with sitagliptin. The proportion of people who discontinued treatment due to adverse events was 6-12% for people treated with oral semaglutide compared to 5% with sitagliptin. ""With the results from the PIONEER 3 trial, we have shown that the two highest doses of oral semaglutide achieved superior improvements in glycaemic control and body weight compared to sitagliptin with a favourable safety profile consistent with GLP-1-based therapy"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""Furthermore, PIONEER 3 is an important trial, as it demonstrates long-term safety and efficacy of oral semaglutide"" About PIONEER 3 and the PIONEER clinical trial programmePIONEER 3 was a 78-week, randomised, double-blind, double-dummy, active-controlled, parallel-group, multicentre, multinational trial with four arms comparing the efficacy and safety of 3, 7 and 14 mg oral semaglutide with 100 mg sitagliptin in people with type 2 diabetes inadequately controlled with metformin, with or without sulfonylurea. PIONEER 3 randomised 1,864 people in a 1:1:1:1 manner to receive either a dose of oral semaglutide 3, 7 and 14 mg or 100 mg sitagliptin once daily. The primary endpoint was change from baseline to week 26 in HbA1c. Key secondary endpoints included change in HbA1c and body weight from baseline to week 78. The PIONEER phase 3a clinical development programme for oral semaglutide is a global development programme with enrolment of 8,845 people with type 2 diabetes across 10 clinical trials, which are all expected to complete in 2018. Further information  [1] Treatment policy estimand approach: treatment effect regardless of discontinuation of treatment or initiation of rescue medication (analysed by pattern mixture model using multiple imputations to handle missing data with an analysis of covariance (ANCOVA)). [2] Hypothetical estimand approach: treatment effect while on treatment without use of rescue medication (analysed by Mixed Models for Repeated Measurements (MMRM)). Similar statistical methodology as applied in the SUSTAIN programme for subcutaneous semaglutide.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=559,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
165,2018-06-28,Oral semaglutid viser større reduktioner i langtidsblodsukker og vægt end sitagliptin i langtidsstudie af sikkerhed og effekt (PIONEER 3),"Bagsværd, den 28. juni 2018 - Novo Nordisk offentliggør i dag de overordnede resultater fra PIONEER 3, et fase 3a-studie med oral semaglutid til behandling af voksne med type 2-diabetes. Oral semaglutid er en ny GLP-1-analog under udvikling, der tages som en tablet én gang dagligt. Studiet, som strakte sig over 78 uger, undersøgte effekten og den langsigtede sikkerhed af 3, 7 og 14 mg oral semaglutid sammenlignet med 100 mg sitagliptin i 1.864 deltagere med type 2-diabetes, som var utilstrækkeligt reguleret med metformin med eller uden et sulfonylurinstof. De bekræftende endepunkter blev vurderet efter 26 ugers behandling. Der blev i PIONEER 3 anvendt to forskellige statistiske metoder til vurdering af effekten af oral semaglutid: en primær statistisk metode[1], som kræves i henhold til nye regulatoriske retningslinjer, og som vurderer effekten uanset ophør af behandlingen og brug af anden behandling; og en sekundær statistisk metode [2], der beskriver effekten, mens behandlingen pågår og uden brug af anden behandling. Studiet opfyldte sit primære mål vurderet ud fra den primære statistiske metode, idet det viste statistisk signifikante og større forbedringer i langtidsblodsukkeret (HbA1c) ved behandling med 7 og 14 mg oral semaglutid sammenlignet med sitagliptin ved uge 26. Deltagere, der blev behandlet med 7 og 14 mg oral semaglutid opnåede endvidere statistisk signifikante og større reduktioner i vægt sammenlignet med sitagliptin ved uge 26. Ved anvendelse af den sekundære statistiske metode ved henholdsvis uge 26 og uge 78 opnåede deltagere i behandling med 7 og 14 mg oral semaglutid statistisk signifikant større reduktioner i HbA1c på 1,1% og 0,7% med 7 mg oral semaglutid, 1,4% og 1,1% med 14 mg oral semaglutid, mod 0,8% og 0,4% med sitagliptin. Reduktionerne i HbA1c med 3 mg oral semaglutid ved uge 26 og uge 78 var henholdsvis 0,5% og 0,3%, og reduktionen var statistisk signifikant mindre end med sitagliptin ved uge 26, men var ikke statistisk forskellig ved uge 78. Reduktionerne i vægt i forhold til udgangspunktet ved studiets begyndelse (baseline) var statistisk signifikant større med 3, 7 og 14 mg oral semaglutid ved henholdsvis uge 26 og 78, med reduktioner på 1,2 og 1,9 kg for 3 mg oral semaglutid, 2,2 og 2,7 kg for 7 mg oral semaglutid og 3,3 og 3,5 kg for 14 mg oral semaglutid, mod 0,7 og 1,1 kg med sitagliptin. Oral semaglutid var i dette 78-ugers studie veltolereret med en profil, der var konsistent med GLP-1-baseret behandling. Den mest almindelige bivirkning for oral semaglutid var mild til moderat kvalme, som aftog med tiden. I PIONEER 3 oplevede 7-15% af deltagerne i behandling med oral semaglutid kvalme, sammenlignet med 7% af dem, der fik sitagliptin. Andelen af deltagere, som afsluttede behandlingen før tid på grund af bivirkninger, var 6-12% for deltagere, der blev behandlet med oral semaglutid, mod 5% for deltagere i behandling med sitagliptin. ""Med resultaterne fra PIONEER 3-studiet har vi vist, at de to højeste doser af oral semaglutid medførte større forbedringer i blodsukkerregulering og vægt sammenlignet med sitagliptin med en gunstig sikkerhedsprofil, der var konsistent med GLP-1-baseret behandling,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Derudover er PIONEER 3 et vigtigt studie, fordi det dokumenterer den langsigtede sikkerhed og effekt af oral semaglutid."" PIONEER 3 var et 78-ugers randomiseret, dobbeltblindet, dobbelt-placebo- og aktivt kontrolleret, multicenter-, multinationalt parallelgruppestudie med fire behandlingsgrupper. Studiet undersøgte effekt og sikkerhed af 3, 7 og 14 mg oral semaglutid med 100 mg sitagliptin hos mennesker med type 2-diabetes, som var utilstrækkeligt reguleret med metformin med eller uden et sulfonylurinstof. PIONEER 3 omfattede 1.864 deltagere, som blev randomiseret 1:1:1:1 til at modtage enten en dosis oral semaglutid på 3, 7 eller 14 mg eller 100 mg sitagliptin én gang dagligt. Det primære endepunkt var ændring i HbA1c ved uge 26 i forhold til baseline. Vigtige sekundære endepunkter var blandt andet ændring i HbA1c og vægt ved uge 78 i forhold til baseline. PIONEER, det kliniske fase 3a-program for oral semaglutid, er et globalt udviklingsprogram med en samlet deltagelse af 8.845 mennesker med type 2-diabetes i 10 kliniske studier, som alle forventes afsluttet i 2018. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information [1] Behandlingspolitisk estimand: behandlingseffekt uanset ophør af behandlingen eller iværksættelse af anden behandling (analyseret ved hjælp af en pattern mixture-model baseret på multiple imputationer til håndtering af manglende data med en analyse af kovarians (ANCOVA)). [2] Hypotetisk estimand: behandlingseffekt mens behandlingen pågår uden brug af anden behandling (analyseret ved hjælp af Mixed Models for Repeated Measurements (MMRM)). Den anvendte statistiske metodik er den samme som den, der blev anvendt i SUSTAIN-programmet for subkutan semaglutid.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=560,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
166,2018-06-23,Oral semaglutide demonstrated significant reduction in blood sugar vs placebo in PIONEER 1 trial,"Orlando, US, 23 June 2018 ­- Oral semaglutide, an investigational GLP-1 analogue taken as a once-daily tablet, achieved significant reductions in blood sugar versus placebo in adults with type 2 diabetes, according to findings from the PIONEER 1 phase 3a trial. The trial evaluated the efficacy and safety of 3, 7 and 14 mg oral semaglutide compared with placebo as monotherapy over 26 weeks in adults with type 2 diabetes.1 The new data will be presented tomorrow, 24 June, 2018 at the American Diabetes Association's 78th Scientific Sessions (ADA) in Orlando, FL, US. Two distinct approaches to evaluating the effects of oral semaglutide were applied in the PIONEER 1 trial; a primary approach utilising an intention-to-treat principle required by recent regulatory guidance, evaluating the treatment effect including the effect of rescue medication and regardless of premature trial product discontinuation; a secondary approach utilising an on-treatment principle evaluated the treatment effect while on trial product and without use of rescue medication. Applying the intention-to-treat principle, the trial achieved its primary objective by demonstrating that people treated with any of the three doses of oral semaglutide achieved significant HbA1c reductions compared to placebo (p<0.001 for all estimated treatment differences in HbA1c for oral semaglutide vs placebo). Furthermore, people treated with 14 mg oral semaglutide achieved significant reductions (p<0.001) in weight vs placebo while weight reductions with 7 mg and 3 mg doses did not reach statistical significance.1 ""Despite advancements in the diabetes treatment landscape, many people with type 2 diabetes still struggle to reach their HbA1c target,"" said Vanita Aroda, MD, associate director, diabetes clinical research, Brigham and Women's Hospital, Boston, MA, U.S. ""Based on the first results of PIONEER, I am optimistic about the potential of having an oral GLP-1 receptor agonist that may help patients achieve their HbA1c and blood sugar goals.""                 When applying the on-treatment principle, from a mean baseline HbA1c of 8.0%, people treated with 3, 7 and 14 mg oral semaglutide achieved HbA1c reductions of 0.8%, 1.3% and 1.5%, respectively, compared to 0.1% with placebo.1 In addition, 59%, 72% and 80% of people, respectively, treated with oral semaglutide achieved the ADA treatment target of HbA1c below 7% compared to 34% treated with placebo.1 Furthermore, when applying the on-treatment principle, people treated with 3, 7 and 14 mg oral semaglutide experienced a weight reduction of 1.7 kg, 2.5 kg and 4.1 kg, respectively, compared to 1.5 kg with placebo.1 Moreover, 21%, 29% and 44% of people treated with oral semaglutide achieved a weight reduction of 5% or more compared to 16% with placebo.1 The most common adverse events (>5%) were mild or moderate nausea, which occurred in 5-16% of people treated with oral semaglutide and diminished over time, compared with 6% in those treated with placebo. Overall, adverse events were reported by 58%, 53% and 57% of people treated with 3, 7 and 14 mg oral semaglutide, respectively, and in 56% of people treated with placebo. Treatment discontinuation due to adverse events ranged from 2% to 7% for people treated with oral semaglutide, compared to 2% for people treated with placebo.1 About oral semaglutide                                             Semaglutide is an analogue of human glucagon-like peptide-1 (GLP-1) that is provided in tablet formulation with an absorption enhancer SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate).2 SNAC increases the bioavailability of semaglutide, facilitating absorption of semaglutide from the stomach, thereby enabling oral dosing.3 Oral semaglutide is in phase 3 development for blood sugar control in adults with type 2 diabetes. About PIONEER 1 and the PIONEER clinical trial programmePIONEER 1 was a 26-week, randomised, double-blinded, placebo-controlled, four-armed, parallel-group, multicentre, multinational trial comparing the efficacy and safety of three dose levels of once-daily oral semaglutide vs placebo in adults with type 2 diabetes treated with diet and exercise only. PIONEER 1 randomized 703 people in a randomised 1:1:1:1 manner to receive either a dose of oral semaglutide (3, 7 or 14 mg) or placebo once daily. The primary endpoint was change in HbA1c from baseline at week 26. The proportion of patients achieving HbA1c of <7% and change in body weight were secondary endpoints. The PIONEER phase 3a clinical development programme for oral semaglutide is a global development programme with enrollment of 8,845 adults with type 2 diabetes across 10 clinical trials, which are all expected to complete in 2018. Further information _______________________  References1.         Aroda VR, Rosenstock J, Terauchi Y, et al. Effect And Safety Of Oral Semaglutide Monotherapy In Type 2 Diabetes: PIONEER 1 Trial. Abstract 2-LB. Presented at the 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, Florida, U.S. 20182.         Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015;58:7370-73803.         Davies M, Pieber T, Hartoft-Nielsen M L, et al. Effect of Oral Semaglutide Compared with Placebo and Subcutaneous Semaglutide on Glycaemic Control in Patients with Type 2 Diabetes. JAMA. 2017;318:1460-1470",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=563,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
167,2018-06-23,Oral semaglutid sænker blodsukkeret signifikant sammenlignet med placebo i PIONEER 1-studiet,"Der blev i PIONEER 1-studiet anvendt to forskellige metoder til at vurdere effekten af oral semaglutid: en primær metode baseret på et 'intention-to-treat'-princip, som kræves i henhold til nye regulatoriske retningslinjer, og som vurderer behandlingseffekten inklusive virkningen af anden behandling og uanset ophør med behandlingen før tiden; og en sekundær metode baseret på et 'on-treatment'- princip, som vurderer effekten, mens behandlingen pågår og uden brug af andre lægemidler. Studiet opfyldte sit primære mål vurderet ud fra 'intention-to-treat'-princippet, idet det viste, at deltagerne opnåede signifikante reduktioner i langtidsblodsukkeret (HbA1c), uanset hvilken af de tre doser af oral semaglutid de modtog, sammenlignet med placebo (p<0,001 for alle estimerede behandlingsforskelle i HbA1c for oral semaglutid sammenlignet med placebo). Deltagere i behandling med 14 mg oral semaglutid opnåede desuden signifikante reduktioner (p<0,001) i vægt sammenlignet med placebo, mens de vægtreduktioner, der blev opnået med doserne på 7 mg og 3 mg ikke var statistisk signifikante.1 ""Selvom der er sket store fremskridt indenfor diabetesbehandlingen, er der stadig mange mennesker med type 2-diabetes, der kæmper for at nå deres behandlingsmål for langtidsblodsukkeret,"" siger Vanita Aroda, læge og vicedirektør for klinisk diabetesforskning på Brigham and Women's Hospital i Boston, Massachusetts, USA. ""De første resultater fra PIONEER giver god grund til at se optimistisk på potentialet i at have en GLP-1 i tabletform, som kan hjælpe patienterne med at nå deres blodsukkermål både på langt og kort sigt."" Vurderet ud fra 'on-treatment'- princippet og målt ud fra et gennemsnitligt HbA1c ved studiets begyndelse (baseline) på 8,0% opnåede deltagere i behandling med 3, 7 og 14 mg oral semaglutid reduktioner i HbA1c på henholdsvis 0,8%, 1,3% og 1,5% mod en reduktion på 0,1% hos deltagere, der fik placebo.1 Endvidere opnåede henholdsvis 59%, 72% og 80% af deltagere, der fik oral semaglutid, behandlingsmålet om HbA1c på under 7% som fastsat af ADA, mod 34% af dem, der fik placebo.1 Ligeledes vurderet ud fra 'on-treatment'-princippet opnåede deltagere i behandling med 3, 7 og 14 mg oral semaglutid desuden en vægtreduktion på henholdsvis 1,7 kg, 2,5 kg og 4,1 kg mod 1,5 kg med placebo.1 Derudover opnåede 21%, 29% og 44% af dem, der fik oral semaglutid, et vægttab på 5% eller mere mod 16% med placebo.1 De mest almindelige bivirkninger (>5%) var mild til moderat kvalme, som forekom hos 5-16% af deltagere i behandling med oral semaglutid og aftog med tiden, mod 6% af dem, der fik placebo. Samlet set blev der indberettet bivirkninger af 58%, 53% og 57% af deltagere i behandling med henholdsvis 3, 7 og 14 mg oral semaglutid og hos 56% af dem, der fik placebo. Afslutning af behandlingen som følge af bivirkninger var mellem 2% og 7% for deltagere, der blev behandlet med oral semaglutid, mod 2% for deltagere, der fik placebo.1 Semaglutid er en analog af det naturlige hormon glukagonlignende peptid-1 (GLP-1), som leveres i en tabletformulering med et absorptionsfremmende hjælpestof, SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate).2 SNAC øger biotilgængeligheden af semaglutid ved at hjælpe med at få det optaget gennem maven og på den måde muliggøre dosering i tabletform.3 Oral semaglutid er i fase 3-udvikling til regulering af blodsukkeret hos voksne med type 2-diabetes. PIONEER 1 var et 26-ugers randomiseret, dobbeltblindet, placebokontrolleret, multicenter-, multinationalt parallelgruppestudie med fire behandlingsgrupper. Studiet undersøgte effekt og sikkerhed for tre dosisniveauer af oral semaglutid givet én gang dagligt sammenlignet med placebo hos voksne med type 2-diabetes, som blev behandlet med diæt og motion alene. PIONEER 1 omfattede 703 deltagere, som blev randomiseret 1:1:1:1 til at modtage enten en dosis oral semaglutid (3, 7 eller 14 mg) eller placebo én gang dagligt. Det primære endepunkt var ændring i langtidsblodsukkerniveauet (HbA1c) ved uge 26 i forhold til udgangspunktet ved studiets begyndelse (baseline). Andelen af deltagere, der opnåede et HbA1c-niveau på <7%, og ændring i kropsvægt var sekundære endepunkter. PIONEER, det kliniske fase 3a-program for oral semaglutid, er et globalt udviklingsprogram med en samlet deltagelse af 8.845 voksne med type 2-diabetes i 10 kliniske studier, som alle forventes afsluttet i 2018. Dette er en oversættelse af den originale engelske pressemeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Referencer1.         Aroda VR, Rosenstock J, Terauchi Y, et al. Effect And Safety Of Oral Semaglutide Monotherapy In Type 2 Diabetes: PIONEER 1 Trial. Abstract 2-LB. Presented at the 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, Florida, U.S. 20182.         Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015;58:7370-73803.         Davies M, Pieber T, Hartoft-Nielsen M L, et al. Effect of Oral Semaglutide Compared with Placebo and Subcutaneous Semaglutide on Glycaemic Control in Patients with Type 2 Diabetes. JAMA. 2017;318:1460-1470",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=564,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
168,2018-06-23,"Ozempic® provided greater weight reductions for adults with a baseline BMI of or above 25 kg/m2 than those with lower baseline BMI <25 kg/m2, in a SUSTAIN 7 post-hoc analysis","Orlando, US, 23 June 2018 ­- Ozempic® (semaglutide) 0.5 mg or 1.0 mg provided greater weight reductions vs dulaglutide 0.75 mg or 1.5 mg, respectively, in adults with type 2 diabetes, regardless of baseline body mass index (BMI), with the greatest reductions occurring in adults with a baseline BMI >25 kg/m2. While the primary endpoint of SUSTAIN 7 was change in HbA1c, this post-hoc exploratory analysis examined the secondary endpoint of change in body weight by baseline BMI.1 The results will be presented 24 June, 2018 at the American Diabetes Association's 78th Scientific Sessions (ADA) in Orlando, US. Greater weight reductions were demonstrated across all BMI subgroups (<25, 25-<30, 30-<35, >35 kg/m2) with Ozempic® 0.5 mg vs dulaglutide 0.75 mg (range of weight reduction across all subgroups: 3.6-5.5 kg vs 0.9-3.4 kg) and with Ozempic® 1.0 mg vs dulaglutide 1.5 mg (range of weight reduction across all subgroups: 5.2-7.6 kg vs 2.0-3.8 kg), from a mean baseline of 95.2 kg.1 Adults with a higher baseline BMI (>25 kg/m2) taking Ozempic® generally achieved greater weight reductions than those with lower baseline BMI (<25 kg/m2).1 In addition, more people achieved weight reductions of >5% and >10% with Ozempic® vs dulaglutide in all BMI subgroups.1 ""Globally, up to ninety percent of people with type 2 diabetes are overweight or have obesity.2 Therefore, it is important to consider how to manage weight in this population,"" said Dr Adie Viljoen, SUSTAIN 7 chief investigator and consultant chemical pathologist, East and North Hertfordshire NHS Trust, UK. ""Based on the SUSTAIN clinical trial programme, Ozempic® can help people living with type 2 diabetes manage their HbA1C and has the potential to help them lose some weight."" Across BMI subgroups, fewer people reported gastrointestinal (GI) adverse events with the low dulaglutide dose (0.75 mg) compared with the other three treatment groups (Ozempic® 0.5 and 1.0 mg and dulaglutide 1.5 mg).1 The most common adverse events (>5%) for both Ozempic® dosages were GI adverse events.1 About Ozempic®Ozempic® (semaglutide) is a once-weekly analogue of human glucagon-like peptide-1 (GLP-1) indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes.3 Ozempic® was approved by the U.S. Food and Drug Administration on 5 December, 2017, by Health Canada on 4 January, 2018, by the European Commission on 9 February, 2018 and on 23 March by the Japanese Ministry of Health, Labour and Welfare.3-6 About the SUSTAIN clinical trial programmeThe SUSTAIN global clinical development programme for Ozempic® comprises eight phase 3a trials, encompassing more than 8,000 adults with type 2 diabetes. The phase 3a programme involves a broad range of people with type 2 diabetes, including some with high cardiovascular risk profiles. The primary analysis of the SUSTAIN 7 trial was published in The Lancet Diabetes & Endocrinology earlier this year. The primary outcome measure was change in HbA1c from baseline after 40 weeks of treatment. Change in body weight from baseline to week 40 was a predefined secondary endpoint.7 In this post-hoc exploratory analysis, which was conducted using Mixed Models for Repeated Measurements, the interaction effect between treatment and subgroup was not statistically significant (semaglutide 0.5 mg vs dulaglutide 0.75 mg: p= 0.9118; semaglutide 1.0 mg vs dulaglutide 1.5 mg: p= 0.8175).1 Further information ______________________  References: 1.       Viljoen A, Blüher M, Chow F, et al. Semaglutide reduces body weight vs dulaglutide across baseline BMI subgroups in SUSTAIN 7. Abstract 1083-P. 78th Scientific Sessions of the American Diabetes Association (ADA), Orlando, USA; 22-26 June 2018.  2.       World Health Organization. Global Strategy on Diet, Physical Activity and Health. http://www.who.int/dietphysicalactivity/media/en/gsfs_obesity.pdf. Updated 2003. Last accessed: May 2018.3.       Novo Nordisk. Ozempic® Prescribing Information. Available at: http://www.novo-pi.com/ozempic.pdf. Last accessed: May 2018.4.       Novo Nordisk. Ozempic® Canada Product Monograph. Available at https://pdf.hres.ca/dpd_pm/00043163.PDF. Last accesed: May 2018.5.       EMA. Ozempic® (semaglutide) SmPC. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR Product_Information/human/004174/WC500244163.pdf. Last accessed: May 2018.6.       Novo Nordisk. Ozempic® approved in Japan for the treatment of type 2 diabetes. Available at: https://www.novonordisk.com/content/Denmark/HQ/www-novonordisk-com/en_gb/home/media/news-details.2178681.html. Last accessed: May 2018.7.       Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide once weekly versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The Lancet Diabetes & Endocrinology. 2018.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=565,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
169,2018-06-23,"Ozempic® giver større vægttab hos voksne med type 2-diabetes og et BMI på 25 eller derover end dem med BMI under 25, viser en SUSTAIN 7 post hoc-analyse","Bagsværd, den 23. juni 2018 ­- Ozempic® (semaglutid) 0,5 mg eller 1,0 mg medførte større vægttab end dulaglutid 0,75 mg eller 1,5 mg hos voksne med type 2-diabetes, uanset deres BMI ved studiets begyndelse (baseline BMI), og voksne med et baseline BMI >25 kg/m2 opnåede de største vægttab. Mens det primære endepunkt i SUSTAIN 7 var ændring i langtidsblodsukkeret (HbA1c), fokuserede denne eksplorative post hoc-analyse på det sekundære endepunkt, nemlig ændring i vægt i forhold til baseline BMI.1 Resultaterne præsenteres den 24. juni 2018 på den 78. videnskabelige kongres i det amerikanske diabetesselskab American Diabetes Association (ADA) i Orlando, USA. Post hoc-analysen viste større vægttab i alle BMI-undergrupper (<25, 25-<30, 30-<35, >35 kg/m2) med Ozempic® 0,5 mg sammenlignet med dulaglutid 0,75 mg (vægttab på tværs af alle undergrupper: 3,6-5,5 kg mod 0,9-3,4 kg) og med Ozempic® 1,0 mg sammenlignet med dulaglutid 1,5 mg (vægttab på tværs af alle undergrupper: 5,2-7,6 kg mod 2,0-3,8 kg), vurderet i forhold til en gennemsnitsvægt på 95,2 kg ved studiets start.1 Voksne med et højere baseline BMI (>25 kg/m2), som fik Ozempic®, opnåede generelt større vægttab end dem, der havde et lavere baseline BMI (<25 kg/m2).1 Derudover var der flere, der opnåede vægttab på >5% og >10% med Ozempic® end med dulaglutid i alle BMI-undergrupper.1 ""Globalt set er op til 90% af alle mennesker med type 2-diabetes overvægtige eller svært overvægtige.2 Derfor er det vigtigt at overveje, hvordan man kan regulere vægten i denne befolkningsgruppe,"" siger dr. Adie Viljoen, forsøgsansvarlig i SUSTAIN 7 og kemisk patolog ved East and North Hertfordshire NHS Trust, Storbritannien. ""Det kliniske udviklingsprogram SUSTAIN har vist, at Ozempic® kan hjælpe mennesker med type 2-diabetes med at regulere deres langtidsblodsukker og potentielt også hjælpe dem med at tabe sig i vægt."" På tværs af BMI-undergrupperne var der færre deltagere, der rapporterede om mave-tarm-bivirkninger med den lave dosis af dulaglutid (0,75 mg) sammenlignet med de andre tre behandlingsgrupper (Ozempic® 0,5 og 1,0 mg og dulaglutid 1,5 mg).1 De mest almindelige bivirkninger (>5%) for begge doseringer af Ozempic® var mave-tarm-bivirkninger.1 Ozempic (semaglutid) er en ugentlig analog af det naturlige hormon glukagonlignende peptid-1 (GLP-1), som er godkendt som tillægsbehandling til diæt og motion med det formål at forbedre blodsukkerreguleringen hos voksne med type 2-diabetes.3 Ozempic® blev godkendt af de amerikanske sundhedsmyndigheder (FDA) den 5. december 2017, af de canadiske sundhedsmyndigheder (Health Canada) den 4. januar 2018, af Europa-Kommissionen den 9. februar 2018 og af det japanske sundhedsministerium (Ministry of Health, Labour and Welfare) den 23. marts 2018.3-6 Det globale kliniske udviklingsprogram SUSTAIN for Ozempic® omfatter otte fase 3a-studier med deltagelse af flere end 8.000 voksne med type 2-diabetes. Fase 3a-programmet omfatter en bred vifte af deltagere med type 2-diabetes, herunder deltagere med høj risiko for hjerte-kar-sygdom. Den primære analyse af SUSTAIN 7-studiet blev publiceret i The Lancet Diabetes & Endocrinology tidligere i år. Det primære effektmål var ændring i HbA1c i forhold til udgangspunktet ved studiets begyndelse (baseline) efter 40 ugers behandling. Ændring i kropsvægt fra baseline til uge 40 var et foruddefineret sekundært endepunkt.7 I denne eksplorative post hoc-analyse, som blev gennemført ved hjælp af Mixed Models for Repeated Measurements-metoden, var interaktionseffekten mellem behandling og undergruppe ikke statistisk signifikant (semaglutid 0,5 mg mod dulaglutid 0,75 mg: p= 0,9118; semaglutid 1,0 mg mod dulaglutid 1,5 mg: p= 0,8175).1 Dette er en oversættelse af den originale engelske pressemeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Referencer: 1.       Viljoen A, Blüher M, Chow F, et al. Semaglutide reduces body weight vs dulaglutide across baseline BMI subgroups in SUSTAIN 7. Abstract 1083-P. 78th Scientific Sessions of the American Diabetes Association (ADA), Orlando, USA; 22-26 June 2018. 2.       World Health Organization. Global Strategy on Diet, Physical Activity and Health. http://www.who.int/dietphysicalactivity/media/en/gsfs_obesity.pdf. Updated 2003. Last accessed: May 2018.3.       Novo Nordisk. Ozempic® Prescribing Information. Available at: http://www.novo-pi.com/ozempic.pdf. Last accessed: May 2018.4.       Novo Nordisk. Ozempic® Canada Product Monograph. Available at https://pdf.hres.ca/dpd_pm/00043163.PDF. Last accesed: May 2018.5.       EMA. Ozempic® (semaglutide) SmPC. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR Product_Information/human/004174/WC500244163.pdf. Last accessed: May 2018.6.       Novo Nordisk. Ozempic® approved in Japan for the treatment of type 2 diabetes. Available at: https://www.novonordisk.com/content/Denmark/HQ/www-novonordisk-com/en_gb/home/media/news-details.2178681.html. Last accessed: May 2018.7.       Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide once weekly versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The Lancet Diabetes & Endocrinology. 2018.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=566,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
170,2018-06-23,Tresiba® demonstrated significantly improved blood sugar control and lower rates of hypoglycaemia versus insulin glargine U300 in real-world evidence study,"Adults with type 2 diabetes treated with Tresiba® (insulin degludec injection) had a significant reduction in HbA1c and a 30% lower rate of hypoglycaemic episodes after starting basal insulin Orlando, US, 23 June 2018 ­- Findings from CONFIRM - a large real-world evidence (RWE) study comparing the effectiveness of Tresiba® (insulin degludec injection) versus insulin glargine U300 - will be presented on Monday, 25 June 2018 at the American Diabetes Association's 78th Scientific Sessions (ADA) in Orlando, US. The retrospective, non-interventional comparative effectiveness study, which included more than 4,000 adults with type 2 diabetes who were starting basal insulin for the first time, showed that after six months those treated with Tresiba® had significantly lower HbA1c compared to those treated with insulin glargine U300 (-1.5% vs. -1.2% respectively; p=0.029).1 As a secondary endpoint, there was a 30% lower rate of hypoglycaemic episodes with Tresiba® compared to insulin glargine U300 (p=0.045).1 In this study, hypoglycaemic events, ranging from mild to severe, were registered using the International Classification of Diseases (ICD) codes 9/10 following diagnosis from a physician.2 This real-world study also showed in another secondary endpoint that people treated with Tresiba® were more likely to stay on their treatment. Those treated with insulin glargine U300 had a 37% higher rate of discontinuing treatment after two years (p<0.001).1 ""Real-world studies are important to understanding how clinical trials may translate into real value for patients in everyday clinical practice,"" said Todd Hobbs, vice president and US chief medical officer of Novo Nordisk. ""The CONFIRM results add to the body of evidence on Tresiba® for adults with type 2 diabetes."" The CONFIRM study is a retrospective, non-interventional comparative effectiveness study that investigated Tresiba® and insulin glargine U300 (Toujeo®) in 4,056 insulin-naïve (defined as no evidence of basal insulin use at least 365 days prior to index date) adults with type 2 diabetes in the US. Study groups were equal in size (n=2,028) and patients in each group were comparable after matching for baseline characteristics. Patients were uncontrolled on one or more oral antidiabetic drugs or a GLP-1 (glucagon-like peptide-1) receptor agonist and prescribed Tresiba® or insulin glargine U300 according to local practice. Electronic health records were sourced from multiple health systems in the US. The primary endpoint was change in HbA1c (blood sugar control) from baseline to six months follow-up. Secondary endpoints included rate of hypoglycaemia, proportion of patients with at least one hypoglycaemic episode and the rate of treatment discontinuation. As with all real-world studies, CONFIRM was not randomised and it carries the limitations of real-world evidence. This includes potential under-reporting of hypoglycaemia (however, this is the case in both treatment arms in CONFIRM meaning that the rate ratio as well as the odds ratio are expected to be preserved), and the short follow-up period of 3-6 months (though this corresponds to when the largest changes in HbA1c tend to occur and is commonly used in many trials). Additionally, in CONFIRM there is only evidence of prescribed basal insulin and not actual use (whether the medication was picked up at the pharmacy). Hypoglycaemia occurs when blood sugar levels are too low and cannot provide the body's organs with the energy they need. Hypoglycaemia can cause a range of symptoms including confusion, trembling, sweating, increased heart rate, difficulty with concentration and speech, and in severe cases can lead to a seizure or coma.3-6 About Tresiba®Tresiba® (insulin degludec) is a once-daily basal insulin that provides a duration of action beyond 42 hours with a flat and stable glucose-lowering effect.7,8 It has been shown to provide a lower risk of overall, nocturnal and severe hypoglycaemia, and low variability in blood sugar levels versus insulin glargine U100.8,9 Tresiba® received its first regulatory approval in September 2012 and has since been approved in more than 80 countries globally. It is now commercially available in more than 61 countries. Further information References 1.         Tibaldi J, Haldrup S, Sandberg V, et al. Clinical Outcome Assessment of the Effectiveness of Insulin Degludec (Degludec) in Real-life Medical Practice (CONFIRM): A Comparative Effectiveness Study of Degludec and Insulin Glargine 300U/mL (Glargine U300) in 4,056 Insulin-Naïve Patients with Type 2 Diabetes (T2D) Oral/poster presentation. 78th Annual Scientific Sessions of the American Diabetes Asosciation (ADA), Orlando, Florida, US; 22-26 June 2018. 2.         Ginde AA, Blanc PG, Lieberman RM, et al. Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits. BMC Endocr Disord. 2008; 8:43.         Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013; 36:1384-1395. 4.         International Hypoglycaemia Study Group. Diagnosis of hypoglycaemia. Available online at http://ihsgonline.com/understanding-hypoglycaemia/diagnosis. Last accessed: June 2018. 5.         Cryer PE. Hypoglycemia, functional brain failure, and brain death. J Clin Invest. 2007; 117:868-870. 6.         Ahrén B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag. 2013; 9:155-163. 7.         Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014; 53:787-800. 8.         EMA. Tresiba® Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002498/WC500138940.pdf. Last accessed: June 2018. 9.         Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017; 377:723-732.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=567,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
171,2018-06-23,"Real-world-studie viser, at Tresiba® medfører signifikant forbedret blodsukkerregulering og lavere forekomst af hypoglykæmi sammenlignet med insulin glargin U300","Voksne med type 2-diabetes, som blev behandlet med Tresiba® (insulin degludec til injektion), opnåede en signifikant reduktion i langtidsblodsukkeret og en 30% lavere forekomst af hypoglykæmi, efter de begyndte behandling med basalinsulin Bagsværd, den 23. juni 2018 ­- Resultaterne fra CONFIRM - et stort såkaldt real-world-studie, som i klinisk praksis har undersøgt effekten af Tresiba® sammenholdt med insulin glargin U300 - præsenteres mandag den 25. juni 2018 på den 78. videnskabelige kongres i det amerikanske diabetesselskab American Diabetes Association (ADA) i Orlando, USA. Det retrospektive, ikke-interventionelle sammenlignende effektstudie omfattede flere end 4.000 voksne med type 2-diabetes, som startede på behandling med basalinsulin for første gang. Studiet viste, at deltagere, der blev behandlet med Tresiba®, efter seks måneder havde et signifikant lavere langtidsblodsukkerniveau (HbA1C) sammenlignet med dem, der fik insulin glargin U300 (henholdsvis -1,5% og -1,2%; p=0,029).1 Som et sekundært endepunkt var der en 30% lavere forekomst af hypoglykæmi (lavt blodsukker) med Tresiba® sammenlignet med insulin glargin U300 (p=0,045).1 Hypoglykæmi (milde til svære tilfælde) blev i dette studie registreret ved hjælp af WHO's internationale klassifikation af sygdomme (ICD-9/10) efter diagnosticering hos en læge.2 Studiet viste desuden i et andet sekundært endepunkt, at deltagere, der blev behandlet med Tresiba®, havde større sandsynlighed for at fastholde behandlingen. De deltagere, der blev behandlet med insulin glargin U300, havde en 37% større hyppighed af behandlingsfrafald efter to år (p<0,001).1 ""Real-world-studier er vigtige for at forstå, hvordan kliniske studier kan omsættes til reel værdi for patienterne i daglig klinisk praksis,"" siger Todd Hobbs, medicinsk chef i Novo Nordisk i USA. ""Resultaterne fra CONFIRM bekræfter yderligere de fordele, vi tidligere har set med Tresiba® til behandling af voksne med type 2-diabetes."" CONFIRM er et retrospektivt, ikke-interventionelt sammenlignende effektstudie, som har undersøgt Tresiba® og insulin glargin U300 (Toujeo®) i 4.056 voksne med type 2-diabetes i USA, som ikke tidligere havde fået insulinbehandling (defineret som ingen evidens for brug af basalinsulin i mindst 365 dage forud for indeksdatoen). Behandlingsgrupperne var lige store (n=2.028), og patienterne i hver gruppe var sammenlignelige efter at være blevet matchet efter baseline-egenskaber. Patienterne var utilstrækkeligt reguleret med et eller flere diabeteslægemidler i tabletform eller en GLP-1- (glukagonlignende peptid-1) receptoragonist og havde fået ordineret Tresiba® eller insulin glargin U300 ifølge lokal praksis. Elektroniske journaler blev indhentet fra flere forskellige sundhedssystemer i USA. Det primære endepunkt var ændring i langtidsblodsukkeret (HbA1C) fra udgangspunktet ved studiets begyndelse (baseline) til opfølgning efter seks måneder. Sekundære endepunkter omfattede forekomsten af hypoglykæmi, andelen af patienter med mindst ét tilfælde af hypoglykæmi og hyppigheden af behandlingsfrafald. Som alle andre real-world-studier var CONFIRM ikke randomiseret og er underlagt de begrænsninger, der følger med real-world evidens. Det omfatter bl.a. potentiel underrapportering af hypoglykæmi (gælder dog for begge behandlingsgrupper i CONFIRM, hvilket betyder, at såvel rate ratio som odds ratio forventes fastholdt) og den korte opfølgningsperiode på 3-6 måneder (omend det svarer til det tidsrum, hvor de største ændringer i HbA1c almindeligvis forekommer, og er almindeligt anvendt i mange studier). Yderligere er der i CONFIRM-studiet kun evidens for ordineret basalinsulin og ikke for den faktiske brug (om medicinen blev hentet på apoteket). Hypoglykæmi opstår, når blodsukkeret falder til et meget lavt niveau, så kroppens organer ikke får tilført den energi, der er nødvendig for at fungere. Typiske symptomer er forvirring, rysten, sveden, hjertebanken, koncentrations- og/eller talebesvær og i alvorlige tilfælde kramper eller bevidstløshed.3-6 Tresiba® (insulin degludec) er en basalinsulin til dosering én gang dagligt med en virkningsvarighed på mere end 42 timer med en flad og stabil blodsukkersænkende effekt.7,8. Studier har vist, at Tresiba® medfører en lavere risiko for generel, natlig og alvorlig hypoglykæmi samt en lav variation i blodsukkeret sammenlignet med insulin glargin U100.8,9. Tresiba® blev godkendt af registreringsmyndighederne første gang i september 2012 og er siden blevet godkendt i flere end 80 lande verden over. Det er nu på markedet i flere end 61 lande. Dette er en oversættelse af den originale engelske pressemeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information  Referencer 1.         Tibaldi J, Haldrup S, Sandberg V, et al. Clinical Outcome Assessment of the Effectiveness of Insulin Degludec (Degludec) in Real-life Medical Practice (CONFIRM): A Comparative Effectiveness Study of Degludec and Insulin Glargine 300U/mL (Glargine U300) in 4,056 Insulin-Naïve Patients with Type 2 Diabetes (T2D) Oral/poster presentation. 78th Annual Scientific Sessions of the American Diabetes Asosciation (ADA), Orlando, Florida, US. June 2018. 2.         Ginde AA, Blanc PG, Lieberman RM, et al. Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits. BMC Endocr Disord. 2008; 8:4.3.         Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013; 36:1384-1395. 4.         International Hypoglycaemia Study Group. Diagnosis of hypoglycaemia. Available online at http://ihsgonline.com/understanding-hypoglycaemia/diagnosis. Last accessed: June 2018. 5.         Cryer PE. Hypoglycemia, functional brain failure, and brain death. J Clin Invest. 2007; 117:868-870. 6.         Ahrén B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag. 2013; 9:155-163. 7.         Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014; 53:787-800. 8.         EMA. Tresiba® Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002498/WC500138940.pdf. Last accessed: June 2018. 9.         Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017; 377:723-732.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=568,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
172,2018-06-23,Significant blood sugar improvement with Xultophy® compared to insulin glargine U-100 when used as add-on to oral diabetes medications,"Adults with type 2 diabetes treated with Xultophy® (insulin degludec and liraglutide injection) also experienced no change in body weight, lower rates of hypoglycaemia and a lower insulin dose at 26 weeks Bagsværd, Denmark, 23 June 2018 ­ - Xultophy® (insulin degludec and liraglutide injection) provided superior blood sugar reduction (HbA1c) compared to insulin glargine U-100 (1.94% vs 1.68% respectively; p<0.0001) when used as an add-on to an SGLT-2i (an oral diabetes medication), according to results from the DUAL IX study presented today at the American Diabetes Association's 78th Scientific Sessions (ADA) in Orlando, US.1 Results from some of the secondary endpoints in DUAL IX included change from baseline in body weight, severe or blood glucose confirmed symptomatic hypoglycaemic events and daily insulin dose at 26 weeks. Mean body weight remained unchanged in the Xultophy® study group versus a 2.0 kg weight gain with insulin glargine U-100. Treatment with Xultophy® demonstrated a 58% lower rate of hypoglycaemia versus insulin glargine U-100 (0.37 events/patient-year of exposure vs 0.90 events/patient-year of exposure respectively; p=0.0035). The average total daily insulin dose was significantly less with Xultophy® than insulin glargine U-100 (36 units per day vs 54 units per day respectively; p<0.0001).1 ""Type 2 diabetes is a progressive disease that often requires treatment intensification,"" said Dr Athena Philis-Tsimikas, DUAL IX lead investigator and corporate vice president, Scripps Whittier Diabetes Institute. ""Xultophy® may be an appropriate treatment option for those adults who are unable to meet their blood sugar goals on their current medication."" Adverse events were similar across both treatment groups; the most common adverse events (>5%) in the Xultophy® treated patients included viral upper respiratory tract infection, headaches, back pain, increased lipase and nausea. The safety profile of Xultophy® in DUAL IX was consistent with previous Xultophy® clinical trials.1 Additional DUAL IX patient-reported outcomes will be presented on Monday 25 June at ADA: About DUAL IXDUAL IX was a phase 3b, 26-week, randomised, open-label, multicentre trial conducted in 11 countries including 420 patients. The trial was designed to investigate the safety and efficacy of Xultophy® versus insulin glargine U-100 as add-on therapy in adults uncontrolled on sodium-glucose co-transporter-2 inhibitor (SGLT-2i) treatment with or without additional oral antidiabetic drug therapy.2 A hypoglycaemic event in DUAL IX was defined as an event requiring assistance from another person or blood glucose (BG) confirmed (less than 56 mg/dL) with symptoms consistent with hypoglycaemia. About Xultophy®Xultophy® is a once-daily fixed-ratio combination injection of insulin degludec, a long-acting human insulin analogue, and liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist. In Europe, Xultophy® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to other oral medicinal products for the treatment of diabetes.3 In the US, Xultophy® is called Xultophy® 100/3.6, and is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes inadequately controlled on basal insulin (less than 50 U daily) or liraglutide (less than or equal to 1.8 mg daily). In the US, Xultophy® 100/3.6 is not indicated for use as an add-on to oral diabetes medications.4 Further information _______________________  References1.         Philis-Tsimikas A, Billings LK, Busch R, et al. Superior Efficacy of Insulin Degludec/Liraglutide (IDegLira) vs Insulin Glargine (IGlar U100) as Add-on to Sodium-Glucose Co-Transporter-2 Inhibitor (SGLT2i) ± Oral Antidiabetic Drug (OAD) Therapy in Patients with Type 2 Diabetes (T2D): DUAL IX Trial (NCT02773368). 78th Annual Scientific Sessions of the American Diabetes Association (ADA), Orlando, Florida, US; 22-26 June 2018. 2.         ClinicalTrials.gov. A clinical trial comparing glycaemic control and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) as add-on therapy to SGLT2i in subjects with type 2 diabetes mellitus (DUAL IX). Available at: https://clinicaltrials.gov/ct2/show/study/NCT02773368. Last accessed: June 2018. 3.         EMA. Xultophy® Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002647/WC500177657.pdf. Last accessed: June 2018. 4.         Xultophy® 100/3.6 [package insert]. Plainsboro, NJ: Novo Nordisk Inc; November 2016.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=569,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
173,2018-06-23,Xultophy® medfører signifikant forbedring af blodsukker sammenlignet med insulin glargin U-100 givet som supplement til diabeteslægemidler i tabletform,"Voksne med type 2-diabetes i behandling med Xultophy® (insulin degludec og liraglutid i én injektion) oplevede desuden uændret vægt, færre tilfælde af hypoglykæmi og en lavere insulindosis ved uge 26 Bagsværd, den 23. juni 2018 ­- Xultophy® (insulin degludec og liraglutid i én injektion) gav en større reduktion i langtidsblodsukkeret (HbA1c) end insulin glargin U-100 (henholdsvis 1,94% og 1,68%; p<0,0001), når det blev givet som supplement til en SGLT-2-hæmmer (et diabeteslægemiddel i tabletform). Det viser resultater fra DUAL IX-studiet, som præsenteres i dag på den 78. videnskabelige kongres i det amerikanske diabetesselskab American Diabetes Association (ADA) i Orlando, USA. Resultaterne fra nogle af de sekundære endepunkter i DUAL IX omfattede ændring i kropsvægt i forhold til udgangspunktet ved studiets begyndelse, forekomst af alvorlig hypoglykæmi (lavt blodsukker) eller symptomatisk hypoglykæmi bekræftet ved blodsukkermåling, samt daglig insulindosis ved uge 26. Gennemsnitsvægten forblev uændret i gruppen, der fik Xultophy®, sammenlignet med en vægtøgning på 2,0 kg i gruppen, der fik insulin glargin U-100. Behandling med Xultophy® medførte en 58% lavere forekomst af hypoglykæmi end med insulin glargin U-100 (henholdsvis 0,37 hændelser/patientår med eksponering mod 0,90 hændelser/patientår med eksponering; p=0,0035). Den gennemsnitlige samlede daglige insulindosis var signifikant mindre med Xultophy® end med insulin glargin U-100 (henholdsvis 36 enheder pr. dag og 54 enheder pr. dag; p<0,0001).1 ""Type 2-diabetes er en progressiv sygdom, som ofte kræver intensivering af behandlingen,"" siger dr. Athena Philis-Tsimikas, direktør for Scripps Whittier Diabetes Institute og DUAL IX forskningsleder. ""Xultophy® kan være en relevant behandlingsmulighed for voksne, som ikke kan nå deres blodsukkermål med deres nuværende medicin."" Bivirkningerne var sammenlignelige i begge behandlingsgrupper. De mest almindelige bivirkninger (>5%) i gruppen, der blev behandlet med Xultophy®, omfattede virusinfektion i de øvre luftveje, hovedpine, rygsmerter, forhøjet lipase samt kvalme. Sikkerhedsprofilen for Xultophy® i DUAL IX var konsistent med tidligere kliniske studier af Xultophy®.1 Der vil blive præsenteret andre patientrapporterede resultater fra DUAL IX mandag den 25. juni på ADA: Fase 3b-studiet DUAL IX var et 26-ugers randomiseret, ikke-blindet, multicenterstudie, der blev gennemført i 11 lande og omfattede 420 patienter. Studiets formål var at undersøge sikkerheden og effekten af Xultophy® sammenlignet med insulin glargin U-100 som supplerende behandling hos voksne, der var utilstrækkeligt reguleret ved behandling med SGLT-2i (sodium-glucose co-transporter-2-inhibitor) med eller uden anden behandling med diabeteslægemidler i tabletform.2 Hypoglykæmi i DUAL IX var defineret som en hændelse, der kræver hjælp fra en anden person, eller som bekræftes ved blodsukkermåling (under 56 mg/dl) med symptomer svarende til hypoglykæmi. Xultophy® er et kombinationsprodukt til dosering én gang dagligt i én injektion bestående af insulin degludec, en langtidsvirkende human insulinanalog, og liraglutid, en glukagonlignende peptid-1 (GLP-1)-receptoragonist, i et fast kombinationsforhold. I Europa er Xultophy® godkendt til behandling af voksne med utilstrækkeligt reguleret type 2-diabetes med henblik på at forbedre blodsukkerreguleringen som et supplement til diæt og motion i tillæg til andre diabeteslægemidler i tabletform.3 I USA er Xultophy® godkendt under navnet Xultophy® 100/3,6 som et supplement til diæt og motion til at forbedre blodsukkerreguleringen hos voksne med type 2-diabetes, som er utilstrækkeligt reguleret med basalinsulin (mindre end 50 enheder dagligt) eller liraglutid (mindre end eller lig med 1,8 mg dagligt).4 I USA er Xultophy® 100/3,6 ikke godkendt til anvendelse som supplement til diabeteslægemidler i tabletform. Yderligere information Referencer1.         Philis-Tsimikas A, Billings LK, Busch R, et al. Superior Efficacy of Insulin Degludec/Liraglutide (IDegLira) vs Insulin Glargine (IGlar U100) as Add-on to Sodium-Glucose Co-Transporter-2 Inhibitor (SGLT2i) ± Oral Antidiabetic Drug (OAD) Therapy in Patients with Type 2 Diabetes (T2D): DUAL IX Trial (NCT02773368). 78th Annual Scientific Sessions of the American Diabetes Association (ADA), Orlando, Florida, US; 22-26 June 2018. 2.         ClinicalTrials.gov. A clinical trial comparing glycaemic control and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) as add-on therapy to SGLT2i in subjects with type 2 diabetes mellitus (DUAL IX). Available at: https://clinicaltrials.gov/ct2/show/study/NCT02773368. Last accessed: June 2018. 3.         EMA. Xultophy® Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002647/WC500177657.pdf. Last accessed: June 2018. 4.         Xultophy® 100/3.6 [package insert]. Plainsboro, NJ: Novo Nordisk Inc; November 2016.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=570,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
174,2018-06-20,Oral semaglutide shows statistically significantly greater reductions in HbA1c and weight compared to Victoza® and sitagliptin in the PIONEER 4 and 7 trials,"Bagsværd, Denmark, 20 June 2018 - Novo Nordisk today announced the successful completion and headline results of the phase 3a trials PIONEER 4 comparing oral semaglutide as a treatment for adults with type 2 diabetes to Victoza® (1.8 mg liraglutide) and placebo, and PIONEER 7 comparing oral semaglutide as a treatment for adults with type 2 diabetes to sitagliptin 100 mg. Oral semaglutide is a new GLP-1 analogue taken once daily as a tablet. Two distinct statistical approaches to evaluate the effects of oral semaglutide were applied in the PIONEER 4 and 7 trials; a primary statistical approach[1] required by recent regulatory guidance, evaluating the effect regardless of discontinuation of treatment and use of rescue medication, and a secondary statistical approach[2] describing the effect while on treatment and without use of rescue medication. PIONEER 4PIONEER 4 was a 52-week double-blinded, double-dummy trial investigating the efficacy and safety of 14 mg oral semaglutide compared with Victoza® 1.8 mg and placebo in 711 people with type 2 diabetes inadequately controlled on metformin, with or without an SGLT-2 inhibitor. PIONEER 4 achieved its primary objective according to the primary statistical approach by demonstrating a non-inferior reduction in HbA1c and statistically significant and superior weight loss at 26 weeks with oral semaglutide compared to Victoza®. Furthermore, oral semaglutide provided statistically significant and superior reductions in HbA1c and weight compared to placebo. When applying the secondary statistical approach for week 26 and week 52, respectively, people treated with oral semaglutide experienced a reduction in HbA1c of 1.3% and 1.2% compared to 1.1% and 0.9% with Victoza® whereas placebo declined by 0.1% and increased by 0.2%. Reductions in HbA1c were statistically significantly greater with oral semaglutide compared to both Victoza® and placebo. Reduction in body weight from baseline was statistically significantly greater with oral semaglutide at 4.7 and 5.0 kg at 26 and 52 weeks, respectively, compared to 3.2 and 3.1 kg with Victoza®, and 0.7 and 1.2 kg with placebo. The American Diabetes Association (ADA) treatment target of HbA1c below 7.0% was achieved by 69% of people treated with oral semaglutide, 63% of people treated with Victoza® and 18% of people treated with placebo after 52 weeks; the difference between oral semaglutide and placebo was statistical significant. In the trial, oral semaglutide was well-tolerated and with a profile consistent with GLP-1-based therapy. The most common adverse event for oral semaglutide was mild to moderate nausea which diminished over time. In PIONEER 4, 20% of people treated with oral semaglutide experienced nausea, compared to 18% of people treated with Victoza® and 4% of people treated with placebo. The proportion of people who discontinued treatment due to adverse events was 11% for people treated with oral semaglutide compared to 9% for people treated with Victoza® and 4% for people receiving placebo. PIONEER 7PIONEER 7 was a 52-week open-label trial investigating the efficacy and safety of oral semaglutide with dose adjustment based on clinical evaluation of glycaemic control and drug tolerability compared with the DPP-IV inhibitor 100 mg sitagliptin in 504 people with type 2 diabetes, inadequately controlled on 1-2 oral antidiabetics. The trial achieved its primary objective according to the primary statistical principle by demonstrating that oral semaglutide was statistically significant and superior to sitagliptin 100 mg in the proportion of people achieving the American Diabetes Association (ADA) treatment target of HbA1c below 7% at week 52. Oral semaglutide also demonstrated statistically significant and superior reductions in body weight versus sitagliptin. When applying the secondary statistical approach, people treated with oral semaglutide experienced a statistically significant reduction in HbA1c of 1.4% compared to 0.7% with sitagliptin at week 52. From a baseline HbA1c of 8.3%, 63% of people treated with oral semaglutide achieved the target HbA1c below 7% after 52 weeks of treatment compared to 28% of people treated with sitagliptin, and the difference was statistically significant. The reduction in body weight of 2.9 kg with oral semaglutide was statistically significantly greater at week 52 compared to 0.8 kg with sitagliptin. After 52 weeks of treatment, approximately 9% of the people receiving oral semaglutide treatment were receiving 3 mg oral semaglutide, while approximately 31% and 60% were receiving 7 mg and 14 mg oral semaglutide, respectively. In the trial, oral semaglutide was well-tolerated and with a profile consistent with GLP-1-based therapy. The most common adverse event for oral semaglutide was mild to moderate nausea, which diminished over time. In PIONEER 7, 21% of people treated with oral semaglutide experienced nausea, compared to 2% of people treated with sitagliptin. The proportion of people who discontinued treatment due to adverse events was 9% for people treated with oral semaglutide compared to 3% for people treated with sitagliptin. ""With the significant one-year results in a real-world dose setting, oral semaglutide was superior to sitagliptin by documenting a greater proportion of people achieving the ADA target,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""At the same time, we have shown that oral semaglutide is even more efficacious in lowering glucose and body weight than the most widely used injectable GLP-1 treatment, Victoza®"". About PIONEER 4, PIONEER 7 and the PIONEER clinical trial programmePIONEER 4 was a 52-week, randomised, double-blinded, double-dummy, active- and placebo-controlled, parallel-group, multicentre, multinational trial with three arms comparing the efficacy and safety of 14 mg oral semaglutide compared to Victoza® and vs placebo in people with type 2 diabetes, inadequately controlled on metformin with or without a sodium-glucose co-transporter-2 (SGLT-2) inhibitor. PIONEER 4 randomised 711 people in a 2:2:1 manner to receive either 14 mg oral semaglutide, Victoza® 1.8 mg, or placebo once daily. The primary endpoint was change from baseline to week 26 in HbA1c. Key secondary endpoints included change in HbA1c and body weight from baseline to week 52. PIONEER 7 was a 52-week, randomised, open-label, active-controlled, parallel-group, multicentre, multinational trial with two arms comparing the efficacy and safety of oral semaglutide using a flexible dose adjustment (3, 7 or 14 mg) based on clinical evaluation (glycaemic target and tolerability) of their response to treatment compared with sitagliptin in people with type 2 diabetes mellitus, inadequately controlled on 1-2 oral antidiabetics. PIONEER 7 enrolled 504 people randomised 1:1 to receive either oral semaglutide or 100 mg sitagliptin once daily. The primary endpoint was HbA1c below 7% as per the ADA treatment target at week 52. Key secondary endpoints included change in HbA1c and body weight from baseline to week 52. Novo Nordisk plans to report the PIONEER 3 trial comparing 3, 7 and 14 mg oral semaglutide with 100 mg sitagliptin before the end of second quarter of 2018. The PIONEER phase 3a clinical development programme for oral semaglutide is a global development programme with enrolment of 8,845 people with type 2 diabetes across 10 clinical trials, which are all expected to complete in 2018. Further information Company announcement No 51 / 2018 [1] Treatment policy estimand approach: treatment effect regardless of discontinuation of treatment or initiation of rescue medication (analysed by pattern mixture model using multiple imputations to handle missing data with an analysis of covariance (ANCOVA) and a logistics regression model). [2] Hypothetical estimand approach: The treatment effect while on treatment without use of rescue medication (analysed by Mixed Models for Repeated Measurements (MMRM)) and a logistics regression model). Similar statistical methodology as applied in the SUSTAIN programme for subcutaneous semaglutide.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=571,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
175,2018-06-20,Oral semaglutid viser statistisk signifikant større reduktioner i langtidsblodsukker og vægt sammenlignet med Victoza® og sitagliptin i PIONEER 4 og 7,"Bagsværd, den 20. juni 2018 - Novo Nordisk offentliggør i dag de overordnede resultater fra fase 3-studierne PIONEER 4, som sammenlignede oral semaglutid til behandling af voksne med type 2-diabetes med Victoza® (1,8 mg liraglutid) og placebo, og PIONEER 7, som sammenlignede oral semaglutid til behandling af voksne med type 2-diabetes med sitagliptin 100 mg. Begge studier er netop afsluttet med succes. Oral semaglutid er en ny GLP-1-analog, der tages én gang dagligt som en tablet. Der blev i PIONEER 4 og 7 anvendt to forskellige statistiske metoder til vurdering af effekten af oral semaglutid: en primær statistisk metode[1], som kræves i henhold til nye regulatoriske retningslinjer, og som vurderer effekten uanset ophør af behandlingen og brug af anden behandling; og en sekundær statistisk metode [2], der beskriver effekten, mens behandlingen pågår og uden brug af anden behandling. PIONEER 4 blev gennemført som et 52-ugers dobbeltblindet, dobbelt-placebokontrolleret studie, som undersøgte effekt og sikkerhed af 14 mg oral semaglutid sammenlignet med Victoza® 1,8 mg og placebo i 711 deltagere med type 2-diabetes, som var utilstrækkeligt reguleret med metformin med eller uden en SGLT-2-hæmmer. PIONEER 4 opfyldte sit primære mål vurderet ud fra den primære statistiske metode, idet det viste en ikke-inferiør reduktion i langtidsblodsukkeret (HbA1c) og et statistisk signifikant og større vægttab ved 26 uger med oral semaglutid sammenlignet med Victoza®. Oral semaglutid medførte desuden statistisk signifikante og større reduktioner i HbA1c og vægt sammenlignet med placebo. Ved anvendelse af den sekundære statistiske metode ved henholdsvis uge 26 og uge 52 opnåede deltagere i behandling med oral semaglutid en reduktion i HbA1c på 1,3% og 1,2% mod 1,1% og 0,9% med Victoza®, mens placebo faldt med 0,1% og steg med 0,2%. Reduktionerne i HbA1c var statistisk signifikant større med oral semaglutid sammenlignet både med Victoza® og placebo. Reduktionen i vægt i forhold til udgangspunktet ved studiets begyndelse (baseline) var statistisk signifikant større med oral semaglutid, nemlig 4,7 og 5,0 kg ved henholdsvis 26 og 52 uger, mod 3,2 og 3,1 kg med Victoza® og 0,7 og 1,2 kg med placebo. Behandlingsmålet om HbA1c på under 7,0% som fastsat af American Diabetes Association (ADA) blev nået af 69% af de deltagere, der blev behandlet med oral semaglutid, 63% af dem, der fik Victoza®, og 18% af dem, der fik placebo, efter 52 uger; forskellen mellem oral semaglutid og placebo var statistisk signifikant. I studiet var oral semaglutid veltolereret med en profil, der var konsistent med GLP-1-baseret behandling. Den mest almindelige bivirkning for oral semaglutid var mild til moderat kvalme, som aftog med tiden. I PIONEER 4 oplevede 20% af deltagerne i behandling med oral semaglutid kvalme, mod 18% af dem, der fik Victoza®, og 4% af dem, der fik placebo. Andelen af deltagere, som afsluttede behandlingen før tid som følge af bivirkninger, var 11% for deltagere, der blev behandlet med oral semaglutid, mod 9% for deltagere, der fik Victoza®, og 4% for deltagere, der fik placebo. PIONEER 7 blev gennemført som et 52-ugers ikke-blindet studie, som undersøgte effekt og sikkerhed af oral semaglutid med dosisjustering baseret på klinisk vurdering af blodsukkerregulering og lægemidlets tolerabilitet sammenlignet med DPP-IV-hæmmeren 100 mg sitagliptin i 504 deltagere med type 2-diabetes, som var utilstrækkeligt reguleret med 1-2 diabeteslægemidler i tabletform. Studiet opfyldte sit primære mål vurderet ud fra den primære statistiske metode, idet det viste, at oral semaglutid var statistisk signifikant og bedre end sitagliptin 100 mg med hensyn til andelen af deltagere, der nåede behandlingsmålet om HbA1c på under 7% som fastsat af American Diabetes Association (ADA) ved uge 52. Oral semaglutid viste desuden statistisk signifikante og større reduktioner i vægt sammenlignet med sitagliptin. Vurderet ud fra den sekundære statistiske metode opnåede deltagere i behandling med oral semaglutid en statistisk signifikant reduktion i HbA1c på 1,4% mod 0,7% med sitagliptin ved uge 52. Fra et baseline-HbA1c-niveau på 8,3% nåede 63% af deltagere i behandling med oral semaglutid behandlingsmålet om HbA1c på under 7% efter 52 ugers behandling mod 28% af deltagere i behandling med sitagliptin, og forskellen var statistisk signifikant. Reduktionen i vægt på 2,9 kg med oral semaglutid var statistisk signifikant større ved uge 52 sammenlignet med 0,8 kg med sitagliptin. Efter 52 ugers behandling fik ca. 9% af de deltagere, der blev behandlet med oral semaglutid, 3 mg oral semaglutid, mens ca. 31% og 60% fik henholdsvis 7 mg og 14 mg oral semaglutid. I studiet var oral semaglutid veltolereret med en profil, der var konsistent med GLP-1-baseret behandling. Den mest almindelige bivirkning for oral semaglutid var mild til moderat kvalme, som aftog med tiden. I PIONEER 7 oplevede 21% af deltagerne i behandling med oral semaglutid kvalme, mod 2% deltagere, der fik sitagliptin. Andelen af deltagere, som afsluttede behandlingen før tid som følge af bivirkninger, var 9% for deltagere, der blev behandlet med oral semaglutid, mod 3% for deltagere i behandling med sitagliptin. ""Disse markante etårsresultater, der er opnået med et doseringsmønster som i klinisk praksis, viste, at oral semaglutid var bedre end sitagliptin, idet de dokumenterede, at en større andel af patienter nåede ADA's behandlingsmål,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Samtidig har vi vist, at oral semaglutid er endnu mere virkningsfuldt med hensyn til at sænke blodsukker og vægt end Victoza®, som er den mest udbredte GLP-1-behandling til injektion."" PIONEER 4 var et 52-ugers randomiseret, dobbeltblindet, dobbelt-placebokontrolleret, aktivt- og placebokontrolleret, multicenter-, multinationalt parallelgruppestudie med tre behandlingsgrupper. Studiet undersøgte effekt og sikkerhed af 14 mg oral semaglutid sammenlignet med Victoza® og med placebo hos mennesker med type 2-diabetes, som var utilstrækkeligt reguleret med metformin med eller uden en sodium-glucose co-transporter (SGLT)-2-hæmmer. PIONEER 4 omfattede 711 deltagere, som blev randomiseret 2:2:1 til at modtage enten 14 mg oral semaglutid, Victoza® 1,8 mg eller placebo én gang dagligt. Det primære endepunkt var ændring i HbA1c ved uge 26 i forhold til baseline. Vigtige sekundære endepunkter var blandt andet ændring i HbA1c og vægt ved uge 52 i forhold til baseline. PIONEER 7 var et 52-ugers randomiseret, ikke-blindet, aktivt kontrolleret, multicenter-, multinationalt parallelgruppestudie med to behandlingsgrupper. Studiet undersøgte effekt og sikkerhed af oral semaglutid ved hjælp af fleksibel dosisjustering (3, 7 eller 14 mg) baseret på klinisk vurdering (glykæmisk behandlingsmål og tolerabilitet) af behandlingsrespons sammenlignet med sitagliptin hos mennesker med type 2-diabetes, som var utilstrækkeligt reguleret med 1-2 diabeteslægemidler i tabletform. PIONEER 7 omfattede 504 deltagere, som blev randomiseret 1:1 til at modtage enten oral semaglutid eller 100 mg sitagliptin én gang dagligt. Det primære endepunkt var HbA1c under ADA's behandlingsmål på 7% ved uge 52. Vigtige sekundære endepunkter var blandt andet ændring i HbA1c og vægt ved uge 52 i forhold til baseline. Novo Nordisk planlægger at rapportere resultater fra PIONEER 3-studiet, der har sammenlignet 3, 7 og 14 mg oral semaglutid med 100 mg sitagliptin, inden udgangen af andet kvartal af 2018. PIONEER, det kliniske fase 3a-program for oral semaglutid, er et globalt udviklingsprogram med en samlet deltagelse af 8.845 mennesker med type 2-diabetes i 10 kliniske studier, som alle forventes afsluttet i 2018. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information [1] Behandlingspolitisk estimand: behandlingseffekt uanset ophør af behandlingen eller iværksættelse af anden behandling (analyseret ved hjælp af en pattern mixture-model baseret på multiple imputationer til håndtering af manglende data med en analyse af kovarians (ANCOVA) og en logistisk regressionsmodel). [2] Hypotetisk estimand: behandlingseffekten mens behandlingen pågår uden brug af anden behandling (analyseret ved hjælp af Mixed Models for Repeated Measurements (MMRM) og en logistisk regressionsmodel). Den anvendte statistiske metodik er den samme som den, der blev anvendt i SUSTAIN-programmet for subkutan semaglutid.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=572,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
176,2018-06-19,Kallyope and Novo Nordisk announce collaboration to discover novel therapeutics for obesity and diabetes,"Bagsværd, Denmark, 19­ June 2018 - Kallyope, Inc and Novo Nordisk A/S today announced that they have entered into a research collaboration and option agreement to discover novel peptide therapeutics to treat obesity and diabetes. Kallyope will receive an upfront payment and research support for activities conducted in the collaboration. Under the terms of the agreement, Novo Nordisk has an option to license exclusive worldwide rights to develop and commercialise up to six products discovered in the collaboration. Kallyope will receive a license fee if Novo Nordisk chooses to exercise an option to a therapeutic discovered and validated in the joint research plan and potential research, development and sales milestones. In addition, Kallyope will receive royalties on worldwide product sales of licensed products. The gut and the brain are tightly linked via bi-directional communication pathways collectively termed the 'gut-brain axis'. These include released circulating peptides and metabolites, immune factors and direct neuronal innervation. The gut-brain axis is involved in many important aspects of physiology and plays a significant role in appetite regulation and energy homoeostasis. Kallyope has developed an innovative platform to interrogate the gut-brain axis and discover new medicines in multiple therapeutic areas. The platform integrates single-cell sequencing, bioinformatics, functional and anatomical circuit mapping and organoids. It has enabled the discovery of new biological mechanisms, including multiple potential secreted products from the gut-brain axis that may play a role in metabolism. Under a joint research plan, Kallyope and Novo Nordisk will collaborate on 'in vitro' and 'in vivo' studies to validate a number of product candidates. Following validation and option exercise, Novo Nordisk will assume responsibility for further preclinical and clinical development, manufacturing and commercialisation. ""Novo Nordisk is renowned for its expertise in the discovery and development of peptide therapeutics, as well as its commitment to and leadership in therapeutics for obesity and diabetes,"" said Nancy Thornberry, CEO of Kallyope. ""Coupling Novo Nordisk's formidable capabilities with Kallyope's unique, sophisticated platform makes for a very attractive strategic collaboration that complements our small molecule focus."" ""Novo Nordisk is very excited about the opportunity to collaborate with Kallyope. The company has developed a unique and innovative platform and is led by an outstanding leadership team. In combination with the experience that Novo Nordisk has in the disease biology understanding, peptidomics and peptide production, the projects that we will collaborate on hold potential to make a real difference for people living with diabetes and obesity,"" said Marcus Schindler, senior vice president, Global Drug Discovery in Novo Nordisk. About Kallyope Inc.Kallyope, headquartered at the Alexandria Center® for Life Science in New York City, is a platform biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis. A cross-disciplinary team integrates sophisticated technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology and human genetics to provide an understanding of gut-brain biology that will lead to transformational therapeutics to improve human health. The company's founders are Charles Zuker, Ph.D., Lasker Award winner Tom Maniatis, Ph.D., and Nobel laureate Richard Axel, M.D. For more information visit www.kallyope.com. Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=573,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
177,2018-06-19,Kallyope og Novo Nordisk indleder samarbejde om opdagelse af nye lægemidler til behandling af svær overvægt og diabetes,"Bagsværd, den 19. juni 2018 - Kallyope, Inc. og Novo Nordisk A/S meddeler i dag, at de har indgået et forskningssamarbejde og en optionsaftale om opdagelse af nye peptidbaserede lægemidler til behandling af svær overvægt og diabetes. Kallyope modtager en betaling ved aftalens indgåelse samt forskningsstøtte til aktiviteter, der udføres under samarbejdet. Aftalen giver Novo Nordisk en mulighed for at licensere eksklusive globale rettigheder til at udvikle og kommercialisere op til seks lægemiddelkandidater, som findes under samarbejdet. Kallyope modtager en licensbetaling, hvis Novo Nordisk vælger at udnytte en option på en lægemiddelkandidat, som er opdaget og valideret under forskningssamarbejdet, samt potentielle milepælsbetalinger relateret til forskning, udvikling og salg. Derudover modtager Kallyope royalties af det fremtidige globale salg af licenserede produkter. Fordøjelseskanalen og hjernen kommunikerer via den såkaldte tarm-hjerne-akse. Kommunikationen er tovejs og foregår via det autonome nervesystem, og involverer derudover immunologiske og hormonale signaler. Tarm-hjerne-aksen er involveret i mange vigtige fysiologiske funktioner og spiller en vigtig rolle i appetitregulering og energibalance. Kallyope har udviklet en innovativ platform til at udforske tarm-hjerne-aksen og finde nye lægemidler indenfor mange forskellige behandlingsområder. Platformen integrerer enkeltcellesekventering, bioinformatik, kortlægning af funktionelle og anatomiske kredsløb og såkaldte organoider. Den platform har gjort det muligt at opdage nye biologiske mekanismer, herunder mange biologiske signalstoffer, som potentielt udskilles fra tarm-hjerne-aksen, og som derfor kan spille en rolle i stofskiftet. I henhold til den fælles forskningsplan vil Kallyope og Novo Nordisk samarbejde om in vitro- og in vivo-studier for at validere en række lægemiddelkandidater. Efter validering og optionsudnyttelse vil Novo Nordisk overtage ansvaret for den yderligere prækliniske og kliniske udvikling, fremstilling og kommercialisering. ""Novo Nordisk er kendt for sin ekspertise indenfor opdagelse og udvikling af peptidbaserede lægemidler samt sit engagement og lederskab indenfor lægemidler til behandling af svær overvægt og diabetes,"" siger Nancy Thornberry, administrerende direktør for Kallyope. ""Kombinationen af Novo Nordisks formidable kompetencer og Kallyopes unikke, avancerede platform giver grundlag for et særdeles attraktivt strategisk samarbejde, som komplementerer vores fokus på små molekyler."" ""Vi er i Novo Nordisk meget glade for denne mulighed for at samarbejde med Kallyope. Det er en virksomhed, der har udviklet en unik og innovativ platform og har et fremragende ledelsesteam. Kombineret med Novo Nordisks erfaring indenfor biologisk sygdomsforståelse, peptidforskning og peptidfremstilling har de projekter, vi skal samarbejde om, potentiale til at gøre en reel forskel for mennesker med diabetes og svær overvægt,"" siger Marcus Schindler, direktør for Global Drug Discovery i Novo Nordisk. Kallyope, som har hovedkvarter i Alexandria Center® for Life Science i New York City, er et platform-biotekselskab, der fokuserer på at udforske det behandlingsmæssige potentiale i tarm-hjerne-aksen. Et tværfagligt team kombinerer avancerede teknologier indenfor sekventering, bioinformatik, neural kortlægning, celle- og molekylærbiologi og human genetik for at opnå en forståelse af tarm-hjerne-biologien, som kan føre til innovative lægemidler, der kan forbedre menneskers sundhed. Virksomheden er stiftet af Charles Zuker, ph.d., Tom Maniatis, ph.d. og vinder af Lasker Award, og Richard Axel, læge og nobelpristager. Læs mere på www.kallyope.com. Dette er en oversættelse af den originale engelske pressemeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=574,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
178,2018-05-29,Oral semaglutide shows superior improvement in HbA1c vs empagliflozin in the PIONEER 2 trial,"Bagsværd, Denmark, 29 May 2018 - Novo Nordisk today announced the headline results from PIONEER 2, the second phase 3a trial with oral semaglutide for treatment of adults with type 2 diabetes. Oral semaglutide is a new GLP-1 analogue taken once daily as a tablet. The 52-week, open label trial investigated the efficacy and safety of 14 mg oral semaglutide compared with 25 mg empagliflozin in 816 people with type 2 diabetes, inadequately controlled on metformin. The confirmatory endpoints were defined after 26 weeks of treatment. Two distinct statistical approaches to evaluating the effects of oral semaglutide were applied in the PIONEER 2 trial; a primary statistical approach[1] required by recent regulatory guidance evaluating the effect regardless of discontinuation of treatment and use of rescue medication, and a secondary statistical approach[2] describing the effect while on treatment and without use of rescue medication. The trial achieved its primary objective according to the primary statistical approach by demonstrating a statistically significant and superior improvement in HbA1c with oral semaglutide compared to empagliflozin at 26 weeks. Difference in weight loss at 26 weeks between oral semaglutide and empagliflozin was not statistically significant when applying the primary statistical approach. When applying the secondary statistical approach, people treated with 14 mg oral semaglutide achieved a statistically significant improvement in HbA1c of 1.4% at 26 weeks and 1.3% at 52 weeks, compared to an improvement in HbA1c of 0.9% and 0.8% with 25 mg empagliflozin at 26 and 52 weeks, respectively. The 14 mg dose of oral semaglutide demonstrated weight loss of 4.2 kg at 26 weeks and 4.7 kg at 52 weeks versus 3.8 kg with 25 mg empagliflozin at both 26 weeks and 52 weeks. The increased weight loss with oral semaglutide was statistically significant compared to empagliflozin at the 52-week time point. In addition, applying the secondary statistical approach, the American Diabetes Association (ADA) treatment target of HbA1c below 7.0% was achieved by 72% of people treated with 14 mg oral semaglutide compared with 47% of people treated with 25 mg empagliflozin at 52 weeks. In the trial, oral semaglutide was well-tolerated and with a profile consistent with GLP-1-based therapy. The most common adverse event for oral semaglutide was mild to moderate nausea, which diminished over time. In PIONEER 2, 20% of people treated with oral semaglutide experienced nausea during the trial. The proportion of subjects who discontinued treatment due to adverse events was 11% for people treated with 14 mg oral semaglutide compared to 4% for people treated with 25 mg empagliflozin. ""We are very excited about these results, which demonstrate that people treated with 14 mg oral semaglutide for one year achieved statistically significant reductions in blood glucose and body weight compared to people treated with 25 mg empagliflozin,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""PIONEER 2 is an important milestone in the clinical development of oral semaglutide and we look forward to further understanding the clinical profile of oral semaglutide in the remaining PIONEER trials."" About PIONEER 2 and the PIONEER clinical trial programmePIONEER 2 was a 52-week, randomised, open-label, active-controlled, parallel-group, multicentre, multinational trial with two arms comparing the efficacy and safety of oral semaglutide with empagliflozin in people with type 2 diabetes mellitus, inadequately controlled on metformin. 816 people were enrolled in PIONEER 2 and randomised 1:1 to receive either 14 mg oral semaglutide or 25 mg empagliflozin once daily. The confirmatory endpoints were change in HbA1c and body weight from baseline to week 26. Key secondary endpoints included change in HbA1c and body weight from baseline to week 52. The PIONEER phase 3a clinical development programme for oral semaglutide is a global development programme with enrolment of 8,845 people with type 2 diabetes across 10 clinical trials, which are all expected to complete in 2018. Further information Company announcement No 47 / 2018 [1] Treatment policy estimand approach: treatment effect regardless of discontinuation of treatment or initiation of rescue medication (analysed by pattern mixture model using multiple imputations to handle missing week 26 data). [2] Hypothetical estimand approach: The treatment effect of oral semaglutide versus empagliflozin for all randomised subjects while on treatment without use of rescue medication (analysed by Mixed Models for Repeated Measurements (MMRM)). Similar statistical methodology as applied in the SUSTAIN programme for subcutaneous semaglutide.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=581,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
179,2018-05-29,Oral semaglutid viser større forbedring i langtidsblodsukker sammenlignet med empagliflozin i PIONEER 2-studiet,"Bagsværd, den 29. maj 2018 - Novo Nordisk offentliggør i dag de overordnede resultater fra PIONEER 2, det andet fase 3a-studie med oral semaglutid til behandling af voksne med type 2-diabetes. Oral semaglutid er en ny GLP-1-analog, der tages som en tablet én gang dagligt. Studiet, som var ikke-blindet og strakte sig over 52 uger, undersøgte effekten og sikkerheden af 14 mg oral semaglutid sammenlignet med 25 mg empagliflozin i 816 deltagere med type 2-diabetes, som var utilstrækkeligt reguleret med metformin. De bekræftende endepunkter blev defineret efter 26 ugers behandling. Der blev i PIONEER 2-studiet anvendt to forskellige statistiske metoder til vurdering af effekten af oral semaglutid: en primær statistisk metode[1], som kræves i henhold til nye regulatoriske retningslinjer, og som vurderer effekten uanset ophør af behandlingen og brug af anden behandling; og en sekundær statistisk metode[2], der beskriver effekten, mens behandlingen pågår og uden brug af anden behandling. Studiet opfyldte sit primære mål vurderet ud fra den primære statistiske metode, idet det viste en statistisk signifikant og større forbedring i langtidsblodsukkeret (HbA1c) ved behandling med oral semaglutid sammenlignet med empagliflozin ved 26 uger. Forskellen i vægttabet ved 26 uger mellem oral semaglutid og empagliflozin var ikke statistisk signifikant vurderet ud fra den primære statistiske metode. Vurderet ud fra den sekundære statistiske metode opnåede deltagere i behandling med 14 mg oral semaglutid en statistisk signifikant forbedring i HbA1c på 1,4% ved 26 uger og 1,3% ved 52 uger, mod en forbedring i HbA1c på 0,9% og 0,8% med 25 mg empagliflozin ved henholdsvis 26 og 52 uger. Behandling med 14 mg oral semaglutid medførte vægttab på 4,2 kg ved 26 uger og 4,7 kg ved 52 uger mod 3,8 kg med 25 mg empagliflozin både ved 26 uger og 52 uger. Det større vægttab med oral semaglutid var statistisk signifikant sammenlignet med empagliflozin ved 52 uger. Ved anvendelse af den sekundære statistiske metode blev endvidere behandlingsmålet om HbA1c på under 7,0% som fastsat af American Diabetes Association (ADA) nået af 72% af deltagere i behandling med 14 mg oral semaglutid, mod 47% af deltagere, der blev behandlet med 25 mg empagliflozin ved 52 uger. I studiet var oral semaglutid veltolereret med en profil, der var konsistent med GLP-1-baseret behandling. Den mest almindelige bivirkning for oral semaglutid var mild til moderat kvalme, som aftog med tiden. I PIONEER 2 oplevede 20% af deltagere i behandling med oral semaglutid kvalme i studiet. Andelen af deltagere, som afsluttede behandlingen før tid som følge af bivirkninger, var 11% for deltagere, der blev behandlet med 14 mg oral semaglutid, mod 4% for deltagere, der fik 25 mg empagliflozin. ""Vi er meget tilfredse med disse resultater, som viser, at mennesker, der er blevet behandlet med 14 mg oral semaglutid i et år, opnår statistisk signifikante reduktioner i blodsukker og vægt i forhold til mennesker, der er blevet behandlet med 25 mg empagliflozin,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""PIONEER 2 er en vigtig milepæl i den kliniske udvikling af oral semaglutid, og vi ser frem til at opnå yderligere indsigt i den kliniske profil for oral semaglutid i de resterende PIONEER-studier."" PIONEER 2 blev gennemført som et 52-ugers randomiseret, ikke-blindet, aktivt kontrolleret, multicenter-, multinationalt parallelgruppestudie med to behandlingsgrupper. Studiet undersøgte effekt og sikkerhed af oral semaglutid sammenlignet med empagliflozin hos mennesker med type 2-diabetes, som var utilstrækkeligt reguleret med metformin. PIONEER 2 omfattede 816 deltagere, som blev randomiseret 1:1 til at modtage enten 14 mg oral semaglutid eller 25 mg empagliflozin én gang dagligt. De bekræftende endepunkter var ændring i HbA1c og vægt ved uge 26 i forhold til udgangspunktet ved studiets begyndelse. Vigtige sekundære endepunkter var blandt andet ændring i HbA1c ved uge 52 i forhold til udgangspunktet ved studiets begyndelse. Det kliniske fase 3a-program for oral semaglutid, PIONEER, er et globalt udviklingsprogram med en samlet deltagelse af 8.845 mennesker med type 2-diabetes i 10 kliniske studier, som alle forventes afsluttet i 2018. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 47 / 2018 [1] Behandlingspolitisk estimand: behandlingseffekt uanset ophør af behandlingen eller iværksættelse af anden behandling (analyseret ved hjælp af en pattern mixture-model baseret på multiple imputationer til håndtering af manglende uge 26-data). [2] Hypotetisk estimand: behandlingseffekten af oral semaglutid sammenlignet med empagliflozin for alle randomiserede deltagere, mens behandlingen pågår uden brug af anden behandling (analyseret ved hjælp af Mixed Models for Repeated Measurements (MMRM)). Den anvendte statistiske metodik er den samme som den, der blev anvendt i SUSTAIN-programmet for subkutan semaglutid.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=582,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
180,2018-05-24,Real-world evidence shows clinically meaningful weight loss in people receiving Saxenda®,"Vienna, Austria, 24 May 2018 - People treated with Saxenda® (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week at both the 25th European Congress on Obesity (ECO 2018) in Vienna, Austria and the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR 2018) in Baltimore, US.1,2 This retrospective effectiveness study investigated the impact of Saxenda® treatment in people with overweight and obesity across six weight management clinics in Canada. After six months, people treated with Saxenda® as an adjunct to diet and exercise achieved 7.1% weight loss from baseline, with 63.4% and 35.2% of people losing >5% and >10% of their body weight, respectively.1,2 Results from the real-world study were in line with those observed in the SCALE clinical trial programme.3 ""Obesity is a chronic and multifactorial disease, requiring a range of treatment options to help people achieve and maintain weight loss,"" said Dr Sean Wharton of the Wharton Medical Clinic, Toronto, Canada and lead investigator of this study. ""Weight loss of 5 to 10% can have significant health benefits, including reducing the risk of developing cardiovascular disease and type 2 diabetes. In this study we are seeing real-world evidence of people treated with Saxenda® achieving clinically meaningful weight loss."" People treated with Saxenda® for at least six months also experienced improvements in cardiometabolic risk factors including blood glucose levels and systolic blood pressure.1,2 ""Saxenda® is an important treatment option for people with obesity and reflects our commitment to help reduce the impact of obesity and improve the health of people living with the disease,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""It is great to see real-world evidence for Saxenda®, demonstrating that people are experiencing the benefits of Saxenda® seen in clinical trials."" Saxenda® was generally well tolerated, with gastrointestinal side effects being the most frequently reported adverse events. The study objective was to investigate the real-world clinical effectiveness of Saxenda® in combination with diet and exercise. This retrospective study included a total of 311 people who had received Saxenda® for weight management, of which 167 people received treatment for at least six months. People whose records were included in the study had an average body mass index (BMI) of 40.7 kg/m2 and weight of 114.8 kg at baseline.1 Saxenda® (liraglutide 3 mg) is a once-daily glucagon-like peptide-1 (GLP-1) analogue with 97% similarity to naturally occurring human GLP-1,4,5 a hormone that is released in response to food intake.6 Like human GLP-1, Saxenda® regulates appetite by increasing feelings of fullness and satiety, while lowering feelings of hunger and prospective food consumption, thereby leading to reduced food intake. As with other GLP-1 analogues, Saxenda® stimulates insulin secretion and lowers glucagon secretion in a glucose-dependent manner.4,5 Saxenda® was evaluated in the SCALE (Satiety and Clinical Adiposity - Liraglutide Evidence) phase 3a clinical trial programme. In Canada, Saxenda® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial BMI of >30 kg/m2 (obese), or >27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.4 Guidance is given in the label that treatment with Saxenda® should be discontinued after 12 weeks on the liraglutide 3.0 mg/day dose, if patients have not lost at least 5% of their initial body weight.4 About obesityObesity is a disease7 that requires long-term management. It is associated with many serious health consequences8 and decreased life expectancy.9 Obesity-related complications include type 2 diabetes,8 heart disease,10 hypertension,10 dyslipidaemia,10 obstructive sleep apnoea,11 chronic kidney disease,12 non-alcoholic fatty liver disease13 and certain types of cancer.14,15 It is a complex and multifactorial disease that is influenced by physiological, psychological, environmental, socio-economic and genetic factors.16,17,18 The global increase in the prevalence of obesity is a public health issue that has severe cost implications to healthcare systems.19,20 In 2016, 13% of adults, or approximately 650 million adults, were living with obesity worldwide.19 Further information _______________________ References 1.            Wharton S, Liu A, Pakseresht A, et al. Real world clinical effectiveness of liraglutide 3.0 mg for weight management in Canada. Abstract (T4PLB2) presented at the 25th European Congress on Obesity (ECO 2018), Vienna, Austria. 23-26 May 2018. 2.            Wharton S, Liu A, Pakseresht A, et al. Real world clinical effectiveness of liraglutide 3.0 mg for weight management in Canada. Abstract (PSY10) presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR 2018). Baltimore, USA. 19-23 May 2018. 3.            Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373:11-22.4.            Novo Nordisk Canada. Saxenda® (liraglutide 3 mg) Canada Product Monograph. 12 July 2017. Available at: http://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-novonordisk-ca/OurProducts/PDF/Saxenda_PM_English.pdf. Last accessed: May 2018. 5.            EMA. Saxenda® (liraglutide 3 mg) summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003780/WC500185786.pdf. Last accessed: May 2018. 6.            Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. Journal of Medicinal Chemistry. 2000;43:1664-1669.7.            American Medical Association. A.M.A Adopts New Policies on Second Day of Voting at Annual Meeting. Obesity as a Disease. Available at: http://news.cision.com/american-medical-association/r/ama-adopts-new-policies-on-second-day-of-voting-at-annual-meeting,c9430649. Last accessed: May 2018. 8.            Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:1-20.9.            Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083-1096.10.          Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113:898-918.11.          Li C, Ford ES, Zhao G, et al. Prevalence of self-reported clinically diagnosed sleep apnea according to obesity status in men and women: National Health and Nutrition Examination Survey, 2005-2006. Prev Med. 2010;51:18-23.12.          Morandi A, Maffeis C. Urogenital complications of obesity. Best Pract Res Clin Endocrinol Metab. 2013;27:209-218.13.          Angulo P. Nonalchoholic fatty liver disease N Engl J Med. 2009;346:1221-1231.14.          Eheman C, Henley SJ, Ballard-Barbash R, et al. Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012;118:2338-2366.15.          Bhaskaran K, Douglas I, Forbes H, et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet. 2014;384:755-765.16.          Badman MK, Flier JS. The gut and energy balance: visceral allies in the obesity wars. Science. 2005;307:1909-1914.17.          Tanaka T. Genome-wide meta-analysis of observational studies shows common genetic variants associated with macronutrient intake. Am J Clin Nutr. 2013;97:1395-1402.18.          Woods SC. Understanding the physiology of obesity: review of recent developments in obesity research. Int J Obes Relat Metab Disord. 2002;26 Suppl 4:S8-S10.19.          World Health Organization. Obesity and Overweight Factsheet no. 311. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/. Last accessed: May 2018. 20.          Cawley J, Meyerhoefer C, Biener A, et al. Savings in Medical Expenditures Associated with Reductions in Body Mass Index Among US Adults with Obesity, by Diabetes Status. Pharmacoeconomics. 2015;33:707-722.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=585,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
181,2018-05-24,"Nyt real-world-studie viser, at behandling med Saxenda® medfører klinisk betydningsfuldt vægttab","Wien, Østrig, den 24. maj 2018 - Personer i behandling med Saxenda® (liraglutid 3 mg) tabte sig i gennemsnit 8,1 kg efter seks måneders behandling i klinisk praksis i kombination med diæt og motion. Det viser nye forskningsdata, som præsenteres i denne uge både på den 25. årlige europæiske fedmekongres, European Congress on Obesity (ECO 2018), i Wien, Østrig, og det 23. årlige internationale møde i International Society for Pharmacoeconomics and Outcomes Research (ISPOR 2018) i Baltimore, USA.1,2 Studiet var et retrospektivt effektivitetsstudie, der undersøgte virkningen af behandling med Saxenda® hos overvægtige og svært overvægtige personer på seks vægttabsklinikker i Canada. Personer, som blev behandlet med Saxenda® som supplement til diæt og motion, havde efter seks måneder opnået et vægttab på 7,1% i forhold til udgangspunktet ved studiets begyndelse (baseline), idet 63,4% og 35,2% af personerne tabte sig henholdsvis >5% og >10%.1,2 Resultaterne fra dette såkaldte real-world-studie, som blev gennemført i klinisk praksis, var i overensstemmelse med resultaterne fra det kliniske udviklingsprogram SCALE.3 ""Svær overvægt er en kronisk og kompleks sygdom, som kræver flere forskellige behandlingsmuligheder for at hjælpe folk til at opnå og fastholde vægttab,"" siger dr. Sean Wharton fra Wharton Medical Clinic, Toronto, Canada, som er forsøgsansvarlig for studiet. ""Et vægttab på 5-10% kan have store sundhedsmæssige fordele, blandt andet ved at nedsætte patientens risiko for at udvikle hjerte-kar-sygdom og type 2-diabetes. Vi har i dette studie set, at mennesker, der får Saxenda®, rent faktisk opnår et klinisk betydningsfuldt vægttab i den virkelige verden."" Personer, som blev behandlet med Saxenda® i mindst seks måneder, oplevede desuden forbedringer i kardiometaboliske risikofaktorer, herunder blodsukker og systolisk blodtryk.1,2 ""Saxenda® er en vigtig behandlingsmulighed for mennesker med svær overvægt og afspejler vores ambition om at medvirke til at mindske påvirkningen fra denne sygdom og forbedre sundheden for mennesker, der lever med svær overvægt,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Det er positivt, at det nu også er dokumenteret i klinisk praksis, at folk oplever de samme fordele ved Saxenda®, som vi har set i kliniske studier."" Saxenda® var generelt veltolereret, og de hyppigst rapporterede bivirkninger var relateret til mave-tarm-systemet. Studiets formål var at undersøge virkningen af Saxenda® i klinisk praksis i kombination med diæt og motion. Dette retrospektive studie omfattede i alt 311 personer, som havde fået Saxenda® til vægtregulering; heraf fik 167 behandling i mindst seks måneder. Personer, hvis data var inkluderet i studiet, havde et gennemsnitligt BMI på 40,7 kg/m2 og en vægt på 114,8 kg ved studiets begyndelse (baseline).1 Saxenda® (liraglutid 3 mg) er en GLP-1-analog (glukagonlignende peptid-1) til dosering én gang dagligt. Molekylet har 97% lighed med kroppens eget GLP-1,4,5 som er et tarmhormon, der frigives, når man spiser.6 Ligesom naturligt GLP-1 regulerer Saxenda® appetitten ved at øge mæthedsfornemmelsen og dæmpe signaler om sult og spisetrang, hvilket fører til et lavere madindtag. Som med andre GLP-1-receptoragonister stimulerer Saxenda® insulinsekretionen og reducerer glukagonsekretionen på en glukoseafhængig måde.4,5 Saxenda® er undersøgt i det kliniske fase 3a-program SCALE (Satiety and Clinical Adiposity - Liraglutide Evidence). I Canada og EU er Saxenda® godkendt som supplement til en kaloriefattig kost og øget fysisk aktivitet til vægtregulering hos voksne med et BMI på >30 kg/m2 (svært overvægtige), eller >27 kg/m2 til <30 kg/m2 (overvægtige) med mindst én vægtrelateret komplikation som f.eks. dysglykæmi (prædiabetes eller type 2-diabetes), forhøjet blodtryk, dyslipidæmi eller obstruktiv søvnapnø.4 Indlægssedlen indeholder vejledning om, at behandling med Saxenda® bør indstilles efter 12 ugers behandling med 3,0 mg liraglutid dagligt, hvis der ikke er opnået et vægttab på mindst 5% af startvægten.4 Svær overvægt er en sygdom,7 der kræver vedvarende indsats. Den er forbundet med mange alvorlige helbredsmæssige følgevirkninger8 og nedsat forventet levetid.9 Følgesygdomme til svær overvægt er bl.a. type 2-diabetes,8 hjertesygdom,10 forhøjet blodtryk,10 dyslipidæmi,10 obstruktiv søvnapnø,11 kronisk nyresygdom,12 ikke-alkoholisk fedtleversygdom13 og visse former for kræft.14,15 Det er en kompleks sygdom, der er påvirket af flere forskellige forhold, herunder fysiologiske, psykologiske, miljømæssige, socioøkonomiske og genetiske faktorer.16,17,18 Den globale stigning i forekomsten af svær overvægt er en trussel mod folkesundheden med betydelig indvirkning på de offentlige sundhedsudgifter.19,20 I 2016 var 13% af verdens voksne befolkning, eller omkring 650 mio. voksne, svært overvægtige.19 Dette er en oversættelse af den originale engelske pressemeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Referencer 1.             Wharton S, Liu A, Pakseresht A, et al. Real world clinical effectiveness of liraglutide 3.0 mg for weight management in Canada. Abstract (T4PLB2) presented at the 25th European Congress on Obesity (ECO 2018), Vienna, Austria. 23-26 May 2018. 2.            Wharton S, Liu A, Pakseresht A, et al. Real world clinical effectiveness of liraglutide 3.0 mg for weight management in Canada. Abstract (PSY10) presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR 2018). Baltimore, USA. 19-23 May 2018. 3.            Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373:11-22.4.            Novo Nordisk Canada. Saxenda® (liraglutide 3 mg) Canada Product Monograph. 12 July 2017. Available at: http://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-novonordisk-ca/OurProducts/PDF/Saxenda_PM_English.pdf. Last accessed: May 2018. 5.            EMA. Saxenda® (liraglutide 3 mg) summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003780/WC500185786.pdf. Last accessed: May 2018. 6.            Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. Journal of Medicinal Chemistry. 2000;43:1664-1669.7.            American Medical Association. A.M.A Adopts New Policies on Second Day of Voting at Annual Meeting. Obesity as a Disease. Available at: http://news.cision.com/american-medical-association/r/ama-adopts-new-policies-on-second-day-of-voting-at-annual-meeting,c9430649. Last accessed: May 2018. 8.            Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:1-20.9.            Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083-1096.10.          Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113:898-918.11.          Li C, Ford ES, Zhao G, et al. Prevalence of self-reported clinically diagnosed sleep apnea according to obesity status in men and women: National Health and Nutrition Examination Survey, 2005-2006. Prev Med. 2010;51:18-23.12.          Morandi A, Maffeis C. Urogenital complications of obesity. Best Pract Res Clin Endocrinol Metab. 2013;27:209-218.13.          Angulo P. Nonalchoholic fatty liver disease N Engl J Med. 2009;346:1221-1231.14.          Eheman C, Henley SJ, Ballard-Barbash R, et al. Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012;118:2338-2366.15.          Bhaskaran K, Douglas I, Forbes H, et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet. 2014;384:755-765.16.          Badman MK, Flier JS. The gut and energy balance: visceral allies in the obesity wars. Science. 2005;307:1909-1914.17.          Tanaka T. Genome-wide meta-analysis of observational studies shows common genetic variants associated with macronutrient intake. Am J Clin Nutr. 2013;97:1395-1402.18.          Woods SC. Understanding the physiology of obesity: review of recent developments in obesity research. Int J Obes Relat Metab Disord. 2002;26 Suppl 4:S8-S10.19.          World Health Organization. Obesity and Overweight Factsheet no. 311. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/. Last accessed: May 2018. 20.          Cawley J, Meyerhoefer C, Biener A, et al. Savings in Medical Expenditures Associated with Reductions in Body Mass Index Among US Adults with Obesity, by Diabetes Status. Pharmacoeconomics. 2015;33:707-722.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=586,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
182,2018-05-21,NovoEight® maintains potency when stored at 40ºC offering people with haemophilia A increased flexibility in their daily lives,"Glasgow, UK, 21 May 2018 ­- A new long term stability study has shown that haemophilia A treatment NovoEight® (turoctocog alfa) remains potent after three months exposure to temperatures of 40ºC.1 The results were presented today at the WFH 2018 World Congress in Glasgow, UK. Treatment storage issues, especially the need for refrigeration, have been shown to be a common problem reported by people with haemophilia A.2 A portability study recently published in Patient Preference and Adherence found that most people are restricted in their personal activities, particularly travel and sports, due to temperature storage issues.2 If efficacy and safety are unaffected, storage flexibility was shown to be a strong driver of product choice.2 ""Establishing the stability of NovoEight® up to 40°C is part of our commitment to helping people with haemophilia A to reduce the burden that this condition places on their lives,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer, Novo Nordisk. ""The recent data demonstrate the reliable nature of NovoEight® as a portable and convenient treatment option, which could help patients enjoy their daily lives without concern about the storage of their treatment."" The storage conditions for NovoEight® allows for it to be kept at temperatures of up to 40ºC for three months.3 This was a long-term stability study comparing the potency of NovoEight® stored at 5ºC for 30 months to NovoEight® stored at 5ºC for 27 months, then followed by storage at 40°C +2°C/75% relative humidity (RH) +5% RH for three months. The potency of NovoEight® was maintained at high storage temperature and humidity conditions. The effect of repeated temperature changes was tested by storage at 5°C +3°C/ambient humidity/darkness for 24 months, followed by cycling between 5°C and 40°C/75% RH up to 10 times; the product was then stored at 40°C/75% RH for three months (resulting in a total of four months at 40°C), and returned to 5°C to attain 30 months shelf life.1 The potency of NovoEight® was maintained at high storage temperature and humidity conditions. Up to 10 cycles of temperature changes and storage at 40°C did not affect potency.1 About NovoEight®NovoEight® is a B-domain truncated recombinant human coagulation factor VIII for the treatment and prevention of bleeding in patients with haemophilia A.3 About haemophilia AHaemophilia is a chronic, inherited bleeding disorder that primarily affects males. People with haemophilia A are either missing or have a malfunctioning factor VIII protein, which is needed for proper blood clotting. People with haemophilia A have a tendency to bleed longer than most or to bleed internally into joints, muscles or organs because they are missing this clotting factor. To manage the disease and stop bleeding, people with haemophilia A must replace the missing factor VIII protein, which is accomplished by intravenous injection of the clotting factor.4 Globally, it is estimated that 150,000 people have been diagnosed with haemophilia A.5 The disease is severely underdiagnosed in developing countries. Further information _______________________ References 1.       Turoctocog alfa is stable during storage at 40°C and multiple sequences of temperature cycling, poster #52. Presented at the WFH 2018 World Congress, Glasgow, UK, 21 May 2018.2.       Tischer B, Marino R, Napolitano M. Patient preferences in the treatment of hemophilia A: impact of storage conditions on product choice. Patient Preference and Adherence. 2018;12:431-4413.       NovoEight® Summary of Product Characteristics, April 20184.       Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19:e1-475.       World Federation of Hemophilia. Report on the Annual Global Survey 2016. Published October 2017. Available online. Last accessed April 2018.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=589,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
183,2018-05-21,NovoEight® fastholder sin styrke ved opbevaring ved 40 ºC og giver dermed mennesker med hæmofili A større fleksibilitet i hverdagen,"Glasgow, Storbritannien, den 21. maj 2018 ­- Et nyt studie til vurdering af langtidsstabiliteten af NovoEight® (turoctocog alfa) til behandling af hæmofili A har vist, at styrken fastholdes efter tre måneders eksponering for temperaturer på op til 40 ºC.1 Disse resultater præsenteres i dag på World Federation of Haemophilia (WFH) 2018 World Congress i Glasgow i Storbritannien. Udfordringer med opbevaring af faktormedicin, især behovet for opbevaring i køleskab, er et almindeligt problem for mennesker med hæmofili A.2 Et studie publiceret for nylig i Patient Preference and Adherence viste, at de fleste mennesker bliver begrænset i deres personlige udfoldelser, især rejser og sport, på grund af problemer med at opbevare deres medicin ved den korrekte temperatur.2 Studiet viste, at fleksibilitet med hensyn til opbevaring er en væsentlig faktor ved valg af produkt, hvis effekt og sikkerhed i øvrigt er upåvirket.2 ""Det, at vi nu har vist, at NovoEight® er stabilt ved op til 40 °C, er et led i vores indsats for at hjælpe mennesker med hæmofili A med at mindske den belastning, der er forbundet med blødersygdom,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""De seneste forskningsresultater dokumenterer, at NovoEight® er en pålidelig og bekvem behandlingsmulighed, som man nemt kan tage med sig udenfor hjemmet. Det kan gøre livet lettere for patienterne, fordi de ikke behøver at bekymre sig om opbevaringen af deres medicin."" Opbevaringsbetingelserne for NovoEight® giver mulighed for opbevaring ved temperaturer på op til 40 ºC i tre måneder.3 Studiet var tilrettelagt som et langtidsstabilitetsstudie, der sammenlignede styrken af NovoEight® opbevaret ved 5 ºC i 30 måneder sammenholdt med NovoEight® opbevaret ved 5 ºC i 27 måneder, efterfulgt af opbevaring ved 40 °C ±2 °C/75% relativ luftfugtighed (RF) ±5% RF i tre måneder. NovoEight® fastholdt sin styrke ved høj opbevaringstemperatur og luftfugtighed. Effekten af gentagne temperaturændringer blev afprøvet ved opbevaring ved 5 °C ±3 °C/omgivende luftfugtighed/mørke i 24 måneder, efterfulgt af vekslen mellem 5 °C og 40 °C/75% RF op til 10 gange; produktet blev derefter opbevaret ved 40 °C/75% RF i tre måneder (dvs. sammenlagt fire måneder ved 40 °C), og derefter ved 5 °C igen for at opnå 30 måneders lagringstid.1 NovoEight® fastholdt sin styrke ved høj opbevaringstemperatur og luftfugtighed. Op til 10 vekslende perioder med temperaturændringer og opbevaring ved 40 °C påvirkede ikke styrken.1 NovoEight® er en B-domæne-trunkeret rekombinant human koagulationsfaktor VIII, som anvendes til behandling og forebyggelse af blødning hos mennesker med hæmofili A.3 Hæmofili er en kronisk, arvelig blødersygdom, som primært rammer mænd. Mennesker med hæmofili A mangler helt eller delvist koagulationsfaktor VIII, som er et af de proteiner, der normalt findes i blodet og er nødvendige for, at blodet kan størkne. Mennesker med hæmofili A har tendens til at bløde i længere tid end normalt eller til at få indre blødninger i led, muskler eller organer, fordi de mangler denne koagulationsfaktor. For at behandle sygdommen og standse blødninger hos mennesker med hæmofili A er det nødvendigt at tilføre den manglende koagulationsfaktor VIII ved intravenøs injektion, dvs. indsprøjtning i en vene.4 Det skønnes, at der på verdensplan er 150.000 mennesker, der er diagnosticeret med hæmofili A.5 Sygdommen er stærkt underdiagnosticeret i udviklingslandene. Dette er en oversættelse af den originale engelske pressemeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Referencer 1.         Turoctocog alfa is stable during storage at 40°C and multiple sequences of temperature cycling, poster #52. Presented at the WFH 2018 World Congress, Glasgow, UK, 21 May 2018. 2.         Tischer B, Marino R, Napolitano M. Patient preferences in the treatment of hemophilia A: impact of storage conditions on product choice. Patient Preference and Adherence. 2018;12:431-441.3.         NovoEight® Summary of Product Characteristics, April 20184.         Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19:e1-47.5.         World Federation of Hemophilia. Report on the Annual Global Survey 2016. Published October 2017. Available online at: http://www1.wfh.org/publications/files/pdf-1690.pdf. Last accessed April 2018.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=590,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
184,2018-05-16,Novo Nordisk increases commitment to stem cell-based therapies,"Bagsværd, Denmark, 16 May 2018 ­- Novo Nordisk today announced an increased commitment to stem cell-based therapies and an expansion of the focus on type 1 diabetes into other serious chronic diseases. This has been made possible through an exclusive collaboration with the University of California San Francisco (UCSF) in which a first milestone in the development of human embryonic stem cell lines has been reached. Under the terms of the agreement with UCSF, Novo Nordisk has licenced a technology to enable the generation of good manufacturing practice (GMP) compliant human embryonic stem cell (hESC) lines as well as the rights to further develop these into future regenerative medicine therapies. In early May, the partners reached an important milestone with the inauguration of a new GMP laboratory at UCSF where employees from the university and Novo Nordisk will be working together on deriving the cell lines that are expected to define a new quality standard in production of stem cell-based therapies. After two decades of intensive research focusing on the differentiation of pluripotent stem cells into insulin-producing beta cells, Novo Nordisk has now achieved preclinical proof-of-concept. Together with Cornell University, Novo Nordisk has also made significant progress in developing an encapsulation device that will protect the beta cells that are transplanted into patients from attack by the immune system. Novo Nordisk anticipates that the first clinical trial could be initiated within the next few years. ""Finding a cure for diabetes is part of Novo Nordisk's vision and recent progress in our stem cell research and the access to robust and high-quality cell lines raises hopes for people with type 1 diabetes. Our collaboration with UCSF is also expected to accelerate current and future partnerships to develop stem cell-based therapies for treatment of other serious chronic diseases"", said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. Stem cell-based therapy is a rapidly growing field that may produce novel treatments for a number of diseases with high unmet medical needs. The development of GMP grade stem cell lines in collaboration with UCSF has enabled Novo Nordisk to expand the focus on serious chronic diseases beyond diabetes. Through partnerships with the Swedish biotech company Biolamina and Lund University, activities have been initiated to develop stem cell-based treatments for Parkinson's disease. In another partnership with Biolamina and the DUKE National University Singapore Medical School, the research focus is on chronic heart failure and age-related macular degeneration. Novo Nordisk has an ambition to pursue further collaborations to develop stem cell-based therapies for other serious chronic diseases. About stem cellsStem cell-based therapy is emerging as a treatment option for a number of serious chronic diseases. It has the potential to provide novel treatments for diseases with high unmet medical needs where no or inadequate therapies exist. Pluripotent stem cells have an unlimited capacity for self-renewal and the potential to be differentiated into any specialised cell type in the body. The Novo Nordisk stem cell technology platform is based on human embryonic stem cells (hESC) that can be used for generation of cell products for a wide range of therapeutic indications. Visit novonordisk.com for photos supporting this press release. Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=591,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
185,2018-05-16,Novo Nordisk øger fokus på stamcellebaseret behandling,"Bagsværd, den 16. maj 2018 ­- Novo Nordisk øger sit engagement i stamcellebaseret behandling og udvider sit fokus til også at omfatte andre alvorlige kroniske sygdomme end type 1-diabetes. Det er blevet muligt gennem et eksklusivt samarbejde med University of California San Francisco (UCSF), hvor den første milepæl i udviklingen af humane embryonale stamcellelinjer er opnået. Ifølge aftalen med UCSF har Novo Nordisk fået licens på en teknologi, der skal gøre det muligt at fremstille humane embryonale stamcellelinjer (hESC) i overensstemmelse med god fremstillingspraksis (GMP). Novo Nordisk har desuden fået rettighederne til yderligere udvikling af disse cellelinjer til fremtidige regenerative medicinske behandlinger. I begyndelsen af maj nåede parterne en vigtig milepæl med indvielsen af et nyt GMP-laboratorium på UCSF, hvor medarbejdere fra universitetet og Novo Nordisk fremover skal arbejde sammen om at udvinde cellelinjer, der ventes at sætte en ny kvalitetsstandard indenfor fremstilling af stamcellebaseret behandling. Efter to årtiers intens forskning med fokus på differentiering af pluripotente stamceller til insulinproducerende betaceller har Novo Nordisk nu opnået præklinisk bevis for effekt (proof of concept). Sammen med det amerikanske Cornell University har Novo Nordisk desuden gjort store fremskridt med udviklingen af et indkapslingssystem, som kan beskytte de betaceller, der implanteres i patienterne, mod kroppens immunforsvar. Novo Nordisk forventer at sætte det første kliniske studie i gang indenfor de kommende år. ""At finde en kur mod diabetes er en del af Novo Nordisks vision, og vores seneste fremskridt indenfor stamcelleforskning, hvor vi har fået adgang til robuste cellelinjer af høj kvalitet, giver håb for mennesker med type 1-diabetes. Vi forventer også, at vores samarbejde med UCSF vil sætte skub i eksisterende og fremtidige partnerskaber om udvikling af stamcellebaseret behandling rettet mod andre alvorlige sygdomme,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. Stamcellebaseret behandling er et område i hastig udvikling, som kan føre til nyskabende behandling af en række sygdomme med udækkede medicinske behov. Udviklingen af GMP-klassificerede stamcellelinjer i samarbejde med UCSF har gjort det muligt for Novo Nordisk at brede sit fokus ud til også at omfatte andre alvorlige kroniske sygdomme end diabetes. Via partnerskaber med det svenske biotekselskab Biolamina og Lunds Universitet er der blevet iværksat aktiviteter med henblik på at udvikle stamcellebaseret behandling rettet mod Parkinsons sygdom. I et andet samarbejde med Biolamina og DUKE National University Singapore Medical School er forskningen rettet mod kronisk hjertesvigt og aldersbetinget degeneration af nethinden. Det er Novo Nordisks ambition at indgå yderligere samarbejder om udvikling af stamcellebaseret behandling rettet mod andre alvorlige kroniske sygdomme. Stamcellebaseret behandling er i stigende grad i fokus til behandling af en række alvorlige kroniske sygdomme. Det har potentiale til at blive banebrydende for behandlingen af sygdomme med et stort udækket medicinsk behov, hvor der ikke findes behandling, eller hvor behandlingen er mangelfuld. Pluripotente stamceller har ubegrænset evne til selvfornyelse og potentiale til at differentiere sig til en hvilken som helst specialiseret celletype i kroppen. Novo Nordisks stamcelleteknologiplatform er baseret på humane embryonale stamceller, der kan anvendes til at frembringe celleprodukter til en lang række terapeutiske indikationer. Fotos kan downloades på novonordisk.com. Dette er en oversættelse af den originale engelske pressemeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=592,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
186,2018-05-02,Novo Nordisk's operating profit decreased by 8% in Danish kroner and increased by 6% in local currencies in the first three months of 2018,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=607,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
187,2018-05-02,Novo Nordisks resultat af primær drift faldt med 8% opgjort i kroner og steg med 6% i lokale valutaer i de første tre måneder af 2018,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=608,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
188,2018-05-01,Novo Nordisk participates in new research project Hypo-RESOLVE to investigate hypoglycaemia and its impact in diabetes,"The international consortium aims to provide evidence-based classification of hypoglycaemia to achieve better treatments for people living with diabetes Copenhagen, Denmark, 1 May 2018 - Within the newly started European research project Hypo-RESOLVE, 23 leading international players from academia, industry and civil society have joined forces to find better solutions to alleviate the burden and consequences of hypoglycaemia in diabetes. Diabetes is a global epidemic, currently affecting around 60 million people in Europe. Hypoglycaemia is a common and serious complication of diabetes, particularly affecting people with diabetes on insulin therapy; very low levels of blood glucose can lead to cognitive decline, cardiovascular events and even death. As much about hypoglycaemia remains unknown, the recently started European research project Hypo-RESOLVE (Hypoglycaemia - Redefining SOLutions for better liVEs) aims to provide researchers and clinicians with more validated data about the condition by: ""Our mission within Hypo-RESOLVE is to provide an evidence-based classification of hypoglycaemia based on secure data from 100 to 150 recently conducted clinical trials,"" explained Dr Bastiaan de Galan, coordinator of Hypo-RESOLVE and internist at the department of Internal Medicine, Radboud University Medical Center, in the Netherlands. ""With this statistical power, we will be able to make valid statements about the glucose thresholds below which hypoglycaemia constitutes a great risk for people living with diabetes."" Dr Stephen Gough, Global Chief Medical Officer at Novo Nordisk in Denmark and Hypo-RESOLVE project leader added: ""This consortium brings together world leaders from the field of diabetes to reduce the burden of hypoglycaemia. Hypo-RESOLVE paves the way for further research on glucose-lowering interventions that will serve people living with diabetes, clinicians and healthcare companies."" The voices of people living with diabetes will be at the heart of Hypo-RESOLVE, through the establishment of a Patient Advisory Committee. It will ensure that patients' insights, opinions and wishes are taken into account across all the multiple components of the project. ""Hypoglycaemia presents a huge psychological burden for people with diabetes. We believe that the Patient Advisory Committee will help contribute to a better understanding of the disease's impact on people with diabetes and ultimately help improve their lives,"" said Prof Nam H. Cho, President of the International Diabetes Federation (IDF). ""Through this project, we also hope to strengthen public awareness of hypoglycaemia and diabetes generally."" Hypo-RESOLVE is supported with funding of 26.8 million euros from the Innovative Medicines Initiative (IMI), a joint undertaking of the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Juvenile Diabetes Research Foundation (JDRF), and the Leona M. and Harry B. Helmsley Charitable Trust. The project will officially kick off its activities with a first meeting in Denmark on May 16-17 2018. PROJECT FACTS Project acronym: Hypo-RESOLVEStart date: 1 May 2018Duration: 48 monthsBudget: 26.8 million eurosCoordination: Radboud University Medical Center, Dr Bastiaan de GalanProject Lead: Novo Nordisk A/S, Dr Stephen GoughProject Management: Eurice - European Research and Project Office GmbH, Caroline Schorn Hypo-RESOLVE Partners at a glance About IMI The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. IMI facilitates collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). For further information: http://www.imi.europa.eu/ Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=611,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
189,2018-05-01,Novo Nordisk deltager i Hypo-RESOLVE - et nyt forskningsprojekt om hypoglykæmi og diabetes,"Målet for det internationale konsortium er at foretage en evidensbaseret klassificering af hypoglykæmi for at skabe bedre behandling for mennesker med diabetes København, den 1. maj 2018 - Treogtyve førende internationale aktører fra universiteter, erhvervsliv og civilsamfund er gået sammen om et nyt europæisk forskningsprojekt, der har fået navnet Hypo-RESOLVE (Hypoglycaemia - REdefining SOLutions for better liVEs). Målet er at finde bedre løsninger, som kan mindske belastningen og konsekvenserne af hypoglykæmi (lavt blodsukker) i forbindelse med diabetes. Hypo-RESOLVE modtager 26,8 mio. euro i støtte fra Innovative Medicines Initiative (IMI), som er et fællesforetagende iværksat af Europa-Kommissionen og European Federation of Pharmaceutical Industries and Associations (EFPIA), Juvenile Diabetes Research Foundation (JDRF) og Leona M. and Harry B. Helmsley Charitable Trust. Diabetes er en global epidemi, som i dag berører omkring 60 mio. mennesker i Europa. Hypoglykæmi er en almindelig og alvorlig komplikation til diabetes, som især rammer mennesker med diabetes i insulinbehandling. Hypoglykæmi er en tilstand, hvor blodsukkeret er så lavt, at det påvirker hjernens funktion og kan føre til hjerte-kar-tilfælde og i de mest udtalte tilfælde dødsfald. Der er meget, man ikke ved om hypoglykæmi, og formålet med det nystartede europæiske forskningsprojekt er derfor at give forskere og klinikere adgang til flere validerede data om denne tilstand. Det skal ske ved at: ""Vores mål med Hypo-RESOLVE er at foretage en evidensbaseret klassificering af hypoglykæmi baseret på sikre data fra 100 til 150 nyligt gennemførte kliniske forsøg,"" forklarer dr. Bastiaan de Galan, koordinator for Hypo-RESOLVE og specialist i intern medicin ved Radboud university medical center i Holland. ""På dette solide statistiske grundlag vil vi mere præcist kunne definere de nedre grænser for blodsukkeret, hvor hypoglykæmi udgør en stor risiko for mennesker med diabetes."" Dr. Stephen Gough, global medicinsk direktør for Novo Nordisk i Danmark og projektleder for Hypo-RESOLVE, tilføjer: ""Det nye konsortium samler verdens førende aktører på diabetesområdet med det formål at mindske den belastning, som hypoglykæmi medfører. Hypo-RESOLVE baner vejen for yderligere forskning i behandlingstiltag, der kan sænke blodsukkerniveauet til gavn for mennesker med diabetes, klinikere og lægemiddelvirksomheder."" Som et centralt element i Hypo-RESOLVE bliver der etableret et rådgivende patientudvalg. Udvalget skal sikre, at der bliver taget hensyn til patienternes erfaringer, synspunkter og ønsker i alle projektets mange aspekter. ""Hypoglykæmi er en stor psykisk belastning for mennesker med diabetes. Vi mener, at det rådgivende patientudvalg kan hjælpe med til at skabe bedre forståelse for, hvordan hypoglykæmi påvirker mennesker med diabetes, og i sidste ende være med til at forbedre deres livskvalitet,"" siger professor Nam H. Cho, præsident for International Diabetes Federation (IDF). ""Samtidig håber vi med dette projekt at kunne øge offentlighedens kendskab til hypoglykæmi og diabetes generelt."" Projektets aktiviteter skydes officielt i gang ved det første møde, som afholdes i Danmark den 16.-17. maj 2018. FAKTA OM PROJEKTETProjektnavn: Hypo-RESOLVEStartdato: 1. maj 2018Varighed: 48 månederBudget: 26,8 mio. euroKoordinering: Radboud university medical center, dr. Bastiaan de GalanProjektledelse: Novo Nordisk A/S, dr. Stephen GoughProjektstyring: Eurice - European Research and Project Office GmbH, Caroline Schorn Samarbejdspartnerne i Hypo-RESOLVE Om IMIInnovative Medicines Initiative (IMI) er Europas største offentligt-private initiativ, som har til formål at forbedre sundheden ved at fremskynde udviklingen af og patienternes adgang til innovativ medicin, særligt indenfor områder, hvor der er et udækket medicinsk eller socialt behov. IMI fremmer samarbejde mellem nøgleaktører indenfor sundhedsforskning, herunder universiteter, lægemiddelindustrien og andre industrier, små og mellemstore virksomheder, patientorganisationer og lægemiddelmyndigheder. Initiativet er et samarbejde mellem EU (repræsenteret ved Europa-Kommissionen) og den europæiske lægemiddelindustri (repræsenteret ved EFPIA, European Federation of Pharmaceutical Industries and Associations). Yderligere information: http://www.imi.europa.eu/ Dette er en oversættelse af den originale engelske pressemeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=612,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
190,2018-04-30,Novo Nordisk A/S - Total number of voting rights and share capital in Novo Nordisk A/S as of 30 April 2018,"Bagsværd, Denmark, 30 April 2018 - In accordance with Section 10 of the Danish Statutory Order on Issuers' Disclosure Obligations, Novo Nordisk is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred. Referring to Company Announcement no 34/2018 dated 24 April 2018, please find below a statement regarding the total number of voting rights and share capital in Novo Nordisk A/S as per 30 April 2018. Further information Company Announcement no. 35 / 2018",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=613,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
191,2018-04-30,Novo Nordisk A/S - Det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 30. april 2018,"Bagsværd, den 30. april 2018 - I henhold til Bekendtgørelse om udstederes oplysningsforpligtelser, § 10, skal Novo Nordisk offentliggøre det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S ved udgangen af en måned, hvor ændringer deri har fundet sted. Nedenstående opgørelse viser det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 30. april 2018, jævnfør også selskabsmeddelelse nr. 34/2018 dateret 24. april 2018. Yderligere information Selskabsmeddelelse nr. 35 / 2018",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=614,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
192,2018-04-24,Novo Nordisk A/S - Reduction of the share capital,"Bagsværd, Denmark, 24 April 2018 - At Novo Nordisk's Annual General Meeting on 22 March 2018, it was decided to reduce the company's B share capital from DKK 392,512,800 to DKK 382,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each. Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled B shares at a nominal value of DKK 10,000,000. After the reduction of the share capital, the company's share capital is nominally DKK 490,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 382,512,800. The reduction of the share capital will not affect Novo Nordisk's share repurchase programme which will continue as previously announced.  Further information Company announcement No 34 / 2018",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=617,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
193,2018-04-24,Novo Nordisk A/S - Nedsættelse af aktiekapitalen,"Bagsværd, den 24. april 2018 - På den ordinære generalforsamling i Novo Nordisk A/S den 22. marts 2018 blev det besluttet at nedsætte selskabets B-aktiekapital fra nominelt 392.512.800 kr. til 382.512.800 kr. ved annullering af en del af selskabets beholdning af egne B-aktier, i alt nominelt 10.000.000 kr. fordelt på 50.000.000 B-aktier á 0,20 kr. Novo Nordisk har i dag registreret kapitalnedsættelsens gennemførelse hos Erhvervsstyrelsen og annulleret nominelt 10.000.000 kr. B-aktier. Efter kapitalnedsættelsen er selskabets aktiekapital nominelt 490.000.000 kr. fordelt på nominelt 107.487.200 kr. A-aktier og nominelt 382.512.800 kr. B-aktier. Kapitalnedsættelsen påvirker ikke Novo Nordisks aktietilbagekøbsprogram, som fortsætter uændret i henhold til det udmeldte. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 34 / 2018",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=618,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
194,2018-04-18,Red Cross and Novo Nordisk announce ground-breaking partnership to tackle chronic care in humanitarian crises,"Copenhagen, Denmark, 18 April 2018 - The International Committee of the Red Cross (ICRC), the Danish Red Cross (DRC) and Novo Nordisk today announced a partnership to tackle the growing issue of chronic diseases that affect millions of people living in humanitarian crises around the world. The partnership has three building blocks: Today, more than 65 million people are fleeing conflict. Humanitarian and health actors have historically focused their efforts on the acute health threats people face, such as injuries and infectious diseases. Yet, the health needs of people in humanitarian settings, including those who are forcibly displaced and the communities that host them, are far greater. ""Non-communicable diseases are a silent killer and often overlooked during times of armed conflict. All people need access to appropriate health infrastructure and medicines to manage their health. If you look at Yemen, Syria, Iraq and beyond, thousands will remain with life-threatening illnesses if they are not able to receive essential medical supplies such as insulin to treat diabetes"", says Peter Maurer, president of the ICRC. For people living in humanitarian crises, the risk of exacerbating their chronic conditions such as diabetes and hypertension is 2-3 times higher than it was beforehand. It is estimated that diabetes is the cause of one in four limb amputations in patients at ICRC Physical Rehabilitation Centres in Yemen, Syria and Iraq.[i]     The partnership will aspire to break new ground for ultimately meeting the urgent needs of millions of vulnerable people living with NCDs. ""Our three organisations are committed to addressing these unmet health needs through an explorative partnership that combines our respective areas of expertise,"" says Lars Fruergaard Jørgensen, CEO of Novo Nordisk. Anders Ladekarl, secretary general in the Danish Red Cross adds: ""As partner organisations we will use our influence and scale to do more to address the needs of people living with NCDs in humanitarian crisis, and advocate together with other humanitarian and health actors to promote this agenda. This partnership is a first step in realising our collective aspiration that all people with NCDs in humanitarian settings have access to care."" To ensure solid data collection and evidence generation, the partnership will collaborate with the Health in Humanitarian Crises Centre at the London School of Hygiene and Tropical Medicine (LSHTM) with Director Karl Blanchet as the lead academic partner. The ICRC will contribute its expertise of humanitarian operations and response, especially on providing healthcare to vulnerable populations in fragile and violent settings. Together with the DRC, the ICRC will lead the implementation of demonstration projects on the ground, including identifying people in need of treatment for diabetes and hypertension through the existing network of ICRC-supported health facilities. The DRC will contribute its knowledge on community health outreach and capacity building activities in humanitarian settings with a focus on prevention and management of chronic diseases. It will facilitate access to nationwide networks of civil society groups, providing relevant services in their specific local contexts. It will mobilize staff and volunteers, including health professionals, with significant experience in humanitarian operations and response. Novo Nordisk will adapt its ordering and production procedures to better serve the needs of humanitarian organisations as well as share its knowledge on handling and distributing cold chain products. It will share its wide experience of building capacity to widen access to diabetes care, including supporting the development of educational materials on diabetes prevention and care for a humanitarian context. The financial contribution to the partnership amounts to 21.5 million Danish kroner. The role of LSHTM will be to conduct needs assessment, guide the design of interventions and evaluate the interventions to improve NCD prevention and care in humanitarian settings. The ICRC helps people around the world affected by armed conflict and other situations of violence, doing everything possible to protect their dignity and relieve their suffering, often together with its Red Cross and Red Crescent partners. The ICRC also seeks to prevent hardship by promoting and strengthening humanitarian law and universal humanitarian principles. For more info, visit Facebook, Twitter, YouTube, ICRC.org. Danish Red Cross (DRC) supports vulnerable people to live safe and healthy lives in humanitarian and development settings as well as in Denmark. The Danish Red Cross equips people with the tools they need to strengthen their resilience. DRC supports people on both sides of a conflict and in the remotest corners of the world with a special expertise in community-based health services. For more information, visit rodekors.dk, Facebook, Twitter, YouTube. Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,100 people in 79 countries and markets its products in more than 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information References [i] Perone SA, Martinez E, du Mortier S, et al. Non-communicable diseases in humanitarian settings: ten essential questions. Conflict and health. 2017;11(1):17. Halford G. Prevalence of Diabetes in ICRC Supported Physical Rehabilitation Centers for Disease Control Prevention. 2016.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=621,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
195,2018-04-18,Røde Kors og Novo Nordisk indgår nyskabende samarbejde om behandling af kroniske sygdomme under humanitære kriser,"København, den 18. april 2018 - Den Internationale Røde Kors Komité (ICRC), Røde Kors i Danmark (DRC) og Novo Nordisk har i dag indgået et nyt partnerskab. Samarbejdet har til formål at tackle det voksende problem med kroniske sygdomme, der berører millioner af mennesker under humanitære kriser verden over. Partnerskabet bygger på tre elementer: Over 65 mio. mennesker lever i dag på flugt fra konflikter. Humanitære organisationer og sundhedsaktører har traditionelt haft fokus på akutte sundhedsproblemer som fysiske skader og smitsomme sygdomme under humanitære kriser. Men mennesker i sådanne kriser, herunder dem, der er fordrevet med magt, og de lokalsamfund, der huser dem, har et langt større sundhedsbehov. ""Ikke-smitsomme sygdomme er en stille, men ofte overset dræber under krig og konflikt. Alle mennesker har behov for adgang til et velfungerende sundhedssystem og medicin for at sikre et godt helbred. Hvis man ser på lande som Yemen, Syrien og Irak, vil tusinder af mennesker blive efterladt med livstruende sygdomme, hvis de ikke får adgang til livsvigtig medicin som for eksempel insulin til behandling af diabetes,"" siger Peter Maurer, præsident for ICRC. Mennesker med kroniske sygdomme som diabetes og forhøjet blodtryk har 2-3 gange større risiko for at opleve en forværring i deres sundhedstilstand under humanitære kriser. Diabetes skønnes at være årsag til en ud af fire benamputationer hos patienter på ICRC's rehabiliteringscentre i Yemen, Syrien og Irak.[1] Den langsigtede ambition for det nye partnerskab er at finde nye veje til at afhjælpe de særlige sundhedsbehov, som millioner af sårbare mennesker med ikke-smitsomme sygdomme har. ""Vores tre organisationer er gået sammen om at løse disse udækkede sundhedsbehov i et nyskabende samarbejde, der kombinerer vores respektive ekspertområder,"" siger Lars Fruergaard Jørgensen, administrerende direktør for Novo Nordisk. Anders Ladekarl, generalsekretær for Røde Kors i Danmark, tilføjer: ""Vi vil som partnerorganisationer bruge vores indflydelse og størrelse til at styrke indsatsen i forhold til mennesker, der lever med ikke-smitsomme sygdomme under humanitære kriser, og sammen med andre humanitære organisationer og sundhedsaktører arbejde for at fremme denne dagsorden. Dette partnerskab er det første skridt på vejen til at realisere vores fælles drøm om, at alle med ikke-smitsomme sygdomme har adgang til behandling under humanitære kriser."" For at sikre indsamling af solide data og generering af dokumentation vil partnerskabet samarbejde med Health in Humanitarian Crises Centre ved London School of Hygiene and Tropical Medicine (LSHTM) med direktør Karl Blanchet som ledende akademisk partner. ICRC bidrager med sin ekspertise indenfor humanitære operationer og hjælpeaktioner, især med hensyn til at yde lægebehandling til sårbare befolkningsgrupper i voldelige krisesituationer. ICRC vil sammen med Røde Kors i Danmark stå for den praktiske implementering af demonstrationsprojekter. Det omfatter bl.a. identificering af mennesker med behov for behandling af diabetes og forhøjet blodtryk gennem det eksisterende netværk af ICRC-støttede behandlingssteder. Røde Kors i Danmark bidrager med sin viden om opsøgende sundhedsarbejde i lokalsamfundet og kapacitetsopbygning under humanitære kriser med fokus på forebyggelse og behandling af kroniske sygdomme. Organisationen vil bygge bro til nationale civilsamfundsnetværk, som leverer relevante ydelser indenfor deres specifikke lokale rammer. Røde Kors vil mobilisere medarbejdere og frivillige, herunder sundhedsprofessionelle, med stor erfaring med humanitære operationer og hjælpeaktioner. Novo Nordisk vil tilpasse sine produktions- og distributionsprocesser til bedre at dække behovene hos humanitære organisationer samt dele sin viden om håndtering og opbevaring af medicinske produkter i kølekæden. Virksomheden vil dele sin brede erfaring indenfor kapacitetsopbygning for at udvide adgangen til diabetesbehandling, herunder hjælpe med til at udvikle undervisningsmateriale om forebyggelse og behandling af diabetes til brug i humanitære situationer. Det økonomiske bidrag til partnerskabet beløber sig til 21,5 mio. kr. LSHTM's rolle bliver at gennemføre en behovsanalyse, vejlede om design, monitorering og evaluering af udvalgte interventioner for at forbedre forebyggelsen og behandlingen af ikke-smitsomme sygdomme under humanitære kriser. Den Internationale Røde Kors Komité (ICRC) hjælper ofre for væbnede konflikter eller andre voldelige krisesituationer overalt i verden og gør sit yderste for at beskytte deres liv og værdighed, ofte i samarbejde med Røde Kors og Røde Halvmåne. ICRC arbejder desuden for at forebygge menneskelig lidelse ved at fremme og styrke den humanitære folkeret og universelle humanitære principper. Læs mere på Facebook, Twitter, YouTube, ICRC.org. Røde Kors i Danmark hjælper udsatte mennesker til at leve et sikkert og sundt liv, ikke bare i Danmark, men også ude i verden gennem humanitær bistand og udviklingshjælp. Røde Kors ruster mennesker til at klare sig igennem, når de har brug for støtte og omsorg. Røde Kors hjælper mennesker på begge sider af en konflikt og i de fjerneste egne af verden med særlig ekspertise i lokalt forankrede sundhedssystemer. Læs mere på rodekors.dk, Facebook, Twitter, YouTube. Novo Nordisk er en global lægemiddelvirksomhed, som igennem 95 år har stået for innovation og lederskab indenfor diabetesbehandling. Dette langvarige engagement har givet os erfaringer og kompetencer, som i dag gør det muligt også at hjælpe med at bekæmpe fedme, hæmofili, vækstforstyrrelser og andre alvorlige kroniske sygdomme. Koncernen har hovedkvarter i Danmark, beskæftiger omkring 42.100 medarbejdere i 79 lande og markedsfører sine produkter i flere end 170 lande. Læs mere på novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Dette er en oversættelse af den originale engelske pressemeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information [1]                 Perone SA, Martinez E, du Mortier S, et al. Non-communicable diseases in humanitarian settings: ten essential questions. Conflict and health. 2017;11(1):17. Halford G. Prevalence of Diabetes in ICRC Supported Physical Rehabilitation Centers for Disease Control Prevention. 2016.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=622,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
196,2018-04-05,Novo Nordisk obtains exclusive worldwide licence to EpiDestiny's sickle cell disease programme,"Bagsværd, Denmark, 5 April 2018 ­- Novo Nordisk and EpiDestiny today announced that Novo Nordisk has obtained an exclusive worldwide licence to EpiDestiny's sickle cell disease (SCD) programme, EPI01. EpiDestiny is eligible to receive more than 400 million US dollars in upfront, development and sales milestone payments and will get royalties on net sales. EpiDestiny and Novo Nordisk will collaborate to develop EPI01 in SCD and beta-thalassaemia. EpiDestiny retains all rights to continue development of EPI01 in oncology. Increasing levels of foetal haemoglobin (HbF) have important clinical benefits in SCD and beta-thalassaemia patients[1]. Elevated HbF correlated with increased red blood cell half-life, reduced number of pain crises and increased life expectancy1. EPI01 is a novel, orally available, disease-modifying therapy to increase HbF and interrupt SCD pathophysiology. EpiDestiny recently completed a phase 1 trial with EPI01 in SCD patients demonstrating increased HbF expression and safety after eight weeks of administration in a small patient cohort[2]. The clinical observations demonstrated the potential for EPI01 to serve as a safe and highly meaningful disease-modifying therapy for SCD. ""This is a great opportunity for Novo Nordisk to enter into a new therapeutic area closely related to our existing biopharmaceutical business and thereby utilise our core R&D and commercial capabilities to make a significant difference for patients living with a serious chronic disease. We are looking forward to working closely with EpiDestiny and their great network among sickle cell disease experts and the sickle cell community. We are confident that together we can make a significant difference for SCD patients and their families globally,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""We would like to extend our gratitude to all the dedicated patients, physicians and nurses who will participate in the clinical studies of EPI01 in SCD and beta-thalassaemia. Further, the collaboration with Novo Nordisk represents an important step in the continued development of EPI01 for patients with this underserved life-threatening disease. We are looking forward to sharing this programme with Novo Nordisk which has a long history of successfully developing and commercialising products within chronic specialty care across the globe"", said Santhosh Vadivelu, PhD, president and chief executive officer of EpiDestiny. ""The support we receive from Novo Nordisk will allow EpiDestiny to invest and explore the full potential of EPI01 within oncology and to pursue our other pipeline compounds in oncology and other indications."" Sickle cell disease (SCD)[3], is among the most common inherited diseases affecting mostly people of African and Asian origin[4], with an estimated 30 million cases worldwide.  SCD is caused by mutations in the gene for the haemoglobin beta chain that carries oxygen in red blood cells. The resulting sickle haemoglobin molecule forms large fibrils in red blood cells which renders red blood cells rigid and deformed (sickle-shaped). The sickle-shaped red blood cells tends to aggregate and can block small blood vessels, lead to chronic anaemia, decreasing oxygen delivery and damaging multiple tissues and organs. Damage to organs such as the spleen impairs immunity and causes high risk of infections such as pneumonia. Large vessels in the brain can be affected by the rigid red blood cells and anaemia, leading to overt strokes in 10-15% of children and silent strokes in many more. Chronic anaemia also affects the heart and lungs, contributing to a life expectancy which may be reduced by several decades, since there are limited medicines that address the root cause of the disease. Beta-thalassaemia[5] is a related group of red blood cell diseases, also arising in human evolution because of malaria, and also caused by mutations in the gene for the haemoglobin beta chain. Instead of producing a mutated haemoglobin molecule, not enough of the haemoglobin chain is produced, leading to varying degrees of anaemia and decreased oxygen delivery. The most severe cases of beta-thalassaemia, thalassaemia major, require regular blood transfusions. The blood transfusions, although initially life-saving, eventually cause too much iron to accumulate in the body; this affects the heart and eventually causes death. EPI01 is an oral, fixed dose formulation of a DNA methyl-transferase enzyme 1 and cytidine deaminase inhibitor, decitabine and tetrahydrouridine, which has potential to work by increasing the amount of foetal haemoglobin that can substitute the defective haemoglobin in SCD patients, thereby intending to prevent the deformation of the red blood cells and improving the oxygen level in the blood. EpiDestiny has been granted Rare Pediatric Disease, Fast Track and Orphan Designations by the U.S. Food and Drug Administration (FDA) for EPI01. EpiDestiny is a privately held, clinical stage biopharmaceutical company. Our goal is to spearhead a new era of gene control therapies that use small molecules to treat inherited and acquired genetic diseases such as sickle cell disease, beta-thalassaemia and cancer. Our mission is to provide access to disease modifying therapies to patients and transform the way patients are treated worldwide. For more information, visit epidestiny.com, Facebook, Twitter, LinkedIn, YouTube. Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,100 people in 79 countries and markets its products in more than 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information References [1] Platt, O S et al; New Engl J Med. 330, 23 (2017): 1639-1644. [2] PLOS Medicine September 7, 2017 3-28; ttps://doi.org/10.1371/journal.pmed.1002382 [3] Pleasants, S. 2014 Nature 515 S2-S3 [4] Piel, F. et al. Lancet 2013 381 142-151 [5] Review K. M. Musallam, A. T. Taher, and E. A. Rachmilewitz: Cold Spring Harb Perspect Med 2012; 2:a013482",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=627,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
197,2018-04-05,Novo Nordisk køber eksklusive globale rettigheder til EpiDestinys udviklingsprogram indenfor seglcelleanæmi,"Bagsværd, den 5. april 2018 ­- Novo Nordisk og EpiDestiny meddeler i dag, at Novo Nordisk har købt de eksklusive globale rettigheder til EpiDestinys udviklingsprogram EPI01 indenfor seglcelleanæmi (SCD). Novo Nordisk betaler mere end 400 mio. amerikanske dollars i samlede betalinger bestående af milepælsbetalinger relateret til udvikling og salg samt betaling ved underskrift af aftalen; EpiDestiny vil derudover modtage royalties af det fremtidige salg. EpiDestiny og Novo Nordisk vil samarbejde om at udvikle EPI01 til de to indikationer SCD og beta-talassæmi. EpiDestiny beholder alle rettigheder til at fortsætte udviklingen af EPI01 til onkologiske anvendelser. Forøgelse af niveauet af føtalt hæmoglobin (HbF) har vigtige kliniske fordele for patienter med SCD og beta-talassæmi[1]. Forøgede mængder af HbF resulterer i forøget levetid af de røde blodlegemer, færre smertetilfælde og en højere forventet levealder1. EPI01 er en ny oral behandling, der sigter mod at modificere sygdomsbilledet ved at øge dannelsen af HbF og derved mindske SCD-symptomerne. EpiDestiny har for nylig færdiggjort et klinisk fase 1-studie med EPI01 i SCD-patienter. Studiet viste forøget ekspression af HbF samt sikkerhed efter otte ugers dosering i en mindre SCD-patientpopulation[2]. De kliniske observationer viste, at EPI01 har potentiale til at fungere som en sikker og særdeles betydningsfuld sygdomsmodificerende behandling af SCD. ""Dette er en fantastisk mulighed for Novo Nordisk for at etablere sig på et nyt terapeutisk område, der er tæt på vores eksisterende biofarmaceutiske forretning, og for at anvende vores kernekompetencer indenfor forskning, udvikling og markedsføring til at gøre en væsentlig forskel for patienter med en alvorlig kronisk sygdom. Vi ser frem til at arbejde tæt sammen med EpiDestiny, som har et stort netværk blandt eksperter og patientforeninger indenfor SCD. Vi har stor tiltro til, at Novo Nordisk og EpiDestiny sammen kan gøre en væsentlig forskel for SCD-patienter og deres familier verden over,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Aftalen med Novo Nordisk et vigtigt skridt i den fortsatte udvikling af EPI01 til behandling af seglcelleanæmi, som er en livstruende, men desværre overset sygdom. Jeg føler mig overbevist om, at samarbejdet med Novo Nordisk, som har en lang historie bag sig med at udvikle og markedsføre nye produkter til behandling af kroniske sygdomme over hele verden, vil være til gavn for de dedikerede patienter, læger og sygeplejersker, der deltager i vores kliniske studier,"" siger Santhosh Vadivelu, ph.d. og administrerende direktør for EpiDestiny. ""Med midlerne fra Novo Nordisk vil EpiDestiny få mulighed for at investere i og undersøge det fulde potentiale af EPI01 indenfor onkologi samt videreudvikle andre lægemiddelkandidater indenfor onkologi og andre indikationer."" Seglcelleanæmi (SCD)[3] er en af de mest almindelige arvelige sygdomme, som næsten udelukkende forekommer i befolkningsgrupper med afrikanske og asiatiske rødder[4]. Det skønnes, at der er omkring 30 mio. patienter globalt. SCD skyldes mutationer i genet for betakæden i det ilttransporterende hæmoglobinmolekyle. Mutationerne resulterer i dannelsen af store fibriller i de røde blodlegemer, hvilket bevirker, at de røde blodlegemer bliver stive og deforme (antager seglform). Disse deforme blodlegemer klistrer sammen og kan blokere de små blodkar, hvorved der opstår kronisk blodmangel (anæmi) og vævsskader, fordi ilten ikke når ud til de forskellige væv og organer. Skade på organer som milten svækker patientens immunitet og medfører høj risiko for infektioner som lungebetændelse. De store blodkar i hjernen kan blive påvirket af de stive røde blodlegemer og blodmangel. Blandt børn med SCD vil ca. 10-15% få akut slagtilfælde (apopleksi). Endnu flere vil få et eller flere uopdagede apoplektiske tilfælde. Kronisk blodmangel påvirker desuden hjerte og lunger og bidrager til at forkorte livslængden med mellem 25 og 30 år, idet der findes meget begrænsede medicinske behandlinger, der kan reducere årsagen til sygdommen. Beta-talassæmi[5] er en beslægtet gruppe af sygdomme i de røde blodlegemer, som evolutionsmæssigt også antages at hænge sammen med malaria og også forårsages af mutationer i genet for betaglobinkæden. I stedet for at danne et muteret hæmoglobinmolekyle dannes der ikke tilstrækkeligt af hæmoglobinkæden, hvilket fører til forskellige grader af blodmangel og nedsat iltforsyning. I de mest alvorlige tilfælde af beta-talassæmi, thalassaemia major, har patienterne behov for regelmæssige blodtransfusioner. Selvom disse på kort sigt er livsnødvendige, ophobes der på længere sigt for meget jern i kroppen; dette påvirker hjertet, og patienterne risikerer for tidlig død. EPI01 er en oral formulering af to lægemidler, decitabin og tetrahydrouridin, som potentielt kan virke ved at øge mængden af føtalt hæmoglobin. Det føtale hæmoglobin vil kunne erstatte det defekte hæmoglobin hos SCD-patienter, så iltforsyningen til vævet forbedres, samtidig med at de røde blodlegemer i blodet ikke deformeres. EpiDestiny har af de amerikanske sundhedsmyndigheder (FDA) fået tildelt Rare Pediatric Disease, Fast Track og Orphan Drug-status for EPI01. EpiDestiny er et privatejet biofarmaceutisk selskab med produkter i klinisk udvikling. Virksomhedens mål er at tage hul på en ny æra af behandling med oralt tilgængelige terapier, der fokuserer på genetisk kontrol i arvelige og erhvervede sygdomme såsom seglcellesygdom, beta-talassæmi og cancer. Virksomhedens mission er at sikre adgangen til sygdomsforbedrende terapier, der kan gøre en forskel for patienter verden over. Læs mere på epidestiny.com, Facebook, Twitter, LinkedIn, YouTube. Yderligere information Referencer [1]    Platt, O S et al; New Engl J Med. 330, 23 (2017): 1639-1644[2]    PLOS Medicine September 7, 2017 3-28; ttps://doi.org/10.1371/journal.pmed.1002382[3]    Pleasants, S. 2014 Nature 515 S2-S3[4]    Piel, F. et al. Lancet 2013 381 142-151[5]    Review K. M. Musallam, A. T. Taher, and E. A. Rachmilewitz: Cold Spring Harb Perspect Med 2012; 2:a013482",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=628,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
198,2018-03-26,FDA approves inclusion of data on cardiovascular outcomes and severe hypoglycaemia in the Tresiba® label,"Bagsværd, Denmark, 26 March 2018 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an update to the US prescribing information for Tresiba® (insulin degludec) to include data from the DEVOTE trial. The DEVOTE trial included 7,637 adults with type 2 diabetes at high cardiovascular risk and demonstrated non-inferiority of Tresiba® compared to insulin glargine U100 with regards to major adverse cardiovascular events (MACE) with a hazard ratio of 0.91. MACE was defined as first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. As a pre-specified secondary end-point, treatment with Tresiba® resulted in 40% statistically significant lower rate of severe hypoglycaemia compared to insulin glargine U100. The glycaemic control between the two groups was similar at baseline and throughout the trial. The Tresiba® label was updated to reflect safety outcomes from the trial, the cardiovascular safety as well as the severe hypoglycaemia data. Furthermore, supplemental applications were submitted to the FDA in September 2016 for including data from the two SWITCH phase 3b trials in the label for Tresiba®. Following interactions with FDA, Novo Nordisk has withdrawn the applications related to the data from the SWITCH trials. ""It is well known that the fear of severe hypoglycaemia is a barrier to achieving good glycaemic control for many people with diabetes,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""We are therefore very pleased that the FDA has approved the updated label for Tresiba® as the only basal insulin to be labelled with a lower rate of severe hypoglycaemia compared to insulin glargine U100."" The EU label for Tresiba® was updated in 2017 to reflect both the cardiovascular outcomes as well as the severe hypoglycaemia data of this long-acting basal insulin. About DEVOTE DEVOTE is a multinational, double-blinded clinical trial which investigated the cardiovascular safety of Tresiba® compared with insulin glargine U100 over 104 weeks. DEVOTE is the first cardiovascular outcomes trial (CVOT) comparing two basal insulins and enrolled 7,637 people with type 2 diabetes. All participants were inadequately controlled with type 2 diabetes and atherosclerotic cardiovascular disease and were already receiving standard of care to reduce their cardiovascular risk. The trial demonstrated that Tresiba® does not increase cardiovascular risk compared with insulin glargine U100, and provides a significant reduction in the rate of severe hypoglycaemia at similar levels of glycaemic control. About SWITCH 1 and 2 The two phase 3b, 2x32-weeks randomised, double-blind, cross-over, treat-to-target trials were initiated in January 2014 to compare the safety profile and efficacy of Tresiba® and insulin glargine U100. In the trials, adults were treated for a 16-week titration period followed by a 16-week maintenance period and subsequently switched to the comparator drug. The overall objective was to document the hypoglycaemia profile in type 1 diabetes and type 2 diabetes, respectively. In SWITCH 1, 501 people with type 1 diabetes were randomised to cross-over treatment with Tresiba® and insulin glargine U100 in combination with insulin aspart. In SWITCH 2, 721 people with type 2 diabetes were randomised to cross-over treatment with Tresiba® and insulin glargine U100 in combination with oral antidiabetic drugs. About Tresiba® Tresiba® (insulin degludec) is a once-daily basal insulin that provides a duration of action beyond 42 hours with a flat and stable glucose-lowering effect. It provides low variability in blood glucose levels and a lower risk of overall, nocturnal and severe hypoglycaemia vs insulin glargine U100. On occasions when administration at the same time of day is not possible, Tresiba® allows for flexibility in day-to-day dosing time with a minimum of eight hours between injections. Tresiba® received its first regulatory approval in September 2012 and has since been approved in more than 80 countries globally. Tresiba® was approved by the FDA on 26 September 2015 and it is now commercially available in more than 50 countries. Further information Company Announcement No 28 / 2018",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=633,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
199,2018-03-26,FDA godkender opdatering af indlægssedlen for Tresiba® med data for forekomsten af hjerte-kar-sygdom og alvorlig hypoglykæmi,"DEVOTE-studiet omfattede 7.637 voksne med type 2-diabetes med høj risiko for hjerte-kar-sygdom og viste, at Tresiba® var ikke-inferiør sammenlignet med insulin glargin U100 med hensyn til alvorlige hjerte-kar-relaterede hændelser (MACE) med en risikoratio på 0,91. MACE var defineret som den første forekomst af hjerte-kar-relateret dødsfald, ikke-dødeligt myokardieinfarkt (hjerteanfald) eller ikke-dødeligt slagtilfælde. Som et præspecificeret sekundært endepunkt medførte behandling med Tresiba® en 40% statistisk signifikant lavere forekomst af alvorlig hypoglykæmi (lavt blodsukker) sammenlignet med insulin glargin U100. Blodsukkerreguleringen i de to grupper var sammenlignelig ved studiets start og gennem hele studiet. Opdateringen af indlægssedlen for Tresiba® sker med henblik på at afspejle de sikkerhedsrelaterede resultater fra studiet, herunder data for hjerte-kar-sikkerhed og alvorlig hypoglykæmi. Novo Nordisk indsendte desuden supplerende ansøgninger til FDA i september 2016 om opdatering af indlægssedlen for Tresiba® med data fra de to kliniske fase 3b-studier i SWITCH-programmet. Efter dialog med FDA har Novo Nordisk trukket ansøgningerne relateret til data fra SWITCH-studierne tilbage. ""Det er velkendt, at frygten for alvorlig hypoglykæmi hos mange mennesker med diabetes er en barriere for at opnå en god blodsukkerregulering,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Vi er derfor meget tilfredse med, at FDA har godkendt den opdaterede indlægsseddel for Tresiba® som den eneste basalinsulin, hvor det fremgår af indlægssedlen, at det giver en lavere forekomst af alvorlig hypoglykæmi sammenlignet med insulin glargin U100."" I EU blev indlægssedlen for Tresiba® opdateret i 2017, så den afspejler data for såvel hjerte-kar-sygdom som for alvorlig hypoglykæmi for denne langtidsvirkende basalinsulin. DEVOTE er et multinationalt, dobbeltblindet klinisk studie, som har undersøgt den kardiovaskulære sikkerhed for Tresiba® sammenlignet med insulin glargin U100 i 104 uger. DEVOTE er det første kardiovaskulære sikkerhedsstudie, der har sammenlignet to basalinsuliner, og omfattede 7.637 mennesker med type 2-diabetes. Alle deltagere var utilstrækkeligt reguleret med type 2-diabetes og åreforkalkningsbetinget hjerte-kar-sygdom og fik i forvejen standardbehandling for at reducere risikoen for hjerte-kar-hændelser. Studiet viste, at Tresiba® ikke øger hjerte-kar-risikoen sammenlignet med insulin glargin U100, og at det medfører en signifikant reduktion i forekomsten af alvorlig hypoglykæmi ved sammenlignelige niveauer af glykæmisk kontrol. De to 2x32-ugers randomiserede, dobbeltblindede, crossover-, treat to target- fase 3b-studier blev påbegyndt i januar 2014 med det formål at sammenligne sikkerhedsprofilen og virkningen af Tresiba® og insulin glargin U100. I studierne blev voksne deltagere behandlet i en 16-ugers titreringsperiode efterfulgt af en 16-ugers vedligeholdelsesperiode, hvorefter de skiftede til den sammenlignende behandling. Det overordnede formål var at dokumentere hypoglykæmiprofilen i henholdsvis type 1- og type 2-diabetes. I SWITCH 1 blev 501 deltagere med type 1-diabetes randomiseret til crossover-behandling med Tresiba® og insulin glargin U100 i kombination med insulin aspart. I SWITCH 2 blev 721 deltagere med type 2-diabetes randomiseret til crossover-behandling med Tresiba® og insulin glargin U100 i kombination med diabeteslægemidler i tabletform. Tresiba® (insulin degludec) er en basalinsulin til dosering én gang dagligt med en virkningsvarighed på mere end 42 timer med en flad og stabil blodsukkersænkende effekt. Tresiba® medfører en lav variation i blodsukkeret og en lavere risiko for generel, natlig og alvorlig hypoglykæmi sammenlignet med insulin glargin U100. I situationer, hvor det ikke er muligt at tage insulin på det samme tidspunkt hver dag, giver Tresiba® mulighed for fleksibilitet med hensyn til injektionstidspunktet fra dag til dag, men med mindst otte timer mellem doserne. Tresiba® blev godkendt af registreringsmyndighederne første gang i september 2012 og er siden blevet godkendt i flere end 80 lande verden over. Tresiba® blev godkendt af FDA den 26. september 2015 og er nu på markedet i flere end 50 lande. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 28 / 2018",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=634,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
200,2018-03-23,Ozempic® approved in Japan for the treatment of type 2 diabetes,"Bagsværd, Denmark, 23 March 2018 - Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Ozempic® (semaglutide), a new once-weekly analogue of human glucagon-like peptide-1 (GLP-1), for the treatment of adults with type 2 diabetes. The approval of Ozempic® in Japan is based on results from the SUSTAIN clinical trial programme, which involved more than 8,000 adults with type 2 diabetes. The approval is based on the results from five SUSTAIN trials, including approximately 1,200 adults from Japan. The approved label reflects that treatment with Ozempic® resulted in greater reductions in HbA1c relative to comparator treatments, as well as greater reductions in mean body weight achieved with Ozempic® in Japanese people compared to placebo in the two SUSTAIN monotherapy trials. ""We are very excited about the approval of Ozempic® in Japan, providing millions of people living with type 2 diabetes with a new and efficacious treatment option to help manage this complex disease,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer. Novo Nordisk expects to launch Ozempic® in Japan in the coming months, when reimbursement has been obtained. About Ozempic® Ozempic® (semaglutide) is a new once-weekly analogue of human glucagon-like peptide-1 (GLP-1) that has been developed for the treatment of type 2 diabetes. The approval of Ozempic® is based on the SUSTAIN programme, a global clinical development programme that comprises six global and two Japanese phase 3a trials, encompassing more than 8,000 adults with type 2 diabetes. Ozempic® was approved by the US FDA on 5 December 2017, by Health Canada on 4 January 2018 and by the European Commission on 9 February 2018. Further information Company announcement No 26 / 2018 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=637,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
201,2018-03-23,Ozempic® godkendt i Japan til behandling af type 2-diabetes,"Bagsværd, den 23. marts 2018 - Novo Nordisk meddeler i dag, at det japanske sundhedsministerium, Ministry of Health, Labour and Welfare, har godkendt Ozempic® (semaglutid), en ny, ugentlig analog af det naturlige hormon glukagonlignende peptid-1 (GLP-1), til behandling af voksne med type 2-diabetes. Godkendelsen af Ozempic® i Japan er baseret på resultater fra det kliniske udviklingsprogram SUSTAIN, som omfattede flere end 8.000 voksne deltagere med type 2-diabetes. Godkendelsen er baseret på data fra fem af SUSTAIN-studierne, som omfattede ca. 1.200 voksne japanske deltagere. Den godkendte indlægsseddel afspejler, at behandling med Ozempic® medførte større reduktioner i langtidsblodsukkerniveauet (HbA1c) end sammenlignende behandlinger, samt at der blev opnået større reduktioner i gennemsnitsvægten med Ozempic® hos japanske deltagere sammenlignet med placebo i de to monoterapistudier i SUSTAIN-programmet. ""Vi er meget tilfredse med godkendelsen af Ozempic® i Japan. Det vil give millioner af mennesker med type 2-diabetes en ny og virkningsfuld behandlingsmulighed, som kan hjælpe dem med at regulere denne komplekse sygdom,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. Novo Nordisk forventer at lancere Ozempic® i Japan i løbet af de kommende måneder, når der er opnået tilskud. Ozempic® (semaglutid) er en ny, ugentlig analog af det naturlige hormon glukagonlignende peptid-1 (GLP-1), som er udviklet til behandling af type 2-diabetes. Godkendelsen af Ozempic® er baseret på SUSTAIN-programmet, et globalt klinisk udviklingsprogram, som omfattede seks globale og to japanske fase 3a-studier med en samlet deltagelse af flere end 8.000 voksne med type 2-diabetes. Ozempic® blev godkendt af de amerikanske sundhedsmyndigheder, FDA, den 5. december 2017, de canadiske sundhedsmyndigheder, Health Canada, den 4. januar 2018 og af Europa-Kommissionen den 9. februar 2018. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 26 / 2018",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=638,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
202,2018-03-22,Resolutions from the Annual General Meeting of Novo Nordisk A/S,"Bagsværd, Denmark, 22 March 2018 - Today, Novo Nordisk A/S held its Annual General Meeting, at which the following were adopted: Financial year 2017 and 2018 Elections Shares and capital Other Composition of the Board of Directors and its committees In February 2018, Novo Nordisk employees in Denmark elected four board members for a period of four years: Mette Bøjer Jensen, Anne Marie Kverneland, Thomas Rantzau and Stig Strøbæk. After the Annual General Meeting, the Board of Directors held a board meeting to appoint members of its committees. The Board of Directors, including its committees, are now composed as follows: Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,100 people in 79 countries and markets its products in more than 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Company Announcement No 25 / 2018",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=639,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
203,2018-03-22,Beslutninger på den ordinære generalforsamling i Novo Nordisk A/S,"Bagsværd, den 22. marts 2018 - Novo Nordisk A/S har i dag afholdt ordinær generalforsamling, hvor følgende blev godkendt: Regnskabsåret 2017 samt 2018 Valg Aktier og kapital Sammensætning af bestyrelsen og dens udvalgVed medarbejdervalget til bestyrelsen i februar 2018 valgte Novo Nordisks medarbejdere i Danmark fire bestyrelsesmedlemmer for en fireårig periode: Mette Bøjer Jensen, Anne Marie Kverneland, Thomas Rantzau og Stig Strøbæk. På et bestyrelsesmøde afholdt efter generalforsamlingen valgte bestyrelsen medlemmer til bestyrelsens udvalg. Bestyrelsen og dens udvalg er herefter sammensat som følger:  Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 25 / 2018",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=640,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
204,2018-02-27,Novo Nordisk files for regulatory approval of long-acting factor VIII (N8-GP) in the US and the EU for treatment of haemophilia A,"Bagsværd, Denmark, 27 February 2018 - Novo Nordisk today announced the submission of a Biologics License Applications (BLA) to the US Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for N8-GP, an extended half-life factor VIII for treatment of people with haemophilia A. The submission is based on results from the pathfinder clinical trial programme. The pathfinder programme included more than 250 people with haemophilia A and investigated efficacy and safety of N8-GP in adults and children as well as people undergoing surgery. In the trial, adults treated prophylactically with N8-GP every fourth day experienced a median annualised bleeding rate of 1.3 episodes compared to 30.9 episodes for people treated on-demand. Paediatric participants experienced a median annualised bleeding rate of 1.95 episodes when administered twice weekly. In the surgery trial, all surgeries were effectively performed with N8-GP, and clinical efficacy evaluated by haemostatic response was reported as 'excellent' or 'good' in 43 out of the 45 performed surgeries. Across the pathfinder clinical trial programme, N8-GP demonstrated a safe and well-tolerated profile. ""We are excited to file the regulatory application for long-acting N8-GP in the US and EU,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""Based on the results from the global pathfinder clinical trial programme, we believe N8-GP can reduce the burden of treatment by decreasing the number of intravenous infusions while achieving the benefits in terms of efficacy and safety for people with haemophilia A."" About N8-GP N8-GP (turoctocog alfa pegol) is a glycopegylated form of turoctocog alfa designed for prolonged half-life. The site specific glycopegylation is within the truncated B-domain. N8-GP is a B-domain modified form of turoctocog alfa and hence the active factor VIII generated by thrombin activation is identical to both activated endogenous FVIII and turoctocog alfa. About the pathfinder phase 3a clinical trial programmeThe pathfinder programme included more than 250 people with haemophilia A and investigated safety and efficacy of N8-GP, treatment of bleeds, prophylaxis and surgery, in adults as well as children. Pathfinder 2 was a global trial evaluating safety and efficacy of N8-GP, when administered for prophylaxis and on-demand treatment in people with haemophilia A, who are 12 years or older. 175 people were treated with a prophylactic regimen of 50 IU/kg every fourth day, and 12 people received on-demand treatment. People were treated for up to 21 months, resulting in median annualised bleeding rates of 1.3 and 30.9 episodes for people treated prophylactically and on-demand, respectively. The pharmacokinetic data documented a single dose half-life of 18.4 hours and a mean trough level of 4% measured immediately before next dose for people on prophylaxis treatment. Pathfinder 3 was a surgery trial which was performed as an open-label, multi-national trial evaluating the efficacy and safety of N8-GP when administered for perioperative management in previously treated patients with severe haemophilia A who were 12 years or older. The trial included 33 people who underwent 45 major surgeries. People received a single preoperative dose of N8-GP, at a median of 51 IU/kg. All surgeries were effectively performed with N8-GP, and clinical efficacy evaluated by haemostatic response was reported as 'excellent' or 'good' in 43 out of the 45 performed surgeries. N8-GP appeared to have a safe and well-tolerated profile. Pathfinder 5 was a paediatric trial which was performed as a global trial evaluating safety and efficacy for N8-GP, when administered for prophylaxis in previously treated children with haemophilia A, who were between 0 to 11 years old. In the trial, 34 children 0-5 years of age and 34 children 6-11 years of age received prophylactic treatment and treatment of bleeding episodes. All children were treated with a regimen of 50-75 IU/kg twice weekly for 26 weeks. Median annualised bleeding rates of 1.95 episodes were obtained in the trial. N8-GP appeared to have a safe and well-tolerated profile. Further information Company announcement No 21 / 2018",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=647,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
205,2018-02-27,Novo Nordisk indsender registreringsansøgning for langtidsvirkende faktor VIII (N8-GP) i USA og EU til behandling af hæmofili A,"Bagsværd, den 27. februar 2018 - Novo Nordisk meddeler i dag, at virksomheden har indsendt registreringsansøgning til de amerikanske sundhedsmyndigheder (FDA) og Det Europæiske Lægemiddelagentur (EMA) for N8-GP, et faktor VIII-præparat med forlænget halveringstid til behandling af mennesker med hæmofili A. Ansøgningerne er baseret på resultaterne fra det kliniske udviklingsprogram pathfinder. Programmet omfattede flere end 250 mennesker med hæmofili A og undersøgte effekt og sikkerhed af N8-GP hos voksne og børn samt i forbindelse med kirurgiske indgreb. I studiet var medianværdien for den årlige blødningsfrekvens hos voksne, der fik forebyggende behandling med N8-GP hver fjerde dag, 1,3 episoder mod 30,9 episoder hos deltagere, der fik akut behandling. Hos børn var medianværdien for den årlige blødningsfrekvens på 1,95 episoder, når N8-GP blev givet to gange om ugen. I kirurgistudiet blev alle operationer gennemført effektivt med N8-GP, og den kliniske effekt vurderet på basis af hæmostatisk respons blev rapporteret som 'excellent' eller 'god' i 43 af de 45 gennemførte operationer. I alle de kliniske studier i pathfinder-programmet viste N8-GP en sikker og veltolereret profil. ""Vi glæder os over indsendelsen af registreringsansøgningen for langtidsvirkende N8-GP i USA og EU,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Vi er på baggrund af resultaterne fra det globale kliniske pathfinder-program overbevist om, at N8-GP kan reducere behandlingsbyrden for mennesker med hæmofili A ved at reducere antallet af intravenøse infusioner, samtidig med at de opnår fordelene i form af effekt og sikkerhed."" N8-GP (turoctocog alfa pegol) er en glykopegyleret udgave af turoctocog alfa, som er designet med henblik på forlængelse af halveringstiden. Den site-specifikke glykopegylering er placeret i det trunkerede B-domæne. N8-GP er en B-domæne-modificeret udgave af turoctocog alfa, hvorved den aktive faktor VIII, som genereres ved aktivering af trombin, er identisk både med aktiveret endogen faktor VIII og turoctocog alfa. Pathfinder-programmet omfattede flere end 250 mennesker med hæmofili A og undersøgte sikkerhed og effekt af N8-GP til behandling af blødninger, forebyggende behandling og behandling i forbindelse med operationer hos voksne og børn. Pathfinder 2 var et globalt studie til vurdering af sikkerhed og effekt af N8-GP anvendt til forebyggelse og akut behandling af blødninger hos mennesker med hæmofili A i alderen 12 år og derover. 175 deltagere fik forebyggende behandling baseret på 50 IU/kg hver fjerde dag, og 12 deltagere fik akut behandling. Deltagerne blev behandlet i op til 21 måneder, hvilket resulterede i en medianværdi for den årlige blødningsfrekvens på henholdsvis 1,3 og 30,9 episoder for deltagere behandlet forebyggende og akut. De farmakokinetiske data dokumenterede en halveringstid for en enkelt dosis på 18,4 timer og et gennemsnitligt faktorniveau (trough level) umiddelbart før næste dosering på 4% for deltagere på forebyggende behandling. Pathfinder 3 var et kirurgistudie, der blev gennemført som et ikke-blindet multinationalt studie til vurdering af effekt og sikkerhed af N8-GP anvendt som perioperativ behandling hos tidligere behandlede patienter med svær hæmofili A i alderen 12 år og derover. Studiet omfattede 33 deltagere, som gennemgik 45 større operationer. Deltagerne modtog en enkelt dosis N8-GP før operationen, baseret på en median på 51 IU/kg. Alle operationer blev gennemført effektivt med N8-GP, og klinisk effekt vurderet på basis af den hæmostatiske respons blev rapporteret som 'excellent' eller 'god' ved 43 af de 45 gennemførte operationer. N8-GP forekom at have en sikker og veltolereret profil. Pathfinder 5 var et pædiatristudie, der blev gennemført som et globalt studie til vurdering af sikkerhed og effekt af N8-GP anvendt til forebyggelse hos tidligere behandlede børn med hæmofili A i alderen 0 til 11 år. I studiet fik 34 børn i alderen 0-5 år og 34 børn i alderen 6-11 år forebyggende behandling og behandling af blødningsepisoder. Alle børn blev behandlet med 50-75 IU/kg givet to gange om ugen i 26 uger. Medianværdien for den årlige blødningsfrekvens i studiet var 1,95 episoder. N8-GP forekom at have en sikker og veltolereret profil. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 21 / 2018",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=648,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
206,2018-02-26,Novo Nordisk A/S: Election of employee representatives to the Board of Directors of Novo Nordisk A/,"Bagsværd, 26 February 2018 - The employees of Novo Nordisk A/S have conducted the election of employee representatives to the Board of Directors of Novo Nordisk A/S. The following members were elected for the next four years: As substitutes to the employee representatives to the Board of Directors of Novo Nordisk A/S, the employees elected Anders Kaae, Karina Bonde Lenau, Jesper Thorning and Tanja Villumsen. The new employee representatives will join the Board of Directors following the annual general meeting of Novo Nordisk A/S, 22 March 2018. At the same event, the former employee representatives, Liselotte Hyveled and Søren Thuesen Pedersen will withdraw from the Board of Directors. According to the Danish Companies Act, the employees in companies, which have for the last three years employed at least 35 employees on average, have a right to elect a number of members to the board of directors. The employee-elected board members shall represent a number that corresponds to at least half of the board members elected by the annual general meeting. Furthermore, substitutes corresponding to the number of employee-elected board members must be elected. The employee-elected board members act on the same terms as the board members elected by the annual general meeting, but are elected for a four-year period. Further information Company announcement no. 20",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=649,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
207,2018-02-26,Novo Nordisk A/S: Valg af medarbejderrepræsentanter til bestyrelsen i Novo Nordisk A/S,"Bagsværd, den 26. februar 2018 - Medarbejderne i Novo Nordisk A/S har afsluttet valg af medarbejderrepræsentanter til bestyrelsen i Novo Nordisk A/S. Følgende medlemmer blev valgt for de næste fire år: Som suppleanter for de medarbejdervalgte bestyrelsesmedlemmer i Novo Nordisk A/S valgte medarbejderne Anders Kaae, Karina Bonde Lenau, Jesper Thorning and Tanja Villumsen. De nye medarbejderrepræsentanter indtræder i bestyrelsen efter den ordinære generalforsamling i Novo Nordisk A/S den 22. marts 2018. Ved samme lejlighed udtræder de tidligere medarbejderrepræsentanter Liselotte Hyveled og Søren Thuesen Pedersen af bestyrelsen. I henhold til dansk selskabslovgivning har medarbejderne i selskaber, der i de sidste tre år har beskæftiget gennemsnitligt mindst 35 medarbejdere, ret til at vælge et antal medlemmer til selskabets bestyrelse. De medarbejdervalgte bestyrelsesmedlemmer skal repræsentere, hvad der svarer til halvdelen af de generalforsamlingsvalgte bestyrelsesmedlemmer. Der vælges desuden suppleanter svarende til antallet af medarbejdervalgte bestyrelsesmedlemmer. De medarbejdervalgte bestyrelsesmedlemmer fungerer på samme vilkår som de øvrige bestyrelsesmedlemmer, men er i henhold til selskabslovgivningen valgt for fire år ad gangen. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse Nr 20",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=650,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
208,2018-02-23,Notice for the Annual General Meeting of Novo Nordisk A/S,"Bagsværd, Denmark, 23 February 2018 - The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 22 March 2018 at 2.00 pm (CET) at Royal Arena, entrance G, Hannemanns Allé 20, 2300 Copenhagen S, Denmark. The notice for the Annual General Meeting, including Appendix 1: Candidates for the Board of Directors and Appendix 2: Revised Remuneration Principles is enclosed. BOARD OF DIRECTORS - PROPOSED CHANGES IN COMPOSITION All board members elected by the Annual General Meeting are up for election. Chairman of the Board of Directors Göran Ando has decided not to seek re-election at the Annual General Meeting in March 2018. The Board of Directors proposes current member of the Board of Directors Helge Lund to be elected as chairman of the Board of Directors. The Board of Directors recommends election of Helge Lund as chairman of the Board primarily due to his extensive experience within management of global companies. Helge Lund is also assessed to have the personal qualifications required to be chairman. The Board of Directors proposes re-election of the following board members elected by the Annual General Meeting: Jeppe Christiansen (vice chairman), Brian Daniels, Sylvie Grégoire, Liz Hewitt and Kasim Kutay. The Board of Directors proposes election of Andreas Fibig and Martin Mackay as new members of the Board of Directors at the Annual General Meeting. Mr Fibig is chairman of the board and chief executive officer of International Flavors & Fragrances, Inc., US, and has previously held a number of management positions with other pharmaceutical companies. The Board of Directors recommends election of Mr Fibig primarily because of his extensive global experience within biopharmaceutical companies, in-depth knowledge of strategy, sales and marketing and knowledge about how large international companies operate. Mr Mackay is former executive vice president and global head of Research and Development at Alexion Pharmaceuticals, Inc., US, and has also been head of Research & Development in both AstraZeneca plc. and Pfizer, Inc. The Board of Directors recommends election of Mr Mackay primarily because of his background as a R&D executive with extensive experience in building a pipeline, acquiring products and managing the portfolio of early-stage and late-stage projects in large international pharmaceutical companies.  Further information Company announcement No 18 / 2018",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=653,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
209,2018-02-23,Indkaldelse til ordinær generalforsamling i Novo Nordisk A/S,"Bagsværd, den 23. februar 2018 - Den ordinære generalforsamling i Novo Nordisk A/S afholdes: torsdag den 22. marts 2018 kl. 14.00 i Royal Arena, indgang G, Hannemanns Allé 20, 2300 København S. Indkaldelse til generalforsamlingen, inklusive appendiks 1: Bestyrelseskandidater og appendiks 2: Reviderede aflønningsprincipper, er vedlagt. Alle selskabets generalforsamlingsvalgte bestyrelsesmedlemmer er på valg. Formanden for bestyrelsen, Göran Ando, har besluttet, at han ikke genopstiller ved generalforsamlingen i marts 2018. Bestyrelsen foreslår, at det nuværende bestyrelsesmedlem Helge Lund vælges som formand for bestyrelsen. Bestyrelsen foreslår valg af Helge Lund som formand for bestyrelsen, først og fremmest på grund af hans omfattende erfaring indenfor ledelse af globale virksomheder. Helge Lund anses desuden for at have de personlige kvalifikationer, der skal til for at være formand for bestyrelsen. Bestyrelsen foreslår genvalg af følgende generalforsamlingsvalgte bestyrelsesmedlemmer: Jeppe Christiansen (næstformand), Brian Daniels, Sylvie Grégoire, Liz Hewitt og Kasim Kutay. Bestyrelsen foreslår, at Andreas Fibig og Martin Mackay vælges som nye bestyrelsesmedlemmer på generalforsamlingen. Andreas Fibig er bestyrelsesformand og administrerende direktør i International Flavors & Fragrances, Inc., USA, og har tidligere besiddet en række ledende stillinger hos andre farmaceutiske virksomheder. Bestyrelsen foreslår valg af Andreas Fibig på grund af hans omfattende globale erfaring fra biofarmaceutiske virksomheder, indgående viden om strategi, salg og marketing samt indsigt i, hvordan store internationale virksomheder arbejder. Martin Mackay er tidligere koncerndirektør og globalt ansvarlig for forskning og udvikling i Alexion Phar­maceuticals, Inc., USA, og har ligeledes været leder af forskning og udvikling i både AstraZeneca plc. og Pfizer, Inc. Bestyrelsen foreslår valg af Martin Mackay på grund af hans ledelsesbaggrund indenfor forskning og udvikling og omfattende erfaring med opbygning af pipeline, opkøb af produkter og styring af porteføljen af projekter i den tidlige og sene fase i store internationale lægemiddelvirksomheder. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 18 / 2018",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=654,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
210,2018-02-22,"Novo Nordisk successfully completes the first phase 3a trial, PIONEER 1, with oral semaglutide","Bagsværd, Denmark, 22 February 2018 - Novo Nordisk today announced the headline results from PIONEER 1, the first phase 3a trial with oral semaglutide for treatment of adults with type 2 diabetes. Oral semaglutide is a new GLP-1 analogue taken once daily as a tablet. The global 26-week trial investigated the efficacy and safety of 3, 7 and 14 mg oral semaglutide compared with placebo in 703 people with type 2 diabetes. Two distinct approaches to evaluating the effect of oral semaglutide were applied in the PIONEER 1 trial; a primary statistical principle[1] required by recent regulatory guidelines evaluating the effect regardless of treatment adherence and a secondary statistical principle[2] describing the effect if people had adhered to treatment and did not initiate rescue medication. The trial achieved its primary objective according to the primary statistical principle by demonstrating significant and superior improvements in HbA1c (long-term blood sugar) for all three doses of oral semaglutide compared to placebo. Moreover, the 14 mg dose of oral semaglutide demonstrated significant and superior weight loss versus placebo, weight loss was observed for the 7 mg and 3 mg doses but did not reach statistical significance. Applying the secondary statistical principle, people treated with 3, 7 and 14 mg oral semaglutide achieved reductions in HbA1c of 0.8%, 1.3% and 1.5%, respectively, compared to a reduction of 0.1% in people treated with placebo from a mean baseline of 8.0%. The American Diabetes Association (ADA) treatment target of HbA1c below 7.0% was achieved by 59%, 72% and 80% of people on treatment with 3, 7 and 14 mg oral semaglutide, respectively, compared to 34% of the people treated with placebo. In addition, from a mean baseline body weight of 88 kg and a BMI of 31.8 kg/m2, people treated with 3, 7 and 14 mg oral semaglutide experienced a weight loss of 1.7 kg, 2.5 kg and 4.1 kg, respectively, compared to a weight loss of 1.5 kg in people treated with placebo. In the trial, oral semaglutide appeared to have a safe and well-tolerated clinical profile. The most common adverse event for all three oral semaglutide doses was mild to moderate nausea, which diminished over time. Between 5% and 16% of people treated with oral semaglutide experienced nausea, compared to 6% of people treated with placebo. Premature treatment discontinuation due to adverse events ranged from 2% to 7% for people treated with oral semaglutide, compared to 2% for people treated with placebo. ""We are very encouraged by the results of the PIONEER 1 trial, which confirm the unprecedented oral efficacy of semaglutide that was reported in the phase 2 clinical trial in type 2 diabetes,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""We look forward to providing data from the remaining nine PIONEER trials throughout this year and an expected regulatory submission in 2019."" About PIONEER 1 and the PIONEER clinical programmePIONEER 1 was a 26-week, randomised, double-blinded, placebo-controlled, four-armed, parallel-group, multicentre, multinational trial comparing the efficacy and safety of three dose levels of once-daily oral semaglutide vs placebo in people with type 2 diabetes treated with diet and exercise only. 703 people were enrolled in PIONEER 1 and randomised 1:1:1:1 to receive either a dose of oral semaglutide (3, 7 or 14 mg) or placebo once daily. The primary endpoint was change in HbA1c from baseline at week 26. The PIONEER phase 3a clinical development programme for oral semaglutide is a global development programme with an expected enrolment of more than 9,000 people with type 2 diabetes across 10 clinical trials, which all are expected to complete in 2018. Further information [1] Treatment policy estimand approach: treatment effect regardless of treatment adherence or initiation of rescue medication (analysed by Pattern mixture model using multiple imputations to handle missing week 26 data). [2] Hypothetical estimand approach: treatment effect if all people adhered to treatment and did not initiate rescue medication (analysed by Mixed Models for Repeated Measurements (MMRM)). Similar statistical methodology as applied in the SUSTAIN programme for subcutaneous semaglutide.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=655,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
211,2018-02-22,"Novo Nordisk: Første fase 3a-studie med oral semaglutid, PIONEER 1, afsluttet med succes","Bagsværd, den 22. februar 2018 - Novo Nordisk offentliggør i dag de overordnede resultater fra PIONEER 1, det første fase 3a-studie med oral semaglutid til behandling af voksne med type 2-diabetes. Oral semaglutid er en ny GLP-1-analog, der tages én gang dagligt som en tablet. Det globale 26-ugers studie undersøgte effekten og sikkerheden af doser af oral semaglutid på 3, 7 og 14 mg sammenlignet med placebo i 703 deltagere med type 2-diabetes. Der er i PIONEER 1-studiet anvendt to forskellige metoder til vurdering af effekten af oral semaglutid: et primært statistisk princip[1], som kræves i henhold til nye regulatoriske retningslinjer, og som vurderer effekten uanset overholdelse af behandlingen, og et sekundært statistisk princip[2], der beskriver effekten ud fra en antagelse om, at deltagerne havde overholdt behandlingen og ikke iværksatte anden behandling. Studiet opfyldte sit primære mål vurderet ud fra det primære statistiske princip, idet det viste væsentlige og statistisk signifikante forbedringer i langtidsblodsukkeret (HbA1c) for alle tre doser af oral semaglutid sammenlignet med placebo. Endvidere medførte dosen på 14 mg oral semaglutid et væsentligt og statistisk signifikant vægttab sammenlignet med placebo. Vægttab blev opnået med doserne på 7 mg og 3 mg, men var ikke statistisk signifikant. Vurderet ud fra det sekundære statistiske princip opnåede deltagere i behandling med 3, 7 og 14 mg oral semaglutid reduktioner i HbA1c på henholdsvis 0,8%, 1,3% og 1,5%, mod en reduktion på 0,1% hos deltagere, der fik placebo, ud fra et gennemsnitligt udgangspunkt på 8,0% ved studiets begyndelse. Behandlingsmålet om HbA1c på under 7,0% som fastsat af American Diabetes Association (ADA) blev nået af 59%, 72% og 80% af deltagere i behandling med henholdsvis 3, 7 og 14 mg oral semaglutid, mod 34% af deltagere, der fik placebo. Ud fra en gennemsnitsvægt på 88 kg og et BMI på 31,8 kg/m2 ved studiets begyndelse opnåede deltagere i behandling med 3, 7 og 14 mg oral semaglutid desuden et vægttab på henholdsvis 1,7 kg, 2,5 kg og 4,1 kg, mod et vægttab på 1,5 kg hos deltagere, der fik placebo. Oral semaglutid forekom i studiet at have en sikker og veltolereret klinisk profil. Den mest almindelige bivirkning for alle tre doser var mild til moderat kvalme, som aftog med tiden. Mellem 5% og 16% af deltagere i behandling med oral semaglutid oplevede kvalme, mod 6% af deltagere, der fik placebo. Afslutning af behandlingen før tid som følge af bivirkninger var mellem 2% og 7% for deltagere, der blev behandlet med oral semaglutid, mod 2% for deltagere, der fik placebo. ""Vi er meget tilfredse med resultaterne af PIONEER 1-studiet, som bekræfter den uovertrufne orale effekt af semaglutid, som vi så i fase 2-studiet indenfor type 2-diabetes,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Vi ser frem til at fremlægge data fra de resterende ni PIONEER-studier i løbet af året og forventer at indsende registreringsansøgning i 2019."" PIONEER 1 var et 26-ugers randomiseret, dobbeltblindet, placebokontrolleret, multicenter-, multinationalt parallelgruppestudie med fire behandlingsgrupper. Studiet undersøgte effekt og sikkerhed for tre dosisniveauer af oral semaglutid givet én gang dagligt sammenlignet med placebo hos mennesker med type 2-diabetes, som blev behandlet med diæt og motion alene. PIONEER 1 omfattede 703 deltagere, som blev randomiseret 1:1:1:1 til at modtage enten en dosis oral semaglutid (3, 7 eller 14 mg) eller placebo én gang dagligt. Det primære endepunkt var ændring i langtidsblodsukkerniveauet (HbA1c) ved uge 26 i forhold til udgangspunktet ved studiets begyndelse. Det kliniske fase 3a-program for oral semaglutid, PIONEER, er et globalt udviklingsprogram med en forventet samlet deltagelse af mere end 9.000 mennesker med type 2-diabetes i 10 kliniske studier, som alle forventes afsluttet i 2018. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information [1] Behandlingspolitisk estimand: behandlingseffekt uanset overholdelse af behandlingen eller iværksættelse af anden behandling (analyseret ved hjælp af en pattern mixture-model baseret på multiple imputationer til håndtering af manglende uge 26-data). [2] Hypotetisk estimand: behandlingseffekt hvis alle deltagere overholdt behandlingen og ikke iværksatte redningsbehandling (analyseret ved hjælp af Mixed Models for Repeated Measurements (MMRM)). Den anvendte statistiske metodik er den samme som den, der blev anvendt i SUSTAIN-programmet for subkutan semaglutid.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=656,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
212,2018-02-09,Novo Nordisk A/S: Ozempic® (semaglutide) approved in the EU for the treatment of type 2 diabetes,"Bagsværd, Denmark, 9 February 2018 - Novo Nordisk today announced that the European Commission (EC) has granted marketing authorisation for Ozempic® (semaglutide) for the treatment of adults with type 2 diabetes. Ozempic® is a new once-weekly analogue of human glucagon-like peptide-1 (GLP-1) indicated as monotherapy when metformin is considered inappropriate due to intolerance or is contraindicated, and as an addition to other medicinal products for the treatment of diabetes. The marketing authorisation applies to all 28 European Union member states. The label reflects the superior and sustained reductions in HbA1c and body weight achieved with Ozempic® relative to comparator treatments, cardiovascular benefits and the statistically significant reduction in diabetic nephropathy with Ozempic® relative to standard of care. Ozempic® has been approved in the EU for use in a multi-dose Ozempic® pen, the latest generation of Novo Nordisk prefilled devices. However, Novo Nordisk intends to submit a variation application to the European Medicines Agency (EMA) seeking approval of an updated Ozempic® pen offering. The new pen offering will help facilitate reimbursement for patients with type 2 diabetes using Ozempic®. The launch of Ozempic® is expected to take place in the first EU countries in the second half of 2018 following the approval of the variation application for the updated pen offering. ""We are very excited about the approval of Ozempic® in the EU, as we believe it has the potential to set a new standard for the treatment of type 2 diabetes,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer. ""Type 2 diabetes is a complex disease and the strong clinical profile of Ozempic® provides a much needed treatment option for people looking for efficacious solutions to manage their disease."" Ozempic® (semaglutide) is a new once-weekly analogue of human glucagon-like peptide-1 (GLP-1) that has been developed for the treatment of type 2 diabetes. The approval of Ozempic® is based on the SUSTAIN programme, a global clinical development programme that comprised eight phase 3a trials, encompassing more than 8,000 adults with type 2 diabetes. The phase 3a programme involved a broad range of people with type 2 diabetes, including some with high cardiovascular risk profiles and people with and without renal disease. Ozempic® was approved by the US FDA on 5 December 2017 and by Health Canada on 9 January 2018. Further information Company announcement No 12 / 2018",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=667,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
213,2018-02-09,Novo Nordisk A/S: Ozempic® (semaglutid) godkendt i EU til behandling af type 2-diabetes,"Bagsværd, den 9. februar 2018 - Novo Nordisk meddeler i dag, at Europa-Kommissionen har givet markedsføringstilladelse til Ozempic® (semaglutid) til behandling af voksne med type 2-diabetes. Ozempic® er en ny ugentlig analog af det naturlige hormon glukagonlignende peptid-1 (GLP-1), som er godkendt til monoterapi, når metformin anses for uhensigtsmæssig på grund af intolerans eller kontraindikationer, samt som tillægsbehandling til andre lægemidler til behandling af diabetes. Markedsføringstilladelsen gælder samtlige 28 EU-medlemslande. Indlægssedlen afspejler de statistisk signifikante og varige reduktioner i langtidsblodsukker (HbA1c) og vægt, der opnås ved behandling med Ozempic® i forhold til sammenlignende behandlinger, samt hjerte-kar-fordelene og den statistisk signifikante reduktion i diabetisk nyresygdom ved behandling med Ozempic® sammenlignet med standardbehandling. Ozempic® er godkendt i EU til brug i én multidosispen, Ozempic® pen, som er Novo Nordisks nyeste generation af præfyldte injektionspenne. Novo Nordisk agter at indsende en variationsansøgning til Det Europæiske Lægemiddelagentur (EMA) om godkendelse af et opdateret Ozempic® penudvalg. Det nye penudvalg vil gøre det nemmere at opnå tilskud for mennesker med type 2-diabetes, der bruger Ozempic®. Lanceringen af Ozempic® forventes at finde sted i de første EU-lande i andet halvår af 2018 efter godkendelsen af variationsansøgningen for det opdaterede penudvalg. ""Vi er meget tilfredse med godkendelsen af Ozempic® i EU, da vi er overbevist om, at det har potentiale til at sætte en ny standard for behandling af type 2-diabetes,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Type 2-diabetes er en kompleks sygdom, og Ozempic® med sin stærke kliniske profil giver en hårdt tiltrængt behandlingsmulighed for mennesker med diabetes, der er på udkig efter virkningsfulde løsninger til at regulere deres sygdom."" Ozempic® (semaglutid) er en ny ugentlig analog af det naturlige hormon glukagonlignende peptid-1 (GLP-1), som er udviklet til behandling af type 2-diabetes. Godkendelsen af Ozempic® er baseret på SUSTAIN-programmet, et globalt klinisk udviklingsprogram, som omfattede otte fase 3a-studier med deltagelse af flere end 8.000 voksne med type 2-diabetes. Fase 3a-programmet omfattede en bred vifte af deltagere med type 2-diabetes, herunder deltagere med høj risiko for hjerte-kar-sygdom samt deltagere med og uden nyresygdom. Ozempic® blev godkendt af de amerikanske sundhedsmyndigheder, FDA, den 5. december 2017 og af de canadiske sundhedsmyndigheder, Health Canada, den 9. januar 2018. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr 12 / 2018",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=668,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
214,2018-02-08,Novo Nordisk files annual report with the SEC,"Bagsværd, Denmark, 8 February 2018 - Novo Nordisk A/S has filed its Annual Report 2017 on Form 20-F for the financial year 2017 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2017. The reports are available at the SEC's website, www.sec.gov, as well as on novonordisk.com. Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=669,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
215,2018-02-06,Novo Nordisk publishes its 2017 Annual Report,"Bagsværd, Denmark, 6 February 2018 - Novo Nordisk has published its 2017 annual report online at novonordisk.com/annualreport. It is the company's fourteenth integrated annual report detailing the company's financial, social and environmental performance. The annual report will be available in print later this month. Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,100 people in 79 countries and markets its products in more than 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=672,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
216,2018-02-06,Novo Nordisk har udgivet sin årsrapport for 2017,"Bagsværd, 6. februar 2018 - Novo Nordisk har udgivet sin årsrapport for 2017 online på novonordisk.com/annualreport. Det er virksomhedens 14. integrerede årsrapport, som redegør for virksomhedens finansielle, sociale og miljømæssige resultater.Årsrapporten udarbejdes udelukkende på engelsk. Et årsskrift rummer en dansk udgave af ledelsesberetningen samt uddrag af koncernregnskabet. Begge publikationer vil være tilgængelige på tryk senere i denne måned. Dette er en oversættelse af den originale engelske pressemeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=673,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
217,2018-02-01,Novo Nordisk increased reported operating profit by 1% in 2017 to DKK 49 billion (5% growth in local currencies),"Reported sales were broadly unchanged at DKK 112 billion (2% growth in local currencies) Sales within diabetes care and obesity increased by 4% to DKK 92.9 billion (7% in local currencies). Sales within biopharmaceuticals declined by 18% to DKK 18.8 billion (16% in local currencies), reflecting the impact in the USA from the introduction of a generic version of the hormone replacement therapy product Vagifem® and a rebate adjustment for growth hormone in Q1 2016. Sales within haemophilia were broadly unchanged (2% growth in local currencies). Sales within International Operations increased by 2% in Danish kroner (5% in local currencies) driven by sales growth in all business regions measured in local currencies. Sales within North America Operations decreased by 2% in Danish kroner and were unchanged in local currencies, reflecting the non-recurring effects in biopharmaceuticals impacting growth negatively by 4 percentage points. Operating profit increased by 1% reported in Danish kroner and by 5% in local currencies to DKK 49.0 billion. Net profit increased by 1% to DKK 38.1 billion. Diluted earnings per share increased by 3% to DKK 15.39. In December, Novo Nordisk received the US Food and Drug Administration (FDA) approval of Ozempic® (semaglutide) for treatment of people with type 2 diabetes and a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) recommending marketing authorisation for Ozempic®. Ozempic® will be launched in the USA next week. Chairman of the Board of Directors Göran Ando has decided not to seek re-election at the Annual General Meeting in March 2018. The Board of Directors proposes current member of the Board of Directors Helge Lund to be elected as chairman of the Board of Directors. As per 15 February 2018, Karsten Munk Knudsen, currently senior vice president of Corporate Finance, will succeed Jesper Brandgaard as chief financial officer. Jesper Brandgaard will continue as executive vice president responsible for Biopharm and Legal Affairs. For 2018, sales growth is expected to be 2-5% measured in local currencies and operating profit growth is expected to be 1-5%. Sales growth reported in Danish kroner is expected to be 7 percentage points lower than in local currencies, reflecting the significant depreciation of the US dollar and related currencies versus the Danish krone. Likewise, reported operating profit growth is expected to be 10 percentage points lower. At the Annual General Meeting on 22 March 2018, the Board of Directors will propose a final dividend of DKK 4.85 for 2017 per share of DKK 0.20. The expected total dividend for 2017 of DKK 7.85 per share, of which DKK 3.00 per share was paid as interim dividend in August 2017, corresponds to an increase of 3% compared to 2016. The Board of Directors furthermore intends to initiate a new 12-month share repurchase programme of up to DKK 14 billion. Lars Fruergaard Jørgensen, president and CEO: ""I am pleased that we delivered on our plans for 2017 and we are continuing to build a platform for sustainable growth. The approval of Ozempic® in the USA was the culmination of a year in which we achieved important product approvals and label updates. In 2018, we will focus on the global launch of Ozempic® and pursue the full value potential of our strong product portfolio in what continues to be a competitive environment."" Contacts for further information Company announcement No 6 / 2018",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=682,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
218,2018-02-01,Novo Nordisks rapporterede resultat af primær drift steg med 1% i 2017 til 49 mia. kr. (5% vækst i lokale valutaer),"Det rapporterede salg var stort set uændret på 112 mia. kr. (2% vækst i lokale valutaer) Salget af produkter til behandling af diabetes og fedme steg med 4% til 92,9 mia. kr. (7% i lokale valutaer). Salget af biofarmaceutiske produkter faldt med 18% til 18,8 mia. kr. (16% i lokale valutaer) som følge af påvirkningen i USA fra introduktionen af en generisk udgave af hormonpræparatet Vagifem® og en rabatjustering for væksthormon i første kvartal af 2016. Salget indenfor hæmofili var stort set uændret (2% vækst i lokale valutaer). Salget i International Operations steg med 2% opgjort i kroner (5% i lokale valutaer) drevet af salgsvækst i alle forretningsregioner opgjort i lokale valutaer. Salget i North America Operations faldt med 2% i kroner og var uændret i lokale valutaer; dette afspejler engangspåvirkninger indenfor biopharmaceuticals, som påvirkede væksten negativt med 4 procentpoint. Resultat af primær drift steg med 1% rapporteret i kroner og med 5% i lokale valutaer til 49,0 mia. kr. Nettoresultatet steg med 1% til 38,1 mia. kr. Udvandet resultat pr. aktie steg med 3% til 15,39 kr. I december fik Novo Nordisk godkendelse fra de amerikanske sundhedsmyndigheder (FDA) for Ozempic® (semaglutid) til behandling af mennesker med type 2-diabetes samt en positiv udtalelse fra Udvalget for Humanmedicinske Lægemidler (CHMP) under Det Europæiske Lægemiddelagentur (EMA) med anbefaling om markedsføringstilladelse for Ozempic®. Ozempic® vil blive lanceret i USA i næste uge. Formanden for Novo Nordisks bestyrelse, Göran Ando, har besluttet, at han ikke genopstiller ved generalforsamlingen i marts 2018. Bestyrelsen foreslår, at det nuværende bestyrelsesmedlem Helge Lund vælges som formand for bestyrelsen. Pr. 15. februar 2018 afløser Karsten Munk Knudsen, som i dag er direktør for Corporate Finance, Jesper Brandgaard som koncernøkonomidirektør. Jesper Brandgaard fortsætter som koncerndirektør med ansvar for Biopharm og Legal Affairs. For 2018 forventes en salgsvækst på 2-5% opgjort i lokale valutaer og en vækst i resultat af primær drift på 1-5%. Salgsvæksten rapporteret i kroner forventes at blive 7 procentpoint lavere end i lokale valutaer som følge af det betydelige kursfald for den amerikanske dollar og relaterede valutaer overfor kronen. Tilsvarende forventes væksten i det rapporterede resultat af primær drift at blive 10 procentpoint lavere. Bestyrelsen vil på generalforsamlingen den 22. marts 2018 fremsætte forslag om en endelig udbyttebetaling på 4,85 kr. for 2017 pr. aktie a 0,20 kr. Det forventede samlede udbytte for 2017 bliver således på 7,85 kr. pr. aktie, hvoraf 3,00 kr. pr. aktie blev udbetalt som interimudbytte i august 2017, hvilket svarer til en stigning på 3% sammenlignet med 2016. Bestyrelsen forventer desuden at iværksætte et nyt 12-måneders aktietilbagekøbsprogram på op til 14 mia. kr. Adm. direktør Lars Fruergaard Jørgensen: ""Jeg er glad for, at vi leverede på vores planer for 2017, og vi arbejder fortsat på at opbygge en platform for bæredygtig vækst. Godkendelsen af Ozempic® i USA var kulminationen på et år, hvor vi opnåede nogle vigtige produktgodkendelser og opdateringer af indlægssedler. I 2018 vil vi fokusere på den globale lancering af Ozempic® og forfølge det fulde værdipotentiale af vores stærke produktportefølje i det, der fortsat må betegnes som en udfordrende konkurrencesituation."" Kontaktoplysninger Selskabsmeddelelse nr. 6 / 2018",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=683,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
219,2018-01-29,Novo Nordisk does not intend to make a revised proposal for Ablynx,"Bagsværd, Denmark, 29 January 2018 ­- Novo Nordisk notes the announcement of Sanofi's agreed acquisition of Ablynx. On 8 January, Novo Nordisk announced its proposal to acquire Ablynx for up to EUR 30.50 per share in cash, consisting of EUR 28.00 upfront and EUR 2.50 in Contingent Value Rights. Novo Nordisk today confirms that it will not be making a revised proposal. Novo Nordisk looks forward to continuing its productive research collaboration with Ablynx. Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=686,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
220,2018-01-29,Novo Nordisk vil ikke fremsætte revideret forslag om overtagelse af Ablynx,"Bagsværd, den 29. januar 2018 - Novo Nordisk har noteret sig offentliggørelsen af Sanofis aftalte overtagelse af Ablynx. Den 8. januar 2018 offentliggjorde Novo Nordisk sit forslag om at overtage Ablynx for op til 30.50 euro pr. aktie i kontant vederlag, heraf 28,00 ved overtagelsen og 2,50 euro i betingede vederlagsrettigheder (Contingent Value Rights). Novo Nordisk bekræfter i dag, at virksomheden ikke vil fremsætte et revideret forslag om overtagelse. Novo Nordisk ser frem til at fortsætte det produktive forskningssamarbejde med Ablynx. Dette er en oversættelse af den originale engelske pressemeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=687,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
221,2018-01-08,"Novo Nordisk has proposed to acquire Ablynx for up to EUR 30.50 per share in cash, consisting of EUR 28.00 upfront and EUR 2.50 in Contingent Value Rights","Bagsværd, Denmark, 8 January 2018 ­- Novo Nordisk today confirms that it made a proposal on 22 December 2017 to acquire Ablynx for EUR 28.00 per share in cash and one CVR with total potential cash payments over time of up to EUR 2.50 per share. This proposal implies a total equity valuation of approximately EUR 2.6 billion1 for Ablynx and represents a premium of up to 60% over Ablynx's share price as of 6 December 2017 of €19.12, which was the day prior to our first proposal, and up to 66% over Ablynx's 3 month VWAP of EUR 18.39 as of 5 January 2018. Novo Nordisk has made a concerted and good faith effort to engage in discussions with Ablynx. This proposal is the second proposal that Novo Nordisk has made to Ablynx's Board of Directors and represents up to approximately a 14% increase over the first proposal. Novo Nordisk regrets that the Board of Directors of Ablynx has so far declined to engage in any discussions, despite the proposals which have been put forward. Novo Nordisk has conducted a deep analysis of Ablynx's business and product portfolio, based on publicly available information, including caplacizumab, ALX-0171, vobarilizumab, its other pipeline products and partnerships. Following that analysis, Novo Nordisk has concluded that combining Ablynx's caplacizumab with Novo Nordisk's strong global haematology franchise and extensive worldwide resources is a compelling opportunity and provides the clearest path to realizing full potential of Ablynx's portfolio in the best interests of all stakeholders, including patients and physicians. The proposed transaction would combine Novo Nordisk's regulatory, scientific and commercial expertise with Ablynx's strong existing medical teams to optimise the development and global commercialisation of caplacizumab. Novo Nordisk has a high regard for Ablynx's other pipeline assets and the Nanobody platform. Novo Nordisk has since 2015 been undertaking a research collaboration with Ablynx on the Nanobody platform. Novo Nordisk would plan to continue to invest in the platform and support its people and activities, including the existing partnerships Ablynx has in place. We firmly believe that the combination of Ablynx's pipeline, R&D team and antibody engineering platform with Novo Nordisk's own R&D organization would create a stronger combined research base. Novo Nordisk recognises the value of maintaining Ablynx's presence in the Ghent area and intends to keep Ablynx's strong R&D base within Ghent and further develop Ablynx as a centre of excellence in Nanobody discovery and engineering. On 7 December 2017, Novo Nordisk made an initial non-binding proposal to acquire Ablynx for EUR 26.75 per share in cash. This proposal was rejected by Ablynx's Board of Directors on 14 December 2017. Following this, Novo Nordisk has made a number of attempts to engage in a dialogue with Ablynx, which were rejected by Ablynx's Board of Directors. On 22 December 2017, Novo Nordisk submitted a revised non-binding proposal to acquire Ablynx for up to EUR 30.50 per share, including EUR 28.00 per share in cash and one CVR with total potential cash payments over time of up to EUR 2.50 per share. This proposal was rejected by Ablynx's Board of Directors on 23 December 2017. The Board of Directors of Ablynx has declined to engage in any discussions which would allow Novo Nordisk to better understand Ablynx management's views on Ablynx's prospects and valuation of Ablynx. Following this, Lars Fruergaard Jørgensen, chief executive efficer of Novo Nordisk, spoke to Edwin Moses, chief executive officer of Ablynx on 5 January 2018 to reiterate Novo Nordisk's commitment to the transaction and to encourage Ablynx to meet with Novo Nordisk in order to have a discussion around key value drivers. Unfortunately, this offer was again refused by the Board of Directors of Ablynx. Novo Nordisk's non-binding proposal submitted on 22 December 2017 consists of an upfront cash consideration of EUR 28.00 per share and one CVR with total potential cash payments over time of up to EUR 2.50 per share. Each CVR would entitle Ablynx's shareholders to receive additional cash payments promptly upon the occurrence of the following events: ""The proposed transaction with Ablynx represents a compelling opportunity for both companies and is in the best interests of all of Ablynx's stakeholders"", said Lars Fruergaard Jørgensen, chief executive officer of Novo Nordisk. ""Novo Nordisk and Ablynx share a common focus on innovation-driven, patient-centric R&D. Novo Nordisk intends to use its full suite of regulatory, scientific and marketing expertise to complement the existing strong management and medical team at Ablynx in order to optimise the development and global commercialisation of caplacizumab for the benefit of patients suffering from aTTP. The proposed transaction is attractive for Novo Nordisk and is in line with Novo Nordisk's stated strategy to invest in its Biopharm operations. Ahead of the rapidly approaching potential EMA approval of caplacizumab, we believe now is the right time to consider a transaction that maximizes value for all of Ablynx's stakeholders."" At this stage, there can be no assurance that any agreement with respect to the proposed transaction will be reached between the two companies. Novo Nordisk's proposal to Ablynx's Board of Directors is subject to satisfactory completion of due diligence and the negotiation, execution and delivery of a mutually acceptable definitive transaction agreement. Novo Nordisk encourages Ablynx's Board of Directors to engage in a negotiated transaction for the benefit of all stakeholders. Evercore is acting as financial advisor to Novo Nordisk and Stibbe cvba/scrl and Davis Polk & Wardwell LLP are acting as legal advisors to Novo Nordisk. This press release contains forward-looking statements. Words such as 'believe', 'expect', 'may', 'would', 'will',  'plan', 'strategy', 'prospect', 'foresee', 'estimate', 'project', 'anticipate', 'can', 'intend', 'target' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or plans or proposals regarding Ablynx identify forward-looking statements. Forward-looking statements are based on current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. Novo Nordisk cautions that a number of important factors could cause actual results or events to differ materially from those contemplated in any forward-looking statements. Unless required by law, Novo Nordisk is under no duty and undertakes no obligation to update or revise any forward-looking statement after the distribution of this press release, whether as a result of new information, future events or otherwise. This is a press release by Novo Nordisk, pursuant to Article 8 Paragraph 1 of the Belgian Royal Decree on Public Takeovers. This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. No tender offer for the shares of Ablynx has commenced at this time. Any offer will be made only in compliance with and by means of an offer memorandum approved further to the Belgian Royal Decree on Public Takeovers, and, in respect of Ablynx's ADSs (and shares held by US holders) definitive tender offer documents that will be mailed to shareholders of Ablynx. Holders of Ablynx securities are urged to read these and other documents filed with the SEC in their entirety if and when they become available because they will contain important information about the proposed transaction. This announcement is not for release, publication or distribution, in whole or in part, in or into, directly or indirectly, any jurisdiction in which such release, publication or distribution would be unlawful. Evercore, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting as financial adviser to Novo Nordisk in relation to the proposal and is not acting for any other persons in relation to the proposal. Evercore is acting exclusively for Novo Nordisk and for no one else in relation to the matters described in this announcement and is not advising any other person and accordingly will not be responsible to anyone other than Novo Nordisk for providing the protections afforded to clients of Evercore, or for providing advice in relation to the contents of this announcement or any matter referred to in it. This announcement has been issued by, and is the sole responsibility of, Novo Nordisk. No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by Evercore or by any of their respective affiliates or agents as to or in relation to, the accuracy or completeness of this announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefore is expressly disclaimed.  [1] On a fully diluted basis",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=694,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
222,2018-01-08,"Novo Nordisk har foreslået at erhverve Ablynx for op til 30,50 EUR pr. aktie i kontant vederlag, heraf 28,00 EUR ved overtagelsen og €2,50 i betingede vederlagsrettigheder (Contingent Value Rights)","Bagsværd, den 8. januar 2018 - Novo Nordisk bekræfter i dag, at virksomheden den 22. december 2017 har foreslået en overtagelse af Ablynx for et kontant vederlag på €28,00 pr. aktie og en betinget vederlagsrettighed (CVR) med samlede kontante betalinger over tid på potentielt op til 2,50 EUR pr. aktie. Dette forslag indebærer en samlet værdiansættelse af egenkapitalen i Ablynx på ca. 2,6 mia EUR.1 og afspejler en præmie på op til 60% over Ablynx' aktiekurs den 6. december 2017 på 19,12 EUR, som var dagen før vores første forslag, og op til 66% over Ablynx' VWAP over en tremåneders periode på 18,39 EUR pr. 5. januar 2018. Novo Nordisk har gjort en aktiv indsats i god tro for at komme i dialog med Ablynx. Dette forslag er det andet forslag, Novo Nordisk har forelagt Ablynx' bestyrelse, og repræsenterer en forhøjelse på op til cirka 14% i forhold til det første forslag. Det er med beklagelse, at Novo Nordisk konstaterer, at Ablynx' bestyrelse indtil nu har afvist at indgå i drøftelser til trods for de forslag, som er forelagt. Novo Nordisk har foretaget en dybtgående analyse af Ablynx' forretning og produktportefølje baseret på offentligt tilgængelig information, herunder om caplacizumab, ALX-0171, vobarilizumab samt øvrige pipelineprodukter og partnerskaber. På baggrund af denne analyse har Novo Nordisk konkluderet, at en sammenlægning af Ablynx' caplacizumab med Novo Nordisks stærke globale hæmatologiforretning og omfattende globale ressourcer er en oplagt mulighed og den klareste vej til at realisere det fulde potentiale af Ablynx' portefølje til fordel for alle interessenter, herunder patienter og læger. Den foreslåede transaktion vil kombinere Novo Nordisks regulatoriske, videnskabelige og salgsmæssige ekspertise med Ablynx' stærke eksisterende medicinske teams for at optimere udviklingen og den globale kommercialisering af caplacizumab. Novo Nordisk nærer stor agtelse for de øvrige aktiver i Ablynx' pipeline samt virksomhedens Nanobody-platform. Novo Nordisk har siden 2015 haft et forskningssamarbejde med Ablynx om Nanobody-platformen. Novo Nordisk påtænker fortsat at investere i platformen og supportere de dertil knyttede medarbejdere og aktiviteter, herunder de eksisterende partnerskaber, som Ablynx har etableret. Vi er overbevist om, at Ablynx' pipeline, forsknings- og udviklingsteam samt antistofteknologiplatform kombineret med Novo Nordisks egen forsknings- og udviklingsorganisation ville skabe et stærkere fælles forskningsgrundlag. Novo Nordisk anerkender værdien af at fastholde Ablynx' tilstedeværelse i Ghent-området og vil således fastholde Ablynx' stærke forsknings- og udviklingsbase i Ghent og yderligere udvikle Ablynx som et kompetencecenter for opdagelse og udvikling af antistoffer ved hjælp af Nanobody-platformen. Den 7. december 2017 fremlagde Novo Nordisk et indledende ikke-bindende forslag om at erhverve Ablynx for €26,75 pr. aktie kontant. Dette forslag blev afvist af Ablynx' bestyrelse den 14. december 2017. Herefter har Novo Nordisk gjort flere forsøg på at komme i dialog med Ablynx, men disse er blevet afvist af Ablynx' bestyrelse. Den 22. december 2017 fremlagde Novo Nordisk et revideret ikke-bindende forslag om at erhverve Ablynx for op til 30,50 EUR pr. aktie, herunder 28,00 EUR pr. aktie kontant og en betinget vederlagsrettighed (CVR) med samlede kontante betalinger over tid på potentielt op til 2,50 EUR pr. aktie. Dette forslag blev afvist af Ablynx' bestyrelse den 23. december 2017. Ablynx' bestyrelse har afvist at deltage i enhver drøftelse, som ville kunne give Novo Nordisk mulighed for bedre at forstå Ablynx' ledelses syn på Ablynx' fremtidsudsigter samt værdiansættelsen af Ablynx. Herefter talte Lars Fruergaard Jørgensen, Novo Nordisks administrerende direktør, med Edwin Moses, Ablynx' administrerende direktør, den 5. januar 2018 for at gentage Novo Nordisks engagement i transaktionen og opfordre Ablynx til at mødes med Novo Nordisk for at drøfte virksomhedens centrale værdiskabende aktiviteter. Desværre blev dette tilbud igen afvist af Ablynx' bestyrelse. Novo Nordisks ikke-bindende forslag af 22. december 2017 består af en kontant betaling ved overtagelsen på 28,00 EUR pr. aktie og en betinget vederlagsrettighed (CVR) med samlede kontante betalinger over tid på potentielt op til 2,50 EUR pr. aktie. Hver betinget vederlagsrettighed (CVR) ville give Ablynx' aktionærer ret til at modtage yderligere kontante betalinger i tilfælde af følgende situationer: ""Den foreslåede transaktion med Ablynx er en oplagt mulighed for begge virksomheder og vil være til fordel for alle Ablynx' interessenter,"" siger Novo Nordisks administrerende direktør, Lars Fruergaard Jørgensen. ""Novo Nordisk og Ablynx har et fælles fokus på innovationsdrevet forskning og udvikling med patienten i centrum. Novo Nordisk ønsker at sætte al sin regulatoriske, videnskabelige og salgsmæssige ekspertise ind på at komplementere Ablynx' stærke ledelse og medicinske team med det mål at optimere udviklingen og den globale kommercialisering af caplacizumab til gavn for patienter med aTTP. Den foreslåede transaktion er attraktiv for Novo Nordisk og er i tråd med Novo Nordisks erklærede strategi om at investere i virksomhedens aktiviteter indenfor det biofarmaceutiske område. I lyset af den snarligt forestående potentielle EMA-godkendelse af caplacizumab mener vi, at tiden nu er moden til at overveje en transaktion, der maksimerer værdien for alle Ablynx' interessenter."" Der kan på nuværende tidspunkt ikke gives nogen sikkerhed for, at de to virksomheder vil nå til en aftale om den foreslåede transaktion. Novo Nordisks forslag til Ablynx' bestyrelse er betinget af en tilfredsstillende due diligence-undersøgelse samt forhandling, eksekvering og levering af en gensidigt acceptabel endelig transaktionsaftale. Novo Nordisk opfordrer Ablynx' bestyrelse til at tage del i en forhandlet transaktion til fordel for alle interessenter. Evercore fungerer som finansiel rådgiver for Novo Nordisk, og Stibbe cvba/scrl og Davis Polk & Wardwell LLP fungerer som juridiske rådgivere for Novo Nordisk. Denne pressemeddelelse indeholder udsagn om fremtiden. I udsagn om fremtiden indgår ofte ord som 'mener', 'forventer', 'eventuelt', 'vil', 'planlægger', 'strategi', 'udsigt', 'forudser', 'skønner', 'fremskriver', 'regner med', 'kan', 'påtænker', 'mål' og andre ord og udtryk med tilsvarende betydning i forbindelse med omtale af fremtidige driftsmæssige eller finansielle resultater, planer eller forslag vedrørende Ablynx. Disse udsagn om fremtiden tager afsæt i nuværende planer, skøn og forventninger. Udsagn om fremtiden er i sagens natur forbundet med risikofaktorer og usikkerhedsmomenter af såvel generel som specifik karakter. Novo Nordisk understreger, at en række væsentlige forhold kan forårsage, at de faktiske resultater eller begivenheder viser sig at afvige væsentligt fra dem, der tidligere er kommet til udtryk i udsagn om fremtiden. Medmindre der er tale om et lovkrav, er Novo Nordisk ikke forpligtet og frasiger sig enhver forpligtelse til at opdatere eller revidere udsagn om fremtiden efter offentliggørelsen af denne pressemeddelelse, hvad enten det skyldes nye oplysninger, fremtidige begivenheder eller andre forhold. Dette er en pressemeddelelse udstedt af Novo Nordisk i henhold til det belgiske kongelige dekret om offentlige overtagelsestilbud artikel 8, stk. 1. Denne meddelelse udgør ikke et tilbud om eller en opfordring til at købe, sælge eller tegne værdipapirer. Der er ikke på nuværende tidspunkt iværksat noget købstilbud for aktierne i Ablynx. Et sådant tilbud vil kun blive fremsat i overensstemmelse med og i form af et tilbudsdokument godkendt i henhold til det belgiske kongelige dekret om offentlige overtagelsestilbud samt, for så vidt angår Ablynx' ADS'er (og aktier ejet af amerikanske aktionærer), endelige tilbudsdokumenter, som vil blive sendt til Ablynx' aktionærer. Indehavere af værdipapirer i Ablynx opfordres til at læse disse og andre dokumenter indsendt til det amerikanske børstilsyn, Securities and Exchange Commission (SEC), i deres helhed, hvis og når de bliver tilgængelige, da de vil indeholde vigtig information om den foreslåede transaktion. Denne meddelelse må ikke offentliggøres, publiceres eller distribueres helt eller delvist, direkte eller indirekte, i eller til nogen jurisdiktion, hvor offentliggørelse, publikation eller distribution ville være ulovlig. Evercore, som er autoriseret og reguleret i Storbritannien af Financial Conduct Authority, fungerer som finansiel rådgiver for Novo Nordisk i relation til forslaget og repræsenterer ingen andre personer i relation til forslaget. Evercore repræsenterer alene Novo Nordisk og ingen andre i relation til de forhold, der er beskrevet i denne meddelelse, og rådgiver ingen andre personer og vil følgelig ikke være ansvarlig overfor nogen andre end Novo Nordisk for at yde den beskyttelse, som Evercore yder til sine klienter, eller for at yde rådgivning i relation til indholdet af denne meddelelse eller forhold, der refereres til i den. Denne meddelelse er udstedt af Novo Nordisk, som er eneansvarlig for meddelelsen. Der gives ingen garantier, hverken direkte eller indirekte, og Evercore og dets associerede selskaber og agenter påtager sig intet ansvar eller erstatningspligt for rigtigheden eller fuldstændigheden af denne meddelelse eller anden skriftlig eller mundtlig information afgivet til eller offentliggjort til en interesseret part eller dennes rådgivere, og ethvert ansvar fraskrives derfor udtrykkeligt. Novo Nordisk er en global lægemiddelvirksomhed, som igennem mere end 90 år har stået for innovation og lederskab indenfor diabetesbehandling. Dette langvarige engagement har givet os erfaringer og kompetencer, som i dag gør det muligt også at hjælpe med at bekæmpe fedme, hæmofili, vækstforstyrrelser og andre alvorlige kroniske sygdomme. Koncernen har hovedkvarter i Danmark, beskæftiger omkring 41.700 medarbejdere i 77 lande og markedsfører sine produkter i flere end 165 lande. Læs mere på novonordisk.com. Dette er en oversættelse af den originale engelske pressemeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information [1] På fuldt udvandet basis",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=695,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
223,2017-12-15,Ozempic® (semaglutide) recommended for approval by the European regulatory authorities,"Bagsværd, Denmark, 15 December 2017 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorisation for Ozempic® (semaglutide) for the treatment of adults with type 2 diabetes mellitus. The CHMP recommends Ozempic®, the intended brand name for once-weekly semaglutide, to be indicated as monotherapy when metformin no longer provides sufficient treatment or is contraindicated and as an addition to other medicinal products for the treatment of diabetes. The indication also refers to specific sections of the label for study results with respect to combination with other diabetes medications, effects on glycaemic control, cardiovascular events and the populations studied. The label furthermore reflects the superior reduction in body weight achieved with Ozempic® relative to comparator treatments and the statistically significant reduction in diabetic nephropathy with Ozempic® relative to standard of care. As an integral part of the approval, Novo Nordisk has committed to conduct post-approval safety studies including a long-term diabetic retinopathy outcome study. Furthermore, as required for all long-acting GLP-1 products approved in the EU, Ozempic® will be enrolled in the data collection for the registry of medullary thyroid carcinoma. ""We are very excited about the positive opinion for Ozempic® for treatment of people with type 2 diabetes in Europe, many of whom are still looking for new and more efficacious solutions to better manage their disease,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer. ""We believe Ozempic®, with its unique clinical profile, has the potential to set a new standard for treatment of type 2 diabetes."" Novo Nordisk expects to receive final marketing authorisation from the European Commission in the first quarter of 2018. About Ozempic®                                                          Ozempic® (semaglutide) is a once-weekly analogue of human glucagon-like peptide-1 (GLP-1) that has been developed for the treatment of type 2 diabetes. The review of Ozempic® is based on the SUSTAIN programme, a global clinical development programme that comprises eight phase 3a trials, encompassing more than 8,000 adults with type 2 diabetes. The phase 3a programme involves a broad range of people with type 2 diabetes, including some individuals with high cardiovascular risk profiles and people with and without renal disease. Ozempic® was recently approved by the US Food and Drug Administration and is currently under review by several regulatory agencies, including the Japanese Pharmaceuticals and Medical Devices Agency. Further information Company announcement No 92 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=702,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
224,2017-12-15,Ozempic® (semaglutid) får anbefaling om godkendelse fra de europæiske lægemiddelmyndigheder,"Bagsværd, den 15. december 2017 - Novo Nordisk meddeler i dag, at Udvalget for Humanmedicinske Lægemidler (CHMP) under Det Europæiske Lægemiddelagentur (EMA) har afgivet en positiv udtalelse om Ozempic® (semaglutid) med anbefaling om markedsføringstilladelse til behandling af voksne med type 2-diabetes. CHMP anbefaler, at Ozempic® - det planlagte varemærke for ugentlig semaglutid - godkendes til monoterapi, når metformin ikke længere giver tilstrækkelig regulering af blodsukkeret eller er kontraindiceret, og som tillægsbehandling til andre lægemidler til behandling af diabetes. Indikationen refererer desuden til specifikke afsnit i indlægssedlen for data fra studier vedrørende kombination med andre diabeteslægemidler, indvirkning på blodsukkerreguleringen, hjerte-kar-relaterede hændelser og de undersøgte patientgrupper. Indlægssedlen afspejler endvidere den statistisk signifikante vægtreduktion, der opnås ved behandling med Ozempic® i forhold til sammenlignende behandlinger, og den statistisk signifikante reduktion i diabetisk nyresygdom ved behandling med Ozempic® i forhold til standardbehandling. Som led i godkendelsen har Novo Nordisk forpligtet sig til at gennemføre sikkerhedsstudier, herunder et langtidsstudie for at undersøge forekomsten af diabetisk øjensygdom (retinopati). Ozempic® vil endvidere, som det kræves af alle langtidsvirkende GLP-1-produkter, der er godkendt i EU, deltage i dataindsamlingen til registrering af kræft i skjoldbruskkirtlen (medullær thyroideacancer). ""Vi er meget begejstrede over den positive udtalelse om Ozempic® til behandling af mennesker med type 2-diabetes i Europa, hvoraf mange til stadighed er på udkig efter nye og mere virkningsfulde behandlingsløsninger, som giver bedre mulighed for at regulere deres sygdom,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Vi er overbevist om, at Ozempic® med sin unikke kliniske profil har potentiale til at sætte en ny standard for behandling af type 2-diabetes."" Novo Nordisk forventer at modtage endelig markedsføringstilladelse fra Europa-Kommissionen i første kvartal af 2018. Ozempic® (semaglutid) er en ugentlig analog af det naturlige hormon glukagonlignende peptid-1 (GLP-1), som er udviklet til behandling af type 2-diabetes. Vurderingen af Ozempic® er baseret på SUSTAIN-programmet, et globalt klinisk udviklingsprogram, som omfatter otte fase 3a-studier med deltagelse af flere end 8.000 voksne med type 2-diabetes. Fase 3a-programmet omfatter en bred vifte af deltagere med type 2-diabetes, herunder deltagere med høj risiko for hjerte-kar-relaterede hændelser samt deltagere med og uden nyresygdom. Ozempic® blev for nylig godkendt af de amerikanske sundhedsmyndigheder (FDA) og er p.t. under vurdering hos flere regulatoriske myndigheder, herunder de japanske sundhedsmyndigheder, Pharmaceuticals and Medical Devices Agency. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 92 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=703,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
225,2017-12-07,Tresiba® reduces hypoglycaemia regardless of blood sugar level,"Abu Dhabi, UAE, 7 December 2017 - People with either type 1 or type 2 diabetes treated with Tresiba® had fewer episodes of low blood sugar (hypoglycaemia) compared with people on insulin glargine U100 regardless of whether they had achieved blood sugar targets.1 These new post-hoc analyses from the SWITCH 1 and 2 trials were presented at the International Diabetes Federation (IDF) Annual Congress in Abu Dhabi today.2,3 ""Achieving target blood sugar levels can be a constant challenge for people with diabetes treated with insulin, and this is made even more complex by the risk of hypoglycaemia,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk. ""Tresiba® has consistently been shown to provide stable blood sugar control while at the same time reducing hypoglycaemia compared with insulin glargine U100; it is very encouraging to see that treatment with Tresiba® helps people to achieve blood sugar control with fewer episodes of hypoglycaemia regardless of their blood sugar levels in this analysis."" The findings of these analyses are consistent with the results of the main SWITCH trials which demonstrated significantly lower rates of overall symptomatic hypoglycaemia versus insulin glargine U100 in people with type 1 and type 2 diabetes.2,3 About hypoglycaemiaHypoglycaemia occurs when blood sugar levels are too low and cannot provide the body's organs with the energy they need. Hypoglycaemia can cause a range of symptoms including confusion, trembling, sweating, increased heart rate, difficulty with concentration and/or speech and in severe cases can lead to a seizure or coma.4-6 Severe hypoglycaemia can cause extensive damage to the body and is significantly associated with cardiovascular death.7 Every month, 46.5% of people with type 2 diabetes and 83.0% of people with type 1 diabetes experience a hypoglycaemic episode.8 About the new analysesThe analyses, based on the recent SWITCH trials, separated people into two groups depending on whether they had achieved target blood sugar levels (defined as HbA1c of 7.0% or less) during the maintenance period of the trial.1 Target blood sugar levels are those recommended by the joint guidelines of the American Diabetes Association and the European Association for the Study of Diabetes.9 About SWITCH 1 and 2SWITCH 1 and SWITCH 2 were two phase 3b, 64-week, double-blind, randomised, treat-to-target, 2-period crossover trials that investigated the hypoglycaemia profile of Tresiba® compared with insulin glargine U100 in people with type 1 and type 2 diabetes, respectively. The trial design included a titration period in which the doses of study treatments (Tresiba® or insulin degludec U100) were gradually increased over a 16 week period, followed by a 16 week maintenance period during which a constant dose of study treatment was maintained.2,3 The primary endpoint was the number of severe or blood glucose-confirmed symptomatic hypoglycaemic episodes observed in participants during the maintenance period.2,3 Tresiba® (insulin degludec) is a once-daily basal insulin that provides a duration of action beyond 42 hours with a flat and stable glucose-lowering effect.10,11 It has been shown to provide a lower risk of overall, nocturnal and severe hypoglycaemia, and low variability in blood glucose levels versus insulin glargine U100.11,12 Tresiba® received its first regulatory approval in September 2012 and has since been approved in more than 80 countries globally. It is now commercially available in more than 50 countries. Further information References1.         Gumprecht J, Lane W, Chaykin LB, et al. Lower rate of hypoglycaemia with insulin degludec vs. insulin glargine U100 after adjusting for HbA1c in SWITCH 1 and 2. Poster presentation. International Diabetes Federation (IDF) Annual Congress 2017, Abu Dhabi, UAE. December 2017.2.         Lane W, Bailey TS, Gerety G, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes: The SWITCH 1 randomized clinical trial. JAMA. 2017;318:33-44.3.         Wysham C, Bhargava A, Chaykin L, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: The SWITCH 2 randomized clinical trial. JAMA. 2017;318:45-56.4.         Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36:1384-1395.5.         International Hypoglycaemia Study Group. Diagnosis of hypoglycaemia. Available online at http://ihsgonline.com/understanding-hypoglycaemia/diagnosis. Last accessed November 2017.6.         Cryer P. Hypoglycemia, functional brain failure, and brain death. Journal of Clinical Investigation. 2007;117:868-870.7.         Pieber TR, Marso SP, McGuire DK, et al. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia. 2017.8.         Khunti K, Alsifri S, Aronson R, et al. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. Diabetes Obes Metab. 2016;18:907-915.9.         Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient Centered Approach. Diabetes Care 2015;38:140-149.10.       Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014;53:787-800.11.       EMA. Tresiba® Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002498/WC500138940.pdf. Last accessed: November 2017.12.       Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377:723-732.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=706,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
226,2017-12-07,Tresiba® giver færre tilfælde af hypoglykæmi uanset blodsukkerniveau,"Abu Dhabi, Forenede Arabiske Emirater, den 7. december 2017 ­- Mennesker med type 1- og type 2-diabetes, som bliver behandlet med Tresiba®, får færre tilfælde af lavt blodsukker (hypoglykæmi) end mennesker i behandling med insulin glargin U100, uanset om de har nået de anbefalede blodsukkermål.1 Det viser nye post hoc-analyser fra SWITCH 1- og 2-studierne, som præsenteres i dag på International Diabetes Federation Congress 2017 (IDF 2017) i Abu Dhabi, Forenede Arabiske Emirater.2,3 ""Det kan være en konstant udfordring for mennesker med diabetes i insulinbehandling at nå de anbefalede blodsukkermål, og risikoen for hypoglykæmi gør det endnu sværere,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Alle studier har konsekvent vist, at Tresiba® giver en stabil blodsukkerregulering og færre tilfælde af hypoglykæmi sammenlignet med insulin glargin U100, og det er meget positivt, at vi i denne analyse kan se, at behandling med Tresiba® hjælper med til at opnå en god blodsukkerregulering med færre tilfælde af hypoglykæmi uanset blodsukkerniveau."" Resultaterne i de nye analyser er i overensstemmelse med resultaterne i de primære SWITCH-studier, som viste en signifikant lavere forekomst af generel symptomatisk hypoglykæmi sammenlignet med insulin glargin U100 hos mennesker med type 1- og type 2-diabetes.2,3 Hypoglykæmi opstår, når blodsukkeret falder til et meget lavt niveau, så kroppens organer ikke får tilført den energi, der er nødvendig for at fungere. Typiske symptomer er forvirring, rysten, sveden, hjertebanken, koncentrations- og/eller talebesvær og i alvorlige tilfælde kramper eller bevidstløshed.4-6 Alvorlig hypoglykæmi kan forårsage omfattende skader i kroppen og er signifikant associeret med hjerte-kar-relateret død.7 Hver måned oplever 46,5% af mennesker med type 2-diabetes og 83,0% af mennesker med type 1-diabetes et tilfælde af hypoglykæmi.8 Analyserne, som var baseret på de nylige SWITCH-studier, inddelte deltagerne i to grupper afhængigt af, om de havde nået de anbefalede blodsukkermål (defineret som HbA1c på 7,0% eller lavere) i studiets vedligeholdelsesperiode.1 De anbefalede mål for blodsukkerniveauet er fastsat i de fælles retningslinjer fra American Diabetes Association og European Association for the Study of Diabetes.9 SWITCH 1 og SWITCH 2 var to fase 3b-, 64-ugers, dobbeltblindede, randomiserede, treat to target-, to-perioders crossover-studier, som undersøgte hypoglykæmiprofilen for Tresiba® sammenlignet med insulin glargin U100 hos mennesker med henholdsvis type 1- og type 2-diabetes. Studiedesignet omfattede en titreringsperiode, hvor doserne af de behandlinger, der blev anvendt i studiet (Tresiba® eller insulin degludec U100), gradvist blev øget gennem en 16-ugers periode, efterfulgt af en 16-ugers vedligeholdelsesperiode, hvor en konstant dosis af behandlingen blev fastholdt.2,3 Det primære endepunkt var antallet af tilfælde af alvorlig eller symptomatisk hypoglykæmi bekræftet ved blodsukkermåling observeret hos deltagerne i vedligeholdelsesperioden.2,3 Tresiba® (insulin degludec) er en basalinsulin til dosering én gang dagligt. Den har en virkningsvarighed på mere end 42 timer med en flad og stabil blodsukkersænkende effekt.10,11 Tresiba® medfører en lavere risiko for generel, natlig og alvorlig hypoglykæmi og en lav variation i blodsukkeret sammenlignet med insulin glargin U100.11,12 Tresiba® blev godkendt af registreringsmyndighederne første gang i september 2012 og er siden blevet godkendt i flere end 80 lande verden over. Det er nu på markedet i flere end 50 lande. Yderligere information Referencer1.         Gumprecht J, Lane W, Chaykin LB, et al. Lower rate of hypoglycaemia with insulin degludec vs. insulin glargine U100 after adjusting for HbA1c in SWITCH 1 and 2. Poster presentation. International Diabetes Federation (IDF) Annual Congress 2017, Abu Dhabi, UAE. December 2017.2.         Lane W, Bailey TS, Gerety G, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes: The SWITCH 1 randomized clinical trial. JAMA. 2017;318:33-44.3.         Wysham C, Bhargava A, Chaykin L, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: The SWITCH 2 randomized clinical trial. JAMA. 2017;318:45-56.4.         Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36:1384-1395.5.         International Hypoglycaemia Study Group. Diagnosis of hypoglycaemia. Available online at http://ihsgonline.com/understanding-hypoglycaemia/diagnosis. Last accessed November 2017.6.         Cryer P. Hypoglycemia, functional brain failure, and brain death. Journal of Clinical Investigation. 2007;117:868-870.7.         Pieber TR, Marso SP, McGuire DK, et al. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia. 2017.8.         Khunti K, Alsifri S, Aronson R, et al. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. Diabetes Obes Metab. 2016;18:907-915.9.         Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient Centered Approach. Diabetes Care 2015;38:140-149.10.       Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014;53:787-800.11.       EMA. Tresiba® Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002498/WC500138940.pdf. Last accessed: November 2017.12.       Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377:723-732.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=707,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
227,2017-12-07,Ryzodeg® significantly reduces the risk of low blood sugar in people with type 2 diabetes who fast during Ramadan,"Abu Dhabi, UAE, 7 December 2017 ­- In people with type 2 diabetes who fast during Ramadan, Ryzodeg® (insulin degludec/insulin aspart) reduced the overall rate of low blood sugar (hypoglycaemia) including severe episodes by 62% and the rate of nocturnal hypoglycaemia by 74% versus biphasic insulin aspart 30 (BIAsp 30 [NovoMix® 30]). The trial results were presented today at the International Diabetes Federation Congress 2017 (IDF 2017).1 ""Millions of people with type 2 diabetes participate in Ramadan every year and we know that periods of prolonged fasting can increase the risk of hypoglycaemia,"" said lead investigator Dr Mohamed Hassanein of the Dubai Hospital, Dubai Health Authority, UAE and chair of the Diabetes and Ramadan International Alliance (DAR). ""This highlights the importance of people with type 2 diabetes preparing for Ramadan with their doctor and discussing treatment options for preventing episodes of hypoglycaemia."" It is estimated that worldwide over 116 million Muslims with diabetes may choose to fast during Ramadan.2 Muslims with type 2 diabetes who fast during Ramadan have up to a 7.5-fold increased risk of severe hypoglycaemia.3 ""This trial has shown that Ryzodeg® is not only a simple treatment option which can make daily life easier for people with diabetes. Ryzodeg® also reduces the risk of potentially dangerous episodes of hypoglycaemia in people with type 2 diabetes who choose to fast during Ramadan,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. The trial was designed to investigate the effects of Ryzodeg® on blood sugar control and hypoglycaemia reduction versus BIAsp 30, both at the end of Ramadan and 4 weeks post-Ramadan. There was no difference in overall blood sugar control between Ryzodeg®      and BIAsp 30.1 The Ramadan trial compared the efficacy and safety of Ryzodeg® twice daily and BIAsp 30 (NovoMix®) twice daily in subjects with type 2 diabetes before, during and after Ramadan. The trial was a 28-week, international, open-label, randomised, treat-to-target trial involving 263 adults from five countries with large Muslim populations (Algeria, India, Lebanon, Malaysia and South Africa). The primary endpoint was change in HbA1c from baseline to the end of the month of Ramadan (four-week period). Secondary confirmatory endpoints included rates of blood sugar confirmed, nocturnal and severe hypoglycaemia.1 Ryzodeg® is a combination of two distinct insulin analogues (insulin degludec and insulin aspart in the ratio of 70% and 30%), making it the first combination of a basal insulin with an ultra-long duration of action and a mealtime insulin in one pen for people with type 1 and 2 diabetes.4-6 Ryzodeg® incorporates the benefits of the degludec molecule.7,8 Ryzodeg® is given as an injection once or twice daily with the main meal(s).4 Ryzodeg® offers a simpler regimen with fewer injections than basal and bolus therapy, in one pen.9 Ryzodeg® received its first regulatory approval in December 2012 and European Medicines Agency approval in January 2013. Since then, Ryzodeg® has been approved in more than 70 countries, including the US in September 2015. It is now commercially available in 13 countries.4 Further information References1.         Hassanein M, Echtay A, Malek R, et al. Efficacy and safety of insulin degludec/insulin aspart in adults with type 2 diabetes fasting during Ramadan. Presented at the International Diabetes Federation Congress 2017, Abu Dhabi, UAE. 4-8 December 2017.2.         International Diabetes Federation and the Diabetes and Ramadan (DAR) International Alliance. Diabetes and Ramadan: Practical Guidelines. Brussels, Belgium: International Diabetes Federation, 2016. Available at: https://www.idf.org/e-library/guidelines/87-diabetes-and-ramadan-practical-25. Last accessed: November 2017.3.         Salti I, Benard E, Detournay B, et al. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care. 2004;27:2306-2311.4.         EMA. Ryzodeg® Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002499/WC500139011.pdf. Last accessed: November 2017.5.         Fulcher GR, Christiansen JS, Bantwal G, et al. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial. Diabetes Care. 2014;37:2084-2090.6.         De Rycke A, Mathieu C. Degludec - first of a new generation of insulins. European Endocrinology. 2011;7:84-87.7.         Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clinical Pharmacokinetics. 2014;53:787-800.8.         Marso SP, McGuire DK, Zinman B, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017;377:723-732.9.         Heise T, Tack CJ, Cuddihy R, et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naïve people with type 2 diabetes: a randomized, controlled trial. Diabetes Care. 2011;34:669-674.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=708,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
228,2017-12-07,"Ryzodeg® reducerer risikoen for lavt blodsukker hos mennesker med type 2-diabetes, som faster under ramadanen","Abu Dhabi, Forenede Arabiske Emirater, den 7. december 2017 ­- Under ramadanen er der mange mennesker med type 2-diabetes, som vælger at faste. Ny forskning viser, at Ryzodeg® (insulin degludec/insulin aspart) reducerer den generelle forekomst af lavt blodsukker (hypoglykæmi), herunder alvorlige tilfælde, med 62% og forekomsten af natlig hypoglykæmi med 74% sammenlignet med bifasisk insulin aspart 30 (BIAsp 30 [NovoMix® 30]). Disse resultater præsenteres i dag på International Diabetes Federation Congress 2017 (IDF 2017).1 ""Hvert år deltager millioner af mennesker med type 2-diabetes i ramadanen, og vi ved, at længere fasteperioder kan øge risikoen for hypoglykæmi,"" siger dr. Mohamed Hassanein fra Dubai Hospital, Dubai Health Authority, Forenede Arabiske Emirater, forsøgsansvarlig læge i studiet og formand for Diabetes and Ramadan International Alliance (DAR). ""Dette bekræfter, hvor vigtigt det er, at mennesker med type 2-diabetes, i samarbejde med deres læge, forbereder sig til ramadanen og bliver enige om, hvilke justeringer af deres behandling der er nødvendige for at forebygge hypoglykæmi."" Man anslår, at der er over 116 mio. muslimer med diabetes i verden, som muligvis faster under ramadanen.2 Muslimer med type 2-diabetes, som faster under ramadanen, har op til 7,5 gange forøget risiko for alvorlig hypoglykæmi.3 ""Dette studie har vist, at Ryzodeg® ikke bare er en enkel behandlingsmulighed, som kan gøre hverdagen lettere for mennesker med diabetes. Ryzodeg® nedsætter også risikoen for potentielt farlige tilfælde af hypoglykæmi hos mennesker med type 2-diabetes, som vælger at faste under ramadanen,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. Studiet havde til formål at undersøge virkningen af Ryzodeg® på blodsukkerregulering og reduktion af hypoglykæmi sammenlignet med BIAsp 30, både ved afslutningen af og fire uger efter ramadanen. Der var ingen forskel i den generelle blodsukkerregulering mellem Ryzodeg® og BIAsp 30.1 Ramadan-studiet sammenlignede effekt og sikkerhed for Ryzodeg® to gange dagligt og BIAsp 30 (NovoMix®) to gange dagligt hos deltagere med type 2-diabetes før, under og efter ramadanen. Studiet blev gennemført som et 28-ugers, internationalt, ikke-blindet, randomiseret treat to target-studie, som omfattede 263 voksne fra fem lande med store muslimske befolkningsgrupper (Algeriet, Indien, Libanon, Malaysia og Sydafrika). Det primære endepunkt var ændring i langtidsblodsukker (HbA1c) fra baseline ved studiets start til afslutningen af ramadanmåneden (fire uger). De sekundære bekræftende endepunkter var bl.a. forekomsten af natlig og alvorlig hypoglykæmi bekræftet ved blodsukkermåling.1 Ryzodeg® er en kombination af to forskellige insulinanaloger (insulin degludec og insulin aspart i forholdet 70/30) og dermed den første kombination af en ultralangtidsvirkende basalinsulin og en måltidsinsulin i én injektionspen til mennesker med type 1- og type 2-diabetes.4-6 Ryzodeg® indeholder degludec-molekylets fordele.7,8 Ryzodeg® gives som injektion én eller to gange dagligt sammen med et hovedmåltid.4 Ryzodeg® giver mulighed for en enklere behandling med færre injektioner end ved basal-bolusbehandling, i én pen.9 Ryzodeg® modtog sin første myndighedsgodkendelse i december 2012 og blev godkendt af Det Europæiske Lægemiddelagentur i januar 2013. Siden da er Ryzodeg® blevet godkendt i mere end 70 lande, herunder USA i september 2015. Det er nu på markedet i 13 lande.4 Yderligere information Referencer1.         Hassanein M, Echtay A, Malek R, et al. Efficacy and safety of insulin degludec/insulin aspart in adults with type 2 diabetes fasting during Ramadan. Presented at the International Diabetes Federation Congress 2017, Abu Dhabi, UAE. 4-8 December 2017.2.         International Diabetes Federation and the Diabetes and Ramadan (DAR) International Alliance. Diabetes and Ramadan: Practical Guidelines. Brussels, Belgium: International Diabetes Federation, 2016. Available at: https://www.idf.org/e-library/guidelines/87-diabetes-and-ramadan-practical-25. Last accessed: November 2017.3.         Salti I, Benard E, Detournay B, et al. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care. 2004;27:2306-2311.4.         EMA. Ryzodeg® Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002499/WC500139011.pdf. Last accessed: November 2017.5.         Fulcher GR, Christiansen JS, Bantwal G, et al. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial. Diabetes Care. 2014;37:2084-2090.6.         De Rycke A, Mathieu C. Degludec - first of a new generation of insulins. European Endocrinology. 2011;7:84-87.7.         Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clinical Pharmacokinetics. 2014;53:787-800.8.         Marso SP, McGuire DK, Zinman B, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017;377:723-732.9.         Heise T, Tack CJ, Cuddihy R, et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naïve people with type 2 diabetes: a randomized, controlled trial. Diabetes Care. 2011;34:669-674.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=709,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
229,2017-12-06,Interim results of first-ever global survey show people with type 2 diabetes underestimate their cardiovascular risk,"December 6, 2017 Abu Dhabi, UAE ­- Today the International Diabetes Federation (IDF) presented the interim results of the first ever multi-country online survey on CVD risk awareness and knowledge among people living with type 2 diabetes, indicating low levels of awareness and limited dialogue between patients and healthcare professionals. The global survey - Taking Diabetes to Heart - developed in partnership with Novo Nordisk, runs until March 2018 and is open to all people with type 2 diabetes. Diabetes currently affects 425 million adults worldwide1, with most cases being type 2 diabetes. Cardiovascular disease, which includes stroke, coronary heart disease and peripheral artery disease3, is the leading cause of disability and death in people with type 2 diabetes1,4. To date, 943 responses to the survey have been received from 32 countries and interim findings show that: ""The interim results of Taking Diabetes to Heart reiterate the importance of raising awareness of the association between type 2 diabetes and cardiovascular disease to promote prevention, timely diagnosis and appropriate treatment to help reduce the current burden that the two conditions represent,"" said Dr Shaukat Sadikot, outgoing IDF President. ""With the world facing an increase in the prevalence of type 2 diabetes, better understanding the link between these conditions is needed more than ever."" Taking Diabetes to Heart - www.idf.org/takingdiabetes2heart/survey - aims to gather insights on current gaps in education and CVD risk behaviour among people with type 2 diabetes, and to put in place advocacy and patient support strategies and tactics to improve health and wellbeing among populations. ""Cardiovascular disease is the leading cause of disability and death among people living with type 2 diabetes. Too few individuals with diabetes are being informed by healthcare professionals of their cardiovascular risk and the impact that risk may have on their longevity and quality of life,"" said Alan Moses, senior vice president and chief medical officer of Novo Nordisk. ""We encourage more people in the diabetes community to complete the Taking Diabetes to Heart survey to strengthen the global findings that will inform future efforts to help improve outcomes."" The results of Taking Diabetes to Heart will serve to define the actions that are required to improve the health outcomes of people with type 2 diabetes. The initiative will culminate in a comprehensive report with country-specific results and resources to help support knowledge and awareness of CVD among people with type 2 diabetes around the world. For more information about Taking Diabetes to Heart, visit www.idf.org/takingdiabetes2heart. For more information about diabetes and CVD, visit www.idf.org/cvd The International Diabetes Federation (IDF) is an umbrella organisation of over 230 national diabetes associations in 165 countries and territories. It represents the interests of the growing number of people with diabetes and those at risk. The Federation has been leading the global diabetes community since 1950. The Federation's activities aim to influence policy, increase public awareness and encourage health improvement, promote the exchange of high-quality information about diabetes, and provide education for people with diabetes and their healthcare providers. IDF is associated with the Department of Public Information of the United Nations and is in official relations with the World Health Organization (WHO). www.idf.org. Taking Diabetes to Heart - www.idf.org/takingdiabetes2heart - consists of an online survey available in multiple languages, including Arabic, Bulgarian, Chinese, Danish, Dutch, English, French, Filipino, Finnish, German, Hindi, Italian, Portuguese, Russian, Spanish, Swahili and Vietnamese. The survey will remain online until March 2018. Results from the survey will be used to inform policy and decision-making around this common and serious complication of diabetes.2,3 Further information _______________________  References 1.    International Diabetes Federation. IDF Diabetes Atlas, 8th Edition. Brussels, Belgium: International Diabetes Federation, 2017. Available at: www.diabetesatlas.org2.    International Diabetes Federation, 2017. Taking Diabetes to Heart - Global IDF survey on CVD risk awareness among people with diabetes. Available at: www.idf.org/takingdiabetes2heart3.    International Diabetes Federation. Diabetes and Cardiovascular Disease. Brussels, Belgium: International Diabetes Federation, 2016. Available at: www.idf.org/cvd4.    World Health Organization, editor. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva, Switzerland: World Health Organization; 2009. 62p.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=710,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
230,2017-12-06,"Foreløbige resultater fra global undersøgelse viser, at mennesker med type 2-diabetes undervurderer deres risiko for hjerte-kar-sygdom","Abu Dhabi, Forenede Arabiske Emirater, den 6. december 2017 ­- International Diabetes Federation (IDF) præsenterer i dag de foreløbige resultater fra den første onlineundersøgelse nogensinde af kendskabet til og viden om hjerte-kar-sygdom blandt mennesker med type 2-diabetes i en lang række lande verden over. Resultaterne tyder på, at der er et lavt niveau af viden om sygdommen samt kun begrænset dialog om den mellem patienter og behandlere. Den globale undersøgelse - Taking Diabetes to Heart - er udviklet i et partnerskab mellem Novo Nordisk og IDF og løber indtil marts 2018; alle mennesker med type 2-diabetes kan deltage. Der er i dag 425 mio. voksne med diabetes i verden1, hvoraf størstedelen har type 2-diabetes. Hjerte-kar-sygdom, der bl.a. omfatter slagtilfælde, kranspulsåresygdom og perifer arteriesygdom 3, er den hyppigste årsag til invaliditet og død blandt mennesker med type 2-diabetes1,4. Der er indtil nu modtaget 943 besvarelser fra 32 lande, og de foreløbige resultater viser, at: ""De foreløbige resultater fra Taking Diabetes to Heart understreger, hvor vigtigt det er at udbrede kendskabet til sammenhængen mellem type 2-diabetes og hjerte-kar-sygdom for at fremme forebyggelse, tidlig diagnose og relevant behandling og på den måde hjælpe med til at mindske den belastning, som de to sygdomme repræsenterer i dag,"" siger dr. Shaukat Sadikot, fratrædende præsident for IDF. ""I en verden, hvor forekomsten af type 2-diabetes er i hastig vækst, er der større behov end nogensinde for at forstå sammenhængen mellem disse sygdomme."" Taking Diabetes to Heart - www.idf.org/takingdiabetes2heart/survey - har til formål at indsamle viden om manglende indsigt i samt risikoadfærd i forhold til hjerte-kar-sygdom blandt mennesker med type 2-diabetes, og at etablere tiltag for oplysning og patientstøtte og planer for at forbedre sundhed og velfærd i befolkningen. ""Hjerte-kar-sygdom er den hyppigste årsag til invaliditet og død blandt mennesker med type 2-diabetes. Alt for få mennesker med diabetes bliver informeret af lægerne om deres risiko for hjerte-kar-sygdom, og hvilken indflydelse den risiko kan have på deres levetid og livskvalitet,"" siger Alan Moses, direktør og chief medical officer i Novo Nordisk. ""Vi vil gerne opfordre endnu flere, der er berørt af diabetes, til at deltage i Taking Diabetes to Heart-undersøgelsen så vi kan blive klogere på, hvilke tiltag der er behov for, hvis vi skal gøre noget ved problemet."" Resultaterne fra Taking Diabetes to Heart vil bidrage til at definere, hvilke tiltag der er behov for i forhold til at forbedre behandlingsresultaterne for mennesker med type 2-diabetes. Initiativet vil udmønte sig i en omfattende rapport med landespecifikke resultater og ressourcer, der skal hjælpe med at understøtte viden om og kendskab til hjerte-kar-sygdom blandt mennesker med type 2-diabetes rundt om i verden. Læs mere om Taking Diabetes to Heart på www.idf.org/takingdiabetes2heart. Læs mere om diabetes og hjerte-kar-sygdom på www.idf.org/cvd International Diabetes Federation (IDF) er en paraplyorganisation for over 230 nationale diabetesforeninger i 165 lande og regioner. Den varetager interesserne hos det voksende antal mennesker, der lever med diabetes, og dem, der er i risikogruppen. IDF har stået i spidsen for det globale diabetessamfund siden 1950. Organisationens aktiviteter sigter mod at påvirke politiske beslutningstagere, skabe øget offentlig opmærksomhed og bane vejen for sundhedsforbedringer, fremme udvekslingen af kvalitetsoplysninger om diabetes og tilbyde undervisning for mennesker med diabetes og deres behandlere. IDF er tilknyttet FN's afdeling for offentlig information (Department of Public Information) og samarbejder med Verdenssundhedsorganisationen (WHO). www.idf.org Taking Diabetes to Heart - www.idf.org/takingdiabetes2heart - består af en onlineundersøgelse, der er tilgængelig på en række forskellige sprog, herunder arabisk, bulgarsk, dansk, engelsk, filippinsk, finsk, fransk, hindi, hollandsk, italiensk, kinesisk, portugisisk, russisk, spansk, swahili, tysk og vietnamesisk. Undersøgelsen vil være tilgængelig online indtil marts 2018. Resultaterne fra undersøgelsen vil danne grundlag for den politiske indsats og den videre beslutningstagning vedrørende denne almindelige og alvorlige komplikation til diabetes.2,3 Yderligere information _______________________  Referencer 1.    International Diabetes Federation. IDF Diabetes Atlas, 8th Edition. Brussels, Belgium: International Diabetes Federation, 2017. Available at: www.diabetesatlas.org2.    International Diabetes Federation, 2017. Taking Diabetes to Heart - Global IDF survey on CVD risk awareness among people with diabetes. Available at: www.idf.org/takingdiabetes2heart3.    International Diabetes Federation. Diabetes and Cardiovascular Disease. Brussels, Belgium: International Diabetes Federation, 2016. Available at: www.idf.org/cvd4.    World Health Organization, editor. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva, Switzerland: World Health Organization; 2009. 62p.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=711,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
231,2017-12-05,Ozempic® (semaglutide) approved in the US,"Bagsværd, Denmark, 5 December 2017 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Ozempic® (semaglutide injection). Ozempic® is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. Ozempic®, the approved brand name for once-weekly semaglutide in the US, is a glucagon-like peptide 1 (GLP-1) receptor agonist. The approval of Ozempic® is based on the results from the SUSTAIN clinical trial programme and follows a positive recommendation from an FDA Advisory Committee meeting on 18 October 2017. In people with type 2 diabetes, Ozempic® produced clinically meaningful and statistically significant reductions in HbA1c compared with placebo, sitagliptin, exenatide extended-release and insulin glargine U100. Furthermore, in the trials, treatment with Ozempic® resulted in statistically significant reductions in body weight. Ozempic® demonstrated a safe and well-tolerated profile across the SUSTAIN programme with the most common adverse event being mild to moderate nausea, which diminished over time. Ozempic® is approved for use in two therapeutic dosages, 0.5 mg and 1 mg, and will be launched in the Ozempic® Pen, the latest generation of Novo Nordisk prefilled devices. Novo Nordisk will, as part of the post-approval requirements, conduct a paediatric trial in adolescents under 18 years of age and will add Ozempic® to the 15-year MTC (medullary thyroid carcinoma) registry that is being conducted for all other long-acting GLP-1 products. ""We are very excited about the first approval of Ozempic® and look forward to making this important innovation available to people in the US with type 2 diabetes in the beginning of 2018,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer. ""Type 2 diabetes is a complex disease, but with the unique clinical profile of Ozempic®, we believe it has the potential to set a new standard for the treatment of the disease."" Conference call On 6 December 2017 at 12.00 pm CET, corresponding to 6.00 am EST, a conference call for investors will be held. Investors will be able to listen in via a link on the investor section of novonordisk.com. About Ozempic® Ozempic® (semaglutide) is a once-weekly analogue of human glucagon-like peptide-1 (GLP-1) that has been developed for the treatment of type 2 diabetes. The review of Ozempic® is based on the SUSTAIN programme, a global clinical development programme that comprises eight phase 3a trials, encompassing more than 8,000 adults with type 2 diabetes. The phase 3a programme involves a broad range of people with type 2 diabetes, including some with high cardiovascular risk profiles and people with and without renal disease. Ozempic® is currently under review by several regulatory agencies, including the European Medicines Agency and the Japanese Pharmaceuticals and Medical Devices Agency. Further information Company announcement No 90 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=712,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
232,2017-12-05,Ozempic® (semaglutid) godkendt i USA,"Bagsværd, den 5. december 2017 - Novo Nordisk meddeler i dag, at de amerikanske sundhedsmyndigheder, FDA, har godkendt Ozempic® (semaglutid i injektionsform). Ozempic® godkendes som tillægsbehandling til diæt og motion med det formål at forbedre blodsukkerreguleringen hos voksne med type 2-diabetes. Ozempic®, det godkendte varemærke for ugentlig semaglutid i USA, er en glukagonlignende peptid-1 (GLP-1) receptoragonist. Godkendelsen af Ozempic® er baseret på resultaterne fra det kliniske udviklingsprogram SUSTAIN og kommer i forlængelse af den positive anbefaling fra FDA's rådgivende komite på mødet den 18. oktober 2017. Studierne viste, at Ozempic® medførte klinisk betydningsfulde og statistisk signifikante reduktioner i langtidsblodsukkeret (HbA1c) hos mennesker med type 2-diabetes sammenlignet med placebo, sitagliptin, exenatid extended-release og insulin glargin U100. Behandling med Ozempic® medførte desuden statistisk signifikante vægtreduktioner i studierne. Ozempic® viste en sikker og veltolereret profil på tværs af SUSTAIN-programmet. Den mest almindelige bivirkning var mild til moderat kvalme, som aftog med tiden. Ozempic® er godkendt til brug i to doseringer, 0,5 mg og 1 mg, og vil blive lanceret i Ozempic® Pen, som er Novo Nordisks nyeste generation af præfyldte injektionspenne. Novo Nordisk vil som en del af myndighedskravene efter godkendelsen gennemføre et pædiatrisk studie blandt unge under 18 år og vil lade Ozempic® indgå i det 15-årige MTC-registerstudie (medullært thyroideakarcinom), hvori alle andre langtidsvirkende GLP-1-produkter også indgår. ""Vi er meget begejstrede over, at Ozempic® nu har fået sin første godkendelse, og ser frem til at gøre dette vigtige innovative produkt tilgængeligt for mennesker med type 2-diabetes i USA i starten af 2018,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Type 2-diabetes er en kompleks sygdom, men vi er overbevist om, at Ozempic® med sin unikke kliniske profil har potentiale til at sætte en ny standard for behandling af denne sygdom."" Der vil den 6. december 2017 kl. 12.00 CET blive afholdt en telekonference. Investorer kan lytte med via et link på novonordisk.com under menupunktet 'Investors'. Ozempic® (semaglutid) er en ugentlig analog af det naturlige hormon glukagonlignende peptid-1 (GLP-1), som er udviklet til behandling af type 2-diabetes. Vurderingen af Ozempic® er baseret på SUSTAIN-programmet, et globalt klinisk udviklingsprogram, som omfatter otte fase 3a-studier med deltagelse af flere end 8.000 voksne med type 2-diabetes. Fase 3a-programmet omfatter en bred vifte af deltagere med type 2-diabetes, heraf nogle med høj risiko for kardiovaskulære hændelser samt deltagere med og uden nyresygdom. Der er indsendt registreringsansøgning for Ozempic® til flere regulatoriske myndigheder, herunder Det Europæiske Lægemiddelagentur og de japanske sundhedsmyndigheder, Japanese Pharmaceuticals and Medical Devices Agency. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 90 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=713,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
233,2017-12-05,Xultophy® reported a better option than basal-bolus insulin therapy to manage type 2 diabetes by participants in the DUAL VII clinical trial,"Abu Dhabi, UAE, 5 December 2017 - Once-daily Xultophy® (insulin degludec/liraglutide) was a better option to manage diabetes compared to multiple daily injections of insulin (basal-bolus regimen). This was reported by people with type 2 diabetes whose blood sugar was not controlled on insulin glargine U100 with metformin, and who completed quality-of-life questionnaires as part of the DUAL VII clinical trial.1 In addition, more people preferred to stay on Xultophy® compared with basal-bolus therapy (84.5% versus 68.1%).1 These results were presented today at the 2017 International Diabetes Federation Congress in Abu Dhabi, UAE. ""Adding insulin injections at mealtime is an effective option to achieve desired blood glucose levels when basal insulin is not enough, but this raises the level of complexity in the patients' daily management of their diabetes. It can also lead to an increased risk of hypoglycaemia (low blood sugar) or weight gain"", said Professor Esteban Jódar, University Hospital Quirón Salud, Madrid, Spain. ""In the main analysis of the DUAL VII trial, Xultophy® delivered similar glucose reductions to a basal-bolus regimen alongside weight loss, as opposed to weight gain, and fewer episodes of hypoglycaemia. We now see that it also reduces treatment burden."" In the patient-reported outcomes (PRO) analysis from the DUAL VII clinical trial, 506 adults living with type 2 diabetes assessed their physical health, mental health and a number of diabetes-specific factors. These scores were measured using the validated Treatment-Related Impact Measure-Diabetes (TRIM-D) questionnaire and the Short Form Health Survey 36 v2 (SF-36)1. The participants in the study treated with Xultophy® reported better experiences for all diabetes-specific factors compared to the ones in the basal-bolus treatment regimen, with the highest improvement in TRIM-D scores given for diabetes management (16.7 versus 6.8), treatment burden (12.4 versus 4.3) and compliance (9.1 versus 3.9). The analysis of the SF-36 questionnaire results found that Xultophy® was associated with a statistically significant higher score compared to basal-bolus insulin regimen for the mental health component of the questionnaire; all other comparisons were non-significant.1 ""Living with diabetes is a complex situation in itself, and the treatment should not add to this. We are very pleased to see that Xultophy® not only helps people with type 2 diabetes reach their blood glucose targets while reducing the risk of hypoglycaemia and helping them to lose weight, but does this in a simple way"", said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""This is a key component of what innovation in diabetes means to us. It's about making the lives of people with diabetes as easy as possible."" This analysis is based on PRO data collected during the DUAL VII clinical trial using different health questionnaires. The TRIM-D questionnaire is specific to diabetes. The SF-36 is a generic health questionnaire used to assess quality of life measures. Motivation to stay on treatment was measured using an additional motivation questionnaire.1 In DUAL VII, Xultophy® induced greater improvements in PROs, mainly in outcome measures related to diabetes management, treatment burden and compliance versus basal-bolus therapy in people with HbA1c 7.0-10% switched from insulin glargine U100 with metformin. People on Xultophy® had an equal reduction in HbA1c, a lower rate of hypoglycaemia, fewer injections per day and weight loss versus basal-bolus insulin treatment. Improvement in the PRO measurements with Xultophy® corresponded with desirable clinical outcomes. The open-label nature of the trial was a limitation and could have influenced the results.1 Changes in PRO scores were calculated from baseline after 26 weeks of treatment. Per definition, PRO data came directly from patients, without interpretation of the patient's response by a clinician or anyone else.2 DUAL VII was a phase 3b, 26-week, randomised, open-label, multicentre trial conducted in 12 countries including 506 patients.3 The trial was designed to investigate the safety and efficacy of Xultophy® versus basal-bolus therapy in adults with type 2 diabetes previously treated with insulin glargine U100 and metformin.3 Xultophy® is a once-daily single injection fixed-ratio combination of long-acting insulin degludec and the glucagon-like peptide-1(GLP-1) receptor agonist liraglutide in one pen. It is indicated for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with a GLP-1 receptor agonist or basal insulin do not provide adequate glycaemic control. Xultophy® can be administered at any time of the day with or without meals, preferably at the same time of the day.4 References 1.       Jodar E, Doshi A, Gouet D, et al. Patient-reported outcomes with insulin degludec/liraglutide (IDegLira) vs. basal-bolus therapy in patients with type 2 diabetes: DUAL VII trial. Congress of the International Diabetes Federation (IDF 2017). 20172.       US Department of Health and Human Services Food and Drug Administration. Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims. 2009. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf Last accessed: November 2017. 3.       ClinicalTrials.gov. A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus. Available at: https://clinicaltrials.gov/ct2/show/NCT02420262?term=ideglira%2C+basal-bolus&rank=1. Last accessed: November 2017. 4.       EMA. Xultophy® Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002647/WC500177657.pdf. Last accessed: November 2017. 5.       Novo Nordisk. Novo Nordisk receives US FDA approval for Xultophy® 100/3.6. Available at:  http://www.novonordisk.com/bin/getPDF.2058006.pdf. Last accessed: November 2017.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=714,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
234,2017-12-05,Xultophy® vurderes som en bedre behandlingsmulighed end basal-bolus-insulinbehandling af deltagere med type 2-diabetes i DUAL VII-studiet,"Abu Dhabi, Forenede Arabiske Emirater, den 5. december 2017 ­- Xultophy® én gang dagligt (insulin degludec/liraglutid) vurderes som en bedre behandlingsmulighed end flere daglige injektioner af insulin (basal-bolus-behandling). Det viser en undersøgelse blandt deltagere med type 2-diabetes, som var utilfredsstillende reguleret med insulin glargin U100 plus metformin, og som besvarede spørgeskemaer om livskvalitet som led i det kliniske studie DUAL VII.1 Der var desuden flere, der foretrak at fortsætte med behandling med Xultophy® end med basal-bolus-behandling (84,5% mod 68,1%).1 Disse resultater præsenteres i dag på International Diabetes Federation Congress 2017 (IDF 2017) i Abu Dhabi, Forenede Arabiske Emirater. ""Når man ikke længere opnår en tilstrækkelig blodsukkerregulering med basalinsulin, er det en virkningsfuld mulighed at supplere med injektioner af måltidsinsulin, men det øger kompleksiteten i den daglige behandling for patienten. Det kan også give større risiko for at få for lavt blodsukker (hypoglykæmi) eller tage på i vægt,"" siger professor Esteban Jódar, University Hospital Quirón Salud, Madrid, Spanien. ""Hovedanalysen af DUAL VII-studiet viste, at Xultophy® medførte blodsukkerreduktioner svarende til basal-bolus-behandling og samtidig gav vægttab i stedet for vægtøgning samt færre tilfælde af lavt blodsukker. Vi ser nu, at det også reducerer den belastning, behandlingen udgør for patienterne."" I analysen af de patientrapporterede behandlingsresultater fra DUAL VII-studiet vurderede 506 voksne med type 2-diabetes deres fysiske og psykiske sundhed samt en række diabetesspecifikke parametre. Scorerne blev beregnet ved hjælp af spørgeskemaerne Treatment-Related Impact Measure-Diabetes (TRIM-D) og Short Form Health Survey 36 v2 (SF-36).1 De af studiets deltagere, der blev behandlet med Xultophy®, rapporterede om bedre erfaringer på alle diabetesspecifikke parametre sammenlignet med parametrene for basal-bolus-behandling, idet den største forbedring i TRIM-D-scorerne sås for diabetesregulering (16,7 mod 6,8), belastning af behandlingen (12,4 mod 4,3) og overholdelse af behandlingen (9,1 mod 3,9). Analysen af resultaterne fra spørgeskemaet SF-36 viste, at Xultophy® var forbundet med en statistisk signifikant højere score sammenlignet med basal-bolus-insulinbehandling for den del af spørgeskemaet, der handlede om psykisk sundhed; alle andre sammenligninger var ikke signifikante.1 ""Det at have diabetes er en kompleks situation i sig selv, og behandlingen skulle helst ikke gøre belastningen større. Vi er meget glade for at se, at Xultophy® ikke bare hjælper mennesker med type 2-diabetes med at nå deres blodsukkermål, nedsætter risikoen for hypoglykæmi og hjælper dem med at tabe sig - men også gør det på en enkel måde,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Det er noget af det helt centrale for os, når vi taler om innovation indenfor diabetes. Det handler om at gøre livet så let som muligt for mennesker med diabetes."" Denne analyse er baseret på patientrapporterede data (PRO) indsamlet som led i det kliniske DUAL VII-studie ved hjælp af forskellige sundhedsrelaterede spørgeskemaer. TRIM-D-spørgeskemaet omhandler specifikt diabetes. SF-36 er et spørgeskema om sundhed generelt, der bruges til at måle livskvalitet. Motivationen for at fortsætte igangværende behandling blev målt ved hjælp af et motivationsspørgeskema.1 I DUAL VII medførte Xultophy® større forbedringer i PRO, primært med hensyn til behandlingsmål relateret til diabetesbehandling, belastning og overholdelse af behandling, sammenlignet med basal-bolus-behandling hos deltagere med et langtidsblodsukkerniveau (HbA1c) på 7,0-10%, som var skiftet fra insulin glargin U100 plus metformin. Deltagere i behandling med Xultophy® opnåede samme reduktion i HbA1c som ved basal-bolus-insulinbehandling foruden færre tilfælde af hypoglykæmi, færre daglige injektioner samt vægttab. Forbedringen i PRO-målingerne med Xultophy® var i tråd med de ønskede kliniske behandlingsresultater. Det, at studiet var ikke-blindet, var en begrænsning og kan have påvirket resultaterne.1 Ændringer i PRO-scorerne blev udregnet i forhold til baseline efter 26 ugers behandling. PRO-data kom pr. definition direkte fra patienterne uden fortolkning af besvarelser fra læger eller andre.2 Fase 3b-studiet DUAL VII var tilrettelagt som et 26-ugers randomiseret, ikke-blindet multicenterstudie, der blev gennemført i 12 lande og omfattede 506 deltagere.3 Studiet havde til formål at undersøge sikkerheden og effekten af Xultophy® sammenlignet med basal-bolus-behandling i voksne med type 2-diabetes, som tidligere var blevet behandlet med insulin glargin U100 og metformin.3 Xultophy® er et kombinationsprodukt bestående af langtidsvirkende insulin degludec og GLP-1-receptoragonisten liraglutid i et fast kombinationsforhold i et præfyldt pensystem til dosering én gang dagligt som én injektion. Xultophy® er godkendt til behandling af voksne med type 2-diabetes med det formål at opnå forbedret blodsukkerregulering i kombination med blodsukkersænkende lægemidler i tabletform, når disse ikke alene eller kombineret med en GLP-1-receptoragonist eller basalinsulin giver en tilstrækkelig regulering af blodsukkerniveauet. Xultophy® kan tages på et hvilket som helst tidspunkt af dagen, sammen med eller uden et måltid, helst på samme tidspunkt hver dag.4 Yderligere information  Referencer 1.       Jodar E, Doshi A, Gouet D, et al. Patient-reported outcomes with insulin degludec/liraglutide (IDegLira) vs. basal-bolus therapy in patients with type 2 diabetes: DUAL VII trial. Congress of the International Diabetes Federation (IDF 2017). 20172.       US Department of Health and Human Services Food and Drug Administration. Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims. 2009. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf Last accessed: November 2017. 3.       ClinicalTrials.gov. A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus. Available at: https://clinicaltrials.gov/ct2/show/NCT02420262?term=ideglira%2C+basal-bolus&rank=1. Last accessed: November 2017. 4.       EMA. Xultophy® Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002647/WC500177657.pdf. Last accessed: November 2017. 5.       Novo Nordisk. Novo Nordisk receives US FDA approval for Xultophy® 100/3.6. Available at: http://www.novonordisk.com/bin/getPDF.2058006.pdf. Last accessed: November 2017.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=715,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
235,2017-11-21,Highlights to be presented at Novo Nordisk's Capital Markets Day 2017,"Bagsværd, Denmark, 21 November 2017 - Novo Nordisk will today host a Capital Markets Day where the company will provide updates on its R&D and commercial strategy as well as current market dynamics. Novo Nordisk's ambition is to further expand its leadership in the global diabetes and obesity care markets by discovering, developing and marketing improved insulin and GLP-1 analogues as well as completely new classes of biologics. Furthermore, it is Novo Nordisk's ambition to return to growth in the Biopharm area. The key topics of the day will be: In addition, the Capital Markets Day 2017 will include break-out sessions covering oral semaglutide and the associated production expansion, the regions in International Operations: Region China and Region AAMEO (Africa, Asia, Middle-East Oceania) as well as an update on the business dynamics in Biopharm Operations. NOVO NORDISK'S R&D STRATEGY AND KEY DEVELOPMENT PROJECTSNovo Nordisk's dedicated R&D strategy will be presented with special focus on key competitive advantages throughout the R&D value chain as well as the expansion into other serious chronic diseases. The presentation will outline the company's R&D strategy for delivering future innovative protein-based therapies addressing unmet medical needs driven by internal R&D capabilities and assets, expansion into other chronic disease areas, as well as an increased focus on external innovation. Furthermore, an update of the recent clinical results for key development projects within diabetes and obesity care, as well as a number of haemophilia and growth disorder projects, will be presented. The expected upcoming development and regulatory milestones for 2018 will also be outlined, including the expected reporting of the PIONEER phase 3a clinical trial programme for oral semaglutide, where all 10 trials in the programme are expected to be completed in 2018. NOVO NORDISK'S COMMERCIAL PRIORITIES WITHIN DIABETES CARENovo Nordisk's commercial priorities within diabetes care will be presented in two dedicated sessions focusing on insulin and GLP-1, respectively. Novo Nordisk has made a clear priority to maximise its global insulin franchise by focusing on improving both value and volume market shares driven by the innovative project portfolio of new-generation insulin and a commercial focus aligned with the specific market maturity and market access situation in the individual countries. Novo Nordisk will remain focused on building the leadership within GLP-1, but also on expanding the total GLP-1 market driven by the expected introduction of once-weekly subcutaneous semaglutide. Following the completion of the phase 3a clinical trial programme for once-daily oral semaglutide, the commercial focus will be directed towards launching in major geographies assuming a successful clinical and regulatory process. NOVO NORDISK'S AMBITION TO EXPAND THE GLOBAL OBESITY MARKETBy launching Saxenda® in more than 20 countries, Novo Nordisk has become a global market leader within obesity care. Novo Nordisk has the ambition to further build the obesity market by continuing the global roll-out of Saxenda® as well as continue its efforts towards having obesity acknowledged as a chronic disease, and thereby expanding the prescriber base. Following the positive clinical phase 2 results with subcutaneous semaglutide in obesity, Novo Nordisk plans to initiate a phase 3a clinical development, STEP, with once-weekly subcutaneous semaglutide in 2018. The global clinical programme is expected to enrol approximately 4,500 people with obesity and all main trials within the programme will have a duration of 68 weeks. In addition to the phase 3a programme, STEP, Novo Nordisk is also planning to initiate a landmark cardiovascular outcome trial in 2018 with once-weekly subcutaneous semaglutide in obesity with an expected enrolment of approximately 12,500 people. MARKET DYNAMICS IN INTERNATIONAL OPERATIONS AND THE USAThe market dynamics for International Operations will be covered with focus on commercial ambitions and the diverse challenges in the five regions. The market opportunity in the USA remains significant despite a challenging payer environment; Novo Nordisk's expected plans for launching once-weekly semaglutide as well as continuing to improve the position within the insulin market will be covered. WEB CAST DETAILS All main sessions of the Capital Markets Day 2017 will be webcast live, and a replay will be made available on the investor section of novonordisk.com. Presentation material for the Capital Markets Day 2017 will be available 21 November at approximately 8.30 am CET, corresponding to 2.30 am EST on the investor section of novonordisk.com. Further information Company announcement No 87 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=720,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
236,2017-11-21,Novo Nordisks kapitalmarkedsdag 2017,"Bagsværd, den 21. november 2017 - Novo Nordisk afholder i dag kapitalmarkedsdag, hvor ledelsen vil give en opdatering om virksomhedens forsknings- og udviklingsstrategi, kommercielle strategi og nuværende markedsdynamikker. Det er Novo Nordisks ambition at styrke sit lederskab yderligere på det globale marked for diabetes- og fedmebehandling gennem forskning, udvikling og markedsføring af forbedrede insulin- og GLP-1-analoger samt helt nye klasser af biologiske lægemidler. Novo Nordisk ønsker desuden at skabe fornyet vækst i Biopharm-området. Programmet omfatter følgende hovedtemaer: Kapitalmarkedsdagen 2017 vil desuden omfatte breakout-sessioner om semaglutid i tabletform (oral semaglutid) og den tilknyttede produktionsudvidelse, regionerne i International Operations: Region China og Region AAMEO (Afrika, Asien, Mellemøsten og Oceanien) samt en opdatering om forretningsdynamikken i Biopharm Operations. NOVO NORDISKS FORSKNINGS- OG UDVIKLINGSSTRATEGI OG VIGTIGE UDVIKLINGSPROJEKTERNovo Nordisks forsknings- og udviklingsstrategi vil blive præsenteret med særlig fokus på vigtige konkurrencefordele gennem hele værdikæden i forskning og udvikling samt udvidelsen til andre alvorlige kroniske sygdomme. Præsentationen vil gennemgå virksomhedens forsknings- og udviklingsstrategi for levering af fremtidens innovative proteinbaserede lægemidler, der retter sig mod udækkede medicinske behov, med afsæt i interne forsknings- og udviklingskompetencer og aktiver, udvidelse til andre kroniske sygdomsområder samt øget fokus på ekstern innovation. Herudover vil der blive givet en opdatering om de seneste kliniske resultater for vigtige udviklingsprojekter indenfor diabetes- og fedmebehandling samt en række projekter indenfor hæmofili og vækstforstyrrelser. De forventede udviklingsmæssige og regulatoriske milepæle i 2018 vil også blive beskrevet, herunder den forventede rapportering af resultater fra det kliniske fase 3a-udviklingsprogram PIONEER med semaglutid i tabletform (oral semaglutid), hvor alle 10 studier i programmet forventes at blive afsluttet i 2018. NOVO NORDISKS KOMMERCIELLE PRIORITERINGER INDENFOR DIABETESBEHANDLINGNovo Nordisks kommercielle prioriteringer indenfor diabetesbehandling vil blive præsenteret i to sessioner med fokus på henholdsvis insulin og GLP-1. Novo Nordisk har foretaget en klar prioritering om at maksimere den globale insulinforretning gennem øgede markedsandele målt i såvel værdi som volumen drevet af den innovative projektportefølje for den nye generation af insulin og et kommercielt fokus i tråd med den specifikke markedsmodenhed og tilskudssituation i de enkelte lande. Novo Nordisk vil fortsat fokusere på at styrke sit lederskab indenfor GLP-1, men også på at udvide det samlede GLP-1-marked drevet af den forventede introduktion af ugentlig semaglutid i injektionsform (subkutan semaglutid). Efter afslutning af det kliniske fase 3a-udviklingsprogram med oral semaglutid til dosering én gang dagligt vil det kommercielle fokus blive rettet mod lancering i større geografiske markeder forudsat en succesfuld klinisk og regulatorisk proces. NOVO NORDISKS AMBITION OM AT UDBYGGE DET GLOBALE MARKED FOR FEDMEBEHANDLINGNovo Nordisk er gennem lanceringen af Saxenda® i flere end 20 lande blevet en af verdens førende virksomheder indenfor fedmebehandling. Novo Nordisk har en ambition om at udbygge markedet for fedmebehandling yderligere, dels ved at fortsætte den globale lancering af Saxenda® og dels ved at fortsætte indsatsen for at få fedme anerkendt som en kronisk sygdom og dermed udvide grundlaget af receptudskrivere. Efter de positive kliniske fase 2-resultater med subkutan semaglutid til behandling af svær overvægt planlægger Novo Nordisk at påbegynde et klinisk fase 3a-udviklingsprogram, STEP, med ugentlig subkutan semaglutid i 2018. Det globale kliniske program forventes at omfatte ca. 4.500 svært overvægtige deltagere, og alle hovedstudier i dette program vil strække sig over 68 uger. Foruden fase 3a-programmet STEP har Novo Nordisk også planer om at påbegynde et stort kardiovaskulært sikkerhedsstudie i 2018 med ugentlig subkutan semaglutid indenfor fedme med en forventet deltagelse af ca. 12.500 deltagere. MARKEDSDYNAMIKKER I INTERNATIONAL OPERATIONS OG USAMarkedsdynamikken i International Operations vil blive gennemgået med fokus på kommercielle ambitioner og de forskelligartede udfordringer, der gælder i de fem regioner. Markedsmulighederne i USA er fortsat signifikante trods den udfordrende situation i forhold til betalerne af sundhedsydelser, og der vil blive redegjort for Novo Nordisks planer for den forventede kommende lancering af ugentlig semaglutid samt for det fortsatte arbejde med at forbedre positionen indenfor insulinmarkedet. WEBCAST Alle vigtige præsentationer kan følges direkte over nettet som webcast via investorsektionen på novonordisk.com og vil efterfølgende være tilgængelige samme sted. Materiale til kapitalmarkedsdagen 2017 vil være tilgængeligt fra den 21. november ca. kl. 8.30 CET på investorsektionen på novonordisk.com. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 87 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=721,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
237,2017-11-01,Novo Nordisks rapporterede resultat af primær drift steg med 5% i de første ni måneder af 2017,"Det rapporterede salg steg med 2% til 83,7 mia. kr. (3% i lokale valutaer) Salget af produkter til behandling af diabetes og fedme steg med 7% til 69,7 mia. kr. (8% i lokale valutaer). Salget af biofarmaceutiske produkter faldt med 18% til 14,0 mia. kr. (18% i lokale valutaer) primært som følge af introduktionen af en generisk udgave af hormonpræparatet Vagifem® og rabatjusteringer for humant væksthormon i første kvartal af 2016, begge dele i USA, mens salget indenfor hæmofili var stort set uændret. Salget indenfor International Operations steg med 3% opgjort i kroner (5% i lokale valutaer) drevet af salgsvækst i alle forretningsregioner. Salget indenfor North America Operations var uændret både opgjort i kroner og i lokale valutaer og afspejler engangspåvirkninger indenfor biopharmaceuticals, som påvirkede væksten negativt med 5 procentpoint. Resultat af primær drift steg med 5% rapporteret i kroner og med 6% i lokale valutaer til 38,9 mia. kr. Nettoresultatet steg med 2% til 29,9 mia. kr. Udvandet resultat pr. aktie steg med 5% til 12,03 kr. I august oplyste Novo Nordisk, at den ugentlige GLP-1 semaglutid udviste superioritet i forhold til ugentlig dulaglutid med hensyn til blodsukkerregulering og vægttab hos mennesker med type 2-diabetes i SUSTAIN 7-studiet. I oktober stemte FDA's rådgivende komite 16-0 til fordel for godkendelse af semaglutid. I august fik Novo Nordisk også godkendt en udvidelse af indlægssedlen for Victoza® i USA til også at omfatte den reducerede risiko for hjerte-kar-sygdom, og i september meddelte de europæiske lægemiddelmyndigheder, CHMP, at de godkendte en udvidelse af indlægssedlen for Tresiba® i EU til også at omfatte den reducerede risiko for alvorlig hypoglykæmi. Ligeledes i september modtog Novo Nordisk godkendelse for den nye hurtigtvirkende måltidsinsulin Fiasp® i USA. De finansielle forventninger til 2017 er blevet opdateret, og salgsvæksten opgjort i lokale valutaer forventes nu at blive i intervallet 2% til 3% mod tidligere 1% til 3%. Der forventes nu en negativ valutapåvirkning på 2 procentpoint. Væksten i resultat af primær drift opgjort i lokale valutaer forventes nu at blive i intervallet 3% til 6% mod tidligere 1% til 5%. Der forventes nu en negativ valutapåvirkning på 3 procentpoint. De foreløbige forventninger til 2018 i lokale valutaer indikerer en vækst på et lavt til medium encifret procentpoint, både for salget og for resultat af primær drift. Salgsvæksten rapporteret i kroner forventes at blive 3 procentpoint lavere end i lokale valutaer, og væksten i det rapporterede resultat af primær drift forventes at blive 4 procentpoint lavere. Adm. direktør Lars Fruergaard Jørgensen: ""Vi leverer fortsat på vores planer for 2017, og vi er meget tilfredse med den seneste tids kliniske og regulatoriske fremskridt i forbindelse med vores vigtigste produkter. Vi er nu i gang med at forberede den globale lancering af semaglutid, som giver en unik mulighed for at forbedre behandlingen af mennesker med type 2-diabetes."" kontaktoplysninger Selskabsmeddelelse nr. 83 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=728,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
238,2017-11-01,Novo Nordisk increased reported operating profit by 5% in the first nine months of 2017,"Reported sales increased by 2% to DKK 83.7 billion (3% in local currencies) Sales within diabetes and obesity care increased by 7% to DKK 69.7 billion (8% in local currencies). Sales within biopharmaceuticals declined by 18% to DKK 14.0 billion (18% in local currencies), primarily reflecting an impact from the introduction of a generic version of the hormone replacement therapy product Vagifem® and from rebate adjustments for human growth hormone in Q1 2016, both in the USA, whereas sales within haemophilia were broadly unchanged. Sales within International Operations increased by 3% in Danish kroner (5% in local currencies) driven by sales growth in all business regions. Sales within North America Operations were unchanged in both Danish kroner and local currencies, reflecting the non-recurring effects in biopharmaceuticals impacting growth negatively by 5 percentage points. Operating profit increased by 5% reported in Danish kroner and by 6% in local currencies to DKK 38.9 billion. Net profit increased by 2% to DKK 29.9 billion. Diluted earnings per share increased by 5% to DKK 12.03. In August, Novo Nordisk showed that the once-weekly GLP-1 semaglutide was superior to once-weekly dulaglutide on glucose control and weight loss in people with type 2 diabetes in the SUSTAIN 7 trial. In October, semaglutide received a positive 16-0 vote in favour of approval from an FDA Advisory Committee. In August, Novo Nordisk also obtained approval of the Victoza® label expansion for cardiovascular risk reduction in the USA, and in September the label expansion for the reduced risk of severe hypoglycaemia with Tresiba® was endorsed by CHMP in the EU. Also in September, Novo Nordisk obtained approval of the new fast-acting mealtime insulin Fiasp® in the USA. The financial outlook for 2017 has been updated and the sales growth measured in local currencies is now expected to be in the range of 2% to 3% compared with the previous range of 1% to 3%. A negative currency impact of 2 percentage points is now expected. Operating profit growth measured in local currencies is now expected to be in the range of 3% to 6% compared with the previous range of 1% to 5%. A negative currency impact of 3 percentage points is now expected. The preliminary outlook for 2018 in local currencies indicates low to mid single-digit growth in both sales and operating profit. Sales growth reported in Danish kroner is expected to be 3 percentage points lower than in local currencies, and reported operating profit growth is expected to be 4 percentage points lower. Lars Fruergaard Jørgensen, president and CEO: ""We continue to deliver on our plans for 2017, and we are very pleased with the recent clinical and regulatory progress for our key products. We are currently preparing the global launch of semaglutide, which provides a unique opportunity to improve the treatment of people with type 2 diabetes."" Contacts for further information Company announcement No 83 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=729,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
239,2017-10-31,New US study reveals key reasons why millions of people with obesity are not receiving adequate care,"Despite increasing recognition of obesity as a disease, many barriers to effective care remain Washington DC, US, October 31, 2017 - Few of the more than 90 million Americans1 with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment In Obesity Management (ACTION) Study published today in Obesity,2 the official journal of The Obesity Society. Among the notable findings is that of the 71% of people with obesity who say they have spoken with a healthcare professional (HCP) about their weight in the past 5 years, only 55% report having been given a diagnosis of obesity and less than a quarter (24%) were offered follow-up care for this disease.2 ACTION data will be presented through poster and symposia forums at ObesityWeek, currently in progress in Washington DC. Designed to identify key barriers to care from the perspective of people with obesity, HCPs and employers, the results of the ACTION Study, according to multi-disciplinary steering committee members who led the initiative, can guide collaborative action to improve care, education and support for those who live with obesity. ""We in the healthcare community must ask why this epidemic is not being diagnosed and treated with the same urgency and focus as any other serious diseases?'"" said Dr Lee Kaplan, director of the Obesity, Metabolism and Nutrition Institute at Massachusetts General Hospital, ACTION steering committee member and lead author of the study. ""We need to fundamentally rethink obesity so that the public and healthcare community understand more about the biology, chronicity and overall health impact of this disease. Real progress can be achieved if we can overcome the entrenched mindsets that generate the barriers revealed by this study."" Conducted with more than 3,500 participants spanning all three target groups, the ACTION Study reveals five key barriers to comprehensive care: ""The barriers identified in the study highlight opportunities to bridge gaps in understanding to facilitate true collaboration among all stakeholders,"" said study co-author and ACTION steering committee member Dr Angela Golden, owner of a specialty obesity practice in Arizona. ""Only by bridging these gaps will obesity care become integral to standard practice, whether in a healthcare or employment setting, and will people with obesity have the care and support needed to effectively treat their obesity."" About ACTIONThe ""Awareness, Care and Treatment In Obesity Management"" (ACTION) Study is the first US nationwide study to investigate barriers to obesity management from the perspective of people with obesity, healthcare professionals and employers. In addition, the study aims to generate insights to guide collaborative action to improve obesity care, education and support. Sponsored by Novo Nordisk, the ACTION Study was led by a multi-disciplinary steering committee comprised of representatives from The Obesity Society, the Obesity Action Coalition, and the Integrated Benefits Institute as well as obesity experts in the fields of primary care, endocrinology, psychology and nursing. The study involved more than 3,000 people with obesity, 600 healthcare professionals, and 150 employers in the United States. To learn more about the study, please visit www.ACTIONStudy.com. About obesityObesity is a disease3,4 that requires long-term management. It is associated with many serious health consequences and decreased life expectancy.5,6 Obesity-related comorbidities include type 2 diabetes, heart disease, obstructive sleep apnoea (OSA) and certain types of cancer.5,7,8 It is a complex and multi-factorial disease that is influenced by physiological, psychological, environmental, socio-economic and genetic factors.9 The global increase in the prevalence of obesity is a public health issue that has severe cost implications to healthcare systems. In 2014, 13% of adults, or approximately 600 million adults, were living with obesity.10 Further information References 1.            Obesity and Overweight. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/nchs/fastats/obesity-overweight.htm. Last accessed: October 2017. 2.            Kaplan L, Golden A, Jinnett K, et al. Perceptions of Barriers to Effective Obesity Care: Results from the National ACTION Study. Obesity. 2017;DOI:10.1002/oby.22054. 3.            American Medical Association. A.M.A Adopts New Policies on Second Day of Voting at Annual Meeting. Obesity as a Disease. Available at: http://news.cision.com/american-medical-association/r/ama-adopts-new-policies-on-second-day-of-voting-at-annual-meeting,c9430649. Last accessed: October 2017.4.            WHO. Obesity: Preventing and managing the global epidemic. Available at: http://www.who.int/iris/handle/10665/42330 Last accessed: October 2017. 5.            Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:1-20.6.            Peeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Annals of Internal Medicine. 2003;138:24-32.7.            Gami AS, Caples SM, Somers VK. Obesity and obstructive sleep apnea. Endocrinology and Metabolism Clinics of North America. 2003;32:869-894.8.            Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083-1096.9.            Wright SM, Aronne LJ. Causes of obesity. Abdominal Imaging. 2012;37:730-732.10.          World Health Organization. Obesity and Overweight Factsheet no. 311. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/. Last accessed: October 2017.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=732,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
240,2017-10-31,"Nyt amerikansk studie afdækker årsager til, at millioner af svært overvægtige ikke får tilstrækkelig behandling","Selvom svær overvægt i stigende grad anerkendes som en sygdom, er der stadig mange barrierer for effektiv behandling Washington DC, USA, den 31. oktober 2017 - Kun få af de flere end 90 mio. amerikanere1, der lever med svær overvægt, opsøger og modtager langsigtet behandling. Det viser nye resultater fra ACTION-studiet (Awareness, Care and Treatment In Obesity Management), som i dag publiceres i Obesity,2 The Obesity Societys officielle tidsskrift. Studiet viser bl.a., at ud af de 71% af de svært overvægtige, som angiver, at de har drøftet deres vægt med en læge i løbet af de seneste fem år, har kun 55% fået stillet diagnosen svær overvægt, og mindre end en fjerdedel (24%) er blevet tilbudt opfølgende behandling for sygdommen.2 Data fra ACTION-studiet vil blive præsenteret via posters og symposier på Obesity Week, der i disse dage løber af stablen i Washington DC. Formålet med ACTION-studiet er at undersøge de væsentligste barrierer for behandling af svær overvægt set fra forskellige perspektiver - de svært overvægtiges, lægernes og arbejdsgivernes. Resultaterne bør ifølge medlemmer af den tværfaglige styregruppe bag initiativet bane vej for et samarbejde om at forbedre indsatsen i forhold til behandling, undervisning og støtte til de mennesker, der lever med svær overvægt. ""Vi i sundhedssektoren bør spørge, hvorfor den her epidemi ikke bliver diagnosticeret og behandlet med samme seriøsitet og fokus som enhver anden alvorlig sygdom,"" siger dr. Lee Kaplan, leder af Obesity, Metabolism and Nutrition Institute ved Massachusetts General Hospital, medlem af styregruppen for ACTION og hovedforfatter til studiet. ""Vi er simpelthen nødt til at redefinere svær overvægt, så befolkningen og sundhedssektoren får en større forståelse for biologien, den kroniske karakter og den generelle effekt på sundheden, som er forbundet med denne sygdom. Først når vi kommer ud over de forudindtagede holdninger, der ligger til grund for de barrierer, studiet påviser, kan vi foretage de forbedringer i behandlingen, som er så nødvendige."" ACTION-studiet, der omfattede flere end 3.500 deltagere på tværs af de tre målgrupper, har afdækket følgende fem væsentlige barrierer for effektiv behandling: ""De barrierer, som studiet påviser, giver os mulighed for at fremme forståelsen af, hvordan vi kan forbedre samarbejdet mellem alle interessenter,"" siger medforfatter og medlem af styregruppen for ACTION dr. Angela Golden, som har sin egen praksis med speciale i svær overvægt i Arizona, USA. ""Og vi er nødt til at arbejde aktivt med at fremme denne forståelse for at gøre svær overvægt til en del af standardpraksis - både hos lægen og på arbejdspladsen - og for at sikre, at mennesker med svær overvægt får den fornødne hjælp og støtte til effektivt at få behandlet deres overvægt."" ACTION-studiet (Awareness, Care and Treatment In Obesity Management) er det første landsdækkende studie i USA, der undersøger barrierer for vægtregulering ud fra forskellige perspektiver - de svært overvægtiges, lægernes og arbejdsgivernes. Formålet med studiet er desuden at opnå en viden, der gør det muligt at samarbejde om at forbedre indsatsen i forhold til behandling af svær overvægt, undervisning og støtte til den overvægtige. ACTION-studiet sponseres af Novo Nordisk og ledes af en tværfaglig styregruppe med repræsentanter for The Obesity Society, Obesity Action Coalition og Integrated Benefits Institute samt eksperter i svær overvægt indenfor primær behandling, endokrinologi, psykologi og sygepleje. I studiet deltog flere end 3.000 svært overvægtige, 600 læger og 150 arbejdsgivere i USA. Læs mere om studiet på www.ACTIONStudy.com. Svær overvægt er en sygdom,3,4 der kræver vedvarende indsats. Den er forbundet med mange alvorlige helbredsmæssige følgevirkninger og nedsat forventet levetid.5,6 Følgesygdomme til svær overvægt er bl.a. type 2-diabetes, hjertesygdom, obstruktiv søvnapnø og visse former for kræft.5,7,8 Det er en kompleks sygdom, der er påvirket af flere forskellige forhold, herunder fysiologiske, psykologiske, miljømæssige, socioøkonomiske og genetiske faktorer.9 Den globale stigning i forekomsten af svær overvægt er en trussel mod folkesundheden med betydelig indvirkning på de offentlige sundhedsudgifter. I 2014 var 13% af verdens voksne befolkning, eller omkring 600 mio. voksne, svært overvægtige.10 Yderligere information Referencer1.            Obesity and Overweight. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/nchs/fastats/obesity-overweight.htm. Last accessed: October 2017. 2.            Kaplan L, Golden A, Jinnett K, et al. Perceptions of Barriers to Effective Obesity Care: Results from the National ACTION Study. Obesity. 2017;DOI:10.1002/oby.22054. 3.            American Medical Association. A.M.A Adopts New Policies on Second Day of Voting at Annual Meeting. Obesity as a Disease. Available at: http://news.cision.com/american-medical-association/r/ama-adopts-new-policies-on-second-day-of-voting-at-annual-meeting,c9430649. Last accessed: October 2017.4.            WHO. Obesity: Preventing and managing the global epidemic. Available at: http://www.who.int/iris/handle/10665/42330 Last accessed: October 2017. 5.            Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:1-20.6.            Peeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Annals of Internal Medicine. 2003;138:24-32.7.            Gami AS, Caples SM, Somers VK. Obesity and obstructive sleep apnea. Endocrinology and Metabolism Clinics of North America. 2003;32:869-894.8.            Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083-1096.9.            Wright SM, Aronne LJ. Causes of obesity. Abdominal Imaging. 2012;37:730-732.10.          World Health Organization. Obesity and Overweight Factsheet no. 311. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/. Last accessed: October 2017.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=733,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
241,2017-10-26,Global city leaders: cut obesity by a quarter to prevent 100m new diabetes cases by 2045,"Bagsværd, Denmark, Thursday 26 October 2017 - An international coalition of cities is calling for an ambitious global goal to prevent more than 100 million new cases of diabetes by 2045. The target is set out alongside new research in a report launched today by the Cities Changing Diabetes partnership at a global summit in Houston, Texas. The report comes with the stark warning that achieving the goal requires cutting rates of obesity by a quarter. Bending the curve Cases of diabetes are accelerating in every part of the world meaning that today, one  in 11 adults live with the condition.1 The report - Bending the Curve on Urban Diabetes - urges governments, city and health leaders to make changing the trajectory of the disease a top global priority in order to 'bend the rising curve' of diabetes prevalence. Bending the curve means holding the rise of diabetes at a ceiling of one in ten adults living with the condition. To do this, ambitious action is needed on the single biggest modifiable risk factor for diabetes: obesity.2 Obesity must be reduced by 25% globally by 2045, from today's level of 14% of the population in order to bend the curve.1 If nothing is done, the research projects that 1.4 billion adults (22.4% of adults) will live with obesity by 2045.1 This would result in diabetes prevalence reaching one in nine adults - a staggering 736 million people, and almost 300 million more than today.1 The impact of diabetes at this scale would be tragic for individuals, families, health systems and economies. As a consequence, annual diabetes-related health expenditure would spiral to more than 1 trillion US dollars in 2045, up from 775 billion US dollars today, an increase of over 39%.1 And that is a conservative estimate. In contrast, bending the curve would prevent an extra 111 million people developing diabetes, more than the combined populations of the nine cities in the coalition, and would save society 200 billion dollars annually by 2045.1 The solution starts in cities  While half of the world's population lives in cities, they are home to two-thirds of people with diabetes - a number set to rise to three quarters of people with diabetes by the 2040s.3 Responding to the findings, Houston Mayor Sylvester Turner said: ""Action against diabetes has to start in cities. The way cities are designed, built and run is fuelling an urban obesity and diabetes pandemic that is already shortening millions of people's lives and resulting in billions in healthcare costs primarily related to the cost of treating complications."" The Cities Changing Diabetes programme was co-founded by Novo Nordisk, University College London and the Steno Diabetes Center Copenhagen. The partnership comprises nine global city partners - Copenhagen, Houston, Johannesburg, Mexico City, Rome, Shanghai, Tianjin, Vancouver and Xiamen - together representing 75 million citizens - to pioneer new approaches to map the challenge, understand the areas of greatest risk and vulnerability, and design interventions that are delivering real impact. Programme researchers are today releasing their findings alongside a bespoke projection tool at the Cities Changing Diabetes Summit in Houston, Texas. The tool enables individual cities to quickly and reliably assess the scale of their local diabetes and obesity challenge to guide future action. Furthermore, for the first time, the Cities Changing Diabetes programme will make publicly available the most innovative and effective approaches from pioneer cities around the world. The 'Urban Diabetes Toolbox' arms city and health leaders in any city to create their own action plan to tackle urban diabetes and obesity. Before addressing the 300 Summit delegates, Lars Fruergaard Jørgensen, president and chief executive officer, Novo Nordisk said:  ""The urban diabetes pandemic is playing out in every major city around the world and the stakes are high. We're calling upon all city leaders and their healthcare counterparts to come together to meet this challenge head on. Now is the time to fully measure and understand the local burden of disease and to create local action plans that together can combine to bend the curve on global diabetes. That means taking ambitious action on the biggest modifiable risk factor for diabetes: obesity."" About Cities Changing DiabetesCities Changing Diabetes is a partnership programme to address the urban diabetes challenge. Initiated by Novo Nordisk, the programme is a response to the dramatic rise of urban diabetes and has been developed in partnership with University College London and Steno Diabetes Center Copenhagen, as well as a range of local partners including the diabetes/health community, city governments, academic institutions, city experts (from a variety of fields) and civil society organisations. The aim of the programme is to map the problem, share solutions and drive concrete action to fight the diabetes challenge in the big cities around the world. Today, the programme represents 75 million citizens in nine cities worldwide: Copenhagen, Houston, Mexico City, Johannesburg, Rome, Tianjin, Shanghai, Vancouver and Xiamen. For more information, visit citieschangingdiabetes.com, Facebook, Twitter References1. Cities Changing Diabetes. Diabetes Projection Model, Global. Data on file. Novo Nordisk. In: Incentive, ed. Holte, Denmark; 20172. World Health Organization. Global report on diabetes, Geneva, Switzerland: World Health Organization; 20163. International Diabetes Federation. IDF Diabetes Atlas, 7 ed. Brussels, Belgium: International Diabetes Federation; 2015 Media contactInternational: Adam Pittard +45 3075 5056US: Marisa Sharkey +1 609-325-9749",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=734,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
242,2017-10-26,Globale storbyer: svær overvægt skal reduceres med en fjerdedel for at forhindre 100 mio. nye tilfælde af diabetes frem mod 2045,"Kurven skal knækkes Flere og flere mennesker i verden får diabetes. I dag lever 437 mio. mennesker med sygdommen på globalt plan, det svarer til 9% af den voksne befolkning. Hvis udviklingen fortsætter, vil det tal stige til omkring 12% i 2045.1 Rapporten viser samtidig, at antallet af svært overvægtige vil være steget til 1,4 mia. voksne i 2045 (22,4% af den voksne befolkning).1 Da svær overvægt er den største modificerbare risikofaktor i forhold til udviklingen af type 2-diabetes2, vil det betyde, at 736 mio. mennesker, næsten 300 mio. flere end i dag, vil leve med diabetes.1 Konsekvenserne vil være katastrofale - for den enkelte, sundhedssystemerne og samfundsøkonomien. De årlige diabetesrelaterede sundhedsudgifter vil nå op på 1 billion amerikanske dollars i 2045, hvilket vil være en stigning på over 39% i forhold til 775 mia. dollars i dag.1 Hvis kurven for diabetes skal knækkes, er der på globalt plan behov for en ambitiøs indsats for at nedbringe antallet af svært overvægtige. Af rapporten fremgår det, at 14% af voksne i verden i dag er svært overvægtige.1 Beregninger viser, at for at knække kurven skal forekomsten af diabetes ned på 1 ud af 10 voksne, ved at antallet af svært overvægtige reduceres med 25% frem mod 2045.1 Hvis det lykkes at knække diabeteskurven, vil 111 mio. færre mennesker udvikle diabetes, hvilket vil spare samfundet for 200 mia. dollars i 2045.1 Løsningen findes i byerne Halvdelen af verdens befolkning bor i byer, og de er hjemsted for to tredjedele af alle mennesker med diabetes - den andel vil stige til tre fjerdedele frem mod 2040'erne.3 Cities Changing Diabetes er startet i 2014 i fællesskab af Novo Nordisk, University College London og Steno Diabetes Center Copenhagen. Partnerskabet omfatter ni storbyer verden over - København, Houston, Johannesburg, Mexico City, Rom, Shanghai, Tianjin, Vancouver og Xiamen med i alt 75 mio. indbyggere. Målet er at udvikle nye metoder til at kortlægge diabetesudfordringen, udveksle viden og erfaringer samt iværksætte handling, der gør en reel forskel. København er med på topmødet i Houston. Her deler byen sine erfaringer om diabetes og sundhedsmæssig ulighed i en by, der ellers er anerkendt globalt for at være sund, grøn og byde på høj livskvalitet. Københavns sundheds- og omsorgsborgmester, Ninna Thomsen, siger: ""Selvom færre mennesker i København har diabetes sammenlignet med mange af verdens andre storbyer, har vi stadig den udfordring, at tallet stiger, og diabetes rammer socialt skævt. Vi skal have lighed i sundhed. Det er kernen i vores sundhedspolitik - alle borgere i byen har ret til et langt og godt liv."" På topmødet deler byerne bag Cities Changing Diabetes-initiativet deres erfaringer og egne handlingsplaner i en såkaldt 'Urban Diabetes Toolbox'. Den består af en ny, specialudviklet model til fremskrivning af forekomsten af svær overvægt og diabetes samt af et væld af initiativer, som byer over hele verden har erfaringer med. Med den kan politiske og sundhedsfaglige ledere verden over få inspiration til at udvikle deres egne handlingsplaner. Lars Fruergaard Jørgensen, administrerende direktør for Novo Nordisk, sagde inden sin tale til de 300 topmødedeltagere: ""Diabetespandemien raser i alle storbyer verden over, og der står meget på spil, både for den enkelte, sundhedssystemerne og samfundsøkonomien. Med Cities Changing Diabetes forsøger vi at samle alle, der vil være med til at gøre noget ved problemet. Vi opfordrer nu ledere og beslutningstagere i verdens storbyer til at forpligte sig til et ambitiøst mål for at knække kurven for diabetes. Ved at sætte ind overfor svær overvægt kan vi gøre størst forskel. Men det er et ambitiøst mål, vi opfordrer til, så nytænkning og samarbejde på tværs af traditionelle skel er helt afgørende, hvis vi skal væk fra den katastrofekurs, vi er på nu."" Om Cities Changing Diabetes Cities Changing Diabetes er et partnerskabsprogram, der skal tackle diabetesudfordringen i verdens storbyer. Programmet er lanceret af Novo Nordisk som reaktion på den kraftige stigning i forekomsten af diabetes i storbyer og er udviklet i samarbejde med University College London (UCL) og Steno Diabetes Center Copenhagen (SDCC) samt en række lokale partnere, herunder diabetes- og sundhedsorganisationer, bystyrer, forskningsinstitutioner, byudviklingseksperter (fra mange specialistområder) og civilsamfundsorganisationer. Formålet med initiativet er at kortlægge problemet, udveksle løsninger og iværksætte konkrete handlinger for at løse diabetesudfordringen i verdens storbyer. I dag repræsenterer programmet 75 mio. borgere i ni byer over hele verden: København, Houston, Mexico City, Johannesburg, Rom, Tianjin, Shanghai, Vancouver og Xiamen. Læs mere på citieschangingdiabetes.com, Facebook, Twitter  Kontaktinformation, medier Mette Kruse Danielsen:  +45 3079 3883",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=735,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
243,2017-10-18,FDA's rådgivende komite stemmer 16-0 til fordel for godkendelse af semaglutid,"Bagsværd, den 18. oktober 2017 - Novo Nordisk meddeler i dag, at Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC), som er en rådgivende komite for de amerikanske sundhedsmyndigheder (FDA), har stemt 16-0 til fordel for godkendelse af ugentlig semaglutid til forbedring af blodsukkerreguleringen hos voksne med type 2-diabetes. Ét panelmedlem undlod at stemme. FDA havde med udgangspunkt i de data, der indgår i registreringsansøgningen for semaglutid, bedt ekspertpanelet om at drøfte, hvorvidt Novo Nordisk har fremlagt tilstrækkelig dokumentation til at fastslå effekt- og sikkerhedsprofilen for semaglutid til behandling af type 2-diabetes hos voksne. Anbefalingen om godkendelse var baseret på et globalt udviklingsprogram, som omfattede flere end 8.000 voksne med type 2-diabetes i de otte kliniske SUSTAIN fase 3a-studier, herunder et kardiovaskulært sikkerhedsstudie. ""Semaglutid har vist, at det har potentiale til at forbedre behandlingen af type 2-diabetes, og den positive anbefaling fra den rådgivende komite er et vigtigt skridt på vejen til at gøre semaglutid tilgængeligt for voksne med type 2-diabetes i USA. Vi ser frem til at samarbejde med FDA om deres færdigbehandling af registreringsansøgningen for semaglutid,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. Registreringsansøgningen for ugentlig semaglutid blev indsendt til FDA i december 2016 i henhold til FDA's bestemmelser under Prescription Drug User Fee Act V (PDUFA V). Semaglutid er under vurdering hos flere regulatoriske myndigheder, herunder Det Europæiske Lægemiddelagentur og de japanske sundhedsmyndigheder, Japanese Pharmaceuticals and Medical Devices Agency. Novo Nordisk afholder en telekonference for investorer den 19. oktober 2017 kl. 8.00 CEST (kl. 2.00 EDT). Investorer kan lytte med via et link under investorsektionen på novonordisk.com/investors. FDA's rådgivende komiteer er uafhængige ekspertpaneler, som rådgiver FDA om specifikke spørgsmål, der rejses af FDA i forbindelse med regulatoriske beslutninger. Komiteens anbefaling er ikke bindende for FDA, men indgår i beslutningsgrundlaget ved FDA's vurdering af data vedrørende sikkerhed og effekt af allerede markedsførte lægemidler eller nye registreringsansøgninger. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 80 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=738,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
244,2017-10-18,Semaglutide receives positive 16-0 vote in favour of approval from FDA Advisory Committee,"Bagsværd, Denmark, 18 October 2017 - Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted 16-0 in favour of the approval of once-weekly semaglutide to improve glycaemic control in adults with type 2 diabetes. One member of the committee abstained. Based on the data included in the New Drug Application (NDA) for semaglutide, the FDA asked the panel members to discuss whether Novo Nordisk has provided adequate evidence to establish the efficacy and safety profile of semaglutide for the treatment of type 2 diabetes in adults. The recommendation for approval was based on a global development programme involving more than 8,000 adults with type 2 diabetes in the eight SUSTAIN phase 3a clinical trials, including a cardiovascular outcomes trial. ""Semaglutide has demonstrated the potential to improve the treatment of type 2 diabetes and the positive recommendation from the Advisory Committee marks an important step towards making semaglutide available to adults with type 2 diabetes in the US. We look forward to working with the FDA as they complete their review of semaglutide,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer. The NDA for once-weekly semaglutide was submitted to the FDA in December 2016 under the US FDA's Prescription Drug User Fee Act V (PDUFA V) regulation. Semaglutide is currently under review by several regulatory agencies, including the European Medicines Agency and the Japanese Pharmaceuticals and Medical Devices Agency. On 19 October 2017 at 8.00 am CEST (2.00 am EDT), Novo Nordisk will host a conference call for investors. Investors will be able to listen in via a link on the investor section of novonordisk.com/investors. FDA advisory committees are panels of independent experts who advise the FDA on specific questions raised by the FDA as they consider regulatory decisions. The FDA is not bound by the committee's recommendation, but it takes its advice into consideration when reviewing data concerning the safety and efficacy of marketed drugs or new drug applications. Company announcement No 80 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=739,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
245,2017-10-16,Novo Nordisk: FDA offentliggør briefingmateriale forud for møde i rådgivende komite om semaglutid,"Bagsværd, den 16. oktober 2017 - Novo Nordisk meddeler i dag, at de amerikanske sundhedsmyndigheder, FDA, har offentliggjort briefingdokumenterne forud for mødet i den rådgivende komite, hvor registreringsansøgningen om godkendelse af semaglutid, en ugentlig analog af det naturlige hormon glukagonlignende peptid-1 (GLP-1) til behandling af type 2-diabetes hos voksne, vil blive drøftet. Mødet finder sted den 18. oktober 2017. Briefingdokumenterne fra Novo Nordisk og FDA danner grundlag for drøftelserne i den rådgivende komite og giver overblik over det globale udviklingsprogram for semaglutid, herunder data fra det kliniske SUSTAIN fase 3a-program, som omfattede flere end 8.000 voksne med type 2-diabetes. Materialet er tilgængeligt på FDA's hjemmeside Registreringsansøgningen for ugentlig semaglutid blev indsendt til FDA i december 2016 i henhold til FDA's bestemmelser under Prescription Drug User Fee Act V (PDUFA V). Semaglutid er under vurdering hos flere regulatoriske myndigheder, herunder Det Europæiske Lægemiddelagentur og de japanske sundhedsmyndigheder, Japanese Pharmaceuticals and Medical Devices Agency. FDA's rådgivende komiteer er uafhængige ekspertpaneler, som rådgiver FDA om specifikke spørgsmål, der rejses af FDA i forbindelse med regulatoriske beslutninger. Komiteens anbefaling er ikke bindende for FDA, men indgår i beslutningsgrundlaget ved FDA's vurdering af data vedrørende sikkerheden og effekten af allerede markedsførte lægemidler eller nye registreringsansøgninger. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 79 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=740,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
246,2017-10-16,Novo Nordisk: FDA posts briefing materials prior to Advisory Committee meeting for semaglutide,"Bagsværd, Denmark, 16 October 2017 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has published the briefing documents ahead of the Advisory Committee meeting to discuss the New Drug Application (NDA) for approval of semaglutide, a once-weekly analogue of human glucagon-like peptide-1 (GLP-1) for the treatment of type 2 diabetes in adults. The meeting takes place on 18 October 2017. The briefing documents from Novo Nordisk and the FDA form the basis for the Advisory Committee's discussion, and provide an overview of the global development programme for semaglutide, including data from the SUSTAIN 3a clinical trial programme, which enrolled more than 8,000 adults with type 2 diabetes. The briefing materials can be accessed on the FDA webpage The NDA for once-weekly semaglutide was submitted to the FDA in December 2016 under the US FDA's Prescription Drug User Fee Act V (PDUFA V) regulation. Semaglutide is currently under review by several regulatory agencies, including the European Medicines Agency and the Japanese Pharmaceuticals and Medical Devices Agency. FDA advisory committees are panels of independent experts who advise the FDA on specific questions raised by the FDA as they consider regulatory decisions. The FDA is not bound by the committee's recommendation, but it takes its advice into consideration when reviewing data concerning the safety and efficacy of marketed drugs or new drug applications. Company announcement No 79 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=741,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
247,2017-09-29,Novo Nordisk's new fast-acting mealtime insulin Fiasp® approved in the US,"Bagsværd, Denmark, 29 September 2017 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Fiasp® (fast-acting insulin aspart), a new fast-acting mealtime insulin, for the treatment of adults with diabetes. The FDA's decision comes after Fiasp® in clinical trials demonstrated benefits for people in need of improved overall glucose control. Fiasp® is an innovative formulation of insulin aspart (NovoLog®) developed with the aim of obtaining pharmacokinetic and pharmacodynamic properties that more closely match the natural physiological insulin mealtime response of a person without diabetes. In clinical trials Fiasp® has demonstrated clinically relevant improvement in long-term glucose level (HbA1c). These results were achieved with a comparable overall rate of severe or blood-sugar confirmed hypoglycaemia, between Fiasp® and insulin aspart. ""We are very pleased that Fiasp® will now also be available to people with diabetes in the US,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""The fast action profile of Fiasp® allows people with diabetes convenient timing in terms of when to take their insulin in connection with meals to achieve the optimal blood sugar control."" About Fiasp® Fiasp® is insulin aspart in an innovative formulation, in which two excipients have been added: Vitamin B3 (niacinamide) to increase the speed of absorption and a naturally occurring amino acid (L-Arginine) for stability. The review of Fiasp® was based on the 'onset' programme, a phase 3 clinical programme comprising four trials encompassing more than 2,100 people with type 1 and type 2 diabetes. Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,400 people in 77 countries and markets its products in more than 165 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube Further information Company Announcement No 74 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=750,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
248,2017-09-29,"Novo Nordisks nye hurtigtvirkende måltidsinsulin, Fiasp®, godkendt i USA","Bagsværd, den 29. september 2017 - Novo Nordisk meddeler i dag, at de amerikanske sundhedsmyndigheder, FDA, har godkendt Fiasp® (hurtigtvirkende insulin aspart), en ny hurtigtvirkende måltidsinsulin, til behandling af voksne med diabetes. FDA's beslutning kommer, efter at kliniske studier har dokumenteret, at Fiasp® giver fordele for mennesker, der har behov for en forbedret generel blodsukkerregulering. Fiasp® er en ny formulering af insulin aspart (NovoLog®), der er udviklet med det formål at opnå farmakokinetiske og farmakodynamiske egenskaber, der i højere grad svarer til den naturlige fysiologiske insulinrespons i forbindelse med måltider hos en person uden diabetes. I kliniske studier har Fiasp® vist en klinisk relevant forbedring i langtidsblodsukkeret (HbA1c). Disse resultater blev opnået med en sammenlignelig samlet forekomst af hypoglykæmi (alvorlig eller bekræftet ved blodsukkermåling) for Fiasp® og insulin aspart. ""Vi er meget glade for, at Fiasp® nu også bliver tilgængeligt for mennesker med diabetes i USA,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Den hurtige virkningsprofil for Fiasp® giver mennesker med diabetes en bekvem mulighed for at bestemme, hvornår de skal tage deres insulin i forbindelse med måltider for at opnå den optimale blodsukkerregulering."" Fiasp® er insulin aspart i en ny formulering, hvor der er tilsat to hjælpestoffer: B3-vitamin (niacinamid) for at øge optagelseshastigheden og en naturligt forekommende aminosyre (L-arginin) for at sikre stabilitet. Gennemgangen af Fiasp® var baseret på 'onset'-programmet, et klinisk fase 3-program omfattende fire studier med deltagelse af mere end 2.100 mennesker med type 1- og type 2-diabetes. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 74 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=751,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
249,2017-09-29,CHMP endorses Tresiba® label update in the EU - new label reflects significant reduction in the risk of severe hypoglycaemia,"Bagsværd, Denmark, 29 September 2017 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), has endorsed an update of the EU label with immediate effect for Tresiba® (insulin degludec) to include results from the DEVOTE trial on severe hypoglycaemia. DEVOTE is a randomised, multinational and double-blinded trial conducted to confirm the cardiovascular safety of Tresiba® compared to insulin glargine U100 when added to standard of care, in people with type 2 diabetes. In the trial, the primary endpoint was achieved by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with Tresiba® compared to insulin glargine U100. Severe hypoglycaemia was evaluated as a secondary endpoint and 27% fewer patients in the Tresiba® treated group experienced an episode of severe hypoglycaemia, resulting in a 40% overall rate reduction of total episodes of adjudicated severe hypoglycaemia. Furthermore, patients in the Tresiba® treated group experienced a 53% relative reduction in the rate of nocturnal severe hypoglycaemia. These differences were all statistically significant. ""Our ambition is to help people with type 2 diabetes reach their treatment goals and at the same time reduce their risk of severe hypoglycaemia,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""With the CHMP's endorsement of the updated label for Tresiba® we have passed a major milestone in insulin therapy."" DEVOTE is the first cardiovascular outcomes trial (CVOT) comparing two basal insulins. DEVOTE is a multinational, double-blinded clinical trial which investigated the cardiovascular safety of Tresiba® compared with insulin glargine U100 over 104 weeks. In the trial, 7,637 people with type 2 diabetes at high risk of, or existing, cardiovascular disease were randomised to treatment with either Tresiba® or insulin glargine U100 in vial in addition to standard of care. In the trial, the primary endpoint was achieved by demonstrating non-inferiority of MACE with Tresiba® compared to insulin glargine U100. The primary endpoint was defined as the MACE composite outcome of the first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke and showed a hazard ratio of 0.91 in favour of Tresiba® relative to insulin glargine U100, with no statistically significant difference between the two treatments. Tresiba® (insulin degludec) is a once-daily basal insulin that provides duration of action of at least 42 hours. Tresiba® is taken once daily, at any time of day. Patients who miss or are delayed in taking their dose of Tresiba® can take their dose as soon as they remember, but ensuring there are at least eight hours between doses. Tresiba® was approved by the European Commission in January 2013 and has since been approved in more than 80 countries globally. Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,400 people in 77 countries and markets its products in more than 165 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube Further information Company Announcement No 73/2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=752,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
250,2017-09-29,CHMP støtter opdatering af indlægssedlen for Tresiba® i EU - ny indlægsseddel afspejler signifikant reduktion i risikoen for alvorlig hypoglykæmi,"Bagsværd, den 29. september 2017 - Novo Nordisk meddeler i dag, at Udvalget for Humanmedicinske Lægemidler (CHMP) under Det Europæiske Lægemiddelagentur (EMA) har udtrykt deres støtte til en opdatering af indlægssedlen for Tresiba® (insulin degludec) i EU med øjeblikkelig virkning til også at omfatte resultaterne fra DEVOTE-studiet om alvorlig hypoglykæmi (lavt blodsukker). DEVOTE er et randomiseret, multinationalt og dobbeltblindet studie, der er gennemført med det formål at bekræfte den kardiovaskulære (hjerte-kar-) sikkerhed for Tresiba® sammenlignet med insulin glargin U100, når det gives som supplement til standardbehandling hos mennesker med type 2-diabetes. I studiet blev det primære endepunkt opfyldt, idet det viste ikke-inferiøritet med hensyn til alvorlige kardiovaskulære hændelser med Tresiba® sammenlignet med insulin glargin U100. Alvorlig hypoglykæmi blev vurderet som et sekundært endepunkt, og 27% færre deltagere i gruppen, der blev behandlet med Tresiba®, oplevede et tilfælde af alvorlig hypoglykæmi, hvilket samlet set resulterede i en 40% reduktion i den samlede forekomst af adjudikerede tilfælde af alvorlig hypoglykæmi. Endvidere oplevede deltagere i gruppen, der blev behandlet med Tresiba®, en 53% relativ reduktion i forekomsten af natlig alvorlig hypoglykæmi. Disse forskelle var alle statistisk signifikante.  ""Det er vores ambition at hjælpe mennesker med type 2-diabetes med at nå deres behandlingsmål og samtidig mindske deres risiko for alvorlig hypoglykæmi,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Med CHMP's støtte til den opdaterede indlægsseddel for Tresiba® har vi passeret en vigtig milepæl indenfor insulinbehandling."" DEVOTE er det første kardiovaskulære sikkerhedsstudie, der har sammenlignet to basalinsuliner. DEVOTE er et multinationalt, dobbeltblindet klinisk studie, som har undersøgt den kardiovaskulære sikkerhed for Tresiba® sammenlignet med insulin glargin U100 over 104 uger. I studiet blev 7.637 mennesker med type 2-diabetes med høj risiko for eller eksisterende hjerte-kar-sygdom randomiseret til behandling med enten Tresiba® eller insulin glargin U100 i hætteglas som supplement til standardbehandling. I studiet blev det primære mål opfyldt, idet det viste ikke-inferiøritet med hensyn til alvorlige kardiovaskulære hændelser med Tresiba® sammenlignet med insulin glargin U100. Det primære endepunkt var defineret som den første forekomst af et sammensat kardiovaskulært endepunkt bestående af kardiovaskulært dødsfald, ikke-dødeligt myokardieinfarkt (hjerteanfald) eller ikke-dødeligt slagtilfælde og viste en risikoratio på 0,91 til fordel for Tresiba® i forhold til insulin glargin U100 med ingen statistisk signifikant forskel mellem de to behandlinger. Tresiba® (insulin degludec) er en basalinsulin til dosering én gang dagligt med en virkningsvarighed på mindst 42 timer. Tresiba® tages én gang dagligt når som helst i løbet af dagen. Patienter, som glemmer en dosis Tresiba®, kan tage den, når de opdager forglemmelsen, men med mindst otte timer mellem doserne. Tresiba® blev godkendt af Europa-Kommissionen i januar 2013 og er siden blevet godkendt i flere end 80 lande verden over. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 73/2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=753,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
251,2017-09-29,IDF and Novo Nordisk launch first-ever global survey on cardiovascular disease awareness among people with type 2 diabetes,"Brussels, Belgium, 29 September 2017 ­- To mark World Heart Day today, the International Diabetes Federation (IDF) has partnered with Novo Nordisk to launch the first-ever multi-country online survey investigating the level of CVD awareness and knowledge among people living with type 2 diabetes. The global survey - Taking Diabetes to Heart - is available in multiple languages until March 2018, and people with type 2 diabetes are encouraged to participate.Cardiovascular disease, which includes stroke, coronary heart disease and peripheral artery disease,2 is one of the leading causes of death in people with type 2 diabetes,1,3 and as the number of people with diabetes continues to increase,4 the outlook for CVD becomes even more alarming. ""The world is facing rising prevalence and incidence of cardiovascular disease among people with type 2 diabetes, due to limited knowledge on prevention, poor access to timely diagnosis, inappropriate treatment and insufficiently informed self-management. Taking Diabetes to Heart is a global effort to tackle the underlying issues behind diabetes and cardiovascular diseases, their escalating costs to societies, and to support cost-effective interventions that can help reduce the current burden that they represent,"" said Dr Shaukat Sadikot, IDF president. Taking Diabetes to Heart - www.idf.org/takingdiabetes2heart/survey - aims to define the actions that are required to support knowledge and awareness of CVD among people living with type 2 diabetes to improve their health outcomes. It builds on the IDF global report Diabetes and Cardiovascular Disease, published in 2016, which includes a series of recommendations to reduce the burden of CVD among people with diabetes and the general population.5 ""It is concerning that cardiovascular disease is the most common cause of death in people with type 2 diabetes when many of these patients are unaware of this risk,"" said Alan Moses, senior vice president and chief medical officer of Novo Nordisk. ""We are delighted to support the IDF in launching the survey, Taking Diabetes to Heart, to better understand the current knowledge and awareness of cardiovascular disease among people with type 2 diabetes, which will ultimately inform actions needed to help improve health outcomes."" Taking Diabetes to Heart will culminate in a comprehensive report with country-specific results and resources to help support knowledge and awareness of CVD among people with type 2 diabetes around the world. For more information about Taking Diabetes to Heart, visit www.idf.org/takingdiabetes2heart For more information about diabetes and CVD, visit www.idf.org/cvdAbout the International Diabetes FederationThe International Diabetes Federation (IDF) is an umbrella organisation of over 230 national diabetes associations in 165 countries and territories. It represents the interests of the growing number of people with diabetes and those at risk. The Federation has been leading the global diabetes community since 1950. The Federation's activities aim to influence policy, increase public awareness and encourage health improvement, promote the exchange of high-quality information about diabetes, and provide education for people with diabetes and their healthcare providers. IDF is associated with the Department of Public Information of the United Nations and is in official relations with the World Health Organization (WHO). www.idf.org. Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,400 people in 77 countries and markets its products in more than 165 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube Taking Diabetes to Heart - www.idf.org/takingdiabetes2heart - consists of an online survey that will be available in multiple languages, including Arabic, Chinese, Danish, Japanese, English, French, Spanish, Russian, Hindi, Korean, Portuguese, German and Urdu. The survey will remain online until March 2018. Results from the survey will be used to inform policy and decision-making around this common and serious complication of diabetes.4 Further information References",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=754,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
252,2017-09-29,IDF og Novo Nordisk i samarbejde om den første globale undersøgelse om kendskabet til hjerte-kar-sygdom blandt mennesker med type 2-diabetes,"Bruxelles, Belgien, den 29. september 2017 - I dag på World Heart Day (den internationale hjertedag) lancerer International Diabetes Federation (IDF) og Novo Nordisk den første undersøgelse nogensinde af kendskabet til og viden om hjerte-kar-sygdom blandt mennesker med type 2-diabetes. Den globale onlineundersøgelse - Taking Diabetes to Heart - vil være tilgængelig på en række forskellige sprog indtil marts 2018, og mennesker med type 2-diabetes verden over opfordres til at deltage. Hjerte-kar-sygdom, der bl.a. omfatter hjertestop, slagtilfælde, kranspulsåresygdom og perifer arteriesygdom,2 er en af de hyppigste dødsårsager blandt mennesker med type 2-diabetes1,3, og udsigterne for disse sygdomme bliver stadig mere foruroligende, i takt med at antallet af mennesker med diabetes er stigende4. ""Vi vil i hele verden opleve en stigende forekomst af hjerte-kar-sygdom blandt mennesker med type 2-diabetes på grund af begrænset viden om forebyggelse, ringe mulighed for at få stillet en diagnose i tide, uhensigtsmæssig behandling og utilstrækkelig information ved egenbehandling. Taking Diabetes to Heart er et globalt initiativ med det formål at bekæmpe de underliggende problemer bag diabetes og hjerte-kar-sygdom og de dermed forbundne stigende omkostninger for samfundet, samt at understøtte omkostningsbesparende interventioner, som kan hjælpe med til at reducere den byrde, de repræsenterer i dag,"" siger dr. Shaukat Sadikot, præsident for IDF. Taking Diabetes to Heart - www.idf.org/takingdiabetes2heart/survey - har til formål at klarlægge, hvilke tiltag der er nødvendige i forhold til at understøtte opmærksomhed og viden om hjerte-kar-sygdom blandt mennesker med type 2-diabetes for at forbedre deres behandlingsresultater. Undersøgelsen bygger på IDF's globale rapport fra 2016, Diabetes and Cardiovascular Disease, som omfatter en række anbefalinger til at lette den belastning, hjerte-kar-sygdom udgør blandt mennesker med diabetes og i befolkningen generelt.5 ""Det er bekymrende, at hjerte-kar-sygdom er den hyppigste dødsårsag blandt mennesker med type 2-diabetes, når mange af disse patienter ikke er klar over denne risiko,"" siger Alan Moses, direktør og chief medical officer i Novo Nordisk. ""Vi er glade for at kunne støtte IDF i lanceringen af Taking Diabetes to Heart, så vi kan få en bedre indsigt i den aktuelle viden om og kendskabet til hjerte-kar-sygdom blandt mennesker med type 2-diabetes. Det vil på sigt gøre os klogere på, hvilke tiltag der er behov for, hvis vi skal forbedre behandlingsresultaterne."" Taking Diabetes to Heart udmønter sig i en omfattende rapport med landespecifikke resultater og ressourcer, der skal hjælpe med at understøtte viden og opmærksomhed om hjerte-kar-sygdom blandt mennesker med type 2-diabetes rundt om i verden. Læs mere om Taking Diabetes to Heart på www.idf.org/takingdiabetes2heart Læs mere om diabetes og hjerte-kar-sygdom på www.idf.org/cvd Om International Diabetes FederationInternational Diabetes Federation (IDF) er en paraplyorganisation for over 230 nationale diabetesforeninger i 165 lande og regioner. Den varetager interesserne hos det voksende antal mennesker, der lever med diabetes, og dem, der er i risikogruppen. IDF har stået i spidsen for det globale diabetessamfund siden 1950. Organisationens aktiviteter sigter mod at påvirke politiske beslutningstagere, skabe øget offentlig opmærksomhed og bane vejen for sundhedsforbedringer, fremme udvekslingen af kvalitetsoplysninger om diabetes og tilbyde undervisning for mennesker med diabetes og deres behandlere. IDF er tilknyttet FN's afdeling for offentlig information (Department of Public Information) og samarbejder med Verdenssundhedsorganisationen (WHO). www.idf.org Taking Diabetes to Heart - www.idf.org/takingdiabetes2heart - består af en onlineundersøgelse, der vil blive tilgængelig på en række forskellige sprog, herunder arabisk, kinesisk, dansk, japansk, engelsk, fransk, spansk, russisk, hindi, koreansk, portugisisk, tysk og urdu. Undersøgelsen vil være tilgængelig online indtil marts 2018. Resultaterne fra undersøgelsen vil danne grundlag for den politiske indsats og den videre beslutningstagning vedrørende denne almindelige og alvorlige komplikation til diabetes.4 Yderligere information Referencer",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=755,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
253,2017-09-15,"Tresiba® studie viser, at mennesker med type 2-diabetes, som undgår alvorlig hypoglykæmi, har nedsat risiko for dødsfald","Lissabon, Portugal, den 15. september 2017 ­- Novo Nordisk præsenterer i dag nye analyser fra det multinationale, dobbeltblindede DEVOTE-studie, som viser, at mennesker med type 2-diabetes, som oplever et tilfælde af alvorlig hypoglykæmi (lavt blodsukker), har større risiko for dødsfald. Risikoen var fire gange højere 15 dage efter et tilfælde og to en halv gange højere når som helst efter et tilfælde af alvorlig hypoglykæmi.1 Resultaterne viste desuden, at daglige udsving i blodsukkerniveauet hos mennesker med type 2-diabetes er forbundet med en højere risiko for dødsfald. Resultaterne præsenteres på EASD 2017, den 53. årlige kongres i det europæiske diabetesselskab European Association for the Study of Diabetes, og publiceres samtidig i Diabetologia.1,2 ""Et tilfælde af alvorlig hypoglykæmi er ikke bare potentielt farligt og noget, alle med diabetes frygter. Det er også forbundet med en øget risiko for dødsfald,"" siger dr. Bernard Zinman fra Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Canada, og medlem af styregruppen for DEVOTE. ""Disse resultater understreger, hvor vigtigt det er at undgå for store udsving i blodsukkerniveauet og mindske risikoen for alvorlig hypoglykæmi, når man behandler mennesker med type 2-diabetes."" I DEVOTE-studiet reducerede Tresiba® (insulin degludec) forekomsten af alvorlig hypoglykæmi med 40% og forekomsten af natlig alvorlig hypoglykæmi med 53% sammenlignet med insulin glargin U100 hos mennesker med type 2-diabetes.3 Lignende reduktioner sås i SWITCH 2-studiet med 51% lavere forekomst af alvorlig hypoglykæmi i den fulde behandlingsperiode af studiet og en 42% reduktion i forekomsten af natlig hypoglykæmi sammenlignet med insulin glargin U100 hos mennesker med type 2-diabetes.4 Studier har desuden vist, at Tresiba® medfører signifikant færre udsving i blodsukkerniveauet sammenlignet med insulin glargin U100 og U300.5,6 DEVOTE er et multinationalt, dobbeltblindet klinisk studie, som undersøgte den kardiovaskulære sikkerhed for Tresiba® sammenlignet med insulin glargin U100 i 104 uger. DEVOTE er det første kardiovaskulære sikkerhedsstudie, der har sammenlignet to basalinsuliner, og det omfattede mere end 7.500 mennesker med type 2-diabetes. Alle deltagere havde enten en høj risiko for eller eksisterende hjerte-kar-sygdom og fik i forvejen standardbehandling for at reducere risikoen for hjerte-kar-tilfælde.3 Studiet viste, at Tresiba® ikke øger hjerte-kar-risikoen sammenlignet med insulin glargin U100 og giver en signifikant reduktion i forekomsten af alvorlig og natlig alvorlig hypoglykæmi med sammenlignelige niveauer af glykæmisk kontrol.3 Tresiba® (insulin degludec) er en basalinsulin til dosering én gang dagligt. Den har en virkningsvarighed på mere end 42 timer med en flad og stabil blodsukkersænkende effekt.6,7 Tresiba® medfører en lav variation i blodsukkeret og en lavere risiko for generel, natlig og alvorlig hypoglykæmi sammenlignet med insulin glargin U100.3,7 I situationer, hvor det ikke er muligt at tage insulin på det samme tidspunkt hver dag, giver Tresiba® mulighed for fleksibilitet med hensyn til injektionstidspunktet fra dag til dag, men med mindst otte timer mellem doserne.7 Tresiba® blev godkendt af registreringsmyndighederne første gang i september 2012 og er siden blevet godkendt i flere end 80 lande verden over. Det er nu på markedet i flere end 50 lande. Yderligere information Referencer 1.       Zinman B, Marso SP, Poulter NR, et al. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia. 2017; TBC:TBC. (In press)2.       Pieber TR, Marso SP, McGuire DK, et al. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia. 2017; TBC:TBC. (In press)3.       Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017; 377:723-7324.       Wysham C, Bhargava A, Chaykin L, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: The SWITCH 2 randomized clinical trial. JAMA. 2017; 318:45-56.5.       Heise T, Norskov M, Nosek L, et al. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. Diabetes Obes Metab. 2017; 19:1032-10396.       Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014; 53:787-800.7.       EMA. Tresiba® Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002498/WC500138940.pdf. Last accessed: September 2017.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=760,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
254,2017-09-15,Tresiba® trial shows that people with type 2 diabetes who avoid severe hypoglycaemia have a reduced risk of death,"Lisbon, Portugal, 15 September 2017 ­- Novo Nordisk today announced new analyses from the multinational, double-blinded DEVOTE trial showing that people with type 2 diabetes who experience severe hypoglycaemia (low blood sugar levels) are at greater risk of death. The risk was four-fold higher 15 days after an event and two and a half-fold higher anytime following an episode of severe hypoglycaemia.1 In addition, results also showed that daily fluctuations in blood sugar levels in people with type 2 diabetes are associated with a higher risk of death. The results were presented at the European Association for the Study of Diabetes 53rd Annual Meeting (EASD) and simultaneously published in Diabetologia.1,2 ""Episodes of severe hypoglycaemia are not only distressing for patients and potentially dangerous, they are also associated with an increased risk of death,"" said Dr Bernard Zinman of the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Canada and member of the DEVOTE Steering Committee. ""These results highlight the importance of maintaining low variability in blood sugar levels and reducing the risk of severe hypoglycaemia when treating people with type 2 diabetes."" In the DEVOTE trial, Tresiba® (insulin degludec) reduced the rate of severe hypoglycaemia by 40% and the rate of nocturnal severe hypoglycaemia by 53% compared to insulin glargine U100 in people with type 2 diabetes.3 Similar reductions were seen in the SWITCH 2 trial with 51% lower rates of severe hypoglycaemia during the full treatment period of the trial and a 42% reduction in the rate of nocturnal hypoglycaemia compared to insulin glargine U100 in people with type 2 diabetes.4 Studies have also shown that Tresiba® provides significantly lower variability in blood sugar levels compared to insulin glargine U100 and U300.5,6 DEVOTE is a multinational, double-blinded clinical trial which investigated the cardiovascular safety of Tresiba® compared with insulin glargine U100 over 104 weeks. DEVOTE is the first cardiovascular outcomes trial (CVOT) comparing two basal insulins and enrolled more than 7,500 people with type 2 diabetes. All participants had a high risk of, or existing, cardiovascular disease and were already receiving standard of care to reduce their cardiovascular risk.3 The trial demonstrated that Tresiba® does not increase cardiovascular risk compared with insulin glargine U100, and provides a significant reduction in the rate of severe and nocturnal severe hypoglycaemia at similar levels of glycaemic control.3 Tresiba® (insulin degludec) is a once-daily basal insulin that provides a duration of action beyond 42 hours with a flat and stable glucose-lowering effect.6,7 It provides low variability in blood glucose levels and a lower risk of overall, nocturnal and severe hypoglycaemia vs. insulin glargine U100.3,7 On occasions when administration at the same time of day is not possible, Tresiba® allows for flexibility in day-to-day dosing time with a minimum of eight hours between injections.7 Tresiba® received its first regulatory approval in September 2012 and has since been approved in more than 80 countries globally. It is now commercially available in more than 50 countries. Further information References 1.         Zinman B, Marso SP, Poulter NR, et al. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia. 2017; TBC:TBC. (In press).2.         Pieber TR, Marso SP, McGuire DK, et al. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia. 2017; TBC:TBC. (In press).3.         Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017; 377:723-732.4.         Wysham C, Bhargava A, Chaykin L, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: The SWITCH 2 randomized clinical trial. JAMA. 2017; 318:45-56.5.         Heise T, Norskov M, Nosek L, et al. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. Diabetes Obes Metab. 2017; 19:1032-1039.6.         Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014; 53:787-800.7.         EMA. Tresiba® Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002498/WC500138940.pdf. Last accessed: September 2017.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=761,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
255,2017-09-13,Xultophy® reduces cardiovascular risk factors in people with type 2 diabetes,"Lisbon, Portugal, 13 September 2017 - In people with type 2 diabetes, Xultophy® (insulin degludec/liraglutide) significantly reduced a number of risk factors associated with an increased risk of cardiovascular disease (CVD), compared to basal insulin.1 According to a new post-hoc analysis presented today at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD 2017), people treated with Xultophy® had significantly lower systolic blood pressure, lower total cholesterol as well as lower low-density lipoprotein cholesterol (so-called 'bad cholesterol'), and significant weight changes in favour of Xultophy® compared to people treated with basal insulin (insulin glargine U100 or insulin degludec). A small but statistically significant increase in heart rate was also observed with Xultophy®.1 ""People with type 2 diabetes have a higher risk of a heart attack or stroke compared to the general population, so reducing this risk as much as possible should be a central goal of treatment"", said Professor Tina Vilsbøll, Steno Diabetes Center Copenhagen, Denmark & Center for Diabetes Research, Gentofte Hospital, Copenhagen, Denmark. ""I am very pleased to see the beneficial effects on cardiovascular risk markers provided by Xultophy®."" CVD is the principal cause of death and disability among people with type 2 diabetes globally, with approximately two-thirds of deaths in people with diabetes attributable to CVD.2 Therefore, treatments for type 2 diabetes should not only lower blood sugar levels but also decrease CV risk.3 ""This added benefit of Xultophy® is certainly great news for the population at risk of developing cardiovascular disease on top of their existing type 2 diabetes"", said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""At Novo Nordisk we strive to develop innovative treatments, reinforcing our long-term commitment to defeat diabetes. Xultophy® is a key component of this commitment."" About the studyThe CV risk markers data came from a new post-hoc analysis of two Xultophy® randomised-controlled clinical trials, comparing the efficacy and safety of Xultophy® against insulin degludec in DUAL II and against insulin glargine U100 in DUAL V, both with metformin for 26 weeks.4,5 These trials were conducted in people with type 2 diabetes not achieving glycaemic control  (HbA1c 7.5-10.0% in DUAL II; 7.0-10.0% in DUAL V) on basal insulin (20-40 units in DUAL II; 20-50 units in DUAL V). The primary results from these trials have been reported previously.4,5 About Xultophy®Xultophy® is a once-daily single injection fixed-ratio combination of long-acting insulin degludec (Tresiba®) and the GLP-1 receptor agonist liraglutide (Victoza®) in one pen. It is indicated for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with basal insulin do not provide adequate glycaemic control. Xultophy® is given once daily by subcutaneous injection. Xultophy® can be administered at any time of the day with or without meals, preferably at the same time of the day.6 On 18 September 2014, Xultophy® was granted marketing authorisation by the European Commission. On 21 November 2016, Xultophy® was approved by the FDA under the brand name Xultophy® 100/3.6.6,7 References",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=762,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
256,2017-09-13,Xultophy® nedsætter hjerte-kar-relaterede risikofaktorer hos mennesker med type 2-diabetes,"Lissabon, Portugal, den 13. september 2017 - Xultophy® (insulin degludec/liraglutid) medfører en signifikant reduktion af en række risikofaktorer forbundet med en øget risiko for hjerte-kar-sygdom hos mennesker med type 2-diabetes, sammenlignet med basalinsulin.1 Det viser en ny post hoc-analyse, som præsenteres i dag på EASD 2017, den 53. årlige kongres i det europæiske diabetesselskab European Association for the Study of Diabetes. Ifølge analysen havde deltagere i behandling med Xultophy® et signifikant lavere systolisk blodtryk, lavere kolesteroltal og lavere LDL-kolesterol ('det dårlige kolesterol') og opnåede desuden signifikante vægtændringer til fordel for Xultophy® sammenlignet med deltagere i behandling med basalinsulin (insulin glargin U100 eller insulin degludec). Der sås desuden en lille, men statistisk signifikant stigning i hjertefrekvens ved behandling med Xultophy®.1 ""Mennesker med type 2-diabetes har større risiko for at få et hjerteanfald eller slagtilfælde end befolkningen generelt, så det bør være et centralt mål for al behandling at få reduceret denne risiko så meget som muligt,"" siger professor Tina Vilsbøll, Steno Diabetes Center Copenhagen og Center for Diabetesforskning ved Gentofte Hospital. ""Jeg er rigtig glad for de positive virkninger på de hjerte-kar-relaterede risikomarkører, vi har set med Xultophy®."" Hjerte-kar-sygdom er den hyppigste årsag til død og invaliditet hos mennesker med type 2-diabetes i verden, og ca. to tredjedele af alle dødsfald blandt mennesker med diabetes skyldes hjerte-kar-sygdom.2 Derfor bør behandling af type 2-diabetes ikke kun have fokus på at sænke blodsukkerniveauet, men også på at mindske hjerte-kar-risikoen.3 ""Denne yderligere fordel ved Xultophy® er gode nyheder for den gruppe mennesker, der har risiko for at udvikle hjerte-kar-sygdom oveni deres eksisterende type 2-diabetes,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Novo Nordisk ønsker at udvikle innovative behandlinger, som kan styrke vores langsigtede forpligtelse til at bekæmpe diabetes. Xultophy® er et centralt element i denne forpligtelse."" Xultophy® er et kombinationsprodukt i et præfyldt pensystem til dosering én gang dagligt som én injektion bestående af langtidsvirkende insulin degludec (Tresiba®) og GLP-1-receptoragonisten liraglutid (Victoza®) i et fast kombinationsforhold. Xultophy® er godkendt til behandling af voksne med type 2-diabetes med det formål at opnå forbedret blodsukkerregulering i kombination med blodsukkersænkende lægemidler, når disse ikke alene eller kombineret med basalinsulin giver en tilstrækkelig regulering af blodsukkerniveauet. Xultophy® doseres én gang dagligt ved injektion i underhuden. Xultophy® kan tages på et hvilket som helst tidspunkt af dagen, sammen med eller uden et måltid, helst på samme tidspunkt hver dag.6 Xultophy® modtog markedsføringstilladelse fra Europa-Kommissionen den 18. september 2014. Den 21. november 2016 blev Xultophy® godkendt af de amerikanske sundhedsmyndigheder, FDA, under varemærket Xultophy® 100/3.6.6,7 Yderligere information  Referencer",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=763,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
257,2017-09-12,More people treated with once-weekly semaglutide achieved reductions in both glucose and weight vs. comparator treatments,"Lisbon, Portugal, 12 September 2017 - A post-hoc analysis of the SUSTAIN 1-5 trials demonstrated that a greater proportion of adults with type 2 diabetes achieved a clinically meaningful reduction in both HbA1c and body weight with once-weekly semaglutide vs. comparator treatments. Comparators included placebo, sitagliptin, insulin glargine U100 or exenatide extended release (ER). The analysis was presented today at the 53rd Annual Meeting of the European Association For The Study Of Diabetes.1 ""As a physician, helping patients with type 2 diabetes achieve glycaemic and weight loss targets can be challenging,"" said Dr Helena Rodbard, SUSTAIN 5 investigator and medical director at Endocrine and Metabolic Consultants, Rockville, Maryland. ""The meaningful reductions demonstrated with semaglutide in both glucose and body weight are encouraging, as more treatment strategies are needed to help meet this challenge."" Significantly more people treated with once-weekly semaglutide achieved the clinically meaningful composite endpoint of >1% HbA1c reduction and >5% weight loss with 0.5 mg (25-35%) and 1.0 mg (38-56%) semaglutide vs. all comparators (2-13%; p<0.0001) in SUSTAIN 1-5.1 In addition, more people achieved the composite endpoint with once-weekly semaglutide 1.0 mg compared with semaglutide 0.5 mg (p<0.0001 for SUSTAIN 2, 4 and 5; p=0.17 for SUSTAIN 1).1 In this post-hoc analysis, semaglutide was well tolerated, with a safety profile similar to that of other glucagon-like peptide-1 receptor agonists. The most common adverse event with semaglutide was nausea. In SUSTAIN 1-4, severe or blood glucose confirmed symptomatic hypoglycaemia events were fewer or similar with once-weekly semaglutide vs. comparators. In SUSTAIN 5, on a background of basal insulin, more events were observed with once-weekly semaglutide than with placebo.1 About semaglutideSemaglutide is a once-weekly analogue of human glucagon-like peptide-1 (GLP-1) that stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner, while decreasing appetite and food intake.2-5 Once-weekly semaglutide is currently under review by seven regulatory agencies, including the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). About the SUSTAIN clinical trial programmeSUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) is a clinical trial programme for semaglutide, administered once weekly, that comprises seven phase 3a global clinical trials and a cardiovascular outcomes trial, involving more than 8,000 adults with type 2 diabetes. References 1.      Rodbard H, Bellary S, Hramiak I, et al. Responder analysis of subjects achieving HbA1c >1% and weight loss >5% across SUSTAIN 1-5 clinical trials. Poster 802. 53rd Annual Meeting of the European Association For The Study Of Diabetes (EASD), Lisbon, Portugal; 11-15 September 2017.2.       Korsatko A, Brunner M, Sach-Friedl S, et al. Effect of once-weekly semaglutide on the counter-regulatory response to hypoglycaemia in subjects with type 2 diabetes. Abstract 764. 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD), Munich, Germany; 12-16 September 2016.3.       Kapitza C, Dahl K, Jaconsen B, et al. The effects of once-weekly semaglutide on ß-cell function in subjects with type 2 diabetes. Abstract 754. 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD), Munich, Germany; 12-16 September 2016.4.       Blundell J, Finlayson G, Axelsen MB, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017; ePub ahad of print. DOI: 10.1111/dom.12932. 5.       Saad H, Hjersted J, Axelsen MB, et al. Semaglutide improves postprandial glucose and lipid metabolism and delays first-hour gastric emptying in subjects with obesity. Canadian Journal of Diabetes. 2016; 40:S34-S35.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=764,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
258,2017-09-12,Flere opnår både blodsukker- og vægtreduktioner med semaglutid én gang ugentligt end med sammenlignende behandlinger,"Lissabon, Portugal, den 12. september 2017 - En post hoc-analyse af studierne SUSTAIN 1-5 viser, at en større andel af voksne med type 2-diabetes opnåede en klinisk betydningsfuld sænkning af både langtidsblodsukker (HbA1c) og vægt ved behandling med semaglutid én gang ugentligt sammenlignet med andre behandlinger, såsom placebo, sitagliptin, insulin glargin U100 eller exenatid extended release (ER). Analysen præsenteres i dag på EASD 2017, den 53. årlige kongres i det europæiske diabetesselskab European Association for the Study of Diabetes.1 ""Som læge kan det være svært at hjælpe patienter med type 2-diabetes med at nå deres behandlingsmål for blodsukker og vægttab,"" siger Helena Rodbard, forsøgsansvarlig læge i SUSTAIN 5 og medicinsk direktør i Endocrine and Metabolic Consultants, Rockville, Maryland, USA. ""De klinisk betydningsfulde reduktioner, vi har set med semaglutid både med hensyn til blodsukker og vægt, tegner lovende, da der er brug for flere behandlingsstrategier for at imødegå denne udfordring."" Signifikant flere deltagere i behandling med semaglutid én gang ugentligt nåede det klinisk betydningsfulde sammensatte endepunkt defineret som >1% reduktion i HbA1c og >5% vægttab ved behandling med 0,5 mg (25-35%) og 1,0 mg (38-56%) semaglutid i forhold til alle sammenligningsbehandlinger (2-13%; p<0,0001) i SUSTAIN 1-5.1 Desuden var der flere deltagere, der nåede det sammensatte endepunkt ved behandling med ugentlig semaglutid 1,0 mg sammenlignet med semaglutid 0,5 mg (p<0,0001 for SUSTAIN 2, 4 og 5; p=0,17 for SUSTAIN 1).1 Semaglutid var veltolereret i denne post hoc-analyse med en sikkerhedsprofil, der var sammenlignelig med profilen for andre GLP-1-receptoragnister. Den mest almindelige bivirkning ved behandling med semaglutid var kvalme. I SUSTAIN 1-4 sås færre eller et sammenligneligt antal tilfælde af alvorlig eller symptomatisk hypoglykæmi (lavt blodsukker) bekræftet ved blodsukkermåling ved behandling med semaglutid én gang ugentligt i forhold til de behandlinger, det blev sammenlignet med. I SUSTAIN 5 sås på en baggrundsbehandling med basalinsulin flere tilfælde med semaglutid én gang ugentligt end med placebo.1 Semaglutid er en ugentlig analog af det naturlige hormon glukagonlignende peptid-1 (GLP-1), som stimulerer udskillelsen af insulin og reducerer sekretionen af glukagon på en glukoseafhængig måde, samt nedsætter appetit og madindtag.2-5 Der er indsendt registreringsansøgning for semaglutid til dosering én gang ugentligt til syv regulatoriske myndigheder, herunder de amerikanske sundhedsmyndigheder (FDA), Det Europæiske Lægemiddelagentur (EMA) og de japanske sundhedsmyndigheder, Japanese Pharmaceuticals and Medical Devices Agency (PMDA). SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) er et klinisk udviklingsprogram for semaglutid doseret én gang ugentligt. Programmet omfatter syv globale kliniske fase 3-studier og et kardiovaskulært sikkerhedsstudie, med en samlet deltagelse af flere end 8.000 voksne med type 2-diabetes. Yderligere information Referencer 1.       Rodbard H, Bellary S, Hramiak I, et al. Responder analysis of subjects achieving HbA1c >1% and weight loss >5% across SUSTAIN 1-5 clinical trials. Poster 802. 53rd Annual Meeting of the European Association For The Study Of Diabetes (EASD), Lisbon, Portugal; 11-15 September 2017. 2.       Korsatko A, Brunner M, Sach-Friedl S, et al. Effect of once-weekly semaglutide on the counter-regulatory response to hypoglycaemia in subjects with type 2 diabetes. Abstract 764. 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD), Munich, Germany; 12-16 September 2016. 3.       Kapitza C, Dahl K, Jaconsen B, et al. The effects of once-weekly semaglutide on ß-cell function in subjects with type 2 diabetes. Abstract 754. 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD), Munich, Germany; 12-16 September 2016. 4.       Blundell J, Finlayson G, Axelsen MB, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017; ePub ahad of print. DOI: 10.1111/dom.12932. 5.       Saad H, Hjersted J, Axelsen MB, et al. Semaglutide improves postprandial glucose and lipid metabolism and delays first-hour gastric emptying in subjects with obesity. Canadian Journal of Diabetes. 2016; 40:S34-S35.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=765,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
259,2017-09-12,Fiasp® forbedrer den generelle blodsukkerregulering signifikant i type 1-diabetes på lang sigt,"Lissabon, Portugal, den 12. september 2017 ­­­- Fiasp® (hurtigtvirkende insulin aspart), den eneste godkendte ultra-hurtigtvirkende1-3 måltidsinsulin i en ny generation af insulin, medførte gennem 52 uger en forbedret blodsukkerregulering både generelt (langtidsblodsukker målt som HbA1c) og efter måltider sammenlignet med konventionel insulin aspart (NovoRapid®)4. Det viser nye forskningsresultater, som præsenteres i dag på EASD, den 53. årlige kongres i det europæiske diabetesselskab European Association for the Study of Diabetes. Resultaterne viser, at Fiasp® fastholdt den signifikante forbedring i den generelle blodsukkerregulering, som var set i en kortere periode af studiet (26 uger)1. De bekræfter desuden sikkerhedsprofilen for Fiasp® og viser en sammenlignelig samlet forekomst af hypoglykæmi (lavt blodsukker), alvorlig eller bekræftet ved blodsukkermåling4. ""Disse resultater bekræfter de positive fordele på lang sigt, som Fiasp® har i forhold til konventionel insulin aspart,"" siger Chantal Mathieu, forsøgsansvarlig professor, leder af Endokrinologisk Afdeling og medicinsk professor ved Katholieke Universiteit Leuven, Belgien. ""Det betyder, at Fiasp® potentielt vil kunne tilbyde mennesker med diabetes, der har problemer med at regulere deres blodsukker efter måltiderne, en bedre mulighed for at opfylde deres behov."" Efter et måltid stiger blodsukkeret hurtigt. Hvis man har diabetes, kan kroppen enten ikke få de høje blodsukkerniveauer ned, eller har meget svært ved det. Vedvarende højt blodsukker efter måltider er forbundet med en øget risiko for hjerte-kar-sygdom og andre diabetesrelaterede komplikationer, herunder skader i øjne og nyrer, samt kræft5,6. Høje blodsukkerniveauer efter måltider medvirker desuden til en utilstrækkelig generel blodsukkerregulering2,5,7. Måltidsinsulin har til formål at sænke blodsukkerniveauet, efter man har spist, men konventionelle hurtigtvirkende insuliner virker ikke lige så hurtigt som kroppens naturlige fysiologiske insulinrespons. Den langsommere respons gør, at mennesker med diabetes kan blive ved med at have forhøjet blodsukker i lang tid efter et måltid2. ""Sammenlignet med konventionel insulin aspart matcher Fiasp® kroppens naturlige fysiologiske insulinrespons bedre og giver dermed en bedre langtidsregulering af blodsukkeret,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Fiasp® giver fordele for mennesker med diabetes og hjælper dem med at opnå bedre blodsukkerregulering, både generelt og efter måltider."" Onset 1-studiet (1.143 deltagere randomiseret) var et delvist dobbeltblindet, basal-bolus, treat to target-studie i fase 3a, som vurderede effekt og sikkerhed af Fiasp® sammenlignet med konventionel insulin aspart i type 1-diabetes gennem 52 uger fordelt på to 26-ugers behandlingsperioder. Resultaterne fra de fulde 52 uger blev præsenteret på EASD 2017. I 52-ugers-perioden viste Fiasp® en statistisk signifikant større generel blodsukkerreduktion på -0,10% hos voksne med type 1-diabetes, sammenlignet med konventionel insulin aspart. Fiasp® viste desuden en statistisk signifikant reduktion i blodsukkerstigningen 1 time efter et måltid på -0,91 mmol/l; der sås ingen signifikant forskel i blodsukkerstigningen 2 timer efter et måltid, sammenlignet med konventionel insulin aspart. Disse resultater blev opnået med en sammenlignelig forekomst af hypoglykæmi (alvorlig eller bekræftet ved blodsukkermåling) ved de to behandlinger4. Fiasp® er den eneste godkendte ultra-hurtigtvirkende1-3 måltidsinsulin i en ny generation af insulin. Fiasp® er insulin aspart i en ny formulering, hvor der er tilsat to hjælpestoffer: B3-vitamin (niacinamid) for at øge optagelseshastigheden og en naturligt forekommende aminosyre (L-arginin) for at sikre stabilitet8. Fiasp® fik markedsføringstilladelse fra Europa-Kommissionen den 9. januar 2017, fra Health Canada den 6. januar, fra Swissmedic den 7. juni og fra Australian Government Department of Health den 28. juni. Fiasp® er p.t. under regulatorisk behandling i flere end 10 lande. Efter at have modtaget et Complete Response Letter (CRL) fra de amerikanske sundhedsmyndigheder (FDA) i oktober 2016 genindsendte Novo Nordisk registreringsansøgningen for hurtigtvirkende insulin aspart som en Class II Resubmission den 29. marts 2017, og FDA-godkendelse forventes i slutningen af tredje kvartal af 2017. Yderligere information Referencer",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=766,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
260,2017-09-12,Fiasp® significantly improved overall blood sugar control in type 1 diabetes long-term,"Lisbon, Portugal, 12 September 2017 ­­­- Fiasp® (fast-acting insulin aspart), the only approved, new-generation, ultra-fast acting1-3 mealtime insulin, improved overall blood sugar (HbA1c) and post-meal sugar (postprandial glucose or PPG) control over 52 weeks, compared to conventional insulin aspart (NovoRapid®), in new study findings4. The findings were presented today at the 53rd European Association for the Study of Diabetes (EASD) Annual Meeting, and showed that Fiasp® maintained the significant improvement in overall blood sugar control that was seen in a shorter-term (26 weeks) study period1. The results also reconfirmed the safety profile of Fiasp®, showing comparable overall numbers of severe or blood-sugar confirmed hypoglycaemia (low blood sugar levels)4. ""These results provide reassurance of the meaningful long-term benefits of Fiasp® versus conventional insulin aspart,"" said Professor Chantal Mathieu, study investigator, chair of Endocrinology and professor of Medicine at Katholieke Universiteit Leuven, Belgium. ""Accordingly, for people with diabetes who struggle to control their post-meal sugar levels, Fiasp® might offer a better option to meet their needs."" After eating, blood sugar levels rise rapidly. In diabetes, the body either cannot bring these high sugar levels down, or struggles to do so. Sustained high post-meal sugar levels are associated with an increased risk of cardiovascular disease and other diabetes-related complications, including damage to eyes and kidneys and cancer5,6. High post-meal sugar levels also contribute to inadequate overall blood sugar control2,5,7. While mealtime insulins aim to bring post-meal sugar levels down, conventional rapid-acting insulins are not as fast as the speed of the natural physiological insulin response. Due to this slower response, people with diabetes can remain in an elevated post-meal sugar state for an extended period2. ""Compared to conventional insulin aspart, Fiasp® is a closer match to the natural physiological insulin response, leading to better long-term blood sugar control,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""Fiasp® delivers benefits for people with diabetes, helping them to achieve better post-meal and overall blood sugar control."" About the studyThe onset 1 trial (1,143 people randomised) was a phase 3a, partially double-blind, basal-bolus, treat-to-target trial, evaluating the efficacy and safety of Fiasp® compared with conventional insulin aspart in type 1 diabetes over 52 weeks, in two 26 week treatment periods. The findings from the 52 week study period were presented at the EASD Annual Meeting 2017. In the 52 week study period, Fiasp® demonstrated a statistically significantly greater overall blood sugar reduction of -0.10% in adults with type 1 diabetes, in comparison to conventional insulin aspart. Fiasp® also showed a statistically significant reduction in 1-hour post-meal sugar increment of -0.91 mmol/L; no significant difference was seen in 2-hour post-meal sugar increment, compared with conventional insulin aspart. These results were achieved with a comparable overall rate of severe or blood-sugar confirmed hypoglycaemia between the two treatments4. About Fiasp®Fiasp® is the only approved, new-generation, ultra-fast acting1-3 mealtime insulin. Fiasp® is insulin aspart in an innovative formulation, in which two excipients have been added: Vitamin B3 (niacinamide) to increase the speed of absorption and a naturally occurring amino acid (L-Arginine) for stability8. Fiasp® received marketing authorisation from the European Commission on 9 January, from Health Canada on 6 January, from Swissmedic on 7 June and from the Australian Government Department of Health on 28 June 2017. It is currently under regulatory review in over 10 countries. After receiving a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) in October 2016, Novo Nordisk resubmitted the fast-acting insulin aspart new drug application (NDA) as a class II resubmission on 29 March 2017 and FDA approval is expected at the end of Q3 2017. _______________________  References",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=767,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
261,2017-09-05,Novo Nordisk announces conclusion of US federal investigation of marketing practices,"Bagsværd, Denmark, 5 September 2017 ­- Today, Novo Nordisk announced it has reached a resolution with the US federal government and the states about an investigation launched in February 2011 concerning sales and marketing practices for Victoza®, a medicine to treat type 2 diabetes. The investigation was disclosed by Novo Nordisk for the first time in a company announcement on 16 February 2011. The settlement resolves claims alleging Novo Nordisk did not fully comply with communicating safety information based on a U.S. Food and Drug Administration (FDA)-approved Risk Evaluation and Mitigation Strategy (REMS) for Victoza®. Under the terms of the settlement agreement, Novo Nordisk will pay approximately 46.5 million US dollars to the federal government and to states that reimbursed for Victoza® under their Medicaid programmes. Additionally, Novo Nordisk will pay 12.15 million dollars to resolve a complaint filed by the government on behalf of the FDA in federal court. In connection with this settlement, the Company has also resolved several private whistle-blower cases related to the government's investigation. The US Department of Health & Human Services, Office of Inspector General, determined that it would not seek a Corporate Integrity Agreement as part of this settlement. ""At Novo Nordisk, we take our responsibility to communicate the safety and clinical benefits of our medicines seriously, and remain committed to properly addressing safety questions healthcare professionals ask every day,"" said Douglas Langa, executive vice president, North America Operations. ""Our focus will always be to ensure that those caring for patients have the data they need to make the most informed treatment decision. While we do not agree with the US government's legal conclusions and deny any wrongdoing, we're pleased to have negotiated a resolution that allows the company to return its full attention to developing medicines that help improve the lives of patients."" Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=770,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
262,2017-09-05,Novo Nordisk indgår forligsaftale i USA om markedsføringspraksis,"Bagsværd, den 5. september 2017 - Novo Nordisk meddeler i dag, at der er indgået et forlig med den amerikanske forbundsregering og delstaterne om en undersøgelse, der blev indledt i februar 2011 vedrørende virksomhedens salgs- og markedsføringspraksis for Victoza®, et lægemiddel til behandling af type 2-diabetes. Novo Nordisk omtalte undersøgelsen første gang i en selskabsmeddelelse den 16. februar 2011. Forligsaftalen bilægger påstandene om, at Novo Nordisk ikke fuldt ud har kommunikeret sikkerhedsinformation relateret til Victoza® i henhold til en såkaldt strategi for risikoevaluering og -begrænsning godkendt af de amerikanske sundhedsmyndigheder, FDA. Forligsaftalen indebærer, at Novo Nordisk betaler ca. 46,5 mio. US dollars til den amerikanske forbundsregering og til stater, som har ydet tilskud til Victoza® under deres Medicaid-programmer. Novo Nordisk vil desuden betale 12,15 mio. dollars med henblik på bilæggelse af en sag anlagt af regeringen på vegne af FDA ved en amerikansk forbundsdomstol. I forbindelse med dette forlig har Novo Nordisk desuden afsluttet flere private whistleblowersager relateret til regeringens undersøgelse. Det amerikanske sundhedsministerium, US Department of Health & Human Services, Office of Inspector General, har besluttet, at der ikke vil blive indgået en integritetsaftale (Corporate Integrity Agreement) som led i dette forlig. ""I Novo Nordisk tager vi vores ansvar alvorligt med hensyn til at informere om de sikkerhedsmæssige og kliniske fordele ved vores lægemidler og vil altid gøre vores yderste for at svare fyldestgørende på lægernes spørgsmål om produktsikkerhed,"" siger Douglas Langa, koncerndirektør med ansvar for North America Operations. ""Vi har altid fokus på at sikre, at behandlerne har alle de oplysninger, der er nødvendige for at træffe beslutninger på et velovervejet grundlag. Selvom vi er uenige i den amerikanske regerings juridiske konklusioner og afviser at have foretaget os noget ulovligt, er vi glade for at have forhandlet os frem til et forlig, der giver virksomheden mulighed for igen at rette sin fulde opmærksomhed mod at udvikle lægemidler, som kan hjælpe med til at skabe en bedre tilværelse for patienterne."" Yderligere information ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=771,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
263,2017-08-25,Victoza® godkendt i USA som eneste behandling af type 2-diabetes med indikation til at nedsætte risikoen for alvorlige kardiovaskulære hændelser,"Bagsværd, den 25. august 2017 - De amerikanske sundhedsmyndigheder (FDA) har godkendt en ny indikation for Victoza® (liraglutid) til nedsættelse af risikoen for alvorlige kardiovaskulære (hjerte-kar-relaterede) hændelser hos voksne med type 2-diabetes og konstateret hjerte-kar-sygdom. FDA's beslutning er baseret på resultaterne fra det store LEADER-studie, som viste, at Victoza® medfører en statistisk signifikant 13% reduktion af risikoen for hjerte-kar-relateret dødsfald, ikke-dødeligt hjerteanfald eller ikke-dødeligt slagtilfælde sammenlignet med placebo, når det blev givet som supplement til standardbehandling, med en absolut risikoreduktion på 1,9%. Den samlede risikoreduktion blev opnået ved en statistisk signifikant 22% reduktion i hjerte-kar-relateret dødsfald ved behandling med Victoza® sammenlignet med placebo, med en absolut risikoreduktion på 1,3%, samt reduktioner, dog ikke statistisk signifikante, i ikke-dødeligt hjerteanfald og ikke-dødeligt slagtilfælde. ""Denne godkendelse er en vigtig milepæl for millioner af amerikanere, der lever med type 2-diabetes, fordi hjerte-kar-sygdom er den hyppigste dødsårsag for disse patienter,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Victoza® tilbyder nu mennesker med type 2-diabetes og konstateret hjerte-kar-sygdom en virkningsfuld behandlingsmulighed, der både kan sænke blodsukkeret og mindske deres risiko for hjerte-kar-sygdom."" Victoza® (liraglutid) er en human GLP-1-analog (glukagonlignende peptid-1) med en aminosyresekvens, der har 97% lighed med det GLP-1, kroppen selv producerer. Victoza® blev godkendt i EU i 2009 og er på markedet i flere end 95 lande; produktet har været anvendt til behandling af mere end 1 mio. mennesker med type 2-diabetes globalt. I USA blev Victoza® i 2010 godkendt som supplement til kost og motion med det formål at forbedre blodsukkerreguleringen hos voksne med type 2-diabetes, og det er nu blevet godkendt til nedsættelse af risikoen for alvorlige kardiovaskulære hændelser (kardiovaskulært dødsfald, ikke-dødeligt myokardieinfarkt eller ikke-dødeligt slagtilfælde) hos voksne med type 2-diabetes og konstateret hjerte-kar-sygdom. I Europa er Victoza® godkendt til behandling af voksne med utilstrækkeligt reguleret type 2-diabetes sammen med kost og motion, dels som monoterapi, når metformin anses for uhensigtsmæssigt på grund af intolerance eller kontraindikationer, og dels i kombination med andre lægemidler til behandling af diabetes. LEADER er et internationalt, randomiseret, dobbeltblindet, placebokontrolleret multicenterstudie, der har undersøgt langtidsvirkningerne (3,5-5 år) af Victoza® (liraglutid) sammenlignet med placebo, begge givet som supplement til standardbehandling, hos mennesker med type 2-diabetes og høj risiko for alvorlige kardiovaskulære hændelser. Standardbehandling omfattede livsstilsændringer, blodsukkersænkende behandling og hjerte-kar-medicin. LEADER-studiet blev påbegyndt i september 2010 og randomiserede 9.340 mennesker med type 2-diabetes fra 32 lande. Det primære endepunkt var defineret som den første forekomst af et sammensat kardiovaskulært endepunkt bestående af hjerte-kar-relateret dødsfald, ikke-dødeligt hjerteanfald eller ikke-dødeligt slagtilfælde. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 67 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=776,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
264,2017-08-25,Victoza® approved in the US as the only type 2 diabetes treatment indicated to reduce the risk of major adverse cardiovascular events,"Bagsværd, Denmark, 25 August 2017 - The U.S. Food and Drug Administration (FDA) has approved a new indication for Victoza® (liraglutide) to reduce the risk of major adverse cardiovascular (CV) events in adults with type 2 diabetes and established CV disease.The FDA's decision is based on the results from the landmark LEADER trial, which demonstrated that Victoza® statistically significantly reduced the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke by 13% vs placebo, when added to standard of care, with an absolute risk reduction of 1.9%. The overall risk reduction was derived from a statistically significant 22% reduction in cardiovascular death with Victoza® treatment vs placebo, with an absolute risk reduction of 1.3%, and non-significant reductions in non-fatal heart attack and non-fatal stroke. ""This approval marks an important milestone for millions of Americans living with type 2 diabetes, as cardiovascular disease is the number one cause of death in this patient population,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""Victoza® now offers people with type 2 diabetes and established cardiovascular disease an effective treatment option to both lower their blood glucose and reduce their cardiovascular risk."" About Victoza®Victoza® (liraglutide) is a human glucagon-like peptide-1 (GLP-1) analogue with an amino acid sequence 97% similar to endogenous human GLP-1. Victoza® was approved in the EU in 2009 and is commercially available in more than 95 countries, treating more than 1 million people with type 2 diabetes globally. In the US, Victoza® was approved in 2010 as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes and now approved to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease. In Europe, Victoza® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes together with diet and exercise, as monotherapy when metformin is considered inappropriate due to intolerance or contraindications and in addition to other medicinal products for the treatment of diabetes. About the LEADER trialLEADER was a multicentre, international, randomised, double-blind, placebo-controlled trial investigating the long-term (3.5-5 years) effects of Victoza® (liraglutide) compared to placebo, both in addition to standard of care, in people with type 2 diabetes at high risk of major cardiovascular events. Standard of care was comprised of lifestyle modifications, glucose-lowering treatments and cardiovascular medications. The landmark LEADER trial was initiated in September 2010 and randomised 9,340 people with type 2 diabetes from 32 countries. The primary endpoint was the first occurrence of a composite cardiovascular outcome comprising cardiovascular death, non-fatal heart attack or non-fatal stroke. Further information Company announcement No 67 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=777,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
265,2017-08-16,Semaglutid viser superioritet sammenlignet med dulaglutid med hensyn til blodsukkerkontrol og vægttab hos mennesker med type 2-diabetes i SUSTAIN 7,"Bagsværd, den 16. august 2017 - Novo Nordisk offentliggør i dag resultaterne fra SUSTAIN 7-studiet, som viser, at deltagere med type 2-diabetes, der blev behandlet med semaglutid én gang ugentligt, opnåede en statistisk signifikant reduktion i langtidsblodsukker (HbA1c) og vægt sammenlignet med behandling med dulaglutid. Studiet, som strakte sig over 40 uger, undersøgte effekten og sikkerheden af 0,5 mg semaglutid sammenlignet med 0,75 mg dulaglutid og 1,0 mg semaglutid sammenlignet med 1,5 mg dulaglutid, når disse blev givet som supplement til metformin. Ud fra et gennemsnitligt HbA1c på 8,2% ved studiets begyndelse opnåede deltagere i behandling med 0,5 mg semaglutid en statistisk signifikant og superiør reduktion på 1,5% mod en reduktion på 1,1% med 0,75 mg dulaglutid. Deltagere, der blev behandlet med 1,0 mg semaglutid, opnåede en statistisk signifikant og superiør reduktion på 1,8% mod en reduktion på 1,4% med 1,5 mg dulaglutid. Vurderet i forhold til behandlingsmålet om HbA1c på 7,0% eller mindre som fastsat af American Diabetes Association (ADA) nåede 69 68% af deltagerne, som fik 0,5 mg semaglutid, behandlingsmålet, mod 52% af dem, som fik 0,75 mg dulaglutid, og 79% af deltagerne, som fik 1,0 mg semaglutid, nåede behandlingsmålet, mod 68 67% af dem, der fik 1,5 mg dulaglutid. Vurderet i forhold til behandlingsmålet om HbA1c på 6,5% eller mindre som fastsat af American Association of Clinical Endocrinologists (AACE) nåede 51 49% af deltagerne, som fik 0,5 mg semaglutid, behandlingsmålet, mod 36 34% af dem, som fik 0,75 mg dulaglutid, og 68 67% af deltagerne, som fik 1,0 mg semaglutid, nåede behandlingsmålet, mod 49 47% af dem, som fik 1,5 mg dulaglutid. Ud fra en gennemsnitsvægt på 95 kg og et BMI på 33,5 kg/m2 ved studiets begyndelse opnåede deltagere i behandling med 0,5 mg semaglutid endvidere et statistisk signifikant og superiørt vægttab på 4,6 kg mod 2,3 kg med 0,75 mg dulaglutid. Deltagere, der blev behandlet med 1,0 mg semaglutid, opnåede et statistisk signifikant og superiørt vægttab på 6,5 kg mod 3,0 kg med 1,5 mg dulaglutid. 44% af deltagerne, som blev behandlet med 0,5 mg semaglutid, mod 23% af dem, der fik 0,75 mg dulaglutid, opnåede et vægttab på 5% eller mere, og 63% af deltagerne, som fik 1,0 mg semaglutid, mod 30% af dem, som blev behandlet med 1,5 mg dulaglutid. Semaglutid viste en sikker og veltolereret profil i studiet, som var konsistent med resultaterne fra SUSTAIN-programmet. Den mest almindelige bivirkning for begge doseringer af semaglutid var mild til moderat kvalme, som generelt set var sammenlignelig med dulaglutid og aftog med tiden. Afslutning af behandlingen før tid som følge af bivirkninger var mindre end 10% på tværs af alle behandlingsgrupper. Antallet af deltagere, som indberettede bivirkningen diabetisk øjensygdom (retinopati), var lav og sammenlignelig i begge semaglutid- og dulaglutid-grupperne (henholdsvis 4 og 5 hændelser). ""Den statistisk signifikante blodsukkerkontrol og vægtreduktion, som deltagerne i dette studie har opnået med semaglutid sammenlignet med dulaglutid, er en yderligere styrkelse af de enestående resultater, vi har set hele vejen igennem SUSTAIN-programmet,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Vi er glade for semaglutids potentiale til at sætte en ny standard for behandlingen af type 2-diabetes."" Semaglutid er en ugentlig analog af det naturlige hormon glukagonlignende peptid-1 (GLP-1), som stimulerer udskillelsen af insulin og reducerer sekretionen af glukagon på en glukoseafhængig måde, samt nedsætter appetit og madindtag. Der er indsendt registreringsansøgning for semaglutid til dosering én gang ugentligt til seks regulatoriske myndigheder, herunder de amerikanske sundhedsmyndigheder, FDA, Det Europæiske Lægemiddelagentur og de japanske sundhedsmyndigheder, Japanese Pharmaceuticals and Medical Devices Agency. SUSTAIN 7 er et 40-ugers fase 3b-studie til vurdering af effekt og sikkerhed af 0,5 mg semaglutid sammenlignet med 0,75 mg dulaglutid samt 1,0 mg semaglutid sammenlignet med 1,5 mg dulaglutid, begge givet én gang ugentligt som tillægsbehandling til metformin hos 1.201 mennesker med type 2-diabetes. Det primære effektmål var ændring i langtidsblodsukkeret (HbA1c) i forhold til udgangspunktet ved studiets start (baseline) efter 40 ugers behandling med semaglutid sammenlignet med dulaglutid. SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) er et klinisk udviklingsprogram for semaglutid doseret én gang ugentligt. Programmet omfatter syv globale kliniske fase 3-studier, herunder et kardiovaskulært sikkerhedsstudie, med en samlet deltagelse af flere end 8.000 voksne med type 2-diabetes. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 65 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=780,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
266,2017-08-16,Semaglutide superior to dulaglutide on glucose control and weight loss in people with type 2 diabetes in SUSTAIN 7,"Bagsværd, Denmark, 16 August 2017 - Novo Nordisk today announced the SUSTAIN 7 trial results, demonstrating that people with type 2 diabetes treated with once-weekly semaglutide experienced superior reduction in HbA1c and body weight compared to treatment with dulaglutide. The 40-week trial investigated the efficacy and safety of 0.5 mg semaglutide compared with 0.75 dulaglutide and 1.0 mg semaglutide compared with 1.5 mg dulaglutide, when added to metformin. From a mean baseline HbA1c of 8.2%, 0.5 mg semaglutide achieved a statistically significant and superior reduction of 1.5% compared with a reduction of 1.1% with 0.75 mg dulaglutide. People treated with 1.0 mg semaglutide experienced a statistically significant and superior reduction of 1.8% compared with a reduction of 1.4% with 1.5 mg dulaglutide. Using the American Diabetes Association (ADA) treatment target of HbA1c below or equal to 7.0%, 69 68% of people treated with 0.5 mg semaglutide compared with 52% of people treated with 0.75 mg dulaglutide reached the treatment goal, and 79% of people treated with 1.0 mg semaglutide compared to 68 67% with 1.5 mg dulaglutide reached the treatment goal. Using the American Association of Clinical Endocrinologists (AACE) treatment target of HbA1c below or equal to 6.5%, 51 49% of people treated with 0.5 mg semaglutide compared with 36 34% of people treated with 0.75 mg dulaglutide reached the treatment goal, and 68 67% of people treated with 1.0 mg semaglutide compared to 49 47% with 1.5 mg dulaglutide reached the treatment goal. Furthermore, from a mean baseline body weight of 95 kg and a BMI of 33.5 kg/m2, people treated with 0.5 mg semaglutide experienced a statistically significant and superior weight loss of 4.6 kg compared to 2.3 kg with 0.75 mg dulaglutide. People treated with 1.0 mg semaglutide experienced a statistically significant and superior weight loss of 6.5 kg compared to 3.0 kg with 1.5 mg dulaglutide. 44% of people treated with 0.5 mg semaglutide compared with 23% of people treated with 0.75 mg dulaglutide achieved more or equal to 5% body weight loss and 63% of people with 1.0 mg semaglutide compared with 30% of people treated with 1.5 mg dulaglutide. In the trial, semaglutide demonstrated a safe and well-tolerated profile consistent with results from the SUSTAIN programme. The most common adverse event for both semaglutide dosages was mild to moderate nausea, which was overall comparable to dulaglutide and diminished over time. Premature treatment discontinuation due to adverse events was less than 10% across all treatment groups. The number of people reporting an adverse event of diabetic retinopathy was low and comparable in both the semaglutide and dulaglutide groups (4 and 5 events, respectively). ""The superior glucose control and weight loss achieved with semaglutide compared to dulaglutide in this trial reinforces the unprecedented results observed in the entire SUSTAIN programme"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""We are excited about the potential of semaglutide to set a new standard for treatment of type 2 diabetes"". About semaglutide Semaglutide is a once-weekly analogue of human glucagon-like peptide-1 (GLP-1) that stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner, while decreasing appetite and food intake. Once-weekly semaglutide is currently under review by seven regulatory agencies, including the US Food and Drug Administration, the European Medicines Agency and the Japanese Pharmaceuticals and Medical Devices Agency. SUSTAIN 7SUSTAIN 7 is a phase 3b, 40-week, efficacy and safety trial of 0.5 mg semaglutide vs 0.75 mg dulaglutide and 1.0 mg semaglutide vs 1.5 mg dulaglutide, both once-weekly, as add-on to metformin in 1,201 people with type 2 diabetes. The primary outcome measure was change in HbA1c from baseline after 40 weeks of treatment with semaglutide compared to dulaglutide. About the SUSTAIN clinical programme SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) is a clinical trial programme for semaglutide, administered once weekly, that comprises seven phase 3 global clinical trials, including a cardiovascular outcomes trial, involving more than 8,000 adults with type 2 diabetes. Company announcement No 65 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=781,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
267,2017-08-15,Ændringer i Novo Nordisks koncerndirektion,"Bagsværd, den 15. august 2017 - Novo Nordisk A/S meddeler i dag, at der vil blive gennemført to ændringer i koncerndirektionen. Pr. 1. oktober er Camilla Sylvest, som i dag er direktør for Novo Nordisks aktiviteter i Region China, udnævnt til koncerndirektør med ansvar for Commercial Strategy & Corporate Affairs. Som leder af denne nye enhed bliver hun overordnet ansvarlig for virksomhedens koncernfunktioner indenfor markedsføring, markedsadgang, strategi, kommunikation, interessentrelationer og bæredygtighed. Camilla Sylvest blev udnævnt til direktør for Novo Nordisks Region China i august 2015 med ansvar for virksomhedens aktiviteter i Kina, Taiwan og Hongkong. Inden da havde hun gennem en årrække stået i spidsen for datterselskaber og forretningsområder af voksende størrelse og kompleksitet i Europa og Asien. Camilla Sylvest blev ansat i Novo Nordisk i 1996 og har varetaget forskellige stillinger i hovedkvarteret og i regionerne inden for prissætning, sundhedsøkonomi, markedsføring og salgseffektivitet. Hun er uddannet cand.oecon. fra Syddansk Universitet og har en Executive MBA fra Scandinavian International Management Institute. Lars Fruergaard Jørgensen, adm. direktør for Novo Nordisk, siger: ""I de mere end 20 år, Camilla Sylvest har været ansat i Novo Nordisk, har hun konsekvent leveret stærke forretningsresultater, opbygget stærke relationer til interessenter og vist en naturlig evne til at få organisationen til at stå sammen og fokusere på centrale prioriteter. Derfor har jeg fuld tillid til, at hun med succes vil kunne drive vores kommercielle strategier såvel som vores strategier for, hvordan vi udvikler Novo Nordisk som en ansvarlig virksomhed med fokus på patienternes behov."" Med virkning fra i dag forfremmes Doug Langa, som i dag er direktør for North America Operations og for Novo Nordisk Inc., til koncerndirektør. Hans ansvarsområder er uændrede. Doug Langa blev udnævnt til direktør for North America Operations og for Novo Nordisk Inc. i marts i år. Inden da var han direktør for Market Access og medlem af ledelsen i Novo Nordisks amerikanske datterselskab. Han kom til Novo Nordisk i 2011 og har mere end 25 års erfaring indenfor medicin- medikoindustrien. Han er dimitteret fra Widener University og har en MBA fra Fordham University, begge i USA. Camilla Sylvest og Doug Langa vil begge rapportere til Lars Fruergaard Jørgensen. Novo Nordisks koncerndirektion består herefter af: Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=782,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
268,2017-08-15,Changes in Novo Nordisk Executive Management,"Bagsværd, Denmark, 15 August 2017 - Novo Nordisk A/S today announced two changes to its Executive Management team. As of 1 October, Camilla Sylvest, senior vice president in charge of Novo Nordisk's operations in Region China, has been appointed executive vice president in charge of Commercial Strategy & Corporate Affairs. At the helm of this new unit she will be overall responsible for the company's corporate functions within marketing, market access, strategy, communication, stakeholder relations and sustainability. Camilla Sylvest was appointed senior vice president and general manager of Novo Nordisk's Region China in August 2015. In this role she is responsible for the company's activities in China, Taiwan and Hong Kong. Prior to this, Camilla Sylvest has led affiliates and business areas of growing size and complexity in Europe and Asia. She started her career in Novo Nordisk in 1996, following which she had roles in headquarters and regions within pricing, health economics, marketing and sales effectiveness. She holds an MSc in Economics from University of Southern Denmark and an Executive MBA from Scandinavian International Management Institute. Lars Fruergaard Jørgensen, president & CEO, says: ""During her more than 20 years in Novo Nordisk, Camilla Sylvest has consistently delivered strong business results, fostered strong relations with stakeholders and demonstrated a natural ability to rally her organisations around key priorities. This makes me very confident in her ability to successfully drive our commercial strategies as well as our strategies for developing Novo Nordisk as a responsible corporation focused on the needs of the patients we serve."" Effective today, Doug Langa, senior vice president, head of North America Operations and president of Novo Nordisk Inc, is promoted to executive vice president. His responsibilities remain unchanged. Doug Langa was appointed head of North America Operations and president of Novo Nordisk Inc in March this year. Previously, he was senior vice president of Market Access and a member of Novo Nordisk's US leadership team. He joined the company in 2011 and has over 25 years of experience in the pharmaceutical and medical device industry. He graduated from Widener University and earned his MBA from Fordham University. Both Camilla Sylvest and Doug Langa will report to Lars Fruergaard Jørgensen. With these changes, the members of Novo Nordisk's Executive Management are: Further information Company announcement No 64 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=783,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
269,2017-08-09,Novo Nordisk increased reported operating profit by 8% in the first six months of 2017,"Sales increased by 4% measured in Danish kroner Sales increased by 4% in Danish kroner and by 3% in local currencies to DKK 57.1 billion. Sales of Tresiba® increased by 155% to DKK 3.7 billion (149% in local currencies) Sales of Victoza® increased by 21% to DKK 11.5 billion (18% in local currencies). Sales of Saxenda® increased by 98% to DKK 1.2 billion (90% in local currencies) Sales in North America Operations increased by 5% (2% in local currencies). Sales in International Operations increased by 4% (5% in local currencies). Sales within diabetes and obesity care increased by 11% to DKK 47.5 billion (10% in local currencies). Sales within biopharmaceuticals declined by 19% to DKK 9.6 billion (20% in local currencies), primarily reflecting an impact from the introduction of a generic version of the hormone replacement therapy product Vagifem® and from rebate adjustments for human growth hormone in Q1 2016, both in the USA, whereas sales within haemophilia were broadly unchanged. Operating profit increased by 8% reported in Danish kroner and by 6% in local currencies to DKK 26.9 billion. Net profit increased by 4% to DKK 20.1 billion. Diluted earnings per share increased by 6% to DKK 8.07. In June, Victoza® received a positive 17-2 vote from the FDA Advisory Committee acknowledging that clinical trial data provided substantial evidence of cardiovascular risk reduction. Furthermore, Novo Nordisk received EU approval for an update of both the Victoza® and Saxenda® labels reflecting the evidence of cardiovascular risk reduction. The Board of Directors has approved an interim dividend for 2017 of DKK 3.00 per share of DKK 0.20 that will be paid in August 2017. The financial outlook for 2017 has been updated and sales growth measured in local currencies is now expected to be in the range of 1% to 3% compared with the previous range of 0% to 3%. A negative currency impact of 3 percentage points is now expected, reflecting the recent and significant depreciation of the US dollar and most other key invoicing currencies versus the Euro and the Danish krone. Operating profit growth measured in local currencies is now expected to be in the range of 1% to 5% compared with the previous range of -1% to 3%. A negative currency impact of 4 percentage points is now expected. For 2018, formulary negotiations with Pharmacy Benefit Managers and managed care organisations in the USA are progressing. Subject to the final outcome of these negotiations, average prices after rebates are expected to be lower compared with the levels in 2017, predominantly driven by the basal insulin segment. The market access for Novo Nordisk's key products is, however, expected to remain broadly unchanged compared to 2017. Lars Fruergaard Jørgensen, president and CEO: ""We are well on track to deliver on our targets for 2017 based on sales growth driven by our new, innovative products within diabetes and obesity care and a continued focus on cost control. Although the formulary negotiations in the USA reflect the tough competitive environment, we remain confident that our long-term financial growth targets are achievable."" Contacts for further information Company announcement No 60 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=790,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
270,2017-08-09,Novo Nordisks rapporterede resultat af primær drift steg med 8% i første halvår af 2017,"Salget steg med 4% opgjort i kroner Salget steg med 4% opgjort i kroner og med 3% i lokale valutaer til 57,1 mia. kr. Salget indenfor diabetes- og fedmebehandling steg med 11% til 47,5 mia. kr. (10% i lokale valutaer). Salget indenfor biopharmaceuticals faldt med 19% til 9,6 mia. kr. (20% i lokale valutaer) primært som følge af en påvirkning fra introduktionen af en generisk udgave af hormonpræparatet Vagifem® og fra rabatjusteringer for humant væksthormon i 1. kvartal af 2016, begge i USA, mens salget indenfor hæmofili var stort set uændret. Resultat af primær drift steg med 8% rapporteret i kroner og med 6% i lokale valutaer til 26,9 mia. kr. Nettoresultatet steg med 4% til 20,1 mia. kr. Udvandet resultat pr. aktie steg med 6% til 8,07 kr. FDA's rådgivende komite stemte i juni med stemmerne 17-2 for, at de kliniske data giver væsentlig dokumentation for, at Victoza® nedsætter risikoen for hjerte-kar-sygdom. Endvidere fik Novo Nordisk EU-godkendelse til at opdatere indlægssedlerne for både Victoza® og Saxenda®, så de afspejler dokumentationen for nedsættelse af risikoen for hjerte-kar-sygdom. Bestyrelsen har godkendt et interimudbytte for 2017 på 3,00 kr. pr. aktie a 0,20 kr., som vil blive udbetalt i august 2017. De finansielle forventninger til 2017 er blevet opdateret, og salgsvæksten opgjort i lokale valutaer forventes nu at blive i intervallet 1 til 3% mod tidligere 0 til 3%. Der forventes nu en negativ valutapåvirkning på 3 procentpoint som følge af den nylige og signifikante svækkelse af den amerikanske dollar og de fleste andre vigtige faktureringsvalutaer overfor euroen og den danske krone. Væksten i resultat af primær drift opgjort i lokale valutaer forventes nu at blive i intervallet 1 til 5% mod tidligere -1 til 3%. Der forventes nu en negativ valutapåvirkning på 4 procentpoint. Kontraktforhandlingerne om priser og medicintilskud for 2018 med pharmacy benefit managers (indkøbsorganisationer) og managed care-organisationer (private sundhedsforsikringsselskaber) i USA skrider fremad. Afhængigt af det endelige udfald af disse forhandlinger forventes det, at gennemsnitspriserne efter rabatter vil blive lavere end i 2017, primært drevet af basalinsulinsegmentet. Markedsadgangen for Novo Nordisks vigtigste produkter forventes dog at forblive stort set uændret sammenlignet med 2017. Adm. direktør Lars Fruergaard Jørgensen: ""Vi er godt på vej til at levere på vores mål for 2017 baseret på salgsvækst drevet af vores nye, innovative produkter indenfor diabetes- og fedmebehandling og et fortsat fokus på omkostningsstyring. Selvom kontraktforhandlingerne i USA afspejler det barske konkurrenceklima, er vi stadig overbeviste om, at vores langsigtede finansielle vækstmål er opnåelige."" Kontaktoplysninger Selskabsmeddelelse nr. 60 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=791,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
271,2017-07-27,"Novo Nordisk A/S: Victoza® godkendt i EU som eneste GLP-1 med indlægsseddel, der omfatter forebyggelse af kardiovaskulære hændelser","Bagsværd, den 27. juli 2017 - Europa-Kommissionen har godkendt en opdatering af indlægssedlen for Victoza® (liraglutid) i EU, der udvider indikationen, så den afspejler både blodsukker- og kardiovaskulære hændelser som integreret del af behandlingen af type-2 diabetes. Victoza® er den eneste GLP-1, der bevisligt kan forebygge kardiovaskulære hændelser hos mennesker med type-2 diabetes og høj risiko for alvorlige kardiovaskulære hændelser. Den opdaterede indlægsseddel indeholder resultater fra LEADER-studiet, der viste, at Victoza® medfører en statistisk signifikant 13% reduktion af risikoen for kardiovaskulært dødsfald, ikke-dødeligt myokardieinfarkt (hjerteanfald) eller ikke-dødeligt slagtilfælde sammenlignet med placebo, når det blev givet som supplement til standardbehandling. Den samlede risikoreduktion blev opnået ved en statistisk signifikant 22% reduktion i kardiovaskulært dødsfald ved behandling med Victoza® sammenlignet med placebo samt reduktioner, dog ikke statistisk signifikante, i ikke-dødeligt myokardieinfarkt og ikke-dødeligt slagtilfælde. ""Hjerte-kar-sygdom er den største dødsårsag for mennesker med type 2-diabetes og kræver en behandlingsstrategi, der kan håndtere både blodsukker- og kardiovaskulære risici for at kunne bidrage til at opnå bedre resultater,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Europa-Kommissionens godkendelse af den udvidede indlægsseddel for Victoza® giver lægerne mulighed for at behandle deres patienter med den eneste GLP-1, der bevisligt forebygger kardiovaskulære hændelser hos mennesker med type 2 diabetes og høj risiko for alvorlige kardiovaskulære hændelser."" Victoza® er en human GLP-1-analog (glukagonlignende peptid-1) med en aminosyresekvens, der har 97% lighed med det GLP-1, kroppen selv producerer. Victoza® blev godkendt i EU i 2009 og er på markedet i flere end 95 lande; produktet har været anvendt til behandling af mere end 1 mio. mennesker med type 2-diabetes globalt. I Europa er Victoza® godkendt som monoterapi til regulering af blodsukkerniveauet hos voksne med type 2-diabetes, når metformin anses for utilstrækkeligt, og i kombination med diabeteslægemidler i tabletform og/eller basalinsulin, når blodsukkeret ikke kan reguleres tilstrækkeligt med disse lægemidler sammen med motion og diæt. I USA blev Victoza® godkendt i 2010 som supplement til diæt og motion med det formål at forbedre blodsukkerreguleringen hos voksne med type 2-diabetes. LEADER er et internationalt, randomiseret, dobbeltblindet, placebokontrolleret multicenterstudie, der har undersøgt langtidsvirkningerne (3,5-5 år) af Victoza® (liraglutid op til 1,8 mg) sammenlignet med placebo, begge givet som supplement til standardbehandling, hos mennesker med type 2-diabetes og høj risiko for alvorlige kardiovaskulære hændelser. Standardbehandling omfattede livsstilsændringer, blodsukkersænkende behandling og hjerte-kar-medicin. LEADER blev påbegyndt i september 2010 og randomiserede 9.340 mennesker med type 2-diabetes fra 32 lande. Det primære endepunkt var defineret som den første forekomst af et sammensat kardiovaskulært endepunkt bestående af kardiovaskulært dødsfald, ikke-dødeligt myokardieinfarkt (hjerteanfald) eller ikke-dødeligt slagtilfælde. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 57 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=796,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
272,2017-07-27,Novo Nordisk A/S: Victoza® has been approved in the EU as the only GLP-1 with a label to include prevention of cardiovascular events,"Bagsværd, Denmark, 27 July 2017 - The European Commission has approved an update to the Victoza® (liraglutide) EU label that expands the indication to reflect both improving blood sugar and cardiovascular (CV) events as integral parts of type 2 diabetes treatment. Victoza® is the only GLP-1 that is proven to prevent CV events in people with type 2 diabetes and high CV risk. The updated label includes results from the LEADER trial, which demonstrated that Victoza® statistically significantly reduced the risk of cardiovascular death, non-fatal myocardial infarction (heart attack) or non-fatal stroke by 13% versus placebo, when added to standard of care. The overall risk reduction was derived from a statistically significant 22% reduction in cardiovascular death with Victoza® treatment versus placebo and non-significant reductions in non-fatal myocardial infarction and non-fatal stroke. ""Cardiovascular disease is the number one cause of death for people with type 2 diabetes and requires treatment strategies that can tackle both blood glucose and cardiovascular risk to help improve outcomes,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""The European Commission's approval of the expanded Victoza® label enables physicians to provide their patients with the only GLP-1 proven to prevent cardiovascular events in people with type 2 diabetes and high cardiovascular risk."" About Victoza®Victoza® (liraglutide) is a human glucagon-like peptide-1 (GLP-1) analogue with an amino acid sequence 97% similar to endogenous human GLP-1. Victoza® was approved in the EU in 2009 and is commercially available in more than 95 countries, treating more than 1 million people with type 2 diabetes globally. In Europe, Victoza® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes together with diet and exercise, as monotherapy when metformin is considered inappropriate due to intolerance or contraindications and in addition to other medicinal products for the treatment of type 2 diabetes. In the US, Victoza® was approved in 2010 as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes. About the LEADER trialLEADER was a multicentre, international, randomised, double-blind, placebo-controlled trial investigating the long-term (3.5-5 years) effects of Victoza® (liraglutide) compared to placebo, both in addition to standard of care, in people with type 2 diabetes at high risk of major cardiovascular events. Standard of care was comprised of lifestyle modifications, glucose-lowering treatments and cardiovascular medications. The landmark LEADER trial was initiated in September 2010 and randomised 9,340 people with type 2 diabetes from 32 countries. The primary endpoint was the first occurrence of a composite cardiovascular outcome comprising cardiovascular death, non-fatal heart attack or non-fatal stroke. Further information Company announcement No 57 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=797,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
273,2017-07-03,Novo Nordisk to present 35 abstracts at the International Society on Thrombosis and Haemostasis Congress,"Bagsværd, Denmark, 3 July 2017 - Novo Nordisk announced today that data from 35 abstracts will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) congress from 8-13 July, in Germany. This data will be featured across posters, abstracts and oral presentations covering a wide range of Novo Nordisk's haemophilia treatment options. The broad range of data to be presented supports Novo Nordisk's commitment to improving lives of people with haemophilia through improved diagnosis, treatment and care. The programme provides updates on the innovative pipeline, as well as clinical data around established treatments. Following are key data highlights to be presented at the meeting: Tuesday 11 July, 09.30 CEST, oral presentation Tuesday 11 July, 12.00 CEST, poster presentation Wednesday 12 July, 12.00 CEST, poster presentation Wednesday 12 July, 14.45 CEST, oral presentation ""Novo Nordisk continues to develop a rich research and development pipeline to ensure we are at the forefront of finding superior next generation of medicines for people with haemophilia,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer, Novo Nordisk. ""The ISTH congress gives us a great opportunity to share updates on our latest approach to improving outcomes as well as learn more about how we can help people with haemophilia live a life with as few limitations as possible."" In addition to the data presentation, ISTH will also feature the launch of CoagulationASSAYS.com, a new online portal to help address the unmet need in the diagnosis and monitoring of selected bleeding disorders by providing information about commonly used diagnostic and monitoring laboratory tests. The portal will officially launch on 9 July, targeting healthcare professionals with an interest in coagulation assays, including laboratory managers, specialists and clinicians. The site will include a comprehensive list of coagulation assay kits and reagents currently marketed and available for diagnostic use specific to the relevant bleeding disorders. The abstracts above are a sampling of the data that will be presented by Novo Nordisk. For a complete list of abstracts please visit: http://www.isth2017.org/abstract-submission.html. To find out more about Novo Nordisk at ISTH, please visit: www.novonordiskisth2017.com. Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=808,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
274,2017-07-03,Novo Nordisk præsenterer 35 abstracts på den internationale hæmostasekongres ISTH,"Bagsværd, den 3. juli 2017 - På den årlige kongres i det internationale selskab for trombose og hæmostase (ISTH), der finder sted i dagene 8.-13. juli 2017 i Tyskland, præsenterer Novo Nordisk data fra 35 abstracts om en bred vifte af virksomhedens behandlingsmuligheder indenfor hæmofili. Det brede udvalg af forskningsdata understøtter Novo Nordisks ambition om at skabe en bedre tilværelse for mennesker med hæmofili gennem bedre diagnose og behandling. Programmet indeholder både opdateringer om nye produkter, der er undervejs i virksomhedens forsknings- og udviklingspipeline, og kliniske data om etablerede behandlinger. Nogle af de vigtigste præsentationer omfatter: Tirsdag den 11. juli kl. 09.30 CEST, mundtlig præsentation Tirsdag den 11. juli kl. 12.00 CEST, posterpræsentation Onsdag den 12. juli kl. 12.00 CEST, posterpræsentation Onsdag den 12. juli kl. 14.45 CEST, mundtlig præsentation ""Novo Nordisk arbejder fortsat med en bred forsknings- og udviklingspipeline for at sikre, at vi er med helt fremme i forreste linje i arbejdet med at finde den næste generation af lægemidler til behandling af mennesker med hæmofili,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""ISTH-kongressen er en god lejlighed til at fortælle om vores nyeste metoder til at forbedre behandlingsresultaterne og samtidig lære mere om, hvordan vi kan hjælpe mennesker med hæmofili til at leve det liv, de ønsker, med så få begrænsninger som muligt."" Udover præsentationen af data vil der på ISTH også blive lanceret en ny onlineportal, CogulationASSAYS.com, der kan hjælpe med til at adressere det udækkede behov indenfor diagnosticering og monitorering af udvalgte koagulationsforstyrrelser gennem information om almindeligt anvendte laboratorietests til diagnostik og monitorering. Portalen bliver lanceret officielt den 9. juli og henvender sig til sundhedspersonale med interesse i koagulationsanalyser, herunder laboratoriechefer, specialister og klinikere. Sitet vil omfatte en udførlig liste over kits og reagenser til koagulationsanalyse, som er på markedet i dag og er tilgængelige til diagnostisk brug specifikt i forbindelse med de udvalgte koagulationsforstyrrelser. De nævnte abstracts er bare nogle af de data, Novo Nordisk fremlægger på kongressen. En komplet oversigt over abstracts kan ses her: http://www.isth2017.org/abstract-submission.html. Læs mere om Novo Nordisk på ISTH her: www.novonordiskisth2017.com. Yderligere information ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=809,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
275,2017-06-23,"Novo Nordisk rapporterer op til 13,8% vægttab hos svært overvægtige mennesker i behandling med semaglutid i fase 2-studie","Bagsværd, den 23. juni 2017 - Novo Nordisk offentliggør i dag de overordnede resultater fra et 52-ugers dobbeltblindet klinisk fase 2-studie med subkutan semaglutid til dosering én gang dagligt. Studiet undersøgte sikkerheden af semaglutid og dets potentiale for at fremkalde og fastholde vægttab hos svært overvægtige mennesker. I studiet blev 957 svært overvægtige deltagere randomiseret til behandling med doser af semaglutid på mellem 0,05 og 0,4 mg/dag eller placebo. Liraglutid 3,0 mg/dag blev inkluderet til sammenligning. Ca. 100 deltagere blev inkluderet i hver aktiv behandlingsarm, og behandlingen blev kombineret med diæt og motion. Alle deltagere i studiet blev behandlet i 52 uger efterfulgt af en syvugers opfølgningsperiode. Fra en gennemsnitsvægt ved studiets start på omkring 111 kg og et BMI på ca. 39 kg/m2 blev der observeret et vægttab på op til 17,8 kg efter 52 ugers behandling med semaglutid. Dette svarede til et anslået vægttab på 13,8% sammenlignet med det vægttab på 2,3%, der var opnået via diæt, motion og placebo alene, efter at alle behandlingsarme var justeret for deltagere, der ophørte med behandling i studiet. Resultaterne fra den behandlingsarm, der fik liraglutid 3,0 mg, var stort set på linje med tidligere rapporterede data. Semaglutid til dosering én gang dagligt havde en veltolereret sikkerhedsprofil, og de mest almindelige bivirkninger var relateret til mave-tarm-systemet. ""Vi er meget glade for disse solide resultater og det potentiale, semaglutid har vist som en ny behandling til svært overvægtige mennesker,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Vi vil nu forberede fase 3-programmet med semaglutid for at bekræfte disse resultater. Vi forventer at påbegynde fase 3-programmet i 2018."" Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Regnskabsmeddelelse nr. 50 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=812,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
276,2017-06-23,Novo Nordisk reports up to 13.8% weight loss in people with obesity receiving semaglutide in phase 2 trial,"Bagsværd, Denmark, 23 June 2017 - Novo Nordisk today announced the headline results from a 52-week double-blind phase 2 clinical trial with once-daily subcutaneous semaglutide investigating safety and potential for inducing and maintaining weight loss in people with obesity. In the trial, 957 people with obesity were randomised to treatment with doses of semaglutide between 0.05 to 0.4 mg/day or placebo. Liraglutide 3.0 mg/day was included for comparison. Approximately 100 people were included in each active treatment arm in combination with diet and exercise. All people in the trial were treated for 52 weeks followed by a 7-week follow-up period. From a mean baseline weight of around 111 kg and a body mass index of approximately 39 kg/m2, a weight loss up to 17.8 kg was observed after 52 weeks of treatment with semaglutide. This corresponded to an estimated 13.8% weight loss compared to the weight loss of 2.3% achieved by diet, exercise and placebo alone, with all treatment arms adjusted for people discontinuing treatment in the study. The results from the liraglutide 3.0 mg treatment arm were broadly in line with previously reported data. Once-daily semaglutide had a well-tolerated safety profile, with the most common adverse events being gastrointestinal side effects. ""We are very excited about these strong results and the potential of semaglutide as a new treatment for people with obesity,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""We will now prepare the phase 3 programme with semaglutide to confirm these results. We expect the phase 3 programme to begin in 2018."" Further information Company announcement No 50 /2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=813,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
277,2017-06-23,Novo Nordisk A/S: CHMP adopts positive opinion for EU label update of Victoza® based on the LEADER trial,"Bagsværd, Denmark, 23 June 2017 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), has issued a positive opinion on update of the EU label for Victoza®. The update is based on the results from the LEADER trial which investigated the long-term effects of Victoza® (liraglutide up to 1.8 mg) in people with type 2 diabetes, at high risk of major cardiovascular (CV) events. In the LEADER trial, Victoza® (liraglutide up to 1.8 mg) statistically significantly reduced the risk of cardiovascular death, non-fatal myocardial infarction (heart attack) and non-fatal stroke by 13% versus placebo, when added to standard of care. The overall risk reduction was derived from a statistically significant 22% reduction in cardiovascular death with Victoza® treatment versus placebo and non-significant reductions in non-fatal myocardial infarction and non-fatal stroke. The CHMP has recommended an update of the indication for Victoza® to reflect both glycaemic control and cardiovascular events as integral parts of type 2 diabetes treatment. ""Cardiovascular disease is the leading cause of death for people with type 2 diabetes,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""There remains an unmet medical need to further reduce cardiovascular risk in people with type 2 diabetes and we are very pleased that the CHMP has recommended the Victoza® label update based on the LEADER trial."" The CHMP positive opinion for Victoza® is now referred to the European Commission, which grants approval in the EU, for final action on the proposed indication. Novo Nordisk expects to receive the European Commission decision for the Victoza® label update in the third quarter of 2017. About Victoza®Victoza® is a human glucagon-like peptide-1 (GLP-1) analogue with an amino acid sequence 97% similar to endogenous human GLP-1. Victoza® was approved in the EU in 2009 and is commercially available in more than 95 countries, treating more than 1 million people with type 2 diabetes globally. In Europe, Victoza® is indicated for the treatment of adults with type 2 diabetes to achieve glycaemic control as monotherapy, when metformin is considered inappropriate, and in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control. In the US, Victoza® was approved in 2010 as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes. About the LEADER trialLEADER was a multicentre, international, randomised, double-blind, placebo-controlled trial investigating the long-term (3.5-5 years) effects of Victoza® (liraglutide up to 1.8 mg) compared to placebo, both in addition to standard of care, in people with type 2 diabetes at high risk of major cardiovascular events. Standard of care was comprised of lifestyle modifications, glucose-lowering treatments and cardiovascular medications. LEADER was initiated in September 2010 and randomised 9,340 people with type 2 diabetes from 32 countries. The primary endpoint was the first occurrence of a composite cardiovascular outcome comprising cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. Further information Company announcement No 49 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=815,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
278,2017-06-23,Novo Nordisk A/S: CHMP afgiver positiv udtalelse om opdatering af indlægssedlen for Victoza® i EU baseret på LEADER-studiet,"Bagsværd, den 23. juni 2017 - Novo Nordisk meddeler i dag, at Udvalget for Humanmedicinske Lægemidler (CHMP) under Det Europæiske Lægemiddelagentur (EMA) har afgivet en positiv udtalelse om opdatering af indlægssedlen for Victoza® i EU. Opdateringen er baseret på resultaterne fra LEADER-studiet, som har undersøgt langtidsvirkningerne af Victoza® (liraglutid op til 1,8 mg) hos mennesker med type 2-diabetes og høj risiko for alvorlige kardiovaskulære hændelser. I LEADER-studiet medførte Victoza® (liraglutid op til 1,8 mg) en statistisk signifikant 13% reduktion af risikoen for kardiovaskulært dødsfald, ikke-dødeligt myokardieinfarkt (hjerteanfald) og ikke-dødeligt slagtilfælde sammenlignet med placebo, når det blev givet som supplement til standardbehandling. Den samlede risikoreduktion blev opnået ved en statistisk signifikant 22% reduktion i kardiovaskulært dødsfald ved behandling med Victoza® sammenlignet med placebo samt reduktioner, dog ikke statistisk signifikante, i ikke-dødeligt myokardieinfarkt og ikke-dødeligt slagtilfælde. CHMP anbefaler, at indikationen for Victoza® opdateres, så den både afspejler blodsukkerregulering og kardiovaskulære hændelser som integrerede dele af behandlingen af type 2-diabetes. ""Hjerte-kar-sygdom er den største dødsårsag for mennesker med type 2-diabetes,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Der er fortsat et udækket medicinsk behov for yderligere at reducere risikoen for kardiovaskulære hændelser hos mennesker med type 2-diabetes, og vi er meget glade for, at CHMP har givet deres anbefaling til opdatering af indlægssedlen for Victoza® baseret på LEADER-studiet."" Den positive udtalelse om Victoza® fra CHMP sendes nu videre til endelig afgørelse i Europa-Kommissionen, som står for godkendelse i EU. Novo Nordisk forventer at modtage Europa-Kommissionens beslutning vedrørende opdatering af indlægssedlen for Victoza® i tredje kvartal af 2017. Victoza® er en human GLP-1-analog (glukagonlignende peptid-1) med en aminosyresekvens, der har 97% lighed med det GLP-1, kroppen selv producerer. Victoza® blev godkendt i EU i 2009 og er på markedet i flere end 95 lande; produktet har været anvendt til behandling af mere end 1 mio. mennesker med type 2-diabetes globalt. I Europa er Victoza® godkendt som monoterapi til regulering af blodsukkerniveauet hos voksne med type 2-diabetes, når metformin anses for utilstrækkeligt, og i kombination med diabeteslægemidler i tabletform og/eller basalinsulin, når blodsukkeret ikke kan reguleres tilstrækkeligt med disse lægemidler sammen med motion og diæt. I USA blev Victoza® godkendt i 2010 som supplement til diæt og motion med det formål at forbedre blodsukkerreguleringen hos voksne med type 2-diabetes. LEADER er et internationalt, randomiseret, dobbeltblindet, placebokontrolleret multicenterstudie, der har undersøgt langtidsvirkningerne (3,5-5 år) af Victoza® (liraglutid op til 1,8 mg) sammenlignet med placebo, begge givet som supplement til standardbehandling, hos mennesker med type 2-diabetes og høj risiko for alvorlige kardiovaskulære hændelser. Standardbehandling omfattede livsstilsændringer, blodsukkersænkende behandling og hjerte-kar-medicin. LEADER blev påbegyndt i september 2010 og randomiserede 9.340 mennesker med type 2-diabetes fra 32 lande. Det primære endepunkt var defineret som den første forekomst af et sammensat kardiovaskulært endepunkt bestående af kardiovaskulært dødsfald, ikke-dødeligt myokardieinfarkt (hjerteanfald) eller ikke-dødeligt slagtilfælde. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 49 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=814,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
279,2017-06-22,Novo Nordisk A/S: CHMP støtter opdatering af indlægssedlen for Saxenda® i EU baseret på LEADER-studiet,"Bagsværd, den 22. juni 2017 - Novo Nordisk meddeler i dag, at Udvalget for Humanmedicinske Lægemidler (CHMP) under Det Europæiske Lægemiddelagentur (EMA) støtter en opdatering af indlægssedlen for Saxenda® i EU. Denne opdatering er baseret på resultaterne fra LEADER-studiet, som har undersøgt langtidsvirkningerne af Victoza® hos mennesker med type 2-diabetes og konstateret hjerte-kar-sygdom. CHMP har tidligere konkluderet, at selvom Saxenda® dosen (liraglutid 3,0 mg) ikke blev undersøgt i LEADER-studiet, ville resultaterne understøtte vurderingen af alle potentielle kardiovaskulære risici forbundet med Saxenda®. Indlægssedlen for Saxenda® er blevet opdateret med øjeblikkelig virkning, så den også afspejler det primære resultat af LEADER-studiet. I LEADER-studiet medførte Victoza® (liraglutid 1,8 mg) en statistisk signifikant 13% reduktion af risikoen for kardiovaskulært dødsfald, ikke-dødeligt myokardieinfarkt (hjerteanfald) og ikke-dødeligt slagtilfælde sammenlignet med placebo, når det blev givet som supplement til standardbehandling. Den samlede risikoreduktion blev opnået ved en statistisk signifikant 22% reduktion i kardiovaskulært dødsfald ved behandling med Victoza® sammenlignet med placebo samt reduktioner, dog ikke statistisk signifikante, i ikke-dødeligt myokardieinfarkt og ikke-dødeligt slagtilfælde. ""Vi er meget glade for, at data fra LEADER-studiet nu er kommet med i indlægssedlen for Saxenda® i Europa,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""LEADER-studiet påviste, at liraglutid er associeret med en signifikant reduktion i den kardiovaskulære risiko for mennesker med type 2 diabetes. Det er en vigtig udvikling for svært overvægtige mennesker i Europa, som lever med vægtrelaterede komplikationer som hjerte-kar-sygdom."" Den 25. oktober 2016 indsendte Novo Nordisk ansøgning til EMA om inkludering af data fra det kardiovaskulære studie LEADER i produktinformationen for Victoza®. Novo Nordisk forventer en tilbagemelding fra EMA vedrørende Victoza® ansøgningen inden længe. Saxenda® (liraglutid 3 mg) er en GLP-1-analog (glukagonlignende peptid-1) til dosering én gang dagligt. Molekylet har 97% lighed med kroppens eget GLP-1, som er et hormon, der frigives, når man spiser. Ligesom naturligt GLP-1 regulerer Saxenda® appetitten ved at øge mæthedsfornemmelsen og dæmpe signaler om sult og spisetrang, hvilket fører til et lavere madindtag. Som med andre GLP-1-receptoragonister stimulerer Saxenda® insulinsekretionen og reducerer glukagonsekretionen på en glukoseafhængig måde. Saxenda® er undersøgt i det kliniske fase 3a-program SCALE (Satiety and Clinical Adiposity - Liraglutide Evidence). I EU er Saxenda® godkendt som supplement til en kaloriefattig kost og øget fysisk aktivitet til vægtregulering hos voksne med et BMI på >30 kg/m2 (svært overvægtige) eller >27 kg/m2 til <30 kg/m2 (overvægtige) med mindst én vægtrelateret komplikation som f.eks. dysglykæmi (prædiabetes eller type 2-diabetes), forhøjet blodtryk, dyslipidæmi eller obstruktiv søvnapnø. Victoza® (liraglutid 1,2 mg og 1,8 mg) er en human GLP-1-analog (glukagonlignende peptid-1) med en aminosyresekvens, der har 97% lighed med det GLP-1, kroppen selv producerer. Victoza® blev godkendt i EU i 2009 og er på markedet i flere end 95 lande; produktet har været anvendt til behandling af mere end 1 mio. mennesker med type 2-diabetes globalt. I Europa er Victoza® godkendt som monoterapi til regulering af blodsukkerniveauet hos voksne med type 2-diabetes, når metformin anses for utilstrækkeligt, og i kombination med diabeteslægemidler i tabletform og/eller basalinsulin, når blodsukkeret ikke kan reguleres tilstrækkeligt med disse lægemidler sammen med motion og diæt. I USA blev Victoza® godkendt i 2010 som supplement til diæt og motion med det formål at forbedre blodsukkerreguleringen hos voksne med type 2-diabetes. LEADER er et internationalt, randomiseret, dobbeltblindet, placebokontrolleret multicenterstudie, der har undersøgt langtidsvirkningerne (3,5-5 år) af Victoza® (liraglutid 1,8 mg) sammenlignet med placebo, begge givet som supplement til standardbehandling, hos mennesker med type 2-diabetes og konstateret hjerte-kar-sygdom. Standardbehandling omfattede livsstilsændringer, blodsukkersænkende behandling og hjerte-kar-medicin. LEADER blev påbegyndt i september 2010 og randomiserede 9.340 mennesker med type 2-diabetes fra 32 lande. Det primære endepunkt var defineret som den første forekomst af et sammensat kardiovaskulært endepunkt bestående af kardiovaskulært dødsfald, ikke-dødeligt myokardieinfarkt (hjerteanfald) eller ikke-dødeligt slagtilfælde. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 48 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=817,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
280,2017-06-22,Novo Nordisk A/S: CHMP endorses EU label update of Saxenda® based on the LEADER trial,"Bagsværd, Denmark, 22 June 2017 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP), under theEuropean Medicines Agency (EMA), has endorsed an update of the EU label for Saxenda®. This update is based on the results from the LEADER trial which investigated the long-term effects of Victoza® in people with type 2 diabetes and established cardiovascular disease. The CHMP has previously concluded that, although the Saxenda® dosing of liraglutide 3.0 mg was not investigated in the LEADER trial, the results would also be supportive for the assessment of Saxenda® for any potential cardiovascular risk. The Saxenda® label has been updated with immediate effect to reflect the primary outcome of the LEADER trial. In the LEADER trial, Victoza® (liraglutide 1.8 mg) statistically significantly reduced the risk of cardiovascular death, non-fatal myocardial infarction (heart attack) and non-fatal stroke by 13% versus placebo, when added to standard of care. The overall risk reduction was derived from a statistically significant 22% reduction in cardiovascular death with Victoza® treatment versus placebo and non-significant reductions in non-fatal myocardial infarction and non-fatal stroke. ""We are very pleased that data from the LEADER trial has been included in the Saxenda® label in Europe,"" said Mads Krogsgaard Thomsen, executive vice president and chief scientific officer of Novo Nordisk. ""The LEADER trial showed that liraglutide is associated with significant cardiovascular risk reduction in people with type 2 diabetes. This is an important development for people with obesity in Europe living with weight-related comorbidities such as cardiovascular disease."" On 25 October 2016, Novo Nordisk submitted an application to the EMA for including data from the LEADER cardiovascular outcomes trial in the product information of Victoza®. Novo Nordisk expects feedback from the EMA on the Victoza® application shortly. About Saxenda® Saxenda® (liraglutide 3 mg) is a once-daily glucagon-like peptide-1 (GLP-1) analogue with 97% similarity to naturally occurring human GLP-1, a hormone that is released in response to food intake. Like human GLP-1, Saxenda® regulates appetite by increasing feelings of fullness and satiety, while lowering feelings of hunger and prospective food consumption, thereby leading to reduced food intake. As with other GLP-1 receptor agonists, Saxenda® stimulates insulin secretion and lowers glucagon secretion in a glucose-dependent manner. Saxenda® was evaluated in the SCALE (Satiety and Clinical Adiposity - Liraglutide Evidence) phase 3a clinical trial programme. In the EU, Saxenda® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial BMI of >30 kg/m2 (obese), or >27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes), hypertension, dyslipidaemia or obstructive sleep apnoea. About Victoza®Victoza® (liraglutide 1.2 mg and 1.8 mg) is a human glucagon-like peptide-1 (GLP-1) analogue with an amino acid sequence 97% similar to endogenous human GLP-1. Victoza® was approved in the EU in 2009 and is commercially available in more than 95 countries, treating more than 1 million people with type 2 diabetes globally. In Europe, Victoza® is indicated for the treatment of adults with type 2 diabetes to achieve glycaemic control as monotherapy, when metformin is considered inappropriate, and in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control. In the US, Victoza® was approved in 2010 as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes. About the LEADER trialLEADER was a multicentre, international, randomised, double-blind, placebo-controlled trial investigating the long-term (3.5-5 years) effects of Victoza® (liraglutide 1.8 mg) compared to placebo, both in addition to standard of care, in people with type 2 diabetes with established cardiovascular disease. Standard of care was comprised of lifestyle modifications, glucose-lowering treatments and cardiovascular medications. LEADER was initiated in September 2010 and randomised 9,340 people with type 2 diabetes from 32 countries. The primary endpoint was the first occurrence of a composite cardiovascular outcome comprising cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. Further information Company announcement No 48 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=816,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
281,2017-06-20,Novo Nordisk receives positive 17-2 vote from FDA Advisory Committee that Victoza® provides substantial evidence of cardiovascular risk reduction in patients with type 2 diabetes,"The discussions at the Advisory Committee meeting were based on data from the LEADER trial, which involved more than 9,300 people with type 2 diabetes at high risk of major cardiovascular events. The Advisory Committee voted 19-0 in favour of Victoza® on the question: ""Do the results of LEADER establish that use of Victoza® in patients with type 2 diabetes is not associated with excess cardiovascular risk?"" The Advisory Committee voted 17-2 in favour of Victoza® on the question: ""Does the LEADER trial provide the substantial evidence needed to establish that Victoza® (liraglutide 1.8 mg) reduces cardiovascular risk in patients with type 2 diabetes?"" ""Cardiovascular disease is the number one cause of death for people with type 2 diabetes,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""With the positive vote today, we are excited to be one step closer towards a cardiovascular indication for Victoza® to reduce the risk of cardiovascular events in people with type 2 diabetes. We look forward to working with the FDA to include the important results from the LEADER trial in the Victoza® label."" The supplemental New Drug Application for Victoza® was submitted to the FDA in October 2016 and regulatory feedback in the US is expected in Q3 2017. In Europe, a Type II Variation application was submitted to the European Medicines Agency (EMA) in October 2016. On 21 June 2017 at 8.00 am CEST (2.00 am EDT), Novo Nordisk will host a conference call for investors. Investors will be able to listen in via a link on the investor section of novonordisk.com/investors. FDA advisory committees are panels of independent experts who advise the FDA on specific questions raised by the FDA as they consider regulatory decisions. The FDA is not bound by the committee's recommendation, but it takes its advice into consideration when reviewing data concerning the safety and effectiveness of marketed or new drug applications. LEADER was a multicentre, international, randomised, double-blind, placebo-controlled trial investigating the long-term (3.5-5 years) effects of Victoza® (liraglutide up to 1.8 mg) compared to placebo, both in addition to standard of care, in people with type 2 diabetes at high risk of major cardiovascular events. Standard of care was comprised of lifestyle modifications, glucose-lowering treatments and cardiovascular medications. LEADER was initiated in September 2010 and randomised 9,340 people with type 2 diabetes from 32 countries. The primary endpoint was the first occurrence of a composite cardiovascular outcome comprising cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. Victoza® (liraglutide) injection is a human glucagon-like peptide-1 (GLP-1) analogue with an amino acid sequence 97% similar to endogenous human GLP-1. Victoza® was approved in the EU in 2009 and is commercially available in more than 90 countries, treating more than 1 million people with type 2 diabetes globally. In Europe, Victoza® is indicated for the treatment of adults with type 2 diabetes to achieve glycaemic control as monotherapy, when metformin is considered inappropriate, and in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control. In the US, Victoza® was approved in 2010 as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes. Further information Company announcement No 47 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=819,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
282,2017-06-20,"Novo Nordisk får positiv 17-2 afstemning fra FDA's rådgivende komite om, at Victoza®  giver væsentlig dokumentation for nedsættelse af kardiovaskulær risiko hos mennesker med type 2-diabetes","Bagsværd, den 20. juni 2017 - Novo Nordisk meddeler i dag, at Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC), som er en rådgivende komite for de amerikanske sundhedsmyndigheder (FDA), har afsluttet sit møde vedrørende den supplerende registreringsansøgning om inkludering af dataene fra det kardiovaskulære studie LEADER i indlægssedlen for Victoza® (liraglutid). Komiteens drøftelser på mødet var baseret på data fra LEADER-studiet, som omfattede mere end 9.300 mennesker med type 2-diabetes og høj risiko for alvorlige kardiovaskulære hændelser. Den rådgivende komite stemte 19-0 til fordel for Victoza® i spørgsmålet: ""Fastslår resultaterne af LEADER, at brugen af Victoza® hos patienter med type 2-diabetes ikke er forbundet med forhøjet kardiovaskulær risiko?"" Den rådgivende komite stemte 17-2 til fordel for Victoza® i spørgsmålet: ""Giver LEADER-studiet den væsentlige dokumentation, der er nødvendig for at fastslå, at Victoza® (liraglutid 1,8 mg) reducerer kardiovaskulær risiko hos patienter med type 2-diabetes?"" ""Hjerte-kar-sygdom er den største dødsårsag for mennesker med type 2-diabetes,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Med den positive afstemning i dag er vi glade for at være kommet et skridt nærmere en kardiovaskulær indikation for Victoza® med henblik på at nedsætte risikoen for kardiovaskulære hændelser hos mennesker med type 2-diabetes. Vi ser frem til at arbejde sammen med FDA om at inkludere de vigtige resultater fra LEADER-studiet i indlægssedlen for Victoza®."" Den supplerende registreringsansøgning for Victoza® blev indsendt til FDA i oktober 2016, og der forventes tilbagemelding fra registreringsmyndighederne i USA i tredje kvartal af 2017. I Europa blev der indsendt en type II-variationsansøgning til Det Europæiske Lægemiddelagentur (EMA) i oktober 2016. Novo Nordisk afholder en telekonference for investorer den 21. juni 2017 kl. 8.00 CEST (kl. 2.00 EDT). Investorer kan lytte med via et link under investorsektionen på novonordisk.com/investors. FDA's rådgivende komiteer er uafhængige ekspertpaneler, som rådgiver FDA om specifikke spørgsmål, der rejses af FDA i forbindelse med regulatoriske beslutninger. Komiteens anbefaling er ikke bindende for FDA, men indgår i beslutningsgrundlaget ved FDA's vurdering af data vedrørende sikkerhed og effekt i forbindelse med registreringsansøgninger vedrørende markedsførte eller nye lægemidler. LEADER er et internationalt, randomiseret, dobbeltblindet, placebokontrolleret multicenterstudie, der har undersøgt langtidsvirkningerne (3,5-5 år) af Victoza® (liraglutid op til 1,8 mg) sammenlignet med placebo, begge givet som supplement til standardbehandling, hos mennesker med type 2-diabetes med høj risiko for alvorlige kardiovaskulære hændelser. Standardbehandling omfattede livsstilsændringer, blodsukkersænkende behandling og hjerte-kar-medicin. LEADER blev påbegyndt i september 2010 og randomiserede 9.340 mennesker med type 2-diabetes fra 32 lande. Det primære endepunkt var defineret som den første forekomst af et sammensat kardiovaskulært endepunkt bestående af kardiovaskulært dødsfald, ikke-dødeligt myokardieinfarkt (hjerteanfald) eller ikke-dødeligt slagtilfælde. Victoza® (liraglutid) til injektion er en human GLP-1-analog (glukagonlignende peptid-1) med en aminosyresekvens, der har 97% lighed med det GLP-1, kroppen selv producerer. Victoza® blev godkendt i EU i 2009 og er på markedet i flere end 90 lande; produktet har været anvendt til behandling af mere end 1 mio. mennesker med type 2-diabetes globalt. I Europa er Victoza® godkendt som monoterapi til regulering af blodsukkerniveauet hos voksne med type 2-diabetes, når metformin anses for utilstrækkeligt, og i kombination med diabeteslægemidler i tabletform og/eller basalinsulin, når blodsukkeret ikke kan reguleres tilstrækkeligt med disse lægemidler sammen med motion og diæt. I USA blev Victoza® godkendt i 2010 som supplement til diæt og motion med det formål at forbedre blodsukkerreguleringen hos voksne med type 2-diabetes. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 47 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=818,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
283,2017-06-16,FDA posts briefing materials prior to Advisory Committee meeting for Victoza® label update,"Bagsværd, Denmark, 16 June 2017 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has published the briefing documents ahead of the Advisory Committee meeting to discuss the supplemental New Drug Application (sNDA) for approval of Victoza® (liraglutide) injection to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and high cardiovascular risk, given as an adjunct to standard treatment of cardiovascular risk factors. The meeting takes place on 20 June 2017. The briefing documents from Novo Nordisk and the FDA form the basis for the Advisory Committee's discussion, and provide an overview of the clinical data from the cardiovascular outcomes trial LEADER. The briefing materials can be accessed on the FDA webpage: https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm560480.htm FDA advisory committees are panels of independent experts who advise the FDA on specific questions raised by the FDA as they consider regulatory decisions. The FDA is not bound by the committee's recommendation, but it takes its advice into consideration when reviewing data concerning the safety and effectiveness of marketed or new drug applications. LEADER was a multicentre, international, randomised, double-blind, placebo-controlled trial investigating the long-term (3.5-5 years) effects of Victoza® (liraglutide up to 1.8 mg) compared to placebo, both in addition to standard of care, in people with type 2 diabetes at high risk of major cardiovascular events. Standard of care was comprised of lifestyle modifications, glucose-lowering treatments and cardiovascular medications. LEADER was initiated in September 2010 and randomised 9,340 people with type 2 diabetes from 32 countries. The primary endpoint was the first occurrence of a composite cardiovascular outcome comprising cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. Victoza® (liraglutide) injection is a human glucagon-like peptide-1 (GLP-1) analogue with an amino acid sequence 97% similar to endogenous human GLP-1. Victoza® was approved in the EU in 2009 and is commercially available in more than 90 countries, treating more than 1 million people with type 2 diabetes globally. In Europe, Victoza® is indicated for the treatment of adults with type 2 diabetes to achieve glycaemic control as monotherapy, when metformin is considered inappropriate, and in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.In the US, Victoza® was approved in 2010 as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes. Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,000 people in 77 countries and markets its products in more than 165 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube Further information Company announcement No 45/2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=822,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
284,2017-06-16,FDA offentliggør briefingmateriale forud for møde i rådgivende komite om opdatering af indlægssedlen for Victoza®,"Bagsværd, den 16. juni 2017 - Novo Nordisk meddeler i dag, at de amerikanske sundhedsmyndigheder, FDA, har offentliggjort briefingdokumenterne forud for det kommende møde i den rådgivende komite. På dette møde drøftes Novo Nordisks supplerende registreringsansøgning om godkendelse af Victoza® (liraglutid) til injektion med det formål at reducere risikoen for alvorlige kardiovaskulære hændelser (kardiovaskulært dødsfald, ikke-dødeligt myokardieinfarkt (hjerteanfald) eller ikke-dødeligt slagtilfælde) hos voksne med type 2-diabetes og høj risiko for hjerte-kar-sygdom, givet som supplement til standardbehandling af kardiovaskulære risikofaktorer. Mødet finder sted den 20. juni 2017. Briefingdokumenterne fra Novo Nordisk og FDA danner grundlag for drøftelserne i den rådgivende komite og giver overblik over de kliniske data fra det kardiovaskulære studie LEADER. Materialet er tilgængeligt på FDA's hjemmeside: https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm560480.htm FDA's rådgivende komiteer er uafhængige ekspertpaneler, som rådgiver FDA om specifikke spørgsmål, der rejses af FDA i forbindelse med regulatoriske beslutninger. Komiteens anbefaling er ikke bindende for FDA, men indgår i beslutningsgrundlaget ved FDA's vurdering af data vedrørende sikkerhed og effekt i forbindelse med registreringsansøgninger vedrørende markedsførte eller nye lægemidler. LEADER er et internationalt, randomiseret, dobbeltblindet, placebokontrolleret multicenterstudie, der har undersøgt langtidsvirkningerne (3,5-5 år) af Victoza® (liraglutid op til 1,8 mg) sammenlignet med placebo, begge givet som supplement til standardbehandling, hos mennesker med type 2-diabetes og høj risiko for alvorlige kardiovaskulære hændelser. Standardbehandling omfattede livsstilsændringer, blodsukkersænkende behandling og hjerte-kar-medicin. LEADER blev påbegyndt i september 2010 og randomiserede 9.340 mennesker med type 2-diabetes fra 32 lande. Det primære endepunkt var defineret som den første forekomst af et sammensat kardiovaskulært endepunkt bestående af kardiovaskulært dødsfald, ikke-dødeligt myokardieinfarkt (hjerteanfald) eller ikke-dødeligt slagtilfælde. Victoza® (liraglutid) til injektion er en human GLP-1-analog (glukagonlignende peptid-1) med en aminosyresekvens, der har 97% lighed med det GLP-1, kroppen selv producerer. Victoza® blev godkendt i EU i 2009 og er på markedet i flere end 90 lande; produktet har været anvendt til behandling af mere end 1 mio. mennesker med type 2-diabetes globalt. I Europa er Victoza® godkendt som monoterapi til regulering af blodsukkerniveauet hos voksne med type 2-diabetes, når metformin anses for utilstrækkeligt, og i kombination med diabeteslægemidler i tabletform og/eller basalinsulin, når blodsukkeret ikke kan reguleres tilstrækkeligt med disse lægemidler sammen med motion og diæt.I USA blev Victoza® godkendt i 2010 som supplement til diæt og motion med det formål at forbedre blodsukkerreguleringen hos voksne med type 2-diabetes. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 45/2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=823,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
285,2017-06-14,Novo Nordisk indsender ansøgning i EU om inkludering af data fra DEVOTE-studiet i indlægssedlen for Tresiba®,"Bagsværd, den 14. juni 2017 - Novo Nordisk meddeler i dag, at virksomheden har indsendt en type II-variationsansøgning til Det Europæiske Lægemiddelagentur (EMA) om inkludering af data fra DEVOTE-studiet i indlægssedlen for Tresiba® (insulin degludec). DEVOTE er et randomiseret, dobbeltblindet og hændelsesdrevet langtidsstudie, der er gennemført med det formål at bekræfte den kardiovaskulære sikkerhed for Tresiba® sammenlignet med insulin glargin U100 givet som supplement til standardbehandling hos mennesker med type 2-diabetes. Yderligere information Selskabsmeddelelse nr. 44/2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=824,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
286,2017-06-14,Novo Nordisk submits application in the EU for including data from the DEVOTE trial in the Tresiba® label,"Bagsværd, Denmark, 14 June 2017 - Novo Nordisk today announced the submission of a Type II Variation application to the European Medicines Agency (EMA) for including data in the label for Tresiba® (insulin degludec) from the DEVOTE trial, a long-term, randomised, double-blinded and event-driven trial conducted to confirm the cardiovascular safety of Tresiba® compared to insulin glargine U100 when added to standard of care, in people with type 2 diabetes. Company announcement No 44/2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=825,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
287,2017-06-12,Tresiba® viser ingen øget risiko for alvorlige kardiovaskulære hændelser samt signifikant reduktion i forekomsten af alvorlig hypoglykæmi sammenlignet med insulin glargin U100 i DEVOTE-studiet,"San Diego, USA, den 12. juni 2017 ­- Novo Nordisk offentliggjorde i dag de primære resultater fra DEVOTE - det første randomiserede, dobbeltblindede, hændelsesdrevne treat to target-studie, der sammenligner to basalinsuliner, Tresiba® (insulin degludec til injektion 100 enheder/ml) og insulin glargin U100, hos voksne med type 2-diabetes med høj risiko for hjerte-kar-sygdom. Studiet viste, at Tresiba® opfyldte det primære endepunkt defineret som ikke-inferiøritet sammenlignet med insulin glargin U100 med hensyn til alvorlige kardiovaskulære hændelser (MACE) med en risikoratio (HR) på 0,91 (95% konfidensinterval [CI]: 0,78; 1,06, p=0,209). Resultaterne for de enkelte komponenter i MACE var desuden konsistente med det primære endepunkt, herunder første forekomst af kardiovaskulært dødsfald (HR=0,96, 95% CI: 0,76; 1,21, p=0,714), ikke-dødeligt myokardieinfarkt (hjerteanfald) (HR=0,85, 95% CI: 0,68; 1,06, p=0,150) eller ikke-dødeligt slagtilfælde (HR=0,90, 95% CI: 0,65; 1,23, p=0,502).1 Resultaterne fra studiet, som fulgte 7.637 mennesker med type 2-diabetes i ca. to år, blev præsenteret på ADA 2017, den 77. videnskabelige kongres i det amerikanske diabetesselskab American Diabetes Association, og blev desuden samtidig publiceret i New England Journal of Medicine.1 Resultater fra studiets sekundære endepunkter viste en signifikant reduktion i forekomsten af alvorlig (40%) og natlig alvorlig (53%) hypoglykæmi (lavt blodsukker) med Tresiba® sammenlignet med insulin glargin U100 (begge p<0,001).* Post hoc-analyser viste endvidere sammenlignelige niveauer af blodsukkerkontrol med en anslået behandlingsforskel i langtidsblodsukkerniveauet (HbA1c) ved studiets afslutning på 0,01% (p=0,779) mellem de to behandlingsgrupper samt signifikant lavere fasteblodsukkerniveauer med Tresiba® efter to år sammenlignet med insulin glargin U100 (anslået behandlingsforskel -7,2 mg/dl, p<0,001).1 ""Degludec viste i DEVOTE-studiet ingen øget risiko for alvorlige kardiovaskulære hændelser. Samtidig sås signifikante reduktioner i forekomsten af alvorlig og natlig alvorlig hypoglykæmi sammenlignet med insulin glargin U100,"" siger dr. Bernard Zinman fra Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada, og medlem af styregruppen for DEVOTE. ""Risikoen for hjerte-kar-sygdom og hypoglykæmi er en vigtig problemstilling for mennesker med type 2-diabetes, og resultaterne fra DEVOTE styrker den stadig mere omfattende dokumentation, som vil spille en vigtig rolle for valget af behandling."" Sikkerhedsprofilen for Tresiba® i DEVOTE var generelt konsistent med tidligere kliniske studier gennemført med Tresiba®.1 Systematisk indsamling af bivirkninger i DEVOTE var begrænset til alvorlige bivirkninger, bivirkninger, der førte til permanent ophør af behandling med det lægemiddel, der blev anvendt i studiet (5,2% af deltagerne i gruppen, der fik Tresiba®, og 5,8% af deltagerne i gruppen, der fik insulin glargin U100), alvorlige bivirkninger som følge af medicineringsfejl og bivirkninger relateret til tekniske klager. *Alvorlig hypoglykæmi blev defineret som episoder, hvor patienten havde behov for hjælp fra andre, og natlig alvorlig hypoglykæmi som episoder mellem midnat og kl. 6.1 DEVOTE er et multinationalt, randomiseret, dobbeltblindet og hændelsesdrevet langtidsstudie, som er gennemført med det formål at bekræfte den kardiovaskulære sikkerhed for Tresiba® (insulin degludec) sammenlignet med insulin glargin U100. I studiet blev 7.637 mennesker (Tresiba®: n=3.818, insulin glargin U100: n=3.819) med type 2-diabetes med høj risiko for at udvikle hjerte-kar-sygdom randomiseret til behandling med enten Tresiba® eller insulin glargin U100 i hætteglas som supplement til standardbehandling.1 Det primære endepunkt i DEVOTE var defineret som tiden fra randomisering til den første forekomst af et sammensat kardiovaskulært endepunkt bestående af tre komponenter: kardiovaskulært dødsfald, ikke-dødeligt myokardieinfarkt (hjerteanfald) eller ikke-dødeligt slagtilfælde. De sekundære endepunkter omfattede alvorlig hypoglykæmi, natlig alvorlig hypoglykæmi, langtidsblodsukker (HbA1c) og fasteblodsukker.1 Tresiba® (insulin degludec) er en basalinsulin til dosering én gang dagligt. Den har en virkningsvarighed på mere end 42 timer med en flad og stabil blodsukkersænkende effekt.2,3 Tresiba® medfører en lav døgn- og dag til dag-variation i blodsukkeret og en lavere risiko for generel, natlig og alvorlig hypoglykæmi sammenlignet med insulin glargin U100.1,2 I situationer, hvor det ikke er muligt at tage insulin på det sædvanlige tidspunkt af dagen, giver Tresiba® mulighed for fleksibilitet med hensyn til injektionstidspunktet fra dag til dag, men med mindst otte timer mellem doserne.2 Tresiba® blev godkendt af registreringsmyndighederne første gang i september 2012 og er siden blevet godkendt i flere end 80 lande verden over. Det er nu på markedet i flere end 50 lande.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=828,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
288,2017-06-12,Tresiba® demonstrated no increased risk of major cardiovascular events and significant reduction in rates of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial,"San Diego, US, 12 June 2017 ­- Novo Nordisk today announced the primary results from DEVOTE - the first randomised, double-blind, treat-to-target, event-driven trial comparing two basal insulins, Tresiba® (insulin degludec injection 100 U/mL) and insulin glargine U100, in adults with type 2 diabetes at high risk of cardiovascular (CV) disease. The trial demonstrated that Tresiba® met the primary endpoint of non-inferiority compared with insulin glargine U100 for major adverse CV events (MACE) with a hazard ratio (HR) of 0.91 (95% confidence interval [CI]: 0.78; 1.06, p=0.209). Additionally, the findings for each component of MACE were consistent with the primary endpoint, including first occurrence of CV death (HR=0.96, 95% CI: 0.76; 1.21, p=0.714), non-fatal myocardial infarction (HR=0.85, 95% CI: 0.68; 1.06, p=0.150) or non-fatal stroke (HR=0.90, 95% CI: 0.65; 1.23, p=0.502).1 Results from the trial, involving 7,637 people with type 2 diabetes followed for approximately two years, were presented at the American Diabetes Association's 77th Scientific Sessions (ADA 2017) and also published simultaneously in the New England Journal of Medicine.1 Results from the secondary endpoints of the trial showed a significant reduction in the rate of severe (40%) and nocturnal severe (53%) hypoglycaemia with Tresiba® vs. insulin glargine U100 (both p<0.001).* Additionally, post hoc analyses showed: similar levels of glycaemic control with an end of trial HbA1c estimated treatment difference of 0.01% (p=0.779) between the two treatment groups and significantly lower fasting plasma glucose levels with Tresiba® after 2 years vs. insulin glargine U100 (estimated treatment difference -7.2 mg/dL, p<0.001).1 ""In the DEVOTE trial degludec demonstrated no increase in the risk of major cardiovascular events and significant reductions in the rates of severe and nocturnal severe hypoglycaemia compared to insulin glargine U100,"" said Dr Bernard Zinman of the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada and member of the DEVOTE Steering Committee. ""Risk of cardiovascular disease and hypoglycaemia are important concerns for those with type 2 diabetes and the results from DEVOTE add to the mounting evidence that will play an important role in treatment decisions."" The safety profile of Tresiba® in DEVOTE was generally consistent with previous Tresiba® clinical trials.1 In DEVOTE, systematic collection of adverse events was limited to serious adverse events, adverse events leading to permanent discontinuation of investigational product (5.2% of patients in the Tresiba® arm and 5.8% of patients in the insulin glargine U100 arm), medication errors leading to serious adverse events and adverse events related to technical complaints. *Severe hypoglycaemia was defined as an episode requiring assistance of another person, and nocturnal severe defined as between the hours of 00:01-05:59, inclusive.1 DEVOTE is a long-term, multi-national, randomised, double-blind and event-driven trial conducted to confirm the CV safety of Tresiba® (insulin degludec) compared to insulin glargine U100. In the trial, 7,637 people (Tresiba®: n=3,818, insulin glargine U100: n=3,819) with type 2 diabetes at high risk of CV disease were randomised to treatment with either Tresiba® or insulin glargine U100 in vial in addition to standard of care.1 The primary endpoint in DEVOTE was time from randomisation to the first occurrence of a three-component composite CV outcome comprising CV death, non-fatal myocardial infarction or non-fatal stroke. Secondary endpoints included severe hypoglycaemia, nocturnal severe hypoglycaemia, HbA1c and fasting plasma glucose.1 Tresiba® (insulin degludec) is a once-daily basal insulin that provides a duration of action beyond 42 hours with a flat and stable glucose-lowering effect.2,3 It provides low within-day and day-to-day variability and a lower risk of overall, nocturnal and severe hypoglycaemia vs. insulin glargine U100.1,2 On occasions when administration at the same time of day is not possible, Tresiba® allows for flexibility in day-to-day dosing time with a minimum of eight hours between injections.2 Tresiba® received its first regulatory approval in September 2012 and has since been approved in more than 80 countries globally. It is now commercially available in more than 50 countries.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=829,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
289,2017-06-07,Lyfebulb and Novo Nordisk team up again to advance entrepreneur innovation in diabetes management,"Bagsværd, Denmark and New York, NY, USA, June 7, 2017 - For the second year in a row, Lyfebulb and Novo Nordisk will support international patient entrepreneurs who develop innovative ideas and concepts aimed to positively empower and impact the lives of people living with type 1 or type 2 diabetes - and ultimately our societies. ""We are excited to be working with Novo Nordisk again, building on the first patient entrepreneur Summit in 2016, empowering people living with diabetes to take charge and improve their quality of life,"" says Karin Hehenberger, MD, PhD, CEO and founder of Lyfebulb. The Lyfebulb-Novo Nordisk Innovation Summit is based on the Lyfebulb Entrepreneur Circle, which was established in 2015. Lyfebulb and Novo Nordisk share a common ambition to stimulate high-impact innovation and to help patient entrepreneurs who have founded start-ups be successful. Patient entrepreneurs have a unique ability to create value-adding disease intervention beyond therapy. Hence, this year's Summit will bring together patient entrepreneurs with Lyfebulb founders, device researchers, engineers and leadership from Novo Nordisk and venture capitalists to facilitate discussion on how we can improve the lives of people living with diabetes, together. Senior Vice President for Novo Nordisk Device R&D Kenneth Strømdahl explains: ""The growing prevalence of diabetes makes the need for disruptive innovation in the way we manage diabetes more relevant than ever. By engaging with patient entrepreneurs, in the role of innovators; we hope to advance breakthroughs in patient-centred innovation that may impact millions of patients."" The Summit will spotlight entrepreneurs' ideas & efforts and announce the 25,000 USD winner of the 2017 Lyfebulb-Novo Nordisk Innovation Award, as well as the 15,000 USD runner-up and 10,000 USD third place winner. The Lyfebulb-Novo Nordisk Innovation Summit will gather 10 patient entrepreneurs, who have founded start-ups, to pitch their ideas to venture capitalists, Novo Nordisk R&D leaders, researchers and engineers as well as the Lyfebulb founders, and engage in Q&A with the judging panel from around the world. The top three patient entrepreneurs will receive monetary awards, with the winner of the Lyfebulb-Novo Nordisk Innovation Award taking home 25,000 USD to further develop his or her idea. ""It is integral for the advancement in the care of diabetes to support young companies and new ideas,"" says Karin Hehenberger, ""as an organisation, Lyfebulb believes that the future of diabetes lies in the hands of the patient, which is why we are certain that the empowerment of patient entrepreneurs will ensure that innovative and effective ideas are brought to market,"" she concluded. All candidates are invited to submit applications to take part in the 2017 Lyfebulb-Novo Nordisk Innovation Summit and Award on Lyfebulb's website at http://lyfebulb.com/innovation-award/novo-nordisk-2017/ Submissions will be accepted between 7 June 2017 and 15 September 2017, a review of which will be made shortly thereafter, and a selection of 10 finalists will be announced in the fall of 2017. Lyfebulb is a business focused on bridging patient communities with industry, and providing a strong voice to people living with chronic disease by empowering patient entrepreneurs. See www.lyfebulb.com, Facebook, Twitter, Instagram, Karin Hehenberger LinkedIn, and Lyfebulb LinkedIn. Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=830,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
290,2017-06-07,Lyfebulb og Novo Nordisk fortsætter samarbejdet om at fremme patientdrevet innovation indenfor diabetesbehandling,"Bagsværd, Danmark, og New York, USA, den 7. juni 2017 - Lyfebulb og Novo Nordisk støtter for andet år i træk internationale patientiværksættere, som udvikler innovative ideer og koncepter, der kan give mennesker med type 1- eller type 2-diabetes større indflydelse på deres eget liv. ""Vi er glade for at samarbejde med Novo Nordisk igen og tage tråden op fra den første konference for patientiværksættere i 2016, så vi sammen kan gøre en indsats for at give mennesker med diabetes mulighed for at styre og forbedre deres egen livskvalitet,"" siger Karin Hehenberger, læge, ph.d., CEO og grundlægger af Lyfebulb. Lyfebulb-Novo Nordisk Innovation Summit er baseret på Lyfebulb Entrepreneur Circle, som blev etableret i 2015. Lyfebulb og Novo Nordisk har en fælles ambition om at fremme innovation og støtte patientiværksættere, der har grundlagt nye opstartsvirksomheder. Patientiværksættere har en unik evne til at skabe værdifulde behandlingsløsninger, der rækker videre end traditionel behandling. Således vil årets konference, som finder sted i København den 6.-8. november, samle en lang række patientiværksættere, som sammen med stifterne af Lyfebulb, forskere, ingeniører og ledere fra Novo Nordisk og ventureselskaber skal diskutere, hvordan man kan forbedre tilværelsen for mennesker med diabetes. Kenneth Strømdahl, direktør for Novo Nordisk Device R&D, forklarer: ""Med den stigende forekomst af diabetes er behovet for radikal nytænkning og innovation indenfor diabetesbehandling mere relevant end nogensinde. Ved at samarbejde med patientiværksættere i rollen som innovatører håber vi at kunne fremme gennembrud i patientcentreret innovation til gavn for millioner af patienter."" Konferencen vil sætte spot på iværksætternes ideer og indsats. Desuden kåres vinderen af innovationsprisen '2017 Lyfebulb-Novo Nordisk Innovation Award' på 25.000 amerikanske dollars, samt vinderne af anden- og tredjepladsen, som får henholdsvis 15.000 og 10.000 dollars. Lyfebulb-Novo Nordisk Innovation Summit samler 10 patientiværksættere, der har grundlagt egne opstartsvirksomheder. På konferencen får de mulighed for at præsentere deres ideer for ventureselskaber, ledere, forskere og ingeniører fra Novo Nordisks forsknings- og udviklingsorganisation samt grundlæggerne af Lyfebulb. De deltager endvidere i en spørgsmål og svar-session med dommerpanelet, der er sammensat af deltagere fra hele verden. De tre bedste patientiværksættere vil modtage pengepræmier, og vinderen af Lyfebulb-Novo Nordisk Innovation Award får 25.000 dollars til videreudvikling af sin ide. ""Det er helt afgørende at støtte op om unge virksomheder og nye ideer for at fremme nytænkning indenfor diabetesbehandling,"" siger Karin Hehenberger. ""Som organisation tror Lyfebulb på, at fremtidens diabetesbehandling ligger i patientens hænder, og derfor er vi sikre på, at opbakningen til patientiværksætterne vil sikre, at innovative og effektive ideer kommer på markedet,"" siger hun. Alle kandidater opfordres til at indsende ansøgning om deltagelse i 2017 Lyfebulb-Novo Nordisk Innovation Summit and Award via Lyfebulbs hjemmeside: http://lyfebulb.com/innovation-award/novo-nordisk-2017/. Ansøgninger kan indsendes mellem 7. juni 2017 og 15. september 2017, hvorefter de gennemgås, og de 10 finalister offentliggøres i efteråret 2017. Lyfebulb er en virksomhed, der fokuserer på brobygning mellem patienter og virksomheder og giver mennesker, der lever med en kronisk sygdom, en stærk stemme ved at støtte patientiværksættere. Se mere på www.lyfebulb.com, Facebook, Twitter, Instagram, Karin Hehenberger LinkedIn, og Lyfebulb LinkedIn. Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=831,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
291,2017-06-06,Refixia® (nonacog beta pegol; N9-GP) approved in the EU,"Bagsværd, Denmark, 6 June 2017 - Novo Nordisk today announced that the European Commission has granted marketing authorisation for Refixia® for the treatment of adolescents and adults with haemophilia B. The authorisation covers all 28 European Union member states. Refixia® is the brand name for nonacog beta pegol; N9-GP. Refixia® is indicated for prophylaxis, on-demand treatment of bleeding and surgical procedures in adolescent (>12 years of age) and adult patients with haemophilia B (congenital factor IX deficiency). The efficacy and safety evaluation was based on 115 patients across the five paradigm clinical trials, and the marketing authorisation follows the positive opinion from the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), provided 24 March 2017. ""We are excited about the approval of Refixia® in the EU, and we consider it an important expansion of the treatment options for patients with haemophilia B,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""The strong clinical profile of Refixia® provides haemophilia B patients with better protection against bleeds, even into damaged joints, and an overall improved quality of life."" Novo Nordisk expects to launch Refixia® in the first European countries in the fourth quarter of 2017. Refixia® (nonacog beta pegol; N9-GP) is an extended half-life factor IX molecule for replacement therapy in patients with haemophilia B. Glycopegylation, the prolongation technology used for the half-life extension, is a novel approach in haemophilia B. Pegylated products have been approved in haemophilia A and other therapeutic areas. The review of Refixia® was based on the paradigm programme, a phase 3 clinical programme enrolling children and adults with severe or moderately severe haemophilia B. In the programme, 115 previously treated patients had a total of more than 8,800 exposure days for up to 2.7 years of treatment with Refixia®. On 31 May 2017, Novo Nordisk received the US FDA approval of nonacog beta pegol; N9-GP indicated for on-demand treatment and control of bleeding episodes and the perioperative management of bleeding around the time of surgery in adults and children with haemophilia B. Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,000 people in 77 countries and markets its products in more than 165 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube Further information Company announcement No 42/2017  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=832,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
292,2017-06-06,Refixia® (nonacog beta pegol; N9-GP) godkendt i EU,"Bagsværd, den 6. juni 2017 - Novo Nordisk meddeler i dag, at Europa-Kommissionen har givet markedsføringstilladelse til Refixia® til behandling af unge og voksne med hæmofili B. Markedsføringstilladelsen gælder samtlige 28 EU-medlemslande. Refixia® er varemærket for nonacog beta pegol; N9-GP. Refixia® er godkendt til forebyggende og akut behandling af blødning samt til brug i forbindelse med operationer hos unge (>12 år) og voksne patienter med hæmofili B (medfødt faktor IX-mangel). Vurderingen af effekt og sikkerhed var baseret på 115 patienter på tværs af de fem kliniske paradigm-studier, og markedsføringstilladelsen følger efter den positive udtalelse fra Udvalget for Humanmedicinske Lægemidler (CHMP) under Det Europæiske Lægemiddelagentur (EMA) den 24. marts 2017. ""Vi er glade for godkendelsen af Refixia® i EU, som vi anser for en vigtig udvidelse af behandlingsmulighederne for mennesker med hæmofili B,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Refixia® vil med sin stærke kliniske profil give mennesker med hæmofili B bedre beskyttelse mod blødninger, også i skadede led, og en generelt forbedret livskvalitet."" Novo Nordisk forventer at lancere Refixia® i de første europæiske lande i fjerde kvartal af 2017. Refixia® (nonacog beta pegol; N9-GP) er et faktor IX-molekyle med forlænget halveringstid, der er beregnet til substitutionsbehandling hos mennesker med hæmofili B. Halveringstiden er forlænget ved hjælp af glykopegyleringsteknikken - en ny tilgang indenfor hæmofili B. Pegylerede produkter er godkendt indenfor hæmofili A og andre behandlingsområder. Vurderingen af Refixia® er baseret på paradigm-programmet, et klinisk fase 3-program gennemført blandt børn og voksne med svær eller moderat svær hæmofili B. I dette program havde 115 tidligere behandlede patienter sammenlagt mere end 8.800 eksponeringsdage i løbet af op til 2,7 års behandling med Refixia®. Den 31. maj 2017 fik Novo Nordisk godkendelse fra de amerikanske sundhedsmyndigheder, FDA, for nonacog beta pegol; N9-GP til akut behandling og standsning af blødningsepisoder samt perioperativ behandling af kirurgiske blødninger omkring operationstidspunktet hos voksne og børn med hæmofili B. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=833,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
293,2017-05-31,Novo Nordisk får FDA-godkendelse for REBINYN® (nonacog beta pegol; N9-GP) i USA,"Bagsværd, den 31. maj 2017 - Novo Nordisk meddeler i dag, at de amerikanske sundhedsmyndigheder, FDA, har godkendt registreringsansøgningen (Biologics License Application) for REBINYN® til behandling af voksne og børn med hæmofili B. REBINYN® er varemærket for nonacog beta pegol; N9-GP. REBINYN® er godkendt til akut behandling og standsning af blødningsepisoder samt perioperativ behandling af kirurgiske blødninger omkring operationstidspunktet hos voksne og børn med hæmofili B. Vurderingen af effekt og sikkerhed var baseret på 115 patienter på tværs af de fem kliniske paradigm-studier, og godkendelsen kommer efter mødet i FDA's rådgivende komite Blood Products Advisory Committee, som blev afholdt den 4. april 2017. ""Vi er glade for godkendelsen af REBINYN® i USA og ser den som en vigtig udvidelse af behandlingsmulighederne for mennesker med hæmofili B,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Vi er overbevist om, at REBINYN® bliver et vigtigt redskab for lægerne i forhold til at hjælpe patienterne med at standse deres blødninger."" Novo Nordisk forventer at lancere REBINYN® i USA i første halvår af 2018. REBINYN® (nonacog beta pegol; N9-GP) er et faktor IX-molekyle med forlænget halveringstid, der er beregnet til substitutionsbehandling hos mennesker med hæmofili B. Vurderingen af REBINYN® er baseret på paradigm-programmet, et klinisk fase 3-program gennemført blandt børn og voksne med svær eller moderat svær hæmofili B. I dette program havde 115 tidligere behandlede patienter sammenlagt mere end 8.800 eksponeringsdage i løbet af op til 2,7 års behandling med REBINYN®. Den 24. marts 2017 modtog Novo Nordisk en positiv udtalelse fra Udvalget for Humanmedicinske Lægemidler (CHMP) under Det Europæiske Lægemiddelagentur (EMA) om nonacog beta pegol; N9-GP til forebyggende og akut behandling af blødning samt til brug i forbindelse med operationer hos unge (>12 år) og voksne patienter med hæmofili B. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 40 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=837,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
294,2017-05-31,Novo Nordisk receives US FDA approval of REBINYN® (nonacog beta pegol; N9-GP),"Bagsværd, Denmark, 31 May 2017 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application for REBINYN® for the treatment of adults and children with haemophilia B. REBINYN® is the brand name for nonacog beta pegol; N9-GP. REBINYN® is indicated for on-demand treatment and control of bleeding episodes and the perioperative management of bleeding around the time of surgery in adults and children with haemophilia B. The efficacy and safety evaluation was based on 115 patients across the four paradigm clinical trials, and the approval follows the Blood Products Advisory Committee meeting held 4 April 2017. ""We are excited about the approval of REBINYN® in the US, and we consider it an important expansion of the treatment options for patients with haemophilia B"", said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""We are confident that REBINYN® will become an important tool for physicians to help patients manage their bleeds."" Novo Nordisk expects to launch REBINYN® in the US in the first half of 2018. REBINYN® (nonacog beta pegol; N9-GP) is an extended half-life factor IX molecule for replacement therapy in patients with haemophilia B. The review of REBINYN® was based on the paradigm programme, a phase 3 clinical programme enrolling children and adults with severe or moderately severe haemophilia B. In the programme, 115 previously treated patients had a total of more than 8,800 exposure days for up to 2.7 years of treatment with REBINYN®. On 24 March 2017, Novo Nordisk received the positive opinion from the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), for nonacog beta pegol; N9-GP, indicated for prophylaxis and on-demand treatment of bleeding as well as for surgical procedures in adolescent (>12 years of age) and adult patients with haemophilia B. Further information Company announcement No 40 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=836,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
295,2017-05-27,Novo Nordisk submits application in the US for including data from the DEVOTE trial in the Tresiba® label,"Bagsværd, Denmark, 27 May 2017 - Novo Nordisk today announced the submission of a supplemental application to the US Food and Drug Administration (FDA) for including data in the label for Tresiba® (insulin degludec) from the DEVOTE trial, a long-term, randomised, double-blinded and event-driven trial conducted to confirm the cardiovascular safety of Tresiba® compared to insulin glargine U100 when added to standard of care, in people with type 2 diabetes. In the DEVOTE trial, the primary endpoint was achieved by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with Tresiba® compared to insulin glargine U100. The trial thereby confirmed the results of the DEVOTE interim analysis submitted to the FDA in March 2015, on the basis of which Tresiba® and Ryzodeg® 70/30 were approved in the US in September 2015. The primary endpoint of the DEVOTE study was defined as the MACE composite outcome of the first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke and showed a hazard ratio of 0.91 in favour of Tresiba® relative to insulin glargine U100, with no statistically significant difference between the two treatments. From a mean HbA1c baseline of 8.4%, the trial showed a similar reduction with Tresiba® compared to insulin glargine U100 with an end-of-trial treatment difference of 0.01 percentage points between the two treatment arms, thus fulfilling the requirements for objectively comparing hypoglycaemia rates between the two treatments. In the trial, Tresiba® demonstrated superiority on the secondary confirmatory endpoint of severe hypoglycaemia: 27% fewer patients in the Tresiba® treated group experienced an episode of severe hypoglycaemia, resulting in a 40% overall rate reduction of total episodes of adjudicated severe hypoglycaemia. Furthermore, patients in the Tresiba® treated group experienced a 53%* relative reduction in the rate of nocturnal severe hypoglycaemia. These differences were all statistically significant. Tresiba® appeared to have a safe and well-tolerated profile consistent with previous clinical studies conducted with Tresiba®. ""The risk of severe hypoglycaemia is a major cause for people with type 2 diabetes not reaching their treatment targets,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""However, with the DEVOTE data, we have demonstrated that the strong clinical profile of Tresiba® leads to a significant reduction in severe hypoglycaemia in people with type 2 diabetes."" DEVOTE is a long-term, multi-centre, multi-national, randomised, double-blinded, parallel group and event-driven trial conducted to confirm the cardiovascular safety of Tresiba® (insulin degludec) compared to insulin glargine U100. In the trial, 7,637 people with type 2 diabetes at high risk of cardiovascular disease were randomised to treatment with either Tresiba® or insulin glargine U100 in vial in addition to standard of care. The DEVOTE trial has been conducted in response to a Complete Response Letter received from the FDA in February 2013 requesting additional cardiovascular data from a dedicated cardiovascular outcomes trial before the review of the New Drug Applications for Tresiba® and Ryzodeg® 70/30 could be concluded. Tresiba® and Ryzodeg® 70/30 were approved in the US in September 2015 on the basis of an interim analysis of DEVOTE. Tresiba® (insulin degludec) is a once-daily basal insulin that provides duration of action of at least 42 hours. Tresiba® is taken once daily, at any time of day. Patients who miss or are delayed in taking their dose of Tresiba® can take their dose as soon as they remember, but ensuring there are at least eight hours between doses. Tresiba® received its first regulatory approval in September 2012 and has since been approved in more than 80 countries globally. It was approved by the US FDA in September 2015. * This number has subsequently been corrected from 54% to 53% Further information Company announcement No 39 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=839,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
296,2017-05-27,Novo Nordisk indsender ansøgning i USA om inkludering af data fra DEVOTE-studiet i indlægssedlen for Tresiba®,"Bagsværd, den 27. maj 2017 - Novo Nordisk meddeler i dag, at virksomheden har indsendt en supplerende ansøgning til de amerikanske sundhedsmyndigheder, FDA, om inkludering af data fra DEVOTE-studiet i indlægssedlen for Tresiba®. DEVOTE er et randomiseret, dobbeltblindet og hændelsesdrevet langtidsstudie, der er gennemført med det formål at bekræfte den kardiovaskulære sikkerhed for Tresiba® sammenlignet med insulin glargin U100 givet som supplement til standardbehandling i mennesker med type 2-diabetes. I DEVOTE-studiet blev det primære mål opfyldt, idet det viste ikke-inferiøritet med hensyn til alvorlige kardiovaskulære hændelser med Tresiba® sammenlignet med insulin glargin U100. Studiet bekræftede dermed resultaterne af interimanalysen af DEVOTE, som blev indsendt til de amerikanske sundhedsmyndigheder i marts 2015 og dannede grundlag for godkendelsen af Tresiba® og Ryzodeg® 70/30 i USA i september 2015. Det primære endepunkt for DEVOTE-studiet var defineret som den første forekomst af et sammensat kardiovaskulært endepunkt bestående af kardiovaskulært dødsfald, ikke-dødeligt myokardieinfarkt (hjerteanfald) eller ikke-dødeligt slagtilfælde og viste en risikoratio på 0,91 til fordel for Tresiba® i forhold til insulin glargin U100 med ingen statistisk signifikant forskel mellem de to behandlinger. Fra et gennemsnitligt langtidsblodsukkerniveau (HbA1c) ved studiets begyndelse på 8,4% viste studiet en sammenlignelig reduktion med Tresiba® sammenlignet med insulin glargin U100 med en behandlingsforskel ved studiets afslutning på 0,01 procentpoint mellem de to behandlingsgrupper. Kravene for objektivt at sammenligne forekomsten af hypoglykæmi (lavt blodsukker) mellem de to behandlinger var dermed opfyldt. I studiet viste Tresiba® superioritet med hensyn til det bekræftende sekundære endepunkt vedrørende alvorlig hypoglykæmi: 27% færre deltagere i gruppen, der blev behandlet med Tresiba®, oplevede en episode af alvorlig hypoglykæmi, hvilket samlet set resulterede i en 40% reduktion i den samlede forekomst af episoder af adjudikeret alvorlig hypoglykæmi. Endvidere oplevede deltagere i gruppen, der blev behandlet med Tresiba®, en 53%* relativ reduktion i forekomsten af natlig alvorlig hypoglykæmi. Disse forskelle var alle statistisk signifikante. Tresiba® forekom at have en sikker og veltolereret profil, der var konsistent med tidligere kliniske studier gennemført med Tresiba®. ""Risikoen for alvorlig hypoglykæmi er en vigtig årsag til, at mennesker med type 2-diabetes ikke når deres behandlingsmål,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Men med resultaterne fra DEVOTE har vi vist, at den stærke kliniske profil for Tresiba® fører til en signifikant reduktion i alvorlig hypoglykæmi hos mennesker med type 2-diabetes."" DEVOTE er et langtids-, multicenter-, multinationalt, randomiseret, dobbeltblindet, parallelgruppe- og hændelsesdrevet studie, som er gennemført med det formål at bekræfte den kardiovaskulære sikkerhed for Tresiba® (insulin degludec) sammenlignet med insulin glargin U100. I studiet blev 7.637 mennesker med type 2-diabetes med høj risiko for at udvikle hjerte-kar-sygdom randomiseret til behandling med enten Tresiba® eller insulin glargin U100 i hætteglas som supplement til standardbehandling. DEVOTE-studiet blev iværksat som opfølgning på et Complete Response Letter i februar 2013 fra FDA, som udbad sig yderligere kardiovaskulære data fra en dedikeret undersøgelse af forekomsten af hjerte-kar-sygdom, før registreringsansøgningerne for Tresiba® og Ryzodeg® 70/30 kunne færdigbehandles. Tresiba® og Ryzodeg® 70/30 blev godkendt i USA i september 2015 på basis af en interimanalyse af DEVOTE. Tresiba® (insulin degludec) er en basalinsulin til dosering én gang dagligt med en virkningsvarighed på mindst 42 timer. Tresiba® tages én gang dagligt når som helst i løbet af dagen. Patienter, som glemmer en dosis Tresiba®, kan tage den, når de opdager forglemmelsen, men med mindst otte timer mellem doserne. Tresiba® blev godkendt af registreringsmyndighederne første gang i september 2012 og er siden blevet godkendt i flere end 80 lande verden over. Det blev godkendt af FDA i USA i september 2015. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. * dette tal er efterfølgende blevet rettet fra 54% til 53% Yderligere information Selskabsmeddelelse nr. 39 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=838,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
297,2017-05-17,Early response to Saxenda® resulted in weight maintenance and additional weight loss over 56 weeks,"Porto, Portugal, 17 May 2017 - Today, results from a post-hoc analysis of data from the SCALE Maintenance trial were presented at the 24th European Congress on Obesity (ECO) 2017. In the trial, adults who lost at least 5% of their initial weight during a low- calorie run-in period were randomised to receive Saxenda® (liraglutide 3 mg) or placebo. After 16 weeks of treatment with Saxenda®, participants who lost an additional 5% or more of their body weight (defined as 'early responders') were more likely to maintain weight loss and achieve greater additional weight loss over 56 weeks, compared with people losing less than 5% body weight after 16 weeks of Saxenda® treatment ('early non-responders').1 ""In the obesity specialist setting, low-calorie diets combined with increased physical activity are commonly used to induce an initial weight loss in people with obesity. However, when the initial weight loss reaches a plateau and patients enter the 'weight maintenance phase' with less stringent caloric restriction, we often see that many experience weight regain,"" said Dr Sean Wharton, medical director at the Wharton Medical Clinic, Ontario and SCALE clinical trial investigator. ""As a consequence, pharmacotherapy can be used to help people with obesity in maintaining the weight loss that has already been achieved by a low-calorie diet and increased physical activity. These data are very encouraging to clinicians in this specialist setting, because they show that early responders to Saxenda® are able to both maintain and achieve additional weight loss"".  Read the full release including references 1. Wharton S, Jacobsen P, Arrone L. Early responders to liraglutide 3.0 mg as adjunct to diet and excercise from the SCALE Maintenance trial. Oral presentation number RS3:3. ECO. 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=842,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
298,2017-05-17,Tidlig respons på Saxenda® giver vægtvedligholdelse og yderligere vægttab over 56 uger,"Porto, Portugal, den 17. maj 2017 - Novo Nordisk præsenterer i dag resultater fra en post hoc-analyse af data fra SCALE Maintenance-studiet. Det sker på den 24. årlige europæiske fedmekongres, European Congress on Obesity (ECO) 2017. I studiet blev voksne, som opnåede et vægttab på mindst 5% af deres startvægt i løbet af en indkøringsperiode med kaloriefattig kost, randomiseret til behandling med Saxenda® (liraglutid 3 mg) eller placebo. Efter 16 ugers behandling med Saxenda® havde deltagere, som tabte yderligere 5% eller mere af deres kropsvægt (defineret som 'early responders'), større sandsynlighed for at opretholde vægttabet og opnå et større yderligere vægttab over 56 uger end deltagere, der havde tabt sig mindre end 5% efter 16 ugers behandling med Saxenda® ('early non-responders'). 1 ""Ved specialistbehandling af svært overvægtige starter man ofte med en lavkaloriediæt kombineret med øget fysisk aktivitet for at opnå et indledende vægttab. Men når vægttabet stagnerer, og patienten når til at skulle vedligeholde vægttabet, ser vi ofte, at mange tager på igen,"" siger Sean Wharton, læge og medicinsk direktør, Wharton Medical Clinic, Ontario, Canada, og forsøgsansvarlig i SCALE-studiet. ""Derfor kan vi bruge medicinsk behandling til at hjælpe svært overvægtige med at opretholde det vægttab, de har opnået ved hjælp af livsstilsændringer. Disse data er interessante, fordi de viser, at gruppen af patienter, der opnår en tidlig effekt af behandling med Saxenda®, er i stand til både at opretholde et vægttab og tabe sig yderligere.""  Yderligere information Læs hele meddelelsen inkl. referencer 1. Wharton S, Jacobsen P, Arrone L. Early responders to liraglutide 3.0 mg as adjunct to diet and excercise from the SCALE Maintenance trial. Oral presentation number RS3:3. ECO. 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=843,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
299,2017-05-16,Change in composition of the Board of Directors of Novo Nordisk A/S,"Bagsværd, Denmark, 16 May 2017 - Novo Nordisk today announced that Mary Szela steps down from Novo Nordisk's board of directors with immediate effect. The decision follows changed strategic focus for Novelion Therapeutics, a US-based rare disease company, where Ms Szela serves as CEO, which could lead to a potential conflict of interest. ""I acknowledge and support Ms Szela's decision to step down from the Board of Directors and I would like to thank Ms Szela for her valuable contribution since joining in March 2015,"" said Göran Ando, chairman of the Board of Directors at Novo Nordisk. Further information Company announcement No 37 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=846,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
300,2017-05-16,Ændring i sammensætningen af bestyrelsen for Novo Nordisk A/S,"Bagsværd, den 16. maj 2017 - Novo Nordisk meddeler i dag, at Mary Szela udtræder af Novo Nordisks bestyrelse med øjeblikkelig virkning. Beslutningen skyldes, at Novelion Therapeutics, en amerikansk baseret virksomhed indenfor sjældne sygdomme, som Mary Szela er administrerende direktør for, har ændret strategisk fokus, hvilket kan føre til en potentiel interessekonflikt. ""Jeg anerkender og støtter Mary Szelas beslutning om at udtræde af bestyrelsen, og jeg vil gerne takke Mary Szela for den store indsats, hun har ydet, siden hun indtrådte i bestyrelsen i marts 2015,"" siger Göran Ando, formand for bestyrelsen i Novo Nordisk. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 37 /2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=847,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
301,2017-05-03,Novo Nordisks rapporterede resultat af primær drift steg med 10% i de første tre måneder af 2017,"Salget steg med 5% opgjort i kroner Salget steg med 5% opgjort i kroner og med 3% i lokale valutaer til 28,5 mia. kr. Salget indenfor diabetes- og fedmebehandling steg med 13% til 23,8 mia. kr. (11% i lokale valutaer). Salget indenfor biopharmaceuticals faldt med 24% til 4,7 mia. kr. (25% i lokale valutaer) primært som følge af en påvirkning fra rabatjusteringer i første kvartal af 2016 og nylig introduktion af en generisk udgave af Vagifem®, begge i USA. Resultat af primær drift steg med 10% rapporteret i kroner og med 6% i lokale valutaer til 13,5 mia. kr. Nettoresultatet steg med 7% til 10,2 mia. kr. Udvandet resultat pr. aktie steg med 9% til 4,06 kr. I første kvartal af 2017 fik Fiasp®, hurtigtvirkende insulin aspart, markedsføringstilladelse fra Europa-Kommissionen og blev desuden godkendt i Norge, Island og Canada. Fiasp® er nu lanceret i de første europæiske lande foruden i Canada. Endvidere genindsendte Novo Nordisk registreringsansøgningen for hurtigtvirkende insulin aspart i USA efter modtagelsen af et Complete Response Letter i oktober 2016. I maj fik Novo Nordisk godkendelse fra Europa-Kommissionen for en opdatering af indlægssedlen for Tresiba® baseret på data fra SWITCH-studierne, som viste en klinisk relevant reduktion i hypoglykæmi sammenlignet med insulin glargin U100. I marts modtog Novo Nordisk en positiv udtalelse fra Det Europæiske Lægemiddelagentur med anbefaling af markedsføringstilladelse til Refixia® (nonacog beta pegol, N9-GP) til behandling af hæmofili B. Med virkning fra 1. juli 2017 udnævnes Lars Green til koncerndirektør med ansvar for Business Services and Compliance. For 2017 forventes den rapporterede salgsvækst nu at blive 1-4% opgjort i kroner, nu afspejlende en positiv valutapåvirkning på 1 procentpoint. Den rapporterede vækst i resultat af primær drift forventes nu at blive 0-4% opgjort i kroner, nu afspejlende en positiv valutapåvirkning på 1 procentpoint. Adm. direktør Lars Fruergaard Jørgensen: ""Med de resultater, vi har opnået i årets første tre måneder, er vi godt på vej mod de mål, vi har sat for 2017. Salget er drevet af vores nye, innovative produkter indenfor diabetes- og fedmebehandling, og vi kan nu se effekten af vores omkostningsbegrænsende tiltag, som vil gøre det muligt for os at investere i fremtidige vækstmuligheder."" Kontaktoplysninger Selskabsmeddelelse nr. 33 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=855,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
302,2017-05-03,Novo Nordisk increased reported operating profit by 10% in the first three months of 2017,"Sales increased by 5% measured in Danish kroner Sales increased by 5% in Danish kroner and by 3% in local currencies to DKK 28.5 billion. Sales within diabetes and obesity care increased by 13% to DKK 23.8 billion (11% in local currencies). Sales within biopharmaceuticals declined by 24% to DKK 4.7 billion (25% in local currencies), primarily reflecting an impact from rebate adjustments in Q1 2016 and a recent introduction of a generic version of Vagifem®, both in the USA. Operating profit increased by 10% reported in Danish kroner and by 6% in local currencies to DKK 13.5 billion. Net profit increased by 7% to DKK 10.2 billion. Diluted earnings per share increased by 9% to DKK 4.06. In the first quarter of 2017, Fiasp®, fast-acting insulin aspart, received marketing authorisation from the European Commission as well as approvals in Norway, Iceland and Canada. Fiasp® has now been launched in the first European countries as well as Canada. Furthermore, Novo Nordisk resubmitted the New Drug Application for fast-acting insulin aspart in the USA following the Complete Response Letter received in October 2016. In May, Novo Nordisk received approval from the EU commission for the label update of Tresiba® based on data from the SWITCH trials, demonstrating a clinically relevant reduction in hypoglycaemia compared with insulin glargine U100. In March, Novo Nordisk received positive opinion from the European Medicines Agency for the recommendation of a marketing authorisation for Refixia® (nonacog beta pegol, N9-GP) for the treatment of haemophilia B. As of 1 July 2017, Lars Green will be appointed executive vice president and head of Business Services and Compliance. For 2017, reported sales growth is now expected to be 1-4% measured in Danish kroner, now reflecting a positive currency impact of 1 percentage point. Reported operating profit growth is now expected to be 0-4% measured in Danish kroner, now reflecting a positive currency impact of 1 percentage point. Lars Fruergaard Jørgensen, president and CEO: ""With the performance in the first three months, we are well on track towards our targets for 2017. Sales were driven by our new, innovative products within diabetes and obesity care, and we are seeing the effects of our cost control initiatives, enabling us to invest in future growth opportunities."" Contacts for further information Company announcement No 33 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=854,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
303,2017-04-28,Novo Nordisk A/S - Total number of voting rights and share capital in Novo Nordisk A/S as of 28 April 2017,"Bagsværd, Denmark, 28 April 2017 - In accordance with Section 10 of the Danish Statutory Order on Issuers' Disclosure Obligations, Novo Nordisk is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred. Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=858,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
304,2017-04-28,Novo Nordisk A/S - Det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 28. april 2017,"Bagsværd, 2017-04-28 - I henhold til Bekendtgørelse om udstederes oplysningsforpligtelser, § 10, skal Novo Nordisk offentliggøre det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S ved udgangen af en måned, hvor ændringer deri har fundet sted. Yderligere information ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=859,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
305,2017-04-21,Novo Nordisk A/S - Nedsættelse af aktiekapitalen,"Bagsværd, 2017-04-21 - På den ordinære generalforsamling i Novo Nordisk A/S den 23. marts 2017 blev det besluttet at nedsætte selskabets B-aktiekapital fra nominelt 402.512.800 kr. til 392.512.800 kr. ved annullering af en del af selskabets beholdning af egne B-aktier, i alt nominelt 10.000.000 kr. fordelt på 50.000.000 B-aktier á 0,20 kr. Novo Nordisk har i dag registreret kapitalnedsættelsens gennemførelse hos Erhvervsstyrelsen og annulleret nominelt 10.000.000 kr. B-aktier. Efter kapitalnedsættelsen er selskabets aktiekapital nominelt 500.000.000 kr. fordelt på nominelt 107.487.200 kr. A-aktier og nominelt 392.512.800 kr. B-aktier. Kapitalnedsættelsen vil ikke have nogen effekt på Novo Nordisks aktietilbagekøbsprogram, som fortsætter uændret i henhold til det udmeldte. Yderligere information Selskabsmeddelelse nr. 29 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=865,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
306,2017-04-21,Novo Nordisk A/S - Reduction of the share capital,"Bagsværd, Denmark, 21 April 2017 - At Novo Nordisk's Annual General Meeting on 23 March 2017, it was decided to reduce the company's B share capital from DKK 402,512,800 to DKK 392,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each. Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled nominally DKK 10,000,000 B shares. After the reduction of the share capital, the company's share capital is nominally DKK 500,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 392,512,800. The reduction in the share capital will not affect Novo Nordisk's share repurchase programme which will continue as previously announced. Company announcement No 29 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=864,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
307,2017-04-03,Once-weekly semaglutide demonstrated consistent blood glucose reductions and weight loss regardless of background oral antidiabetic treatment,"Bagsværd, Denmark, 3 April 2017 - Findings from a post hoc analysis of the phase 3a SUSTAIN 2-4 trials demonstrated greater mean reductions in HbA1c and body weight with once-weekly semaglutide treatment compared to sitagliptin, exenatide extended release (ER) and insulin glargine U100 in adults with type 2 diabetes, across multiple background oral antidiabetic (OAD) treatment categories. The results were presented at the Endocrine Society's 99th Annual Meeting and Expo (ENDO 2017) in Orlando, FL, US.1 ""Type 2 diabetes is a complex disease, and as a result many patients are not reaching their targets on current oral antidiabetic therapy,"" said Vanita Aroda, SUSTAIN 4 investigator and physician investigator at the MedStar Health Research Institute, Hyattsville, MD, US. ""Results from this post hoc analysis show that once-weekly semaglutide consistently lowered blood glucose and weight in people with type 2 diabetes regardless of their current oral antidiabetic therapy."" Read the full release including references",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=873,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
308,2017-04-03,Én gang ugentlig semaglutid sænker konsistent blodsukker og vægt uanset baggrundsbehandling med diabeteslægemidler i tabletform,"Bagsværd, den 3. april 2017 - En post hoc-analyse af fase 3a-studierne SUSTAIN 2-4 viser, at behandling med semaglutid én gang ugentligt giver større gennemsnitlige reduktioner i langtidsblodsukkerniveauet (HbA1c) og kropsvægten sammenlignet med sitagliptin, exenatid extended-release (ER) og insulin glargin U100 hos voksne med type 2-diabetes, uanset baggrundsbehandling i form af forskellige typer af diabeteslægemidler i tabletform. Disse resultater er netop blevet præsenteret på ENDO 2017, den 99. årskongres i det amerikanske videnskabelige selskab Endocrine Society i Orlando, Florida, USA.1 ""Type 2-diabetes er en kompleks sygdom, og derfor er der mange, der ikke når deres behandlingsmål med gængs diabetesbehandling i tabletform,"" siger Vanita Aroda, forsøgsansvarlig i SUSTAIN 4-studiet og lægefaglig investigator ved MedStar Health Research Institute, Hyattsville, Maryland, USA. ""Resultaterne fra denne post hoc-analyse viser, at én gang ugentlig semaglutid konsistent sænkede blodsukkerniveauet og vægten hos mennesker med type 2-diabetes uanset deres igangværende behandling med diabeteslægemidler i tabletform."" Læs hele meddelelsen Yderligere information ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=872,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
309,2017-03-31,"FDA offentliggør briefingmateriale forud for møde i rådgivende komite om nonacog beta pegol, langtidsvirkende faktor IX til behandling af hæmofili B","Bagsværd, den 31. marts 2017 - Novo Nordisk meddeler i dag, at de amerikanske sundhedsmyndigheder, FDA, har offentliggjort briefingdokumenterne forud for mødet i den rådgivende komite, hvor registreringsansøgningen (Biologics License Application) for nonacog beta pegol, langtidsvirkende faktor IX til behandling af hæmofili B, vil blive drøftet. Mødet finder sted den 4. april 2017. Briefingdokumenterne fra Novo Nordisk og FDA danner grundlag for drøftelserne i den rådgivende komite. De giver overblik over de ikke-kliniske og kliniske data for nonacog beta pegol til behandling af hæmofili B. Materialet er tilgængeligt på FDA's hjemmeside Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 25 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=874,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
310,2017-03-31,"FDA posts briefing materials prior to Advisory Committee meeting for nonacog beta pegol, a long-acting factor IX for the treatment of haemophilia B","Bagsværd, Denmark, 31 March 2017 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has published the briefing documents ahead of the Advisory Committee meeting to discuss the Biologics License Application for nonacog beta pegol, a long-acting factor IX for the treatment of haemophilia B. The meeting takes place on 4 April 2017. The briefing documents from Novo Nordisk and the FDA, which will form the basis for the Advisory Committee's discussion, provide an overview of the non-clinical and clinical data for nonacog beta pegol for the treatment of haemophilia B. The briefing materials can be accessed on the FDA webpage Further information Company announcement No 25 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=875,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
311,2017-03-29,Novo Nordisk resubmits new drug application for fast-acting insulin aspart in the US,"Bagsværd, Denmark, 29 March 2017 - Novo Nordisk today announced that the company has resubmitted the new drug application (NDA) for fast-acting insulin aspart as a class II re-submission to the US Food and Drug Administration (FDA). In October 2016, Novo Nordisk announced that it had received a Complete Response Letter from the FDA regarding the NDA for fast-acting insulin aspart. In the letter, the FDA requested additional information related to the assay for the immunogenicity and the assay used to generate the clinical pharmacokinetics data before the review of the NDA could be completed. Novo Nordisk has now evaluated the content of the Complete Response Letter and completed the End-of-Review meeting with FDA; based on this, Novo Nordisk has resubmitted the fast-acting insulin aspart NDA as a class II re-submission. Novo Nordisk expects to receive feedback from the FDA in the last quarter of 2017. Fast-acting insulin aspart is a mealtime insulin for the control of postprandial glucose excursions in type 1 and type 2 diabetes as well as in pump treatment. Fast-acting insulin aspart is insulin aspart (NovoLog®/NovoRapid®) in a new formulation in which two new excipients have been added to ensure early and fast absorption. Fast-acting insulin aspart received marketing authorisation from the European Commission on 9 January 2017, covering all 28 European Union member states. Approvals were also received in Norway, Iceland and Canada. It is also currently under regulatory review in Switzerland, Australia, Brazil, South Africa, Argentina and Israel. Further information Company announcement No 24 / 2107",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=876,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
312,2017-03-29,Novo Nordisk genindsender registreringsansøgningen for hurtigtvirkende insulin aspart i USA,"Bagsværd, den 29. marts 2017 - Novo Nordisk meddeler i dag, at virksomheden har genindsendt registreringsansøgningen for hurtigtvirkende insulin aspart som en Class II Resubmission til de amerikanske sundhedsmyndigheder (FDA). I oktober 2016 modtog Novo Nordisk et Complete Response Letter fra FDA vedrørende registreringsansøgningen for hurtigtvirkende insulin aspart. I brevet udbad FDA sig yderligere information vedrørende immunogenicitetsanalysen og det assay, der blev benyttet til generering af de kliniske farmakokinetiske data, før registreringsansøgningen kunne færdigbehandles. Novo Nordisk har nu evalueret brevets indhold, og der er afholdt et afsluttende møde med FDA efter deres gennemgang af materialet. På denne baggrund har Novo Nordisk genindsendt registreringsansøgningen for hurtigtvirkende insulin aspart. Novo Nordisk forventer at modtage tilbagemelding fra FDA i sidste kvartal af 2017. Hurtigtvirkende insulin aspart er en måltidsinsulin til regulering af måltidsrelaterede blodsukkerstigninger i type 1- og type 2-diabetes samt i pumpebehandling. Hurtigtvirkende insulin aspart er insulin aspart (NovoLog®/NovoRapid®) i en ny formulering, hvor der er tilsat to nye hjælpestoffer for at sikre tidlig og hurtig optagelse.Hurtigtvirkende insulin aspart modtog markedsføringstilladelse fra Europa-Kommissionen den 9. januar 2017 gældende for samtlige 28 EU-medlemslande og er desuden godkendt i Norge, Island og Canada. Det er desuden under regulatorisk behandling i Schweiz, Australien, Brasilien, Sydafrika, Argentina og Israel. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 24 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=877,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
313,2017-03-24,"Novo Nordisk receives positive opinion from the European regulatory authorities for Refixia® (nonacog beta pegol, N9-GP) for the treatment of haemophilia B","Bagsværd, Denmark, 24 March 2017 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), adopted a positive opinion for the use of Refixia® (nonacog beta pegol, N9-GP), recommending marketing authorisation for the treatment of adolescents and adults with haemophilia B. The CHMP recommends Refixia®, the brand name for nonacog beta pegol, N9-GP, to be indicated for prophylaxis and on-demand treatment of bleeding as well as for surgical procedures in adolescent (>12 years of age) and adult patients with haemophilia B (congenital factor IX deficiency). The recommendation is based on the results from the paradigm clinical trial programme, where 115 previously treated children and adults with haemophilia B were treated with Refixia®. ""We are excited about the positive opinion obtained for Refixia® and it represents a significant milestone in our efforts to expand the treatment options for patients with haemophilia,"" said Mads Krogsgaard Thomsen, executive vice president and chief scientific officer of Novo Nordisk. ""We believe Refixia® with its strong clinical profile provides haemophilia B patients better protection against bleeds, even into damaged joints, and an overall improved quality of life."" About Refixia® Refixia® (nonacog beta pegol, N9-GP) is an extended half-life factor IX molecule for replacement therapy in patients with haemophilia B. Glycopegylation, the prolongation technology used for the half-life extension, is a novel approach in haemophilia B. Pegylated products have been approved in haemophilia A and other therapeutic areas. The review of Refixia® was based on the paradigm programme, a phase 3 clinical programme enrolling children and adults with severe or moderately severe haemophilia B. In the programme, 115 previously treated patients had a total of more than 8,800 exposure days for up to 2.7 years of treatment with Refixia®. Further information Company announcement No 22 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=881,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
314,2017-03-24,"Novo Nordisk får positiv udtalelse fra de europæiske lægemiddelmyndigheder om Refixia® (nonacog beta pegol, N9-GP) til behandling af hæmofili B","Bagsværd, den 24. marts 2017 - Novo Nordisk meddeler i dag, at Udvalget for Humanmedicinske Lægemidler (CHMP) under Det Europæiske Lægemiddelagentur (EMA) har afgivet en positiv udtalelse om brug af Refixia® (nonacog beta pegol, N9-GP) og anbefaler markedsføringstilladelse til behandling af unge og voksne med hæmofili B. CHMP anbefaler, at Refixia®, varemærket for nonacog beta pegol, N9-GP, godkendes til forebyggende og akut behandling af blødning samt til brug i forbindelse med operationer hos unge (>12 år) og voksne patienter med hæmofili B (medfødt faktor IX-mangel). Anbefalingen er baseret på resultaterne fra det kliniske udviklingsprogram paradigm, hvor 115 tidligere behandlede børn og voksne med hæmofili B blev behandlet med Refixia®. ""Vi er glade for den positive udtalelse om Refixia®, som repræsenterer en væsentlig milepæl i vores indsats for at udvide behandlingsmulighederne for mennesker med hæmofili,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Vi er overbevist om, at Refixia® med sin stærke kliniske profil vil give mennesker med hæmofili B bedre beskyttelse mod blødninger, også i skadede led, og en generelt forbedret livskvalitet."" Refixia® (nonacog beta pegol, N9-GP) er et faktor IX-molekyle med forlænget halveringstid, der er beregnet til substitutionsbehandling hos mennesker med hæmofili B. Halveringstiden er forlænget ved hjælp af glykopegyleringsteknikken - en ny tilgang indenfor hæmofili B. Pegylerede produkter er godkendt indenfor hæmofili A og andre behandlingsområder. Vurderingen af Refixia® er baseret på paradigm-programmet, et klinisk fase 3-program gennemført blandt børn og voksne med svær eller moderat svær hæmofili B. I dette program havde de 115 tidligere behandlede patienter sammenlagt mere end 8.800 eksponeringsdage i løbet af op til 2,7 års behandling med Refixia®. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 22 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=880,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
315,2017-03-24,CHMP provides positive opinion for EU label update for Novo Nordisk's Tresiba® based on data from SWITCH trials,"Bagsværd, Denmark, 24 March 2017 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), has issued a positive opinion, recommending an update of the label for Tresiba® (insulin degludec) to include data from the SWITCH 1 and 2 clinical trials. In the trials, Tresiba®, the new-generation once-daily basal insulin, demonstrated clinically relevant reductions in hypoglycaemia compared with insulin glargine U100 in people with type 1 and type 2 diabetes. For the SWITCH 1 trial, the CHMP recommends the updated label to include results reflecting the significant reductions in hypoglycaemia. In the trial, adults with type 1 diabetes treated with Tresiba® vs. insulin glargine U100, both in addition to meal-time insulin aspart, experienced statistically significant reductions in hypoglycaemia, including 11% reduction of overall symptomatic hypoglycaemia (severe or blood glucose confirmed), 36% reduction in nocturnal symptomatic hypoglycaemia and 35% reduction in severe hypoglycaemia during the trial maintenance period. For the SWITCH 2 trial, the CHMP recommends the updated label to include results reflecting the significant reductions in hypoglycaemia. In the trial, adults with type 2 diabetes treated with Tresiba® vs. insulin glargine U100 experienced statistically significant reductions in hypoglycaemia, including 30% reduction in overall symptomatic hypoglycaemia (severe or blood glucose confirmed) and 42% decrease in nocturnal symptomatic hypoglycaemia, during the trial maintenance period. ""Following the submission of the application to the EMA in November 2016, we are very pleased to have received a positive opinion from the CHMP for the label update already at this point in time,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk. ""An inclusion of the SWITCH trial results in the label will further support the clinical profile of Tresiba®"". The CHMP positive opinion is now referred for final action to the European Commission, which grants approval in the EU. Novo Nordisk expects to receive the updated marketing authorisation in the second quarter of 2017. About Tresiba® Tresiba® (insulin degludec) is a once-daily basal insulin that provides duration of action beyond 42 hours with a flat and stable glucose-lowering effect. It provides low within-day variability and day-to-day variability and a lower risk of overall, nocturnal and severe hypoglycaemia vs. insulin glargine U100. On occasions when administration at the same time of day is not possible, Tresiba® allows for flexibility in day-to-day dosing time with a minimum of eight hours between injections. Tresiba® received its first regulatory approval in September 2012 and has since been approved in more than 80 countries globally. It was approved by the FDA in the United States on 26 September 2015. It is now commercially available in more than 50 countries. About SWITCH 1 and 2The two phase 3b, 2x32-week randomised, double-blind, crossover, treat-to-target trials were initiated to investigate the hypoglycaemia profile of Tresiba® compared to insulin glargine U100 in people with type 1 and type 2 diabetes, respectively. The primary endpoint was the number of severe or blood glucose confirmed symptomatic hypoglycaemic episodes observed in participants. The two secondary endpoints included: the number of severe or blood glucose confirmed nocturnal episodes experienced in participants; and the proportion of people with one or more severe hypoglycaemic episodes. In SWITCH 1, 501 people with type 1 diabetes were randomised to crossover treatment with Tresiba® and insulin glargine U100 in combination with insulin aspart. In SWITCH 2, 721 people with type 2 diabetes were randomised to crossover treatment with Tresiba® and insulin glargine U100 in combination with oral antidiabetic drugs. Further information Company announcement No 21 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=883,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
316,2017-03-24,CHMP afgiver positiv udtalelse om opdatering af indlægssedlen for Novo Nordisks Tresiba® i EU baseret på data fra SWITCH-studierne,"Bagsværd, den 24. marts 2017 - Novo Nordisk meddeler i dag, at Udvalget for Humanmedicinske Lægemidler (CHMP) under Det Europæiske Lægemiddelagentur (EMA) har afgivet en positiv udtalelse med anbefaling om en opdatering af indlægssedlen for Tresiba® (insulin degludec) med data fra de kliniske studier SWITCH 1 og 2. I disse studier viste Tresiba®, en ny generation af basalinsulin til dosering én gang dagligt, klinisk relevante reduktioner i hypoglykæmi (lavt blodsukker) sammenlignet med insulin glargin U100 hos mennesker med type 1- og type 2-diabetes. For SWITCH 1-studiet anbefaler CHMP, at indlægssedlen opdateres med resultater, som afspejler de signifikante reduktioner i hypoglykæmi. I dette studie oplevede voksne med type 1-diabetes, som blev behandlet med Tresiba® sammenlignet med insulin glargin U100, begge givet i tillæg til insulin aspart som måltidsinsulin, statistisk signifikante reduktioner i hypoglykæmi i studiets vedligeholdelsesperiode, herunder 11% reduktion i generel symptomatisk hypoglykæmi (alvorlig eller bekræftet ved blodsukkermåling), 36% reduktion i natlig symptomatisk hypoglykæmi og 35% reduktion i alvorlig hypoglykæmi. For SWITCH 2-studiet anbefaler CHMP, at indlægssedlen opdateres med resultater, som afspejler de signifikante reduktioner i hypoglykæmi. I dette studie oplevede voksne med type 2-diabetes, som blev behandlet med Tresiba® sammenlignet med insulin glargin U100, statistisk signifikante reduktioner i hypoglykæmi i studiets vedligeholdelsesperiode, herunder 30% reduktion i generel symptomatisk hypoglykæmi (alvorlig eller bekræftet ved blodsukkermåling) og 42% reduktion i natlig symptomatisk hypoglykæmi. ""Vi indsendte ansøgningen til EMA i november 2016 og er meget glade for, at vi allerede nu har fået en positiv udtalelse fra CHMP om opdatering af indlægssedlen,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Det vil være en yderligere bekræftelse af den kliniske profil for Tresiba® at få resultaterne fra SWITCH-studierne med i indlægssedlen."" Den positive udtalelse fra CHMP sendes nu videre til endelig afgørelse i Europa-Kommissionen, som står for godkendelse i EU. Novo Nordisk forventer at modtage den opdaterede markedsføringstilladelse i andet kvartal af 2017. Tresiba® (insulin degludec) er en basalinsulin til dosering én gang dagligt, som har en virkningsvarighed på mere end 42 timer med en flad og stabil blodsukkersænkende effekt. Tresiba® medfører en lav døgn- og dag-til-dag-variation og en lavere risiko for general, natlig og alvorlig hypoglykæmi sammenlignet med insulin glargin U100. I situationer, hvor det ikke er muligt at tage insulin på det sædvanlige tidspunkt af dagen, giver Tresiba® mulighed for fleksibilitet med hensyn til injektionstidspunktet fra dag til dag, men med mindst otte timer mellem doserne. Tresiba® blev godkendt af registreringsmyndighederne første gang i september 2012 og er siden blevet godkendt i flere end 80 lande verden over. Tresiba® blev godkendt af de amerikanske sundhedsmyndigheder, FDA, i USA den 26. september 2015 og er nu på markedet i flere end 50 lande. De to 2x32-ugers randomiserede, dobbeltblindede, crossover-, treat to target- fase 3b-studier blev iværksat med det formål at undersøge hypoglykæmiprofilen for Tresiba® sammenlignet med insulin glargin U100 hos mennesker med henholdsvis type 1- og type 2-diabetes. Det primære endepunkt var antallet af episoder af alvorlig hypoglykæmi eller symptomatisk hypoglykæmi bekræftet ved blodsukkermåling, der blev observeret hos deltagerne. De to sekundære endepunkter var: antallet af episoder af alvorlig hypoglykæmi eller natlig hypoglykæmi bekræftet ved blodsukkermåling samt andelen af deltagere, der oplevede én eller flere episoder af alvorlig hypoglykæmi. I SWITCH 1 blev 501 deltagere med type 1-diabetes randomiseret til crossover-behandling med Tresiba® og insulin glargin U100 i kombination med insulin aspart. I SWITCH 2 blev 721 deltagere med type 2-diabetes randomiseret til crossover-behandling med Tresiba® og insulin glargin U100 i kombination med diabeteslægemidler i tabletform. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 21 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=882,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
317,2017-03-23,Resolutions from the Annual General Meeting of Novo Nordisk A/S,"Bagsværd, Denmark, 23 March 2017 - Today, Novo Nordisk A/S held its Annual General Meeting, at which the following were adopted: After the Annual General Meeting, the Board of Directors held a board meeting to appoint members of its committees. The Board of Directors decided at the same time to establish a temporary Research & Development Committee in light of the recently updated research and development strategy and priorities. The Research & Development Committee will assist the Board of Directors with oversight of the research and development strategy, the pipeline and other tasks. The Board of Directors, including its committees, are now composed as follows: Further information Company announcement No 20 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=885,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
318,2017-03-23,Beslutninger på den ordinære generalforsamling i Novo Nordisk A/S,"Bagsværd, den 23. marts 2017 - Novo Nordisk A/S har i dag afholdt ordinær generalforsamling, hvor følgende blev godkendt: På et bestyrelsesmøde afholdt efter generalforsamlingen valgte bestyrelsen medlemmer til bestyrelsens udvalg. Bestyrelsen besluttede samtidig at nedsætte et midlertidigt forsknings- og udviklingsudvalg på baggrund af den nylige opdatering af virksomhedens forsknings- og udviklingsstrategi og -prioriteter. Forsknings- og udviklingsudvalget skal assistere bestyrelsen med at føre tilsyn med forsknings- og udviklingsstrategien, pipelinen og andre opgaver. Bestyrelsen og dens udvalg er herefter sammensat som følger: Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 20 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=884,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
319,2017-03-01,Ændring i Novo Nordisks koncerndirektion,"Bagsværd, den 1. marts 2017 - Novo Nordisk A/S meddeler i dag, at Jakob Riis, koncerndirektør med ansvar for North America Operations og direktør for virksomhedens amerikanske datterselskab Novo Nordisk Inc., har sagt op. Med virkning fra i dag er Doug Langa, direktør for Market Access i Novo Nordisk Inc., udnævnt til direktør for North America Operations og for Novo Nordisk Inc. Han får reference til Lars Fruergaard Jørgensen, administrerende direktør for Novo Nordisk A/S. Jakob Riis forbliver i Novo Nordisk i en overgangsperiode for at sikre en smidig overdragelse af ledelsesopgaverne. Göran Ando, formand for bestyrelsen i Novo Nordisk A/S, siger: ""Vi er selvfølgelig kede af, at se Jakob Riis forlade os. Han har gjort det godt gennem sin karriere i Novo Nordisk, og vi ønsker ham alt godt fremover. Vi ønsker Doug Langa velkommen som vores nye leder af North America Operations. Dougs erfaring fra det amerikanske farmamarked, hans ledelseskompetencer og ekspertise indenfor Market Access gør ham til en naturlig arvtager for Jakob Riis."" Doug Langa er direktør for Market Access og medlem af ledelsen i Novo Nordisks amerikanske datterselskab. Han kom til Novo Nordisk i 2011 som senior director for Managed Markets fra en stilling som senior director, Payer Marketing i GlaxoSmithKline. Inden GSK, havde Doug Langa gjort størstedelen af sin karriere i Johnson & Johnson, hvor han bestred stillinger med stigende ansvarsområde indenfor Managed Markets, salgsledelse og marketing. Han har mere end 25 års erfaring inden for medicin- og medikoindustrien. Han er dimitteret fra Widener University og har en MBA fra Fordham University. Yderligere information Selskabsmeddelelse nr. 16 / 2017 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=893,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
320,2017-03-01,Change in Novo Nordisk Executive Management,"Bagsværd, Denmark, 1 March 2017 - Novo Nordisk A/S today announced that Jakob Riis, executive vice president, head of North America Operations and president of Novo Nordisk Inc. has resigned from the company. Effective today, Doug Langa, senior vice president for Market Access, Novo Nordisk Inc., has been appointed senior vice president, head of North America Operations and president of Novo Nordisk Inc. He will report to Lars Fruergaard Jørgensen, president and CEO, Novo Nordisk A/S. Jakob Riis will remain with Novo Nordisk in a transition period to help ensure a smooth handover. Göran Ando, chairman of the Board of Directors of Novo Nordisk A/S, said: ""We are of course sad to see Jakob Riis leave. He has done a great job throughout his career in Novo Nordisk, and we wish him all the best. We welcome Doug Langa as our new head of North America Operations. Doug's experience in the US pharmaceutical market, his leadership skills and expertise in the area of market access make him the natural successor to Jakob Riis."" Doug Langa is senior Vice president, Market Access and a member of Novo Nordisk's US leadership team. He joined the company in 2011 as senior director, Managed Markets.  He came from GlaxoSmithKline where he was senior director of Payer Marketing.  Prior to GSK, Doug Langa spent the majority of his career at Johnson & Johnson, where he held various roles of increasing responsibility within Managed Markets, Sales Leadership and Marketing. He has over 25 years of experience in the pharmaceutical and medical device industry. He graduated from Widener University and earned his MBA from Fordham University. Further information Company announcement No 16 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=892,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
321,2017-02-28,Novo Nordisk indsender registreringsansøgning for semaglutid til dosering én gang ugentligt til behandling af type 2-diabetes i Japan,"Bagsværd, den 28. februar 2017 - Novo Nordisk meddeler i dag, at virksomheden har indsendt registreringsansøgning til det japanske sundhedsministerium, Ministry of Health, Labour and Welfare, for semaglutid, en ny GLP-1-analog (glukagonlignende peptid-1) til dosering én gang ugentligt, til behandling af voksne med type 2-diabetes. Den japanske ansøgning følger efter tilsvarende indsendelser for nylig til de regulatoriske myndigheder i USA (FDA), EU (EMA), Canada (Health Canada) og Schweiz (SwissMedic). Den japanske registreringsansøgning er baseret på resultater fra det kliniske udviklingsprogram SUSTAIN. SUSTAIN-programmet omfattede flere end 8.000 voksne deltagere med type 2-diabetes, hvoraf ca. 1.200 var fra Japan. Deltagerne blev behandlet med semaglutid doseret én gang ugentligt som monoterapi, eller sammen med diabeteslægemidler i tabletform, eller i kombination med diabeteslægemidler i tabletform og basalinsulin. På tværs af SUSTAIN-programmet viste semaglutid til dosering én gang ugentligt statistisk signifikante reduktioner i HbA1c samt statistisk signifikante reduktioner i gennemsnitsvægten sammenlignet med sitagliptin, exenatid extended-release, insulin glargin U100 til dosering én gang dagligt og placebo. På tværs af SUSTAIN-programmet havde semaglutid til dosering én gang ugentligt en veltolereret sikkerhedsprofil, hvor den mest almindelige bivirkning var kvalme. ""Det glæder os, at registreringsansøgningen for semaglutid til dosering én gang ugentligt nu er indsendt i Japan,"" siger Mads Krogsgaard Thomsen, koncerndirektør med ansvar for forskning og udvikling i Novo Nordisk. ""På baggrund af resultaterne fra det globale SUSTAIN-program er vi overbevist om, at semaglutid til dosering én gang ugentligt har potentiale til yderligere at forbedre behandlingen for mange mennesker med type 2-diabetes i Japan."" Yderligere information Selskabsmeddelelse nr. 15 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=895,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
322,2017-02-28,Novo Nordisk files for regulatory approval of once-weekly semaglutide for the treatment of type 2 diabetes in Japan,"Bagsværd, Denmark, 28 February 2017 - Novo Nordisk today announced the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for semaglutide, a new glucagon-like peptide-1 (GLP-1) analogue administrated once-weekly, for the treatment of adults with type 2 diabetes. The Japanese filing follows the recent once-weekly semaglutide regulatory submissions to the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada and SwissMedic. The Japanese submission is based on results from the SUSTAIN clinical trial programme. The SUSTAIN programme involved more than 8,000 adults with type 2 diabetes, with approximately 1,200 participants from Japan. Trial participants were treated with once-weekly semaglutide as monotherapy, or with oral-antidiabetic (OAD) agents or in combination with OADs and basal insulin. Across the SUSTAIN programme, once-weekly semaglutide demonstrated statistically significant reductions in HbA1c as well as statistically significant reductions in mean body weight compared to sitagliptin, exenatide extended-release, once-daily insulin glargine U100 and placebo. Across the SUSTAIN clinical trial programme, once-weekly semaglutide had a well-tolerated safety profile, with the most common adverse event being nausea. ""We are very excited about having filed the regulatory application for once-weekly semaglutide in Japan,"" said Mads Krogsgaard Thomsen, executive vice president and chief scientific officer of Novo Nordisk. ""Based on the results from the global SUSTAIN clinical trial programme, we believe that once-weekly semaglutide has the potential to improve the treatment for many type 2 patients in Japan."" Further information Company announcement No 15 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=894,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
323,2017-02-24,Indkaldelse til ordinær generalforsamling i  Novo Nordisk A/S,"Bagsværd, den 24. februar 2017 - Den ordinære generalforsamling i Novo Nordisk A/S afholdes: torsdag den 23. marts 2017 kl. 14.00 i Bella Center, indgang Vest, Center Boulevard 5, 2300 København S. Indkaldelse til generalforsamlingen, inklusive appendiks 1: Bestyrelseskandidater og appendiks 2: Reviderede aflønningsprincipper, er vedlagt. Alle selskabets generalforsamlingsvalgte bestyrelsesmedlemmer er på valg. Bruno Angelici søger ikke genvalg. Bestyrelsen foreslår genvalg af følgende generalforsamlingsvalgte bestyrelsesmedlemmer: Göran Ando (formand), Jeppe Christiansen (næstformand), Brian Daniels, Sylvie Grégoire, Liz Hewitt and Mary Szela. Bestyrelsen foreslår, at Kasim Kutay og Helge Lund vælges som nye bestyrelsesmedlemmer på generalforsamlingen. Kasim Kutay er administrerende direktør i Novo A/S. Bestyrelsen foreslår valg af Kasim Kutay på grund af hans omfattende erfaring som finansrådgiver for lægemiddel- og biotekindustrien samt industrien for medicinsk udstyr. Kasim Kutay har endvidere rådgivet lægemiddelvirksomheder på international basis, herunder virksomheder hjemmehørende i Europa, USA, Japan og Indien. Helge Lund er tidligere administrerende direktør i det integrerede gasselskab, BG Group plc. Bestyrelsen foreslår valg af Helge Lund primært på grund af hans om­fattende ledelses- og bestyrelseserfaring i store multinatio­nale virksomheder med hovedkontor i Skandinavien indenfor regulerede markeder og hans betydelige viden om finansielle forhold.  Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Selskabsmeddelelse nr. 13 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=899,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
324,2017-02-24,Notice for the Annual General Meeting of  Novo Nordisk A/S,"Bagsværd, Denmark, 24 February 2017 - The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 23 March 2017 at 2.00 pm (CET) at Bella Center, entrance West, Center Boulevard 5, 2300 Copenhagen S, Denmark. The notice for the Annual General Meeting, including Appendix 1: Candidates for the Board of Directors and Appendix 2: Revised Remuneration Principles, is enclosed. All board members elected by the Annual General Meeting are up for election. Bruno Angelici does not seek re-election as member of the Board of Directors. The Board of Directors proposes re-election of the following board members elected by the Annual General Meeting: Göran Ando (chairman), Jeppe Christiansen (vice chairman), Brian Daniels, Sylvie Grégoire, Liz Hewitt and Mary Szela. The Board of Directors proposes election of Kasim Kutay and Helge Lund as new members of the Board of Directors at the Annual General Meeting. Mr Kutay is chief executive officer of Novo A/S, Denmark. The Board of Directors recommends election of Mr Kutay primarily because of his extensive experience as financial advisor to the pharmaceutical, biotechnology and medical device industries. Furthermore, Mr Kutay has advised healthcare companies on an international basis including companies based in Europe, the USA, Japan and India. Mr Lund is former chief executive officer of the integrated gas company, BG Group plc. The Board of Directors recommends election of Mr Lund primarily because of his extensive executive and board experience in large multinational companies headquartered in Scandinavia within regulated markets and significant financial knowledge. Company announcement No 13 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=898,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
325,2017-02-09,Novo Nordisk files annual report with the SEC,"Bagsværd, Denmark, 9 February 2017 - Novo Nordisk A/S has filed its Annual Report 2016 on Form 20-F for the financial year 2016 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2016. The reports are available at the SEC's website, www.sec.gov, as well as on novonordisk.com. Shareholders and ADR holders may receive a hard copy of the annual reports free of charge upon request by filling out a request form on novonordisk.com or upon request to chqt@novonordisk.com - please state the exact mailing address and the document(s) you wish to receive. ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=906,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
326,2017-02-07,Novo Nordisk har udgivet sin årsrapport for 2016," Bagsværd, 7. februar 2017 - Novo Nordisk har udgivet sin årsrapport for 2016 online på http://www.novonordisk.com/annualreport. Det er virksomhedens 13. integrerede årsrapport, som redegør for virksomhedens finansielle, sociale og miljømæssige resultater. Årsrapporten udarbejdes udelukkende på engelsk. Et årsskrift rummer en dansk udgave af ledelsesberetningen samt uddrag af koncernregnskabet. Begge publikationer vil være tilgængelige på tryk senere i denne måned.   ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=910,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
327,2017-02-07,Novo Nordisk publishes its 2016 Annual Report," Bagsværd, Denmark, 7 February 2017 Novo Nordisk has published its 2016 annual report online at http://www.novonordisk.com/annualreport. It is the company's thirteenth integrated annual report detailing the company's financial, social and environmental performance. The annual report will be available in print later this month.   ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=909,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
328,2017-02-02,Novo Nordisk increased adjusted operating profit by 6% in local currencies in 2016,"Sales increased by 6% in local currencies and by 4% in Danish kroner to DKK 111.8 billion. Net profit increased by 9% to DKK 37.9 billion. Diluted earnings per share increased by 11% to DKK 14.96. Adjusted for the partial divestment of NNIT, net profit and diluted earnings per share increased by 17% and 19%, respectively. In November 2016, Novo Nordisk announced that Tresiba® demonstrated a safe cardiovascular profile and a statistically significant 40% reduced risk of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial. Also in November 2016, Novo Nordisk received the FDA approval of Xultophy® 100/3.6, the once-daily combination of insulin degludec (Tresiba®) and liraglutide (Victoza®). In January 2017, Novo Nordisk received EU approval of Fiasp®, the new-generation fast-acting insulin. On 1 January 2017, Lars Fruergaard Jørgensen replaced Lars Rebien Sørensen as president and CEO, who retired after 34 years of loyal service with the company, the last 16 years as CEO. For 2017, reported sales growth is expected to be 1-6% measured in Danish kroner, positively impacted by currencies of 2 percentage points. Reported operating profit growth is expected to be 0-5% measured in Danish kroner, positively impacted by currencies of 2 percentage points. At the Annual General Meeting on 23 March 2017, the Board of Directors will propose a final dividend of DKK 4.60 for 2016 per share of DKK 0.20. The expected total dividend for 2016 of DKK 7.60 per share, of which DKK 3.00 per share was paid as interim dividend in August 2016, corresponds to an increase of 19% compared to 2015. The Board of Directors furthermore intends to initiate a new 12-months share repurchase programme of up to DKK 16 billion. Lars Fruergaard Jørgensen, president and CEO: ""2016 was a challenging year. While we met our financial guidance for the year, strong market headwinds in the USA meant that we had to revise our long-term financial targets. However, 2016 was also a year in which we announced very encouraging clinical data for our key products, providing a solid foundation for future growth."" Contacts for further information Company announcement No 7 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=914,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
329,2017-02-02,"Novo Nordisks resultat af primær drift, justeret, steg med 6% i lokale valutaer i 2016","Salget steg med 6% opgjort i lokale valutaer og med 4% i kroner til 111,8 mia. kr. Resultat af primær drift var uændret rapporteret i lokale valutaer og faldt med 2% i kroner til 48,4 mia. kr. Justeret for engangsindtægten fra det delvise frasalg af NNIT og indtægten fra udlicensering af aktiver vedrørende inflammatoriske sygdomme, begge i 2015, steg resultat af primær drift opgjort i lokale valutaer med 6%, hvilket er i tråd med den seneste forventning om en vækst på ""5-7% opgjort i lokale valutaer"" fra oktober 2016. Nettoresultatet steg med 9% til 37,9 mia. kr. Udvandet resultat pr. aktie steg med 11% til 14,96 kr. Justeret for det delvise frasalg af NNIT steg nettoresultatet og udvandet resultat pr. aktie med henholdsvis 17% og 19%. I november 2016 meddelte Novo Nordisk, at Tresiba® i DEVOTE-studiet viste en sikker kardiovaskulær profil og en statistisk signifikant risikoreduktion på 40% for alvorlig hypoglykæmi sammenlignet med insulin glargin U100. Ligeledes i november 2016 fik Novo Nordisk FDA-godkendelse for Xultophy® 100/3.6, et kombinationsprodukt til dosering én gang dagligt bestående af insulin degludec (Tresiba®) og liraglutid (Victoza®). I januar 2017 fik Novo Nordisk EU-godkendelse for Fiasp®, den nye generation af hurtigtvirkende insulin. Den 1. januar 2017 overtog Lars Fruergaard Jørgensen posten som administrerende direktør efter Lars Rebien Sørensen, som fratrådte efter 34 års loyal tjeneste i virksomheden, de sidste 16 år som administrerende direktør. For 2017 forventes en rapporteret salgsvækst på 1-6% opgjort i kroner inklusive en positiv valutapåvirkning på 2 procentpoint. Den rapporterede vækst i resultat af primær drift forventes at blive 0-5% opgjort i kroner inklusive en positiv valutapåvirkning på 2 procentpoint. Bestyrelsen vil på generalforsamlingen den 23. marts 2017 fremsætte forslag om en endelig udbyttebetaling på 4,60 kr. for 2016 pr. aktie a 0,20 kr. Det forventede samlede udbytte for 2016 bliver således på 7,60 kr. pr. aktie, hvoraf 3,00 kr. pr. aktie blev udbetalt som interimudbytte i august 2016, hvilket svarer til en stigning på 19% sammenlignet med 2015. Bestyrelsen forventer desuden at iværksætte et nyt 12-måneders aktietilbagekøbsprogram på op til 16 mia. kr. Adm. direktør Lars Fruergaard Jørgensen: ""2016 var et udfordrende år. Vi opfyldte vores finansielle forventninger for året, men stærk modvind på det amerikanske marked betød, at vi blev nødt til at revidere vores langsigtede finansielle mål. 2016 var dog også et år, hvor vi offentliggjorde særdeles lovende kliniske data for vores nøgleprodukter, som giver et solidt grundlag for fremtidig Kontaktoplysninger Selskabsmeddelelse nr. 7 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=913,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
330,2017-01-30,Novo Nordisk indgår samarbejde med University of Oxford om type 2-diabetes og investerer 1 mia. kr. i nyt forskningscenter,"Bagsværd, den 30. januar 2017­ ­- University of Oxford og Novo Nordisk meddeler i dag, at de indleder et forskningssamarbejde med fokus på type 2-diabetes. Partnerskabet skal give forskere fra Novo Nordisk og University of Oxford mulighed for at samarbejde om udviklingen af lægemidler til at behandle type 2-diabetes. Som led i samarbejdet investerer Novo Nordisk i et nyt forskningscenter, som skal ligge på University of Oxfords område. Novo Nordisk Research Centre Oxford vil beskæftige op imod 100 forskere fra Novo Nordisk, som får til huse i et forskningscenter under Oxford University. Novo Nordisks samlede investering ventes at blive på omkring 1 mia. kr. (115 mio. britiske pund) over en periode på 10 år. Centret skal have fokus på innovation indenfor tidlig forskning, som har potentiale til i væsentlig grad at påvirke den fremtidige behandling af type 2-diabetes og diabetesrelaterede komplikationer. ""Samarbejdet kommer til at omfatte nogle af verdens skarpeste hjerner på diabetesområdet, som skal arbejde sammen om at identificere nye innovationsmål. Det kombinerer Novo Nordisks 90 års erfaring indenfor udvikling af diabetesbehandling med ekspertisen fra verdens førende forskere fra University of Oxford. Det er vores vision, at den unikke kombination af knowhow fra industrien og den akademiske verden vil føre til, at der udvikles en ny generation af behandling, som kan forbedre livet for mennesker med type 2-diabetes,"" siger Mads Krogsgaard Thomsen, koncerndirektør i Novo Nordisk med ansvar for forskning og udvikling. Partnerskabet skal aktivt søge at fremme udveksling af idéer mellem akademiske forskere fra University of Oxford og forskere ansat i Novo Nordisk og vil støtte forskningssamarbejdet økonomisk. Sir John Bell, Regius Professor i medicin ved University of Oxford, udtaler: ""For os er samarbejdet med Novo Nordisk en enestående mulighed for at knytte de kompetencer, der er til stede hos os, sammen med Novo Nordisks banebrydende forskning og resultater indenfor diabetes. Samarbejdet understreger vigtigheden af dels fælles forskning, dels banebrydende forskning på tværs af landegrænser. Medarbejderne på Novo Nordisk Research Centre Oxford og forskerne ved University of Oxford får mulighed for daglig interaktion og vil på den måde kunne dele viden og indsigt, som potentielt kan frembringe nye lægemidler til mennesker med type 2-diabetes og diabetesrelaterede komplikationer."" James D. Johnson, professor, er udnævnt til leder af Novo Nordisk Research Centre Oxford. Han er en verdenskendt forsker indenfor den grundlæggende biologi, der knytter sig til bygspytkirtlens langerhanske øer, insulins virkning, diabetes og relaterede sygdomme. Dr. Johnson er i dag professor ved Department of Cellular and Physiological Sciences og Department of Surgery ved University of British Columbia, Canada. Novo Nordisk og University of Oxford har samarbejdet siden 2013 gennem International Postdoctoral Fellowship Programme. Programmet blev forlænget i 2015 og vil omfatte op imod 32 fellows. Besøg novonordisk.com for fotos vedrørende denne pressemeddelelse. Afdelingen er et af de største biomedicinske forskningscentre i Europa, med over 2.500 forskningsmedarbejdere og flere end 2.800 studerende. Universitetet er nummer et i verden indenfor medicin og er hjemsted for Storbritanniens højest rangerede medicinske fakultet. Oxford er i front indenfor medicinsk forskning, hvilket gælder alt lige fra sygdommes genetiske og molekylære grundlag til de seneste fremskridt indenfor neurovidenskabelig forskning. Universitetet har en af Storbritanniens største porteføljer af kliniske studier og stor ekspertise i at omsætte forskningsresultater fra laboratoriet til klinisk praksis. Partnerskaber med de lokale NHS Trust-enheder gavner patienter ved at skabe tætte bånd mellem den medicinske forskning og sundhedsvæsenet. En stor styrke ved Oxfords medicinske fakultet er dets mangeårige netværk af kliniske forskningsenheder i Asien og Afrika, som muliggør globalt førende forskning i verdens mest presserende sundhedsudfordringer som for eksempel malaria, tuberkulose, HIV/AIDS og influenza. Oxford er desuden kendt for sine omfattende undersøgelser af, hvilken indflydelse faktorer som rygning, alkohol og kost har på kræft, hjertesygdomme og andre sygdomme. Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=918,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
331,2017-01-30,Novo Nordisk enters collaboration with University of Oxford on type 2 diabetes and invests GBP 115m in new research centre,"Bagsværd, Denmark, 30 January 2017 ­ ­- University of Oxford and Novo Nordisk today announced a landmark research collaboration focused on type 2 diabetes. The partnership will enable scientists from Novo Nordisk and University of Oxford to collaborate to discover innovative approaches for treating type 2 diabetes. As part of the collaboration, Novo Nordisk is also investing in a new research centre on the premises of the University of Oxford. The Novo Nordisk Research Centre Oxford will employ up to 100 Novo Nordisk researchers, based in an Oxford University research centre. The total investment from Novo Nordisk is expected to be around 1 billion Danish kroner (115 million British pounds) over a period of 10 years. The centre will focus on innovation within early stage research that has potential to substantially impact future treatment of type 2 diabetes and its complications. ""This collaboration brings together some of the world's sharpest minds in the field of diabetes to seek new targets for therapeutic innovation. It combines Novo Nordisk's 90 years' experience in developing treatments for diabetes with the expertise of world leading scientists from the University of Oxford. Our vision is that the unique combination of industrial and academic know-how will eventually lead to a new generation of treatments to improve the lives of people with type 2 diabetes"", said Chief Science Officer and Executive Vice President of Novo Nordisk, Mads Krogsgaard Thomsen. The collaboration will actively seek to encourage cross-fertilisation of ideas between academic researchers from the University of Oxford and researchers employed by Novo Nordisk with funds to sponsor the collaborative research. Sir John Bell, Regius Professor of Medicine, University of Oxford, said: ""We see the collaboration with Novo Nordisk as an outstanding opportunity to mix competence embedded at our campus with Novo Nordisk's groundbreaking research and results in diabetes. This collaboration underlines the importance of shared research and cutting-edge science across boundaries. Employees at Novo Nordisk Research Centre Oxford and researchers at the University of Oxford will have the opportunity for daily interaction to share knowledge and insights that will potentially produce new medicines for people living with type 2 diabetes and its complications"". James D. Johnson, Professor, PhD, has been appointed head of the Novo Nordisk Research Centre Oxford. He is a world-renowned researcher in the fundamental biology of pancreatic islets, insulin action, diabetes and related conditions. Dr Johnson is currently Professor at the Department of Cellular and Physiological Sciences and the Department of Surgery at the University of British Columbia. Novo Nordisk and University of Oxford have had a collaboration since 2013 through the International Postdoctoral Fellowship Programme. The programme was extended in 2015 and will include up to 32 fellows. Visit novonordisk.com for photos supporting this press release. About Oxford University's Medical Sciences DivisionThe Division is one of the largest biomedical research centres in Europe, with over 2,500 people involved in research and more than 2,800 students. The University is rated the best in the world for medicine, and it is home to the UK's top-ranked medical school. From the genetic and molecular basis of disease to the latest advances in neuroscience, Oxford is at the forefront of medical research. It has one of the largest clinical trial portfolios in the UK and great expertise in taking discoveries from the lab into the clinic. Partnerships with the local NHS Trusts enable patients to benefit from close links between medical research and healthcare delivery. A great strength of Oxford medicine is its long-standing network of clinical research units in Asia and Africa, enabling world-leading research on the most pressing global health challenges such as malaria, TB, HIV/AIDS and flu. Oxford is also renowned for its large-scale studies which examine the role of factors such as smoking, alcohol and diet on cancer, heart disease and other conditions. Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=917,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
332,2017-01-10,Fiasp® (hurtigtvirkende insulin aspart) godkendt i Europa,"Bagsværd, den 10. januar 2017 - Novo Nordisk meddeler i dag, at Europa-Kommissionen har givet markedsføringstilladelse til Fiasp® til behandling af diabetes hos voksne. Markedsføringstilladelsen gælder samtlige 28 EU-medlemslande. Fiasp® er varemærket for hurtigtvirkende insulin aspart. Fiasp® giver forbedret blodsukkerregulering, både generelt og i forbindelse med måltider, med en sammenlignelig sikkerhedsprofil i forhold til NovoRapid®. ""Fiasp® er en ny generation af måltidsinsulin; det er en innovativ hurtigere formulering af insulin aspart, som nøjere efterligner kroppens naturlige insulinrespons i forbindelse med måltider. De ekstra fordele, Fiasp® giver, er sammenlignelige med dem, vi så, da den sidste generation af måltidsinsuliner blev introduceret for mere end 10 år siden,"" siger Mads Krogsgaard Thomsen, koncernforskningsdirektør i Novo Nordisk. Fiasp® vil blive tilgængeligt i hætteglas, Penfill® og i pensystemet FlexTouch®. Novo Nordisk forventer at lancere Fiasp® i de første europæiske markeder i løbet af første halvår af 2017. Fiasp® (hurtigtvirkende insulin aspart) er en ultrahurtigtvirkende insulin, som nu er godkendt i Europa. Den giver en forbedret regulering af blodsukkerstigninger efter måltider og er udviklet til behandling af mennesker med type 1- og type 2-diabetes samt til pumpebehandling. Fiasp® er insulin aspart (NovoRapid®) i en ny formulering, hvor der er tilsat to nye hjælpestoffer for at sikre tidligere, bedre og hurtigere optagelse, hvilket bevirker, at insulinen virker hurtigere. Evalueringen af Fiasp® var baseret på det kliniske fase 3-program 'onset', der omfattede fire studier med tilsammen over 2.100 mennesker med type 1- og type 2-diabetes. Fiasp® har også netop modtaget markedsføringstilladelse fra de canadiske sundhedsmyndigheder, Health Canada, den 6. januar 2017, og der er indsendt registreringsansøgning i USA, Schweiz, Australien, Canada, Brasilien, Sydafrika og Argentina. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 3 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=924,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
333,2017-01-10,Fiasp® (fast-acting insulin aspart) approved in Europe,"Fiasp® is the brand name for fast-acting insulin aspart. Fiasp® provides improved mealtime and overall glucose control with a similar safety profile versus NovoRapid®. ""Fiasp® is a new-generation mealtime insulin; it is an innovative faster formulation of insulin aspart that more closely mimics the physiological insulin response around meals. The incremental benefits with Fiasp® are comparable to those observed for the last generation of mealtime insulins when introduced more than a decade ago"", said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. Fiasp® will be available in vial, Penfill® and FlexTouch® pen. Novo Nordisk expects to launch Fiasp® in the first European countries in the first half of 2017. About Fiasp®Fiasp® (fast-acting insulin aspart) is an ultra-fast rapid-acting insulin now approved in Europe that improves control of postprandial glucose (PPG) excursions and has been developed for the treatment of people with type 1 and type 2 diabetes, as well as for pump treatment. Fiasp® is insulin aspart (NovoRapid®) in a new formulation, in which two new excipients have been added to ensure earlier, greater and faster absorption, thereby providing earlier insulin action. The review of Fiasp® was based on the onset programme, a phase 3 clinical programme comprising of four trials encompassing more than 2,100 people with type 1 and type 2 diabetes. Fiasp® also received marketing authorisation from Health Canada on 6 January 2017, and has been filed for regulatory review in the US, Switzerland, Australia, Canada, Brazil, South Africa and Argentina. Further information Company announcement No 3 / 2017",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=923,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
334,2017-01-09,Novo Nordisk and Glooko partner to develop digital health solutions for people with diabetes,"Bagsværd, Denmark and Mountain View, California, 9 January 2017 - Novo Nordisk and Glooko today announced that the two companies will work together to deliver jointly-developed and branded digital health solutions for people with diabetes. The non-exclusive collaboration will combine Novo Nordisk's deep knowledge of diabetes with Glooko's digital platform and data analytics expertise. Building on Glooko's mobile and web platforms, the companies aim to deliver personalised, digital services to support people with diabetes in areas including treatment adherence and blood glucose management. The partnership's joint offerings will also assist healthcare professionals to engage and manage patients with the aid of population-wide data reporting. By integrating these offerings within its Digital Health Platform developed with IBM Watson Health, Novo Nordisk aims to generate increasingly valuable insights into diabetes management and treatment outcomes. Commenting on the agreement, Christian Kanstrup, senior vice president, Strategy, Access & Marketing, Novo Nordisk said: ""We are excited to partner with Glooko and to take another step towards delivering digital health offerings that help people with diabetes to improve their blood glucose control. Working in partnerships will furthermore enhance our ability to demonstrate the real-world value of our portfolio of diabetes treatments."" Glooko is a leading population health platform for diabetes management and enables people with diabetes to more easily track and better manage their condition using mobile, web and cloud technology. Glooko's award-winning mobile health app enables individuals to synchronise their data from a majority of the world's most popular diabetes and exercise devices including blood glucose meters. Glooko's population health application enables care teams to remotely support people with diabetes to improve patient satisfaction and outcomes at a lower cost. ""Glooko's partnership with Novo Nordisk aims to empower tens of millions of patients with digital tools to make diabetes management easier"", said Rick Altinger, Glooko CEO. ""We look forward to delivering jointly-branded capabilities that will enhance the collaboration between patient and healthcare professionals and enable us to provide joint offerings to people living with diabetes around the world."" Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=925,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
335,2017-01-09,Novo Nordisk og Glooko går sammen om at udvikle digitale sundhedsløsninger til mennesker med diabetes,"Bagsværd, Danmark, og Mountain View, Californien, USA, den 9. januar 2017 - Novo Nordisk og Glooko meddeler i dag, at de to virksomheder har indgået samarbejde om at udvikle digitale sundhedsløsninger under fælles navn til mennesker med diabetes. Den ikke-eksklusive aftale kombinerer Novo Nordisks omfattende viden om diabetes med Glookos digitale platform og ekspertise indenfor dataanalyse. Virksomhederne vil med udgangspunkt i Glookos mobil- og webbaserede platforme levere individualiserede digitale løsninger, der kan hjælpe mennesker med diabetes med f.eks. at overholde deres behandling og holde blodsukkerniveauet under kontrol. De digitale løsninger skal desuden hjælpe sundhedspersonale med at inddrage patienterne og styre patientforløb ved hjælp af tværgående datarapportering. Det er Novo Nordisks mål, at man ved at integrere disse produkter i virksomhedens digitale sundhedsplatform, som bliver udviklet sammen med IBM Watson Health, opnår stadig mere værdifuld viden om behandling og behandlingsresultater på diabetesområdet. Christian Kanstrup, direktør for Strategy, Access & Marketing i Novo Nordisk, siger i en kommentar til aftalen: ""Vi glæder os til samarbejdet med Glooko, som vil bringe os endnu et skridt tættere på at kunne levere digitale sundhedsløsninger, der kan hjælpe mennesker med diabetes til at opnå bedre blodsukkerkontrol. Samarbejder som dette vil desuden øge vores muligheder for at dokumentere værdien af vores diabetesprodukter i den virkelige verden."" Glooko er en førende sundhedsplatform indenfor diabetesbehandling, som gør det nemmere for mennesker med diabetes at overvåge deres sundhedsstatus ved hjælp af mobil-, web- og cloud-teknologi. Glookos prisvindende mobile sundhedsapp sætter brugerne i stand til at synkronisere deres data fra de fleste af verdens mest populære motionstrackere og diabetesdevices, herunder blodsukkermålere. Glookos folkesundhedsapplikation gør det muligt for sundhedspersonale at hjælpe mennesker med diabetes via fjernsupport med det formål at sikre øget patienttilfredshed og bedre behandlingsresultater med mindre omkostninger. ""Målet for Glookos samarbejde med Novo Nordisk er at give millioner af patienter større indflydelse på deres egen behandling ved hjælp af digitale værktøjer, som gør diabetesbehandlingen nemmere,"" siger Rick Altinger, administrerende direktør for Glooko. ""Vi glæder os til at levere digitale sundhedsløsninger under fælles navn, som vil forbedre samarbejdet mellem patienter og sundhedspersonale og sætte os i stand til at levere fælles løsninger til mennesker med diabetes verden over."" Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=926,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
336,2016-12-05,Novo Nordisk indsender registreringsansøgning i USA og EU for semaglutid til dosering én gang ugentligt til behandling af type 2-diabetes,"Bagsværd, den 5. december 2016 - Novo Nordisk meddeler i dag, at virksomheden har indsendt registreringsansøgninger til de amerikanske sundhedsmyndigheder (FDA) og Det Europæiske Lægemiddelagentur (EMA) for semaglutid, en ny GLP-1-analog, som doseres én gang ugentligt, til behandling af voksne med type 2-diabetes. Ansøgningerne er baseret på resultaterne fra det kliniske udviklingsprogram SUSTAIN, som omfattede flere end 8.000 voksne med type 2-diabetes. I SUSTAIN-programmet blev semaglutid til dosering én gang ugentligt undersøgt i kombination med diabeteslægemidler i tabletform og basalinsulin. Semaglutid viste statistisk signifikant og varig blodsukkerkontrol sammenlignet med sitagliptin, exenatid extended-release, insulin glargin U100 til dosering én gang dagligt og placebo. Endvidere viste det kardiovaskulære sikkerhedsstudie, SUSTAIN 6, en statistisk signifikant reduktion af risikoen for kardiovaskulære hændelser sammenlignet med placebo, når det blev givet som tillægsbehandling til standardbehandling hos patienter med høj risiko for kardiovaskulære hændelser. Semaglutid viste desuden statistisk signifikant større reduktioner i gennemsnitsvægten i forhold til sammenligningsprodukterne. Semaglutid til dosering én gang ugentligt havde på tværs af SUSTAIN-programmet en sikker og veltolereret profil, hvor den mest almindelige bivirkning var kvalme. ""Det er stadig en stor udfordring for voksne med type 2-diabetes at opnå en god blodsukkerregulering, vægttab og en reduktion af risikoen for hjerte-kar-tilfælde,"" siger Mads Krogsgaard Thomsen, koncerndirektør med ansvar for forskning og udvikling i Novo Nordisk. ""Vi er rigtig glade for denne registreringsansøgning, fordi resultaterne fra SUSTAIN-programmet viser, at semaglutid til dosering én gang ugentligt har potentiale til yderligere at forbedre behandlingen af voksne med type 2-diabetes."" Semaglutid er en ny analog af det naturlige hormon glukagonlignende peptid-1 (GLP-1), som stimulerer udskillelsen af insulin og reducerer sekretionen af glukagon på en glukoseafhængig måde, samt nedsætter appetit og madindtag. Novo Nordisk forventer at levere semaglutid til dosering én gang ugentligt i en præfyldt doseringspen baseret på den samme teknologiplatform som FlexTouch®. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Læs hele meddelelsen Yderligere information Selskabsmeddelelse nr. 86 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=938,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
337,2016-12-05,Novo Nordisk files for regulatory approval of once-weekly semaglutide in the US and EU for the treatment of type 2 diabetes,"Bagsværd, Denmark, 5 December 2016 - Novo Nordisk today announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for semaglutide, a new glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, for the treatment of adults with type 2 diabetes. The submission is based on the results from the SUSTAIN clinical trial programme, which included more than 8,000 adults with type 2 diabetes. In the SUSTAIN programme, once-weekly semaglutide was studied in combination with oral-antidiabetic agents and basal insulin. Semaglutide demonstrated statistically significant and sustained blood glucose control compared to sitagliptin, exenatide extended-release, once-daily insulin glargine U100 and placebo. Furthermore, the cardiovascular outcomes trial, SUSTAIN 6, demonstrated a statistically significant cardiovascular risk reduction compared to placebo, as add-on to standard of care in patients with high cardiovascular risk. In addition, semaglutide demonstrated statistically significantly greater reductions in mean body weight versus comparators. Across the SUSTAIN clinical trial programme, once-weekly semaglutide had a safe and well tolerated profile with the most common adverse event being nausea. ""Achieving blood glucose control, weight loss and reducing the risk of cardiovascular events remains a significant challenge for adults with type 2 diabetes,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""We are excited with this regulatory filing, as results from the SUSTAIN programme show that once-weekly semaglutide has the potential to further improve the treatment of adults with type 2 diabetes."" About semaglutideSemaglutide is a new once-weekly analogue of human GLP-1 that stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner, while decreasing appetite and food intake. Novo Nordisk intends to make once-weekly semaglutide available in a prefilled delivery device based on the same technology platform as FlexTouch®. Read the full announcement Further information Company announcement No 86 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=937,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
338,2016-12-03,NovoSeven® resolved 96.5% of bleeds when initiated within one hour after bleed onset in people with haemophilia A or B with inhibitors,"Bagsværd, Denmark, 3 December 2016 - Novo Nordisk today announced that NovoSeven® (rFVIIa), a portable room temperature stable recombinant activated factor VIIa, resolved 96.5% of bleeds when initiated within one hour after onset of bleeding, demonstrating efficacy of early treatment in people with haemophilia A or B with inhibitors.1 Efficacy also remained high for bleeds treated after 4 hours.1 A subanalysis of the SMART-7(TM) study, evaluating the efficacy of NovoSeven® in a real-world setting, was presented today at the 58th American Society of Haematology (ASH) annual meeting. Read the full release Further information References ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=942,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
339,2016-12-03,"NovoSeven® standser 96,5% af blødningerne, når behandling iværksættes indenfor en time efter blødningens start hos mennesker med hæmofili A eller B med inhibitorer","Bagsværd, den 3. december 2016 - Novo Nordisk præsenterer i dag resultater, der viser, at NovoSeven® (rFVIIa), et rekombinant aktiveret faktor VIIa-produkt, som er stabilt ved stuetemperatur og dermed transportabelt, standser 96,5% af blødningerne, når behandlingen iværksættes indenfor en time efter, at blødningen er opstået. Dette dokumenterer effekt af tidlig behandling af mennesker med hæmofili A eller B med inhibitorer.1 Effekten forblev også høj for blødninger, der blev behandlet efter fire timer.1 En subanalyse af SMART-7(TM) studiet, som har undersøgt effekten af NovoSeven® i normal klinisk praksis, præsenteres i dag på det 58. årlige møde i American Society of Hematology (ASH). Læs hele meddelelsen  Yderligere information Referencer 1.    Benson, G. et al. Benefit of early treatment with Room Temperature Stable Recombinant Activated Factor VII (rFVIIa) in patients with Hemophilia A or B with inhibitors: Subgroup Analysis from the Prospective, Post-Authorization, Non-interventional SMART-7(TM) Study. Poster number 1439. 58th American Society of Haematology (ASH) annual meeting. 3 December 2016.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=941,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
340,2016-11-29,Novo Nordisk A/S: Tresiba® viser en sikker kardiovaskulær profil og reducerer risikoen for alvorlig hypoglykæmi sammenlignet med insulin glargin U100 i DEVOTE-studiet,"Bagsværd, den 29. november 2016 - Novo Nordisk offentliggør i dag de overordnede resultater fra DEVOTE-studiet, et randomiseret, dobbeltblindet og hændelsesdrevet langtidsstudie, der er gennemført med det formål at bekræfte den kardiovaskulære sikkerhed for Tresiba® (insulin degludec) sammenlignet med insulin glargin U100 givet som supplement til standardbehandling. I studiet blev flere end 7.500 mennesker med type 2-diabetes med høj risiko for alvorlige kardiovaskulære hændelser behandlet i en periode på ca. to år. Studiet opfyldte sit primære mål, idet det viste ikke-inferiøritet med hensyn til alvorlige kardiovaskulære hændelser med Tresiba® sammenlignet med insulin glargin U100. Studiet bekræftede dermed resultaterne af interimanalysen af DEVOTE, som blev indsendt til de amerikanske sundhedsmyndigheder, FDA, i marts 2015 og dannede grundlag for godkendelsen af Tresiba® og Ryzodeg® 70/30 i USA i september 2015. Det primære endepunkt for DEVOTE-studiet var defineret som den første forekomst af et sammensat kardiovaskulært endepunkt bestående af kardiovaskulært dødsfald, ikke-dødeligt myokardieinfarkt (hjerteanfald) eller ikke-dødeligt slagtilfælde og viste en risikoratio på 0,91 til fordel for Tresiba® i forhold til insulin glargin U100 med ingen statistisk signifikant forskel mellem de to behandlinger. Fra et gennemsnitligt langtidsblodsukkerniveau (HbA1c) ved studiets begyndelse på 8,4% viste studiet en sammenlignelig reduktion med Tresiba® sammenlignet med insulin glargin U100 med en behandlingsforskel ved studiets afslutning på 0,01 procentpoint mellem de to behandlingsgrupper. Kravene for objektivt at sammenligne forekomsten af hypoglykæmi (lavt blodsukker) mellem de to behandlinger var dermed opfyldt. I studiet viste Tresiba® superioritet med hensyn til det bekræftende sekundære endepunkt vedrørende alvorlig hypoglykæmi: 27% færre deltagere i gruppen, der blev behandlet med Tresiba®, oplevede en episode af alvorlig hypoglykæmi, hvilket samlet set resulterede i en 40% reduktion i det samlede antal episoder af adjudikeret alvorlig hypoglykæmi. Endvidere oplevede deltagere i gruppen, der blev behandlet med Tresiba®, en 54% relativ reduktion i forekomsten af natlig alvorlig hypoglykæmi. Disse forskelle var alle statistisk signifikante.* Tresiba® forekom at have en sikker og veltolereret profil, der var konsistent med tidligere kliniske studier gennemført med Tresiba®. ""Vi er meget glade for, at DEVOTE-studiet viser den kardiovaskulære sikkerhed for Tresiba® og samtidig bekræfter fordelen med hensyn til hypoglykæmi for denne nye generation af insulin. Alvorlig hypoglykæmi er stadig den alvorligste behandlingsrelaterede risiko i forbindelse med insulinbehandling. Resultaterne fra DEVOTE styrker yderligere potentialet for, at Tresiba® kan blive den nye standardbehandling indenfor basalinsulinbehandling,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. Novo Nordisk forventer at offentliggøre de detaljerede resultater fra DEVOTE-studiet på et videnskabeligt møde og indsende konklusionerne til drøftelse med de regulatoriske myndigheder i første halvår af 2017. Der vil den 30. november 2016 kl. 08.00 CET blive afholdt en telekonference, som vil være tilgængelig for investorer via et link på investorsektionen på novonordisk.com. DEVOTE er et langtids-, multicenter-, multinationalt, randomiseret, dobbeltblindet, parallelgruppe- og hændelsesdrevet studie, som er gennemført med det formål at bekræfte den kardiovaskulære sikkerhed for Tresiba® (insulin degludec) sammenlignet med insulin glargin U100. I studiet blev 7.637 mennesker med type 2-diabetes med høj risiko for at udvikle hjerte-kar-sygdom randomiseret til behandling med enten Tresiba® eller insulin glargin U100 i hætteglas som supplement til standardbehandling. DEVOTE-studiet blev iværksat som opfølgning på et Complete Response Letter i februar 2013 fra FDA, som udbad sig yderligere kardiovaskulære data fra en dedikeret undersøgelse af forekomsten af hjerte-kar-sygdom, før registreringsansøgningerne for Tresiba® og Ryzodeg® 70/30 kunne færdigbehandles. Tresiba® og Ryzodeg® 70/30 blev godkendt i USA i september 2015 på basis af en interimanalyse af DEVOTE. Tresiba® (insulin degludec) er en basalinsulin til dosering én gang dagligt med en virkningsvarighed på mindst 42 timer. Tresiba® tages én gang dagligt når som helst i løbet af dagen. Patienter, som glemmer en dosis Tresiba®, kan tage den, når de opdager forglemmelsen, men med mindst otte timer mellem doserne. Tresiba® blev godkendt af registreringsmyndighederne første gang i september 2012 og er siden blevet godkendt i flere end 80 lande verden over. Det blev godkendt af FDA i USA i september 2015. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. * I dette afsnit skal 54% erstattes af 53% Yderligere information Selskabsmeddelelse nr. 84 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=943,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
341,2016-11-29,Novo Nordisk A/S: Tresiba® demonstrates a safe cardiovascular profile and reduces the risk of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial,"Bagsværd, 29 November 2016 - Today, Novo Nordisk announced the headline results from the DEVOTE trial, a long-term, randomised, double-blinded and event-driven trial conducted to confirm the cardiovascular safety of Tresiba® (insulin degludec) compared to insulin glargine U100 when added to standard of care. In the trial, more than 7,500 people with type 2 diabetes at high risk of major adverse cardiovascular events were treated for a period of approximately two years. The trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with Tresiba® compared to insulin glargine U100. The trial thereby confirmed the results of the DEVOTE interim analysis submitted to the US Food and Drug Administration (FDA) in March 2015, on the basis of which Tresiba® and Ryzodeg® 70/30 were approved in the US in September 2015. The primary endpoint of the DEVOTE study was defined as the MACE composite outcome of the first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke and showed a hazard ratio of 0.91 in favour of Tresiba® relative to insulin glargine U100, with no statistically significant difference between the two treatments. From a mean HbA1c baseline of 8.4%, the trial showed a similar reduction with Tresiba® compared to insulin glargine U100 with an end-of-trial treatment difference of 0.01 percentage-points between the two treatment arms, thus fulfilling the requirements for objectively comparing hypoglycaemia rates between the two treatments. In the trial, Tresiba® demonstrated superiority on the secondary confirmatory endpoint of severe hypoglycaemia: 27% fewer patients in the Tresiba® treated group experienced an episode of severe hypoglycaemia, resulting in a 40% overall reduction of total episodes of adjudicated severe hypoglycaemia. Furthermore, patients in the Tresiba® treated group experienced a 54% relative reduction in the rate of nocturnal severe hypoglycaemia. These differences were all statistically significant.* Tresiba® appeared to have a safe and well-tolerated profile consistent with previous clinical studies conducted with Tresiba®. ""We are very pleased that the DEVOTE study demonstrates the cardiovascular safety of Tresiba® and also confirms the hypoglycaemia benefit of this new generation insulin. Severe hypoglycaemia remains the most serious treatment risk related to insulin therapy. The DEVOTE results further strengthen the potential of Tresiba® to become the new standard of care within basal insulin therapy,"" says Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. Novo Nordisk expects to present the detailed results of the DEVOTE trial at a scientific meeting and submit the findings for review with regulatory authorities during the first half of 2017. On 30 November 2016 at 8.00 am CET, corresponding to 2.00 am EST, a conference call for investors will be held. Investors will be able to listen in via a link on the investor section of novonordisk.com. DEVOTE is a long-term, multi-centre, multi-national, randomised, double-blinded, parallel group and event-driven trial conducted to confirm the cardiovascular safety of Tresiba® (insulin degludec) compared to insulin glargine U100. In the trial, 7,637 people with type 2 diabetes at high risk of cardiovascular disease were randomised to treatment with either Tresiba® or insulin glargine U100 in vial in addition to standard of care. The DEVOTE trial has been conducted in response to a Complete Response Letter received from the FDA in February 2013 requesting additional cardiovascular data from a dedicated cardiovascular outcomes trial before the review of the New Drug Applications for Tresiba® and Ryzodeg® 70/30 could be concluded. Tresiba® and Ryzodeg® 70/30 were approved in the US in September 2015 on the basis of an interim analysis of DEVOTE. Tresiba® (insulin degludec) is a once-daily basal insulin that provides duration of action of at least 42 hours. Tresiba® is taken once daily, at any time of day. Patients who miss or are delayed in taking their dose of Tresiba® can take their dose as soon as they remember, but ensuring there are at least eight hours between doses. Tresiba® received its first regulatory approval in September 2012 and has since been approved in more than 80 countries globally. It was approved by the US FDA in September 2015. Further information Company announcement No 84 / 2016 * in this section 54% must be replaced by 53%",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=944,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
342,2016-11-21,Novo Nordisk receives US FDA approval for Xultophy® 100/3.6,"Bagsværd, Denmark, 21 November 2016 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Xultophy® 100/3.6. Xultophy® 100/3.6 is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 50 units daily) or liraglutide (less than or equal to 1.8 mg daily). Xultophy® 100/3.6, the approved brand name for IDegLira in the US, is a once-daily, single injection fixed combination of long-acting insulin degludec (Tresiba®) and the GLP-1 analogue liraglutide (Victoza®). In the DUAL phase 3 clinical trial programme, Xultophy® 100/3.6 consistently showed an improvement of glycaemic control in adults with type 2 diabetes uncontrolled on liraglutide or basal insulin therapy. For adults inadequately controlled on insulin glargine U100, treatment with Xultophy® 100/3.6 demonstrated a reduction in HbA1c of 1.7% after 26 weeks. Xultophy® 100/3.6 can be taken at the same time each day with or without food and will be available in a prefilled pen. ""We are pleased with the approval of Xultophy® 100/3.6 and look forward to launching it in the US in the first half of 2017"", said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""We believe Xultophy® 100/3.6 offers significant benefits and is an important and convenient treatment option especially for people not achieving sufficient glycaemic control with basal insulin"". The approval follows the recommendation of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC), which voted 16-0 in favour of an approval of Xultophy® 100/3.6 for the treatment of adults with type 2 diabetes, at its meeting on 24 May 2016. About Xultophy® 100/3.6Xultophy® 100/3.6 is a once-daily, single injection fixed combination of long-acting insulin degludec (Tresiba®) and the GLP-1 analogue liraglutide (Victoza®). The Xultophy® 100/3.6 pen delivers doses from 10 to 50 units with each injection. Each unit of Xultophy® 100/3.6 contains 1 unit of insulin degludec and 0.036 mg of liraglutide. Further information Company announcement No 82 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=947,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
343,2016-11-21,Novo Nordisk får FDA-godkendelse for Xultophy® 100/3.6 i USA,"Bagsværd, den 21. november 2016 - Novo Nordisk meddeler i dag, at de amerikanske sundhedsmyndigheder (FDA) har godkendt registreringsansøgningen for Xultophy® 100/3.6. Xultophy® 100/3.6 er indiceret som supplement til diæt og motion med det formål at opnå forbedret glykæmisk kontrol hos voksne med type 2-diabetes, som er utilstrækkeligt reguleret med basalinsulin (mindre end 50 enheder dagligt) eller liraglutid (1,8 mg eller mindre dagligt). Xultophy® 100/3.6 (det godkendte varemærke for IDegLira i USA) er et kombinationsprodukt til dosering én gang dagligt i én injektion bestående af langtidsvirkende insulin degludec (Tresiba®) og GLP-1-analogen liraglutid (Victoza®). I det kliniske fase 3-program DUAL viste Xultophy® 100/3.6 konsistent en forbedring af den glykæmiske kontrol hos voksne med type 2-diabetes, som var utilstrækkeligt reguleret med liraglutid eller basalinsulin. Hos voksne, som var utilstrækkeligt reguleret med insulin glargin U100, viste behandling med Xultophy® 100/3.6 en reduktion i langtidsblodsukkerniveauet (HbA1c) på 1,7% efter 26 uger. Xultophy® 100/3.6 kan tages på samme tidspunkt hver dag med eller uden mad og vil blive tilgængeligt i en præfyldt injektionspen. ""Vi er glade for godkendelsen af Xultophy® 100/3.6 og ser frem til at lancere det i USA i første halvår af 2017,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Vi mener, at Xultophy® 100/3.6 giver væsentlige fordele og er en vigtig og bekvem behandlingsmulighed navnlig for mennesker, som ikke kan regulere deres blodsukker tilfredsstillende ved hjælp af basalinsulin."" Godkendelsen kommer, efter at FDA's rådgivende komite Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) på et møde den 24. maj 2016 med stemmerne 16-0 anbefalede godkendelse af Xultophy® 100/3.6 til behandling af voksne med type 2-diabetes. Xultophy® 100/3.6 er et kombinationsprodukt til dosering én gang dagligt i én injektion bestående af langtidsvirkende insulin degludec (Tresiba®) og GLP-1-analogen liraglutid (Victoza®). Xultophy® 100/3.6-pennen kan levere fra 10 til 50 dosistrin i én injektion. Et dosistrin Xultophy® 100/3.6 indeholder 1 enhed insulin degludec og 0,036 mg liraglutid. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 82 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=948,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
344,2016-11-14,Novo Nordisk forlænger og udvider program for børn med type 1-diabetes i udviklingslande,"Bagsværd, den 14. november 2016 ­- Novo Nordisk har besluttet at forlænge sit Changing Diabetes® in Children-program med fire år - et program, som giver børn med type 1-diabetes i udviklingslande adgang til behandling og gratis insulin. Samtidig kommer fem nye lande med i programmet: Cambodia, Elfenbenskysten, Myanmar, Senegal og Sudan. Ambitionen er, at programmet i 2020 over en 11-årig periode har hjulpet flere end 20.000 børn. For 10 år siden var den forventede levetid for et barn med type 1-diabetes i afrikanske lande syd for Sahara ofte mindre end et år[1]. Det fik Novo Nordisk til at etablere Changing Diabetes® in Children-programmet, som skal bidrage til at forbedre kvaliteten af behandlingen og mulighederne for at diagnosticere sygdommen. Siden programmet blev etableret i 2009, har 13.700 børn i ni lande i Afrika og Sydøstasien haft adgang til diabetesbehandling og gratis human insulin. ""Changing Diabetes® in Children-programmet har været ikonisk,"" siger professor Azad Khan, formand for Diabetic Association of Bangladesh. ""Det har ændret tilværelsen for børn med type 1-diabetes i Bangladesh. Deres overlevelse er afhængig af, at de får insulin og bliver undervist i, hvordan de skal håndtere sygdommen. Alt dette sørger programmet for."" Et stort antal børn i programmet har nu fået deres diabetes under kontrol, så de kan leve et godt og sundt liv. Indtil nu er der etableret 108 klinikker, og flere end 7.000 læger og andet sundhedspersonale er blevet undervist i diabetesbehandling. Udover at donere gratis insulin har Changing Diabetes® in Children-programmet til formål at støtte udviklingen af de lokale sundhedssystemer. Lars Rebien Sørensen, administrerende direktør for Novo Nordisk, siger: ""Udlevering af gratis medicin kan ikke i sig selv løse komplekse sundhedsmæssige udfordringer. Lige fra vi lancerede programmet, har vi derfor arbejdet tæt sammen med lokale partnere om at levere bæredygtige behandlingsløsninger sammen med insulinen for at forbedre tilværelsen for børn med type 1-diabetes både nu og i fremtiden."" De globale partnere i programmet er Novo Nordisk, Roche, International Society for Pediatric and Adolescent Diabetes (ISPAD) og Verdensdiabetesfonden (WDF). I hvert af de ni lande, der allerede deltager (Cameroun, Den Demokratiske Republik Congo, Etiopien, Guinea, Kenya, Tanzania, Uganda, Bangladesh og Indien), drives programmet som et privat-offentligt partnerskab med en gruppe lokale samarbejdspartnere. Landenes sundhedsministerier spiller en afgørende rolle i at sikre, at Changing Diabetes® forankres i det eksisterende sundhedssystem. Yderligere information Referencer [1] Beran, Yudkin, Diabetes care in sub-Saharan Africa, 2006 http://www.sciencedirect.com/science/article/pii/S0140673606697043",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=954,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
345,2016-11-14,"Novo Nordisk expands programme to reach 20,000 children with diabetes in developing countries","Bagsværd, Denmark, 14 November 2016 ­- Today, Novo Nordisk announced a four-year extension of its Changing Diabetes® in Children programme which provides access to diabetes care and free insulin to children with type 1 diabetes in developing countries. The expansion sees five new countries join the programme; Cambodia, Ivory Coast, Myanmar, Senegal and Sudan. By 2020, more than 20,000 children over the course of 11 years will have benefited from the programme. Ten years ago, a child in Sub-Saharan Africa diagnosed with type 1 diabetes often had a life expectancy of less than a year[i]. In response, Novo Nordisk established the Changing Diabetes® in Children programme to support sustainable quality care and improved diagnosis of the condition. Since the start of the programme in 2009, 13,700 children in nine countries in Africa and South-East Asia have received free human insulin and access to diabetes care. ""The Changing Diabetes® in Children programme has been iconic,"" says Professor Azad Khan, president of the Diabetic Association of Bangladesh. ""It has changed the lives of children with type 1 diabetes in Bangladesh. Their survival depends on the supply of insulin as well as education on how to cope with diabetes, and the programme provides all of this."" A large number of children enrolled in the program are experiencing good control and have a chance to lead healthier lives. To date, 108 clinics have been established and more than 7,000 healthcare professionals have been trained in diabetes care. In addition to providing access to insulin, the Changing Diabetes® in Children programme aims to support the development of sustainable healthcare systems. Lars Rebien Sørensen, president and CEO of Novo Nordisk, expressed: ""The provision of free medicine alone doesn't solve complex healthcare challenges. From the outset of this programme, we have therefore worked closely with local partners to deliver sustainable solutions alongside insulin to improve the lives of children with type 1 diabetes both now and in the future."" About Changing Diabetes® in ChildrenThe global partners in the programme are Novo Nordisk, Roche, the International Society for Pediatric and Adolescent Diabetes (ISPAD) and the World Diabetes Foundation (WDF). In each of the nine already established countries (Cameroon, Democratic Republic of Congo, Ethiopia, Guinea, Kenya, Tanzania, Uganda, Bangladesh and India), the programme is implemented as a public-private partnership with a group of local partners. The national ministries of health in these countries play a key role to ensure that Changing Diabetes® in Children is anchored within the existing healthcare system. Further information References [i] Beran, Yudkin, Diabetes care in sub-Saharan Africa, 2006 http://www.sciencedirect.com/science/article/pii/S0140673606697043",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=953,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
346,2016-11-12,Tresiba® viser lavere dag-til-dag- og døgnvariation i blodsukkersænkende effekt sammenlignet med insulin glargin U300,"Bagsværd, den 12. november 2016 - Resultater fra et farmakodynamisk studie, der sammenlignede Tresiba® (insulin degludec) med insulin glargin U300 hos mennesker med type 1-diabetes, viser, at behandling med Tresiba® (0,4 U/kg) medførte lavere dag-til-dag- og døgnvariation* i blodsukkersænkende effekt sammenlignet med insulin glargin U300 (0,4 U/kg).[1] Disse resultater er netop blevet præsenteret på 16th Annual Diabetes Technology Meeting i Bethesda, USA. Studiet viste, at dag-til-dag-variationen var ca. fire gange lavere med Tresiba® end med insulin glargin U300. Døgnvariationen var ca. 40% lavere med Tresiba®, hvor den blodsukkersænkende effekt var mere jævnt fordelt over 24 timer sammenlignet med insulin glargin U300.1 Desuden viste resultaterne, at insulin glargin U300 var 30% mindre potent vurderet ud fra den totale blodsukkersænkende effekt sammenlignet med Tresiba®.1 ""Store sammenligningsstudier er nødvendige for at vurdere effekten og sikkerheden ved nye insuliner; men farmakodynamiske studier er også vigtige, fordi de hjælper os til en bedre forståelse af de farmakologiske egenskaber. Jo mere stabil den blodsukkersænkende profil er, jo nemmere er insulinen at titrere, og det kan bidrage til at nedsætte risikoen for hypoglykæmi og hyperglykæmi hos patienter med diabetes,"" siger dr. Tim Heise, chefforsker ved Profil Institut i Tyskland. Dette var et fase 1-, enkeltcenter-, dobbeltblindet overkrydsningsstudie gennemført over to forsøgsperioder, hvor deltagere med type 1-diabetes blev tilfældigt fordelt til at modtage Tresiba® eller insulin glargin U300 i en dosis på 0,4 U/kg/dag. I alt 57 deltagere gennemførte studiet. Begge behandlinger blev administreret én gang dagligt i 12 dage, efterfulgt af en 7-21-dages periode, hvor deltagerne ikke modtog studiebehandling, før de blev krydset over til den anden behandling i yderligere 12 dage. For at vurdere den farmakodynamiske variation i den blodsukkersænkende effekt for Tresiba® og insulin glargin U300 gennemgik hver deltager seks 24-timers blodsukker-clampforsøg (tre i løbet af hver 12-dages forsøgsperiode) gennemført ved steady state (hvor deltagernes blodsukker holdes stabilt).1 Tresiba® er en basalinsulin til dosering én gang dagligt med en virkningsvarighed på mere end 42 timer.[2],[3] Det er vigtigt for mennesker med type 1- og type 2-diabetes at etablere en rutine for deres insulinbehandling, men i situationer, hvor det ikke er muligt at tage insulin på det sædvanlige tidspunkt af dagen, giver Tresiba® mulighed for fleksibilitet med hensyn til injektionstidspunktet.2,[4],[5] Tresiba® blev godkendt af registreringsmyndighederne første gang i september 2012 og er siden blevet godkendt i flere end 80 lande verden over. Senest blev det godkendt af FDA i USA den 26. september 2015. * døgnvariationen blev vurderet i en post hoc-analyse og beregnet som den relative fluktuation for at tage højde for forskellen i potens mellem Tresiba® og insulin glargin U300. Yderligere information   [1]    Heise T, Nørskov M, Nosek L, et al. Insulin degludec: Four-times lower pharmacodynamic within-patient variability compared to insulin glargine U300 in type 1 diabetes. Annual Diabetes Technology Meeting 2016, Poster presentation. [2]    EMA. Tresiba Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002498/WC500138940.pdf Last accessed: November 2016. [3]    Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clinical Pharmacokinetics. 2014; 53:787-800. [4]    Meneghini L, Atkin SL, Gough SC, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013; 36:858-864. [5]    Mathieu C, Hollander P, Miranda-Palma B, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. The Journal of Clinical Endocrinology & Metabolism. 2013; 98:1154-1162.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=956,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
347,2016-11-12,Tresiba® demonstrated lower day-to-day and within-day variability in glucose-lowering effect compared with insulin glargine U300,"Bagsværd, Denmark, 12 November 2016 - Results from a study comparing the pharmacodynamics of Tresiba® (insulin degludec) with insulin glargine U300 in people with type 1 diabetes were presented today at the 16th Annual Diabetes Technology Meeting in Bethesda, US. Treatment with Tresiba® (0.4 U/kg) resulted in lower day-to-day and within-day variability* in glucose-lowering effect, compared with insulin glargine U300 (0.4 U/kg).1 The study showed that the day-to-day variability was approximately four times lower with Tresiba® than with insulin glargine U300. Within-day variability was approximately 40% lower with Tresiba®, with the glucose-lowering effect being more evenly distributed across 24 hours compared to insulin glargine U300.1 In addition, insulin glargine U300 showed a 30% lower potency assessed by the total glucose-lowering effect compared to Tresiba®.1 ""While large-scale head-to-head trials are needed to compare the efficacy and safety of new insulins, pharmacodynamic studies are important, as they enable us to better understand their pharmacological properties. The more stable the glucose lowering profile of insulin, the easier it is to titrate and can help reduce the risk of hypoglycaemia and hyperglycaemia in patients with diabetes,"" says Dr Tim Heise, lead scientist at the Profil Institute in Germany. About the NN1250-4227 study This was a phase 1, single-centre, double-blind, two-period, cross-over trial, where people with type 1 diabetes were randomly assigned to receive Tresiba® or insulin glargine U300 at a dose of 0.4 U/kg/day. A total of 57 people completed the study. Both treatments were administered once daily for 12 days, followed by a 7-21 day period in which the participants received no study treatment, before being crossed over to receive the other treatment for a further 12 days. In order to assess the pharmacodynamic variability in the glucose-lowering effect of Tresiba® and insulin glargine U300, each participant underwent six 24-hour glucose clamps (three during each 12-day study period) performed at steady state (where glucose levels are stabilised in the participants).1 About Tresiba®Tresiba® is a once-daily basal insulin that provides a duration of action beyond 42 hours.2,3 It is important for people with type 1 and type 2 diabetes to establish a routine for insulin treatment. On occasions when administration at the same time of day is not possible, Tresiba® allows for flexibility in day-to-day dosing time when needed.2,4,5 Tresiba® received its first regulatory approval in September 2012 and has since been approved in more than 80 countries globally. It was most recently approved by the FDA in the United States on 26 September 2015. References 1.   Heise T, Nørskov M, Nosek L, et al. Insulin degludec: Four-times lower pharmacodynamic within-patient variability compared to insulin glargine U300 in type 1 diabetes. Annual Diabetes Technology Meeting 2016, Poster presentation 2.   EMA. Tresiba Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002498/WC500138940.pdf Last accessed: November 2016 3.   Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clinical Pharmacokinetics. 2014; 53:787-8004.   Meneghini L, Atkin SL, Gough SC, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013; 36:858-8645.   Mathieu C, Hollander P, Miranda-Palma B, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. The Journal of Clinical Endocrinology & Metabolism. 2013; 98:1154-1162",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=955,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
348,2016-11-11,Novo Nordisk får positiv udtalelse fra de europæiske lægemiddelmyndigheder om Fiasp® (hurtigtvirkende insulin aspart) til behandling af diabetes,"Bagsværd, den 11. november 2016 - Novo Nordisk meddeler i dag, at Udvalget for Humanmedicinske Lægemidler (CHMP) under Det Europæiske Lægemiddelagentur (EMA) har afgivet en positiv udtalelse om brug af Fiasp® (hurtigtvirkende insulin aspart) med anbefaling om markedsføringstilladelse til behandling af voksne med type 1- og type 2-diabetes. CHMP anbefaler, at Fiasp®, det planlagte varemærke for hurtigtvirkende insulin aspart, indiceres til brug som boluskomponenten i basal-bolus-behandling i kombination med basalinsulin og til kontinuerlig subkutan infusion via en insulinpumpe. Novo Nordisk har udviklet Fiasp® som en måltidsinsulin med en tidligere og større blodsukkersænkende effekt end NovoRapid® (insulin aspart). ""Vi mener, at Fiasp® repræsenterer en vigtig evolution indenfor måltidsinsulin, som kan adressere det udækkede medicinske behov hos mennesker, der har behov for en endnu bedre regulering af blodsukkeret omkring måltiderne eller større doseringsfleksibilitet,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. Novo Nordisk forventer at modtage endelig markedsføringstilladelse fra Europa-Kommissionen i første kvartal af 2017. Fiasp® (hurtigtvirkende insulin aspart) er en måltidsinsulin til forbedret regulering af blodsukkerstigninger efter måltider og er udviklet til behandling af mennesker med type 1- og type 2-diabetes samt til pumpebehandling. Fiasp® er insulin aspart (NovoRapid®) i en ny formulering, hvor der er tilsat to nye hjælpestoffer for at sikre tidlig og hurtig optagelse, hvilket bevirker, at insulinen virker hurtigere. Evalueringen af Fiasp® var baseret på det kliniske fase 3-program 'onset', der omfatter fire studier med tilsammen over 2.100 mennesker med type 1- og type 2-diabetes. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Selskabsmeddelelse nr. 78 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=959,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
349,2016-11-11,Novo Nordisk receives positive opinion from the European regulatory authorities for Fiasp® (fast-acting insulin aspart) for the treatment of diabetes,"Bagsværd, Denmark, 11 November 2016 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), adopted a positive opinion for the use of Fiasp® (fast-acting insulin aspart), recommending marketing authorisation for the treatment of adults with type 1 and type 2 diabetes. The CHMP recommends Fiasp®, the intended brand name for fast-acting insulin aspart, to be indicated for use as the bolus component of basal-bolus therapy in combination with basal insulin and for continuous subcutaneous insulin infusion via an insulin pump. Novo Nordisk has developed Fiasp® as mealtime insulin with an earlier and greater glucose-lowering effect than NovoRapid® (insulin aspart). ""We believe Fiasp® provides an important evolution in mealtime insulin, which can address the unmet medical need for people requiring further improved blood glucose control around meals or flexibility of dosing,"" says Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. Novo Nordisk expects to receive final marketing authorisation from the European Commission in the first quarter of 2017. Fiasp® (fast-acting insulin aspart) is a mealtime insulin for improved control of postprandial glucose (PPG) excursions and has been developed for the treatment of people with type 1 and type 2 diabetes, as well as for pump treatment. Fiasp® is insulin aspart (NovoRapid®) in a new formulation, in which two new excipients have been added to ensure early and fast absorption thereby providing earlier insulin action. The review of Fiasp® was based on the onset programme, a phase 3 clinical programme comprising of four trials encompassing more than 2,100 people with type 1 and type 2 diabetes. Company announcement No 78 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=960,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
350,2016-11-10,Novo Nordisk indsender ansøgning i EU om inkludering af data fra de to SWITCH-studier i indlægssedlen for Tresiba®,"Bagsværd, den 10. november 2016 - Novo Nordisk meddeler i dag, at virksomheden har indsendt en type II-variationsansøgning til Det Europæiske Lægemiddelagentur (EMA) med henblik på inkludering af data fra de to fase 3b-SWITCH-studier i indlægssedlen for Tresiba®. I SWITCH 1 blev deltagere med type 1-diabetes randomiseret til cross-over-behandling med henholdsvis Tresiba® og insulin glargin U100, begge i kombination med insulin aspart. I studiets vedligeholdelsesperiode oplevede deltagere i behandling med Tresiba® i gennemsnit 11% færre episoder af generel symptomatisk hypoglykæmi (lavt blodsukker) bekræftet ved blodsukkermåling, 36% færre episoder af natlig symptomatisk hypoglykæmi bekræftet ved blodsukkermåling og 35% færre episoder af alvorlig hypoglykæmi. Alle ovenstående resultater var statistisk signifikante, og der blev observeret sammenlignelige resultater i den fulde behandlingsperiode. I SWITCH 2 blev deltagere med type 2-diabetes randomiseret til cross-over-behandling med henholdsvis Tresiba® og insulin glargin U100, begge i kombination med diabeteslægemidler i tabletform. I studiets vedligeholdelsesperiode oplevede deltagere i behandling med Tresiba® i gennemsnit 30% færre episoder af generel symptomatisk hypoglykæmi bekræftet ved blodsukkermåling og 42% færre episoder af natlig symptomatisk hypoglykæmi bekræftet ved blodsukkermåling, begge til fordel for Tresiba® sammenlignet med insulin glargin U100. Begge observationer var statistisk signifikante, og der blev observeret sammenlignelige resultater i den fulde behandlingsperiode. For alvorlig hypoglykæmi var der en 46%, men ikke statistisk signifikant reduktion i antallet af episoder i vedligeholdelsesperioden og en statistisk signifikant 51% reduktion i antallet af episoder i den fulde behandlingsperiode for Tresiba® sammenlignet med insulin glargin U100. I begge studier var det gennemsnitlige langtidsblodsukkerniveau (HbA1c) ved studiets begyndelse 7,6%, og i begge studier viste Tresiba® ikke-inferiøritet med hensyn til reduktion af HbA1c sammenlignet med insulin glargin U100. Det betyder, at kravene for objektivt at sammenligne antallet af episoder af hypoglykæmi mellem de to behandlinger var opfyldt. Tresiba® forekom generelt i begge studier at have en sikker og veltolereret profil. ""Med indsendelsen af SWITCH-dataene til EMA har vi nu færdiggjort registreringsansøgningerne både i EU og USA. Vi mener, at forsøgsresultaterne fra SWITCH bør indgå i ordineringsinformationen for Tresiba®, fordi de vil give lægerne vigtig information i forhold til at træffe et kvalificeret valg, når de ordinerer basalinsulin,"" siger Mads Krogsgaard Thomsen, koncerndirektør med ansvar for forskning og udvikling i Novo Nordisk. Tresiba® (insulin degludec) er en basalinsulin til dosering én gang dagligt med en virkningsvarighed på mere end 42 timer. Det er vigtigt for mennesker med type 1- og type 2-diabetes at etablere en rutine for deres insulinbehandling. Tresiba® tages én gang dagligt når som helst i løbet af dagen. Patienter, som glemmer en dosis Tresiba®, kan tage den, når de opdager forglemmelsen, men med mindst otte timer mellem doserne. Tresiba® blev godkendt af registreringsmyndighederne første gang i september 2012 og er siden blevet godkendt i flere end 70 lande verden over. Det blev godkendt af FDA i USA den 25. september 2015. De to 2x32-ugers randomiserede, dobbeltblindede, cross-over-, treat to target- fase 3b-studier blev påbegyndt i januar 2014 med det formål at sammenligne sikkerhedsprofil og effekt af Tresiba® og insulin glargin U100. I studierne blev deltagerne behandlet i en 16-ugers titreringsperiode efterfulgt af en 16-ugers vedligeholdelsesperiode, hvorefter de blev skiftet over til sammenligningsproduktet. Det overordnede formål med studierne var at dokumentere hypoglykæmiprofilen i henholdsvis type 1- og type 2-diabetes. I SWITCH 1 blev 501 deltagere med type 1-diabetes randomiseret til cross-over-behandling med Tresiba® og insulin glargin U100 i kombination med insulin aspart. I SWITCH 2 blev 721 deltagere med type 2-diabetes randomiseret til cross-over-behandling med Tresiba® og insulin glargin U100 i kombination med diabeteslægemidler i tabletform. Den 23. september 2016 meddelte Novo Nordisk, at virksomheden havde indsendt en supplerende ansøgning til de amerikanske sundhedsmyndigheder, FDA, med henblik på inkludering af data fra SWITCH-studierne i indlægssedlen for Tresiba®. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Selskabsmeddelelse nr. 77 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=961,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
351,2016-11-10,Novo Nordisk submits application in the EU for including data from the two SWITCH trials in Tresiba® label,"Bagsværd, Denmark, 10 November 2016 - Novo Nordisk today announced the submission of a type II Variation application to the European Medicines Agency (EMA) for including data from the two SWITCH phase 3b trials in the label for Tresiba®. In SWITCH 1, people with type 1 diabetes were randomised to cross-over treatment with Tresiba® and insulin glargine U100 respectively, both in combination with insulin aspart. During the study's maintenance period, people treated with Tresiba® on average had 11% fewer episodes of overall symptomatic blood glucose confirmed hypoglycaemia, 36% fewer episodes of nocturnal blood glucose confirmed symptomatic hypoglycaemia and 35% fewer episodes of severe hypoglycaemia. All of the above results were statistically significant and similar results were seen in the full treatment period. In SWITCH 2, people with type 2 diabetes were randomised to cross-over treatment with Tresiba® and insulin glargine U100 respectively, both in combination with oral antidiabetic drugs. During the study's maintenance period, people treated with Tresiba® on average had 30% fewer episodes of overall blood glucose confirmed symptomatic hypoglycaemia and 42% fewer episodes of nocturnal blood glucose confirmed symptomatic hypoglycaemia, both favouring Tresiba® over insulin glargine U100. Both observations were statistically significant and similar results were observed for the full treatment period. For severe hypoglycaemia there was a 46%, but not statistically significant, reduction of the episodes in the maintenance period, and a statistically significant 51% reduction of the episodes in the full treatment period for Tresiba® compared to insulin glargine U100. In both studies, the mean baseline for HbA1c was 7.6%, and both studies showed that Tresiba® was non-inferior in terms of HbA1c reduction compared to insulin glargine U100. This means that the requirements for objectively comparing hypoglycaemia episodes between the two treatments were fulfilled. In both studies, Tresiba® generally appeared to have a safe and well-tolerated profile. ""With the submission of the SWITCH data to the EMA, we have now completed the regulatory submissions in both the EU and the USA. We believe that inclusion of the SWITCH trial results in the prescribing information for Tresiba® will provide healthcare professionals with important information to make an informed choice when prescribing basal insulin"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. Tresiba® (insulin degludec) is a once-daily basal insulin that provides a duration of action beyond 42 hours. It is important for people with type 1 and type 2 diabetes to establish a routine for insulin treatment. Tresiba® is taken once daily, at any time of day. Patients who miss or are delayed in taking their dose of Tresiba® can take their dose as soon as they remember, making sure there are at least eight hours between doses. Tresiba® received its first regulatory approval in September 2012 and has since been approved in more than 70 countries globally. It was approved by the FDA in the United States on 25 September 2015. About SWITCH 1 and 2 The two phase 3b, 2x32-weeks randomised, double-blind, cross-over, treat-to-target trials were initiated in January 2014 to compare the safety profile and efficacy of Tresiba® and insulin glargine U100. In the trials, people were treated for a 16-week titration period followed by a 16-week maintenance period and subsequently switched to the comparator drug. The overall objective was to document the hypoglycaemia profile in type 1 diabetes and type 2 diabetes, respectively. In SWITCH 1, 501 people with type 1 diabetes were randomised to cross-over treatment with Tresiba® and insulin glargine U100 in combination with insulin aspart. In SWITCH 2, 721 people with type 2 diabetes were randomised to cross-over treatment with Tresiba® and insulin glargine U100 in combination with oral antidiabetic drugs. On 23 September 2016, Novo Nordisk announced the submission of a supplemental application to the US Food and Drug Administration (FDA) for including data from the SWITCH trials in the label for Tresiba®. Further information Company announcement No 77 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=962,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
352,2016-11-03,"Nyt studie viser, at kun 55% af svært overvægtige mennesker har fået en formel diagnose","Amerikansk studie afdækker en række barrierer for vægtregulering hos svært overvægtige New Orleans, USA, den 3. november 2016 - Forskellige opfattelser af og holdninger til svær overvægt kan gå ud over behandlingsresultaterne indenfor fedmebehandling. Det viser resultater fra ACTION-studiet (Awareness, Care & Treatment In Obesity Management), der blev præsenteret på Obesity Week 2016, den fjerde årlige kombinerede kongres for American Society for Metabolic and Bariatric Surgery og The Obesity Society. ACTION er det første landsdækkende studie, der undersøger barrierer for effektiv fedmebehandling ud fra forskellige perspektiver - de svært overvægtiges, lægernes og arbejdsgivernes. Studiet var tilrettelagt med henblik på at opnå viden om, hvordan indsatsen kan forbedres i forhold til behandling af svær overvægt, undervisning og støtte til de næsten 79 mio. mennesker i USA, der lever med svær overvægt. Svær overvægt blev anerkendt som en kronisk sygdom af American Medical Association i 2013.[1],[2] ""Svær overvægt skal forstås som en alvorlig, ofte progressiv sygdom, hvor der skal både forebyggelses- og behandlingsstrategier til for at få den under kontrol,"" siger dr. Lee Kaplan, leder af Obesity, Metabolism and Nutrition Institute ved Massachusetts General Hospital Weight Center og medlem af styregruppen for ACTION. ""ACTION-studiet er vigtigt, fordi det tydeligt viser de udfordringer, der skal løses, og fremhæver, at det er ubetinget nødvendigt, at mange forskellige parter arbejder sammen om at udvikle og gennemføre effektive løsninger."" Ifølge studiet er en af disse udfordringer, at de fleste mennesker med svær overvægt (65%) opfatter overvægt som en sygdom, men at hovedparten (82%) anser vægttab for at være ""udelukkende"" deres eget ansvar. 73% oplyste, at de har drøftet vægt med en læge, mens 36% svarede, at de ikke går til lægen for at få hjælp til vægttab.[3] En anden væsentlig barriere for behandling var ifølge studiet, at der ikke er en løbende dialog mellem lægen og den svært overvægtige om vægtregulering. Selvom 72% af lægerne følte, at de havde et ""ansvar for at bidrage aktivt"" til patienters vægttabsindsats, var kun 55% af de svært overvægtige ifølge dem selv blevet diagnosticeret. Desuden svarede kun 16% af de svært overvægtige, at de havde aftalt en opfølgende samtale med deres læge efter den indledende samtale om vægtregulering. Og selvom lægerne sagde, at de havde det ""fint"" med at tale om vægtregulering, blev deres indsats ofte nedprioriteret på grund af manglende tid.[4] Studiet fandt desuden, at kun 23% af de svært overvægtige havde haft et vægttab på 10% i de seneste tre år trods flere ""seriøse"" forsøg på vægttab, og at kun 44% af dem var i stand til at opretholde vægttabet i mere end et år.4 Dataene indikerer, at initiativer, der øger lægernes forståelse for deres patienters opfattelse af situationen og muliggør en bedre dialog om vægtregulering, kan have en positiv effekt på vægtreguleringsindsatsen.3,4 ACTION-studiet (Awareness, Care and Treatment In Obesity Management) er det første landsdækkende studie i USA, der skal undersøge barrierer for vægtregulering ud fra forskellige perspektiver - de svært overvægtiges, lægernes og arbejdsgivernes. Formålet med studiet er desuden at opnå en viden, der gør det muligt at samarbejde om at forbedre indsatsen i forhold til behandling af svær overvægt, undervisning og støtte til den overvægtige. ACTION-studiet sponseres af Novo Nordisk og ledes af en tværfaglig styregruppe med repræsentanter for The Obesity Society, Obesity Action Coalition og Integrated Benefits Institute samt eksperter i svær overvægt indenfor primær behandling, endokrinologi, fysiologi og sygepleje. I studiet deltog flere end 3.000 svært overvægtige, 600 læger og 150 arbejdsgivere i USA. Læs mere om studiet på www.ACTIONStudy.com. Svær overvægt er en sygdom, der kræver vedvarende indsats.2,[5] Den er forbundet med mange alvorlige helbredsmæssige følgevirkninger og nedsat forventet levetid.[6],[7] Følgesygdomme til svær overvægt er bl.a. type 2-diabetes, hjertesygdom, obstruktiv søvnapnø og visse former for kræft.6,[8],[9] Det er en kompleks sygdom, der er påvirket af flere forskellige forhold, herunder fysiologiske, psykologiske, miljømæssige, socioøkonomiske og genetiske faktorer.[10] Den globale stigning i forekomsten af svær overvægt er en trussel mod folkesundheden med betydelig indvirkning på de offentlige sundhedsudgifter. I 2014 var 13% af verdens voksne befolkning, eller omkring 600 mio. voksne, svært overvægtige.[11] Yderligere information [1]    Centers for Disease Control and Prevention. Adult Obesity Facts. Available at: http://www.cdc.gov/obesity/data/adult.html. Last accessed: October 2016. [2]    American Medical Association. A.M.A Adopts New Policies on Second Day of Voting at Annual Meeting. Obesity as a Disease. Available at: http://www.ama-assn.org/ama/pub/news/news/2013/2013-06-18-new-ama-policies-annual-meeting.page. Last accessed: October 2016. [3]    Golden A, Dhurandhar NV, Jinnett K, et al. Insights and Perceptions of Obesity Management in People with Obesity: Results from a National Study. ObesityWeek. 2016. [4]    Kaplan LM, Golden A, Jinnett K, et al. Divergence in Perceptions and Attitudes among People with Obesity, Healthcare Professionals, and Employers create Barriers to Effective Obesity Management: Results of the National ACTION Study. ObesityWeek. 2016 [5]    WHO. Obesity: Preventing and managing the global epidemic. Available at: http://www.who.int/iris/handle/10665/42330 Last accessed: October 2016. [6]    Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009; 25:88. [7]    Peeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Annals of Internal Medicine. 2003; 138:24-32. [8]    Gami AS, Caples SM, Somers VK. Obesity and obstructive sleep apnea. Endocrinology and Metabolism Clinics of North America. 2003; 32:869-894. [9]    Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009; 373:1083-1096. [10] Wright SM, Aronne LJ. Causes of obesity. Abdominal Imaging. 2012; 37:730-732. [11] WHO. Obesity and Overweight Factsheet no. 311. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/. Last accessed: October 2016.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=965,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
353,2016-11-03,New study showed that only 55% of people with obesity have received a formal obesity diagnosis,"US study identified multiple barriers to weight management for people living with obesity New Orleans, US, 3 November 2016 - Divergent perceptions and attitudes about obesity may jeopardise obesity management outcomes, according to findings from the Awareness, Care & Treatment In Obesity Management (ACTION) study. The findings were presented at Obesity Week 2016, the fourth annual combined congress of the American Society for Metabolic and Bariatric Surgery and The Obesity Society. ACTION is the first national study to investigate barriers to effective obesity management from the perspective of people with obesity, healthcare professionals (HCPs) and employers in the US. The study was designed to generate insights to improve obesity care, education and support for the nearly 79 million people in the US living with obesity, a condition that was recognised as a chronic disease by the American Medical Association in 2013.1,2 ""Obesity must be understood as a serious, often progressive disease requiring both prevention and treatment strategies to bring it under control"" said Dr Lee Kaplan, director of the Obesity, Metabolism and Nutrition Institute at Massachusetts General Hospital Weight Center and ACTION steering committee member. ""The value of the ACTION study is that it clearly identifies the challenges that must be overcome, and underscores the critical need for multiple communities working together to develop and implement effective solutions."" One such challenge, according to study findings, is that most people with obesity (PwO) (65%) perceived obesity as a disease; however, most (82%) considered weight loss to be ""completely"" their responsibility. While PwO (73%) reported that they had discussed weight with an HCP, 36% indicated they did not seek support from their HCP for weight loss.3 Another significant barrier to care revealed by the study was an inconsistent HCP-patient dialogue about weight management. Although HCPs (72%) felt they had ""a responsibility to actively contribute"" to patients' weight loss efforts, only 55% of PwO reported receiving an obesity diagnosis from an HCP. Also, only 16% of PwO reported having a follow-up appointment with their HCP following initial conversations about obesity management, and whereas HCPs said they were ""comfortable"" having obesity management conversations, their efforts were often deprioritised due to limited time.4 The study also found that despite several ""serious"" weight loss attempts, only 23% of PwO reported a 10% weight loss during the past three years, and of those, 44% maintained weight loss for more than one year.4 These data suggest that initiatives which foster greater understanding among HCPs of their patients' beliefs, and facilitate more robust dialogue about weight management, could positively impact obesity management efforts.3,4 About ACTIONThe ""Awareness, Care and Treatment In Obesity Management"" (ACTION) study is the first US nationwide study to investigate barriers to obesity management from the perspective of people with obesity, healthcare professionals and employers. In addition, the study aims to generate insights to guide collaborative action to improve obesity care, education and support. Sponsored by Novo Nordisk, the ACTION study was led by a multi-disciplinary steering committee comprised of representatives from The Obesity Society, the Obesity Action Coalition, and the Integrated Benefits Institute, as well as obesity experts in the fields of primary care, endocrinology, physiology and nursing. The study involved more than 3,000 people with obesity, 600 healthcare professionals and 150 employers in the United States. To learn more about the study, please visit www.ACTIONStudy.com. About obesityObesity is a disease that requires long-term management.2,5 It is associated with many serious health consequences and decreased life-expectancy.6,7 Obesity-related comorbidities include type 2 diabetes, heart disease, obstructive sleep apnoea (OSA) and certain types of cancer.6,8,9 It is a complex and multi-factorial disease that is influenced by physiological, psychological, environmental, socio-economic and genetic factors.10 The global increase in the prevalence of obesity is a public health issue that has severe cost implications to healthcare systems. In 2014, 13% of adults, or approximately 600 million adults, were living with obesity.11 _______________________  References 1.         Centers for Disease Control and Prevention. Adult Obesity Facts. Available at: http://www.cdc.gov/obesity/data/adult.html. Last accessed: October 2016. 2.         American Medical Association. A.M.A Adopts New Policies on Second Day of Voting at Annual Meeting. Obesity as a Disease. Available at: http://www.ama-assn.org/ama/pub/news/news/2013/2013-06-18-new-ama-policies-annual-meeting.page. Last accessed: October 2016. 3.         Golden A, Dhurandhar NV, Jinnett K, et al. Insights and Perceptions of Obesity Management in People with Obesity: Results from a National Study. . ObesityWeek. 2016.4.         Kaplan LM, Golden A, Jinnett K, et al. Divergence in Perceptions and Attitudes among People with Obesity, Healthcare Professionals, and Employers create Barriers to Effective Obesity Management: Results of the National ACTION Study. ObesityWeek. 2016.5.         WHO. Obesity: Preventing and managing the global epidemic. Available at: http://www.who.int/iris/handle/10665/42330 Last accessed: October 2016. 6.         Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009; 25:88.7.         Peeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Annals of Internal Medicine. 2003; 138:24-32.8.         Gami AS, Caples SM, Somers VK. Obesity and obstructive sleep apnea. Endocrinology and Metabolism Clinics of North America. 2003; 32:869-894.9.         Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009; 373:1083-1096.10.       Wright SM, Aronne LJ. Causes of obesity. Abdominal Imaging. 2012; 37:730-732.11.       WHO. Obesity and Overweight Factsheet no. 311. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/. Last accessed: October 2016.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=966,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
354,2016-11-01,"Nye data viser, at højt blodsukker efter måltiderne har negativ indvirkning på livskvaliteten for mennesker med diabetes","Wien, Østrig, den 1. november 2016 ­- Nye data fra det første studie af helbredsrelateret livskvalitet i forbindelse med måltidsblodsukkerkontrol (postprandial glukose, PPG) viser, at dårlig blodsukkerkontrol efter måltider har en signifikant negativ indvirkning på livskvaliteten hos mennesker med diabetes[1]. Resultaterne præsenteres i dag på den 19. årlige europæiske kongres i International Society for Pharmacoeconomics and Outcomes Research (ISPOR) i Wien, Østrig. Studiet havde til formål at evaluere, hvorledes postprandial hyperglykæmi (for højt blodsukker efter måltider) opfattes hos mennesker med type 1- og type 2-diabetes. I studiet blev tre helbredstilstande, der hver især beskriver symptomer på postprandial hyperglykæmi af varierende hyppighed og sværhedsgrad (mild, moderat og svær), målt blandt den almindelige befolkning i Storbritannien og mennesker med diabetes i Sverige ved hjælp af Time Trade-Off (TTO)[*]-metoden1. Resultaterne viste følgende gennemsnitlige værdier for helbredstilstand, hvor 0 angiver død og 1 angiver optimalt helbred: TTO 0,89 og 0,76 for den milde tilstand, TTO 0,75 og 0,71 for den moderate tilstand og TTO 0,56 og 0,58 for den svære tilstand, henholdsvis blandt den almindelige befolkning i Storbritannien og blandt svenskere med type 1- og type 2-diabetes1. ""God blodsukkerkontrol kan ikke kun bestemmes ud fra procentdelen af patienter, der når deres behandlingsmål for langtidsblodsukkeret målt som HbA1c. Man er også nødt til at tage blodsukkerudsving og graden af hyperglykæmi efter måltiderne i betragtning,"" siger Johan Jendle, professor ved Örebro Universitet i Sverige og videnskabelig sekretær for Swedish Society of Diabetology. ""Måltidsrelateret blodsukkerkontrol er vigtigt for livskvaliteten hos mennesker med både type 1- og type 2-diabetes."" Samlet set indikerer studiet, at sværhedsgraden af symptomerne på postprandial hyperglykæmi opfattes som havende signifikante negative konsekvenser for helbredsrelateret livskvalitet på kort sigt for mennesker med diabetes1. Formålet med analysen var at kvantificere indvirkningen af måltidsrelateret blodsukkerkontrol på helbredsrelateret livskvalitet hos mennesker med diabetes, udtrykt som helbredsrelateret nytteværdi ved hjælp af TTO-metoden (Time Trade-Off). I studiets første del blev der gennemført en indledende litteraturgennemgang, efterfulgt af interviews med mennesker med diabetes, klinikere og sygeplejersker for at identificere karakteristika for indvirkningen af symptomer på postprandial hyperglykæmi af varierende sværhedsgrad og hyppighed. Baseret på disse resultater blev der udarbejdet tre beskrivelser af helbredstilstande med henholdsvis milde, moderate og svære symptomer på postprandial hyperglykæmi. Til studiets vurderingsdel blev der rekrutteret i alt 300 deltagere, heraf 150 repræsentanter for den almindelige befolkning i Storbritannien og 150 svenskere med type 1- og type 2-diabetes, til at deltage i et ansigt-til-ansigt TTO-interview, hvilket er en standardteknik til at fastsætte en nytteværdi for hver af de tre helbredstilstande. Deltagerne blev bedt om at vælge mellem at leve med den pågældende helbredstilstand i en 10-årig periode eller at leve med optimalt helbred i en kortere periode. Studiet blev finansieret af Novo Nordisk A/S. Postprandial glukose (PPG) er blodsukkerkoncentrationen målt 1-2 timer efter et måltid. Når PPG-værdierne stiger til for høje koncentrationer efter et måltid, kaldes det måltidsrelateret eller postprandial hyperglykæmi. Postprandial hyperglykæmi er forbundet med øget risiko for hjerte-kar-sygdom, cancer, øjenskade, nedsat kognitiv funktion (hos mennesker med type 2-diabetes) og andre diabetesrelaterede komplikationer[2],[3]. Jo længere tid i hyperglykæmisk tilstand, desto dårligere er den generelle blodsukkerkontrol. Opnåelse af en stram PPG-kontrol er vigtig for at kunne opnå en optimal regulering af blodsukkeret, behandlingsmål for langtidsblodsukkeret (HbA1c)[4] og for at reducere risikoen for kort- og langsigtede komplikationer i forbindelse med hyperglykæmi[5]. Yderligere information [*] TTO-metoden blev anvendt til at identificere en nytteværdi for hver tilstand. Deltagerne blev bedt om at vælge mellem at leve med en bestemt helbredstilstand i en 10-årig periode eller at leve med optimalt helbred i en kortere periode. [1]    Sandberg A, et al. Improvements in health-related quality of life associated with increased control of postprandial glucose levels in diabetes. Research supported by Novo Nordisk. Poster presentation at the ISPOR 19th Annual European Congress. 29 October-2 November 2016; Vienna, Austria. [2]    IDF 2011 Guideline for Management of Post Meal Glucose. Available at: http://www.idf.org. Last accessed: October 2016. [3]    Madsbad S. Impact of postprandial glucose control on diabetes-related complications: How is the evidence evolving? Journal of Diabetes and its Complications 2016; 30(2):374-385. [4]    Monnier L, et al. Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes? European Journal of Clinical Investigation 2000; 30(Suppl. 2):3-11. [5]    Ceriello A, et al. Guideline for management of postmeal glucose. Nutrition, Metabolism and Cardiovascular Disease 2008; 18:S17-S33.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=970,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
355,2016-11-01,New data show post-meal hyperglycaemia is associated with a negative impact on quality of life for people with diabetes,"Vienna, Austria, 1 November 2016 ­- New data from the first health-related quality of life (HRQL) study related to post-meal or postprandial glucose (PPG) control, show that poor PPG control has a significant negative impact on quality of life for people with diabetes1. Findings will be presented today at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in Vienna, Austria. The study sought to evaluate the perceived impact of postprandial hyperglycaemia on people with type 1 and type 2 diabetes. Three health state descriptions characterising postprandial hyperglycaemia symptoms of varying frequency and severity (mild, moderate and severe) were evaluated using a Time Trade-Off (TTO)[*] approach by members of the general public in the UK and people with diabetes in Sweden1. Findings showed the following mean health state utility values, where 0 indicates death and 1 indicates full health: TTO 0.89 and 0.76 for the mild state, TTO 0.75 and 0.71 for the moderate state and TTO 0.56 and 0.58 for the severe state, among the UK general public and Swedish people with type 1 and type 2 diabetes respectively1. ""Good metabolic control cannot solely be indicated by the percentage of patients reaching their glycaemic targets measured as HbA1c. Also the glucose excursions and the degree of postprandial hyperglycaemia need to be addressed,"" said Professor Johan Jendle, Örebro University of Sweden and scientific secretary for the Swedish Society of Diabetology. ""Postprandial glucose control is important for the quality of life of people with both type 1 and type 2 diabetes."" Overall, the study indicates that increasing severity in postprandial hyperglycaemic symptoms is perceived to have significant negative consequences for the short-term HRQL of people with diabetes1. About the study1The aim of this analysis was to quantify the impact of PPG control on HRQL of people with diabetes, expressed as health utilities using a TTO approach. In the first stage of the study, an initial literature review was conducted, followed by interviews with people with diabetes, clinicians and nurses, to characterise the nature of impact of postprandial hyperglycaemic symptoms of varying severity and frequency. Based on these findings, three health state descriptions were drafted with mild, moderate and severe symptoms of postprandial hyperglycaemia. For the valuation part of the study, a total of 300 people, including 150 members of the UK general public and 150 Swedish people with type 1 and type 2 diabetes, were recruited to take part in a face-to-face TTO interview, a standard technique used to determine a utility value for each of the three health states. Participants were asked to choose between living in the health state for a 10-year time frame or living in full health for a reduced amount of time. The study was funded by Novo Nordisk A/S. About postprandial glucose (PPG) controlPost-meal or postprandial, glucose (PPG) is the level of blood glucose concentration measured 1-2 hours after eating. When PPG levels rise too high after eating, it is known as post-meal, or postprandial, hyperglycaemia. Postprandial hyperglycaemia is associated with increased risk of cardiovascular disease, cancer, damage to eyes, impaired cognitive function (in people with type 2 diabetes) among other diabetes-related complications2,3. The longer time spent in a hyperglycaemic state, the worse overall blood glucose control. Achieving tight PPG control is important to achieve optimal blood glucose control, HbA1c targets4, and to reduce risk of short-term and long-term complications associated with hyperglycaemia5. References1.    Sandberg A, et al. Improvements in health-related quality of life associated with increased control of postprandial glucose levels in diabetes. Research supported by Novo Nordisk. Poster presentation at the ISPOR 19th Annual European Congress. 29 October-2 November 2016; Vienna, Austria.2.    IDF 2011 Guideline for Management of Post Meal Glucose. Available at: http://www.idf.org. Last accessed: October 2016. 3.    Madsbad S. Impact of postprandial glucose control on diabetes-related complications: How is the evidence evolving? Journal of Diabetes and its Complications 2016; 30(2):374-385.4.    Monnier L, et al. Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes? European Journal of Clinical Investigation 2000; 30(Suppl. 2):3-11.5.    Ceriello A, et al. Guideline for management of postmeal glucose. Nutrition, Metabolism and Cardiovascular Disease 2008; 18:S17-S33. [*] A TTO approach was used to provide a utility value for each state. Participants were asked to choose between living in a selected health state for a 10-year time frame or living in full health for a reduced amount of time.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=969,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
356,2016-10-28,"Novo Nordisks resultat af primær drift, justeret, steg med 7% i lokale valutaer i de første ni måneder af 2016","Salget steg med 6% opgjort i lokale valutaer Resultat af primær drift faldt med 1% rapporteret i lokale valutaer og med 3% i kroner til 37,2 mia. kr. Justeret for engangsindtægten fra det delvise frasalg af NNIT og indtægten fra udlicensering af aktiver vedrørende inflammatoriske sygdomme, begge i 2015, steg resultat af primær drift opgjort i lokale valutaer med 7%. Nettoresultatet steg med 10% til 29,2 mia. kr. Udvandet resultat pr. aktie steg med 12% til 11,50 kr. Justeret for det delvise frasalg af NNIT steg nettoresultatet og udvandet resultat pr. aktie med henholdsvis 20% og 22%. I september meddelte Novo Nordisk, at Lars Rebien Sørensen fratræder som administrerende direktør for virksomheden med udgangen af 2016. Lars Fruergaard Jørgensen, nuværende koncerndirektør med ansvar for Corporate Development, bliver ny administrerende direktør med virkning fra 1. januar 2017. I september annoncerede Novo Nordisk planer om at reducere medarbejderstaben med ca. 1.000 ansatte ud af de 42.600 stillinger i virksomhedens globale organisation. De finansielle forventninger til 2016 er blevet opdateret, og salgsvæksten forventes nu at blive i intervallet 5-6%, mens væksten i justeret resultat af primær drift nu forventes at blive på 5-7%, begge opgjort i lokale valutaer. Markedssituationen i USA er i løbet af 2016 blevet signifikant mere udfordrende med en negativ indvirkning på den fremtidige prisfastsættelse for Novo Nordisks produkter. Derfor indikerer de foreløbige forventninger til 2017 en lav encifret vækst i salget og en flad til lav encifret vækst i resultat af primær drift, begge opgjort i lokale valutaer. Hvad angår de langsigtede finansielle mål anser Novo Nordisk det ikke længere for muligt at nå det mål om vækst i resultat af primær drift på 10%, der blev fastsat i februar 2016. Følgelig er målet blevet revideret, og Novo Nordisk sigter nu efter en gennemsnitlig vækst i resultat af primær drift på 5%. De to andre finansielle mål er uændrede. Adm. direktør Lars Rebien Sørensen: ""Vi har revurderet vores langsigtede mål for væksten i resultat af primær drift og vores forsknings- og udviklingsstrategi i lyset af den udfordrende markedssituation i USA. Vi er derfor i gang med at reducere vores globale omkostningsbase og må desværre sige farvel til nogle af vores dygtige medarbejdere. Fremadrettet er vi overbevist om, at vores stærke produktportefølje med innovative produkter som Tresiba®, Victoza® og semaglutid vil sætte os i stand til at opfylde vores reviderede vækstmål."" Kontaktoplysninger Selskabsmeddelelse nr. 74 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=974,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
357,2016-10-28,Novo Nordisk increased adjusted operating profit by 7% in local currencies in the first nine months of 2016,"Sales increased by 6% in local currencies Operating profit decreased by 1% reported in local currencies and by 3% in Danish kroner to DKK 37.2 billion. Adjusted for the non-recurring income related to the partial divestment of NNIT and the income related to out-licensing of assets for inflammatory disorders, both in 2015, operating profit in local currencies increased by 7%. Net profit increased by 10% to DKK 29.2 billion. Diluted earnings per share increased by 12% to DKK 11.50. Adjusted for the partial divestment of NNIT, net profit and diluted earnings per share increased by 20% and 22% respectively. In September, Novo Nordisk announced that Lars Rebien Sørensen, president and chief executive officer, will retire from the company by the end of 2016. Lars Fruergaard Jørgensen, currently executive vice president and head of Corporate Development, will succeed him, effective 1 January 2017. In September, Novo Nordisk announced plans to reduce the workforce by approximately 1,000 employees of the 42,600 positions in the company's global organisation. For 2016, the range for sales growth is now expected to be 5-6%, and growth in adjusted operating profit is now expected to be 5-7%, both measured in local currencies. During 2016, the market environment in the USA has become significantly more challenging, negatively impacting future pricing for Novo Nordisk's products. Consequently, the preliminary outlook for 2017 in local currencies indicates low single-digit growth in sales and flat to low single-digit growth in operating profit. Furthermore, Novo Nordisk no longer deems it achievable to reach the operating profit growth target of 10%, set in February 2016. As a result, the target has been revised and Novo Nordisk is now aiming for an average operating profit growth of 5%. The two other long-term financial targets remain unchanged. Lars Rebien Sørensen, president and CEO: ""We have reassessed our long-term target for operating profit growth and our R&D strategy in the light of the challenging market environment in the USA. As a result, we are reducing our global cost base and parting company with some of our valued employees. Going forward we are confident that our strong product portfolio with innovative products like Tresiba®, Victoza® and semaglutide will enable us to deliver on our revised growth targets."" Contacts for further information Company announcement No 74 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=973,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
358,2016-10-25,Novo Nordisk submits application to regulatory authorities to include LEADER data in Victoza® label,"Bagsværd, Denmark, 25 October 2016 - Novo Nordisk today announced the submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) and a Type II Variation application to the European Medicines Agency (EMA) for including data from the LEADER cardiovascular outcomes trial in the product information of Victoza® (liraglutide). In the LEADER trial, Victoza® statistically significantly reduced the risk of cardiovascular death, non-fatal myocardial infarction (heart attack) and non-fatal stroke by 13% versus placebo, when added to standard of care. The overall risk reduction was derived from a statistically significant 22% reduction in cardiovascular death with Victoza® treatment versus placebo and non-significant reductions in non-fatal myocardial infarction and non-fatal stroke. The safety profile of Victoza® in LEADER was generally consistent with previous liraglutide clinical trials. ""Reducing the risk of cardiovascular death in people with type 2 diabetes remains a significant unmet need and it is encouraging that we now have the opportunity to help address this challenge,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""Victoza® is the first GLP-1 receptor agonist to show cardiovascular risk reduction in adults with type 2 diabetes at high cardiovascular risk and we look forward to working with the regulatory authorities as they review the data from the LEADER trial."" About the LEADER trialLEADER was a multicentre, international, randomised, double-blind, placebo-controlled trial investigating the long-term (3.5-5 years) effects of Victoza® (liraglutide up to 1.8 mg) compared to placebo, both in addition to standard of care, in people with type 2 diabetes at high risk of major cardiovascular events. Standard of care was comprised of lifestyle modifications, glucose-lowering treatments and cardiovascular medications. LEADER was initiated in September 2010 and randomised 9,340 people with type 2 diabetes from 32 countries. The primary endpoint was the first occurrence of a composite cardiovascular outcome comprising cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. About Victoza®Victoza® (liraglutide) is a human glucagon-like peptide-1 (GLP-1) analogue with an amino acid sequence 97% similar to endogenous human GLP-1. Victoza® was approved in the EU in 2009 and is commercially available in more than 85 countries, treating more than 1 million people with type 2 diabetes globally. In Europe, Victoza® is indicated for the treatment of adults with type 2 diabetes to achieve glycaemic control as monotherapy, when metformin is considered inappropriate, and in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control. In the US, Victoza® was approved in 2010 as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes. Further information Company announcement No 72 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=977,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
359,2016-10-25,Novo Nordisk indsender ansøgning til registreringsmyndighederne om inkludering af data fra LEADER-studiet i indlægssedlen for Victoza®,"Bagsværd, den 25. oktober 2016 - Novo Nordisk meddeler i dag, at virksomheden har indsendt en supplerende registreringsansøgning til de amerikanske sundhedsmyndigheder (FDA) og en type II-variationsansøgning til Det Europæiske Lægemiddelagentur (EMA) med henblik på inkludering af data fra det kardiovaskulære sikkerhedsstudie LEADER i produktinformationen for Victoza® (liraglutid). LEADER-studiet viste, at Victoza® medførte en statistisk signifikant 13% reduktion af risikoen for kardiovaskulært dødsfald, ikke-dødeligt myokardieinfarkt (hjerteanfald) og ikke-dødeligt slagtilfælde sammenlignet med placebo, når det blev givet som supplement til standardbehandling. Den samlede risikoreduktion blev opnået ved en statistisk signifikant 22% reduktion i kardiovaskulært dødsfald ved behandling med Victoza® sammenlignet med placebo samt reduktioner, dog ikke statistisk signifikante, i ikke-dødeligt myokardieinfarkt og ikke-dødeligt slagtilfælde. Sikkerhedsprofilen for Victoza® i LEADER var generelt konsistent med tidligere kliniske studier af liraglutid. ""Der eksisterer stadig et stort udækket behov for at reducere risikoen for, at mennesker med type 2-diabetes dør af hjerte-kar-sygdom, og det er positivt, at vi nu har mulighed for at hjælpe med til at gøre noget ved denne udfordring,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Victoza® er den første GLP-1-receptoragonist, der har vist sig at nedsætte risikoen for kardiovaskulære tilfælde hos voksne med type 2-diabetes med høj risiko for hjerte-kar-sygdom, og vi ser frem til at arbejde sammen med registreringsmyndighederne, når de evaluerer dataene fra LEADER-studiet."" LEADER er et internationalt, randomiseret, dobbeltblindet, placebokontrolleret multicenterstudie, der har undersøgt langtidsvirkningerne (3,5-5 år) af Victoza® (liraglutid op til 1,8 mg) sammenlignet med placebo, begge givet som supplement til standardbehandling, i mennesker med type 2-diabetes med høj risiko for alvorlige kardiovaskulære hændelser. Standardbehandling omfattede livsstilsændringer, blodsukkersænkende behandling og hjerte-kar-medicin. LEADER blev påbegyndt i september 2010 og randomiserede 9.340 mennesker med type 2-diabetes fra 32 lande. Det primære mål var den første forekomst af et sammensat kardiovaskulært endepunkt bestående af kardiovaskulært dødsfald, ikke-dødeligt myokardieinfarkt (hjerteanfald) eller ikke-dødeligt slagtilfælde. Victoza® (liraglutid) er en human GLP-1-analog (glukagonlignende peptid-1) med en aminosyresekvens, der har 97% lighed med det GLP-1, kroppen selv producerer. Victoza® blev godkendt i EU i 2009 og er på markedet i flere end 85 lande; produktet har været anvendt til behandling af mere end 1 mio. mennesker med type 2-diabetes globalt. I Europa er Victoza® godkendt som monoterapi til regulering af blodsukkerniveauet hos voksne med type 2-diabetes, når metformin anses for utilstrækkeligt, og i kombination med diabeteslægemidler i tabletform og/eller basalinsulin, når blodsukkeret ikke kan reguleres tilstrækkeligt med disse lægemidler sammen med motion og diæt. I USA blev Victoza® godkendt i 2010 som supplement til diæt og motion med det formål at forbedre blodsukkerreguleringen hos voksne med type 2-diabetes. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Selskabsmeddelelse nr. 72 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=978,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
360,2016-10-07,Novo Nordisk receives Complete Response Letter in the US for faster-acting insulin aspart,"Bagsværd, Denmark 7 October 2016 - Novo Nordisk today announced that it has received a Complete Response Letter from the US Food and Drug Administration (FDA) regarding the New Drug Application for faster-acting insulin aspart. In the letter, the FDA requests additional information related to the assay for the immunogenicity and clinical pharmacology data before the review of the New Drug Application can be completed. Novo Nordisk is evaluating the content of the Complete Response Letter and will work closely with the FDA to resolve the outstanding issues. ""We believe faster-acting insulin aspart can address an unmet medical need for people requiring improved blood glucose control around meals, and our ambitions for this innovative drug are unchanged"", says Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""We acknowledge the request for information from FDA and will work closely with the agency to determine the best path forward to complete the review."" The New Drug Application for faster-acting insulin aspart was submitted to the FDA in December 2015. Faster-acting insulin aspart is currently also under review in the EU, Switzerland, Canada, Brazil, South Africa and Argentina. Company announcement No 69 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=983,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
361,2016-10-07,Novo Nordisk modtager Complete Response Letter i USA vedrørende hurtigerevirkende insulin aspart,"Bagsværd, den 7. oktober 2016 - Novo Nordisk meddeler i dag, at virksomheden har modtaget et Complete Response Letter fra de amerikanske sundhedsmyndigheder, FDA, vedrørende registreringsansøgningen for hurtigerevirkende insulin aspart. I brevet udbeder FDA sig yderligere information vedrørende assayet for immunogenicitet og kliniske farmakologiske data, før registreringsansøgningen kan færdigbehandles. Novo Nordisk er i gang med at evaluere indholdet af brevet og vil arbejde tæt sammen med FDA om at afklare de resterende spørgsmål. ""Vi mener, at hurtigerevirkende insulin aspart kan imødekomme et udækket medicinsk behov hos mennesker, der har brug for en bedre blodsukkerregulering i forbindelse med måltiderne, og vores ambitioner for dette innovative lægemiddel er uændrede,"" siger Mads Krogsgaard Thomsen, koncerndirektør med ansvar for forskning og udvikling i Novo Nordisk. ""Vi noterer os FDA's anmodning om information og vil arbejde tæt sammen med myndighederne om at finde den bedst mulige løsning for at afslutte behandlingen af vores registreringsansøgning."" Registreringsansøgningen for hurtigerevirkende insulin aspart blev indsendt til FDA i december 2015. Hurtigerevirkende insulin aspart er desuden også under registrering i EU, Schweiz, Canada, Brasilien, Sydafrika og Argentina. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 69 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=984,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
362,2016-09-29,"Novo Nordisk announces plans to reduce workforce by approximately 1,000 employees","Bagsværd, Denmark, 29 September 2016 - Novo Nordisk has today announced its intention to reduce its workforce by approximately 1,000 employees of the 42,300 positions in the company's global organisation. This is one of several actions taken to reduce operating costs as the company faces a challenging competitive environment in 2017, especially in its large US market. The reductions are expected to affect R&D units and headquarter staff functions, as well as positions in the global commercial organisation. Around 500 of the layoffs are expected to be in Denmark. The majority of layoffs are expected to be communicated to affected employees over the next two months, pending negotiations as per local legal labour market requirements. The workforce reduction and the costs associated herewith do not change the financial outlook for 2016 communicated in connection with Novo Nordisk's half-year financial statement on 5 August 2016. ""We deeply regret that good colleagues stand to lose their jobs, and it has been a difficult decision to make,"" says President and CEO Lars Rebien Sørensen. ""However, we have concluded that it is needed in order for us to have a sustainable balance between income and costs. In the current situation, we have to prioritise investments in key product launches that will bring innovation to patients and drive our future growth."" Company announcement No 66 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=989,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
363,2016-09-29,Novo Nordisk annoncerer planer om at reducere medarbejderstaben med ca. 1.000 ansatte,"Bagsværd, den 29. september 2016 - Novo Nordisk har i dag offentliggjort planer om at reducere medarbejderstaben med ca. 1.000 ansatte ud af de 42.300 stillinger i virksomhedens globale organisation. Dette er et af flere tiltag, der er iværksat for at reducere driftsomkostningerne som følge af den udfordrende konkurrencesituation, virksomheden står overfor i 2017, navnlig i det store amerikanske marked. Nedskæringerne forventes at ramme forsknings- og udviklingsenheder og stabsfunktioner i hovedkvarteret samt stillinger i den globale kommercielle organisation. Det ventes, at omkring 500 af de nedlagte stillinger skal findes i Danmark. De fleste af afskedigelserne ventes at blive kommunikeret til berørte medarbejdere i løbet af de næste to måneder efter forhandling i henhold til lokale arbejdsmarkedsregler. Reduktionen af medarbejderstaben og de dermed forbundne omkostninger ændrer ikke på de finansielle forventninger til 2016, der blev kommunikeret i forbindelse med Novo Nordisks halvårsregnskab den 5. august 2016. ""Vi beklager dybt, at gode kolleger står til at miste deres job, og det har været en tung beslutning at træffe,"" siger administrerende direktør Lars Rebien Sørensen. ""Vi er imidlertid kommet til den konklusion, at det er nødvendigt for at sikre, at vi har en bæredygtig balance mellem indtægter og udgifter. I den nuværende situation er vi nødt til at prioritere investeringer i vigtige produktlanceringer, som vil bringe innovation til patienter og drive vores fremtidige vækst."" Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information Selskabsmeddelelse nr. 66 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=990,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
364,2016-09-23,Novo Nordisk indsender ansøgning i USA om inkludering af data fra de to SWITCH-studier i indlægssedlen for Tresiba®,"Bagsværd, den 23. september 2016 - Novo Nordisk meddeler i dag, at virksomheden har indsendt en supplerende ansøgning til de amerikanske sundhedsmyndigheder, FDA, med henblik på inkludering af data fra de to fase 3b-SWITCH-studier i indlægssedlen for Tresiba®. I SWITCH 1 blev deltagere med type 1-diabetes randomiseret til cross-over-behandling med henholdsvis Tresiba® og insulin glargin U100, begge i kombination med insulin aspart. I studiets vedligeholdelsesperiode oplevede deltagere i behandling med Tresiba® i gennemsnit 11% færre episoder af generel symptomatisk hypoglykæmi (lavt blodsukker) bekræftet ved blodsukkermåling, 36% færre episoder af natlig symptomatisk hypoglykæmi bekræftet ved blodsukkermåling og 35% færre episoder af alvorlig hypoglykæmi. Alle ovenstående resultater var statistisk signifikante, og der blev observeret sammenlignelige resultater i den fulde behandlingsperiode. I SWITCH 2 blev deltagere med type 2-diabetes randomiseret til cross-over-behandling med henholdsvis Tresiba® og insulin glargin U100, begge i kombination med diabeteslægemidler i tabletform. I studiets vedligeholdelsesperiode oplevede deltagere i behandling med Tresiba® i gennemsnit 30% færre episoder af generel symptomatisk hypoglykæmi bekræftet ved blodsukkermåling og 42% færre episoder af natlig symptomatisk hypoglykæmi bekræftet ved blodsukkermåling, begge til fordel for Tresiba® sammenlignet med insulin glargin U100. Begge observationer var statistisk signifikante, og der blev observeret sammenlignelige resultater i den fulde behandlingsperiode. For alvorlig hypoglykæmi var der en 46%, men ikke statistisk signifikant reduktion i antallet af episoder i vedligeholdelsesperioden og en statistisk signifikant 51% reduktion i antallet af episoder i den fulde behandlingsperiode for Tresiba® sammenlignet med insulin glargin U100. I begge studier var det gennemsnitlige langtidsblodsukkerniveau (HbA1c) ved studiets begyndelse 7,6%, og i begge studier viste Tresiba® ikke-inferiøritet med hensyn til reduktion af HbA1c sammenlignet med insulin glargin U100. Det betyder, at kravene for objektivt at sammenligne antallet af episoder af hypoglykæmi mellem de to behandlinger var opfyldt. Tresiba® forekom generelt i begge studier at have en sikker og veltolereret profil. ""Hypoglykæmi er til stadighed et stort problem for mange mennesker med type 1- og type 2-diabetes. Vi mener, at forsøgsresultaterne fra SWITCH bør indgå i ordineringsinformationen for Tresiba®, fordi de vil give lægerne vigtig information i forhold til at træffe et kvalificeret valg, når de ordinerer basalinsulin,"" siger Mads Krogsgaard Thomsen, koncerndirektør med ansvar for forskning og udvikling i Novo Nordisk. Om Tresiba® Tresiba® (insulin degludec) er en basalinsulin til dosering én gang dagligt med en virkningsvarighed på mere end 42 timer. Det er vigtigt for mennesker med type 1- og type 2-diabetes at etablere en rutine for deres insulinbehandling. Tresiba® tages én gang dagligt når som helst i løbet af dagen. Patienter, som glemmer en dosis Tresiba®, kan tage den, når de opdager forglemmelsen, men med mindst otte timer mellem doserne. Tresiba® blev godkendt af registreringsmyndighederne første gang i september 2012 og er siden blevet godkendt i flere end 70 lande verden over. Det blev godkendt af FDA i USA den 25. september 2015. Om SWITCH 1 og 2 De to 2x32-ugers randomiserede, dobbeltblindede, cross-over-, treat to target- fase 3b-studier blev påbegyndt i januar 2014 med det formål at sammenligne sikkerhedsprofil og effekt af Tresiba® og insulin glargin U100. I studierne blev deltagerne behandlet i en 16-ugers titreringsperiode efterfulgt af en 16-ugers vedligeholdelsesperiode, hvorefter de blev skiftet over til sammenligningsproduktet. Det overordnede formål med studierne var at dokumentere hypoglykæmiprofilen i henholdsvis type 1- og type 2-diabetes. I SWITCH 1 blev 501 deltagere med type 1-diabetes randomiseret til cross-over-behandling med Tresiba® og insulin glargin U100 i kombination med insulin aspart. I SWITCH 2 blev 721 deltagere med type 2-diabetes randomiseret til cross-over-behandling med Tresiba® og insulin glargin U100 i kombination med diabeteslægemidler i tabletform. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=994,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
365,2016-09-23,Novo Nordisk submits application in the US for including data from the two SWITCH trials in Tresiba® label,"Bagsværd, Denmark, 23 September 2016 - Novo Nordisk today announced the submission of a supplemental application to the US Food and Drug Administration (FDA) for including data from the two SWITCH phase 3b trials in the label for Tresiba®. In SWITCH 1, people with type 1 diabetes were randomised to cross-over treatment with Tresiba® and insulin glargine U100, respectively, both in combination with insulin aspart. During the study's maintenance period, people treated with Tresiba® on average had 11% fewer episodes of overall symptomatic blood glucose confirmed hypoglycaemia, 36% fewer episodes of nocturnal blood glucose confirmed symptomatic hypoglycaemia and 35% fewer episodes of severe hypoglycaemia. All of the above results were statistically significant and similar results were seen in the full treatment period. In SWITCH 2, people with type 2 diabetes were randomised to cross-over treatment with Tresiba® and insulin glargine U100, respectively, both in combination with oral antidiabetic drugs. During the study's maintenance period, people treated with Tresiba® on average had 30% fewer episodes of overall blood glucose confirmed symptomatic hypoglycaemia and 42% fewer episodes of nocturnal blood glucose confirmed symptomatic hypoglycaemia, both favouring Tresiba® over insulin glargine U100. Both observations were statistically significant and similar results were observed for the full treatment period. For severe hypoglycaemia there was a 46%, but not statistically significant reduction of the episodes in the maintenance period, and a statistically significant 51% reduction of the episodes in the full treatment period for Tresiba® compared to insulin glargine U100. In both studies, the mean baseline for HbA1c was 7.6%, and both studies showed that Tresiba® was non-inferior in terms of HbA1c reduction compared to insulin glargine U100. This means that the requirements for objectively comparing hypoglycaemia episodes between the two treatments were fulfilled. In both studies, Tresiba® generally appeared to have a safe and well-tolerated profile. ""Hypoglycaemia continues to be a real challenge for many people with type 1 and type 2 diabetes. We believe that inclusion of the SWITCH trial results in the prescribing information for Tresiba® will provide healthcare professionals with important information to make an informed choice when prescribing basal insulin"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. About Tresiba® Tresiba® (insulin degludec) is a once-daily basal insulin that provides a duration of action beyond 42 hours. It is important for people with type 1 and type 2 diabetes to establish a routine for insulin treatment. Tresiba® is taken once daily, at any time of day. Patients who miss or are delayed in taking their dose of Tresiba® can take their dose as soon as they remember, making sure there are at least eight hours between doses. Tresiba® received its first regulatory approval in September 2012 and has since been approved in more than 70 countries globally. It was approved by the FDA in the United States on 25 September 2015. About SWITCH 1 and 2 The two phase 3b, 2x32-weeks randomised, double-blind, cross-over, treat-to-target trials were initiated in January 2014 to compare the safety profile and efficacy of Tresiba® and insulin glargine U100. In the trials, people were treated for a 16-week titration period followed by a 16-week maintenance period and subsequently switched to the comparator drug. The overall objective was to document the hypoglycaemia profile in type 1 diabetes and type 2 diabetes, respectively. In SWITCH 1, 501 people with type 1 diabetes were randomised to cross-over treatment with Tresiba® and insulin glargine U100 in combination with insulin aspart. In SWITCH 2, 721 people with type 2 diabetes were randomised to cross-over treatment with Tresiba® and insulin glargine U100 in combination with oral antidiabetic drugs. Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=993,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
366,2016-09-16,Semaglutid reducerer forekomsten af alvorlige kardiovaskulære tilfælde med 26% hos voksne med type 2-diabetes med høj risiko for hjerte-kar-sygdom,"München, Tyskland, den 16. september 2016 - Novo Nordisk meddeler i dag, at semaglutid, en GLP-1-analog (glukagonlignende peptid-1) under udvikling til dosering én gang om ugen, reducerede risikoen signifikant for det primære sammensatte endepunkt: tiden til første forekomst af kardiovaskulært dødsfald, ikke-fatalt myokardieinfarkt (hjerteanfald) eller ikke-fatalt slagtilfælde, med 26% sammenlignet med placebo, når det blev givet som supplement til standardbehandling hos 3.297 voksne med type 2-diabetes med høj risiko for hjerte-kar-sygdom.[i] Disse resultater er baseret på en akkumulering af første alvorlige kardiovaskulære hændelser hos 254 deltagere.1 Hovedresultaterne fra SUSTAIN 6 blev præsenteret i dag på det 52. årsmøde i European Association for the Study of Diabetes (EASD) 2016[i] og blev desuden publiceret i New England Journal of Medicine.1  Yderligere information  [i]    Marso SP, Bain S, Consoli A, et al. Semaglutide and cardiovascular outcomes, efficacy and safety in type 2 diabetes. New England Journal of Medicine. 2016; In Press.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1002,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
367,2016-09-16,Semaglutide reduced major cardiovascular events by 26% in adults with type 2 diabetes at high cardiovascular risk,"Munich, Germany, 16 September 2016 - Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, significantly reduced the risk of the primary composite endpoint of time to first occurrence of either cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke by 26% vs placebo, when added to standard of care in 3,297 adults with type 2 diabetes at high CV risk.1 These results were based on an accumulation of first major adverse CV events (MACE) in 254 people.1 The main results from SUSTAIN 6 were presented today at the 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 20162 and also published in the New England Journal of Medicine.1  Further information References ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1000,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
368,2016-09-15,Victoza® reducerer progressionen af nyreskade hos voksne med type 2-diabetes med høj risiko for hjerte-kar-sygdom,"München, Tyskland, den 15. september 2016 - Novo Nordisk har i dag præsenteret resultater, der viser, at progressionen af nyreskade var signifikant lavere ved behandling med Victoza® (liraglutid) sammenlignet med placebo (målt ved urin albumin/kreatinin ratio), når begge blev givet som supplement til standardbehandling i et studie med 9.340 voksne med type 2-diabetes med høj risiko for kardiovaskulære hændelser. Desuden blev tilsvarende signifikante resultater observeret mellem Victoza® og placebo på tværs af undergrupper (med ingen, mildt eller moderat nedsat nyrefunktion).[i] Resultaterne er en del af LEADER-studiet, der i dag blev præsenteret på det 52. årsmøde i European Association for the Study of Diabetes (EASD) 2016.1 Yderligere information  [i]    Results of the liraglutide effect and action in diabetes - evaluation of cardiovascular outcome results (LEADER) trial. Scientific Sessions at the 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2016. 15 September 2016.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1005,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
369,2016-09-15,Victoza® lowered the progression of kidney damage in adults with type 2 diabetes at high CV risk,"Munich, Germany, 15 September 2016 - Novo Nordisk today announced that the progression of kidney damage was significantly lower with Victoza® treatment vs placebo, as measured by urinary albumin creatinine ratio, both added to standard of care in 9,340 adults with type 2 diabetes at high cardiovascular (CV) risk. Similar significant results were observed between Victoza® and placebo across subgroups (with no, mild or moderate renal impairment).1 The results were presented today at the 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2016.1 Further information References 1.    Results of the liraglutide effect and action in diabetes - evaluation of cardiovascular outcome results (LEADER) trial. Scientific Sessions at the 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2016. 15 September 2016.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1004,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
370,2016-09-14,Saxenda® giver konsistent vægttab og bedre blodsukkerregulering på tværs af BMI-kategorier efter tre års behandling,"München, Tyskland, den 14. september 2016 - Resultaterne fra en post hoc-analyse af den treårige del af fase 3a-studiet SCALE (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes viser, at deltagere, der blev behandlet med Saxenda® (liraglutid 3 mg), oplevede konsistent vægttab og bedre blodsukkerregulering på tværs af BMI-kategorierne over tre år sammenlignet med placebobehandling. Disse data blev præsenteret i dag på det 52. årsmøde i European Association for the Study of Diabetes (EASD) 2016. Yderligere information  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1007,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
371,2016-09-14,Saxenda® provides consistent weight loss and improvements in blood glucose control across BMI categories after three years of treatment,"Munich, Germany, 14 September 2016 - Results from a post hoc analysis of the three-year part of the phase 3a SCALE (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial show that people treated with Saxenda® (liraglutide 3 mg) experienced consistent weight loss and improved blood glucose control across baseline body mass index (BMI) categories over three years as compared to placebo treatment. These data were presented today at the 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2016. Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1006,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
372,2016-09-13,Semaglutid reducerer blodsukker signifikant bedre sammenlignet med placebo givet som tillægsbehandling til basalinsulin alene eller i kombination med metformin hos voksne med type 2-diabetes,"München, Tyskland, den 13. september 2016 - Semaglutid, en GLP-1-analog (glukagonlignende peptid-1) under udvikling til dosering én gang om ugen, giver en signifikant bedre blodsukkerregulering sammenlignet med placebo som tillægsbehandling til basalinsulin alene eller i kombination med metformin hos voksne, der i gennemsnit har haft type 2-diabetes 13 år. Det viser resultaterne fra SUSTAIN 5, som blev præsenteret i dag på det 52. årsmøde i European Association for the Study of Diabetes (EASD) 2016.[i] Læs hele meddelelsen inkl. referencer Yderligere information [i]   Rodbard, H, Lingvay, I, Reed, J et al. Efficacy and safety of semaglutide onceweekly vs placebo as addon to basal insulin alone or in combination with metformin in subjects with type 2 diabetes (SUSTAIN 5). Poster number 766. European Association for the Study of Diabetes, Munich, Germany; 12-16 September 2016.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1009,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
373,2016-09-13,Semaglutide demonstrated superior HbA1c reduction vs placebo as add-on to basal insulin alone or with metformin in adults with type 2 diabetes,"Munich, Germany, 13 September 2016 - Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, significantly improved glycaemic control compared to placebo, as add-on to basal insulin alone or in combination with metformin, in adults with a mean type 2 diabetes duration of 13 years. Results from SUSTAIN 5 were presented today at the 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2016.1 Read the full release including references Further information  1.         Rodbard, H, Lingvay, I, Reed, J et al. Efficacy and safety of semaglutide onceweekly vs placebo as addon to basal insulin alone or in combination with metformin in subjects with type 2 diabetes (SUSTAIN 5). Poster number 766. European Association for the Study of Diabetes, Munich, Germany; 12-16 September 2016.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1008,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
374,2016-09-13,"Voksne med type 2-diabetes i behandling med Xultophy® (IDegLira) har op til 4,5 gange så stor sandsynlighed for at opnå blodsukkerkontrol uden hypoglykæmi og vægtøgning sammenlignet med...","Voksne med type 2-diabetes i behandling med Xultophy® (IDegLira) har op til 4,5 gange så stor sandsynlighed for at opnå blodsukkerkontrol uden hypoglykæmi og vægtøgning sammenlignet med patienter, der titrerer op med insulin glargin U100 München, Tyskland, den 13. september 2016 - Novo Nordisk præsenterede i dag data, der viser, at voksne med type 2-diabetes, som ikke er i kontrol med insulin glargin U100 (20-50 enheder), har signifikant højere sandsynlighed for at nå behandlingsmål for fasteblodsukker (FPG) uden hypoglykæmi (lavt blodsukker) og vægtøgning med Xultophy® (IDegLira) sammenlignet med patienter, der titrerer op med insulin glargin U100. Xultophy® er den første kombination i Europa af langtidsvirkende insulin (insulin degludec) og en glukagonlignende peptid-1 (GLP-1)-receptoragonist (liraglutid) til dosering én gang dagligt. Resultaterne blev præsenteret på det 52. årsmøde for European Association for the Study of Diabetes (EASD) 2016.[1] Læs hele meddelelsen inkl. referencer [1]   Lingvay I, Norwood P, Begtrup K et al. Patients with T2D Treated with IDegLira Have a Greater Chance of Reaching Glycaemic targets without Hypoglycaemia and Weight Gain than with Insulin Glargine U100 (IGlar U100). Abstract 890 blev præsenteret på det 52. årsmøde i European Association for the Study of Diabetes (EASD), München, Tyskland. 13. september 2016.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1011,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
375,2016-09-13,Adults with type 2 diabetes treated with Xultophy® (IDegLira) were up to 4.5 times more likely to reach glycaemic targets without hypoglycaemia and weight gain vs up-titration with...,"Adults with type 2 diabetes treated with Xultophy® (IDegLira) were up to 4.5 times more likely to reach glycaemic targets without hypoglycaemia and weight gain vs up-titration with insulin glargine U100 Munich, Germany, 13 September 2016 - Novo Nordisk today presented data showing the odds of reaching fasting plasma glucose (FPG) targets without hypoglycaemia and weight gain were significantly greater for Xultophy® (IDegLira) compared to up-titration with insulin glargine U100 in adults with type 2 diabetes uncontrolled on insulin glargine U100 (20-50 units). Xultophy® is the first once-daily combination of a long-acting insulin (insulin degludec) and a glucagon-like peptide-1 (GLP-1) receptor agonist (liraglutide) in Europe. Results were presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2016.1 Read the full release including references Further information _______________________ 1.         Lingvay I, Norwood P, Begtrup K et al. Patients with T2D Treated with IDegLira Have a Greater Chance of Reaching Glycaemic targets without Hypoglycaemia and Weight Gain than with Insulin Glargine U100 (IGlar U100). Abstract 890 presented at the 52nd European Association for the Study of Diabetes (EASD), Munich, Germany. 13 September 2016.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1010,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
376,2016-09-13,Adults with type 2 diabetes treated with Xultophy® (IDegLira) were up to 4.5 times more likely to reach glycaemic targets without hypoglycaemia and weight gain vs up-titration with...,"Adults with type 2 diabetes treated with Xultophy® (IDegLira) were up to 4.5 times more likely to reach glycaemic targets without hypoglycaemia and weight gain vs up-titration with insulin glargine U100 Munich, Germany, 13 September 2016 - Novo Nordisk today presented data showing the odds of reaching fasting plasma glucose (FPG) targets without hypoglycaemia and weight gain were significantly greater for Xultophy® (IDegLira) compared to up-titration with insulin glargine U100 in adults with type 2 diabetes uncontrolled on insulin glargine U100 (20-50 units). Xultophy® is the first once-daily combination of a long-acting insulin (insulin degludec) and a glucagon-like peptide-1 (GLP-1) receptor agonist (liraglutide) in Europe. Results were presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2016.1 Read the full release including references Further information _______________________ 1.         Lingvay I, Norwood P, Begtrup K et al. Patients with T2D Treated with IDegLira Have a Greater Chance of Reaching Glycaemic targets without Hypoglycaemia and Weight Gain than with Insulin Glargine U100 (IGlar U100). Abstract 890 presented at the 52nd European Association for the Study of Diabetes (EASD), Munich, Germany. 13 September 2016.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1012,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
377,2016-09-13,"Voksne med type 2-diabetes i behandling med Xultophy® (IDegLira) har op til 4,5 gange så stor sandsynlighed for at opnå blodsukkerkontrol uden hypoglykæmi og vægtøgning sammenlignet med...","Voksne med type 2-diabetes i behandling med Xultophy® (IDegLira) har op til 4,5 gange så stor sandsynlighed for at opnå blodsukkerkontrol uden hypoglykæmi og vægtøgning sammenlignet med patienter, der titrerer op med insulin glargin U100 München, Tyskland, den 13. september 2016 - Novo Nordisk præsenterede i dag data, der viser, at voksne med type 2-diabetes, som ikke er i kontrol med insulin glargin U100 (20-50 enheder), har signifikant højere sandsynlighed for at nå behandlingsmål for fasteblodsukker (FPG) uden hypoglykæmi (lavt blodsukker) og vægtøgning med Xultophy® (IDegLira) sammenlignet med patienter, der titrerer op med insulin glargin U100. Xultophy® er den første kombination i Europa af langtidsvirkende insulin (insulin degludec) og en glukagonlignende peptid-1 (GLP-1)-receptoragonist (liraglutid) til dosering én gang dagligt. Resultaterne blev præsenteret på det 52. årsmøde for European Association for the Study of Diabetes (EASD) 2016.[1] Læs hele meddelelsen inkl. referencer [1]   Lingvay I, Norwood P, Begtrup K et al. Patients with T2D Treated with IDegLira Have a Greater Chance of Reaching Glycaemic targets without Hypoglycaemia and Weight Gain than with Insulin Glargine U100 (IGlar U100). Abstract 890 blev præsenteret på det 52. årsmøde i European Association for the Study of Diabetes (EASD), München, Tyskland. 13. september 2016.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1013,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
378,2016-09-02,FDA extends regulatory review period for IDegLira by three months,"Bagsværd, Denmark, 2 September 2016 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has extended the regulatory review period for IDegLira, the fixed-ratio combination of insulin degludec and liraglutide in adults with type 2 diabetes. The FDA informed Novo Nordisk that a three-month extension was required in order to complete its review of the new drug application (NDA) for IDegLira. Novo Nordisk submitted the NDA to the FDA in September 2015, and with the extension of the review the action date is now expected in December 2016. ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1018,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
379,2016-09-02,FDA forlænger registreringsprocessen for IDegLira med tre måneder,"Bagsværd, den 2. september 2016 - Novo Nordisk A/S meddeler i dag, at de amerikanske sundhedsmyndigheder (FDA) har forlænget registreringsprocessen for IDegLira, et kombinationsprodukt bestående af insulin degludec og liraglutid i et fast kombinationsforhold til behandling af voksne med type 2-diabetes. FDA meddelte Novo Nordisk at en tre-måneders forlængelse var påkrævet for at gennemgå ansøgningen og færdiggøre registreringsprocessen af IDegLira. Novo Nordisk indsendte ansøgningen til FDA i september 2015, og med forlængelsen af registreringsprocessen forventes en tilbagemelding i december 2016. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1019,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
380,2016-09-01,Lars Rebien Sørensen stopper som administrerende direktør for Novo Nordisk; hans afløser bliver Lars Fruergaard Jørgensen,"Bagsværd, den 1. september 2016 - Novo Nordisk A/S meddeler i dag, at Lars Rebien Sørensen fratræder som administrerende direktør for virksomheden med udgangen af 2016. Lars Fruergaard Jørgensen, nuværende koncerndirektør med ansvar for Corporate Development, bliver ny administrerende direktør med virkning fra 1. januar 2017. I forbindelse hermed gennemføres en række andre ændringer på direktionsniveau med omgående virkning. I en kommentar til Lars Rebien Sørensens fratrædelse siger Göran Ando, formand for bestyrelsen i Novo Nordisk A/S: ""Det bliver en stor opgave at føre stafetten videre efter Lars, som gennem 16 år som administrerende direktør har stået i spidsen for Novo Nordisks udvikling til en global, særdeles succesrig og højt respekteret lægemiddelvirksomhed. På vegne af Novo Nordisks bestyrelse og virksomhedens medarbejdere vil jeg gerne takke Lars for hans fremragende lederskab, støtte kurs og engagement i Novo Nordisk gennem såvel gode som svære tider igennem hans 34 år i virksomheden."" Bestyrelserne for Novo Nordisk Fonden og Fondens holdingselskab, Novo A/S, vil indstille Lars Rebien Sørensen som medlem af de to bestyrelser i marts 2017. Om udnævnelsen af Lars Fruergaard Jørgensen siger Göran Ando: ""Beslutningen om at udnævne Lars Fruergaard Jørgensen som ny administrerende direktør er resultat af en meget grundig proces, hvor en række kvalificerede kandidater har været i betragtning. På baggrund af hans evne til at skabe resultater, drive forandring og være en rollemodel for at lede en virksomhed the Novo Nordisk Way er bestyrelsen overbevist om, at han er den perfekte afløser for Lars Rebien Sørensen. Han får i sin nye rolle ansvar for at lede Novo Nordisk igennem en tid præget af store forandringer i sundhedssystemer overalt i verden, med virksomhedens langsigtede strategi, forretningsprincippet om den tredobbelte bundlinje og de langsigtede finansielle mål som pejlemærker."" Lars Rebien Sørensen siger om sin lange karriere i Novo Nordisk: ""Det har været en ære at arbejde her i mere end 30 år og at have haft rollen som administrerende direktør i en periode, hvor vi har haft mulighed for at skabe vækst i forretningen, opbygget en stærk pipeline og lanceret vigtige nye produkter til gavn for vores patienter, vores aktionærer og vores medarbejdere."" Han fortsætter: ""Jeg har været tæt involveret i de vurderinger, der har ført til bestyrelsens beslutning om at udnævne Lars Fruergaard Jørgensen til min efterfølger - en beslutning, jeg støtter fuldt ud. Han er en dygtig forretningsmand med fremragende lederegenskaber og har en naturlig evne til at finde løsninger, hvor andre ser problemer."" Lars Fruergaard Jørgensen siger, at han er ""stolt og ydmyg over at få tilbudt jobbet som administrerende direktør"" og fortsætter: ""På den ene side har Novo Nordisk aldrig haft en stærkere produktportefølje og organisation; på den anden side står vi overfor et hidtil uset pres både fra de private og offentlige betalere af sundhedsydelser og fra vores konkurrenter. Jeg elsker udfordringer og kan derfor ikke forestille mig et mere spændende tidspunkt at få tilbudt jobbet som topchef for Novo Nordisk på - en virksomhed, jeg har arbejdet for i mere end 25 år, og som jeg virkelig brænder for."" Øvrige organisationsændringer Med virkning fra i dag gennemføres følgende yderligere ændringer på direktionsniveau: Jakob Riis, nuværende koncerndirektør med ansvar for Region China, Pacific & Marketing, udnævnes til koncerndirektør med ansvar for North America Operations. Han afløser Jesper Høiland, som udtræder af koncerndirektionen, og hvis fremtidige rolle i Novo Nordisk vil blive meddelt på et senere tidspunkt. Maziar Mike Doustdar, koncerndirektør med ansvar for International Operations, fortsætter i sin nuværende rolle, men med forøget ansvar for et udvidet International Operations, som nu omfatter alle områder undtagen Nordamerika og er organiseret i følgende fem regioner: Europe; Latin America; Africa, Asia, Middle East & Oceania; Japan & Korea; og Region China. Jerzy Gruhn, nuværende koncerndirektør med ansvar for Europe, udtræder af koncerndirektionen og vil fortsat være ansvarlig for Europe, nu som funktionsdirektør med rapport til Maziar Mike Doustdar. Novo Nordisks koncerndirektion består herefter af: Lars Fruergaard Jørgensens efterfølger som leder af Corporate Development vil blive meddelt på et senere tidspunkt. Om Lars Fruergaard Jørgensen Lars Fruergaard Jørgensen blev ansat i Novo Nordisk i 1991 som økonom i Health Care, Economy & Planning og har gennem årene været udstationeret i Holland, USA og Japan. I 2004 blev han udnævnt til direktør for IT & Corporate Development. I januar 2013 blev han udnævnt til koncerndirektør med ansvar for IT, Quality & Corporate Development. I november 2014 overtog han yderligere ansvaret for Corporate People & Organisation og Business Assurance. Lars Fruergaard Jørgensen er formand for bestyrelsen i NNE Pharmaplan A/S, Danmark. Han er uddannet cand.merc. fra Handelshøjskolen i Århus i 1991. Han er dansk statsborger og er født i november 1966. Telekonference Der vil den 1. september 2016 kl. 13.00 CEST blive afholdt en telekonference. Investorer kan lytte med via et link på novonordisk.com under menupunktet 'Investors'. Dette er en oversættelse af den originale engelske selskabsmeddelelse. I tilfælde af uoverensstemmelser mellem den danske og den engelske version er den engelske gældende. Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1021,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
381,2016-09-01,Lars Rebien Sørensen to retire as CEO of Novo Nordisk; Lars Fruergaard Jørgensen appointed as successor,"Bagsværd, Denmark, 1 September 2016 - Novo Nordisk A/S today announced that Lars Rebien Sørensen, president and chief executive officer, will retire from the company by the end of 2016. Lars Fruergaard Jørgensen, currently executive vice president and head of Corporate Development, will succeed him, effective 1 January 2017. The company also announced a number of other executive-level changes, effective immediately. Commenting on the retirement of Lars Rebien Sørensen, Göran Ando, chairman of the Board of Directors of Novo Nordisk A/S, said: ""Succeeding Lars, who during 16 years as CEO of Novo Nordisk has spearheaded Novo Nordisk into a global, very successful and highly respected pharmaceutical company, is a tall order. On behalf of Novo Nordisk's Board of Directors and the company's employees, I want to thank Lars for his outstanding leadership, steady course and commitment to Novo Nordisk through good and difficult times during his 34 years with the company."" The boards of the Novo Nordisk Foundation and the Foundation's holding company, Novo A/S, will nominate Lars Rebien Sørensen to become a member of the two boards in March 2017. Commenting on the appointment of Lars Fruergaard Jørgensen, Göran Ando said: ""The decision to appoint Lars Fruergaard Jørgensen as new CEO is the result of a rigorous process during which a number of qualified candidates were considered. With his track record of creating results, driving change and being a role model for the Novo Nordisk Way of running a company, the Board is confident that he is the perfect successor to Lars Rebien Sørensen. In his new role, he will be charged with leading Novo Nordisk through a time of extraordinary change in healthcare systems around the world, with the company's long-term strategy, the Triple Bottom Line business principle and long-term financial targets as his guiding posts."" Reflecting on his long career in Novo Nordisk, Lars Rebien Sørensen said: ""It has been an honour to work here for more than 30 years and to serve as CEO during a period where we have been able to grow our business, build a strong pipeline and launch important new products to the benefit of our patients, our shareholders and our employees."" He continued: ""I have been closely involved in the assessments that have led to the Board's decision to appoint Lars Fruergaard Jørgensen as my successor, a decision which I fully support. He is a great businessman and people leader and has a natural ability to find solutions where others see problems."" Lars Fruergaard Jørgensen said that he is ""proud and humble to be offered the job as CEO"" and continued: ""On the one hand, Novo Nordisk has never had a stronger portfolio and organisation; on the other hand, we are facing an unprecedented level of payer pressure and competition. I love challenges, and therefore I can't think of a more exciting time to be offered the job of CEO in Novo Nordisk - a company I have served for more than 25 years and am really passionate about."" Other executive-level changes are announced today, effective immediately: Jakob Riis, currently executive vice president and head of Region China, Pacific & Marketing, is appointed executive vice president and head of North America Operations. He succeeds Jesper Høiland, who steps down from Executive Management and whose future role in Novo Nordisk will be announced at a later date. Maziar Mike Doustdar, currently executive vice president and head of International Operations, continues in this role, but with enlarged responsibility for an expanded International Operations unit, now covering all territories except for North America and organised in the following five regions: Europe; Latin America; Africa, Asia, Middle East & Oceania; Japan & Korea; and Region China. Jerzy Gruhn, currently executive vice president and head of Europe, steps down from Executive Management and will continue as head of Europe, now as senior vice president, reporting to Maziar Mike Doustdar. With these changes, the members of Novo Nordisk's Executive Management are: Lars Fruergaard Jørgensen's successor as head of Corporate Development will be announced at a later date. Lars Fruergaard Jørgensen joined Novo Nordisk in 1991 as an economist in Health Care, Economy & Planning and has over the years completed overseas postings in the Netherlands, US and Japan. In 2004 he was appointed senior vice president for IT & Corporate Development. In January 2013 he was appointed executive vice president and chief information officer assuming responsibility for IT, Quality & Corporate Development. In November 2014 he took over additional responsibilities for Corporate People & Organisation and Business Assurance. Lars Fruergaard Jørgensen is chairman of the Board of NNE Pharmaplan A/S, Denmark. He earned an MSc in Finance and Business Administration from Aarhus School of Business, Aarhus University, Denmark, in 1991. He is a Danish national, born November 1966. On 1 September 2016 at 1.00 pm CEST, corresponding to 7.00 am EDT, a conference call for investors will be held. Investors will be able to listen in via a link on the investor section of novonordisk.com.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1020,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
382,2016-08-05,Novo Nordisk increased adjusted operating profit by 8% in local currencies in the first six months of 2016,"Sales increased by 7% in local currencies and by 5% in Danish kroner to DKK 54.7 billion. Operating profit decreased by 3% reported in local currencies and by 6% in Danish kroner to DKK 24.8 billion. Adjusted for the non-recurring income related to the partial divestment of NNIT and the income related to out-licensing of assets for inflammatory disorders, both in 2015, operating profit in local currencies increased by 8%. Net profit increased by 7% to DKK 19.4 billion. Diluted earnings per share increased by 9% to DKK 7.63. Adjusted for the partial divestment of NNIT, net profit and diluted earnings per share increased by 22% and 23% respectively. In May, IDegLira the combination of insulin degludec (Tresiba®) and liraglutide (Victoza®) received a positive 16-0 vote from FDA's Advisory Committee recommending the approval of the treatment for adults with type 2 diabetes. In June, at an American Diabetes Association (ADA) hosted symposium the detailed results from the LEADER trial were presented, demonstrating that Victoza® significantly reduced the risk of major cardiovascular events by 13% versus placebo when added to standard of care in 9,340 adults with type 2 diabetes at high cardiovascular risk. The Board of Directors has decided to introduce an interim dividend for 2016 of DKK 3.00 per share of DKK 0.20 that will be paid in August 2016. For 2016, the range for expected sales growth has been narrowed to 5-7% and growth in adjusted operating profit is now expected to be 5-8%, both measured in local currencies. For 2017, Novo Nordisk has completed the majority of formulary negotiations in the USA and average prices after rebates are expected to be moderately lower, while the market access for the Novo Nordisk products is expected to remain largely unchanged. Lars Rebien Sørensen, president and CEO: ""Overall, we are satisfied with the performance in the first six months of 2016 where Victoza® and Tresiba® continued to deliver strong sales growth and Region China improved faster than expected. In the USA, the market environment is becoming increasingly challenging and contract negotiations for 2017 have reflected an intensifying price competition. In spite of this, we see significant growth opportunities based on our strong diabetes care portfolio"". Contacts for further information Company announcement No 55 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1031,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
383,2016-08-05,"Novo Nordisks resultat af primær drift, justeret, steg med 8% i lokale valutaer i første halvår af 2016","Salget steg med 7% opgjort i lokale valutaer og med 5% i kroner til 54,7 mia. kr. Resultat af primær drift faldt med 3% rapporteret i lokale valutaer og med 6% i danske kroner til 24,8 mia. kr. Justeret for engangsindtægten fra det delvise frasalg af NNIT og indtægten fra udlicensering af aktiver vedrørende inflammatoriske sygdomme, begge i 2015, steg resultat af primær drift opgjort i lokale valutaer med 8%. Nettoresultatet steg med 7% til 19,4 mia. kr. Udvandet resultat pr. aktie steg med 9% til 7,63 kr. Justeret for det delvise frasalg af NNIT steg nettoresultatet og udvandet resultat pr. aktie med henholdsvis 22% og 23%. I maj vedtog en rådgivende komite for de amerikanske sundhedsmyndigheder, FDA, med stemmerne 16-0 at anbefale godkendelse af kombinationsproduktet IDegLira, som består af insulin degludec (Tresiba®) og liraglutid (Victoza®), til behandling af voksne med type 2-diabetes. I juni præsenterede Novo Nordisk de detaljerede resultater fra LEADER-studiet på et symposium på den amerikanske diabeteskongres ADA. Studiet viste, at Victoza® reducerede risikoen for alvorlige kardiovaskulære hændelser signifikant med 13% sammenlignet med placebo, når det blev givet som supplement til standardbehandling hos 9.340 voksne med type 2-diabetes med høj risiko for kardiovaskulære hændelser. Bestyrelsen har besluttet at introducere udbetalingen af et interimudbytte for 2016 på 3,00 kr. pr. aktie a 0,20 kr. i august 2016. For 2016 er intervallet for forventet salgsvækst indsnævret til 5-7%, mens væksten i justeret resultat af primær drift nu forventes at blive på 5-8%, begge opgjort i lokale valutaer. Novo Nordisk har afsluttet de fleste forhandlinger om priser og medicintilskud i USA for 2017, og gennemsnitspriserne efter rabatter forventes at blive moderat lavere, mens markedsadgangen for Novo Nordisks produkter forventes at forblive stort set uændret. Adm. direktør Lars Rebien Sørensen: ""Overordnet set er vi tilfredse med resultaterne i første halvår af 2016, hvor Victoza® og Tresiba® fortsat har leveret stærk salgsvækst, og Region Kina har vist fremgang hurtigere end forventet. I USA er markedsforholdene i stigende grad udfordrende, og kontraktforhandlingerne for 2017 afspejler en intensiveret priskonkurrence. Til trods for dette ser vi signifikante vækstmuligheder baseret på vores stærke portefølje af produkter til diabetesbehandling."" Kontaktoplysninger Selskabsmeddelelse nr. 55 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1030,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
384,2016-07-11,Novo Nordisk to present 28 abstracts at the World Federation of Hemophilia Congress,"Bagsværd, Denmark, 11 July 2016 - Novo Nordisk announced today that data from 28 abstracts will be shared at the upcoming World Federation of Hemophilia World Congress (WFH) in Orlando, Florida, from 24-28 July. The WFH Congress is the largest international meeting for the global bleeding disorders community, taking place every second year. The broad spectrum of data demonstrates exciting new advances in the area of haemophilia and establishes Novo Nordisk's commitment to driving innovation and research. The comprehensive programme provides updates on Novo Nordisk's haemophilia pipeline, new clinical data regarding established treatments and insights into the psychosocial and functional impact of haemophilia on quality of life. Following are key highlights that will be presented at the meeting: Monday, 25 July, 3:50 pm EDT, poster presentation Tuesday, 26 July, 3:30 pm EDT, poster presentations Wednesday, 27 July, 3:30 pm EDT, poster presentations ""The presentation of 28 abstracts at WFH 2016 is unparalleled and a clear signal to the haemophilia community that Novo Nordisk is committed to finding solutions to improve the lives of people living with haemophilia worldwide,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""We look forward to the opportunity for scientific exchange at this important meeting."" The abstracts above are a sampling of the data that will be presented or published by Novo Nordisk. For a complete list of abstracts please visit: www.wfh.org/congress/2016_Abstracts",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1040,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
385,2016-07-04,Novo Nordisk investerer 400 mio. kr. i udbygning af produktionen i Kalundborg,"Bagsværd, den 4. juli 2016 - Novo Nordisk investerer 400 mio. kr. i en 500 m2 stor udbygning af verdens største insulinfabrik i Kalundborg. ""Udvidelsen af fabriksanlægget understreger vores ambition om en fortsat styrket tilstedeværelse i Kalundborg. Den giver os større fleksibilitet og mulighed for at installere udstyr, der øger vores effektivitet, og er således med til at øge produktionskapaciteten på anlægget i Kalundborg,"" siger Michael Hallgren, produktionsdirektør, Novo Nordisk Kalundborg. Novo Nordisks fabrikspark i Kalundborg blev etableret i 1969 og dækker i dag et areal på 1,1 mio. kvadratmeter. Novo Nordisk Kalundborg beskæftiger 3.400 medarbejdere og udgør en hjørnesten i Novo Nordisks globale produktion, og her produceres 50% af verdens insulin samt en række biofarmaceutiske produkter. Første spadestik til udbygningen af fabrikken bliver taget i dag, den 4. juli, og udbygningen forventes færdig i slutningen af 2018.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1044,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
386,2016-07-04,Novo Nordisk invests DKK 400 million in an expanded production plant in Kalundborg,"Bagsværd, Denmark, 4 July 2016 - Novo Nordisk is investing 400 million Danish kroner in a 500 m2 extension of the world's largest insulin production plant in Kalundborg. ""The expansion of our production plant highlights our ambition to continue strengthening our presence in Kalundborg. The new facilities will give us greater flexibility and enable the installation of equipment that will enhance efficiency and increase the long-term production capacity of the plant,"" says Michael Hallgren, senior vice president and head of production in Kalundborg. Established in 1969, the Kalundborg production site today covers a total area of 1.1 million square metres. With its 3,400 employees, Novo Nordisk Kalundborg is a cornerstone of Novo Nordisk's global production and produces 50% of the world's insulin as well as a range of biopharmaceutical products. Groundbreaking for the plant extension will take place today and the extension is expected to be completed at the end of 2018.  Further information   ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1043,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
387,2016-07-01,Novo Nordisk and Aarhus University team up on world-class talents,"Bagsværd, Denmark, 1 July 2016 - Novo Nordisk and Aarhus University's Science and Technology faculty today signed a collaboration agreement to strengthen protein technology research and development. Under the new collaboration, a total of nine PhD students will be offered three-year research scholarships. The research will take place in the leading technological research environments at Science and Technology, Aarhus University, and in Novo Nordisk's research and development department in Måløv. The Aarhus Novo Nordisk Science and Talent Network programme will run for five years. ""This is the starting point for a stronger collaboration between Aarhus University and Novo Nordisk, which is exploiting the powerful and growing synergy between research and industrial development,"" says Niels Chr. Nielsen, dean of the Faculty of Science and Technology, Aarhus University. ""The collaboration creates a unique opportunity to focus on talent development while uniting and further developing excellent research environments within the development of protein- and peptide-based medicines at Aarhus University and Novo Nordisk."" Aarhus University and Novo Nordisk are also seizing the opportunity to initiate collaboration on education. The intention is that students will have the opportunity to combine highly theoretical training directly with practical and industry-relevant problems. ""With this agreement, we are building an important relationship with some of the best research environments at Aarhus University in areas of technology that are significant to Novo Nordisk. Partnerships like this with leading research environments - and the training of talented young researchers - are important for driving innovation at Novo Nordisk,"" says Peter Kurtzhals, senior vice president, Global Research, Novo Nordisk. Aarhus University belongs to the scientific elite and has, among other things, core competences within organic chemistry, protein chemistry and structural biology. Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. Over 5,400 employees work in research and development at Novo Nordisk in Denmark, the US and China, many of them in partnership with external biotech and academic researchers. The company has about 120 PhD students and postdocs worldwide - and soon also some in Aarhus. A joint steering committee with members from Aarhus University and Novo Nordisk will have overall responsibility for the programme. The first three PhD students are expected to begin their research in 2017.  Media:",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1049,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
388,2016-07-01,Novo Nordisk og Aarhus Universitet indgår samarbejde om talenter i verdensklasse,"Bagsværd, den 1. juli 2016 - Novo Nordisk og Aarhus Universitet, Science and Technology, har underskrevet en samarbejdsaftale, der skal styrke forskning og udvikling af proteinteknologi. I det nye samarbejde vil i alt ni ph.d.-studerende blive tilbudt et treårigt stipendium til forskning. Forskningen vil foregå både i de stærke teknologiske forskningsmiljøer på Science and Technology på Aarhus Universitet og i Novo Nordisks forsknings- og udviklingsafdeling i Måløv. Programmet 'Aarhus Novo Nordisk Science and Talent Network' vil køre i fem år. ""Dette er startskuddet på et styrket samarbejde mellem Aarhus Universitet og Novo Nordisk, der udnytter en stærk og voksende synergi mellem forskning og industriel udvikling,"" siger Niels Chr. Nielsen, dekan ved Science and Technology, Aarhus Universitet. ""Samarbejdet skaber en unik mulighed for at sætte fokus på talentudvikling samt samle og videreudvikle excellente forskningsmiljøer indenfor protein- og peptid-baseret lægemiddeludvikling på Aarhus Universitet og hos Novo Nordisk."" Aarhus Universitet og Novo Nordisk indleder ved samme lejlighed et samarbejde omkring uddannelse. Hensigten er, at studerende får mulighed for at kombinere en uddannelse på højt teoretisk niveau direkte med praktiske og industrirelevante problemstillinger. ""Med denne aftale bygger vi en vigtig relation til nogle af de bedste forskningsmiljøer på Aarhus Universitet indenfor teknologiområder af betydning for Novo Nordisk. Samarbejder som dette med førende forskningsmiljøer - og uddannelse af unge, talentfulde forskere - er en vigtig del af innovationskraften i Novo Nordisk,"" siger forskningsdirektør i Novo Nordisk, Peter Kurtzhals. Aarhus Universitet hører til i den videnskabelige elite og har blandt andet kernekompetencer indenfor organisk kemi, proteinkemi og strukturel biologi. Novo Nordisk er en global lægemiddelvirksomhed, som igennem mere end 90 år har stået for innovation og lederskab indenfor diabetesbehandling. Over 5.400 medarbejdere arbejder i Novo Nordisks forskning og udvikling i Danmark, USA og Kina, heraf mange i partnerskab med eksterne bioteknologiske og akademiske forskere. Virksomheden har omkring 120 ph.d.-studerende og postdocs i hele verden - og fremover også adskillige i Aarhus. En fælles styrekomité med medlemmer fra Aarhus Universitet og Novo Nordisk får det overordnede ansvar for programmet. De første tre ph.d.-studerende forventes at begynde forskningen i 2017. ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1050,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
389,2016-06-13,Victoza® significantly reduced the risk of major cardiovascular events and death in adults with type 2 diabetes in the LEADER trial,"New Orleans, US, 13 June 2016 - Novo Nordisk today announced that Victoza® (liraglutide) significantly reduced the risk of the composite primary endpoint of cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke by 13% vs placebo (95% confidence interval [CI]: 0.78; 0.97, p=0.01), when added to standard of care in 9,340 adults with type 2 diabetes at high CV risk. The main results of the LEADER trial were presented today at the American Diabetes Association's 76th Scientific Sessions (ADA 2016) and also published in the New England Journal of Medicine (ref 1, 2). Victoza® is the only approved GLP-1 receptor agonist to demonstrate a superior reduction of major CV events vs placebo, both on top of standard of care, in a cardiovascular outcomes trial. There was a significant 22% reduction in cardiovascular death with Victoza® treatment vs placebo (95% CI: 0.66; 0.93, p=0.007) and reductions in non-fatal myocardial infarction (HR=0.88, 95% CI: 0.75; 1.03, p=0.11) and non-fatal stroke (HR=0.89, 95% CI: 0.72; 1.11, p=0.30).(ref 1, 2) ""These findings are exciting, as it demonstrates that Victoza® can improve outcomes beyond glucose reduction and weight loss by helping to avoid cardiovascular complications and death in people with type 2 diabetes,"" said Dr John Buse, chairman of the LEADER Steering Committee and chief of Endocrinology and director of the Diabetes Care Centre at the University of North Carolina School of Medicine. ""Type 2 diabetes treatments that can also reduce cardiovascular risk are important since cardiovascular disease is the leading cause of death worldwide in this patient population."" Read the full release including references Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1055,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
390,2016-06-13,Victoza® viser signifikant reduktion af risikoen for alvorlige kardiovaskulære hændelser og død hos voksne med type 2-diabetes i LEADER-studiet,"New Orleans, USA, den 13. juni 2016 - Novo Nordisk har i dag på det 76. årsmøde i den amerikanske diabetesforening, American Diabetes Association (ADA), i New Orleans, USA, præsenteret detaljerede resultater fra LEADER-studiet, der viser at Victoza® (liraglutid) signifikant reducerede risikoen på det sammensatte primære endepunkt omfattende kardiovaskulær død, ikke-dødeligt myokardieinfarkt (hjerteanfald) eller ikke-dødeligt slagtilfælde med 13% sammenlignet med placebo (95% konfidensinterval [CI]: 0,78; 0,97, p=0,01), når det blev givet som supplement til standardbehandling hos 9.340 voksne med type 2-diabetes med høj risiko for kardiovaskulære hændelser. Victoza® er således den eneste godkendte GLP-1-receptoragonist, der har vist en bedre reduktion af alvorlige kardiovaskulære hændelser sammenlignet med placebo, når begge bliver givet som supplement til standardbehandling, i et kardiovaskulært effekt- og sikkerhedsstudie. Studiet er netop publiceret i New England Journal of Medicine.[i],[ii] Resultaterne viste en signifikant 22% reduktion i kardiovaskulær død ved behandling med Victoza® sammenlignet med placebo (95% CI: 0,66; 0,93, p=0,007) samt reduktioner i ikke-dødeligt myokardieinfarkt (HR=0,88, 95% CI: 0,75; 1,03, p=0,11) og ikke-dødeligt slagtilfælde (HR=0,89, 95% CI: 0,72; 1,11, p=0,30).1,2 ""LEADER-resultaterne er spændende, fordi de viser, at Victoza®, udover at sænke blodsukkeret og kropsvægten, også hjælper med til at undgå kardiovaskulære komplikationer og dødsfald hos mennesker med type 2-diabetes,"" siger Dr. John Buse, formand for styrekomiteen for LEADER samt ledende endokrinolog og leder af Diabetes Care Centre ved University of North Carolina School of Medicine. ""Lægemidler til behandling af type 2-diabetes, som samtidig kan reducere kardiovaskulære risici, er vigtige, eftersom hjerte-kar-sygdom globalt set er den største dødsårsag i denne patientpopulation."" Læs hele meddelelsen inkl. referencer [i]     Results of the liraglutide effect and action in diabetes - evaluation of cardiovascular outcome results (LEADER) trial. Symposium 3-CT-SY24 at the 76th Scientific Sessions of the American Diabetes Association (ADA). 13 June 2016. [ii]     Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine. 2016; In Press. DOI: 10.1056/NEJMoa1603827.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1056,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
391,2016-06-13,Faster-acting insulin aspart showed a statistically significant reduction in HbA1c in type 1 diabetes and a comparable HbA1c reduction in type 2 diabetes versus NovoRapid® (insulin aspart),"Faster-acting insulin aspart improved postprandial glucose (PPG) control in type 1 and type 2 diabetes New Orleans, US, 13 June 2016 - New phase 3a findings showed that faster-acting insulin aspart demonstrated a statistically significant reduction in HbA1c in type 1 diabetes, compared with NovoRapid® (insulin aspart)1, a comparable HbA1c reduction in type 2 diabetes versus NovoRapid®2 and improved post-meal or postprandial glucose (PPG) control in type 1 and type 2 diabetes1,2. Results from the onset 1 and onset 2 treat-to-target trials comparing faster-acting insulin aspart with NovoRapid® were presented at the 76th annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, US. Read the full release including references Further information ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1057,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
392,2016-06-13,Hurtigerevirkende insulin aspart viste en statistisk signifikant reduktion i HbA1c v. type 1-diabetes og sammenlignelig HbA1c-reduktion v. type 2-diabetes sammenlignet m. NovoRapid® (insulin aspart),"Hurtigerevirkende insulin aspart forbedrede den måltidsrelaterede blodsukkerregulering i type 1- og type 2-diabetes New Orleans, USA, den 13. juni 2016 - Nye resultater fra fase 3a viser, at hurtigerevirkende insulin aspart gav en statistisk signifikant reduktion i langtidsblodsukkeret (HbA1c) for type 1-diabetes sammenlignet med NovoRapid® (insulin aspart)[i], en sammenlignelig HbA1c-reduktion for type 2-diabetes sammenlignet med NovoRapid® og forbedret blodsukker efter måltider, eller postprandialt blodsukker (PPG), for type 1- og type 2-diabetes1,[ii]. Resultaterne fra treat to target-studierne onset 1 og onset 2, hvor hurtigerevirkende insulin aspart blev sammenlignet med NovoRapid®, blev præsenteret på det 76. årsmøde i den amerikanske diabetesforening, American Diabetes Association (ADA), i New Orleans, USA. Læs hele meddelelsen inkl. referencer Yderligere information  [i]    Russell-Jones D, et al. Double-blind mealtime faster-acting insulin aspart vs insulin aspart in basal-bolus improves glycemic control in T1D: the onset® 1 trial. Oral presentation at: 76th Scientific Sessions of the American Diabetes Association (ADA). June 10-14, 2016; New Orleans, US. [ii]    Bowering K, et al. Faster-acting insulin aspart vs insulin aspart as part of basal-bolus therapy improves postprandial glycemic control in uncontrolled T2D in the double-blinded onset® 2 trial. Oral presentation at: 76th Scientific Sessions of the American Diabetes Association (ADA). June 10-14, 2016; New Orleans, US.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1058,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
393,2016-06-12,Semaglutid giver større forbedringer i glykæmisk kontrol sammenlignet med sitagliptin (SUSTAIN 2) og exenatid ER (SUSTAIN 3) i to kliniske studier med voksne med type 2-diabetes,"New Orleans, USA, den 12. juni 2016 - Resultaterne fra et klinisk fase 3a-studie med semaglutid, en GLP-1-analog (glukagonlignende peptid-1) under udvikling, blev præsenteret i dag på det 76. årsmøde i den amerikanske diabetesforening, American Diabetes Association (ADA).[i],[ii] I SUSTAIN 2-studiet forbedrede 0,5 mg og 1,0 mg semaglutid administreret én gang om ugen signifikant glykæmisk kontrol sammenlignet med sitagliptin (100 mg), en dipeptidylpeptidase-4 (DPP-4)-hæmmer, hos voksne med type 2-diabetes.1 I SUSTAIN 3-studiet forbedrede 1,0 mg semaglutid administreret én gang om ugen signifikant glykæmisk kontrol sammenlignet med 2,0 mg exenatid med forlænget frigivelse (ER), en GLP-1-receptoragonist, hos voksne med type 2-diabetes.2  [i]    Ahrén B, Comas LM, Kumar H, et al. Efficacy and safety of once-weekly semaglutide vs sitagliptin as add-on to metformin and/or thiazolidinediones after 56 weeks in subjects with type 2 diabetes (SUSTAIN 2). Abstract number 185-OR. American Diabetes Association 76th Scientific Session, New Orleans, US; 10-14 June 2016. [ii]    Ahmann A, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide vs exenatide ER after 56 weeks in subjects with type 2 diabetes (SUSTAIN 3). Abstract number 187-OR. American Diabetes Association 76th Scientific Session, New Orleans, US; 10-14 June 2016.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1064,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
394,2016-06-12,Semaglutide demonstrated superior improvements in glycaemic control vs sitagliptin (SUSTAIN 2) and exenatide ER (SUSTAIN 3) in two clinical trials in adults with type 2 diabetes,"New Orleans, US, 12 June 2016 - Findings from two phase 3a clinical trials for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, were presented today at the American Diabetes Association 76th Scientific Sessions.1,2 In the SUSTAIN 2 trial, 0.5 mg and 1.0 mg semaglutide administered once-weekly significantly improved glycaemic control compared to sitagliptin (100 mg), a dipeptidyl peptidase-4 (DPP-4) inhibitor, in adults with type 2 diabetes (ref 1). In the SUSTAIN 3 trial, 1.0 mg semaglutide administered once-weekly significantly improved glycaemic control compared to 2.0 mg exenatide extended-release (ER), a GLP-1 receptor agonist, in adults with type 2 diabetes (ref 2). Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1061,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
395,2016-06-12,Semaglutid giver større forbedringer i glykæmisk kontrol sammenlignet med sitagliptin (SUSTAIN 2) og exenatid ER (SUSTAIN 3) i to kliniske studier med voksne med type 2-diabetes,"New Orleans, USA, den 12. juni 2016 - Resultaterne fra et klinisk fase 3a-studie med semaglutid, en GLP-1-analog (glukagonlignende peptid-1) under udvikling, blev præsenteret i dag på det 76. årsmøde i den amerikanske diabetesforening, American Diabetes Association (ADA).[i],[ii] I SUSTAIN 2-studiet forbedrede 0,5 mg og 1,0 mg semaglutid administreret én gang om ugen signifikant glykæmisk kontrol sammenlignet med sitagliptin (100 mg), en dipeptidylpeptidase-4 (DPP-4)-hæmmer, hos voksne med type 2-diabetes.1 I SUSTAIN 3-studiet forbedrede 1,0 mg semaglutid administreret én gang om ugen signifikant glykæmisk kontrol sammenlignet med 2,0 mg exenatid med forlænget frigivelse (ER), en GLP-1-receptoragonist, hos voksne med type 2-diabetes.2  [i]    Ahrén B, Comas LM, Kumar H, et al. Efficacy and safety of once-weekly semaglutide vs sitagliptin as add-on to metformin and/or thiazolidinediones after 56 weeks in subjects with type 2 diabetes (SUSTAIN 2). Abstract number 185-OR. American Diabetes Association 76th Scientific Session, New Orleans, US; 10-14 June 2016. [ii]    Ahmann A, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide vs exenatide ER after 56 weeks in subjects with type 2 diabetes (SUSTAIN 3). Abstract number 187-OR. American Diabetes Association 76th Scientific Session, New Orleans, US; 10-14 June 2016.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1062,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
396,2016-06-12,Semaglutide demonstrated superior improvements in glycaemic control vs sitagliptin (SUSTAIN 2) and exenatide ER (SUSTAIN 3) in two clinical trials in adults with type 2 diabetes,"New Orleans, US, 12 June 2016 - Findings from two phase 3a clinical trials for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, were presented today at the American Diabetes Association 76th Scientific Sessions.1,2 In the SUSTAIN 2 trial, 0.5 mg and 1.0 mg semaglutide administered once-weekly significantly improved glycaemic control compared to sitagliptin (100 mg), a dipeptidyl peptidase-4 (DPP-4) inhibitor, in adults with type 2 diabetes (ref 1). In the SUSTAIN 3 trial, 1.0 mg semaglutide administered once-weekly significantly improved glycaemic control compared to 2.0 mg exenatide extended-release (ER), a GLP-1 receptor agonist, in adults with type 2 diabetes (ref 2). Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1063,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
397,2016-06-11,"Tresiba® (insulin degludec injection U-100) demonstrated significantly lower rates of overall, nocturnal and severe hypoglycaemia vs insulin  glargine U-100","New Orleans, US, 11 June 2016 - New findings from the two phase 3b SWITCH trials showed that treatment with long-acting basal insulin Tresiba® (insulin degludec injection U-100) resulted in significantly lower rates of overall, nocturnal and severe hypoglycaemia compared with insulin glargine U-100 (ref.1,2). Results from the SWITCH 1 and 2 trials, the first completed double-blinded basal insulin studies evaluating the safety profile and efficacy of Tresiba® versus insulin glargine U-100 (ref.1,2), were presented today at the American Diabetes Association 76th Scientific Sessions in New Orleans, US.  Further information 1.             Lane W, Bailey T, Gerety G, et al. SWITCH 1: Reduced Hypoglycaemia With Insulin Degludec (IDeg) vs Insulin Glargine (IGlar), both U100, in Patients With T1D at High Risk of Hypoglycaemia: A Randomised, Double-Blind Crossover Trial. Abstract 87-LB presented at the 76th Annual Scientific Sessions of the American Diabetes Association (ADA), New Orleans, USA. 11 June 2016. 2.             Wysham C, Bhargava A, Chaykin L, et al. SWITCH 2: Reduced Hypoglycaemia With Insulin Degludec (IDeg) vs Insulin Glargine (IGlar), both U100, in Patients With T2D at High Risk of Hypoglycaemia: A Randomised, Double-Blind Crossover Trial. Abstract 90-LB presented at the 76th Annual Scientific Sessions of the American Diabetes Association (ADA), New Orleans, USA. 11 June 2016.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1065,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
398,2016-06-11,"Tresiba® (insulin degludec U-100) viser signifikant lavere forekomst af generel, natlig og alvorlig hypoglykæmi sammenlignet med insulin glargin U-100","New Orleans, USA, den 11. juni 2016 - Nye resultater fra de to fase 3b SWITCH-studier viser, at behandling med den langtidsvirkende basalinsulin Tresiba® (insulin degludec U-100) medfører en signifikant lavere forekomst af generel, natlig og alvorlig hypoglykæmi sammenlignet med insulin glargin U-100.[i],[ii] Det fremgår af resultater fra SWITCH 1 og 2, de to første dobbeltblindede studier af basalinsulin, som vurderer effekten og sikkerheden af Tresiba®, sammenlignet med insulin glargin U-100,1,2 som præsenteres i dag på det 76. årsmøde i den amerikanske diabetesforening, American Diabetes Association (ADA), i New Orleans, USA. Yderligere information  [i]    Lane W, Bailey T, Gerety G, et al. SWITCH 1: Reduced Hypoglycaemia With Insulin Degludec (IDeg) vs Insulin Glargine (IGlar), both U100, in Patients With T1D at High Risk of Hypoglycaemia: A Randomised, Double-Blind Crossover Trial. Abstract 87-LB presented at the 76th Annual Scientific Sessions of the American Diabetes Association (ADA), New Orleans, USA. 11 June 2016. [ii]    Wysham C, Bhargava A, Chaykin L, et al. SWITCH 2: Reduced Hypoglycaemia With Insulin Degludec (IDeg) vs Insulin Glargine (IGlar), both U100, in Patients With T2D at High Risk of Hypoglycaemia: A Randomised, Double-Blind Crossover Trial. Abstract 90-LB presented at the 76th Annual Scientific Sessions of the American Diabetes Association (ADA), New Orleans, USA; 11 June 2016.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1066,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
399,2016-06-11,"Tresiba® (insulin degludec injection U-100) demonstrated significantly lower rates of overall, nocturnal and severe hypoglycaemia vs insulin  glargine U-100","New Orleans, US, 11 June 2016 - New findings from the two phase 3b SWITCH trials showed that treatment with long-acting basal insulin Tresiba® (insulin degludec injection U-100) resulted in significantly lower rates of overall, nocturnal and severe hypoglycaemia compared with insulin glargine U-100 (ref.1,2). Results from the SWITCH 1 and 2 trials, the first completed double-blinded basal insulin studies evaluating the safety profile and efficacy of Tresiba® versus insulin glargine U-100 (ref.1,2), were presented today at the American Diabetes Association 76th Scientific Sessions in New Orleans, US.  Further information 1.             Lane W, Bailey T, Gerety G, et al. SWITCH 1: Reduced Hypoglycaemia With Insulin Degludec (IDeg) vs Insulin Glargine (IGlar), both U100, in Patients With T1D at High Risk of Hypoglycaemia: A Randomised, Double-Blind Crossover Trial. Abstract 87-LB presented at the 76th Annual Scientific Sessions of the American Diabetes Association (ADA), New Orleans, USA. 11 June 2016. 2.             Wysham C, Bhargava A, Chaykin L, et al. SWITCH 2: Reduced Hypoglycaemia With Insulin Degludec (IDeg) vs Insulin Glargine (IGlar), both U100, in Patients With T2D at High Risk of Hypoglycaemia: A Randomised, Double-Blind Crossover Trial. Abstract 90-LB presented at the 76th Annual Scientific Sessions of the American Diabetes Association (ADA), New Orleans, USA. 11 June 2016.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1067,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
400,2016-06-11,"Tresiba® (insulin degludec U-100) viser signifikant lavere forekomst af generel, natlig og alvorlig hypoglykæmi sammenlignet med insulin glargin U-100","New Orleans, USA, den 11. juni 2016 - Nye resultater fra de to fase 3b SWITCH-studier viser, at behandling med den langtidsvirkende basalinsulin Tresiba® (insulin degludec U-100) medfører en signifikant lavere forekomst af generel, natlig og alvorlig hypoglykæmi sammenlignet med insulin glargin U-100.[i],[ii] Det fremgår af resultater fra SWITCH 1 og 2, de to første dobbeltblindede studier af basalinsulin, som vurderer effekten og sikkerheden af Tresiba®, sammenlignet med insulin glargin U-100,1,2 som præsenteres i dag på det 76. årsmøde i den amerikanske diabetesforening, American Diabetes Association (ADA), i New Orleans, USA. Yderligere information  [i]    Lane W, Bailey T, Gerety G, et al. SWITCH 1: Reduced Hypoglycaemia With Insulin Degludec (IDeg) vs Insulin Glargine (IGlar), both U100, in Patients With T1D at High Risk of Hypoglycaemia: A Randomised, Double-Blind Crossover Trial. Abstract 87-LB presented at the 76th Annual Scientific Sessions of the American Diabetes Association (ADA), New Orleans, USA. 11 June 2016. [ii]    Wysham C, Bhargava A, Chaykin L, et al. SWITCH 2: Reduced Hypoglycaemia With Insulin Degludec (IDeg) vs Insulin Glargine (IGlar), both U100, in Patients With T2D at High Risk of Hypoglycaemia: A Randomised, Double-Blind Crossover Trial. Abstract 90-LB presented at the 76th Annual Scientific Sessions of the American Diabetes Association (ADA), New Orleans, USA; 11 June 2016.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1068,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
401,2016-06-06,"Novo Nordisk to present 53 abstracts at 76th Annual American Diabetes Association Scientific Sessions in New Orleans, LA","Bagsværd, Denmark, 6 June 2016 - Novo Nordisk, a global leader in diabetes care, today announced that data from 53 abstracts including 8 oral presentations will be shared at the upcoming 76th annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, LA, from 10-14 June. Following are key highlights that will be presented at the meeting: 12 June, 8.30 am CDT, oral presentation 12 June, 9.00 am CDT, oral presentation 12 June, 12.00 pm CDT, poster presentation 12 June, 3.00 pm CDT and 13 June, 8.45 am CDT, oral presentations 12 June, 2.45 pm CDT, oral presentation 13 June, 2.15 pm CDT, oral presentation 11 June, 12.30 pm CDT, moderated poster discussion; 13 June, 12.00 pm CDT, poster presentation ""ADA 2016 will be a landmark congress for Novo Nordisk. This year, we have an unprecedented amount of key clinical data on our new insulins and GLP-1, and we look forward to sharing it all with the medical and scientific community,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""The presented research demonstrates advances in several areas of diabetes, underscoring our focus on developing innovative treatments with the potential to improve the lives of people with diabetes."" The above abstracts are a sampling of the data that will be presented or published by Novo Nordisk. For a complete list of abstracts: http://www.abstractsonline.com/pp8/#!/4008. This press release contains forward-looking statements about investigational products currently in development by Novo Nordisk. As is expected, there is significant risk with drug development and there is no guarantee that future studies will reflect similar results as presented at ADA. For further information about the Novo Nordisk drug pipeline, visit www.novonordisk.us.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1071,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
402,2016-06-02,Three-year data show early response to Saxenda® resulted in improvements in weight loss and cardiometabolic risk factors,"Read the full release Gothenburg, Sweden, 2 June 2016 - Today, data from a post hoc analysis of the three-year part of the phase 3a SCALE(TM) (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial were presented at the first European Obesity Summit (EOS 2016). Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1072,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
403,2016-06-02,Treårsdata for Saxenda® viser at tidlig respons kan forudsige forbedringer i vægttab og kardiometaboliske risikofaktorer,"Læs pressemeddelelsenGöteborg, Sverige, 2. juni 2016 - I dag blev data fra en post hoc-analyse af den treårige del af fase 3a-studiet SCALE(TM) (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes præsenteret på den første europæiske fedmekonference (European Obesity Summit, EOS 2016). Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1073,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
404,2016-06-02,Three-year data show early response to Saxenda® resulted in improvements in weight loss and cardiometabolic risk factors,"Read the full release Gothenburg, Sweden, 2 June 2016 - Today, data from a post hoc analysis of the three-year part of the phase 3a SCALE(TM) (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial were presented at the first European Obesity Summit (EOS 2016). Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1074,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
405,2016-06-02,Treårsdata for Saxenda® viser at tidlig respons kan forudsige forbedringer i vægttab og kardiometaboliske risikofaktorer,"Læs pressemeddelelsenGöteborg, Sverige, 2. juni 2016 - I dag blev data fra en post hoc-analyse af den treårige del af fase 3a-studiet SCALE(TM) (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes præsenteret på den første europæiske fedmekonference (European Obesity Summit, EOS 2016). Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1075,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
406,2016-05-27,Semaglutide demonstrated superior glycaemic control vs insulin glargine U100 in adults with type 2 diabetes,"Read the full release with references Orlando, US, 27 May 2016 - Findings from a phase 3a clinical trial for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, demonstrated that treatment with semaglutide, administered once-weekly, significantly improved glycaemic control compared to insulin glargine U100 in adults with type 2 diabetes. Results from the SUSTAIN 4 trial were presented today at the American Association of Clinical Endocrinologists 25th Annual Scientific and Clinical Congress (AACE) in Orlando, US.1 Further information References 1. Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly seamglutide vs once-daily insulin glargine in insulin-naïve subjects with type 2 diabetes (SUSTAIN 4). Abstract number 290. American Association of Clinical Endocrinologists 25th Annual Scientific and Clinical Congress (AACE), Orlando, FL, US; 25-29 May 2016.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1078,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
407,2016-05-27,Bedre blodsukkerregulering med semaglutid sammenlignet med insulin glargin U100 hos voksne med type 2-diabetes,"Læs hele meddelelsen inkl. referencer Orlando, USA, den 27. maj 2016 - Behandling med semaglutid doseret én gang om ugen giver en signifikant forbedret blodsukkerregulering sammenlignet med insulin glargin U100 hos voksne med type 2-diabetes. Det viser resultaterne af SUSTAIN 4-studiet, et klinisk fase 3a-studie med GLP-1-analogen (glukagonlignende peptid-1) semaglutid, som i dag blev præsenteret på American Association of Clinical Endocrinologists' 25. årlige videnskabelige og kliniske kongres i Orlando, USA.1 Yderligere information  _______________________ Referencer 1. Aroda VR, Bain SC, Cariou B, m.fl. Efficacy and safety of once-weekly semaglutide vs once-daily insulin glargine in insulin-naïve subjects with type 2 diabetes (SUSTAIN 4). Abstract number 290. American Association of Clinical Endocrinologists 25th Annual Scientific and Clinical Congress (AACE), Orlando, Florida, USA; 25.-29. maj 2016.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1079,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
408,2016-05-27,Semaglutide demonstrated superior glycaemic control vs insulin glargine U100 in adults with type 2 diabetes,"Read the full release with references Orlando, US, 27 May 2016 - Findings from a phase 3a clinical trial for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, demonstrated that treatment with semaglutide, administered once-weekly, significantly improved glycaemic control compared to insulin glargine U100 in adults with type 2 diabetes. Results from the SUSTAIN 4 trial were presented today at the American Association of Clinical Endocrinologists 25th Annual Scientific and Clinical Congress (AACE) in Orlando, US.1 Further information References 1. Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly seamglutide vs once-daily insulin glargine in insulin-naïve subjects with type 2 diabetes (SUSTAIN 4). Abstract number 290. American Association of Clinical Endocrinologists 25th Annual Scientific and Clinical Congress (AACE), Orlando, FL, US; 25-29 May 2016.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1080,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
409,2016-05-27,Bedre blodsukkerregulering med semaglutid sammenlignet med insulin glargin U100 hos voksne med type 2-diabetes,"Læs hele meddelelsen inkl. referencer Orlando, USA, den 27. maj 2016 - Behandling med semaglutid doseret én gang om ugen giver en signifikant forbedret blodsukkerregulering sammenlignet med insulin glargin U100 hos voksne med type 2-diabetes. Det viser resultaterne af SUSTAIN 4-studiet, et klinisk fase 3a-studie med GLP-1-analogen (glukagonlignende peptid-1) semaglutid, som i dag blev præsenteret på American Association of Clinical Endocrinologists' 25. årlige videnskabelige og kliniske kongres i Orlando, USA.1 Yderligere information  _______________________ Referencer 1. Aroda VR, Bain SC, Cariou B, m.fl. Efficacy and safety of once-weekly semaglutide vs once-daily insulin glargine in insulin-naïve subjects with type 2 diabetes (SUSTAIN 4). Abstract number 290. American Association of Clinical Endocrinologists 25th Annual Scientific and Clinical Congress (AACE), Orlando, Florida, USA; 25.-29. maj 2016.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1081,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
410,2016-05-24,IDegLira receives positive 16-0 vote in favour of approval from FDA Advisory Committee,"Bagsværd, Denmark, 24 May 2016 - Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted 16-0, recommending the approval of IDegLira for the treatment of adults with type 2 diabetes. IDegLira is a once-daily, single injection fixed combination of insulin degludec (Tresiba®) and liraglutide (Victoza®) for the treatment of adults with type 2 diabetes. Based on the data contained in the New Drug Application (NDA) for IDegLira, the FDA asked the panel members to discuss whether Novo Nordisk has provided adequate evidence to establish the efficacy and safety profile of IDegLira for the treatment of adults with type 2 diabetes. The recommendation for approval was based on data from clinical trials of IDegLira, including the DUAL phase 3 clinical trial programme, which involved more than 3,000 adults with type 2 diabetes. In addition to the DUAL clinical trial programme, both insulin degludec and liraglutide have been studied extensively in separate clinical trial programmes and the products are commercially available across the globe. ""The unanimous recommendation from the Advisory Committee marks an important step towards making IDegLira available to adults with type 2 diabetes in the US. We look forward to working with the FDA as they complete their review of IDegLira,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. The NDA for IDegLira was submitted to the FDA in September 2015 under the FDA's Prescription Drug User Fee Act V (PDUFA V) regulation. In Europe, IDegLira was approved in September 2014 and is marketed under the brand name Xultophy®. About advisory committee meetingsFDA advisory committees are panels of independent experts who advise the FDA on specific questions raised by the FDA as they consider regulatory decisions. The FDA is not bound by the committee's recommendation, but it takes its advice into consideration when reviewing new drug applications. According to the FDA Amendment Act of 2007 (FDAAA), the FDA should refer new drugs to an advisory committee meeting, or alternatively justify why an advisory committee meeting was not requested. IDegLira is a once-daily, single injection fixed combination product consisting of insulin degludec (Tresiba®), a once-daily new-generation basal insulin analogue, and liraglutide (Victoza®), a once-daily GLP-1 analogue. For further information Company announcement No 42 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1082,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
411,2016-05-24,FDA's rådgivende komite anbefaler godkendelse af IDegLira med stemmerne 16-0,"Bagsværd, den 24. maj 2016 - Novo Nordisk meddeler i dag, at Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC), som er en rådgivende komite for de amerikanske sundhedsmyndigheder (FDA) med stemmerne 16-0 anbefaler en godkendelse af IDegLira til behandling af voksne med type 2-diabetes. IDegLira er et kombinationsprodukt til dosering én gang dagligt i én injektion. Det består af insulin degludec (Tresiba®) og liraglutid (Victoza®) til behandling af voksne med type 2-diabetes. På mødet blev komiteens medlemmer bedt om, med udgangspunkt i de data, der indgår i registreringsansøgningen for IDegLira, at drøfte, hvorvidt Novo Nordisk har fremlagt tilstrækkelige data til at fastslå effekt- og sikkerhedsprofilen for IDegLira til behandling af voksne med type 2-diabetes. Anbefalingen af godkendelse var baseret på data fra de kliniske studier af IDegLira, herunder det kliniske fase 3-program DUAL, som omfattede mere end 3.000 voksne med type 2-diabetes. Foruden i det kliniske forsøgsprogram DUAL er både insulin degludec og liraglutid blevet undersøgt grundigt i separate kliniske udviklingsprogrammer, og produkterne markedsføres i en lang række lande. ""Den enstemmige anbefaling fra den rådgivende komite er et vigtigt skridt på vejen til at gøre IDegLira tilgængeligt for voksne med type 2-diabetes i USA. Vi ser frem til at arbejde sammen med FDA, når de færdiggør deres vurdering af IDegLira,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. Registreringsansøgningen for IDegLira blev indsendt til FDA i september 2015 i henhold til den amerikanske lov Prescription Drug User Fee Act V (PDUFA V). I Europa blev IDegLira godkendt i september 2014 og markedsføres under navnet Xultophy®. FDA's rådgivende komiteer er uafhængige ekspertpaneler, som rådgiver FDA om specifikke spørgsmål, der rejses af FDA i forbindelse med regulatoriske beslutninger. Komiteens anbefaling er ikke bindende for FDA, men indgår i beslutningsgrundlaget ved FDA's behandling af registreringsansøgninger. I henhold til FDA Amendment Act of 2007 (FDAAA) skal FDA henvise nye lægemidler til drøftelse på et møde i en rådgivende komite eller alternativt begrunde, hvorfor et sådant møde ikke berammes. IDegLira er et kombinationsprodukt til dosering én gang dagligt i én injektion. Det består af insulin degludec (Tresiba®), en basal insulinanalog til dosering én gang dagligt, og liraglutid (Victoza®), en GLP-1-analog til dosering én gang dagligt. Yderligere information Regnskabsmeddelelse nr. 42 /2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1083,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
412,2016-05-20,"FDA posts briefing materials prior to Advisory Committee meeting for IDegLira, a fixed combination product of insulin degludec and liraglutide","Bagsværd, Denmark, 20 May 2016 - Novo Nordisk announced today that the US Food and Drug Administration (FDA) has published the briefing documents ahead of the 24 May 2016 Advisory Committee meeting to discuss the New Drug Application (NDA) for IDegLira, the fixed combination product of insulin degludec (Tresiba®) and liraglutide (Victoza®). The briefing documents from Novo Nordisk and the FDA, which will form the basis for the Advisory Committee's discussion, provide an overview of the non-clinical and clinical data for IDegLira for the treatment of type 2 diabetes. The briefing materials can be accessed on the FDA webpage FDA advisory committees are panels of independent experts who advise the FDA on specific questions raised by the FDA as they consider regulatory decisions. The FDA is not bound by the committee's recommendation, but it takes its advice into consideration when reviewing a new drug application. According to the FDA Amendment Act of 2007 (FDAAA), the FDA should refer new drugs to an advisory committee meeting, or alternatively justify why an advisory committee meeting was not requested. IDegLira is a once-daily, single injection combination product consisting of insulin degludec (Tresiba®), a once-daily new-generation basal insulin analogue, and liraglutide (Victoza®), a once-daily GLP-1 analogue. IDegLira was submitted to the FDA in September 2015 under the US FDA's Prescription Drug User Fee Act V (PDUFA V) regulation. In Europe, IDegLira was approved in September 2014 and is marketed under the brand name Xultophy®. For further information Company announcement No 41 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1084,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
413,2016-05-20,"FDA offentliggør briefingmateriale forud for møde i rådgivende komite om IDegLira, en kombination af insulin degludec og liraglutid","Bagsværd, den 20. maj 2016 - Novo Nordisk meddeler i dag, at de amerikanske sundhedsmyndigheder, FDA, har offentliggjort briefingdokumenterne forud for mødet i FDA's rådgivende komite den 24. maj 2016, hvor registreringsansøgningen for IDegLira, kombinationsproduktet bestående af insulin degludec (Tresiba®) og liraglutid (Victoza®), vil blive drøftet. Briefingdokumenterne fra Novo Nordisk og FDA, som vil danne grundlag for drøftelserne i den rådgivende komite, giver overblik over de ikke-kliniske og kliniske data for IDegLira til behandling af type 2-diabetes. Materialet er tilgængeligt på FDA's hjemmeside. FDA's rådgivende komiteer er uafhængige ekspertpaneler, som rådgiver FDA om specifikke spørgsmål, der rejses af FDA i forbindelse med regulatoriske beslutninger. Komiteens anbefaling er ikke bindende for FDA, men indgår i beslutningsgrundlaget ved FDA's behandling af registreringsansøgninger. I henhold til FDA Amendment Act of 2007 (FDAAA) skal FDA henvise nye lægemidler til drøftelse på et møde i en rådgivende komite eller alternativt begrunde, hvorfor et sådant møde ikke berammes. IDegLira er et kombinationsprodukt til dosering én gang dagligt i én injektion. Det består af insulin degludec (Tresiba®), en basal insulinanalog til dosering én gang dagligt, og liraglutid (Victoza®), en GLP-1-analog til dosering én gang dagligt. Registreringsansøgningen for IDegLira blev indsendt til FDA i september 2015 i henhold til den amerikanske lov Prescription Drug User Fee Act V (PDUFA V). I Europa blev IDegLira godkendt i september 2014 og markedsføres under navnet Xultophy®. Yderligere information Selskabsmeddelelse nr. 41 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1085,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
414,2016-05-16,Novo Nordisk indsender registreringsansøgning i USA for langtidsvirkende faktor IX til behandling af hæmofili B,"Bagsværd, den 16. maj 2016 - Novo Nordisk meddeler i dag, at virksomheden har indsendt registreringsansøgning (Biologics License Application) til de amerikanske sundhedsmyndigheder (FDA) for langtidsvirkende faktor IX, nonacog beta pegol. Nonacog beta pegol er et glykopegyleret rekombinant faktor IX-præparat med en signifikant forbedret farmakokinetisk profil, udviklet til behandling af hæmofili B. Registreringsansøgningen for nonacog beta pegol er baseret på resultaterne fra det kliniske udviklingsprogram 'paradigm', som omfattede 115 deltagere med svær eller moderat svær hæmofili B. Studierne viste, at nonacog beta pegol var virkningsfuldt til rutinemæssig forebyggende behandling, behandling af blødningsepisoder samt ved kirurgiske indgreb hos voksne, unge og børn. Nonacog beta pegol forekom endvidere at være veltolereret, og der blev ikke identificeret sikkerhedsmæssige problemer. Nonacog beta pegol har en fem gange længere halveringstid sammenlignet med gængse faktor IX-produkter. Deltagere i paradigm-studiet opnåede et højere faktor IX-niveau i kredsløbet trods mindre hyppig dosering af nonacog beta pegol. Én ugentlig dosering på 40 IU/kg nonacog beta pegol opretholdt i fase 3-studierne et faktor IX-aktivitetsniveau på over 15%, reducerede medianværdien for den årlige blødningsfrekvens til 1,0 og viste potentiale til at forebygge blødninger i såkaldte target joints (led, der er særligt udsat for gentagne blødninger). Disse deltagere rapporterede desuden om signifikant forbedret livskvalitet i studiet. ""Med indsendelsen af registreringsansøgningerne i 2016 for vores langtidsvirkende faktor IX, er mennesker med hæmofili B både i EU og i USA kommet et skridt tættere på en ny behandlingsmulighed,"" siger Mads Krogsgaard Thomsen, koncerndirektør i Novo Nordisk med ansvar for forskning og udvikling. ""Nonacog beta pegol har med sit høje faktoraktivitetsniveau, den mindre hyppige dosering og den reducerede blødningsfrekvens potentiale til at forbedre livskvaliteten både for patienterne og deres familie."" Nonacog beta pegol er et faktor IX-molekyle med forlænget halveringstid, der er beregnet til substitutionsbehandling hos mennesker med hæmofili B. Halveringstiden er forlænget ved hjælp af glykopegylerings-teknikken - en ny tilgang indenfor hæmofili B, som allerede har vist sig sikker og virkningsfuld indenfor hæmofili A og andre behandlingsområder. Det kliniske udviklingsprogram paradigm for nonacog beta pegol er gennemført blandt børn og voksne med svær eller moderat svær hæmofili B - i alt 115 tidligere behandlede patienter med sammenlagt mere end 10.625 dages eksponering for op til 3,3 års behandling med nonacog beta pegol. Paradigm 1, farmakokinetisk studie (16 deltagere behandlet) - et enkeltdosis-eskaleringsstudie, der undersøgte sikkerhed og farmakokinetik for nonacog beta pegol sammenlignet med markedsførte rekombinante og plasmabaserede faktor IX-produkter. Nonacog beta pegol viste op til to gange forhøjet genfindelse i blodbanen, højere aktivitetsniveau og en fem gange længere halveringstid sammenlignet med eksisterende behandling. Paradigm 2, pivotalstudie (74 deltagere behandlet, inklusive en undergruppe af deltagere fra paradigm 1-studiet) - et 52-ugers enkeltblindet, randomiseret studie, der undersøgte sikkerhed, effekt og farmakokinetik hos voksne og unge ved rutinemæssig forebyggelse og behandling af blødninger. Ved forebyggende behandling med 40 IU/kg doseret én gang ugentligt forekom nonacog beta pegol at have en sikker og veltolereret profil og viste en medianværdi for den årlige blødningsfrekvens for spontane blødninger på 0,0. Endvidere blev 97% af såkaldte breakthrough bleeds (spontane blødninger under behandlingsforløbet) stoppet, og 90% af såkaldte target joints (led, der er særligt udsat for gentagne blødninger) blev ikke længere klassificeret som sådan. Paradigm 3, kirurgistudie (13 deltagere behandlet, inklusive en undergruppe af deltagere fra paradigm 2-studiet) - et dedikeret studie, der bekræftede sikkerhed og effekt under og efter større kirurgiske indgreb. Hos alle deltagere var en enkelt dosis forud for operationen tilstrækkeligt til at forebygge blødning, og der var ikke behov for at give yderligere doser på operationsdagen. Endvidere viste det sig, at tre doser var tilstrækkelige til at opretholde hæmostase i de første to uger efter operationen. Paradigm 4, forlængelsesstudie (71 deltagere, som tidligere var blevet behandlet i paradigm 2- eller paradigm 3-studiet) - et sikkerhedsstudie med længere tids eksponering, der viste en veltolereret profil uden identifikation af inhibitorer (neutraliserende antistoffer) eller andre sikkerhedsmæssige signaler. Paradigm 5, pædiatrisk studie (25 deltagere behandlet) - et 52-ugers enkeltgruppestudie, der undersøgte forebyggende behandling doseret én gang ugentligt og behandling af blødningsepisoder hos tidligere behandlede børn i alderen 1-12 år. Nonacog beta pegol forekom at have en sikker profil, og alle deltagere opretholdt et gennemsnitligt faktoraktivitetsniveau på over 15% én uge efter dosering af 40 IU/kg og en medianværdi for den årlige blødningsfrekvens på henholdsvis 0,0 og 2,0 for børn i alderen 0-6 og 7-12 år. Selskabsmeddelelse nr. 39 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1089,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
415,2016-05-16,Novo Nordisk files for regulatory approval in the US of long-acting factor IX for the treatment of haemophilia B,"Bagsværd, Denmark, 16 May 2016 - Novo Nordisk today announced the submission to the US Food and Drug Administration (FDA) of the Biologics License Application for the approval of long-acting factor IX, nonacog beta pegol. Nonacog beta pegol is a glycopegylated recombinant factor IX with a significantly improved pharmacokinetic (PK) profile, developed for patients with haemophilia B. The filing of nonacog beta pegol is based on the results from the paradigm clinical trial programme which involved 115 patients with severe or moderately severe haemophilia B. Nonacog beta pegol was found to be efficacious in routine prophylaxis, treatment of bleeding episodes and surgery for adults, adolescents and children. Furthermore, nonacog beta pegol appeared to be well-tolerated and no safety concerns were identified. Compared to standard factor IX products, nonacog beta pegol has a five times longer half-life. Patients in the paradigm study achieved a higher level of factor IX in the circulation despite less frequent dosing of nonacog beta pegol. In the phase 3 trials, once-weekly administration of 40 IU/kg nonacog beta pegol maintained factor IX activity levels above 15%, reduced the median annualised bleeding rate (ABR) to 1.0 and showed a potential to prevent bleeds in target joints. Furthermore, these patients reported a significant improvement in quality of life during the trial. ""With the regulatory filings in 2016 of our long-acting factor IX, people with haemophilia B in both the EU and the US are one step closer to having a new treatment option"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""With its high factor activity level, less frequent dosing and reduced bleeding rate, nonacog beta pegol has the potential to improve the quality of life for both patients and their families."" Nonacog beta pegol is a factor IX molecule with an extended half-life intended for replacement therapy in patients with haemophilia B. Glycopegylation, the prolongation technology used for the half-life extension, is a novel approach in haemophilia B, already proven safe and efficacious in haemophilia A and other therapeutic areas. The paradigm clinical trial programme for nonacog beta pegol enrolled children and adults with severe or moderately severe haemophilia B. A total of 115 previously treated patients with a total of more than 10,625 exposure days for up to 3.3 years of treatment with nonacog beta pegol. The paradigm 1 PK trial (16 patients treated) - a single-dose escalation trial evaluating safety and PK of nonacog beta pegol compared with marketed recombinant and plasma-derived factor IX products. Nonacog beta pegol showed up to twofold increase in recovery, higher activity levels and a fivefold prolongation of half-life compared to existing treatment. The paradigm 2 pivotal trial (74 patients treated, including a subset of patients from the paradigm 1 trial) - a 52-week single-blinded randomised trial evaluating safety, efficacy and PK for adults and adolescents in routine prophylaxis and treatment of bleeds. When provided prophylactic at 40 IU/kg weekly, nonacog beta pegol appeared to have a safe and well-tolerated profile and showed a median annualised spontaneous bleeding rate of 0.0. Furthermore, 97% of breakthrough bleeds were treated successfully and 90% of target joints no longer classified as such. The paradigm 3 surgery trial (13 patients treated, including a subset of people from the paradigm 2 trial) - a dedicated trial confirming safety and efficacy during and after major surgical procedures. In all patients, a single preoperative dose provided effective haemostatic coverage, and no patient required additional doses on the day of surgery. Additionally, three doses proved sufficient in maintaining haemostasis during the first two weeks following the procedure. The paradigm 4 extension trial (71 patients previously treated in the paradigm 2 or paradigm 3 trials) - a safety extension trial with longer-term exposure demonstrated a well-tolerated profile with no inhibitors or other safety signals identified. The paradigm 5 paediatric trial (25 patients treated) - a 52-week single-arm trial evaluating once-weekly prophylaxis and treatment of bleeding episodes in previously treated children 1-12 years of age. Nonacog beta pegol appeared to have a safe profile, and all patients maintained mean factor activity levels above 15% one week after dosing of 40 IU/kg and a median ABR of 0.0 and 2.0 for children aged 0-6 and 7-12 years old respectively. For further information Company announcement No 39 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1088,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
416,2016-04-29,Novo Nordisk increased adjusted operating profit by 10% in local currencies in the first quarter of 2016,"Sales increased by 9% in local currencies Sales increased by 9% in local currencies and by 8% in Danish kroner to DKK 27.2 billion. Operating profit decreased by 10% reported in local currencies and by 11% in Danish kroner to DKK 12.3 billion. Adjusted for the non-recurring income related to the partial divestment of NNIT and the income related to out-licensing of assets for inflammatory disorders, both in 2015, operating profit in local currencies increased by 10%. Net profit decreased by 4% to DKK 9.5 billion. Diluted earnings per share decreased by 2% to DKK 3.71. Adjusted for the partial divestment of NNIT, net profit and diluted earnings per share increased by 20% and 23% respectively. In February, Novo Nordisk announced the successful completion of the SWITCH 1 trial demonstrating the ability of Tresiba® to lower the rate of hypoglycaemia compared to insulin glargine U100 in people with type 1 diabetes. In March, Novo Nordisk announced that Victoza® in the LEADER trial, comprising more than 9,300 people with an average treatment of approximately four years, significantly reduced the risk of major adverse cardiovascular events. On 28 April, Novo Nordisk announced that semaglutide, a once-weekly GLP-1 analogue, significantly reduced the risk of major adverse cardiovascular events in the SUSTAIN 6 trial. Following the successful completion of the SUSTAIN programme, Novo Nordisk intends to file for regulatory review in the US and EU in the fourth quarter of 2016. For 2016, sales growth is still expected to be 5-9% measured in local currencies. Growth in adjusted operating profit is also still expected to be 5-9% measured in local currencies. Lars Rebien Sørensen, president and CEO: ""We are pleased with the results during the first quarter of 2016 where Victoza® and Tresiba® both delivered significant growth. Furthermore, we are very encouraged by the successful outcomes of the SWITCH, LEADER and SUSTAIN trials, which further strengthen the clinical profiles of Tresiba®, Victoza® and semaglutide."" Contacts for further information: Company announcement No 34 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1098,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
417,2016-04-29,"Novo Nordisks resultat af primær drift, justeret, steg med 10% i lokale valutaer i det første kvartal af 2016","Salget steg med 9% opgjort i lokale valutaer Salget steg med 9% opgjort i lokale valutaer og med 8% i kroner til 27,2 mia. kr. Resultat af primær drift faldt med 10% rapporteret i lokale valutaer og med 11% i danske kroner til 12,3 mia. kr. Justeret for engangsindtægten fra det delvise frasalg af NNIT og indtægten fra udlicensering af aktiver vedrørende inflammatoriske sygdomme, begge i 2015, steg resultat af primær drift opgjort i lokale valutaer med 10%. Nettoresultatet faldt med 4% til 9,5 mia. kr. Udvandet resultat pr. aktie faldt med 2% til 3,71 kr. Justeret for det delvise frasalg af NNIT steg nettoresultatet og udvandet resultat pr. aktie med henholdsvis 20% og 23%. I februar meddelte Novo Nordisk, at SWITCH 1-studiet var afsluttet med succes. Studiet viste, at Tresiba® var i stand til at nedsætte forekomsten af hypoglykæmi sammenlignet med insulin glargin U100 hos mennesker med type 1-diabetes. I marts meddelte Novo Nordisk, at Victoza® i LEADER-studiet, som omfattede flere end 9.300 deltagere med en gennemsnitlig behandlingsperiode på ca. fire år, reducerede risikoen for alvorlige hjerte-kar-hændelser signifikant. Den 28. april meddelte Novo Nordisk, at semaglutid, en GLP-1-analog, som doseres én gang ugentligt, reducerede risikoen for alvorlige kardiovaskulære hændelser signifikant i SUSTAIN 6-studiet. Efter den succesfulde afslutning af SUSTAIN-programmet forventer Novo Nordisk at indsende registreringsansøgning i USA og EU i fjerde kvartal af 2016. For 2016 forventes fortsat en salgsvækst på 5-9% opgjort i lokale valutaer. Væksten i justeret resultat af primær drift forventes også fortsat at blive på 5-9% opgjort i lokale valutaer. Adm. direktør Lars Rebien Sørensen: ""Vi er tilfredse med de resultater, vi har opnået i første kvartal af 2016, hvor både Victoza® og Tresiba® udviste betydelig vækst. Vi er også meget glade for de positive resultater af SWITCH-, LEADER- og SUSTAIN-studierne, som yderligere styrker den kliniske profil for Tresiba®, Victoza® og semaglutid."" Kontaktoplysninger Selskabsmeddelelse nr. 34 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1099,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
418,2016-04-28,Novo Nordisk A/S - Total number of voting rights and share capital in Novo Nordisk A/S as of 28 April 2016,"Bagsværd, Denmark, 28 April 2016 - In accordance with Section 10 of the Danish Statutory Order on Issuers' Disclosure Obligations, Novo Nordisk is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred. Further information Company announcement No 33 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1100,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
419,2016-04-28,Novo Nordisk A/S - Det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 28. april 2016,"Bagsværd, 2016-04-28 - I henhold til Bekendtgørelse om udstederes oplysningsforpligtelser, § 10, skal Novo Nordisk offentliggøre det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S ved udgangen af en måned, hvor ændringer deri har fundet sted. Yderligere information Selskabsmeddelelse nr. 33 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1101,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
420,2016-04-28,Semaglutide significantly reduces the risk of major adverse cardiovascular events in the SUSTAIN 6 trial,"Bagsværd, Denmark, 28 April 2016 - Novo Nordisk today announced the top-line results from the sixth and last global phase 3a trial, SUSTAIN6, for semaglutide; a new GLP-1 analogue, which is administered subcutaneously once weekly in the SUSTAIN trials. This double-blinded trial investigated the long-term cardiovascular and other safety outcomes of 0.5 mg and 1.0 mg semaglutide compared with placebo, both in addition to standard-of-care. In the trial, approximately 3,300 people with type 2 diabetes were treated for 104 weeks. The trial achieved its primary endpoint of showing non-inferiority of major cardiovascular events (MACE) with semaglutide compared with placebo, as well as a statistically significant reduction in cardiovascular risk. In the trial, around 250 MACE were accrued. The primary endpoint of the study was defined as the composite outcome of the first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. The safety profile of semaglutide in SUSTAIN 6 was as expected and consistent with previous semaglutide clinical studies. ""We are very encouraged by the potential for reduction of CV risk in people with type 2 diabetes with semaglutide based on the results of SUSTAIN 6. In addition to the strong efficacy profile, we have also established the safety profile for semaglutide by concluding the six SUSTAIN trials"" says Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""With the strong results from SUSTAIN 6, we look forward to the regulatory filing of semaglutide."" Novo Nordisk expects to file semaglutide for regulatory review in the US and EU in the fourth quarter of 2016. About semaglutide Semaglutide is a new glucagon-like peptide-1 (GLP-1) analogue that can help people with type 2 diabetes achieve substantial improvement of blood glucose with a low risk of hypoglycaemia. In addition, semaglutide induces weight loss by decreasing appetite and food intake. Semaglutide administered subcutaneously once weekly is in phase 3 development for the treatment of type 2 diabetes. Furthermore, semaglutide is currently being developed in an oral tablet version for treatment of type 2 diabetes as well as in once-daily subcutaneous versions for treatment of type 2 diabetes and weight management. About the SUSTAIN clinical programme The SUSTAIN programme is a phase 3 clinical programme comprising six global trials of semaglutide administered subcutaneously once weekly encompassing more than 7,000 people with type 2 diabetes. SUSTAIN 1 - a 30-week efficacy and safety trial of semaglutide versus placebo in 388 drug-naïve people with type 2 diabetes. The results were reported in July 2015. SUSTAIN 2 - a 56-week efficacy and safety trial of semaglutide versus sitagliptin once-daily as add-on to metformin and/or TZD in 1,231 people with type 2 diabetes. The results were reported in December 2015. SUSTAIN 3 - a 56-week efficacy and safety trial of semaglutide versus 2.0 mg exenatide once-weekly as add-on to 1-2 oral antidiabetic drugs in 813 people with type 2 diabetes. The results were reported in September 2015. SUSTAIN 4 - a 30-week efficacy and safety trial of semaglutide versus insulin glargine once-daily as add-on to metformin with or without sulfonylurea in 1,089 insulin-naïve people with type 2 diabetes. The results were reported in November 2015. SUSTAIN 5 - a 30-week efficacy and safety trial of semaglutide versus placebo as add-on to basal insulin alone or basal insulin in combination with metformin in 397 people with type 2 diabetes. The results were reported in February 2016. SUSTAIN 6 - a 2-year trial to evaluate cardiovascular and other long-term outcomes with semaglutide in approximately 3,300 people with type 2 diabetes. For further information Company announcement No 31 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1104,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
421,2016-04-28,Semaglutid reducerer risikoen for alvorlige kardiovaskulære hændelser signifikant i SUSTAIN 6-studiet,"Bagsværd, den 28. april 2016 - Novo Nordisk offentliggør i dag de overordnede resultater fra SUSTAIN6, det sjette og sidste globale fase 3a-studie med semaglutid: en ny GLP-1-analog, som doseres ved injektion i underhuden (subkutant) én gang ugentligt i SUSTAIN-studierne. Dette dobbeltblindede studie undersøgte den langsigtede forekomst af hjerte-kar-sygdom og andre sikkerhedsmæssige målepunkter ved brug af 0,5 mg og 1,0 mg semaglutid sammenlignet med placebo, begge givet som supplement til standardbehandling. I studiet blev ca. 3.300 mennesker med type 2-diabetes behandlet i 104 uger. Studiet opfyldte sit primære mål om at vise ikke-inferiøritet med hensyn til alvorlige kardiovaskulære hændelser (MACE) med semaglutid sammenlignet med placebo, samt en statistisk signifikant reduktion i kardiovaskulær risiko. I studiet blev omkring 250 MACE akkumuleret. Det primære mål for studiet var defineret som et sammensat endepunkt bestående af den første forekomst af kardiovaskulær død, ikke-dødeligt myokardieinfarkt eller ikke-dødeligt slagtilfælde. Sikkerhedsprofilen for semaglutid i SUSTAIN 6 var som forventet og konsistent med tidligere kliniske studier af semaglutid. ""Vi er meget opmuntrede over potentialet for reduktion af risikoen for hjerte-kar-bivirkninger hos mennesker med type 2-diabetes ved behandling med semaglutid på basis af resultaterne fra SUSTAIN 6. Foruden den stærke effektprofil har vi også etableret sikkerhedsprofilen for semaglutid ved at gennemføre de seks SUSTAIN-studier,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Med disse stærke resultater fra SUSTAIN 6 ser vi frem til at indsende registreringsansøgningen for semaglutid."" Novo Nordisk forventer at indsende registreringsansøgning for semaglutid i USA og EU i fjerde kvartal af 2016. Om semaglutid Semaglutid er en ny GLP-1-analog (glukagonlignende peptid-1), som kan hjælpe mennesker med type 2-diabetes med at opnå en markant forbedring af blodsukkeret med lav risiko for hypoglykæmi (lavt blodsukker). Semaglutid medfører endvidere vægttab ved at nedsætte appetit og madindtag. Semaglutid til subkutan dosering (ved injektion i underhuden) én gang ugentligt er i fase 3-udvikling til behandling af type 2-diabetes. Semaglutid er endvidere p.t. under udvikling i tabletform til oral behandling af type 2-diabetes samt i injicerbare udgaver til subkutan dosering én gang dagligt til behandling af type 2-diabetes og vægtregulering. Om det kliniske udviklingsprogram SUSTAIN SUSTAIN er et klinisk fase 3-program, som omfatter seks globale studier med semaglutid doseret subkutant én gang om ugen med deltagelse af flere end 7.000 mennesker med type 2-diabetes. SUSTAIN 1 - et 30-ugers effekt- og sikkerhedsstudie, der undersøger semaglutid i forhold til placebo hos 388 deltagere med type 2-diabetes, som ikke tidligere har fået medicinsk behandling. Resultaterne blev rapporteret i juli 2015. SUSTAIN 2 - et 56-ugers effekt- og sikkerhedsstudie, der undersøger semaglutid i forhold til sitagliptin én gang dagligt som tillægsbehandling til metformin og/eller TZD hos 1.231 deltagere med type 2-diabetes. Resultaterne blev rapporteret i december 2015. SUSTAIN 3 - et 56-ugers effekt- og sikkerhedsstudie, der undersøger semaglutid i forhold til 2,0 mg exenatid én gang ugentligt som tillægsbehandling til 1-2 diabeteslægemidler i tabletform hos 813 deltagere med type 2-diabetes. Resultaterne blev rapporteret i september 2015. SUSTAIN 4 - et 30-ugers effekt- og sikkerhedsstudie, der undersøger semaglutid i forhold til insulin glargin én gang dagligt som tillægsbehandling til metformin med eller uden sulfonylurinstof hos 1.089 deltagere med type 2-diabetes, som ikke tidligere er blevet behandlet med insulin. Resultaterne blev rapporteret i november 2015. SUSTAIN 5 - et 30-ugers effekt- og sikkerhedsstudie, der undersøger semaglutid i forhold til placebo som tillægsbehandling til basal insulin alene eller basal insulin i kombination med metformin hos 397 deltagere med type 2-diabetes. Resultaterne blev rapporteret i februar 2016. SUSTAIN 6 - et toårigt studie, der undersøger forekomsten af hjerte-kar-sygdom og andre langsigtede målepunkter ved brug af semaglutid hos ca. 3.300 deltagere med type 2-diabetes.  Yderligere information Pressemeddelelse nr. 31 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1105,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
422,2016-04-21,"Novo Nordisk plans to invest more than 100 million euros in production plants in Chartres, France","Bagsværd, Denmark, 21 April 2016 ­- Novo Nordisk today announced that it plans to invest more than 100 million euros in production facilities at its site in Chartres, France. The expansions will help Novo Nordisk meet the increasing worldwide demand for its diabetes medicines. The new facilities will be built on Novo Nordisk's existing 31,000 m2 site in Chartres, which produces a range of the company's insulin products as well as FlexPen®, the world's most widely used insulin injection device. The products are exported to more than 40 countries all over the world. Novo Nordisk has invested 300 million euros in France over the past 15 years and today employs 1,100 employees at the site. The planned expansion is estimated to create around 250 new jobs once the facilities are fully operational within three to four years. ""Novo Nordisk has been operating in France for more than 50 years,"" says Lars Rebien Sørensen, president and CEO of Novo Nordisk. ""Over the years we have built a very strong organisation in France, and our site in Chartres is today one of our most important strategic production sites. With the coming expansion we will further strengthen Chartres' position in our global product supply organisation."" In addition to the 1,100 employees in Chartres, Novo Nordisk employs 300 people in its affiliate in Paris, which is responsible for the company's medical, regulatory and commercial activities in France.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1106,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
423,2016-04-21,"Novo Nordisk vil investere mere end 100 mio. euro i produktionsanlæg i Chartres, Frankrig","Bagsværd, den 21. april 2016 ­- Novo Nordisk meddelte i dag, at virksomheden vil investere mere end 100 mio. euro i produktionsanlæg på virksomhedens fabrik i Chartres, Frankrig. Udvidelserne skal hjælpe Novo Nordisk med at dække den stigende globale efterspørgsel efter virksomhedens diabetesmedicin. De nye produktionsanlæg vil blive opført på Novo Nordisks eksisterende 31.000 m2 fabriksområde i Chartres, som fremstiller en række af virksomhedens insulinprodukter og FlexPen®, verdens mest udbredte injektionspen til dosering af insulin. Produkterne eksporteres til flere end 40 lande over hele verden. Novo Nordisk har investeret 300 mio. euro i Frankrig over de sidste 15 år og beskæftiger i dag 1.100 medarbejdere på fabrikken. Den planlagte udvidelse ventes at skabe omkring 250 nye arbejdspladser, når produktionsanlæggene er i fuld drift indenfor de næste tre til fire år. ""Novo Nordisk har drevet virksomhed i Frankrig gennem mere end 50 år,"" siger Lars Rebien Sørensen, administrerende direktør for Novo Nordisk. ""I årenes løb har vi opbygget en meget stærk organisation i Frankrig, og fabrikken i Chartres er i dag et af vores vigtigste strategiske produktionssteder. Den kommende udvidelse vil yderligere styrke Chartres-fabrikkens position i vores globale produktionsorganisation."" Foruden de 1.100 medarbejdere i Chartres beskæftiger Novo Nordisk 300 medarbejdere i datterselskabet i Paris, som er ansvarligt for Novo Nordisks medicinske, regulatoriske og kommercielle aktiviteter i Frankrig.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1107,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
424,2016-04-18,Novo Nordisk A/S - Nedsættelse af aktiekapitalen,"Bagsværd, 2016-04-18 - På den ordinære generalforsamling i Novo Nordisk A/S den 18. marts 2016 blev det besluttet at nedsætte selskabets B-aktiekapital fra nominelt 412.512.800 kr. til 402.512.800 kr. ved annullering af en del af selskabets beholdning af egne B-aktier, i alt nominelt 10.000.000 kr. fordelt på 50.000.000 B-aktier á 0,20 kr. Yderligere information Selskabsmeddelelse nr. 29 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1113,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
425,2016-04-18,Novo Nordisk A/S - Reduction of the share capital,"Bagsværd, Denmark, 18 April 2016 - At Novo Nordisk's Annual General Meeting on 18 March 2016, it was decided to reduce the company's B share capital from DKK 412,512,800 to DKK 402,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each. Further information Company announcement No 29 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1112,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
426,2016-04-08,Novo Nordisk A/S: Johannesburg Tilslutter Sig Cities Changing Diabetes,"I en kommentar siger Ms. Nonceba Molwele, byrådsmedlem og medlem af udvalget for sundhed og social udvikling i Johannesburg: ""Diabetes er den sjettestørste blandt de 10 hyppigste dødsårsager i Johannesburg og er en stor trussel mod folkesundheden i byen. Cities Changing Diabetes er en fantastisk mulighed for os for at lære mere om, hvad vi kan gøre for at bremse sygdommens fremmarch. Vi ser frem til at lære af de erfaringer, andre af verdens storbyer har gjort sig, så vi kan skabe et Johannesburg, der er sundere at bo i, og hvor færre mennesker har risiko for at udvikle diabetes."" Cities Changing Diabetes blev startet i Mexico City i marts 2014 af Novo Nordisk, University College London (UCL) og Steno Diabetes Center. Formålet med Cities Changing Diabetes er i første omgang at kortlægge problemet, derefter udveksle ideer og bud på løsninger og til slut udarbejde konkrete handlingsplaner for de storbyer, der deltager i programmet. I november 2015 blev de første resultater af partnerskabet præsenteret på en stor konference i København. De viste, at risikoen for diabetes i storbyer i højere grad end før antaget knytter sig til sociale og kulturelle faktorer1 - faktorer, som dels øger indbyggernes risiko for at udvikle type 2-diabetes, og som dels gør det mindre sandsynligt, at de bliver diagnosticeret, modtager behandling og bevarer en god sundhedstilstand. For eksempel viste resultaterne, at mange i Houston traditionelt forbinder diabetes med lavere samfundsøkonomisk status, mens virkeligheden er, at alle uanset økonomisk formåen er sårbare i forhold til at udvikle sygdommen. I Mexico City fandt man, at kønsroller var med til at øge risikoen for diabetes blandt kvinder, fordi de ofte tilsidesætter deres eget helbred og derfor ikke bliver diagnosticeret. David Napier, professor i medicinsk antropologi ved UCL og leder af det globale forskningsarbejde, forklarer: ""Vi forsøger at hjælpe byerne ved at se ud over de traditionelle biomedicinske risikofaktorer for udvikling af diabetes for at finde frem til, hvorfor risikoen er større for mennesker i byerne. Samarbejdet med Johannesburg er af stor betydning for initiativet, fordi det er den første by på det afrikanske kontinent, og fordi vi tror, initiativet vil kunne gøre en forskel for byens indbyggere."" Initiativets første fase har allerede i februar 2016 dannet grundlag for en beslutning i København, som er en af byerne i partnerskabet, om at etablere et nyt diabetescenter. Centret skal forbedre adgangen til diabetesbehandling for alle borgere, herunder de befolkningsgrupper, der ifølge programmets forskningsresultater har stor risiko for at udvikle diabetes, og som er svære at komme i kontakt med. Foruden Johannesburg deltager Houston, Mexico City, København, Shanghai og Tianjin i Cities Changing Diabetes-programmet.  Om cities changing diabetes Cities Changing Diabetes er et partnerskabsprogram, der skal tackle diabetesudfordringen i verdens storbyer. Programmet er lanceret af Novo Nordisk som reaktion på den kraftige stigning i forekomsten af diabetes i storbyer og er udviklet i samarbejde med University College London og Steno Diabetes Center samt en række lokale partnere, herunder diabetes- og sundhedsorganisationer, bystyrer, forskningsinstitutioner, byudviklingseksperter (fra mange specialistområder) og civilsamfundsorganisationer. Følgende byer har indtil nu tilsluttet sig: Mexico City, Houston, København, Shanghai, Tianjin og Johannesburg. Formålet med initiativet er at kortlægge problemet, udveksle løsninger og iværksætte konkrete handlinger for at løse diabetesudfordringen i verdens storbyer. Læs mere på citieschangingdiabetes.com Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1117,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
427,2016-04-08,Novo Nordisk A/S: Johannesburg joins Cities Changing Diabetes,"Bagsværd, Denmark, Friday 8 April 2016 - Today, the city of Johannesburg joins the Cities Changing Diabetes programme and becomes the first African city to join the global initiative. The addition of the largest city in South Africa as a partner city means Cities Changing Diabetes now brings together six cities across four continents in the fight against urban diabetes. Johannesburg City Member of the Mayoral Council on Health and Social Development Ms Nonceba Molwele says: ""Diabetes is ranked 6th among the top 10 leading causes of death in Johannesburg and represents a significant public health challenge here. Joining Cities Changing Diabetes is an exciting opportunity for us to learn more about what we can do to combat this growing condition. We look forward to learning from the experiences of other cities around the world, so that we can create a more liveable and healthy Johannesburg with fewer people at risk of developing diabetes."" Cities Changing Diabetes was established in 2014 by founding partners Novo Nordisk, University College London (UCL) and Steno Diabetes Center. The programme aims to tackle the rise of diabetes in cities through three distinct but interconnecting phases: mapping, sharing and action. In November 2015, the partnership presented findings of first-of-its-kind research that found that diabetes vulnerability in cities is linked to a complex mix of social and cultural factors1- responsible for both putting people at greater initial risk of developing type 2 diabetes and subsequently making them less likely to be diagnosed, receive treatment and maintain good health. For example the study findings showed that in Houston many people link diabetes with lower socio-economic status, while people of all economic classes are in fact vulnerable to the condition. In Mexico City, gender roles were linked to increased diabetes vulnerability among women, who sometimes went undiagnosed after neglecting their personal health. Global research lead David Napier, professor of Medical Anthropology, UCL explains: ""We are helping cities to look beyond traditional biomedical risk factors for diabetes to consider why it is that urban inhabitants are at increased risk of diabetes. Working with Johannesburg is significant for the programme as it will provide our first insights into urban diabetes in Africa and crucially, will enable the city to take action for the health of its citizens."" The programme insights have already informed a decision in February 2016 by Cities Changing Diabetes partner city Copenhagen to establish a new diabetes centre. The centre will enable improved access to diabetes for all citizens including care for vulnerable, hard-to-reach populations identified by the programme's research efforts. In addition to Johannesburg, Houston, Mexico City and Copenhagen, the cities of Shanghai and Tianjin are sharing insights and taking action as part of the Cities Changing Diabetes programme. About Cities Changing Diabetes  Further information ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1116,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
428,2016-04-04,Saxenda® demonstrated significant improvements in cardiometabolic risk factors over three years compared with placebo,"Read the full release with references in PDF Boston, US, 4 April 2016 - Today, new data from the three-year part of the phase 3a SCALE(TM) (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial were presented at the Endocrine Society's 98th Annual Meeting and Expo (ENDO 2016). The three-year part of the trial (n=2,254 adults with obesity or who were overweight with comorbidities and had prediabetes at baseline) data demonstrated that 160 weeks of treatment with Saxenda® (liraglutide 3 mg) (n=1,505) in combination with a reduced-calorie diet and increased physical activity resulted in significant improvements in cardiometabolic risk factors (such as blood pressure and cholesterol) compared with placebo (reduced-calorie diet and increased physical activity alone) (n=749).1",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1118,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
429,2016-04-04,Saxenda® demonstrated significant improvements in cardiometabolic risk factors over three years compared with placebo,"Read the full release with references in PDF Boston, US, 4 April 2016 - Today, new data from the three-year part of the phase 3a SCALE(TM) (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial were presented at the Endocrine Society's 98th Annual Meeting and Expo (ENDO 2016). The three-year part of the trial (n=2,254 adults with obesity or who were overweight with comorbidities and had prediabetes at baseline) data demonstrated that 160 weeks of treatment with Saxenda® (liraglutide 3 mg) (n=1,505) in combination with a reduced-calorie diet and increased physical activity resulted in significant improvements in cardiometabolic risk factors (such as blood pressure and cholesterol) compared with placebo (reduced-calorie diet and increased physical activity alone) (n=749).1",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1120,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
430,2016-04-04,Behandling med Saxenda® i tre år giver signifikante forbedringer i kardiometaboliske risikofaktorer sammenlignet med placebo,"Læs hele meddelelsen med referencer i pdf-format. Boston, USA, den 4. april 2016 - Novo Nordisk præsenterer i dag nye data fra den treårige del af fase 3a-studiet SCALE (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes. Det sker på ENDO 2016, den 98. årskongres i det amerikanske videnskabelige selskab Endocrine Society. Dataene fra den treårige del af studiet (n=2.254 voksne med svær overvægt eller overvægtige med komplikationer og prædiabetes ved studiets start) viste, at 160 ugers behandling med Saxenda® (liraglutid 3 mg) (n=1.505) i kombination med en kaloriefattig kost og øget fysisk aktivitet medførte signifikante forbedringer i kardiometaboliske risikofaktorer (som blodtryk og kolesterol) sammenlignet med placebo (kaloriefattig kost og øget fysisk aktivitet alene) (n=749).1  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1121,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
431,2016-04-04,Behandling med Saxenda® i tre år giver signifikante forbedringer i kardiometaboliske risikofaktorer sammenlignet med placebo,"Læs hele meddelelsen med referencer i pdf-format. Boston, USA, den 4. april 2016 - Novo Nordisk præsenterer i dag nye data fra den treårige del af fase 3a-studiet SCALE (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes. Det sker på ENDO 2016, den 98. årskongres i det amerikanske videnskabelige selskab Endocrine Society. Dataene fra den treårige del af studiet (n=2.254 voksne med svær overvægt eller overvægtige med komplikationer og prædiabetes ved studiets start) viste, at 160 ugers behandling med Saxenda® (liraglutid 3 mg) (n=1.505) i kombination med en kaloriefattig kost og øget fysisk aktivitet medførte signifikante forbedringer i kardiometaboliske risikofaktorer (som blodtryk og kolesterol) sammenlignet med placebo (kaloriefattig kost og øget fysisk aktivitet alene) (n=749).1  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1119,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
432,2016-04-02,"Victoza® (liraglutid 1,8 mg) reducerer langtidsblodsukkeret hos voksne med type 2-diabetes bedre, end hvis de fortsætter med sitagliptin","Læs hele pressemeddelelsen Boston, USA, den 2. april 2016 - Resultaterne fra et klinisk studie, der sammenlignede Victoza® (liraglutid 1,8 mg) og sitagliptin (100 mg), begge i kombination med metformin, viste, at skift fra sitagliptin til Victoza® medførte bedre reduktioner i langtidsblodsukkerniveauet (HbA1c)sammenlignet med fortsat behandling med sitagliptin hos voksne med type 2-diabetes. Disse og andre resultater fra LIRA-SWITCH-studiet præsenteres i dag på ENDO 2016, det amerikanske videnskabelige selskab Endocrine Societys 98. årskongres i Boston, USA.[i] Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1127,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
433,2016-04-02,"Victoza® (liraglutid 1,8 mg) reducerer langtidsblodsukkeret hos voksne med type 2-diabetes bedre, end hvis de fortsætter med sitagliptin","Læs hele pressemeddelelsen Boston, USA, den 2. april 2016 - Resultaterne fra et klinisk studie, der sammenlignede Victoza® (liraglutid 1,8 mg) og sitagliptin (100 mg), begge i kombination med metformin, viste, at skift fra sitagliptin til Victoza® medførte bedre reduktioner i langtidsblodsukkerniveauet (HbA1c)sammenlignet med fortsat behandling med sitagliptin hos voksne med type 2-diabetes. Disse og andre resultater fra LIRA-SWITCH-studiet præsenteres i dag på ENDO 2016, det amerikanske videnskabelige selskab Endocrine Societys 98. årskongres i Boston, USA.[i] Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1125,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
434,2016-04-02,Victoza® (liraglutide 1.8 mg) provided superior HbA1c reductions in adults with type 2 diabetes compared to continued sitagliptin treatment,"Read the full release Boston, US, 2 April 2016 - Findings from a clinical trial comparing Victoza® (liraglutide 1.8 mg) and sitagliptin (100 mg), both in combination with metformin, demonstrated that switching from sitagliptin to Victoza® provided superior HbA1c reductions vs continuing with sitagliptin treatment in adults with type 2 diabetes. Results from the LIRA-SWITCH trial were presented at the Endocrine Society's 98th Annual Meeting and Expo (ENDO 2016) in Boston, MA, US.1 Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1124,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
435,2016-04-02,Victoza® (liraglutide 1.8 mg) provided superior HbA1c reductions in adults with type 2 diabetes compared to continued sitagliptin treatment,"Read the full release Boston, US, 2 April 2016 - Findings from a clinical trial comparing Victoza® (liraglutide 1.8 mg) and sitagliptin (100 mg), both in combination with metformin, demonstrated that switching from sitagliptin to Victoza® provided superior HbA1c reductions vs continuing with sitagliptin treatment in adults with type 2 diabetes. Results from the LIRA-SWITCH trial were presented at the Endocrine Society's 98th Annual Meeting and Expo (ENDO 2016) in Boston, MA, US.1 Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1126,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
436,2016-04-02,Semaglutide demonstrated superior improvements in glycaemic control vs placebo in adults with type 2 diabetes,"Boston, US, 2 April 2016 - Findings from the first phase 3a clinical trial for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, demonstrated that treatment with semaglutide administered once-weekly, significantly improved glycaemic control compared to placebo in adults with type 2 diabetes previously managed with diet and exercise alone. Results from the SUSTAIN 1 trial were presented today at the Endocrine Society's 98th Annual Meeting and Expo (ENDO 2016) in Boston, MA, US.1 Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1130,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
437,2016-04-02,Semaglutid viser større forbedringer i reguleringen af blodsukkeret end placebo hos voksne med type 2-diabetes,"Læs hele meddelelsen Boston, USA, den 2. april 2016 - Resultaterne fra det første kliniske fase 3a-studie af semaglutid, en GLP-1-analog (glukagonlignende peptid-1) under udvikling, viser, at behandling med semaglutid doseret én gang om ugen giver en signifikant forbedret blodsukkerregulering sammenlignet med placebo hos voksne med type 2-diabetes, som tidligere var blevet reguleret med diæt og motion alene. Disse og andre resultater fra SUSTAIN 1-studiet præsenteres i dag på ENDO 2016, det amerikanske videnskabelige selskab Endocrine Societys 98. årskongres i Boston, USA.[i]  [i]    Sorli C, Harashima S, Tsoukas G, et al. SUSTAIN 1: efficacy and safety of once-weekly semaglutide monotherapy versus placebo in subjects with type 2 diabetes. Abstract number OR15-1. Endocrine Society's 98th Annual Meeting and Expo (ENDO 2016), Boston, MA, US; 1-4 April 2016.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1131,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
438,2016-04-02,Semaglutide demonstrated superior improvements in glycaemic control vs placebo in adults with type 2 diabetes,"Boston, US, 2 April 2016 - Findings from the first phase 3a clinical trial for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, demonstrated that treatment with semaglutide administered once-weekly, significantly improved glycaemic control compared to placebo in adults with type 2 diabetes previously managed with diet and exercise alone. Results from the SUSTAIN 1 trial were presented today at the Endocrine Society's 98th Annual Meeting and Expo (ENDO 2016) in Boston, MA, US.1 Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1128,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
439,2016-04-02,Semaglutid viser større forbedringer i reguleringen af blodsukkeret end placebo hos voksne med type 2-diabetes,"Læs hele meddelelsen Boston, USA, den 2. april 2016 - Resultaterne fra det første kliniske fase 3a-studie af semaglutid, en GLP-1-analog (glukagonlignende peptid-1) under udvikling, viser, at behandling med semaglutid doseret én gang om ugen giver en signifikant forbedret blodsukkerregulering sammenlignet med placebo hos voksne med type 2-diabetes, som tidligere var blevet reguleret med diæt og motion alene. Disse og andre resultater fra SUSTAIN 1-studiet præsenteres i dag på ENDO 2016, det amerikanske videnskabelige selskab Endocrine Societys 98. årskongres i Boston, USA.[i]  [i]    Sorli C, Harashima S, Tsoukas G, et al. SUSTAIN 1: efficacy and safety of once-weekly semaglutide monotherapy versus placebo in subjects with type 2 diabetes. Abstract number OR15-1. Endocrine Society's 98th Annual Meeting and Expo (ENDO 2016), Boston, MA, US; 1-4 April 2016.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1129,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
440,2016-03-29,"Første spadestik taget til ny fabrik til 2 mia. dollars i Clayton, USA","Bagsværd, den 29. marts 2016 ­- Novo Nordisk tog i går det første spadestik til en ny fabrik i Clayton, North Carolina, USA. Fabrikken repræsenterer en investering på 2 mia. US dollars. Den kommende nye fabrik skal fremstille aktive lægemiddelstoffer (API) til såvel oral semaglutid som en række af Novo Nordisks eksisterende og fremtidige GLP-1- og insulinprodukter. Når fabrikken i Clayton er i drift i 2020, vil den sikre produktionskapaciteten til diabetesprodukter i USA i det næste årti. ""Efterspørgslen efter god diabetesbehandling stiger i takt med den stigende udbredelse af diabetes i USA,"" sagde Lars Rebien Sørensen, administrerende direktør for Novo Nordisk. ""Jeg er stolt over at kunne tage det første spadestik til vores nye fabrik i Clayton, hvor vi allerede har en stærk og veletableret organisation. Dette anlæg vil komme til at spille en afgørende rolle i forhold til at imødekomme behovene hos mennesker med diabetes i USA i de næste mange år."" Det nye anlæg er placeret i umiddelbar nærhed af Novo Nordisks eksisterende 42.000 m2 store fabrik, som monterer og pakker de præfyldte insulinpenne FlexPen® og FlexTouch® til det amerikanske marked. Udvidelsen ventes at skabe op mod 700 nye jobs, og Novo Nordisk forventer at skabe en betydelig beskæftigelseseffekt i byggeperioden, hvor op til 2.500 personer ventes beskæftiget, når byggeprojektet topper.  Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1137,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
441,2016-03-29,"Novo Nordisk breaks ground on USD 2bn production facility in Clayton, North Carolina","Bagsværd, Denmark, 29 March 2016 ­- Yesterday, Novo Nordisk broke ground on its new 2 billion US dollar production facility in Clayton, North Carolina. The facility will produce active pharmaceutical ingredients (API) for a range of Novo Nordisk's current and future GLP-1 and insulin products. Once fully operational in 2020, Clayton will ensure production capacity for diabetes care products in the US for the decade ahead. ""As the prevalence of diabetes has grown in the US, so too has the demand for effective treatments,"" said Lars Rebien Sørensen, president and chief executive officer of Novo Nordisk. ""It gives me great pride to break ground on our new facility site in Clayton where we have an existing, strong organisation. This site will play a vital role in enabling us to meet the needs of people living with diabetes in the US for years to come."" The new site is situated adjacent to Novo Nordisk's existing 42,000 m2 facility which assembles and packages FlexPen® and FlexTouch® prefilled insulin devices for the US market. The expansion is expected to create close to 700 new jobs and Novo Nordisk expects to create a significant employment effect during the construction period with up to 2,500 people working on the project at its peak.  Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1136,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
442,2016-03-18,Resolutions from the Annual General Meeting of Novo Nordisk A/S,"Bagsværd, Denmark, 18 March 2016 - Today, Novo Nordisk A/S held its Annual General Meeting, at which the following were adopted: Financial year 2015 and 2016 Elections Re-election of PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab as the Company's auditor. Other Composition of the Board of Directors and its committees After the Annual General Meeting, the Board of Directors held a board meeting to appoint members of its committees. The Board of Directors, including its committees are now composed as follows: Further information Company announcement No 23 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1142,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
443,2016-03-18,Beslutninger på den ordinære generalforsamling i  Novo Nordisk A/S,"Bagsværd, den 18. marts 2016 - Novo Nordisk A/S har i dag afholdt ordinær generalforsamling, hvor følgende blev besluttet: Valg    Sammensætning af bestyrelsen og dens udvalg På et bestyrelsesmøde afholdt efter generalforsamlingen valgte bestyrelsen medlemmer til bestyrelsens udvalg. Bestyrelsen og dens udvalg er herefter sammensat som følger:  Yderligere information: Selskabsmeddelelse nr. 23 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1143,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
444,2016-03-04,Victoza® significantly reduces the risk of major adverse cardiovascular events in the LEADER trial,"Bagsværd, Denmark, 4 March 2016 - Novo Nordisk today announced the top-line results from the LEADERtrial, which investigated the cardiovascular safety of Victoza® (liraglutide) over a period of up to 5 years in more than 9,000 adults with type 2 diabetes at high risk of major adverse cardiovascular events. The trial compared the addition of either Victoza® or placebo to standard of care and met the primary endpoint of showing non-inferiority as well as demonstrating superiority, with a statistically significant reduction in cardiovascular risk. The primary endpoint of the study was defined as the composite outcome of the first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. The superior reduction of major adverse cardiovascular events demonstrated by Victoza® was derived from all three components of the endpoint. The safety profile of Victoza® in LEADER was generally consistent with previous liraglutide clinical studies. ""People with type 2 diabetes generally have a higher risk of experiencing major adverse cardiovascular events. That's why we are very excited about the results from LEADER, which showed that Victoza®, in addition to helping people with type 2 diabetes control their blood sugar levels, also reduces their risk of major adverse cardiovascular events "", said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""LEADER is the largest and longest Novo Nordisk clinical trial to report to date, and we look forward to sharing the detailed results with the medical community and submitting the findings to the regulatory authorities."" The detailed results are planned to be presented at the 76th Scientific Sessions of the American Diabetes Association in June 2016. Conference call On 4 March 2016 at 2.00 pm CET, corresponding to 8.00 am EST, a conference call for investors will be held. Investors will be able to listen in via a link on the investor section of novonordisk.com. About LEADER LEADER was a multicentre, international, randomised, double-blind, placebo-controlled trial investigating the long-term effects of Victoza® (1.2 and 1.8 mg) compared to placebo, both in addition to standard of care, in people with type 2 diabetes at high risk of cardiovascular events. The trial was initiated in September 2010 and randomised 9,340 people with type 2 diabetes from 32 countries that were followed for 3.5-5 years. The primary endpoint was the first occurrence of a composite cardiovascular outcome comprising cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. About Victoza® Victoza® (liraglutide) is a human glucagon-like peptide-1 (GLP-1) analogue with an amino acid sequence 97% similar to endogenous human GLP-1. Victoza® was launched in the EU in 2009 and is commercially available in more than 80 countries with more than 3 million patient years of use in people with type 2 diabetes globally. In Europe, Victoza® is indicated for treatment of adults with type 2 diabetes to achieve glycaemic control in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control. Victoza® was approved by the U.S. Food and Drug Administration in 2010, as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes. For further information Company announcement No 20 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1148,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
445,2016-03-04,Victoza® reducerer risikoen for alvorlige kardiovaskulære hændelser signifikant i LEADER-studiet,"Bagsværd, den 4. marts 2016 - Novo Nordisk offentliggør i dag de overordnede resultater fra LEADER-studiet, som undersøgte den kardiovaskulære (hjerte-kar-mæssige) sikkerhed for Victoza® (liraglutid) over en periode på op til fem år i flere end 9.000 voksne med type 2-diabetes med høj risiko for alvorlige kardiovaskulære hændelser. Studiet sammenlignede tilføjelsen af enten Victoza® eller placebo til standardbehandling og opfyldte det primære mål om at vise ikke-inferiøritet samt at dokumentere superioritet med en statistisk signifikant reduktion i kardiovaskulær risiko. Det primære mål for studiet var defineret som et sammensat endepunkt bestående af den første forekomst af kardiovaskulær død, ikke-dødeligt myokardieinfarkt eller ikke-dødeligt slagtilfælde. Den signifikante reduktion af alvorlige kardiovaskulære hændelser, der blev vist for Victoza®, hidrørte fra alle tre komponenter i dette endepunkt. Sikkerhedsprofilen for Victoza® i LEADER var generelt konsistent med tidligere kliniske studier af liraglutid. ""Mennesker med type 2-diabetes har generelt en forøget risiko for alvorlige kardiovaskulære hændelser. Det er derfor, vi er meget begejstrede for resultaterne fra LEADER, som viser, at Victoza® ikke bare hjælper mennesker med type 2-diabetes med at regulere deres blodsukkerniveau, men også reducerer deres risiko for alvorlige kardiovaskulære hændelser,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""LEADER er det hidtil største og længste kliniske studie, Novo Nordisk har rapporteret resultater fra, og vi ser frem til at dele de detaljerede resultater med lægeverdenen og indsende konklusionen til de regulatoriske myndigheder."" De detaljerede resultater vil efter planen blive præsenteret på det 76. årsmøde i den amerikanske diabetesforening, American Diabetes Association (ADA), i juni 2016. Telekonference Der vil den 4. marts 2016 kl. 14.00 CET blive afholdt en telekonference for investorer. Investorer kan lytte med via et link under investorsektionen på novonordisk.com. Om LEADER LEADER er et internationalt, randomiseret, dobbeltblindet, placebokontrolleret multicenterstudie, der har undersøgt langtidsvirkningerne af Victoza® (1,2 og 1,8 mg) sammenlignet med placebo, begge givet som supplement til standardbehandling, i mennesker med type 2-diabetes med høj risiko for kardiovaskulære hændelser. Studiet blev påbegyndt i september 2010 og randomiserede 9.340 mennesker med type 2-diabetes fra 32 lande, som blev fulgt i 3,5 til 5 år. Det primære mål var den første forekomst af et sammensat kardiovaskulært endepunkt bestående af kardiovaskulær død, ikke-dødeligt myokardieinfarkt eller ikke-dødeligt slagtilfælde. Om Victoza® Victoza® (liraglutid) er en human GLP-1-analog (glukagonlignende peptid-1) med en aminosyresekvens, der har 97% lighed med det GLP-1, kroppen selv producerer. Victoza® blev lanceret i EU i 2009 og er i dag på markedet i flere end 80 lande; produktet har været anvendt til behandling af mennesker med type 2-diabetes i mere end tre mio. patientår globalt. I Europa er Victoza® godkendt til regulering af blodsukkerniveauet hos voksne med type 2-diabetes som tillægsbehandling til diabeteslægemidler i tabletform og/eller basalinsulin, når blodsukkeret ikke kan reguleres tilstrækkeligt med disse lægemidler sammen med motion og diæt. Victoza® blev godkendt af de amerikanske sundhedsmyndigheder, FDA, i 2010 som supplement til diæt og motion med det formål at forbedre blodsukkerreguleringen hos voksne med type 2-diabetes Yderligere information Selskabsmeddelelse nr. 20 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1149,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
446,2016-02-23,Novo Nordisk afslutter med succes det femte fase 3a-studie med semaglutid i mennesker med type 2-diabetes,"Bagsværd, den 23. februar 2016 - Novo Nordisk offentliggør i dag de overordnede resultater fra SUSTAIN5, det femte fase 3a-studie med semaglutid. Semaglutid er en ny GLP-1-analog, som doseres ved injektion i underhuden (subkutant) én gang ugentligt i SUSTAIN-studierne. Det dobbeltblindede studie undersøgte effekt og sikkerhed for 0,5 mg og 1,0 mg semaglutid sammenlignet med placebo som tillægsbehandling til basalinsulin alene eller basalinsulin i kombination med metformin, efter 30 ugers behandling hos 397 deltagere med type 2-diabetes. Studiet opfyldte succesfuldt sit mål, idet det viste, at deltagere, som blev behandlet med 0,5 mg eller 1,0 mg semaglutid, fra et gennemsnitligt langtidsblodsukkerniveau (HbA1c) på 8,4% ved studiets begyndelse opnåede en statistisk signifikant og større forbedring i HbA1c på henholdsvis 1,4% og 1,8% sammenlignet med en forbedring i HbA1c på 0,1% med placebo. Endvidere var insulindosis ved studiets afslutning reduceret med henholdsvis 10% og 15% for deltagere i behandling med 0,5 mg og 1,0 mg semaglutid, mod 3% for placebogruppen. 61% af deltagere, som blev behandlet med 0,5 mg semaglutid, og 79% af deltagere, som fik 1,0 mg semaglutid, nåede behandlingsmålet om HbA1c under 7% som fastsat af American Diabetes Association (ADA) og European Association for the Study of Diabetes (EASD), mod 11% af dem, som blev behandlet med placebo. Fra en gennemsnitsvægt på 92 kg ved studiets begyndelse opnåede deltagere i behandling med 0,5 mg og 1,0 mg semaglutid et statistisk signifikant og større vægttab på henholdsvis 3,7 kg og 6,4 kg sammenlignet med et vægttab på 1,4 kg hos deltagere i behandling med placebo. Semaglutid forekom i studiet at have en sikker og veltolereret profil. Den mest almindelige bivirkning var kvalme. Kvalme blev rapporteret hos 11% af deltagere i behandling med 0,5 mg semaglutid og hos 17% af deltagere i behandling med 1,0 mg semaglutid, mod 5% af deltagere i behandling med placebo. Alvorlig eller symptomatisk hypoglykæmi bekræftet ved blodsukkermåling sås hos 8% og 11% af deltagere i behandling med henholdsvis 0,5 mg eller 1,0 mg semaglutid én gang ugentligt, mod 5% i placebogruppen. Frafaldsprocenten som følge af bivirkninger var 5% og 6% for deltagere i behandling med henholdsvis 0,5 mg semaglutid og 1,0 mg semaglutid, mod 1% for deltagere i behandling med placebo. ""Vi er rigtig glade for resultaterne fra SUSTAIN 5, som viste, at semaglutid givet som én ugentlig injektion gav bedre effekt med hensyn til blodsukkerregulering og vægttab hos patienter, som er utilstrækkeligt reguleret med basalinsulin,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Resultaterne fra de fem første SUSTAIN-studier understøtter potentialet for bred anvendelse af semaglutid til behandling af type 2-diabetes, da vores undersøgelser har vist konsistente resultater for behandling af mennesker med type 2-diabetes både i tidlige og sene stadier."" Novo Nordisk forventer at offentliggøre de overordnede resultater fra det sidste af studierne i SUSTAIN-programmet, SUSTAIN 6, i første halvår af 2016. Om semaglutid Semaglutid er en ny GLP-1-analog (glukagonlignende peptid-1), som kan hjælpe mennesker med type 2-diabetes med at opnå en markant forbedring af blodsukkeret med lav risiko for hypoglykæmi (lavt blodsukker). Semaglutid medfører endvidere vægttab ved at nedsætte appetit og madindtag. Semaglutid til subkutan dosering (ved injektion i underhuden) én gang ugentligt er i fase 3-udvikling til behandling af type 2-diabetes. Semaglutid er endvidere under udvikling i tabletform til oral behandling af type 2-diabetes samt i injicerbare udgaver til subkutan dosering én gang dagligt til behandling af type 2-diabetes og vægtregulering.  Om det kliniske udviklingsprogram SUSTAIN SUSTAIN er et klinisk fase 3-program, som omfatter seks globale studier med semaglutid doseret subkutant én gang om ugen med deltagelse af flere end 7.000 mennesker med type 2-diabetes. SUSTAIN 1 - et 30-ugers effekt- og sikkerhedsstudie, der undersøger semaglutid i forhold til placebo hos 388 deltagere med type 2-diabetes, som ikke tidligere har fået medicinsk behandling. Resultaterne blev rapporteret i juli 2015. SUSTAIN 2 - et 56-ugers effekt- og sikkerhedsstudie, der undersøger semaglutid i forhold til sitagliptin én gang dagligt som tillægsbehandling til metformin og/eller TZD hos 1.231 deltagere med type 2-diabetes. Resultaterne blev rapporteret i december 2015. SUSTAIN 3 - et 56-ugers effekt- og sikkerhedsstudie, der undersøger semaglutid i forhold til 2,0 mg exenatid én gang ugentligt som tillægsbehandling til 1-2 diabeteslægemidler i tabletform hos 813 deltagere med type 2-diabetes. Resultaterne blev rapporteret i september 2015. SUSTAIN 4 - et 30-ugers effekt- og sikkerhedsstudie, der undersøger semaglutid i forhold til insulin glargin én gang dagligt som tillægsbehandling til metformin med eller uden sulfonylurinstof hos 1.089 deltagere med type 2-diabetes, som ikke tidligere er blevet behandlet med insulin. Resultaterne blev rapporteret i november 2015. SUSTAIN 5 - et 30-ugers effekt- og sikkerhedsstudie, der undersøger semaglutid i forhold til placebo som tillægsbehandling til basal insulin alene eller basal insulin i kombination med metformin hos 397 deltagere med type 2-diabetes. SUSTAIN 6 - et toårigt studie, der undersøger forekomsten af hjerte-kar-sygdom og andre langsigtede målepunkter ved brug af semaglutid hos 3.297 deltagere med type 2-diabetes. Resultaterne fra dette studie er endnu ikke rapporteret.  Yderligere information  Selskabsmeddelelse nr. 18 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1153,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
447,2016-02-23,Novo Nordisk successfully completes fifth phase 3a trial with semaglutide in people with type 2 diabetes,"Bagsværd, Denmark, 23 February 2016 - Novo Nordisk today announced the headline results from the fifth phase 3a trial for semaglutide, SUSTAIN5. Semaglutide is a new GLP-1 analogue, which in the SUSTAIN trials is administered subcutaneously once weekly. The double-blinded trial investigated the efficacy and safety of 0.5 mg and 1.0 mg semaglutide compared with placebo as add-on to basal insulin alone or basal insulin in combination with metformin, after 30 weeks of treatment in 397 people with type 2 diabetes. The trial successfully achieved its objective by demonstrating that people treated with 0.5 mg or 1.0 mg semaglutide achieved a statistically significant and superior improvement in HbA1c of 1.4% and 1.8% respectively, from a mean baseline HbA1c of 8.4%, compared with an improvement in HbA1c of 0.1% with placebo. Additionally, the end of trial insulin dose for people treated with 0.5 mg and 1.0 mg semaglutide was reduced by 10% and 15% respectively, compared with 3% for the placebo group. 61% of the people treated with 0.5 mg semaglutide and 79% of the people treated with 1.0 mg semaglutide achieved the treatment target of HbA1c below 7% set by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), compared with 11% of the people treated with placebo. From a mean baseline body weight of 92 kg, people treated with 0.5 mg and 1.0 mg semaglutide experienced a statistically significant and superior weight loss of 3.7 kg and 6.4 kg respectively, compared with a weight loss of 1.4 kg for people treated with placebo. In the trial, semaglutide appeared to have a safe and well-tolerated profile. The most common adverse event was nausea. Nausea was reported by 11% of the people treated with 0.5 mg semaglutide and by 17% of the people treated with 1.0 mg semaglutide, compared with 5% of people treated with placebo. Severe or blood glucose-confirmed symptomatic hypoglycaemia was experienced by 8% and 11% of people treated with 0.5 mg or 1.0 mg once-weekly semaglutide respectively, compared with 5% in the placebo group. The discontinuation rate due to adverse events was 5% and 6% for people treated with 0.5 mg semaglutide and 1.0 mg semaglutide respectively, compared to 1% for people treated with placebo. ""We are excited about the results of SUSTAIN 5, showing superior efficacy in glycaemic control and weight loss with semaglutide administered once-weekly in patients inadequately controlled on basal insulin"" says Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""The results from the first five SUSTAIN trials support the potential for broad usage of semaglutide in people with type 2 diabetes, as results have been consistent when exploring people with both early onset as well as late stage type 2 diabetes."" Novo Nordisk expects to announce headline results of the final SUSTAIN trial, SUSTAIN 6 in the first half of 2016. Semaglutide is a new glucagon-like peptide-1 (GLP-1) analogue that can help people with type 2 diabetes achieve substantial improvement of blood glucose with a low risk of hypoglycaemia. In addition, semaglutide induces weight loss by decreasing appetite and food intake. Semaglutide administered subcutaneously once weekly is in phase 3 development for the treatment of type 2 diabetes. Furthermore, semaglutide is being developed in an oral tablet version for treatment of type 2 diabetes as well as once-daily subcutaneous versions for treatment of type 2 diabetes and weight management. About the SUSTAIN clinical programme The SUSTAIN programme is a phase 3 clinical programme comprising six global trials of semaglutide administered subcutaneously once weekly encompassing more than 7,000 people with type 2 diabetes. SUSTAIN 1 - a 30-week efficacy and safety trial of semaglutide versus placebo in 388 drug-naïve people with type 2 diabetes. SUSTAIN 2 - a 56-week efficacy and safety trial of semaglutide versus sitagliptin once-daily as add-on to metformin and/or TZD in 1,231 people with type 2 diabetes. SUSTAIN 3 - a 56-week efficacy and safety trial of semaglutide versus 2.0 mg exenatide once-weekly as add-on to 1-2 oral antidiabetic drugs in 813 people with type 2 diabetes. SUSTAIN 4 - a 30-week efficacy and safety trial of semaglutide versus insulin glargine once-daily as add-on to metformin with or without sulfonylurea in 1,089 insulin-naïve people with type 2 diabetes. SUSTAIN 5 - a 30-week efficacy and safety trial of semaglutide versus placebo as add-on to basal insulin alone or basal insulin in combination with metformin in 397 people with type 2 diabetes. SUSTAIN 6 - a 2-year trial not yet reported to evaluate cardiovascular and other long-term outcomes with semaglutide in 3,297 people with type 2 diabetes.  For further information Company announcement No 18 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1152,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
448,2016-02-23,Tresiba® demonstrates significantly lower rate of hypoglycaemia than insulin glargine U100 in blinded phase 3b trial in people with type 1 diabetes,"Bagsværd, Denmark, 23 February 2016 - Novo Nordisk today announced the headline results from SWITCH 1, the second of two 2x32-weeks randomised, double-blind, cross-over, treat-to-target trials, comparing the safety and efficacy of Tresiba® (insulin degludec) and Lantus® (insulin glargine U100). The overall purpose of the trial was to compare the hypoglycaemia occurrence in people with type 1 diabetes treated with Tresiba® or insulin glargine. In the trial, 501 people with type 1 diabetes were randomised to cross-over treatment with Tresiba® and insulin glargine U100 in combination with insulin aspart. The timing of the daily injections of both Tresiba® and insulin glargine was randomised equally to take place either in the morning or evening. The primary end-point of the trial was the number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemia episodes during the maintenance period (ie after 16 weeks of treatment) in each treatment period. From a mean baseline of 7.6%, the trial showed non-inferiority in HbA1c reduction for Tresiba® compared to insulin glargine, thus fulfilling the requirements for objectively comparing hypoglycaemia rates between the two treatments. Likewise, the end-of-trial insulin doses were similar at the end of treatment in the two treatment periods. The trial met the primary end-point by demonstrating non-inferiority in the rate of severe or blood glucose confirmed symptomatic hypoglycemia of Tresiba® compared to insulin glargine. The observed rate was 2,201 events per 100 patient years exposed to Tresiba® and 2,463 events per 100 patient years exposed to insulin glargine during the maintenance period, corresponding to a statistically significant reduction of 11%. Similarly, non-inferiority was demonstrated for the rate of severe or blood glucose confirmed symptomatic nocturnal hypoglycaemia in the maintenance period. The observed rate of severe or blood glucose confirmed symptomatic nocturnal hypoglycaemia was 277 events per 100 patient years exposed to Tresiba® and 429 events per 100 patient years exposed to insulin glargine, corresponding to a statistically significant 36% reduction with Tresiba® compared to insulin glargine. Finally, superiority was demonstrated for the confirmatory secondary endpoint of proportions of subjects experiencing severe hypoglycaemia during the maintenance period. The proportion of patients experiencing severe hypoglycaemia was 10% for Tresiba® and 17% for insulin glargine, corresponding to a statistically significant reduction with Tresiba® compared to insulin glargine. The rates of severe hypoglycaemia were 69 and 92 events per 100 patient years exposed, respectively, corresponding to a statistically significant 35% reduction. All of the above analyses showed similar results for the total treatment period. In the trial, Tresiba® appeared to have a safe and well-tolerated profile. Adverse events were comparable between the two treatment arms. The most common adverse events were nasopharyngitis, upper respiratory tract infections and hypoglycaemia. ""We are very excited about these trial results, which document that Tresiba® also in people with type 1 diabetes significantly reduces the risk of hypoglycaemia compared to insulin glargine"" says Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""We expect to initiate filing of the data from the SWITCH trials with regulatory authorities in Q3 2016 with the aim of updating the label for Tresiba®"". Conference call On 24 February 2016 at 8.30 am CET, corresponding to 2.30 am EST, a conference call for investors will be held. Investors will be able to listen in via a link on the investor section of novonordisk.com. About SWITCH 1 and 2 The two 2x32-weeks randomised, double-blind, cross-over, treat-to-target trials were initiated in January 2014 with the purpose of comparing the safety and efficacy of Tresiba® and Lantus® (insulin glargine U100). The overall purpose of the trials is to document the hypoglycaemia profile in type 1 diabetes and type 2 diabetes respectively, compared to insulin glargine U100. In SWITCH 1, 501 people with type 1 diabetes were randomised to cross-over treatment with Tresiba® and insulin glargine U100 in combination with insulin aspart. In SWITCH 2, 721 people with type 2 diabetes were randomised to cross-over treatment with Tresiba® and insulin glargine U100 in combination with oral antidiabetics. The results from SWITCH 2 were reported on 29 January 2016. Lantus® is a registered trademark of Sanofi.  For further information Company announcement No 17 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1154,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
449,2016-02-23,Tresiba® viser signifikant lavere forekomst af hypoglykæmi end insulin glargin U100 i blindet fase 3b-studie i mennesker med type 1-diabetes,"Bagsværd, den 23. februar 2016 - Novo Nordisk offentliggør i dag de overordnede resultater fra SWITCH 1, det andet af to 2x32-ugers randomiserede, dobbeltblindede, cross-over, treat to target-studier, der sammenligner sikkerhed og effekt for Tresiba® (insulin degludec) og Lantus® (insulin glargin U100). Det overordnede formål med studiet var at sammenligne forekomsten af hypoglykæmi (lavt blodsukker) hos mennesker med type 1-diabetes, der blev behandlet med Tresiba® eller insulin glargin. I dette studie blev 501 mennesker med type 1-diabetes randomiseret til cross-over-behandling med Tresiba® og insulin glargin U100 i kombination med insulin aspart. Timingen af de daglige injektioner af både Tresiba® og insulin glargin blev ved randomisering ligeligt fordelt til at finde sted enten morgen eller aften. Studiets primære mål var antallet af episoder af alvorlig eller symptomatisk hypoglykæmi bekræftet ved blodsukkermåling, der opstod i forbindelse med behandlingen i vedligeholdelsesperioden (dvs. efter 16 ugers behandling) i hver enkelt behandlingsperiode. Fra et gennemsnitligt udgangspunkt på 7,6% (baseline) viste studiet ikke-inferiøritet med hensyn til reduktion af langtidsblodsukkerniveauet (HbA1c)for Tresiba® sammenlignet med insulin glargin og opfyldte dermed kravene for objektivt at sammenligne forekomsten af hypoglykæmi mellem de to behandlinger. Ligeledes var insulindoserne ved studiets afslutning sammenlignelige, når behandlingen i de to behandlingsperioder sluttede. Studiet opfyldte sit primære mål, idet det viste ikke-inferiøritet med hensyn til forekomsten af alvorlig eller symptomatisk hypoglykæmi bekræftet ved blodsukkermåling for Tresiba® sammenlignet med insulin glargin. Den observerede forekomst var 2.201 episoder pr. 100 patientårs eksponering for Tresiba® og 2.463 episoder pr. 100 patientårs eksponering for insulin glargin i vedligeholdelsesperioden, svarende til en statistisk signifikant reduktion på 11%. Tilsvarende blev der vist ikke-inferiøritet for forekomsten af alvorlig eller symptomatisk natlig hypoglykæmi bekræftet ved blodsukkermåling i vedligeholdelsesperioden. Den observerede forekomst af alvorlig eller symptomatisk natlig hypoglykæmi bekræftet ved blodsukkermåling var 277 episoder pr. 100 patientårs eksponering for Tresiba® og 429 episoder pr. 100 patientårs eksponering for insulin glargin, svarende til en statistisk signifikant reduktion på 36% med Tresiba® sammenlignet med insulin glargin. Endelig blev der vist superioritet vedrørende det bekræftende sekundære mål vedrørende andelen af deltagere, der oplevede alvorlig hypoglykæmi i vedligeholdelsesperioden. Andelen af deltagere, der oplevede alvorlig hypoglykæmi var 10% for Tresiba® og 17% for insulin glargin, svarende til en statistisk signifikant reduktion med Tresiba® sammenlignet med insulin glargin. Forekomsten af alvorlig hypoglykæmi var henholdsvis 69 og 92 episoder pr. 100 patientårs eksponering, svarende til en statistisk signifikant reduktion på 35%. Alle ovennævnte analyser viste sammenlignelige resultater for den fulde behandlingsperiode. Tresiba® forekom i studiet at have en sikker og veltolereret profil. Bivirkninger var sammenlignelige i de to behandlingsarme. De mest almindelige bivirkninger var forkølelse, infektioner i de øvre luftveje og hypoglykæmi. ""Vi er overordentlig glade for disse resultater, som dokumenterer, at Tresiba® også hos mennesker med type 1-diabetes reducerer risikoen for hypoglykæmi signifikant sammenlignet med insulin glargin,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Vi forventer, at den første indsendelse af data fra SWITCH-studierne til registreringsmyndighederne sker i tredje kvartal af 2016 med henblik på opdatering af indlægssedlen for Tresiba®."" Der vil den 24. februar 2016 kl. 8.30 CET blive afholdt en telekonference for investorer. Investorer kan lytte med via et link under investorsektionen på novonordisk.com. Om SWITCH 1 og 2 De to 2x32-ugers randomiserede, dobbeltblindede, cross-over, treat to target-studier blev påbegyndt i januar 2014 med det formål at sammenligne sikkerhed og effekt for Tresiba® og Lantus® (insulin glargin U100). Det overordnede formål med studierne er at dokumentere hypoglykæmiprofilen i henholdsvis type 1- og type 2-diabetes sammenlignet med insulin glargin U100. I SWITCH 1 blev 501 deltagere med type 1-diabetes randomiseret til cross-over-behandling med Tresiba® og insulin glargin U100 i kombination med insulin aspart. I SWITCH 2 blev 721 deltagere med type 2-diabetes randomiseret til cross-over-behandling med Tresiba® og insulin glargin U100 i kombination med diabeteslægemidler i tabletform. Resultaterne fra SWITCH 2 blev rapporteret den 29. januar 2016. Lantus® er et registreret varemærke, der tilhører Sanofi.  Yderligere information   Selskabsmeddelelse nr. 17 / 2016 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1155,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
450,2016-02-23,Indkaldelse til ordinær generalforsamling i  Novo Nordisk A/S,"Bagsværd, den 23. februar 2016 - Den ordinære generalforsamling i Novo Nordisk A/S afholdes: fredag den 18. marts 2016 kl. 14.00 i Bella Center, Indgang Vest, Center Boulevard 5, 2300 København S. Indkaldelse til generalforsamlingen, inklusive appendiks 1: Bestyrelseskandidater og appendiks 2: Reviderede aflønningsprincipper, er vedlagt. Yderligere information Selskabsmeddelelse nr. 16 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1157,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
451,2016-02-23,Notice for the Annual General Meeting of  Novo Nordisk A/S,"Bagsværd, Denmark, 23 February 2016 - The Annual General Meeting of Novo Nordisk A/S will be held on: Friday 18 March 2016 at 2.00 pm (CET) at Bella Center, entrance West, Center Boulevard 5, 2300 Copenhagen S, Denmark. The notice for the Annual General Meeting, including Appendix 1: Candidates for the Board of Directors and Appendix 2: Revised Remuneration Principles, is enclosed. Further information Company announcement No 16 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1156,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
452,2016-02-12,Proposed changes in composition of the Board of Directors of Novo Nordisk A/S,"Bagsværd, Denmark, 12 February 2016 - The Annual General Meeting of Novo Nordisk A/S is planned to be held on Friday 18 March 2016. All board members elected by the Annual General Meeting are up for election. Thomas Paul Koestler and Eivind Kolding do not seek re-election. At the Annual General Meeting, the Board of Directors proposes re-election of the following board members elected by the shareholders: Göran Ando (chairman), Jeppe Christiansen (vice chairman), Bruno Angelici, Sylvie Grégoire, Liz Hewitt and Mary Szela. Furthermore, the Board of Directors proposes that Brian Daniels is elected as new member to the Board of Directors. Brian Daniels, MD, is a senior advisor with the Boston Consulting Group and venture partner with 5AM Venture Management, LLC, both in the US. The Board of Directors recommends election of Brian Daniels because of his extensive experience in clinical development, medical affairs and corporate strategy across a broad range of therapeutics areas within the pharmaceutical industry, especially in the US. Further information Company announcement No 13 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1162,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
453,2016-02-12,Foreslåede ændringer i sammensætningen af bestyrelsen i Novo Nordisk A/S,"Bagsværd, den 12. februar 2016 - Den ordinære generalforsamling i Novo Nordisk A/S planlægges afholdt fredag den 18. marts 2016. Alle selskabets generalforsamlingsvalgte bestyrelsesmedlemmer er på valg. Thomas Paul Koestler og Eivind Kolding søger ikke genvalg. På generalforsamlingen foreslår bestyrelsen genvalg af følgende bestyrelsesmedlemmer: Göran Ando (formand), Jeppe Christiansen (næstformand), Bruno Angelici, Sylvie Grégoire, Liz Hewitt og Mary Szela. Bestyrelsen foreslår endvidere, at Brian Daniels vælges som nyt bestyrelsesmedlem. Brian Daniels er læge, seniorrådgiver hos Boston Consulting Group og venturepartner hos 5AM Venture Management, LLC, begge i USA. Bestyrelsen anbefaler valg af Brian Daniels på grund af hans store erfaring med klinisk udvikling, medicinske forhold og virksomhedsstrategi på en lang række behandlingsområder indenfor lægemiddelindustrien, særligt i USA.  Yderligere information Selskabsmeddelelse nr. 13 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1163,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
454,2016-02-10,Novo Nordisk files annual report with the SEC,"Bagsværd, Denmark, 10 February 2016 - Novo Nordisk A/S has filed its Annual Report 2015 on Form 20-F for the financial year 2015 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2015. The reports are available at the SEC's website, www.sec.gov, as well as on novonordisk.com. Shareholders and ADR holders may receive a hard copy of the annual reports free of charge upon request by filling out a request form on novonordisk.com or upon request to kasq@novonordisk.com - please state the exact mailing address and the document(s) you wish to receive. Further information:",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1164,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
455,2016-02-08,Novo Nordisk publishes its 2015 Annual Report,"Bagsværd, Denmark, 8 February 2016 - Novo Nordisk has published its 2015 annual report online at http://www.novonordisk.com/annual-report-2015.html. It is the company's twelfth integrated annual report detailing the company's financial, social and environmental performance. The annual report will be available in print later this month. Further information ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1171,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
456,2016-02-08,Novo Nordisk har udgivet sin årsrapport for 2015,"Bagsværd, 8. februar 2016 - Novo Nordisk har udgivet sin årsrapport for 2015 online på http://www.novonordisk.com/annual-report-2015.html. Det er virksomhedens 12. integrerede årsrapport, som redegør for virksomhedens finansielle, sociale og miljømæssige resultater. Årsrapporten udarbejdes udelukkende på engelsk. Et nyt årsskrift rummer en dansk udgave af ledelsesberetningen samt uddrag af koncernregnskabet. Begge publikationer vil være tilgængelige på tryk senere i denne måned.  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1172,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
457,2016-02-03,Novo Nordisk increased operating profit by 43% in 2015 to DKK 49.4 billion,"14% local currency operating profit growth adjusted for NNIT divestment Sales increased by 22% in Danish kroner and by 8% in local currencies to 107.9 billion. Net profit increased by 32% to DKK 34.9 billion. Diluted earnings per share increased by 34% to DKK 13.52. Adjusted for the partial divestment of NNIT, net profit and diluted earnings per share increased by 22% and 25% respectively. In 2015, Novo Nordisk achieved its four long-term financial targets established in January 2013 and consequently, the Board of Directors has approved three updated long-term financial targets to guide Novo Nordisk's performance. The target for operating profit growth has now been set at 10%, whereas no target for operating margin development has been established, as the operating margin is expected to stay at the current level around 44%. The targets for operating profit after tax to net operating assets and cash to earnings remain unchanged at 125% and 90% respectively. For 2016, sales growth is expected to be 5-9% measured in local currencies. Growth in operating profit is also expected to be 5-9% measured in local currencies, adjusted for the non-recurring impact of the partial divestment of NNIT and the income related to the out-licensing of assets for inflammatory disorders, both in 2015. Growth reported in DKK, for both items, is expected to be around 1 percentage point lower than the local currency levels. At the Annual General Meeting on 18 March 2016, the Board of Directors will propose a 28% increase in dividend to DKK 6.40 per share of DKK 0.20 and intends to initiate a new 12-months share repurchase programme of up to DKK 14 billion. Lars Rebien Sørensen, president and CEO: ""We are very pleased with Novo Nordisk's performance in 2015 and the achievement of our four long-term financial targets. In 2016 we will continue to focus on the global launch of Tresiba® and we are encouraged by the recent SWITCH 2 data, which further demonstrate the ability of Tresiba® to reduce the risk of hypoglycaemia in people with type 2 diabetes on basal insulin therapy."" Contacts for further information Company announcement No 8 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1175,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
458,2016-02-03,"Novo Nordisks resultat af primær drift steg med 43% i 2015 til 49,4 mia. kr.","Resultat af primær drift steg med 14% i lokale valutaer justeret for salg af NNIT Salget steg med 22% opgjort i kroner og med 8% i lokale valutaer til 107,9 mia. kr. Resultat af primær drift steg med 43% opgjort i kroner og med 21% i lokale valutaer til 49,4 mia. kr. Justeret for engangsindtægten på 2,4 mia. kr. relateret til det delvise frasalg af NNIT var overskudsgraden (primær drift) 43,6%, svarende til en stigning i resultat af primær drift opgjort i lokale valutaer på 14%. Nettoresultatet steg med 32% til 34,9 mia. kr. Udvandet resultat pr. aktie steg med 34% til 13,52 kr. Justeret for det delvise frasalg af NNIT steg nettoresultatet og udvandet resultat pr. aktie med henholdsvis 22% og 25%. I 2015 nåede Novo Nordisk de fire langsigtede finansielle mål, der blev etableret i januar 2013, og bestyrelsen har derfor godkendt tre opdaterede langsigtede finansielle mål for Novo Nordisks resultater. Målet for væksten i resultat af primær drift er nu fastsat til 10%, mens der ikke er etableret et mål for udviklingen i overskudsgraden (primær drift), da overskudsgraden (primær drift) forventes at forblive på det nuværende niveau på omkring 44%. Målene for resultat af primær drift efter skat i procent af nettodriftsaktiver og cash to earnings forbliver uændrede på henholdsvis 125% og 90%. For 2016 forventes en salgsvækst på 5-9% opgjort i lokale valutaer. Væksten i resultat af primær drift forventes ligeledes at blive 5-9% opgjort i lokale valutaer, justeret for engangspåvirkningen fra det delvise frasalg af NNIT og indtægten relateret til udlicensering af aktiver vedrørende inflammatoriske sygdomme, begge i 2015. Væksten rapporteret i kroner for begge poster ventes at blive omkring 1 procentpoint lavere end niveauet for væksten opgjort i lokale valutaer. Bestyrelsen vil på generalforsamlingen den 18. marts 2016 fremsætte forslag om en 28% stigning i udbyttebetalingen til 6,40 kr. pr. aktie a 0,20 kr. og forventer at iværksætte et nyt 12-måneders aktietilbagekøbsprogram på op til 14 mia. kr. Adm. direktør Lars Rebien Sørensen: ""Vi er meget tilfredse med de resultater, Novo Nordisk har opnået i 2015, og med, at vi har opfyldt vores  fire langsigtede finansielle mål. I 2016 vil vi fortsætte vores fokus på den globale lancering af Tresiba®, og vi glæder os over de seneste SWITCH 2-resultater, som yderligere viser, at Tresiba® kan reducere risikoen for hypoglykæmi hos mennesker med type 2-diabetes behandlet med basalinsulin."" Kontaktoplysninger Selskabsmeddelelse nr. 8 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1176,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
459,2016-01-29,Tresiba® demonstrates significantly lower rate of hypoglycaemia than insulin glargine in blinded phase 3b trial in people with type 2 diabetes,"Bagsværd, Denmark, 29 January 2016 - Novo Nordisk today announced the headline results from SWITCH 2, the first of two 2x32-weeks randomised, double-blind, cross-over, treat-to-target trials, comparing the safety and efficacy of Tresiba® (insulin degludec) and insulin glargine. The overall purpose of the trial was to compare the hypoglycaemia occurrence in people with type 2 diabetes treated with Tresiba® or insulin glargine. In the trial, 721 people with type 2 diabetes were randomised to cross-over treatment with Tresiba® and insulin glargine in combination with metformin. The timing of the daily injections of both Tresiba® and insulin glargine was randomised equally to take place either in the morning or evening. The primary end-point of the trial was the number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemia episodes during the maintenance period (ie after 16 weeks of treatment) in each treatment period. From a mean baseline of 7.6%, the trial showed non-inferiority in HbA1c reduction of Tresiba® compared to insulin glargine, thus fulfilling the requirements for objectively comparing hypoglycaemia rates between the two treatments. Likewise, the end-of-trial insulin doses were similar at the end of treatment in the two treatment periods. The observed rate of severe or blood glucose confirmed symptomatic hypoglycemia was 186 events per 100 patient years exposed to Tresiba® and 265 events per 100 patient years exposed to insulin glargine during the maintenance period. This reduction was statistically significant, and the trial thus met its primary endpoint by demonstrating a reduction of 30% when people were treated with Tresiba® compared to insulin glargine. The observed rate of severe or blood glucose symptomatic nocturnal confirmed hypoglycaemia in the maintenance period was 55 events per 100 patient years exposed to Tresiba® and 94 events per 100 patient years exposed to insulin glargine, corresponding to a 42% reduction with Tresiba® compared to insulin glargine and showing statistical significance on this confirmatory secondary end-point. The confirmatory secondary endpoint of proportions of subjects experiencing severe hypoglycaemia during the maintenance period did not reach statistical significance. However, the supportive end-point, rate of severe hypoglycaemia, showed a 46% reduction with Tresiba® in the maintenance period and a statistical significant reduction of 51% with Tresiba® in the full treatment period. In the trial, Tresiba® appeared to have a safe and well-tolerated profile. Adverse events were comparable between the two treatment arms. The most common adverse events were nasopharyngitis and upper respiratory tract infections. ""We are excited about these trial results, which in a blinded setting confirm the significant reduction in the risk of hypoglycaemia for Tresiba® compared to insulin glargine"" says Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""We look forward to reporting the outcome of the SWITCH 1 trial in people with type 1 diabetes and to evaluating the results from both trials"". Novo Nordisk expects to announce headline results of SWITCH 1 later in the first quarter of 2016. About SWITCH 1 and 2 The two 2x32-weeks randomised, double-blind, cross-over, treat-to-target trials were initiated in January 2014 with purpose of comparing the safety and efficacy of Tresiba® and insulin glargine. The overall purpose of the trials is to document the hypoglycaemia profile in type 1 diabetes and type 2 diabetes respectively, compared to insulin glargine. In SWITCH 1, 501 people with type 1 diabetes were randomised to crossover treatment with Tresiba® and insulin glargine in combination with insulin aspart. In SWITCH 2, 721 people with type 2 diabetes were randomised to crossover treatment with Tresiba® and insulin glargine in combination with oral antidiabetics. For further information   ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1179,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
460,2016-01-29,Tresiba® viser signifikant lavere forekomst af hypoglykæmi end insulin glargin i blindet fase 3b-studie i mennesker med type 2-diabetes,"Bagsværd, den 29. januar 2016 - Novo Nordisk offentliggør i dag de overordnede resultater fra SWITCH 2, det første af to 2x32-ugers randomiserede, dobbeltblindede, cross-over, treat to target-studier, der sammenligner sikkerhed og effekt for Tresiba® (insulin degludec) og insulin glargin. Det overordnede formål med studiet var at sammenligne forekomsten af hypoglykæmi (lavt blodsukker) i mennesker med type 2-diabetes, der blev behandlet med Tresiba® eller insulin glargin. I studiet blev 721 mennesker med type 2-diabetes randomiseret til cross-over-behandling med Tresiba® og insulin glargin i kombination med metformin. Timingen af de daglige injektioner af både Tresiba® og insulin glargin blev ved randomisering ligeligt fordelt til at finde sted enten morgen eller aften. Studiets primære mål var antallet af episoder af alvorlig eller symptomatisk hypoglykæmi bekræftet ved blodsukkermåling, der opstod i forbindelse med behandlingen i vedligeholdelsesperioden (dvs. efter 16 ugers behandling) i hver enkelt behandlingsperiode. Fra et gennemsnitligt udgangspunkt på 7,6% (baseline) viste studiet ikke-inferiøritet med hensyn til reduktion af langtidsblodsukkerniveauet (HbA1c)for Tresiba® sammenlignet med insulin glargin og opfyldte dermed kravene for objektivt at sammenligne forekomsten af hypoglykæmi mellem de to behandlinger. Ligeledes var insulindoserne ved studiets afslutning sammenlignelige, når behandlingen i de to behandlingsperioder sluttede. Den observerede forekomst af alvorlig eller symptomatisk hypoglykæmi bekræftet ved blodsukkermåling var 186 episoder pr. 100 patientårs eksponering for Tresiba® og 265 episoder pr. 100 patientårs eksponering for insulin glargin i vedligeholdelsesperioden. Denne reduktion var statistisk signifikant, og studiet opfyldte dermed sit primære mål, idet det viste en reduktion på 30%, når deltagerne blev behandlet med Tresiba®,sammenlignet med insulin glargin. Den observerede forekomst af alvorlig eller symptomatisk natlig hypoglykæmi bekræftet ved blodsukkermåling i vedligeholdelsesperioden var 55 episoder pr. 100 patientårs eksponering for Tresiba® og 94 episoder pr. 100 patientårs eksponering for insulin glargin, svarende til en 42% reduktion med Tresiba® sammenlignet med insulin glargin, og viste dermed statistisk signifikans for dette bekræftende sekundære mål. Det bekræftende sekundære mål vedrørende andelen af deltagere, der oplevede alvorlig hypoglykæmi i vedligeholdelsesperioden, nåede ikke statistisk signifikans. Imidlertid viste det understøttende mål vedrørende forekomst af alvorlig hypoglykæmi en 46% reduktion med Tresiba® i vedligeholdelsesperioden og en statistisk signifikant reduktion på 51% med Tresiba® i den fulde behandlingsperiode. Tresiba® forekom i studiet at have en sikker og veltolereret profil. Bivirkninger var sammenlignelige i de to behandlingsarme. De mest almindelige bivirkninger var forkølelse og infektioner i de øvre luftveje. ""Vi er rigtig glade for disse resultater, som i et blindet forsøg bekræfter, at risikoen for hypoglykæmi nedsættes signifikant ved brug af Tresiba® sammenlignet med insulin glargin,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Vi ser frem til at rapportere om udfaldet af SWITCH 1-studiet, hvor det gælder type 1-diabetes, og at evaluere resultaterne fra begge studier."" Novo Nordisk forventer at offentliggøre de overordnede resultater fra SWITCH 1 senere i første kvartal af 2016. Om SWITCH 1 og 2 De to 2x32-ugers randomiserede, dobbeltblindede, cross-over, treat to target-studier blev påbegyndt i januar 2014 med det formål at sammenligne sikkerhed og effekt for Tresiba® og insulin glargin. Det overordnede formål med studierne er at dokumentere hypoglykæmiprofilen i henholdsvis type 1- og type 2-diabetes sammenlignet med insulin glargin. I SWITCH 1 blev 501 deltagere med type 1-diabetes randomiseret til cross-over-behandling med Tresiba® og insulin glargin i kombination med insulin aspart. I SWITCH 2 blev 721 deltagere med type 2-diabetes randomiseret til cross-over-behandling med Tresiba® og insulin glargin i kombination med diabeteslægemidler i tabletform. Yderligere information Selskabsmeddelelse nr. 6 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1180,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
461,2016-01-07,Novo Nordisk files for regulatory approval of long-acting factor IX in the EU for the treatment of haemophilia B,"Bagsværd, Denmark, 7 January 2016 - Novo Nordisk today announced the submission to the European Medicines Agency of the Marketing Authorisation Application for the approval of long-acting factor IX, nonacog beta pegol. Nonacog beta pegol is a glycopegylated recombinant factor IX with a significantly improved pharmacokinetic (PK) profile, developed for patients with haemophilia B. Novo Nordisk expects to file the Biologics License Application (BLA) for nonacog beta pegol to the US Food and Drug Administration during first half of 2016. The filing of nonacog beta pegol is based on the results from the paradigm clinical trial programme, which involved 115 patients with severe or moderately severe haemophilia B. Nonacog beta pegol was found to be efficacious in routine prophylaxis, treatment of bleeding episodes and surgery for adults, adolescents and children. Furthermore, nonacog beta pegol appeared to be well-tolerated and no safety concerns were identified. Compared to standard factor IX products, nonacog beta pegol has a five times longer half-life. Patients in the paradigm study achieved a higher level of factor IX in the blood despite less frequent dosing of nonacog beta pegol. In the phase 3 trials, once-weekly administration of 40 IU/kg nonacog beta pegol maintained factor IX activity levels above 15%, reduced the median annualised bleeding rate (ABR) to 1.0 and showed a potential to prevent bleeds in target joints. Furthermore, these patients reported an improvement in quality of life during the trial. ""With the regulatory filing of our long-acting factor IX, patients with haemophilia B are one step closer to having a new treatment option"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""With its high factor activity level, less frequent dosing and very low ABRs, nonacog beta pegol has the potential to improve the quality of life for both patients and their families."" Nonacog beta pegol is an extended half-life factor IX molecule intended for replacement therapy in patients with haemophilia B. Glycopegylation, the prolongation technology used for the half-life extension, is a novel approach in haemophilia B, already proven safe and efficacious in haemophilia A and other therapeutic areas. The paradigm clinical trial programme for nonacog beta pegol enrolled children and adults with severe or moderately severe haemophilia B. A total of 115 previously treated patients with a total of more than 8,800 exposure days for up to 2.7 years of treatment with nonacog beta pegol. The paradigm 1 PK trial (16 people treated) - a single-dose escalation trial evaluating safety and PK of nonacog beta pegol compared with marketed recombinant and plasma-derived factor IX products. Nonacog beta pegol showed up to twofold increase in recovery, higher activity levels and a fivefold prolongation of half-life compared to existing treatment. The paradigm 2 pivotal trial (74 people treated) - a 52-week single-blinded randomised trial evaluating safety, efficacy and PK for adults and adolescents in routine prophylaxis and treatment of bleeds. When provided prophylactic at 40 IU/kg weekly, nonacog beta pegol appeared to have a safe and well-tolerated profile and showed a median annualised spontaneous bleeding rate of 0.0. Furthermore, 97% of breakthrough bleeds were treated successfully and 90% of target joints no longer classified as such. The paradigm 3 surgery trial (13 people treated) - a dedicated trial confirming safety and efficacy during and after major surgical procedures. In all patients, a single preoperative dose provided effective haemostatic coverage, and no patient required additional doses on the day of surgery. Additionally, three doses proved sufficient in maintaining haemostasis during the first two weeks following the procedure. The paradigm 4 extension trial (71 people treated) - a safety extension trial with longer-term exposure demonstrated a well-tolerated profile with no inhibitors or other safety signals identified. The paradigm 5 paediatric trial (25 people treated) - a 52-week single-arm trial evaluating once-weekly prophylaxis and treatment of bleeding episodes in previously treated children 1-12 years of age. Nonacog beta pegol appeared to have a safe profile, and all patients maintained mean factor activity levels above 15% one week after dosing of 40 IU/kg and a median ABR of 0.0 and 2.0 for children aged 0-6 and 7-12 years old respectively. For further information Company announcement No 2 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1187,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
462,2016-01-07,Novo Nordisk indsender registreringsansøgning i EU for langtidsvirkende faktor IX til behandling af hæmofili B,"Bagsværd, den 7. januar 2016 - Novo Nordisk meddeler i dag, at virksomheden har indsendt ansøgning om markedsføringstilladelse til Det Europæiske Lægemiddelagentur for langtidsvirkende faktor IX, nonacog beta pegol. Nonacog beta pegol er et glykopegyleret rekombinant faktor IX-præparat med en signifikant forbedret farmakokinetisk profil, udviklet til behandling af hæmofili B. Novo Nordisk forventer at indsende registreringsansøgning (Biologics License Application - BLA) for nonacog beta pegol til de amerikanske sundhedsmyndigheder, FDA, i første halvår af 2016. Registreringsansøgningen for nonacog beta pegol er baseret på resultaterne fra det kliniske udviklingsprogram 'paradigm', som omfattede 115 deltagere med svær eller moderat svær hæmofili B. Studierne viste, at nonacog beta pegol var virkningsfuldt til rutinemæssig forebyggende behandling, behandling af blødningsepisoder samt ved kirurgiske indgreb hos voksne, unge og børn. Nonacog beta pegol forekom endvidere at være veltolereret, og der blev ikke identificeret sikkerhedsmæssige problemer. Nonacog beta pegol har en fem gange længere halveringstid sammenlignet med gængse faktor IX-produkter. Deltagere i paradigm-studiet opnåede et højere faktor IX-niveau i blodet trods mindre hyppig dosering af nonacog beta pegol. Én ugentlig dosering på 40 IU/kg nonacog beta pegol opretholdt i fase 3-studierne et faktor IX-aktivitetsniveau på over 15%, reducerede medianværdien for den årlige blødningsfrekvens til 1,0 og viste potentiale til at forebygge blødninger i såkaldte target joints (led, der er særligt udsat for gentagne blødninger). Disse deltagere rapporterede desuden om forbedret livskvalitet i studiet. ""Med indsendelsen af registreringsansøgningen for vores langtidsvirkende faktor IX er mennesker med hæmofili B kommet et skridt tættere på en ny behandlingsmulighed,"" siger Mads Krogsgaard Thomsen, koncerndirektør i Novo Nordisk med ansvar for forskning og udvikling. ""Nonacog beta pegol har med sit høje faktoraktivitetsniveau, den mindre hyppige dosering og meget lave årlige blødningsfrekvens potentiale til at forbedre livskvaliteten både for patienterne og deres familie."" Nonacog beta pegol er et faktor IX-molekyle med forlænget halveringstid, der er beregnet til substitutionsbehandling hos mennesker med hæmofili B. Halveringstiden er forlænget ved hjælp af glykopegylerings-teknikken - en ny tilgang indenfor hæmofili B, som allerede har vist sig sikker og virkningsfuld indenfor hæmofili A og andre behandlingsområder. Det kliniske udviklingsprogram paradigm for nonacog beta pegol er gennemført blandt børn og voksne med svær eller moderat svær hæmofili B - i alt 115 tidligere behandlede patienter med sammenlagt mere end 8.800 dages eksponering for op til 2,7 års behandling med nonacog beta pegol. Paradigm 1, farmakokinetisk studie (16 deltagere behandlet) - et enkeltdosis-eskaleringsstudie, der undersøgte sikkerhed og farmakokinetik for nonacog beta pegol sammenlignet med markedsførte rekombinante og plasmabaserede faktor IX-produkter. Nonacog beta pegol viste op til to gange forhøjet genfindelse i blodbanen, højere aktivitetsniveau og en fem gange længere halveringstid sammenlignet med eksisterende behandling. Paradigm 2, pivotalstudie (74 deltagere behandlet) - et 52-ugers enkeltblindet, randomiseret studie, der undersøgte sikkerhed, effekt og farmakokinetik hos voksne og unge ved rutinemæssig forebyggelse og behandling af blødninger. Ved forebyggende behandling med 40 IU/kg doseret én gang ugentligt forekom nonacog beta pegol at have en sikker og veltolereret profil og viste en medianværdi for den årlige blødningsfrekvens for spontane blødninger på 0,0. Endvidere blev 97% af såkaldte breakthrough bleeds (spontane blødninger under behandlingsforløbet) stoppet, og 90% af såkaldte target joints (led, der er særligt udsat for gentagne blødninger) blev ikke længere klassificeret som sådan. Paradigm 3, kirurgistudie (13 deltagere behandlet) - et dedikeret studie, der bekræftede sikkerhed og effekt under og efter større kirurgiske indgreb. Hos alle deltagere var en enkelt dosis forud for operationen tilstrækkeligt til at forebygge blødning, og der var ikke behov for at give yderligere doser på operationsdagen. Endvidere viste det sig, at tre doser var tilstrækkelige til at opretholde hæmostase i de første to uger efter operationen. Paradigm 4, forlængelsesstudie (71 deltagere behandlet) - et sikkerhedsstudie med længere tids eksponering, der viste en veltolereret profil uden identifikation af inhibitorer (neutraliserende antistoffer) eller andre sikkerhedsmæssige signaler. Paradigm 5, pædiatrisk studie (25 deltagere behandlet) - et 52-ugers enkeltgruppestudie, der undersøgte forebyggende behandling doseret én gang ugentligt og behandling af blødningsepisoder hos tidligere behandlede børn i alderen 1-12 år. Nonacog beta pegol forekom at have en sikker profil, og alle deltagere opretholdt et gennemsnitligt faktoraktivitetsniveau på over 15% én uge efter dosering af 40 IU/kg og en medianværdi for den årlige blødningsfrekvens på henholdsvis 0,0 og 2,0 for børn i alderen 0-6 og 7-12 år. Yderligere information Selskabsmeddelelse nr. 2 / 2016",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1188,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
463,2015-12-18,Novo Nordisk i partnerskab med C40 om at forbedre miljø og sundhed i byerne,"Bagsværd, Danmark, og London, Storbritannien, den 18. december 2015 - Novo Nordisk og C40 Cities Climate Leadership Group (C40) meddeler i dag, at de har indgået et forskningsbaseret partnerskab, der har til formål at dokumentere, at grøn politik i byerne er til gavn for både miljøet og indbyggernes sundhed. Ved at kombinere de to organisationers ekspertise og specialistviden ventes samarbejdet at skabe ny viden om en række sidegevinster ved klimaindsatsen i byerne, herunder sundhed. Årsagen til partnerskabet er den stigende betydning, verdens storbyer spiller i kampen mod både klimaforandringer og usund livsstil. De hastigt voksende byer tegner sig for to tredjedele af det globale energiforbrug og mere end 70% af CO2-udledningen,[i] og to tredjedele af verdens 415 mio. diabetikere bor i byområder.[ii] Mange byer er allerede i dag godt i gang med at træffe foranstaltninger, som reducerer CO2-udledningen og på andre måder kommer indbyggerne til gavn - lige fra delecykelordninger til klimatilpasningsplaner, der skal mindske følgerne af oversvømmelser og hedebølger. Partnerskabets forskning skal hjælpe byerne med at skabe grundlag for andre specifikke klimaindsatser, der har størst mulig effekt med hensyn til såvel CO2-reduktion som forbedret sundhed og velfærd. ""I Mexico City har vi på første hånd erfaret, hvordan politikker for reduktion af drivhusgasudledninger kan have vidtrækkende positive virkninger for indbyggernes sundhed og trivsel,"" siger Miguel Ángel Mancera, borgmester i Mexico City. ""Den forskning, som dette partnerskab skal være med til at tilvejebringe, vil forhåbentlig skabe det evidensgrundlag, vi har brug for til at bekræfte, hvad enhver borgmester i byerne i C40-netværket allerede ved, nemlig at miljøpolitik har fordele, der rækker langt ud over blot at reducere CO2-udledningen."" Som en af verdens førende virksomheder indenfor diabetes vil Novo Nordisk bidrage til partnerskabet med en solid viden om, hvordan type 2-diabetes påvirker enkeltpersoner, familier, sundhedssystemer og samfundet. Partnerskabets forskning vil bygge videre på den forskning, der netop er præsenteret fra Cities Changing Diabetes-studiet, der er verdens største undersøgelse af diabetes i verdens storbyer gennemført under ledelse af University College London (UCL) med støtte fra Novo Nordisk. ""Med Cities Changing Diabetes-initiativet, som vi lancerede i 2014, ønsker vi at bidrage til at øge sundheden i verdens storbyer,"" siger Jakob Riis, koncerndirektør i Novo Nordisk. ""Gennem samarbejdet med C40-netværket ønsker vi at hjælpe byerne med at udvikle bymiljøer, der fremmer en sund livsstil og dermed forebygger udviklingen af livsstilssygdomme som diabetes."" I en kommentar til partnerskabet siger Mark Watts, direktør for C40: ""Hver uge er der 1,4 mio. mennesker, der flytter til byerne. Det er ikke kun den globale opvarmning, der gør det vigtigt at håndtere klimaforandringerne og reducere drivhusgasudledningerne fra byerne - det handler også om indbyggernes sundhed og trivsel i byerne. Grøn politik giver renere luft, nye arbejdspladser, øgede indtægter til byerne og mange andre fordele. Vi er overbevist om, at denne forskning vil give større klarhed over disse sidegevinster og dermed give borgmestre og andre beslutningstagere et endnu bedre grundlag for at iværksætte klimaindsatser i byer overalt i verden."" Om Cities Changing Diabetes Novo Nordisk lancerede Cities Changing Diabetes-initiativet i 2014 i samarbejde med University College London (UCL) og Steno Diabetes Center som reaktion på den kraftige stigning i forekomsten af diabetes i verdens storbyer. De første byer, der tilsluttede sig initiativet, var Mexico City, Houston, København, Tianjin og Shanghai. Læs mere om initiativet på: citieschangingdiabetes.com. Om C40 Cities Climate Leadership Group C40 Cities Climate Leadership Group, som blev dannet for 10 år siden, er et globalt netværk af mere end 80 af verdens største byer, der repræsenterer over 600 mio. mennesker og en fjerdedel af den globale økonomi. C40 er skabt og ledet af bystyrer og arbejder for at håndtere klimaforandringer og igangsætte bymæssige initiativer, der kan reducere udledningen af drivhusgasser og klimarisici og samtidig forbedre indbyggernes sundhedstilstand, trivsel og økonomiske muligheder. Den nuværende formand for C40 er Rio de Janeiros borgmester Eduardo Paes, og bestyrelsesformanden er Michael R. Bloomberg, som har været borgmester i New York City i tre perioder. Tre strategiske sponsorer gør arbejdet i C40 muligt: Bloomberg Philanthropies, Children's Investment Fund Foundation (CIFF) og Realdania. Læs mere om arbejdet i C40 og de tilsluttede byer på www.c40.org, følg os på Twitter @c40cities og like os på Facebook på http://www.facebook.com/C40Cities.  Referencer [1]    International Diabetes Federation, IDF Atlas, 7th edition, 2015. [2]    World Energy Outlook, 2008",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1194,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
464,2015-12-18,Novo Nordisk and C40 partner to improve environment and health in cities,"Bagsværd, Denmark and London, UK, 18 December 2015 - Novo Nordisk and the C40 Cities Climate Leadership Group (C40) today announced a research-based partnership aimed at establishing that green policies in cities are beneficial to both the state of the environment and the health of their citizens. The collaboration will see the organisations' expertise and specialist knowledge combine to generate new insights on a range of co-benefits of climate action - in particular the health of city populations. At the heart of the partnership lies the pivotal role of cities in the fight against climate change and poor health. City lifestyles are contributing to the diabetes epidemic and two thirds of the world's 415 million people living with the condition can be found in urban areas.1 Meanwhile, the rapid rise of cities accounts for two thirds of global energy consumption and more than 70% of carbon dioxide (CO2) emissions.2 From bike share schemes to adaptation efforts that lessen the impact of floods and heatwaves, civic leaders are already taking decisions that will reduce emissions and deliver additional benefits to their citizens. The research will help city leaders to build a case for other specific climate actions that will have the greatest impact on both emission reductions and improved health and prosperity. ""Mexico City has seen first-hand how policies designed to reduce greenhouse gas emissions can have far-reaching positive effects on the health and wellbeing of our citizens,"" said Mexico City Mayor Miguel Ángel Mancera. ""This research will create the evidence base to confirm what every mayor within the C40 network knows; that environmental policies have benefits far beyond the narrow focus of reducing emissions."" As a leader in the field of diabetes, Novo Nordisk brings to the partnership a deep understanding of how the condition affects individuals, families, health systems and societies. The partnership's research will benefit from insights secured via the Cities Changing Diabetes study - the world's largest study of urban diabetes led by University College London (UCL) and supported by Novo Nordisk. ""Improving the health of city dwellers has been a priority for Novo Nordisk since we initiated the Cities Changing Diabetes programme in 2014,"" said Novo Nordisk executive vice president Jakob Riis. ""By working with a world-renowned group in C40, we aim to help city leaders to develop and maintain urban environments that facilitate good health and prevent conditions such as diabetes."" Commenting on the aims of the partnership, Mark Watts, executive director, C40 said ""Each week 1.4 million people move into cities. Tackling climate change and reducing cities greenhouse gas emissions is not just important because of global warming but also for the health and well-being of urban citizens around the world. Green policies provide cleaner air, new jobs, increased city revenue and many other benefits. By more clearly identifying these co-benefits, C40 believes this research will allow mayors and urban policy makers to make an even stronger case for taking climate action in cities around the world."" Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 40,300 people in 75 countries and markets its products in more than 180 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. In 2014, in partnership with University College London (UCL) and the Steno Diabetes Center, Novo Nordisk initiated the Cities Changing Diabetes programme. Initially working with Mexico City, Houston, Copenhagen, Tianjin and Shanghai, the partnership is a response to the rapid rise of diabetes in cities. Learn more about the programme at: citieschangingdiabetes.com. The C40 Cities Climate Leadership Group, now in its 10th year, connects more than 80 of the world's greatest cities, representing 600+ million people and one quarter of the global economy. Created and led by cities, C40 is focused on tackling climate change and driving urban action that reduces greenhouse gas emissions and climate risks, while increasing the health, wellbeing and economic opportunities of urban citizens. The current chair of the C40 is Rio de Janeiro Mayor Eduardo Paes; three-term Mayor of New York City Michael R. Bloomberg serves as President of the Board. C40's work is made possible by our three strategic funders: Bloomberg Philanthropies, Children's Investment Fund Foundation (CIFF), and Realdania. To learn more about the work of C40 and our cities, please visit www.c40.org, follow us on Twitter @c40cities and like us on Facebook at http://www.facebook.com/C40Cities. References",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1193,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
465,2015-12-17,Novo Nordisk afslutter med succes det fjerde fase 3a-studie med semaglutid til behandling af type 2-diabetes,"Bagsværd, den 17. december 2015 - Novo Nordisk offentliggør i dag de overordnede resultater fra det fjerde fase 3a-studie med semaglutid, SUSTAIN2. Semaglutid er en ny GLP-1-analog, som doseres ved injektion i underhuden (subkutant) én gang ugentligt. Det dobbeltblindede studie undersøgte effekt og sikkerhed for 0,5 mg og 1,0 mg semaglutid sammenlignet med 100 mg sitagliptin, en DPP-IV-hæmmer til dosering én gang dagligt, efter 56 ugers behandling hos 1.231 deltagere med type 2-diabetes, hvor begge lægemidler blev givet som supplement til metformin, thiazolidindion (TZD) eller en kombination af metformin/TZD. Studiet opfyldte succesfuldt sit mål, idet det viste, at deltagere, som blev behandlet med 0,5 mg eller 1,0 mg semaglutid, fra et gennemsnitligt langtidsblodsukkerniveau (HbA1c) på 8,1% ved studiets begyndelse opnåede en statistisk signifikant og større forbedring i HbA1c på henholdsvis 1,3% og 1,6% sammenlignet med en forbedring i HbA1c på 0,5% med 100 mg sitagliptin. 69% af de deltagere, som blev behandlet med 0,5 mg semaglutid, og 78% af deltagere, som fik 1,0 mg semaglutid, nåede behandlingsmålet om HbA1c under 7% som anbefalet af American Diabetes Association (ADA) og European Association for the Study of Diabetes (EASD), mod 36% af dem, som blev behandlet med 100 mg sitagliptin. Fra en gennemsnitsvægt på 89 kg ved studiets begyndelse opnåede deltagere i behandling med 0,5 mg og 1,0 mg semaglutid desuden et statistisk signifikant og større vægttab på henholdsvis 4,3 kg og 6,1 kg sammenlignet med et vægttab på 1,9 kg hos deltagere i behandling med 100 mg sitagliptin. Semaglutid forekom i studiet at have en sikker og veltolereret profil. Den mest almindelige bivirkning var kvalme, som aftog over tid. Kvalme blev rapporteret hos 18% af deltagere i behandling med 0,5 mg semaglutid, og hos 18% af deltagere i behandling med 1,0 mg semaglutid, sammenlignet med 7% af deltagere i behandling med 100 mg sitagliptin. Frafaldsprocenten som følge af bivirkninger var 8% og 10% for deltagere i behandling med henholdsvis 0,5 mg semaglutid og 1,0 mg semaglutid, mod 3% for deltagere i behandling med 100 mg sitagliptin. ""Vi er rigtig glade for resultaterne fra SUSTAIN 2, som viste, at semaglutid givet som én ugentlig injektion gav bedre effekt med hensyn til blodsukkerregulering og vægttab sammenlignet med 100 mg sitagliptin. Det er konsistent med det resultat, vi har set på tværs af alle de SUSTAIN-studier, der er rapporteret resultater fra indtil nu,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""De resultater, vi har set indtil nu i SUSTAIN-programmet, understøtter, at semaglutid har potentiale til at blive det mest virkningsfulde GLP-1-produkt for mennesker med type 2-diabetes."" Novo Nordisk forventer at offentliggøre de overordnede resultater fra de resterende to SUSTAIN-studier i første halvår af 2016. Om semaglutid Semaglutid er en ny GLP-1-analog (glukagonlignende peptid-1), som kan hjælpe mennesker med type 2-diabetes med at opnå en markant forbedring af blodsukkeret med lav risiko for hypoglykæmi. Semaglutid medfører endvidere vægttab ved at nedsætte appetit og madindtag. Semaglutid til subkutan dosering (ved injektion i underhuden) én gang ugentligt er i fase 3-udvikling til behandling af type 2-diabetes. Semaglutid er endvidere under udvikling i tabletform til oral behandling af type 2-diabetes samt i injicerbare udgaver til subkutan dosering én gang dagligt til behandling af type 2-diabetes og vægtregulering. Om det kliniske udviklingsprogram SUSTAIN SUSTAIN er et klinisk fase 3-program, som omfatter seks globale studier med semaglutid doseret subkutant én gang om ugen med deltagelse af flere end 7.000 mennesker med type 2-diabetes. SUSTAIN 1 - et 30-ugers effekt- og sikkerhedsstudie, der undersøger semaglutid i forhold til placebo hos 388 deltagere med type 2-diabetes, som ikke tidligere har fået medicinsk behandling. SUSTAIN 2 - et 56-ugers effekt- og sikkerhedsstudie, der undersøger semaglutid i forhold til sitagliptin én gang dagligt som tillægsbehandling til metformin og/eller TZD hos 1.231 deltagere med type 2-diabetes. SUSTAIN 3 - et 56-ugers effekt- og sikkerhedsstudie, der undersøger semaglutid i forhold til 2,0 mg exenatid én gang ugentligt som tillægsbehandling til 1-2 diabeteslægemidler i tabletform hos 813 deltagere med type 2-diabetes. SUSTAIN 4 - et 30-ugers effekt- og sikkerhedsstudie, der undersøger semaglutid i forhold til insulin glargin én gang dagligt som tillægsbehandling til metformin med eller uden sulfonylurinstof hos 1.089 deltagere med type 2-diabetes, som ikke tidligere er blevet behandlet med insulin. SUSTAIN 5 - et 30-ugers effekt- og sikkerhedsstudie, der undersøger semaglutid i forhold til placebo som tillægsbehandling til basal insulin alene eller basal insulin i kombination med metformin hos 397 deltagere med type 2-diabetes. Resultaterne fra dette studie er endnu ikke rapporteret. SUSTAIN 6 - et toårigt studie, der undersøger forekomsten af hjerte-kar-sygdom og andre langsigtede målepunkter ved brug af semaglutid hos 3.297 deltagere med type 2-diabetes. Resultaterne fra dette studie er endnu ikke rapporteret. Yderligere information Selskabsmeddelelse nr. 79 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1196,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
466,2015-12-17,Novo Nordisk successfully completes fourth phase 3a trial with semaglutide in people with type 2 diabetes,"Bagsværd, Denmark, 17 December 2015 - Novo Nordisk today announced the headline results from the fourth phase 3a trial for semaglutide, SUSTAIN2. Semaglutide is a new GLP-1 analogue administered subcutaneously once weekly. The double-blinded trial investigated the efficacy and safety of 0.5 mg and 1.0 mg semaglutide compared with 100 mg sitagliptin, a once-daily DPP-IV inhibitor, after 56 weeks of treatment in 1,231 people with type 2 diabetes, where both drugs were added on to metformin, thiazolidinedione (TZD) or a combination of metformin/TZD. The trial successfully achieved its objective by demonstrating that from a mean baseline HbA1c of 8.1%, people treated with 0.5 mg or 1.0 mg semaglutide achieved a statistically significant and superior improvement in HbA1c of 1.3% and 1.6% respectively, compared to an improvement in HbA1c of 0.5% with 100 mg sitagliptin. 69% of the people treated with 0.5 mg semaglutide and 78% of the people treated with 1.0 mg semaglutide achieved the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) treatment target of HbA1c below 7% compared with 36% of the people treated with 100 mg sitagliptin. Furthermore, from a mean baseline body weight of 89 kg, people treated with 0.5 mg and 1.0 mg semaglutide experienced a statistically significant and superior weight loss of 4.3 kg and 6.1 kg respectively, compared with a weight loss of 1.9 kg for people treated with 100 mg sitagliptin. In the trial, semaglutide appeared to have a safe and well-tolerated profile. The most common adverse event was nausea which diminished over time. Nausea was reported by 18% of the people treated with 0.5 mg semaglutide and by 18% of the people treated with 1.0 mg semaglutide, compared with 7% of people treated with 100 mg sitagliptin. The discontinuation rate due to adverse events was 8% and 10% for people treated with 0.5 mg semaglutide and 1.0 mg semaglutide respectively, compared to 3% for people treated with 100 mg sitagliptin. ""We are excited about the results of SUSTAIN 2, showing superior efficacy in glycaemic control and weight loss with semaglutide administered once-weekly compared with 100 mg sitagliptin, which is consistent with the outcome seen across all SUSTAIN trials reported to date,"" says Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""The results from the SUSTAIN programme thus far support that semaglutide has the potential to become the most efficacious GLP-1 product for people with type 2 diabetes."" Novo Nordisk expects to announce headline results of the two remaining SUSTAIN trials in the first half of 2016. Semaglutide is a new glucagon-like peptide-1 (GLP-1) analogue that can help people with type 2 diabetes achieve substantial improvement of blood glucose with a low risk of hypoglycaemia. In addition, semaglutide induces weight loss by decreasing appetite and food intake. Semaglutide administered subcutaneously once weekly is in phase 3 development for the treatment of type 2 diabetes. Furthermore, semaglutide is being developed in an oral tablet version for treatment of type 2 diabetes as well as once-daily subcutaneous versions for treatment of type 2 diabetes and weight management. About the SUSTAIN clinical programme The SUSTAIN programme is a phase 3 clinical programme comprising six global trials of semaglutide administered subcutaneously once weekly encompassing more than 7,000 people with type 2 diabetes. SUSTAIN 1 - a 30-week efficacy and safety trial of semaglutide versus placebo in 388 drug-naïve people with type 2 diabetes. SUSTAIN 2 - a 56-week efficacy and safety trial of semaglutide versus sitagliptin once-daily as add-on to metformin and/or TZD in 1,231 people with type 2 diabetes. SUSTAIN 3 - a 56-week efficacy and safety trial of semaglutide versus 2.0 mg exenatide once-weekly as add-on to 1-2 oral antidiabetic drugs in 813 people with type 2 diabetes. SUSTAIN 4 - a 30-week efficacy and safety trial of semaglutide versus insulin glargine once-daily as add-on to metformin with or without sulfonylurea in 1,089 insulin-naïve people with type 2 diabetes. SUSTAIN 5 - a 30-week efficacy and safety trial not yet reported of semaglutide versus placebo as add-on to basal insulin alone or basal insulin in combination with metformin in 397 people with type 2 diabetes. SUSTAIN 6 - a 2-year trial not yet reported to evaluate cardiovascular and other long-term outcomes with semaglutide in 3,297 people with type 2 diabetes. For further information Company announcement No 79 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1195,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
467,2015-12-10,Novo Nordisk indgår samarbejde med IBM om diabetesløsninger baseret på Watson Health Cloud,"Bagsværd, Danmark, og Armonk, USA, den 10. december 2015 - Novo Nordisk og IBM Watson Health meddeler i dag, at de to virksomheder har indgået samarbejde om at skabe diabetesløsninger bygget på Watson Health Cloud. Aftalen kombinerer Novo Nordisks indgående indsigt i diabetes med IBM's lederskab indenfor kognitiv computeranvendelse. Virksomhederne vil undersøge mulighederne for forbedret diabetesbehandling på basis af såkaldte real-time, real-world data om Novo Nordisks diabeteslægemidler og doseringssystemer, dvs. hentet fra 'den virkelige verden'. Ved at udnytte potentialet i Watson Health Cloud håber Novo Nordisk at skabe endnu bedre behandlingsløsninger til mennesker med diabetes og deres behandlere. Koncerndirektør Jakob Riis, Novo Nordisk, siger i en kommentar til aftalen: ""Et samarbejde med ambitiøse partnere som IBM Watson Health hjælper os til at undersøge de muligheder, der ligger i det stadig mere digitaliserede sundhedssystem. Tanken er at udnytte vores fælles kompetencer til at skabe en bedre tilværelse for mennesker med diabetes ved at gøre behandlingen enklere, mere effektiv og målbar."" IBM Watson er den første kommercielt tilgængelige kognitive teknologiplatform og repræsenterer en ny æra indenfor computeranvendelse. Der er tale om en cloud-baseret platform, som kan analysere store mængder af data (Big Data) for at afdække mønstre og viden, forstår komplekse spørgsmål stillet i helt almindeligt sprog, foreslår evidensbaserede svar og lærer af hver interaktion. Watson Health Cloud er en udviklingsplatform for løsninger indenfor sundhedsområdet. ""IBM glæder sig til at arbejde sammen med Novo Nordisk, en af verdens førende virksomheder på diabetesområdet, om at bidrage til at skabe nye e-sundhedsløsninger baseret på Watson Health Cloud - dvs. ved hjælp af kognitiv computeranvendelse skabe individualiserede sundhedsforløb,"" siger Deborah DiSanzo, direktør for IBM Watson Health. International Diabetes Federation (IDF) anslår, at der i dag er 415 mio. diabetikere i verden - og det tal ventes ifølge IDF at stige til 642 mio. i 2040. En dårligt reguleret diabetes kan føre til følgesygdomme som hjerte-kar-sygdom, nyresygdom, nerveskader og blindhed. Diabetes og dens følgesygdomme tegner sig for 12% af de samlede globale sundhedsomkostninger (673 mia. US dollars).[1] IBM lancerede IBM Watson Health og Watson Health Cloud-platformen i april 2015. Den nye enhed vil hjælpe med til at forbedre lægers, forskeres og forsikringsselskabers evne til at innovere ved at afdække viden fra den enorme mængde af personlige sundhedsdata, der hver dag genereres og deles. Watson Health Cloud gør det muligt at anonymisere, dele og kombinere denne viden med et dynamisk og konstant voksende aggregeret datasæt såsom kliniske, forskningsmæssige og sociale sundhedsdata. Yderligere information om IBM Watson Health: ibm.com/watsonhealth. IBM Watson press kit: http://www-03.ibm.com/press/us/en/presskit/27297.wss. Deltag i debatten på #ibmwatson og #watsonhealth. Følg Watson på Facebook og se Watson på YouTube og Flickr. Yderligere information Referencer [1] International Diabetes Federation, IDF Atlas, 7. udgave, 2015.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1200,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
468,2015-12-10,Novo Nordisk and IBM partner to build diabetes care solutions on the Watson Health Cloud,"Bagsværd, Denmark and Armonk, US, 10 December 2015 - Novo Nordisk and IBM Watson Health today announced that the two companies will work together to create diabetes solutions built on the Watson Health Cloud. The agreement combines Novo Nordisk's deep understanding of diabetes with IBM's leadership in cognitive computing. The companies will explore possibilities for improved diabetes care via insights from real-time, real-world evidence of Novo Nordisk diabetes treatments and devices. By harnessing the potential of the Watson Health Cloud, Novo Nordisk aims to further advance its offerings to people living with diabetes and their healthcare professionals.Commenting on the agreement, Jakob Riis, executive vice president, Novo Nordisk said: ""Working with ambitious partners like IBM Watson Health helps us explore the opportunities presented by an increasingly digitalised healthcare system. We aim to leverage our combined capabilities to improve the lives of people with diabetes by making the management of the condition more simple, effective and measurable."" IBM Watson is the first commercially available cognitive computing platform and represents a new era of computing. The platform, delivered through the cloud, processes vast amounts of big data to uncover patterns and insights, understands complex questions posed in natural language, proposes evidence-based answers, and learns from each interaction. The Watson Health Cloud is a development platform for health and wellness solutions. ""IBM is excited to work with Novo Nordisk, a global leader in diabetes, to help the company create new e-health solutions on the Watson Health Cloud - accessing cognitive computing to help personalise care,"" said Deborah DiSanzo, general manager of IBM Watson Health. The International Diabetes Federation (IDF) estimates that 415 million people have diabetes today - a figure that IDF estimates could rise to 642 million by 2040. Complications from poorly managed diabetes include cardiovascular disease, kidney disease, nerve damage and blindness. Diabetes and its complications account for 12% of global health expenditure ($673 billion US dollars).1 Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 40,300 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube In April 2015, IBM launched IBM Watson Health and the Watson Health Cloud platform. The new unit will help improve the ability of doctors, researchers and insurers to innovate by surfacing insights from the massive amount of personal health data being created and shared daily. The Watson Health Cloud allows this information to be de-identified, shared and combined with a dynamic and constantly growing aggregated set of data such as clinical, research and social health data.For more information on IBM Watson Health, visit: ibm.com/watsonhealth Check out the IBM Watson press kit at: http://www-03.ibm.com/press/us/en/presskit/27297.wss Join the conversation at #ibmwatson and #watsonhealth. Follow Watson on Facebook and see Watson on YouTube and Flickr. Further information Reference",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1199,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
469,2015-12-09,Novo Nordisk files for regulatory approval of faster-acting insulin aspart in the US for the treatment of type 1 and 2 diabetes,"Bagsværd, Denmark, 9 December 2015 - Novo Nordisk today announced the submission of the New Drug Application (NDA) for faster-acting insulin aspart to the US Food and Drug Administration (FDA). Faster-acting insulin aspart is a mealtime insulin for improved control of postprandial glucose excursions and has been developed for the treatment of people with type 1 and type 2 diabetes. The filing of faster-acting insulin aspart is based on the results from the 'onset' clinical trial programme which involved around 2,100 people with type 1 and 2 diabetes. In the onset programme, people treated with faster-acting insulin aspart achieved improvements in postprandial control versus NovoLog® (marketed as NovoRapid® outside the US) and an HbA1c reduction on par with NovoLog®. For people with type 1 diabetes, faster-acting insulin aspart results from the double-blinded onset 1 trial showed statistically significantly greater HbA1c reduction when dosed at mealtime or similar HbA1c reduction when dosed 20 minutes after a meal compared to NovoLog®. Across the onset trials, faster-acting insulin aspart had a safe and well tolerated profile, with the most common adverse event being hypoglycaemia, similar to the levels observed with NovoLog®. ""We are happy to be able to file faster-acting insulin aspart for regulatory approval in the US and have the opportunity to address unmet medical needs for people requiring improved blood glucose control around meals,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""Onset 1 shows that faster-acting insulin aspart has the potential to offer improved postprandial glucose and either an additional reduction of HbA1c or added flexibility compared with NovoLog®."" Novo Nordisk intends to make faster-acting insulin aspart available in the prefilled delivery device FlexTouch®. About faster-acting insulin aspart Faster-acting insulin aspart is a mealtime insulin for the control of postprandial glucose excursions in type 1 and type 2 diabetes as well as in pump treatment. Faster-acting insulin aspart is insulin aspart (NovoLog®) in a new formulation in which two new excipients have been added to ensure early and fast absorption. About the onset clinical programme The onset programme is a phase 3 clinical programme with faster-acting insulin aspart consisting of four trials encompassing more than 2,100 people with type 1 and type 2 diabetes. The onset 1 trial (1,143 people randomised) - a 26+26-week randomised, double-blinded, basal-bolus, treat-to-target trial investigating faster-acting insulin aspart compared to NovoLog®, both in combination with Levemir® in adults with type 1 diabetes. The results were reported in March and October 2015. The onset 2 trial (689 people randomised) - a 26-week randomised, double-blinded, basal-bolus, treat-to-target trial investigating faster-acting insulin aspart compared to NovoLog®, both in combination with insulin glargine in adults with type 2 diabetes. The results were reported in March 2015. The onset 3 trial (236 people randomised) - an 18-week randomised, open-label, basal bolus vs basal trial confirming superiority (in terms of HbA1c) of mealtime faster-acting insulin aspart in a full basal-bolus regimen versus basal insulin therapy, both in combination with metformin. The results were reported in January 2015. The onset 4 trial (37 people randomised) - a six-week randomised, double-blinded, parallel-group trial confirming pump compatibility and safety of faster-acting insulin aspart and NovoLog® in type 1 diabetes. The results were reported in August 2014. For further information Company announcement No 77 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1201,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
470,2015-12-09,Novo Nordisk indsender registreringsansøgning for hurtigerevirkende insulin aspart i USA til behandling af type 1- og type 2-diabetes,"Bagsværd, den 9. december 2015 - Novo Nordisk meddeler i dag, at virksomheden har indsendt registreringsansøgning for hurtigerevirkende insulin aspart til de amerikanske sundhedsmyndigheder (FDA). Hurtigerevirkende insulin aspart er en måltidsinsulin til forbedret regulering af blodsukkerstigning efter måltiderne og er udviklet til behandling af mennesker med type 1- og type 2-diabetes. Registreringsansøgningen for hurtigerevirkende insulin aspart er baseret på resultaterne fra det kliniske udviklingsprogram 'onset', som omfattede omkring 2.100 deltagere med type 1- og type 2-diabetes. I onset-programmet opnåede deltagere i behandling med hurtigerevirkende insulin aspart forbedringer i blodsukkerreguleringen efter måltiderne sammenlignet med NovoLog® (markedsføres som NovoRapid® udenfor USA) og en reduktion af langtidsblodsukkerniveauet (HbA1c) på linje med NovoLog®. Resultaterne fra det dobbeltblindede onset 1-studie viste, at deltagere med type 1-diabetes, som blev behandlet med hurtigerevirkende insulin aspart, opnåede en statistisk signifikant større reduktion i HbA1c, når det blev givet ved et måltid, eller en sammenlignelig HbA1c-reduktion, når det blev givet 20 minutter efter et måltid, sammenlignet med NovoLog®. På tværs af onset-studierne havde hurtigerevirkende insulin aspart en sikker og veltolereret profil, og den mest almindelige bivirkning var hypoglykæmi (lavt blodsukker) svarende til de observerede niveauer med NovoLog®. ""Vi er glade for at kunne indsende registreringsansøgning for hurtigerevirkende insulin aspart i USA, så vi får mulighed for at imødekomme udækkede medicinske behov hos diabetikere, der har brug for bedre blodsukkerregulering i forbindelse med måltiderne,"" siger Mads Krogsgaard Thomsen, koncerndirektør med ansvar for forskning og udvikling i Novo Nordisk. ""Onset 1 viser, at hurtigerevirkende insulin aspart har potentiale til at forbedre blodsukkerniveauet efter måltiderne og samtidig enten give yderligere reduktion af langtidsblodsukkeret eller ekstra fleksibilitet sammenlignet med NovoLog®."" Novo Nordisk forventer at gøre hurtigerevirkende insulin aspart tilgængelig i den præfyldte injektionspen FlexTouch®. Om hurtigerevirkende insulin aspart Hurtigerevirkende insulin aspart er en måltidsinsulin til regulering af måltidsrelaterede blodsukkerstigninger i type 1- og type 2-diabetes samt i pumpebehandling. Hurtigerevirkende insulin aspart er insulin aspart (NovoLog®) i en ny formulering, hvor der er tilsat to nye hjælpestoffer for at sikre tidlig og hurtig optagelse. Om det kliniske udviklingsprogram 'onset' Onset-programmet er et klinisk fase 3-program med hurtigerevirkende insulin aspart. Det består af fire studier med tilsammen flere end 2.100 deltagere med type 1- og type 2-diabetes. Onset1 (1.143 deltagere randomiseret) - et 26+26-ugers randomiseret, dobbeltblindet, basal-bolus treat to target-studie, der undersøgte hurtigerevirkende insulin aspart sammenlignet med NovoLog®, begge dele i kombination med Levemir®, hos voksne med type 1-diabetes. Resultaterne fra dette studie blev rapporteret i marts og oktober 2015. Onset2 (689 deltagere randomiseret) - et 26-ugers randomiseret, dobbeltblindet, basal-bolus treat to target-studie, der undersøgte hurtigerevirkende insulin aspart sammenlignet med NovoLog®, begge dele i kombination med insulin glargin, hos voksne med type 2-diabetes. Resultaterne fra dette studie blev rapporteret i marts 2015. Onset3 (236 deltagere randomiseret) - et 18-ugers randomiseret, ikke-blindet studie, der sammenlignede basal-bolus-behandling med basalinsulin. Studiet bekræftede superioritet (med hensyn til HbA1c) for hurtigerevirkende insulin aspart givet som måltidsinsulin i et fuldt basal-bolus-behandlingsprogram sammenlignet med basalinsulin, begge dele i kombination med metformin. Resultaterne fra dette studie blev rapporteret i januar 2015. Onset4 (37 deltagere randomiseret) - et seks-ugers randomiseret, dobbeltblindet parallelgruppestudie, der bekræftede pumpekompatibilitet og sikkerhed for hurtigerevirkende insulin aspart og NovoLog® i type 1-diabetes. Resultaterne fra dette studie blev rapporteret i august 2014. Yderligere information Selskabsmeddelelse nr. 77 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1202,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
471,2015-12-04,Novo Nordisk files for regulatory approval of faster-acting insulin aspart in the EU for the treatment of type 1 and 2 diabetes,"Bagsværd, Denmark, 4 December 2015 - Novo Nordisk today announced the submission to the European Medicines Agency of the Marketing Authorisation Application (MAA) for the approval of faster-acting insulin aspart. Faster-acting insulin aspart is a mealtime insulin for improved control of postprandial glucose excursions and has been developed for the treatment of people with type 1 and type 2 diabetes. Novo Nordisk expects to file the new drug application for faster-acting insulin aspart to the US Food and Drug Administration before year-end 2015. The filing of faster-acting insulin aspart is based on the results from the 'onset' clinical trial programme which involved around 2,100 people with type 1 and 2 diabetes. In the onset programme, people treated with faster-acting insulin aspart achieved improvements in postprandial control versus NovoRapid® and an HbA1c reduction on par with NovoRapid®. For people with type 1 diabetes, faster-acting insulin aspart results from the double-blinded onset 1 trial showed statistically significantly greater HbA1c reduction when dosed at mealtime or similar HbA1c reduction when dosed 20 minutes after a meal compared to NovoRapid®. Across the onset trials, faster-acting insulin aspart had a safe and well tolerated profile, with the most common adverse event being hypoglycaemia, similar to the levels observed with NovoRapid®. ""With the regulatory filing of faster-acting insulin aspart, we take yet another step in helping people with diabetes improve their blood glucose control around meals,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""Onset 1 shows that faster-acting insulin aspart has the potential to offer improved postprandial glucose and either an additional reduction of HbA1c or added flexibility compared with NovoRapid®."" Novo Nordisk intends to make faster-acting insulin aspart available in the prefilled delivery device FlexTouch®. Faster-acting insulin aspart is a mealtime insulin for the control of postprandial glucose excursions in type 1 and type 2 diabetes as well as in pump treatment. Faster-acting insulin aspart is insulin aspart (NovoRapid®) in a new formulation in which two new excipients have been added to ensure early and fast absorption. The onset programme is a phase 3 clinical programme with faster-acting insulin aspart consisting of four trials encompassing more than 2,100 people with type 1 and type 2 diabetes. The onset 1 trial (1,143 people randomised) - a 26+26-week randomised, double-blinded, basal-bolus, treat-to-target trial investigating faster-acting insulin aspart compared to NovoRapid®, both in combination with Levemir® in adults with type 1 diabetes. The results were reported in March and October 2015. The onset 2 trial (689 people randomised) - a 26-week randomised, double-blinded, basal-bolus, treat-to-target trial investigating faster-acting insulin aspart compared to NovoRapid®, both in combination with insulin glargine in adults with type 2 diabetes. The results were reported in March 2015. The onset 3 trial (236 people randomised) - an 18-week randomised, open-label, basal bolus vs basal trial confirming superiority (in terms of HbA1c) of mealtime faster-acting insulin aspart in a full basal-bolus regimen versus basal insulin therapy, both in combination with metformin. The results were reported in January 2015. The onset 4 trial (37 people randomised) - a six-week randomised, double-blinded, parallel-group trial confirming pump compatibility and safety of faster-acting insulin aspart and NovoRapid® in type 1 diabetes. The results were reported in August 2014. For further information Company announcement No 75 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1205,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
472,2015-12-04,Novo Nordisk indsender registreringsansøgning for hurtigerevirkende insulin aspart i EU til behandling af type 1- og type 2-diabetes,"Bagsværd, den 4. december 2015 - Novo Nordisk meddeler i dag, at virksomheden har indsendt ansøgning om markedsføringstilladelse (MAA) til Det Europæiske Lægemiddelagentur for hurtigerevirkende insulin aspart. Hurtigerevirkende insulin aspart er en måltidsinsulin til forbedret regulering af blodsukkerstigning efter måltiderne og er udviklet til behandling af mennesker med type 1- og type 2-diabetes. Novo Nordisk forventer at indsende registreringsansøgning for hurtigerevirkende insulin aspart til de amerikanske sundhedsmyndigheder, FDA, inden udgangen af 2015. Registreringsansøgningen for hurtigerevirkende insulin aspart er baseret på resultaterne fra det kliniske udviklingsprogram 'onset', som omfattede omkring 2.100 deltagere med type 1- og type 2-diabetes. I onset-programmet opnåede deltagere i behandling med hurtigerevirkende insulin aspart forbedringer i blodsukkerreguleringen efter måltiderne sammenlignet med NovoRapid® og en reduktion af langtidsblodsukkerniveauet (HbA1c) på linje med NovoRapid®. Resultaterne fra det dobbeltblindede onset 1-studie viste, at deltagere med type 1-diabetes, som blev behandlet med hurtigerevirkende insulin aspart, opnåede en statistisk signifikant større reduktion i HbA1c, når det blev givet ved et måltid, eller en sammenlignelig HbA1c-reduktion, når det blev givet 20 minutter efter et måltid, sammenlignet med NovoRapid®. På tværs af onset-studierne havde hurtigerevirkende insulin aspart en sikker og veltolereret profil, og den mest almindelige bivirkning var hypoglykæmi (lavt blodsukker) svarende til de observerede niveauer med NovoRapid®. ""Med indsendelsen af registreringsansøgningen for hurtigerevirkende insulin aspart har vi taget endnu et skridt på vejen til at hjælpe mennesker med diabetes med at opnå en bedre blodsukkerregulering i forbindelse med måltiderne,"" siger Mads Krogsgaard Thomsen, koncerndirektør med ansvar for forskning og udvikling i Novo Nordisk. ""Onset 1 viser, at hurtigerevirkende insulin aspart har potentiale til at forbedre blodsukkerniveauet omkring måltiderne og samtidig enten give yderligere reduktion af langtidsblodsukkeret eller ekstra fleksibilitet sammenlignet med NovoRapid®."" Novo Nordisk forventer at gøre hurtigerevirkende insulin aspart tilgængelig i den præfyldte injektionspen FlexTouch®. Hurtigerevirkende insulin aspart er en måltidsinsulin til regulering af måltidsrelaterede blodsukkerstigninger i type 1- og type 2-diabetes samt i pumpebehandling. Hurtigerevirkende insulin aspart er insulin aspart (NovoRapid®) i en ny formulering, hvor der er tilsat to nye hjælpestoffer for at sikre tidlig og hurtig optagelse. Onset-programmet er et klinisk fase 3-program med hurtigerevirkende insulin aspart. Det består af fire studier med tilsammen flere end 2.100 deltagere med type 1- og type 2-diabetes. Onset1 (1.143 deltagere randomiseret) - et 26+26-ugers randomiseret, dobbeltblindet, basal-bolus treat to target-studie, der undersøgte hurtigerevirkende insulin aspart sammenlignet med NovoRapid®, begge dele i kombination med Levemir®, hos voksne med type 1-diabetes. Resultaterne fra dette studie blev rapporteret i marts og oktober 2015. Onset2 (689 deltagere randomiseret) - et 26-ugers randomiseret, dobbeltblindet, basal-bolus treat to target-studie, der undersøgte hurtigerevirkende insulin aspart sammenlignet med NovoRapid®, begge dele i kombination med insulin glargin, hos voksne med type 2-diabetes. Resultaterne fra dette studie blev rapporteret i marts 2015. Onset3 (236 deltagere randomiseret) - et 18-ugers randomiseret, ikke-blindet studie, der sammenlignede basal-bolus-behandling med basalinsulin. Studiet bekræftede superioritet (med hensyn til HbA1c) for hurtigerevirkende insulin aspart givet som måltidsinsulin i et fuldt basal-bolus-behandlingsprogram sammenlignet med basalinsulin, begge dele i kombination med metformin. Resultaterne fra dette studie blev rapporteret i januar 2015. Onset4 (37 deltagere randomiseret) - et seks-ugers randomiseret, dobbeltblindet parallelgruppestudie, der bekræftede pumpekompatibilitet og sikkerhed for hurtigerevirkende insulin aspart og NovoRapid® i type 1-diabetes. Resultaterne fra dette studie blev rapporteret i august 2014. Yderligere information Selskabsmeddelelse nr. 75 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1206,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
473,2015-12-01,"Nye data viser, hvorfor type 2-diabetikere, som er utilstrækkeligt reguleret med basalinsulin, og læger tøver med at intensivere insulinbehandlingen","Læs hele meddelelsen med referencer Vancouver, Canada, den 1. december 2015 - Resultater fra studiet Perceptions of Control (POC) viser, at mennesker med type 2-diabetes, som ikke er reguleret godt nok med basalinsulin, tøver med at intensivere deres insulinbehandling, bl.a. fordi de er bange for bivirkninger af medicinen, vil føle sig mere syge og ikke har lyst til at tage flere injektioner. Lægernes bekymringer i forhold til intensivering af insulinbehandlingen omfatter bl.a. manglende accept hos patienterne, hypoglykæmi (lavt blodsukker) og patienternes kognitive tilstand.[i] Disse og andre resultater fra POC-studiet, som har undersøgt patienters og lægers opfattelse af god blodsukkerregulering, fremlægges i dag på verdenskongressen i International Diabetes Federation, IDF. ""En bedre forståelse af, hvordan patienter og læger træffer beslutninger i forhold til intensivering af diabeteshandlingen, kan forbedre kommunikationen mellem patient og læge under konsultationen og samtidig hjælpe mennesker med type 2-diabetes, som ikke er reguleret godt nok med basalinsulin, til at intensivere behandlingen, når der er behov for det,"" siger Meryl Brod, ph.d., forsøgsansvarlig for POC-studiet. ""Hvis vi kan komme patienternes bekymring i møde med mere information og forskellige behandlingsmuligheder, kan det bevirke, at flere patienter går med til at ændre deres behandling, så de opnår en bedre regulering af deres diabetes.""  [i]    Brod M, Pfeiffer KM, Barnett AH, et al. Patient/physicians inertia in insulin intensification for patients with uncontrolled type 2 diabetes using basal insulin. Poster presentation (1081-P) at the International Diabetes Federation (IDF) World Diabetes Congress, 1 December 2015.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1208,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
474,2015-12-01,New data reveal why physicians and people with type 2 diabetes uncontrolled on basal insulin are reluctant to intensify insulin therapy,"See the full release including references Vancouver, Canada, 1 December 2015 - Results from the Perceptions of Control (POC) study showed that people with type 2 diabetes uncontrolled on basal insulin were reluctant to intensify insulin therapy due to concerns such as medication side effects, perceptions of getting sicker and not wanting to add more injections. Physicians' concerns around insulin intensification included a lack of patient agreement to intensify insulin therapy, hypoglycaemia and patients' cognitive status.1 Findings from the Perceptions of Control study which evaluated the perceptions of diabetes control amongst patients and physicians were presented today at the World Diabetes Congress of the International Diabetes Federation (IDF). ""A better understanding of how patients and physicians make decisions around insulin intensification could significantly improve communication during consultations and help people with type 2 diabetes, uncontrolled on basal insulin, to intensify treatment when needed,"" said Meryl Brod, PhD, lead investigator of the POC study. ""Addressing patient concerns with additional information and treatment options may lead to an increased number of patients agreeing to change their treatment to get into better control."" Reference 1. Brod M, Pfeiffer KM, Barnett AH, et al. Patient/physicians inertia in insulin intensification for patients with uncontrolled type 2 diabetes using basal insulin. Poster presentation (1081-P) at the International Diabetes Federation (IDF) World Diabetes Congress, 1 December 2015. Further Information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1207,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
475,2015-12-01,New data highlight impact of post-meal hyperglycaemia on people with diabetes,"See the full release including references Vancouver, Canada, 1 December 2015 - New data from four analyses1,2,3,4 demonstrate that post-meal hyperglycaemia (when blood sugar goes too high after eating) is associated with a negative physical and emotional impact on people with type 1 and type 2 diabetes3, greater use of healthcare resources1, missed work time and reduced productivity4. These results were presented todayat the World Diabetes Congress of the International Diabetes Federation (IDF). Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1209,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
476,2015-11-24,Alle Novo Nordisks fabrikker skal producere på vedvarende energi i 2020,"Bagsværd, den 24. november 2015 - Novo Nordisk har i dag offentliggjort en ny ambition om kun at anvende elektricitet fra vedvarende energikilder på alle sine globale produktionsanlæg i 2020. Efter implementeringen vil der ikke være nogen CO2-udledning fra den elektricitet, der anvendes på virksomhedens fabrikker. Allerede i dag anvender virksomhedens produktionsanlæg i Danmark, Brasilien og Japan elektricitet fra vedvarende energikilder. ""Det er ambitiøst at sætte et absolut mål om nul CO2-udledning fra elektricitet på alle vores globale produktionsanlæg om bare fem år, mens vi samtidig øger produktionen for at følge med den stigende globale efterspørgsel på vores diabetesprodukter,"" siger Henrik Wulff, koncerndirektør med ansvar for Novo Nordisks globale produktion. Der blev taget et stort skridt på vejen mod at nå 2020-ambitionen i sidste måned, da Novo Nordisks produktionsanlæg Tianjin i Kina underskrev en aftale om køb af elektricitet fra en vindmøllepark i Indre Mongoliet. Andre produktionsanlæg i USA, Frankrig, Rusland, Algeriet og Iran vil indgå lignende aftaler i de kommende år. ""I Danmark får vi vores elektricitet fra vindmøller, og det bliver også tilfældet i Kina, men der findes ikke en standardløsning. Vi vil derfor finde frem til de mest effektive vedvarende energikilder til den elektricitet, vi skal bruge på vores produktionsanlæg i de andre lande,"" forklarer Henrik Wulff. ""Det giver god mening at skifte til elektricitet fra vedvarende energikilder, både i forhold til klima og omkostninger. I takt med at flere og flere virksomheder investerer i elektricitet fra vedvarende energikilder, bliver teknologien både mere effektiv og billigere."" Novo Nordisk har for nylig, sammen med nogle af verdens mest indflydelsesrige virksomheder, tilsluttet sig RE100, som er et fælles initiativ for globale virksomheder, der har forpligtet sig til at anvende elektricitet udelukkende fra vedvarende energikilder. Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1215,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
477,2015-11-24,All Novo Nordisk production plants to run on renewable power in 2020,"Bagsværd, Denmark, 24 November 2015 - Today, Novo Nordisk announced a new ambition to only use electricity from renewable sources at all its global production sites by 2020. Once implemented, there will be no CO2 emissions from the electricity used at the company's plants. Already today, the company's production sites in Denmark, Brazil and Japan use electricity from renewable sources. ""Setting an absolute target of zero CO2 emissions from electricity at all our global production sites in just five years is ambitious, as our production is growing to meet the increasing global demand for our diabetes products,"" says Henrik Wulff, executive vice president and head of Novo Nordisk Product Supply.  An important step in achieving the 2020 ambition was taken last month when Novo Nordisk's production site Tianjin in China signed an agreement on purchasing electricity from a windmill farm in Inner Mongolia. Other production sites in the US, France, Russia, Algeria and Iran will enter similar agreements in the coming years. ""In Denmark, we get our electricity from windmills and this will also be the case in China, but there is not a one-size-fits-all solution and we will identify the most efficient renewable electricity sources for our production facilities in the other countries,"" explains Henrik Wulff. ""Switching to renewable electricity makes sense from both a climate and a cost perspective. As more companies invest in renewable electricity, the technology is likely to get even more efficient and less costly."" Novo Nordisk has recently, together with some of world's most influential companies, joined the RE100, which is a collaborative initiative of global businesses committed to using 100% renewable electricity. Further information  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1214,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
478,2015-11-18,Novo Nordisks kapitalmarkedsdag 2015,"Bagsværd, den 18. november 2015 - På Novo Nordisks kapitalmarkedsdag i morgen, den 19. november 2015, vil ledelsen give en opdatering på vigtige projekter i udviklingsporteføljen, markedsdynamik og virksomhedens kommercielle strategi. Det er Novo Nordisks ambition at styrke sit lederskab på det globale diabetesmarked yderligere gennem forskning, udvikling og markedsføring af forbedrede insulin- og GLP-1-analoger og kombinationer heraf samt helt nye klasser af biologiske diabeteslægemidler. Programmet omfatter bl.a. følgende hovedtemaer: Kapitalmarkedsdagen vil endvidere omfatte præsentationer om virksomhedens produktionsstrategi og planer om at opbygge en førende position indenfor medicinsk behandling af fedme, samt mindre breakout-sessioner med fokus på International Operations, Kina og biopharmaceuticals-forretningen. NOVO NORDISKS FORSKNINGSSTRATEGI OG VIGTIGE UDVIKLINGSPROJEKTER INDENFOR DIABETESBEHANDLING Dette programpunkt omfatter bl.a.: Introduktion til Novo Nordisks forskningsstrategi og vigtige udviklingsprojekter i tidlige faser Novo Nordisks forsknings- og udviklingsstrategi præsenteres med særligt fokus på det, som virksomheden betragter som sine vigtigste konkurrencefordele i den forsknings- og udviklingsmæssige værdikæde. Præsentationen vil gøre rede for Novo Nordisks forskningsstrategi med hensyn til at levere fremtidens innovative proteinbaserede lægemidler, der adresserer udækkede medicinske behov indenfor de fire valgte terapiområder i Novo Nordisks koncernstrategi: diabetesbehandling, fedme, hæmofili og vækstforstyrrelser. Præsentationen vil endvidere gennemgå Novo Nordisks udviklingsorganisation med fokus på klinisk forsøgsdesign og -udførelse. Resultater fra SUSTAIN 4-studiet, der undersøger GLP-1-analogen semaglutid doseret subkutant én gang ugentligt sammenlignet med insulin glargin doseret én gang dagligt SUSTAIN 4, det tredje fase 3a-studie med semaglutid, der rapporterer resultater, omfattede i alt 1.089 deltagere med type 2-diabetes, som tidligere var blevet behandlet med metformin med eller uden sulfonylurinstof. Fra et gennemsnitligt langtidsblodsukkerniveau (HbA1c) på 8,2% ved studiets begyndelse opnåede deltagere, som én gang ugentligt blev behandlet med doser på 0,5 mg og 1,0 mg semaglutid, statistisk signifikante og større forbedringer i HbA1c på henholdsvis 1,2% og 1,6%, sammenlignet med 0,8% med insulin glargin, efter 30 ugers behandling. Den gennemsnitlige daglige dosis af insulin glargin var 29 enheder. Fra en gennemsnitsvægt på 93 kg ved studiets begyndelse opnåede deltagere i behandling med 0,5 mg og 1,0 mg semaglutid desuden et statistisk signifikant og større vægttab på henholdsvis 3,5 kg og 5,2 kg, sammenlignet med en vægtstigning på 1,2 kg med insulin glargin. Semaglutid forekom i studiet at have en sikker og veltolereret profil. Den mest almindelige bivirkning var kvalme, som aftog med tiden. Kvalme blev rapporteret af op til 22% af deltagere i behandling med semaglutid, sammenlignet med 4% af deltagere i behandling med insulin glargin. Alvorlig eller symptomatisk hypoglykæmi bekræftet ved blodsukkermåling blev rapporteret hos 4% og 6% af deltagere i behandling med henholdsvis 0,5 mg eller 1,0 mg semaglutid én gang ugentligt, sammenlignet med 11% i gruppen, der fik insulin glargin. Resultater fra fase 2-programmet med oral semaglutid og studiedesignet i fase 3a-programmet PIONEER Der vil blive præsenteret yderligere detaljer fra fase 2-programmet med oral semaglutid, GLP-1-analogen i tabletform til dosering én gang dagligt. Endvidere vil der blive gjort rede for tilrettelæggelsen af studierne i det afsluttende fase 3a-program for oral semaglutid, PIONEER. Der vil blive påbegyndt i alt 10 studier med flere end 9.000 patienter i det planlagte fase 3a-program. Det første studie vil blive påbegyndt i første kvartal af 2016, og størstedelen af de resterende studier vil blive påbegyndt i 2016. Resultaterne fra de 10 kliniske studier forventes at foreligge i 2018. Novo Nordisks planer for fase 3b- og fase 4-studier efter produktgodkendelse Foruden de omfattende investeringer i afsluttende fase 3a-udviklingsprogrammer planlægger Novo Nordisk at udvide investeringerne i kliniske fase 3b- og fase 4-studier med det formål at understøtte de nyligt godkendte produkter. Flere end 20 studier i de afsluttende udviklingsfaser indenfor diabetesbehandling er p.t. i gang eller planlagt til påbegyndelse i de kommende år. Breakout-session om biopharmaceuticals sætter fokus på resultater fra pathfinder 2-forlængelsesstudiet af N8-GP (NN7088) Novo Nordisk vil i en separat session præsentere biopharmaceuticals-forretningen, herunder resultater fra afslutningen af den første del af pathfinder 2-forlængelsesstudiet. De rapporterede data understøtter yderligere, at den langtidsvirkende rekombinante faktor VIII, N8-GP (turoctocog alfa pegol), forekommer at have en sikker og veltolereret profil, og at 95% af milde til moderate blødninger kan behandles med 1-2 infusioner. Endvidere blev en undergruppe bestående af 55 patienter, som havde =<2 blødninger ved forebyggende behandling hver fjerde dag i seks måneder, i forlængelsesfasen randomiseret til behandling enten hver fjerde dag (50 IU/kg) eller én gang ugentligt (75 IU/kg). I observationsperioden på 180 dage i dette delstudie var den gennemsnitlige årlige blødningsfrekvens 0 (nul) for patienter i begge behandlingsgrupper. NOVO NORDISKS KOMMERCIELLE STRATEGI I DET GLOBALE MARKED FOR DIABETESBEHANDLING Med udgangspunkt i en gennemgang af dynamikken i det globale marked for diabetesbehandling fokuseres på de nuværende og forventede fremtidige vækstskabende faktorer for Novo Nordisk. Disse omfatter bl.a. den underliggende volumenvækst i diabetesmarkedet og Novo Nordisks introduktion af nye lægemiddelkandidater på diabetesmarkedet, som potentielt vil kunne føre til vundne markedsandele og værdiopgradering. Novo Nordisk vil i de kommende år arbejde for et komplet udbud af diabetesprodukter ved at fortsætte de globale lanceringer af Tresiba®, Ryzodeg® og Xultophy® samt den planlagte introduktion af hurtigerevirkende insulin aspart og semaglutid efter succesfuld afslutning af de kliniske studier og efterfølgende regulatoriske processer. NOVO NORDISKS KOMMERCIELLE STRATEGI I DET AMERIKANSKE LÆGEMIDDELMARKED MED FOKUS PÅ KOMMENDE PRODUKTLANCERINGER Dette programpunkt omfatter en opdatering på de seneste ændringer indenfor det amerikanske sundhedssystem og betalerne af sundhedsydelser. Opdateringen om forretningen vil fokusere på Novo Nordisks position på det amerikanske marked for diabetesbehandling, hvor segmentet for basal insulin repræsenterer de største muligheder for virksomheden. Tresiba® forventes at blive lanceret i begyndelsen af 2016, og lanceringsplanerne vil blive gennemgået under dette programpunkt. WEBCAST Kapitalmarkedsdagen kan følges direkte over nettet som webcast via investorsektionen på novonordisk.com, og præsentationerne vil efterfølgende være tilgængelige samme sted. Materiale til kapitalmarkedsdagen 2015 vil være tilgængeligt fra den 19. november ca. kl. 8.00 CET på investorsektionen på novonordisk.com. Yderligere information Selskabsmeddelelse nr 72 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1219,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
479,2015-11-18,Highlights to be presented at Novo Nordisk's Capital Markets Day 2015,"Bagsværd, Denmark, 18 November 2015 - At Novo Nordisk's Capital Markets Day tomorrow, 19 November 2015, the company will provide updates on key development projects, market dynamics and commercial strategy. Novo Nordisk's ambition is to further expand its leadership in the global diabetes care market by discovering, developing and marketing improved insulin and GLP-1 analogues, and combinations hereof, as well as completely new classes of anti-diabetic biologics. The key topics of the day will be: In addition, the Capital Markets Day will include presentations of the company's production strategy, plans for building a leading position within medical treatment of obesity, as well as break-out sessions covering International Operations, China and the company's biopharmaceuticals business. NOVO NORDISK'S RESEARCH STRATEGY AND KEY DEVELOPMENT PROJECTS WITHIN DIABETES CARE Highlights from this session include: Introduction to Novo Nordisk's research strategy and key early development projects Novo Nordisk's dedicated research and development strategy will be presented with special focus on what Novo Nordisk considers its key competitive advantages throughout the research and development value chain. The presentation will outline the company's research strategy for delivering future innovative protein-based therapies addressing unmet medical needs within the four core disease areas in Novo Nordisk's corporate strategy; Diabetes Care, Obesity, Haemophilia and Growth Disorders. Moreover, it will review Novo Nordisk's development organisation with focus on clinical trial design and execution. Results from the SUSTAIN 4 trial comparing once-weekly subcutaneous administration of the GLP-1 analogue semaglutide with once-daily insulin glargine SUSTAIN 4, the third phase 3a trial for semaglutide to report results, included a total of 1,089 people with type 2 diabetes previously treated with metformin with or without sulfonylurea. From a mean baseline, HbA1c of 8.2%, people treated once-weekly with doses of 0.5 mg and 1.0 mg semaglutide achieved statistically significant and superior improvements in HbA1c of 1.2% and 1.6%, respectively, compared to 0.8% with insulin glargine after 30 weeks of treatment. The mean daily insulin glargine dose was 29 units. Furthermore, from a mean baseline body weight of 93 kg, people treated with 0.5 mg and 1.0 mg semaglutide experienced statistically significant and superior weight loss of 3.5 kg and 5.2 kg, respectively, compared with a weight gain of 1.2 kg with insulin glargine. In the trial, semaglutide appeared to have a safe and well-tolerated profile. The most common adverse event was nausea which diminished over time. Nausea was reported by up to 22% of people treated with semaglutide compared with 4% of people treated with insulin glargine. Severe or blood glucose-confirmed symptomatic hypoglycaemia was experienced by 4% and 6% of people treated with 0.5 mg or 1.0 mg once-weekly semaglutide, respectively, compared with 11% in the insulin glargine group. Results from the phase 2 programme with oral semaglutide and the design of the phase 3a programme PIONEER Further details from the phase 2 programme with the once-daily oral GLP-1 analogue, oral semaglutide, will be presented. The design of the pivotal phase 3a programme for oral semaglutide, PIONEER, will be highlighted. A total of 10 studies with more than 9,000 patients will be initiated under the planned phase 3a programme. The first trial will be initiated in the first quarter of 2016 and the majority of the remaining trials will be initiated in 2016. Results from the 10 clinical trials are expected to be available in 2018. Novo Nordisk's plans for post-approval phase 3b and phase 4 development trials In addition to the extensive investments in pivotal phase 3a development programmes, Novo Nordisk plans to expand investments in phase 3b and phase 4 clinical trials, in order to support the recently approved products. More than 20 late-stage diabetes care development trials are currently ongoing or planned for initiation in the coming years. Biopharmaceuticals break-out session to highlight results from the N8-GP (NN7088) pathfinder 2 extension trial In a separate session, Novo Nordisk will present the company's biopharmaceuticals business including results from the completion of the first part of the pathfinder 2 extension trial. The reported data provide additional support that the long-acting recombinant factor VIII, N8-GP (turoctocog alfa pegol), appears to have a safe and well-tolerated profile, and that 95% of mild to moderate bleeds can be managed with 1-2 infusions. Additionally, a subset of 55 patients, who experienced <=2 bleeds during 6 months on every four days prophylaxis, were in the extension phase randomised to either every four days (50 IU/kg) or once-weekly (75 IU/kg) treatment. During the 180-day observation period of this sub-study, the median annualised bleeding rate (ABR) was 0 (zero) for patients in both treatment arms. NOVO NORDISK'S COMMERCIAL STRATEGY IN THE GLOBAL DIABETES CARE MARKET Based on a review of the dynamics of the global diabetes care market, this session will highlight Novo Nordisk's current and expected future growth drivers. These include focusing on the underlying diabetes care market volume growth and Novo Nordisk's introduction of novel drug candidates in the diabetes care market leading to potential market share gains and value upgrade. In the coming years, Novo Nordisk will promote  a complete diabetes care product offering by continuing the global launches of Tresiba®, Ryzodeg® and Xultophy® as well as the planned introduction of faster-acting insulin aspart and semaglutide upon successful completion of the clinical trials and subsequent regulatory processes. NOVO NORDISK'S COMMERCIAL STRATEGY IN THE UNITED STATES PHARMACEUTICAL MARKET WITH FOCUS ON UPCOMING PRODUCT LAUNCHES This session includes an update on recent changes in the US healthcare system and payer landscape. The business update will highlight Novo Nordisk's position in the US diabetes care market where the basal insulin segment represents the company's largest opportunity. Tresiba® is expected to be launched in early 2016, and the launch plans will be outlined during the session. WEB CAST DETAILS All sessions of the Capital Markets Day will be webcast live, and replay will be made available on the investor section of novonordisk.com. Presentation material for the Capital Markets Day 2015 will be available 19 November at approximately 8.00 CET, corresponding to 2.00 am EST on the investor section of novonordisk.com. Further information Company announcement No 72 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1218,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
480,2015-11-16,"Novo Nordisk og Københavns Kommune bag ny forskning, der kræver nytænkning af diabetesindsatsen","Bagsværd, 16. November 2015 - International forskning udført i samarbejde mellem University College London (UCL), Københavns Universitet og Steno Diabetes Center som led i partnerskabsprogrammet 'Cities Changing Diabetes' udfordrer den gængse videnskabelige forståelse af den hastigt stigende forekomst af diabetes i storbyer, herunder København. Forskningsresultaterne indikerer, at sociale og kulturelle faktorer spiller en langt større rolle for sygdommens udbredelse end hidtil antaget. Referencer   Yderligere information, medier",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1223,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
481,2015-11-16,International study prompts rethink on the rise of diabetes in cities,"Bagsværd, Denmark, 16 November 2015 - International research led by University College London (UCL) as part of the 'Cities Changing Diabetes' partnership programme challenges current scientific understanding of the rapid rise of diabetes in cities. The findings suggest that in cities around the world, social and cultural factors play a far more important role in the spread of the epidemic than previously thought.  Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1222,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
482,2015-11-04,"Novo Nordisk investerer 2,1 mia. kr. i ny insulinfylde-fabrik i Hillerød og skaber 450 nye arbejdspladser","Bagsværd, den 4. november 2015 - Novo Nordisk investerer 2,1 mia. kr. i en ny fabrik på 10.300 m2 i Hillerød. Fabrikken skal producere medicin til behandling af diabetes og behandling af overvægt. Første spadestik bliver taget i dag, onsdag den 4. november i Hillerød, hvor Hillerøds borgmester Dorte Meldgaard vil sætte byggeriet i gang. Fabrikken forventes at stå færdig i 2019 og kommer til at skabe 450 nye produktions- og ingeniørjobs i Hillerød, hvor Novo Nordisk i forvejen beskæftiger 1.900 medarbejdere. Den nye fyldefabrik kommer til at indeholde den seneste teknologi indenfor insulin-produktion og skal sikre produktionskapacitet til eksisterende og fremtidige produkter indenfor diabetes. ""Investeringen i Hillerød understreger vores langsigtede ambition om at skabe og fastholde arbejdspladser i Danmark. Alene i år har vi skabt 1.000 nye arbejdspladser i Danmark, og heraf er 500 arbejdspladser i produktionen, hovedsageligt i Kalundborg og Hillerød,"" siger Henrik Wulff, der er koncerndirektør for Novo Nordisks globale produktion. Første spadestik finder sted onsdag den 4. november fra kl. 15-16 i Hillerød, Brennum Park. Om Novo Nordisk i Hillerød Fabriksparken i Hillerød blev grundlagt i 1992 med et samlet areal på omkring 1.650.000 m2, hvoraf omkring 90.000 m2 anvendes til produktion, forskning og udvikling. Området huser faciliteter til forskning og udvikling indenfor Novo Nordisks injektionspenne samt tre produktionsanlæg: en fabrik til støbning og præmontage af komponenter, en til påfyldning, montage og pakning af diabetesfærdigvarer og en til fremstilling af aktive lægemiddelstoffer til blødermedicin. Novo Nordisk har løbende foretaget investeringer i fabriksparken på i gennemsnit omkring 350 mio. kr. om året. Yderligere information ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1233,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
483,2015-11-04,"Novo Nordisk invests DKK 2.1 billion in new insulin filling facility in Denmark, creating 450 new jobs","Bagsværd, Denmark, 4 November 2015 - Novo Nordisk is investing 2.1 billion Danish kroner in a new 10,300 m2 facility in Hillerød, Denmark. The facility will produce medicines for the treatment of diabetes and obesity. A groundbreaking ceremony marking the start of construction work will be held today, Wednesday 4 November, at the company's Hillerød site, attended by the mayor of Hillerød, Dorte Meldgaard. The facility is expected to be operational in 2019 and will create 450 new production and engineering jobs in Hillerød, where Novo Nordisk already employs 1,900 people. Incorporating the latest state-of-the-art insulin production technology, the new insulin filling facility will ensure production capacity for existing and future products within diabetes. ""The investment in Hillerød underscores our long-term ambition to create and maintain jobs in Denmark. This year alone we have created 1,000 new jobs in Denmark, of which 500 are in production, primarily in Kalundborg and Hillerød,"" said Henrik Wulff, executive vice president and head of Product Supply, Novo Nordisk. Today's groundbreaking event takes place from 3 to 4 pm at Brennum Park, Hillerød. Established in 1992, the Hillerød site covers an area of about 1,650,000 m2, of which 90,000 m2 is used for production, research and development. The site houses a facility for device R&D and three production facilities: one for moulding and pre-assembly of components, one for filling, assembly and packaging of diabetes finished products and one for the production of active pharmaceutical ingredients for haemophilia products. Novo Nordisk has made ongoing investments in the site of approximately 350 million kroner per year on average. Further information  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1232,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
484,2015-11-03,Novo Nordisk og University of Washington indgår samarbejde om forskning i hjernens rolle i regulering af blodsukker og fedme,"Bagsværd, den 3. november 2015 - Novo Nordisk meddeler i dag, at virksomheden har indgået et forskningssamarbejde med dr. Michael Schwartz, leder af Diabetes and Obesity Center of Excellence ved UW Medicine. Forskningssamarbejdet har til formål at forstå de faktorer, der styrer hjernens regulering af blodsukker og appetit, med det ultimative mål at udvikle nye lægemidler til behandling af diabetes og fedme. Forskningen vil finde sted på UW Medicines South Lake Union forskningscampus i Seattle, Washington, og i Novo Nordisk. Michael W. Schwartz, læge og professor i medicin ved University of Washington, vil sammen med sit forskerteam og Novo Nordisks forskere over de næste tre år gennemføre et forskningsprogram, der skal kortlægge effekten af kendte hormonelle faktorer, der arbejder i hjernen for at regulere kroppens glukosestofskifte og appetit. Michael Schwartz er en internationalt førende ekspert indenfor diabetes og fedme med fokus på hjernens rolle i reguleringen af energibalance, insulinresistens og glukosestofskifte. Han er førende indenfor sit felt, og hans arbejde publiceres løbende i anerkendte videnskabelige tidsskrifter. ""Vi glæder os meget til fremover at arbejde tæt sammen med Michael Schwartz. Der er et stort potentiale i at forfølge denne vinkel på blodsukker- og appetitreguleringen, og vi håber, det vil resultere i nye lægemidler til behandling af diabetes og fedme til gavn for patienterne,"" siger Peter Kurtzhals, direktør for Global Research i Novo Nordisk. Michael Schwartz siger: ""Vi glæder os til at starte på dette nye samarbejde med vores fagfæller i Novo Nordisk. Vores samlede faglige kunnen og ekspertise vil hjælpe os til både at opnå en bedre forståelse af hjernens rolle i reguleringen af blodsukkeret og udvikle nye tilgange til behandling af diabetes."" UW Medicines mission er at forbedre den generelle sundhedstilstand ved at fremme medicinsk viden og tilbyde fremragende primær- og specialbehandling til regionens borgere samt uddanne fremtidens læger, forskere og andre sundhedsprofessionelle. UW Medicine ejer eller driver Harborview Medical Center, Northwest Hospital & Medical Center, Valley Medical Center, University of Washington Medical Center, et netværk bestående af 10 UW Neighborhood Clinics, som tilbyder primær og sekundær behandling, lægepraksissen UW Physicians, UW School of Medicine og Airlift Northwest. Derudover er UW Medicine medejer og deltager i ledelsen af Children's University Medical Group og Seattle Cancer Care Alliance, et partnerskab blandt UW Medicine, Fred Hutchinson Cancer Research Center og Seattle Children's. Fakultetet omfatter tre nulevende nobelpristagere (fem i alt historisk set), 36 medlemmer af National Academy of Medicine, 32 medlemmer af National Academy of Sciences og 13 Howard Hughes Medical Institute-forskere. Læs mere på uwmedicine.org. ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1235,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
485,2015-11-03,Novo Nordisk and University of Washington to collaborate on exploring the role of the brain in regulating blood glucose and obesity,"Bagsværd, Denmark, 3 November 2015 - Novo Nordisk today announced that a research collaboration has been initiated with Dr Michael Schwartz, director of The Diabetes and Obesity Center of Excellence at UW Medicine. The collaboration aims to understand factors mediating brain control of blood glucose and appetite with the ultimate goal of developing new therapeutic agents for the treatment of diabetes and obesity. The research will be conducted at UW Medicine's South Lake Union research campus in Seattle, Washington, and at Novo Nordisk. Over the next three years, Michael W Schwartz, MD, a University of Washington professor of medicine and his team together with Novo Nordisk researchers will conduct a research programme on the effect of known hormonal factors working in the brain to regulate whole body glucose metabolism and appetite. Dr Schwartz is a world expert in diabetes and obesity with focus on the role of the brain in the regulation of energy balance, insulin resistance and glucose metabolism. His work is continuously published in high-ranking journals and is setting direction for this field of research. ""We are very happy to enter into a close collaboration with Dr Schwartz. There is a large potential in following this angle for blood glucose and appetite control, and we hope it will bring new agents for the treatment of diabetes and obesity to the patients,"" says Peter Kurtzhals, senior vice president, Global Research Novo Nordisk. Dr Michael Schwartz says, ""We are excited to launch this new collaboration with colleagues at Novo Nordisk. Our collective skill and expertise will help us to both advance our understanding of the brain's role in blood sugar control and to develop novel approaches to diabetes treatment."" UW Medicine's mission is to improve the health of the public by advancing medical knowledge, providing outstanding primary and specialty care to the people of the region, and preparing tomorrow's physicians, scientists and other health professionals. UW Medicine owns or operates Harborview Medical Center, Northwest Hospital & Medical Center, Valley Medical Center, University of Washington Medical Center, a network of 10 UW Neighborhood Clinics that provide primary care and secondary care, the physician practice UW Physicians, the UW School of Medicine and Airlift Northwest. In addition, UW Medicine shares in the ownership and governance of Children's University Medical Group and Seattle Cancer Care Alliance, a partnership among UW Medicine, Fred Hutchinson Cancer Research Center and Seattle Children's. Our faculty includes 3 living Nobel Prize winners (5 in our history), 36 National Academy of Medicine members, 32 National Academy of Sciences members and 13 Howard Hughes Medical Institute investigators. For more information, visit uwmedicine.org.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1234,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
486,2015-10-29,"Novo Nordisks resultat af primær drift steg med 51% i de første ni måneder af 2015 til 38,3 mia. kr.","Resultat af primær drift steg med 16% i lokale valutaer justeret for salget af NNIT Salget steg med 23% opgjort i kroner og med 9% i lokale valutaer til 79,1 mia. kr. Bruttomarginen steg med 1,8 procentpoint opgjort i kroner til 85,4% drevet af en positiv påvirkning fra valutakursudviklingen. Resultat af primær drift steg med 51% opgjort i kroner og med 26% i lokale valutaer til 38,3 mia. kr. Justeret for engangsindtægten på 2,4 mia. kr. i relation til det delvise salg af NNIT steg resultat af primær drift opgjort i lokale valutaer med 16%. Nettoresultatet steg med 33% til 26,6 mia. kr. Udvandet resultat pr. aktie steg med 36% til 10,28 kr. Justeret for det delvise salg af NNIT steg nettoresultatet og udvandet resultat pr. aktie med henholdsvis 22% og 24%. I september meddelte Novo Nordisk, at de amerikanske sundhedsmyndigheder (FDA) har godkendt Tresiba® og Ryzodeg® 70/30 efter endt behandling af de genindsendte registreringsansøgninger. For 2015 forventes fortsat en salgsvækst på 7-9% opgjort i lokale valutaer, mens væksten i resultat af primær drift opgjort i lokale valutaer forhøjes med 1 procentpoint og nu ventes at blive på omkring 20%. De foreløbige forventninger til 2016 i lokale valutaer indikerer en medium til høj encifret vækst i salget og en medium til høj encifret vækst i resultat af primær drift justeret for engangspåvirkningen fra det delvise salg af NNIT samt indtægterne i relation til udlicensering af aktiver vedrørende inflammatoriske sygdomme, begge i 2015. Adm. direktør Lars Rebien Sørensen: ""Vi er tilfredse med de resultater, vi har opnået i de første ni måneder af 2015. Salgsvæksten har primært været drevet af Victoza®, støttet af den høje vækst i GLP-1-markedet. I tredje kvartal nåede vi en vigtig milepæl med FDA's godkendelse af Tresiba® i USA, som vi ser frem til at lancere i begyndelsen af 2016."" kontaktoplysninger Selskabsmeddelelse nr. 65 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1239,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
487,2015-10-29,Novo Nordisk increased operating profit by 51% in the first nine months of 2015 to DKK 38.3 billion,"16% local currency operating profit growth adjusted for the NNIT divestment Sales increased by 23% in Danish kroner and by 9% in local currencies to DKK 79.1 billion. Gross margin improved by 1.8 percentage points in Danish kroner to 85.4% driven by a positive currency impact. Operating profit increased by 51% in Danish kroner and by 26% in local currencies to DKK 38.3 billion. Adjusted for the DKK 2.4 billion non-recurring income related to the partial divestment of NNIT, operating profit in local currencies increased by 16%. Net profit increased by 33% to DKK 26.6 billion. Diluted earnings per share increased by 36% to DKK 10.28. Adjusted for the partial divestment of NNIT, net profit and diluted earnings per share increased by 22% and 24% respectively. In September, Novo Nordisk announced the US FDA approval of Tresiba® and Ryzodeg® 70/30 after the review of the class II resubmission of the New Drug Applications. For 2015, sales growth measured in local currencies is still expected to be 7-9%, whereas operating profit growth measured in local currencies is raised by 1 percentage point and now expected to be around 20%. The preliminary outlook for 2016 in local currencies indicates mid to high single-digit growth in sales and mid to high single-digit growth in operating profit adjusted for the non-recurring impact of the partial divestment of NNIT and the income related to the out-licensing of assets for inflammatory disorders, both in 2015. Lars Rebien Sørensen, president and CEO: ""We are satisfied with the results of the first nine months of 2015. Sales growth was primarily driven by Victoza® aided by the high growth of the GLP-1 market. In the third quarter, a significant milestone was achieved with the US FDA approval of Tresiba®, and we look forward to launching Tresiba® early 2016."" Contacts for further information Company announcement No 65 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1238,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
488,2015-09-25,Novo Nordisk receives US FDA approval for Tresiba® and Ryzodeg® 70/30,"Bagsværd, Denmark, 25 September 2015 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Tresiba® and Ryzodeg® 70/30 for the treatment of diabetes mellitus in adults after review of the class II resubmissions of the New Drug Applications (NDAs). Tresiba®, the approved brand name for insulin degludec, is a once-daily new-generation basal insulin analogue with a half-life of 25 hours and a duration of action of at least 42 hours. In 'treat-to-target' studies comparing Tresiba® to insulin glargine, people using Tresiba® achieved similar reduction in long-term blood glucose (HbA1c), numerically greater fasting plasma glucose reduction, while using numerically lower doses of insulin in a majority of the studies. Furthermore, the studies demonstrated that Tresiba® is the first basal insulin to offer people with diabetes the possibility of injecting their basal insulin at any time of the day with the option to adjust the time of injection. Ryzodeg® 70/30, the approved brand name for insulin degludec/insulin aspart, contains insulin degludec in a soluble co-formulation with insulin aspart. Ryzodeg® 70/30 can be administered once or twice daily with any main meal. In a 'treat-to-target' study supporting the new drug application where Ryzodeg® 70/30 was compared to NovoLog® Mix 70/30, Ryzodeg® 70/30 showed equivalent reductions in HbA1c. Novo Nordisk expects to launch Tresiba® in the US during the first quarter of 2016. Tresiba® will be available in the FlexTouch® device and be offered in two concentrations enabling maximum doses of 80 units and 160 units per injection, respectively. On 26 March 2015, Novo Nordisk announced the decision to submit the class II resubmissions of the NDAs following the completion of the interim analysis of the cardiovascular outcomes trial for insulin degludec, DEVOTE. In order to preserve the integrity of the ongoing DEVOTE trial, only a small dedicated team within Novo Nordisk has access to the data. Novo Nordisk management does not have access to the results of the interim analysis. The trial is still expected to have accrued the prespecified number of major adverse cardiovascular events (MACE) for the full trial analysis in mid-2016. ""We are very happy with FDA's decision to approve Tresiba® and Ryzodeg® 70/30 as we believe these products offer significant benefits and important treatment options for people with type 1 and type 2 diabetes"", said Lars Rebien Sørensen, president and chief executive officer of Novo Nordisk. ""The approvals mark an important milestone for Novo Nordisk and we look forward to making Tresiba® available for people in the US"". Reflecting a separate action, Novo Nordisk today also announced that a New Drug Application for Xultophy®, the first once-daily single-injection combination of Tresiba® (insulin degludec) and Victoza® (liraglutide), has been submitted to the FDA. The submission is expected to be reviewed under US FDA's Prescription Drug User Fee Act V (PDUFA V). Conference call On 28 September 2015 at 8.00 am CEST, corresponding to 2.00 am EDT, a conference call for investors will be held. Investors will be able to listen in via a link on the investor section of novonordisk.com. Further information Company announcement No 58 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1252,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
489,2015-09-25,Novo Nordisk får FDA-godkendelse for Tresiba® og Ryzodeg® 70/30 i USA,"Bagsværd, den 25. september 2015 - Novo Nordisk meddeler i dag, at de amerikanske sundhedsmyndigheder (FDA) efter at have afsluttet behandlingen af de genindsendte registreringsansøgninger har godkendt Tresiba® og Ryzodeg® 70/30 til behandling af diabetes hos voksne. Tresiba®, det godkendte varemærke for insulin degludec, er en basal insulinanalog i en ny generation, der doseres én gang dagligt med en halveringstid på 25 timer og en virkningsvarighed på mindst 42 timer. I såkaldte treat to target-studier, som sammenlignede Tresiba® med insulin glargin, opnåede deltagere i behandling med Tresiba® en sammenlignelig reduktion i langtidsblodsukkerniveauet (HbA1c) og en numerisk større reduktion i fasteblodsukkeret ved brug af numerisk lavere doser af insulin i et flertal af studierne. Studierne viste desuden, at Tresiba® er den første basale insulin, der giver diabetikere mulighed for at tage deres basale insulin når som helst i løbet af dagen og samtidig mulighed for at justere injektionstidspunktet. Ryzodeg® 70/30, det godkendte varemærke for insulin degludec/insulin aspart, indeholder insulin degludec i en opløselig kombineret formulering med insulin aspart. Ryzodeg® 70/30 kan doseres én eller to gange dagligt sammen med et hovedmåltid. I et treat to target-studie til understøttelse af registreringsansøgningen, hvor Ryzodeg® 70/30 blev sammenlignet med NovoLog® Mix 70/30, viste Ryzodeg® 70/30 tilsvarende reduktioner i HbA1c. Novo Nordisk forventer at lancere Tresiba® i USA i første kvartal af 2016. Tresiba® vil blive markedsført i injektionspennen FlexTouch® og vil blive tilgængelig i to koncentrationer, som giver mulighed for maksimumdoser på henholdsvis 80 og 160 enheder pr. injektion. Den 26. marts 2015 meddelte Novo Nordisk, at virksomheden havde besluttet at genindsende registreringsansøgningerne efter gennemførelse af interimanalysen af DEVOTE-studiet, der undersøger forekomsten af hjerte-kar-sygdom i forbindelse med brug af insulin degludec. For at sikre integriteten i det igangværende DEVOTE-studie har kun en lille gruppe personer internt i Novo Nordisk adgang til dataene. Novo Nordisks ledelse har ikke adgang til resultaterne af interimanalysen. Det præspecificerede antal alvorlige kardiovaskulære tilfælde (MACE) til den fulde analyse forventes fortsat at være akkumuleret i studiet medio 2016. ""Vi er meget glade for FDA's beslutning om at godkende Tresiba® og Ryzodeg® 70/30, da vi mener, at disse produkter giver væsentlige fordele og vigtige behandlingsmuligheder for mennesker med type 1- og type 2-diabetes,"" siger Lars Rebien Sørensen, administrerende direktør for Novo Nordisk. ""Godkendelserne er en vigtig milepæl for Novo Nordisk, og vi ser frem til at gøre Tresiba® tilgængelig i USA."" I en separat handling meddeler Novo Nordisk desuden i dag, at virksomheden har indsendt registreringsansøgning til FDA for Xultophy®, det første kombinationsprodukt bestående af Tresiba® (insulin degludec) og Victoza® (liraglutid) til dosering én gang dagligt i én injektion. Ansøgningen forventes at blive behandlet i henhold til den amerikanske lov Prescription Drug User Fee Act V (PDUFA V). Der vil den 28. september 2015 kl. 08.00 CEST blive afholdt en telekonference for investorer. Investorer kan lytte med via et link under investorsektionen på novonordisk.com. Selskabsmeddelelse nr. 58 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1253,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
490,2015-09-25,Novo Nordisk successfully completes second phase 3a trial with semaglutide in people with type 2 diabetes,"Bagsværd, Denmark, 25 September 2015 - Novo Nordisk today announced the headline results from the second phase 3a trial for semaglutide, SUSTAIN3. Semaglutide is a new GLP-1 analogue administered subcutaneously once weekly. The trial investigated the efficacy and safety of 1.0 mg semaglutide compared with 2.0 mg exenatide once-weekly after 56 weeks of treatment added on to 1-2 oral antidiabetic drugs in 813 people with type 2 diabetes. The trial achieved its objective by demonstrating that from a mean baseline HbA1c of 8.4%, people treated with 1.0 mg semaglutide achieved a statistically significant and superior improvement in HbA1c of 1.5% compared to the improvement in HbA1c of 0.9% with 2.0 mg exenatide once-weekly. 66%* of the people treated with 1.0 mg semaglutide achieved the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) treatment target of HbA1c below 7% compared with 40% of the people treated with 2.0 mg exenatide once-weekly. Furthermore, from a mean baseline body weight of 96 kg, people treated with 1.0 mg semaglutide experienced a statistically significant and superior weight loss of 5.6 kg compared with a weight loss of 1.8 kg** for people treated with 2.0 mg exenatide once-weekly. In the trial, semaglutide appeared to have a safe and well-tolerated profile. The most common adverse event was nausea which diminished over time. Nausea was reported by 22% of people treated with 1.0 mg semaglutide once-weekly compared with 11%*** of people treated with 2.0 mg exenatide once-weekly. The discontinuation rate due to all adverse events for 1.0 mg semaglutide was 9.4% compared to 7.2% for 2.0 mg exenatide. ""We are excited about these trial results, which show that 1.0 mg semaglutide injected once weekly provided better glycaemic control and greater weight loss than 2.0 mg exenatide once-weekly,"" says Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""These results support that semaglutide has the potential to become the most efficacious GLP-1 product for people with type 2 diabetes. We look forward to further results from the SUSTAIN clinical development programme."" Novo Nordisk expects to announce headline results of the four remaining SUSTAIN trials within the next coming quarters. * In this section 66% must be replaced by 67% **In this section 1.8 kg must be replaced by 1.9 kg ***In this section 11% must be replaced by 12% About semaglutide Semaglutide is a new glucagon-like peptide-1 (GLP-1) analogue that can help people with type 2 diabetes achieve substantial improvement of blood glucose with a low risk of hypoglycaemia. In addition, semaglutide induces weight loss by decreasing appetite and food intake. Semaglutide administered once weekly is in development for the treatment of type 2 diabetes. About the SUSTAIN clinical programme The SUSTAIN programme is a phase 3 clinical programme comprising six global trials of semaglutide administered once weekly encompassing more than 7,000 people with type 2 diabetes. SUSTAIN 1 - a 30-week efficacy and safety trial of semaglutide versus placebo in 388 drug-naïve people with type 2 diabetes. SUSTAIN 2 - a 56-week efficacy and safety trial of semaglutide versus sitagliptin once-daily as add-on to metformin and/or TZD in 1,231 people with type 2 diabetes. SUSTAIN 3 - a 56-week efficacy and safety trial of semaglutide versus 2.0 mg exenatide once-weekly as add-on to 1-2 oral antidiabetic drugs in 813 people with type 2 diabetes. SUSTAIN 4 - a 30-week efficacy and safety trial of semaglutide versus insulin glargine once-daily as add-on to metformin with or without sulfonylurea in 1,089 insulin-naïve people with type 2 diabetes. SUSTAIN 5 - a 30-week efficacy and safety trial of semaglutide versus placebo as add-on to basal insulin alone or basal insulin in combination with metformin in 397 people with type 2 diabetes. SUSTAIN 6 - a 2-year trial to evaluate cardiovascular and other long-term outcomes with semaglutide in 3,297 people with type 2 diabetes. For further information Company announcement No 57 / 2015   ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1254,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
491,2015-09-25,Novo Nordisk afslutter med succes det andet fase 3a-studie med semaglutid til behandling af type 2-diabetes,"Bagsværd, den 25. september 2015 - Novo Nordisk offentliggør i dag de overordnede resultater fra det andet fase 3a-studie med semaglutid, SUSTAIN 3. Semaglutid er en ny GLP-1-analog, der doseres ved injektion i underhuden (subkutant) én gang ugentligt. Studiet undersøgte effekt og sikkerhed for 1,0 mg semaglutid sammenlignet med 2,0 mg exenatid én gang ugentligt efter 56 ugers behandling givet som supplement til 1-2 diabeteslægemidler i tabletform hos 813 mennesker med type 2-diabetes. Studiet opfyldte sit mål, idet det viste, at deltagere, som blev behandlet med 1,0 mg semaglutid, fra et gennemsnitligt langtidsblodsukkerniveau (HbA1c) på 8,4% ved studiets begyndelse opnåede en statistisk signifikant og større forbedring i HbA1c på 1,5% sammenlignet med en forbedring i HbA1c på 0,9% med 2,0 mg exenatid én gang ugentligt. 66%* af de deltagere, som blev behandlet med 1,0 mg semaglutid, nåede behandlingsmålet om HbA1c under 7% som anbefalet af American Diabetes Association (ADA) og European Association for the Study of Diabetes (EASD), mod 40% af dem, som blev behandlet med 2,0 mg exenatid én gang ugentligt. Fra en gennemsnitsvægt på 96 kg ved studiets begyndelse opnåede deltagere i behandling med 1,0 mg semaglutid desuden et statistisk signifikant og større vægttab på 5,6 kg sammenlignet med et vægttab på 1,8 kg* hos deltagere i behandling med 2,0 mg exenatid én gang ugentligt. Semaglutid forekom i studiet at have en sikker og veltolereret profil. Den mest almindelige bivirkning var kvalme, som aftog over tid. Kvalme blev rapporteret hos 22% af deltagere i behandling med 1,0 mg semaglutid én gang ugentligt, sammenlignet med 11%* af deltagere i behandling med 2,0 mg exenatid én gang ugentligt. Frafaldsprocenten som følge af alle bivirkninger for 1,0 mg semaglutid var 9,4% mod 7,2% for 2,0 mg exenatid. ""Vi er rigtig glade for resultaterne fra dette studie, som viser, at én ugentlig injektion af 1,0 mg semaglutid gav bedre blodsukkerregulering og større vægttab end 2,0 mg exenatid én gang ugentligt,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Disse resultater understøtter, at semaglutid har potentiale til at blive det mest virkningsfulde GLP-1-produkt for mennesker med type 2-diabetes. Vi glæder os til at se flere resultater fra det kliniske udviklingsprogram SUSTAIN."" Novo Nordisk forventer at offentliggøre de overordnede resultater fra de resterende fire SUSTAIN-studier i løbet af de næstkommende kvartaler. * I dette afsnit skal 66% erstattes af 67% ** I dette afsnit skal 1.8 kg erstattes af 1.9 kg  *** I dette afsnit skal 11% erstattes af 12% Om semaglutid Semaglutid er en ny GLP-1-analog (glukagonlignende peptid-1), som kan hjælpe mennesker med type 2-diabetes med at opnå en markant forbedring af blodsukkeret med lav risiko for hypoglykæmi. Semaglutid medfører endvidere vægttab ved at nedsætte appetit og madindtag. Semaglutid doseret én gang om ugen er under udvikling til behandling af type 2-diabetes. Om det kliniske udviklingsprogram SUSTAIN SUSTAIN er et klinisk fase 3-program, som omfatter seks globale studier med semaglutid doseret én gang om ugen med deltagelse af flere end 7.000 mennesker med type 2-diabetes. SUSTAIN 1 - et 30-ugers effekt- og sikkerhedsstudie, der undersøger semaglutid i forhold til placebo hos 388 deltagere med type 2-diabetes, som ikke tidligere har fået medicinsk behandling. SUSTAIN 2 - et 56-ugers effekt- og sikkerhedsstudie, der undersøger semaglutid i forhold til sitagliptin én gang dagligt som tillægsbehandling til metformin og/eller TZD hos 1.231 deltagere med type 2-diabetes. SUSTAIN 3 - et 56-ugers effekt- og sikkerhedsstudie, der undersøger semaglutid i forhold til 2,0 mg exenatid én gang ugentligt som tillægsbehandling til 1-2 diabeteslægemidler i tabletform hos 813 deltagere med type 2-diabetes. SUSTAIN 4 - et 30-ugers effekt- og sikkerhedsstudie, der undersøger semaglutid i forhold til insulin glargin én gang dagligt som tillægsbehandling til metformin med eller uden sulfonylurinstof hos 1.089 deltagere med type 2-diabetes, som ikke tidligere er blevet behandlet med insulin. SUSTAIN 5 - et 30-ugers effekt- og sikkerhedsstudie, der undersøger semaglutid i forhold til placebo som tillægsbehandling til basal insulin alene eller basal insulin i kombination med metformin hos 397 deltagere med type 2-diabetes. SUSTAIN 6 - et toårigt studie, der undersøger forekomsten af hjerte-kar-sygdom og andre langsigtede målepunkter ved brug af semaglutid hos 3.297 deltagere med type 2-diabetes. Yderligere information Selskabsmeddelelse nr. 57 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1255,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
492,2015-09-22,Novo Nordisk and the Food and Drug Administration of the Islamic Republic of Iran sign memorandum of understanding to build manufacturing facility in Iran,"Tehran, 22 September 2015 - Novo Nordisk today announced that Novo Nordisk Iran and the Food and Drug Administration of the Islamic Republic of Iran have signed a Memorandum of Understanding committing Novo Nordisk to build a local manufacturing plant for FlexPen® prefilled devices in Iran. The project is expected to last five years and represents a Novo Nordisk investment of approximately 70 million euros. The production will function in compliance with Good Manufacturing Practices (GMP), which will ensure the quality and reliability of the products. ""We are happy to commit to this manufacturing facility in Iran. It signals our long-term commitment to Iran, a country where close to 5 million people have diabetes according to the International Diabetes Federation. This investment will ensure availability of our modern insulins and will bring us a step closer to the people who rely on our products"", said Ole Moelskov Bech, corporate vice president of Novo Nordisk Business Area Near East. With construction of the new facility, Novo Nordisk will create 160 jobs; Novo Nordisk already employs around 130 people in Iran. UPDATE: This is an updated version of the original press release. In this version, the US investor contact has been deleted.  Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1256,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
493,2015-09-22,Novo Nordisk og de iranske sundhedsmyndigheder underskriver hensigtserklæring om byggeri af fabrik i Iran,"Teheran, Iran, den 22. september 2015 - Novo Nordisk meddeler i dag, at Novo Nordisk i Iran og de iranske sundhedsmyndigheder har underskrevet en hensigtserklæring om, at Novo Nordisk skal bygge en lokal fabrik til den præfyldte insulinpen FlexPen® i Iran. Projektet, som forventes at strække sig over fem år, repræsenterer en investering fra Novo Nordisk på ca. 70 mio. euro. Produktionen vil blive tilrettelagt i overensstemmelse med retningslinjerne for god produktionspraksis (GMP), hvilket vil sikre produkternes kvalitet og pålidelighed. ""Vi er glade for denne aftale om at etablere produktion i Iran. Den understreger vores langsigtede engagement i Iran, et land, hvor der ifølge International Diabetes Federation er tæt ved fem millioner mennesker med diabetes. Denne investering vil sikre tilgængeligheden af vores moderne insuliner og samtidig bringe os et skridt tættere på de mennesker, som er afhængige af vores produkter,"" siger Ole Mølskov Bech, leder af Novo Nordisk Business Area Near East. Opførelsen af den nye fabrik vil skabe 160 arbejdspladser. Novo Nordisk beskæftiger i forvejen omkring 130 medarbejdere i Iran. Yderligere information ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1257,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
494,2015-09-15,New study shows different perceptions of control among physicians and patients may lead to suboptimal type 2 diabetes management,"Download the full release Stockholm, Sweden, 15 September 2015 - Results presented today at the European Association for the Study of Diabetes (EASD) showed that increased awareness about how patients' and physicians' perceptions of control differ, could benefit physician-patient communication and improve diabetes management.1 New findings from the Perceptions of Control (POC) study showed adults with type 2 diabetes uncontrolled on basal insulin had a broader definition of control, perceived greater obstacles to maintaining control and that life was impacted significantly more than physicians expected.1 ""There is a significant gap in perceptions of control between physicians and patients in how they define control, the obstacles and how being uncontrolled on basal insulin impacts patients' daily lives,"" said Meryl Brod, PhD, lead investigator of the POC research study. ""Having a more open dialogue during consultations may provide more insight into these critical factors which could improve diabetes management and lead to more effective individualised treatment plans."" Further Information ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1260,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
495,2015-09-15,"Nyt studie viser, at type 2-diabetes ikke behandles optimalt, fordi læger og patienter ikke deler opfattelsen af, hvad god blodsukkerkontrol er","Download hele meddelelsen Stockholm, Sverige, den 15. september 2015 - Øget bevidsthed om forskelle i opfattelsen af god blodsukkerregulering blandt patienter og læger kan fremme kommunikationen mellem læger og patienter og i sidste ende forbedre behandlingen af diabetes.[i]Det fremgår af nye resultater fra studiet Perceptions of Control (POC), som præsenteres i dag på den europæiske diabeteskongres, European Association for the Study of Diabetes (EASD). Studiet viste, at voksne med type 2-diabetes, som ikke var tilfredsstillende reguleret med basal insulin, havde en bredere definition af, hvad det vil sige at være godt reguleret, oplevede større udfordringer i forhold til at være i god kontrol og følte, at diabetes forringede deres livskvalitet væsentligt mere, end lægerne forventede.1 ""Læger og patienter har vidt forskellige opfattelser af god blodsukkerregulering, både hvordan de definerer det, hvilke hindringer de ser, og hvordan det påvirker hverdagen for patienterne, når de ikke kan regulere deres blodsukker tilfredsstillende med basal insulin,"" siger ph.d. Meryl Brod, forsøgsansvarlig i POC-studiet. ""En mere åben dialog om disse spørgsmål i forbindelse med konsultationer vil kunne bidrage til øget indsigt og i sidste ende bidrage til at forbedre behandlingen af diabetes for den enkelte patient.""  [i]    Brod M, et al. Perceptions of diabetes control among physicians and patients with uncontrolled type 2 diabetes using basal insulin. Poster presentation (#890) at the 51st European Association for the Study of Diabetes (EASD) Annual Meeting, 16 September 2015.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1261,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
496,2015-09-07,Novo Nordisk and MIT to collaborate on researching the next generation of drug delivery devices,"Bagsværd, Denmark, 7 September 2015 - Novo Nordisk today announced that a research collaboration has been initiated with the Langer Laboratory at the Massachusetts Institute of Technology for what is hoped to be the next generation of drug delivery devices for the administration of peptides. The aim of the research collaboration, which is conducted at both MIT in Boston, US and at Novo Nordisk's research facilities in Måløv and Hillerød, Denmark, is to develop the next generation of drug delivery devices as an alternative to parenteral or injection-based delivery of peptides. Professor Robert Langer's laboratory are world-leading experts in creating new approaches for delivering drugs such as peptides and proteins across complex barriers in the body such as the blood-brain barrier, the intestine, the lung and the skin. Together with Dr Giovanni Traverso, a gastroenterologist and biomedical engineer at Harvard Medical School, and research affiliate of MIT, they will lead a team in the development of a platform enabling the oral delivery of peptides. There are many challenges of developing and producing a reliable peptide delivery vehicle. They include avoiding premature degradation in the body, overcoming poor peptide transport over epithelial barriers, limiting variability of absorption (caused, for example, by interaction with food in the stomach), and producing both peptide and the delivery vehicle in sufficient scale and numbers cost-effectively. If these challenges can be overcome, as recent research suggests, drug delivery devices hold great therapeutic promise for a plethora of diseases where patients need to take frequent injections. ""Drug delivery devices hold great potential and I am looking forward to this exciting research collaboration with one of the world's leading drug delivery laboratories,"" says Peter Kurtzhals, senior vice president and head of global research at Novo Nordisk. Robert Langer, professor and head of the Langer Laboratory at MIT, says, ""We are very excited to be doing research sponsored by Novo Nordisk to address one of the current greatest challenges in drug delivery"". The collaboration will establish a number of research positions to be hosted by the Langer Laboratory and funded by Novo Nordisk. The initial term of the collaboration is three years with the option to extend for up to three additional years. ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1264,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
497,2015-09-07,Novo Nordisk og MIT indleder samarbejde om forskning i næste generation af doseringssystemer til lægemidler,"Bagsværd, den 7. september 2015 - Novo Nordisk har i dag meddelt, at de har indgået et forskningssamarbejde med Langer Laboratory ved Massachusetts Institute of Technology (MIT) om det, der forhåbentlig bliver den næste generation af doseringssystemer til peptid-baserede lægemidler. Målet med forskningssamarbejdet, som foregår på både MIT i Boston, USA, og på Novo Nordisks forskningscentre i Måløv og Hillerød, er at udvikle næste generation af doseringssystemer til lægemidler som alternativ til parenteral- eller injektionsbaseret dosering af peptider. I professor Robert Langers laboratorium arbejder verdens førende eksperter med at udvikle nye metoder til dosering af lægemidler som f.eks. peptider og proteiner over komplekse barrierer i kroppen, f.eks. blod-hjerne-barrieren, tarmsystemet, lungerne og huden. Sammen med Dr. Giovanni Traverso, mave-tarmspecialist og biomediciner på Harvard Medical School, som er tilknyttet MIT, står de i spidsen for et team, der skal udvikle en platform, som gør det muligt at dosere peptider oralt. Der er mange udfordringer forbundet med at udvikle og fremstille et pålideligt peptid-doseringssystem. Disse omfatter at forhindre for tidlig nedbrydning i kroppen, at afhjælpe dårlig peptidtransport over epitelbarrierer, at begrænse absorptionsvariabilitet (f.eks. forårsaget af interaktion med føde i maven) samt at fremstille både peptid og doseringssystem i tilstrækkelige mængder på en omkostningseffektiv måde. Hvis disse udfordringer kan løses, hvilket ny forskning tyder på, er der gode fremtidige behandlingsmuligheder med denne type af doseringssystemer ved en lang række sygdomme, hvor patienterne i dag har brug for hyppige injektioner. ""Der er et stort potentiale for disse nye doseringssystemer til lægemidler, og jeg glæder mig til dette spændende samarbejde med et af verdens førende laboratorier indenfor dette felt,"" siger Peter Kurtzhals, koncerndirektør med ansvar for Global Research hos Novo Nordisk. ""Vi er meget glade for at udføre forskning sponsoreret af Novo Nordisk med det formål at løse en af de største udfordringer i lægemiddeladministration i dag"", udtaler Robert Langer, professor og chef for Langer Laboratory ved MIT. Som led i samarbejdet oprettes en række forskerstillinger ved Langer Laboratory finansieret af Novo Nordisk. I første omgang varer samarbejdet i tre år, og Novo Nordisk har mulighed for at forlænge med yderligere tre år. ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1265,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
498,2015-09-03,Novo Nordisk invests DKK 500 million in a new raw material warehouse in Denmark,"Bagsværd, Denmark, 3 September 2015 - Novo Nordisk just announced that the company is investing 500 million Danish kroner in a new 19,000 m2 warehouse in Hillerød, Denmark. The warehouse will handle all inbound raw materials for Novo Nordisk's production in Denmark and will have a capacity of around 17,000 pallets. Novo Nordisk's site in Hillerød currently has about 1,900 employees and 70 employees will work in the warehouse. ""The investment in Hillerød underpins our long-term plans to invest in Denmark. Hillerød is a strategic site in Novo Nordisk and we're consolidating our inbound flow of materials at this site,"" said Susanne Hundsbæk-Pedersen, senior vice president of Devices & Supply Chain Management, Novo Nordisk. Groundbreaking will take place today, 3 September, and the warehouse is expected to be fully operational end 2017. Established in 1992, the Hillerød site has a total area of about 1,650,000 m2 of which about 90,000 m2 is used for production and R&D facilities. The site encompasses a facility for Device R&D and three production facilities. One with moulding and pre-assembly of components, one with filling, assembly and packaging of diabetes finished products and one with production of haemophilia API. Novo Nordisk has made ongoing investments on the site of approx 350 million per year in average. Further information ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1268,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
499,2015-09-03,Novo Nordisk investerer 500 mio. kr. i nyt råvarelager i Hillerød,"Bagsværd, den 3. september 2015 - Novo Nordisk investerer 500 mio. kr. i nye lagerfaciliteter på 19.000 m2 i Hillerød. Lageret skal håndtere alle indgående råvarer til Novo Nordisks produktion i Danmark og får en kapacitet på omkring 17.000 paller. Novo Nordisks fabrik i Hillerød har i dag omkring 1.900 medarbejdere, og lageret vil beskæftige 70 medarbejdere. ""Investeringen i Hillerød understreger vores langsigtede planer om at investere i Danmark. Hillerød er et af Novo Nordisks strategiske produktionssteder, og vi ønsker at samle vores indgående flow af råvarer her,"" siger Susanne Hundsbæk-Pedersen, direktør for Devices & Supply Chain Management i Novo Nordisk. Første spadestik bliver taget i dag, den 3. september, og råvarelagret forventes at være i fuld drift i slutningen af 2017. Om Novo Nordisk i Hillerød Fabriksparken i Hillerød blev grundlagt i 1992 med et samlet areal på omkring 1.650.000 m2, hvoraf omkring 90.000 m2 anvendes til produktion, forskning og udvikling. Området huser faciliteter til forskning og udvikling indenfor Novo Nordisks injektionspenne samt tre produktionsanlæg: en fabrik til støbning og præmontage af komponenter, en til påfyldning, montage og pakning af diabetesfærdigvarer og en til fremstilling af aktive lægemiddelstoffer til blødermedicin. Novo Nordisk har løbende foretaget investeringer i fabriksparken på i gennemsnit omkring 350 mio. kr. om året. ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1269,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
500,2015-08-27,Novo Nordisk to acquire Calibrium LLC and MB2 LLC,"Acquisition expands Novo Nordisk's portfolio of projects within diabetes and obesity Bagsværd, Denmark, 27 August 2015 - Novo Nordisk today announced that it has entered into a definitive agreement under which Novo Nordisk will acquire Calibrium LLC and MB2 LLC, two privately held biopharmaceutical research companies based in Indiana, US. Formed in 2013 and 2014, respectively, Calibrium and MB2 are focused on developing a portfolio of novel drug candidates for the treatment of diabetes and related metabolic diseases. The acquisition will expand Novo Nordisk's portfolio of projects and intellectual property rights within diabetes and obesity and provide a basis for expanding Novo Nordisk's research presence in the US. Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk says: ""We are always on the lookout for ways to strengthen our leadership position within therapeutic proteins. This research team has demonstrated world-class capabilities in protein design and created a project portfolio of innovative product leads that fit very well with our aspirations within diabetes and obesity."" Dr Richard DiMarchi, chief scientific officer and co-founder of Calibrium and MB2 says: ""It's an honour to join the global Novo Nordisk research community. Their intense focus on metabolic diseases, which over the years has led to numerous breakthrough protein-based medicines, aligns perfectly with my career-long priorities. I'm optimistic that together we can create novel, transformative therapies in the fight against the global epidemic of diabetes and obesity."" The parties have agreed not to disclose the financial details of the transactions. The closing of the transaction is subject to US regulatory approval and is expected to occur during the third quarter of 2015. Calibrium is an emerging biopharmaceutical company focused on the discovery and early development of novel peptides for the treatment of diabetes and related metabolic diseases. Calibrium was co-founded by Fritz French, chief executive officer, and Richard DiMarchi, PhD, chief scientific officer. MB2 is a clinical-stage biopharmaceutical company advancing a pipeline of first-in-class, mixed agonist drugs for the treatment of diabetes and obesity. MB2 was co-founded by Kent Hawryluk, chief executive officer and Richard DiMarchi, PhD, chief scientific officer. Both companies are privately held and located in Carmel, IN, US. ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1272,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
501,2015-08-27,Novo Nordisk køber Calibrium LLC og MB2 LLC,"Købet udvider Novo Nordisks portefølje af projekter indenfor diabetes og fedme Bagsværd, den 27. august 2015 - Novo Nordisk meddeler i dag, at virksomheden har indgået en endelig aftale om at købe Calibrium LLC og MB2 LLC, to privatejede biofarmaceutiske forskningsvirksomheder, der er baseret i Indiana i USA. Calibrium og MB2 er etableret i henholdsvis 2013 og 2014 og fokuserer på at udvikle en portefølje af nye lægemiddelkandidater til behandling af diabetes og relaterede metaboliske sygdomme. Købet af de to virksomheder vil udvide Novo Nordisks portefølje af projekter og immaterielle rettigheder indenfor diabetes og fedme og danne grundlag for en udvidelse af Novo Nordisks forskningsaktiviteter i USA. Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk, siger: ""Vi er altid på udkig efter muligheder, der kan styrke vores lederskab indenfor terapeutiske proteiner. Dette forskningsteam har vist kompetencer i verdensklasse indenfor proteindesign og har skabt en projektportefølje af innovative produktkandidater, som passer rigtig godt sammen med vores ambitioner indenfor diabetes og fedme."" Dr. Richard DiMarchi, forskningsdirektør og medstifter af Calibrium og MB2, siger: ""Det er en ære at blive en del af Novo Nordisks globale forskningsmiljø. Deres intense fokus på metaboliske sygdomme, som gennem årene har resulteret i adskillige banebrydende proteinbaserede lægemidler, stemmer helt perfekt med mine egne prioriteringer gennem hele min karriere. Jeg er overbevist om, at vi sammen kan skabe nye, transformative behandlingsmuligheder i kampen mod den globale diabetes- og fedmeepidemi."" Parterne har aftalt ikke at oplyse om de finansielle vilkår for transaktionerne. Transaktionen er betinget af de amerikanske myndigheders godkendelse og forventes afsluttet i tredje kvartal af 2015. Calibrium er en relativt ny biofarmaceutisk virksomhed, der fokuserer på opdagelse og tidlig udvikling af nye peptider til behandling af diabetes og relaterede metaboliske sygdomme. Calibrium er stiftet af Fritz French, administrerende direktør, og Richard DiMarchi, ph.d., forskningsdirektør. MB2 er en klinisk biofarmaceutisk virksomhed, som arbejder med en pipeline af førende kombinerede agonister til behandling af diabetes og fedme. MB2 er stiftet af Kent Hawryluk, administrerende direktør, og Richard DiMarchi, ph.d., forskningsdirektør. Begge virksomheder er privatejede og placeret i Carmel, Indiana, USA.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1273,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
502,2015-08-26,Novo Nordisk planlægger at investere 2 mia. dollars i nye fabrikker i USA og Danmark,"Bagsværd, den 26. august 2015 - Novo Nordisk har planer om at investere anslået 2 mia. US dollars over de næste fem år i nye fabrikker i Clayton i USA og Måløv i Danmark. Udvidelserne skal hjælpe Novo Nordisk med at dække den stigende globale efterspørgsel efter virksomhedens diabetesmedicin. I en separat selskabsmeddelelse tidligere i dag meddelte Novo Nordisk, at det er besluttet at påbegynde fase 3a-udvikling af oral semaglutid, en GLP-1-analog i tabletform til dosering én gang dagligt til behandling af type 2-diabetes (selskabsmeddelelse nr. 52/2015). Fabrikken i Clayton skal fremstille aktive lægemiddelstoffer (API) til såvel oral semaglutid som en række af Novo Nordisks eksisterende og fremtidige GLP-1- og insulinprodukter. Investeringen ventes at skabe op mod 700 nye produktions- og ingeniørjobs i Clayton, hvor Novo Nordisk i forvejen beskæftiger flere end 700 medarbejdere. Novo Nordisk har desuden planer om at etablere en ny fabrik i Måløv til tabletformulering og pakning af oral semaglutid og fremtidige tabletprodukter. Investeringen i Måløv ventes at skabe omkring 100 nye arbejdspladser. ""Med den nye fabrik i Clayton og løbende investeringer i vores eksisterende API-produktionsanlæg i Kalundborg får vi tilstrækkelig API-kapacitet til diabetesprodukter langt ind i det næste årti,"" siger Henrik Wulff, koncerndirektør med ansvar for Novo Nordisks globale produktion. ""Vi besluttede at placere den nye API-fabrik i USA af strategiske årsager,"" tilføjer Henrik Wulff. ""USA er langt det største marked for os, og der er mange logistiske og økonomiske fordele ved at have en større del af produktionen i vores primære marked. Efter en grundig gennemgang og evaluering af flere forskellige mulige produktionssteder endte Clayton som vores foretrukne placering. Vi har allerede en stor og meget professionel organisation på stedet og et fremragende samarbejde med de kommunale, lokale og statslige myndigheder, og vi værdsætter de incitamenter, de har sikret i forbindelse med denne investering."" Den endelige projekt- og investeringsplan for de nye fabrikker vil blive præsenteret til godkendelse i Novo Nordisks bestyrelse i 2016. Fabrikkerne forventes at være i drift i 2020. Om Novo Nordisks produktionssteder i Clayton, Kalundborg og MåløvNovo Nordisks eksisterende fabrik i Clayton, North Carolina, blev taget i brug i 1993 og er udvidet flere gange siden da. Fabrikken er i dag et af virksomhedens strategiske produktionssteder og udfører formulering, påfyldning og pakning af lægemidler til behandling af diabetes. Fabrikken udfører desuden montage og pakning af de præfyldte insulinpenne FlexPen® og FlexTouch® til det amerikanske marked. Fabriksparken i Kalundborg blev grundlagt i 1969 og er det største produktionsanlæg i Novo Nordisks globale produktionsnetværk. Området huser flere fabrikker til fremstilling af lægemidler til behandling af diabetes og hæmofili (blødersygdom) og beskæftiger over 2.800 medarbejdere. Der forventes at blive skabt flere hundrede nye jobs i de kommende år som resultat af igangværende og fremtidige investeringer i fabrikkerne. Fabrikken i Måløv beskæftiger i dag 250 medarbejdere, som fremstiller hormonpræparater (HRT) i tabletform. Den nuværende fabrik er nabo til Novo Nordisks største forsknings- og udviklingscampus, som beskæftiger flere end 2.300 medarbejdere. Fotos samt b-roll fra Novo Nordisks produktionssteder kan downloades fra novonordisk.com.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1275,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
503,2015-08-26,"Novo Nordisk plans 2 billion US dollar investment in new production facilities in Clayton, North Carolina and Måløv, Denmark","Bagsværd, Denmark, 26 August 2015 - Novo Nordisk plans to invest an estimated 2 billion US dollars over the next five years in new production facilities in Clayton, North Carolina, US and Måløv, Denmark. The expansions will help Novo Nordisk meet the increasing worldwide demand for its diabetes medicines. In a separate company announcement today, Novo Nordisk announced a decision to initiate phase 3a development of oral semaglutide, a GLP-1 analogue formulated as a once-daily tablet for the treatment of type 2 diabetes (company announcement 52/2015). The facilities in Clayton will produce active pharmaceutical ingredients (API) for both oral semaglutide and a range of Novo Nordisk's current and future GLP-1 and insulin products. The investment is estimated to create close to 700 new production and engineering jobs in Clayton where Novo Nordisk already employs more than 700 people. Novo Nordisk also plans to establish a new production facility in Måløv, Denmark for tableting and packaging of oral semaglutide and future oral products. The investment in Måløv will create an estimated 100 new jobs. ""With the new plant in Clayton and continuous investments in our current API production plants in Kalundborg, Denmark, we will have sufficient API capacity for diabetes products well into the next decade,"" says Henrik Wulff, executive vice president and head of Product Supply at Novo Nordisk. ""We decided to place the new API facilities in the US for strategic reasons,"" adds Henrik Wulff. ""The US is by far our largest market and there are many logistical and economic advantages of having a larger part of our manufacturing in our main market. After a thorough evaluation of multiple sites and an extensive vetting process, Clayton ended up being our preferred location. We already have a large and very professional organisation there and an excellent collaboration with city, local and state leadership, and we appreciate the incentives they have secured in connection with this investment."" The final design and cost of the new production facilities will be presented for approval by the company's board of directors in 2016. The facilities are expected to be operational during 2020. About Novo Nordisk's production sites in Clayton, Kalundborg and Måløv Expanded several times since it went into operation in 1993, Novo Nordisk's current plant in Clayton, NC is today one of the company's strategic production sites responsible for formulation, filling and packaging of diabetes care products. The plant also assembles and packages the FlexPen® and FlexTouch® prefilled insulin device for the US market. Established in 1969, the Kalundborg production site is the largest in Novo Nordisk's global manufacturing network. Housing several production plants for both diabetes and haemophilia products, the site employs more than 2,800 people. Several hundred new jobs are expected in the coming years as a result of ongoing and future investments in the plants. In Måløv, 250 employees today produce tablets for hormone replacement therapy. The current plant is located next door to Novo Nordisk's largest Research & Development campus, which employs more than 2,300 employees. Visit novonordisk.com for photos or b-roll of Novo Nordisk production sites.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1274,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
504,2015-08-26,"Novo Nordisk to initiate phase 3a development of oral semaglutide, a once-daily oral GLP-1 analogue","Bagsværd, Denmark, 26 August 2015 - Novo Nordisk today announced the decision to initiate a phase 3a programme with oral semaglutide; a once-daily oral formulation of the long-acting GLP-1 analogue semaglutide. The decision follows the encouraging results of the proof-of-concept phase 2 trial announced on 20 February 2015 and the subsequent consultations with regulatory authorities. Novo Nordisk intends to initiate a global phase 3a programme, named PIONEER, comprising seven trials with approximately 8,000 people with type 2 diabetes. The PIONEER programme will include six safety and efficacy trials and one trial for evaluating the cardio-vascular safety of oral semaglutide. The first trial in the programme is planned for initiation in first quarter of 2016 and will investigate the efficacy and safety of once-daily oral semaglutide doses of 3 mg, 7 mg and 14 mg, compared to once-daily oral anti-diabetic sitagliptin dose of 100 mg. The remaining six trials of the PIONEER programme are all expected to be initiated during 2016. In order to meet capacity requirements for current and future diabetes care products, including oral semaglutide, Novo Nordisk expects to invest an estimated 2 billion US dollars over the coming five years in two new production facilities; a new production facility for a range of active pharmaceutical ingredients in Clayton, North Carolina, US and a new drug-product facility in Måløv, Denmark. The final design and cost of the new production facilities will be presented for approval by the company's board of directors in 2016. ""Delivering protein-based medicine like semaglutide in the form of a tablet and producing it on a large scale is a major challenge, and with the announcement today we have reached a significant milestone towards achieving that goal"", said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""We are excited about the opportunities oral semaglutide represents as a new oral anti-diabetic agent to further improve type 2 diabetes treatment"". Semaglutide (NN9924) is a new glucagon-like peptide-1 (GLP-1) analogue that can help people with type 2 diabetes achieve substantial lowering of blood glucose with a low risk of hypoglycaemia. In addition, semaglutide induces weight loss by decreasing appetite and food intake. The oral formulation of semaglutide is provided in a tablet formulation with SNAC, an absorption-enhancing excipient included in the Eligen® Carrier Concept. The Eligen® technology is licenced from Emisphere Technologies, Inc. Further information Company announcement No 52 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1276,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
505,2015-08-26,"Novo Nordisk påbegynder fase 3a-udvikling af oral semaglutid, en GLP-1-analog i tabletform til dosering én gang dagligt","Bagsværd, den 26. august 2015 - Novo Nordisk meddeler i dag, at det er besluttet at påbegynde et fase 3a-program med oral semaglutid, en tabletformulering af den langtidsvirkende GLP-1-analog semaglutid til dosering én gang dagligt. Beslutningen er truffet på baggrund af de positive resultater fra fase 2-studiet (proof of concept), som blev rapporteret den 20. februar 2015, samt de efterfølgende drøftelser med registreringsmyndighederne. Novo Nordisk forventer at påbegynde et globalt fase 3a-program med navnet PIONEER, som vil omfatte syv studier med i alt ca. 8.000 deltagere med type 2-diabetes. PIONEER-programmet vil omfatte seks sikkerheds- og effektstudier foruden et studie, der skal undersøge hjerte-kar-sikkerheden for oral semaglutid. Det første studie i programmet forventes påbegyndt i første kvartal af 2016 og vil undersøge effekt og sikkerhed for oral semaglutid givet én gang dagligt i doser på 3 mg, 7 mg og 14 mg sammenlignet med én daglig dosis på 100 mg af oral sitagliptin, et diabeteslægemiddel i tabletform. De resterende seks studier i PIONEER-programmet ventes alle at blive påbegyndt i løbet af 2016. For at imødekomme kapacitetsbehov i relation til eksisterende og kommende produkter til behandling af diabetes, herunder oral semaglutid, forventer Novo Nordisk at investere anslået 2 mia. US dollars over de næste fem år i to nye fabrikker: et nyt produktionsanlæg til fremstilling af en række aktive lægemiddelstoffer i Clayton, North Carolina i USA, samt en ny færdigvarefabrik i Måløv i Danmark. Den endelige projekt- og investeringsplan for de nye fabrikker vil blive præsenteret til godkendelse i Novo Nordisks bestyrelse i 2016. ""Det er en stor udfordring at fremstille proteinbaserede lægemidler som semaglutid i tabletform og producere dem i stor skala, og med den beslutning, vi har meldt ud i dag, har vi nået en vigtig milepæl på vejen til at nå det mål,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Vi er spændte på de muligheder, oral semaglutid repræsenterer som et nyt diabeteslægemiddel i tabletform i forhold til yderligere at forbedre behandlingen af type 2-diabetes."" Semaglutid (NN9924) er en ny GLP-1-analog (glukagonlignende peptid-1), som kan hjælpe mennesker med type 2-diabetes med at opnå en markant forbedring af blodsukkeret med lav risiko for hypoglykæmi (lavt blodsukker). Semaglutid medfører endvidere vægttab ved at nedsætte appetit og madindtag. Den orale udgave af semaglutid er en tabletformulering med et absorptionsfremmende hjælpestof, SNAC, som er en del af Eligen® Carrier Concept. Eligen® teknologien er licenseret fra Emisphere Technologies, Inc.  Yderligere information Selskabsmeddelelse nr. 52 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1277,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
506,2015-08-24,Novo Nordisk afslutter andet og sidste fase 3a-studie med liraglutid som tillægsbehandling til insulin ved behandling af type 1-diabetes (NN9211),"Bagsværd, den 24. august 2015 - Novo Nordisk offentliggør i dag de overordnede resultater fra det andet og sidste fase 3a-studie med liraglutid som tillægsbehandling til insulin til behandling af mennesker med type 1-diabetes. ADJUNCT ONE(TM) er et randomiseret, dobbeltblindet, placebokontrolleret studie, der undersøger effekt og sikkerhed for daglige doser på 0,6 mg, 1,2 mg og 1,8 mg liraglutid sammenlignet med placebo som tillægsbehandling til insulin. 1.398 deltagere med type 1-diabetes blev behandlet i 52 uger. Fra et gennemsnitligt langtidsblodsukkerniveau (HbA1c) på omkring 8,2% ved studiets begyndelse opnåede deltagere, der blev behandlet med 1,2 mg og 1,8 mg liraglutid som tillægsbehandling til insulin, det primære mål om ikke-inferiøritet for HbA1c og viste en større forbedring i HbA1c på omkring 0,5% sammenlignet med 0,3% for deltagere, der fik placebo. Det primære mål om ikke-inferiøritet for HbA1c blev ikke bekræftet for doseringen på 0,6 mg. Fra en gennemsnitsvægt på omkring 86 kg ved studiets begyndelse opnåede deltagere, der blev behandlet med 1,2 mg og 1,8 mg liraglutid som tillægsbehandling til insulin, endvidere et statistisk signifikant større vægttab på mellem 3 kg og 4 kg, mens deltagere, der fik placebo, oplevede en vægtstigning på omkring 1 kg. I studiet var de mest almindelige bivirkninger relateret til mave-tarm-systemet, primært forbigående kvalme og opkastning. Forekomsten af svær hypoglykæmi (lavt blodsukker) var numerisk lavere, omend forskellen ikke var statistisk signifikant, for alle doseringer af liraglutid som tillægsbehandling til insulin sammenlignet med placebo. Der blev observeret en statistisk signifikant højere forekomst af bekræftet symptomatisk hypoglykæmi blandt deltagere, der blev behandlet med 1,2 mg og 1,8 mg liraglutid, sammenlignet med deltagere, der fik placebo. Andelen af deltagere med alvorlige bivirkninger var sammenlignelig i alle behandlingsgrupper. Baseret på en risk/benefit-vurdering af det samlede datasæt fra de to ADJUNCT-studier har Novo Nordisk for nærværende ikke til hensigt at indsende ansøgning om en indikationsudvidelse for Victoza® til brug i type 1-diabetes. Novo Nordisk vil gennemføre grundige analyser med henblik på at evaluere de kliniske data og definere potentielle fremtidige kliniske og regulatoriske initiativer. ""Resultaterne fra de to ADJUNCT-studier viser, at liraglutid givet som tillægsbehandling til insulin opfyldte det primære mål om at forbedre blodsukkerreguleringen for mennesker med type 1-diabetes, men desværre uden fordelen i forhold til hypoglykæmi, som vi har set indenfor type 2-diabetes,"" siger Mads Krogsgaard Thomsen, koncerndirektør for forskning og udvikling i Novo Nordisk. ""Vi er skuffede, fordi vi troede på dets potentiale til at give mennesker med type 1-diabetes en ny behandlingsmulighed, og vi vil fortsætte med at investere i nye behandlingsmuligheder til denne gruppe mennesker."" Liraglutid er en human analog af det naturligt forekommende hormon glukagonlignende peptid-1 (GLP-1) til dosering én gang dagligt. Præparatet er godkendt til behandling af type 2-diabetes og er p.t. i fase 3 af det kliniske udviklingsforløb til behandling af type 1-diabetes som tillægsbehandling til insulin. Liraglutid virker ved kun at stimulere insulinsekretionen, når blodsukkerniveauet er for højt, mens leverens glukagonproduktion hæmmes, samt ved at hæmme appetitten. I modsætning til de fleste andre diabeteslægemidler medfører liraglutid desuden vægttab i stedet for vægtstigning. Det kliniske fase 3-program ADJUNCT omfatter to globale studier af liraglutid som tillægsbehandling til insulin med tilsammen flere end 2.000 deltagere med type 1-diabetes. ADJUNCT ONE(TM) (1.398 deltagere randomiseret) - et 52-ugers dobbeltblindet, placebokontrolleret treat-to-target-studie, der undersøger liraglutid som tillægsbehandling til insulin. ADJUNCT TWO(TM) (835 deltagere randomiseret) - et 26-ugers dobbeltblindet, placebokontrolleret studie med en fast øvre grænse for dosering af insulin for derved at undersøge den yderligere effekt på blodsukkerreguleringen, der opnås ved brug af liraglutid som tillægsbehandling til insulin. Resultaterne fra dette studie blev offentliggjort den 6. august 2015.  Yderligere information Selskabsmeddelelse nr. 51 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1279,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
507,2015-08-24,Novo Nordisk completes second and final phase 3a trial with liraglutide as adjunct therapy to insulin for people with type 1 diabetes (NN9211),"Bagsværd, Denmark, 24 August 2015 - Novo Nordisk today announced headline results from the second and final phase 3a trial with liraglutide as adjunct therapy to insulin for people with type 1 diabetes. ADJUNCT ONE(TM) is a randomised, double-blind, placebo-controlled trial investigating efficacy and safety of daily doses of 0.6 mg, 1.2 mg and 1.8 mg liraglutide compared with placebo as adjunct to insulin treatment. 1,398 people with type 1 diabetes were treated for 52 weeks. From a mean baseline HbA1c of around 8.2%, people treated with 1.2 mg and 1.8 mg liraglutide as adjunct to insulin therapy achieved the primary objective of non-inferiority in HbA1c and showed a greater improvement in HbA1c of around 0.5% compared with 0.3% for people treated with placebo. The primary objective of HbA1c non-inferiority was not confirmed for the 0.6 mg dose. Furthermore, from a mean baseline weight of around 86 kg, people treated with 1.2 mg and 1.8 mg liraglutide as adjunct to insulin therapy achieved a statistically significantly greater weight loss between 3 kg and 4 kg whereas people treated with placebo experienced a weight gain of around 1 kg. In the trial, the most common adverse events were related to the gastrointestinal system, primarily transient nausea and vomiting. The rate of severe hypoglycaemia appeared numerically, but not statistically significantly lower for all doses of liraglutide as adjunct to insulin therapy compared with placebo. A statistically significant higher rate of confirmed symptomatic hypoglycaemia was observed among people treated with liraglutide 1.2 mg and 1.8 mg compared with people treated with placebo. The proportion of people with serious adverse events was similar in all treatment groups. Based on a risk/benefit assessment of the overall dataset from the two ADJUNCT trials, Novo Nordisk does currently not intend to submit an application to expand the label of Victoza® for use in type 1 diabetes. Novo Nordisk intends to conduct thorough analyses to evaluate the clinical data and define potential future clinical and regulatory initiatives. ""The results of the two ADJUNCT trials show that liraglutide as adjunct to insulin therapy met the primary end-point of improving blood glucose control for people with type 1 diabetes, however, unfortunately without the hypoglycaemic benefit experienced in type 2 diabetes "" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""We are disappointed as we believed in the potential to provide people with type 1 diabetes with a new treatment option, and we will continue to invest in new treatment options for this group of people."" Liraglutide is a once-daily human analogue of the naturally occurring hormone Glucagon-Like Peptide-1 (GLP-1). The compound is approved for the treatment of type 2 diabetes, and is currently in phase 3 development for the treatment of type 1 diabetes as adjunct to insulin therapy. Liraglutide works by stimulating the release of insulin only when glucose levels become too high, supressing the glucagon production by the liver and by inhibiting appetite. In contrast to most other antidiabetic treatments, liraglutide also leads to weight loss instead of weight increase. The ADJUNCT programme is a phase 3 clinical programme comprising two global trials of liraglutide as adjunct to insulin therapy encompassing more than 2,000 people with type 1 diabetes. ADJUNCT ONE(TM) (1,398 people randomised) - a 52-week, double-blind, placebo-controlled treat-to-target trial investigating liraglutide as adjunct to insulin therapy. ADJUNCT TWO(TM) (835 people randomised) - a 26-week, double-blind, insulin-capped, placebo-controlled trial investigating the additional glucose control of liraglutide as adjunct to insulin therapy. The results were announced on 6 August 2015. Further information  Company announcement No 51 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1278,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
508,2015-08-06,Novo Nordisk increased operating profit in Danish kroner by 57% in the first six months of 2015 to DKK 26.3 billion,"16% local currency operating profit growth adjusted for the NNIT divestment Sales increased by 25% in Danish kroner and by 9% in local currencies to DKK 52.3 billion. Gross margin improved by 2.2 percentage points in Danish kroner to 85.2% driven by a positive currency impact and product mix. Operating profit increased by 57% in Danish kroner and by 30% in local currencies to DKK 26.3 billion. Adjusted for the DKK 2.4 billion non-recurring income related to the partial divestment of NNIT, operating profit in local currencies increased by 16%. Net profit increased by 35% to DKK 18.2 billion. Diluted earnings per share increased by 38% to DKK 7.02. Adjusted for the partial divestment of NNIT, net profit and diluted earnings per share increased by 20% and 22% respectively. In July, Novo Nordisk announced the successful completion of the first phase 3a trial with semaglutide, a new GLP-1 analogue to be administered subcutaneously once weekly. Novo Nordisk successfully completed the first phase 3a trial with liraglutide as adjunct therapy to insulin for people with type 1 diabetes, in July. For 2015, sales growth measured in local currencies is still expected to be 7-9%, whereas operating profit growth measured in local currencies is raised by two percentage points and now expected to be around 19%. Lars Rebien Sørensen, President and CEO: ""We are satisfied with the results of the first six months of 2015, during which Victoza® and Levemir® continued to drive sales growth. In the second quarter, we have successfully launched NovoEight® and Saxenda® in the US and announced positive results from the first phase 3a trial for semaglutide, our once-weekly GLP-1 analogue."" Contacts for further information  Company announcement No 46 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1288,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
509,2015-08-06,"Novo Nordisks resultat af primær drift opgjort i kroner steg med 57% i første halvår af 2015 til 26,3 mia. kr.",Kontaktoplysninger,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1289,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
510,2015-07-28,"Team Novo Nordisk, the world's first all-diabetes professional cycling team, to race in Post Danmark Rundt for third consecutive year","Bagsværd, Denmark, 28 July 2015 - Team Novo Nordisk, the world's first all-diabetes professional cycling team, returns to Denmark for its third appearance at the six-stage Post Danmark Rundt, beginning in Struer 4 August. Last year, Team Novo Nordisk got its first jersey at the race when veteran Chris Williams (AUS) earned most aggressive rider honours on Stage 4, following a bold late race move that saw the Australian nearly hold on for a solo win. This year, the team arrives with its best results since launching in December 2012. As of July, Team Novo Nordisk earned its first win, three podium appearances and 26 top 10 finishes. ""Last year's Post Danmark Rundt was bitter sweet. I earned the award for attacking and racing hard, but I also missed a chance to stand on the podium by metres,"" Williams said. ""I plan to race aggressively again this year and hopefully go one better. Our team loves to race in Denmark. We see Novo Nordisk flags flying along the course and the cheers from our fans keep us motivated."" The team's mission is to inspire, educate and empower people affected by diabetes. Every day at the start and finish of each stage, there will be a Changing Diabetes® tent where it will be possible to meet the riders and learn more about diabetes. Medier:Lars Pallisgaard        +45 3079 3730         lplg@novonordisk.com",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1293,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
511,2015-07-28,Team Novo Nordisk stiller for tredje år i træk til start i Post Danmark Rundt,"Bagsværd, den 28. juli 2015 - Team Novo Nordisk, verdens første professionelle cykelhold bestående udelukkende af cykelryttere med diabetes, er for tredje gang tilbage i Danmark for at køre de seks etaper i Post Danmark Rundt fra 4. til 8. august. Sidste år vandt Team Novo Nordisk for første gang en etapetrøje, da veteranen Chris Williams (AUS) blev udnævnt til 'Dagens fighter' på 4. etape, hvor et modigt angreb på etapens sidste del var tæt på at få ham på sejrsskamlen. I år stiller holdet til start med de hidtil bedste resultater siden stiftelsen i december 2012, herunder holdets første etapesejr, tre podieplaceringer og 26 Top 10-placeringer. ""Sidste års Post Danmark Rundt var en bittersød oplevelse. Jeg vandt prisen som dagens fighter for et aggressivt angreb, men jeg missede samtidig chancen for at komme på podiet med få meter,"" udtaler Chris Williams. ""Jeg har planer om at køre aggressivt igen i år og forhåbentlig gøre det endnu bedre. Vores team elsker at køre i Danmark, og de mange tilråb fra vores fans holder os motiverede."" Team Novo Nordisks mål er at udbrede kendskabet til diabetes og vise, at man kan nå sine mål, selvom man har diabetes. Hver dag under Post Danmark Rundt er der mulighed for at møde cykelrytterne og lære mere om diabetes i Changing Diabetes® teltet i start- og målområderne.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1292,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
512,2015-07-10,Novo Nordisk afslutter med succes det første fase 3a-studie med semaglutid til type 2-diabetes,"Bagsværd, den 10. juli 2015 - Novo Nordisk offentliggør i dag de overordnede resultater fra SUSTAIN1, det første fase 3a-studie med den nye GLP-1-analog semaglutid doseret én gang om ugen. Studiet har undersøgt effekt og sikkerhed for 0,5 mg og 1,0 mg semaglutid givet som monoterapi (eneste behandling) i 30 uger sammenlignet med placebo hos 388 mennesker med type 2-diabetes, som tidligere blev behandlet med diæt og motion. Studiet opfyldte sit primære mål, idet det viste, at deltagere, som blev behandlet med doser på 0,5 mg og 1,0 mg semaglutid, fra et gennemsnitligt langtidsblodsukkerniveau (HbA1c) på 8,1% ved studiets begyndelse opnåede større forbedringer i HbA1c på henholdsvis 1,5% og 1,6% mod ingen ændring i HbA1c i placebogruppen. 74% og 73%* af deltagere, som blev behandlet med henholdsvis 0,5 mg og 1,0 mg semaglutid, nåede behandlingsmålet om HbA1c under 7% som anbefalet af American Diabetes Association (ADA) og European Association for the Study of Diabetes (EASD), mod 25% af deltagere, som blev behandlet med placebo. Fra en gennemsnitsvægt på 92 kg ved studiets begyndelse opnåede deltagere, som blev behandlet med 0,5 mg og 1,0 mg semaglutid, endvidere ved begge doseringer et større vægttab på henholdsvis 3,8** kg og 4,6*** kg i forhold til et vægttab på 1,0 kg hos deltagere, som blev behandlet med placebo. Semaglutid forekom i studiet at have en sikker og veltolereret profil. De mest almindelige bivirkninger var relateret til mave-tarm-systemet, hovedsageligt kvalme, var sammenlignelige med Victoza® i lignende studier og aftog over tid. Frafaldsprocenten som følge af alle alvorlige bivirkninger for 0,5 mg og 1,0 mg semaglutid var 6% og 5% mod 2% for placebo. ""Vi er meget glade for disse resultater, som bekræfter, at semaglutid har potentiale til at hjælpe mennesker med type 2-diabetes med både at opnå en god blodsukkerregulering og et betydeligt vægttab med én ugentlig injektion,"" siger Mads Krogsgaard Thomsen, koncernforskningsdirektør i Novo Nordisk. ""Vi glæder os til at se flere resultater fra det kliniske udviklingsprogram SUSTAIN."" Novo Nordisk forventer at offentliggøre de overordnede resultater fra de resterende fem SUSTAIN-studier i løbet af de næste ni måneder. Om semaglutidSemaglutid er en ny human GLP-1-analog (glukagonlignende peptid-1), som kan hjælpe mennesker med type 2-diabetes opnå markant forbedring af blodsukkeret med en lav risiko for hypoglykæmi. Semaglutid medfører endvidere vægttab ved at reducere appetit og madindtag. Semaglutid doseret én gang om ugen er under udvikling til behandling af type 2-diabetes. Om det kliniske udviklingsprogram SUSTAIN SUSTAIN er et klinisk fase 3-program, som omfatter seks globale studier af semaglutid doseret én gang om ugen med deltagelse af flere end 7.000 mennesker med type 2-diabetes. SUSTAIN 1 - et 30-ugers effekt- og sikkerhedsstudie, der undersøger semaglutid i forhold til placebo hos 388 deltagere med type 2-diabetes, som ikke tidligere har fået medicinsk behandling. SUSTAIN 2 - et 56-ugers effekt- og sikkerhedsstudie, der undersøger semaglutid i forhold til sitagliptin én gang dagligt som tillægsbehandling til metformin og/eller TZD hos 1.231 deltagere med type 2-diabetes. SUSTAIN 3 - et 56-ugers effekt- og sikkerhedsstudie, der undersøger semaglutid i forhold til exenatid ER 2,0 mg én gang ugentligt som tillægsbehandling til 1-2 diabeteslægemidler i tabletform hos 811 deltagere med type 2-diabetes. SUSTAIN 4 - et 30-ugers effekt- og sikkerhedsstudie, der undersøger semaglutid i forhold til insulin glargin én gang dagligt som tillægsbehandling til metformin med eller uden sulfonylurinstof hos 1.089 deltagere med type 2-diabetes, som ikke tidligere er blevet behandlet med insulin. SUSTAIN 5 - et 30-ugers effekt- og sikkerhedsstudie, der undersøger semaglutid i forhold til placebo som tillægsbehandling til basal insulin alene eller basal insulin i kombination med metformin hos 397 deltagere med type 2-diabetes. SUSTAIN 6 - et toårigt studie, der undersøger forekomsten af hjerte-kar-sygdom og andre langsigtede målepunkter ved brug af semaglutid hos 3.297 deltagere med type 2-diabetes. * I dette afsnit skal 73% erstattes af 72% ** I dette afsnit skal 3,8 kg erstattes af 3,7 kg *** I dette afsnit skal 4,6 kg erstattes af 4,5 kg Yderligere information Selskabsmeddelelse nr. 41 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1301,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
513,2015-07-10,Novo Nordisk successfully completes first phase 3a trial with semaglutide in people with type 2 diabetes,"Bagsværd, Denmark, 10 July 2015 - Novo Nordisk today announced the headline results from SUSTAIN1, the first phase 3a trial for semaglutide, a new GLP-1 analogue administered once-weekly. The trial investigated the efficacy and safety of 0.5 mg and 1.0 mg semaglutide as monotherapy during 30 weeks of treatment compared with placebo in 388 people with type 2 diabetes previously on diet and exercise. The trial achieved its primary objective by demonstrating that from a mean baseline HbA1c of 8.1%, people treated with doses of 0.5 mg and 1.0 mg semaglutide, achieved superior improvements in HbA1c of 1.5% and 1.6%, respectively, compared to no change in HbA1c in the placebo group. 74% and 73*% of the people treated with 0.5 mg and 1.0 mg semaglutide, respectively, achieved the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) treatment target of HbA1c below 7% compared with 25% of the people treated with placebo. Furthermore, from a mean baseline of 92 kg, people treated with semaglutide in both doses of 0.5 mg and 1.0 mg experienced a superior weight loss of 3.8** kg and 4.6*** kg, respectively, compared with a weight loss of 1.0 kg for people treated with placebo. In the trial, semaglutide appeared to have a safe and well-tolerated profile. The most common adverse events were related to the gastrointestinal system, primarily nausea, were comparable to Victoza® in similar trials and diminished over time. The discontinuation rates due to all adverse events for 0.5 mg and 1.0 mg semaglutide were 6% and 5% compared to a discontinuation rate of 2% for placebo. ""We are excited about these results, which confirm that semaglutide has the potential to help people with type 2 diabetes achieve both good glycaemic control and a significant weight loss with one weekly injection,"" says Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""We look forward to further results from the SUSTAIN clinical development programme."" Novo Nordisk expects to announce headline results of the five remaining SUSTAIN trials within the next nine months. Semaglutide is a new glucagon-like peptide-1 (GLP-1) analogue that can help people with type 2 diabetes achieve substantial improvement of blood glucose with a low risk of hypoglycaemia. In addition, semaglutide induces weight loss by decreasing appetite and food intake. Semaglutide administered once-weekly is in development for the treatment of type 2 diabetes. About the SUSTAIN clinical programme The SUSTAIN programme is a phase 3 clinical programme comprising  six global trials of semaglutide administered once-weekly encompassing more than 7,000 people with type 2 diabetes. SUSTAIN 1 - a 30-week efficacy and safety trial of semaglutide versus placebo in 388 drug-naïve people with type 2 diabetes. SUSTAIN 2 - a 56-week efficacy and safety trial of semaglutide versus sitagliptin once-daily as add-on to metformin and/or TZD in 1,231 people with type 2 diabetes. SUSTAIN 3 - a 56-week efficacy and safety trial of semaglutide versus exenatide ER 2.0 mg once-weekly as add-on to 1-2 oral antidiabetic drugs in 811 people with type 2 diabetes. SUSTAIN 4 - a 30-week efficacy and safety trial of semaglutide versus insulin glargine once-daily as add-on to metformin with or without sulphonylurea in 1,089 insulin-naïve people with type 2 diabetes. SUSTAIN 5 - a 30-week efficacy and safety trial of semaglutide versus placebo as add-on to basal insulin alone or basal insulin in combination with metformin in 397 people with type 2 diabetes. SUSTAIN 6 - a 2-year trial to evaluate cardiovascular and other long-term outcomes with semaglutide in 3,297 people with type 2 diabetes. * In this section 73% must be replaced by 72% ** In this section 3.8kg must be replaced by 3.7kg *** In this section 4.6kg must be replaced by 4.5kg For further information Company announcement No 41 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1300,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
514,2015-05-29,Novo Nordisk og Københavns Universitet sætter  blus på udveksling af talentstuderende,"Bagsværd, Danmark, fredag 29. maj 2015 - Novo Nordisk og Københavns Universitet har underskrevet en treårig aftale om et stipendieprogram for talentfulde studerende. Novo Nordisk International Programme of Talents skal styrke studentermobiliteten mellem Københavns Universitet og udvalgte partneruniversiteter i elitesamlingen International Alliance of Research Universities (IARU), som Københavns Universitet er en del af. Novo Nordisk giver op til 5 mio. kroner årligt til stipendieprogrammet. ""Internationale talenter er afgørende for København som vidensmetropol og for Novo Nordisk som virksomhed. Vi ønsker at bidrage til, at danske studerende rejser mere ud og henter ny viden, og at flere udenlandske studerende får smag for Danmark som et attraktivt sted at studere. Således håber vi, at aftalen med Københavns Universitet vil  sikre et stærkere, mere globalt og konkurrencedygtigt studie- og forskningsmiljø i København'', siger koncernforskningsdirektør i Novo Nordisk, Mads Krogsgaard Thomsen. Stipendieprogrammet bliver administreret af Københavns Universitet. Det begynder i 2015 og vil være fuldt implementeret i 2016. ""Universitetsmiljøer og virksomheder verden over indgår i disse år samarbejder, hvor viden og kompetencer fra de to verdener skaber banebrydende resultater til gavn for begge parter og for det omgivende samfund. Her er internationale studieophold og viden universiteterne imellem en vigtig brik, som det nye talentprogram giver mulighed for at styrke"", siger rektor ved Københavns Universitet, Ralf Hemmingsen. Fotos fra underskriften af aftalen kan downloades på novonordisk.com. Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1317,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
515,2015-05-29,Novo Nordisk and the University of Copenhagen to boost exchange of talented students,"Bagsværd, Denmark, 29 May 2015 - Novo Nordisk and the University of Copenhagen have signed a three-year agreement on a scholarship programme for talented students. The Novo Nordisk International Programme of Talents will boost student mobility between the University of Copenhagen and selected partner universities within the International Alliance of Research Universities (IARU), of which the University of Copenhagen is a member. Novo Nordisk will grant up to 5 million Danish kroner annually to the scholarship programme. ""International talents are vital for Copenhagen as a science metropolis and for Novo Nordisk as a company. We want to encourage Danish students to study more abroad to tap into new knowledge, and we also want more international students to become aware of Denmark as an attractive place of study. We hope this agreement with the University of Copenhagen will create a stronger, more global and competitive study and research environment in Copenhagen,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk. The scholarship programme will be administered by the University of Copenhagen. It commences in 2015 and will be fully implemented in 2016. ""Universities and companies worldwide are increasingly forging alliances in which knowledge and expertise from the two worlds are generating ground-breaking results for the benefit of both parties and society at large. In this connection, studying abroad and exchange of knowledge between universities are important elements which the new talent programme will be able to strengthen,"" said Ralf Hemmingsen, rector of the University of Copenhagen. Visit novonordisk.com for photos from the signing of the agreement.  Further information ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1316,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
516,2015-05-20,Janssen Biotech Inc. acquires licence from Novo Nordisk for a development programme focused on autoimmune diseases,"Bagsværd, Denmark, 20 May 2015 - Novo Nordisk A/S has signed an agreement with Janssen Biotech, Inc. (Janssen) under which Janssen will acquire an exclusive global licence to further develop and commercialise a clinical programme focused on therapy within autoimmune diseases. The programme targets modulation of certain immune cells via a cell surface receptor (NKG2D receptor). Terms of the agreement have not been disclosed. The agreement is subject to final clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with the U.S. Department of Justice Antitrust Division and the Federal Trade Commission.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1318,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
517,2015-05-20,"Janssen Biotech Inc. får licens fra Novo Nordisk til et udviklingsprogram, der fokuserer på autoimmune sygdomme","Bagsværd, den 20. maj 2015 - Novo Nordisk A/S har underskrevet en aftale med Janssen Biotech, Inc. (Janssen), som giver Janssen eksklusiv global licens til at videreudvikle og kommercialisere et klinisk program, der fokuserer på behandling indenfor autoimmune sygdomme. Programmet fokuserer på modulering af visse immunceller via en celleoverfladereceptor (NKG2D-receptor). Aftalens vilkår oplyses ikke. Aftalen er betinget af endelig godkendelse i det amerikanske justitsministerium, U.S. Department of Justice Antitrust Division, og den amerikanske handelskommission, Federal Trade Commission, i henhold til den amerikanske antitrustlov Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR).",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1319,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
518,2015-05-04,"Novo Nordisk investerer 1,5 mia. kr. i ny fabrik i Kalundborg til produktion af blødermedicin","Bagsværd, den 4. maj 2015 - Novo Nordisk investerer 1,5 mia. kr. i en ny fabrik på 7.500 m2 i Kalundborg. Fabrikken skal producere aktive lægemiddelstoffer til hæmofilipræparatet NovoSeven® og fremtidige lægemidler til bløderbehandling. Investeringen vurderes at ville skabe 100 nye produktions- og ingeniørjob i Kalundborg, hvor Novo Nordisk i forvejen beskæftiger over 2.800 medarbejdere. ""Investeringen i Kalundborg understreger vores langsigtede ambition om at skabe og fastholde arbejdspladser i Danmark. Alene i år forventer vi, at Novo Nordisk vil skabe omkring 250 nye arbejdspladser i Kalundborg, og vi er altid på jagt efter dygtige og veluddannede medarbejdere,"" siger Henrik Wulff, der er direktør for Novo Nordisks globale produktion. Første spadestik bliver taget i dag, den 4. maj, og fabrikken forventes at være godkendt og i fuld drift i 2020. Om Novo Nordisk i Kalundborg Fabriksparken i Kalundborg blev grundlagt i 1969 og er Novo Nordisks største med et samlet areal på 1.000.000 m2, svarende til 140 fodboldbaner. Siden 1999 har Novo Nordisk investeret løbende i anlægget og dermed skabt over 1.600 nye jobs. Hæmofili er en blødersygdom, der rammer 1 ud af 10.000. Mennesker med hæmofili mangler helt eller delvist en vigtig koagulationsfaktor, som er nødvendig, for at blodet kan størkne. Mennesker med hæmofili får ofte blødninger, især i knæ og ankler. Blødninger kan også opstå i muskler, blødt væv, mave-tarm-kanalen og i hjernen. Uden behandling er blødningerne smertefulde og kan medføre varig skade og nedsat mobilitet. Novo Nordisk gør en engageret indsats for at ændre mulighederne indenfor hæmofili og har en ambition om at skabe en fremtid, hvor alle mennesker med hæmofili har mulighed for at leve det liv, de ønsker. Læs mere på novonordisk.com ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1325,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
519,2015-05-04,Novo Nordisk invests DKK 1.5 billion in new haemophilia treatment manufacturing facility in Denmark,"Bagsværd, Denmark, 4 May 2015 - Novo Nordisk is investing 1.5 billion Danish kroner in a new 7,500 m2 facility in Kalundborg, Denmark. The facility will produce active pharmaceutical ingredients for NovoSeven® and future products for treating haemophilia. The investment is estimated to create 100 new production and engineering jobs in Kalundborg, where Novo Nordisk currently employs more than 2,800 people. ""The investment in Kalundborg underscores our long-term ambition to create and maintain jobs in Denmark. This year alone we expect Novo Nordisk will create about 250 new jobs in Kalundborg, and we are always on the lookout for capable and highly skilled employees,"" said Henrik Wulff, executive vice president, Product Supply, Novo Nordisk. Groundbreaking will take place today, 4 May, and the facility is expected to be approved and fully operational in 2020. About Novo Nordisk in Kalundborg Established in 1969, the Kalundborg production site is Novo Nordisk's largest with a total area of 1,000,000 m2. Novo Nordisk has made ongoing investments in the site since 1999, creating more than 1,600 new jobs. About haemophilia Haemophilia is a bleeding disorder affecting 1 in 10,000 people. People with haemophilia have either decreased, defective or absent production of blood clotting protein. For people with haemophilia, bleeds often occur in the joints, particularly knees and ankles. Bleeds can also occur in the muscles, soft tissues, gastrointestinal tract or even the brain. Without adequate care and treatment, bleeds are painful and can cause lasting damage and lead to impaired mobility. Novo Nordisk is committed to Changing Possibilities in Haemophilia® working towards a future where all people living with haemophilia have the opportunity to lead the life they desire. Further information ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1324,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
520,2015-04-30,"Novo Nordisks resultat af primær drift i kroner steg med 73% i første kvartal af 2015 til 13,9 mia. kr.","17% vækst i resultat af primær drift i lokale valutaer justeret for salget af NNIT Salget steg med 24% i kroner og med 9% opgjort i lokale valutaer til 25,2 mia. kr. Bruttomarginen steg med 1,6 procentpoint opgjort i kroner til 84,6% drevet af en positiv påvirkning fra valutakursudviklingen. Resultat af primær drift steg med 73% opgjort i kroner og med 47% i lokale valutaer til 13,9 mia. kr. Justeret for engangsindtægten på 2,4 mia. kr. i relation til det delvise salg af NNIT steg resultat af primær drift opgjort i lokale valutaer med 17%. Nettoresultatet steg med 53% til 9,9 mia. kr. Udvandet resultat pr. aktie steg med 56% til 3,79 kr. Justeret for det delvise salg af NNIT steg nettoresultatet og udvandet resultat pr. aktie med henholdsvis 22% og 24%. I marts meddelte Novo Nordisk, at selskabet havde besluttet at indsende den præspecificerede interimanalyse af DEVOTE-studiet, der undersøger forekomsten af hjerte-kar-sygdom i forbindelse med brug af Tresiba®, til de amerikanske sundhedsmyndigheder (FDA). I april accepterede FDA at behandle indsendelsen. Novo Nordisk reorganiserer koncerndirektionen og forfremmer lederne af koncernens forretningsaktiviteter i USA, Europa og International Operations samt Product Supply til medlemmer af koncerndirektionen. Kåre Schultz, viceadministrerende direktør, ansvarlig for Sales og Product Supply, forlader Novo Nordisk. For 2015 forventes nu en salgsvækst på 7-9% opgjort i lokale valutaer, mens væksten i resultat af primær drift opgjort i lokale valutaer ventes at blive på omkring 17%. Adm. direktør Lars Rebien Sørensen: ""Vi er meget tilfredse med de resultater, Novo Nordisk har opnået i første kvartal af 2015. Victoza® og Levemir® driver fortsat salgsvæksten, og vi har med succes passeret flere vigtige milepæle for vores portefølje af diabetesprojekter i de afsluttende faser."" I en kommentar til ændringerne i koncerndirektionen tilføjer han: ""Kåre Schultz har igennem de 26 år, han har været hos os, været stærkt medvirkende til at gøre Novo Nordisk til en succesrig global virksomhed. Jeg ønsker ham alt det bedste i hans fremtidige virke."" Kontaktoplysninger Selskabsmeddelelse nr. 31 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1328,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
521,2015-04-30,Increased operating profit in Danish kroner by 73% in the first quarter of 2015 to DKK 13.9 billion,"Sales increased by 24% in Danish kroner and by 9% in local currencies to DKK 25.2 billion. Gross margin improved by 1.6 percentage points in Danish kroner to 84.6% driven by a positive currency impact. Operating profit increased by 73% in Danish kroner and by 47% in local currencies to DKK 13.9 billion. Adjusted for the DKK 2.4 billion non-recurring income related to the partial divestment of NNIT, operating profit in local currencies increased by 17%. Net profit increased by 53% to DKK 9.9 billion. Diluted earnings per share increased by 56% to DKK 3.79. Adjusted for the partial divestment of NNIT, net profit and diluted earnings per share increased by 22% and 24% respectively. In March, Novo Nordisk announced the decision to submit the prespecified interim analysis of DEVOTE, the cardiovascular outcomes trial for Tresiba®, to the US FDA. The submission was accepted for review by the FDA in April. Novo Nordisk reorganises its Executive Management, elevating the leaders of the commercial activities in the US, Europe and International Operations and of Product Supply to Executive Management. Kåre Schultz, president and COO, leaves Novo Nordisk. For 2015, sales growth measured in local currencies is now expected to be 7-9%, whereas operating profit growth measured in local currencies is expected to be around 17%. Lars Rebien Sørensen, CEO: ""We are very pleased with the results during the first quarter of 2015. Victoza® and Levemir® continue to drive sales growth, and we have successfully passed several critical milestones for our portfolio of late-stage diabetes care projects."" Commenting on the changes in Executive Management, he adds: ""Kåre Schultz has during his 26 years with us played a key role in making Novo Nordisk a successful global company. I wish him all the best in his future endeavours."" Further information Company announcement No 31 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1327,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
522,2015-04-29,Total number of voting rights and share capital in Novo Nordisk A/S as of 29 April 2015,"Bagsværd, Denmark, 29 April 2015 - In accordance with Section 6 of the Danish Statutory Order on Issuers' Disclosure Obligations, Novo Nordisk is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred. Referring to Company Announcement no 27/2015 dated 22 April 2015, please find below a statement regarding the total number of voting rights and share capital in Novo Nordisk A/S as per 29 April 2015. Further information Company announcement No 30 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1330,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
523,2015-04-29,Det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 29. april 2015,"Bagsværd, 2015-04-29 - I henhold til Bekendtgørelse om udstederes oplysningsforpligtelser, § 6, skal Novo Nordisk offentliggøre det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S ved udgangen af en måned, hvor ændringer deri har fundet sted. Nedenstående opgørelse viser det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 29. april 2015, jævnfør også selskabsmeddelelse nr. 27/2015 dateret 22. april 2015.  Selskabsmeddelelse nr. 30 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1329,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
524,2015-04-22,United States first country to launch Saxenda®,"Bagsværd, Denmark, 22 April 2015 - Novo Nordisk today announced that Saxenda® (liraglutide 3 mg) is now available in the United States (US). Saxenda® is the first glucagon-like peptide-1 (GLP-1) receptor agonist for weight management, approved in the US, EU and Canada. In the US, it is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI >=30 kg/m2) or who are overweight (BMI >=27 kg/m2) in the presence of at least one weight-related comorbid condition.1 Saxenda® was evaluated in the SCALE(TM) (Satiety and Clinical Adiposity-Liraglutide Evidence in Nondiabetic and Diabetic people) phase 3 clinical trial programme, which involved more than 5,000 study participants who have obesity (BMI >=30 kg/m2) or who are overweight (BMI >=27 kg/m2) with weight-related comorbidities. Trial data showed that Saxenda®, in combination with a reduced-calorie diet and increased physical activity, resulted in greater weight loss than reduced calorie diet and physical activity alone.1 ""We are pleased to make this new treatment option available, which we believe has the potential to help people with obesity lose weight and reduce weight-related comorbidities"" said Executive Vice President Jakob Riis, Marketing, Medical Affairs & Stakeholder Engagement of Novo Nordisk. ""The launch of Saxenda is an important milestone in Novo Nordisk's long-term commitment to obesity treatment and we look forward to launching Saxenda in other countries later in 2015."" Recognised as a disease by the American Medical Association and other medical societies,obesity has grown in prevalence in the United States and around the world.2-4 Affecting approximately 35% of the US adult population in 2011-2012, obesity is associated with serious co-morbidities, including type 2 diabetes, heart disease and certain types of cancer.5,6  Novo Nordisk expects to launch Saxenda® in several other markets starting in 2015. About obesityObesity is a disease that requires chronic management.3,7 It is associated with serious comorbidities including type 2 diabetes, heart disease, obstructive sleep apnoea (OSA), certain types of cancer and a decreased life expectancy.6,8,9 The risk of morbidity and mortality increases with the severity of obesity.10 It is a complex and multifactorial disease that is influenced by genetic, physiological, environmental and psychological factors.11 The global increase in the prevalence of obesity is a public health issue that has severe cost implications to healthcare systems.4,12 In 2011-2012 in the US, approximately 35% of adults, or nearly 80 million adults, lived with obesity.5 About Saxenda®Saxenda® is a once-daily glucagon-like peptide-1 (GLP-1) analogue with 97% similarity to naturally occurring human GLP-1,13 a hormone that is released in response to food intake.14 Like human GLP-1, Saxenda® regulates appetite and lowers body weight through decreased food intake.15,16 As with other GLP-1 receptor agonists, liraglutide stimulates insulin secretion and reduces glucagon secretion in a glucose-dependent manner. These effects can lead to a reduction of blood glucose. Saxenda® has been approved by the US Food and Drug Administration, the European Commission and Health Canada. Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy, and is now entering the obesity therapy area. Novo Nordisk employs approximately 41,500 employees in 75 countries, and markets its products in more than 180 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube Further information References1.         FDA. Saxenda® (liraglutide 3 mg) US Prescribing Information. January 2015. Available at: http://www.novo-pi.com/saxenda.pdf. 2.         AMA. A.M.A Adopts New Policies on Second Day of Voting at Annual Meeting. Obesity as a Disease. Available at: http://www.ama-assn.org/ama/pub/news/news/2013/2013-06-18-new-ama-policies-annual-meeting.page Last accessed 10.04.15. 3.         Mechanick JI, Garber AJ, Garvey WT. American Association of Clinical Enodocrinologists' Position Statement on Obesity and Obesity Medicine. Endocrine Practice. 2012; 18:642-648.4.         WHO. Obesity and Overweight Factsheet no. 311. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/. Last accessed 10.04.15. 5.         Ogden CL, Carroll MD, Kit BK, et al. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014; 311:806-814.6.         Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009; 9:88.7.         Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014; 129:S102-138.8.         Gami AS, Caples SM, Somers VK. Obesity and obstructive sleep apnea. Endocrinology and Metabolism Clinics of North America. 2003; 32:869-894.9.         Peeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Annals of Internal Medicine. 2003; 138:24-32.10.       Bray GA, Bellanger T. Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine. 2006; 29:109-117.11.       Wright SM, Aronne LJ. Causes of obesity. Abdominal Imaging. 2012; 37:730-732.12.       Cawley J, Meyerhoefer C. The medical care costs of obesity: an instrumental variables approach. Journal of Health Economics. 2012; 31:219-230.13.       Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. Journal of Medicinal Chemistry. 2000; 43:1664-1669.14.       Orskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scandinavian Journal of Gastroenterology. 1996; 31:665-670.15.       van Can J, Sloth B, Jensen CB, et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. International Journal of Obesity. 2014; 38:784-793.16.       Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014; 124:4473-4488.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1333,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
525,2015-04-22,"USA bliver første land, der lancerer Saxenda®","Bagsværd, den 22. april 2015 - Novo Nordisk meddeler i dag, at Saxenda® (liraglutid 3 mg) nu er tilgængeligt på det amerikanske marked. Saxenda® er den første GLP-1-receptoragonist (glukagonlignende peptid-1) til vægtregulering, som er godkendt i USA, EU og Canada. I USA er Saxenda® godkendt som supplement til en kaloriereduceret diæt og øget fysisk aktivitet til kronisk vægtregulering hos svært overvægtige voksne (BMI >=30 kg/m2) eller overvægtige voksne (BMI >=27 kg/m2) med mindst én vægtrelateret komorbiditet (komplikation).[i] Saxenda® er undersøgt i det kliniske fase 3-program SCALE(TM) (Satiety and Clinical Adiposity-Liraglutide Evidence in Nondiabetic and Diabetic people), som har omfattet flere end 5.000 svært overvægtige deltagere (BMI >=30 kg/m2) eller overvægtige deltagere (BMI >=27 kg/m2) med vægtrelaterede komplikationer. Resultaterne viste, at Saxenda®, i kombination med en kaloriereduceret diæt og øget fysisk aktivitet, resulterede i et større vægttab end kaloriereduceret diæt og fysisk aktivitet alene.1 ""Vi er glade for nu at kunne tilbyde denne nye behandlingsmulighed, som kan hjælpe svært overvægtige mennesker med vægttab og vægtrelaterede følgesygdomme,"" siger Jakob Riis, koncerndirektør med ansvar for Marketing, Medical Affairs & Stakeholder Engagement i Novo Nordisk. ""Lanceringen af Saxenda® er en vigtig milepæl i Novo Nordisks indsats for at bekæmpe svær overvægt, og vi ser frem til at gøre Saxenda® tilgængeligt i flere lande i de kommende år."" Fedme er anerkendt som en sygdom af American Medical Association og andre medicinske organisationer, og forekomsten er stigende i USA og resten af verden.[ii],[iii],[iv] Fedme er forbundet med alvorlige komplikationer som type 2-diabetes, hjertesygdom og visse former for kræft, og i 2011-2012 var ca. 35% af den voksne befolkning i USA svært overvægtige.[v],[vi] Novo Nordisk forventer at lancere Saxenda® i flere andre markeder fra og med 2015. Om fedmeFedme er en sygdom, der kræver vedvarende indsats.3,[vii] Den er forbundet med alvorlige komplikationer (komorbiditeter) som type 2-diabetes, hjertesygdom, obstruktiv søvnapnø og visse former for kræft samt en nedsættelse af den forventede levetid.6,[viii],[ix] Risikoen for sygelighed (morbiditet) og dødelighed (mortalitet) stiger i takt med sværhedsgraden af fedme.[x] Det er en kompleks sygdom, der er betinget af flere forskellige forhold, herunder genetiske, fysiologiske, miljømæssige og psykologiske faktorer.[xi] Den globale stigning i forekomsten af fedme er en trussel mod folkesundheden med betydelig indvirkning på sundhedsudgifterne.4,[xii] I 2011-2012 var ca. 35% af den voksne befolkning i USA, eller næsten 80 mio. voksne, svært overvægtige.5 Om Saxenda® Saxenda® er en GLP-1-analog (glukagonlignende peptid-1) til dosering én gang dagligt. Molekylet har 97% lighed med kroppens eget GLP-1,[xiii] som er et tarmhormon, der frigives, når man spiser.[xiv] Ligesom naturligt GLP-1 regulerer Saxenda® appetitten og reducerer kropsvægten gennem mindre madindtag.[xv],[xvi]Som med andre GLP-1-receptoragonister stimulerer liraglutid insulinsekretionen og reducerer glukagonsekretionen på en glukoseafhængig måde. Disse virkninger kan føre til en reduktion af blodsukkeret. Saxenda® er godkendt af de amerikanske sundhedsmyndigheder (FDA), Europa-Kommissionen og de canadiske sundhedsmyndigheder (Health Canada). Referencer [i]    FDA. Saxenda® (liraglutide 3 mg) US Prescribing Information. January 2015. Available at: http://www.novo-pi.com/saxenda.pdf. [ii]    AMA. A.M.A. Adopts New Policies on Second Day of Voting at Annual Meeting. Obesity as a Disease. Available at: http://www.ama-assn.org/ama/pub/news/news/2013/2013-06-18-new-ama-policies-annual-meeting.page. Last accessed 10.04.15. [iii]   Mechanick JI, Garber AJ, Garvey WT. American Association of Clinical Endocrinologists' Position Statement on Obesity and Obesity Medicine. Endocrine Practice. 2012; 18:642-648. [iv]   WHO. Obesity and Overweight Factsheet no. 311. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/. Last accessed 10.04.15. [v]    Ogden CL, Carroll MD, Kit BK, et al. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014; 311:806-814. [vi]   Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009; 9:88. [vii]   Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014; 129:S102-138. [viii] Gami AS, Caples SM, Somers VK. Obesity and obstructive sleep apnea. Endocrinology and Metabolism Clinics of North America. 2003; 32:869-894. [ix]   Peeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Annals of Internal Medicine. 2003; 138:24-32. [x]    Bray GA, Bellanger T. Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine. 2006; 29:109-117. [xi]   Wright SM, Aronne LJ. Causes of obesity. Abdominal Imaging. 2012; 37:730-732. [xii]   Cawley J, Meyerhoefer C. The medical care costs of obesity: an instrumental variables approach. Journal of Health Economics. 2012; 31:219-230. [xiii] Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. Journal of Medicinal Chemistry. 2000; 43:1664-1669. [xiv] Orskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scandinavian Journal of Gastroenterology. 1996; 31:665-670. [xv] van Can J, Sloth B, Jensen CB, et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. International Journal of Obesity. 2014; 38:784-793. [xvi] Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014; 124:4473-4488.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1334,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
526,2015-04-22,Novo Nordisk A/S - Nedsættelse af aktiekapitalen,"Bagsværd, 2015-04-22 - På den ordinære generalforsamling i Novo Nordisk A/S den 19. marts 2015 blev det besluttet at nedsætte selskabets B-aktiekapital fra nominelt 422.512.800 kr. til 412.512.800 kr. ved annullering af en del af selskabets beholdning af egne B-aktier, i alt nominelt 10.000.000 kr. fordelt på 50.000.000 B-aktier á 0,20 kr. Selskabsmeddelelse nr. 27 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1339,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
527,2015-04-22,Novo Nordisk A/S - Reduction of the share capital,"Bagsværd, Denmark, 22 April 2015 - At Novo Nordisk's Annual General Meeting on 19 March 2015, it was decided to reduce the company's B share capital from DKK 422,512,800 to DKK 412,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each. Further information Company announcement No 27 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1340,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
528,2015-04-14,Novo Nordisk extends programme for children with diabetes in developing countries,"Bagsværd, Denmark, 14 April 2015 - Today, Novo Nordisk announced a three-year extension of its Changing Diabetes® in Children programme. Since 2009, free insulin and access to diabetes care have been provided to more than 13,000 children in nine countries in Africa and South-East Asia. During the five years, 108 diabetes clinics have been established and 5,479 healthcare professionals have received diabetes care training. A child in sub-Saharan Africa diagnosed with type 1 diabetes often has a life expectancy of less than a year[1]. As a response to this situation and as a call to action by the International Diabetes Federation, Novo Nordisk established the Changing Diabetes® in Children programme. The idea originated from a visit to a district hospital in Kenya by Lars Rebien Sørensen, CEO of Novo Nordisk. At the hospital, he met a Masai boy diagnosed with type 1 diabetes who had been deserted by his parents at a highway and taken to the hospital by some passers-by. ""It became clear to me that this boy had dire perspectives for staying alive,"" says Lars Rebien Sørensen. ""This is obviously hugely disturbing to anyone that has any way of influencing the situation."" In Guinea, almost 400 children have been enrolled in the programme: ""Before we had the programme for children with diabetes in Guinea, the situation was very difficult. Many children diagnosed with diabetes had no access to treatment or stopped it because their parents could not afford buying insulin,"" explains Professor Naby Baldé, project partner at Donka University Hospital in Conakry, Guinea. ""It's a great progress for the children and their families; they will no longer have to choose between providing food for the family or treatment of one child."" The Changing Diabetes® in Children programme will run until 2017 in order to consolidate the work that has been done and to strengthen the sustainability of the programme in each country. About Changing Diabetes® in Children The programme is run as a private-public partnership between Novo Nordisk, Roche, the International Society for Pediatric and Adolescent Diabetes (ISPAD) and the World Diabetes Foundation (WDF). In each country (Cameroon, Democratic Republic of Congo, Ethiopia, Guinea, Kenya, Tanzania and Uganda, Bangladesh and India), the programme is implemented by a group of local partners with the national Ministry of Health playing a key role to ensure that the programme is anchored within the existing healthcare system. Being part of the programme means that each child receives insulin free of charge along with strips and a glucometer to measure his blood sugar levels. But since type 1 diabetes is a chronic condition which needs to be monitored closely, insulin does not do it alone. Therefore, patient education for children and families and training of healthcare personnel is an essential part. Further information  [1] Beran, Yudkin, Diabetes care in sub-Saharan Africa, 2006 http://www.sciencedirect.com/science/article/pii/S0140673606697043",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1341,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
529,2015-04-14,Novo Nordisk forlænger program for børn med diabetes i udviklingslande,"Bagsværd, den 14. april 2015 - Novo Nordisk har besluttet at forlænge programmet Changing Diabetes® in Children med tre år. Siden 2009 har flere end 13.000 børn i ni lande i Afrika og Sydøstasien via dette program fået gratis insulin og adgang til diabetesbehandling. Der er etableret 108 diabetesklinikker, og 5.479 læger og andet sundhedspersonale har modtaget undervisning i diabetesbehandling. I afrikanske lande syd for Sahara har et barn, som får stillet diagnosen type 1-diabetes, ofte en forventet levetid på mindre end et år[1]. Det var ønsket om at gøre noget for at afhjælpe denne situation - og samtidig efterkomme en opfordring fra International Diabetes Federation - der bevirkede, at Novo Nordisk etablerede programmet Changing Diabetes® in Children. Ideen blev født, da Novo Nordisks administrerende direktør, Lars Rebien Sørensen, besøgte et distriktshospital i Kenya. Her mødte han en masaidreng med type 1-diabetes, som var blevet efterladt af sine forældre ved en landevej og derefter bragt til hospitalet af nogle forbipasserende. ""Det stod klart for mig, at denne dreng ikke havde mange chancer for at overleve,"" fortæller Lars Rebien Sørensen. ""Og det er selvsagt en rystende erkendelse for enhver, der har bare den mindste mulighed for at påvirke situationen."" I Guinea er næsten 400 børn tilmeldt programmet: ""Inden Guinea kom med i programmet, var situationen meget vanskelig. Mange børn, der var blevet diagnosticeret med diabetes, havde ikke adgang til behandling eller stoppede med behandlingen, fordi deres forældre ikke havde råd til at købe insulin,"" forklarer professor Naby Baldé, projektpartner på Donka University Hospital i Conakry, Guinea. ""Programmet er et stort fremskridt for børnene og deres familier; de er nu ikke længere nødt til at vælge mellem at købe mad til familien eller medicin til et af børnene."" Changing Diabetes® in Children løber indtil 2017 for at styrke det arbejde, der er gjort indtil nu, og sikre programmets fortsatte eksistens i de enkelte lande. Om Changing Diabetes® in Children Programmet drives som et privat-offentligt partnerskab mellem Novo Nordisk, Roche, International Society for Pediatric and Adolescent Diabetes (ISPAD) og Verdensdiabetesfonden (WDF). I de enkelte lande (Cameroun, Den Demokratiske Republik Congo, Etiopien, Guinea, Kenya, Tanzania, Uganda, Bangladesh og Indien) implementeres programmet af en gruppe lokale samarbejdspartnere, og landenes sundhedsministerier spiller en afgørende rolle i at sikre, at programmet forankres i det eksisterende sundhedssystem. Børnene i programmet får gratis insulin, teststrimler og en blodsukkermåler. Men da type 1-diabetes er en kronisk sygdom, som skal følges tæt, er insulin i sig selv ikke nok. Derfor er patientundervisning for børnene, deres familier og sundhedspersonalet en lige så vigtig del af programmet. Yderligere information  Referencer [1] Beran, Yudkin, Diabetes care in sub-Saharan Africa, 2006 http://www.sciencedirect.com/science/article/pii/S0140673606697043",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1342,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
530,2015-04-10,Novo Nordisk opens new insulin formulation and filling facility in Russia,"Moscow, Russia, 10 April 2015 - Today, Novo Nordisk opens a new manufacturing facility in Russia for formulation and filling of modern insulin for the treatment of diabetes. The production will cover both Penfill® cartridges and FlexPen® prefilled insulin injection pens for the Russian market. The new facility will be operating in accordance with current Good Manufacturing Practices (GMP), and is located in Technopark Grabtsevo in the Kaluga region of Russia. ""The manufacturing facility in Kaluga is a sign of our long-term commitment to people with diabetes in Russia, where close to 10 million people have the disease according to local studies. With our investment in local manufacturing, we ensure availability of high-quality modern insulins to the people with diabetes in Russia who rely on our products every day,"" said Lars Rebien Sørensen, CEO of Novo Nordisk. This is the first and only greenfield facility for the manufacturing of modern insulin in Russia. Environmental targets for CO² emission, water consumption and use of energy have been established. With the construction of the new facility, Novo Nordisk has so far created around 150 new jobs. ""The opening of Novo Nordisk manufacturing facility in Kaluga is a sign of confidence in our region, as well as an important stage in the formation of a pharmaceutical cluster in Kaluga. I am convinced that the new facility will have a significant impact on improving the quality of life for people with diabetes in Kaluga as well as in the rest of Russia,"" said Kaluga Region Governor, Anatoly Artamonov. Novo Nordisk also has production sites in Denmark, Brazil, China, France and the US. Further information:",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1345,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
531,2015-04-10,Novo Nordisk åbner ny fabrik til formulering og påfyldning af insulin i Rusland,"Moskva, Rusland, den 10. april 2015 - Novo Nordisk åbner i dag en ny fabrik i Rusland til formulering og påfyldning af moderne insulin til det russiske marked. Produktionen omfatter både Penfill® insulinampuller og FlexPen® insulininjektionspenne. Den nye fabrik vil operere i overensstemmelse med gældende god fremstillingspraksis (GMP) og er placeret i Technopark Grabtsevo i Kaluga-regionen i Rusland. ""Fabrikken i Kaluga er et signal om vores engagement overfor mennesker med diabetes i Rusland. Lokale undersøgelser viser, at op imod 10 millioner russere har sygdommen, og med vores investering er vi med til at sikre, at moderne insulin af høj kvalitet er tilgængelig for de mange diabetikere i Rusland, som hver dag er afhængige af vores produkter,"" siger Lars Rebien Sørensen, administrerende direktør for Novo Nordisk. Dette er den første og eneste nyetablerede fabrik til fremstilling af moderne insulin i Rusland. Der er blevet fastsat miljømål for CO2-udledning samt for vand- og energiforbrug. Med etableringen af den nye fabrik har Novo Nordisk indtil videre skabt omkring 150 nye jobs. ""Åbningen af Novo Nordisks nye fabrik i Kaluga demonstrerer tillid til vores region og er et vigtigt skridt i etableringen af en klynge af lægemiddelvirksomheder i Kaluga. Jeg er overbevist om, at den nye fabrik i høj grad vil medvirke til at forbedre livskvaliteten for diabetikere i Kaluga og i resten af Rusland,"" udtaler guvernør i Kaluga-regionen Anatoly Artamonov. Novo Nordisk har også produktion i Danmark, Brasilien, Kina, Frankrig og USA. Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1346,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
532,2015-04-07,Novo Nordisk A/S: Amerikanske FDA accepterer at behandle genindsendelserne af Tresiba® og Ryzodeg®,"Bagsværd, den 7. april 2015 - Novo Nordisk meddeler i dag, at de amerikanske sundhedsmyndigheder (FDA) har accepteret de genindsendte registreringsansøgninger for Tresiba® (insulin degludec) og Ryzodeg® (insulin degludec/insulin aspart) til behandling som en 'Class II Resubmission'. For at sikre integriteten i det igangværende DEVOTE-studie har kun en lille gruppe personer internt i Novo Nordisk adgang til dataene. Denne gruppe har udarbejdet interimanalysen til genindsendelsen og vil arbejde sammen med FDA om alle spørgsmål vedrørende interimanalysen under sagsbehandlingen. Som tidligere kommunikeret er resultatet af en interimanalyse behæftet med en højere grad af usikkerhed end de endelige studieresultater, da det foreløbige estimat bygger på betydeligt færre observationer. Derfor kan det relative risikoestimat udarbejdet på basis af interimanalysen kun give en indikation om studiets endelige udfald. Novo Nordisks ledelse har ikke adgang til resultaterne af interimanalysen. Studiet forventes afsluttet i andet halvår af 2016. Yderligere information Selskabsmeddelelse nr. 26 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1349,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
533,2015-04-07,US FDA accepts Tresiba® and Ryzodeg® resubmissions for review,"Bagsværd, Denmark, 7 April 2015 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has accepted for review the Class II Resubmissions for Tresiba® (insulin degludec) and Ryzodeg® (insulin degludec/insulin aspart). To preserve the integrity of the ongoing DEVOTE trial, only a small team within Novo Nordisk has access to the data. This team has prepared the interim analysis for the Class II resubmission and will interact with the FDA during the review, on matters related to the interim analysis. As previously communicated, the result of an interim analysis carries a higher level of uncertainty than the final study results as this preliminary estimate is built on a substantially lower number of observations. Accordingly, the relative risk estimate derived from the interim analysis is thus only an indication of the final trial results. Novo Nordisk management does not have access to the results of the interim analysis. The trial is expected to be completed in the second half of 2016. For further information Company announcement No 26 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1348,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
534,2015-03-26,Novo Nordisk has decided to resubmit the New Drug Applications of Tresiba® and Ryzodeg® in the US,"Bagsværd, Denmark, 26 March 2015 - Novo Nordisk today announced that the company has decided to submit the prespecified interim analysis of DEVOTE as part of a Class II Resubmission of the New Drug Applications (NDAs) of Tresiba® and Ryzodeg® to the US Food and Drug Administration (FDA). The resubmission is expected to take place within the next month.For further information Company Announcement No 23 / 2015  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1357,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
535,2015-03-26,Novo Nordisk har besluttet at genindsende registreringsansøgningerne for Tresiba® og Ryzodeg® i USA,"Bagsværd, den 26. marts 2015 - Novo Nordisk meddeler i dag, at virksomheden har besluttet at indsende den præspecificerede interimanalyse af DEVOTE-studiet til de amerikanske sundhedsmyndigheder (FDA) i forbindelse med genindsendelse af registreringsansøgningerne for Tresiba® og Ryzodeg® (en såkaldt Class II Resubmission). Genindsendelsen ventes at finde sted indenfor den næste måned. Selskabsmeddelelse nr. 23 / 2015 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1359,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
536,2015-03-26,Novo Nordisk has decided to resubmit the New Drug Applications of Tresiba® and Ryzodeg® in the US,"Bagsværd, Denmark, 26 March 2015 - Novo Nordisk today announced that the company has decided to submit the prespecified interim analysis of DEVOTE as part of a Class II Resubmission of the New Drug Applications (NDAs) of Tresiba® and Ryzodeg® to the US Food and Drug Administration (FDA). The resubmission is expected to take place within the next month.For further information Company Announcement No 23 / 2015  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1356,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
537,2015-03-26,Novo Nordisk har besluttet at genindsende registreringsansøgningerne for Tresiba® og Ryzodeg® i USA,"Bagsværd, den 26. marts 2015 - Novo Nordisk meddeler i dag, at virksomheden har besluttet at indsende den præspecificerede interimanalyse af DEVOTE-studiet til de amerikanske sundhedsmyndigheder (FDA) i forbindelse med genindsendelse af registreringsansøgningerne for Tresiba® og Ryzodeg® (en såkaldt Class II Resubmission). Genindsendelsen ventes at finde sted indenfor den næste måned. Selskabsmeddelelse nr. 23 / 2015 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1358,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
538,2015-03-25,Novo Nordisk A/S: Novo Nordisk completes phase 3a trials comparing faster-acting insulin aspart with NovoRapid® in people with type 1 and type 2 diabetes,"Bagsværd, Denmark, 25 March 2015 - Novo Nordisk today announced headline results from the final phase 3a trials for faster-acting insulin aspart, onset® 1 and onset® 2. The trials investigated the efficacy and safety of faster-acting insulin aspart compared with NovoRapid® (insulin aspart) in a basal-bolus regimen in people with type 1 and type 2 diabetes, respectively. For further information Company Announcement No 22 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1361,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
539,2015-03-25,"Novo Nordisk A/S : Novo Nordisk afslutter fase 3a-studier, der sammenligner hurtigerevirkende insulin aspart med NovoRapid® i type 1- og type 2-diabetes","Bagsværd, den 25. marts 2015 - Novo Nordisk offentliggør i dag de overordnede resultater fra de sidste fase 3a-studier med hurtigerevirkende insulin aspart, onset® 1 og onset® 2. Studierne har undersøgt effekt og sikkerhed for hurtigerevirkende insulin aspart sammenlignet med NovoRapid® (insulin aspart) i basal-bolus-behandling hos mennesker med henholdsvis type 1- og type 2-diabetes. Selskabsmeddelelse nr. 22 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1362,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
540,2015-03-23,Novo Nordisk A/S: Saxenda® approved in Europe for the treatment of obesity,"Bagsværd, Denmark, 23 March 2015 - Novo Nordisk today announced that the European Commission has granted marketing authorisation for Saxenda® (liraglutide 3 mg) for the treatment of obesity. The authorisation covers all 28 European Union (EU) member states. For further information Company announcement No 21 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1366,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
541,2015-03-23,Novo Nordisk A/S: Saxenda® godkendt i Europa til behandling af fedme,"Bagsværd, den 23. marts 2015 - Novo Nordisk meddeler i dag, at Europa-Kommissionen har givet markedsføringstilladelse til Saxenda® (liraglutid 3 mg) til behandling af fedme. Markedsføringstilladelsen gælder samtlige 28 EU-medlemslande.  Selskabsmeddelelse nr. 21 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1367,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
542,2015-03-19,Resolutions from the Annual General Meeting of Novo Nordisk A/S,Further information,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1370,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
543,2015-03-19,Beslutninger på den ordinære generalforsamling i Novo Nordisk A/S, Yderligere information,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1371,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
544,2015-03-08,"Nye data for svært overvægtige voksne eller overvægtige voksne med vægtrelaterede komplikationer, der taber sig mindst 5% med Saxenda®, viser forbedringer i ...",,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1377,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
545,2015-03-08,"New data in adults with obesity - or who are overweight with comorbidities losing at least 5% body weight with Saxenda® showed improvement in blood glucose, CV risk factors and quality of life outc...","San Diego, US, 8 March 2015 - 8 March, new data from the phase 3a SCALE(TM) Obesity and Prediabetes trial were presented at The Endocrine Society's 97th Annual Meeting (ENDO), showing that adults with obesity or who are overweight with comorbidities who had lost >% of their body weight at 56 weeks (ie weight loss responders), demonstrated greater improvements across a range of efficacy outcomes with Saxenda® (liraglutide 3 mg) treatment in combination with a reduced-calorie diet and increased physical activity, compared with those that had a weight loss of <5% (ie non-responders).[i]",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1376,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
546,2015-03-06,Novo Nordisk A/S gennemfører succesfuld børsnotering af NNIT A/S,"MÅ IKKE UDLEVERES, DISTRIBUERES ELLER OFFENTLIGGØRES, DIREKTE ELLER INDIREKTE, I ELLER TIL USA, AUSTRALIEN, CANADA, JAPAN ELLER NOGEN ANDEN JURISDIKTION, HVOR DISTRIBUTION ELLER OFFENTLIGGØRELSE ER ULOVLIG Dette er en pressemeddelelse og udgør ikke et prospekt. Ethvert tilbud om at erhverve værdipapirer i forbindelse med udbuddet skal udelukkende foretages på grundlag af oplysningerne i det prospekt med tillæg, der er offentliggjort i Danmark i forbindelse med udbud og optagelse til handel og officiel notering på NASDAQ OMX Copenhagen A/S (""Nasdaq Copenhagen""), og enhver investor bør tage sin egen investeringsbeslutning. Prospektet med tillæg er tilgængeligt for personer i Danmark på NNIT's hovedkontor og, med visse undtagelser, på NNIT's hjemmeside. Bagsværd, den 6. marts 2015 - Novo Nordisk A/S meddeler i dag, at børsnoteringen af NNIT A/S er gennemført med en endelig udbudskurs på 125 kr. pr. aktie. Optagelse til handel og officiel notering på Nasdaq Copenhagen af NNIT-aktierne forventes at finde sted i dag under symbolet ""NNIT"" (ISIN DK0060580512). Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1379,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
547,2015-03-06,Novo Nordisk successfully completes Initial Public Offering of NNIT A/S,"NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL This is a press release and does not constitute an offering circular. The offer to acquire securities pursuant to the offering is made, and any investor should make his or her investment decision, solely on the basis of information in the offering circular as supplemented made generally available in Denmark in connection with the offering and admission to trading and official listing on NASDAQ OMX Copenhagen A/S (""Nasdaq Copenhagen""). Copies of the offering circular as supplemented may be obtained by persons in Denmark from NNIT's registered office and, subject to certain exceptions, through the website of NNIT. Bagsværd, Denmark, 6 March 2015 - Novo Nordisk A/S today announced that it has completed the Initial Public Offering of NNIT A/S with a final offer price of DKK 125 per share. Admission to trading and official listing on Nasdaq Copenhagen of the shares of NNIT A/S is expected to take place today under the symbol ""NNIT"" (ISIN DK0060580512).",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1378,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
548,2015-03-02,Novo Nordisk forhøjer det indikative udbudskursinterval for børsnoteringen af NNIT A/S,"MÅ IKKE UDLEVERES, DISTRIBUERES ELLER OFFENTLIGGØRES, DIREKTE ELLER INDIREKTE, I ELLER TIL USA, AUSTRALIEN, CANADA, JAPAN ELLER NOGEN ANDEN JURISDIKTION, HVOR DISTRIBUTION ELLER OFFENTLIGGØRELSE ER ULOVLIG Dette er en pressemeddelelse og udgør ikke et prospekt. Ethvert tilbud om at erhverve værdipapirer i forbindelse med udbuddet skal udelukkende foretages på grundlag af oplysningerne i det prospekt med tillæg, der er offentliggjort i Danmark i forbindelse med udbud og optagelse af værdipapirer til handel og officiel notering på NASDAQ OMX Copenhagen A/S (""Nasdaq Copenhagen""), og enhver investor bør foretage sin egen investeringsbeslutning. Prospektet med tillæg vil være tilgængeligt for personer i Danmark på NNIT's hovedkontor og, med visse undtagelser, på NNIT's hjemmeside. Bagsværd, den 2. marts 2015 - Novo Nordisk meddeler i dag, at det er besluttet at justere det indikative udbudskursinterval for børsnoteringen af NNIT A/S på Nasdaq Copenhagen som nærmere beskrevet i prospektet, som blev offentliggjort den 23. februar 2015. Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1387,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
549,2015-03-02,Novo Nordisk increases indicative offer price range for the initial public offering of NNIT A/S,"NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL This is a press release and does not constitute an offering circular. The offer to acquire securities pursuant to the offering is made, and any investor should make his or her investment decision, solely on the basis of information in the offering circular, as supplemented, made generally available in Denmark in connection with the offering and admission of such securities to trading and official listing on NASDAQ OMX Copenhagen A/S (""Nasdaq Copenhagen""). Copies of the offering circular as supplemented may be obtained by persons in Denmark from NNIT's registered office and, subject to certain exceptions, through the website of NNIT. Bagsværd, Denmark, 2 March 2015 - Novo Nordisk today announced an adjustment to the indicative offer price range for the initial public offering (the ""IPO"") of NNIT A/S on Nasdaq Copenhagen as further described in the offering circular, which was published on 23 February 2015. Further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1386,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
550,2015-02-23,Novo Nordisk A/S fastsætter indikativt kursinterval for den påtænkte børsnotering af NNIT A/S,"MÅ IKKE UDLEVERES, DISTRIBUERES ELLER OFFENTLIGGØRES, DIREKTE ELLER INDIREKTE, I ELLER TIL USA, AUSTRALIEN, CANADA, JAPAN ELLER NOGEN ANDEN JURISDIKTION, HVOR DISTRIBUTION ELLER OFFENTLIGGØRELSE ER ULOVLIG Dette er en pressemeddelelse og udgør ikke et prospekt. Ethvert tilbud om at erhverve værdipapirer i forbindelse med udbuddet skal udelukkende foretages på grundlag af oplysningerne i det prospekt, der er offentliggjort i Danmark i forbindelse med udbuddet, og enhver investor bør foretage sin egen investeringsbeslutning. Prospektet vil være tilgængeligt for personer i Danmark på NNIT's hovedkontor og, med visse undtagelser, på NNIT's hjemmeside. Bagsværd, den 23. februar 2015 - Novo Nordisk meddeler i dag, at prospektet i forbindelse med den påtænkte børsnotering af NNIT A/S på NASDAQ OMX Copenhagen A/S (Nasdaq Copenhagen) nu er offentliggjort. Offentliggørelsen af prospektet sker i forlængelse af meddelelsen den 9. februar 2015 om Novo Nordisks hensigt om at gennemføre en børsnotering. Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1391,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
551,2015-02-23,Novo Nordisk A/S sets indicative price range for the contemplated IPO of NNIT A/S,"NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL This is a press release and does not constitute an offering circular. The offer to acquire securities pursuant to the offering is made, and any investor should make his or her investment decision, solely on the basis of information in the offering circular made generally available in Denmark in connection with the offering. Copies of the offering circular may be obtained by persons in Denmark from NNIT's registered office and, subject to certain exceptions, through the website of NNIT. Bagsværd, Denmark, 23 February 2015 - Novo Nordisk today announced that the offering circular in connection with the contemplated Initial Public Offering (IPO) of NNIT A/S on NASDAQ OMX Copenhagen A/S (Nasdaq Copenhagen) has been published.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1390,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
552,2015-02-20,Novo Nordisk announces positive results for phase 2 trial with oral semaglutide in people with type 2 diabetes,"Bagsværd, Denmark, 20 February 2015 - Novo Nordisk today announced that it has successfully completed the phase 2 trial for OG217SC; an oral formulation of the long-acting GLP-1 analogue semaglutide, investigating dose range, escalation, efficacy and safety of once-daily oral semaglutide compared with oral placebo or once-weekly subcutaneously administered semaglutide in around 600 people with type 2 diabetes treated for 26 weeks. Further information Company announcement No 14 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1393,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
553,2015-02-20,Novo Nordisk annoncerer positive resultater af fase 2-studie med tabletformulering af semaglutid til type 2-diabetes,"Bagsværd, den 20. februar 2015 - Novo Nordisk meddeler i dag, at fase 2-studiet for OG217SC, en tabletformulering af den langtidsvirkende GLP-1-analog semaglutid (oral semaglutid), er succesfuldt afsluttet. Studiet har undersøgt doseringsinterval, dosiseskalering, effekt og sikkerhed for oral semaglutid doseret én gang dagligt sammenlignet med oral placebo eller subkutan semaglutid (givet som injektion i underhuden) én gang ugentligt hos omkring 600 deltagere med type 2-diabetes, som blev behandlet i 26 uger. Yderligere information Selskabsmeddelelse nr. 14 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1392,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
554,2015-02-20,Novo Nordisk A/S: Indkaldelse til ordinær generalforsamling i  Novo Nordisk A/S,"Den ordinære generalforsamling i Novo Nordisk A/S afholdes: torsdag den 19. marts 2015 kl. 14.00 i Bella Center, Indgang Vest, Center Boulevard 5, 2300 København S. Indkaldelse til generalforsamlingen, inklusive appendiks 1: Bestyrelseskandidater og appendiks 2: Reviderede aflønningsprincipper, er vedlagt. Alle selskabets generalforsamlingsvalgte bestyrelsesmedlemmer er på valg. Helge Lund og Hannu Ryöppönen søger ikke genvalg. Bestyrelsen foreslår genvalg af følgende generalforsamlingsvalgte bestyrelsesmedlemmer: Göran Ando (formand), Jeppe Christiansen (næstformand), Bruno Angelici, Liz Hewitt og Thomas Paul Koestler. Bestyrelsen foreslår, at Sylvie Grégoire, Eivind Kolding og Mary Szela vælges som nye bestyrelsesmedlemmer på generalforsamlingen. Sylvie Grégoire er tidligere direktør i Human Genetic Therapies Shire PLC, USA og Schweiz (2007-2013). Bestyrelsen anbefaler valg af Sylvie Grégoire først og fremmest på grund af hendes omfattende viden om de lovgivningsmæssige forhold i både USA og EU, hvor hun har erfaring fra alle faser af et produkts livscyklus fra opdagelse, registrering og prælancering til styring af livscyklus, når produktet er på markedet. Derudover har Sylvie Grégoire viden om finansielle forhold fra bl.a. P&L-ansvar. Eivind Kolding er administrerende direktør for Novo A/S. Bestyrelsen anbefaler valg af Eivind Kolding først og fremmest på grund af hans omfattende ledelseserfaring fra store multinationale selskaber med hovedkontor i Danmark indenfor regulerede markeder samt hans betydelige viden om finansielle forhold. Mary Szela er administrerende direktør for Melinta Therapeutics, Inc., USA.Bestyrelsen anbefaler valg af Mary Szela først og fremmest på grund af hendes store forståelse af kliniske, lovgivningsmæssige og markedsføringsmæssige aspekter af lægemiddelindustrien i Nordamerika, hvor hun har både operationel og strategisk erfaring. Yderligere information Selskabsmeddelelse nr. 13 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1396,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
555,2015-02-20,Notice for the Annual General Meeting of  Novo Nordisk A/S,"The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 19 March 2015 at 2.00 pm (CET) at Bella Center, entrance West, Center Boulevard 5, 2300 Copenhagen S, Denmark. The notice for the Annual General Meeting, including Appendix 1: Candidates for the Board of Directors and Appendix 2: Revised Remuneration Principles is enclosed. All board members elected by the Annual General Meeting are up for election. Helge Lund and Hannu Ryöppönen do not seek re-election. The Board of Directors proposes re-election of the following board members elected by the shareholders: Göran Ando (chairman), Jeppe Christiansen (vice chairman), Bruno Angelici, Liz Hewitt, and Thomas Paul Koestler. The Board of Directors proposes that Sylvie Grégoire, Eivind Kolding and Mary Szela are elected as new members to the Board of Directors at the Annual General Meeting. Ms Grégoire is former president of Human Genetic Therapies Shire PLC, US and Switzerland, from 2007 to 2013. The Board of Directors recommends election of Ms Grégoire primarily because of her deep knowledge of the regulatory environment in both the US and the EU having experience with all phases of the product life cycle from discovery, registration, pre-launch and managing the life cycle while on the market. In addition, Sylvie Grégoire has financial insight from i.a. P&L responsibility. Mr Kolding is chief executive officer of Novo A/S, Denmark. The Board of Directors recommends election of Mr Kolding primarily because of his extensive executive experience in large multinational companies headquartered in Denmark within regulated markets and his significant financial knowledge. Ms Szela is chief executive officer of Melinta Therapeutics, Inc., US. The Board of Directors recommends election of Ms Szela primarily because of her deep understanding of the clinical, regulatory and marketing aspects of the pharmaceutical industry in North America having both operational and strategic experience. Company announcement No 13 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1395,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
556,2015-02-10,Novo Nordisk og Karolinska Institutet indgår samarbejde indenfor diabetes,"Bagsværd, den 10. februar 2015 - Karolinska Institutet og Novo Nordisk har i dag underskrevet en samarbejdsaftale indenfor diabetesområdet. Programmet finansieres i sin helhed af Novo Nordisk. I det nye internationale postdoc-stipendieprogram vil i alt 12 postdoc-forskere blive tilbudt et treårigt stipendium til forskning primært indenfor diabetes og stofskifte. Forskningen skal foregå på Karolinska Institutet i Stockholm, men der vil desuden blive mulighed for forskningsudveksling, der kan foregå i Novo Nordisks forsknings- og udviklingsafdeling i Danmark. ""Novo Nordisk er førende i verden indenfor diabetes, og denne satsning er strategisk vigtig både for dem og os,"" siger professor Anders Hamsten, rektor ved Karolinska Institutet. ""Samarbejdet skaber en unik mulighed for at rekruttere yngre diabetesforskere til Karolinska Institutet."" I en kommentar til samarbejdsaftalen siger Novo Nordisks koncernforskningsdirektør, Mads Krogsgaard Thomsen: ""Men denne aftale kan vi sammen uddanne forskere i at omsætte grundlæggende diabetesforskning til nye potentielle behandlinger for patienterne. Samarbejdet bygger på Karolinska Institutets unikke akademiske og kliniske tradition og Novo Nordisks ekspertise indenfor forskning og udvikling - et samspil, der har stort potentiale for at styrke innovationen og på længere sigt forbedre tilværelsen for patienterne."" ­Novo Nordisk har forsknings- og udviklingsfaciliteter i Danmark, USA, Kina og Indien. Flere end 6.000 medarbejdere er beskæftiget indenfor forskning og udvikling, heraf mange i partnerskab med eksterne bioteknologiske og akademiske forskere. ""Dette samarbejde er endnu et eksempel på Karolinska Institutets ambition om at styrke samarbejdet med erhvervssektoren, i dette tilfælde Novo Nordisk, som er en af Nordens førende lægemiddelvirksomheder,"" siger professor Hans-Gustaf Ljunggren, forskningsdekan ved Karolinska Institutet. En fælles styrekomité med medlemmer fra Karolinska Institutet og Novo Nordisk får det overordnede ansvar for programmet og får ansvar for rekrutteringen af forskere. De fire første forventes at starte i efteråret 2015. Fotos fra indvielsesceremonien ved Karolinska Institutet kan tilsendes ved henvendelse til mediekontaktpersonerne herunder. Karolinska Institutet er et af verdens førende medicinske universiteter. Karolinska Institutets vision er at bidrage væsentligt til forbedring af menneskers sundhed. I Sverige står Karolinska Institutet for over 40% af den medicinske akademiske forskning og har det største udbud af medicinske og sundhedsvidenskabelige uddannelser. Nobelforsamlingen ved Karolinska Institutet udpeger modtagere af Nobelprisen i fysiologi eller medicin. ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1400,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
557,2015-02-10,Novo Nordisk and Karolinska Institutet join forces in the field of diabetes,"Bagsværd, Denmark, 10 February 2015 - test Karolinska Institutet and Novo Nordisk today signed a collaboration agreement in the field of diabetes. The programme will be fully funded by Novo Nordisk. In the new international post-doctoral fellowship programme, a total of 12 post-doctoral researchers will be offered a three-year grant to support their research primarily within the field of diabetes and metabolism. The research will be performed at Karolinska Institutet in Stockholm, Sweden, but there will also be possibility for research exchange performed at Novo Nordisk Research and Development in Denmark. ""Novo Nordisk is the world leader in diabetes, and this initiative is of strategic importance both to them and to us,"" said Professor Anders Hamsten, vice-chancellor at Karolinska Institutet. ""The agreement creates a unique opportunity for recruiting young diabetes researchers to Karolinska Institutet."" In a comment to the collaboration agreement, Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk, said: ""Together, we will train scientists in exploring basic diabetes research and translating this into new potential treatments for patients. Building upon the unique academic and clinical tradition at Karolinska Institutet and our company's excellence in research and development, the collaboration holds great potential to stimulate innovation and ultimately to improve the lives of the patients."" Novo Nordisk has research and development facilities in Denmark, US, China and India. More than 6,000 employees are involved in research and development activities, many of them working in partnerships with external biotech and academic researchers. ""This agreement is yet another example of Karolinska Institutet's ambition to strengthen collaboration with the business community, in this case Novo Nordisk, one of the leading pharmaceutical companies in the Nordic region,"" said Professor Hans-Gustaf Ljunggren, dean of research at Karolinska Institutet. A joint steering committee with members from both Karolinska Institutet and Novo Nordisk will oversee the programme and will be responsible for recruiting researchers.The first four fellows in the programme are expected to start in the autumn of 2015. Photos from the inaugural ceremony at Karolinska Institutet can be sent upon request to the media relations managers below. Karolinska Institutet is one of the world's leading medical universities. Its vision is to significantly contribute to the improvement of human health. Karolinska Institutet accounts for over 40% of the medical academic research conducted in Sweden and offers the country's broadest range of education in medicine and health sciences. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine. ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1399,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
558,2015-02-09,Novo Nordisk A/S søger børsnotering af NNIT A/S,"MÅ IKKE UDLEVERES, DISTRIBUERES ELLER OFFENTLIGGØRES, DIREKTE ELLER INDIREKTE, I ELLER TIL USA, AUSTRALIEN, CANADA, JAPAN ELLER NOGEN ANDEN JURISDIKTION, HVOR DISTRIBUTION ELLER OFFENTLIGGØRELSE ER ULOVLIG Dette er en pressemeddelelse og udgør ikke et prospekt. Ethvert tilbud om at erhverve værdipapirer i forbindelse med udbuddet skal udelukkende foretages på grundlag af oplysningerne i et prospekt, der er offentliggjort i Danmark i forbindelse med udbuddet, og enhver investor bør foretage sin egen investeringsbeslutning. Prospektet vil efter offentliggørelse være tilgængeligt for personer i Danmark på NNIT's hovedkontor og, med visse undtagelser, på NNIT's hjemmeside. Bagsværd, den 9. februar 2015 - Novo Nordisk A/S meddeler i dag, at det er besluttet at søge om børsnotering af NNIT A/S på NASDAQ OMX Copenhagen A/S (""Nasdaq Copenhagen""). NNIT er en af Danmarks førende leverandører af it-service og -rådgivning og leverer en bred vifte af it-løsninger til virksomhedens kunder. NNIT er et helejet datterselskab af Novo Nordisk A/S.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1406,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
559,2015-02-09,Novo Nordisk A/S seeks an initial public offering of NNIT,"NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL This is a press release and does not constitute an offering circular. The offer to acquire securities pursuant to the offering is made, and any investor should make his or her investment decision, solely on the basis of information in any offering circular made generally available in Denmark in connection with the offering. Copies of the offering circular may, following publication, be obtained by persons in Denmark from NNIT's registered office and, subject to certain exceptions, through the website of the NNIT. Bagsværd, Denmark, 9 February 2015 - Novo Nordisk A/S today announced the decision to seek an Initial Public Offering (IPO) of NNIT A/S on NASDAQ OMX Copenhagen A/S (Nasdaq Copenhagen). NNIT is one of Denmark's leading IT service providers and consultancies, offering a range of IT services and solutions to its customers. NNIT is a fully-owned subsidiary of Novo Nordisk A/S.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1405,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
560,2015-02-05,Novo Nordisk files annual report with the SEC,"Bagsværd, Denmark, 5 February 2015 - Novo Nordisk A/S has filed its Annual Report 2014 on Form 20-F for the financial year 2014 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2014. The reports are available at the SEC's website, www.sec.gov, as well as on novonordisk.com. Shareholders and ADR holders may receive a hard copy of the annual reports free of charge upon request by filling out a request form on novonordisk.com or upon request to kasq@novonordisk.com - please state the exact mailing address and the document(s) you wish to receive.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1409,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
561,2015-02-03,Novo Nordisk har udgivet sin årsrapport for 2014,"Bagsværd, 3. februar 2015 - Novo Nordisk har udgivet sin årsrapport for 2014 online på novonordisk.com/annualreport. Det er virksomhedens 11. integrerede årsrapport, som redegør for virksomhedens finansielle, sociale og miljømæssige resultater. Årsrapporten udarbejdes nu udelukkende på engelsk. Et nyt årsskrift rummer en dansk udgave af ledelsesberetningen samt uddrag af koncernregnskabet. Begge publikationer vil være tilgængelige på tryk senere i denne måned.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1411,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
562,2015-02-03,Novo Nordisk publishes its 2014 Annual Report,"Bagsværd, Denmark, 3 February 2015 - Novo Nordisk has published its 2014 annual report online at novonordisk.com/annualreport. It is the company's eleventh integrated annual report detailing the company's financial, social and environmental performance. The annual report will be available in print later this month.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1410,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
563,2015-01-30,Novo Nordisks resultat af primær drift i lokale valutaer steg med 13% i 2014,"8% salgsvækst i lokale valutaer drevet af vækst i salget af Levemir® og Victoza® Salget steg med 8% i lokale valutaer og med 6% opgjort i kroner til 88,8 mia. kr. Bruttomarginen steg med 0,5 procentpoint opgjort i kroner til 83,6% drevet af en gunstig udvikling i priser og en positiv påvirkning fra produktsammensætning. Resultat af primær drift steg med 13% opgjort i lokale valutaer og med 10% i kroner til 34,5 mia. kr. Nettoresultatet steg med 5% til 26,5 mia. kr. Udvandet resultat pr. aktie steg med 8% til 10,07 kr. Lanceringen af Tresiba® fortsætter. I Japan har Tresiba® nu opnået en andel af markedsværdien for basal insulin på 26% opgjort på månedsbasis siden lanceringen i marts 2013. I december 2014 godkendte de amerikanske sundhedsmyndigheder (FDA) Saxenda® (liraglutid 3 mg), den første humane GLP-1-analog (glukagonlignende peptid-1) til dosering én gang dagligt til behandling af fedme. For 2015 forventes en salgsvækst på 6-9% og en vækst i resultat af primær drift på omkring 10%, begge dele opgjort i lokale valutaer. Som følge af styrkelsen af vigtige faktureringsvalutaer og den relaterede effekt af valutaafdækningen ventes det rapporterede resultat af primær drift at stige med omkring 29%, mens resultatet før skat ventes at stige med ca. 16%. Bestyrelsen vil på generalforsamlingen den 19. marts 2015 fremsætte forslag om en 11% stigning i udbyttebetalingen til 5,00 kr. pr. aktie a 0,20 kr. Bestyrelsen har endvidere besluttet at iværksætte et nyt 12-måneders aktietilbagekøbsprogram på op til 15 mia. kr. Adm. direktør Lars Rebien Sørensen: ""Vi er tilfredse med de finansielle resultater, Novo Nordisk har opnået i 2014, som var et år med flere udfordringer end normalt. Salgsvæksten var overvejende drevet af Levemir® og Victoza®, og vores nye langtidsvirkende insulin, Tresiba®, klarer sig fortsat godt. 2015 bliver et vigtigt år for os med de første lanceringer af Saxenda® og Xultophy® samt væsentlige resultater fra vores udviklingsportefølje."" Kontaktoplysninger Selskabsmeddelelse nr. 7 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1415,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
564,2015-01-30,Novo Nordisk increased operating profit in local currencies by 13% in 2014,"Sales growth of 8% in local currencies driven by growth in sales ofLevemir® and Victoza® Sales increased by 8% in local currencies and by 6% in Danish kroner to 88.8 billion. Gross margin improved by 0.5 percentage point in Danish kroner to 83.6% driven by a favourable price development and a positive impact from product mix. Operating profit increased by 13% in local currencies and by 10% in Danish kroner to DKK 34.5 billion. Net profit increased by 5% to DKK 26.5 billion. Diluted earnings per share increased by 8% to DKK 10.07. The roll-out of Tresiba® continues. In Japan, Tresiba® has now captured 26% of the basal insulin market measured in monthly value market share since its launch in March 2013. In December 2014, the US Food and Drug Administration (FDA) approved Saxenda® (liraglutide 3 mg), the first once-daily human glucagon-like peptide-1 (GLP-1) analogue for the treatment of obesity. For 2015, sales growth is expected to be 6-9% and operating profit growth is expected at around 10%, both measured in local currencies. Reflecting the appreciation of key invoicing currencies and the related currency hedging effects, operating profit as reported is expected to grow by around 29%, whereas pre-tax profit is expected to grow approximately 16%. At the Annual General Meeting on 19 March 2015, the Board of Directors will propose an 11% increase in dividend to DKK 5.00 per share of DKK 0.20. The Board of Directors has furthermore decided to initiate a new 12-months share repurchase programme of up to DKK 15 billion. Lars Rebien Sørensen, president and CEO: ""We are pleased with Novo Nordisk's financial performance in 2014; a more challenging year than usual. Levemir® and Victoza® drove most of our sales growth, and our new long-acting insulin Tresiba® continues to perform well. 2015 will be an important year for us with the first launches of Saxenda® and Xultophy® as well as significant results from our late-stage development portfolio."" Further information Company announcement No 7 / 2015 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1414,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
565,2015-01-22,Novo Nordisk receives positive opinion from the European regulatory authorities for Saxenda® (liraglutide 3 mg) for the treatment of obesity,"Bagsværd, Denmark, 22 January 2015 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinion for the use of Saxenda® (liraglutide 3 mg) for the treatment of obesity. Saxenda®, the intended brand name of liraglutide 3 mg, is a once-daily glucagon-like peptide-1 (GLP-1) analogue, with 97% homology to naturally occurring human GLP-1, a hormone involved in appetite regulation.The CHMP positive opinion recommends that Saxenda® will be indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of >= 30 kg/m2 (obese), or >= 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. For further information Company announcement No 4 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1422,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
566,2015-01-22,Novo Nordisk får positiv udtalelse fra de europæiske registreringsmyndigheder for Saxenda® (liraglutid 3 mg) til behandling af fedme,"Bagsværd, den 22. januar 2015 - Novo Nordisk meddeler i dag, at Udvalget for Humanmedicinske Lægemidler (CHMP) under Det Europæiske Lægemiddelagentur (EMA) har afgivet en positiv udtalelse om brug af Saxenda® (liraglutid 3 mg) til behandling af fedme. Saxenda®, det planlagte varemærke for liraglutid 3 mg,er en GLP-1-analog (glukagonlignende peptid-1) til dosering én gang dagligt. Den har 97% lighed med kroppens eget GLP-1, som er et hormon, der regulerer appetitten. CHMP anbefaler, at Saxenda® indiceres som supplement til en kaloriereduceret diæt og øget fysisk aktivitet til vægtregulering hos voksne med et BMI på >=30 kg/m2 (svært overvægtig) eller >=27 kg/m2 til <30 kg/m2 (overvægtig) med mindst én vægtrelateret komplikation såsom dysglykæmi (prædiabetes eller type 2-diabetes), hypertension (forhøjet blodtryk), dyslipidæmi (lipidforstyrrelser i blodet) eller obstruktiv søvnapnø. Selskabsmeddelels nr 4 / 2015",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1421,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
567,2014-12-23,Novo Nordisk receives FDA approval for Saxenda® for the treatment of obesity,"Bagsværd, Denmark, 23 December 2014 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Saxenda® (liraglutide 3 mg), the first once-daily human glucagon-like peptide-1 (GLP-1) analogue for the treatment of obesity. Saxenda® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI =>30 kg/m2) or who are overweight (BMI =>27 kg/m2) with at least one weight-related comorbidity such as type 2 diabetes and cardiovascular disease. For further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1430,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
568,2014-12-23,Novo Nordisk får FDA-godkendelse for Saxenda® til behandling af fedme,"Bagsværd, den 23. december 2014 - Novo Nordisk meddeler i dag, at de amerikanske sundhedsmyndigheder (FDA) har godkendt registreringsansøgningen for Saxenda® (liraglutid 3 mg), den første humane GLP-1-analog (glukagonlignende peptid-1) til dosering én gang dagligt til behandling af fedme. Saxenda® er indiceret som supplement til en kaloriereduceret diæt og øget fysisk aktivitet til kronisk vægtregulering hos svært overvægtige voksne (BMI =>30 kg/m2) eller overvægtige voksne (BMI =>27 kg/m2) med mindst én vægtrelateret komplikation (komorbiditet) såsom type 2-diabetes og hjerte-kar-sygdom. Selskabsmeddelelse nr. 77/ 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1431,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
569,2014-12-19,Tresiba® receives positive opinion from CHMP for treatment of children with diabetes,"Copenhagen, Denmark, 19 December 2014 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for expanded use of Tresiba® (insulin degludec) in children and adolescents aged 1-17 years with diabetes. Once the European Commission approves the label expansion, physicians in the European Union will be able to prescribe Tresiba® to children with type 1 and type 2 diabetes. According to the International Diabetes Federation, an estimated 497,100 children are living globally with type 1 diabetes and rates of type 2 diabetes among children are also on the increase1. ""When treating children and adolescents with diabetes, getting patients to target while minimising side effects is always a priority,"" said Dr Nandu Thalange, paediatric endocrinologist at Norfolk and Norwich University Hospital, Norwich, United Kingdom and the lead study investigator of the BEGIN® YOUNG 1 trial. ""This latest CHMP recommendation for Tresiba® offers patients between the ages of 1 and 17 a new once-daily basal insulin which allows patients to get to target with a reduced risk of hyperglycaemia with ketosis versus insulin detemir.""The positive CHMP opinion for expanded use of Tresiba® in children and adolescents is based on efficacy and tolerability data from the BEGIN® YOUNG 1 trial, which is the first study to look into the long-term safety of Tresiba® in children with type 1 diabetes. Results show that Tresiba® given once daily in combination with insulin aspart effectively improved long-term glycaemic control2. Tresiba® was approved in Europe in 2013 for once-daily use in adults with type 1 and type 2 diabetes as a monotherapy and in combination with oral anti-diabetic (OAD) medicinal products or with mealtime insulin. In May 2014, Tresiba® was approved for combination use with GLP-1 receptor agonists3. About the studyThe BEGIN® YOUNG 1 trial was a randomised controlled, 26-week open-label, treat-to-target trial (with a 26-week extension) investigating the efficacy and safety of Tresiba®, given once daily, and insulin detemir, given once or twice daily, both in combination with bolus insulin aspart in children and adolescents with type 1 diabetes2. Tresiba® met the primary endpoint of non-inferiority to insulin detemir for mean change in HbA1c (p<0.05) at 26 weeks. In the 26-week extension a lower insulin dose and a significantly greater reduction in fasting plasma glucose (FPG[1]) versus insulin detemir (p<0.05) was achieved2. Both regimens had similar rates of overall and nocturnal hypoglycaemia, and the rate of severe hypoglycaemia was numerically higher with Tresiba® plus insulin aspart2. Of note, patients on Tresiba® had significantly lower rates of hyperglycaemia with ketosis (p<0.05)2. Weight (measured as SD score[2]) increased with Tresiba® and remained unchanged with insulin detemir2. Adverse event profiles were similar for Tresiba® and insulin detemir2. About Tresiba® Tresiba® (insulin degludec) is a once-daily basal insulin that provides an ultra-long duration of action beyond 42 hours3,4. It is important for people with type 1 and type 2 diabetes to establish a routine for insulin treatment. On occasions when administration at the same time of day is not possible, Tresiba® allows for flexibility in day-to-day dosing time when needed3,5,6. Tresiba® has received regulatory approval in Argentina, Aruba, Azerbaijan, Bangladesh, Bosnia & Herzegovina, Brazil, Chile, Colombia, Costa Rica, El Salvador, the EU, Honduras, Hong Kong, Iceland, India, Israel, Japan, Kazakhstan, Lebanon, Lichtenstein, Macedonia, Mexico, Nepal, Norway, Russia, South Korea, Switzerland and the UAE. Further information References [1] FPG measures the concentration of glucose in the plasma after the patient has not eaten for at least eight hours. [2] Standard deviation (SD) measures the amount of variation from the average. A low standard deviation indicates that the data points are close to the average; a high standard deviation indicates that the data points are spread out over a large range of values.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1434,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
570,2014-12-19,Tresiba® (insulin degludec) får positiv udtalelse fra CHMP til behandling af børn med diabetes,"København, den 19. december 2014 - Udvalget for Humanmedicinske Lægemidler (CHMP) under Det Europæiske Lægemiddelagentur (EMA) har i dag afgivet en positiv udtalelse om udvidet brug af Tresiba® til behandling af børn og unge i alderen 1-17 år med diabetes. Når Europa-Kommissionen har godkendt den udvidede anvendelse, vil lægerne i EU kunne ordinere Tresiba® til børn med type 1- og type 2-diabetes. Den internationale diabetesforening, IDF, anslår, at 497.100 børn i verden har type 1-diabetes, og forekomsten af type 2-diabetes blandt børn er også stigende[1]. ""Når man behandler børn og unge med diabetes, er der særlig fokus på, at de opnår det anbefalede blodsukkermål med færrest mulige bivirkninger,"" siger dr. Nandu Thalange, børnelæge ved Norfolk and Norwich University Hospital, Norwich, Storbritannien, og forsøgsansvarlig for BEGIN® YOUNG 1-studiet. ""CHMP's seneste anbefaling af Tresiba® åbner mulighed for at behandle børn og unge mellem 1 og 17 år med en ny basalinsulin én gang dagligt, som hjælper dem med at nå det ønskede blodsukkermål med mindre risiko for hyperglykæmi med ketose sammenlignet med insulin detemir."" CHMP's anbefaling af den udvidede brug af Tresiba® til behandling af børn og unge er baseret på effekt- og tolerabilitetsdata fra BEGIN® YOUNG 1, som er det første studie, der har undersøgt den langsigtede sikkerhed for Tresiba® hos børn med type 1-diabetes. Resultaterne viser, at Tresiba® givet én gang dagligt i kombination med insulin aspart forbedrede den langsigtede blodsukkerregulering[2]. Tresiba® blev godkendt i Europa i 2013 til brug én gang dagligt hos voksne med type 1- og type 2-diabetes som monoterapi, i kombination med diabeteslægemidler i tabletform samt i kombination med måltidsinsulin. I maj 2014 blev Tresiba® godkendt til kombinationsbehandling med GLP-1-receptoragonister[3]. BEGIN® YOUNG 1-studiet blev gennemført som et randomiseret, kontrolleret, 26-ugers ikke-blindet treat to target-studie (med en 26-ugers forlængelse), der undersøgte effekt og sikkerhed for Tresiba® doseret én gang dagligt og insulin detemir doseret én eller to gange dagligt, begge i kombination med bolus insulin aspart hos børn og unge med type 1-diabetes2. Tresiba® opfyldte det primære målepunkt om ikke-inferiøritet overfor insulin detemir for gennemsnitlig ændring i HbA1c (p<0,05) ved 26 uger. I 26-ugers forlængelsen opnåedes en lavere insulindosis og en signifikant større reduktion i fasteblodsukkeret[*] sammenlignet med insulin detemir (p<0,05)2. Begge behandlingsregimer havde sammenlignelige forekomster af generel og natlig hypoglykæmi, og forekomsten af alvorlig hypoglykæmi var numerisk højere med Tresiba® plus insulin aspart2. Desuden havde patienter, der blev behandlet med Tresiba®, en signifikant lavere forekomst af hyperglykæmi (højt blodsukker) med ketose (p<0,05)2. Vægten (målt som SD-score**) steg med Tresiba® og forblev uændret med insulin detemir2. Bivirkningsprofilerne var sammenlignelige for Tresiba® og insulin detemir2. Tresiba® (insulin degludec) er en basalinsulin til dosering én gang dagligt med en lang virkningsvarighed på mere end 42 timer3,[4]. Det er vigtigt for mennesker med type 1- og type 2-diabetes at etablere en rutine for deres insulinbehandling, men i situationer, hvor det ikke er muligt at tage insulin på samme tidspunkt af dagen, giver Tresiba® mulighed for fleksibilitet med hensyn til injektionstidspunktet3,[5],[6]. Tresiba® er godkendt i Argentina, Aruba, Aserbajdsjan, Bangladesh, Bosnien & Hercegovina, Brasilien, Chile, Colombia, Costa Rica, El Salvador, EU, Forenede Arabiske Emirater, Honduras, Hongkong, Island, Israel, Indien, Japan, Kasakhstan, Libanon, Lichtenstein, Makedonien, Mexico, Nepal, Norge, Rusland, Schweiz og Sydkorea. [*] Fasteblodsukkeret er koncentrationen af glukose i plasma, målt når patienten ikke har spist i mindst otte timer ** Standardafvigelsen er udtryk for afvigelse fra gennemsnittet. En lav standardafvigelse indikerer, at dataværdierne er tæt på gennemsnittet; en høj standardafvigelse indikerer, at dataværdierne er spredt over et stort interval. [1]    International Diabetes Federation. Diabetes Atlas, sixth edition. The global burden. Available at: http://www.idf.org/sites/default/files/EN_6E_Ch2_the_Global_Burden.pdf Last accessed: November 2014. [2]    Thalange N, et al. Long-term efficacy and safety of insulin degludec in combination with bolus insulin aspart in children and adolescents with type 1 diabetes. Diabetologia. 2014;57(Suppl.1): S395. [3]    Tresiba® Summary of Product Characteristics. Bagsværd, Denmark, Novo Nordisk A/S; 2014. [4]    Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014;53:787-800. [5]    Meneghini L, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily. Diabetes Care. 2013;36:858-64. [6]    Mathieu C, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab. 2013;98:1154-62.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1435,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
571,2014-12-07,"Fase 3-data for NovoEight® viser, at frekvensen af blødninger reduceres over tid hos mennesker med hæmofili A","lSan Francisco, USA, den 7. december 2014 - Novo Nordisk offentliggør i dag på en konference for læger med speciale i hæmatologi i San Fransisco, USA, en ny analyse af fase 3-data for NovoEight® (turoctocog alfa) til behandling af blødersygdommen hæmofili A. Analysen viser, at de deltagere, som ved starten på behandling med NovoEight® havde den højeste årlige blødningsfrekvens, opnåede den største reduktion i antallet af blødninger i behandlingsforløbet. De nye data for det rekombinante faktor VIII-produkt (rFVIII) NovoEight® præsenteres i dag på det 56. årsmøde i American Society of Hematology (ASH).[1] Post hoc-analysen fra guardian(TM)2-studiet viser desuden, at voksne og unge ved fortsat behandling med NovoEight® reducerede den årlige blødningsfrekvens på henholdsvis 69% og 63% sammenlignet med resultaterne fra guardian(TM)1. Guardian(TM)1 (og guardian(TM)3) viste, at NovoEight® var virkningsfuldt til at forebygge og reducere blødninger uden tegn på udvikling af inhibitorer (neutraliserende antistoffer) hos 213 tidligere behandlede patienter.[2],[3] ""Analysen indikerer, at forebyggende behandling med NovoEight® ikke blot reducerer en høj blødningsfrekvens ved behandlingens start, men også fastholder en lav blødningsfrekvens over tid hos patienter, så længe de er i behandling med NovoEight®,"" siger forsøgsleder, læge og ph.d. Margareth Ozelo fra Hemocentre, IHTC, University of Campinas, Sao Paulo, Brasilien. De almindeligste bivirkninger (=>0,5%), der blev observeret i studiet, var reaktioner på injektionsstedet, øgede leverenzymer og feber.[4]  NovoEight® er godkendt af de amerikanske sundhedsmyndigheder, FDA, (oktober 2013) og de europæiske lægemiddelmyndigheder, EMA, (november 2013) til behandling og forebyggelse af blødning hos patienter med hæmofili A. NovoEight® er også godkendt i Japan (januar 2014), Australien (januar 2014) og Schweiz (februar 2014), og registreringsansøgninger er indsendt i en række andre lande.  Det afsluttende kliniske udviklingsprogram guardian(TM) er et af de største og mest omfattende programmer inden registrering indenfor hæmofili, og flere end 210 mennesker med svær hæmofili A er blevet behandlet i dette program. Guardian(TM)2-studiet er en forlængelse af det kliniske program. Post hoc-analysen af guardian(TM)2-studiet omfattede 166 patienter, som havde deltaget i guardian(TM)2 foruden enten guardian(TM)1 eller 3, havde modtaget <=1 uges behandling i forbindelse med kirurgi i guardian(TM)1 eller 3 (indledende periode), og havde haft =>3 måneders eksponering for turoctocog alfa som forebyggende behandling i en udvalgt periode (1. januar 2012-30. juni 2013) i guardian(TM)2.  Hæmofili er en kronisk, arvelig blødersygdom, som primært rammer mænd. Mennesker med hæmofili A mangler helt eller delvist koagulationsfaktor VIII, som er et af de proteiner, der normalt findes i blodet og er nødvendige for, at blodet kan størkne. Mennesker med hæmofili A har tendens til at bløde i længere tid end normalt eller til at få indre blødninger i muskler, led eller organer, fordi de mangler denne koagulationsfaktor. For at behandle sygdommen og standse blødninger hos mennesker med hæmofili A er det nødvendigt at tilføre den manglende koagulationsfaktor VIII ved intravenøs injektion, dvs. indsprøjtning i en vene.[5]  Det skønnes, at der på verdensplan er flere end 400.000 mennesker med hæmofili.[6] Sygdommen er stærkt underdiagnosticeret i udviklingslandene.   [1]    Ozelo M. et al. Changes in annualized bleeding rate over time and relationship with dosing of turoctocog alfa during the guardian(TM) programme. Poster presentation #2850. 56th Annual Meeting and Exposition of the American Society of Hematology. December 6-9, 2014. [2]    Lentz SR. et al. Results from a large multinational clinical trial (guardian(TM)1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia. 2013; 19(5):691-697. [3]    Kulkarni R. et al. Results from a large multinational clinical trial (guardian(TM)3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics. Haemophilia. 2013; 19(5):698-705. [4]    Novoeight® (Antihemophilic Factor [Recombinant]) Prescribing Information. Plainsboro, NJ: Novo Nordisk Inc.; November 2014. [5]    Srivastava A., et al. Guidelines for the management of hemophilia. Haemophilia. 2013; 19(1):e1-e47. [6]    National Hemophilia Foundation. Fast Facts. http://www.hemophilia.org/About-Us/Fast-Facts.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1443,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
572,2014-12-07,"NovoEight®, phase 3 data show reduction in annualised bleeding rate over time in people with haemophilia A","San Francisco, US, 7 December 2014 - Today, Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia A who had the highest annualised bleeding rate (ABR) during initial treatment with NovoEight® (turoctocog alfa) showed the largest reduction in bleeding over the duration of treatment. Data for the recombinant factor VIII (rFVIII) product NovoEight® were presented at the 56th Annual Meeting of the American Society of Hematology (ASH).1 The post hoc analysis from the guardian(TM)2 trial further found that, when continued on treatment with NovoEight®, adults and adolescents showed reductions of 69% and 63%, respectively, in ABR compared with their ABRs from guardian(TM)1. The guardian(TM)1 trial (along with guardian(TM)3) showed that NovoEight® was efficacious in preventing and reducing bleeds with no confirmed inhibitor development in 213 previously treated patients.2,3 ""This post hoc analysis gives an indication that patients with high baseline bleed rate can benefit from prophylaxis with NovoEight®, as well as patients who maintain low ABR,"" said Margareth Ozelo, M.D., Ph.D., Hemocentre, IHTC, University of Campinas, Sao Paulo, Brazil, and lead investigator.  The most common adverse reactions (=>0.5%) seen in the study were injection site reactions, increased hepatic enzymes, and fever.4  About NovoEight® NovoEight® is approved by the US Food and Drug Administration (October 2013) and the European Medicines Agency (November 2013) for the treatment and prophylaxis of bleeding in patients with haemophilia A. NovoEight® is also approved in Japan (January 2014), Australia (January 2014), and Switzerland (February 2014), and applications for regulatory approvals have been submitted in a range of other countries. About guardian(TM) The pivotal guardian(TM) clinical programme is one of the largest and most comprehensive preregistration clinical trial programmes in haemophilia, with more than 210 patients with severe haemophilia A treated. The guardian(TM)2 trial is an extension of the clinical programme. The post hoc analysis of the guardian(TM)2 trial involved 166 patients who had participated in guardian(TM)2 and either guardian(TM)1 or 3, had <=1 week of surgery treatment in guardian(TM)1 or 3 (initial period), and had =>3 months of exposure to turoctocog alfa prophylaxis during a selected time period (1 January 2012-30 June 2013) in guardian(TM)2. About Haemophilia A Haemophilia is a chronic, inherited bleeding disorder that primarily affects males. People with haemophilia A are either missing or have a malfunctioning factor VIII protein, which is essential for proper blood clotting. People with haemophilia A have a tendency to bleed longer than most or to bleed internally into muscles, joints or organs because they are missing this clotting factor. To manage the disease and stop bleeding, people with haemophilia A must replace the missing factor VIII protein, which is accomplished by intravenous injection of the clotting factor.5 Globally, it is estimated that more than 400,000 people have haemophilia.6 The disease is severely underdiagnosed in developing countries. About Novo Nordisk Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 41,000 employees in 75 countries, and markets its products in more than 180 countries. For more information, visit novonordisk.com.  References",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1442,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
573,2014-11-24,Ændringer i Novo Nordisks koncerndirektion,"Bagsværd, den 24. november 2014 - Novo Nordisk har ændret ansvarsfordelingen i koncerndirektionen og reducerer som følge heraf antallet af koncerndirektører fra syv til seks. I forbindelse hermed har koncerndirektør Lise Kingo besluttet at forlade Novo Nordisk. Med virkning fra i dag overtages hendes ansvarsområder af andre medlemmer af koncerndirektionen: Adm. direktør Lars Rebien Sørensen siger i forbindelse med ændringerne: ""Jeg vil gerne takke Lise for den store indsats, hun har ydet igennem sin imponerende karriere i Novo Nordisk. Især vil jeg gerne fremhæve hendes lederskab i udviklingen af virksomhedens strategi indenfor bæredygtig udvikling, corporate branding og public affairs, som har været stærkt medvirkende til, at Novo Nordisk i dag nyder anseelse som en velrespekteret global virksomhed. Jeg ønsker hende alt mulig held og lykke fremover."" Lise Kingo siger: ""Jeg har nydt at være en del af Novo Nordisk gennem hele min karriere, ikke mindst min tid som medlem af koncerndirektionen. Det har været en fantastisk rejse, og jeg ønsker virksomheden og mine kolleger alt det bedste i deres videre færd. Dette er begyndelsen til et nyt kapitel, hvor jeg vil bruge min erfaring og viden i virksomhedsbestyrelser og organisationer internationalt."" Novo Nordisks koncerndirektion består herefter af: Lars Rebien Sørensen, adm. direktør (chief executive officer). Kåre Schultz, viceadministrerende direktør (president and chief operating officer), ansvarlig for Sales og Product Supply. Jesper Brandgaard, koncerndirektør (chief financial officer), ansvarlig for Finance, Legal og Investor Relations. Lars Fruergaard Jørgensen, koncerndirektør, ansvarlig for Corporate IT, Corporate Quality, Corporate Development, Corporate People & Organisation og Business Assurance. Jakob Riis, koncerndirektør, ansvarlig for Marketing, Medical Affairs og Corporate Stakeholder Engagement. Mads Krogsgaard Thomsen, koncerndirektør (chief science officer), ansvarlig for Research, Development og Regulatory Affairs.  Yderligere information Selskabsmeddelelse nr. 72 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1449,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
574,2014-11-24,Changes in Novo Nordisk's Executive Management,"Bagsværd, Denmark, 24 November 2014 - Following a change in the distribution of responsibilities among the members of its Executive Management, Novo Nordisk has reduced the number of executives from seven to six. In this connection Executive Vice President and Chief of Staffs Lise Kingo has decided to leave Novo Nordisk. Her areas of responsibility will be taken over by other members of Executive Management. As from today:  Commenting on the changes, Lars Rebien Sørensen, CEO, says: ""I would like to thank Lise for her many contributions to Novo Nordisk during her impressive career in the company. Of special note is her leadership in driving the company's strategy within sustainable development, corporate branding and public affairs, which has earned Novo Nordisk recognition as a respected global business. I wish her the best of luck in the future."" Lise Kingo says: ""I have really enjoyed being part of Novo Nordisk throughout my career, not least during my time as a member of its Executive Management. It has been a fantastic journey and I wish the company and my colleagues all the best in their onward journey. This is the beginning of a new chapter in which I plan to utilise my experience and insights in boards of companies and organisations internationally."" Following the above-mentioned changes, Novo Nordisk's Executive Management is now composed as follows: Lars Rebien Sørensen, CEO (chief executive officer) Kåre Schultz, president and COO (chief operating officer), responsible for Sales and Product Supply. Jesper Brandgaard, executive vice president and CFO (chief financial officer), responsible for Finance, Legal, and Investor Relations. Lars Fruergaard Jørgensen, executive vice president, responsible for Corporate IT, Corporate Quality, Corporate Development, Corporate People & Organisation and Business Assurance. Jakob Riis, executive vice president, responsible for Marketing, Medical Affairs and Corporate Stakeholder Engagement. Mads Krogsgaard Thomsen, executive vice president and chief science officer, responsible for Research, Development and Regulatory Affairs. Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 41,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com. Company announcement No 72 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1448,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
575,2014-11-21,Victoza® (liraglutid) får positiv udtalelse fra CHMP for anvendelse til voksne med type 2-diabetes og moderat nedsat nyrefunktion,"København, den 21. november 2014 - Udvalget for Humanmedicinske Lægemidler (CHMP) under Det Europæiske Lægemiddelagentur (EMA) har i dag afgivet en positiv udtalelse om brug af Victoza® til behandling af voksne med type 2-diabetes og moderat nedsat nyrefunktion. Når Europa-Kommissionen har godkendt den udvidede anvendelse, vil lægerne i EU kunne ordinere Victoza®, den humane GLP-1-analog (glukagonlignende peptid-1) til dosering én gang dagligt, til voksne med type 2-diabetes og moderat nedsat nyrefunktion uden dosisjusteringer. Nedsat nyrefunktion er en udfordrende og almindelig senkomplikation ved type 2-diabetes, som kræver hyppig monitorering af blodsukkerniveau og nyrefunktion. Afhængig af alder, hvor længe man har haft diabetes, og hvor velreguleret blodsukkeret er, vil op til 40% af mennesker med type 2-diabetes udvikle nedsat nyrefunktion i en eller anden grad.[1] ""Det er meget almindeligt, at mennesker med type 2-diabetes har nedsat nyrefunktion, og der findes et begrænset udvalg af blodsukkersænkende lægemidler til behandling af mennesker med begge tilstande,"" siger Melanie Davies, professor i diabetesmedicin, overlæge ved Diabetes Research Centre, University of Leicester, Storbritannien, og forsøgsansvarlig i studiet. ""Den udvidede anvendelse giver lægerne en ekstra mulighed for at hjælpe patienter med type 2-diabetes og moderat nedsat nyrefunktion med at opnå en god blodsukkerregulering."" CHMP's anbefaling af Victoza® er baseret på effekt- og sikkerhedsdata fra det kliniske fase 3b-studie LIRA-RENAL. Om LIRA-RENAL-studietStudiet, der var tilrettelagt som et 26-ugers dobbeltblindet, randomiseret, kontrolleret klinisk forsøg, undersøgte effekt og sikkerhed for Victoza® sammenlignet med placebo anvendt som tillægsbehandling til igangværende behandling med et diabeteslægemiddel i tabletform og/eller insulin hos voksne med type 2-diabetes og moderat nedsat nyrefunktion.[2] Studiet viste bl.a.:[3] Om Victoza® Victoza® (liraglutid) er en human GLP-1-analog (glukagonlignende peptid-1) med en aminosyresekvens, der har 97% lighed med det GLP-1, kroppen selv producerer. Ligesom naturligt GLP-1 virker Victoza® ved at stimulere betacellerne til at frigive insulin og ved at undertrykke glukagonsekretionen fra alfacellerne, når blodsukkerniveauet er højt. Som følge af denne glukoseafhængige virkningsmekanisme er Victoza® forbundet med en lav forekomst af hypoglykæmi (lavt blodsukker)*. Victoza® reducerer desuden legemsvægt og kropsfedtmasse gennem mekanismer, der involverer reduceret appetit og mindre madindtag. Victoza® er ikke godkendt til vægtregulering hos mennesker, som ikke har type 2-diabetes. Victoza® blev lanceret i EU i 2009 og er på markedet i flere end 70 lande med over 2,3 mio. patientårs eksponering hos mennesker med type 2-diabetes globalt. I Europa er Victoza® godkendt til regulering af blodsukkerniveauet hos voksne med type 2-diabetes som tillægsbehandling til diabeteslægemidler i tabletform og/eller basal insulin, når blodsukkeret ikke kan holdes tilstrækkeligt under kontrol med disse lægemidler i kombination med motion og diæt.[4] I USA blev Victoza® godkendt den 25. januar 2010 som supplement til diæt og motion med det formål at forbedre blodsukkerreguleringen hos voksne med type 2-diabetes.[5] * Hypoglykæmi er primært observeret, når Victoza® kombineres med et sulfonylurinstof. [1] Bailey CJ, Day C. Diabetes therapies in renal impairment. B J Diabetes Vas Dis 2012; 12(4):167-171. [2] ClinicalTrials.gov study registration: NCT01620489. [3] Davies M, et al. Efficacy and Safety of Liraglutide versus Placebo as Add-on to Existing Diabetes Medication in Subjects with Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL). Poster 0965-P at 74th Scientific Sessions of the American Diabetes Association (ADA), 15 June 2014. [4] EMA. Victoza® EU Summary of Product Characteristics. Available at: http://www.medicines.org.uk/emc/medicine/21986/ Last accessed 31.10.2014. [5] FDA. Victoza® US prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022341lbl.pdf Last accessed 31.10.2014. ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1457,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
576,2014-11-21,Victoza® receives positive CHMP opinion for use in adults with type 2 diabetes and moderate renal impairment,"Copenhagen, Denmark, 21 November 2014 - The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion for the use of Victoza® (liraglutide) in adults with type 2 diabetes and moderate renal impairment. Once the European Commission approves the label expansion, physicians in the European Union will be able to prescribe Victoza®, the once-daily human glucagon-like peptide-1 (GLP-1) analogue, to adults with type 2 diabetes and moderate renal impairment without dose adjustments. Renal impairment is a challenging and common long-term complication of type 2 diabetes that requires frequent monitoring of blood glucose levels and kidney function. Depending on age, duration of diabetes and blood glucose control, up to 40% of people with type 2 diabetes will develop some degree of renal impairment.[1] ""Renal impairment is very common in patients with type 2 diabetes, and the choice of glucose-lowering therapies available to people with both conditions is limited"", said Melanie Davies, professor of Diabetes Medicine and honorary consultant, Diabetes Research Centre, University of Leicester, UK and clinical trial investigator. ""This label update gives physicians an additional treatment option to help their patients with type 2 diabetes and moderate renal impairment achieve glycaemic control."" The CHMP recommendation for Victoza® was based on efficacy and safety data from the LIRA-RENAL phase 3b clinical trial. About the LIRA-RENAL study The 26-week, double-blind, randomised, controlled study investigated the efficacy and safety of Victoza® compared with placebo when added to pre-existing oral antidiabetic treatment, insulin or a combination thereof in adults with type 2 diabetes and moderate renal impairment.[2] Study results include:[3] About Victoza® Victoza® (liraglutide) is a human glucagon-like peptide-1 (GLP-1) analogue with an amino acid sequence 97% similar to endogenous human GLP-1. Like natural GLP-1, Victoza® works by stimulating the beta cells to release insulin and suppressing glucagon secretion from the alpha cells only when blood sugar levels are high. Due to this glucose-dependent mechanism of action, Victoza® is associated with a low rate of hypoglycaemia*. In addition, Victoza® reduces body weight and body fat mass through mechanisms involving reduced appetite and lowered food intake. Victoza® is not approved for weight management or for use in people who do not have type 2 diabetes. Victoza® was launched in the EU in 2009 and is commercially available in more than 70 countries with more than 2.3 million patient years of exposure in people with type 2 diabetes globally. In Europe, Victoza® is indicated for treatment of adults with type 2 diabetes to achieve glycaemic control in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.[4]In the US, Victoza® was approved on 25 January 2010 as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes.[5] * Hypoglycaemia has primarily been observed when Victoza® is combined with a sulfonylurea. Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 41,000 employees in 75 countries, and markets its products in more than 180 countries. References [1] Bailey CJ, Day C. Diabetes therapies in renal impairment. B J Diabetes Vas Dis 2012; 12(4):167-171 [2] ClinicalTrials.gov study registration: NCT01620489 [3] Davies M, et al. Efficacy and Safety of Liraglutide versus Placebo as Add-on to Existing Diabetes Medication in Subjects with Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL). Poster 0965-P at 74th Scientific Sessions of the American Diabetes Association (ADA), 15 June 2014. [4] EMA. Victoza® EU Summary of Product Characteristics. Available at: http://www.medicines.org.uk/emc/medicine/21986/ Last accessed 31.10.2014. [5] FDA. Victoza® US prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022341lbl.pdf Last accessed 31.10.2014. ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1456,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
577,2014-11-17,Novo Nordisk andenbedst i verden til at sikre adgang til medicin,"Bagsværd, den 17. november 2014 - Novo Nordisk er rykket op på andenpladsen i Access to Medicine Index for 2014 fra en sjetteplads i 2012. Novo Nordisks placering er et resultat af virksomhedens fokus på 'adgang til medicin' som en vigtig del af kerneforretningen. Det omfatter blandt andet en differentieret prispolitik, opbygning af lokale kompetencer samt integrering af velgørenhed i forretningsaktiviteterne. I 2013 leverede Novo Nordisk medicin til omkring 24,3 millioner mennesker med diabetes overalt i verden - en stigning på 7% i forhold til 2012. Ambitionen er nu at sikre adgang til 40 millioner mennesker med diabetes inden 2020. ""I dag bor mere end 80% af verdens diabetikere i lav- og mellemindkomstlande, hvor adgangen til medicin og behandling ikke er tilstrækkelig for de mange millioner mennesker med diabetes,"" siger Novo Nordisks administrerende direktør, Lars Rebien Sørensen. ""Sidste år lancerede vi et langsigtet globalt mål for adgang til diabetesbehandling, som skal styrke vores igangværende indsats for at nedbryde de barrierer, der hindrer adgangen til sundhed, og hjælpe os med at nå ud til 40 millioner mennesker med diabetes i 2020."" Siden Novo Nordisk lancerede sin første strategi for adgang til sundhed i 2001, er diabetes blevet en stor sundhedsmæssig udfordring. På verdensplan skønnes der nu at være 387 millioner mennesker med diabetes, og dette tal ventes at stige til over en halv milliard i 2035[1]. Access to Medicine Index for 2014 fremhæver to af Novo Nordisks tiltag indenfor adgang til diabetesbehandling: Base of the Pyramid-projektet og Changing Diabetes® in Children. Base of the Pyramid-projektet samarbejder med lokale kirkelige organisationer om at forbedre mulighederne for diagnosticering, behandling og diabetesundervisning for mennesker på bunden af den økonomiske pyramide i udviklingslandene. Changing Diabetes® in Children leverer gratis medicin, behandling og patientundervisning til børn med type 1-diabetes i lavindkomstlande. ""Vi har den viden, de kompetencer og det engagement, der skal til for at forbedre sundheden for mennesker med diabetes, uanset hvor de bor,"" siger Lars Rebien Sørensen. ""Som verdens førende indenfor diabetesbehandling vil vi fortsætte vores samarbejde med regeringer, sundhedsorganisationer og lokalsamfund for at nå dette mål overalt i verden."" Ranglistningen i Access to Medicine Index for 2014 er baseret på målinger af 21 lægemiddelvirksomheders politik og praksis, når det gælder om at forbedre adgangen til medicin, målt på en række specifikke lande, sygdomme og produkttyper. Indekset offentliggøres hvert andet år af Access to Medicine Foundation. Læs mere om Novo Nordisk og adgang til diabetesbehandling Se hele Access to Medicine Index for 2014 [1] IDF Diabetes Atlas 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1463,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
578,2014-11-17,Novo Nordisk second best in the world at providing access to medicine,"Bagsværd, Denmark, 17 November 2014 - Today, it was announced that Novo Nordisk ranks second on the 2014 Access to Medicine Index, climbing four places since the 2012 Index. Novo Nordisk's ranking is a reflection of the company's inclusion of access to medicine within its core business, including equitable pricing strategies, local capability building and integrating philanthropy with business activities. In 2013, Novo Nordisk provided medical treatments for approximately 24.3 million people with diabetes worldwide, showing a 7% increase compared with 2012. ""Today, more than 80% of people with diabetes live in low- and middle-income countries where access to medicine and treatment is simply not adequate for the millions in need,"" says Lars Rebien Sørensen, chief executive officer at Novo Nordisk. ""Last year, we launched our Strategy for Global Access to Diabetes Care strengthening our already existing efforts to break down barriers that inhibit access to care and help us reach 40 million people living with diabetes by 2020."" Since Novo Nordisk launched its first access to care strategy in 2001, diabetes has become a major global health challenge. There are now an estimated 387 million people worldwide with diabetes and the number is expected to rise to over half a billion by 2035[1]. The 2014 Access to Medicine Index highlighted two of the company's access to diabetes care initiatives - the Base of the Pyramid project and the Changing Diabetes® in Children programme. The Base of the Pyramid project takes an integrated approach together with faith-based organisations to improve diagnosis, treatment and diabetes education for the working poor in developing countries. The Changing Diabetes® in Children programme provides medicine free of cost, treatment and patient education for children living with type 1 diabetes in low-income countries. ""We have the knowledge, capabilities and commitment to improve the health of people living with diabetes regardless of where they live,"" says Lars Rebien Sørensen. ""As the world leader in diabetes care, we will continue to work with governments, health organisations and communities to make this a reality across the globe."" About the Access to Medicine IndexThe ranking of the 2014 Access to Medicine Index is based on measurements of 21 pharmaceutical companies' policies and practices in improving access to medicine across a specific range of countries, diseases and product types. The Access to Medicine Index is published every two years. Read more about Novo Nordisk's approach to access to diabetes care View the full 2014 Access to Medicine Index Further information [1] IDF Diabetes Atlas 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1462,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
579,2014-11-14,Tianjin og Shanghai tilslutter sig Cities Changing Diabetes på Verdensdiabetesdagen,"Bagsværd, den 14. november 2014 - I dag, på Verdensdiabetesdagen, tilslutter de to kinesiske storbyer Tianjin og Shanghai sig initiativet Cities Changing Diabetes, der er et ambitiøst globalt partnerskabsprogram, som har til formål at bremse udviklingen i forekomsten af diabetes i verdens storbyer. Programmet er iværksat af Novo Nordisk og blev lanceret i Mexico City i marts 2014. Siden har København og senest Houston i USA tilsluttet sig initiativet. Ifølge nye tal fra den internationale diabetesforening, IDF, anslås det, at 387 mio. mennesker i verden har diabetes, og at flere end to tredjedele af dem bor i byområder[1]. På globalt plan er der 2-5 gange større risiko for at få type 2-diabetes, hvis man bor i en storby[2]. Cities Changing Diabetes er det første initiativ af sin art, hvis formål det er at få offentlige og private organisationer til at arbejde sammen om at finde bæredygtige løsninger på den store udfordring, verdens storbyer står overfor i forhold til udbredelsen af type 2-diabetes. Formålet med Cities Changing Diabetes er i første omgang at kortlægge problemet, derefter udveksle ideer og bud på løsninger og til slut udarbejde konkrete handlingsplaner for de storbyer, der deltager i programmet. Kina har 96 mio. mennesker med diabetes og dermed en af de højeste forekomster af diabetes i verden[3]. Over halvdelen af dem, der har diabetes i Kina, bor i storbyområder, og Shanghai og Tianjin er nogle af de største storbyer i Kina. Tianjins indbyggertal er fordoblet siden 1995 til omkring 11 mio. mennesker[4], og det anslås, at 9,5% i dag har diabetes[5]. I Shanghai, som har 23,8 mio. indbyggere[6], anslås det, at 12,6% har diabetes[7]. Både The People's Municipal Government of Shanghai og Shanghai Municipal Commission of Health and Family Planning er optaget af at tackle den store udfordring, byen står overfor i forhold til den stigende udbredelse af diabetes. Derfor har myndighederne iværksat en række tiltag for at sætte øget fokus på forebyggelse og behandling af type 2-diabetes og andre kroniske sygdomme. Shanghai hilser derfor alle relevante tiltag, der er baseret på akademisk forskning og innovative partnerskaber, velkomne. I Tianjin gør myndighederne en målrettet indsats for at fremme en sund livsstil, hvilket er helt afgørende i forhold til at bremse udviklingen i forekomsten af type 2-diabetes. Cities Changing Diabetes passer fint ind de initiativer, National Health and Planning Commission allerede har sat i værk for at bremse udviklingen af type 2-diabetes. Tianjin Medical Association og Shanghai Diabetes Institute vil stå i spidsen for den indledende analyse for Cities Changing Diabetes i Kina. Det sker i samarbejde med University College London (UCL) i Storbritannien, der er den globale akademiske partner i programmet. ""Cities Changing Diabetes-partnerskabet vil give et solidt grundlag for at identificere fremtidige initiativer, der kan bidrage til at dæmme op for væksten af diabetes i Shanghai,"" siger professor Jia Weiping fra Shanghai Diabetes Institute. ""Jeg er sikker på, at deltagelsen i Cities Changing Diabetes vil være til gavn for byens forsatte arbejde på at bekæmpe udbredelsen af type 2-diabetes,"" siger Mr. Xiong Zhi, generalsekretær for Tianjin Medical Association. Lars Rebien Sørensen, administrerende direktør for Novo Nordisk, hilser de to storbyer velkommen i partnerskabet: ""Det er mit håb, at vi gennem samarbejdet i Cities Changing Diabetes kan være med til at hjælpe de to byer i deres bestræbelser på at dæmme op for den kæmpemæssige udfordring, som udbredelsen af type 2-diabetes er, og således aktivt være med til at bidrage med løsninger til, hvordan dette alvorlige sundhedsproblem bedst tackles."" Cities Changing Diabetes er et ambitiøst partnerskabsprogram, der skal dæmme op for det voksende problem, som den hastige udbredelse af diabetes udgør i verdens storbyer. Ifølge nye tal, som International Diabetes Federation (IDF) har offentliggjort i dag, anslås det, at 592 mio. mennesker vil have diabetes i 2035. I dag bor næsten to tredjedele af alle med diabetes i storbyerne, og de, der flytter til byen, har betydeligt større risiko for at udvikle type 2-diabetes end dem, der bliver på landet. Formålet med Cities Changing Diabetes er i første omgang at kortlægge problemet i udvalgte storbyområder, derefter udveksle ideer og bud på løsninger og udarbejde handlingsplaner for storbyer i hele verden. Det britiske University College London (UCL) er den globale akademisk partner for initiativet, som også omfatter Steno Diabetes Center i Danmark, en af verdens førende institutioner indenfor diabetesbehandling og -forebyggelse, foruden Novo Nordisk. Se mere på Cities Changing Diabetes - og følg med på Facebook og Twitter. Hvert år den 14. november går Novo Nordisk sammen med International Diabetes Federation (IDF) om at støtte op om FN's resolution om diabetes. Dagen markeres overalt i verden af medarbejdere, partnere, mennesker med diabetes og offentligheden for at sætte fokus på diabetessagen. Dagen er valgt, fordi det er Frederick Bantings fødselsdag. Det var ham, der sammen med Charles Best startede det arbejde, som førte til opdagelsen af insulin i 1921. Siden vedtagelsen af FN's resolution om diabetes i december 2006 er dagen blevet fejret som officiel FN-mærkedag, United Nations World Health Day. Læs mere om kampagnen, som er drevet af International Diabetes Federation. Læs mere om Verdensdiabetesdagen 2014 og slut op om kampen mod diabetes i storbyerne på bit.ly/urbanwdd eller følg @NovoNordisk og brug #UrbanDiabetes og/eller #WDD2014 online. Fotos og dækbilleder til denne pressemeddelelse kan downloades på novonordisk.com. [1] International Diabetes Federation. IDF Diabetes Atlas, 7th edn. Brussels, Belgium: International Diabetes Federation, 2014 [2] Mbanya JC et al. Diabetes in sub-Saharan Africa. Lancet 2010; 375(9733):2254-2266 [3] International Diabetes Federation. IDF Diabetes Atlas, 7th edn. Brussels, Belgium: International Diabetes Federation, 2014 [4] United Nations Department of Economic and Social Affairs, World Urbanization Prospects, the 2014 Revision [5] Xu W et al. Detection of Prediabetes and Undiagnosed Type 2 Diabetes: A Large Population-Based Study, Can J of Diabetes 2012 (36):108-113 [6] United Nations Department of Economic and Social Affairs, World Urbanization Prospects, the 2014 Revision [7] Li, R. Increasing Prevalence of Type 2 Diabetes in Chinese Adults in Shanghai, Diabetes Care 35:1028-1030, 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1465,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
580,2014-11-14,Tianjin and Shanghai join Cities Changing Diabetes on World Diabetes Day,"Bagsværd, Denmark, 14 November 2014 - Today, on World Diabetes Day, the Chinese cities of Tianjin and Shanghai join the Cities Changing Diabetes initiative and the global fight against the urban diabetes epidemic. These two major metropolitan centres are the first Chinese cites to become part of the global partnership programme, which was initiated in Mexico City in March 2014, followed by Copenhagen in Europe and Houston in the United States last week. New numbers released today estimate 387 million people worldwide have diabetes today and more than two thirds hereof live in urban areas[1]. Globally, those who live in cities are two to five times more likely to have type 2 diabetes[2]. Cities Changing Diabetes is a first-of-its-kind collaboration to gather public and private partners to identify practical long-term solutions. The programme seeks to understand the root causes behind the rise in type 2 diabetes in cities and use that knowledge to share and recommend effective interventions. With 96 million people with diabetes, China has one of the highest rates of diabetes in the world[3]. More than half of the people with diabetes live in cities, and Shanghai and Tianjin rank among the largest urban areas in China. Tianjin's population has doubled since 1995 to around 11 million people[4] and an estimated 9.5% now suffering from diabetes[5]. In Shanghai, with a population of 23.8[6] million people, it is estimated that 12.6% have diabetes[7]. The People's Municipal Government of Shanghai and the Shanghai Municipal Commission of Health and Family Planning are committed to tackle the growing urban diabetes challenge. As a consequence, the city is taking active measures to increase the focus on prevention and treatment of type 2 diabetes and other chronic diseases. Shanghai therefore welcomes relevant input based on academic research and innovative partnerships. In Tianjin, the government is very committed to promoting a healthy lifestyle and a balanced diet, which are key factors in tackling type 2 diabetes. The Cities Changing Diabetes initiative fits well into the National Health and Planning Commission's agenda and will support other initiatives to halt the progress of type 2 diabetes. The Tianjin Medical Association and the Shanghai Diabetes Institute will lead the initial research for Cities Changing Diabetes in collaboration with the global academic institution, University College London (UCL) from the UK. ""The Cities Changing Diabetes partnership will provide a solid foundation for identifying future initiatives of high impact to tackle urban diabetes in Shanghai"" said Professor Jia Weiping of the Shanghai Diabetes institute. ""I am confident the city of Tianjin will benefit significantly in the fight against type 2 diabetes by participating in Cities Changing Diabetes"" said Mr. Xiong Zhi, Secretary General of the Tianjin Medical Association. Lars Rebien Sørensen, chief executive officer of Novo Nordisk welcomed the global leadership the two significant cities are showing in the fight against urban diabetes: ""It is my hope that by working in partnership through Cities Changing Diabetes, we can complement and support the cities' objective to reduce the growing type 2 diabetes burden and tackle this urgent problem"". Cities Changing Diabetes is an ambitious partnership programme to fight the urban diabetes challenge. According to new numbers released today by the International Diabetes Federation, IDF, it is estimated that 592 million will have diabetes by 2035. Today, nearly two-thirds of all people with diabetes live in cities, and people who move to cities have a significantly higher risk of developing type 2 diabetes than those who remain in rural settings. The aim of Cities Changing Diabetes is to map the problem in selected urban areas, to share learning and solutions and to drive action to fight the diabetes challenge in cities across the world. University College London (UCL) is the global academic partner for the programme that also includes Steno Diabetes Center, a world-leading institution in diabetes care and prevention in Denmark, and Novo Nordisk. For more information, visit Cities Changing Diabetes - see also Facebook and Twitter About World Diabetes Day Every 14 November, Novo Nordisk partners with the International Diabetes Federation (IDF) in support of the United Nations Resolution on Diabetes. On this day, employees, partners, people with diabetes and the general public unite with a call to change diabetes. The date, 14 November, was chosen because it is the birthday of Frederick Banting who, along with Charles Best, first conceived the idea which led to the discovery of insulin in 1921. Since the adoption of the United Nations Resolution on diabetes in December 2006, World Diabetes Day has become an official United Nations World Health Day.Read more about the campaign driven by the International Diabetes FederationFor more information on World Diabetes Day 2014 and to join the fight against urban diabetes, visit bit.ly/urbanwdd or follow @NovoNordisk and use #UrbanDiabetes and/or #WDD2014 online. Visit novonordisk.com for photos and b-roll supporting this press release. Further information [1] International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels, Belgium: International Diabetes Federation, 2014 update. [2] Mbanya JC et al. Diabetes in sub-Saharan Africa. Lancet 2010; 375(9733):2254-2266 [3] International Diabetes Federation. IDF Diabetes Atlas, 7th edn. Brussels, Belgium: International Diabetes Federation, 2014. [4] United Nations Department of Economic and Social Affairs, World Urbanization Prospects, the 2014 Revision [5] Xu W. et al. Detection of Prediabetes and Undiagnosed Type 2 Diabetes: A Large Population-Based Study, Can J of Diabetes 2012 (36):108-113 [6] United Nations Department of Economic and Social Affairs, World Urbanization Prospects, the 2014 Revision. [7] Li, R, Increasing Prevalence of Type 2 Diabetes in Chinese Adults in Shanghai, Diabetes Care 35:1028-1030, 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1464,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
581,2014-11-04,New phase 3a data demonstrate that 9 out of 10 adults with obesity lost weight with liraglutide 3 mg and clinical trial completers lost an average of 9.2%,"Boston, US, 4 November 2014 - Today, new data from the phase 3a SCALE(TM) Obesity and Prediabetes trial were presented at ObesityWeek 2014, the 2nd Annual Congress of The American Society for Metabolic and Bariatric Surgery and The Obesity Society. 92% (9 out of 10) of trial participants lost weight with liraglutide 3 mg treatment, in combination with diet and exercise, compared with 65% on placebo treatment.[1] People who completed the trial (56 weeks) demonstrated significantly greater weight loss of 9.2% compared with a 3.5% reduction in the placebo group (estimated difference [ED] 5.7%, p<0.0001).1 In addition, weight loss with liraglutide 3 mg was similar across a range of baseline body mass index (BMI) subgroups in people with obesity, from overweight to Class III obesity,* at 56 weeks (p=0.054, %; p=0.54, kg) and independent of prediabetes status at screening (-8.0% with vs -7.9% without, p=0.59).1 A larger proportion of people treated with liraglutide 3 mg completed the trial compared with those on placebo (72% vs. 64%).1 All treatment groups followed a reduced-calorie diet and an increased physical activity programme. Weight loss associated with liraglutide 3 mg was accompanied by improvements in health-related quality of life (HRQoL) as measured by three different questionnaires.[2] Greater improvements were seen with liraglutide 3 mg vs placebo.2 The Impact of Weight on Quality of Life-Lite (IWQoL),[3] total score improved mostly due to better physical function. Both the Short-Form (36) Health Survey (SF-36)[4] summary of physical scores and mental health scores improved.2 ""Obesity is more than a disease of excess weight,"" said Dr Ken Fujioka, Department of Nutrition and Metabolic Research, Scripps Clinic, La Jolla, California and a SCALE(TM) clinical trial investigator. ""We know that people with obesity may experience increased physical and mental health problems, as well as a reduced quality of life. It is encouraging to see data suggesting that the weight loss benefits of liraglutide 3 mg are associated with improved health-related quality of life for people with obesity."" In addition, the total Treatment Related Impact Measure-Weight (TRIM-W)[5] score was better at 56 weeks with liraglutide 3 mg compared with placebo treatment.2 Obesity is a disease[6] that requires chronic management. It is associated with serious comorbidities including type 2 diabetes, heart disease, obstructive sleep apnoea (OSA), certain types of cancer and a decreased life expectancy. The risk of morbidity and mortality increases with the severity of obesity. It is a complex and multi-factorial disease that is influenced by genetic, physiological, environmental and psychological factors. The global increase in the prevalence of obesity is a public health issue that has severe cost implications to healthcare systems. In the US, approximately 35% of adults, equivalent to around 80 million adults, live with obesity.[7],[8] About liraglutide 3 mgLiraglutide 3 mg is a once-daily, glucagon-like peptide-1 (GLP-1) analogue with 97% similarity to naturally occurring human GLP-1, a hormone that is released in response to food intake.[9] Like human GLP-1, liraglutide 3 mg regulates appetite and food intake by decreasing hunger and increasing feelings of fullness and satiety after eating.[10],[11] The dual actions of liraglutide 3 mg on both appetite and blood glucose regulation (for adults with prediabetes or type 2 diabetes) hold therapeutic potential for adults with obesity, both those with and without type 2 diabetes. Liraglutide 3 mg is an investigational product and is not approved by the FDA or the European Medicines Agency (EMA). About SCALE(TM) Obesity and Prediabetes The SCALE(TM) Obesity and Prediabetes trial[12] is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. There were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo in combination with diet and exercise. In addition, participants were further stratified to 56 weeks or 160 weeks of treatment based on prediabetes status at screening. The objectives of this trial were to demonstrate clinically meaningful weight loss at 56 weeks, as well as to investigate the long-term efficacy of liraglutide 3 mg to delay the onset of type 2 diabetes in participants with prediabetes at screening. It is the largest of the phase 3a trials in the SCALE(TM) clinical development programme, which encompassed more than 5,000 people with obesity or people who are overweight with comorbidities. About Novo NordiskHeadquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 40,700 employees in 75 countries, and markets its products in more than 180 countries. This information was presented at ObesityWeek 2014, the inaugural scientific event by The Obesity Society and the American Society for Metabolic and Bariatric Surgery. *BMI subgroups: =>27-29.9 kg/m2, 30-34.9 kg/m2, 35-39.9 kg/m2, =>40 kg/m2. [1]    Greenway F, Le Roux C, Lau D, et al. Additional analyses of the weight-lowering efficacy of liraglutide 3.0 mg in overweight and obese adults: the SCALE Obesity and Prediabetes randomized trial. Obesity Week 2014. Oral presentation T-3027-OR. [2]    Fujioka K, Astrup A, Greenway F, et al. Liraglutide 3.0 mg reduces body weight and improves Health-Related Quality of Life (HRQoL) in overweight or obese adults without diabetes: the SCALE Obesity and Prediabetes randomized, double blind, placebo-controlled, 56-week trial. Obesity Week 2014. Oral presentation T-3031-OR. [3]    Kolotkin RL, Crosby RD, Kosloski KD, et al. Development of a brief measure to assess quality of life in obesity. Obes Res. 2001; 9:102-111. [4]    Ware JE, Kosinski M, Dewey J. How to Score Version Two of the SF-36 Health Survey. Edition 3 ed. Lincoln RI: QualityMetric, Incorporated, 2000. [5]    Brod M, Hammer M, Kragh N, et al. Development and validation of the Treatment Related Impact Measure of Weight (TRIM-Weight). Health Qual Life Outcomes. 2010; 8:19. [6]    American Medical Association A. Declaration to classify obesity as a disease. Annual Meeting Report. 19 June 2013. [7]    Ogden CL, Carroll MD, Kit BK, et al. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014; 311:806-814. [8]    Centers for Disease Control and Prevention. Adult Obesity Facts. Available at: http://www.cdc.gov/obesity/data/adult.html. Last accessed 16.10.2014. [9]    Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. Journal of Medicinal Chemistry. 2000; 43:1664-1669. [10] Flint A, Raben A, Ersboll AK, et al. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. International Journal of Obesity and Related Metabolic Disorders. 2001; 25:781-792. [11] van Can J, Sloth B, Jensen CB, et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. International Journal of Obesity. 2014; 38:784-793. [12] SCALE(TM) Obesity and Prediabetes ClinicalTrials.gov study registration: NCT01272219.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1474,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
582,2014-11-04,"Nye fase 3a-data viser, at ni ud af 10 svært overvægtige voksne tabte sig med liraglutid 3 mg, og deltagere, der gennemførte studiet, tabte sig i gennemsnit 9,2%","Boston, USA, den 4. november 2014 - Novo Nordisk har i dag præsenteret nye data fra fase 3a-studiet SCALE(TM) Obesity and Prediabetes. Det skete på ObesityWeek 2014, den anden fælles årskongres for The American Society for Metabolic and Bariatric Surgery og The Obesity Society. 92% (9 ud af 10) af deltagerne i studiet tabte sig ved behandling med liraglutid 3 mg i kombination med diæt og motion, sammenlignet med 65% ved behandling med placebo.[1] Deltagere, som gennemførte studiet (56 uger), opnåede et signifikant større vægttab på 9,2% sammenlignet med et vægttab på 3,5% i placebogruppen (estimeret forskel [ED] 5,7%, p<0,001).1 Endvidere var vægttabet med liraglutid 3 mg sammenligneligt på tværs af en række undergrupper med forskellige grader af overvægt ved studiets start, spændende fra overvægt til fedme klasse III[*] efter 56 uger (p=0,054, %; p=0,54, kg), og uafhængigt af status med hensyn til prædiabetes ved screening (-8,0% med; -7,9% uden, p=0,59).1 En større andel af deltagere, der blev behandlet med liraglutid 3 mg, gennemførte studiet sammenlignet med dem, der fik placebo (72% mod 64%).1 Alle behandlingsgrupper fulgte et program med kaloriereduceret diæt og øget fysisk aktivitet. Vægttab i forbindelse med liraglutid 3 mg var ledsaget af forbedret livskvalitet målt ved hjælp af tre forskellige spørgeskemaer.[2] Der sås større forbedringer med liraglutid 3 mg sammenlignet med placebo.2 Den samlede score i Impact of Weight on Quality of Life-Lite (IWQoL)[3] forbedredes hovedsagelig på grund af bedre fysisk tilstand. I Short-Form (36) Health Survey (SF-36)[4] forbedredes de summerede scorer både for fysisk helbred og psykisk helbred.2 ""Fedme er ikke bare en sygdom, der handler om, at man vejer for meget,"" siger dr. Ken Fujioka fra Department of Nutrition and Metabolic Research, Scripps Clinic, La Jolla, Californien, som er en af de forsøgsansvarlige i SCALE(TM) studiet. ""Vi ved, at mange svært overvægtige mennesker ikke bare oplever flere fysiske og psykiske helbredsproblemer, men også en forringelse af deres livskvalitet. Det er positivt at se data, der tyder på, at vægttabsfordelene ved liraglutid 3 mg er associeret med forbedret sundhedsrelateret livskvalitet for svært overvægtige mennesker."" Endvidere var den samlede score i Treatment Related Impact Measure-Weight (TRIM-W)[5] bedre efter 56 uger med liraglutid 3 mg sammenlignet med placebo.2 Fedme er en sygdom,[6] der kræver kronisk regulering. Den er forbundet med alvorlige komplikationer som type 2-diabetes, hjertesygdom, obstruktiv søvnapnø og visse former for kræft samt en nedsættelse af den forventede levetid. Risikoen for sygelighed (morbiditet) og dødelighed (mortalitet) stiger i takt med sværhedsgraden af fedme. Det er en kompleks sygdom, der er betinget af flere forskellige forhold, herunder genetiske, fysiologiske, miljømæssige og psykologiske faktorer. Den globale stigning i forekomsten af fedme er en trussel mod folkesundheden med betydelig indvirkning på sundhedsudgifterne. I USA er ca. 35% af den voksne befolkning - omkring 80 mio. mennesker - svært overvægtige.[7],[8] Liraglutid 3 mg er en GLP-1-analog (glukagonlignende peptid-1) til dosering én gang dagligt. Den har 97% lighed med kroppens eget GLP-1, som er et tarmhormon, der frigives, når man spiser.[9] Ligesom naturligt GLP-1 regulerer liraglutid 3 mg appetitten og indtagelsen af mad ved at dæmpe signaler om sult og øge mæthedsfornemmelsen efter et måltid.[10],[11]Liraglutid 3 mg virker både på appetitten og blodsukkerreguleringen (hos mennesker med prædiabetes eller type 2-diabetes) og rummer dermed potentiale til behandling af svært overvægtige voksne med eller uden type 2-diabetes. Liraglutid 3 mg er et produkt under udvikling, og det er ikke godkendt af FDA eller EMA (European Medicines Agency). SCALE(TM) Obesity and Prediabetes[12] er et randomiseret, dobbeltblindet, placebokontrolleret multinationalt studie med svært overvægtige mennesker, der ikke har diabetes, og overvægtige mennesker, der ikke har diabetes, men som har komplikationer (komorbiditeter). Studiet omfattede 3.731 deltagere, der blev randomiseret til behandling med liraglutid 3 mg eller placebo i kombination med diæt og motion. Herudover blev deltagerne yderligere fordelt i grupper til 56 ugers eller 160 ugers behandling baseret på deres status mht. prædiabetes ved screening. Studiet havde til formål at dokumentere klinisk meningsfuldt vægttab efter 56 uger samt at undersøge langtidseffekten af liraglutid 3 mg i forhold til at forsinke udviklingen af type 2-diabetes hos deltagere med prædiabetes ved screening. Det er det største af fase 3a-studierne i det kliniske udviklingsprogram SCALE(TM), som omfattede flere end 5.000 deltagere, som er svært overvægtige eller overvægtige med komplikationer. Denne information blev præsenteret på ObesityWeek 2014, den videnskabelige åbningsevent for The Obesity Society og American Society for Metabolic and Bariatric Surgery. [*] BMI-undergrupper: =>27-29,9 kg/m2, 30-34,9 kg/m2, 35-39,9 kg/m2, =>40 kg/m2. [1]    Greenway F, Le Roux C, Lau D, et al. Additional analyses of the weight-lowering efficacy of liraglutide 3.0 mg in overweight and obese adults: the SCALE Obesity and Prediabetes randomized trial. Obesity Week 2014. Oral presentation T-3027-OR. [2]    Fujioka K, Astrup A, Greenway F, et al. Liraglutide 3.0 mg reduces body weight and improves Health-Related Quality of Life (HRQoL) in overweight or obese adults without diabetes: the SCALE Obesity and Prediabetes randomized, double blind, placebo-controlled, 56-week trial. Obesity Week 2014. Oral presentation T-3031-OR. [3]    Kolotkin RL, Crosby RD, Kosloski KD, et al. Development of a brief measure to assess quality of life in obesity. Obes Res. 2001; 9:102-111. [4]    Ware JE, Kosinski M, Dewey J. How to Score Version Two of the SF-36 Health Survey. Edition 3 ed. Lincoln RI: QualityMetric, Incorporated, 2000. [5]    Brod M, Hammer M, Kragh N, et al. Development and validation of the Treatment Related Impact Measure of Weight (TRIM-Weight). Health Qual Life Outcomes. 2010; 8:19. [6]    American Medical Association A. Declaration to classify obesity as a disease. Annual Meeting Report. 19 June 2013. [7]    Ogden CL, Carroll MD, Kit BK, et al. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014; 311:806-814. [8]    Centers for Disease Control and Prevention. Adult Obesity Facts. Available at: http://www.cdc.gov/obesity/data/adult.html. Last accessed 16.10.2014. [9]    Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. Journal of Medicinal Chemistry. 2000; 43:1664-1669. [10] Flint A, Raben A, Ersboll AK, et al. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. International Journal of Obesity and Related Metabolic Disorders. 2001; 25:781-792. [11] van Can J, Sloth B, Jensen CB, et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. International Journal of Obesity. 2014; 38:784-793. [12] SCALE(TM) Obesity and Prediabetes ClinicalTrials.gov study registration: NCT01272219.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1475,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
583,2014-11-03,Novo Nordisk og Roche Diabetes Care lancerer ny behandlingsmulighed til insulinpumper,"Bagsværd, den 3. november 2014 - Novo Nordisk lancerer i dag NovoRapid® PumpCart®, den første præfyldte insulinampul, der er specifikt designet til brug i pumpesystemer. Den nye behandlingsløsning, der indeholder Novo Nordisks hurtigtvirkende insulin NovoRapid® (insulin aspart), ventes at gøre det mere bekvemt at bruge insulinpumpebehandling, både for brugere og behandlere. Den præfyldte 1,6 ml ampul er udviklet i et ikke-eksklusivt partnerskab mellem Roche Diabetes Care og Novo Nordisk og passer til det nye Accu-Chek® Insight insulinpumpesystem fra Roche Diabetes Care. ""En af udfordringerne ved at bruge en traditionel pumpe er, at insulinbeholderen skal fyldes manuelt. Det er en omstændelig proces, der ofte opleves som kompleks og tidskrævende både af brugerne og deres behandlere,"" siger dr. Parth Narendran, klinisk seniorlektor og honorær konsulent i medicin ved University of Birmingham. ""Det kan være en stor hurdle, når man starter på insulinpumpebehandling, og det kræver, at sundhedspersonalet bruger en masse tid på oplæring og støtte, når pumpebehandlingen påbegyndes. En enklere proces vil kunne mindske dette problem og give konkrete fordele for de patienter, der i deres dagligdag er afhængige af insulinpumpebehandling for at holde deres diabetes i kontrol,"" fortsætter han. I forhold til behandling med mange daglige injektioner kan insulinpumpebehandling give større fleksibilitet i forhold til den enkeltes livsstil og potentielt en strammere blodsukkerregulering uden øget risiko for lavt blodsukker (hypoglykæmi).[1]-[2] ""Det kan medføre fordele for visse patienter,"" forklarer dr. Mark Evans, lektor og honorær konsulent i medicin ved University of Cambridge. ""I Europa har vi set en langsom, men støt stigning i antallet af insulinpumpebrugere i de senere år, men der er stadig plads til forbedring; i Storbritannien er det i dag 19% af børn og 6% af voksne med type 1-diabetes, der bruger pumper."" NovoRapid® PumpCart® bliver lanceret i Storbritannien, Sverige og Østrig i dag og vil blive lanceret i flere europæiske lande i løbet af 2015 og 2016. Accu-Chek® Insight insulinpumpesystemet blev lanceret i Østrig i første halvår i år og lanceres i Storbritannien i dag, og andre europæiske markeder følger i løbet af 2015. En insulinpumpe tilfører insulin til kroppen fra en beholder i pumpen ved hjælp af et infusionssæt og en meget lille kanyle. Insulinpumper bruger hurtigtvirkende insulin som f.eks. insulin aspart. Insulinen tilføres ved kontinuerlig infusion og bruges ofte af mennesker med type 1-diabetes, som får intensiv insulinbehandling og måler deres blodsukker regelmæssigt. Insulinpumper er velegnede til visse patienter og giver større fleksibilitet og potentielt en bedre regulering af blodsukkeret og øget livskvalitet1-2. I Europa varierer andelen af mennesker med type 1-diabetes, der bruger insulinpumpe, fra mindre end 5% i nogle lande til over 15% i andre lande. I USA er andelen af insulinpumpebrugere 40%[3]. NovoRapid® (insulin aspart) er en hurtigtvirkende insulinanalog til behandling af diabetes hos voksne, unge og børn i alderen fra to år og opefter og kan anvendes under graviditet. NovoRapid® har været tilgængelig i Europa siden 1999 og er godkendt i flere end 100 lande.   Alle produktnavne i denne meddelelse er beskyttede varemærker.  [1] Cohen ND, et al. Diabetes Technol Ther 2013; 15:544-9. [2] Pickup JC. Nat Rev Endocrinol 2012; 8:425-33. [3] Pickup JC. Insulin pumps. Int J Clin Pract 2011; 65(Suppl.170):16-19.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1476,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
584,2014-11-03,Novo Nordisk and Roche Diabetes Care launch new treatment option to simplify insulin pump therapy,"Bagsværd, Denmark, 3 November 2014 - Today, Novo Nordisk launches NovoRapid® PumpCart®, the first prefilled pump cartridge with an insulin analogue that has been specifically designed for insulin pumps. This new treatment solution, which contains NovoRapid® (insulin aspart) - a rapid-acting insulin from Novo Nordisk - is expected to make insulin pump therapy more convenient for people with diabetes and their care staff. The 1.6 ml cartridgeis developedin a non-exclusive partnership between Roche Diabetes Care and Novo Nordisk and is compatible with the new Accu-Chek® Insight insulin pump therapy system from Roche Diabetes Care. ""One of the challenges in operating a traditional pump lies in the manual filling of the insulin reservoir, a procedure with multiple steps, which can often be perceived as a complex and time-consuming process by patients and healthcare professionals alike,"" commented Dr Parth Narendran, clinical senior lecturer and honorary consultant in medicine at the University of Birmingham. He continued: ""This can be a difficult hurdle to overcome when starting on insulin pump therapy, and is exacerbated by the extensive amount of time needed by healthcare staff to provide the necessary support during pump initiation. A simpler process could address this issue and deliver tangible benefits for those patients who rely on insulin pump therapy every day to manage their diabetes."" Compared to multiple daily injections, insulin pumps can provide greater flexibility of lifestyle and potentially tighter blood glucose control without an increased risk of hypoglycaemia.1-2 ""This can provide benefits to certain patients,"" explained Dr Mark Evans, lecturer and honorary consultant in medicine at the University of Cambridge. ""In Europe, we've seen a slow but steady increase in insulin pump therapy uptake in recent years, but there is still room for improvement; in the United Kingdom pumps are currently used by 19% of children and 6% of adults with type 1 diabetes."" NovoRapid® PumpCart® is being launched in the UK, Sweden and Austria today and will be made available in more European countries throughout 2015 and 2016. The Accu-Chek® Insight insulin pump therapy system has been launched in Austria in the first half of this year and is being launched in the UK today, with other European markets following throughout 2015. An insulin pump delivers insulin from a reservoir inside the pump to a patient's body using an infusion set and a tiny cannula. Insulin pumps use fast-acting insulin such as insulin aspart. The insulin is delivered using continuous infusion and is often used by people with type 1 diabetes who receive intensified insulin therapy and test their blood glucose levels on a regular basis. An insulin pump is suitable for certain patients and provides more flexibility, with the potential to improve glycaemic control and quality of life1-2. In Europe, use of insulin pumps among people with type 1 diabetes varies with less than 5% using a pump in some countries to more than 15% in other countries. In the US, 40% are treated with insulin from a pump3. About NovoRapid® NovoRapid® (insulin aspart) is a mealtime insulin analogue indicated for the treatment of diabetes mellitus in adults, adolescents, children aged 2 years and above and can be used in pregnancy. NovoRapid® has been available for use in Europe since 1999 and is approved in more than 100 countries. About Novo Nordisk Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 40,700 employees in 75 countries, and markets its products in more than 180 countries. For more information, visit novonordisk.com. All trademarks used or mentioned in this release are legally protected.  References: 1. Cohen ND, et al. Diabetes Technol Ther. 2013;15:544-9. 2. Pickup JC. Nat Rev Endocrinol. 2012;8:425-33. 3. Pickup JC. Insulin pumps. Int J Clin Pract. 2011;65(Suppl.170):16-19.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1477,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
585,2014-11-03,Novo Nordisk: Houston tilslutter sig Cities Changing Diabetes,"Houston, TX & Plainsboro, NJ, USA, den 3. november 2014 - se multimedie meddelelsen Houston og Novo Nordisk har i dag indledt et innovativt partnerskab om at bremse væksten i forekomsten af diabetes i den amerikanske storby. Houston er den tredje by i verden og den første i USA, der tilslutter sig initiativet Cities Changing Diabetes, som Novo Nordisk lancerede tidligere på året. De første to byer er Mexico City og København. Af de anslået omkring 382 millioner mennesker i verden med diabetes bor næsten to tredjedele i byområder.[1] Globalt set er der 2-5 gange større risiko for at have diabetes, hvis man bor i en storby.[2] Cities Changing Diabetes er det første initiativ af sin art, der har til formål at bekæmpe den stigende udbredelse af diabetes i verdens storbyer gennem praktiske, langsigtede løsninger. Parterne arbejder sammen om i første omgang at forstå, hvad der ligger bag væksten, og derefter bruge den viden til at udarbejde konkrete, realiserbare handlingsplaner. ""Diabetes og fedme er en stor trussel mod folkesundheden i vores by,"" udtaler Houstons borgmester Annise D. Parker. ""Cities Changing Diabetes er en unik mulighed for at udarbejde sundhedsstrategier, der tager kampen op mod diabetes på en måde, der passer til befolkningen i Houston og Harris County. Vi ser frem til at samarbejde med partnere både lokalt og globalt om at udvikle løsninger på, hvordan vi bekæmper denne globale epidemi."" Som første skridt i Cities Changing Diabetes-initiativet gennemføres en omfattende analyse for at afdække de væsentligste årsager til udvikling af diabetes. Resultaterne af denne analyse anvendes til i samarbejde med lokale interessenter at identificere, hvilke tiltag der virker bedst i forhold til at forebygge og behandle diabetes. De bedste løsninger deles dernæst med andre storbyer i verden. De første data fra Houston vil foreligge i starten af 2015. ""Houston er en ideel partner, fordi der er et stort ønske om at forbedre sundheden for byens indbyggere. Det fremgår af de mange stærke initiativer, der allerede er sat i søen for at tage kampen op mod alvorlige sundhedsproblemer som for eksempel diabetes,"" siger Lars Rebien Sørensen, administrerende direktør for Novo Nordisk. ""Det er tvingende nødvendigt, at beslutningstagere, sundhedsmyndigheder, forskere, non-profit-organisationer og private virksomheder arbejder sammen om at udvikle løsninger, der kan dæmme op for væksten i diabetes i storbyerne. Vi vil arbejde sammen med vores partnere i Houston og andre steder i verden om at finde frem til løsninger og sætte gang i en fælles indsats."" Sundhedsforvaltningen i Houston (The Health & Human Services Department) og University of Texas' fakultet for folkesundhed (School of Public Health) er Novo Nordisks centrale partnere i projektet og skal stå i spidsen for den indledende analyse i Houston. De øvrige lokale partnere er Harris County Healthcare Alliance, American Diabetes Association Houston og Clinton Health Matters Initiative. På globalt plan vil initiativet få støtte fra det britiske University College London (UCL) og Steno Diabetes Center i Danmark, en af verdens førende institutioner indenfor diabetesbehandling og -forebyggelse, foruden Novo Nordisk. Houston er USA's fjerdestørste by med 2,1 mio. indbyggere i selve byen og 4,3 mio. i Harris County.[3] Ca. én ud af 10 voksne i Houston/Harris County har diabetes.[4] Fedme er den mest almindelige kroniske sygdom i Houston, som berører 32% af byens voksne indbyggere.[5] Svært overvægtige mænd og kvinder har henholdsvis 7 og 12 gange større risiko for at udvikle diabetes.[6] Som borgmester anerkender Annise D. Parker, at der skal handling til, og hun har derfor sat særligt fokus på at forbedre indbyggernes sundhed og trivsel i Houston. I 2012 lancerede hun Healthy Houston, som er et initiativ rettet mod at mindske udbredelsen af fedme og fremme sunde kostvaner og motion. Healthy Houston støtter initiativer, strategier og aktioner, der skal mindske de såkaldte 'food deserts' (områder, hvor der ikke er mulighed for at købe friske råvarer) samt fremme tilgængeligheden af lokalt dyrkede fødevarer, udviklingen af bæredygtige fødevaresystemer og rekreative muligheder. Cities Changing Diabetes er et ambitiøst partnerskabsprogram, der skal dæmme op for det voksende problem, som den hastige udbredelse af diabetes udgør i verdens storbyer. Det anslås, at mere end en halv milliard mennesker vil have diabetes i 2030. I dag bor næsten to tredjedele af alle med diabetes i storbyerne, og de, der flytter til byen, har betydelig større risiko for at få diabetes end dem, der bliver på landet.[7] Formålet med Cities Changing Diabetes er i første omgang at kortlægge problemet, derefter udveksle ideer og bud på løsninger og til slut udarbejde konkrete handlingsplaner for de storbyer, der deltager i programmet. Se mere på Cities Changing Diabetes - og følg med på Twitter og Facebook. [1]           IDF Diabetes Atlas. International Diabetes Federation. 2013. 6th edn. [2]           Mbanya JC et al. Diabetes in sub-Saharan Africa. Lancet 2010; 375(9733):2254-2266. [3]              The State of Health in Houston/Harris County 2012. Harris County Healthcare Alliance, Houston, Texas. [4]           Health of Houston Survey. HHS 2010 A First Look. Houston, TX: Institute for Health Policy, The University of Texas School of Public Health, 2011. [5]           Health of Houston Survey. HHS 2010 A First Look. Houston, TX: Institute for Health Policy, The University of Texas School of Public Health, 2011. [6]           Guh DP et al. The incidence of comorbidities related to obesity and overweight. BMC Pub Health 2009; 9:88. [7]           Mbanya JC et al. Diabetes in sub-Saharan Africa. Lancet 2010; 375(9733):2254-2266.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1479,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
586,2014-11-03,Novo Nordisk: City of Houston and Novo Nordisk partner to lead fight against urban diabetes epidemic,"Houston First US city to join global Cities Changing Diabetes partnership - see multimedia release HOUSTON, TX & PLAINSBORO, NJ, 3 November 2014 - The City of Houston and Novo Nordisk today announced an innovative partnership to fight the urban diabetes epidemic. Houston is the third city globally and the first in the United States to join the Cities Changing Diabetes programme, which was initiated earlier in 2014 by Novo Nordisk. The first two cities are Mexico City and Copenhagen. Of the estimated 382 million people worldwide who have diabetes, nearly two thirds live in urban areas.[1] Globally, those who live in cities are two to five times more likely to have diabetes.[2] Cities Changing Diabetes is a first-of-its-kind collaboration developed to stem the tide of urban diabetes by providing practical, long-term solutions. The partnership aims to tackle the challenge by first understanding the driving factors behind the rise in diabetes in cities and use that knowledge to share concrete, real-world solutions. ""Diabetes and obesity pose a significant health threat to our city,'' said Houston Mayor Annise D. Parker. ""Cities Changing Diabetes is a unique opportunity to identify the health strategies that combat diabetes in a way that meet the individual needs of the people of Houston and Harris County. We look forward to collaborating with partners locally and around the world to develop solutions to this global epidemic.'' The Cities Changing Diabetes programme will kick off with a comprehensive analysis of the major gaps and vulnerabilities associated with diabetes. The results will be used in collaboration with local stakeholders to identify efforts that will have the greatest impact on prevention and management of diabetes. The best practices will then be shared with cities around the world. Initial data on Houston will be available in early 2015. ""The City of Houston is an ideal partner as there is a strong commitment to improving health, which is seen with several strong programmes already in existence to combat major health issues such as diabetes,"" said Lars Rebien Sørensen, chief executive officer of Novo Nordisk. ""It is urgent that policymakers, health authorities, academia, the non-profit sector and private industry work together to develop solutions to reverse the rise of urban diabetes. We are committed to working with our partners in Houston and around the world to identify solutions and spur concerted action.'' The Houston Health & Human Services Department and The University of Texas School of Public Health serve as core partners on the project and will lead the initial research for Cities Changing Diabetes in Houston. Other local partners include the Harris County Healthcare Alliance, American Diabetes Association Houston and the Clinton Health Matters Initiative. Globally, the programme will be supported by University College London (UCL), UK and Steno Diabetes Center, Denmark, a world-leading institution in diabetes care and prevention, and Novo Nordisk. DIABETES IN HOUSTON Houston is the fourth largest city in the United States. There are 2.1 million people living in Houston and 4.3 million in Harris County.[3] Approximately one in 10 adults in Houston/Harris County have diabetes.[4] Obesity is the most common chronic condition in Houston, affecting 32% of adults.[5] Men and women with obesity have a 7- and 12-fold risk, respectively, of developing diabetes.[6] Recognising the need for action, Mayor Parker has dedicated significant attention to improving health and wellness in Houston. In 2012, she launched Healthy Houston, an initiative designed to reduce obesity and increase healthy eating and exercise. Healthy Houston promotes programmes, policies and actions designed to reduce food deserts, promote the availability of locally grown foods, encourage the development of sustainable food systems and promote recreational opportunities. About Cities Changing DiabetesCities Changing Diabetes is an ambitious partnership programme to fight the urban diabetes challenge. By 2030, it is estimated that more than half a billion people will have diabetes. Today, nearly two-thirds of all people with diabetes live in cities, and people who move to cities have a significantly higher risk of developing diabetes than those who remain in rural settings.[7] The aim of Cities Changing Diabetes is to map the problem, share solutions and drive concrete action to fight the diabetes challenge in selected focus cities across the world. For more information, visit Cities Changing Diabetes. Also, visit Cities Changing Diabetes on Twitter and Facebook, or follow the news in the US on Twitter: @novonordiskus. About Novo NordiskHeadquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 41,000 employees in 75 countries, and markets its products in more than 180 countries. For more information, visit novonordisk.com or novonordisk.us. Further information Media: Novo Nordisk Inc. Media RelationsKen Inchausti, +1 609-514-8316kiau@novonordisk.com Novo Nordisk A/S, Media RelationsKatrine Sperling, +45 4442 6718krsp@novonordisk.com Public/Media Affairs, Houston Department of Health and Human ServicesKathy Barton, +1 832-393-5045kathy.barton@houstontx.gov [1] IDF Diabetes Atlas. International Diabetes Federation. 2013. 6th edn. [2] Mbanya JC et al. Diabetes in sub-Saharan Africa. Lancet 2010; 375(9733):2254-2266 [3]The State of Health in Houston/Harris County 2012. Harris County Healthcare Alliance, Houston, Texas. [4] Health of Houston Survey. HHS 2010 A First Look. Houston, TX: Institute for Health Policy, The University of Texas School of Public Health, 2011. [5] Health of Houston Survey. HHS 2010 A First Look. Houston, TX: Institute for Health Policy, The University of Texas School of Public Health, 2011. [6] Guh DP et al. The incidence of comorbidities related to obesity and overweight. BMC Pub Health. 2009; 9:88. [7] Mbanya JC et al. Diabetes in sub-Saharan Africa. Lancet 2010; 375(9733):2254-2266",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1478,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
587,2014-10-31,Novo Nordisk investerer 750 millioner kroner i nye laboratorier til diabetesforskning i Danmark,"Bagsværd, den 31. oktober - Novo Nordisk investerer omkring 750 millioner kroner kr. i nye laboratorier på sin forskningscampus i Måløv. Byggeriet er sat i gang og forventes at være klar til indflytning i begyndelsen af 2016. Den ny bygning - Diabetes Research House - bliver arbejdsplads for omkring 350 medarbejdere. Mens byggeriet står på, forventes det at skabe mere end 1000 arbejdspladser udenfor Novo Nordisk. ""De nye laboratorier bliver rammen om den fremmeste diabetesforskning indenfor bioteknologi og proteinkemi,"" siger koncerndirektør for Forskning og Udvikling, Mads Krogsgaard Thomsen. ""Her vil vore forskere arbejde tæt sammen med førende forskere i ind- og udland om at identificere og udvikle nye lægemidler til behandling af type 1- og type 2-diabetes."" Bygningen indeholder to laboratoriefløje, en mellembygning med kontorarbejdspladser og et auditorium med plads til 450 personer. Byggeriet bliver på 16.500 m2 fordelt på tre etager. Novo Nordisk åbnede sin forsknings- og udviklingscampus i Måløv i 1991 med omkring 300 medarbejdere.  I dag er den arbejdsplads for mere end 2.300 medarbejdere.  Globalt arbejder der omkring 5.000 medarbejdere i Novo Nordisk Forskning og Udvikling i Danmark, USA og Kina. Grafik af Diabetes Research House kan downloades på novonordisk.com under 'Photos'. ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1485,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
588,2014-10-31,Novo Nordisk invests DKK 750 million in new laboratories for diabetes research in Denmark,"Bagsværd, Denmark, 31 October 2014 - Novo Nordisk today announced an investment of approximately 750 million Danish kroner (around 130 million US dollars) in new laboratories at the company's R&D campus in Måløv, Denmark. Construction has started, and the new laboratory facility is expected to be ready for occupation in early 2016. The new facility - Diabetes Research House - will accommodate approximately 350 employees. During the construction phase, the project is expected to generate more than 1,000 jobs outside Novo Nordisk. ""The new lab facility will provide an environment for cutting-edge diabetes research within biotechnology and protein chemistry,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""Here our researchers will be working closely together with leading scientists in Denmark and abroad on the discovery and development of new medicines for the treatment of type 1 and type 2 diabetes."" The facility comprises two laboratory wings, a middle building with office space and an auditorium seating 450 people. The facility will have a floorage of 16,500 square metres distributed on three storeys. Novo Nordisk opened its R&D campus in Måløv in 1991 with about 300 employees. Today the campus accommodates more than 2,300 employees. Globally, about 5,000 employees are involved in research and development activities at Novo Nordisk's R&D units in Denmark, the US and China. Graphics of Diabetes Research House can be downloaded on novonordisk.com under Photos. Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 40,700 employees in 75 countries, and markets its products in more than 180 countries. Further information  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1484,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
589,2014-10-30,Resultat af primær drift opgjort i lokale valutaer steg med 11% i de første ni måneder af 2014,"Salgsvækst på 8% i lokale valutaer drevet af Levemir® og Victoza® Salget steg med 8% opgjort i lokale valutaer og med 4% i kroner til 64,2 mia. kr. i de første ni måneder af 2014 i forhold til samme periode i 2013. Bruttomarginen steg med 1,0 procentpoint opgjort i kroner til 83,6% drevet af en gunstig prisudvikling samt en positiv påvirkning fra produktsammensætning og produktivitet. Resultat af primær drift steg med 11% opgjort i lokale valutaer og med 5% i kroner til 25,3 mia. kr. Nettoresultatet steg med 4% til 20,0 mia. kr. Udvandet resultat pr. aktie steg med 7% til 7,56 kr. Lanceringen af Tresiba® fortsætter. I Japan repræsenterer Tresiba® nu 24% af markedsværdien for basal insulin opgjort på månedsbasis. I september gav Europa-Kommissionen markedsføringstilladelse til Xultophy® til behandling af type 2-diabetes hos voksne. Xultophy® er en fast kombination af insulin degludec (Tresiba®) og liraglutid (Victoza®). For 2014 forventes nu en salgsvækst opgjort i lokale valutaer på 7-9%, og væksten i resultat af primær drift opgjort i lokale valutaer forventes fortsat at blive på omkring 10%. De foreløbige forventninger til 2015 indikerer en høj etcifret salgsvækst og omkring 10% vækst i resultat af primær drift, begge dele opgjort i lokale valutaer. Adm. direktør Lars Rebien Sørensen: ""Vi er tilfredse med de finansielle resultater, vi har opnået i de første ni måneder af 2014. I USA klarer Levemir® sig fortsat godt, og med godkendelsen af Xultophy® i Europa ser vi nu frem til at lancere dette produkt i første halvår af 2015."" Kontaktoplysninger Selskabsmeddelelse nr. 66 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1487,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
590,2014-10-30,Increased operating profit in local currencies by 11% in the first nine months of 2014,"8% sales growth in local currencies driven by Levemir® and Victoza® Sales increased by 8% in local currencies and by 4% in Danish kroner to DKK 64.2 billion during the first nine months of 2014 compared to the same period in 2013. Gross margin improved by 1.0 percentage point in Danish kroner to 83.6% driven by a favourable price development as well as a positive impact from product mix and productivity. Operating profit increased by 11% in local currencies and by 5% in Danish kroner to DKK 25.3 billion. Net profit increased by 4% to DKK 20.0 billion. Diluted earnings per share increased by 7% to DKK 7.56. The roll-out of Tresiba® continues. In Japan, Tresiba® now represents 24% of the basal insulin market measured in monthly value market share. In September, the European Commission granted marketing authorisation for Xultophy® for the treatment of type 2 diabetes mellitus in adults. Xultophy® is a fixed combination of insulin degludec (Tresiba®) and liraglutide (Victoza®). For 2014, sales growth measured in local currencies is now expected to be 7-9% and operating profit growth measured in local currencies is still expected at around 10%. The preliminary outlook for 2015 indicates high single-digit sales growth and around 10% operating profit growth, both measured in local currencies. Lars Rebien Sørensen, CEO: ""We are satisfied with the financial results for the first nine months of 2014. In the US, Levemir® continues to perform well, and with the approval of Xultophy® in Europe we now look forward to launching this product in the first half of 2015."" Contacts for further information Company announcement No 66 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1486,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
591,2014-10-24,Novo Nordisk modtager begæring om udlevering af dokumenter i USA,"Bagsværd, den 24. oktober 2014 - Statsadvokaten for District of Massachusetts har anmodet Novo Nordisk om at udlevere dokumenter vedrørende mulige produktionsproblemer i visse produktionsanlæg i Kalundborg. Novo Nordisk samarbejder med statsadvokaten om undersøgelsen. Novo Nordisk kan ikke på nuværende tidspunkt fastslå eller forudsige udfaldet af denne sag eller vurdere konsekvenserne deraf, ligesom det ikke er muligt at forudsige, hvor længe undersøgelsen vil vare, eller hvornår virksomheden kan give yderligere information. Novo Nordisk tager patientsikkerhed og produktkvalitet meget alvorligt og har fuld tillid til sikkerheden af virksomhedens produkter. Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1495,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
592,2014-10-24,Novo Nordisk receives subpoena from US Attorney,"Bagsværd, Denmark 24 October 2014 - Novo Nordisk today announced that it has been served with a subpoena by the office of the US Attorney for the District of Massachusetts requesting documents regarding potential manufacturing issues within certain production units located in Kalundborg, Denmark. Novo Nordisk is cooperating fully with the US Attorney in this investigation. At this time, Novo Nordisk cannot determine or predict the outcome of this matter or assess the consequences thereof. In addition, the company cannot predict how long the investigation will take or when it will be able to provide additional information. Novo Nordisk takes patient safety and product quality very seriously and is confident in the safety of its products.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1494,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
593,2014-10-17,Novo Nordisk verdens anden bedste forsknings-arbejdsplads,"Bagsværd, den 17. oktober 2014 - Novo Nordisk er netop blevet kåret som nr. 2 i 2014 Science Careers Top Employers Survey, der ranglister verdens bedste forskningsarbejdspladser. Dermed har Novo Nordisk taget et stort spring op på listen fra sidste års placering som nr. 11. Blandt begrundelserne for den placering fremhæves kategorierne 'Behandler medarbejdere med respekt', 'Har loyale medarbejdere' og 'Er social ansvarlig'. ""Vi er stolte over at være rykket op på en andenplads i år på denne prestigefyldte rangliste over verdens bedste forskningsarbejdspladser,"" siger Mads Krogsgaard Thomsen, koncernforskningsdirektør i Novo Nordisk. ""Vores forskere verden over gør et fantastisk arbejde, ikke bare med at udvikle innovative og patientfokuserede produkter, men også med at fortælle om det. At forskerverdenen betragter Novo Nordisk som en af verdens allerbedste arbejdspladser, har rigtig meget at sige for en virksomhed, der vokser så hurtigt som Novo Nordisk."" Novo Nordisk har i dag flere end 40.000 medarbejdere på verdensplan og forventer, at medarbejderantallet vil stige til flere end 60.000 over de næste ti år. Novo Nordisks forskningsorganisation omfatter over 6.000 medarbejdere i Danmark, Kina, USA og Indien. Novo Nordisk har mere end 90 års erfaring som forskningsbaseret virksomhed, der sætter patienterne i centrum. ""Vi kombinerer videnskabelig, farmaceutisk og klinisk ekspertise med høje etiske standarder i vores fortsatte arbejde for at skabe bedre livskvalitet for mennesker med kroniske sygdomme. Vi er verdens førende virksomhed indenfor diabetesbehandling, og millioner af mennesker overalt i verden er afhængige af vores produkter hver dag. Desuden investerer vi fortsat i at udvikle innovative lægemidler til behandling af fedme, hæmofili og vækstforstyrrelser,"" siger Mads Krogsgaard Thomsen. 2014 Science Careers Top Employers Survey er baseret på 5.394 svar fra læsere af det videnskabelige tidsskrift Science og fra medarbejdere i bioteknologiske og farmaceutiske virksomheder, som blev bedt om at rangliste de 20 bedste arbejdspladser baseret på en række forskellige egenskaber. Om 2014 Science Careers Top Employer Survey Video om forskning i Novo Nordisk",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1501,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
594,2014-10-17,Novo Nordisk second best science employer in the world,"Bagsværd, Denmark, 17 October 2014 - Novo Nordisk ranked second in the 2014 Science Careers Top Employers Survey, which is a big jump up the list from last year's ranking where Novo Nordisk came in at number 11. The key drivers of the ranking were the categories 'Treats employees with respect', 'Has loyal employees' and 'Is socially responsible'. ""We're really proud of being ranked number two this year on the prestigious list of the world's best science employers,"" said Mads Krogsgaard Thomsen, chief science officer and executive vice president at Novo Nordisk. ""Our researchers around the world are doing a tremendous job of discussing and developing truly innovative and patient-focused products. The fact that the research community feels that Novo Nordisk is one of the very best places to work matters a great deal for a company growing at Novo Nordisk's pace."" Today Novo Nordisk employs more than 40,000 people globally - a number the company anticipates will rise to more than 60,000 over the next decade. Novo Nordisk Research and Development is a global organisation with more than 6,000 employees working at sites in Denmark, China, US and India. Novo Nordisk has more than 90 years of experience as a science-driven company with a strong commitment to patients. ""We combine scientific, pharmaceutical and clinical expertise with high ethical standards to continue to improve the quality of life of people living with chronic diseases. As the global leader in diabetes care, millions of people worldwide rely on us to deliver treatments for their disease every day. Additionally, we continue to invest in developing innovative treatments for obesity, haemophilia and growth disorders,"" says Mads Krogsgaard Thomsen. The 2014 Science Careers Top Employers Survey is based on 5,394 responses from readers of Science and from employees in the biotechnology and pharmaceutical industry, who were asked to rank the 20 best employers on a number of characteristics. About the 2014 Science Careers Top Employer Survey Video about Novo Nordisk R&D Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 40,700 employees in 75 countries, and markets its products in more than 180 countries. For more information, visit novonordisk.com.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1500,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
595,2014-09-25,Novo Nordisk etablerer ny enhed for fedmeforskning i Seattle,"Bagsværd, den 25. september 2014 - Novo Nordisk meddelte i dag, at virksomheden vil etablere en ny enhed for fedmeforskning i Seattle, Washington, USA. Den ny enhed er et resultat af Novo Nordisks stigende fokus på fedmeområdet. Enhedens primære opgave bliver at identificere nye mekanismer og targets for lægemidler til behandling af fedme og samtidig øge den videnskabelige forståelse af eksisterende targets indenfor fedme. ""Det er vores ambition at drive videnskabelige fremskridt indenfor sygdomsområdet fedme og herigennem identificere og udvikle nye behandlingsmuligheder for svært overvægtige mennesker,"" siger Mads Krogsgaard Thomsen, koncernforskningsdirektør i Novo Nordisk. Dr. Kevin Grove er ansat som leder af Novo Nordisk Obesity Research Unit i Seattle. Han er en anerkendt ekspert i endokrinologi med speciale i fedme og sundhedsrelateret livskvalitet og kommer fra en stilling som senior scientist ved Oregon Health & Science University og founding division chief, Division of Diabetes, Obesity & Metabolism. ""Jeg glæder mig til at stå i spidsen for Novo Nordisk Obesity Research Unit i Seattle og samle et team af de bedste forskere indenfor fedme og endokrinologi. Vi har en reel mulighed for at gøre en meningsfyldt forskel i behandlingen af denne sygdom, som berører så mange mennesker overalt i verden,"" siger Kevin Grove. Novo Nordisk Obesity Research Unit får til en start omkring 10 medarbejdere, der understøttes af de eksisterende fedmeforsknings- og hovedkvartersfunktioner. Enheden ventes at beskæftige omkring 60 medarbejdere, når den er fuldt funktionsklar i slutningen af 2016. Globalt arbejder omkring 300 ansatte i Novo Nordisk med forsknings- og udviklingsaktiviteter indenfor fedme. Den nye fedmeforskningsenhed vil dele adresse med diabetesforskningsenheden Novo Nordisk Type 1 Diabetes Research Unit i virksomhedens forskningscenter i Seattle, som åbnede i 2009. Fedme er en sygdom[1], der kræver kronisk regulering. Den er forbundet med alvorlige komplikationer som type 2-diabetes, hjertesygdom, obstruktiv søvnapnø og visse former for kræft samt en nedsættelse af den forventede levetid[2][3][4]. Risikoen for sygelighed (morbiditet) og dødelighed (mortalitet) stiger i takt med sværhedsgraden af fedme. Det er en kompleks sygdom, der er betinget af flere forskellige forhold, herunder genetiske, fysiologiske, miljømæssige og psykologiske faktorer[5]. Den globale stigning i forekomsten af fedme er en trussel mod folkesundheden med betydelig indvirkning på sundhedsudgifterne. I USA er ca. 35% af den voksne befolkning - omkring 100 mio. mennesker - svært overvægtige[6]. Fotos og dækbilleder kan downloades på novonordisk.com. [1]    American Medical Association, (AMA). Declaration to classify obesity as a disease. Annual Meeting Report. 19 June 2013. [2]    WHO. Obesity and Overweight Factsheet no. 311. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/ [3]    Gami AS, Caples SM, Somers VK. Obesity and obstructive sleep apnea. Endocrinology and Metabolism Clinics of North America. 2003; 32:869-894. [4]    Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009; 9:88. [5]    Wright SM, Aronne LJ. Causes of obesity. Abdominal Imaging. 2012; 37:730-732. [6]    Ogden CL, Carroll MD, Kit BK, et al. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014; 311:806-814.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1519,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
596,2014-09-25,Novo Nordisk establishes new obesity research unit in Seattle,"Bagsværd, Denmark, 25 September 2014 - Novo Nordisk today announced that the company will establish a new obesity research unit in Seattle, Washington, in the US. The new unit is a result of Novo Nordisk's increasing focus on treatment of obesity. Its main task will be to identify novel approaches and targets for obesity treatments while increasing the scientific understanding of existing obesity targets. ""Our ambition is to drive scientific progress in the obesity disease area and through this identify and develop new treatment options for people with obesity"", said Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk. Dr Kevin Grove has accepted the position as head of the Novo Nordisk Obesity Research Unit in Seattle. Grove is a renowned expert in endocrinology specialising in obesity and health-related quality of life, and joins Novo Nordisk from a position as senior scientist at the Oregon Health & Science University, and founding division chief, Division of Diabetes, Obesity & Metabolism. ""I'm looking forward to leading the Novo Nordisk Obesity Research Unit in Seattle and gather a team of preeminent researchers within the obesity and endocrinology field. We have a real opportunity to make a meaningful difference in the management of this disease that impacts so many people globally"", said Dr Kevin Grove. The Novo Nordisk Obesity Research Unit will initially employ around 10 people, supported by the current obesity research and corporate functions. When fully operational by the end of 2016, the unit is expected to employ around 60 employees. Globally, around 300 employees are working within obesity research and development at Novo Nordisk. The Obesity Research Unit will be co-located with the Novo Nordisk Type 1 Diabetes Research Unit at the company's research centre in Seattle, which opened in 2009. Obesity is a disease[i] that requires chronic management. It is associated with serious comorbidities including type 2 diabetes, heart disease, obstructive sleep apnoea (OSA), certain types of cancer and a decreased life expectancy[ii][iii][iv]. The risk of morbidity and mortality increases with the severity of obesity. It is a complex and multi-factorial disease that is influenced by genetic, physiological, environmental and psychological factors[v]. The global increase in the prevalence of obesity is a public health issue that has severe cost implications to healthcare systems. In the US, approximately 35% of adults, or some 100 million people, live with obesity[vi]. Visit novonordisk.com for photos and b-roll supporting this press release. Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 40,700 employees in 75 countries, and markets its products in more than 180 countries. For more information, visit novonordisk.com.  Further information References [i] American Medical Association, (AMA). Declaration to classify obesity as a disease. Annual Meeting Report. 19 June 2013. [ii] WHO. Obesity and Overweight Factsheet no. 311. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/ [iii] Gami AS, Caples SM, Somers VK. Obesity and obstructive sleep apnea. Endocrinology and Metabolism Clinics of North America. 2003; 32:869-894. [iv] Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009; 9:88. [v] Wright SM, Aronne LJ. Causes of obesity. Abdominal Imaging. 2012; 37:730-732. [vi] Ogden CL, Carroll MD, Kit BK, et al. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014; 311:806-814.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1518,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
597,2014-09-18,Xultophy® (IDegLira) godkendt i Europa,"Bagsværd, den 18. september 2014 - Novo Nordisk meddelte i dag, at Europa-Kommissionen har givet markedsføringstilladelse til Xultophy® til behandling af type 2-diabetes hos voksne. Markedsføringstilladelsen gælder samtlige 27 EU-medlemslande. Yderligere information Selskabsmeddelelse nr. 58 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1525,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
598,2014-09-18,Xultophy® (IDegLira) approved in Europe,"Bagsværd, Denmark, 18 September 2014 - Novo Nordisk today announced that the European Commission has granted marketing authorisation for Xultophy® for the treatment of type 2 diabetes mellitus in adults. The authorisation covers all 27 European Union member states. Company announcement No 58 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1526,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
599,2014-09-18,Ryzodeg® provides successful glycaemic control with fewer injections than a basal-bolus regimen,"Vienna, Austria, Thursday 18 September 2014 - Data presented today at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD) show that Ryzodeg® (insulin degludec/insulin aspart) administered twice daily, provides successful glycaemic control with fewer injections than a basal-bolus regimen1[*]. Ryzodeg® is a combination of two distinct insulin analogues (insulin degludec and insulin aspart in the ratio of 70% and 30%), making it the first combination of a basal insulin with an ultra-long duration of action and a well-established mealtime insulin in one pen for people with type 2 diabetes2-4. ""Patients currently using basal-bolus regimens may need to take up to four daily injections, which can be a great burden and very inconvenient. Ryzodeg® is a new treatment option which provides proven glycaemic control, with fewer injections and reduced rates of hypoglycaemia compared to basal-bolus regimens,"" said Dr Helena Rodbard, the study's principal investigator and endocrinologist in Rockville, MD, USA. ""This new treatment offers the potential for a simple alternative to basal-bolus for patients who require intensification of basal insulin regimens,"" she added. The study presented at EASD was a 26-week randomised multinational phase 3b trial, where patients previously treated with basal insulin were randomised to a regimen of either twice daily Ryzodeg®, or a basal-bolus regimen of once-daily insulin degludec plus two to four injections of insulin aspart1. The studydid not meet its primary endpoint of non-inferiority; however, the results showed that HbA1c was reduced for patients on either regimen, to 7.0% and 6.8% respectively, with no significant difference between the two regimens1. Patients who received Ryzodeg® experienced a numerically lower rate of overall and nocturnal confirmed hypoglycaemic episodes1, 19% and 20% less, respectively. They also gained significantly less weight (p<0.05) over the course of the study and used a significantly lower daily insulin dose1 (12%; p<0.05) versus the basal-bolus regimen. Type 2 diabetes is a progressive disease5, which means some patients will need to intensify insulin treatment eventually by adding mealtime insulin - bolus therapy ­- to achieve or maintain their glycaemic targets over time5. Studies have shown that more than 50% of people with type 2 diabetes on basal insulin alone are not achieving their glycaemic targets as measured by HbA1c6-8. Complications from diabetes caused by failing to keep optimal glycaemic control can be serious and may include problems such as heart disease, stroke, blindness, kidney disease, nerve damage and premature mortality9,10. About Ryzodeg®Ryzodeg® is a combination of two distinct insulin analogues, insulin degludec and insulin aspart in the ratio of 70% and 30%. In a multinational trial, Ryzodeg® delivered twice daily at main meals offered a successful reduction in HbA1c2,4 with lower risk of hypoglycaemia versus biphasic insulin aspart 30 in people with type 2 diabetes4. In other studies no apparent differences were shown between Ryzodeg® and its comparators, with respect to adverse events and standard safety parameters4,11-13. Ryzodeg® has been approved in Aruba, Brazil, Chile, Costa Rica, El Salvador, the EU, Hong Kong, Iceland, India, Israel, Japan, Kazakhstan, Macedonia, Mexico, Norway, Russia, South Korea and Switzerland. About the clinical trial programmeThe clinical trial programmes for insulin degludec (BEGIN®) and Ryzodeg® (BOOST®) comprise the largest in the field of insulin therapy, with more than 11,000 people included. Novo Nordisk completed the phase 3a BOOST® programme in 2010. This programme consisted of six randomised, controlled, treat-to-target trials in more than 30 countries. More than 2,000 people were included in the development programme. The programme was designed after consultancy with regulatory agencies in Europe, Japan and USA. Further information References [*]A basal-bolus routine involves taking a longer acting form of insulin to keep blood glucose levels stable through periods of fasting and separate injections of shorter acting insulin to prevent rises in blood glucose levels resulting from meals.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1529,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
600,2014-09-18,Ryzodeg® giver god blodsukkerregulering med færre injektioner end basal-bolusbehandling,"Wien, Østrig, den 18. september 2014 - Ryzodeg® (insulin degludec/insulin aspart) doseret to gange dagligt giver god blodsukkerregulering med færre injektioner end basal-bolusbehandling1[*]. Det viser data, der blev præsenteret i dag på den årlige europæiske diabeteskonference EASD (European Association for the Study of Diabetes). Ryzodeg® er den første kombination af to forskellige insulinanaloger (insulin degludec og insulin aspart i forholdet 70/30), nemlig en basal insulinanalog med lang virkningsvarighed og en veletableret måltidsinsulinanalog, i én injektionspen til behandling af type 2-diabetes2-4. ""Patienter, der bruger basal-bolusbehandling i dag, kan være nødt til at tage op til fire injektioner om dagen, hvilket kan være en stor belastning og til stor gene. Ryzodeg® er en ny behandlingsmulighed, der giver dokumenteret blodsukkerregulering med færre injektioner og mindre hypoglykæmi sammenlignet med basal-bolusbehandling,"" siger dr. Helena Rodbard, forsøgsansvarlig for studiet og endokrinolog i Rockville, Maryland, USA. ""Denne nye behandling har potentiale til at blive et enkelt alternativ til basal-bolusbehandling for patienter, der har behov for at intensivere den basale insulinbehandling,"" tilføjer hun. Studiet, der blev præsenteret på EASD, var et 26-ugers randomiseret, multinationalt fase 3b-studie, hvor deltagere, der tidligere havde fået basal insulin, blev randomiseret til behandling med enten Ryzodeg® to gange dagligt eller basal-bolusbehandling med insulin degludec én gang dagligt plus to til fire injektioner af insulin aspart1. Studiet opfyldte ikke det primære målepunkt om ikke-inferiøritet, men resultaterne viste, at langtidsblodsukkeret (HbA1c) blev reduceret for deltagerne i begge behandlingsgrupper, til henholdsvis 7,0% og 6,8%, uden signifikant forskel mellem de to behandlingsformer1. Deltagere, der fik Ryzodeg®, oplevede en numerisk lavere forekomst af generel og natlig bekræftet hypoglykæmi1, henholdsvis 19% og 20% færre episoder. De tog også signifikant mindre på i vægt (p<0,05) i løbet af studiet og brugte en signifikant lavere daglig insulindosis1 (12%; p<0,05) sammenlignet med basal-bolusbehandlingen. Type 2-diabetes er en progressiv sygdom5. Det betyder, at nogle patienter med tiden er nødt til at intensivere deres insulinbehandling ved også at tage måltidsinsulin, også kaldet bolusinsulin, for at nå eller fastholde deres blodsukkermål5. Studier har vist, at over 50% af alle med type 2-diabetes i behandling med basal insulin alene ikke når de anbefalede mål for langtidsblodsukkeret6-8. Dårlig blodsukkerregulering kan medføre alvorlige diabetiske følgesygdomme som hjertekarsygdom, slagtilfælde, blindhed, nyresygdom og nerveskader samt for tidlig død9,10. Om Ryzodeg®Ryzodeg® er den første kombination af to forskellige insulinanaloger, insulin degludec og insulin aspart i forholdet 70/30. Et multinationalt studie har vist, at Ryzodeg® givet to gange dagligt i forbindelse med hovedmåltiderne gav en succesfuld reduktion i HbA1c2,4 med lavere risiko for hypoglykæmi sammenlignet med bifasisk insulin aspart 30 hos mennesker med type 2-diabetes4. Andre studier har vist, at der ikke var nogen klare forskelle mellem Ryzodeg® og sammenligningsprodukterne med hensyn til bivirkninger og gængse sikkerhedsparametre4,11-13. Ryzodeg® er godkendt i Aruba, Brasilien, Chile, Costa Rica, El Salvador, EU, Hongkong, Indien, Island, Israel, Japan, Kasakhstan, Makedonien, Mexico, Norge, Rusland, Schweiz og Sydkorea. Om det kliniske udviklingsprogramDe kliniske udviklingsprogrammer for insulin degludec (BEGIN®) og Ryzodeg® (BOOST®) er med over 11.000 deltagere de største nogensinde indenfor insulinområdet. Novo Nordisk afsluttede fase 3a-programmet BOOST® i 2010. Det bestod af seks randomiserede, kontrollerede treat to target-studier i flere end 30 lande. Programmet omfattede flere end 2.000 deltagere og var tilrettelagt i samråd med de regulatoriske myndigheder i Europa, Japan og USA. [*] Ved basal-bolusbehandling tages længerevirkende insulin for at holde blodsukkerniveauet stabilt dagen igennem mellem måltiderne og separate injektioner af hurtigerevirkende insulin for at undgå blodsukkerstigning efter måltiderne.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1530,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
601,2014-09-16,New data show long-term efficacy and safety of Tresiba® in children and adolescents with type 1 diabetes,"Vienna, Austria, 16 September - Today, at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), Novo Nordisk announced new data from the BEGIN® YOUNG 1 trial. The study investigates once-daily Tresiba® (insulin degludec) versus insulin detemir, both in combination with bolus insulin aspart in a 52-week trial in children and adolescents with type 1 diabetes. This trial is the first to look into the long-term safety of Tresiba® in children and adolescents (from age 1 to less than 18 years). The results show that Tresiba® in combination with insulin aspart effectively improved long-term glycaemic control1. ""When treating children and adolescents with type 1 diabetes, it is critical that the right balance between glycaemic control and side effect management is maintained to ensure the best possible long-term outcomes. These data show that Tresiba® has the potential to offer youngsters with diabetes a new treatment option, which may help them achieve better control of their diabetes,"" said Dr Nandu Thalange, paediatric endocrinologist at Norfolk and Norwich University Hospital, Norwich, United Kingdom. The BEGIN® YOUNG 1 trial was a randomised controlled, 26 week open-label, treat-to-target trial (with a 26-week extension) investigating the efficacy and safety of Tresiba®, given once daily, and insulin detemir, given once or twice daily, both in combination with bolus insulin aspart in children and adolescents with type 1 diabetes. Tresiba® met the primary endpoint of non-inferiority to insulin detemir for mean change in HbA1c (p<0.05) at 26 weeks. In the 26-week extension a lower insulin dose and a significantly greater reduction in fasting plasma glucose (FPG*) versus insulin detemir (p<0.05) was achieved1. Both regimens had similar rates of overall and nocturnal hypoglycaemia, the rate of severe hypoglycaemia was numerically higher with insulin degludec plus insulin aspart1. Of note, patients on Tresiba® had significantly lower rates of hyperglycaemia with ketosis (p<0.05)1. Weight (measured as SD score[**]) increased with Tresiba® and remained unchanged with insulin detemir1. Adverse event profiles were similar for insulin degludec and insulin detemir1. About Tresiba® Tresiba® (insulin degludec) is a once-daily basal insulin that provides an ultra-long duration of action beyond 42 hours2,3. It is important for people with type 1 and type 2 diabetes to establish a routine for insulin treatment.  On occasions when administration at the same time of day is not possible, Tresiba® allows for flexibility in day-to-day dosing time3-5. Tresiba® has received regulatory approval in Argentina, Aruba, Bangladesh, Bosnia & Herzegovina, Brazil, Chile, Colombia, Costa Rica, El Salvador, the EU, Honduras, Hong Kong, Iceland, Israel, India, Japan, Kazakhstan, Lichtenstein, Lebanon, Macedonia, Mexico, Nepal, Norway, South Korea, Switzerland and Russia. References * FPG measures the concentration of glucose in the plasma after the patient has not eaten for at least eight hours. [**] Standard deviation (SD) measures the amount of variation from the average. A low standard deviation indicates that the data points are close to the average; a high standard deviation indicates that the data points are spread out over a large range of values.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1531,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
602,2014-09-16,Nye data viser langsigtet effekt og sikkerhed for Tresiba® hos børn og unge med type 1-diabetes,"Wien, Østrig, den 16. september 2014 - Novo Nordisk præsenterede i dag på den årlige europæiske diabeteskonference EASD (European Association for the Study of Diabetes) nye data fra det kliniske studie BEGIN® YOUNG 1. Studiet undersøger Tresiba® (insulin degludec) én gang dagligt sammenlignet med insulin detemir, begge i kombination med bolus insulin aspart i et 52-ugers studie i børn og unge med type 1-diabetes. Studiet er det første, der har undersøgt den langsigtede sikkerhed for Tresiba® hos børn og unge (i alderen fra 1 og op til 18 år). Resultaterne viser, at Tresiba® i kombination med insulin aspart forbedrede den langsigtede blodsukkerregulering1. ""Når man behandler børn og unge med type 1-diabetes, er det utrolig vigtigt at opretholde den rette balance mellem en god blodsukkerregulering og styring af bivirkninger for at sikre de bedst mulige resultater på langt sigt. Disse data viser, at Tresiba® har potentiale til at tilbyde unge mennesker en ny behandlingsmulighed, som kan hjælpe dem til at opnå en bedre regulering af deres diabetes,"" siger dr. Nandu Thalange, børnelæge ved Norfolk and Norwich University Hospital, Norwich, Storbritannien. BEGIN® YOUNG 1-studiet blev gennemført som et randomiseret, kontrolleret, 26-ugers ikke-blindet treat to target-studie (med en 26-ugers forlængelse), der undersøgte effekt og sikkerhed for Tresiba® doseret én gang dagligt og insulin detemir doseret én eller to gange dagligt, begge i kombination med bolus insulin aspart hos børn og unge med type 1-diabetes. Tresiba® opfyldte det primære målepunkt om ikke-inferiøritet overfor insulin detemir for gennemsnitlig ændring i HbA1c (p<0,05) ved 26 uger. I 26-ugers forlængelsen opnåedes en lavere insulindosis og en signifikant større reduktion i fasteblodsukkeret[*] sammenlignet med insulin detemir (p<0,05)1. Begge behandlingsregimer havde sammenlignelige forekomster af generel og natlig hypoglykæmi, og forekomsten af alvorlig hypoglykæmi var numerisk højere med insulin degludec plus insulin aspart1. Desuden havde patienter, der blev behandlet med Tresiba®, en signifikant lavere forekomst af hyperglykæmi (højt blodsukker) med ketose (p<0,05)1. Vægten (målt som SD-score**) steg med Tresiba® og forblev uændret med insulin detemir1. Bivirknings­profilerne var sammenlignelige for insulin degludec og insulin detemir1. Tresiba® (insulin degludec) er en basal insulin til dosering én gang dagligt med en lang virkningsvarighed på mere end 42 timer2,3. Det er vigtigt for mennesker med type 1- og type 2-diabetes at etablere en rutine for deres insulinbehandling, men i situationer, hvor det ikke er muligt at tage insulin på samme tidspunkt af dagen, giver Tresiba® mulighed for fleksibilitet med hensyn til injektionstidspunktet3-5. Tresiba® er godkendt i Argentina, Aruba, Bangladesh, Bosnien & Hercegovina, Brasilien, Chile, Colombia, Costa Rica, El Salvador, EU, Honduras, Hongkong, Island, Israel, Indien, Japan, Kasakhstan, Libanon, Lichtenstein, Makedonien, Mexico, Nepal, Norge, Rusland, Schweiz og Sydkorea. [*] Fasteblodsukkeret er koncentrationen af glukose i plasma målt, når patienten ikke har spist i mindst otte timer. ** Standardafvigelsen er udtryk for afvigelse fra gennemsnittet. En lav standardafvigelse indikerer, at dataværdierne er tæt på gennemsnittet; en høj standardafvigelse indikerer, at dataværdierne er spredt over et stort interval.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1532,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
603,2014-09-11,Saxenda® for the treatment of obesity receives positive 14-1 vote in favour of approval from FDA Advisory Committee,"Bagsværd, Denmark, 11 September 2014 - Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the United States Food and Drug Administration (FDA) has completed its meeting regarding the New Drug Application (NDA) for Saxenda®, the intended brand name for liraglutide 3 mg, a once-daily human GLP-1 analogue for the treatment of obesity.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1538,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
604,2014-09-11,FDA's rådgivende komite anbefaler godkendelse af Saxenda® til behandling af fedme med stemmerne 14-1,"Bagsværd, den 11. september 2014 - Novo Nordisk meddelte i dag, at Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC), som er en rådgivende komite for de amerikanske sundhedsmyndigheder (FDA), har afsluttet sit møde vedrørende registreringsansøgningen for Saxenda®. Saxenda® er det planlagte produktnavn for liraglutid 3 mg, en human GLP-1-analog til dosering én gang dagligt til behandling af fedme. Selskabsmeddelelse nr. 56 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1539,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
605,2014-09-09,FDA posts briefing materials prior to Advisory Committee meeting for Saxenda® for the treatment of obesity,"Bagsværd, Denmark, 9 September 2014 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has published the briefing documents ahead of the 11 September 2014 Advisory Committee meeting to discuss the New Drug Application (NDA) for Saxenda®, the intended brand name forliraglutide 3 mg for the treatment of obesity. Further information Company announcement No 55 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1543,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
606,2014-09-09,FDA offentliggør briefingmateriale forud for mødet i den rådgivende komite om Saxenda® til behandling af fedme,"Bagsværd, den 9. september 2014 - Novo Nordisk meddelte i dag, at de amerikanske sundhedsmyndigheder, FDA, har offentliggjort briefingdokumenterne forud for mødet i den rådgivende komite den 11. september 2014, hvor registreringsansøgningen for Saxenda® vil blive drøftet. Saxenda® er det planlagte varemærke for liraglutid 3 mg til behandling af fedme. Yderligere information Selskabsmeddelelse nr. 55 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1544,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
607,2014-09-02,Novo Nordisk indstiller aktiviteterne indenfor inflammatoriske sygdomme,"Bagsværd, den 2. september 2014 - Novo Nordisk meddelte i dag, at det er besluttet at indstille alle forsknings- og udviklingsaktiviteter indenfor inflammatoriske sygdomme og samtidig øge indsatsen indenfor forebyggelse og behandling af diabetes, fedme og diabetiske følgesygdomme. Yderligere information Selskabsmeddelelse nr. 53 / 2014 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1551,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
608,2014-09-02,Novo Nordisk discontinues its activities within inflammatory disorders,"Bagsværd, Denmark, 2 September 2014 - Novo Nordisk today announced a decision to discontinue all its research and development (R&D) activities within inflammatory disorders while increasing its efforts within diabetes prevention and treatment, obesity and diabetes complications. Company announcement No 53 / 2014  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1552,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
609,2014-09-01,Ryzodeg® lanceres i Mexico som første land,"Bagsværd, den 1. september 2014 - Novo Nordisk lancerer nu Ryzodeg® (insulin degludec/insulin aspart) i Mexico som det første land i verden. Ryzodeg® er en kombination af to forskellige insulinanaloger (insulin degludec og insulin aspart i forholdet 70/30) og er den første kombination af en basal insulin med lang virkningsvarighed og en veletableret måltidsinsulin i én injektionspen til behandling af type 2-diabetes1-3. Ryzodeg® reducerer langtidsblodsukkeret (HbA1c) hos voksne med type 2-diabetes1,3-5 med lavere risiko for hypoglykæmi (lavt blodsukker) sammenlignet med bifasisk insulin aspart 303,4[*]. Ryzodeg® er et kombinationsprodukt og kræver derfor færre daglige injektioner, end hvis basal- og måltidsinsulin doseres hver for sig. ""Ryzodeg® er en ny tilgang til behandling af diabetes, og vi er meget glade for, at denne insulin nu bliver tilgængelig for mennesker med diabetes. Kliniske studier har vist, at Ryzodeg® giver en god blodsukkerregulering med lav risiko for at få for lavt blodsukker. Det er utrolig velegnet til intensiveret insulinbehandling, fordi det kræver færre injektioner end andre behandlinger,"" siger Novo Nordisks koncernforskningsdirektør, Mads Krogsgaard Thomsen. Type 2-diabetes er en progressiv sygdom6. Det betyder, at nogle patienter med tiden er nødt til at intensivere deres insulinbehandling ved også at tage måltidsinsulin - også kaldet bolusinsulin - for at nå eller fastholde deres blodsukkermål6. Studier har vist, at over 50% af alle med type 2-diabetes i behandling med basal insulin ikke når de anbefalede mål for langtidsblodsukkeret7-9. De følgesygdomme, der kan opstå på grund af dårlig blodsukkerregulering, kan være alvorlige og omfatte komplikationer som hjertekarsygdom, slagtilfælde, blindhed, nyresygdom og nerveskader samt for tidlig død10,11. I Mexico, hvor 8,7 mio. mennesker lever med diabetes12, var der 70.281 diabetesrelaterede dødsfald i 201313. Novo Nordisk forventer at gøre Ryzodeg® tilgængeligt i andre lande i verden i løbet af det næste år. Et multinationalt studie har vist, at Ryzodeg® (insulin degludec/insulin aspart) givet to gange dagligt i forbindelse med hovedmåltiderne gav en succesfuld reduktion i HbA1c1,3 med lavere risiko for hypoglykæmi sammenlignet med bifasisk insulin aspart 30 hos mennesker med type 2-diabetes. Studiet viste således en3:               ·           32% lavere risiko for generel bekræftet hypoglykæmi               ·           73% lavere risiko for natlig bekræftet hypoglykæmi. Andre studier har vist, at der ikke var nogen klare forskelle mellem Ryzodeg® og sammenligningsprodukterne med hensyn til bivirkninger og gængse sikkerhedsparametre3,5,14,15. Ryzodeg® er godkendt i Aruba, Brasilien, Chile, Costa Rica, El Salvador, EU, Hongkong, Indien, Island, Israel, Japan, Kasakhstan, Makedonien, Mexico, Norge, Rusland, Schweiz og Sydkorea. De kliniske udviklingsprogrammer for insulin degludec (BEGIN®) og Ryzodeg® (BOOST®) er med over 11.000 deltagere de største nogensinde indenfor insulinområdet. Novo Nordisk afsluttede fase 3a-programmet BOOST® i 2010. Det bestod af seks randomiserede, kontrollerede treat to target-studier i flere end 30 lande. Programmet omfattede flere end 2.000 deltagere og var tilrettelagt i samråd med de regulatoriske myndigheder i Europa, Japan og USA. [*] Fra to multinationale studier, der sammenlignede Ryzodeg® med bifasisk insulin aspart 30 hos deltagere, der tidligere henholdsvis havde fået insulin og ikke havde fået insulin3,4.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1560,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
610,2014-09-01,Mexico first country to launch Ryzodeg®,"Bagsværd, Denmark, 1 September 2014 - Novo Nordisk today announced that in Mexico, as the first country in the world, Ryzodeg® is now launched and made available for people with type 2 diabetes. Ryzodeg® is a combination of two distinct insulin analogues (insulin degludec and insulin aspart in the ratio of 70% and 30%), making it the first combination of a basal insulin with an ultra-long duration of action and a well-established mealtime insulin in one pen for people with type 2 diabetes1-3. Ryzodeg® offers adults with type 2 diabetes successful reductions in HbA1c1,3-5, with lower risk of hypoglycaemia versus biphasic insulin aspart 303,4[*]. As Ryzodeg® is a combination product it requires fewer daily injections than administering basal and mealtime insulin in separate injections. ""Ryzodeg® is a new approach to diabetes management, and we are very pleased to make it available now for people with diabetes. Ryzodeg® has documented excellent glucose control and a low risk of hypoglycaemia in clinical trials, and it represents an excellent opportunity for intensification of insulin treatment with fewer injections than other treatment options,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. Type 2 diabetes is a progressive disease6, which means some patients will need to eventually intensify insulin treatment by adding mealtime insulin - bolus therapy - to achieve or maintain their glycaemic targets over time6. Studies have shown that more than 50% of people with type 2 diabetes on basal insulin are not achieving their glycaemic targets as measured by HbA1c7-9. Complications from diabetes caused by failing to keep optimal glycaemic control can be serious, and may include problems such as heart disease, stroke, blindness, kidney disease, nerve damage and premature mortality10,11. In Mexico, where 8.7 million people live with diabetes12, the number of diabetes-related deaths was 70,281 in 201313. Novo Nordisk expects to make Ryzodeg® available in additional countries around the world within the next year. In a multinational trial, Ryzodeg® (insulin degludec/insulin aspart) delivered twice daily at main meals offered a successful reduction in HbA1c1,3 with lower risk of hypoglycaemia versus biphasic insulin aspart 30 in people with type 2 diabetes, showing a3: In other studies no apparent differences were shown between Ryzodeg® and its comparators, with respect to adverse events and standard safety parameters3,5,14,15. Ryzodeg® has been approved in Aruba, Brazil, Chile, Costa Rica, El Salvador, the EU, Hong Kong, Iceland, India, Israel, Japan, Kazakhstan, Macedonia, Mexico, Norway, Russia, South Korea and Switzerland. The clinical trial programmes for insulin degludec (BEGIN®) and Ryzodeg® (BOOST®) comprise the largest in the field of insulin therapy, including more than 11,000 people. Novo Nordisk completed the phase 3a BOOST® programme in 2010. This programme consisted of six randomised, controlled, treat-to-target trials in more than 30 countries. More than 2000 people were included in the development programme. The programme was designed after consultancy with regulatory agencies in Europe, Japan and USA. Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 40,700 employees in 75 countries, and markets its products in more than 180 countries. References [*]From two multinational trials comparing Ryzodeg® with biphasic insulin aspart 30 in previous insulin-using and insulin-naïve patients3,4.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1559,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
611,2014-08-27,"Novo Nordisk køber fabrik i New Hampshire, USA","Bagsværd, den 27. august 2014 - Novo Nordisk meddelte i dag, at virksomheden har købt en fabrik i West Lebanon, New Hampshire, USA, fra Olympus Biotech. Fabrikken blev etableret i 1989, udvidet i 2003-2006 og overtaget af Olympus Biotech i 2011. Den har primært været anvendt til produktion baseret på mammale celler, indtil produktionen blev udfaset tidligere i år. Novo Nordisk vil anvende fabrikken til fremstilling af aktive lægemiddelstoffer primært til virksomhedens portefølje af biofarmaceutiske produkter. Nogle af fabrikkens tidligere medarbejdere er blevet tilbudt ansættelse, i første omgang med fokus på at planlægge det fremtidige produktions-setup. De endelige planer vil afgøre potentialet og tidsplanen for fremtidige udvidelser af medarbejderstaben. Novo Nordisk og Olympus Biotech har aftalt ikke at oplyse om de nærmere vilkår for overtagelsen.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1562,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
612,2014-08-27,Novo Nordisk buys production plant in New Hampshire,"Bagsværd, Denmark, 27 August 2014 - Novo Nordisk today announced the acquisition of a manufacturing facility in West Lebanon, New Hampshire, USA, from Olympus Biotech. The facility was established in 1989, expanded in 2003-2006 and acquired by Olympus Biotech in 2011. It has been used primarily for mammalian cell manufacturing until production was phased out earlier this year. Novo Nordisk intends to use the facility for production of active pharmaceutical ingredients primarily for its portfolio of biopharmaceuticals. Some of the plant's former employees have been offered jobs, which initially will focus on planning of the future plant setup. Final plans will determine potential and timing for future staffing increases. Novo Nordisk and Olympus Biotech have agreed not to disclose the terms of the acquisition. Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 40,700 employees in 75 countries, and markets its products in more than 180 countries. For more information, visit novonordisk.com.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1561,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
613,2014-08-18,Novo Nordisk A/S : Press release test,Press release test,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1571,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
614,2014-08-18,Novo Nordisk A/S : Press release test,Press release test,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1572,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
615,2014-08-07,Novo Nordisks resultat af primær drift opgjort i lokale valutaer steg med 12% i første halvår af 2014,"Salget steg med 7% opgjort i lokale valutaer og med 1% i kroner til 42,0 mia. kr. i første halvår af 2014 i forhold til samme periode i 2013. Bruttomarginen steg med 0,4 procentpoint opgjort i kroner til 83,0% drevet af en gunstig prisudvikling samt en positiv påvirkning fra produktsammensætning og produktivitet. Resultat af primær drift steg med 12% opgjort i lokale valutaer og med 4% i kroner til 16,8 mia. kr. Nettoresultatet steg med 6% til 13,5 mia. kr. Udvandet resultat pr. aktie steg med 9% til 5,09 kr. Lanceringen af Tresiba® (insulin degludec), den nye generation af insulin med ultralang virkningsvarighed til dosering én gang dagligt, fortsætter. I Japan, der som det første land i marts 2013 lancerede Tresiba® med tilskud på samme niveau som insulin glargin, repræsenterer Tresiba® nu 21% af markedsværdien for basal insulin opgjort på månedsbasis. DEVOTE-studiet, der undersøger forekomsten af hjerte-kar-sygdom i forbindelse med brug af Tresiba®, går hurtigere end planlagt, og Novo Nordisk forventer nu at have data til at understøtte en interimanalyse omkring årsskiftet 2014/2015, hvilket potentielt vil muliggøre en indsendelse af interimanalysen til de amerikanske sundhedsmyndigheder, FDA, i første halvår af 2015. For 2014 forventes fortsat en salgsvækst opgjort i lokale valutaer på 7-10%, og væksten i resultat af primær drift opgjort i lokale valutaer forventes fortsat at blive på omkring 10%. Adm. direktør Lars Rebien Sørensen: ""Vi er tilfredse med de finansielle resultater opnået i et udfordrende første halvår af 2014. Tresiba® klarer sig godt på vigtige markeder, og det går fortsat hurtigere end forventet med DEVOTE-studiet. Det har gjort det muligt yderligere at fremrykke tidsplanen for interimanalysen og en potentiel lancering af Tresiba® i USA. Derudover har vi med den positive udtalelse for Xultophy® fra de europæiske registreringsmyndigheder passeret en vigtig milepæl på vejen mod at bringe det første kombinationsprodukt af insulin og GLP-1 på markedet."" Selskabsmeddelelse nr. 48 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1578,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
616,2014-08-07,Novo Nordisk increased operating profit in local currencies by 12% in the first six months of 2014,"Sales increased by 7% in local currencies and by 1% in Danish kroner to DKK 42.0 billion during the first six months of 2014 compared to the same period in 2013. Sales in Region China increased by 17% (13% in Danish kroner). Gross margin improved by 0.4 percentage point in Danish kroner to 83.0% driven by a favourable price development as well as a positive impact from product mix and productivity. Operating profit increased by 12% in local currencies and by 4% in Danish kroner to DKK 16.8 billion.  Net profit increased by 6% to DKK 13.5 billion. Diluted earnings per share increased by 9% to DKK 5.09.  The roll-out of Tresiba® (insulin degludec), the once-daily new-generation insulin with an ultra-long duration of action, continues. In Japan, the first country to launch Tresiba® with reimbursement at a similar level as insulin glargine in March 2013, it now represents 21% of the basal insulin market measured in monthly value market share.  The cardiovascular outcomes trial for Tresiba®, DEVOTE, is progressing ahead of plans and Novo Nordisk now expects to have data to support an interim analysis around the turn of the year 2014/2015 which potentially enables a submission of the interim analysis to the US FDA in the first half of 2015.  For 2014, sales growth measured in local currencies is still expected to be 7-10% and operating profit growth measured in local currencies is still expected at around 10%.  Lars Rebien Sørensen, CEO: ""We are satisfied with the financial results achieved in a challenging first half of 2014. Tresiba® is doing well in key markets and the DEVOTE trial continues to progress ahead of plans. This has enabled us to shorten further the timeline towards the interim analysis and a potential US launch of Tresiba®. Furthermore, with the positive opinion for Xultophy® from the EU regulatory authorities, we have passed a key milestone in bringing the first insulin and GLP-1 combination product to the market."" Contacts for further information Company announcement No 48 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1577,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
617,2014-07-25,Novo Nordisk modtager positiv udtalelse om Xultophy® (IDegLira) fra de europæiske registreringsmyndigheder,"Bagsværd, den 25. juli 2014 - Novo Nordisk meddelte i dag, at Xultophy® har fået en positiv udtalelse fra Udvalget for Humanmedicinske Lægemidler (CHMP) under Det Europæiske Lægemiddelagentur (EMA) med anbefaling om markedsføringstilladelse til behandling af type 2-diabetes hos voksne. Xultophy® er det planlagte varemærke for IDegLira, den første kombination af Tresiba® (insulin degludec) og Victoza® (liraglutid) til dosering én gang dagligt som én injektion, der er udviklet til behandling af type 2-diabetes. Den positive udtalelse fra CHMP anbefaler, at Xultophy® bliver indiceret til behandlingen af voksne med type 2 diabetes mellitus for at forbedre glykæmisk kontrol i kombination med orale glukosesænkende lægemidler når disse, alene eller i kombination med basal insulin, ikke giver en tilstrækkelig glykæmisk kontrol. Yderligere information Selskabsmeddelelse nr. 45 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1590,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
618,2014-07-25,Novo Nordisk receives positive opinion on Xultophy® (IDegLira) from the European regulatory authorities,"Bagsværd, Denmark, 25 July 2014 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinion, recommending marketing authorisation for Xultophy® for the treatment of type 2 diabetes mellitus in adults. Xultophy® is the intended brand name for IDegLira,  the first once-daily single injection combination of Tresiba® (insulin degludec) and Victoza® (liraglutide), developed for the treatment of type 2 diabetes. The CHMP positive opinion recommends that Xultophy® will be indicated for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with basal insulin do not provide adequate glycaemic control. Company Announcement No 45 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1589,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
619,2014-05-20,FDA berammer møde i rådgivende komite om liraglutid 3 mg til behandling af fedme,"Bagsværd, den 20. maj 2014 - Novo Nordisk meddelte i dag, at de amerikanske sundhedsmyndigheder, FDA, har oplyst, at man vil afholde et møde i FDA's rådgivende komite, hvor registreringsansøgningen for liraglutid 3 mg til behandling af fedme vil blive drøftet. Mødet er foreløbigt planlagt til at blive afholdt den 11. september 2014. Registreringsansøgningen blev indsendt den 20. december 2013. Selskabsmeddelelse nr. 35 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1638,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
620,2014-05-20,FDA schedules Advisory Committee meeting for liraglutide 3 mg for the treatment of obesity,"Bagsværd, Denmark, 20 May 2014 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has informed the company that an FDA Advisory Committee meeting is tentatively scheduled to be held on 11 September 2014 to discuss the New Drug Application (NDA) for liraglutide 3 mg for the treatment of obesity. The NDA was submitted to the FDA on 20 December 2013. Company announcement No 35 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1637,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
621,2014-05-01,Novo Nordisks resultat af primær drift opgjort i lokale valutaer steg med 15% i første kvartal af 2014,"Salgsvækst på 7% i lokale valutaer drevet af Levemir® og Victoza® Salget steg med 7% opgjort i lokale valutaer og med 2% i kroner til 20,3 mia. kr. Bruttomarginen steg med 1,1 procentpoint opgjort i kroner til 83,0% drevet af en gunstig prisudvikling samt en positiv påvirkning fra produktivitet og produktsammensætning. Resultat af primær drift steg med 15% opgjort i lokale valutaer og med 6% i kroner til 8,0 mia. kr. Nettoresultatet steg med 8% til 6,5 mia. kr. Udvandet resultat pr. aktie steg med 10% til 2,43 kr. Udrulningen af Tresiba® (insulin degludec), den nye generation af insulin med ultralang virkningsvarighed til dosering én gang dagligt, fortsætter. I de første lande, der har lanceret Tresiba® med tilskud på samme niveau som insulin glargin, repræsenterer Tresiba® nu en andel af markedsværdien for basal insulin på mellem 10% og 17% på månedsbasis. Rekrutteringen til DEVOTE-studiet, der undersøger forekomsten af hjerte-kar-sygdom i forbindelse med brug af Tresiba®, går hurtigere end planlagt, og Novo Nordisk forventer nu at have tilstrækkelige data til at understøtte en interimanalyse omkring midten af 2015. For 2014 forventes nu en salgsvækst opgjort i lokale valutaer på 7-10%, mens forventningen til væksten i resultat af primær drift opgjort i lokale valutaer fastholdes på omkring 10%. Adm. direktør Lars Rebien Sørensen: ""Vi er glade for at kunne fastholde vores forventninger til væksten i resultat af primær drift for 2014 trods en udfordrende start på året og lavere forventninger til salgsvæksten. Vi glæder os over udviklingen for Tresiba® i vigtige markeder og over den hurtige rekruttering til DEVOTE-studiet, som giver os mulighed for at fremrykke tidsplanen for interimanalysen og en potentiel lancering i USA."" Kontaktoplysninger Selskabsmeddelelse nr. 29 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1665,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
622,2014-05-01,Increased operating profit in local currencies by 15% in the first quarter of 2014,"7% sales growth in local currencies driven by Levemir® and Victoza® Sales increased by 7% in local currencies and by 2% in Danish kroner to DKK 20.3 billion. Gross margin improved by 1.1 percentage points in Danish kroner to 83.0% driven by a favourable price development as well as a positive impact from productivity and product mix. Operating profit increased by 15% in local currencies and by 6% in Danish kroner to DKK 8.0 billion. Net profit increased by 8% to DKK 6.5 billion. Diluted earnings per share increased by 10% to DKK 2.43. The roll-out of Tresiba® (insulin degludec), the once-daily new-generation insulin with an ultra-long duration of action, is progressing. In the first countries to launch Tresiba® with reimbursement on a similar level as insulin glargine, it now represents between 10% and 17% of the basal insulin market measured in monthly value market share. Recruitment for the cardiovascular outcomes trial for Tresiba®, DEVOTE, is progressing ahead of plans and Novo Nordisk now expects to have sufficient data to support an interim analysis mid-2015. For 2014, sales growth measured in local currencies is now expected to be 7-10%, whereas expected operating profit growth measured in local currencies is maintained at around 10%. Lars Rebien Sørensen, CEO: ""We are pleased to reiterate our expectations to operating profit growth for 2014 despite a challenging start of the year and a lower outlook for sales growth. We are encouraged by the performance of Tresiba® in key markets and by the rapid recruitment into the DEVOTE study, which enables us to shorten the timeline for the interim analysis and a potential US launch."" Contacts for further information Company announcement No 29 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1664,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
623,2014-04-30,Det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 30. april 2014,"Bagsværd, 2014-04-30 - I henhold til Bekendtgørelse om udstederes oplysningsforpligtelser, § 6, skal Novo Nordisk offentliggøre det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S ved udgangen af en måned, hvor ændringer deri har fundet sted. Selskabsmeddelelse nr. 28 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1669,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
624,2014-04-30,Total number of voting rights and share capital in Novo Nordisk A/S as of 30 April 2014,"Bagsværd, Denmark, 30 April 2014 - In accordance with Section 6 of the Danish Statutory Order on Issuers' Disclosure Obligations, Novo Nordisk is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred. Company announcement No 28 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1668,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
625,2014-04-23,Reduction of the share capital,"Bagsværd, Denmark, 23 April 2014 - At Novo Nordisk's Annual General Meeting on 20 March 2014, it was decided to reduce the company's B share capital from DKK 442,512,800 to DKK 422,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 20,000,000 divided into 100,000,000 B shares of DKK 0.20 each. Company announcement No 25 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1681,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
626,2014-04-23,Nedsættelse af aktiekapitalen,"Bagsværd, 2014-04-23 - På den ordinære generalforsamling i Novo Nordisk A/S den 20. marts 2014 blev det besluttet at nedsætte selskabets B-aktiekapital fra nominelt 442.512.800 kr. til 422.512.800 kr. ved annullering af en del af selskabets beholdning afegne B-aktier, i alt nominelt 20.000.000 kr. fordelt på 100.000.000 B-aktier á 0,20 kr. Selskabsmeddelelse nr.25 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1682,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
627,2014-03-21,Den langsigtede aktiebaserede incitamentsordning for Novo Nordisks Senior Management Board for 2014,"Bagsværd, den 21. marts 2014 - Bestyrelsen har godkendt den langsigtede aktiebaserede incitamentsordning for 2014 for Novo Nordisks Senior Management Board. Efter godkendelsen på generalforsamlingen i går af de opdaterede aflønningsprincipper, herunder en justering af den relative størrelse af koncerndirektørernes faste grundløn i forhold til den samlede værdi af koncerndirektørernes lønpakke, har bestyrelsen godkendt den langsigtede aktiebaserede incitamentsordning for 2014 for Senior Management Board. Selskabsmeddelelse nr. 18 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1715,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
628,2014-03-21,"2014 long-term, share based incentive programme for Novo Nordisk's  Senior Management Board","Bagsværd, Denmark, 21 March 2014 - The long-term, share-based incentive programme for 2014 for Novo Nordisk's Senior Management Board has been approved by the Board of Directors. Following yesterday's approval at the Annual General Meeting of the revised Remuneration Principles including an adjustment of the relative size of the executives' fixed base salary out of the total value of the executive remuneration package, the Board of Directors approved the long-term, share based incentive programme for 2014 for the Senior Management Board. Company announcement No 18 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1714,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
629,2014-03-20,Beslutninger på den ordinære generalforsamling i Novo Nordisk A/S,"Bagsværd, den 20. marts 2014 - Novo Nordisk A/S har i dag afholdt ordinær generalforsamling, hvor følgende blev besluttet: Regnskabsåret 2013 samt 2014 Valg Aktier og kapital Øvrigt Forslag fra en aktionær blev ikke godkendt. Selskabsmeddelelse nr. 17 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1719,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
630,2014-03-20,Resolutions from the Annual General Meeting of Novo Nordisk A/S,"Bagsværd, Denmark, 20 March 2014 - Today, Novo Nordisk A/S held its Annual General Meeting, at which the following were adopted: Financial year 2013 and 2014 Elections Shares and capital Other Proposals from a shareholder were not adopted. Company announcement No 17 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1718,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
631,2014-03-19,"Positive resultater fra det første fase 3-studie med N8-GP, en langtidsvirkende faktor VIII til behandling af hæmofili A","Bagsværd, den 19. marts 2014 - Novo Nordisk meddelte i dag, at pathfinder(TM)2, det første fase 3-studie med langtidsvirkende rekombinant faktor VIII, N8-GP (turoctocog alfa pegol), til behandling af hæmofili A, nu er afsluttet. Pathfinder(TM)2 er et multinationalt studie til vurdering af sikkerhed og effekt af N8-GP, når det anvendes til forebyggelse og behandling af akut opståede blødninger hos mennesker med hæmofili A i alderen 12 år og derover. Selskabsmeddelelse nr. 16 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1723,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
632,2014-03-19,"Positive results from first phase 3 trial with N8-GP, a long-acting factor VIII for treatment of haemophilia A","Bagsværd, Denmark, 19 March 2014 - Novo Nordisk today announced the completion of pathfinder(TM)2, the first phase 3 trial with long-acting recombinant factor VIII, N8-GP (turoctocog alfa pegol) for haemophilia A patients. Pathfinder(TM)2 is a multi-national trial evaluating safety and efficacy of N8-GP, when administered for prophylaxis and on-demand treatment  in patients with haemophilia A, who are 12 years or older. Company announcement No 16 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1722,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
633,2014-02-27,Election of employee representatives to the Board of Directors of Novo Nordisk A/S,"Bagsværd, 27 February 2014 - The employees of Novo Nordisk A/S have conducted the election of employee representatives to the Board of Directors of Novo Nordisk A/S. The following members were elected for the next four years:  Company announcement No 12 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1738,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
634,2014-02-27,Valg af medarbejderrepræsentanter til bestyrelsen i Novo Nordisk A/S,"Bagsværd, den 27. februar 2014 - Medarbejderne i Novo Nordisk A/S har afsluttet valg af medarbejderrepræsentanter til bestyrelsen i Novo Nordisk A/S. Følgende medlemmer blev valgt for de næste fire år: Selskabsmeddelelse nr. 12 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1739,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
635,2014-02-21,Indkaldelse til ordinær generalforsamling i  Novo Nordisk A/S,"Den ordinære generalforsamling i Novo Nordisk A/S afholdes: torsdag den 20. marts 2014 kl. 14.00 i Bella Center, Center Boulevard 5, 2300 København S. Indkaldelse til generalforsamlingen, inklusive appendiks 1: Bestyrelseskandidater og appendiks 2: Reviderede aflønningsprincipper, er vedlagt. Selskabsmeddelelse nr. 10 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1748,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
636,2014-02-21,Novo Nordisk A/S : Notice for the Annual General Meeting of  Novo Nordisk A/S,"The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 20 March 2014 at 2.00 pm (CET) at Bella Center, Center Boulevard 5, 2300 Copenhagen S, Denmark. The notice for the Annual General Meeting, including Appendix 1: Candidates for the Board of Directors and Appendix 2: Revised Remuneration Principles is enclosed. Company announcement No 10 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1747,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
637,2014-01-30,Novo Nordisks resultat af primær drift i lokale valutaer steg med 15% i 2013,"12% salgsvækst i lokale valutaer drevet af vækst i salget af Victoza®, NovoRapid® og Levemir® Salget steg med 12% i lokale valutaer og med 7% opgjort i kroner til 83,6 mia. kr. Bruttomarginen steg med 0,4 procentpoint opgjort i kroner til 83,1% som følge af en gunstig udvikling i priser og produktsammensætning, som delvis blev modsvaret af en negativ påvirkning fra valutakursudviklingen på 0,3 procentpoint. Resultat af primær drift steg med 15% opgjort i lokale valutaer og med 7% i kroner til 31,5 mia. kr. Nettoresultatet steg med 18% til 25,2 mia. kr. Resultat pr. aktie a 0,20 kr. (udvandet) steg med 20% til 9,35 kr. Novo Nordisk indsendte i december 2013 produktgodkendelsesansøgning for en 3 mg dosis af liraglutid til behandling af fedme til registreringsmyndighederne både i USA og EU. Liraglutid er en human GLP-1-analog til dosering én gang dagligt. Kåre Schultz, koncerndirektør med ansvar for salg og produktion, udnævnes til viceadministrerende direktør. I den ny rolle vil han arbejde tæt sammen med administrerende direktør Lars Rebien Sørensen om anliggender af relevans for virksomhedens øverste ledelse og bestyrelse. For 2014 forventes en salgsvækst opgjort i lokale valutaer på 8-11%, og resultat af primær drift opgjort i lokale valutaer ventes at blive omkring 10%. Bestyrelsen vil på generalforsamlingen den 20. marts 2014 fremsætte forslag om en 25% stigning i udbyttebetalingen til 4,50 kr. pr. aktie a 0,20 kr. Bestyrelsen har endvidere besluttet at iværksætte et nyt 12-måneders aktietilbagekøbsprogram på op til 15 mia. kr. Adm. direktør Lars Rebien Sørensen: ""Vi er glade for Novo Nordisks finansielle resultater i 2013, som var et år, der også bød på udfordringer. Den tocifrede salgsvækst var igen i 2013 drevet af robust vækst i vores portefølje af moderne insuliner og Victoza®. For Tresiba® var modtagelsen af FDA's Complete Response Letter i USA en skuffelse, men i de markeder, hvor produktet er lanceret, har resultaterne været lovende."" kontaktoplysninger Selskabsmeddelelse nr. 5 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1768,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
638,2014-01-30,Novo Nordisk increased operating profit in local currencies by 15% in 2013,"Sales growth of 12% in local currencies driven by growth in sales of Victoza®, NovoRapid® and Levemir® Sales increased by 12% in local currencies and by 7% to 83.6 billion in Danish kroner. Gross margin improved by 0.4 percentage point in Danish kroner to 83.1%, reflecting a favourable price and product mix development partly offset by a 0.3 percentage point negative currency impact. Operating profit increased by 15% in local currencies and by 7% in Danish kroner to DKK 31.5 billion. Net profit increased by 18% to DKK 25.2 billion. Diluted earnings per share of DKK 0.20 increased by 20% to DKK 9.35. In December 2013, Novo Nordisk filed for regulatory approval of a 3 mg dose of liraglutide, the once-daily human GLP-1 analogue, as a treatment for obesity with the regulatory agencies in both the US and in EU. Kåre Schultz is appointed president & COO, a role in which he will work closely with CEO Lars Rebien Sørensen on matters relevant to the company's senior leadership and the Board of Directors. For 2014, sales growth measured in local currencies is expected to be 8-11%, whereas operating profit growth measured in local currencies is expected to be around 10%. At the Annual General Meeting on 20 March 2014, the Board of Directors will propose a 25% increase in dividend to DKK 4.50 per share of DKK 0.20. The Board of Directors has furthermore decided to initiate a new 12 months share repurchase programme of up to DKK 15 billion. Lars Rebien Sørensen, president and CEO: ""We are pleased with Novo Nordisk's financial performance in 2013, a year which also posed challenges for us. The double-digit sales growth has again in 2013 been driven by robust growth of our portfolio of modern insulins and Victoza®. For Tresiba®, the Complete Response Letter in the US was a disappointment, but in markets where we have launched the product, performance has been encouraging."" Contacts for further information Company announcement No 5 / 2014",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1767,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
639,2013-12-20,Novo Nordisk indsender registreringsansøgning for liraglutid 3 mg til behandling af fedme,"Bagsværd, den 20. december 2013 - Novo Nordisk meddelte i dag, at virksomheden har indsendt to separate registreringsansøgninger for en 3 mg dosis af liraglutid (en human GLP-1-analog til dosering én gang dagligt) som supplement til en kaloriereduceret diæt og øget fysisk aktivitet til kronisk vægtregulering hos svært overvægtige voksne eller overvægtige voksne med andre eksisterende tilstande (komorbiditeter). Novo Nordisk har indsendt en NDA-ansøgning (New Drug Application) til de amerikanske sundhedsmyndigheder (FDA) og en MAA-ansøgning (Marketing Authorisation Application) til Det Europæiske Lægemiddelagentur (EMA). Selskabsmeddelelse nr. 78 / 2013",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1793,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
640,2013-12-20,Novo Nordisk files for regulatory approval of liraglutide  3 mg for the treatment of obesity,"Bagsværd, Denmark, 20 December 2013 - Novo Nordisk today announced two separate regulatory submissions for a 3 mg dose of liraglutide, a once-daily human GLP-1 analogue, as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity, or who are overweight with comorbidities. The company filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA). Company announcement No 78 / 2013",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1792,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
641,2013-12-10,Information om aktiesplit,"Bagsværd, 2013-12-10 - Som oplyst den 31. oktober 2013 i forbindelse med offentliggørelsen af Novo Nordisks regnskab for de ni første måneder af 2013 har Novo Nordisks bestyrelse vedtaget at gennemføre et aktiesplit for selskabets B-aktier, der er noteret på NASDAQ OMX Copenhagen, og selskabets ADR (American Depositary Receipts), der er noteret på New York Stock Exchange (NYSE). Noteringsenheden for Novo Nordisks B-aktier på børsen i København ændres fra 1 kr. til 0,20 kr. Forholdet mellem B-aktier og ADR på New York Stock Exchange vil forblive 1:1. De ændrede noteringsenheder træder i kraft den 2. januar 2014 for Novo Nordisks B-aktier og den 9. januar 2014 for selskabets ADR. Selskabsmeddelelse nr. 76 / 2013",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1800,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
642,2013-12-10,Stock split information,"Bagsværd, Denmark, 10 December 2013 - As communicated on 31 October 2013 in connection with the release of Novo Nordisk's financial results for the first nine months of 2013, Novo Nordisk's Board of Directors has approved a stock split of the Novo Nordisk B shares listed on NASDAQ OMX Copenhagen and of the American Depositary Receipts (ADRs) listed on New York Stock Exchange (NYSE). The trading unit of the Novo Nordisk B shares listed on the stock exchange in Copenhagen will be changed from DKK 1 to DKK 0.20. The ratio of B shares to ADRs listed on NYSE will remain 1:1. These changes in trading units will take effect as of 2 January 2014 for the Novo Nordisk B shares and as of 9 January 2014 for the ADRs.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1801,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
643,2013-12-03,Hovedpunkter fra Novo Nordisks kapitalmarkedsdag 2013,"Bagsværd, den 3. december 2013 - På kapitalmarkedsdagen i dag giver Novo Nordisk en opdatering på forretningsresultater og vigtige udviklingsprojekter, som ventes at understøtte koncernens langsigtede vækst. Yderligere information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1809,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
644,2013-12-03,Highlights from Novo Nordisk's Capital Markets Day 2013,"Bagsværd, Denmark, 3 December 2013 - Today at its Capital Markets Day, Novo Nordisk will present an update on its commercial performance and key development projects, which are expected to drive long-term growth. Company announcement No 74 / 2013",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1808,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
645,2013-10-31,Novo Nordisks resultat af primær drift steg med 10% i de første ni måneder af 2013,"Salgsvækst på 8% drevet af Victoza®, Levemir® og NovoRapid® Salget steg med 13% opgjort i lokale valutaer og med 8% i kroner til 61,9 mia. kr. Bruttomarginen steg med 0,7 procentpoint opgjort i kroner til 82,6% som følge af en gunstig udvikling i priser og produktsammensætning. Resultat af primær drift steg med 17% opgjort i lokale valutaer og med 10% i kroner til 24,1 mia. kr. Nettoresultatet steg med 22% til 19,1 mia. kr. Udvandet resultat pr. aktie steg med 25% til 35,39 kr. Udrulningen af Tresiba® (insulin degludec), den nye generation af insulin med ultralang virkningsvarighed til dosering én gang dagligt, skrider fortsat frem. Tresiba® er nu også lanceret i Sverige og Indien. I oktober blev den første patient indrulleret i DEVOTE, hjerte-kar-studiet af Tresiba®. Data til en interimanalyse af studiet forventes at være tilgængelige indenfor to til tre år. Forventningerne til driften for hele 2013 i lokale valutaer er uændrede. Der forventes en salgsvækst opgjort i lokale valutaer på 11-13% og en vækst i resultat af primær drift opgjort i lokale valutaer på 12-15%. De foreløbige forventninger til 2014 indikerer en høj etcifret vækst i salg og resultat af primær drift, begge dele opgjort i lokale valutaer. Adm. direktør Lars Rebien Sørensen: ""Vi er glade for den vedvarende robuste økonomiske udvikling. Det er stadig vores portefølje af moderne insuliner og Victoza®, der driver salgsvæksten. Salget af Tresiba® viser lovende takter, og med påbegyndelsen af DEVOTE har vi rundet en vigtig milepæl på vejen mod at gøre Tresiba® tilgængeligt for mennesker med diabetes i USA."" kontaktoplysninger",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1832,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
646,2013-10-31,Novo Nordisk Increased operating profit by 10% in the first nine months of 2013,"Sales growth of 8% driven by Victoza®, Levemir® og NovoRapid® Gross margin improved by 0.7 percentage points in Danish kroner to 82.6%, reflecting a favourable price and product mix development. Operating profit increased by 17% in local currencies and by 10% in Danish kroner to DKK 24.1 billion. Net profit increased by 22% to DKK 19.1 billion. Diluted earnings per share increased by 25% to DKK 35.39. The roll-out of Tresiba® (insulin degludec), the once-daily new-generation insulin with an ultra-long duration of action, continues to progress. Tresiba® has now also been commercially launched in Sweden and India. In October, the first patient was enrolled in DEVOTE, the cardiovascular outcomes trial for Tresiba®. Data for an interim analysis of the trial are expected to be available within two to three years. For 2013, expectations to operating performance in local currencies are unchanged. Sales growth measured in local currencies is expected to be 11-13% and operating profit growth measured in local currencies is expected to be 12-15%. The preliminary outlook for 2014 indicates high single-digit growth in sales and operating profit, both measured in local currencies. Lars Rebien Sørensen, president and CEO: ""We are pleased with the sustained robust financial performance. Sales growth continues to be driven by our portfolio of modern insulins and Victoza®. Tresiba® performance is encouraging and with the initiation of DEVOTE we have passed a significant milestone in the process of making Tresiba® available for people with diabetes in the US."" Contacts for further information",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1833,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
647,2013-08-08,Novo Nordisk increased operating profit by 15% in the first six months of 2013,"Sales growth of 11% driven by Victoza®, NovoRapid® and Levemir® Gross margin improved by 0.9 percentage points in Danish kroner to 82.6%, reflecting a favourable price and product mix development. Operating profit increased by 19% in local currencies and by 15% in Danish kroner to DKK 16.1 billion. Net profit increased by 27% to DKK 12.7 billion. Diluted earnings per share increased by 30% to DKK 23.43. The launch of Tresiba® (insulin degludec), the once-daily new-generation insulin with an ultra-long duration of action continues. Tresiba® has now also been commercially launched in Mexico and Switzerland. In the US, Novo Nordisk has received feedback from FDA on the clinical trial protocol for the cardiovascular outcomes trial for Tresiba® confirming the previously announced expectations to trial design. Novo Nordisk has now successfully completed the SCALE(TM) phase 3a clinical programme investigating the efficacy and safety of liraglutide 3 mg for the treatment of obesity. Novo Nordisk expects to file liraglutide 3 mg for regulatory review in the US and EU around the turn of the year. For 2013, expectations to operating performance have been raised. Sales growth measured in local currencies is now expected to be 11-13%, whereas operating profit growth measured in local currencies is now expected to be 12-15%. Lars Rebien Sørensen, president and CEO: ""We are pleased with the strong results in the first six months of 2013. Our portfolio of modern insulins and Victoza® are driving solid sales growth. Based on the feedback from  FDA in the US regarding the design of the cardiovascular outcomes trial for Tresiba®, we now expect to start the trial before the end of the year."" Contacts for further information Company announcement No 54 / 2013 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1889,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
648,2013-08-08,Novo Nordisks resultat af primær drift steg med 15% i første halvår af 2013,"Salgsvækst på 11% drevet af Victoza®, NovoRapid® og Levemir® Bruttomarginen steg med 0,9 procentpoint opgjort i kroner til 82,6% som følge af en gunstig udvikling i priser og produktsammensætning. Resultat af primær drift steg med 19% opgjort i lokale valutaer og med 15% i kroner til 16,1 mia. kr. Nettoresultatet steg med 27% til 12,7 mia. kr. Udvandet resultat pr. aktie steg med 30% til 23,43 kr. Lanceringen af Tresiba® (insulin degludec), den nye generation af insulin med ultralang virkningsvarighed til dosering én gang dagligt, fortsætter. Tresiba® er nu også lanceret i Mexico og Schweiz. I USA har Novo Nordisk modtaget tilbagemelding fra FDA vedrørende den kliniske forsøgsprotokol for hjerte-kar-studiet af Tresiba®, som bekræfter de tidligere meddelte forventninger omkring studiedesignet. Novo Nordisk har med tilfredsstillende resultat afsluttet SCALE(TM), det kliniske fase 3a-program, som har undersøgt effekt og sikkerhed for liraglutid 3 mg til behandling af fedme. Novo Nordisk forventer at indsende registreringsansøgning for liraglutid 3 mg til myndighederne i USA og EU omkring årsskiftet. Forventningerne til driften for 2013 er øget. Der forventes nu en salgsvækst opgjort i lokale valutaer på 11-13%, mens væksten i resultat af primær drift opgjort i lokale valutaer nu ventes at blive på 12-15%. Adm. direktør Lars Rebien Sørensen: ""Vi er glade for det stærke resultat for første halvår af 2013. Vores portefølje af moderne insuliner og Victoza® er drivkræfterne bag en solid salgsvækst. Med baggrund i tilbagemeldingen fra FDA i USA på tilrettelæggelsen af hjerte-kar-studiet for Tresiba® forventer vi nu at påbegynde studiet inden årets udgang."" kontaktoplysninger Selskabsmeddelelse nr. 54 / 2013 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1890,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
649,2013-06-18,Federal Circuit Court rules on patent litigation involving Prandin® (repaglinide),"Bagsværd, Denmark & Plainsboro, NJ 18 June 2013 - Today, the U.S. Court of Appeals for the Federal Circuit partially affirmed a 2011 District Court decision, with a 2-1 ruling that a claim in a Novo Nordisk patent related to the use of repaglinide in combination with metformin for the treatment of type 2 diabetes was invalid. This decision favors approval and launch of a generic repaglinide product. Company announcement No 45 / 2013",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1925,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
650,2013-06-18,Federal Circuit Court afsiger dom i patentsag om Prandin® (repaglinid),"Bagsværd, Danmark, og Plainsboro, USA, den 18. juni 2013 - Den amerikanske retsinstans U.S. Court of Appeals for the Federal Circuit har i dag delvist stadfæstet en distriktsdomstols kendelse fra 2011, idet den med en stemmefordeling på 2-1 har vurderet, at et Novo Nordisk-patent relateret til brug af repaglinid i kombination med metformin til behandling af type 2-diabetes er ugyldigt. Denne kendelse støtter godkendelse og lancering af et generisk repaglinid-produkt. Selskabsmeddelelse nr. 45 / 2013",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1926,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
651,2013-05-31,Novo Nordisk files for regulatory approval of IDegLira in the EU for the treatment of type 2 diabetes,"Bagsværd, Denmark, 31 May 2013 - Novo Nordisk today announced the submission to the European Medicines Agency of the marketing authorisation application for the approval of IDegLira, the combination product of insulin degludec (Tresiba®), the once-daily new-generation basal insulin analogue, with an ultra-long duration of action, and liraglutide (Victoza®), the once-daily human GLP-1 analogue. IDegLira has been developed for the treatment of people with type 2 diabetes. Company announcement No 41 / 2013",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1941,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
652,2013-05-31,Novo Nordisk indsender registreringsansøgning for IDegLira i EU til behandling af type 2-diabetes,"Bagsværd, den 31. maj 2013 - Novo Nordisk meddelte i dag, at virksomheden har indsendt ansøgning om markedsføringstilladelse til Det Europæiske Lægemiddelagentur med henblik på godkendelse af IDegLira - kombinationsproduktet bestående af insulin degludec (Tresiba®), den nye basale insulinanalog med ultralang virkningsvarighed til dosering én gang dagligt, og liraglutid (Victoza®), den humane GLP-1-analog til dosering én gang dagligt. IDegLira er udviklet til behandling af type 2-diabetes. Selskabsmeddelelse nr. 41 / 2013",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1942,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
653,2013-05-23,Novo Nordisk rapporterer 8% vægttab i fase 3a-fedmestudie med liraglutid 3 mg,"Bagsværd, den 23. maj 2013 - Novo Nordisk har i dag offentliggjort hovedresultaterne fra et 56-ugers dobbeltblindt klinisk fase 3a-studie, som har undersøgt liraglutids potentiale med hensyn til at fremkalde og opretholde vægttab hos henholdsvis svært overvægtige mennesker, der ikke har diabetes, og overvægtige mennesker, der ikke har diabetes, men som har andre eksisterende tilstande (komorbiditeter) såsom forstadier til diabetes (prædiabetes), forhøjet blodtryk og forstyrrelser i blodets lipidindhold (dyslipidæmi). Det er det tredje fase 3a-studie, der er gennemført som led i SCALE(TM), det kliniske udviklingsprogram for liraglutid 3 mg anvendt til behandling af fedme. Selskabsmeddelelse nr. 39 / 2013  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1950,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
654,2013-05-23,Novo Nordisk reports 8% weight loss in phase 3a obesity trial with liraglutide 3 mg,"Bagsværd, Denmark, 23 May 2013 - Novo Nordisk today announced the headline results from a 56-week double-blind phase 3a clinical trial investigating the potential of liraglutide to induce and maintain weight loss in people without diabetes who are obese or overweight with comorbidities such as prediabetes, hypertension and dyslipidaemia. This is the third phase 3a trial to be completed as part of SCALE(TM), the clinical development programme for liraglutide 3 mg as an obesity treatment. Company announcement No 39 2013 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1949,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
655,2013-05-17,Novo Nordisk reports positive results from first phase 3 trial with long-acting factor IX for treatment of haemophilia B,"Bagsværd, Denmark, 17 May 2013 - Novo Nordisk today announced the completion of paradigm(TM) 2, the first phase 3 trial with a long-acting FIX derivative, N9-GP (glycopegylated recombinant factor IX), for haemophilia B patients. Paradigm(TM) 2 is a multi-centre, blinded trial evaluating the safety and efficacy of N9-GP when used for on-demand or prophylactic treatment in patients with haemophilia B. Company announcement No 37 / 2013",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1957,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
656,2013-05-17,Novo Nordisk rapporterer positive resultater fra det første fase 3-studie med langtidsvirkende faktor IX til behandling af hæmofili B,"Bagsværd, den 17. maj 2013 - Novo Nordisk meddelte i dag, at paradigm(TM)2, det første fase 3-studie med et langtidsvirkende faktor IX-derivat, N9-GP (glykopegyleret rekombinant faktor IX), til behandling af hæmofili B, nu er afsluttet. Paradigm(TM)2 er et blindet multicenterstudie til vurdering af sikkerhed og effekt af N9-GP anvendt som akut eller forebyggende behandling til mennesker med hæmofili B. Selskabsmeddelelse nr. 37 / 2013",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1958,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
657,2013-05-01,Increased operating profit by 18% in the first quarter of 2013,"Sales increased by 14% in local currencies and by 13% to 20.0 billion in Danish kroner. Gross margin improved by 1.1 percentage points in Danish kroner to 81.9%, reflecting a favourable price and product mix development. Reported operating profit increased by 21% in local currencies and by 18% in Danish kroner to DKK 7.6 billion. Net profit increased by 28% to DKK 6.0 billion. Diluted earnings per share increased by 32% to DKK 10.98. Tresiba®, the new-generation insulin with an ultra-long duration of action, has been launched in the UK, Denmark and Japan. In the US, Novo Nordisk received a Complete Response Letter from the FDA regarding the New Drug Applications for Tresiba® and Ryzodeg® in February 2013. In the letter, the FDA requests that Novo Nordisk conducts a dedicated cardiovascular outcomes trial before the review of the New Drug Applications can be completed. For 2013, sales growth measured in local currencies is now expected to be 9-11%, whereas operating profit growth measured in local currencies is still expected to be around 10%. Lars Rebien Sørensen, president and CEO: ""We are pleased with the strong sales in the first quarter of 2013 driven by our portfolio of modern insulins and Victoza®. We have launched Tresiba®, the new-generation insulin with an ultra-long duration of action, in a number of countries and are encouraged by the early feedback from patients and doctors. In the US, we are in a constructive dialogue with the FDA on how to resolve the issues raised in the Complete Response Letter for Tresiba® and Ryzodeg®."" Contacts for further information Company announcement No 32 / 2013 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1977,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
658,2013-05-01,Resultat af primær drift steg med 18% i første kvartal af 2013,"Salget steg med 14% opgjort i lokale valutaer og med 13% i kroner til 20,0 mia. kr. Bruttomarginen steg med 1,1 procentpoint opgjort i kroner til 81,9% som følge af en gunstig udvikling i priser og produktsammensætning. Det rapporterede resultat af primær drift steg med 21% opgjort i lokale valutaer og med 18% i kroner til 7,6 mia. kr. Nettoresultatet steg med 28% til 6,0 mia. kr. Udvandet resultat pr. aktie steg med 32% til 10,98 kr. Tresiba®, den nye generation af insulin med ultralang virkningsvarighed, er lanceret i Storbritannien, Danmark og Japan. I USA modtog Novo Nordisk et såkaldt Complete Response Letter fra de amerikanske sundhedsmyndigheder, FDA, vedrørende registreringsansøgningerne for Tresiba® og Ryzodeg® i februar 2013. I brevet anmoder FDA om, at Novo Nordisk gennemfører et dedikeret hjerte-kar-studie, før registreringsansøgningerne kan færdigbehandles. For 2013 forventes nu en salgsvækst opgjort i lokale valutaer på 9-11%, mens væksten i resultat af primær drift opgjort i lokale valutaer fortsat ventes at blive på omkring 10%. Adm. direktør Lars Rebien Sørensen: ""Vi er glade for det stærke salg i første kvartal af 2013, som er drevet af vores portefølje af moderne insuliner og Victoza®. Vi har lanceret Tresiba®, den nye generation af insulin med ultralang virkningsvarighed, i en række lande og glæder os over, at de første tilbagemeldinger fra patienter og læger er lovende. I USA er vi i konstruktiv dialog med FDA om afklaringen af de forhold, de påtalte i deres Complete Response Letter vedrørende Tresiba® og Ryzodeg®."" Kontaktoplysninger Selskabsmeddelelse nr. 32 / 2013  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1978,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
659,2013-04-30,Novo Nordisk A/S : Total number of voting rights and share capital in Novo Nordisk A/S as of 30 April 2013,"Bagsværd, Denmark, 30 April 2013 - In accordance with Section 6 of the Danish Statutory Order on Issuers' Disclosure Obligations, Novo Nordisk is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred. Company announcement No 31 / 2013 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1981,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
660,2013-04-30,Novo Nordisk A/S : det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 30. april 2013,"Bagsværd, den 30. april 2013 - I henhold til Bekendtgørelse om udstederes oplysningsforpligtelser, § 6, skal Novo Nordisk offentliggøre det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S ved udgangen af en måned, hvor ændringer deri har fundet sted. Selskabsmeddelelse nr. 31 / 2013 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1982,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
661,2013-04-22,Reduction of the share capital,"Bagsværd, Denmark, 22 April 2013 - At Novo Nordisk's Annual General Meeting on 20 March 2013, it was decided to reduce the company's B share capital from DKK 452,512,800 to DKK 442,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 10,000,000 divided into 10,000,000 B shares of DKK 1 each. Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled nominally DKK 10,000,000 B shares. After the reduction of the share capital, the company's share capital is nominally DKK 550,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 442,512,800. The reduction in the share capital will not affect Novo Nordisk's share repurchase programme which will continue as previously announced. Further information Company announcement No 28 / 2013",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1993,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
662,2013-04-22,Nedsættelse af aktiekapitalen,"Bagsværd, 2013-04-22 - På den ordinære generalforsamling i Novo Nordisk A/S den 20. marts 2013 blev det besluttet at nedsætte selskabets B-aktiekapital fra nominelt 452.512.800 kr. til 442.512.800 kr. ved annullering af en del af selskabets beholdning af egne B-aktier, i alt nominelt 10.000.000 kr. fordelt på 10.000.000 B-aktier a 1 kr. Novo Nordisk har i dag registreret kapitalnedsættelsens gennemførelse hos Erhvervsstyrelsen og annulleret nominelt 10.000.000 kr. B-aktier. Efter kapitalnedsættelsen er selskabets aktiekapital nominelt 550.000.000 kr. fordelt på nominelt 107.487.200 kr. A-aktier og nominelt 442.512.800 kr. B-aktier. Kapitalnedsættelsen vil ikke have nogen effekt på Novo Nordisks aktietilbagekøbsprogram, som fortsætter uændret i henhold til det udmeldte. Selskabsmeddelelse nr. 28 / 2013",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=1994,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
663,2013-03-21,"2013 long-term, share based incentive programme for the Senior Management Board","Bagsværd, Denmark, 21 March 2013 - The long-term, share-based incentive programme for 2013 for the Senior Management Board has been approved by the Board of Directors. Company announcement No 22 / 2013",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2019,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
664,2013-03-21,Den langsigtede aktiebaserede incitamentsordning for Senior Management Board for 2013,"Bagsværd, den 21. marts 2013 - Bestyrelsen har godkendt den langsigtede aktiebaserede incitamentsordning for 2013 for Senior Management Board. Selskabsmeddelelse nr. 22 / 2013 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2020,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
665,2013-03-20,Resolutions from the Annual General Meeting of Novo Nordisk A/S,"Bagsværd, Denmark, 20 March 2013 - Today, 20 March 2013, Novo Nordisk A/S held the Annual General Meeting at Tivoli Hotel & Congress Center, Arni Magnussons Gade 2, 1577 Copenhagen V, Denmark. At the General Meeting, the shareholders adopted the following... Company announcement No 21 / 2013",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2023,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
666,2013-03-20,Beslutninger på den ordinære generalforsamling i Novo Nordisk A/S,"Bagsværd, den 20. marts 2013 - Novo Nordisk A/S har i dag, den 20. marts 2013, afholdt ordinær generalforsamling i Tivoli Hotel & Congress Center, Arni Magnussons Gade 2, 1577 København V. På generalforsamlingen vedtog aktionærerne følgende... Selskabsmeddelelse nr. 21 / 2013",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2024,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
667,2013-03-18,People with type 2 diabetes achieve 6% weight loss with liraglutide 3 mg in phase 3a obesity trial,"Bagsværd, Denmark, 18 March 2013 - Novo Nordisk today announced the headline results from a 56-week, double-blind phase 3a clinical trial investigating the potential of liraglutide to induce and maintain weight loss in overweight or obese people with type 2 diabetes. This is the second phase 3a trial to be completed as part of SCALE(TM), the clinical development programme for liraglutide 3 mg as an obesity treatment. Company announcement No 19 / 2013",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2031,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
668,2013-03-18,Type 2-diabetikere opnår 6% vægttab med liraglutid 3 mg i fase 3a-fedmestudie,"Bagsværd, den 18. marts 2013 - Novo Nordisk har i dag offentliggjort hovedresultaterne fra et 56-ugers dobbeltblindt klinisk studie i fase 3a, som har undersøgt liraglutids potentiale med hensyn til at fremkalde og opretholde vægttab hos overvægtige eller svært overvægtige mennesker med type 2-diabetes. Det er det andet fase 3a-studie, der er gennemført som led i SCALE(TM), det kliniske udviklingsprogram for liraglutid 3 mg anvendt til behandling af fedme. Selskabsmeddelelse nr. 19 / 2013",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2032,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
669,2013-02-22,Notice for the Annual General Meeting of  Novo Nordisk A/S,"The Annual General Meeting of Novo Nordisk A/S will be held on: Wednesday 20 March 2013 at 2.00 pm (CET) at Tivoli Hotel & Congress Center, Arni Magnussons Gade 2, 1577 Copenhagen V, Denmark. Company announcement No 15 / 2013  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2047,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
670,2013-02-22,Indkaldelse til ordinær generalforsamling i  Novo Nordisk A/S,"Den ordinære generalforsamling i Novo Nordisk A/S afholdes: onsdag den 20. marts 2013 kl. 14.00 på Tivoli Hotel & Congress Center, Arni Magnussons Gade 2, 1577 København V. Selskabsmeddelelse nr. 15 / 2013   ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2048,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
671,2013-02-10,Novo Nordisk modtager Complete Response Letter i USA vedrørende Tresiba® og Ryzodeg®,"Bagsværd, den 10. februar 2013 - Novo Nordisk meddeler i dag, at virksomheden den 8. februar 2013 har modtaget et såkaldt Complete Response Letter fra de amerikanske sundhedsmyndigheder, FDA, vedrørende registreringsansøgningerne for Tresiba® (insulin degludec) og Ryzodeg® (insulin degludec/insulin aspart). FDA udsteder et sådant Complete Response Letter, når en registreringsansøgning ikke kan godkendes i den foreliggende form. Selskabsmeddelelse nr. 11 / 2013",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2063,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
672,2013-02-10,Novo Nordisk receives Complete Response Letter in the US for Tresiba® and Ryzodeg®,"Bagsværd, Denmark, 10 February 2013 - Novo Nordisk today announced that on 8 February 2013 it received a Complete Response Letter from the US Food and Drug Administration (FDA) regarding the New Drug Applications for Tresiba® (insulin degludec) and Ryzodeg® (insulin degludec/insulin aspart). A Complete Response Letter is issued by the FDA, when the agency determines that an application cannot be approved in its current form. Company announcement No 11 /2013",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2064,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
673,2013-02-07,Press release: Novo Nordisk files annual report with the SEC,"Bagsværd, Denmark, 7 February 2013 - Novo Nordisk A/S has filed its Annual Report 2012 on Form 20-F for the financial year 2012 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2012. The reports are available at the SEC's website, www.sec.gov as well as on novonordisk.com. Shareholders and ADR holders may receive a hard copy of the annual reports free of charge upon request by filling out a request form on novonordisk.com or upon request to either Tel: (+1) 609 786 4575 or by e-mail to jlis@novonordisk.com. When e-mailing, please state the exact mailing address and the document(s) you wish to receive.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2067,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
674,2013-02-05,Previously announced FDA Warning Letter published,"Bagsværd, Denmark, 5 February 2013 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has published the Warning Letter, which the company mentioned in its Financial Statement for 2012 on 31 January. Company announcement No 10 / 2013",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2068,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
675,2013-02-05,Det tidligere omtalte Warning Letter fra FDA publiceret,"Bagsværd, den 5. februar 2013 - Novo Nordisk meddeler i dag, at de amerikanske sundhedsmyndigheder, FDA, har publiceret det Warning Letter, som blev nævnt i Novo Nordisks årsregnskabsmeddelelse for 2012 den 31. januar. Selskabsmeddelelse nr. 10 / 2013",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2069,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
676,2013-01-31,Novo Nordisk increased operating profit by 32% in 2012,"Sales growth of 18% driven by Victoza®, NovoRapid® and Levemir® Sales increased by 18% to 78.0 billion in Danish kroner and by 12% in local currencies. Reported operating profit increased by 32% to DKK 29.5 billion including a 1.7 percentage points improvement in the gross margin. Measured in local currencies, operating profit increased by 20%. Net profit increased by 25% to DKK 21.4 billion. Earnings per share (diluted) increased by 30% to DKK 38.85. Novo Nordisk has in December 2012 received, and submitted its response to, a Warning Letter from the US Food and Drug Administration (FDA) in relation to an inspection of an aseptic filling facility in Denmark. Novo Nordisk does not expect the letter to have an impact on products currently marketed in the US. The regulatory process for the new-generation insulins, Tresiba® and Ryzodeg®, continues to progress in the major markets. In Japan and Europe both products have now been approved. In November 2012, an FDA Advisory Committee voted eight to four in favour of approving the products with a post-approval outcomes trial commitment. In 2012, Novo Nordisk reached its four long-term financial targets. Consequently, two of the four targets have been increased. The core target of 15% annual operating profit growth on average is maintained. For 2013, sales growth measured in local currencies is expected to be 8-11%, and operating profit growth measured in local currencies is expected to be around 10%. Effective 31 January 2013, Novo Nordisk's Executive Management is expanded with two new members who will be responsible for Marketing & Medical Affairs and IT, Quality & Corporate Development respectively. At the Annual General Meeting on 20 March 2013, the Board of Directors will propose a 29% increase in dividend to DKK 18 per share. The Board of Directors has furthermore decided to initiate a new 12 months share repurchase programme of up to DKK 14 billion. Lars Rebien Sørensen, president and CEO: ""2012 has been another year with strong results for Novo Nordisk driven by the sales growth of Victoza® and the two modern insulins NovoRapid® and Levemir®. We are pleased that Tresiba® and Ryzodeg® have been approved in key markets like Japan and the EU and look forward to launching Tresiba® in several markets in 2013."" Contacts for further information: Company announcement No 8 / 2013",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2078,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
677,2013-01-31,Novo Nordisks resultat af primær drift steg med 32% i 2012,"Salgsvækst på 18% drevet af Victoza®, NovoRapid® og Levemir® Salget steg med 18% til 78,0 mia. kr. opgjort i kroner og med 12% i lokale valutaer. Det rapporterede resultat af primær drift steg med 32% til 29,5 mia. kr. med en forbedring i bruttomarginen på 1,7 procentpoint. Opgjort i lokale valutaer steg resultat af primær drift med 20%. Nettoresultatet steg med 25% til 21,4 mia. kr. Resultat pr. aktie (udvandet) steg med 30% til 38,85 kr. Novo Nordisk har i december 2012 modtaget og indsendt sit svar til et 'Warning Letter' fra de amerikanske sundhedsmyndigheder (FDA) i forbindelse med en inspektion i en aseptisk påfyldningsfabrik i Danmark. Novo Nordisk forventer ikke, at brevet vil få nogen konsekvenser for de markedsførte produkter i USA. Registreringsprocessen for den nye generation af insuliner, Tresiba® og Ryzodeg®, fortsætter i de store markeder. I Japan og Europa er begge produkter nu godkendt. I november 2012 stemte en rådgivende komite under FDA otte imod fire for en godkendelse af produkterne med en forpligtelse til at gennemføre et hjerte-kar-studie efter godkendelsen. Novo Nordisk nåede sine langsigtede finansielle mål i 2012. To af de fire mål er derfor blevet opjusteret. Målet om en gennemsnitlig 15% årlig vækst i resultat af primær drift fastholdes. For 2013 forventes en salgsvækst på 8-11% opgjort i lokale valutaer, og resultat af primær drift opgjort i lokale valutaer ventes at blive omkring 10%. Med virkning fra den 31. januar 2013 er Novo Nordisks koncerndirektion blevet udvidet med to nye medlemmer, der bliver ansvarlige for henholdsvis Marketing & Medical Affairs og IT, Quality & Corporate Development. Bestyrelsen vil på generalforsamlingen den 20. marts 2013 fremsætte forslag om en 29% stigning i udbyttebetalingen til 18 kr. pr. aktie. Bestyrelsen har endvidere besluttet at iværksætte et nyt 12-måneders aktietilbagekøbsprogram på op til 14 mia. kr. Adm. direktør Lars Rebien Sørensen: ""2012 var endnu et år med et stærkt resultat for Novo Nordisk med Victoza® og de to moderne insuliner NovoRapid® og Levemir® som de vigtigste drivkræfter for salgsvæksten. Vi er glade for, at Tresiba® og Ryzodeg® er blevet godkendt i vigtige markeder som Japan og EU og ser frem til at lancere Tresiba® i flere markeder i 2013."" Kontaktoplysninger: Selskabsmeddelelse nr. 8 / 2013",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2079,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
678,2013-01-21,Tresiba® and Ryzodeg® receive marketing authorisations in Europe,"Bagsværd, Denmark, 21 January 2013 - Novo Nordisk today announced that the European Commission has granted marketing authorisations for Tresiba® (insulin degludec) and Ryzodeg® (insulin degludec/insulin aspart) for the treatment of diabetes in adults. The authorisations cover all 27 European Union member states. Company announcement No 6 / 2013",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2086,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
679,2013-01-21,Tresiba® (insulin degludec) og Ryzodeg® (insulin degludec/insulin aspart) får markedsføringstilladelse i Europa,"Bagsværd, den 21. januar 2013 - Novo Nordisk meddelte i dag, at Europa-Kommissionen har givet markedsføringstilladelse til Tresiba® (insulin degludec) og Ryzodeg® (insulin degludec/insulin aspart) til behandling af diabetes hos voksne. Markedsføringstilladelserne gælder samtlige 27 EU-medlemslande. Selskabsmeddelelse nr. 6 / 2013",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2087,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
680,2012-12-25,Ryzodeg® (insulin degludec/insulin aspart) godkendt i Japan,"Bagsværd, den 25. december 2012 - Novo Nordisk meddelte i dag, at det japanske ministerium for sundhed, arbejde og velfærd har godkendt Ryzodeg® (insulin degludec/insulin aspart) til behandling af diabetes. Selskabsmeddelelse nr. 84 / 2012 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2110,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
681,2012-12-25,Ryzodeg® (insulin degludec/insulin aspart) approved in Japan,"Bagsværd, Denmark, 25 December 2012 - Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Ryzodeg® (insulin degludec/insulin aspart) for the treatment of diabetes. Company announcement No 84 /2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2111,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
682,2012-12-19,"The final phase 3a trial for IDegLira completed, and FIAsp approved for phase 3 development","Bagsværd, Denmark, 19 December 2012 - Novo Nordisk today announced the completion of the phase 3a programme for IDegLira, a fixed-ratio combination of insulin degludec (Tresiba®), a once-daily new-generation basal insulin analogue, with an ultra-long duration of action, and liraglutide (Victoza®), the once-daily human GLP-1 analogue, as well as the decision to initiate phase 3 development for FIAsp, a faster-acting formulation of insulin aspart (NovoRapid®). Company announcement No 83 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2114,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
683,2012-12-19,"Det sidste fase 3a-studie for IDegLira afsluttet, og FIAsp godkendt til fase 3-udvikling","Bagsværd, den 19. december 2012 - Novo Nordisk meddeler i dag, at fase 3a-programmet for IDegLira, en kombination af insulin degludec (Tresiba®), den første basale insulin med en ultralang virkningsvarighed, og liraglutid (Victoza®), den humane GLP-1-analog til dosering en gang dagligt, i et fast indbyrdes forhold, nu er afsluttet. Det er endvidere besluttet at påbegynde fase 3-udvikling af FIAsp, en hurtigere virkende formulering af insulin aspart (NovoRapid®). Selskabsmeddelelse nr. 83",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2115,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
684,2012-12-03,Ryzodeg® (insulin degludec/insulin aspart) passerer evaluering i japansk medicinkomite,"Bagsværd, den 3. december 2012 - Novo Nordisk meddelte i dag, at Ryzodeg® (insulin degludec/insulin aspart) har passeret evalueringen i en medicinsk komite under de japanske sundhedsmyndigheder, First Committee on Drugs of Japan's Pharmaceutical Affairs. Det sidste skridt i registreringsprocessen vil herefter være en godkendelse fra det japanske ministerium for sundhed, arbejde og velfærd.  Selskabsmeddelelse nr. 78 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2134,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
685,2012-12-03,Ryzodeg® (insulin degludec/insulin aspart) passed review by First Committee on Drugs of Pharmaceutical Affairs in Japan,"Bagsværd, Denmark, 3 December 2012 - Novo Nordisk today announced that Ryzodeg® (insulin degludec/insulin aspart) has passed the review by the First Committee on Drugs of Japan's Pharmaceutical Affairs. The remaining step in the regulatory process is an approval from the Ministry of Health, Labour and Welfare. Company announcement No 78 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2135,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
686,2012-11-08,Insulin degludec and insulin degludec/insulin aspart receive positive vote for approval from FDA Advisory Committee,"Bagsværd, Denmark, 9 November 2012 Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the United States Food and Drug Administration (FDA) has completed its meeting regarding the New Drug Applications (NDA) for insulin degludec and insulin degludec/insulin aspart. Company announcement No 72 /2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2158,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
687,2012-11-08,Positiv afstemning i FDA's rådgivende komite vedrørende godkendelse af insulin degludec og insulin degludec/ insulin aspart,"Bagsværd, den 9. november 2012 Novo Nordisk meddelte i dag, at Endocrinologic and Metabolic Drugs Advisory Committee, som er en rådgivende komite for de amerikanske sundhedsmyndigheder (FDA), har afsluttet sit møde vedrørende registreringsansøgningerne for insulin degludec og insulin degludec/insulin aspart. Selskabsmeddelelse nr. 72 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2159,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
688,2012-11-06,FDA posts briefing materials prior to Advisory Committee meeting for insulin degludec and insulin degludec/insulin aspart,"Bagsværd, Denmark, 6 November 2012 Novo Nordisk announced today that the US Food and Drug Administration (FDA) has published the briefing documents ahead of the Advisory Committee meeting to discuss the New Drug Applications (NDA) for insulin degludec and insulin degludec/insulin aspart, which will take place on 8 November 2012. The briefing documents from Novo Nordisk and the FDA, which will form the basis for the Advisory Committee's discussion, provide an overview of the non-clinical and clinical data for insulin degludec and insulin degludec/insulin aspart for the treatment of diabetes. The briefing materials can be accessed on the FDA webpage here Company Announcement no. 71 2012    ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2162,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
689,2012-11-06,FDA offentliggør briefingmateriale forud for mødet i den rådgivende komite om insulin degludec og insulin degludec/insulin aspart,"Bagsværd, den 6. november 2012 Novo Nordisk meddelte i dag, at de amerikanske sundhedsmyndigheder, FDA, har offentliggjort briefingdokumenterne forud for mødet i den rådgivende komite den 8. november 2012, hvor registreringsansøgningerne for insulin degludec og insulin degludec/insulin aspart vil blive drøftet. Briefingdokumenterne fra Novo Nordisk og FDA, som vil danne grundlag for drøftelserne i den rådgivende komite, giver et overblik over såvel de ikke-kliniske som kliniske data for insulin degludec og insulin degludec/insulin aspart til behandling af diabetes. Dokumenterne er tilgængelige på FDA's hjemmeside her Selskabsmeddelelse nr. 71 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2163,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
690,2012-10-31,Novo Nordisks resultat af primær drift steg med 34% i de første ni måneder af 2012,"Adm. direktør Lars Rebien Sørensen: ""Det er et fortsat stærkt salg af vores moderne insuliner og Victoza®, der ligger bag det solide resultat, vi har set i de første ni måneder af 2012. Med godkendelsen af Tresiba® i Japan og de positive udtalelser fra CHMP i Europa om Tresiba® og Ryzodeg® har vi passeret to vigtige milepæle på vejen mod at bringe den nye generation af insulin på markedet."" Selskabsmeddelelse nr. 70 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2167,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
691,2012-10-31,Novo Nordisk increased operating profit by 34% in the first nine months of 2012,"Lars Rebien Sørensen, president and CEO: ""Continued strong sales of our modern insulins and Victoza® have led to a robust financial performance in the first nine months of 2012. The approval of Tresiba® in Japan and the positive CHMP opinions in Europe for Tresiba® and Ryzodeg® constitute two significant milestones in the process of bringing this new generation of insulin to the market."" Company announcement No 70 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2166,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
692,2012-10-25,FDA discloses focus of Advisory Committee meeting on insulin degludec and insulin degludec/insulin aspart,Novo Nordisk today announced that the US Food and Drug Administration (FDA) has published information pertaining to the focus of the Advisory Committee meeting scheduled for 8 November 2012 to discuss the New Drug Applications for insulin degludec and insulin degludec/insulin aspart. Further information:  Company announcement No 68 / 2012,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2174,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
693,2012-10-25,FDA offentliggør fokus for mødet i den rådgivende komite om insulin degludec og insulin degludec/insulin aspart,"Novo Nordisk meddelte i dag, at de amerikanske sundhedsmyndigheder, FDA, har offentliggjort information om fokus for mødet i den rådgivende komite den 8. november 2012, hvor registreringsansøgningerne for insulin degludec og insulin degludec/insulin aspart vil blive drøftet. Yderligere information: Selskabsmeddelelse nr. 68 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2175,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
694,2012-10-19,Tresiba® (insulin degludec) and Ryzodeg® (insulin degludec/insulin aspart) receive positive opinions from the European regulatory authorities,"Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted positive opinions, recommending marketing authorisations, for Tresiba® and Ryzodeg® for the treatment of diabetes mellitus in adults. Further information: Company announcement No 66 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2182,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
695,2012-10-19,Novo Nordisk modtager positive udtalelser om Tresiba® (insulin degludec) og Ryzodeg® (insulin degludec/insulin aspart) fra de europæiske registreringsmyndigheder,"Novo Nordisk meddelte i dag, at Udvalget for Humanmedicinske Lægemidler (CHMP) under Det Europæiske Lægemiddelagentur har afgivet positive udtalelser om Tresiba® og Ryzodeg® og anbefaler, at der bliver givet markedsføringstilladelser til de to produkter til behandling af diabetes mellitus hos voksne. Yderligere information: Selskabsmeddelelse nr. 66 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2183,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
696,2012-10-18,Japansk lægemiddelagentur offentliggør evalueringsrapport om Tresiba®,"Novo Nordisk meddelte i dag, at det japanske lægemiddelagentur, Pharmaceuticals and Medical Devices Agency (PMDA), har offentliggjort deres evalueringsrapport om Tresiba® (insulin degludec). Rapporten danner grundlag for godkendelsen af produktet, som blev meddeltden 28. september 2012. Yderligere information: Selskabsmeddelelse nr. 65 / 2012   ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2186,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
697,2012-10-18,Japan's Pharmaceuticals and Medical Devices Agency publishes assessment report of Tresiba®,Novo Nordisk today announced that Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has published their assessment report of Tresiba® (insulin degludec). The report forms the basis of the approval of the product announced on 28 September 2012. Further information: Company Announcement No 65 / 2012   ,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2187,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
698,2012-09-28,Novo Nordisk A/S: Novo Nordisk indstiller udviklingen af vatreptacog alfa efter analyse af fase 3-resultater,"Novo Nordisk meddelte i dag, at det er besluttet at indstille udviklingen af den hurtigtvirkende rekombinante faktor VIIa-analog, vatreptacog alfa, til hæmofilipatienter med inhibitorer. Beslutningen er truffet på grundlag af en analyse af resultaterne fra fase 3a-studiet adept(TM) 2. Den 9. august meddelte Novo Nordisk, at nogle få patienter i studiet havde udviklet antistoffer mod vatreptacog alfa, hos én patient med potentielt neutraliserende effekt. Yderligere information: Selskabsmeddelelse nr. 60 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2206,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
699,2012-09-28,Novo Nordisk A/S: Novo Nordisk discontinues development of vatreptacog alfa following analysis of phase 3 results,"Novo Nordisk today announced the decision to discontinue the development of vatreptacog alfa, a fast-acting recombinant factor VIIa analogue for haemophilia patients with inhibitors. The decision follows analysis of the data from the phase 3a trial adeptTM 2. On 9 August, Novo Nordisk announced that a few patients in the trial had developed anti-drug antibodies to vatreptacog alfa, one patient with a potentially neutralising effect. Company Announcement No 60 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2207,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
700,2012-09-28,Novo Nordisk A/S: Tresiba® (insulin degludec) godkendt i Japan,"Novo Nordisk meddelte i dag, at det japanske ministerium for sundhed, arbejde og velfærd har godkendt Tresiba® (insulin degludec) til behandling af diabetes. Yderligere information: Selskabsmeddelelse nr. 59 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2210,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
701,2012-09-28,Novo Nordisk A/S: Tresiba® (insulin degludec) approved in Japan,"Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Tresiba® (insulin degludec) for the treatment of diabetes. Company Announcement No 59 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2211,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
702,2012-08-31,Novo Nordisk A/S : Insulin degludec passed the review by the First Committee on Drugs of Pharmaceutical Affairs in Japan,"Novo Nordisk today announced that insulin degludec has passed the review by the First Committee on Drugs of Japan's Pharmaceutical Affairs. The remaining step in the regulatory process will now be an official approval from the Ministry of Health, Labour and Welfare (MHLW). The First Committee on Drugs of Pharmaceutical Affairs serves as an advisory body to the MHLW, related to pharmaceuticals including new drug applications. The passing of the review by the drug committee is a critical milestone in the Japanese review process prior to a marketing authorisation from the MHLW. ""We are very excited about the result of the review of insulin degludec,"" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""This is a significant milestone towards what may be the first approval of insulin degludec, an insulin with potential to fulfil unmet medical needs for millions of people with diabetes who require insulin."" Novo Nordisk expects to receive marketing authorisation from the MHLW within a few months and that insulin degludec will be launched shortly after completion of the subsequent price negotiations. Insulin degludec is a once-daily, ultra-long-acting basal insulin analogue discovered and developed by Novo Nordisk. Insulin degludec has a distinct slow absorption which provides a flat and stable action profile. Insulin degludec has been studied in a large-scale clinical trial programme, BEGIN(TM), examining its impact on glucose control, hypoglycaemia and the possibility to flexibly adjust insulin degludec dosing time to suit patient needs. Insulin degludec was submitted for regulatory approval to the Japanese Ministry of Health, Labour and Welfare (MHLW) in December 2011 and to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) in September 2011. In addition, applications have been submitted for regulatory approval in Canada, Switzerland and a range of other countries. Company Announcement No 54 / 2012   ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2230,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
703,2012-08-31,Novo Nordisk A/S : Insulin degludec passerer evalueringen i japansk medicinkomite,"Novo Nordisk meddelte i dag, at insulin degludec har passeret evalueringen i en medicinsk komite under de japanske sundhedsmyndigheder, First Committee on Drugs of Pharmaceutical Affairs. Det sidste skridt i godkendelsesprocessen vil herefter være en officiel godkendelse fra det japanske ministerium for sundhed, arbejde og velfærd. First Committee on Drugs of Pharmaceutical Affairs er en rådgivende komite for ministeriet vedrørende lægemidler, herunder registreringsansøgninger. Komiteens evaluering er en væsentlig milepæl i den japanske registreringsproces forud for markedsføringstilladelse fra ministeriet. ""Vi er meget glade for udfaldet af denne evaluering af insulin degludec,"" siger Mads Krogsgaard Thomsen, koncernforskningschef i Novo Nordisk. ""Det er en vigtig milepæl på vejen mod det, der kan blive den første godkendelse af insulin degludec, en insulin med potentiale til at opfylde udækkede medicinske behov hos millioner af insulinkrævende diabetikere."" Novo Nordisk forventer at modtage markedsføringstilladelse fra ministeriet inden for få måneder og forventer desuden at kunne lancere insulin degludec kort efter afslutning af de efterfølgende prisforhandlinger. Insulin degludec er en ultralangtidsvirkende basal insulinanalog til dosering en gang dagligt, der er opfundet og udviklet af Novo Nordisk. Insulin degludec har en særlig langsom absorption, der giver en flad og stabil virkningsprofil. Insulin degludec er afprøvet i et omfattende klinisk forsøgsprogram, BEGIN(TM), som har undersøgt dets indvirkning på blodsukkerregulering, hypoglykæmi samt mulighed for fleksibel justering af tidspunktet for dosering af insulin degludec efter den enkelte diabetikers behov. Registreringsansøgning for insulin degludec blev indsendt til det japanske ministerium for sundhed, arbejde og velfærd i december 2011 og til Det Europæiske Lægemiddelagentur (EMA) og de amerikanske sundhedsmyndigheder (FDA) i september 2011. Derudover er der indsendt registreringsansøgninger i Canada, Schweiz og en række andre lande. Yderligere information: Selskabsmeddelelse nr. 54 / 2012 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2231,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
704,2012-08-09,Novo Nordisk increased operating profit by 31% in the first half of 2012,"Sales grew 17% to 37.2 billion in Danish kroner and by 12% in local currencies. - Reported gross margin improved by 1.3 percentage points to 81.7%. - Reported operating profit increased by 31% to DKK 14,038 million. Measured in local currencies, operating profit increased by 21%. - Net profit increased by 22% to DKK 10,010 million. Earnings per share (diluted) increased by 26% to DKK 17.99.- The regulatory reviews of the new ultra-long-acting insulins, with the intended brand names Tresiba® and Ryzodeg®, progress in the major markets. - In the US, the review has been extended with the tentative scheduling of an FDA advisory committee meeting 8 November. - The first phase 3a trial for IDegLira, a fixed ratio combination of insulin degludec and liraglutide, demonstrates superior glucose control in the IDegLira-treated patients while reconfirming the competitive profiles of Tresiba® and Victoza®. - In the recently completed pivotal phase 3 trial for vatreptacog alfa, a fast-acting recombinant coagulation factor VIIa analogue, one patient developed antibodies with a potentially neutralising effect. The impact of this finding on the project is currently being evaluated. - For 2012, sales growth measured in local currencies is now expected to be 9-12% (previously 8-11%), and operating profit growth measured in local currencies is now expected to be around 15% (previously at least 10%). Lars Rebien Sørensen, president and CEO: ""We are very satisfied with the financial performance in the first half of 2012, driven by a continued strong performance of our modern insulins and Victoza®. We are also encouraged by the IDegLira data which show the benefits of Tresiba® in combination with Victoza®."" Company Announcement No 50 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2246,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
705,2012-08-09,Novo Nordisk A/S: Novo Nordisks resultat af primær drift steg med 31% i første halvår af 2012,"- Salget steg med 17% til 37,2 mia. kr. og med 12% i lokale valutaer. - Den rapporterede bruttomargin steg med 1,3 procentpoint til 81,7%. - Det rapporterede resultat af primær drift steg med 31% til 14.038 mio. kr. Opgjort i lokale valutaer steg resultat af primær drift med 21%. - Nettoresultatet steg med 22% til 10.010 mio. kr. Resultat pr. aktie (udvandet) steg med 26% til 17,99 kr. - Registreringsprocessen for de nye, ultralangtidsvirkende insuliner med de planlagte produktnavne Tresiba® og Ryzodeg® fortsætter i de store markeder. I USA er processen blevet forlænget med den foreløbige berammelse af et møde i en af de amerikanske sundhedsmyndigheders (FDA) rådgivende komiteer den 8. november. - Det første fase 3a-studie for IDegLira, en fast kombination af insulin degludec og liraglutid, viser en bedre blodsukkerregulering hos patienter behandlet med IDegLira og bekræfter igen de konkurrencedygtige profiler for Tresiba® og Victoza®. - I det nyligt afsluttede afgørende fase 3-studie med vatreptacog alfa, en hurtigtvirkende rekombinant koagulationsfaktor VIIa-analog, udviklede én patient antistoffer med en potentielt neutraliserende effekt. Konsekvenserne for projektet af dette fund er i færd med at blive vurderet. - For 2012 forventes salgsvæksten opgjort i lokale valutaer nu at udgøre 9-12% (tidligere 8-11%), og resultat af primær drift opgjort i lokale valutaer ventes nu at stige med omkring 15% (tidligere mindst 10%). Adm. direktør Lars Rebien Sørensen: ""Vi er meget tilfredse med den finansielle udvikling i første halvår af 2012, som især skyldes et fortsat stærkt salg af vores moderne insuliner og Victoza®. Vi er også glade for de kliniske data for IDegLira, som viser fordelene ved Tresiba® i kombination med Victoza®.  Selskabsmeddelelse nr. 50 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2247,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
706,2012-07-18,Novo Nordisk A/S: FDA schedules Advisory Committee meeting for insulin degludec and insulin degludec/insulin aspart,Novo Nordisk today announced that the US Food and Drug Administration (FDA) has informed the company that an FDA Advisory Committee meeting is tentatively scheduled to be held on 8 November 2012 to discuss the New Drug Applications (NDA) for the ultra-long-acting insulin degludec and insulin degludec/insulin aspart. Further information: Company Announcement No 46 / 2012,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2262,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
707,2012-07-18,Novo Nordisk A/S: FDA berammer møde i rådgivende komite om insulin degludec og insulin degludec/insulin aspart,"Novo Nordisk meddelte i dag, at de amerikanske sundhedsmyndigheder, FDA, har oplyst, at man vil afholde et møde i FDA's rådgivende komite, hvor registreringsansøgningerne for ultralangtidsvirkende insulin degludec og insulin degludec/insulin aspart vil blive drøftet. Mødet er foreløbigt planlagt til at blive afholdt den 8. november 2012. Yderligere information: Selskabsmeddelelse nr. 46 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2263,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
708,2012-06-21,Novo Nordisk påbegynder fase 3-udvikling af  GLP-1-analogen semaglutid til brug en gang om ugen,"Novo Nordisk har i dag meddelt, at det er besluttet at påbegynde det globale fase 3-udviklingsprogram for semaglutid, en human GLP-1-analog (glukagonlignende peptid-1) til dosering en gang om ugen. Yderligere information: Selskabsmeddelelse nr. 40 / 2012  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2287,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
709,2012-06-21,"Novo Nordisk to initiate phase 3 development of semaglutide, a once-weekly GLP-1 analogue","Novo Nordisk today announced the decision to initiate the global phase 3 development programme for semaglutide, a once-weekly human GLP-1 (Glucagon-Like Peptide-1) analogue. Further information: Company announcement No 40 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2286,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
710,2012-06-08,Novo Nordisk A/S: FDA forlænger registreringssprocessen for insulin degludec og insulin degludec/insulin aspart med tre måneder,"Novo Nordisk har i dag meddelt, at de amerikanske sundhedsmyndigheder (FDA) har forlænget registreringssprocessen for den ultralangtidsvirkende insulin degludec og insulin degludec/insulin aspart til behandling af type 1- og type 2-diabetes. Yderligere information: Selskabsmeddelelse nr. 37 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2299,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
711,2012-06-08,Novo Nordisk A/S: FDA extends regulatory review period for insulin degludec and insulin degludec/insulin aspart by three months,Novo Nordisk today announced that the US Food and Drug Administration (FDA) has extended the regulatory review period for the ultra-long-acting insulins degludec and insulin degludec/insulin aspart for the treatment of type 1 and type 2 diabetes. Further information: Company Announcement No 37 / 2012,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2298,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
712,2012-04-30,Novo Nordisk A/S: Det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 30. april 2012,"I henhold til Bekendtgørelse om udstederes oplysningsforpligtelser, § 6, skal Novo Nordisk offentliggøre det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S ved udgangen af en måned, hvor ændringer deri har fundet sted. Yderligere information: Selskabsmeddelelse nr. 30 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2327,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
713,2012-04-30,Novo Nordisk A/S: Total number of voting rights and share capital in Novo Nordisk A/S as of 30 April 2012,"In accordance with Section 6 of the Danish Statutory Order on Issuers' Disclosure Obligations, Novo Nordisk is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred. Further information: Company Announcement No 30 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2326,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
714,2012-04-27,Novo Nordisk A/S forventer at vælge ny formand i 2013,"Novo Nordisk Fonden har i dag udsendt en pressemeddelelse, hvori den meddeler, at den nuværende formand for bestyrelsen i Novo Nordisk A/S, Sten Scheibye, er blevet indvalgt i bestyrelsen for Novo Nordisk Fonden med henblik på at overtage formandshvervet i 2013. Yderligere information: Selskabsmeddelelse nr. 29 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2331,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
715,2012-04-27,Novo Nordisk A/S expects to elect new chairman in 2013,"In a press release today, the Novo Nordisk Foundation announced that the current chairman of the Board of Novo Nordisk A/S, Sten Scheibye, has been elected to the Board of the Novo Nordisk Foundation with a view to becoming its chairman in 2013. Further information: Company Announcement No 29 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2330,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
716,2012-04-27,Novo Nordisk A/S: Operating profit increased by 18% in the first quarter of 2012,"Sales growth of 13% driven by Victoza®, NovoRapid® and Levemir® Sales increased by 13% to 17.8 billion in Danish kroner and by 10% in local currencies. Gross margin improved by 0.7 percentage points in Danish kroner to 80.8% in the first quarter of 2012, reflecting a favourable price and product mix development. Reported operating profit increased by 18% to DKK 6,385 million. Measured in local currencies, operating profit increased by approximately 13%. Net profit increased by 15% to DKK 4,664 million. Earnings per share (diluted) increased by 18% to DKK 8.32. The regulatory reviews of the new ultra-long-acting insulins Degludec and DegludecPlus continue to progress in the major markets. The intended global brand name for Degludec is Tresiba® and the intended global brand name for DegludecPlus is Ryzodeg®. Novo Nordisk has initiated a phase 3a programme for the long-acting recombinant factor VIII compound N8-GP for the treatment of haemophilia A. For 2012, sales growth measured in local currencies is now expected to be 8-11% (previously 7-11%), and operating profit growth measured in local currencies is now expected to be at least 10% (previously around 10%). Lars Rebien Sørensen, president and CEO: ""We are satisfied with the solid sales growth during the first quarter of 2012 - still driven by the modern insulins NovoRapid® and Levemir® as well as our once-daily human GLP-1 Victoza®. Furthermore, the regulatory reviews for Tresiba® and Ryzodeg®, our new generation of insulins, continue to progress well in the major markets."" Further information: Company Announcement No 28 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2334,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
717,2012-04-27,Novo Nordisk A/S: Resultat af primær drift steg med 18% i første kvartal af 2012,"Salgsvækst på 13% drevet af Victoza®, NovoRapid® og Levemir® Salget steg med 13% til 17,8 mia. kr. og med 10% i lokale valutaer. Bruttomarginen steg med 0,7 procentpoint opgjort i kroner til 80,8% i første kvartal af 2012. Dette afspejler en gunstig udvikling i priser og produktsammensætning. Det rapporterede resultat af primær drift steg med 18% til 6.385 mio. kr. Opgjort i lokale valutaer steg resultat af primær drift med ca. 13%. Nettoresultatet steg med 15% til 4.664 mio. kr. Resultat pr. aktie (udvandet) steg med 18% til 8,32 kr. Myndighedernes behandling af registreringsansøgningerne for de nye, ultralangtidsvirkende insuliner, Degludec og DegludecPlus, udviser fortsatte fremskridt i de store markeder. Det planlagte globale varemærke for Degludec er Tresiba®, og det planlagte globale varemærke for DegludecPlus er Ryzodeg®. Novo Nordisk har påbegyndt et fase 3a-program for det langtidsvirkende rekombinante faktor VIII-præparat N8-GP til behandling af blødersygdommen type A-hæmofili. For 2012 forventes salgsvæksten opgjort i lokale valutaer nu at udgøre 8-11% (tidligere 7-11%), og resultat af primær drift opgjort i lokale valutaer ventes nu at stige med mindst 10% (tidligere omkring 10%). Adm. direktør Lars Rebien Sørensen: ""Vi er tilfredse med den solide salgsvækst i årets første kvartal - som endnu engang er drevet af de moderne insuliner NovoRapid® og Levemir® og af Victoza®, vores humane GLP-1-lægemiddel til dosering én gang dagligt. Godkendelses­processen for Tresiba® og Ryzodeg®, vores nye generation af insuliner, gør fortsat gode fremskridt i de store markeder."" Kontaktoplysninger: Selskabsmeddelelse nr. 28 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2335,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
718,2012-04-23,Novo Nordisk A/S :  Novo Nordisk A/S - Reduction of the share capital,"At Novo Nordisk's Annual General Meeting on 21 March 2012, it was decided to reduce the company's B share capital from DKK 472,512,800 to DKK452,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 20,000,000 divided into 20,000,000 B shares of DKK 1 each. Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled nominally DKK 20,000,000 B shares. After the reduction of the share capital, the company's share capital is nominally DKK 560,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 452,512,800. The reduction in the share capital will not affect Novo Nordisk's share repurchase programme which will continue as previously announced.  Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 32,700 employees in 75 countries, and markets its products in more than 190 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com. Further information: Company Announcement no 26 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2342,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
719,2012-04-23,Novo Nordisk A/S : Novo Nordisk A/S - Nedsættelse af aktiekapitalen,"På den ordinære generalforsamling i Novo Nordisk A/S den 21. marts 2012 blev det besluttet at nedsætte selskabets B-aktiekapital fra nominelt 472.512.800 kr. til 452.512.800 kr. ved annullering af en del af selskabets beholdning af egne B-aktier, i alt nominelt 20.000.000 kr. fordelt på 20.000.000 B-aktier a 1 kr. Novo Nordisk har i dag registreret kapitalnedsættelsens gennemførelse hos Erhvervsstyrelsen og annulleret nominelt 20.000.000 kr. B-aktier. Efter kapitalnedsættelsen er selskabets aktiekapital nominelt 560.000.000 kr. fordelt på nominelt 107.487.200 kr. A-aktier og nominelt 452.512.800 kr. B-aktier. Kapitalnedsættelsen vil ikke have nogen effekt på Novo Nordisks aktietilbagekøbsprogram, som fortsætter uændret i henhold til det udmeldte. Yderligere information:  Selskabsmeddelelse nr. 26 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2343,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
720,2012-04-17,Novo Nordisk A/S: Højesteretskendelse i USA giver Caraco Pharmaceutical mulighed for at gøre indsigelse mod Novo Nordisks patent på Prandin® (repaglinid),"Novo Nordisk meddelte i dag, at den amerikanske højesteret har omstødt en kendelse, som retsinstansen 'US Court of Appeals for the Federal Circuit' afsagde i april 2010. Den kendelse medførte, at den generiske lægemiddelproducent Caraco Pharmaceutical ikke kunne forfølge en ændring af Novo Nordisks patentanmeldelse vedrørende kombinationsanvendelsen af repaglinid og metformin til behandling af type 2-diabetes. Yderligere information: Selskabsmeddelelse nr. 25 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2346,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
721,2012-04-17,Novo Nordisk A/S: US Supreme Court ruling allows Caraco Pharmaceutical to challenge Novo Nordisk's patent submissions for Prandin® (repaglinide),"Today, Novo Nordisk announced that the US Supreme Court has reversed the US Court of Appeals for the Federal Circuit's April 2010 decision. That decision dismissed generic manufacturer Caraco Pharmaceutical's claim to change Novo Nordisk's patent submissions regarding the combination use of repaglinide and metformin for the treatment of type 2 diabetes. Further information:",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2347,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
722,2012-04-06,"Indlægsseddel for Victoza® i USA opdateret med data, som viser, at Victoza® virker bedre end Januvia®","Opdateringen indeholder også FDA-godkendelse af kombinationsterapi med langtidsvirkende insulin til behandling af voksne med type 2 diabetes Novo Nordisk meddelte i dag, at de amerikanske sundhedsmyndigheder (FDA) har godkendt, at indlægssedlen for Victoza® (liraglutid) opdateres med data, som viser at Victoza® giver bedre blodsukkerkontrol og vægtreduktion end Januvia® (sitagliptin). Yderligere information: Selskabsmeddelelse nr. 22 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2358,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
723,2012-04-06,Victoza® label in the US updated to include data showing superior efficacy when compared to Januvia®,Label update also includes FDA approval of combination therapy with basal insulin for the treatment of adults with type 2 diabetes  Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved to update the product label for Victoza® (liraglutide [rDNA] injection) to include data showing superior blood sugar control and weight reduction when compared to Januvia® (sitagliptin). Further information: Company Announcement no 22 / 2012,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2359,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
724,2012-03-21,Novo Nordisk A/S: Beslutninger på den ordinære generalforsamling i Novo Nordisk A/S,"Novo Nordisk A/S har i dag, den 21. marts 2012, afholdt ordinær generalforsamling på Radisson Blu Falconer Hotel & Conference Center, Falkoner Allé 9, 2000 Frederiksberg. Yderligere information: Selskabsmeddelelse nr. 18 / 2012 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2376,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
725,2012-03-21,Novo Nordisk A/S: Resolutions from the Annual General Meeting of Novo Nordisk A/S,"Today, 21 March 2012, Novo Nordisk A/S held the Annual General Meeting at Radisson Blu Falconer Hotel & Conference Center, Falkoner Allé 9, DK-2000 Frederiksberg, Denmark. Further information: Company Announcement no 18 / 2012 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2377,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
726,2012-02-23,Novo Nordisk A/S: Indkaldelse til ordinær generalforsamling i Novo Nordisk A/S,"Den ordinære generalforsamling i Novo Nordisk A/S afholdes: onsdag den 21. marts 2012 kl. 14.00 på Radisson Blu Falconer Hotel & Conference Center, Falkoner Allé 9, 2000 Frederiksberg. Yderligere information:  Selskabsmeddelelse nr. 13 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2397,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
727,2012-02-23,Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S,"The Annual General Meeting of Novo Nordisk A/S will be held on: Wednesday 21 March 2012 at 2.00 pm (CET) at Radisson Blu Falconer Hotel & Conference Center, Falkoner Allé 9, 2000 Frederiksberg, Denmark. Further information: Company Announcement no 13 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2396,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
728,2012-02-08,Novo Nordisk files annual report with the SEC,"Novo Nordisk A/S has filed its Annual Report 2011 on Form 20-F for the financial year 2011 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2011. The reports are available at the SEC's website, www.sec.gov as well as at novonordisk.com - Investors - Download centre (listed under 2011).  Shareholders and ADR holders may receive a hard copy of the annual reports free of charge upon request by filling out a request form at novonordisk.com/investors/download-centre or upon request to either tel no Tel: (+1) 609 786 4575 or by e-mail to jlis@novonordisk.com. When e-mailing, please state the exact mailing address and the document(s) you wish to receive.  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2412,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
729,2012-02-02,Novo Nordisk increased operating profit by 18% in 2011,"Sales growth of 9% driven by Victoza®, NovoRapid® and Levemir® Lars Rebien Sørensen, president and CEO: ""2011 has been a very positive year for Novo Nordisk, with Victoza®, NovoRapid® and Levemir® continuing to drive strong sales growth. In addition, we saw significant progress for our portfolio of clinical development projects which is very encouraging for the long-term outlook for Novo Nordisk."" Contacts for further information:  Company Announcement no 7 / 2012",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2423,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
730,2012-02-02,Novo Nordisks resultat af primær drift steg med 18% i 2011,"Salgsvækst på 9% drevet af Victoza®, NovoRapid® og Levemir® Adm. direktør Lars Rebien Sørensen: ""2011 var et rigtig godt år for Novo Nordisk, hvor vi igen så Victoza®, NovoRapid® og Levemir® drive salgsvæksten. Vi har også set betydelige fremskridt for vores portefølje af kliniske udviklingsprojekter, hvilket er lovende for Novo Nordisks fremtidsudsigter."" Kontaktinfomation:",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2424,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
731,2011-12-22,Novo Nordisk files for regulatory approval of the ultra-long-acting insulin Degludec in Japan,"Novo Nordisk today announced the submission to the Japanese Pharmaceuticals and Medical Devices Agency, PMDA, of a new drug application for the approval of ultra-long-acting insulin Degludec. This new-generation basal insulin has been developed for the treatment of people with type 1 and type 2 diabetes. Further information:  Company Announcement no 80 / 2011",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2457,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
732,2011-12-22,"Novo Nordisk indsender registreringsansøgning for den ultralangtidsvirkende insulinanalog, Degludec, i Japan","Novo Nordisk meddelte i dag, at virksomheden har indsendt ansøgning til de japanske sundhedsmyndigheder, Pharmaceuticals and Medical Devices Agency (PMDA), om godkendelse af den ultralangtidsvirkende insulinanalog, Degludec. Denne nye generation af basal insulin er udviklet til behandling af type 1- og type 2-diabetes.  Yderligere information: Selskabsmeddelelse nr. 80 / 2011",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2458,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
733,2011-11-07,Novo Nordisk A/S: DegludecPlus provides superior glycaemic control compared to insulin glargine in a phase 3a trial in Japanese people with type 2 diabetes,"Novo Nordisk today announced clinical results from a 26-week phase 3a treat-to-target study comparing DegludecPlus, a soluble combination of ultra-long-acting insulin degludec and insulin aspart, to insulin glargine in Japanese people with type 2 diabetes inadequately controlled on oral antidiabetic drugs. This is the 18th announced phase 3a study in the Degludec and DegludecPlus clinical trial development programme.  Further information Company Announcement no 70 / 2011",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2502,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
734,2011-11-07,Novo Nordisk A/S: DegludecPlus giver bedre blodsukkerregulering end insulin glargin i et fase 3a-studie med japanske type 2-diabetikere,"Novo Nordisk har i dag offentliggjort kliniske resultater fra et 26-ugers fase 3a-treat-to-target-studie, der har sammenlignet DegludecPlus - en opløselig kombination af ultralangtidsvirkende insulin degludec og insulin aspart - med insulin glargin i japanere med type 2-diabetes, der ikke opnåede tilfredsstillende regulering med diabeteslægemidler i tabletform. Dette er det 18. offentliggjorte fase 3a-studie i det kliniske udviklingsprogram for Degludec og DegludecPlus.  Yderligere information: Selskabsmeddelelse nr. 70 / 2011",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2503,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
735,2011-10-27,Novo Nordisk A/S: Interim financial report for the period 1 January 2011 to 30 September 2011,"Novo Nordisk increased operating profit by 12% in the first nine months of 2011 Sales growth of 11% in local currencies driven by Victoza®, NovoRapid® and Levemir® Sales increased by 11% in local currencies and by 8% in Danish kroner. Gross margin improved by 0.2 percentage point in local currencies, reflecting a favourable product mix development due to increased sales of modern insulin versus lower human insulin sales. Measured in Danish kroner, the gross margin declined by 0.4 percentage points to 80.4%. Reported operating profit increased by 12% to DKK 16,293 million. In local currencies, operating profit increased by approximately 18%. Net profit increased by 19% to DKK 12,408 million. Earnings per share (diluted) increased by 22% to DKK 21.66. Novo Nordisk submitted the regulatory dossiers for the new generation of insulins, Degludec and DegludecPlus, to the European and US regulatory authorities in September 2011. The outlook for 2011 has been updated: sales growth measured in local currencies is now expected to be 10-11% (previously 9-11%), and operating profit growth measured in local currencies is now expected to be 17-19% (previously 15-19%). The preliminary outlook for 2012 indicates high single-digit sales growth and operating profit growth of close to 10%, both measured in local currencies. The outlook is associated with unusual uncertainty given the challenging financial situation in major countries around the world. The outlook for operating profit furthermore reflects costs related to the expected launch of Degludec. Lars Rebien Sørensen, president and CEO: ""We are pleased to see our key products, NovoRapid®, Levemir® and Victoza®, continue to drive strong underlying sales growth. The filing of our new-generation insulins, ultra-long-acting Degludec and DegludecPlus, in the US and Europe is a major milestone in the expansion of our leadership in diabetes care."" Further information: Company Announcement no 67 / 2011",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2517,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
736,2011-10-27,Novo Nordisk A/S: Delårsrapport for perioden 1. januar til 30. september 2011,"Novo Nordisks resultat af primær drift steg med 12% i de første ni måneder af 2011 Salgsvækst på 11% i lokale valutaer drevet af Victoza®, NovoRapid® og Levemir® Salget steg med 11% opgjort i lokale valutaer og med 8% opgjort i kroner. Bruttomarginen steg med 0,2 procentpoint opgjort i lokale valutaer. Dette afspejler en gunstig udvikling i produktsammensætningen som følge af et øget salg af moderne insuliner og et lavere salg af humane insuliner. Opgjort i kroner faldt bruttomarginen med 0,4 procentpoint til 80,4%. Det rapporterede resultat af primær drift steg med 12% til 16.293 mio. kr. Opgjort i lokale valutaer steg resultatet af primær drift med ca. 18%. Nettoresultatet steg med 19% til 12.408 mio. kr. Resultat pr. aktie (udvandet) steg med 22% til 21,66 kr. Novo Nordisk indsendte i september 2011 registreringsansøgninger for den nye generation af insuliner, Degludec og DegludecPlus, til de europæiske og amerikanske registrerings­myndigheder. Opdatering af forventningerne til 2011: der forventes nu en salgsvækst opgjort i lokale valutaer på 10-11% (mod tidligere 9-11%) og en vækst i resultat af primær drift opgjort i lokale valutaer på 17-19% (mod tidligere 15-19%). Den foreløbige prognose for 2012 indikerer høj encifret salgsvækst og vækst i resultat af primær drift på tæt ved 10%, begge dele opgjort i lokale valutaer. Prognosen er forbundet med usædvanlig usikkerhed på grund af den udfordrende økonomiske situation i mange af verdens største lande. Prognosen for resultat af primær drift afspejler endvidere omkostninger i relation til den forventede lancering af Degludec. Adm. direktør Lars Rebien Sørensen: ""Vi er meget tilfredse med, at vores nøgleprodukter, NovoRapid®, Levemir® og Victoza®, fortsat driver en stærk underliggende salgsvækst. Samtidig er indsendelsen af registreringsansøgningerne for vores nye generation af insuliner, ultralangtids­virkende Degludec og DegludecPlus, i USA og Europa en vigtig milepæl i udbygningen af vores førerposition inden for diabetesbehandling."" Kontaktoplysninger Selskabsmeddelelse nr. 67 / 2011",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2518,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
737,2011-09-29,Novo Nordisk indsender registreringsansøgning for de ultralangtidsvirkende insulinpræparater Degludec og DegludecPlus i USA,"Novo Nordisk meddelte i dag, at virksomheden har indsendt to registrerings­ansøgninger til de amerikanske sundhedsmyndigheder, FDA, med henblik på godkendelse af den ultralangtidsvirkende insulinanalog Degludec og kombinationsanalogen DegludecPlus. Denne nye generation af insuliner er udviklet til behandling af type 1- og type 2-diabetes.   Yderligere information:  Selskabsmeddelelse nr. 61 / 2011  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2547,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
738,2011-09-29,Novo Nordisk files for regulatory approval of the ultra-long-acting insulins Degludec and DegludecPlus in the US,"Novo Nordisk today announced the submission to the US Food and Drug Administration of two new drug applications for the approval of ultra-long-acting insulin Degludec and the insulin combination analogue DegludecPlus, respectively. This new generation of insulins has been developed for the treatment of people with type 1 and type 2 diabetes.   Further information:   Company Announcement no 61 / 2011   ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2548,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
739,2011-09-26,Novo Nordisk indsender registreringsansøgning for de ultralangtidsvirkende insulinpræparater Degludec og DegludecPlus i Europa,"Novo Nordisk meddelte i dag, at virksomheden har indsendt to ansøgninger om markedsføringstilladelse til Det Europæiske Lægemiddelagentur med henblik på godkendelse af den ultralangtidsvirkende insulinanalog Degludec og kombinations­analogen DegludecPlus. Denne nye generation af insuliner er udviklet til behandling af type 1- og type 2-diabetes.  Yderligere information:   Selskabsmeddelelse nr. 60 / 2011",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2553,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
740,2011-09-26,Novo Nordisk files for regulatory approval of the ultra-long-acting insulins Degludec and DegludecPlus in Europe,"Novo Nordisk today announced the submission to the European Medicines Agency of two marketing authorisation applications for the approval of ultra-long acting insulin Degludec and the insulin combination analogue DegludecPlus, respectively. This new generation of insulins has been developed for the treatment of people with type 1 and type 2 diabetes.   Company Announcement no 60 / 2011",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2552,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
741,2011-08-04,Novo Nordisk increased operating profit by 13% in the first six months of 2011,"Sales growth of 11% in local currencies driven by Victoza®, NovoRapid® and Levemir® Sales increased by 11% in local currencies and by 9% in Danish kroner. Gross margin improved by 0.3 percentage points in local currencies, reflecting a favourable product mix development due to increased sales of modern insulin versus lower human insulin sales. Measured in Danish kroner, the gross margin declined slightly with 0.1 percentage point to 80.4%. Reported operating profit increased by 13% to DKK 10,683 million. In local currencies, operating profit increased by approximately 17%. Net profit increased by 19% to DKK 8,207 million. Earnings per share (diluted) increased by 23% to DKK 14.27. Significant progress has been achieved for the clinical development pipeline. Phase 3a programmes have been initiated for the following three product candidates: a fixed-ratio insulin/GLP-1 combination for type 2 diabetes, a fast-acting recombinant factor VIIa analogue for haemophilia patients with inhibitors, and a long-acting recombinant factor IX for haemophilia B. Further, two phase 3a trials investigating liraglutide for obesity have been initiated. The outlook for 2011 has improved: sales growth measured in local currencies is now expected to be 9-11% (previously 8-10%), and operating profit growth measured in local currencies is now expected to be 15-19% (previously around 15%).  Lars Rebien Sørensen, president and CEO: ""We are satisfied with the results of the first six months with 11% underlying sales growth driven by Victoza® and our modern insulins. This leads us to raise the outlook for the full year results.""  Company Announcement no 46 / 2011 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2622,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
742,2011-08-04,Novo Nordisks resultat af primær drift steg med 13%  i første halvår af 2011,"Salgsvækst på 11% i lokale valutaer drevet af Victoza®, NovoRapid® og Levemir® Salget steg med 11% opgjort i lokale valutaer og med 9% opgjort i kroner. Bruttomarginen steg med 0,3 procentpoint opgjort i lokale valutaer. Dette afspejler en gunstig udvikling i produktsammensætningen som følge af et øget salg af moderne insuliner og et lavere salg af humane insuliner. Opgjort i kroner faldt bruttomarginen marginalt med 0,1 procentpoint til 80,4%. Det rapporterede resultat af primær drift steg med 13% til 10.683 mio. kr. Opgjort i lokale valutaer steg resultatet af primær drift med ca. 17%. Nettoresultatet steg med 19% til 8.207 mio. kr. Resultat pr. aktie (udvandet) steg med 23% til 14,27 kr.  Den kliniske udviklingsportefølje udviser væsentlig fremdrift. Der er iværksat fase 3a-programmer for følgende tre produktkandidater: et kombinationspræparat bestående af insulin og GLP-1 til behandling af type 2-diabetes; en hurtigtvirkende rekombinant faktor VIIa-analog til behandling af hæmofilipatienter med inhibitorer; og et langtidsvirkende rekombinant faktor IX-præparat til behandling af hæmofili B. Endvidere er der påbegyndt to fase 3a-studier af liraglutid til behandling af fedme. Forventningerne til 2011 er øget: der forventes nu en salgsvækst opgjort i lokale valutaer på 9-11% (mod tidligere 8-10%) og en vækst i resultat af primær drift opgjort i lokale valutaer på 15-19% (mod tidligere omkring 15%). Adm. direktør Lars Rebien Sørensen: ""Vi er tilfredse med halvårsresultatet og den underliggende salgsvækst på 11%, som især skyldes Victoza® og vores moderne insuliner. Det er baggrunden for, at vi opjusterer vores forventninger til hele året.""   Selskabsmeddelelse nr. 46 / 2011 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2623,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
743,2011-06-10,Novo Nordisk Inc. indgår forlig med det amerikanske justitsministerium,"Novo Nordisk meddelte i dag, at virksomheden har indgået en aftale med det amerikanske justitsministerium og to privatpersoner om afslutning af en undersøgelse og et civilt søgsmål vedrørende påstået ulovlig markedsførings­praksis i USA i relation til NovoSeven®. Undersøgelsen blev omtalt i Novo Nordisks årsregnskabsmeddelelse for 2009 den 2. februar 2010. Aftalen indebærer, at Novo Nordisk betaler 25 mio. US dollars til forligsparterne.  Yderligere information: Selskabsmeddelelse nr. 36 / 2011  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2672,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
744,2011-06-10,Novo Nordisk Inc. reaches agreements with US Department of Justice,"Novo Nordisk announced today that it has reached an agreement with the US Department of Justice and two individuals to settle an investigation and civil lawsuit related to alleged improper marketing practices in the United States regarding NovoSeven®. The company disclosed this investigation on 2 February 2010 in the company's 2009 financial statement. Under the agreement, Novo Nordisk will pay USD 25 million to the settling parties.  Further information: Company Announcement no 36 / 2011  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2673,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
745,2011-05-31,Det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 31. maj 2011,"I henhold til Bekendtgørelse om udstederes oplysningsforpligtelser, § 6, skal Novo Nordisk offentliggøre det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S ved udgangen af måneder, hvor ændringer deri har fundet sted. Yderligere information:  Selskabsmeddelelse nr. 34 / 2011",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2682,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
746,2011-05-31,Total number of voting rights and share capital in Novo Nordisk A/S as of 31 May 2011,"In accordance with Section 6 of the Danish Statutory Order on Issuers Disclosure Obligations, Novo Nordisk is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of the month where changes have occurred. Further information:  Company Announcement no 34 / 2011",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2683,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
747,2011-05-05,Hovedpunkter fra Novo Nordisks kapitalmarkedsdag 2011,På kapitalmarkedsdagen i dag fremlægger Novo Nordisk aspirationerne for opretholdelse af virksomhedens fortsatte konkurrenceevne i den globale farmaceutiske industri.  Yderligere information:  Selskabsmeddelelse nr. 27 / 2011,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2718,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
748,2011-05-05,Highlights from Novo Nordisk's Capital Markets Day 2011,"At its Capital Markets Day today, Novo Nordisk outlines the aspirations for how to sustain competitiveness in the global pharmaceutical industry.  Further information:  Company Announcement no 27 / 2011  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2717,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
749,2011-05-02,Novo Nordisk A/S - Nedsættelse af aktiekapitalen,"På den ordinære generalforsamling i Novo Nordisk A/S den 23. marts 2011 blev det besluttet at nedsætte selskabets B-aktiekapital fra nominelt 492.512.800 kr. til 472.512.800 kr. ved annullering af en del af selskabets beholdning af egne B-aktier, i alt nominelt 20.000.000 kr. fordelt på 20.000.000 B-aktier a 1 kr. Yderligere information: Selskabsmeddelelse nr. 26 / 2011 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2725,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
750,2011-05-02,Novo Nordisk A/S - Reduction of the share capital,"At Novo Nordisk's Annual General Meeting on 23 March 2011, it was decided to reduce the company's B share capital from DKK 492,512,800 to DKK 472,512,800 by  cancellation of part of the company's portfolio of own B shares at a  nominal value of DKK 20,000,000 divided into 20,000,000 B shares of DKK 1 each. Further information: Company Announcement no 26 / 2011 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2724,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
751,2011-04-28,Novo Nordisks resultat af primær drift steg med 24%  i første kvartal af 2011,"Organisk salgsvækst på 15% drevet af Victoza®, NovoRapid® og Levemir® Salget steg med 15% opgjort i kroner og med 11% opgjort i lokale valutaer. Bruttomarginen steg med 0,3 procentpoint opgjort i lokale valutaer som følge af en gunstig udvikling i produktsammensætningen, men på grund af en negativ påvirkning fra valutakursudviklingen faldt bruttomarginen med 0,2 procentpoint til 80,1% i forhold til første kvartal af 2010. Det rapporterede resultat af primær drift steg med 24% til 5.418 mio. kr. Opgjort i lokale valutaer steg resultat af primær drift med ca. 20%. Nettoresultatet steg med 23% til 4.073 mio. kr. Resultat pr. aktie (udvandet) steg med 26% til 7,06 kr. Novo Nordisk har afsluttet en præspecificeret metaanalyse baseret på fase 3a-studieprogrammet for Degludec. Metaanalysen bekræftede, at Degludec er forbundet med en lavere risiko for hypoglykæmi sammenlignet med insulin glargin, både med hensyn til det samlede antal bekræftede tilfælde af hypoglykæmi og antallet af bekræftede tilfælde af natlig hypoglykæmi. Begge resultater er statistisk signifikante. Forventningerne til 2011 er uændrede: en salgsvækst på 8-10% og en vækst i resultat af primær drift på omkring 15%, begge dele opgjort i lokale valutaer. Adm. direktør Lars Rebien Sørensen siger: ""Vi glæder os over den fortsatte tocifrede salgsvækst, som især skyldes Victoza® og de moderne insuliner. Den styrker vores tiltro til virksomhedens langsigtede vækstmuligheder til trods for den kortsigtede effekt på salgsvæksten fra sundhedsreformer i USA og andre større markeder, som er afspejlet i forventningerne til 2011.""  Kontaktoplysninger  Selskabsmeddelelse nr. 25 / 2011 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2730,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
752,2011-04-28,Novo Nordisk increased operating profit by 24% in the first quarter of 2011,"Organic sales growth of 15% driven by Victoza®, NovoRapid® and Levemir® Sales increased by 15% in Danish kroner and by 11% in local currencies. Gross margin improved by 0.3 percentage points in local currencies, reflecting a favourable product mix development, but due to a negative currency effect, the gross margin declined by 0.2 percentage points to 80.1% compared to the first quarter of 2010. Reported operating profit increased by 24% to DKK 5,418 million. Measured in local currencies, operating profit increased by approximately 20%. Net profit increased by 23% to DKK 4,073 million. Earnings per share (diluted) increased by 26% to DKK 7.06. Novo Nordisk has completed a pre-specified meta-analysis based on the Degludec phase 3a trial programme. The meta-analysis confirmed that Degludec is associated with a lower risk of hypoglycaemia compared to insulin glargine, both on the total number of confirmed hypoglycaemic events, and on the number of confirmed nocturnal hypoglycaemic events. Both findings are statistically significant. The 2011 outlook remains unchanged: sales growth of 8-10% and operating profit growth of around 15%, both measured in local currencies. Lars Rebien Sørensen, president and CEO, says: ""We are encouraged by the continued double-digit sales growth driven by Victoza® and modern insulins. It strengthens our confidence in the company's long term growth prospects despite the near-term impact on sales growth from healthcare reforms in the US and other major markets, which is reflected in the 2011 outlook.""  Contact details   Company Announcement no 25 /2011  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2729,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
753,2011-03-23,Beslutninger fra den ordinære generalforsamling i  Novo Nordisk A/S,Novo Nordisk A/S har i dag afholdt ordinær generalforsamling. Kontaktinformation:   Selskabsmeddelelse nr. 18 / 2011 ,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2767,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
754,2011-03-23,Resolutions from the Annual General Meeting at Novo Nordisk A/S,The Annual General Meeting of Novo Nordisk A/S was held today. Contact information Company announcement no 18 / 2011,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2766,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
755,2011-03-15,Novo Nordisk opnår godkendelse af Victoza® i Kina," Novo Nordisk meddelte i dag, at de kinesiske sundhedsmyndigheder, State Food and Drug Administration (SFDA), har godkendt Victoza® til behandling af type 2-diabetes. Yderligere information: Selskabsmeddelelse nr. 16 2011    ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2777,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
756,2011-03-15,Novo Nordisk receives approval for Victoza® in China, ,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2776,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
757,2011-02-26,Notice for the Annual General Meeting of Novo Nordisk A/S," Annual General Meeting on 23 March 2011 The ordinary Annual General Meeting will be held on: Wednesday 23 March 2011 at 2.00 pm (CET) at Radisson Blu Falconer Hotel  & Conference Center, Falkoner Allé 9, 2000 Frederiksberg, Denmark.  Further information:  Company Announcement no 12 / 2011  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2796,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
758,2011-02-26,Ordinær generalforsamling i Novo Nordisk A/S,Ordinær generalforsamling den 23. marts 2011. Selskabets ordinære generalforsamling afholdes onsdag den 23. marts 2011 kl. 14.00 Yderligere information: Selskabsmeddelelse nr. 12 / 2011 ,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2797,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
759,2011-02-16,Novo Nordisk har modtaget begæring om udlevering af dokumenter i USA,"Statsadvokaten for District of Massachusetts har anmodet Novo Nordisk om at udlevere dokumenter vedrørende mulige strafbare forhold i relation til virksomhedens markedsførings- og salgsaktiviteter for følgende produkter: NovoLog®, Levemir® og Victoza®. Novo Nordisk vil samarbejde med statsadvokaten om denne undersøgelseNovo Nordisk kan ikke på nuværende tidspunkt fastslå eller forudsige udfaldet af denne sag eller vurdere konsekvenserne deraf, ligesom det ikke er muligt at forudsige, hvor længe undersøgelsen vil vare, eller hvornår virksomheden kan give yderligere information. Yderligere information: Selskabsmeddelelse nr. 10 / 2011      ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2806,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
760,2011-02-16,Novo Nordisk receives subpoena in the US,"The office of the US Attorney for the District of Massachusetts has served Novo Nordisk with a subpoena calling for the production of documents regarding potential criminal offences relating to the company's marketing and promotion practices for the following products:  NovoLog® , Levemir®, and Victoza®. Novo Nordisk will cooperate with the US Attorney in this investigation. At this time, Novo Nordisk cannot determine or predict the outcome of this matter or assess the consequences thereof. In addition, the company cannot predict how long the investigation will take or when it will be able to provide additional information.  Further information:  Company Announcement no 10 / 2011 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2807,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
761,2011-02-02,Novo Nordisk increased operating profit by 27% in 2010,"Organic sales growth of 19% driven by Victoza®, NovoRapid® and Levemir® Sales increased by 19% in Danish kroner and by 13% in local currencies. Gross margin improved by 1.2 percentage points in Danish kroner to 80.8% in 2010, reflecting a favourable product mix development and a positive currency impact. Reported operating profit increased by 27% to DKK 18,891 million. Measured in local currencies, operating profit increased by approximately 16%. Net profit increased by 34% to DKK 14,403 million. Earnings per share (diluted) increased by 38% to DKK 24.60. The phase 3a programme for Degludec and DegludecPlus has now been completed. In the largest trial, the one-year trial comparing Degludec and insulin glargine when added to oral anti-diabetic therapy in type 2 diabetes, Degludec met the primary endpoint of non-inferior glucose control while reducing nocturnal hypoglycaemia by more than 35% compared to insulin glargine. For 2011, sales growth measured in local currencies is expected to be 8-10%, and operating profit growth measured in local currencies is expected to be around 15%. In 2010, Novo Nordisk reached the four long-term financial targets announced in the annual report for 2008. Consequently, three of the four targets have been increased while the core target of 15% annual operating profit growth has been maintained.At the Annual General Meeting on 23 March 2011, the Board of Directors will propose a 33% increase in dividend to DKK 10 per share. The Board of Directors has furthermore decided to initiate a new share repurchase programme of DKK 10 billion in 2011. Lars Rebien Sørensen, president and CEO: ""2010 was a very good year for Novo Nordisk with strong organic sales growth driven by the modern insulins and Victoza®. We expect continued sales growth from these products and are encouraged by the results from the phase 3 programme with our new generation insulins.""",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2846,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
762,2011-02-02,Novo Nordisks resultat af primær drift steg med 27% i 2010,"Organisk salgsvækst på 19% drevet af Victoza®, NovoRapid® og Levemir® Salget steg med 19% opgjort i kroner og med 13% opgjort i lokale valutaer. Bruttomarginen steg med 1,2 procentpoint opgjort i kroner til 80,8% i 2010 som følge af en gunstig udvikling i produktsammensætning og en positiv påvirkning fra valutakursudviklingen. Det rapporterede resultat af primær drift steg med 27% til 18.891 mio. kr. Opgjort i lokale valutaer steg resultat af primær drift med ca. 16%. Nettoresultatet steg med 34% til 14.403 mio. kr. Resultat pr. aktie (udvandet) steg med 38% to DKK 24.60. Fase 3a-programmet for Degludec og DegludecPlus er nu afsluttet. I det største studie, det etårige studie, der sammenlignede Degludec og insulin glargin, når de blev givet som supplement til tabletbehandling i type 2-diabetes, opfyldte Degludec det primære mål om ikke-inferiør glukoseregulering, mens forekomsten af natlig hypoglykæmi var mere end 35% lavere sammenlignet med insulin glargin. For 2011 forventes en vækst i salget opgjort i lokale valutaer på 8-10%, og resultat af primær drift opgjort i lokale valutaer ventes at stige med omkring 15%. I 2010 nåede Novo Nordisk de fire langsigtede finansielle mål, der blev offentliggjort i årsrapporten for 2008. Tre af de fire mål er derfor blevet opjusteret, mens målet om 15% årlig vækst i resultat af primær drift er blevet fastholdt. Bestyrelsen vil på generalforsamlingen den 23. marts 2011 fremsætte forslag om en 33% stigning i udbyttebetalingen til 10 kr. pr. aktie. Bestyrelsen har endvidere besluttet at iværksætte et nyt aktietilbagekøbsprogram på 10 mia. kr. i 2011. Adm. direktør Lars Rebien Sørensen: ""2010 var et rigtig godt år for Novo Nordisk med stærk organisk salgsvækst drevet af de moderne insuliner og Victoza®. Vi forventer fortsat salgsvækst fra disse produkter og glæder os over resultaterne fra fase 3-programmet med vores nye generation af insuliner.""",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2847,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
763,2011-01-19,Novo Nordisk intends to appeal adverse ruling in Prandin® (repaglinide) patent case,"Today, Novo Nordisk announced that Judge Avern Cohn of the US District Court for the Eastern District of Michigan issued an adverse ruling in a patent litigation case regarding Novo Nordisk's US Patent No. 6,677,358. The district court ruled that the patent, which covers the combination use of repaglinide and metformin for the treatment of type 2 diabetes, is invalid and unenforceable. Novo Nordisk markets repaglinide under the trade name Prandin® and a fixed dose repaglinide/metformin tablet under the trade name PrandiMet®. The district court ruling has the potential to facilitate launch of a generic repaglinide. At present, it is unclear whether or when a generic version of Prandin® or PrandiMet® will be available in the U.S. market. Novo Nordisk intends to appeal this ruling and is evaluating its best options for doing so. Further information:  Company Announcement no 2 / 2011  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2849,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
764,2011-01-19,Novo Nordisk forventer at anke kendelse i amerikansk patentsag om Prandin® (repaglinid),"Novo Nordisk meddelte i dag, at dommer Avern Cohn ved US District Court for the Eastern District of Michigan har afsagt kendelse imod Novo Nordisk i en sag om patentkrænkelse vedrørende Novo Nordisks amerikanske patent nr. 6.677.358. Ifølge domstolens kendelse er patentet, som dækker kombinationen af repaglinid og metformin til behandling af type 2-diabetes, ugyldigt og kan ikke håndhæves. Novo Nordisk markedsfører repaglinid under varemærket Prandin® (NovoNorm® uden for USA) og en fast kombination af repaglinid/metformin i tabletform under varemærket PrandiMet®. Kendelsen vil potentielt åbne op for lancering af generisk repaglinid. Det er på nuværende tidspunkt uklart, hvorvidt eller hvornår en generisk udgave af Prandin® eller PrandiMet® bliver tilgængelig på det amerikanske marked. Novo Nordisk har til hensigt at anke kendelsen og evaluerer i øjeblikket, hvorledes dette gøres mest hensigtsmæssigt.  Yderligere information: Selskabsmeddelelse nr. 2 / 2011  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2848,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
765,2010-12-22,Degludec significantly reduces risk of hypoglycaemia during the night compared to insulin glargine in two long-term studies,"Novo Nordisk today announced clinical results from two 52-week phase 3a treat-to-target studies comparing Degludec, an ultra long-acting basal insulin, to insulin glargine in basal-bolus treatment of type 1 and type 2 diabetes. Basal-bolus treatment is comprised of treatment with long-acting (basal) insulin and a rapid-acting (bolus) insulin, and in both studies insulin aspart was used as the bolus insulin. These studies, as well as three additional studies reported today, are part of the largest clinical development programme ever conducted for an insulin.  Further information: Company Announcement no 71 / 2010",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2863,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
766,2010-12-22,Degludec giver væsentligt nedsat risiko for natlig hypoglykæmi sammenlignet med insulin glargin i to langtidsstudier,"Novo Nordisk har i dag rapporteret kliniske resultater fra to 52-ugers fase 3a treat-to-target-studier, der har sammenlignet Degludec, en ultralangtids­virkende basal insulin, med insulin glargin i basal/bolus-behandling af type 1- og type 2-diabetes. Basal/bolus-behandling omfatter behandling med langtidsvirkende (basal) insulin og en hurtigvirkende (bolus) insulin, og i begge studier blev insulin aspart anvendt som bolus-insulin. Disse studier samt tre yderligere studier, der blev rapporteret i dag, er delstudier i det største kliniske udviklings­program nogensinde for et insulinpræparat.   Yderligere information: Selskabsmeddelelse nr. 71 / 2010",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2864,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
767,2010-10-28,Interim financial report for the period 1 January 2010 to 30 September 2010,"Gross margin improved by 1.3 percentage points in Danish kroner to 80.8% in the first nine months of 2010, primarily reflecting a positive product mix development.  Reported operating profit increased by 24% to DKK 14,547 million. Adjusted for the impact from currencies, operating profit in local currencies increased by around 15%.  Net profit increased by 24% to DKK 10,457 million. Earnings per share (diluted) increased by 28% to DKK 17.78.  In the second phase 3a study for DegludecPlus, the trial results document at least similar glycaemic control compared to NovoMix® 30 and with a reduced rate of hypoglycaemia. The first phase 3a study for Degludec, the new generation ultra long-acting basal insulin, shows the potential for Degludec to provide dosing flexibility without compromising the glycaemic control or safety profile.  In the first phase 3 study with liraglutide in obesity, patients treated for 56 weeks with liraglutide lost 6 kg more than patients in the placebo group. Two additional phase 3 studies will be initiated in the first half of 2011.  The guidance for 2010 has been raised: sales growth measured in local currencies is now expected to be 11-12%, and operating profit growth measured in local currencies is now expected to be more than 15%.  Lars Rebien Sørensen, president and CEO: ""We are increasing our guidance for 2010 based on the continued double-digit sales growth from Victoza®, NovoRapid® and Levemir®. We are also encouraged by the latest results from the phase 3a trials with DegludecPlus and Degludec, our two new generation insulins and by the progress made within our haemophilia pipeline."" Contacts for further information: Company Announcement no 60 / 2010",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2918,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
768,2010-10-28,Delårsrapport for perioden 1. januar 2010 til 30. september 2010,"Bruttomarginen steg med 1,3 procentpoint opgjort i kroner til 80,8% i de første ni måneder af 2010, primært som følge af en positiv udvikling i produktsammensætningen.  Det rapporterede resultat af primær drift steg med 24% til 14.547 mio. kr. Korrigeret for valutapåvirkning steg resultat af primær drift opgjort i lokale valutaer med omkring 15%.  Nettoresultatet steg med 24% til 10.457 mio. kr. Resultat pr. aktie (udvandet) steg med 28% til 17,78 kr.  Resultaterne fra det andet fase 3-studie med DegludecPlus dokumenterer som minimum sammenlignelig glykæmisk kontrol i forhold til NovoMix® 30 og færre tilfælde af hypoglykæmi (for lavt blodsukker). Det første fase 3a-studie med Degludec, den nye generation af ultralangtidsvirkende basal insulin, viser, at Degludec har potentiale til doseringsfleksibilitet uden at gå på kompromis med glykæmisk kontrol eller sikkerhedsprofil  I det første fase 3-studie med liraglutid til behandling af fedme tabte patienter, der blev behandlet med liraglutid i 56 uger, sig 6 kg mere end patienter, der fik placebo. Yderligere to fase 3-studier vil blive påbegyndt i første halvår af 2011  Forventningerne til 2010 er øget: salgsvæksten opgjort i lokale valutaer ventes nu at blive 11-12%, og væksten i resultat af primær drift opgjort i lokale valutaer ventes nu at blive mere end 15%.  Adm. direktør Lars Rebien Sørensen: ""Vi har opjusteret vores forventninger til hele året på baggrund af den fortsatte tocifrede vækst i salget, som især skyldes Victoza®, NovoRapid® og Levemir®. Desuden glæder vi os over de seneste resultater fra fase 3a-studierne med DegludecPlus og Degludec - vores nye generation af insuliner - og over fremgangen i vores portefølje inden for hæmofili."" Kontaktoplysninger:  Selskabsmeddelelse nr. 60 / 2010 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2919,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
769,2010-10-08,"Novo Nordisk completes divestment of ZymoGenetics, Inc.","As communicated in the Company Announcement no 50 on 8 September 2010, Bristol-Myers Squibb Company and ZymoGenetics, Inc. have signed a definitive agreement providing for the acquisition of ZymoGenetics by Bristol-Myers Squibb for USD 9.75 per share in cash. Novo Nordisk has been a shareholder of ZymoGenetics since 1988 and at the time of the transaction, Novo Nordisk owned 22,143,320 shares, equalling close to 26% of the share capital. Pursuant to an agreement between the companies, Novo Nordisk has tendered all of its shares to Bristol-Myers Squibb.  Further information: Company Announcement no 56 / 2010 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2938,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
770,2010-10-08,"Novo Nordisks salg af ZymoGenetics, Inc. gennemført","Som meddelt i selskabsmeddelelse nr. 50 udsendt den 8. september 2010 har Bristol-Myers Squibb Company og ZymoGenetics, Inc. underskrevet en endelig aftale, der giver Bristol-Myers Squibb mulighed for at overtage ZymoGenetics for 9,75 USD pr. aktie kontant. Novo Nordisk har været aktionær i ZymoGenetics siden 1988 og ejede på tidspunktet for transaktionen 22.143.320 aktier, svarende til knap 26% af aktiekapitalen. I henhold til en aftale mellem selskaberne har Novo Nordisk accepteret at sælge sin samlede aktiepost til Bristol-Myers Squibb. Further information: Selskabsmeddelelese nr. 56 / 2010   ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2939,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
771,2010-09-07,"Novo Nordisk divests its ownership of ZymoGenetics, Inc.","Bristol-Myers Squibb Company and ZymoGenetics, Inc. have announced the signing of a definitive agreement providing for the acquisition of ZymoGenetics by Bristol-Myers Squibb for USD 9.75 per share in cash. The transaction has been unanimously approved by the Boards of Directors of both companies. Novo Nordisk has been a shareholder in ZymoGenetics, Inc. since 1988. Currently, Novo Nordisk owns 22,143,320 shares, equalling close to 26% of the share capital, and has nominated two board members to the ZymoGenetics, Inc. Board of Directors. ""As a significant shareholder with a long-term financial investment in ZymoGenetics, we find the offer from Bristol-Myers Squibb attractive and have entered into an agreement with Bristol-Myers Squibb to support the transaction and tender all of our ZymoGenetics shares in the offer,"" says Jesper Brandgaard, executive vice president and chief financial officer of Novo Nordisk. The closing of the tender offer is subject to customary terms and conditions, including the tender of minimum 48,282,192 shares equalling approximately 56% of the share capital, ie the majority of the share capital on a fully-diluted basis. In addition, expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act is required. Assuming completion of the tender offer, Novo Nordisk expects to record a non-recurring income of approximately DKK 1.1 billion in relation to the sale of its shares in ZymoGenetics, Inc., which will be recorded under 'Share of profit in associated companies' in the 'Net financials' part of the income statement for 2010. The income from the transaction is exempt from tax charges under applicable Danish tax laws and is expected to have a positive non-recurring effect on the effective tax rate for the group of approximately 1.5 percentage points. Updated guidance for the full year of 2010 will be provided in connection with the release of the financial statement for the first nine months of 2010 on 27 October 2010. Company Announcement no 50 / 2010  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2968,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
772,2010-09-07,"Novo Nordisk sælger ejerandel i ZymoGenetics, Inc.","Bristol-Myers Squibb Company og ZymoGenetics, Inc. har underskrevet en endelig aftale, der giver Bristol-Myers Squibb mulighed for at overtage ZymoGenetics for 9,75 USD pr. aktie kontant. Transaktionen er enstemmigt vedtaget af bestyrelserne i begge selskaber. Novo Nordisk har været aktionær i ZymoGenetics, Inc. siden 1988. Novo Nordisk ejer i dag 22.143.320 aktier, svarende til knap 26% af aktiekapitalen, og har nomineret to bestyrelsesmedlemmer til ZymoGenetics' bestyrelse. ""Som en af de større aktionærer med en langsigtet finansiel investering i ZymoGenetics vurderer vi, at Bristol-Myers Squibbs tilbud er attraktivt, og har indgået en aftale med Bristol-Myers Squibb om at støtte transaktionen og acceptere købstilbuddet for vores samlede aktiepost i ZymoGenetics,"" siger Jesper Brandgaard, koncernøkonomidirektør i Novo Nordisk. Gennemførelse af købstilbuddet er betinget af sædvanlige vilkår, herunder modtagelse af accept fra aktionærer, der ejer minimum 48.282.192 aktier svarende til ca. 56% af aktiekapitalen, dvs. majoriteten af aktiekapitalen på fuldt udvandet basis. Det kræves endvidere, at ventetiden i henhold til den amerikanske konkurrencelov Hart-Scott-Rodino Antitrust Improvements Act er udløbet eller bragt til ophør. Såfremt købstilbuddet gennemføres, forventer Novo Nordisk at bogføre en indtægt af engangskarakter på ca. 1,1 mia. kr. i relation til salget af aktierne i ZymoGenetics, Inc. Dette vil indgå i 'Resultat af kapitalandele i associerede virksomheder' under nettofinans i resultatopgørelsen for 2010. Indtægterne fra denne transaktion er ifølge gældende danske skatteregler fritaget for beskatning og ventes at medføre en positiv engangspåvirkning på koncernens effektive skattesats på ca. 1,5 procentpoint. Opdaterede forventninger til hele 2010 vil foreligge i forbindelse med regnskabsmeddelelsen for de første ni måneder af 2010, som udsendes den 27. oktober 2010. ZymoGenetics er en biofarmaceutisk virksomhed, der fokuserer på udvikling og kommercialisering af proteinbaserede lægemidler til behandling af humane sygdomme. ZymoGenetics har udviklet og markedsfører RECOTHROM®, der er et rekombinant lokaltvirkende blødningshæmmende lægemiddel, i USA. ZymoGenetics har to produktkandidater i klinisk fase 2-udvikling: PEG-Interferon lambda, som vurderes i samarbejde med Bristol-Myers Squibb til behandling af hepatitis C-virusinfektion, samt IL-21, der afprøves som potentiel behandling af metastatisk melanom. Herudover har ZymoGenetics et anti-IL-31 monoklonalt antistof i præklinisk udvikling, som i første omgang ventes afprøvet til behandling af atopisk dermatitis. Flere af de produktkandidater, der tidligere er identificeret gennem ZymoGenetics' forskningsindsats, er udlicenseret til og udvikles af andre virksomheder, bl.a. Merck Serono og Novo Nordisk. ZymoGenetics er berettiget til at modtage milepælsbetalinger og royalties i relation til disse aktiver. Læs mere på zymogenetics.com.  Yderligere information:   Selskabsmeddelelse nr. 50 / 2010      ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2969,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
773,2010-08-05,Delårsrapport for perioden 1. januar 2010 til 30. juni 2010,"Novo Nordisks resultat af primær drift steg med 19% i første halvår af 2010 Salgsvækst på 14% drevet af moderne insuliner og Victoza® Salget steg med 14% opgjort i kroner og med 11% opgjort i lokale valutaer. Bruttomarginen steg med 0,6 procentpoint opgjort i kroner til 80,5% i første halvår af 2010, primært som følge af en positiv udvikling i produktsammensætningen. Det rapporterede resultat af primær drift steg med 19% til 9.423 mio. kr. Korrigeret for valutapåvirkning steg resultat af primær drift opgjort i lokale valutaer med omkring 15%. Nettoresultatet steg med 21% til 6.872 mio. kr. Resultat pr. aktie (udvandet) steg med 25% til 11,63 kr. Den globale lancering af Victoza® forløber positivt. I USA har Victoza® nu opnået en andel på 27% af udskrevne recepter på GLP-1-lægemidler opgjort på ugebasis (pr. udgangen af uge 29), og produktet er også blevet lanceret i Japan og Canada. Novo Nordisk meddelte i juni 2010, at rekrutteringen af patienter til det globale fase 3a-program for Degludec og DegludecPlus er afsluttet. De første fase 3a-resultater for DegludecPlus til behandling af type 1-diabetes bekræfter, at DegludecPlus sænker patienters langtidsblodsukker med færre tilfælde af hypoglykæmi. Forventningerne til 2010 er øget: der forventes nu en salgsvækst opgjort i lokale valutaer på 9-10% og en vækst i resultat af primær drift opgjort i lokale valutaer på 12-15%. Adm. direktør Lars Rebien Sørensen: ""Væksten i den underliggende forretning er solid, drevet af vores portefølje af moderne insuliner og Victoza®, og vi opjusterer derfor vores forventninger til 2010. Vi glæder os desuden over den fortsatte fremgang i vores pipeline, både for så vidt angår nye insuliner, liraglutid til behandling af fedme og hæmostaseprojekter."" Kontaktoplysninger: Selskabsmeddelelse nr. 43 / 2010",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3004,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
774,2010-08-05,Interim financial report for the period 1 January 2010 to 30 June 2010,"Novo Nordisk increased operating profit by 19% in the first half of 2010Sales growth of 14% driven by modern insulins and Victoza®. Sales increased by 14% in Danish kroner and by 11% in local currencies. Gross margin improved by 0.6 percentage points in Danish kroner to 80.5% in the first six months of 2010, primarily reflecting a positive product mix development. Reported operating profit increased by 19% to DKK 9,423 million. Adjusted for the impact from currencies, operating profit in local currencies increased by around 15% Net profit increased by 21% to DKK 6,872 million. Earnings per share (diluted) increased by 25% to DKK 11.63. The global roll-out of Victoza® is progressing well. In the US, Victoza® has now achieved 27% GLP-1 market share of total weekly prescriptions for the week ending 23 July 2010, and the product has also been launched in Japan and Canada. In June 2010, Novo Nordisk announced that the enrolment of patients into the global phase 3a programme for Degludec and DegludecPlus has been completed. The first phase 3a results for DegludecPlus in type 1 diabetes substantiate that DegludecPlus lowers blood glucose long-term whilst at the same time reducing hypoglycaemic events. The guidance for 2010 has been raised; sales growth measured in local currencies is now expected to be 9-10%, and operating profit growth measured in local currencies is now expected to be 12-15%.  Lars Rebien Sørensen, president and CEO: ""The underlying business growth is solid, driven by our portfolio of modern insulins and Victoza®, and we therefore raise our guidance for 2010. We are also very encouraged by the continued progress within our pipeline including both new insulins, liraglutide for obesity and haemostasis projects."" Contacts for further information: Company Announcement no 43 / 2010",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3003,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
775,2010-06-30,Det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 30. juni 2010,"I henhold til Bekendtgørelse om udstederes oplysningsforpligtelser, § 6, skal Novo Nordisk offentliggøre det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S ved udgangen af måneder, hvor ændringer deri har fundet sted. For yderligere information kontakt:  Selskabsmeddelelse nr. 35 / 2010 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3044,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
776,2010-06-30,Total number of voting rights and share capital in Novo Nordisk A/S as of 30 June 2010,"In accordance with Section 6 of the Danish Statutory Order on Issuers Disclosure Obligations, Novo Nordisk is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk as per the end of the month where changes have occurred. For further information please contact:  Company announcement no 35 / 2010 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3043,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
777,2010-06-22,Novo Nordisk genoptager fase 3-udviklingsprogram for liraglutid til behandling af fedme,"Novo Nordisk har i dag offentliggjort beslutningen om at genoptage det globale fase 3-udviklingsprogram for liraglutid til behandling af fedme.Efter Victoza® blev godkendt i USA til behandling af type 2-diabetes, har Novo Nordisk været i dialog med de amerikanske sundhedsmyndigheder, FDA, vedrørende udviklingsprogrammet, der undersøger liraglutids potentiale inden for fedmebehandling. På baggrund af FDA's tilbagemelding har Novo Nordisk nu planer om at genoptage det globale fase 3-program i første halvår af 2011 i kliniske forsøg, der omfatter omkring 5.000 patienter. Med genoptagelsen af liraglutid-fedmeforsøgene understreger Novo Nordisk sit fokus på udvikling af liraglutidporteføljen - dvs. hjerte-kar-studiet af Victoza® (LEADER(TM)), fedmeprogrammet, kombinationsproduktet bestående af insulin degludec og liraglutid, og endelig en ugentlig udgave af liraglutid. Novo Nordisk satser fortsat på udviklingen af en længerevarende GLP-1-analog og forventer nu at redegøre for den kliniske udviklingsstrategi for semaglutid, en ugentlig GLP-1-analog og den ugentlige udgave af liraglutid i andet halvår af 2011. Victoza® én gang dagligt er den første humane GLP-1-analog (glukagon¬lignende peptid-1), der er udviklet til behandling af type 2-diabetes. Victoza® sænker blodsukkeret ved at stimulere frigivelsen af insulin og reducere udskillelsen af glukagon, når blodsukkerniveauet bliver for højt, og ved at forsinke tømningen af mavesækken. Victoza® reducerer desuden vægt og kropsfedtmasse ved hjælp af en række mekanismer, som bl.a. omfatter nedsat sultfornemmelse og lavere energiindtag. Victoza® tages som injektion én gang dagligt på et vilkårligt tidspunkt, uafhængigt af måltider. Novo Nordisk modtog markedsføringstilladelse for Victoza® den 30. juni 2009 i EU, den 20. januar 2010 i Japan og den 25. januar 2010 i USA. Produktet er lanceret i USA, Canada, Japan, Indien, Storbritannien, Tyskland, Frankrig og flere andre europæiske markeder. LEADER(TM) (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) er et multicenter, internationalt, randomiseret, dobbeltblindt, placebokontrolleret fase 3b-langtidsstudie. Der vil indgå omkring 9.000 patienter i studiet, som løber over en femårig periode. Studiet skal sammenligne liraglutid givet som supplement til standardbehandling med standardbehandling alene hos mennesker med type 2-diabetes. Yderligere information: Selskabsmeddelelse nr. 32 2010  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3061,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
778,2010-06-22,Novo Nordisk re-initiates phase 3 development of liraglutide for obesity,"Novo Nordisk today announced the decision to re-initiate the global phase 3 development programme of liraglutide for the treatment of obesity. Following the US approval of Victoza® for the treatment of type 2 diabetes, Novo Nordisk has been in dialogue with the FDA regarding the further progression of the development programme investigating the potential of liraglutide within obesity. Based on the feedback from the FDA, Novo Nordisk now plans to re-initiate the global phase 3 programme in the first half of 2011 in clinical trials comprising approximately 5,000 patients. The re-initiation of liraglutide obesity trials underlines Novo Nordisk's dedication to the development of the liraglutide portfolio, that is the cardiovascular outcomes trial for Victoza® (LEADER(TM)), the obesity programme, the fixed-ratio combination of insulin degludec and liraglutide, and finally a once-weekly version of liraglutide.Novo Nordisk remains committed to the development of a longer-acting GLP-1 analogue and now expects to outline the clinical development strategy for semaglutide, a once-weekly GLP-1 analogue, and the once-weekly version of liraglutide in the second half of 2011. Once-daily Victoza® is the first human GLP-1 (Glucagon-Like Peptide-1) analogue developed for the treatment of type 2 diabetes. Victoza® lowers blood glucose by stimulating the release of insulin and lowering of glucagon secretion when blood sugar levels are high and also by slowing gastric emptying. Victoza® also reduces body weight and body fat mass through mechanisms involving reduced hunger and lowered energy intake. Victoza® is a once-daily injection taken any time of day independent of meals.Novo Nordisk received marketing authorisation for Victoza® on 30 June 2009 in the EU, 20 January 2010 in Japan and 25 January 2010 in the US. It has been launched in the US, Canada, Japan, India, UK, Germany, France and several other European markets. LEADER(TM) (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) is a long-term, multicentre, international, randomised, double-blind, placebo-controlled, phase 3b trial which will include around 9,000 patients over a five-year period.The trial will compare liraglutide added to standard of care with standard of care alone in people with type 2 diabetes. Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs more than 29,650 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com. Yderligere information: Company Announcement no 32 2010 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3060,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
779,2010-04-27,Interim financial report for the period 1 January 2010 to 31 March 2010,"Operating profit increased by 15% in the first quarter of 2010Sales growth driven by modern insulins and Victoza®  Sales increased by 9% in Danish kroner and by 11% in local currencies. Sales of modern insulins increased by 17% (20% in local currencies). Sales of NovoSeven® increased by 6% (8% in local currencies). Sales of Norditropin® increased by 5% (7% in local currencies). Sales in North America increased by 15% (21% in local currencies). Sales in International Operations increased by 10% (10% in local currencies). Gross margin improved by 1.0 percentage point in local currencies and by 0.4 percentage points in Danish kroner to 80.3% in the first quarter of 2010, reflecting continued productivity improvements, higher average selling prices in the US, favourable product mix development and a negative currency impact of around 0.6 percentage points. Reported operating profit increased by 15% to DKK 4,382 million. Adjusted for the impact from currencies, operating profit in local currencies increased by around 20%. Net profit increased by 23% to DKK 3,324 million. Earnings per share (diluted) increased by 27% to DKK 5.61. Following the approval of Victoza® in the US on 25 January 2010, the product was launched in February 2010. The initial performance in the US, as measured by prescription level data, is encouraging. The European launch continues to progress as expected, with Victoza® now launched in 14 countries including France. The largest clinical trial programme in the history of insulin therapy, the phase 3 programmes BEGIN(TM) and BOOST(TM) for the next generation of modern insulin analogues, Degludec and DegludecPlus, involving 10,000 patients in 43 countries, is progressing according to plan with more than three quarters of the patients enrolled. For 2010, sales growth measured in local currencies is now expected to be in the range of 7-10%, and operating profit measured in local currencies is now expected to increase by more than 10%. Lars Rebien Sørensen, president and CEO: ""We are encouraged by the solid business performance in the first quarter of 2010. The increasing use of our modern insulins is the primary driver of growth. Furthermore, the roll-out of Victoza®, our new treatment for type 2 diabetes, is progressing well in both the US and Europe."" Contacts for further information  Company Announcement no 23 / 2010",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3105,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
780,2010-04-27,Delårsrapport for perioden 1. januar 2010 til 31. marts 2010,"Resultat af primær drift steg med 15% i første kvartal af 2010Salgsvæksten drevet af de moderne insuliner og Victoza® Salget steg med 9% opgjort i kroner og med 11% opgjort i lokale valutaer. Salget af moderne insuliner steg med 17% (20% i lokale valutaer). Salget af NovoSeven® steg med 6% (8% i lokale valutaer). Salget af Norditropin® steg med 5% (7% i lokale valutaer). Salget i Nordamerika steg med 15% (21% i lokale valutaer). Salget i International Operations steg med 10% (10% i lokale valutaer). Bruttomarginen steg med 1,0 procentpoint opgjort i lokale valutaer og med 0,4 procentpoint opgjort i kroner til 80,3% i første kvartal af 2010 på baggrund af fortsatte produktivitetsforbedringer, højere gennemsnitlige salgspriser i USA, en positiv udvikling i produktsammensætning og en negativ valutapåvirkning på omkring 0,6 procentpoint. Det rapporterede resultat af primær drift steg med 15% til 4.382 mio. kr. Korrigeret for valutapåvirkning steg resultat af primær drift opgjort i lokale valutaer med omkring 20%. Nettoresultatet steg med 23% til 3.324 mio. kr. Resultat pr. aktie (udvandet) steg med 27% til 5,61 kr. Victoza® blev lanceret på det amerikanske marked i februar 2010. De første resultater i USA målt på antallet af udskrevne recepter er opmuntrende. Den europæiske lancering fortsætter som forventet, og Victoza® er nu lanceret i 14 lande inklusive Frankrig. Det største kliniske forsøgsprogram i insulinbehandlingens historie, fase 3-programmerne BEGIN(TM) og BOOST(TM) med den næste generation af moderne insulin­analoger, Degludec og DegludecPlus, forløber planmæssigt. Programmet vil omfatte 10.000 patienter i 43 lande, hvoraf mere end tre fjerdedele er indrulleret. For 2010 forventes salgsvæksten i lokale valutaer nu at blive 7-10%, og resultat af primær drift opgjort i lokale valutaer ventes nu at stige med mere end 10%. Adm. direktør Lars Rebien Sørensen: ""Vi glæder os over det solide driftsresultat i første kvartal af 2010. Det er primært den stigende brug af vores moderne insuliner, der driver væksten. Også lanceringen af Victoza®, vores nye lægemiddel til behandling af type 2-diabetes, går godt både i USA og Europa."" Kontaktoplysninger  Selskabsmeddelelse nr. 23 / 2010",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3106,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
781,2010-03-24,Generalforsamling i Novo Nordisk A/S,Yderligere information: Medier: Investorer:   Mike Rulis Klaus Bülow Davidsen Tlf.: 3079 3573 Tlf.: 4442 3176 mike@novonordisk.com klda@novonordisk.com    Kasper Roseeuw Poulsen  Tlf.: 4442 4471  krop@novonordisk.com Selskabsmeddelelse nr. 16 / 2010,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3144,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
782,2010-03-24,Annual General Meeting at Novo Nordisk A/S,Further information: Media: Investors:   Mike Rulis Klaus Bülow Davidsen Tel: (+45) 3079 3573 Tel: (+45) 4442 3176 mike@novonordisk.com klda@novonordisk.com    Kasper Roseeuw Poulsen  Tel: (+45) 4442 4471  krop@novonordisk.com   In North America: In North America: Sean Clements Hans Rommer Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937 secl@novonordisk.com hrmm@novonordisk.com  Company Announcement no 16 / 2010 ,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3143,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
783,2010-02-26,Ordinær generalforsamling i Novo Nordisk A/S,"Selskabets ordinære generalforsamling afholdes onsdag den 24. marts 2010 kl. 14.00 i Bella Center, Center Boulevard 5, 2300 København S Yderligere information: Medier: Investorer:   Mike Rulis Klaus Bülow Davidsen Tlf.: 4442 3573 Tlf.: 4442 3176 mike@novonordisk.com klda@novonordisk.com    Kasper Roseeuw Poulsen  Tlf.: 4442 4471  krop@novonordisk.com  Selskabsmeddelelse nr. 11 / 2010 Indkaldelse til generalforsamlingen og forslag til reviderede retningslinjer for incitamentsbaseret aflønning er vedhæftet.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3169,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
784,2010-02-26,Annual General Meeting of Novo Nordisk A/S,"The ordinary Annual General Meeting will be held on Wednesday 24 March 2010 at 2.00 pm (CET) Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com. Further information: Media: Investors:   Mike Rulis Klaus Bülow Davidsen Tel: (+45) 4442 3573 Tel: (+45) 4442 3176 mike@novonordisk.com klda@novonordisk.com    Kasper Roseeuw   Poulsen  Tel: (+45) 4442 4471  krop@novonordisk.com   In North America: In North America: Sean Clements Hans Rommer Tel: (+1) 609 514   8316 Tel: (+1) 609 919   7937 secl@novonordisk.com hrmm@novonordisk.com Company Announcement no 11 / 2010 The notice for the Annual General Meeting and proposal for revised Incentive Guidelines are attached.",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3168,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
785,2010-02-02,Financial statement for 2009,"In 2010, operating profit is expected to increase by around 10% Sales increased by 12% in Danish kroner and by 11% in local currencies. Sales of modern insulins increased by 24% (23% in local currencies). Sales of NovoSeven® increased by 11% (10% in local currencies). Sales of Norditropin® increased by 14% (10% in local currencies). Sales in North America increased by 21% (15% in local currencies). Sales in International Operations increased by 17% (19% in local currencies).  Gross margin improved by 1.8 percentage points to 79.6% in 2009, primarily reflecting continued productivity improvements, price increases in the US and a positive currency impact of around 0.4 percentage points.  Reported operating profit increased by 21% to DKK 14,933 million. Adjusted for the impact from currencies underlying operating profit increased by more than 15%.  Net profit increased by 12% to DKK 10,768 million. Earnings per share (diluted) increased by 15% to DKK 17.82.  At the Annual General Meeting on 24 March 2010, the Board of Directors will propose a 25% increase in dividend to DKK 7.50 per share of DKK 1. The Board of Directors has furthermore decided to initiate a new share repurchase programme of DKK 7.5 billion during 2010.  In January 2010, Novo Nordisk received marketing authorisation for Victoza®, the once-daily human GLP-1 analogue for the treatment of type 2 diabetes, from both the US Food and Drug Administration (FDA) and the Japanese Ministry of Health, Labour and Welfare.  For 2010, sales growth measured in local currencies is expected to be in the range of 6-10% whereas operating profit measured in local currencies is expected to increase by around 10%.  Lars Rebien Sørensen, president and CEO, said: ""We are satisfied with the solid business performance in 2009, which is primarily driven by the robust sales growth for our portfolio of modern insulins. The launch of Victoza® in Europe is very encouraging and we look forward to continuing the global roll-out of Victoza® following the recent approvals in the US and Japan.""  Media: Investors:   Mike Rulis Klaus Bülow Davidsen Tel: (+45) 4442 3573 Tel: (+45) 4442 3176 mike@novonordisk.com klda@novonordisk.com    Kasper Roseeuw Poulsen  Tel: (+45) 4442 4471  krop@novonordisk.com   In North America: In North America Sean Clements Hans Rommer Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937 secl@novonordisk.com hrmm@novonordisk.com  Company Announcement no 4 / 2010 ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3206,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
786,2010-02-02,Årsregnskabsmeddelelse for året 2009,"I 2010 ventes resultat af primær drift at stige med omkring 10%  Adm. direktør Lars Rebien Sørensen udtaler: ""Vi er tilfredse med det solide driftsresultat i 2009, som primært har været drevet af en robust salgsvækst for vores moderne insuliner. Lanceringen af Victoza® i Europa er forløbet særdeles lovende, og vi ser frem til at fortsætte den globale udrulning af Victoza® efter de seneste godkendelser i USA og Japan.""  Kontaktoplysninger  Medier: Investorer:   Mike Rulis Klaus Bülow Davidsen Tlf. 4442 3573 Tlf. 4442 3176 mike@novonordisk.com klda@novonordisk.com    Kasper Roseeuw Poulsen  Tlf. 4442 4471  krop@novonordisk.com   I Nordamerika:  Sean Clements Hans Rommer Tlf. (+1) 609 514 8316 Tlf. (+1) 609 919 7937 secl@novonordisk.com hrmm@novonordisk.com  Selskabsmeddelelse nr 4 / 2010  ",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3209,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
787,2010-02-02,Financial statement for 2009,"In 2010, operating profit is expected to increase by around 10%    Lars Rebien Sørensen, president and CEO, said: ""We are satisfied with the solid business performance in 2009, which is primarily driven by the robust sales growth for our portfolio of modern insulins. The launch of Victoza® in Europe is very encouraging and we look forward to continuing the global roll-out of Victoza® following the recent approvals in the US and Japan."" Contacts for further information Media: Investors:   Mike Rulis Klaus Bülow Davidsen Tel: (+45) 4442 3573 Tel: (+45) 4442 3176 mike@novonordisk.com klda@novonordisk.com    Kasper Roseeuw   Poulsen  Tel: (+45) 4442 4471  krop@novonordisk.com   In North America: In North America Sean Clements Hans Rommer Tel:   (+1) 609 514 8316 Tel: (+1) 609 919   7937 secl@novonordisk.com hrmm@novonordisk.com Company Announcement no 4 / 2010",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3208,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
788,2010-01-26,Novo Nordisk receives US approval for Victoza® (liraglutide) for the treatment of type 2 diabetes,"Novo Nordisk receives US approval for Victoza® (liraglutide) for the treatment of type 2 diabetes Novo Nordisk announced today that the US Food and Drug Administration (FDA) has granted marketing authorisation for Victoza® for the treatment of type 2 diabetes in adults. Victoza® is the brand name approved in the US and Europe for liraglutide, the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analogue developed for the treatment of type 2 diabetes. In the US, Victoza® is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes. This provides for Victoza® to be used in monotherapy, as second-line treatment and in combination with commonly prescribed oral medications for diabetes. ""The US approval of Victoza® represents a major advancement in the treatment of type 2 diabetes and is an important milestone for Novo Nordisk that follows the recent approval in Japan and the ongoing successful launch in Europe."" says Lars Rebien Sørensen, president and CEO. ""We are convinced that Victoza® will prove to be a valuable treatment option for people with type 2 diabetes in the US. The ability of Victoza® to substantially improve glucose control with a low risk of hypoglycaemia creates an opportunity for more patients with type 2 diabetes to achieve their individual treatment goals."" Novo Nordisk expects to introduce Victoza® in the US market within weeks. The Victoza® phase 3 clinical trial programme, entitled LEAD(TM), which formed the basis of the regulatory submission, is comprised of randomised, controlled, double-blinded studies comparing Victoza® to commonly prescribed treatments. These multinational trials evaluated Victoza® in monotherapy as well as in combination with one or two oral antidiabetic medications and showed better or equivalent lowering of blood glucose than active comparators such as sulphonylureas and thiazolidinediones. Unlike many other diabetes medications, Victoza® is not associated with weight gain. For patients with type 2 diabetes, clinical trial data demonstrate a reduction in body weight in the LEAD(TM) programme. Body weight was a secondary endpoint in the clinical development trials. The most common adverse events reported during the clinical development programme in patients treated with Victoza® were associated with the gastrointestinal system. Gastrointestinal adverse events, including nausea, vomiting and diarrhoea were reported most frequently in the early part of the treatment period with Victoza® and few patients withdrew due to these adverse events. The US prescribing information includes a boxed warning for the risk of thyroid c-cell tumours. In preclinical testing, Victoza® caused thyroid c-cell tumours in rodents. In clinical trials there were no reported cases of medullary thyroid carcinoma (MTC) in patients treated with Victoza®, but human relevance of the rodent findings could not be ruled out by clinical or non-clinical studies. Victoza® is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2. The marketing authorisation further includes a risk evaluation and mitigation strategy (REMS) programme comprised of a Medication Guide to patients and a Communication Plan directed at healthcare providers - both informing about the risk of pancreatitis and the potential risk of MTC. On 26 January 2010 at 08:00 am CET, corresponding to 02:00 am EST, a conference call for investors will be held. Investors will be able to listen in via a link on the investor section of novonordisk.com. Presentation material for the conference call will be made available approximately one hour before on the same page, and a replay of the conference call will be available approximately two hours after its conclusion. Once-daily Victoza® is the first human Glucagon-Like Peptide-1 (GLP-1) analogue developed for the treatment of type 2 diabetes. Victoza® works by stimulating the release of insulin from the pancreatic beta cells only when blood sugar levels are high. Clinical trial data demonstrate a reduction in body weight. Victoza® is broken down naturally in the body and does not depend upon renal excretion. In Europe, Novo Nordisk received marketing authorisation for Victoza® on 30 June and Victoza® has subsequently been launched in the UK, Germany, Denmark, Norway and Ireland. In Japan, Novo Nordisk received marketing authorisation for Victoza® on 20 January 2010. A regulatory decision is pending in China where a New Drug Application was submitted in August 2009. Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 29,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com. Further information: Media: Investors:   Katrine Sperling Klaus Bülow Davidsen Tel: (+45) 3079 6718 Tel: (+45) 4442 3176 krsp@novonordisk.com klda@novonordisk.com Kasper Roseeuw Poulsen Tel: (+45) 4442 4471 krop@novonordisk.com In North America: In North America: An Phan Hans Rommer Tel: (+1) 609 558 0420 Tel: (+1) 609 919 7937 anph@novonordisk.com hrmm@novonordisk.com Company Announcement no 3 / 2010",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3213,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
789,2010-01-26,Novo Nordisk modtager godkendelse for Victoza® (liraglutid) i USA til behandling af type 2-diabetes,"Novo Nordisk meddelte i dag, at de amerikanske sundhedsmyndigheder, FDA, har givet markedsføringstilladelse for Victoza® til behandling af type 2-diabetes hos voksne. Victoza® er det godkendte varemærke i USA og Europa for liraglutid - den første humane GLP-1-analog (glukagonlignende peptid-1) til dosering én gang dagligt, der er udviklet til behandling af type 2-diabetes. I USA er Victoza® godkendt som supplement til diæt og motion med det formål at forbedre glykæmisk kontrol hos voksne med type 2-diabetes. Victoza® kan dermed anvendes som monoterapi, som andetvalgsbehandling og i kombination med almindeligt ordinerede diabeteslægemidler i tabletform. ""Den amerikanske godkendelse af Victoza® er et vigtigt fremskridt i behandlingen af type 2-diabetes og en vigtig milepæl for Novo Nordisk efter den seneste godkendelse i Japan og den igangværende succesfulde lancering i Europa,"" siger Novo Nordisks administrerende direktør, Lars Rebien Sørensen. ""Vi er overbevist om, at Victoza® vil vise sig som en værdifuld behandlings­mulighed for mennesker med type 2-diabetes i USA. Victoza® giver en væsentligt forbedret blodsukker­regulering med lav risiko for hypoglykæmi og gør det dermed muligt for flere patienter med type 2-diabetes at nå deres individuelle behandlingsmål."" Novo Nordisk forventer at lancere Victoza® på det amerikanske marked inden for de kommende uger. Det kliniske fase 3-program for Victoza®, også kaldet LEAD(TM) programmet, der har dannet grundlag for registreringsansøgningen, består af randomiserede, kontrollerede, dobbeltblindede studier, der har sammenlignet Victoza® med almindeligt ordinerede behandlinger. Disse multinationale studier vurderede Victoza® dels som monoterapi og dels i kombination med et eller to diabetes­lægemidler i tabletform og viste en bedre eller tilsvarende reduktion af blodglukose i forhold til aktive komparatorer som sulfonylurinstoffer og thiazolidinedioner. Til forskel fra mange andre diabeteslægemidler er Victoza® ikke forbundet med vægtøgning. De kliniske forsøgsdata fra LEAD(TM) programmet viste, at patienter med type 2-diabetes opnåede en vægtreduktion. Vægt var et sekundært effektmål i de kliniske udviklingsstudier. De hyppigst rapporterede bivirkninger i det kliniske udviklingsprogram hos patienter, der blev behandlet med Victoza®, var gastrointestinale forstyrrelser. Gastrointestinale bivirkninger, herunder kvalme, opkastning og diarré, blev hyppigst rapporteret tidligt i behandlingsperioden med Victoza®, og få patienter trak sig ud af programmet som følge af disse bivirkninger. De amerikanske ordinationsoplysninger indeholder en advarsel mod risiko for C-celletumorer i skjoldbruskkirtlen (thyroidea). Der blev i prækliniske forsøg med Victoza® konstateret C-celletumorer i skjoldbruskkirtlen hos gnavere. I de kliniske studier var der ingen indberettede tilfælde af medullært thyroidea-karcinom (MTC) hos patienter, der blev behandlet med Victoza®, men relevansen for mennesker af resultaterne af forsøgene med gnavere har ikke kunnet udelukkes ved kliniske eller ikke-kliniske studier. Victoza® er kontra­indiceret til patienter med eller familiehistorie for MTC eller multipel endokrin neoplasi type 2. Markedsføringstilladelsen indeholder endvidere en strategi for risikovurdering og -begrænsning bestående af en brugervejledning til patienter og en kommunikationsplan til sundhedsudbydere - som begge informerer om risikoen for betændelse i bugspytkirtlen og den potentielle risiko for MTC. Der vil den 26. januar 2010 kl. 8.00 blive afholdt en telekonference for investorer. Der vil blive mulighed for at lytte med via et link under investorsektionen på novonordisk.com, hvor der også vil kunne hentes præsentationsmateriale ca. en time før selve konferencen, ligesom en båndet optagelse vil være tilgængelig her ca. to timer efter, at telekonferencen er slut. Victoza® én gang dagligt er den første humane GLP-1-analog (glukagon­lignende peptid-1), der er udviklet til behandling af type 2-diabetes. Victoza® virker ved kun at stimulere frigivelsen af insulin fra bugspytkirtlens betaceller, når blodsukkerniveauet bliver for højt. Kliniske forsøgsdata viser en reduktion i kropsvægt. Victoza® nedbrydes naturligt i kroppen og udskilles ikke via nyrerne. I Europa modtog Novo Nordisk markedsføringstilladelse for Victoza® den 30. juni 2009, og Victoza® er efterfølgende blevet lanceret i Storbritannien, Tyskland, Danmark, Norge og Irland. I Japan modtog Novo Nordisk markedsføringstilladelse for Victoza® den 20. januar 2010. Myndighedernes afgørelse afventes i Kina, hvor registreringsansøgning blev indsendt i august 2009. Yderligere information: Medier: Investorer: Katrine Sperling Klaus Bülow Davidsen Tlf.: 3079 6718 Tlf.: 4442 3176 krsp@novonordisk.com klda@novonordisk.com Kasper Roseeuw Poulsen Tlf.: 4442 4471 krop@novonordisk.com Selskabsmeddelelse nr. 3 / 2010",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3214,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
790,2010-01-20,Novo Nordisk får markedsføringstilladelse for Victoza® i Japan,"Novo Nordisk meddelte i dag, at det japanske sundhedsministerium har godkendt Victoza® til behandling af type 2-diabetes. Victoza® er varemærket for liraglutid og er den første GLP-1-analog (glukagon­lignende peptid-1), der er godkendt i Japan, udviklet til behandling af type 2-diabetes. Victoza® er godkendt som monoterapi eller som supplement til sulfonylurinstof (SU) ved behandling af type 2-diabetes. ""Den japanske godkendelse af Victoza® er et stort fremskridt i behandlingen af type 2-diabetes og en vigtig milepæl for Novo Nordisk,"" udtaler Novo Nordisks koncern­forsknings­direktør, Mads Krogsgaard Thomsen. ""Det bliver spændende at være de første på GLP-1-markedet i Japan, hvor vi er overbevist om, at Victoza® vil vise sig som en værdifuld behandlingsmulighed for mennesker med type 2-diabetes. De kliniske studier i Japan viste, at Victoza® gav en fremragende blodsukkerregulering med lav risiko for hypoglykæmi."" Novo Nordisk venter at lancere Victoza® i Japan i første halvår af 2010, når prisforhandlingerne er afsluttet. Victoza® én gang dagligt er den første humane GLP-1-analog (glukagon­lignende peptid-1), der er udviklet til behandling af type 2-diabetes. Victoza® virker ved kun at stimulere frigivelsen af insulin fra bugspytkirtlens betaceller, når blodsukkerniveauet bliver for højt. Vægttab i forbindelse med Victoza® skyldes, at det øger mæthedsfornemmelsen efter et måltid, dels fordi det forsinker mavesækkens tømning, og dels på grund af andre mekanismer. Victoza® nedbrydes naturligt i kroppen og udskilles ikke via nyrerne. I Europa modtog Novo Nordisk markedsføringstilladelse for Victoza® den 30. juni 2009, og Victoza® er efterfølgende blevet lanceret i flere lande. Registreringsansøgning blev indsendt i USA i maj 2008 og i Kina i august 2009, og myndighedernes afgørelse i disse lande afventes.  Yderligere information: Medier: Investorer:   Mike Rulis Klaus Bülow Davidsen Tlf.: 4442 3573 Tlf.: 4442 3176 mike@novonordisk.com klda@novonordisk.com    Kasper Roseeuw Poulsen  Tlf.: 4442 4471  krop@novonordisk.com  Selskabsmeddelelse nr. 2 / 2010",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3219,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
791,2010-01-20,Novo Nordisk receives approval for Victoza® in Japan,"Novo Nordisk receives approval for Victoza® in Japan Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Victoza® for the treatment of type 2 diabetes. Victoza® is the brand name for liraglutide, the first Glucagon-Like Peptide-1 (GLP-1) analogue approved in Japan, developed for the treatment of type 2 diabetes. Victoza® is indicated as monotherapy or as an add-on to sulphonylurea (SU) in people with type 2 diabetes. ""The Japanese approval of Victoza® represents a major advancement in the treatment of type 2 diabetes and an important milestone for Novo Nordisk."" says Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. ""We are excited to pioneer the GLP-1 market in Japan, where we are convinced Victoza® will prove to be a valuable treatment option for people with type 2 diabetes. The clinical studies conducted in Japan showed Victoza® to provide superior glucose control with a low risk of hypoglycaemia."" Novo Nordisk expects to launch Victoza® in Japan in the first half of 2010 upon completion of price negotiations. Once-daily Victoza® is the first human Glucagon-Like Peptide-1 (GLP-1) analogue developed for the treatment of type 2 diabetes. Victoza® works by stimulating the release of insulin from the pancreatic beta cells only when blood sugar levels are high. Weight loss with Victoza® is attributed to the fact that it leads to increased satiety after meals in part by slowing gastric emptying and, in part, by other mechanisms. Victoza® is broken down naturally in the body and does not depend upon renal excretion. In Europe, Novo Nordisk received marketing authorisation for Victoza® on 30 June and Victoza® has subsequently been launched in several countries. A New Drug Application was submitted for regulatory approval in the US in May 2008 and in China in August 2009, respectively, and regulatory decisions are pending. Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 29,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com. Further information: Media: Investors:   Mike Rulis Klaus Bülow Davidsen Tel: (+45) 4442 3573 Tel: (+45) 4442 3176 mike@novonordisk.com klda@novonordisk.com    Kasper Roseeuw Poulsen  Tel: (+45) 4442 4471  krop@novonordisk.com   In North America: In North America: An Phan Hans Rommer Tel: (+1) 609 558 0420 Tel: (+1) 609 919 7937 anph@novonordisk.com hrmm@novonordisk.com  Company Announcement no 2 / 2010",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3218,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
792,2009-12-30,Update on timeline for formal feedback on liraglutide from the FDA,"Novo Nordisk today announced that formal feedback from the United States Food and Drug Administration (FDA) regarding liraglutide, a once-daily human GLP-1 analogue, is expected within weeks. Novo Nordisk continues the constructive dialogue with the FDA regarding the regulatory process for liraglutide. Novo Nordisk expects to provide an update on the regulatory process for liraglutide in connection with the announcement of the financial results for 2009 on 2 February 2010, if formal feedback is not received before then. Liraglutide is the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analogue developed for the treatment of type 2 diabetes. Liraglutide works by stimulating the release of insulin only when glucose levels become too high and by inhibiting appetite. On 23 May 2008, Novo Nordisk submitted a New Drug Application to the Food and Drug Administration in the US for the approval of liraglutide for the treatment of people with type 2 diabetes. In Europe, Novo Nordisk received marketing authorisation for liraglutide under the brand name Victoza® on 30 June, and Victoza® has subsequently been launched. A New Drug Application was also submitted for approval in Japan on 14 July 2008. Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 29,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com Further information: Media: Investors:   Mike Rulis Mads Veggerby Lausten Tel: (+45) 3079 3573 Tel: (+45) 4443 7919 mike@novonordisk.com mlau@novonordisk.com    Kasper Roseeuw Poulsen  Tel: (+45) 3079 4471  krop@novonordisk.com   In North America: In North America: Sean Clements Hans Rommer Tel: (+1) 609 514 8316 Tel: (+1) 609 216 4834 secl@novonordisk.com hrmm@novonordisk.com  Company Announcement no 75 / 2009",https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3229,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
793,2009-10-29,Interim financial report for the period 1 January 2009 to 30 September 2009,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3301,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
794,2009-10-29,Delårsrapport for perioden 1. januar 2009 til 30. september 2009,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3302,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
795,2009-09-23,Update on timeline for formal feedback on liraglutide from the FDA,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3344,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
796,2009-08-06,Interim financial report for the period 1 January 2009 to 30 June 2009,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3405,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
797,2009-08-06,Delårsrapport for perioden 1. januar 2009 til 30. juni 2009,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3406,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
798,2009-07-03,Novo Nordisk's  Victoza® (liraglutide) receives marketing authorisation in Europe,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3441,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
799,2009-07-03,Novo Nordisks Victoza® (liraglutid) får markedsføringstilladelse i Europa,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3442,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
800,2009-06-30,Total number of voting rights and share capital in Novo Nordisk A/S as of 30 June 2009.,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3453,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
801,2009-06-30,Det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 30. juni 2009,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3454,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
802,2009-06-28,Novo Nordisk insulin analogues have proven safety profiles,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3467,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
803,2009-06-28,Novo Nordisks insulinanaloger har veldokumenterede sikkerhedsprofiler,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3468,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
804,2009-06-22,Reduction of the share capital and holding of own shares (22 June 2009),,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3474,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
805,2009-04-30,Interim financial report for the period 1 January 2009 to 31 March 2009,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3534,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
806,2009-04-30,Delårsrapport for perioden 1. januar 2009 til 31. marts 2009,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3535,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
807,2009-04-23,Novo Nordisk modtager positiv udtalelse om Victoza® (liraglutide) fra de europæiske registreringsmyndigheder,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3546,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
808,2009-04-23,Novo Nordisk receives positive opinion on Victoza® (liraglutide) from the European regulatory authorities,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3547,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
809,2009-04-02,Update on FDA Advisory Committee meeting on liraglutide for the treatment of type 2 diabetes,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3568,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
810,2009-03-31,Liraglutide briefing documents now available for the FDA Advisory Committee meeting on 2 April,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3576,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
811,2009-03-31,Briefingdokumenterne om liraglutide til mødet i FDA's rådgivende komite den 2. april er nu tilgængelige,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3577,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
812,2009-03-18,Annual General Meeting at Novo Nordisk A/S,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3598,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
813,2009-03-18,Generalforsamling i Novo Nordisk A/S,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3597,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
814,2009-02-24,Annual General Meeting of Novo Nordisk A/S,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3621,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
815,2009-02-24,Ordinær generalforsamling i Novo Nordisk A/S,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3622,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
816,2009-01-29,Financial statement for 2008,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3678,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
817,2009-01-29,Regnskabsmeddelelse for året 2008,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3679,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
818,2008-11-18,FDA reschedules Advisory Committee meeting for liraglutide - no change of review timeline anticipated,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3726,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
819,2008-11-18,FDA meddeler ny dato for møde i rådgivende komite om liraglutide - samlet tidsplan forventes ikke ændret,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3727,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
820,2008-11-07,Major shareholder notification,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3744,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
821,2008-11-07,Storaktionærmeddelelse,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3745,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
822,2008-10-30,Financial statement for the period 1 January 2008 to 30 September 2008,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3775,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
823,2008-10-30,Regnskabsmeddelelse for perioden 1. januar til 30. september 2008,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3776,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
824,2008-09-26,Novo Nordisks kapitalmarkedsdag: opdatering på koncernstrategi,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3817,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
825,2008-09-26,Novo Nordisk provides update on corporate strategy at its Capital Markets Day,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3818,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
826,2008-09-09,Major shareholder notification,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3835,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
827,2008-09-09,Storaktionærmeddelelse,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3836,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
828,2008-09-05,FDA schedules Advisory Committee meeting for liraglutide,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3847,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
829,2008-09-05,FDA berammer møde i rådgivende komite om liraglutide,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3848,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
830,2008-09-03,Major shareholder notification,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3853,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
831,2008-09-03,Storaktionærmeddelelse,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3854,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
832,2008-08-07,Financial statement for the period 1 January 2008 to 30 June 2008,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3889,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
833,2008-08-07,Regnskabsmeddelelse for perioden 1. januar til 30. juni 2008,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3890,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
834,2008-07-15,Novo Nordisk files for regulatory approval of liraglutide in Japan,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3913,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
835,2008-07-15,Novo Nordisk indsender registreringsansøgning for liraglutide i Japan,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3914,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
836,2008-06-30,Total number of voting rights and share capital in Novo Nordisk A/S as of 30 June 2008.,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3943,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
837,2008-06-30,Det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 30. juni 2008,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3944,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
838,2008-06-24,Novo Nordisk receives approval in the US for PrandiMet(TM),,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3949,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
839,2008-06-24,Novo Nordisk opnår godkendelse for PrandiMet® i USA,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3950,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
840,2008-06-16,Significant weight loss sustained in obese people treated with liraglutide for one year,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3967,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
841,2008-06-16,Signifikant vægttab fastholdes hos svært overvægtige efter behandling med liraglutide i et år,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3968,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
842,2008-06-11,Novo Nordisk indstiller klinisk fase 3-forsøg med NovoSeven® til traumebehandling,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3982,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
843,2008-06-11,Novo Nordisk discontinues phase 3 clinical trial with NovoSeven® in trauma,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3983,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
844,2008-06-06,Clinical study shows liraglutide provides statistically significantly better blood glucose control than exenatide,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3994,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
845,2008-06-06,"Klinisk studie viser, at liraglutide giver statistisk signifikant bedre blodsukkerregulering end exenatide",,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=3995,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
846,2008-05-23,Novo Nordisk indsender registreringsansøgning for liraglutide i USA og Europa,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4012,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
847,2008-05-23,Novo Nordisk files for regulatory approval of liraglutide in both the US and Europe,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4013,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
848,2008-04-30,Financial statement for the period 1 January 2008 to 31 March 2008,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4042,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
849,2008-04-30,Regnskabsmeddelelse for perioden 1. januar til 31. marts 2008,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4043,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
850,2008-04-01,Total number of voting rights and share capital in Novo Nordisk A/S as of 31 March 2008.,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4081,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
851,2008-04-01,Opgørelse af det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 31. marts 2008,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4082,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
852,2008-03-12,Generalforsamling i Novo Nordisk A/S,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4100,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
853,2008-03-12,Annual General Meeting at Novo Nordisk A/S,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4101,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
854,2008-02-20,Annual General Meeting of Novo Nordisk A/S,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4127,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
855,2008-02-20,Ordinær generalforsamling i Novo Nordisk A/S,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4128,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
856,2008-01-31,Regnskabsmeddelelse for året 2007,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4181,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
857,2008-01-31,Financial statement for 2007,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4182,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
858,2008-01-14,Novo Nordisk omprioriterer sine aktiviteter inden for inhalerbar insulin og indstiller udviklingen af AERx®,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4187,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
859,2008-01-14,Novo Nordisk refocuses its activities within inhaled insulin and discontinues the development of AERx®,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4188,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
860,2007-12-12,Major shareholder notification,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4199,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
861,2007-12-12,Storaktionærmeddelelse,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4200,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
862,2007-12-11,"Afsluttende fase 3-studie bekræfter, at liraglutide har en overbevisende effekt på blodsukkerregulering og vægt",,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4205,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
863,2007-12-11,Final phase 3 study confirms very favourable effect of liraglutide on blood glucose control and body weight,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4206,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
864,2007-12-05,Storaktionærmeddelelse,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4213,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
865,2007-12-05,Major shareholder notification,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4214,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
866,2007-11-23,Novo Nordisk stock split information,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4219,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
867,2007-11-23,Information om Novo Nordisks aktiesplit,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4220,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
868,2007-11-20,New phase 2 study shows that liraglutide leads to significant weight loss in obese people,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4223,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
869,2007-11-20,"Nyt fase 2-studie viser, at liraglutide medfører signifikant vægttab hos svært overvægtige",,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4224,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
870,2007-10-31,Regnskabsmeddelelse for perioden 1. januar til 30. september 2007,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4241,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
871,2007-10-31,Financial statement for the period 1 January 2007 to 30 September 2007,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4242,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
872,2007-10-24,Major shareholder notification,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4247,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
873,2007-10-24,Storaktionærmeddelelse,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4248,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
874,2007-10-09,Major shareholder notification,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4253,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
875,2007-10-09,Storaktionærmeddelelse,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4254,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
876,2007-09-14,Phase 3 study confirms that liraglutide treatment leads to both glucose and weight reduction with a low risk of hypoglycaemic events,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4267,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
877,2007-09-14,"Fase 3-studie bekræfter, at behandling med liraglutide sænker både blodsukker og vægt med lav risiko for hypoglykæmi",,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4268,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
878,2007-08-20,"Liraglutide improves glucose control and lowers body weight in two phase 3 studies comprising more than 2,000 patients",,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4271,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
879,2007-08-20,"Liraglutide forbedrer blodsukkerregulering og medfører vægttab, viser to fase 3-studier med mere end 2.000 patienter",,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4272,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
880,2007-08-03,Financial statement for the period 1 January 2007 to 30 June 2007,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4295,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
881,2007-08-03,Regnskabsmeddelelse for perioden 1. januar til 30. juni 2007,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4296,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
882,2007-06-29,Total number of voting rights and share capital in Novo Nordisk A/S as of 29 June 2007,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4307,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
883,2007-06-29,Det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 29. juni 2007,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4308,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
884,2007-06-21,Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4315,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
885,2007-06-21,Liraglutide giver en væsentligt bedre blodsukkerregulering end insulin glargine i fase 3-studie,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4316,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
886,2007-06-19,Reduction of the share capital and holding of own shares (19 June 2007),,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4324,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
887,2007-06-01,Total number of voting rights and size of share capital in Novo Nordisk A/S as of 1 June 2007,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4330,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
888,2007-06-01,Det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 1. juni 2007,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4331,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
889,2007-05-31,Novo Nordisk's divestment of its ownership of Dako's business activities has now been completed,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4336,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
890,2007-05-31,Salget af Novo Nordisks ejerandel af Dakos forretningsaktiviteter er nu gennemført,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4337,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
891,2007-05-02,Financial statement for the period 1 January 2007 to 31 March 2007,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4367,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
892,2007-05-02,Regnskabsmeddelelse for perioden 1. januar til 31. marts 2007,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4366,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
893,2007-03-07,Annual General Meeting at Novo Nordisk A/S,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4376,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
894,2007-03-07,Generalforsamling i Novo Nordisk A/S,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4377,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
895,2007-02-28,Novo Nordisk sælger sin ejerandel af Dakos forretningsaktiviteter,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4384,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
896,2007-02-28,Novo Nordisk divests its ownership of Dako's business activities,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4385,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
897,2007-02-26,"Fase 3-forsøg inden for hjerneblødning viser, at NovoSeven® reducerer blødning, men forbedrer ikke det langsigtede behandlingsresultat",,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4389,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
898,2007-02-26,"Phase 3 stroke trial shows that NovoSeven® reduces bleeding in the brain, but does not improve long-term clinical outcomes",,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4390,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
899,2007-02-20,Ordinær generalforsamling i Novo Nordisk A/S,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4394,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
900,2007-02-20,Annual General Meeting of Novo Nordisk A/S,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4395,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
901,2007-01-31,Financial statement for 2006,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4404,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
902,2007-01-31,Regnskabsmeddelelse for året 2006,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4405,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
903,2007-01-15,Novo Nordisk koncentrerer sine forskningsaktiviteter om terapeutiske proteiner - indstiller forskning i små molekyler,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4409,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
904,2007-01-15,Novo Nordisk focuses research and development on therapeutic proteins - discontinues R&D within small molecules,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4410,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
905,2006-11-30,Novo Nordisk planlægger betydelig udvidelse af sin diabetessalgsorganisation i USA,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4417,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
906,2006-11-30,Novo Nordisk announces major expansion of its diabetes care field force in the US,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4418,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
907,2006-10-27,Regnskabsmeddelelse for perioden 1. januar til 30. september 2006,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4423,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
908,2006-10-27,Financial statement for the period 1 January 2006 to 30 September 2006,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4424,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
909,2006-10-06,Novo Nordisk annoncerer påbegyndelse af tre nye kliniske studier på kapitalmarkedsdag,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4426,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
910,2006-10-06,Novo Nordisk announces initiation of three new clinical studies at Capital Markets Day,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4427,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
911,2006-08-02,Regnskabsmeddelelse for perioden 1. januar til 30. juni 2006,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4447,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
912,2006-08-02,Financial statement for the period 1 January 2006 to 30 June 2006,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4449,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
913,2006-06-23,Reduction of the share capital and holding of own shares (23 June 2006),,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4455,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
914,2006-04-28,Regnskabsmeddelelse for perioden 1. januar til 31. marts 2006,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4482,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
915,2006-04-28,Financial statement for the period 1 January 2006 to 31 March 2006,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4483,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
916,2006-03-31,Ændringer i Novo Nordisks koncerndirektion,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4490,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
917,2006-03-31,Changes in Novo Nordisk's Executive Management,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4491,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
918,2006-03-08,Annual General Meeting at Novo Nordisk A/S,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4495,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
919,2006-03-08,Generalforsamling i Novo Nordisk A/S,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4496,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
920,2006-02-21,Ordinær generalforsamling i Novo Nordisk A/S,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4499,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
921,2006-02-21,Annual General Meeting of Novo Nordisk A/S,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4500,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
922,2006-02-20,Amerikansk undersøgelse vedrørende FN's Olie-for-Mad-program,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4503,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
923,2006-02-20,SEC investigation relating to the United Nations Oil-for Food-Programme,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4504,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
924,2006-01-27,Regnskabsmeddelelse for året 2005,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4547,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
925,2006-01-27,Financial statement for 2005,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4548,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
926,2005-12-20,Novo Nordisk har modtaget begæring om udlevering af dokumenter i USA,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4555,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
927,2005-12-20,Novo Nordisk receives subpoena in the US,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4556,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
928,2005-11-25,Lovende kliniske resultater fra fase 2b-studiet med liraglutide,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4559,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
929,2005-11-25,Promising clinical results from liraglutide phase 2b study,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4560,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
930,2005-10-27,Regnskabsmeddelelse for perioden 1. januar til 30. september 2005,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4572,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
931,2005-10-27,Financial statement for the period 1 January 2005 to 30 September 2005,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4573,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
932,2005-08-11,Regnskabsmeddelelse for perioden 1. januar til 30. juni 2005,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4592,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
933,2005-08-11,Financial statement for the period 1 January 2005 to 30 June 2005,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4593,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
934,2005-06-16,Novo Nordisk opnår FDA-godkendelse af Levemir® og kan dermed som de første tilbyde et fuldt sortiment af insulinanaloger i USA,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4600,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
935,2005-06-16,Novo Nordisk receives US approval of Levemir® and becomes the first company with a full range of insulin analogues in the US,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4601,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
936,2005-04-28,Regnskabsmeddelelse for perioden 1. januar til 31. marts 2005,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4608,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
937,2005-04-28,Financial statement for the period 1 January 2005 to 31 March 2005,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4609,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
938,2005-03-09,Generalforsamling i Novo Nordisk A/S,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4614,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
939,2005-03-09,Annual General Meeting at Novo Nordisk A/S,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4615,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
940,2005-02-18,Ordinær generalforsamling i Novo Nordisk A/S - Ændring af bestyrelsens sammensætning,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4617,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
941,2005-02-18,Annual General Meeting of Novo Nordisk A/S - Change of members of the Board of Directors,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4618,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
942,2005-02-16,Opgørelse over besiddelsen af Novo Nordisk-aktier for medlemmerne af bestyrelse og direktion samt for alle insidere og disses nærtstående pr. 11. februar 2005,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4620,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
943,2005-02-16,"Holding of Novo Nordisk shares by the members of the Board of Directors, of Executive Management and all insiders and connected persons as per 11 February 2005",,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4621,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
944,2005-02-10,Novo Nordisk afhænder aktiepost i Ferrosan A/S,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4626,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
945,2005-02-10,Novo Nordisk divests shareholding in Ferrosan A/S,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4627,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
946,2005-01-28,Regnskabsmeddelelse for året 2004,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4644,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
947,2005-01-28,Financial statement for 2004,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4645,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
948,2005-01-04,Novo Nordisk continues to make progress towards label expansion for NovoSeven® in Europe,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4649,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
949,2005-01-03,Indikationsudvidelsen for NovoSeven® i Europa skrider fortsat fremad,,https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=4652,https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico,Novonordisk
